PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Weinman, SA; Carruth, MW; Dawson, PA				Weinman, SA; Carruth, MW; Dawson, PA			Bile acid uptake via the human apical sodium-bile acid cotransporter is electrogenic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; ISOLATED RAT HEPATOCYTES; TAUROCHOLATE TRANSPORT; INTESTINAL TRANSPORT; SALT TRANSPORT; VESICLES; SYSTEM; ILEUM; EXPRESSION; CLONING	Intestinal absorption of bile acids depends on a sodium-bile acid cotransport protein in the apical membrane of the ileal epithelial cell. Transport is Na+-dependent, but the Na+-bile acid stoichiometry and electrogenicity of transport are not known. Studies in whole intestine, isolated cells, and ileal membrane vesicles have been unable to resolve this issue because transport currents are small and can be obscured by other ionic conductances and transport proteins present in these membranes. In this study, the human apical sodium-bile acid transporter was expressed in stably transfected Chinese hamster ovary cells that lack other bile acid transporters. The Na+-dependent transport of a fluorescent bile acid analog, chenodeoxycholyl-N-epsilon-nitrobenzoxadiazol-lysine, was monitored by fluorescence microscopy in single, voltage-clamped cells, Bile acid movement was bidirectional and voltage-dependent with negative intracellular voltage-stimulating influx. A 3-fold reduction in extracellular Naf produced a negative 52 mV shift of the flux-voltage relationship, consistent with a 2:1 Na+:bile acid coupling stoichiometry, No Na+- or voltage-dependent uptake was observed in nontransfected Chinese hamster ovary cells. These results indicate that the cotransport of bile acids and Na+ by human apical sodium-bile acid transporter is electrogenic and bidirectional and is best explained by a 2:1 Na+:bile acid coupling stoichiometry. These results suggest that membrane potential may regulate bile acid transport rates under physiological and pathophysiological conditions.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Wake Forest University	Weinman, SA (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, 301 Univ Blvd, Galveston, TX 77555 USA.	sweinman@utmb.edu	Weinman, Steven/E-7012-2011		NIDDK NIH HHS [DK47987, DK42917, R29 DK047987] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047987, R01DK042917, R29DK042917, R29DK047987] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpini G, 1997, GASTROENTEROLOGY, V113, P1734, DOI 10.1053/gast.1997.v113.pm9352879; BARNARD JA, 1985, J CLIN INVEST, V75, P869, DOI 10.1172/JCI111785; BARNARD JA, 1987, GASTROENTEROLOGY, V93, P925, DOI 10.1016/0016-5085(87)90553-1; BERGMAN J, 1989, J MEMBRANE BIOL, V111, P241, DOI 10.1007/BF01871009; BOYER JL, 1994, AM J PHYSIOL, V266, pG382, DOI 10.1152/ajpgi.1994.266.3.G382; Christie DM, 1996, AM J PHYSIOL-GASTR L, V271, pG377, DOI 10.1152/ajpgi.1996.271.2.G377; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; DEBNAM ES, 1984, J PHYSIOL-LONDON, V355, P449, DOI 10.1113/jphysiol.1984.sp015430; GRUBB BR, 1987, AM J PHYSIOL, V253, pG211, DOI 10.1152/ajpgi.1987.253.2.G211; Grune S, 1996, AM J PHYSIOL-GASTR L, V270, pG339, DOI 10.1152/ajpgi.1996.270.2.G339; Hagenbuch B, 1996, SEMIN LIVER DIS, V16, P129, DOI 10.1055/s-2007-1007226; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; Holzinger F, 1997, HEPATOLOGY, V26, P1263; JAUCH P, 1986, J MEMBRANE BIOL, V94, P99, DOI 10.1007/BF01871191; KIMMICH GA, 1990, J MEMBRANE BIOL, V114, P1, DOI 10.1007/BF01869381; KRAMER W, 1992, BIOCHIM BIOPHYS ACTA, V1111, P93, DOI 10.1016/0005-2736(92)90278-T; LACK L, 1979, ENVIRON HEALTH PERSP, V33, P79, DOI 10.2307/3429075; LESAGE GD, 1993, GASTROENTEROLOGY, V104, P937; LEZARIDIS KN, 1997, J CLIN INVEST, V100, P2714; LIDOFSKY SD, 1993, AM J PHYSIOL, V264, pG478, DOI 10.1152/ajpgi.1993.264.3.G478; LUCKE H, 1978, BIOCHEM J, V174, P951; MAGLOVA LM, 1995, HEPATOLOGY, V22, P637; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; ROUSE DJ, 1979, LIFE SCI, V25, P45, DOI 10.1016/0024-3205(79)90488-0; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; WEHNER F, 1993, PFLUG ARCH EUR J PHY, V424, P145, DOI 10.1007/BF00374605; WEINBERG SL, 1986, J CLIN INVEST, V78, P44, DOI 10.1172/JCI112571; WEINMAN SA, 1994, AM J PHYSIOL-GASTR L, V267, pG922, DOI 10.1152/ajpgi.1994.267.5.G922; WEINMAN SA, 1993, AM J PHYSIOL, V265, pG73, DOI 10.1152/ajpgi.1993.265.1.G73; WILSON FA, 1979, BIOCHIM BIOPHYS ACTA, V554, P430, DOI 10.1016/0005-2736(79)90382-1; WILSON FA, 1981, AM J PHYSIOL, V241, pG83, DOI 10.1152/ajpgi.1981.241.2.G83; WILSON FA, 1991, HDB PHYSL GASTROINTE, V4, P389; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; WONG MH, 1994, J BIOL CHEM, V269, P1340	35	74	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34691	34695		10.1074/jbc.273.52.34691	http://dx.doi.org/10.1074/jbc.273.52.34691			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856990	hybrid			2022-12-25	WOS:000077719700008
J	Keck, JL; Goedken, ER; Marqusee, S				Keck, JL; Goedken, ER; Marqusee, S			Activation/attenuation model for RNase H - A one-metal mechanism with second-metal inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RIBONUCLEASE-H; VIRUS REVERSE-TRANSCRIPTASE; DNA-POLYMERASE-I; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACTIVE-SITE; 3'-5' EXONUCLEASE; CATALYTIC DOMAIN; AMINO-ACID; RESOLUTION	Ribonucleases H (RNases H) comprise a family of metal-dependent enzymes that catalyze the hydrolysis of the 3'-O-P bond of RNA in RNA. DNA hybrids. The mechanism by which RNases H use active-site metal(s) for catalysis is unclear. Based upon the seemingly contradictory structural observations of one divalent metal bound to Escherichia coli RNase HI and two divalent metals bound to the HN RNase H domain, two models explaining RNase H metal dependence have been proposed: a one-metal mechanism and a two-metal mechanism, In this paper, we show that the Mn2+-dependent activity off. coli RNase HI is not consistent with either of these mechanisms. RNase H activity in the presence of Mn2+ is complex, with activation and inhibition of the enzyme at low and high Mn2+ concentrations, respectively. Mutations at Asp-134 result in a partial loss of this inhibition, with Little effect on activation. Neutralization of His-124 by mutation to Ala results in an enzyme with a significantly decreased specific activity and an absolute loss of Mn2+ inhibition, Inhibition by high Mn2+ concentrations is shown to be due to a reduction in k(cat); this attenuation has a critical dependence on the presence of His-124. Based upon these results, we propose an "activation/attenuation" model explaining the metal dependence of RNase H activity where one metal is required for enzyme activation and binding of a second metal is inhibitory.	Univ Calif Berkeley, Dept Cell & Mol Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Marqusee, S (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.			Keck, James/0000-0002-5961-0220	NIGMS NIH HHS [GM53321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Blain SW, 1996, J BIOL CHEM, V271, P1448, DOI 10.1074/jbc.271.3.1448; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; CASARENO RLB, 1995, J AM CHEM SOC, V117, P11011, DOI 10.1021/ja00149a026; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; CORNISHBOWDEN A, 1995, ANAL ENZYME KINETIC, P133; DABORA JM, 1994, PROTEIN SCI, V3, P1401, DOI 10.1002/pro.5560030906; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EVANS DB, 1991, J BIOL CHEM, V266, P20583; Goedken ER, 1997, BIOCHEMISTRY-US, V36, P7256, DOI 10.1021/bi970060q; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HOSTOMSKY Z, 1994, NUCLEASES, P341; HUANG HW, 1994, EUR J BIOCHEM, V219, P25; ISHIKAWA K, 1993, J MOL BIOL, V230, P529, DOI 10.1006/jmbi.1993.1169; KANAYA S, 1990, J BIOL CHEM, V265, P4615; Kashiwagi T, 1996, PROTEIN ENG, V9, P857, DOI 10.1093/protein/9.10.857; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Keck JL, 1996, J BIOL CHEM, V271, P19883, DOI 10.1074/jbc.271.33.19883; Keck JL, 1997, TECH PROT CHEM, V8, P409, DOI 10.1016/S1080-8914(97)80041-5; KECK JL, 1995, P NATL ACAD SCI USA, V92, P2740, DOI 10.1073/pnas.92.7.2740; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; ODA Y, 1991, Journal of Biomolecular NMR, V1, P247, DOI 10.1007/BF01875518; ODA Y, 1993, J BIOL CHEM, V268, P88; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; SMITH JS, 1993, J VIROL, V67, P4037, DOI 10.1128/JVI.67.7.4037-4049.1993; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; VENCLOVAS C, 1995, NAT STRUCT BIOL, V2, P838, DOI 10.1038/nsb1095-838; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZHAN XY, 1994, BIOCHEMISTRY-US, V33, P1366, DOI 10.1021/bi00172a012	43	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34128	34133		10.1074/jbc.273.51.34128	http://dx.doi.org/10.1074/jbc.273.51.34128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852071	hybrid			2022-12-25	WOS:000077542200037
J	Oishi, H; Sasaki, T; Nagano, F; Ikeda, W; Ohya, T; Wada, M; Ide, N; Nakanishi, H; Takai, Y				Oishi, H; Sasaki, T; Nagano, F; Ikeda, W; Ohya, T; Wada, M; Ide, N; Nakanishi, H; Takai, Y			Localization of the Rab3 small G protein regulators in nerve terminals and their involvement in Ca2+-dependent exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADRENAL CHROMAFFIN CELLS; HUMAN GROWTH-HORMONE; SYNAPTIC VESICLES; ACTIVATING PROTEIN; PC12 CELLS; SMG P25A; TARGET PROTEIN; RABPHILIN-3A; RAS	The Rab3 small G protein subfamily (Rab3) consists of four members, Rab3A, -B, -C, and -D. We have recently isolated and characterized the Rab3 regulators, GDP/GTP exchange protein (GEP) and GTPase activating protein (GAP), both of which are specific for the Rab3 subfamily. Rab3 GEP stimulates the conversion of the GDP-bound inactive form to the GTP-bound active form, whereas Rab3 GAP stimulates the reverse reaction. Of the four members of the Rab3 subfamily, evidence is accumulating that Rab3A is involved in Ca2+-dependent exocytosis, particularly in neurotransmitter release. We first analyzed the subcellular localization of Rab3 GEP and GAP in rat brain. Subcellular fractionation analysis showed that both Rab3 GEP and GAP were enriched in the synaptic soluble fraction. Immunocytochemical analysis in primary cultured rat hippocampal neurons showed that both Rab3 GEP and GAP were concentrated at the presynaptic nerve terminals. We then examined whether Rab3 GEP and GAP were involved in Ca2+-dependent exocytosis by use of human growth hormone (GH) co-expression assay system of cultured PC12 cells. Overexpression of the deletion mutant of Rab3 GEP possessing the catalytic activity reduced the high K+-induced GH release without affecting the basal GH release, whereas that of the deletion mutant lacking the catalytic activity showed no effect on the high K+-induced GN release. In contrast, overexpression of Rab3 GAP or its deletion mutant possessing the catalytic activity did not affect the high K+-induced GH release or the basal GH release. These results indicate that Rab3 GEP and GAP are colocalized with Rab3A at the synaptic release sites and suggest that they regulate the activity of Rab3A and are involved in Ca2+-dependent exocytosis.	Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; JCR Pharmaceut Co Ltd, Japan Sci & Technol Corp, ERATO, Tokai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058; Nakanishi, Hiroyuki/0000-0002-9765-0266				BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; Burns ME, 1998, J GEN PHYSIOL, V111, P243, DOI 10.1085/jgp.111.2.243; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Iwasaki K, 1997, NEURON, V18, P613, DOI 10.1016/S0896-6273(00)80302-5; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WICK PF, 1993, J BIOL CHEM, V268, P10983; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9	37	50	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34580	34585		10.1074/jbc.273.51.34580	http://dx.doi.org/10.1074/jbc.273.51.34580			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852129	hybrid			2022-12-25	WOS:000077542200095
J	Benning, MM; Wesenberg, G; Liu, RQ; Taylor, KL; Dunaway-Mariano, D; Holden, HM				Benning, MM; Wesenberg, G; Liu, RQ; Taylor, KL; Dunaway-Mariano, D; Holden, HM			The three-dimensional structure of 4-hydroxybenzoyl-CoA thioesterase from Pseudomonas sp. strain CBS-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; PROTEIN STRUCTURES; 4-CHLOROBENZOATE DEHALOGENASE; MOLECULAR-CLONING; ACTIVE-SITE; DEGRADATION; HYDROLASE; IDENTIFICATION; EXPRESSION; REFINEMENT	The soil-dwelling microbe, Pseudomonas sp, strain CBS-3, has attracted recent attention due to its ability to survive on 4-chlorobenzoate as its sole carbon source. The biochemical pathway by which this organism converts 4-chlorobenzoate to 4-hydroxybenzoate consists of three enzymes: 4-chlorobenzoyl-CoA ligase, 4-chlorobenzoyl-CoA dehalogenase, and 4-hydroxybenzoyl-CoA thioesterase. Here we describe the three-dimensional structure of the thioesterase determined to 2.0-Angstrom resolution. Each subunit of the homotetramer is characterized by a five-stranded anti-parallel beta-sheet and three major alpha-helices. While previous amino acid sequence analyses failed to reveal any similarity between this thioesterase and other known proteins, the results from this study clearly demonstrate that the molecular architecture of 4-hydroxybenzoyl-CoA thioesterase is topologically equivalent to that observed for beta-hydroxydecanoyl thiol ester dehydrase from Escherichia coli. On the basis of the structural similarity between these two enzymes, the active site of the thioesterase has been identified and a catalytic mechanism proposed.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53705 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA	University of Wisconsin System; University of Wisconsin Madison; University of New Mexico	Holden, HM (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53705 USA.	HOLDEN@ENZYME.WISC.EDU			NIGMS NIH HHS [GM28688, GM55513] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028688] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOWICZ DA, 1990, CRIT REV BIOTECHNOL, V10, P241, DOI 10.3109/07388559009038210; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; CHANG KH, 1992, BIOCHEMISTRY-US, V31, P5605, DOI 10.1021/bi00139a025; CHO HS, 1993, J BIOL CHEM, V268, P9238; Commandeur LCM, 1990, BIODEGRADATION, V1, P207, DOI 10.1007/BF00058837; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dunaway-Mariano Debra, 1994, Biodegradation, V5, P259, DOI 10.1007/BF00696464; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; GRIBBLE GW, 1994, J CHEM EDUC, V71, P907, DOI 10.1021/ed071p907; Hawes JW, 1996, J BIOL CHEM, V271, P26430, DOI 10.1074/jbc.271.42.26430; HELMKAMP GM, 1969, J BIOL CHEM, V244, P6014; HIGSON FK, 1992, ADV APPL MICROBIOL, V37, P135, DOI 10.1016/S0065-2164(08)70254-5; HILEMAN B, 1993, CHEM ENG NEWS, V71, P11, DOI 10.1021/cen-v071n016.p011; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KLAGES U, 1980, ZBL BAKT MIK HYG I C, V1, P215, DOI 10.1016/S0172-5564(80)80002-9; KLAGES U, 1981, J BACTERIOL, V146, P64, DOI 10.1128/JB.146.1.64-68.1981; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSSMANN MG, 1960, ACTA CRYSTALLOGR, V13, P221, DOI 10.1107/S0365110X60000510; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; Schneider A, 1998, ARCH MICROBIOL, V169, P404, DOI 10.1007/s002030050590; SLATER JH, 1995, BIODEGRADATION, V6, P181, DOI 10.1007/BF00700456; TAYLOR K, 1996, THESIS U MARYLAND CO; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Yuan L, 1996, J BIOL CHEM, V271, P3417	38	93	96	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33572	33579		10.1074/jbc.273.50.33572	http://dx.doi.org/10.1074/jbc.273.50.33572			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837940	hybrid			2022-12-25	WOS:000077462500070
J	Ruelland, E; Johansson, K; Decottignies, P; Djukic, N; Miginiac-Maslow, M				Ruelland, E; Johansson, K; Decottignies, P; Djukic, N; Miginiac-Maslow, M			The autoinhibition of sorghum NADP malate dehydrogenase is mediated by a C-terminal negative charge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; DEPENDENT REGULATORY SITE; ACTIVE-SITE; THIOREDOXIN; ACTIVATION; PHOTOSYNTHESIS; PROTEINS; ENZYMES; UNIQUE; ACID	The chloroplastic NADP malate dehydrogenase is completely inactive in its oxidized form and is activated by thiol/disulfide interchange with reduced thioredoxin, To elucidate the molecular mechanism underlying the absence of activity of the oxidized enzyme, we used site-directed mutagenesis to delete or substitute the two most C-terminal residues (C-terminal Val, penultimate Glu, both bearing negative charges). We also combined these mutations with the elimination of one or both of the possible regulatory N-terminal disulfides by mutating the corresponding cysteines. Proteins mutated at the C-terminal residues had no activity in the oxidized form but were partially inhibited when pretreated with the histidine-specific reagent diethyl pyrocarbonate before activation, showing that the active site was partially accessible. Proteins missing both N-terminal regulatory disulfides reached almost full activity without activation upon elimination of the negative charge of the penultimate Glu, These results strongly support a model where the C-terminal extension is docked into the active site through a negatively charged residue, acting as an internal inhibitor, They show also that the reduction of both N-terminal bridges is necessary to release the C-terminal extension from the active site. This is the first report for a thiol-activated enzyme of a regulatory mechanism resembling the well known intrasteric inhibition of protein kinases.	Inst Biotechnol Plantes, CNRS, ERS 569, F-91405 Orsay, France; Swedish Univ Agr Sci, Ctr Biomed, Dept Mol Biol, S-75124 Uppsala, Sweden	Centre National de la Recherche Scientifique (CNRS); Swedish University of Agricultural Sciences	Miginiac-Maslow, M (corresponding author), Inst Biotechnol Plantes, CNRS, ERS 569, Batiment 630, F-91405 Orsay, France.		Ruelland, Eric/D-4863-2012					Andersson A, 1997, FEBS LETT, V400, P173, DOI 10.1016/S0014-5793(96)01382-8; Buchanan Bob B., 1994, Seminars in Cell Biology, V5, P285, DOI 10.1006/scel.1994.1035; CRETIN C, 1990, EUR J BIOCHEM, V192, P299, DOI 10.1111/j.1432-1033.1990.tb19227.x; DECOTTIGNIES P, 1988, J BIOL CHEM, V263, P11780; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; FICKENSCHER K, 1988, ARCH BIOCHEM BIOPHYS, V260, P771, DOI 10.1016/0003-9861(88)90507-3; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; HATCH MD, 1987, BIOCHIM BIOPHYS ACTA, V895, P81, DOI 10.1016/S0304-4173(87)80009-5; ISSAKIDIS E, 1993, FEBS LETT, V321, P55, DOI 10.1016/0014-5793(93)80620-A; ISSAKIDIS E, 1994, J BIOL CHEM, V269, P3511; Issakidis E, 1996, FEBS LETT, V392, P121, DOI 10.1016/0014-5793(96)00801-0; ISSAKIDIS E, 1992, J BIOL CHEM, V267, P21577; JACKSON RM, 1992, J COMPUT AID MOL DES, V6, P1, DOI 10.1007/BF00124383; JOHNSON HS, 1970, BIOCHEM J, V119, P273, DOI 10.1042/bj1190273; KELLY CA, 1993, BIOCHEMISTRY-US, V32, P3913, DOI 10.1021/bi00066a010; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMAIRE M, 1994, J BIOL CHEM, V269, P27291; MiginiacMaslow M, 1997, AUST J PLANT PHYSIOL, V24, P529, DOI 10.1071/PP97004; Riessland R, 1997, BIOL CHEM, V378, P983, DOI 10.1515/bchm.1997.378.9.983; Ruelland E, 1997, J BIOL CHEM, V272, P19851, DOI 10.1074/jbc.272.32.19851; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEIBE R, 1993, ARCH BIOCHEM BIOPHYS, V300, P635, DOI 10.1006/abbi.1993.1088; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WENER SJ, 1984, J AM CHEM SOC, V106, P765	28	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33482	33488		10.1074/jbc.273.50.33482	http://dx.doi.org/10.1074/jbc.273.50.33482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837927	hybrid			2022-12-25	WOS:000077462500057
J	Gaudet, F; Talbot, D; Leonhardt, H; Jaenisch, R				Gaudet, F; Talbot, D; Leonhardt, H; Jaenisch, R			A short DNA methyltransferase isoform restores methylation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; SEQUENCE SPECIFICITY; MURINE; EXPRESSION; GENES; REVEALS	Two murine DNA methyltransferase isoforms (MTases) have been observed, a longer form in somatic and embryonic stem (ES) cells and a shorter form in oocytes and preimplantation embryos. While the longer MTase is associated with maintenance methyltransferase activity in replicating cells, little is known about the shorter form. We present genetic and biochemical evidence that both isoforms are expressed from the same Dnmt1 gene by using different translation initiation sites in exons 1 and 4. We further demonstrate that the shorter isoform can functionally rescue Dnmt1 null ES cells that have a hypomethylated genome. These rescued ES cells differentiate in vivo into a variety of cell types, unlike the Dnmt1 null ES cells that die upon induction of differentiation. These results show that the shorter isoform can substitute for the longer maintenance MTase in ES and differentiated cells. Our data further indicate that the shorter MTase isoform found in oocytes is fully functional in vivo and may play an active role in the regulation of DNA methylation and the establishment of imprinting patterns.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Leonhardt, Heinrich/B-2791-2014					BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; CARLSON LL, 1992, GENE DEV, V6, P2536, DOI 10.1101/gad.6.12b.2536; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; CZANK A, 1991, GENE, V109, P259, DOI 10.1016/0378-1119(91)90618-L; Glickman JF, 1997, J BIOL CHEM, V272, P17851, DOI 10.1074/jbc.272.28.17851; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MANIATIS, 1989, MOL CLONING LAB MANU; Mertineit C, 1998, DEVELOPMENT, V125, P889; Obata Y, 1998, DEVELOPMENT, V125, P1553; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1998, NUCLEIC ACIDS RES, V26, P2536, DOI 10.1093/nar/26.11.2536; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; RAZIN A, 1995, HUM MOL GENET, V4, P1751, DOI 10.1093/hmg/4.suppl_1.1751; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Tucker KL, 1996, P NATL ACAD SCI USA, V93, P12920, DOI 10.1073/pnas.93.23.12920; Van den Wyngaert I, 1998, FEBS LETT, V426, P283, DOI 10.1016/S0014-5793(98)00362-7; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; Yoder JA, 1996, J BIOL CHEM, V271, P31092, DOI 10.1074/jbc.271.49.31092; Yoder JA, 1998, HUM MOL GENET, V7, P279, DOI 10.1093/hmg/7.2.279	29	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32725	32729		10.1074/jbc.273.49.32725	http://dx.doi.org/10.1074/jbc.273.49.32725			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830015	hybrid			2022-12-25	WOS:000077329100054
J	Karoor, V; Wang, L; Wang, HY; Malbon, CC				Karoor, V; Wang, L; Wang, HY; Malbon, CC			Insulin stimulates sequestration of beta-adrenergic receptors and enhanced association of beta-adrenergic receptors with Grb2 via tyrosine 350	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; PROTEIN-LINKED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; KINASE-ACTIVITY; RAT ADIPOCYTES; SH2 DOMAINS; DYNAMIN; INTERNALIZATION; PHOSPHORYLATION	G-protein-linked receptors, such as the beta(2)-adrenergic receptor, are substrates for growth factor receptors with intrinsic tyrosine kinase activity (Karoor, V,, Baltensperger, K., Paul, H,, Czech, M. P,, and Malbon C, C, (1995) J. Biol. Chem, 270, 25305-25308). In the present work, the counter-regulatory action of insulin on catecholamine action is shown to stimulate enhanced sequestration of beta(2)-adrenergic receptors in either DDT1MF-2 smooth muscle cells or Chinese hamster ovary cells stably expressing beta(2)-adrenergic receptors, Both insulin and insulin-like growth factor-1 stimulate internalization of beta-adrenergic receptors, contributing to the counter-regulatory effects of these growth factors on catecholamine action, In combination with beta-adrenergic agonists, insulin stimulates internalization of 50-60% of the complement of beta-adrenergic receptors, Insulin administration in vitro and in vivo stimulates phosphorylation of Tyr-350 of the beta-adrenergic receptor, creating an Src homology 2 domain available for binding of the adaptor molecule Grb2, The association of Grb2 with beta-adrenergic receptors was established using antibodies to Grb2 as well as a Grb2-glutathione S-transferase fusion protein. Insulin treatment of cells provokes binding of Grb2 to beta(2)-adrenergic receptors, Insulin also stimulates association of phosphatidylinositol 3-kinase and dynamin, via the Src homology 3 domain of Grb2, Both these interactions as well as internalization of the beta-adrenergic receptor are shown to be enhanced by insulin, beta-agonist, or both, The Tyr-350 --> Phe mutant form of the beta(2)-adrenergic receptor, lacking the site for tyrosine phosphorylation, fails to bind Grb2 in response to insulin, fails to display internalization of beta(2)-adrenergic receptor in response to insulin, and is no longer subject to the counter-regulatory effects of insulin on cyclic AMP accumulation. These data are the first to demonstrate the ability of a growth factor insulin to counter-regulate G-protein-Linked receptor, the beta-adrenergic receptor, via a new mechanism, Le. internalization.	SUNY Stony Brook, Hlth Sci Ctr, Dept Mol Pharmacol, Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Malbon, CC (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Mol Pharmacol, Diabet & Metab Dis Res Ctr, Stony Brook, NY 11794 USA.	craig@pharm.som.sunysb.edu	malbon, craig/ABF-3604-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025410] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25410] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1995, J BIOL CHEM, V270, P23816, DOI 10.1074/jbc.270.40.23816; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CZECH MP, 1980, J CLIN INVEST, V66, P574, DOI 10.1172/JCI109889; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; GEAHLEN RL, 1989, PEPTIDES PROTEIN PHO, P239; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; Karoor V, 1996, PROG NEUROBIOL, V48, P555, DOI 10.1016/0301-0082(96)00004-4; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; Karoor V, 1996, J BIOL CHEM, V271, P29347, DOI 10.1074/jbc.271.46.29347; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Malbon CC, 1998, CELL SIGNAL, V10, P523, DOI 10.1016/S0898-6568(97)00194-0; MOORE RH, 1995, J CELL SCI, V108, P2983; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OKADA T, 1994, J BIOL CHEM, V269, P3568; OKAMOTO M, 1993, BIOCHEM J, V290, P327, DOI 10.1042/bj2900327; QUON MJ, 1994, TRENDS ENDOCRIN MET, V5, P369, DOI 10.1016/1043-2760(94)90104-X; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shih ML, 1998, CELL SIGNAL, V10, P575, DOI 10.1016/S0898-6568(97)00195-2; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIQUETTE M, 1995, EMBO J, V14, P5542, DOI 10.1002/j.1460-2075.1995.tb00241.x; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WHITE MF, 1994, J BIOL CHEM, V269, P1; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33035	33041		10.1074/jbc.273.49.33035	http://dx.doi.org/10.1074/jbc.273.49.33035			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830057	hybrid			2022-12-25	WOS:000077329100096
J	Tse, C; Georgieva, EI; Ruiz-Garcia, AB; Sendra, R; Hansen, JC				Tse, C; Georgieva, EI; Ruiz-Garcia, AB; Sendra, R; Hansen, JC			Gcn5p, a transcription-related histone acetyltransferase, acetylates nucleosomes and folded nucleosomal arrays in the absence of other protein subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN; YEAST; ACTIVATION; REPRESSION; COMPLEX; ADA2; H4; H3	Gcn5p is the catalytic subunit of several type A histone acetyltransferases (HATs), Previous studies performed under a limited range of solution conditions have found that nucleosome core particles and nucleosomal arrays can be acetylated by Gcn5p only when it is complexed with other proteins, e,g, Gcn5-Ada, HAT-A2, and SAGA. Here we demonstrate that when assayed in buffer containing optimum concentrations of either NaCl or MgCl2, purified yeast recombinant Gcn5p (rGcn5p) efficiently acetylates both nucleosome core particles and nucleosomal arrays. Furthermore, under conditions where nucleosomal arrays are extensively folded, rGcn5p acetylates folded arrays similar to 40% faster than nucleosome core particles. Finally, rGcn5p polyacetylates the N termini of free histone H3 but only monoacetylates H3 in nucleosomes and nucleosomal arrays. These results demonstrate both that rGcn5p in and of itself is catalytically active when assayed under optimal solution conditions and that this enzyme prefers folded nucleosomal arrays as a substrate. They further suggest that the structure of the histone H3 N terminus, and concomitantly the accessibility of the H3 acetylation sites, changes upon assembly into nucleosomes and nucleosomal arrays.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Burjassot, Spain	University of Texas System; University of Texas Health San Antonio; University of Valencia	Tse, C (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Ruiz-Garcia, Ana Belen/ABB-1915-2021; Georgieva, Elena/O-1674-2019; Sendra, Ramón/K-3549-2014	Ruiz-Garcia, Ana Belen/0000-0001-5704-2138; Sendra, Ramón/0000-0002-5519-4362	NIGMS NIH HHS [GM45916] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045916, R01GM045916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Davie JR, 1997, MOL BIOL REP, V24, P197, DOI 10.1023/A:1006811817247; FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGEL P, 1993, J BIOL CHEM, V268, P1947; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZRODAS G, 1985, ARCH BIOCHEM BIOPHYS, V239, P184, DOI 10.1016/0003-9861(85)90825-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; Smith ER, 1998, NUCLEIC ACIDS RES, V26, P2948, DOI 10.1093/nar/26.12.2948; Syntichaki P, 1998, J BIOL CHEM, V273, P24414, DOI 10.1074/jbc.273.38.24414; TORDERA V, 1993, EXPERIENTIA, V49, P780, DOI 10.1007/BF01923548; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; van Holde K.E., 1988, CHROMATIN; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Walia H, 1998, J BIOL CHEM, V273, P14516, DOI 10.1074/jbc.273.23.14516; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	38	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32388	32392		10.1074/jbc.273.49.32388	http://dx.doi.org/10.1074/jbc.273.49.32388			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829967	hybrid			2022-12-25	WOS:000077329100006
J	Wu, X; Kekuda, R; Huang, W; Fei, YJ; Leibach, FH; Chen, JW; Conway, SJ; Ganapathy, V				Wu, X; Kekuda, R; Huang, W; Fei, YJ; Leibach, FH; Chen, JW; Conway, SJ; Ganapathy, V			Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake(2)) and evidence for the expression of the transporter in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINES SK-MG-1; ISOLATED RAT-HEART; FUNCTIONAL EXPRESSION; ELECTROGENIC PROPERTIES; SUBSTRATE-SPECIFICITY; TAURINE TRANSPORTER; SYSTEM; KIDNEY; (2-CHLOROETHYL)-3-SARCOSINAMIDE-1-NITROSOUREA; NORADRENALINE	We investigated the transport of cationic neurotoxins and neurotransmitters by the potential-sensitive organic transporter OCT3 and its steroid sensitivity using heterologous expression systems and also analyzed the expression of OCT3 in the brain. When expressed in mammalian cells, OCT3 mediates the uptake of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) and the neurotransmitter dopamine. Competition experiments show that several cationic neuroactive agents including amphetamines interact with OCT3, When expressed in Xenopus laevis oocytes, OCT3-mediated MPP+ uptake is associated with inward currents under voltage-clamp conditions. The MPP+-induced currents are saturable with respect to MPP+ concentration, and half-maximal saturation (K-0.5) occurs at about 25 mu M MPP+ with membrane potential clamped at -50 mV. The K-0.5 for MPP+ is markedly influenced by membrane potential. OCT3 is inhibited by several steroids, and beta-estradiol is the most potent inhibitor (K-i similar to 1 mu M). The pattern of steroid sensitivity of OCT3 is different from that of OCT1 and OCT2 but correlates significantly with that of the extraneuronal monoamine transporter (uptake(2)). The transport characteristics and steroid sensitivity provide strong evidence for the molecular identity of OCT3 as uptake,. OCT3 is expressed in the brain as evidenced from Northern blot analysis, reverse transcription-polymerase chain reaction, and in situ hybridization using OCT3-specific probes. The molecular identity of the transcript hybridizing to the probe has been established by sequencing the reverse transcription-polymerase chain reaction product and also by the isolation of the OCT3 cDNA from a brain cDNA library. Regional distribution studies with in situ hybridization show that OCT3 is expressed widely in different brain regions, especially in the hippocampus, cerebellum, and cerebral cortex, OCT3 is likely to play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.				NHLBI NIH HHS [HL 60714, HL 60104] Funding Source: Medline; NIDA NIH HHS [DA 10045] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060104, R01HL060714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010045] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BONISCH H, 1980, PHARMACOLOGY, V21, P93, DOI 10.1159/000137422; BONISCH H, 1978, N-S ARCH PHARMACOL, V303, P121, DOI 10.1007/BF00508057; Busch AE, 1996, J BIOL CHEM, V271, P32599, DOI 10.1074/jbc.271.51.32599; Busch AE, 1996, FEBS LETT, V395, P153, DOI 10.1016/0014-5793(96)01030-7; Busch AE, 1998, MOL PHARMACOL, V54, P342, DOI 10.1124/mol.54.2.342; Eisenhofer G, 1996, N-S ARCH PHARMACOL, V354, P287; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; Friedgen B, 1996, N-S ARCH PHARMACOL, V354, P275; GANAPATHY V, 1988, J BIOL CHEM, V263, P4561; GANAPATHY V, 1995, PLACENTAL TOXICOLOGY, P161; GREEFE KH, 1998, ADV PHARMACOL, V42, P360; GROHMANN M, 1984, N-S ARCH PHARMACOL, V328, P164, DOI 10.1007/BF00512067; Grundemann D, 1997, J BIOL CHEM, V272, P10408; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Huang W, 1997, INVEST OPHTH VIS SCI, V38, P1578; IVERSEN LL, 1970, BRIT J PHARMACOL, V40, P528, DOI 10.1111/j.1476-5381.1970.tb10637.x; Iverson L., 1967, UPTAKE STORAGE NORAD; KAYE AH, 1992, CURR OPIN NEUROL NEU, V5, P526; Kekuda R, 1997, AM J PHYSIOL-GASTR L, V272, pG1463, DOI 10.1152/ajpgi.1997.272.6.G1463; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Laforenza U, 1998, J MEMBRANE BIOL, V161, P151, DOI 10.1007/s002329900322; LESSER GJ, 1994, SEMIN ONCOL, V21, P220; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mackenzie B, 1996, BBA-BIOMEMBRANES, V1284, P125, DOI 10.1016/S0005-2736(96)00170-8; Martel F, 1996, N-S ARCH PHARMACOL, V354, P320; MIYAMOTO Y, 1988, AM J PHYSIOL, V255, pG85, DOI 10.1152/ajpgi.1988.255.1.G85; Noe AJ, 1996, BIOCHEM PHARMACOL, V51, P1639, DOI 10.1016/0006-2952(96)00129-3; NOE AJ, 1994, CANCER RES, V54, P1491; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PRASAD PD, 1992, J BIOL CHEM, V267, P23632; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; RAMAMOORTHY S, 1994, BIOCHEM J, V300, P893, DOI 10.1042/bj3000893; RAMAMOORTHY S, 1994, CURR EYE RES, V13, P523, DOI 10.3109/02713689408999884; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Russ H, 1996, EUR J NEUROSCI, V8, P1256, DOI 10.1111/j.1460-9568.1996.tb01294.x; SALT PJ, 1972, EUR J PHARMACOL, V20, P329, DOI 10.1016/0014-2999(72)90194-X; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Schomig E, 1998, Adv Pharmacol, V42, P356; Schweifer N, 1996, MAMM GENOME, V7, P735, DOI 10.1007/s003359900223; Seth P, 1998, J NEUROCHEM, V70, P922; SKALSKI V, 1988, CANCER CHEMOTH PHARM, V22, P137; Streich S, 1996, N-S ARCH PHARMACOL, V353, P328, DOI 10.1007/BF00168636; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; Tamai I, 1998, J BIOL CHEM, V273, P20378, DOI 10.1074/jbc.273.32.20378; Terashita S, 1998, BBA-BIOMEMBRANES, V1369, P1, DOI 10.1016/S0005-2736(97)00207-1; Trendelenburg U, 1988, HDB EXP PHARM, P279; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; Wu X, 1998, BIOCHEM BIOPH RES CO, V246, P589, DOI 10.1006/bbrc.1998.8669; Zevin S, 1997, PHARMACEUT RES, V14, P401, DOI 10.1023/A:1012022810550; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	52	297	304	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32776	32786		10.1074/jbc.273.49.32776	http://dx.doi.org/10.1074/jbc.273.49.32776			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830022	hybrid			2022-12-25	WOS:000077329100061
J	Yu, GS; Lu, YC; Gulick, T				Yu, GS; Lu, YC; Gulick, T			Co-regulation of tissue-specific alternative human carnitine palmitoyltransferase I beta gene promoters by fatty acid enzyme substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; TRANSCRIPTION FACTORS; MALONYL-COA; RETINOIC ACID; EXPRESSION; OXIDATION; HEART; RAT; MUSCLE; CARBOXYLASE	Carnitine palmitoyltransferase I (CPT-I) catalyzes the rate-determining step in mitochondrial fatty acid beta-oxidation. CPT-I has two structural genes (alpha and beta) that are differentially expressed among tissues. Our CPT-I beta isolates from a human cardiac cDNA library contained two different extreme 5'-sequences derived from short alternative first untranslated exons that utilize a common splice acceptor site in exon 2. Primer extension identified single dominant start sites for each transcript, and ribonuclease protection assays showed the presence of one 5'-exon in liver, muscle, and heart mRNAs, indicating that the cognate promoter U (upstream/ubiquitous) is active in each of these tissues. By contrast, mRNAs containing the alternative 5'-exon were present only in muscle and heart, indicating a muscle-specific promoter M (muscle). CPT-I beta mRNA levels increased markedly in tissues of fasted rats, when circulating free fatty acid concentrations are elevated. Using CPT-I beta promoter/reporter transient transfection of murine C2C12 myotubes and HepG2 hepatocyte, fatty acids were found to increase promoter activity in a peroxisome proliferator-activated receptor alpha (PPAR alpha)-dependent fashion. A promoter fatty acid response element (FARE) was mapped, mutation of which ablated fatty acid-mediated production of both transcripts. PPAR alpha/retinoid X receptor a formed specific complexes with oligonucleotides containing the FARE, and anti-PPAR alpha antibody shifted nuclear protein-DNA complexes, confirming the role of this factor in regulating the expression of this critical metabolic enzyme gene. The constitutive repressor chicken ovalbumin upstream promoter transcription factor competitively binds at the FARE and modulates fatty acid induction of the promoters.	Massachusetts Gen Hosp, Diabet Res Lab, Diabet Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Med Serv, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Gulick, T (corresponding author), Massachusetts Gen Hosp, Diabet Res Lab, Diabet Unit, MGH E,CNY 149 8218,149 13th St, Charlestown, MA 02129 USA.	gulick@helix.mgh.harvard.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD035685] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35685] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; Chatelain F, 1996, EUR J BIOCHEM, V235, P789, DOI 10.1111/j.1432-1033.1996.00789.x; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Gamble J, 1997, METABOLISM, V46, P1270, DOI 10.1016/S0026-0495(97)90229-8; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRANTHAM BD, 1986, BIOCHEM J, V239, P485, DOI 10.1042/bj2390485; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KELLY DP, 1989, J BIOL CHEM, V264, P18921; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LOPASCHUK GD, 1994, J BIOL CHEM, V269, P25871; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MCMILLIN JB, 1994, ARCH BIOCHEM BIOPHYS, V312, P375, DOI 10.1006/abbi.1994.1322; MUSCAT GEO, 1995, NUCLEIC ACIDS RES, V23, P1311, DOI 10.1093/nar/23.8.1311; Neville C, 1997, METHOD CELL BIOL, V52, P85, DOI 10.1016/S0091-679X(08)60375-1; NOTHIAS JY, 1995, J BIOL CHEM, V270, P22077, DOI 10.1074/jbc.270.38.22077; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; RANDLE PJ, 1994, DIABETOLOGIA, V37, pS155, DOI 10.1007/BF00400839; Sack MN, 1997, P NATL ACAD SCI USA, V94, P6438, DOI 10.1073/pnas.94.12.6438; SADDIK M, 1993, J BIOL CHEM, V268, P25836; SAGGERSON ED, 1981, FEBS LETT, V129, P229, DOI 10.1016/0014-5793(81)80171-8; SAGGERSON ED, 1982, FEBS LETT, V150, P177; THUMELIN S, 1994, BIOCHEM J, V300, P583, DOI 10.1042/bj3000583; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; vanderLeij FR, 1997, BBA-GENE STRUCT EXPR, V1352, P123, DOI 10.1016/S0167-4781(97)00037-7; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G; Yu GS, 1998, BIOCHEM J, V334, P225, DOI 10.1042/bj3340225; Yu GS, 1998, BBA-LIPID LIPID MET, V1393, P166, DOI 10.1016/S0005-2760(98)00075-7; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	52	89	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32901	32909		10.1074/jbc.273.49.32901	http://dx.doi.org/10.1074/jbc.273.49.32901			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830040	hybrid			2022-12-25	WOS:000077329100079
J	Engelman, JA; Lisanti, MP; Scherer, PE				Engelman, JA; Lisanti, MP; Scherer, PE			Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TUMOR-NECROSIS-FACTOR; MAP KINASE; TRANSCRIPTION FACTOR; ADIPOSE CONVERSION; PPAR-GAMMA; ECTOPIC EXPRESSION; TRANSPORT PROTEIN; CHOP GADD153; DIFFERENTIATION	SB203580 and SB202190, pyridinyl imidazoles that selectively inhibit p38 mitogen-activated protein (MAP) kinase, are widely utilized to assess the physiological roles of p38, Here, we demonstrate that treatment of 3T3-L1 fibroblasts with these p38 MAP kinase inhibitors prevents their differentiation into adipocytes as judged by an absence of lipid accumulation, a lack of expression of adipocyte-specific genes, and a fibroblastic morphological appearance. In 3T3-L1 fibroblasts and developing adipocytes, p38 is active. p38 activity decreases dramatically during later stages of differentiation. In accordance with the time course of p38 activity, p38 inhibitor treatment during only the early stages of differentiation is sufficient to block adipogenesis. In addition, we constructed a 3T3-L1 cell line harboring an inducible dominant negative p38 mutant. The induction of this dominant negative mutant of p38 prevents adipocyte differentiation. Thus, it is likely that the antiadipogenic activity of SB203580 and SB202190 is indeed due to inhibition of p38 MAP kinase, This study points out that CCAAT/enhancer-binding protein beta (C/EBP beta), a transcription factor critical for the initial stages of 3T3-L1 adipogenesis, bears a consensus site for p38 phosphorylation and serves as a substrate for p38 MAP kinase in vitro. Although the induction of C/EBP beta is not significantly altered in the presence of the p38 inhibitor, the amount of in vivo phosphorylated C/EBP beta is reduced by SB203580, The transcriptional induction of PPAR gamma, a gene whose expression is induced by C/EBP beta, and a factor critically involved in terminal differentiation of adipocytes, is impaired in the presence of p38 inhibitors. Thus, transcription factors such as C/EBP beta that promote adipocyte differentiation may be p38 targets during adipogenesis. Collectively, the data in this study suggest that p38 MAP kinase activity is important for proper 3T3-L1 differentiation.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Scherer, PE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Scherer, Philipp E/K-7819-2012; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; 	NIGMS NIH HHS [GM-50443, T32-GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443, T32GM007288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BERNLOHR DA, 1985, J BIOL CHEM, V260, P5563; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Chen KD, 1998, J BIOL CHEM, V273, P749, DOI 10.1074/jbc.273.2.749; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KASTURI I, 1982, J BIOL CHEM, V257, P12224; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Loftus TM, 1997, CURR OPIN GENET DEV, V7, P603, DOI 10.1016/S0959-437X(97)80006-8; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAWLINA W, 1989, ENDOCRINOLOGY, V125, P2049, DOI 10.1210/endo-125-4-2049; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RON D, 1992, J CLIN INVEST, V89, P223, DOI 10.1172/JCI115566; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566	65	304	313	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32111	32120		10.1074/jbc.273.48.32111	http://dx.doi.org/10.1074/jbc.273.48.32111			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822687	hybrid			2022-12-25	WOS:000077207000069
J	Janssen, RAJ; Veenstra, KG; Jonasch, P; Jonasch, E; Mier, JW				Janssen, RAJ; Veenstra, KG; Jonasch, P; Jonasch, E; Mier, JW			Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; CELLULAR-TRANSFORMATION; DIFFERENTIAL EXPRESSION; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; NRK CELLS; V-RAF; CARCINOMA; ONCOGENE	Transformation is accompanied by the down-regulation of the high molecular weight isoforms of non-muscle tropomyosin. Several lines of evidence suggest that tropomyosin down-regulation may be essential for ras-induced tumorigenicity. It is unclear which of the many signaling pathways downstream of Ras are involved in tropomyosin down-regulation. Here we demonstrate that Raf activation induces tropomyosin down-regulation comparable to that induced by Ras. Expression of the effector-domain mutant Ras-G12V;Y40C, which is unable to bind Raf, induced only modest down-modulation of tropomyosin, Treatment with the MEK-specific inhibitor PD98059 had little effect on tropomyosin levels in ras- or raf-transformed cells. In contrast, a mutant form of MEK-1, MEK-1-S2118A,S222A, restored tropomyosin levels in ras-transformed NIH3T3 cells almost to the levels observed in non-transformed cells. MEK-1-S218A,S222A does not inhibit MEK phosphorylation and is a poor inhibitor of ERK phosphorylation. These data suggest that this mutant, form of MEK-1 interferes with a yet uncharacterized pathway controlled by Raf. We conclude that the ras-induced down-modulation of tropomyosin is predominantly Raf-mediated, but MEK-independent, and that a novel pathway exists downstream of Raf which may play an important role in regulation of the cytoskeleton.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mier, JW (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, RE 302,41 Ave Louis Pasteur, Boston, MA 02115 USA.	jmier@bidmc.harvard.edu						Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Braverman RH, 1996, ONCOGENE, V13, P537; COOPER HL, 1987, CANCER RES, V47, P4493; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FRANZEN B, 1996, BRIT J CANCER, V73, P1632; GABBIANI G, 1976, AM J PATHOL, V83, P457; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; Hashimoto Y, 1996, CANCER RES, V56, P5266; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; Masuda A, 1996, ONCOGENE, V12, P2081; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Nantel A, 1998, J BIOL CHEM, V273, P10475, DOI 10.1074/jbc.273.17.10475; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Prasad SC, 1997, ELECTROPHORESIS, V18, P629, DOI 10.1002/elps.1150180348; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SEGER R, 1994, J BIOL CHEM, V269, P25699; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STAMM S, 1993, P NATL ACAD SCI USA, V90, P9857, DOI 10.1073/pnas.90.21.9857; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Syu LJ, 1997, J CELL BIOCHEM, V67, P367, DOI 10.1002/(SICI)1097-4644(19971201)67:3<367::AID-JCB8>3.3.CO;2-N; TAKENAGA K, 1988, MOL CELL BIOL, V8, P3934, DOI 10.1128/MCB.8.9.3934; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang FL, 1996, CANCER RES, V56, P3634; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wu XY, 1996, J BIOL CHEM, V271, P3265, DOI 10.1074/jbc.271.6.3265; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	45	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32182	32186		10.1074/jbc.273.48.32182	http://dx.doi.org/10.1074/jbc.273.48.32182			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822696	hybrid			2022-12-25	WOS:000077207000078
J	McGilvray, ID; Lu, Z; Wei, AC; Dackiw, APB; Marshall, JC; Kapus, A; Levy, G; Rotstein, OD				McGilvray, ID; Lu, Z; Wei, AC; Dackiw, APB; Marshall, JC; Kapus, A; Levy, G; Rotstein, OD			Murine hepatitis virus strain 3 induces the macrophage prothrombinase fgpl-2 through p38 mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR EXPRESSION; INDUCED LETHAL TOXICITY; FIBRINOGEN-LIKE PROTEIN; MAP KINASE; CARCINOEMBRYONIC ANTIGEN; PROCOAGULANT ACTIVITY; IN-VIVO; BILIARY GLYCOPROTEIN; HUMAN MONOCYTES; TYROSINE PHOSPHORYLATION	The clinical syndrome of acute liver failure produced by fulminant viral hepatitis can be reproduced in mice by infection with murine hepatitis virus strain 3 (MHV-3), Although it is clear that MHV-3-induced hepatitis depends upon macrophage activation and the expression of a specific prothrombinase, fgl-2, the signaling pathways involved in virally stimulated cell activation are unclear. Since we had previously found that MHV-3 induces the tyrosine phosphorylation of cellular proteins, we investigated the roles of the mitogen-activated protein kinase (MAPK) proteins. In a series of Western blots, immunoprecipitation and in vitro kinase assay studies, we found that both the extracellular signal-related kinase (ERR) and p38 MAPK proteins are tyrosine-phosphorylated and activated following exposure of murine peritoneal exudative macrophages (PEM) to MHV-3. Although p38 phosphorylation and activity are induced soon after MHV-3 exposure, peaking by 1-5 min, ERK phosphorylation and activity increase more gradually, peaking at 20-30 min and gradually fading thereafter. Interestingly, whereas selective p38 inhibition with SB203580 (1-20 mu M) abolished the virally stimulated induction of fgl-2 mRNA, protein, and functional activity, selective ERK inhibition with PD98059 (1-50 mu M) limited fgl-2 functional activity but had little to no effect on fgl-2 mRNA or protein levels. Moreover, whereas inhibition of ERR had no effect on p38 activity, p38 inhibition consistently increased MHV-3-induced ERK activity,To ensure that these pathways were relevant in vivo, MIN-S was injected intraperitoneally, and peritoneal exudative macrophages were collected. Again, MHV-3 exposure led to increased p38 and ERR tyrosine phosphorylation, These data argue that MHV-3 induces tightly interconnected ERR and p38 MAPK cascades in the macrophage both in vitro and in vivo. Although the ERK and p38 MAPK proteins have discordant effects at the level of fgl-2 expression, both converge at the level of its activity, suggesting that targeted MAPK inhibition may ultimately be useful in the modulation of viral hepatitis.	Toronto Hosp, Gen Div, Dept Surg, Toronto, ON M5G 2C4, Canada; Toronto Hosp, Gen Div, Dept Med, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Rotstein, OD (corresponding author), Toronto Hosp, Gen Div, Dept Surg, 200 Elizabeth St,EN9-232, Toronto, ON M5G 2C4, Canada.	ori.rotstein@utoronto.ca		McGilvray, Ian/0000-0003-4649-546X; Wei, Alice Chia-Chi/0000-0002-2505-959X				ABECASSIS M, 1987, J CLIN INVEST, V80, P881, DOI 10.1172/JCI113147; AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bouchard BA, 1997, J BIOL CHEM, V272, P9244; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; BRUMMER J, 1995, ONCOGENE, V11, P1649; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CHUNG S, 1994, IMMUNOLOGY, V83, P353; CHUNG SW, 1991, PROSTAGLANDINS, V42, P501, DOI 10.1016/0090-6980(91)90013-6; Cohen PS, 1997, MOL MED, V3, P339, DOI 10.1007/BF03401812; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; DACKIW APB, 1995, J VIROL, V69, P5824, DOI 10.1128/JVI.69.9.5824-5828.1995; Dent P, 1996, J BIOL CHEM, V271, P3119, DOI 10.1074/jbc.271.6.3119; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DURDEN DL, 1995, J IMMUNOL, V154, P4039; DVEKSLER GS, 1993, J VIROL, V67, P1; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Fingerote RJ, 1996, J VIROL, V70, P4275, DOI 10.1128/JVI.70.7.4275-4282.1996; FISHER SN, 1994, J IMMUNOL, V153, P3210; FUNG LS, 1991, J BIOL CHEM, V266, P1789; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hirano T, 1998, Int Rev Immunol, V16, P249; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEVY G, 1989, REV INFECT DIS, V11, pS712; LEVY GA, 1983, HEPATOLOGY, V3, P964; LI C, 1992, J EXP MED, V176, P689, DOI 10.1084/jem.176.3.689; LI XM, 1995, AM J PHYSIOL-CELL PH, V269, pC986, DOI 10.1152/ajpcell.1995.269.4.C986; Liu LH, 1996, BLOOD, V88, P2989, DOI 10.1182/blood.V88.8.2989.bloodjournal8882989; LIU MK, 1994, J IMMUNOL, V153, P2642; LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994; McGilvray ID, 1997, J BIOL CHEM, V272, P10287; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; NEDELLEC P, 1994, J VIROL, V68, P4525; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAPPAS SC, 1995, GASTROENTEROL CLIN N, V24, P161; PARR RL, 1995, J VIROL, V69, P5033, DOI 10.1128/JVI.69.8.5033-5038.1995; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; POPE M, 1995, J VIROL, V69, P5252, DOI 10.1128/JVI.69.9.5252-5260.1995; Popik W, 1996, MOL CELL BIOL, V16, P6532; Pouliot M, 1997, J IMMUNOL, V158, P4930; Ridley SH, 1997, J IMMUNOL, V158, P3165; RUEGG C, 1995, GENE, V160, P257, DOI 10.1016/0378-1119(95)00240-7; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SEKIYA F, 1994, J BIOL CHEM, V269, P32441; Sevransky JE, 1997, J CLIN INVEST, V99, P1966, DOI 10.1172/JCI119364; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; SKUBITZ KM, 1993, FEBS LETT, V318, P200, DOI 10.1016/0014-5793(93)80021-L; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Suzuki H, 1998, BIOCHEM BIOPH RES CO, V242, P697, DOI 10.1006/bbrc.1997.8040; Vanichkin A, 1996, J INFECT DIS, V173, P927, DOI 10.1093/infdis/173.4.927; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397	66	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32222	32229		10.1074/jbc.273.48.32222	http://dx.doi.org/10.1074/jbc.273.48.32222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822700	hybrid			2022-12-25	WOS:000077207000082
J	Berry, L; Stafford, A; Fredenburgh, J; O'Brodovich, H; Mitchell, L; Weitz, J; Andrew, M; Chan, AKC				Berry, L; Stafford, A; Fredenburgh, J; O'Brodovich, H; Mitchell, L; Weitz, J; Andrew, M; Chan, AKC			Investigation of the anticoagulant mechanisms of a covalent antithrombin-heparin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT HEPARINS; DERMATAN SULFATE; ANTI-THROMBIN; BINDING; PHARMACOKINETICS; INHIBITOR	Recently, we developed a covalent antithrombin-heparin complex (ATH) as a possible treatment for respiratory distress syndrome. ATH reacted rapidly with thrombin and efficiently catalyzed the inhibition of either thrombin or factor Xa by exogenous antithrombin, In order to investigate mechanisms for the conjugate's unusual anticoagulant properties, changes in fluorescence due to covalent linkage or addition of exogenous antithrombin were studied in relation to reaction with thrombin derivatives or factor Xa. The emission spectrum of ATH was similar to that of antithrombin plus heparin mixtures. ATH quickly inhibited thrombin or factor Xa activities, as measured by a fluorogenic substrate. Fluorescein-labeled heparin was displaced from either thrombin or active site blocked thrombin by ATH, indicating that thrombin must bind to the conjugate's heparin moiety. Interaction of thrombin with ATH's heparin component was confirmed by a slow reaction rate of conjugate with a thrombin mutant that has weak heparin binding. Total intrinsic fluorescence increased when exogenous antithrombin was added to ATH, indicating that the catalytic mechanism may occur through a second inhibitor binding site. Thus, ATH reacts directly with thrombin through a bridge mechanism and probably catalyzes the reaction of thrombin with antithrombin by a second binding sequence on its heparin chain.	Hamilton Civ Hosp, Res Ctr, Henderson Gen Div, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; Univ Toronto, Hosp Sick Children, Res Inst,Resp Res Div, Dept Pediat,Med Res Council,Grp Dev Lung Biol, Toronto, ON M5G 1X8, Canada	McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Chan, AKC (corresponding author), Hamilton Civ Hosp, Res Ctr, Henderson Gen Div, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Chan, Anthony K. C./AAR-8892-2021; Weitz, Jeffrey/AAD-1929-2019	Chan, Anthony K. C./0000-0003-1551-3995; Weitz, Jeffrey/0000-0002-1092-7550				BACHOFEN M, 1982, CLIN CHEST MED, V3, P35; BARA L, 1985, THROMB RES, V39, P631, DOI 10.1016/0049-3848(85)90244-0; BARRITT DW, 1960, LANCET, V1, P1309; BENDAYAN P, 1994, THROMB HAEMOSTASIS, V71, P576; Bergqvist D, 1996, J INTERN MED, V240, P63, DOI 10.1046/j.1365-2796.1996.494834000.x; Chan A, 1997, J BIOL CHEM, V272, P22111, DOI 10.1074/jbc.272.35.22111; Chan AKC, 1998, AM J PHYSIOL-LUNG C, V274, pL914, DOI 10.1152/ajplung.1998.274.6.L914; Dietze EC, 1996, BIOCHEMISTRY-US, V35, P6745, DOI 10.1021/bi9530346; ESTES JW, 1969, CLIN PHARMACOL THER, V10, P329; FUKUDA Y, 1987, AM J PATHOL, V126, P171; GETTINS P, 1992, J BIOL CHEM, V267, P21946; GITLIN D, 1956, PEDIATRICS, V17, P64; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; Hirsh J., 1994, HEMOSTASIS THROMBOSI, P1346; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFOREST MD, 1991, BRIT J HAEMATOL, V77, P201, DOI 10.1111/j.1365-2141.1991.tb07978.x; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MILLE B, 1994, J BIOL CHEM, V269, P29435; OFOSU FA, 1987, BIOCHEM J, V248, P889, DOI 10.1042/bj2480889; OLSON ST, 1981, J BIOL CHEM, V256, P1065; PETERSEN LC, 1983, BIOCHEM J, V211, P91, DOI 10.1042/bj2110091; PLETCHER CH, 1982, J BIOL CHEM, V257, P5342; ROSENBERG RD, 1979, BIOCHEM BIOPH RES CO, V86, P1319, DOI 10.1016/0006-291X(79)90260-2; SEEGER W, 1985, J APPL PHYSIOL, V58, P326, DOI 10.1152/jappl.1985.58.2.326; STOWELL C, 1980, ADV CARBOHYD CHEM BI, V37, P242; TIMPERMAN AT, 1995, ANAL CHEM, V67, P3421, DOI 10.1021/ac00115a009; WRIGHT CJ, 1981, CAN J SURG, V24, P130; YE J, 1994, J BIOL CHEM, V269, P17965	29	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34730	34736		10.1074/jbc.273.52.34730	http://dx.doi.org/10.1074/jbc.273.52.34730			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856996	hybrid			2022-12-25	WOS:000077719700014
J	Cui, L; Yu, WP; Pallen, CJ				Cui, L; Yu, WP; Pallen, CJ			Insulin secretagogues activate the secretory granule receptor-like protein-tyrosine phosphatase IAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PANCREATIC-ISLETS; NORMAL MOUSE ISLETS; BETA-CELLS; MOLECULAR-CLONING; TUMOR PROMOTER; KINASE-II; GLUCOSE; AUTOANTIGEN; RELEASE; LANGERHANS	To investigate the potential role of protein-tyrosine phosphatases (PTPs) in regulated secretion, cellular PTP activity was measured in pancreatic beta cell lines after exposure to insulin secretagogues. A peak, of elevated PTP activity was detected in whole cell lysates after 15-20 min of treatment of the cells with high KCl, glucose, or TPA, which did not appear upon treatment with control compounds. Neither was it detected in cells that do not undergo regulated secretion. The PTP activation was transient, SDS-resistant, and localized to the cytoskeleton fraction of cells. The cytoskeletal localization of IAR, a receptor-like PTP associated with secretory granules of neuroendocrine cells, suggested the possibility that IAR is the secretagogue-activated PTP, The transient expression of human IAR in beta TC3 and HIT-T15 beta cells, followed by treatment with secretagogues or control compounds and immunoprecipitation of human IAR, showed that immunoprecipitates from the secretagogue-treated cells contained an elevated PTP activity. The secretagogue-induced activation of LAR had identical kinetics to that of the endogenous PTP, Although ectopic IAR was present in membrane and cytoskeletal fractions from the cells, only the cytoskeleton-associated IAR could be activated. Thus IAR represents the endogenous secretagogue-responsive PTP, or at least a component of it, and is one of the few receptor-like PTPs for which enzymatic activation has been demonstrated. Insulin secretion is detected prior to IAR activation, suggesting that IAR is not required for immediate secretion but likely plays a role in events downstream of insulin secretion or in another pathway related to the specialized function of secretory cells.	Inst Mol & Cell Biol, Cell Regulat Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Pallen, CJ (corresponding author), Inst Mol & Cell Biol, Cell Regulat Lab, 30 Med Dr, Singapore 117609, Singapore.			Pallen, Catherine/0000-0002-3576-5295				AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ASHCROFT SJ, 1994, DIABETOLOG, V37, P21; Atwater Illani, 1996, P78; Chiang MK, 1996, DEVELOPMENT, V122, P2239; COLCA JR, 1983, BIOCHEM J, V212, P819, DOI 10.1042/bj2120819; Cui L, 1996, J BIOL CHEM, V271, P24817, DOI 10.1074/jbc.271.40.24817; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; EASOM RA, 1989, BIOCHEM J, V264, P27, DOI 10.1042/bj2640027; FAGIN JA, 1987, DIABETES, V36, P1448, DOI 10.2337/diabetes.36.12.1448; Fitzgerald LR, 1997, J NEUROCHEM, V68, P1820; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; HOWELL SL, 1994, DIABETOLOGIA, V37, P30; HUTTON JC, 1984, BIOCHEM J, V249, P825; Johnson John H., 1996, P42; Jonas JC, 1996, BIOCHEM J, V315, P49, DOI 10.1042/bj3150049; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; Konrad RJ, 1996, J BIOL CHEM, V271, P24179, DOI 10.1074/jbc.271.39.24179; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; LI GD, 1994, MOL BIOL CELL, V5, P1199, DOI 10.1091/mbc.5.11.1199; Lim KL, 1997, EUR J BIOCHEM, V245, P693, DOI 10.1111/j.1432-1033.1997.00693.x; Lu J, 1996, P NATL ACAD SCI USA, V93, P2307, DOI 10.1073/pnas.93.6.2307; Malaisse W., 1996, DIABETES REV, P145; MALAISSE WJ, 1980, CANCER RES, V40, P3827; Metz Stewart A., 1996, P57; Mohlig M, 1997, ENDOCRINOLOGY, V138, P2577, DOI 10.1210/en.138.6.2577; PERSAUD SJ, 1990, BIOCHEM BIOPH RES CO, V173, P833, DOI 10.1016/S0006-291X(05)80862-9; RABIN DU, 1994, J IMMUNOL, V152, P3183; RATCLIFF H, 1993, BIOCHIM BIOPHYS ACTA, V1175, P188, DOI 10.1016/0167-4889(93)90022-H; Robertson R. Paul, 1996, P49; ROOME J, 1988, BIOCHEM J, V256, P493, DOI 10.1042/bj2560493; Smith PD, 1996, BIOCHEM BIOPH RES CO, V229, P402, DOI 10.1006/bbrc.1996.1817; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; VIRJI MAG, 1978, ENDOCRINOLOGY, V102, P706, DOI 10.1210/endo-102-3-706; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wasmeier C, 1996, J BIOL CHEM, V271, P18161, DOI 10.1074/jbc.271.30.18161; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; ZAWALICH WS, 1996, DIABETES REV, V4, P160; ZHANG A, 1991, J BIOL CHEM, V266, P21649; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	41	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34784	34791		10.1074/jbc.273.52.34784	http://dx.doi.org/10.1074/jbc.273.52.34784			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857003	hybrid			2022-12-25	WOS:000077719700021
J	Garcia, AJ; Takagi, J; Boettiger, D				Garcia, AJ; Takagi, J; Boettiger, D			Two-stage activation for alpha(5)beta(1) integrin binding to surface-adsorbed fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; HUMAN-PLATELETS; BETA-SUBUNIT; RECEPTOR; ALPHA-5-BETA-1; AFFINITY; HETERODIMERS; SUPPRESSION; MODULATION; ANTIBODIES	By analyzing the functional binding of alpha(5)beta(1) integrin to adsorbed fibronectin in intact cells, we demonstrate that integrin activation results in linear increases in adhesion strength as a function of ligand density, suggesting that modulation of the receptor-ligand interaction is the dominant mechanism for adhesion during the initial stages of adhesion and that cooperative binding contributes little to initial adhesion strength. Using this experimental framework, we show the existence of three distinct activation states for alpha(5)beta(1) integrin binding to adsorbed fibronectin for both passive, antibody-induced and active, cell-controlled activation. During the initial phase of adhesion, alpha(5)beta(1) integrin is activated in an energy-dependent process from the nonbinding ground state to an intermediate state in which the receptor binds fibronectin and provides significant mechanical coupling. In later stages of adhesion maturation, alpha(5)beta(1) integrin is activated to a higher binding state, which provides significant increases in adhesion strength compared with the intermediate state. These multiple binding states most likely result from different integrin conformations and reflect distinct interactions between alpha(5)beta(1) and sites on adsorbed fibronectin, Multiple activation states for alpha(5)beta(1) suggest the existence of distinct stages in adhesion signaling and strengthening and can provide a versatile mechanism for the regulation of adhesive interactions.	Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Tokyo Inst Technol, Dept Sci Biol, Yokohama, Kanagawa 227, Japan	University of Pennsylvania; Tokyo Institute of Technology	Garcia, AJ (corresponding author), Georgia Inst Technol, Sch Mech Engn, 281 Ferst Dr NW, Atlanta, GA 30332 USA.							ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AOTA S, 1994, J BIOL CHEM, V269, P24756; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DEMBO M, 1988, PROC R SOC SER B-BIO, V234, P55, DOI 10.1098/rspb.1988.0038; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EVANS EA, 1985, BIOPHYS J, V48, P185, DOI 10.1016/S0006-3495(85)83771-1; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FUJIMOTO T, 1982, J CLIN INVEST, V69, P1212, DOI 10.1172/JCI110560; Garcia AJ, 1997, BIOMATERIALS, V18, P1091, DOI 10.1016/S0142-9612(97)00042-2; Garcia AJ, 1998, J BIOL CHEM, V273, P10988, DOI 10.1074/jbc.273.18.10988; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KUO SC, 1993, BIOPHYS J, V65, P2191, DOI 10.1016/S0006-3495(93)81277-3; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; SCHOEN RC, 1982, HYBRIDOMA, V1, P99, DOI 10.1089/hyb.1.1982.1.99; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMYTH SS, 1993, BLOOD, V81, P2827; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TAKAGI J, 1997, J BIOCHEM-TOKYO, V121, P111; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	29	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34710	34715		10.1074/jbc.273.52.34710	http://dx.doi.org/10.1074/jbc.273.52.34710			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856993	hybrid			2022-12-25	WOS:000077719700011
J	Keryer, G; Yassenko, M; Labbe, JC; Castro, A; Lohmann, SM; Evain-Brion, D; Tasken, K				Keryer, G; Yassenko, M; Labbe, JC; Castro, A; Lohmann, SM; Evain-Brion, D; Tasken, K			Mitosis-specific phosphorylation and subcellular redistribution of the RII alpha regulatory subunit of cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY BINDING-PROTEIN; GOLGI-COMPLEX; SUBSTRATE-SPECIFICITY; STARFISH OOCYTES; HUMAN-CELLS; CYCLIN-B; INHIBITOR; BETA; IDENTIFICATION; PHOSPHATASES	Phosphorylation of the RII regulatory subunits of cyclic AMP-dependent protein kinases (PKAs) was examined during the HeLa cell cycle. Three RII alpha isoforms of 51, 54, and 57 kDa were identified by RII alpha immunodetection and labeling with 8-azido[P-32]cAMP in different cell cycle phases. These isoforms were characterized as different phosphorylation states by the use of selective PKA and cyclin-directed kinase inhibitors. Whereas RII alpha autophosphorylation by PKA caused RII alpha to shift from 51 to 54 kDa, phosphorylation of RII alpha by one other or a combination of several kinases activated during ;mitosis caused RII alpha to shift from 51 to 57 kDa. In vivo incorporation of [P-32]orthophosphate into mitotic cells and RII alpha immunoprecipitation demonstrated that RII alpha was hyperphosphorylated on a different site than the one phosphorylated by PRA, Deletion and mutation analysis demonstrated that the cyclin B-p34(cdc2) kinase (CDK1) phosphorylated human recombinant RII alpha in vitro on Thr(54). Whereas RII alpha was associated with the Golgi-centrosomal region during interphase, it was dissociated from its centrosomal localization at metaphase-anaphase transition. Furthermore, particulate RII alpha from HeLa cell extracts was solubilized following incubation with CDK1 in vitro, Our results suggest that at the onset of mitosis, CDK1 phosphorylates RII alpha, and this may alter its subcellular localization.	Univ Paris 05, Fac Sci Pharmaceut & Biol, INSERM, U427, F-75270 Paris 06, France; Univ Oslo, Inst Med Biochem, N-0317 Oslo, Norway; Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; CNRS, Ctr Rech Biochim Macromol, F-34033 Montpellier 1, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Oslo; University of Wurzburg; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Keryer, G (corresponding author), Univ Paris 05, Fac Sci Pharmaceut & Biol, INSERM, U427, 4 Ave Observ, F-75270 Paris 06, France.	keryer@pharmacie.univ-paris5.fr	CASTRO, ANNA/F-4350-2010; labbe, jean-claude/B-2277-2009	CASTRO, ANNA/0000-0002-3655-1352; Tasken, Kjetil/0000-0003-2841-4697				ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BOSC DG, 1995, J BIOL CHEM, V270, P25872, DOI 10.1074/jbc.270.43.25872; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN RK, 1991, ARCH BIOCHEM BIOPHYS, V289, P187, DOI 10.1016/0003-9861(91)90460-Z; CARMICHAEL DF, 1982, J BIOL CHEM, V257, P440; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COGHLAN VM, 1995, BIOCHEM SOC T, V23, P592, DOI 10.1042/bst0230592; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; DELLACQUA M, 1977, J BIOL CHEM, V272, P12881; ERLICHMAN J, 1983, METHOD ENZYMOL, V99, P176; FANTES P, 1993, CELL CYCLE; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; GRIFFITHS G, 1990, J CELL SCI, V96, P691; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1991, METHOD ENZYMOL, V200, P291; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LOHMANN SM, 1980, J BIOL CHEM, V255, P9985; MARCUS S, 1995, PROTEIN KINASE FACTS, P67; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MARSHAK DR, 1991, J CELL BIOCHEM, V45, P391, DOI 10.1002/jcb.240450413; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OYEN O, 1989, FEBS LETT, V246, P57, DOI 10.1016/0014-5793(89)80253-4; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P1037, DOI 10.1073/pnas.78.2.1037; SCOTT CW, 1985, J BIOL CHEM, V260, P2274; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; STUART RA, 1993, J BIOL CHEM, V268, P4050; TAKIO K, 1980, FEBS LETT, V114, P83, DOI 10.1016/0014-5793(80)80865-9; TASKEN K, 1993, J BIOL CHEM, V268, P21276; TASKEN K, 1995, PROTEIN KINASE FACTS, P58; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; VEREB G, 1986, FEBS LETT, V197, P139, DOI 10.1016/0014-5793(86)80314-3; WALTER U, 1977, J BIOL CHEM, V252, P6494; WEBER W, 1982, BIOCHEM BIOPH RES CO, V104, P1134, DOI 10.1016/0006-291X(82)91368-7; Woodgett J.R., 1994, PROTEIN KINASES; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; ZEILIG CE, 1976, J CELL BIOL, V71, P515, DOI 10.1083/jcb.71.2.515	52	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34594	34602		10.1074/jbc.273.51.34594	http://dx.doi.org/10.1074/jbc.273.51.34594			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852131	hybrid			2022-12-25	WOS:000077542200097
J	Miki, E; Eddy, EM				Miki, E; Eddy, EM			Identification of tethering domains for protein kinase A type I alpha regulatory subunits on sperm fibrous sheath protein FSC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORING PROTEINS; MOUSE SPERM; TARGETED DISRUPTION; EPIDIDYMAL SPERM; BINDING-PROTEINS; BETA SUBUNIT; RAT SPERM; LOCALIZATION; CELLS; CDNA	The fibrous sheath is a unique cytoskeletal structure in the sperm flagellum believed to modulate sperm motility. FSC1 is the major structural protein of the fibrous sheath. The yeast two-hybrid system was used to identify other proteins that contribute to the structure of the fibrous sheath or participate in sperm motility. When FSC1 was used as the bait to screen a mouse testis cDNA library, two clones were isolated encoding the type I alpha regulatory subunit (RI alpha) of cAMP-dependent protein kinase. Deletion analysis using the yeast two-hybrid system and in vitro binding assays with glutathione S-transferase-FSC1 fusion proteins identified two RI alpha tethering domains on FSC1. A domain located at residues 219-232 (termed domain A) corresponds to the reported tethering domain for a type II regulatory subunit (RII) of cAMP-dependent protein kinase, indicating that this binding domain has dual specificity to RI and RII. Another RI alpha tethering site (termed domain B) at residues 335-344 shows specific binding of RI alpha and had no significant sequence homology with known RII tethering domains. However, helical wheel projection analysis indicates that domain B is likely to form an amphipathic helix, the secondary structure of RII tethering domains of protein kinase A anchoring proteins. This was supported by the finding that site-directed mutagenesis to disrupt the amphipathic helix eliminated RI alpha binding. This is apparently the first report of an RI alpha-specific protein kinase A anchoring protein tethering domain.	NIEHS, Gamete Biol Grp, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eddy, EM (corresponding author), NIEHS, Gamete Biol Grp, Reprod & Dev Toxicol Lab, NIH, MD C4-01, Res Triangle Pk, NC 27709 USA.	eddy@niehs.nih.gov						Bradley MP, 1996, MOL REPROD DEV, V44, P452, DOI 10.1002/(SICI)1098-2795(199608)44:4&lt;452::AID-MRD4&gt;3.0.CO;2-K; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BRANDT H, 1980, J BIOL CHEM, V255, P982; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Bunch DO, 1998, BIOL REPROD, V58, P834, DOI 10.1095/biolreprod58.3.834; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; DEVILLER P, 1984, MOL CELL ENDOCRINOL, V38, P21, DOI 10.1016/0303-7207(84)90141-2; Eddy E. M., 1994, P29; EDDY EM, 1991, ANN NY ACAD SCI, V637, P224, DOI 10.1111/j.1749-6632.1991.tb27312.x; FULCHER KD, 1995, MOL REPROD DEV, V42, P415, DOI 10.1002/mrd.1080420407; FULCHER KD, 1995, BIOL REPROD, V52, P41, DOI 10.1095/biolreprod52.1.41; Garbers D L, 1980, Adv Cyclic Nucleotide Res, V13, P251; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOROWITZ JA, 1984, J BIOL CHEM, V259, P832; HOROWITZ JA, 1988, J BIOL CHEM, V263, P2098; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Huang LJS, 1997, P NATL ACAD SCI USA, V94, P11184, DOI 10.1073/pnas.94.21.11184; ImaizumiScherrer T, 1996, J CELL BIOL, V134, P1241, DOI 10.1083/jcb.134.5.1241; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DC, 1983, P NATL ACAD SCI-BIOL, V80, P3608, DOI 10.1073/pnas.80.12.3608; LEISER M, 1986, J BIOL CHEM, V261, P1904; LINDEMANN CB, 1992, J CELL SCI, V102, P249; MACLEOD J, 1994, EUR J BIOCHEM, V225, P107, DOI 10.1111/j.1432-1033.1994.00107.x; Moos J, 1998, MOL REPROD DEV, V50, P79, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;79::AID-MRD10&gt;3.0.CO;2-T; Mori C, 1998, MOL REPROD DEV, V49, P374, DOI 10.1002/(SICI)1098-2795(199804)49:4&lt;374::AID-MRD4&gt;3.0.CO;2-K; PRINTEN JA, 1994, GENETICS, V138, P609; Robinson ML, 1996, ARCH BIOCHEM BIOPHYS, V330, P181, DOI 10.1006/abbi.1996.0240; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; SI YM, 1993, EXP CELL RES, V208, P170, DOI 10.1006/excr.1993.1235; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; TASH JS, 1984, CELL, V38, P551, DOI 10.1016/0092-8674(84)90509-9; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768	43	84	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34384	34390		10.1074/jbc.273.51.34384	http://dx.doi.org/10.1074/jbc.273.51.34384			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852104	hybrid			2022-12-25	WOS:000077542200070
J	Okuwaki, M; Nagata, K				Okuwaki, M; Nagata, K			Template activating factor-I remodels the chromatin structure and stimulates transcription from the chromatin template	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2A; MAJOR LATE PROMOTER; HISTONE ACETYLATION; REPLICATION FACTOR; ADENOVIRUS GENOME; GENE-EXPRESSION; DNA-REPLICATION; SET; LEUKEMIA; COMPLEX	To study the mechanisms of replication and transcription on chromatin, we have been using the adenovirus DNA complexed with viral basic core proteins, called Ad core. We have identified template activating factor (TAF)-I from uninfected HeLa cells as the factor that stimulates replication and transcription from the Ad core. The nuclease sensitivity assays have revealed that TAF-I remodels the Ad core, thereby making transcription and replication apparatus accessible to the template DNA To examine whether TAF-I remodels the chromatin consisting of histones, the chromatin structure was reconstituted on the DNA fragment with core histones by the salt dialysis method. The transcription from the reconstituted chromatin was completely repressed, while TAF-I remodeled the chromatin and stimulated the transcription. TAF-I was found to interact with histones. Furthermore, it was shown that TAF-I is capable not only of disrupting the chromatin structure but also of preventing the formation of DNA-histone aggregation and transferring histones to naked DNA. The possible function of TAF-I in conjunction with a histone chaperone activity is discussed.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Nagata, K (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	knagata@bio.titech.ac.jp	Okuwaki, Mitsuru/R-3038-2019	Okuwaki, Mitsuru/0000-0003-2118-442X				ADACHI Y, 1994, FEBS LETT, V340, P231, DOI 10.1016/0014-5793(94)80144-4; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; CORDEN J, 1976, P NATL ACAD SCI USA, V73, P401, DOI 10.1073/pnas.73.2.401; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hampsey M, 1997, TRENDS GENET, V13, P427, DOI 10.1016/S0168-9525(97)01292-4; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JANSENDURR P, 1989, J VIROL, V63, P5124, DOI 10.1128/JVI.63.12.5124-5132.1989; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kawase H, 1996, GENES CELLS, V1, P1045, DOI 10.1046/j.1365-2443.1996.d01-223.x; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; MATSUMOTO K, 1995, J BIOL CHEM, V270, P9645, DOI 10.1074/jbc.270.16.9645; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; MONDESERT G, 1991, NUCLEIC ACIDS RES, V19, P3221, DOI 10.1093/nar/19.12.3221; Nagata K, 1998, EXP CELL RES, V240, P274, DOI 10.1006/excr.1997.3930; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TATE VE, 1979, NUCLEIC ACIDS RES, V6, P2769, DOI 10.1093/nar/6.8.2769; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	39	107	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34511	34518		10.1074/jbc.273.51.34511	http://dx.doi.org/10.1074/jbc.273.51.34511			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852120	hybrid			2022-12-25	WOS:000077542200086
J	Ramos, JW; Kojima, TK; Hughes, PE; Fenczik, CA; Ginsberg, MH				Ramos, JW; Kojima, TK; Hughes, PE; Fenczik, CA; Ginsberg, MH			The death effector domain of PEA-15 is involved in its regulation of integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; R-RAS; SIGNAL-TRANSDUCTION; APOPTOSIS; PHOSPHOPROTEIN; SPECIFICITY; EXPRESSION; MODULATION; SUBSTRATE; INTERACTS	Increased integrin ligand binding affinity (activation) is triggered by intracellular signaling events. A Ras-initiated mitogen-activated protein kinase pathway suppresses integrin activation in fibroblasts. We used expression cloning to isolate cDNAs that prevent Ras suppression of integrin activation. Here, we report that PEA-15, a small death effector domain (DED)-containing protein, blocks Pas suppression. PEA-15 does not block the capacity of Has to activate the ERK mitogen-activated protein kinase pathway. Instead, it inhibits suppression via a pathway blocked by a dominant-negative form of the distinct small GTPase, R-Ras. Heretofore, all known DEDs functioned in the regulation of apoptosis. In contrast, the DED of PEA-15 is essential for its capacity to reverse suppression of integrin activation. Thus, certain DED-containing proteins can regulate integrin activation as opposed to apoptotic protease cascades.	Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-2,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ginsberg@scripps.edu	Ramos, Joe/G-4074-2010	Ramos, Joe/0000-0002-9708-2115	NATIONAL CANCER INSTITUTE [F32CA074529] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA074529-01, F32 CA074529] Funding Source: Medline; PHS HHS [12067] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Baker EK, 1997, P NATL ACAD SCI USA, V94, P1973, DOI 10.1073/pnas.94.5.1973; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Estelles A, 1996, J BIOL CHEM, V271, P14800, DOI 10.1074/jbc.271.25.14800; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kubes M, 1998, J NEUROCHEM, V71, P1307; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Ramos JW, 1996, DEVELOPMENT, V122, P2873; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	43	78	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33897	33900		10.1074/jbc.273.51.33897	http://dx.doi.org/10.1074/jbc.273.51.33897			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852038	hybrid			2022-12-25	WOS:000077542200004
J	Zhang, Y; Willson, T; Metcalf, D; Cary, D; Hilton, DJ; Clark, R; Nicola, NA				Zhang, Y; Willson, T; Metcalf, D; Cary, D; Hilton, DJ; Clark, R; Nicola, NA			The box-1 region of the leukemia inhibitory factor receptor alpha-chain cytoplasmic domain is sufficient for hemopoietic cell proliferation and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; IL-6 SIGNAL TRANSDUCER; CILIARY NEUROTROPHIC FACTOR; GROWTH-FACTOR RECEPTOR; ONCOSTATIN-M RECEPTOR; C-KIT RECEPTOR; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODY; STAT3 ACTIVATION	Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that acts on a variety of cell types and regulates cell proliferation and differentiation. The functional receptor for LIF is composed of LIFR alpha-chain (LIFR alpha) and gp130 both of which are shared in the functional receptors for oncostatin M, ciliary neurotrophic factor, and cardiotrophin-1. By using stable transfection of wildtype or cytoplasmic deletion mutants of LIFR alpha together with full-length gp130 into Ba/F3 cells, we found that cells expressing gp130 and an extensively deleted mutant LIFR alpha containing only the box-1 region were capable of proliferating in response to LIF, although LIF-dependent long term growth of these cells was seriously impaired. Using a similar strategy to generate WEHI-3BD+ cells expressing gp130 and wild-type or truncation mutants of LIFR alpha, studies revealed that the box-1 region of the LIFR alpha was also sufficient for LIF-dependent induction of different aspects of differentiation, including up-regulation of macrophage surface marker expression, morphological change, and cell migration in agar culture. However, the C-terminal region of the LIFR alpha although not essential for intracellular signaling, was important for efficient receptor-mediated ligand internalization. In summary, the membrane-proximal box-1 region plays a dominant role in LIF-induced signal transduction of both proliferation and differentiation.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Nicola, NA (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	nicola@wehi.edu.au	Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889	NCI NIH HHS [CA22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; Benigni F, 1996, BLOOD, V87, P1851, DOI 10.1182/blood.V87.5.1851.bloodjournal8751851; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; Gommerman JL, 1997, J BIOL CHEM, V272, P30519, DOI 10.1074/jbc.272.48.30519; Govers P, 1998, J BIOL CHEM, V273, P16426, DOI 10.1074/jbc.273.26.16426; GUILBERT LJ, 1986, J BIOL CHEM, V261, P4024; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HILTON DJ, 1992, J BIOL CHEM, V267, P10238; Ihle JN, 1996, ADV CANCER RES, V68, P23, DOI 10.1016/S0065-230X(08)60351-6; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1979, INT J CANCER, V24, P616, DOI 10.1002/ijc.2910240515; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; METCALF D, 1989, LEUKEMIA, V3, P349; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOREAU JF, 1987, J IMMUNOL, V138, P3844; MOREAU JF, 1986, ANN INST PASTEUR IMM, VC137, P25, DOI 10.1016/S0771-050X(86)80003-1; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYERS AC, 1987, J BIOL CHEM, V262, P6494; NICOLA NA, 1997, GROW FACT CYTOK  A&B, V2, P613; NICOLA NA, 1988, GROWTH FACTORS, V1, P40; Nicola NA, 1988, GROWTH FACTORS, V1, P29, DOI 10.3109/08977198809000244; NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; Subtil A, 1998, EUR J BIOCHEM, V253, P525, DOI 10.1046/j.1432-1327.1998.2530525.x; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Thiel S, 1998, BIOCHEM J, V330, P47, DOI 10.1042/bj3300047; TOMIDA M, 1995, BLOOD, V85, P217, DOI 10.1182/blood.V85.1.217.bloodjournal851217; VANDAMME J, 1992, EUR J IMMUNOL, V22, P2801, DOI 10.1002/eji.1830221108; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Ware MF, 1997, J BIOL CHEM, V272, P30185, DOI 10.1074/jbc.272.48.30185; YEE NS, 1994, J BIOL CHEM, V269, P31991; Zhang JG, 1997, BIOCHEM J, V325, P693, DOI 10.1042/bj3250693; ZHANG XG, 1994, J EXP MED, V179, P1337, DOI 10.1084/jem.179.4.1337	67	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34370	34383		10.1074/jbc.273.51.34370	http://dx.doi.org/10.1074/jbc.273.51.34370			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852103	hybrid			2022-12-25	WOS:000077542200069
J	Chai, SH; Welch, TJ; Crosa, JH				Chai, SH; Welch, TJ; Crosa, JH			Characterization of the interaction between Fur and the iron transport promoter of the virulence plasmid in Vibrio anguillarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPTAKE REGULATION PROTEIN; OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; GENETIC-DETERMINANTS; ANTISENSE RNA; UPTAKE SYSTEM; BINDING; DNA; EXPRESSION	The expression of iron transport genes fatDCBA in Vibrio anguillarum strain 775 is negatively regulated by two iron-responsive repressors, the Fur protein and the antisense RNA, RNA alpha. Here we report the identification of the promoter for the iron transport genes and studied the interaction between the V. anguillarum Fur protein and this promoter. The iron transport promoter was localized in a region approximately 300 base pairs upstream of fatD by both primer extension and S1 mapping analysis. High activity of the promoter was measured in response to iron depletion in the wild-type strain when a promoter-lacZ fusion was examined, whereas the promoter was constitutive in the Fur-deficient strain. Gel retardation and DNase I fool;print analysis showed that Fur binds specifically to two contiguous sites comprising the promoter region and the region downstream of the transcription start site. The identified Fur binding sites showed a low degree of homology to each other as well as to the consensus sequence for the Escherichia coli Fur protein. DNase I footprints pattern suggested a sequential interaction of Fur with these two sites that renders a protection in the template strand and a hyper sensitivity to the nuclease in the nontemplate strand. The periodicity of the hypersensitive sites suggested that the promoter DNA undergoes a structural change upon binding to Fur, which might play a role in the repression of gene expression.	Oregon Hlth Sci Univ, Sch Med L 220, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	Oregon Health & Science University	Crosa, JH (corresponding author), Oregon Hlth Sci Univ, Sch Med L 220, Dept Mol Microbiol & Immunol, 3181 SW Sam Jackson Pk Rd,Mail Code L-220, Portland, OR 97201 USA.	crosajor@ohsu.edu		Welch, Tim/0000-0003-1096-3006	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019018] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19018] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACTIS LA, 1988, J BIOL CHEM, V263, P2853; ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BOLIVAR F, 1978, GENE, V4, P121, DOI 10.1016/0378-1119(78)90025-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; Chen Q, 1996, MOL MICROBIOL, V22, P127, DOI 10.1111/j.1365-2958.1996.tb02662.x; Chen Q, 1996, J BIOL CHEM, V271, P18885, DOI 10.1074/jbc.271.31.18885; COY M, 1991, BIOCHEMISTRY-US, V30, P8201, DOI 10.1021/bi00247a016; CROSA JH, 1980, NATURE, V284, P566, DOI 10.1038/284566a0; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FARRELL DH, 1990, GENE, V86, P45, DOI 10.1016/0378-1119(90)90112-5; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GRAF J, 1994, J BACTERIOL, V176, P6986, DOI 10.1128/JB.176.22.6986-6991.1994; KOSTER WL, 1991, J BIOL CHEM, V266, P23829; Miller J.H., 1972, EXPT MOL GENETICS; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; RIMSKY S, 1990, BIOCHEMISTRY-US, V29, P3765, DOI 10.1021/bi00467a024; SAITO T, 1991, EUR J BIOCHEM, V197, P43, DOI 10.1111/j.1432-1033.1991.tb15880.x; SALINAS PC, 1993, GENE, V123, P33, DOI 10.1016/0378-1119(93)90535-B; Sambrook J., 2002, MOL CLONING LAB MANU; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; SILVER S, 1992, MICROBIOL REV, V56, P195, DOI 10.1128/MMBR.56.1.195-228.1992; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; TOLMASKY ME, 1994, J BACTERIOL, V176, P213, DOI 10.1128/JB.176.1.213-220.1994; TOLMASKY ME, 1984, J BACTERIOL, V160, P860, DOI 10.1128/JB.160.3.860-866.1984; TOLMASKY ME, 1988, J BACTERIOL, V170, P1913, DOI 10.1128/jb.170.4.1913-1919.1988; VONGABAIN A, 1983, P NATL ACAD SCI-BIOL, V80, P653; WALDBESER LS, 1993, J BIOL CHEM, V268, P10433; Wee S, 1988, Biol Met, V1, P62, DOI 10.1007/BF01128019; WERTHEIMER AM, 1994, J BACTERIOL, V176, P5116, DOI 10.1128/jb.176.16.5116-5122.1994	32	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33841	33847		10.1074/jbc.273.50.33841	http://dx.doi.org/10.1074/jbc.273.50.33841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837975	hybrid			2022-12-25	WOS:000077462500105
J	Adimoolam, S; Jin, LH; Grabbe, E; Shieh, JJ; Jonas, A				Adimoolam, S; Jin, LH; Grabbe, E; Shieh, JJ; Jonas, A			Structural and functional properties of two mutants of lecithin-cholesterol acyltransferase (T123I and N228K)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; SITE-DIRECTED MUTAGENESIS; HIGH-DENSITY-LIPOPROTEINS; FISH EYE DISEASE; VITRO EXPRESSION; LCAT DEFICIENCY; ACTIVATION; BINDING; GENE; PHOSPHATIDYLCHOLINES	Two naturally occurring mutants of human lecithin-cholesterol acyltransferase (LCAT), T123I and N228K, were expressed in COS-1 and Chinese hamster ovary cells, overproduced, and purified to homogeneity in order to study the structural and functional defects that lead to the LCAT deficiency phenotypes of these mutations. The mutants were expressed and secreted by transfected cells normally and had molecular weights and levels of glycosylation similar to wild type LCAT, The purified proteins (>98% purity) had almost indistinguishable structures and stabilities as determined by CD and fluorescence spectroscopy, Enzymatic activities and kinetic analysis of the pure enzyme forms showed that wild type LCAT and both mutants were reactive with the water-soluble substrate, p-nitrophenyl butyrate, indicating the presence of an intact core active site and catalytic triad, Both the T123I and N228K mutants had markedly depressed reactivity with reconstituted HDL (rHDL), but T123I retained activity with low density lipoprotein. To determine whether defective binding to rHDL was responsible for the low activity of both mutants with rHDL, the equilibrium binding constants were measured directly with isothermal titration calorimetry and surface plasmon resonance (SPR) methods. The results indicated that the affinities of the mutants for rHDL were only about 2-fold lower than the affinity of wild type LCAT (K-d = 2.3 x 10(-7) M). Together, the activity and equilibrium binding results suggest that the T123I mutant is defective in activation by apolipoprotein A-I, and the N228K mutant has impaired binding of lipid substrate to the active site. In addition, the kinetic binding rate constants determined by the SPR method indicate that normal LCAT dissociates from rHDL, on average, after one catalytic cycle.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Monsanto Co, St Louis, MO 63167 USA	University of Illinois System; University of Illinois Urbana-Champaign; Monsanto	Jonas, A (corresponding author), Univ Illinois, Coll Med, Dept Biochem, 506 S Mathews Ave, Urbana, IL 61801 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029939] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29939] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adimoolam S, 1997, BIOCHEM BIOPH RES CO, V232, P783, DOI 10.1006/bbrc.1997.6375; Adimoolam S, 1998, BIOCHEM BIOPH RES CO, V243, P337, DOI 10.1006/bbrc.1997.7995; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Assmann G, 1991, CURR OPIN LIPIDOL, V2, P110; Bolin DJ, 1996, J BIOL CHEM, V271, P19152, DOI 10.1074/jbc.271.32.19152; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BONELLI FS, 1989, J BIOL CHEM, V264, P14723; CARLSON LA, 1983, ACTA MED SCAND, V213, P177; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCONE OL, 1991, P NATL ACAD SCI USA, V88, P1716, DOI 10.1073/pnas.88.5.1716; FUNKE H, 1991, P NATL ACAD SCI USA, V88, P4855, DOI 10.1073/pnas.88.11.4855; GLOMSET JA, 1989, METABOLIC MOL BASES, P1933; GOTODA T, 1991, LANCET, V338, P778, DOI 10.1016/0140-6736(91)90665-C; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P435, DOI 10.1016/0005-2736(86)90541-9; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; Jin LH, 1997, J LIPID RES, V38, P1085; JONAS A, 1987, J BIOL CHEM, V262, P3969; JONAS A, 1992, HIGH DENSITY LIPOPRO, V3, P67; KARMIN O, 1993, J LIPID RES, V34, P81; KLEIN HG, 1993, J LIPID RES, V34, P49; KLEIN HG, 1995, J BIOL CHEM, V270, P9443, DOI 10.1074/jbc.270.16.9443; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Lee YP, 1997, BBA-LIPID LIPID MET, V1344, P250, DOI 10.1016/S0005-2760(96)00149-X; LOWE ME, 1994, GASTROENTEROLOGY, V107, P1524, DOI 10.1016/0016-5085(94)90559-2; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; MINNICH A, 1992, J BIOL CHEM, V267, P16553; NORUM KR, 1967, SCAND J CLIN LAB INV, V20, P231, DOI 10.3109/00365516709076948; Peelman F, 1998, PROTEIN SCI, V7, P587, DOI 10.1002/pro.5560070307; Peelman F, 1997, EUR J BIOCHEM, V249, P708, DOI 10.1111/j.1432-1033.1997.t01-2-00708.x; QU SJ, 1995, J LIPID RES, V36, P967; SCHIMKE RT, 1986, CANCER, V57, P1912, DOI 10.1002/1097-0142(19860515)57:10<1912::AID-CNCR2820571004>3.0.CO;2-O; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SKRETTING G, 1992, FEBS LETT, V309, P307, DOI 10.1016/0014-5793(92)80795-I; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; SORCITHOMAS M, 1993, J BIOL CHEM, V268, P21403; STOKKE KT, 1971, SCAND J CLIN LAB INV, V27, P21, DOI 10.3109/00365517109080184; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; Wang JC, 1997, J BIOL CHEM, V272, P280	42	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32561	32567		10.1074/jbc.273.49.32561	http://dx.doi.org/10.1074/jbc.273.49.32561			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829992	hybrid			2022-12-25	WOS:000077329100031
J	O'Flaherty, JT; Taylor, JS; Thomas, MJ				O'Flaherty, JT; Taylor, JS; Thomas, MJ			Receptors for the 5-oxo class of eicosanoids in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; G-PROTEIN; POLYMORPHONUCLEAR LEUKOCYTES; HUMAN MONOCYTES; 5-HYDROXYEICOSATETRAENOIC ACID; ACTIN REORGANIZATION; CELLULAR LIPIDS; LEUKOTRIENE B-4; METABOLISM; 5-LIPOXYGENASE	5-Hydroxy- and 5-oxo-eicosatetraenoate (5-HETE and 5-oxoETE) activate polymorphonuclear neutrophils (PMNs) through a common, receptor-like recognition system. To define this system, we examined the interaction of these eicosanoids with human PMNs. PMNs esterified 5-[H-3]HETE to glycerolipids at 37 and 4 degrees C. At 37 but not 4 degrees C, the cells also hydroxylated the label to 5,20-[H-3]diHETE. The acyl:CoA synthetase blocker, triacsin C, inhibited esterification but also led to an increase in the hydroxylation of the label. PMNs processed 5-[H-3]oxoETE through the same pathways but only or principally after reducing it to 5-[H-3]HETE (37 or 4 degrees C). In the presence of these varying metabolic reactions, PMNs (37 or 4 degrees C; +/- triacsin C) could not be shown to receptor bind either radiolabel. Plasma membranes isolated from PMNs esterified but unlike whole cells did not reduce or hydroxylate 5-[H-3]oxoETE. Triacsin C blocked esterification, thereby rendering the membranes unable to metabolize this radiolabel. Indeed, triacsin C-treated membranes bound (K-d = 3.8 nM) 5-[H-3]oxoETE specifically and reversibly to 86 pmol of sites per 25 mu g of membrane protein. 5-OxoETE, 5-HETE, and 5,15-diHETE displaced this binding at concentrations correlating with their potency in eliciting PMN Ca2+ transients. GTP and GTP gamma S, but not ATP or ATP gamma S, also reduced 5 [H-3]oxoETE binding, whereas 15-HETE, leukotriene B-4, platelet-activating factor, IL-8, C5a, and N-formyl-Met-Leu-Phe lacked this effect. We conclude that PMNs and their plasma membranes use an acyl:CoA synthetase-dependent route to esterify 5-HETE and 5-oxoETE into lipids. Blockade of the synthetase uncovers cryptic plasmalemma sites that bind 5-oxoETE with exquisite specificity. These sites apparently mediate responses to the 5-oxo class of eicosanoids and are likely members of the serpentine superfamily of G protein-linked receptors.	Wake Forest Univ, Med Ctr, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Med Ctr, Dept Internal Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University	O'Flaherty, JT (corresponding author), Wake Forest Univ, Med Ctr, Dept Internal Med, Med Ctr Blvd, Winston Salem, NC 27151 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038949] Funding Source: NIH RePORTER; NHLBI NIH HHS [1 RO1 HL56710] Funding Source: Medline; NIAID NIH HHS [R01 AI38949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai M, 1997, EUR J BIOCHEM, V244, P513, DOI 10.1111/j.1432-1033.1997.00513.x; BONSER RW, 1981, BIOCHEMISTRY-US, V20, P5297, DOI 10.1021/bi00521a032; BORGEAT P, 1985, ADV LIPID RES, V21, P47; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Czech W, 1997, J INVEST DERMATOL, V108, P108, DOI 10.1111/1523-1747.ep12285653; Edwin SS, 1996, PROSTAG OTH LIPID M, V51, P403, DOI 10.1016/0090-6980(96)00046-9; Foley TD, 1997, BIOCHEM BIOPH RES CO, V235, P374, DOI 10.1006/bbrc.1997.6790; GALLWITZ WE, 1993, J BIOL CHEM, V268, P10087; Ghosh J, 1997, BIOCHEM BIOPH RES CO, V235, P418, DOI 10.1006/bbrc.1997.6799; HALUSHKA PV, 1989, ANNU REV PHARMACOL, V29, P213; KORCHAK HM, 1994, J BIOL CHEM, V269, P30281; Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972; Norgauer J, 1996, EUR J BIOCHEM, V236, P1003, DOI 10.1111/j.1432-1033.1996.01003.x; OFLAHERTY J, 1986, J CELL PHYSIOL, V126, P359, DOI 10.1002/jcp.1041260306; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; OFLAHERTY JT, 1985, PROSTA LEUKOTR MED, V17, P199, DOI 10.1016/0262-1746(85)90107-6; OFLAHERTY JT, 1988, J IMMUNOL, V140, P4323; OFLAHERTY JT, 1986, J IMMUNOL, V137, P3277; OFLAHERTY JT, 1990, J CELL PHYSIOL, V142, P299, DOI 10.1002/jcp.1041420212; OFLAHERTY JT, 1994, BBA-GEN SUBJECTS, V1201, P505, DOI 10.1016/0304-4165(94)90083-3; OFLaherty JT, 1996, J IMMUNOL, V157, P336; OFLAHERTY JT, 1993, J BIOL CHEM, V268, P14708; POWELL WS, 1994, BIOCHEMISTRY-US, V33, P3927, DOI 10.1021/bi00179a019; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1993, J BIOL CHEM, V268, P9280; Powell WS, 1996, J IMMUNOL, V156, P336; POWELL WS, 1995, J IMMUNOL, V154, P4123; RICHARDS CF, 1989, PROSTAGLANDINS, V38, P565, DOI 10.1016/0090-6980(89)90150-0; ROSSI AG, 1988, FEBS LETT, V240, P163, DOI 10.1016/0014-5793(88)80360-0; ROSSI AG, 1989, PROSTAGLANDINS, V37, P641, DOI 10.1016/0090-6980(89)90102-0; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; Sozzani S, 1996, J IMMUNOL, V157, P4664; SUMIMOTO H, 1990, J BIOL CHEM, V265, P4348; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; ZHANG Y, 1994, FASEB J, V8, pA356	37	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32535	32541		10.1074/jbc.273.49.32535	http://dx.doi.org/10.1074/jbc.273.49.32535			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829988	hybrid			2022-12-25	WOS:000077329100027
J	Maccarrone, M; van der Stelt, M; Rossi, A; Veldink, GA; Vliegenthart, JFG; Agrio, AF				Maccarrone, M; van der Stelt, M; Rossi, A; Veldink, GA; Vliegenthart, JFG; Agrio, AF			Anandamide hydrolysis by human cells in culture and brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS CANNABINOID ANANDAMIDE; FATTY-ACID AMIDES; NITRIC-OXIDE; RAT-BRAIN; MOLECULAR CHARACTERIZATION; LINOLEOYL AMIDES; RECEPTOR; DEATH; PALMITOYLETHANOLAMIDE; LIPOXYGENASE	Anandamide (arachidonylethanolamide; AnNH) has important neuromodulatory and immunomodulatory activities. This lipid is rapidly taken up and hydrolyzed to arachidonate and ethanolamine in many organisms. As yet, AnNH inactivation has not been studied in humans. Here, a human brain fatty-acid amide hydrolase (FAAH) has been characterized as a single protein of 67 kDa with a pi of 7.6, showing apparent K-m and V-max values for AnNH of 2.0 +/- 0.2 mu M and 800 +/- 75 pmol min-l mg of protein-l, respectively. The optimum pH and temperature for AnNH hydrolysis were 9.0 and 37 degrees C, respectively, and the activation energy of the reaction was 43.5 +/- 4.5 kJ.mol(-1). Hydro(pero)xides derived from AnNH or its linoleoyl analogues by Lipoxygenase action were competitive inhibitors of human brain FAAH, with apparent K-i values in the low micromolar range. One of these compounds, linoleoylethanolamide is the first natural inhibitor (K-i = 9.0 +/- 0.9 mu M) of FAAH as yet discovered. An FAAH activity sharing several biochemical properties with the human brain enzyme was demonstrated in human neuroblastoma CHP100 and lymphoma U937 cells. Both cell lines have a high affinity transporter for AnNH, which had apparent K-m and V-max values for AnNH of 0.20 +/- 0.02 mu M and 30 +/- 3 pmol.min(-1).mg of protein(-1) (CHP100 cells) and 0.13 +/- 0.01 mu M and 140 +/- 15 pmol.min(-1).mg of protein(-1) (U937 cells), respectively. The AnNH carrier of both cell lines was activated up to 170% of the control by nitric oxide.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Carattere Sci Ctr S Giovanni Dio, Ist Ricovero & Cura, I-25100 Brescia, Italy; Univ Utrecht, Dept Bioorgan Chem, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands	University of Rome Tor Vergata; Utrecht University	Agrio, AF (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Tor Vergata 135, I-00133 Rome, Italy.	Finazzi@utovrm.it						Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; CORASANITI MT, 1995, NEURODEGENERATION, V4, P315, DOI 10.1016/1055-8330(95)90021-7; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Derkinderen P, 1996, SCIENCE, V273, P1719, DOI 10.1126/science.273.5282.1719; Derocq JM, 1998, FEBS LETT, V425, P419, DOI 10.1016/S0014-5793(98)00275-0; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diTomaso E, 1996, NATURE, V382, P677, DOI 10.1038/382677a0; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; *GEN COMP INC, 1994, PROGR MAN GCG SEQ AN; Giang DK, 1997, P NATL ACAD SCI USA, V94, P2238, DOI 10.1073/pnas.94.6.2238; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; HAMPSON AJ, 1995, BBA-LIPID LIPID MET, V1259, P173, DOI 10.1016/0005-2760(95)00157-8; Hillard CJ, 1997, J NEUROCHEM, V69, P631, DOI 10.1046/j.1471-4159.1997.69020631.x; HILLARD CJ, 1995, BBA-LIPID LIPID MET, V1257, P249, DOI 10.1016/0005-2760(95)00087-S; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Kurahashi Y, 1997, BIOCHEM BIOPH RES CO, V237, P512, DOI 10.1006/bbrc.1997.7180; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Maccarrone M, 1996, EUR J BIOCHEM, V241, P297, DOI 10.1111/j.1432-1033.1996.0297t.x; MACCARRONE M, 1991, J BIOL CHEM, V266, P21014; Maccarrone M, 1997, CELL DEATH DIFFER, V4, P396, DOI 10.1038/sj.cdd.4400255; Maccarrone M, 1996, BIOCHEM BIOPH RES CO, V219, P128, DOI 10.1006/bbrc.1996.0193; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Maurelli S, 1995, FEBS LETT, V377, P82, DOI 10.1016/0014-5793(95)01311-3; Mechoulam R, 1997, NATURE, V389, P25, DOI 10.1038/37891; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; NATARAJAN V, 1984, J NEUROCHEM, V42, P1613, DOI 10.1111/j.1471-4159.1984.tb12750.x; Paria BC, 1996, MOL REPROD DEV, V45, P183, DOI 10.1002/(SICI)1098-2795(199610)45:2&lt;183::AID-MRD11&gt;3.0.CO;2-2; Perry A, 1997, AM J SURG PATHOL, V21, P1455, DOI 10.1097/00000478-199712000-00008; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; Sasaki T, 1997, LIFE SCI, V61, P1803, DOI 10.1016/S0024-3205(97)00804-7; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SEGEL IH, 1976, BIOCH CALCULATIONS, P277; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Stefano GB, 1996, J BIOL CHEM, V271, P19238, DOI 10.1074/jbc.271.32.19238; UEDA N, 1995, BBA-LIPID LIPID MET, V1254, P127, DOI 10.1016/0005-2760(94)00170-4; UEDA N, 1995, J BIOL CHEM, V270, P23823, DOI 10.1074/jbc.270.40.23823; Valk P, 1997, BLOOD, V90, P1448, DOI 10.1182/blood.V90.4.1448.1448_1448_1457; vanderStelt M, 1997, FEBS LETT, V415, P313, DOI 10.1016/S0014-5793(97)01148-4; vanderStelt M, 1997, FEBS LETT, V411, P287, DOI 10.1016/S0014-5793(97)00718-7; WARTMANN M, 1995, FEBS LETT, V359, P133, DOI 10.1016/0014-5793(95)00027-7; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	46	155	164	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32332	32339		10.1074/jbc.273.48.32332	http://dx.doi.org/10.1074/jbc.273.48.32332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822713	Green Published, hybrid			2022-12-25	WOS:000077207000095
J	Ujita, M; McAuliffe, J; Schwientek, T; Almeida, R; Hindsgaul, O; Clausen, H; Fukuda, M				Ujita, M; McAuliffe, J; Schwientek, T; Almeida, R; Hindsgaul, O; Clausen, H; Fukuda, M			Synthesis of poly-N-acetyllactosamine in core 2 branched O-glycans - The requirement of novel beta-1,4-galtactosyltransferase IV and beta-1,3-N-acetylglucosaminyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; WISKOTT-ALDRICH SYNDROME; LINKED OLIGOSACCHARIDES; L-SELECTIN; CELL-ADHESION; HUMAN GALACTOSYLTRANSFERASE; EXPRESSION CLONING; LEUKEMIC-CELLS; SIALYL LE(X); HL-60 CELLS	Poly-N-acetyllactosamine is a unique carbohydrate composed of N-acetyllactosamine repeats and provides the backbone structure for additional modifications such as sialyl Le(x), Poly-N-acetyllactosamines in mucin-type O-glycans can be formed in core 2 branched oligosaccharides, which are synthesized by core 2 beta-1,6-N-acetylglucosaminyltransferase. Using a beta-1,4-galactosyltransferase (beta 4Gal-TI) present in milk and the recently cloned beta-1,3-N-acetylglucosaminyltransferase, the formation of poly-N-acetyllactosamine was found to be extremely inefficient starting from a core 2 branched oligosaccharide, GlcNAc beta 1-->6-(Gal beta 1-->3)GalNAc alpha-->R. Since the majority of synthesized oligosaccharides contained N-acetylglucosamine at the nonreducing ends, galactosylation was judged to be inefficient, prompting us to test novel members of the beta 4Gal-T gene family for this synthesis. Using various synthetic accepters and recombinant beta 4Gal-Ts, beta 4Gal-TIV was found to be most efficient in the addition of a single galactose residue to GlcNAc beta 1-->6(Gal beta 1-->3)Gal-NAc alpha-->R. Moreover, beta 4Gal-TIV, together with beta-1,3-N-acetylglucosaminyltransferase, was capable of synthesizing poly-N-acetyllactosamine in core 2 branched oligosaccharides. On the other hand, beta 4Gal-TI was found to be most efficient for poly-N-acetyllactosamine synthesis in N-glycans, In contrast to beta 4Gal-TI, the efficiency of beta 4Gal-TIV decreased dramatically as the accepters contained more N-acetyllactosamine repeats, consistent with the fact that core 2 branched O-glycans contain fewer and shorter poly-N-acetyllactosamines than N-glycans in many cells. These results, as a whole, indicate that beta 4Gal-TIV is responsible for poly-N-acetyllactosamine synthesis in core 2 branched O-glycans.	Burnham Inst, Glycobiol Program, Ctr Canc Res, La Jolla, CA 92037 USA; Univ Copenhagen, Sch Dent, DK-2200 Copenhagen, Denmark	Sanford Burnham Prebys Medical Discovery Institute; University of Copenhagen	Ujita, M (corresponding author), Burnham Inst, Glycobiol Program, Ctr Canc Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Almeida, Raquel/B-9647-2012; clausen, henrik/AAD-8016-2021	Almeida, Raquel/0000-0002-5622-1633; 	NATIONAL CANCER INSTITUTE [P01CA071932, R37CA033000, R01CA048737] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA33000, R01 CA48737, P01 CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; AOKI D, 1990, EMBO J, V9, P3171, DOI 10.1002/j.1460-2075.1990.tb07515.x; ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BELL JE, 1976, J BIOL CHEM, V251, P3003; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BROCKHAUSEN I, 1991, CANCER RES, V51, P1257; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FUKUDA M, 1984, MOL GLYCOBIOLOGY, P1; FUKUDA MN, 1985, J BIOL CHEM, V260, P6623; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; KitazumeKawaguchi S, 1997, P NATL ACAD SCI USA, V94, P3650, DOI 10.1073/pnas.94.8.3650; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEE N, 1990, J BIOL CHEM, V265, P20476; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MAEMURA K, 1994, TETRAHEDRON-ASYMMETR, V5, P2093, DOI 10.1016/S0957-4166(00)86286-2; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MERKLE RK, 1988, J BIOL CHEM, V263, P16143; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; OEHRLEIN R, 1993, CARBOHYD RES, V244, P149, DOI 10.1016/0008-6215(93)80011-3; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; SAITOH O, 1991, BLOOD, V77, P1491; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Shaper NL, 1997, J BIOL CHEM, V272, P31389, DOI 10.1074/jbc.272.50.31389; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; Shimodaira K, 1997, CANCER RES, V57, P5201; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SRIVASTAVA G, 1992, CARBOHYD RES, V224, P83, DOI 10.1016/0008-6215(92)84095-A; Tsuboi S, 1998, J BIOL CHEM, V273, P30680, DOI 10.1074/jbc.273.46.30680; Tsuboi S, 1997, EMBO J, V16, P6364, DOI 10.1093/emboj/16.21.6364; Tsuboi S, 1996, J BIOL CHEM, V271, P27213, DOI 10.1074/jbc.271.44.27213; WALTZ G, 1990, SCIENCE, V250, P1132; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	55	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34843	34849		10.1074/jbc.273.52.34843	http://dx.doi.org/10.1074/jbc.273.52.34843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857011	hybrid			2022-12-25	WOS:000077719700029
J	Garcia, J; Lemercier, B; Roman-Roman, S; Rawadi, G				Garcia, J; Lemercier, B; Roman-Roman, S; Rawadi, G			A Mycoplasma fermentans-derived synthetic lipopeptide induces AP-1 and NF-kappa B activity and cytokine secretion in macrophages via the activation of mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; TUMOR-NECROSIS-FACTOR; TREPONEMA-PALLIDUM; MURINE MACROPHAGES; MAPKAP KINASE-2; C-FOS; CELLS; LIPOPOLYSACCHARIDE; IDENTIFICATION; DISTINCT	Mycoplasma lipoproteins have been demonstrated to stimulate monocytic cells and induce proinflammatory cytokine secretion. In this paper, we show that a synthetic analog of the Mycoplasma fermentans membrane-associated lipopeptide macrophage-activating lipopeptide-2 (MALP-2) induces mRNA synthesis and protein secretion of interleukin-1 beta and tumor necrosis factor-alpha in human monocytes/macrophages and the murine macrophage cell line RAW 264.7, whereas the nonlipidated counterpart lacks this effect, underscoring the importance of protein acylation for cell activation. Synthetic MALP-2 (sMALP-2) induced the activation of MAPK family members extracellular signal regulated kinases 1 and 2, c-Jun NH2-terminal kinase, and p38 and induced NF-kappa B and AP-1 transactivation in macrophages, Whereas the specific p38 inhibitor SB203580 abrogated both cytokine synthesis and NF-kappa B and AP-1 transactivation in response to MALP-2, the selective MAPK/extracellular signal-regulated kinase-1 inhibitor PD-98059 decreased interleukin-1 beta and tumor necrosis factor-alpha production in response to sMALP-2 without affecting the transactivation of NP-kappa B or AP-1. These results indicate that activation of MAPKs by sMALP2 is a crucial event leading to the expression of proinflammatory cytokines. Our findings demonstrate that the synthetic analog of MALP-2 reproduces the macrophage stimulation activity found in different fractions of mycoplasmas, Given that MALP-2 has been recently shown to be expressed at the surface of M. fermentans as a molecular entity, sMALP-2 constitutes a valuable surrogate for investigating immunomodulation by these microorganisms and evaluating the role that this activity plays in the development of inflammatory diseases associated with mycoplasma infections.	Inst Pasteur, Lab Mycoplasmes, F-75724 Paris 15, France; Univ Paris 07, UFR Biochim, F-75251 Paris, France; Hoechst Marion Roussel, Ctr rech Romainville, F-93230 Romainville, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis; Sanofi France	Rawadi, G (corresponding author), Inst Pasteur, Lab Mycoplasmes, 25 Rue Docteur Roux, F-75724 Paris 15, France.		Roman-Roman, Sergio/K-9993-2014	Roman-Roman, Sergio/0000-0001-6459-2613; Rawadi, Georges/0000-0003-4735-2188				Adcock I M, 1997, Monaldi Arch Chest Dis, V52, P178; AKINS DR, 1993, INFECT IMMUN, V61, P1202, DOI 10.1128/IAI.61.4.1202-1210.1993; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BALDARI CT, 1995, EUR J IMMUNOL, V25, P1843, DOI 10.1002/eji.1830250708; Baseman JB, 1997, EMERG INFECT DIS, V3, P21, DOI 10.3201/eid0301.970103; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; BLANCHARD A, 1994, ANNU REV MICROBIOL, V48, P687, DOI 10.1146/annurev.mi.48.100194.003351; BRASIER AR, 1994, CURRENT PROTOCOLS MO; CALCUTT MJ, 1998, 12 ORG MYC C SYDN AU, P170; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; Cano E, 1996, ONCOGENE, V12, P805; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Foletta VC, 1998, J LEUKOCYTE BIOL, V63, P139, DOI 10.1002/jlb.63.2.139; HAUSCHILDT S, 1990, EUR J IMMUNOL, V20, P63, DOI 10.1002/eji.1830200110; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; KIM MF, 1998, 12 ORG MYC C SYDN AU, P168; KOSTYAL DA, 1994, INFECT IMMUN, V62, P3793, DOI 10.1128/IAI.62.9.3793-3800.1994; Kravchenko VV, 1996, SHOCK, V5, P194, DOI 10.1097/00024382-199603000-00005; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; Metzger J W, 1995, J Pept Sci, V1, P184, DOI 10.1002/psc.310010305; METZGER JW, 1991, INT J PEPT PROT RES, V38, P545; Muhlradt PF, 1996, BIOCHEMISTRY-US, V35, P7781, DOI 10.1021/bi9602831; MUHLRADT PF, 1994, INFECT IMMUN, V62, P3801; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; RADOLF JD, 1991, J IMMUNOL, V147, P1968; RADOLF JD, 1995, J IMMUNOL, V154, P2866; Rawadi G, 1996, J IMMUNOL, V156, P670; Rawadi G, 1996, INFECT IMMUN, V64, P637, DOI 10.1128/IAI.64.2.637-643.1996; Rawadi G, 1998, J IMMUNOL, V160, P1330; Rawadi Georges, 1993, Methods in Molecular and Cellular Biology, V4, P147; RAZIN S, 1985, MYCOPLASMAS, V4; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Sellati TJ, 1998, J IMMUNOL, V160, P5455; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; Taghian D G, 1995, Methods Mol Biol, V48, P115; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TaylorRobinson D, 1996, J CLIN PATHOL, V49, P781, DOI 10.1136/jcp.49.10.781; TEBO JM, 1994, J IMMUNOL, V153, P4713; Wooten RM, 1996, J IMMUNOL, V157, P4584; Wooten RM, 1998, J IMMUNOL, V160, P5485; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078	49	96	102	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34391	34398		10.1074/jbc.273.51.34391	http://dx.doi.org/10.1074/jbc.273.51.34391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852105	hybrid			2022-12-25	WOS:000077542200071
J	Kuhne, C; Banks, L				Kuhne, C; Banks, L			ES ubiquitin ligase E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION LICENSING SYSTEM; CELL-CYCLE REGULATION; DNA-REPLICATION; CATALYTIC SUBUNIT; ANGELMAN-SYNDROME; MCM PROTEINS; PROTEASOME PATHWAY; SYNDROME GENE; IN-VIVO; COMPLEX	Ubiquitin Ligases are generally assumed to play a major role in substrate recognition and thus provide specificity to a particular ubiquitin modification system. The multicopy maintenance protein (Mcm) 7 subunit of the replication licensing factor-M was identified as a substrate of the ES-ubiquitin ligase/E6-AP by its interaction with human papillomavirus-18E6. Mcm7 is ubiquitinated in vivo in both an E6-AP-dependent and -independent manner. EG-AP functions in these reactions independently of the viral oncogene E6, We show that recognition of Mcm7 by EG-AP is mediated by a homotypic interaction motif present in both proteins, called the L2G box. These findings served as the basis for the definition of substrate specificity for EG-AP. A small cluster of proteins whose function is intimately associated with the control of cell growth and/or proliferation contains the L2G box and is thereby implicated in an EG-AP and, by default, HPV-EG-dependent ubiquitination pathway.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Kuhne, C (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	kuehne@icgeb.trieste.it						Albrecht U, 1997, NAT GENET, V17, P75, DOI 10.1038/ng0997-75; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BERNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chen JJ, 1998, J BIOL CHEM, V273, P13537, DOI 10.1074/jbc.273.22.13537; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1996, PAPILLOMAVIRUS REV C, P55; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Elston RC, 1998, J GEN VIROL, V79, P371, DOI 10.1099/0022-1317-79-2-371; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Kubota Y, 1997, EMBO J, V16, P3320, DOI 10.1093/emboj/16.11.3320; Li XQ, 1996, J VIROL, V70, P4509, DOI 10.1128/JVI.70.7.4509-4516.1996; Li Y, 1997, J BIOL CHEM, V272, P32337, DOI 10.1074/jbc.272.51.32337; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Schulte D, 1996, EUR J BIOCHEM, V235, P144, DOI 10.1111/j.1432-1033.1996.00144.x; Schwarz SE, 1998, J BIOL CHEM, V273, P12148, DOI 10.1074/jbc.273.20.12148; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; Wu JR, 1998, EMBO J, V17, P1810, DOI 10.1093/emboj/17.6.1810; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270; ZURHAUSEN H, 1990, VIROLOGY, V184, P9	62	133	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34302	34309		10.1074/jbc.273.51.34302	http://dx.doi.org/10.1074/jbc.273.51.34302			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852095	hybrid			2022-12-25	WOS:000077542200061
J	Schulte, U; Hahn, H; Wiesinger, H; Ruppersberg, JP; Fakler, B				Schulte, U; Hahn, H; Wiesinger, H; Ruppersberg, JP; Fakler, B			pH-dependent gating of ROMK (K(ir)1.1) channels involves conformational changes in both N and C termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNELS; NUCLEOTIDE-GATED CHANNEL; POTASSIUM CHANNELS; INTRACELLULAR SPERMINE; IDENTIFICATION; PHOSPHORYLATION; HETEROMULTIMER; RECTIFICATION; SENSITIVITY; ACTIVATION	ROMK channels (K(ir)1.1) are members of the superfamily of inward rectifier potassium channels (K-ir) and represent the channels underlying K+ secretion in the kidney. As their native counterparts, K(ir)1.1 channels are gated by intracellular pH, with acidification leading to channel closure. Although a lysine residue (Lys(80)) close to the first hydrophobic segment M1 has been identified as the pH sensor, little is known about how opening and closing of the channel is accomplished. Here we investigate the gating process of K(ir)1.1 channels exploiting their state-dependent modification by water-soluble oxidants and sulfhydryl reagents. Mutagenesis of all intracellular cysteines either alone or in combination revealed two residues targeted by these reagents, one in the N terminus (Cys(49)) and one in the C terminus (Cys(308)) Of the channel protein. Both sites reacted with the thiol reagents only in the closed state and not in the open state. These results indicate that pH-dependent gating of K(ir)1.1 channels involves movement of protein domains in both N and C termini of the K(ir)1.1 protein.	Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Univ Tubingen, Dept Physiol Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Fakler, B (corresponding author), Univ Tubingen, Dept Physiol 2, Ob Himmelreich 7, D-72074 Tubingen, Germany.	bernd.fakler@uni-tuebingen.de						AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ali S, 1998, P NATL ACAD SCI USA, V95, P10274, DOI 10.1073/pnas.95.17.10274; BOIM MA, 1995, AM J PHYSIOL-RENAL, V268, pF1132, DOI 10.1152/ajprenal.1995.268.6.F1132; Broillet MC, 1997, NEURON, V18, P951, DOI 10.1016/S0896-6273(00)80334-7; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; Doi T, 1996, J BIOL CHEM, V271, P17261, DOI 10.1074/jbc.271.29.17261; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Fakler B, 1996, CELL PHYSIOL BIOCHEM, V6, P195, DOI 10.1159/000154823; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; FAKLER B, 1994, FEBS LETT, V356, P199, DOI 10.1016/0014-5793(94)01258-X; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; Fakler B, 1996, EMBO J, V15, P4093, DOI 10.1002/j.1460-2075.1996.tb00784.x; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; HERLITZE S, 1990, GENE, V91, P143, DOI 10.1016/0378-1119(90)90177-S; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Kubo Y, 1996, BIOCHEM BIOPH RES CO, V227, P240, DOI 10.1006/bbrc.1996.1496; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LEE WS, 1995, AM J PHYSIOL-RENAL, V268, pF1124, DOI 10.1152/ajprenal.1995.268.6.F1124; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; Wright FS, 1992, KIDNEY PHYSL PATHOPH, P2209; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; ZHOU H, 1994, AM J PHYSIOL, V266, pC809, DOI 10.1152/ajpcell.1994.266.3.C809	40	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34575	34579		10.1074/jbc.273.51.34575	http://dx.doi.org/10.1074/jbc.273.51.34575			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852128	hybrid			2022-12-25	WOS:000077542200094
J	Ayvazian, L; Crenon, I; Hermoso, J; Pignol, D; Chapus, C; Kerfelec, B				Ayvazian, L; Crenon, I; Hermoso, J; Pignol, D; Chapus, C; Kerfelec, B			Ion pairing between lipase and colipase plays a critical role in catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSE PANCREATIC LIPASE; X-RAY; PROCOLIPASE COMPLEX; CRYSTAL-STRUCTURE; ACTIVATION; PROTEINS; REFINEMENT; DOMAIN	Among the polar interactions occurring in pancreatic lipase/colipase binding, only one ion pair involving lysine 400 on lipase and glutamic acid 45 on colipase has been described. These residues are strictly conserved among species, suggesting that the ion pair is likely to play an important role. Therefore, in order to prevent this interaction, mutations intended to neutralize or inverse the charge of these residues have been introduced in the cDNAs encoding horse lipase and colipase, The recombinant proteins have been expressed in insect cells, and their catalytic properties have been investigated. In all cases, preventing the formation of the correct ion pair Lys(400)/Glu(45) leads to lipase-colipase complexes of reduced affinity unable to perform an efficient catalysis, notably in the presence of bile salt micelles, Diethyl p-nitrophenyl phosphate inhibition experiments with either mutant lipase or mutant colipase indicate a poor stabilization of the lipase flap. These results suggest that the ion pair plays a critical role in the active conformation of the lipase-colipase-micelle ternary complex by contributing to a correct orientation of colipase relative to lipase resulting in a proper opening of the flap.	CNRS, UPR 9036, Unite Bioenerget & Ingn Prot, F-13402 Marseille, France; CSIC, Inst Quim Fis Rocasolano, Dept Cristalog, E-28006 Madrid, Spain; CNRS, CEA, Inst Biol Struct Jean Pierre Ebel, Lab Cristallog & Cristallogenese Prot, F-38027 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Kerfelec, B (corresponding author), CNRS, UPR 9036, Unite Bioenerget & Ingn Prot, 31 Chemin Joseph Aiguier, F-13402 Marseille, France.		Hermoso, Juan/J-3433-2012	Hermoso, Juan/0000-0002-1862-8950; PIGNOL, David/0000-0002-8070-0319				ABOUSALHAM A, 1992, PROTEIN ENG, V5, P105, DOI 10.1093/protein/5.1.105; Ayvazian L, 1996, PROTEIN ENG, V9, P707, DOI 10.1093/protein/9.8.707; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1988, CRYSTALLOGRAPHIC COM, V3, P126; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Hermoso J, 1997, EMBO J, V16, P5531, DOI 10.1093/emboj/16.18.5531; Hermoso J, 1996, J BIOL CHEM, V271, P18007, DOI 10.1074/jbc.271.30.18007; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDO D, 1989, J MOL BIOL, V205, P259, DOI 10.1016/0022-2836(89)90380-X; Lowe ME, 1997, J BIOL CHEM, V272, P9; MAHEGOUHIER N, 1988, BIOCHIM BIOPHYS ACTA, V229, P286; MOMSEN WE, 1995, BIOCHEMISTRY-US, V34, P7271, DOI 10.1021/bi00021a044; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P546; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	23	15	15	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33604	33609		10.1074/jbc.273.50.33604	http://dx.doi.org/10.1074/jbc.273.50.33604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837944	hybrid			2022-12-25	WOS:000077462500074
J	Biswas, DK; Reddy, PV; Pickard, M; Makkad, B; Pettit, N; Pardee, AB				Biswas, DK; Reddy, PV; Pickard, M; Makkad, B; Pettit, N; Pardee, AB			Calmodulin is essential for estrogen receptor interaction with its motif and activation of responsive promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; BINDING PROTEIN; DOWN-REGULATION; DNA-BINDING; CYCLIN D1; GENE; INHIBITION; GROWTH; ANTAGONIST; TAMOXIFEN	Calmodulin (CaM) has been reported to have affinity for the estrogen receptor (ER:), Observations reported here reveal a direct physical interaction between purified CaM and ER, This direct ER-CaM interaction may he an initial event preceding the assembly of ER plus auxiliary proteins into the active ER complex with its DNA motif the estrogen response element. We demonstrate that CaM is an integral component of this complex by using a system reconstituted from purified ER and nuclear extract from ER-negative breast cancer cells and also with ER-depleted nuclear extract of an ER-positive breast cancer cell line. Although CaM is essential for formation of this complex, it is not sufficient, suggesting roles also of auxiliary proteins. CaM also is functionally required for activation of an ER-responsive promoter, in the 17 beta-estradiol-ER pathway of hormone action and regulation of 17 beta-estradiol-responsive gene expression that is associated with proliferation of mammary epithelial cells.	Dana Farber Canc Inst, Div Canc Biol, Boston, MA 02115 USA; Henry Ford Hlth Syst, Detroit, MI 48202 USA	Harvard University; Dana-Farber Cancer Institute; Henry Ford Health System; Henry Ford Hospital	Biswas, DK (corresponding author), Dana Farber Canc Inst, Div Canc Biol, 44 Binney St, Boston, MA 02115 USA.	biswas@mbcrr.harvard.edu			NCI NIH HHS [CA61253-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061253] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BISWAS DK, 1995, J VIROL, V69, P7437, DOI 10.1128/JVI.69.12.7437-7444.1995; BISWAS DK, 1993, P NATL ACAD SCI USA, V90, P11044, DOI 10.1073/pnas.90.23.11044; Biswas DK, 1998, MOL MED, V4, P454, DOI 10.1007/BF03401751; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; Bouhoute A, 1996, BIOCHEM BIOPH RES CO, V227, P651, DOI 10.1006/bbrc.1996.1564; BOUHOUTE A, 1992, BIOCHEM BIOPH RES CO, V184, P1432, DOI 10.1016/S0006-291X(05)80043-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V11, P2067; FRANKFURT OS, 1995, CANCER LETT, V97, P149, DOI 10.1016/0304-3835(95)03970-8; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; KRISHNARAJU K, 1991, BRIT J CANCER, V63, P346, DOI 10.1038/bjc.1991.82; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; MUSGROVE EA, 1984, CANCER RES, V49, P2398; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; OBOURN JD, 1993, BIOCHEMISTRY-US, V32, P6229, DOI 10.1021/bi00075a016; RATAJCZAK T, 1995, BIOCHEM BIOPH RES CO, V209, P117, DOI 10.1006/bbrc.1995.1478; REDDY GPV, 1994, BIOCHEMISTRY-US, V33, P6605, DOI 10.1021/bi00187a030; REDDY GPV, 1994, J CELL BIOCHEM, V54, P379, DOI 10.1002/jcb.240540404; SEBILLE S, 1998, P AM ASSOC CANC RES, V39, P142; SINGER AL, 1996, CANCER RES, V36, P60; STROBL JS, 1994, BIOCHEM PHARMACOL, V47, P2157, DOI 10.1016/0006-2952(94)90250-X; STROBL JS, 1992, J PHARMACOL EXP THER, V263, P186; SUBRAMANYAM C, 1990, J CELL PHYSIOL, V144, P423, DOI 10.1002/jcp.1041440309; TUCCARI G, 1993, EUR J HISTOCHEM, V37, P57; WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YASWEN P, 1990, P NATL ACAD SCI USA, V87, P7360, DOI 10.1073/pnas.87.19.7360; ZAJCHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613, DOI 10.1210/mend-5-11-1613; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	46	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33817	33824		10.1074/jbc.273.50.33817	http://dx.doi.org/10.1074/jbc.273.50.33817			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837972	hybrid			2022-12-25	WOS:000077462500102
J	Gallia, GL; Safak, M; Khalili, K				Gallia, GL; Safak, M; Khalili, K			Interaction of the single-stranded DNA-binding protein Pur alpha with the human polyomavirus JC virus early protein T-antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE TUMOR-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTIONAL REGULATION; SIMIAN VIRUS-40; GLIAL-CELLS; SV40-TRANSFORMED CELLS; DELETED REGION; HUMAN-BRAIN; REPLICATION; SEQUENCE	Large T-antigen, the major regulatory protein encoded by polyomaviruses, including Simian Virus 40 (SV40) and JC virus (JCV), is a multifunctional phosphoprotein that is involved in many viral and cellular events. In addition to its integral role in viral replication and cellular transformation, T-antigen also regulates transcription of both viral and cellular genes. In particular, the viral late promoter has been used as a model for the analysis of T-antigen-mediated transcriptional activation. Earlier studies have demonstrated that the cellular protein Pur alpha is able to attenuate the transcriptional activity of JCV T-antigen, We investigated the mechanism whereby Pur alpha affects T-antigen function. Co-immunoprecipitation studies demonstrated that Pur alpha and JCV T-antigen associate in vivo, and glutathione S-transferase affinity binding assays revealed that these two proteins interact in vitro. Moreover, we localized the sequences of Pur alpha that are important for the interaction between Pur alpha and JCV T-antigen, In addition, we demonstrated that Pur alpha interacts with the SV40 T-antigen, Transient transfection studies demonstrated that Pur alpha and JCV T-antigen interact functionally as well. More specifically, Pur alpha and a deletion mutant that interacts with T-antigen attenuated T-antigen-mediated transcriptional activation. A Pur alpha deletion mutant that is unable to interact with JCV T-antigen, however, was found to be incapable of abrogating JCV T-antigen transactivation. Taken together, these data demonstrate that Pur alpha and T-antigen interact both physically and functionally and that this interaction modulates T-antigen-mediated transcriptional activation, The implication of these findings with respect to the cellular role of Pur alpha is discussed.	Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA	Drexel University	Khalili, K (corresponding author), Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, 245 N 15th St,Mail Stop 406, Philadelphia, PA 19102 USA.	khalili@auhs.edu						BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Chang CF, 1996, J VIROL, V70, P4150, DOI 10.1128/JVI.70.6.4150-4156.1996; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; DEB S, 1995, INT J ONCOL, V6, P243; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAAS S, 1995, J CELL BIOL, V130, P1171, DOI 10.1083/jcb.130.5.1171; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Jurk M, 1996, NUCLEIC ACIDS RES, V24, P2799, DOI 10.1093/nar/24.14.2799; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lezon-Geyda K. A., 1997, FASEB Journal, V11, pA100; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MA ZW, 1994, GENE, V149, P311, DOI 10.1016/0378-1119(94)90167-8; MA ZW, 1995, CYTOGENET CELL GENET, V71, P64, DOI 10.1159/000134065; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MEITZ JA, 1992, EMBO J, V11, P5013; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Osugi T, 1996, FEBS LETT, V391, P11, DOI 10.1016/0014-5793(96)00696-5; PEDERSEN B, 1993, ANTICANCER RES, V13, P1913; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SEGAWA K, 1993, ONCOGENE, V8, P543; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOCK E, 1993, VIROLOGY, V197, P537, DOI 10.1006/viro.1993.1627; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; SWENSON JJ, 1995, VIROLOGY, V212, P295, DOI 10.1006/viro.1995.1487; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, pL76; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Zambrano N, 1997, BIOCHEM J, V328, P293, DOI 10.1042/bj3280293	47	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32662	32669		10.1074/jbc.273.49.32662	http://dx.doi.org/10.1074/jbc.273.49.32662			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830007	hybrid			2022-12-25	WOS:000077329100046
J	Garcia-Calvo, M; Peterson, EP; Leiting, B; Ruel, R; Nicholson, DW; Thornberry, NA				Garcia-Calvo, M; Peterson, EP; Leiting, B; Ruel, R; Nicholson, DW; Thornberry, NA			Inhibition of human caspases by peptide-based and macromolecular inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; COMBINATORIAL APPROACH; CYSTEINE PROTEASES; MICE DEFICIENT; ICE INHIBITOR; SERPIN CRMA; CELL-DEATH; LAMIN-A; IN-VIVO; APOPTOSIS	Studies with peptide-based and macromolecular inhibitors of the caspase family of cysteine proteases have helped to define a central role for these enzymes in inflammation and mammalian apoptosis. A clear interpretation of these studies has been compromised by an incomplete understanding of the selectivity of these molecules. Here we describe the selectivity of several peptide-based inhibitors and the coxpox serpin CrmA against 10 human caspases. The peptide aldehydes that were examined (Ac-WEHD-CHO, Ac-DEVD-CHO, Ac-YVAD-CHO, t-butoxycarbonyl-IETD-CHO, and t-butoxycarbonyl-AEVD-CHO) included several that contain the optimal tetrapeptide recognition motif for various caspases. These aldehydes display a wide range of selectivities and potencies against these enzymes, with dissociation constants ranging from 75 pM to >10 mu M. The halomethyl ketone benzyloxycarbonyl-VAD fluoromethyl ketone is a broad specificity irreversible caspase inhibitor, with second-order inactivation rates that range from 2.9 x 10(2) M-1 s(-1) for caspase-2 to 2.8 x 10(5) M-1 s(-1) for caspase-1. The results obtained with peptide-based inhibitors are in accord with those predicted from the substrate specificity studies described earlier. The cowpox serpin CrmA is a potent (K-i < 20 nM) and selective inhibitor of Group I caspases (caspase-1, -4, and -5) and most Group III caspases (caspase-8, -9, and -10), suggesting that this virus facilitates infection through inhibition of both apoptosis and the host inflammatory response.	Merck Res Labs, Dept Enzymol, Rahway, NJ 07065 USA; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Med Chem, Pointe Claire, PQ H9R 4P8, Canada	Merck & Company; Merck & Company; Merck & Company	Garcia-Calvo, M (corresponding author), Merck Res Labs, Dept Enzymol, R80W-250,POB 2000, Rahway, NJ 07065 USA.							Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FRANKFATER A, 1981, BIOCHEMISTRY-US, V20, P5517, DOI 10.1021/bi00522a026; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kamada S, 1997, CELL DEATH DIFFER, V4, P473, DOI 10.1038/sj.cdd.4400268; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Rouquet N, 1996, CURR BIOL, V6, P1192, DOI 10.1016/S0960-9822(02)70688-X; Sambrook J., 2002, MOL CLONING LAB MANU; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; Thornberry Nancy A., 1995, Perspectives in Drug Discovery and Design, V2, P389, DOI 10.1007/BF02172032; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	36	821	866	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32608	32613		10.1074/jbc.273.49.32608	http://dx.doi.org/10.1074/jbc.273.49.32608			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829999	hybrid			2022-12-25	WOS:000077329100038
J	Lindsey, LA; Garcia-Blanco, MA				Lindsey, LA; Garcia-Blanco, MA			Functional conservation of the human homolog of the yeast pre-mRNA splicing factor Prp17p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2ND CATALYTIC STEP; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; G-PROTEIN; SPLICEOSOME; REQUIREMENT; MUTATIONS; NUCLEUS; SLU7P	Splicing of pre-mRNAs involves two sequential transesterification reactions commonly referred to as the first and second steps. In Saccharomyces cerevisiae, four proteins, Prp16p, Prp17p, Prp18p, and Slu7p are exclusively required for the second step of splicing. The human homologs of Prp16p, Prp17p, and Prp18p have been identified, and the human proteins hPrp16 and hPrp18 have been shown to be required for the second step of splicing in vitro. Here we provide further evidence for the functional conservation of the second step factors between yeast and humans. Human hPrp17, which is 35% identical to the S. cerevisiae protein, is able to partially rescue the temperature sensitive phenotype in a yeast strain where PRP17 has been knocked out, suggesting that the human and yeast proteins are functionally conserved. Overexpression of hPrp17 in the knockout yeast strain partially rescues the splicing defect seen in vitro and in vivo. In HeLa cells, hPrp17 is highly concentrated in the nuclear speckles, as is SC35 and many other splicing factors, thus providing further support that this protein also functions as a splicing factor in humans.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Levine Sci Res Ctr, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	garci001@mc.duke.edu	Lindsey-Boltz, Laura/A-3121-2010	Lindsey-Boltz, Laura/0000-0001-6493-8194	NIGMS NIH HHS [R01 GM49639] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049639] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; Ayadi L, 1997, RNA, V3, P197; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; FRANK D, 1992, MOL CELL BIOL, V12, P5197, DOI 10.1128/MCB.12.11.5197; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Harlow E., 1988, ANTIBODIES LAB MANUA; Horowitz DS, 1997, GENE DEV, V11, P139, DOI 10.1101/gad.11.1.139; HOROWITZ DS, 1993, GENE DEV, V7, P320, DOI 10.1101/gad.7.2.320; HOROWITZ DS, 1993, MOL CELL BIOL, V13, P2959, DOI 10.1128/MCB.13.5.2959; JONES MH, 1995, P NATL ACAD SCI USA, V92, P9687, DOI 10.1073/pnas.92.21.9687; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lauber J, 1997, RNA, V3, P926; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDSEY LA, 1995, J BIOL CHEM, V270, P13415, DOI 10.1074/jbc.270.22.13415; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Nilsen TW, 1998, COLD SPRING HARBOR M, P279; OKeefe RT, 1996, CELL, V86, P679, DOI 10.1016/S0092-8674(00)80140-3; ONO W, 1994, MOL CELL BIOL, V14, P7611, DOI 10.1128/MCB.14.11.7611; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RYMOND BC, 1993, NUCLEIC ACIDS RES, V21, P3501, DOI 10.1093/nar/21.15.3501; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHENA M, 1991, VECTORS CONSTITUTIVE, V194; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Umen JG, 1996, GENETICS, V143, P723; UMEN JG, 1995, RNA, V1, P584; Umen JG, 1995, RNA, V1, P869; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Xu DM, 1998, MOL CELL BIOL, V18, P2055, DOI 10.1128/MCB.18.4.2055; Zhou ZL, 1998, EMBO J, V17, P2095, DOI 10.1093/emboj/17.7.2095	34	18	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32771	32775		10.1074/jbc.273.49.32771	http://dx.doi.org/10.1074/jbc.273.49.32771			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830021	hybrid			2022-12-25	WOS:000077329100060
J	Shimabukuro, M; Higa, M; Zhou, YT; Wang, MY; Newgard, CB; Unger, RH				Shimabukuro, M; Higa, M; Zhou, YT; Wang, MY; Newgard, CB; Unger, RH			Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats - Role of serine palmitoyltransferase overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID SYNTHESIS; INSULIN-SECRETION; LEPTIN; CERAMIDE; PATHOGENESIS; INHIBITION; MUTATION; ISLETS	We reported that the lipoapoptosis of beta-cells observed in fat-laden islets of obese fa/fa Zucker Diabetic Fatty (ZDF) rats results from overproduction of ceramide, an initiator of the apoptotic cascade and is induced by long-chain fatty acids (FA), Whereas the ceramide of cytokine-induced apoptosis may be derived from sphingomyelin hydrolysis, FA-induced ceramide overproduction seems to be derived from FA. We therefore semiquantified mRNA of serine palmitoyltransferase (SPT), which catalyzes the first step in ceramide synthesis. It was 2-3-fold higher in fa/fa islets than in +/+ controls. [H-3]Ceramide formation from [H-3]serine was 2.2-4.5-fold higher in fa/fa islets, Triacsin-C, which blocks palmitoyl-CoA synthesis, and L-cycloserine, which blocks SPT activity, completely blocked [H-3]ceramide formation from [H-3]serine. Islets of fa/fa rats are unresponsive to the lipopenic action of leptin, which normally depletes fat and prevents FA up-regulation of SPT, To determine the role of leptin unresponsiveness in the SPT overexpression, we transferred wild type OB-Rb cDNA to their islets; now leptin completely blocked the exaggerated FA-induced increase of SPT mRNA while reducing the fat content. Beta-cell lipoapoptosis was partially prevented in vivo by treating prediabetic ZDF rats with L-cycloserine for 2 weeks. Ceramide content and DNA fragmentation both declined 40-50%. We conclude that lipoapoptosis of ZDF rats is mediated by enhanced ceramide synthesis from FA and that blockade by SPT inhibitors prevents lipoapoptosis.	Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Gifford Labs Diabet Res, Dept Biochem, Dallas, TX 75235 USA; Vet Affairs Med Ctr, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Ctr Diabet Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Runger@mednet.SWmed.edu		Shimabukuro, Michio/0000-0001-7835-7665	NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; DUKE RC, 1989, CELLULAR BASIS IMMUN, P311; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HOPCROFT DW, 1985, HORM METAB RES, V17, P559, DOI 10.1055/s-2007-1013606; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Kwon G, 1996, BBA-LIPID LIPID MET, V1300, P63, DOI 10.1016/0005-2760(95)00223-5; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; *NAT CTR HLTH STAT, 1994, NEWSWEEK, V127, P62; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; SJOHOLM A, 1995, FEBS LETT, V367, P283, DOI 10.1016/0014-5793(95)00470-T; SUNDARAM KS, 1984, J NEUROCHEM, V42, P577, DOI 10.1111/j.1471-4159.1984.tb02716.x; WANG E, 1991, J BIOL CHEM, V266, P14486; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	25	311	324	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32487	32490		10.1074/jbc.273.49.32487	http://dx.doi.org/10.1074/jbc.273.49.32487			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829981	hybrid			2022-12-25	WOS:000077329100020
J	Tamburrini, M; Romano, M; Carratore, V; Kunzmann, A; Coletta, M; di Prisco, G				Tamburrini, M; Romano, M; Carratore, V; Kunzmann, A; Coletta, M; di Prisco, G			The hemoglobins of the antarctic fishes Artedidraco orianae and Pogonophryne scotti - Amino acid sequence, lack of cooperativity, and ligand binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOTOTHENIA-CORIICEPS-NEGLECTA; ASCARIS HEMOGLOBIN; OXYGEN AVIDITY; PURIFICATION; ADAPTATION	The oxygen-transport system of two species of Antarctic fishes belonging to the family Artedidraconidae, Artedidraco orianae and Pogonophryne scotti, was thoroughly investigated. The complete amino acid sequence of the alpha and beta chains of the single hemoglobins of the two species was established. The oxygen-binding properties were also investigated, and were found not to differ significantly from those shown by blood, intact erythrocytes, and unstripped hemolysates. Both hemoglobins have unusually high oxygen affinity and display a relatively small Bohr effect; the Root effect is elicited only by organophosphates and is also reduced. Remarkably, the Hill coefficient is close to one in the whole pH range, indicating absence of cooperative oxygen binding which, in A. orianae hemoglobin, could be ascribed to the subunit heterogeneity shown upon oxygen dissociation. In comparison with the other families of the suborder Notothenioidei, the oxygen-transport system of these two species of Artedidraconidae has unique characteristics, which raise interesting questions on the mode of function of a multisubunit molecule and the relationship with cold adaptation.	CNR, Inst Prot Biochem & Enzymol, I-80125 Naples, Italy; Inst Polar Ecol, D-24148 Kiel, Germany; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); University of Rome Tor Vergata	di Prisco, G (corresponding author), CNR, Inst Prot Biochem & Enzymol, Via Marconi 10, I-80125 Naples, Italy.	diprisco@dafne.ibpe.na.cnr.it	Coletta, Massimo/N-9049-2015; Kunzmann, Andreas/O-5459-2019; Coletta, Massimiliano/GSN-5927-2022; Kunzmann, Andreas/O-1345-2013	Kunzmann, Andreas/0000-0002-9500-4332; Kunzmann, Andreas/0000-0002-9500-4332; TAMBURRINI, MAURIZIO/0000-0001-5987-0957; COLETTA, Massimiliano/0000-0002-5489-9467				Andriashev A.P., 1965, MONOGRAPHIAE BIOL, V15, P491; BALUSHKIN AV, 1992, J ICHTHYOL, V30, P132; BARGELLONI L, 1994, MOL BIOL EVOL, V11, P854; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; BRITTAIN T, 1987, COMP BIOCHEM PHYS B, V86, P473, DOI 10.1016/0305-0491(87)90434-2; COLETTA M, 1992, FEBS LETT, V296, P184, DOI 10.1016/0014-5793(92)80375-Q; COLETTA M, 1985, J BIOL CHEM, V260, P4151; COLETTA M, 1988, J BIOL CHEM, V263, P18286; DAVINO R, 1989, EUR J BIOCHEM, V179, P707, DOI 10.1111/j.1432-1033.1989.tb14604.x; DAVINO R, 1994, J BIOL CHEM, V269, P9675; DAVINO R, 1989, EUR J BIOCHEM, V179, P699, DOI 10.1111/j.1432-1033.1989.tb14603.x; DAVINO R, 1988, COMP BIOCHEM PHYS B, V90, P579, DOI 10.1016/0305-0491(88)90298-2; di Prisco G., 1991, P263; Di Prisco G., 1998, Society for Experimental Biology Seminar Series, V66, P143; Di Prisco G., 1996, Society for Experimental Biology Seminar Series, V59, P23; DIPRISCO G, 1988, COMP BIOCHEM PHYS B, V90, P631, DOI 10.1016/0305-0491(88)90304-5; DIPRISCO G, 1989, ANTARCT SCI, V1, P119; DIPRISCO G, 1988, COMP BIOCHEM PHYS B, V90, P585, DOI 10.1016/0305-0491(88)90299-4; DIPRISCO G, 1990, POLAR BIOL, V10, P269, DOI 10.1007/BF00238425; DIPRISCO G, 1997, P SCAR 6 BIOL S VEN, P251; DIPRISCO G, 1994, P 2 M ANT BIOL, P157; Eastman J. T, 1993, ANTARCTIC FISH BIOL; Everson I., 1968, Bulletin British Antarctic Survey, VNo. 15, P59; FAGO A, 1993, EUR J BIOCHEM, V218, P829, DOI 10.1111/j.1432-1033.1993.tb18438.x; GARLAND T, 1994, ANNU REV PHYSIOL, V56, P579, DOI 10.1146/annurev.ph.56.030194.003051; Giardina B, 1981, Methods Enzymol, V76, P417; GON O, 1990, FISHES SO OCEAN; HUREAU JC, 1977, ADAPTATIONS ANTARCTI, P459; IWAMI T, 1985, MEM NATL I POLAR R E, V36, P1; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; REEVE HK, 1993, Q REV BIOL, V68, P1, DOI 10.1086/417909; Root RW, 1931, BIOL BULL-US, V61, P427, DOI 10.2307/1536959; RUUD JT, 1954, NATURE, V173, P848, DOI 10.1038/173848a0; TAMBURRINI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P295, DOI 10.1016/0003-9861(92)90082-8; TETENS V, 1984, COMP BIOCHEM PHYS B, V79, P119, DOI 10.1016/0305-0491(84)90086-5; WELLS RMG, 1983, NATURE, V306, P500, DOI 10.1038/306500a0; WELLS RMG, 1980, J FISH BIOL, V17, P517, DOI 10.1111/j.1095-8649.1980.tb02783.x; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224	40	18	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32452	32459		10.1074/jbc.273.49.32452	http://dx.doi.org/10.1074/jbc.273.49.32452			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829976	hybrid			2022-12-25	WOS:000077329100015
J	Jensen-Jarolim, E; Leitner, A; Kalchhauser, H; Zurcher, A; Ganglberger, E; Bohle, B; Scheiner, O; Boltz-Nitulescu, G; Breiteneder, H				Jensen-Jarolim, E; Leitner, A; Kalchhauser, H; Zurcher, A; Ganglberger, E; Bohle, B; Scheiner, O; Boltz-Nitulescu, G; Breiteneder, H			Peptide mimotopes displayed by phage inhibit antibody binding to Bet v 1, the major birch pollen allergen, and induce specific IgG response in mice	FASEB JOURNAL			English	Article						Bet v 1; allergy; phage; mimotope; oral immunization; monoclonal antibodies	DISCONTINUOUS EPITOPES; MONOCLONAL-ANTIBODIES; AFFINITY PURIFICATION; FILAMENTOUS PHAGE; LIBRARY; BET-V-1; LIGANDS; INDIVIDUALS; EXPRESSION; SELECTION	The major birch pollen allergen Bet v 1 is one of the most extensively characterized allergens both on the molecular and the immunological level. To define conformational B cell epitopes on Bet v 1, we screened filamentous phage libraries expressing circular or linear nonapeptides to select-ligands specific for anti-Bet v 1 murine monoclonal antibodies BIP1 and BIP4. The deduced amino acid sequence of the BIP1 ligand was CFPYCYPSESA, and of the BIP4-ligand, CRQTRTMPGC. Both sequences derived from the circular phage library. Alignments to the sequence of Bet v 1 showed no similarities, indicating that the antibodies most likely recognize discontinuous epitopes. Phages displaying these mimotopes were capable of inhibiting interactions of the anti-Bet v 1 monoclonals with Bet v 1 in a dose-dependent manner in ELISA. In contrast, sequence-identical synthetic peptides were ineffective in blocking the antibody-allergen interactions. This is in agreement with the conformational inhomogeneity of the peptides in solution as observed by nuclear magnetic resonance spectroscopy. Intragastric administration of phages expressing the BIP1 mimotope induced a Bet v 1-specific IgG response in Balb/c mice. We conclude that peptide mimotopes, when displayed on phages, may induce a protective IgG response preventing IgE-mediated allergic reactions, suggesting a possible clinical application.	Univ Vienna, Dept Gen & Expt Pathol, AKH, A-1090 Vienna, Austria; Univ Vienna, Dept Organ Chem, A-1010 Vienna, Austria; Univ Bern, Inst Immunol & Allergol, CH-3012 Bern, Switzerland	University of Vienna; University of Vienna; University of Bern	Jensen-Jarolim, E (corresponding author), Univ Vienna, Dept Gen & Expt Pathol, AKH, EBO-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765; Bohle, Barbara/0000-0002-5105-7985				BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Delmastro P, 1997, VACCINE, V15, P1276, DOI 10.1016/S0264-410X(97)00072-8; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GOVIL G, 1982, CONFORMATION BIOL MO; HAMBURGER RN, 1975, SCIENCE, V189, P389, DOI 10.1126/science.1145208; HAMBURGER RN, 1989, PROGR ALLERGY CLIN I, V1, P109; HASLINGER E, 1984, MONATSH CHEM, V115, P779, DOI 10.1007/BF01120974; Helm BA, 1997, ALLERGY, V52, P1155, DOI 10.1111/j.1398-9995.1997.tb02518.x; Hurd R. E., 1996, ENCY NMR, V3, P1990; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MEOLA A, 1995, J IMMUNOL, V154, P3162; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAULI G, 1992, ACI NEWS, V4, P43; ROHAC M, 1991, MOL IMMUNOL, V28, P879; Schafer T, 1997, ALLERGY, V52, P14, DOI 10.1111/j.1398-9995.1997.tb04864.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STANWORTH DR, 1991, LANCET, V337, P1608; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; VALENTA R, 1998, IN PRESS INT ARCH AL; Weiss C, 1996, INT ARCH ALLERGY IMM, V110, P282, DOI 10.1159/000237300; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836	36	64	76	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1635	1642		10.1096/fasebj.12.15.1635	http://dx.doi.org/10.1096/fasebj.12.15.1635			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837853				2022-12-25	WOS:000077574500005
J	Turner, RMO; Johnson, LR; Haig-Ladewig, L; Gerton, GL; Moss, SB				Turner, RMO; Johnson, LR; Haig-Ladewig, L; Gerton, GL; Moss, SB			An x-linked gene encodes a major human sperm fibrous sheath protein, hAKAP82	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ANCHORING PROTEINS; II REGULATORY SUBUNITS; A-KINASE; TYROSINE PHOSPHORYLATION; MOUSE SPERM; MOTILITY; LOCALIZATION; CAPACITATION; IDENTIFICATION; SPERMATOZOA	Mammalian sperm motility is regulated by a cascade of cAMP-dependent protein phosphorylation events mediated by protein kinase A. A-kinase anchor proteins (AKAPs) direct protein kinase A activity by tethering the enzyme near its physiological substrates, We have characterized a major human sperm fibrous sheath AKAP, hAKAP82, and its precursor, pro-hAKAP82, the homologues of the mouse fibrous sheath proteins mAKAP82 and pro-mAKAP82. The cDNA sequence of pro-hAKAP82 was highly homologous to the mouse sequence, and the functional domains of the pro-hAKAP82 protein, the protein kinase A binding, and the pro-hAKAP82/hAKAP82 cleavage sites were identical to those of the mouse protein. The genomic organization of mouse pro-AKAP82 was determined. Alternative splicing occurred in both the mouse and human pro-AKAP82 genes that resulted in at least two distinct transcripts and possibly two different proteins. Compared with pro-mAKAP82, considerably less pro-hAKAP8a was processed to hAKAP82 in human sperm. Although pro-mAKAP82 localizes only to the proximal portion of the principal piece of the flagellum, pro-hAKAP82 localized to the entire length of the principal piece. The pro-hAKAP82 gene mapped to human chromosome Xp11.2, indicating that defects in this gene are maternally inherited, These studies suggest several roles for hAKAP82 in sperm motility, including the regulation of signal transduction pathways.	Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Moss, SB (corresponding author), Univ Penn, Sch Med, Ctr Res Reprod & Womens Hlth, Dept Obstet & Gynecol, 3620 Hamilton Walk,John Morgan Bldg,Rm 305, Philadelphia, PA 19104 USA.	smoss@mail.med.upenn.edu	Gerton, George L/A-1039-2007	Gerton, George L/0000-0001-9894-5640	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001189] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01189, HD06274] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BELL C, 1994, TRENDS BIOCHEM SCI, V19, P427, DOI 10.1016/0968-0004(94)90093-0; BROKAW CJ, 1987, J CELL BIOCHEM, V35, P175, DOI 10.1002/jcb.240350302; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; CARR DW, 1992, J BIOL CHEM, V267, P16816; Carrera A, 1996, DEV BIOL, V180, P284, DOI 10.1006/dbio.1996.0301; CARRERA A, 1994, DEV BIOL, V165, P272, DOI 10.1006/dbio.1994.1252; CHEMES HE, 1987, FERTIL STERIL, V48, P664; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Dong F, 1998, J BIOL CHEM, V273, P6533, DOI 10.1074/jbc.273.11.6533; EFZELIUS BA, 1979, J ULTRASTRUCT RES, V69, P43; ELIASSON R, 1977, NEW ENGL J MED, V297, P1, DOI 10.1056/NEJM197707072970101; FULCHER KD, 1995, BIOL REPROD, V52, P41, DOI 10.1095/biolreprod52.1.41; GalantinoHomer HL, 1997, BIOL REPROD, V56, P707, DOI 10.1095/biolreprod56.3.707; Han JD, 1997, J BIOL CHEM, V272, P26611, DOI 10.1074/jbc.272.42.26611; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; Johnson LR, 1997, DEV BIOL, V192, P340, DOI 10.1006/dbio.1997.8767; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIN RY, 1995, J BIOL CHEM, V270, P27804, DOI 10.1074/jbc.270.46.27804; LINDEMANN CB, 1992, J CELL SCI, V102, P249; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Mohapatra B, 1998, BIOCHEM BIOPH RES CO, V244, P540, DOI 10.1006/bbrc.1998.8079; MORALES P, 1988, J REPROD FERTIL, V83, P119; Moss SB, 1997, MAMM GENOME, V8, P37, DOI 10.1007/s003359900342; NARAYAN D, 1994, J MED GENET, V31, P493, DOI 10.1136/jmg.31.6.493; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; RUBIN CS, 1994, BIOCHIM BIOPHYS ACTA, V1224, P407; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TASH JS, 1988, J CELL BIOL, V106, P1625, DOI 10.1083/jcb.106.5.1625; TASH JS, 1982, BIOL REPROD, V26, P745, DOI 10.1095/biolreprod26.4.745; TASH JS, 1994, J ANDROL, V15, P505; Vijayaraghavan S, 1997, J BIOL CHEM, V272, P4747, DOI 10.1074/jbc.272.8.4747; Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	41	78	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32135	32141		10.1074/jbc.273.48.32135	http://dx.doi.org/10.1074/jbc.273.48.32135			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822690	hybrid			2022-12-25	WOS:000077207000072
J	Young, ET; Saario, J; Kacherovsky, N; Chao, A; Sloan, JS; Dombek, KM				Young, ET; Saario, J; Kacherovsky, N; Chao, A; Sloan, JS; Dombek, KM			Characterization of a p53-related activation domain in Adr1p that is sufficient for ADR1-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ADR1; REPRESSIBLE ALCOHOL-DEHYDROGENASE; REGULATORY PROTEIN ADR1; SACCHAROMYCES-CEREVISIAE; ADH2 EXPRESSION; DNA-BINDING; PEROXISOME PROLIFERATION; MESSENGER-RNA; YEAST; TRANSACTIVATION	The yeast transcriptional activator Adr1p controls expression of the glucose-repressible alcohol dehydrogenase gene (ADH2), genes involved in glycerol metabolism, and genes required for peroxisome biogenesis and function. Previous data suggested that promoter-specific activation domains might contribute to expression of the different types of ADR1-dependent genes, By using gene fusions encoding: the Gal4p DNA binding domain and portions of Adr1p, we identified a single, strong acidic activation domain spanning amino acids 420-462 of Adr1p. Both acidic and hydrophobic amino acids within this activation domain were important for its function. The critical hydrophobic residues are in a motif previously identified in p53 and related acidic activators. A mini-Adr1 protein consisting of the DNA binding domain of Adr1p fused to this 42-residue activation domain carried out all of the known functions of wild-type ADR1. It conferred stringent glucose repression on the ADH2 locus and on UAS1-containing reporter genes. The putative inhibitory region of Adr1p encompassing the protein kinase A phosphorylation site at Ser-230 is thus not essential for glucose repression mediated by ADR1. Mini-ADR1 allowed efficient derepression of gene expression. In addition it complemented an ADR1-null allele for growth on glycerol and oleate media, indicating efficient activation of genes required for glycerol metabolism and peroxisome biogenesis. Thus, a single activation domain can activate all ADR1-dependent promoters.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Young, ET (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	ety@u.washington.edu			NIGMS NIH HHS [GM 26079] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026079] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; BEIER DR, 1982, NATURE, V300, P724, DOI 10.1038/300724a0; BLUMBERG H, 1987, THESIS U WASHINGTON; Brown SA, 1998, EMBO J, V17, P3146, DOI 10.1093/emboj/17.11.3146; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CIRIACY M, 1979, MOL GEN GENET, V176, P427, DOI 10.1007/BF00333107; CIRIACY M, 1976, MOL GEN GENET, V145, P327, DOI 10.1007/BF00325831; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DENIS CL, 1986, MOL CELL BIOL, V6, P4026, DOI 10.1128/MCB.6.11.4026; DENIS CL, 1992, MOL CELL BIOL, V12, P1507, DOI 10.1128/MCB.12.4.1507; DENIS CL, 1981, J MOL BIOL, V148, P355, DOI 10.1016/0022-2836(81)90181-9; Ding WV, 1997, MOL CELL BIOL, V17, P2538, DOI 10.1128/MCB.17.5.2538; Dombek KM, 1997, MOL CELL BIOL, V17, P1450, DOI 10.1128/MCB.17.3.1450; DOMBEK KM, 1993, MOL CELL BIOL, V13, P4391, DOI 10.1128/MCB.13.7.4391; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; FINLEY RL, 1990, MOL CELL BIOL, V10, P5663, DOI 10.1128/MCB.10.11.5663; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAMPSEY M, 1997, CURR BIOL, V7, P44; HARTSHORNE TA, 1986, NATURE, V320, P283, DOI 10.1038/320283a0; Huang J, 1998, MOL CELL BIOL, V18, P5478, DOI 10.1128/MCB.18.9.5478; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; James P, 1996, GENETICS, V144, P1425; KARNITZ L, 1992, GENETICS, V132, P351; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Moqtaderi Z, 1996, P NATL ACAD SCI USA, V93, P14654, DOI 10.1073/pnas.93.25.14654; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHUSTER J, 1986, MOL CELL BIOL, V6, P1894, DOI 10.1128/MCB.6.6.1894; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; THUKRAL SK, 1992, MOL CELL BIOL, V12, P2784, DOI 10.1128/MCB.12.6.2784; THUKRAL SK, 1991, MOL CELL BIOL, V11, P1566, DOI 10.1128/MCB.11.3.1566; THUKRAL SK, 1989, MOL CELL BIOL, V9, P2360, DOI 10.1128/MCB.9.6.2360; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VALLARI RC, 1992, MOL CELL BIOL, V12, P1663, DOI 10.1128/MCB.12.4.1663; ZAWEL M, 1995, ANNU REV BIOCHEM, V64, P533	57	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32080	32087		10.1074/jbc.273.48.32080	http://dx.doi.org/10.1074/jbc.273.48.32080			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822683	hybrid			2022-12-25	WOS:000077207000065
J	Schmidt, T; Karsunky, H; Gau, E; Zevnik, B; Elsasser, HP; Moroy, T				Schmidt, T; Karsunky, H; Gau, E; Zevnik, B; Elsasser, HP; Moroy, T			Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis	ONCOGENE			English	Article						oncogene cooperation; zinc finger	E-MU-MYC; TRANSGENIC MICE; N-MYC; C-MYC; ACTIVATION; TUMORS	The gfi-1 gene encodes a zinc finger containing protein that is specifically expressed in T-lymphocytes and is a frequent target of proviral insertion in T-cell lymphoma provoked by infection with MoMuLV-a non acute transforming retrovirus. Expression of a gfi-1 transgene targeted to T-cells by the lck proximal promoter provokes a reduction of peripheral CD4 and CD8 positive T-cells but nevertheless weakly predisposes transgenic animals for the development of T-cell lymphoma. Forced coexpression of the serine/threonine kinase Pim-1 can partially restore normal T-cell numbers in double pim-1/gfi-1 transgenic mice. Moreover, the combinatorial expression of Pim-1 and Gfi-1 leads to accelerated development of T-cell lymphoma with a mean latency period of 114 days. A similar accelerated rate of lymphoma development was observed when lck-gfi-1 mice were crossed with mice that carry a L-myc gene targeted to be expressed at high levels in T-cells. The results show that gfi-1 can act with low activity as a dominant oncogene when overexpressed but also demonstrate that it is most efficient only in the presence of a cooperative partner protein as for example Pim-1 or L-Myc. In addition, the results suggest that Pim-1 and Gfi-1 are acting synergistically in both T-cell lymphomagenesis and T-cell development.	Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumourforsch, IFZ, D-45122 Essen, Germany; Univ Marburg, Inst Zytobiol & Zytopathol, D-35033 Marburg, Germany	University of Duisburg Essen; Philipps University Marburg	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, Inst Zellbiol Tumourforsch, IFZ, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011; Zevnik, Branko/AAB-7853-2020	Zevnik, Branko/0000-0001-7845-9522				BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOGAN B, 1986, MANIPULATION MOUSE E; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; Sambrook J., 2002, MOL CLONING LAB MANU; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Zornig M, 1996, ONCOGENE, V12, P1789	15	98	100	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2661	2667		10.1038/sj.onc.1202191	http://dx.doi.org/10.1038/sj.onc.1202191			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840930				2022-12-25	WOS:000077058900014
J	Choe, CY; Im, HJ; Ko, JL; Loh, HH				Choe, CY; Im, HJ; Ko, JL; Loh, HH			Mouse mu opioid receptor gene expression - A 34-base pair cis-acting element inhibits transcription of the mu opioid receptor gene from the distal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SECONDARY STRUCTURE; REGION; RAT; TRANSLATION; SEQUENCES; CLONING	The 5'-flanking region of the mouse mu opioid receptor (MOR) gene has two promoters, referred to as distal and proximal, and the activities of each in the brain are quite different from each other. The 5'-distal promoter regulatory sequences (5'-DPRS), positioned between these two promoters, have strong inhibitory effects on the reporter gene expression driven by the MOR distal promoter. In our studies, detailed 3' deletion mapping of the 5'-DPRS narrowed down the negative cis-acting element to a 34-base pair (bp) segment (position -721 to -687). This 34-bp cis-acting element functions in both neuronal (NMB) and non-neuronal (CHO and RAW264.7) cultured cells. S1 nuclease protection assays indicated that this 34-bp cis-acting element suppresses distal promoter activity at the transcriptional level. Linker scanning mutagenesis demonstrated that nucleotides around position -721 and -689 in the 34-bp cis-acting element are essential for the regulation of distal promoter activity. Operational characterization of the 34-bp cis-acting element in the homologous MOR distal promoter and the heterologous SV40 promoter showed that its effects are position- and promoter-dependent while being orientation-independent in both promoters. Collectively, these data suggested that this 34-bp segment is a conditional transcriptional cis-acting element that blocks mouse MOR gene expression from the distal promoter.	Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Choe, CY (corresponding author), Univ Minnesota, Dept Pharmacol, Sch Med, 3-249 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.	choex003@ec.umn.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA005695, R37DA001583, R01DA001583] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002647] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR053220-04, R01 AR053220] Funding Source: Medline; NIDA NIH HHS [DA-00546, DA-01583, DA-05695] Funding Source: Medline; BLRD VA [I01 BX002647] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); Veterans Affairs(US Department of Veterans Affairs); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); BLRD VA		ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BAUMHAKER Y, 1994, BRAIN RES, V665, P94, DOI 10.1016/0006-8993(94)91156-8; BRODSKY M, 1995, NEUROREPORT, V6, P725, DOI 10.1097/00001756-199503270-00005; DELFS JM, 1994, J NEUROCHEM, V63, P777; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KIM SJ, 1992, J BIOL CHEM, V267, P13702; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRAUS J, 1995, BIOCHEM BIOPH RES CO, V215, P591, DOI 10.1006/bbrc.1995.2505; LIANG YB, 1995, BRAIN RES, V679, P82, DOI 10.1016/0006-8993(95)00222-C; Liang YB, 1997, BRAIN RES, V769, P372, DOI 10.1016/S0006-8993(97)00854-8; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; MA CK, 1994, MOL MICROBIOL, V14, P1033, DOI 10.1111/j.1365-2958.1994.tb01337.x; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; Olson GA, 1997, PEPTIDES, V18, P1651, DOI 10.1016/S0196-9781(97)00264-7; PATEL RC, 1992, J BIOL CHEM, V267, P1159; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Ruzicka BB, 1997, NEUROSCIENCE, V79, P517, DOI 10.1016/S0306-4522(96)00669-0; SIMANTOV R, 1989, J NEUROCHEM, V52, P305, DOI 10.1111/j.1471-4159.1989.tb10931.x; SIMANTOV R, 1986, DEV BRAIN RES, V391, P301; SNYDER SH, 1984, SCIENCE, V224, P22, DOI 10.1126/science.6322304; Wendel B, 1998, J MOL MED-JMM, V76, P525, DOI 10.1007/s001090050246; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; YANOFSKY C, 1988, J BIOL CHEM, V263, P609	29	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34926	34932		10.1074/jbc.273.52.34926	http://dx.doi.org/10.1074/jbc.273.52.34926			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857022	Green Accepted, hybrid			2022-12-25	WOS:000077719700040
J	Urbano, A; McCaffrey, R; Foss, F				Urbano, A; McCaffrey, R; Foss, F			Isolation and characterization of NUC70, a cytoplasmic, hematopoietic apoptotic endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL-ELECTROPHORESIS; DNA FRAGMENTATION; CELL-DEATH; CA2+/MG2+-DEPENDENT ENDONUCLEASE; INTRACELLULAR ACIDIFICATION; ENDO-EXONUCLEASE; RAT THYMOCYTES; JURKAT CELLS; IDENTIFICATION; PURIFICATION	Endonucleolytic DNA fragmentation is the common end point and the prevailing indicator of apoptosis, We have identified a 70-kDa endonuclease (NUC70) that is activated in drug-induced apoptosis of human hematopoietic cells. We purified NUC7O to homogeneity and generated a rabbit polyclonal antibody to distinguish it from previously identified nucleases. Biochemical characterization of isolated NUC70 demonstrates that it is Ca2+/Mg2+-dependent and active over a pH range of 6-8, When incubated with isolated HeLa nuclei, NUC70 was capable of generating internucleosomal DNA fragmentation. This endonucleolytic activity was inhibited by Zn2+, aurintricarboxylic acid, N-ethylnaleimide, spermine, and iodoacetamide. Western immunoblots using the anti-NUC70 antibody and DNA-SDS-polyacrylamide gel electrophoresis assays indicate that NUC70 expression and activity is restricted to human hematopoietic cells. No such activity was detected in human epithelial cell lines or murine hematopoietic cells. We also observed no difference in levels of NUC70 expression between apoptotic and nonapoptotic cells, suggesting that activation of NUC70 may be by posttranslational modification. We demonstrate that NUC70 activity is diminished in cells pretreated with the caspase inhibitors z-DEVD-fmk, z-VAD-fmk, and Z-CH2-Asp-DCB. Time course studies of cytoplasmic and nuclear endonuclease activities during apoptosis show that NUC70 is a cytoplasmic endonuclease that is translocated to the nucleus after the initiation of apoptosis, We confirmed this with immuno staining studies using anti-NUC70 antibody. These results demonstrate that NUC70 is an endogenous cytoplasmic endonuclease that is activated during apoptosis in a caspase-dependent mechanism.	Tufts Univ, New England Med Ctr, Dept Hematol Oncol, Boston, MA 02111 USA; Boston Univ, Dept Pathol, Sch Med, Boston, MA 02111 USA; Boston Univ, Dept Lab Med, Sch Med, Boston, MA 02111 USA; Boston Med Ctr, Dev Therapeut Program, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Boston University; Boston University; Boston Medical Center	Foss, F (corresponding author), Tufts Univ, New England Med Ctr, Dept Hematol Oncol, 750 Washington St, Boston, MA 02111 USA.							ARENDS MJ, 1990, AM J PATHOL, V136, P593; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; Bendjennat M, 1997, J BACTERIOL, V179, P2210, DOI 10.1128/jb.179.7.2210-2220.1997; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONLESLIE LAM, 1991, J STEROID BIOCHEM, V40, P661, DOI 10.1016/0960-0760(91)90288-G; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V231, P717, DOI 10.1006/bbrc.1997.6176; CHOW TYK, 1983, J BIOL CHEM, V258, P2010; Collins MKL, 1996, J CELL SCI, V109, P2393; COMPTON MM, 1987, J BIOL CHEM, V262, P8288; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FLECKENSTEIN E, 1994, LEUKEMIA, V8, P1424; Fraser MJ, 1996, J CELL SCI, V109, P2343; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GENDIMENICO GJ, 1988, ANAL BIOCHEM, V173, P45, DOI 10.1016/0003-2697(88)90156-X; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; GOTTLIEB RA, 1995, BLOOD, V86, P2414, DOI 10.1182/blood.V86.6.2414.bloodjournal8662414; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Kawabata H, 1997, BIOCHEM BIOPH RES CO, V233, P133, DOI 10.1006/bbrc.1997.6362; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khodarev NN, 1998, INT J RADIAT BIOL, V73, P455; Khodarev NN, 1996, J IMMUNOL, V156, P922; Krueger E, 1998, ANTICANCER RES, V18, P983; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MCGREW BR, 1990, ANAL BIOCHEM, V189, P68, DOI 10.1016/0003-2697(90)90045-B; Mesner P W Jr, 1997, Adv Pharmacol, V41, P461, DOI 10.1016/S1054-3589(08)61069-8; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Nishikawa A, 1997, BIOCHEM BIOPH RES CO, V231, P305, DOI 10.1006/bbrc.1997.6091; Paddenberg R, 1996, EUR J CELL BIOL, V71, P105; Pandey S, 1997, BIOCHEMISTRY-US, V36, P711, DOI 10.1021/bi962387h; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; POLZAR B, 1993, EUR J CELL BIOL, V62, P397; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; ROSENTHAL AL, 1977, ANAL BIOCHEM, V80, P76, DOI 10.1016/0003-2697(77)90627-3; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Shiokawa D, 1997, ARCH BIOCHEM BIOPHYS, V346, P15, DOI 10.1006/abbi.1997.0275; TAKAUJI R, 1995, JPN J CANCER RES, V86, P677, DOI 10.1111/j.1349-7006.1995.tb02452.x; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Walker PR, 1997, BIOCHEM CELL BIOL, V75, P287, DOI 10.1139/bcb-75-4-287; ZHANG CH, 1995, CELL IMMUNOL, V165, P161, DOI 10.1006/cimm.1995.1201	44	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34820	34827		10.1074/jbc.273.52.34820	http://dx.doi.org/10.1074/jbc.273.52.34820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857008	hybrid			2022-12-25	WOS:000077719700026
J	Domon, C; Lorkovic, ZJ; Valcarcel, J; Filipowicz, W				Domon, C; Lorkovic, ZJ; Valcarcel, J; Filipowicz, W			Multiple forms of the U2 small nuclear ribonucleoprotein auxiliary factor U2AF subunits expressed in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICE-SITE SELECTION; PROTEIN-PROTEIN INTERACTIONS; NICOTIANA-PLUMBAGINIFOLIA; ARABIDOPSIS-THALIANA; BINDING PROTEINS; SEQUENCE; CLONING; YEAST; RECOGNITION	Requirements for intron recognition during pre-mRNA splicing in plants differ from those in vertebrates and yeast. Plant introns contain neither conserved branch points nor distinct 3' splice site-proximal polypyrimidine tracts characteristic of the yeast and vertebrate introns, respectively. However, they are strongly enriched in U residues throughout the intron, property essential for splicing. To understand the roles of different sequence elements in splicing, we are characterizing proteins involved in intron recognition in plants. In this work we show that Nicotiana plumbaginifolia, a dicotyledonous plant, contains two genes encoding different homologs of the large 50-65-kDa subunit of the polypyrimidine tract binding factor U2AF, characterized previously in animals and Schizosaccharomyces pombe. Both plant U2AF(65) isoforms, referred to as NpU2AF(65)a and NpU2AF(65)b, support splicing of an adenovirus pre-mRNA in HeLa cell nuclear extracts depleted of the endogenous U2AF factor. Both proteins interact with RNA fragments containing plant introns and show affinity for poly(U) and, to a lesser extend, poly(C) and poly(G). The branch point or the 3' splice site regions do not contribute significantly to intron recognition by NpU2AF(65). The existence of multiple isoforms of U2AF may be quite general in plants because two genes expressing U2AF(65) have been identified in Arabidopsis, and different isoforms of the U2AF small subunit are expressed in rice.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	Friedrich Miescher Institute for Biomedical Research; European Molecular Biology Laboratory (EMBL)	Filipowicz, W (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.	Filipowi@FMI.CH	Domon-Dell, Claire/P-2368-2017; Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571; Lorkovic, Zdravko/0000-0002-3074-7258; DOMON-DELL, Claire/0000-0002-8445-9593				ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; Arrand J., 1985, NUCLEIC ACID HYBRIDI, P17; Baynton CE, 1996, PLANT J, V10, P703, DOI 10.1046/j.1365-313X.1996.10040703.x; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Egoavil C, 1997, PLANT J, V12, P971, DOI 10.1046/j.1365-313X.1997.12050971.x; Filipowicz W., 1994, PREMRNA PROCESSING, P65; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Genschik P, 1997, J BIOL CHEM, V272, P13211, DOI 10.1074/jbc.272.20.13211; Gniadkowski M, 1996, NUCLEIC ACIDS RES, V24, P619, DOI 10.1093/nar/24.4.619; Golovkin M, 1996, PLANT CELL, V8, P1421, DOI 10.1105/tpc.8.8.1421; GOODALL GJ, 1991, EMBO J, V10, P2635, DOI 10.1002/j.1460-2075.1991.tb07806.x; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; KANAAR R, 1993, SCIENCE, V262, P569, DOI 10.1126/science.7692602; Ko CH, 1998, PLANT MOL BIOL, V36, P573, DOI 10.1023/A:1005932620374; Liu HX, 1996, PLANT J, V9, P381, DOI 10.1046/j.1365-313X.1996.09030381.x; LOU H, 1993, MOL CELL BIOL, V13, P4485, DOI 10.1128/MCB.13.8.4485; LUEHRSEN KR, 1994, PROG NUCLEIC ACID RE, V47, P149, DOI 10.1016/S0079-6603(08)60252-4; LUEHRSEN KR, 1994, GENE DEV, V8, P1117, DOI 10.1101/gad.8.9.1117; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCCULLOUGH AJ, 1993, MOL CELL BIOL, V13, P1323, DOI 10.1128/MCB.13.3.1323; Merritt H, 1997, PLANT J, V12, P937, DOI 10.1046/j.1365-313X.1997.12040937.x; MIESZCZAK M, 1992, MOL GEN GENET, V234, P390, DOI 10.1007/BF00538698; Moore M., 1993, RNA WORLD, P303; OROZCO BM, 1993, PLANT PHYSIOL, V102, P227, DOI 10.1104/pp.102.1.227; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; Rudner DZ, 1998, MOL CELL BIOL, V18, P1765, DOI 10.1128/MCB.18.4.1765; RYMOND BC, 1992, MOL CELLULAR BIOL YE, V2, P143; Schuler MA, 1998, LOOK BEYOND TRANSCRIPTION, P1; Simpson CG, 1996, PLANT J, V9, P369, DOI 10.1046/j.1365-313X.1996.09030369.x; SIMPSON CG, 1993, PLANT MOL BIOL, V21, P205, DOI 10.1007/BF00019937; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; STAKNIS D, 1995, NUCLEIC ACIDS RES, V23, P4081, DOI 10.1093/nar/23.20.4081; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VALCARCEL J, 1997, MRNA FORMATION FUNCT, P31; WentzHunter K, 1996, NUCLEIC ACIDS RES, V24, P1849, DOI 10.1093/nar/24.10.1849; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769; Zorio DAR, 1997, MOL CELL BIOL, V17, P946, DOI 10.1128/MCB.17.2.946; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	52	37	44	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34603	34610		10.1074/jbc.273.51.34603	http://dx.doi.org/10.1074/jbc.273.51.34603			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852132	hybrid			2022-12-25	WOS:000077542200098
J	Fisher, BM; Grilley, JE; Raines, RT				Fisher, BM; Grilley, JE; Raines, RT			A new remote subsite in ribonuclease A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC RIBONUCLEASE; CATALYTIC PROPERTIES; BINDING-ENERGY; NUCLEIC-ACID; ENZYME; SITE; CONFORMATION; STABILITY; COMPLEX; MODEL	The interaction between bovine pancreatic ribonuclease A (RNase A) and its RNA substrate extends beyond the scissile bond. Enzymic subsites interact with the bases and the phosphoryl groups of a bound substrate. We evaluated the four cationic residues closest to known subsites for their abilities to interact with a bound nucleic acid. Lys-37, Arg-39, Arg-85, and Lys-104 were replaced individually by an alanine residue, and the resulting enzymes were assayed as catalysts of poly(cytidylic acid) (poly(C)) cleavage. The values of K-m and k(cat)/K-m for poly(C) cleavage were affected only by replacing Arg-85. Moreover, the contribution of Arg-85 to the binding of the ground state and the transition state was uniform-K-m increased by 15-fold and k(cat)/K-m decreased by 10-fold, The contribution of Arg-85 to binding was also apparent in the values of K-d for complexes with oligonucleotides of different length. This contribution was dependent on salt concentration, as expected from a coulombic interaction between a cationic side chain and an anionic phosphoryl group. Together, these data indicate that Arg-85 interacts with a particular phosphoryl group of a bound nucleic acid. We propose that Arg-85 comprises a new distal subsite in RNase A-the P(-1) subsite.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53706 USA.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NIGMS NIH HHS [GM-44783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEINTEMA JJ, 1987, LIFE CHEM REPORTS, V4, P333; BOIX E, 1994, J BIOL CHEM, V269, P2529; Cleland W W, 1979, Methods Enzymol, V63, P103; Cuchillo C. M., 1997, RIBONUCLEASES STRUCT, P271; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; Eberhardt ES, 1996, PROTEIN SCI, V5, P1697, DOI 10.1002/pro.5560050823; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; FISHER BM, 1998, IN PRESS BIOCHEMISTR, V37; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; HANSEN DE, 1990, J CHEM EDUC, V67, P483, DOI 10.1021/ed067p483; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JENSEN DE, 1976, J BIOL CHEM, V251, P7198; Kelemen BR, 1997, TECH PROT CHEM, V8, P565, DOI 10.1016/S1080-8914(97)80056-7; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P916; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; Nogues MV, 1998, CELL MOL LIFE SCI, V54, P766, DOI 10.1007/s000180050205; PAGE MI, 1977, ANGEW CHEM INT EDIT, V16, P449, DOI 10.1002/anie.197704491; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WALZ FG, 1971, BIOCHEMISTRY-US, V10, P2156, DOI 10.1021/bi00787a031; YAKOVLEV GI, 1992, EUR J BIOCHEM, V204, P187, DOI 10.1111/j.1432-1033.1992.tb16622.x; ZEGERS I, 1994, PROTEIN SCI, V3, P2322, DOI 10.1002/pro.5560031217	30	58	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34134	34138		10.1074/jbc.273.51.34134	http://dx.doi.org/10.1074/jbc.273.51.34134			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852072	hybrid			2022-12-25	WOS:000077542200038
J	Janne, M; Hammond, GL				Janne, M; Hammond, GL			Hepatocyte nuclear factor-4 controls transcription from a TATA-less human sex hormone-binding globulin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM STIMULATORY FACTOR; DIRECT BASAL TRANSCRIPTION; TISSUE-SPECIFIC EXPRESSION; ACID SYNTHASE PROMOTER; COUP-TF; THYROID-HORMONE; CELL-LINE; PROTEIN; RECEPTOR; RAT	Hepatocytes are the major source of sex hormone-binding globulin (SHBG), a glycoprotein that transports sex steroids in the blood and regulates their access to target tissues. The human SHBG proximal promoter was analyzed by DNase I footprinting, and the functional significance of 6 footprinted regions (FP1-FP6) within the proximal promoter was studied in human HepG2 hepatoblastoma cells. Two footprinted regions (FP1 and FP3) contain binding sites for the chicken ovalbumin upstream promoter-transcription factor (COUP-TF) and hepatocyte nuclear factor-4 (HNF-4). In experiments where SHBG promoter-luciferase reporter gene constructs were co-transfected into HepG2 cells with COUP-TF and/or HNF-4 expression vectors, HNF-4 markedly increased transcription, whereas COUP-TF suppressed this probably by displacing HNF-4 from their common FP1-binding site. This COUP-TF/HNF-4-binding site within FP1 includes a TTTAA sequence, located at nucleotides -30/-26 upstream of the transcription start site, which fails to interact with human TFIID, TATA-binding protein in vitro, When this sequence was replaced with an idealized HNF-4-binding site, the transcriptional activity of the promoter increased in HepG2 cells. Taken together, these data imply that an interplay between COUP-TF and HNF-4 at a site within FP1 regulates human SHBG expression and that HNF-4 controls transcription from this TATA-less promoter by somehow substituting for TATA-binding protein in the recruitment of a transcription preinitiation complex.	Univ Western Ontario, London Reg Canc Ctr, Dept Obstet & Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Pharmacol & Toxicol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, MRC, Grp Fetal & Neonatal Hlth & Dev, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Hammond, GL (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Dept Obstet & Gynecol, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	ghamnmond@julian.uwo.ca		Hammond, Geoffrey/0000-0002-4639-7336				ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ANDERSON DC, 1974, CLIN ENDOCRINOL, V3, P69, DOI 10.1111/j.1365-2265.1974.tb03298.x; Becchis M, 1996, STEROIDS, V61, P392, DOI 10.1016/0039-128X(96)00049-9; Berkowitz EA, 1997, ONCOGENE, V14, P2229, DOI 10.1038/sj.onc.1201051; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BIRKELAND KI, 1993, J CLIN ENDOCR METAB, V76, P275, DOI 10.1210/jc.76.2.275; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; Drewes T, 1996, MOL CELL BIOL, V16, P925; Fenton SE, 1996, J BIOL CHEM, V271, P30870, DOI 10.1074/jbc.271.48.30870; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GERSHAGEN S, 1989, NUCLEIC ACIDS RES, V17, P9245, DOI 10.1093/nar/17.22.9245; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HAMMOND GL, 1989, MOL ENDOCRINOL, V3, P1869, DOI 10.1210/mend-3-11-1869; HAMMOND GL, 1993, FRONTIERS MOL BIOL, P1; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; ING NH, 1992, J BIOL CHEM, V267, P17617; INNIS JW, 1991, J BIOL CHEM, V266, P21765; Janne M, 1998, MOL ENDOCRINOL, V12, P123; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; JOSEPH DR, 1994, VITAM HORM, V49, P197; JOSEPH DR, 1988, MOL ENDOCRINOL, V2, P3, DOI 10.1210/mend-2-1-3; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KHAN MS, 1981, J CLIN ENDOCR METAB, V53, P448, DOI 10.1210/jcem-53-2-448; KIMURA A, 1993, J BIOL CHEM, V268, P11125; LAPIDUS L, 1986, CLIN CHEM, V32, P146; Leng X, 1996, MOL CELL BIOL, V16, P2332; LINDSTEDT G, 1991, DIABETES, V40, P123, DOI 10.2337/diabetes.40.1.123; LOUKOVAARA M, 1995, J CLIN ENDOCR METAB, V80, P160, DOI 10.1210/jc.80.1.160; Malik S, 1996, MOL CELL BIOL, V16, P1824; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REED MJ, 1987, J CLIN ENDOCR METAB, V64, P1083, DOI 10.1210/jcem-64-5-1083; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REVENTOS J, 1993, MOL CELL ENDOCRINOL, V96, P69, DOI 10.1016/0303-7207(93)90096-3; ROLLIER A, 1993, MOL BIOL CELL, V4, P59, DOI 10.1091/mbc.4.1.59; ROSNER W, 1984, J CLIN ENDOCR METAB, V59, P806, DOI 10.1210/jcem-59-4-806; SARNE DH, 1988, J CLIN ENDOCR METAB, V66, P740, DOI 10.1210/jcem-66-4-740; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; SIERRA F, 1990, BIOMETHODS LAB GUIDE; SLADEK FM, 1993, RECEPTOR, V3, P223; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zhou YD, 1996, BIOCHEM BIOPH RES CO, V223, P48, DOI 10.1006/bbrc.1996.0844	57	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34105	34114		10.1074/jbc.273.51.34105	http://dx.doi.org/10.1074/jbc.273.51.34105			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852068	hybrid			2022-12-25	WOS:000077542200034
J	Wu, J; Bag, J				Wu, J; Bag, J			Negative control of the poly(A)-binding protein mRNA translation is mediated by the adenine-rich region of its 5 '-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; MESSENGER-RNA; DEPENDENT TRANSLATION; ESCHERICHIA-COLI; EXPRESSION; INITIATION; YEAST; IDENTIFICATION; CELLS; LOCALIZATION	Translation of the mRNA for the poly(A)-binding protein (PABP) may be autoregulated by the binding of PABP to the A-rich segment of its 5'-untranslated region (UTR). To test this hypothesis, we examined the effect of different fragments of the 5'-UTR from human PABP cDNA on the translation of the p-galactosidase (beta-Gal) reporter gene. Presence of the A-rich sequence from the 5'-UTR of PABP mRNA inhibited expression of the chimeric beta-Gal gene in transfected HeLa cells. The differences in expression of beta-Gal polypeptide was due to the translational repression of beta-Gal mRNA containing the A-rich 5'-UTR of PABP mRNA The A-rich region of the 5'-UTR located within nucleotides 58-146 of PABP mRNA was sufficient to mediate translational control of this mRNA expression. We also examined the effect of overexpression of PABP mRNA in HeLa cells. The ectopic PABP mRNA without the A-rich 5'-UTR region was translated efficiently, whereas the translation of the endogenous PABP mRNA was substantially inhibited in the transfected cells. In contrast, the ectopic PABP mRNA containing the A-rich 5'-UTR region did not show similar effect on the translation of the endogenous PABP mRNA in these cells. These results suggest that feedback control of mRNA translation is involved in regulating PABP expression in HeLa cells.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Bag, J (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada.	jbag@uoguelph.ca						ADAMOU J, 1992, EUR J BIOCHEM, V209, P803, DOI 10.1111/j.1432-1033.1992.tb17351.x; Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Bag J, 1996, EUR J BIOCHEM, V237, P143, DOI 10.1111/j.1432-1033.1996.0143n.x; BAG J, 1984, EUR J BIOCHEM, V141, P247, DOI 10.1111/j.1432-1033.1984.tb08184.x; BAG J, 1976, J BIOL CHEM, V251, P7600; BAUGHMAN G, 1984, P NATL ACAD SCI-BIOL, V81, P5389, DOI 10.1073/pnas.81.17.5389; BELOSTOTSKY DA, 1993, P NATL ACAD SCI USA, V90, P6686, DOI 10.1073/pnas.90.14.6686; BERGER LC, 1992, EUR J BIOCHEM, V204, P733, DOI 10.1111/j.1432-1033.1992.tb16688.x; BERGER LC, 1992, BIOCHEM CELL BIOL, V70, P770, DOI 10.1139/o92-117; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; Black BL, 1997, MOL CELL BIOL, V17, P2756, DOI 10.1128/MCB.17.5.2756; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig AWB, 1998, NATURE, V392, P520, DOI 10.1038/33198; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DEAN D, 1981, NATURE, V289, P89, DOI 10.1038/289089a0; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; EISENSTEIN RS, 1991, ENZYME BASEL, V44, P42; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; GREENBERG JR, 1981, P NATL ACAD SCI-BIOL, V78, P2923, DOI 10.1073/pnas.78.5.2923; KO CG, 1997, J BIOL CHEM, V272, P10448; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; MAUNDRELL K, 1983, J BIOL CHEM, V258, P1387; MERCER WE, 1989, EXP CELL RES, V181, P531, DOI 10.1016/0014-4827(89)90109-2; NETO OPD, 1995, NUCLEIC ACIDS RES, V23, P2198, DOI 10.1093/nar/23.12.2198; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; ULLRICH SJ, 1988, EXP CELL RES, V178, P273, DOI 10.1016/0014-4827(88)90398-9; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; YANG HD, 1995, MOL CELL BIOL, V15, P6770; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	42	68	69	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34535	34542		10.1074/jbc.273.51.34535	http://dx.doi.org/10.1074/jbc.273.51.34535			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852123	hybrid			2022-12-25	WOS:000077542200089
J	Harris, D; Kaushik, N; Pandey, PK; Yadav, PNS; Pandey, VN				Harris, D; Kaushik, N; Pandey, PK; Yadav, PNS; Pandey, VN			Functional analysis of amino acid residues constituting the dNTP binding pocket of HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-POLYMERASE-I; SITE-SPECIFIC MUTAGENESIS; DOUBLE-STRANDED DNA; ESCHERICHIA-COLI; REPLICATION FIDELITY; INHIBITOR SENSITIVITY; MUTATIONAL ANALYSIS; KINETIC MECHANISM; KLENOW FRAGMENT	In order to understand the functional implication of residues constituting the dNTP-binding pocket of human immunodeficiency virus type 1 reverse transcriptase, we performed site-directed mutagenesis at positions 65, 72, 113, 115, 151, 183, 184, and 219, and the resulting mutant enzymes were examined for their biochemical properties and nucleotide selectivity on RNA and DNA templates. Mutations at positions 65, 115, 183, 184, and 219 had negligible to moderate influence on the polymerase activity, while Ala substitution at positions 72 and 151 as well as substitution with Ala or Glu at position 113 severely impaired the polymerase function of the enzyme. The K219A, Y115F, and Q151M mutants had no influence on the fidelity; Y183A, Y183F, K65A, and Q151N mutants exhibited higher fidelity on both RNA and DNA templates, while Y115A was less error-prone selectively on a DNA template. Analysis of the three-dimensional model of the enzyme-template primer-dNTP ternary complex suggests that residues Tyr-183, Lys-65, and Gln-151 may have impact on the flexibility of the dNTP-binding pocket by virtue of their multiple interactions with the dNTP, template, primer, and other neighboring residues constituting the pocket. Recruitment of the correct versus incorrect nucleotides may be a function of the flexibility of this pocket. A relatively rigid pocket would provide greater stringency, resulting in higher fidelity of DNA synthesis in contrast to a flexible pocket. Substitution of a residue having multiple interactions with a residue having reduced interaction capability will alter the internal geometry of the pocket, thus directly influencing the fidelity.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Pandey, VN (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA.	pandey@umdnj.edu		Pandey, Virendra N/0000-0001-6041-6786	NATIONAL CANCER INSTITUTE [R01CA072821, R29CA072821] Funding Source: NIH RePORTER; NCI NIH HHS [CA72821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arion D, 1996, J BIOL CHEM, V271, P19860, DOI 10.1074/jbc.271.33.19860; ARTS EJ, 1994, J BIOL CHEM, V269, P14672; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Bakhanashvili M, 1996, FEBS LETT, V391, P257, DOI 10.1016/0014-5793(96)00747-8; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BOYER PL, 1994, J MOL BIOL, V243, P472, DOI 10.1006/jmbi.1994.1673; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Chowdhury K, 1996, BIOCHEMISTRY-US, V35, P16610, DOI 10.1021/bi961462l; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Ding JP, 1997, BIOPOLYMERS, V44, P125, DOI 10.1002/(SICI)1097-0282(1997)44:2&lt;125::AID-BIP2&gt;3.0.CO;2-X; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GOODMAN MF, 1988, MUTAT RES, V200, P11, DOI 10.1016/0027-5107(88)90067-X; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; GU ZX, 1994, J BIOL CHEM, V269, P28118; Harris D, 1998, BIOCHEMISTRY-US, V37, P9630, DOI 10.1021/bi980549z; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; HUBNER A, 1992, J MOL BIOL, V223, P595, DOI 10.1016/0022-2836(92)90975-P; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kaushik N, 1997, BIOCHEMISTRY-US, V36, P14430, DOI 10.1021/bi970645k; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P11536, DOI 10.1021/bi960364x; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Kew Y, 1998, J BIOL CHEM, V273, P7529, DOI 10.1074/jbc.273.13.7529; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARDER BA, 1991, J VIROL, V65, P5232, DOI 10.1128/JVI.65.10.5232-5236.1991; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lee R, 1998, BIOCHEMISTRY-US, V37, P900, DOI 10.1021/bi972197m; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; MartinHernandez AM, 1996, EMBO J, V15, P4434, DOI 10.1002/j.1460-2075.1996.tb00816.x; MartinHernandez AM, 1997, NUCLEIC ACIDS RES, V25, P1383, DOI 10.1093/nar/25.7.1383; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; Misra HS, 1998, J BIOL CHEM, V273, P9785, DOI 10.1074/jbc.273.16.9785; MIZRAHI V, 1985, BIOCHEMISTRY-US, V24, P4010, DOI 10.1021/bi00336a031; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Rezende LF, 1998, J VIROL, V72, P2890, DOI 10.1128/JVI.72.4.2890-2895.1998; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; SARAFIANOS SG, 1995, BIOCHEMISTRY-US, V34, P7207, DOI 10.1021/bi00021a036; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; Ueno T, 1997, BIOCHEMISTRY-US, V36, P1092, DOI 10.1021/bi962393d; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; YADAV PNS, 1994, J BIOL CHEM, V269, P716; YU H, 1992, J BIOL CHEM, V267, P10888	72	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33624	33634		10.1074/jbc.273.50.33624	http://dx.doi.org/10.1074/jbc.273.50.33624			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837947	hybrid			2022-12-25	WOS:000077462500077
J	Kozik, A; Moore, RB; Potempa, J; Imamura, T; Rapala-Kozik, M; Travis, J				Kozik, A; Moore, RB; Potempa, J; Imamura, T; Rapala-Kozik, M; Travis, J			A novel mechanism for bradykinin production at inflammatory sites - Diverse effects of a mixture of neutrophil elastase and mast cell tryptase versus tissue and plasma kallikreins on native and oxidized kininogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-PROTEINASE INHIBITOR; GINGIVAL CREVICULAR FLUID; RHEUMATOID-ARTHRITIS; SYNOVIAL-FLUID; PERIODONTITIS PATIENTS; GRANULOCYTE ELASTASE; BRONCHIAL LAVAGE; ACTIVATION; RELEASE; BRONCHOALVEOLAR	Coprocessing of kininogens by a mixture of human mast cell tryptase and neutrophil elastase was explored as a potential substitute for the kallikrein-dependent pathway for kinin generation during inflammation. Tryptase easily excised bradykinin from the synthetic heptadecapeptide, ISLMKRPPGFSPFRSSR, but was unable to produce significant amounts of kinin by proteolysis of kininogens. However, a mixture of tryptase and elastase released bradykinin from each protein with a yield comparable to that of human plasma kallikrein, Significantly, neither plasma nor tissue kallikrein was able to effectively process N-chlorosuccinimide-oxidized high molecular weight kininogen, an effect attributed to the oxidation of a methionine residue upstream from the N terminus of the kinin domain. In support of these results the model heptadecapetide, ISL(MO)KRPPGFSPFRSSR, was also resistant to hydrolysis by either kallikrein. In contrast, the release of bradykinin from oxidized peptide or protein substrates by the tryptase/elastase mixture was not altered. Because kininogen modification may occur at inflammatory sites, as a result of the oxidative burst of recruited neutrophils and macrophages, these results suggest an alternative pathway for kinin production and the necessity for the novel utilization of two specific proteinases known to be released from these cells during inflammatory episodes.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Inst Mol Biol, PL-31120 Krakow, Poland; Kumamoto Univ, Grad Sch Med Sci, Div Mol Pathol, Kumamoto 860, Japan	University System of Georgia; University of Georgia; Jagiellonian University; Kumamoto University	Travis, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	jtravis@arches.uga.edu			NHLBI NIH HHS [HL 26148] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham SN, 1997, INFECT IMMUN, V65, P3501, DOI 10.1128/IAI.65.9.3501-3508.1997; ALTER SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P26, DOI 10.1016/0003-9861(90)90005-J; BARANIUK JN, 1990, AM REV RESPIR DIS, V141, P706, DOI 10.1164/ajrccm/141.3.706; BARNES PJ, 1988, PHARMACOL REV, V40, P49; BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BERTON G, 1988, RESP BURST ITS PHYSL, P33; Buckley MG, 1997, CLIN SCI, V93, P363, DOI 10.1042/cs0930363; CARMASSI F, 1994, INT J TISSUE REACT, V16, P89; CARRETERO OA, 1989, KALLIKREINKANIN SYST, P63; COX SW, 1992, J CLIN PERIODONTOL, V19, P333, DOI 10.1111/j.1600-051X.1992.tb00655.x; COX SW, 1989, J PERIODONTAL RES, V24, P41, DOI 10.1111/j.1600-0765.1989.tb00855.x; CRESTANI B, 1994, AM J RESP CRIT CARE, V150, P1363, DOI 10.1164/ajrccm.150.5.7952565; DARANY DG, 1992, J PERIODONTOL, V63, P743, DOI 10.1902/jop.1992.63.9.743; DVORAK AM, 1991, BASOPHIL MAST CELL D; Eckle I, 1988, Adv Exp Med Biol, V240, P531; ELGEBALY SA, 1992, J UROLOGY, V147, P1382, DOI 10.1016/S0022-5347(17)37578-X; Erdei A, 1997, EXP CLIN IMMUNOGENET, V14, P16; GADEK JE, 1979, SCIENCE, V206, P1315, DOI 10.1126/science.316188; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Galli SJ, 1996, NATURE, V381, P21, DOI 10.1038/381021a0; GRUBER BL, 1988, J IMMUNOL, V140, P3936; GUSTAFSSON A, 1992, J CLIN PERIODONTOL, V19, P535, DOI 10.1111/j.1600-051X.1992.tb00680.x; Imamura T, 1996, LAB INVEST, V74, P861; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KATZ HR, 1992, J IMMUNOL, V148, P868; KLENIEWSKI J, 1988, J EXP MED, V167, P1895, DOI 10.1084/jem.167.6.1895; LAVERY JP, 1994, ANN ALLERGY, V72, P425; LEVIS DC, 1987, J PEDIAT GASTROENTER, V6, P430; LITTLE SS, 1995, BIOCHEM J, V307, P341, DOI 10.1042/bj3070341; LOHI J, 1992, J CELL BIOCHEM, V50, P337, DOI 10.1002/jcb.240500402; LUNDBLAD RL, 1995, TECHNIQUES PROTEIN M, P97; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; MATHESON NR, 1979, BIOCHEM BIOPH RES CO, V88, P402, DOI 10.1016/0006-291X(79)92062-X; Mecheri S, 1997, IMMUNOL TODAY, V18, P212; MEIER M, 1983, J IMMUNOL, V130, P2352; MOLLER A, 1993, J IMMUNOL, V151, P3261; MULLERESTER W, 1986, METHODS ENZYMATIC AN, V9; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Nordstrom D, 1996, CLIN RHEUMATOL, V15, P35, DOI 10.1007/BF02231682; OSSANNA PJ, 1986, J CLIN INVEST, V77, P1939, DOI 10.1172/JCI112523; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; PILLINGER MH, 1995, RHEUM DIS CLIN N AM, V21, P691; PROUD D, 1983, J CLIN INVEST, V72, P1678, DOI 10.1172/JCI111127; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; PROUD D, 1988, BIOCHEM PHARMACOL, V37, P1473, DOI 10.1016/0006-2952(88)90008-1; PROUD D, 1994, BRAZ J MED BIOL RES, V27, P2021; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1089; Renoux M, 1995, INT J CLIN PHARM RES, V15, P135; Renoux M, 1996, OSTEOARTHR CARTILAGE, V4, P175, DOI 10.1016/S1063-4584(96)80013-6; RIISE GC, 1995, THORAX, V50, P360, DOI 10.1136/thx.50.4.360; SATO F, 1988, BIOL CHEM H-S, V369, P1009, DOI 10.1515/bchm3.1988.369.2.1009; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; Schwartz L B, 1986, Adv Exp Med Biol, V198 Pt A, P105; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1994, CURR OPIN IMMUNOL, V6, P91, DOI 10.1016/0952-7915(94)90039-6; SCHWARTZ LB, 1985, J IMMUNOL, V135, P2762; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; Sepper R, 1997, EUR RESPIR J, V10, P2788, DOI 10.1183/09031936.97.10122788; STEWART JM, 1993, PROTEASES PROTEASE I, P145; STEWART JM, 1989, MEDIATORS INFLAMMATO, P189; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P823; Thomas VA, 1998, BIOCHEMISTRY-US, V37, P2291, DOI 10.1021/bi972119z; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WALLS AF, 1991, CLIN SCI, V81, P183, DOI 10.1042/cs0810183; WALLS AF, 1992, BIOCHEM PHARMACOL, V43, P1243, DOI 10.1016/0006-2952(92)90498-8; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WONG PS, 1980, BIOCHEM BIOPH RES CO, V96, P1449, DOI 10.1016/0006-291X(80)90113-8; Wright CL, 1998, AM J SURG PATHOL, V22, P383, DOI 10.1097/00000478-199804000-00001; YASUOKA S, 1992, INTERNAL MED, V31, P599, DOI 10.2169/internalmedicine.31.599; Youssef PP, 1996, ARTHRITIS RHEUM, V39, P216, DOI 10.1002/art.1780390207; YUNGINGER JW, 1991, J FORENSIC SCI, V36, P857	73	95	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33224	33229		10.1074/jbc.273.50.33224	http://dx.doi.org/10.1074/jbc.273.50.33224			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837892	hybrid			2022-12-25	WOS:000077462500022
J	Layton, MJ; Harpur, AG; Panayotou, G; Bastiaens, PIH; Waterfield, MD				Layton, MJ; Harpur, AG; Panayotou, G; Bastiaens, PIH; Waterfield, MD			Binding of a diphosphotyrosine-containing peptide that mimics activated platelet-derived growth factor receptor beta induces oligomerization of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAINS; PHOSPHOINOSITIDE 3-KINASE; P85 SUBUNIT; PI 3-KINASE; REGULATORY SUBUNIT; TYROSINE KINASES; ASSOCIATION; 3'-KINASE; PROTEINS; INSULIN	Phosphatidylinositol 3-kinase (PI3K) is a heterodimeric enzyme comprising a p110 catalytic subunit and a p85 regulatory subunit, We have recently shown that the isolated p85 subunit exists as a dimer; therefore, we examined whether the heterodimeric enzyme was capable of further self-association. Size-exclusion chromatography demonstrated that :PI3K was a 1:1 complex of p85 and p110 under native conditions. However, binding of a diphosphotyrosine-containing peptide that mimics an activated platelet-derived growth factor receptor beta induced an increase in the apparent molecular mass of PI3K. This increase was due to dimerization of PI3K and was dependent on PI3K concentration but not diphosphopeptide concentration. Dimer formation was also observed directly using fluorescence resonance energy transfer. Diphosphopeptide-induced activation of PI3K (Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S., and Cantley, L. C. (1993) J. Biol. Chem. 268, 9478-9483; Rordorf-Nikolic, T., Van Horn, D. J., Chen, D., White, M. F., and Backer, J. M. (1995) J. Biol. Chem. 270, 3662-3666) was not a direct result of dimerization and occurred only when phosphatidylinositol, and not phosphatidylinositol-4,5-diphosphate, was the phosphorylation substrate. Binding of the tandem SH2 domains of the p85 regulatory subunit to activated receptor tyrosine kinases therefore induces dimerization of PI3K, which may be an early step in inositol lipid-mediated signal transduction.	Imperial Canc Res Fund, Cell Biophys Lab, London WC2A 3PX, England; Ludwig Inst Canc Res, London W1P 8BT, England; Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London	Harpur, AG (corresponding author), Imperial Canc Res Fund, Cell Biophys Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	A.Harpur@icrf.icnet.uk	Layton, Meredith/E-9171-2014					Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEN JK, 1994, BIOORG MED CHEM LETT, V4, P1755, DOI 10.1016/S0960-894X(00)80375-3; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Dixon M., 1979, ENZYMES, P47; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREUND GG, 1995, BIOCHEM BIOPH RES CO, V206, P272, DOI 10.1006/bbrc.1995.1038; Harlow E., 1988, ANTIBODIES LAB MANUA; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; Inukai K, 1997, J BIOL CHEM, V272, P7873, DOI 10.1074/jbc.272.12.7873; KIM HH, 1994, J BIOL CHEM, V269, P24747; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; REGNIER FE, 1983, METHOD ENZYMOL, V91, P137; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHIBASAKI F, 1993, BIOCHEM J, V289, P227, DOI 10.1042/bj2890227; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOUTHWICK PL, 1990, CYTOMETRY, V11, P418, DOI 10.1002/cyto.990110313; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VICIANA PR, 1996, EMBO J, V15, P2442; VICIANA PR, 1994, NATURE, V370, P527; WELSH LC, 1988, MOL CELL BIOL, V8, P3476; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WOSCHOLSKI R, 1994, J BIOL CHEM, V269, P25067; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	46	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33379	33385		10.1074/jbc.273.50.33379	http://dx.doi.org/10.1074/jbc.273.50.33379			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837914	hybrid			2022-12-25	WOS:000077462500044
J	Santamaria, D; de la Cueva, G; Martinez-Robles, ML; Krimer, DB; Hernandez, P; Schvartzman, JB				Santamaria, D; de la Cueva, G; Martinez-Robles, ML; Krimer, DB; Hernandez, P; Schvartzman, JB			DnaB helicase is unable to dissociate RNA-DNA hybrids - Its implication in the polar pausing of replication forks at ColE1 origins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGAROSE-GEL ELECTROPHORESIS; PAPILLOMAVIRUS TYPE-1 DNA; E1 PLASMID DNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; TERMINATOR PROTEIN; POTENTIAL ORIGINS; BACILLUS-SUBTILIS; RIBONUCLEASE-H; IN-VIVO	A series of plasmids were constructed containing two unidirectional ColE1 replication origins in either the same or opposite orientations and their replication mode was investigated using two-dimensional agarose gel electrophoresis. The results obtained showed that, in these plasmids, initiation of DNA replication occurred at only one of the two potential origins per replication round regardless of origins orientation, In those plasmids with inversely oriented origins, the silent origin act as a polar pausing site for the replication fork initiated at the other origin. The distance between origins (up to 5.8 kilobase pairs) affected neither the interference between them to initiate replication nor the pausing function of the silent origin. A deletion analysis indicated that the presence of a transcription promoter upstream of the origin was the only essential requirement for it to initiate replication as well as to account for its polar pausing function. Finally, in vitro helicase assays showed that Escherichia coli DnaB is able to melt DNA-DNA homoduplexes but is very inefficient to unwind RNA-DNA hybrids. Altogether, these observations strongly suggest that replication forks pause at silent ColE1 origins due to the inability of DnaB helicase, which leads the replication fork in vivo, to unwind RNA-DNA hybrids.	CSIC, Ctr Invest Biol, Dept Biol Celular & Desarrollo, E-28006 Madrid, Spain; CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Schvartzman, JB (corresponding author), CSIC, Ctr Invest Biol, Dept Biol Celular & Desarrollo, Velazquez 144, E-28006 Madrid, Spain.	cibjb21@fresno.csic.es	Santamaria, David/D-3930-2011; de la Cueva Méndez, Guillermo/K-3292-2015; Krimer, Dora/J-9176-2014; Schvartzman, Jorge B/J-9171-2014	Santamaria, David/0000-0002-4711-3569; de la Cueva Méndez, Guillermo/0000-0003-4675-6498; Krimer, Dora/0000-0001-9972-3994; Pablo, Hernandez/0000-0002-8113-1277				Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BASTIA D, 1996, DNA REPLICATION EUKA; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1994, P NATL ACAD SCI USA, V91, P3418, DOI 10.1073/pnas.91.8.3418; BREWER BJ, 1993, SCIENCE, V262, P1728, DOI 10.1126/science.8259517; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CEGLOWSKI P, 1994, GENE, V145, P33, DOI 10.1016/0378-1119(94)90319-0; CESARENI G, 1982, J MOL BIOL, V160, P123, DOI 10.1016/0022-2836(82)90135-8; COLLINS J, 1980, COLD SPRING HARB SYM, V45, P409, DOI 10.1101/SQB.1981.045.01.055; DASGUPTA S, 1987, CELL, V51, P1113, DOI 10.1016/0092-8674(87)90597-6; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; EliasArnanz M, 1997, EMBO J, V16, P5775, DOI 10.1093/emboj/16.18.5775; Ermakova OV, 1996, J BIOL CHEM, V271, P33009, DOI 10.1074/jbc.271.51.33009; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; HERNANDEZ P, 1993, EMBO J, V12, P1475, DOI 10.1002/j.1460-2075.1993.tb05791.x; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; INSELBURG J, 1974, P NATL ACAD SCI USA, V71, P2256, DOI 10.1073/pnas.71.6.2256; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; Kalejta RF, 1996, MOL CELL BIOL, V16, P4915; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOBAYASHI T, 1992, MOL GEN GENET, V233, P355, DOI 10.1007/BF00265431; KRONBERG A, 1992, DNA REPLICATION; KUEMPEL PL, 1989, CELL, V59, P581, DOI 10.1016/0092-8674(89)90001-9; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; LIU B, 1995, SCIENCE, V267, P1131, DOI 10.1126/science.7855590; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; LIU Y, 1990, J VIROL, V64, P5903, DOI 10.1128/JVI.64.12.5903-5911.1990; Lopez-Estrano C, 1998, J MOL BIOL, V277, P249, DOI 10.1006/jmbi.1997.1607; LOPEZESTRANO C, 1997, CHROMOSOMES TODAY, V12, P149; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARTINPARRAS L, 1992, J BIOL CHEM, V267, P22496; MARTINPARRAS L, 1991, J MOL BIOL, V220, P843, DOI 10.1016/0022-2836(91)90357-C; MATSON SW, 1989, P NATL ACAD SCI USA, V86, P4430, DOI 10.1073/pnas.86.12.4430; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; Mohanty BK, 1998, J BIOL CHEM, V273, P3051, DOI 10.1074/jbc.273.5.3051; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; NAKASU S, 1992, P NATL ACAD SCI USA, V89, P10139, DOI 10.1073/pnas.89.21.10139; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; OKA A, 1979, MOL GEN GENET, V172, P151, DOI 10.1007/BF00268276; PANAYOTATOS N, 1984, NUCLEIC ACIDS RES, V12, P2641, DOI 10.1093/nar/12.6.2641; PELEG M, 1995, NUCLEIC ACIDS RES, V23, P1292, DOI 10.1093/nar/23.8.1292; RAO BS, 1994, GENE, V140, P233, DOI 10.1016/0378-1119(94)90549-5; SAHOO T, 1995, J BIOL CHEM, V270, P29138, DOI 10.1074/jbc.270.49.29138; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; SCHVARTZMAN JB, 1993, NUCLEIC ACIDS RES, V21, P5474, DOI 10.1093/nar/21.23.5474; SCHVARTZMAN JB, 1990, MOL CELL BIOL, V10, P3078, DOI 10.1128/MCB.10.6.3078; STILLMAN B, 1996, DNA REPLICATION EUKA, P435; TOMIZAWA JI, 1974, P NATL ACAD SCI USA, V71, P2260, DOI 10.1073/pnas.71.6.2260; VANDERENDE A, 1983, J MOL BIOL, V167, P751, DOI 10.1016/S0022-2836(83)80108-9; Viguera E, 1998, GENE, V217, P41, DOI 10.1016/S0378-1119(98)00375-8; Viguera E, 1996, J BIOL CHEM, V271, P22414, DOI 10.1074/jbc.271.37.22414; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WIESENDANGER B, 1994, NUCLEIC ACIDS RES, V22, P5038, DOI 10.1093/nar/22.23.5038; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713	66	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33386	33396		10.1074/jbc.273.50.33386	http://dx.doi.org/10.1074/jbc.273.50.33386			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837915	hybrid, Green Published			2022-12-25	WOS:000077462500045
J	Slaaby, R; Jensen, T; Hansen, HS; Frohman, MA; Seedorf, K				Slaaby, R; Jensen, T; Hansen, HS; Frohman, MA; Seedorf, K			PLD2 complexes with the EGF receptor and undergoes tyrosine phosphorylation at a single site upon agonist stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PROTEIN-KINASE-C; PHOSPHOLIPASE-D ACTIVATION; ADP-RIBOSYLATION FACTOR; SWISS 3T3 CELLS; PHOSPHATIDIC-ACID; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; LYSOPHOSPHATIDIC ACID; D DEFINES; PHOSPHATIDYLCHOLINE	Mammalian phospholipase D (PLD) activity becomes upregulated when cells are stimulated by a variety of hormones, growth factors, and other extracellular signals. Two distinct PLDs, PLD1 and PLD2, have been identified. The mechanism through which each PLD is activated, however, is poorly understood. Using transiently transfected human embryonic kidney fibroblasts (HEK293), we demonstrate here that PLD1 activity, and to a lesser extent PLD2 activity, is stimulated in response to epidermal growth factor (EGF), PLD2, but not PLD1, associates with the EGF receptor in a ligand-independent manner and becomes tyrosine-phosphorylated upon EGF receptor activation. Tyrosine 11 (Tyr-11) of PLD2 was identified as the specific phosphorylation site. Mutation of this residue to phenylalanine enhanced basal activity almost a-fold, but did not alter the magnitude of the EGF-mediated increase in PLD2 activity. In conclusion, we show here for the first time agonist-stimulated activation of both PLD1 and PLD2 in vivo and provide evidence of a distinct type of interaction for each iso form with the EGF receptor, Moreover, our results suggest that agonist-induced tyrosine phosphorylation plays a role in PLD2 regulation.	Hagedorn Res Inst, Dept Mol Signaling, DK-2820 Gentofte, Denmark; Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen O, Denmark; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	Novo Nordisk; Hagedorn Research Institute; Royal Danish School of Pharmacy; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Slaaby, R (corresponding author), Hagedorn Res Inst, Dept Mol Signaling, Niels Steensens Vej 6, DK-2820 Gentofte, Denmark.							AHMED S, 1993, J BIOL CHEM, V268, P10709; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Cockcroft S, 1996, CHEM PHYS LIPIDS, V80, P59, DOI 10.1016/0009-3084(96)02546-7; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jiang YW, 1996, J BIOL CHEM, V271, P29529, DOI 10.1074/jbc.271.47.29529; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Liscovitch M, 1996, CHEM PHYS LIPIDS, V80, P37, DOI 10.1016/0009-3084(96)02544-3; Luo JQ, 1997, BIOCHEM BIOPH RES CO, V235, P854, DOI 10.1006/bbrc.1997.6793; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Natarajan V, 1997, AM J RESP CELL MOL, V17, P251, DOI 10.1165/ajrcmb.17.2.2623; Natarajan V, 1996, CHEM PHYS LIPIDS, V80, P103, DOI 10.1016/0009-3084(96)02548-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PETTITT TR, 1994, BIOCHEM J, V298, P655, DOI 10.1042/bj2980655; RYDZEWSKA G, 1995, PANCREAS, V10, P59, DOI 10.1097/00006676-199501000-00008; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; SONG JG, 1994, CELL GROWTH DIFFER, V5, P79; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vinggaard AM, 1996, BIOCHEM J, V319, P861, DOI 10.1042/bj3190861; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; WAKELAM MJO, 1995, SIGNAL TRANSDUCTION, P271; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980	40	103	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33722	33727		10.1074/jbc.273.50.33722	http://dx.doi.org/10.1074/jbc.273.50.33722			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837959	hybrid			2022-12-25	WOS:000077462500089
J	Zhu, T; Goh, ELK; LeRoith, D; Lobie, PE				Zhu, T; Goh, ELK; LeRoith, D; Lobie, PE			Growth hormone stimulates the formation of a multiprotein signaling complex involving p130(Cas) and CrkII - Resultant activation of c-Jun N-terminal kinase/stress-activatedprotein kinase (JNK/SAPK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INSULIN-RECEPTOR SUBSTRATE-1; PROMOTED TYROSYL PHOSPHORYLATION; SRC FAMILY KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VIVO; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; PROLACTIN RECEPTOR; ACTIN CYTOSKELETON	We have demonstrated previously that growth hormone (GH) activates focal adhesion kinase (FAK), and this activation results in the tyrosine phosphorylation of two FAK substrates, namely paxillin and tensin, We now show here in Chinese hamster ovary cells stably transfected with rat GH receptor cDNA that human (h)GH induces the formation of a large multiprotein signaling complex centered around another FAK-associated protein, p130(Cas) and the adaptor protein CrkII, hGH stimulates the tyrosine phosphorylation of both p130(Cas) and CrkII, their association, and the association of multiple other tyrosine-phosphorylated proteins to the complex. Both the c-Src and c-Fyn tyrosine kinases are tyrosine phosphorylated and activated by cellular hGH stimulation and form part of the multiprotein signaling complex as does tensin, paxillin, IRS-1, the p85 subunit of phosphatidylinositol 3-kinase, C3G, SHC, Grb-2, and Sos-1. c-Cbl and Nck are also tyrosine-phosphorylated by cellular stimulation with hGH and associate with the p130(Cas)-CrkII complex, c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is activated in response to hGH in accordance with the formation of the abovementioned signaling complex, and hGH stimulated JNK/SAPK activity is increased in CrkII overexpressing NIH3T3 cells compared with vector transfected NIH3T3 cells. The formation of such a large multiprotein signaling complex by GH, with the resultant activation of multiple downstream effector molecules, may be central to many of the pleiotropic effects of GH.	Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Def Med Res Inst, Singapore 117609, Singapore; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lobie, PE (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Goh, Eyleen/A-8006-2013	Goh, Eyleen/0000-0002-8244-6959				AlSakkaf KA, 1996, BIOCHEM BIOPH RES CO, V221, P779, DOI 10.1006/bbrc.1996.0673; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BeitnerJohnson D, 1996, J BIOL CHEM, V271, P9287, DOI 10.1074/jbc.271.16.9287; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; Blakesley VA, 1997, J BIOL CHEM, V272, P16211, DOI 10.1074/jbc.272.26.16211; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Cary LA, 1996, J CELL SCI, V109, P1787; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; Goh ELK, 1997, ENDOCRINOLOGY, V138, P3207, DOI 10.1210/en.138.8.3207; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Guan JL, 1996, INT REV CYTOL, V168, P81, DOI 10.1016/S0074-7696(08)60883-9; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Hunter S, 1997, MOL ENDOCRINOL, V11, P1213, DOI 10.1210/me.11.9.1213; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Patel HV, 1997, PROTEINS, V29, P545, DOI 10.1002/(SICI)1097-0134(199712)29:4<545::AID-PROT13>3.0.CO;2-M; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Uddin S, 1996, BIOCHEM BIOPH RES CO, V225, P833, DOI 10.1006/bbrc.1996.1259; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WIEDERMANN CJ, 1993, BLOOD, V82, P954; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Zhu T, 1998, J BIOL CHEM, V273, P10682, DOI 10.1074/jbc.273.17.10682	68	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33864	33875		10.1074/jbc.273.50.33864	http://dx.doi.org/10.1074/jbc.273.50.33864			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837978	hybrid			2022-12-25	WOS:000077462500108
J	Chapell, R; Bueno, OF; Alvarez-Hernandez, X; Robinson, LC; Leidenheimer, NJ				Chapell, R; Bueno, OF; Alvarez-Hernandez, X; Robinson, LC; Leidenheimer, NJ			Activation of protein kinase C induces gamma-aminobutyric acid type a receptor internalization in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; PHOSPHORYLATION SITES; TYROSINE PHOSPHORYLATION; INTRACELLULAR DOMAINS; SUBUNIT COMPOSITION; BETA-SUBUNIT; MODULATION; RAT; CURRENTS; CHANNELS	The inhibition of gamma-aminobutyric acid (GABA)-gated chloride currents by the protein kinase C (PKC) activator 4 beta-phorbol 12-myristate 13-acetate (PMA) was investigated using recombinant human GABA(A) receptors expressed in Xenopus oocytes, PMA (5 nM) reduced the GABA response in oocytes expressing the alpha 1 beta 2 gamma 2L receptor construct, as measured by the two-electrode voltage-clamp method. GABA responses declined to approximately 25% of their pretreatment value within 45 min. GABA responses in oocytes expressing a receptor con struct from which the known PKC phosphorylation sites were absent, alpha 1 beta 2(S410A), were comparably inhibited. Phorbol 12-monomyristate (PMM; 5 nM), which does not activate PKC, did not alter the GABA response in either construct, while the PKC inhibitor calphostin C (0.5 mu M) prevented the PMA effect. To further investigate PMA inhibition of the GABA response, a GABA(A) receptor alpha 1 subunit/green fluorescent protein (GFP) chimera (alpha 1GFP) was used to visualize GABA(A) receptor distribution. Similar to the wild type constructs, PMA robustly decreased GABA responses in oocytes expressing alpha 1GFP beta 2 gamma 2L and alpha 1GFP beta 2(S410A) receptor constructs. Following PMA treatment, GFP fluorescence in the oocyte plasma membrane was decreased to approximately 45% of the pretreatment values indicating GABA(A) receptor internalization. This effect of PMA was prevented by calphostin C and was not produced by PMM, Experiments with bd24, a monoclonal antibody which recognizes an extracellular epitope of the alpha 1 subunit, were used to demonstrate that PMA, but not PMM, decreases alpha 1 subunit immunoreactivity in the plasma membrane of intact oocytes expressing the alpha 1 beta 2 gamma 2L construct, thus confirming the results obtained with the chimeric receptor. It is concluded that, in Xenopus oocytes, PMA induces an internalization of the GABA(A) receptor through PKC-mediated phosphorylation of an unidentified protein(s) and that this contributes to the decrease in electrophysiological responses to GABA following PKC activation.	Louisiana State Univ, Med Ctr, Dept Pharmacol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Dept Med, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Dept Biochem, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Leidenheimer, NJ (corresponding author), Louisiana State Univ, Med Ctr, Dept Pharmacol, 1501 Kings Hwy, Shreveport, LA 71130 USA.		Robinson, Lucy C/M-6865-2019	Robinson, Lucy/0000-0001-6454-040X	NINDS NIH HHS [R29NS32131] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032131] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; BORDEN LA, 1984, SCIENCE, V226, P857, DOI 10.1126/science.6093257; BROWNING MD, 1990, P NATL ACAD SCI USA, V87, P1315, DOI 10.1073/pnas.87.4.1315; Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; COREY JL, 1994, J BIOL CHEM, V269, P14759; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; Gillette MA, 1996, J NEUROPHYSIOL, V76, P3070, DOI 10.1152/jn.1996.76.5.3070; HARA M, 1993, ANESTHESIOLOGY, V79, P781, DOI 10.1097/00000542-199310000-00021; Kellenberger S, 1996, NEUROPHARMACOLOGY, V35, P1403, DOI 10.1016/S0028-3908(96)00034-2; KELLENBERGER S, 1992, J BIOL CHEM, V267, P25660; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; Leidenheimer NJ, 1997, MOL BRAIN RES, V52, P173, DOI 10.1016/S0169-328X(97)00255-6; LEIDENHEIMER NJ, 1992, MOL PHARMACOL, V41, P1116; LEIDENHEIMER NJ, 1993, J NEUROCHEM, V60, P1972, DOI 10.1111/j.1471-4159.1993.tb13432.x; LIN JL, 1994, J FORECASTING, V13, P1, DOI 10.1002/for.3980130102; MACHU TK, 1993, J NEUROCHEM, V61, P375, DOI 10.1111/j.1471-4159.1993.tb03582.x; MCDONALD BJ, 1994, J BIOL CHEM, V269, P18111; MORAN O, 1989, MOL BRAIN RES, V5, P193, DOI 10.1016/0169-328X(89)90035-1; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MOSS SJ, 1992, J BIOL CHEM, V267, P14470; Peretz T, 1996, FEBS LETT, V381, P71, DOI 10.1016/0014-5793(96)00085-3; PETER AB, 1991, J CELL BIOL, V114, P455, DOI 10.1083/jcb.114.3.455; PETERS JA, 1988, BRIT J PHARMACOL, V94, P1257, DOI 10.1111/j.1476-5381.1988.tb11646.x; PUIA G, 1990, NEURON, V4, P759, DOI 10.1016/0896-6273(90)90202-Q; Quick MW, 1997, J NEUROSCI, V17, P2967; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SHINGAI R, 1991, EUR J PHARM-MOLEC PH, V206, P77, DOI 10.1016/0922-4106(91)90149-C; SIGEL E, 1988, P NATL ACAD SCI USA, V85, P6192, DOI 10.1073/pnas.85.16.6192; SIGEL E, 1991, FEBS LETT, V291, P150, DOI 10.1016/0014-5793(91)81124-Q; SIGEL E, 1994, J BIOL CHEM, V269, P8204; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; Thompson SA, 1996, BRIT J PHARMACOL, V117, P521, DOI 10.1111/j.1476-5381.1996.tb15221.x; TURNER DM, 1989, J PHARMACOL EXP THER, V248, P960; VALENZUELA CF, 1995, MOL BRAIN RES, V31, P165, DOI 10.1016/0169-328X(95)00048-W; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Wan Q, 1997, J NEUROSCI, V17, P5062; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; Wright EM, 1997, J EXP BIOL, V200, P287; YAMAKURA T, 1993, BIOCHEM BIOPH RES CO, V196, P1537, DOI 10.1006/bbrc.1993.2426	42	92	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32595	32601		10.1074/jbc.273.49.32595	http://dx.doi.org/10.1074/jbc.273.49.32595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829997	hybrid			2022-12-25	WOS:000077329100036
J	Meinild, AK; Klaerke, DA; Zeuthen, T				Meinild, AK; Klaerke, DA; Zeuthen, T			Bidirectional water fluxes and specificity for small hydrophilic molecules in aquaporins 0-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELL; COLLECTING DUCT; XENOPUS-OOCYTES; RAT-KIDNEY; CHANNEL; CLONING; MEMBRANE; EXPRESSION; PROTEIN; PERMEABILITY	The dimensions of the aqueous pore in aquaporins (AQP) 0, 1, 2, 3, 4, and 5 expressed in Xenopus laevis oocytes were probed by comparing the ability of various solutes to generate osmotic flow. By improved techniques, volume flows were determined from initial rates of changes. Identical values for the osmotic water permeability (L-p) were obtained in swelling as in shrinkage experiments demonstrating, for the first time, that aquaporins are bidirectional. The reflection coefficients (sigma) of urea, glycerol, acetamide, and formamide at 23 degrees C were: AQP0: 1, 1, 0.8, 0.6; AQP1: 1, 0.8, 1, 1; AQP2: 1, 0.8, 1, 1; AQP3: 1, 0.2, 0.7, 0.4; AQP4: 1, 0.9, 1, 1; and AQP5: 1, 1, 1, 0.8. As seen there is no clear connection between solute size and permeation. At 13 degrees C the sigma s for AQP3 were 1, 0.4, 1, and 0.5; functionally, this pore narrows at lower temperatures. HgCl2 reversibly reduced the L-p of AQP3 and increased sigma(glyc) to 1 and sigma(form) to 0.6. We conclude that the pore of the various aquaporins are structurally different and that a simple steric model is insufficient to explain solute-pore interactions.	Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Zeuthen, T (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	T.Zeuthen@mfi.ku.dk						Abrami L, 1996, PFLUG ARCH EUR J PHY, V431, P408, DOI 10.1007/BF02207279; ABRAMI L, 1995, PFLUG ARCH EUR J PHY, V430, P447, DOI 10.1007/BF00373921; ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; Echevarria M, 1996, J BIOL CHEM, V271, P25079, DOI 10.1074/jbc.271.41.25079; ELLORY JC, 1988, COMP BIOCHEM PHYS A, V90, P533, DOI 10.1016/0300-9629(88)90663-9; Finkelstein A., 1987, WATER MOVEMENT LIPID, P228; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GUTIERREZ AM, 1995, J MEMBRANE BIOL, V143, P189; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HILL AE, 1994, J MEMBRANE BIOL, V137, P197; Hille B., 1992, IONIC CHANNELS EXCIT, P607; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6369; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Li HL, 1997, NAT STRUCT BIOL, V4, P263, DOI 10.1038/nsb0497-263; LOIKE JD, 1993, J GEN PHYSIOL, V102, P897, DOI 10.1085/jgp.102.5.897; Loo DDF, 1996, P NATL ACAD SCI USA, V93, P13367, DOI 10.1073/pnas.93.23.13367; MA TH, 1993, J BIOL CHEM, V268, P22756; MA TH, 1994, J BIOL CHEM, V269, P21845; MACEY RI, 1993, J MEMBRANE BIOL, V134, P241; MANNUZZU LM, 1993, J MEMBRANE BIOL, V133, P85; Meinild AK, 1998, J PHYSIOL-LONDON, V508, P15, DOI 10.1111/j.1469-7793.1998.015br.x; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; OLIVES B, 1994, J BIOL CHEM, V269, P31649; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; Toon MR, 1996, J MEMBRANE BIOL, V153, P137, DOI 10.1007/s002329900117; TOON MR, 1990, BIOCHIM BIOPHYS ACTA, V1022, P57, DOI 10.1016/0005-2736(90)90400-I; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Yang BX, 1998, J BIOL CHEM, V273, P9369, DOI 10.1074/jbc.273.16.9369; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; Zeuthen T, 1997, BIOL CELL, V89, P307, DOI 10.1016/S0248-4900(97)83383-7; ZHANG R, 1991, AM J PHYSIOL, V260, P26	41	136	140	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32446	32451		10.1074/jbc.273.49.32446	http://dx.doi.org/10.1074/jbc.273.49.32446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829975	hybrid			2022-12-25	WOS:000077329100014
J	Nony, P; Hannon, R; Gould, H; Felsenfeld, G				Nony, P; Hannon, R; Gould, H; Felsenfeld, G			Alternate promoters and developmental modulation of expression of the chicken GATA-2 gene in hematopoietic progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; DNA-BINDING SPECIFICITIES; XENOPUS GATA-2; ERYTHROID-DIFFERENTIATION; HYPERSENSITIVE SITES; ENDOTHELIAL-CELLS; FACTOR FAMILY; PROTEINS; INDUCTION; MESODERM	We have isolated and characterized the chicken GATA-2 (cGATA-2) gene. We show that, as in the case of some other members of the GATA gene family, the gene is expressed from alternative first exons. One of the resulting mRNAs represents only a minor form of the GATA-2 mRNA in the cells and tissues we analyzed; the other is ubiquitously expressed. We have defined the minimal promoter that controls expression of this most abundant mRNA and that is necessary for full activity in hematopoietic progenitor cells. The activity of this promoter in transient assays is consistent with developmental differences of expression levels in these cells. We identify within the promoter a previously unrecognized extended CCAAT motif essential for its activity. The organization of the cGATA-2 gene, with alternative first exons and a CCAAT box in the proximal promoter, is similar to that recently described for mouse GATA-2, and the proximal promoter also resembles the only promoter so far described in Xenopus. Nonetheless, the roles of the promoters in development and tissue-specific expression are quite different in these organisms, most strikingly in the mouse, which assigns developmental roles to its proximal and distal promoters that are quite different from those in the chicken. We suggest that although the overall organization may remain the same, the role assigned to each promoter varies among organisms. We identify distant upstream regulatory elements in the cGATA-2 gene that modulate expression from the proximal promoter and that may be responsible for this variation.	NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Kings Coll London, Div Biomol Sci, London WC2B 5RL, England	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; King's College London	Felsenfeld, G (corresponding author), NIDDK, Mol Biol Lab, NIH, Bldg 5, Bethesda, MD 20892 USA.							BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BREWER AC, 1995, EMBO J, V14, P757, DOI 10.1002/j.1460-2075.1995.tb07054.x; BREWER AC, 1994, THESIS U LONDON; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; ELGIN SCR, 1988, J BIOL CHEM, V263, P19259; ENGEL JD, 1992, J CELL SCI, P21; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Fleenor DE, 1996, GENE, V179, P219, DOI 10.1016/S0378-1119(96)00355-1; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; ISHIHARA H, 1995, J BIOCHEM-TOKYO, V117, P499, DOI 10.1093/oxfordjournals.jbchem.a124736; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KELLEY C, 1994, DEV BIOL, V165, P193, DOI 10.1006/dbio.1994.1246; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LABASTIE MC, 1994, GENOMICS, V21, P1, DOI 10.1006/geno.1994.1217; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEONARD MW, 1993, DEVELOPMENT, V119, P519; Ma GT, 1997, DEVELOPMENT, V124, P907; MacNeill C, 1997, J BIOL CHEM, V272, P8396, DOI 10.1074/jbc.272.13.8396; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; MAHONEY KA, 1977, DEV BIOL, V56, P412, DOI 10.1016/0012-1606(77)90280-9; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; Meng AM, 1997, P NATL ACAD SCI USA, V94, P6267, DOI 10.1073/pnas.94.12.6267; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; Minegishi N, 1998, J BIOL CHEM, V273, P3625, DOI 10.1074/jbc.273.6.3625; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOUTHON MA, 1993, BLOOD, V81, P647; NAGAI T, 1994, BLOOD, V84, P1074, DOI 10.1182/blood.V84.4.1074.bloodjournal8441074; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; ORLIC D, 1995, P NATL ACAD SCI USA, V92, P4601, DOI 10.1073/pnas.92.10.4601; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Partington GA, 1997, DEV BIOL, V181, P144, DOI 10.1006/dbio.1996.8432; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WALMSLEY ME, 1994, DEVELOPMENT, V120, P2519; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10642, DOI 10.1073/pnas.88.23.10642	50	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32910	32919		10.1074/jbc.273.49.32910	http://dx.doi.org/10.1074/jbc.273.49.32910			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830041	hybrid			2022-12-25	WOS:000077329100080
J	Parchmann, S; Mueller, MJ				Parchmann, S; Mueller, MJ			Evidence for the formation of dinor isoprostanes E-1 from alpha-linolenic acid in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN BIOSYNTHESIS; BICYCLO ENDOPEROXIDES; LIPID-PEROXIDATION; MASS-SPECTROMETRY; FATTY-ACIDS; IN-VIVO; HYDROPEROXIDES; LIPOXYGENASE; EICOSANOIDS; CYCLIZATION	The free radical oxidation of arachidonic acid is known to generate complex metabolites, termed isoprostanes, that share structural features of prostaglandins and exert potent receptor-mediated biological activities. In the present study, we show that alpha-linolenic acid can undergo a similar oxidation process, resulting in a series of isomeric dinor isoprostanes E-1. E-ring dinor isoprostane formation from linolenate was found to be catalyzed by soybean lipoxygenase, The main enzymatic products were 13- and 9-hydroperoxylinolenate but in addition, two dinor isoprostane E-1 regioisomers were formed with a yield of 0.31%. Identification and quantification of two dinor isoprostane E-1 regioisomers in plant cell cultures was achieved by a negative chemical ionization gas chromatography-mass spectrometry method using [O-18]dinor isoprostanes E-1 as internal standards. Endogenous levels of these compounds were determined in four taxonomically distant plant species and found to be in the range of 4.5 to 60.9 ng/g of dry weight. Thus analogous pathways in animals and plants exist, each leading to a family of prostaglandin-like compounds derived from polyunsaturated fatty acids. It remains to be shown whether the dinor isoprostanes exert biological activities in plants as has been demonstrated for their C20 congeners in mammals.	Univ Munich, Inst Pharmaceut Biol, D-80333 Munich, Germany	University of Munich	Mueller, MJ (corresponding author), Univ Munich, Inst Pharmaceut Biol, Karlstr 29, D-80333 Munich, Germany.		mueller, martin j/C-7616-2019					ANDERSEN NH, 1969, J LIPID RES, V10, P320; BILD GS, 1978, J BIOL CHEM, V253, P21; BUNDY GL, 1985, ADV PROSTAG THROMB L, V14, P229; Conconi A, 1996, PLANT PHYSIOL, V111, P797, DOI 10.1104/pp.111.3.797; GARDNER HW, 1991, BIOCHIM BIOPHYS ACTA, V1084, P221, DOI 10.1016/0005-2760(91)90063-N; GUIDO DM, 1993, ANAL BIOCHEM, V209, P123, DOI 10.1006/abio.1993.1091; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; Herold M, 1996, CHEM PHYS LIPIDS, V79, P113, DOI 10.1016/0009-3084(95)02518-9; Morrow JD, 1996, J BIOL CHEM, V271, P23185, DOI 10.1074/jbc.271.38.23185; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; NUTGEREN DH, 1967, RECL TRAV CHIM PAY B, V86, P1237; OCONNOR DE, 1981, J AM CHEM SOC, V103, P223, DOI 10.1021/ja00391a056; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; Parchmann S, 1997, PLANT PHYSIOL, V115, P1057, DOI 10.1104/pp.115.3.1057; PORTER NA, 1975, J ORG CHEM, V40, P3614, DOI 10.1021/jo00912a037; PRYOR WA, 1976, LIPIDS, V11, P370, DOI 10.1007/BF02532843; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P853, DOI 10.1016/S0090-6980(97)00184-6; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045	22	72	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32650	32655		10.1074/jbc.273.49.32650	http://dx.doi.org/10.1074/jbc.273.49.32650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830005	hybrid			2022-12-25	WOS:000077329100044
J	Wang, N; Arai, T; Ji, Y; Rinninger, F; Tall, AR				Wang, N; Arai, T; Ji, Y; Rinninger, F; Tall, AR			Liver-specific overexpression of scavenger receptor BI decreases levels of very low density lipoprotein ApoB, low density lipoprotein ApoB, and high density lipoprotein in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; SR-BI; CHOLESTEROL ACYLTRANSFERASE; HEPATIC LIPASE; HDL METABOLISM; ADRENAL-GLAND; UP-REGULATION; PLASMA; LECITHIN; CELLS	Scavenger receptor BI (SR-BI) is known to mediate the selective uptake of high density lipoprotein (HDL) cholesteryl ester (CE) in liver and steroidogenic tissues. To evaluate the role of SR-BI in plasma lipoprotein metabolism, we have generated transgenic mice with liver-specific overexpression of murine SR-BI, On a chow diet SR-BI transgenic (SR-BI Tg) mice have decreased HDL-CE, apoA-I, and apoA-II levels; plasma triglycerides, low density lipoprotein (LDL) cholesterol, and very low density lipoprotein (VLDL) and LDL apoB were also decreased, compared with control mice. Turnover studies using non-degradable CE and protein labels showed markedly increased total and selective uptake of HDL-CE in the liver and increased HDL protein catabolism in both liver and kidney. To evaluate the changes in apoB further, mice were challenged with high fat, high cholesterol diets. In SR-BI Tg mice plasma apoB levels were only 3-15% of control levels, and the dietary increase in VLDL and LDL apoB was virtually abolished. These studies show that steady state overexpression of hepatic SR-BI reduces HDL levels and increases reverse cholesterol transport. They also indicate that SR-BI can play a role in the metabolism of apoB-containing lipoproteins. The dual effects of increased reverse cholesterol transport and lowering of apoB-containing lipoproteins that result hom hepatic SR-BI overexpression could have anti-atherogenic consequences.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Tall, AR (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.		Tall, Alan/AAT-8528-2021; Eckhardt, Erik/G-1567-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058033, P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54591, HL 58033] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; Cao GP, 1997, J BIOL CHEM, V272, P33068, DOI 10.1074/jbc.272.52.33068; DIXON JL, 1993, J LIPID RES, V34, P167; EISENBERG S, 1984, J LIPID RES, V25, P1017; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1974, SCAND J CLIN LAB INV, V33, P165, DOI 10.3109/00365517409100646; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; HAMILTON RL, 1971, SCIENCE, V172, P475, DOI 10.1126/science.172.3982.475; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Kim E, 1998, J LIPID RES, V39, P703; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Le N A, 1986, Methods Enzymol, V129, P384; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; PARKS JS, 1995, J LIPID RES, V36, P349; Pittman R C, 1986, Methods Enzymol, V129, P612; Plump AS, 1997, J LIPID RES, V38, P1033; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RINNINGER F, 1987, J LIPID RES, V28, P1313; Sakai N, 1997, J BIOL CHEM, V272, P7506, DOI 10.1074/jbc.272.11.7506; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TALL AR, 1996, ATHEROSCLEROSIS CORO, P105; TORSVIK H, 1972, FEBS LETT, V24, P165, DOI 10.1016/0014-5793(72)80758-0; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; YOKOYAMA S, 1980, J BIOL CHEM, V255, P7333	35	247	253	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32920	32926		10.1074/jbc.273.49.32920	http://dx.doi.org/10.1074/jbc.273.49.32920			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830042	hybrid			2022-12-25	WOS:000077329100081
J	Roussel, A; Yang, YQ; Ferrato, F; Verger, R; Cambillau, C; Lowe, M				Roussel, A; Yang, YQ; Ferrato, F; Verger, R; Cambillau, C; Lowe, M			Structure and activity of rat pancreatic lipase-related protein 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANDIDA-RUGOSA LIPASE; INTERFACIAL ACTIVATION; PROCOLIPASE COMPLEX; KINETIC-PROPERTIES; CRYSTAL-STRUCTURE; GUINEA-PIG; COLIPASE; IDENTIFICATION; DEPENDENCE; CLONING	The pancreas expresses several members of the lipase gene family including pancreatic triglyceride lipase (PTL) and two homologous proteins, pancreatic lipase-related proteins 1 and 2 (PLRP1 and PLRP2), Despite their similar amino acid sequences, PTL, PLRP1, and PLRP2 differ in important kinetic properties. PLRP1 has no known activity. PTL and PLRP2 differ in substrate specificity, bile acid inhibition, colipase requirement, and interfacial activation. To begin understanding the structural explanations for these functional differences, we solved the crystal structure of rat (r)PLRP2 and further characterized its kinetic properties. The 1.8 Angstrom structure of rPLRP2, like the tertiary structure of human PTL, has a globular N-terminal domain and a beta-sandwich C-terminal domain. The lid domain occupied the closed position, suggesting that rPLRP2 should show interfacial activation. When we reexamined this issue with tripropionin as substrate, rPLRP2 exhibited interfacial activation. Because the active site topology of rPLRP2 resembled that of human PTL, we predicted and demonstrated that the lipase inhibitors E600 and tetrahydrolipstatin inhibit rPLRP2, Although PTL and rPLRP2 have similar active sites, rPLRP2 has a broader substrate specificity that we confirmed using a monolayer technique, With this assay, we showed for the first time that rPLRP2 prefers phosphatidylglycerol and ethanolamine over phosphatidylcholine. In summary, we confirmed and extended the observation that PLRP2 lipases have a broader substrate specificity than PTL, we demonstrated that PLRP2 lipases show interfacial activation, and we solved the first crystal structure of a PLRP2 lipase that contains a lid domain.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; CNRS, IFR1, UPR 9039, F-13402 Marseille 20, France; CNRS, IFR1, UPR 9025, Lab Lipolyse Enzymat, F-13402 Marseille 20, France	Washington University (WUSTL); Washington University (WUSTL); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Lowe, M (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.				NICHD NIH HHS [HD3306002] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033060] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andersson L, 1996, BBA-LIPID LIPID MET, V1302, P236, DOI 10.1016/0005-2760(96)00068-9; Bezzine S, 1999, METH MOL B, V109, P187; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; CUDREY C, 1993, BIOCHEMISTRY-US, V32, P13800, DOI 10.1021/bi00213a008; DEREWENDA U, 1994, J LIPID RES, V35, P524; EGLOFF MP, 1995, BIOCHEMISTRY-US, V34, P2751, DOI 10.1021/bi00009a003; EGLOFF MP, 1995, PROTEIN SCI, V4, P44; EGLOFF MP, 1995, THESIS U PARIS ORSAY; Ferrato F, 1997, METHOD ENZYMOL, V286, P327; GILLER T, 1992, J BIOL CHEM, V267, P16509; GROCHULSKI P, 1994, PROTEIN SCI, V3, P82; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; GRUSBY MJ, 1990, CELL, V60, P451, DOI 10.1016/0092-8674(90)90596-7; Hermoso J, 1996, J BIOL CHEM, V271, P18007, DOI 10.1074/jbc.271.30.18007; HJORTH A, 1993, BIOCHEMISTRY-US, V32, P4702, DOI 10.1021/bi00069a003; JENNENS ML, 1995, J LIPID RES, V36, P2374; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lowe ME, 1996, BBA-LIPID LIPID MET, V1302, P177, DOI 10.1016/0005-2760(96)00058-6; Lowe ME, 1999, METH MOL B, V109, P59; MARTINELLE M, 1995, BBA-LIPID LIPID MET, V1258, P272, DOI 10.1016/0005-2760(95)00131-U; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OTWINOVSKY A, 1993, DENZO OSCILLATION DA; PAYNE RM, 1994, AM J PHYSIOL, V266, pG914, DOI 10.1152/ajpgi.1994.266.5.G914; Ransac S, 1997, METHOD ENZYMOL, V286, P263; Roussel A, 1998, PROTEINS, V32, P523; Roussel A, 1991, SILICON GRAPHICS GEO, P86; THIRSTRUP K, 1994, BIOCHEMISTRY-US, V33, P2748, DOI 10.1021/bi00176a002; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R, 1997, TRENDS BIOTECHNOL, V15, P32, DOI 10.1016/S0167-7799(96)10064-0; VERGER R, 1973, CHEM PHYS LIPIDS, V10, P127, DOI 10.1016/0009-3084(73)90009-1; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WISHART MJ, 1993, J BIOL CHEM, V268, P10303; WithersMartinez C, 1996, STRUCTURE, V4, P1363, DOI 10.1016/S0969-2126(96)00143-8	39	68	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32121	32128		10.1074/jbc.273.48.32121	http://dx.doi.org/10.1074/jbc.273.48.32121			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822688	hybrid			2022-12-25	WOS:000077207000070
J	Notterman, D; Young, S; Wainger, B; Levine, AJ				Notterman, D; Young, S; Wainger, B; Levine, AJ			Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity	ONCOGENE			English	Article						p53; p21; G(2)/M; DNA; transactivation; nocodazole	CELL-CYCLE ARREST; WILD-TYPE P53; GROWTH SUPPRESSION; G(1) ARREST; ACTIVATION; APOPTOSIS; LACKING; DOMAIN; P21; IDENTIFICATION	The tumor suppressor p53 has been identified as a component of a mitotic spindle checkpoint. When exposed to a spindle-disrupting drug such as nocodazole, fibroblasts derived from mice having wild-type p53 are blocked with a 4N content of DNA, Conversely, fibroblasts from p53-deficient mice become polyploid, To learn if transcriptional activation of downstream genes by p53 plays a role in this putative checkpoint, three cell lines mere exposed to nocodazole, In one line, p53 protein is not expressed, while the other two cell lines over-express p53, In one of these two lines, the N-terminal transactivation domain is wild-type and in the second, this region contains a mutation that eliminates the ability of the protein to act as a transcription factor. Incubation with nocodazole of cells containing wild-type p53 results in accumulation of both 2N and 4N populations of cells. Under the same conditions, cells containing a transactivation-deficient mutant of p53 accumulate a 4N population of cells, but not a 2N population of cells. Cells entirely deficient in p53 protein become hyperdiploid, and display 8N to 16N DNA content. In all three cell lines, nocodazole elicited an initial increase in mitotic cells, but within 24 h the mitotic index returned to baseline. Expression patterns of cyclins B and D indicated that following entry into mitosis, the cells returned to a G(1) state but with 4N DNA content. Subsequent re-duplication of DNA beyond 4N is prevented in cells containing either wild-type or transcriptionally inactive p53 protein. In cells entirely lacking p53 protein, DNA is re-duplicated (without an intervening mitosis) and the cells become hyperdiploid. These experiments indicate that p53 does not participate in the transient mitotic arrest that follows spindle disruption, but is essential to prevent subsequent reduplication of DNA and the resulting hyperdiploid state. This function is intact in a mutant that is transcriptionally inactive.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Levine, AJ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Wainger, Brian/L-7553-2017					BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARBRE A, 1986, PRACTICAL PROTEIN CH, P227; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Leonardo A, 1997, CANCER RES, V57, P1013; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Starostik P, 1996, MOL CELL BIOL, V16, P3606; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335	33	53	53	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2743	2751		10.1038/sj.onc.1202210	http://dx.doi.org/10.1038/sj.onc.1202210			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840938				2022-12-25	WOS:000077146700007
J	Borgonovo, B; Racchetti, G; Malosio, M; Benfante, R; Podini, P; Rosa, P; Meldolesi, J				Borgonovo, B; Racchetti, G; Malosio, M; Benfante, R; Podini, P; Rosa, P; Meldolesi, J			Neurosecretion competence, an independently regulated trait of the neurosecretory cell phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETOGRANIN-II; PROTEIN; OVEREXPRESSION; EXOCYTOSIS; MEMBRANE; RECEPTOR; STEP; ACID; GENE	Neurosecretion competence is intended as the ability of neurosecretory cells to express dense and clear vesicles discharged by regulated exocytosis (neurotransmitter release). Such a property, which so far has never been studied independently, is investigated here by a heterotypic cell fusion approach, using a clone of rat pheochromocytoma PC12 cells totally incompetent for neurosecretion that still largely maintains its typical molecular and cellular phenotype. When fused with wild-type partners of various species (rat, human) and specialization (PC12, neuroblastoma SH-SY5Y, HeLa), the defective cells reacquire their competence as revealed by the expression of their secretion-specific proteins. Fused wild-type cells therefore appear able to complement defective cells by providing them with factor(s) inducing the reactivation of their secretory program. The mechanism of action of these factors may consist not in a coordinate unblocking of transcription but in the prevention of a rapid post-transcriptional degradation of the mRNAs for secretion-specific genes.	San Raffaele Sci Inst, DIBIT, Dept Neurosci, I-20132 Milan, Italy; Univ Milan, Dept Pharmacol, B Ceccarelli Ctr, I-20132 Milan, Italy; Univ Milan, Consiglio Nazl Ric, Ctr Mol & Cellular Pharmacol, I-20129 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Milan	Meldolesi, J (corresponding author), San Raffaele Sci Inst, DIBIT, Dept Neurosci, Via Olgettina 58, I-20132 Milan, Italy.		Malosio, Maria Luisa/C-1695-2013; Benfante, Roberta/C-1513-2015; racchetti, Gabriella/ABG-7347-2020; podini, paola/AAN-4766-2020	Malosio, Maria Luisa/0000-0003-0626-3066; Benfante, Roberta/0000-0001-5396-5429; Rosa, Patrizia/0000-0002-2590-6955; Racchetti, Gabriella/0000-0003-0062-8300				Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corradi N, 1996, J BIOL CHEM, V271, P27116, DOI 10.1074/jbc.271.43.27116; Daly C, 1997, J NEUROSCI, V17, P2365; Fabbri M, 1996, TISSUE ANTIGENS, V48, P47, DOI 10.1111/j.1399-0039.1996.tb02604.x; FARRELL CM, 1995, J BIOL CHEM, V270, P3400, DOI 10.1074/jbc.270.7.3400; GALFRE G, 1977, NATURE, V266, P550, DOI 10.1038/266550a0; Gatti G, 1997, MOL BIOL CELL, V8, P1789, DOI 10.1091/mbc.8.9.1789; GIUDICI AM, 1992, EUR J CELL BIOL, V58, P383; GREENBERG ME, 1989, CURRENT PROTOCOLS MO; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; LEONI C, 1998, IN PRESS MOL BIOL CE; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; Ninomiya Y, 1997, EMBO J, V16, P929, DOI 10.1093/emboj/16.5.929; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSA P, 1992, J HISTOCHEM CYTOCHEM, V40, P523, DOI 10.1177/40.4.1552186; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5	24	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34683	34686		10.1074/jbc.273.52.34683	http://dx.doi.org/10.1074/jbc.273.52.34683			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856988	hybrid			2022-12-25	WOS:000077719700006
J	Cao, J; Drews, M; Lee, HM; Conner, C; Bahou, WF; Zucker, S				Cao, J; Drews, M; Lee, HM; Conner, C; Bahou, WF; Zucker, S			The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE BINDING; C-TERMINAL DOMAIN; PROGELATINASE-A; TRANSMEMBRANE DOMAIN; CYSTEINE SWITCH; IV COLLAGENASE; TIMP-2; EXPRESSION; COMPLEX; CLONING	Activation of secreted latent matrix metalloproteinases (MMPs) is accompanied by cleavage of the N-terminal propeptide, thereby liberating the active zinc from binding to the conserved cysteine in the pro-domain. It has been assumed that an analogous mechanism is responsible for the activation of membrane type 1 MMP (MT1-MMP). Using recombinant wild-type MT1-MMP cDNA and mutant cDNAs transfected into COS-l cells lacking endogenous MT1-MMP, we have examined the function of the propeptide domain of MT1-MMP. MT1-MMP was characterized by immunoblotting, surface biotinylation, gelatin substrate zymography, and I-125-tissue inhibitor of metalloproteinases 2 (TIMP-2) binding. In Contrast to wild-type MT1-MMP-transfected COS-l cells, transfected COS-l cells containing a deletion of the N-terminal propeptide domain of MT1-MMP or a chimeric construction (substitution of the pro-domain of MT1-MMP with that of collagenase 3) were functionally inactive in terms of binding of I-125-Iabeled TIMP-2 to the cell surface and initiating the activation of progelatinase A These results support the concept that in its native plasma membrane-inserted form, the pro-domain of MT1-MMP plays an essential role in TIMP-2 binding and subsequent activation of pro-gelatinase A.	Vet Affairs Med Ctr, Northport, NY 11768 USA; SUNY Stony Brook, Sch Med, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Dept Oral Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Dent, Dept Oral Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Dent, Dept Med, Stony Brook, NY 11794 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zucker, S (corresponding author), Vet Affairs Med Ctr, Mail Code 151, Northport, NY 11768 USA.				NHLBI NIH HHS [HL-02431, HL-49149] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002431] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; Cha JH, 1996, BIOCHEMISTRY-US, V35, P15831, DOI 10.1021/bi962085f; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; EMONARD HP, 1992, CANCER RES, V52, P5845; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FREIMARK BD, 1994, J BIOL CHEM, V269, P26982; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Imai K, 1996, CANCER RES, V56, P2707; Kinoh H, 1996, J CELL SCI, V109, P953; Kinoshita T, 1996, CANCER RES, V56, P2535; Ko YC, 1997, BIOCHEM BIOPH RES CO, V236, P100, DOI 10.1006/bbrc.1997.6859; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; PARK AJ, 1991, J BIOL CHEM, V266, P1584; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; STOKER W, 1995, CURR OPIN STRUC BIOL, V5, P383; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yang MZ, 1996, J BIOL CHEM, V271, P25548, DOI 10.1074/jbc.271.41.25548; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	39	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34745	34752		10.1074/jbc.273.52.34745	http://dx.doi.org/10.1074/jbc.273.52.34745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856998	hybrid			2022-12-25	WOS:000077719700016
J	Datta, PK; Chytil, A; Gorska, AE; Moses, HL				Datta, PK; Chytil, A; Gorska, AE; Moses, HL			Identification of STRAP, a novel WD domain protein in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; I RECEPTOR; FAMILY; ANTAGONIST; INHIBITOR; MUTATIONS; SEQUENCE; SUBUNIT; FKBP12; SMAD7	Transforming growth factor-beta 1 (TGF-beta 1) is the prototype of a large family of proteins that regulate a variety of biological processes. The pleiotropic responses to TGF-beta are mediated via ligand-induced heteromeric complex formation by type I (T beta R-I) and type II (T beta R-II) serine-threonine kinase receptors. Several studies have shown that T beta R-II acts as a primary receptor, binding TGF-beta and phosphorylating T beta R-I, whose kinase activity then propagates the signals. Therefore, intracellular proteins that interact with type I receptors are likely to play important roles in TGF-beta signaling. We have identified a novel WD domain-containing protein, designated STRAP (serine-threonine kinase receptor-associated protein), which interacts with T beta R-I in a yeast two-hybrid system. STRAP associates with both functional T beta R-I and T beta R-II in vivo. Overexpression of STRAP leads to inhibition of TGF-beta-mediated transcriptional activation. It also shows synergistic inhibition of TGF-beta signaling in concert with Smad7, but not with Smad6, as measured by TGF-beta-dependent transcriptional reporters. The existence of the STRAP gene from yeast to mammals indicates an evolutionarily conserved function in eukaryotes. The data suggest a potential role for STRAP in TGF-beta signal transduction.	Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Moses, HL (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Canc Ctr, 649 MRB 2, Nashville, TN 37232 USA.				NCI NIH HHS [CA42572, CA48799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048799, R35CA042572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; Charng MJ, 1998, J BIOL CHEM, V273, P9365, DOI 10.1074/jbc.273.16.9365; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DATTA PK, 1994, J BIOL CHEM, V269, P25392; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; HARPER JW, 1993, CELL, V75, P805; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KLAGES SA, 1996, CELL, V86, P937; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	27	101	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34671	34674		10.1074/jbc.273.52.34671	http://dx.doi.org/10.1074/jbc.273.52.34671			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856985	hybrid			2022-12-25	WOS:000077719700003
J	Hays, WS; VanderJagt, DJ; Bose, B; Serianni, AS; Glew, RH				Hays, WS; VanderJagt, DJ; Bose, B; Serianni, AS; Glew, RH			Catalytic mechanism and specificity for hydrolysis and transglycosylation reactions of cytosolic beta-glucosidase from guinea pig liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVE-SITE; GALACTOSIDASE; SPECTROSCOPY; NUCLEOPHILE; EXPRESSION; GLU-461; BINDING	Cytosolic beta-glucosidase (CBG) from mammalian Liver is known for its broad substrate specificity and has been implicated in the transformation of xenobiotic glycosides, CBG also catalyzes a variety of transglycosylation reactions, which have been been shown with other glycosylhydrolases to function in synthetic and genetic regulatory pathways. We investigated the catalytic mechanism, substrate specificity, and transglycosylation acceptor specificity of guinea pig liver CBG by several methods. These studies indicate that CBG employs a two-step catalytic mechanism with the formation of a covalent enzyme-sugar intermediate and that CBG mill transfer sugar residues to primary hydroxyls and equatorial but not axial C-4 hydroxyls of aldopyranosyl sugars, Kinetic studies revealed that correction for transglycosylation reactions is necessary to derive correct kinetic parameters for CBG. Further analyses revealed that for aldopyranosyl substrates, the activation energy barrier is affected most by the presence of a C-6 carbon and by the configuration of the C-2 hydroxyl, whereas the binding energy is affected modestly by the configuration and substituents at C-2, C-4, and C-5. These data indicate that the transglycosylation activity of CBG derives from the formation of a covalently linked enzyme-sugar intermediate and that the specificity of CBG; for transglycosylation reactions is different from its specificity for hydrolysis reactions.	Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of Notre Dame	Glew, RH (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA.	rglew@salud.unm.edu						BADER DE, 1988, BIOCHEM BIOPH RES CO, V153, P301, DOI 10.1016/S0006-291X(88)81222-1; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BOCK K, 1983, ADV CARBOHYD CHEM BI, V41, P27, DOI 10.1016/S0065-2318(08)60055-4; DINTER A, 1995, ADV EXP MED BIOL, V376, P53; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GLEW RH, 1993, ACS SYM SER, V533, P83; GOPALAN V, 1992, J BIOL CHEM, V267, P14027; GOPALAN V, 1992, J BIOL CHEM, V267, P9629; GOPALAN V, 1989, J BIOL CHEM, V264, P15418; GRACE ME, 1994, J BIOL CHEM, V269, P2283; Hays WS, 1996, BIOCHEM J, V319, P829, DOI 10.1042/bj3190829; JOBE A, 1972, J MOL BIOL, V69, P397, DOI 10.1016/0022-2836(72)90253-7; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P427, DOI 10.1016/0003-9861(88)90466-3; LEGLER G, 1988, ARCH BIOCHEM BIOPHYS, V260, P437, DOI 10.1016/0003-9861(88)90467-5; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MCCARTER JD, 1992, BIOCHEM J, V286, P721, DOI 10.1042/bj2860721; MIAO SC, 1994, J BIOL CHEM, V269, P10975; POCSI I, 1988, BIOCHEM J, V256, P139, DOI 10.1042/bj2560139; PODLASEK CA, 1995, J AM CHEM SOC, V117, P8635, DOI 10.1021/ja00138a020; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; Thompson JE, 1997, BIOCHEM J, V327, P699; WALSH C, 1979, ENZYMATIC REACTION M, P267	24	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34941	34948		10.1074/jbc.273.52.34941	http://dx.doi.org/10.1074/jbc.273.52.34941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857024	hybrid			2022-12-25	WOS:000077719700042
J	Xie, Z; Ho, WT; Exton, JH				Xie, Z; Ho, WT; Exton, JH			Association of N- and C-terminal domains of phospholipase D is required for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; D DEFINES; EXPRESSION; FAMILY; PROTEINS; CLONING; SUPERFAMILY; SYNTHASES; ENZYMES; BRAIN	Rat brain phospholipase D1 (rPLD1) belongs to a superfamily defined by the highly conserved catalytic motif (H(X)K(X)(4)D, denoted HKD, RPLD1 contains two HKD domains, located in the N- and C-terminal regions. Deletion mutants of rPLD1 that contained only an N- or C-terminal HKD domain exhibited no catalytic activity when expressed in COS 7 cells. However, when N-terminal fragments containing one of the HAD domains were cotransfected with a C-terminal fragment containing the other HKD domain, PLD activity was restored. Furthermore, immunoprecipitation assays showed that the N- and C-terminal halves of rPLD1 were physically associated when expressed in COS 7 cells. In addition, deletion of 168 amino acids from the N terminus of rPLD1 significantly enhanced basal PLD activity while inhibiting the response to phorbol ester, Likewise, the coexpression of this truncated N-terminal half with the C-terminal half resulted in increased PLD activity. In summary, this study provides direct evidence that the enzymatic activity of rPLD1 requires the presence of the HRD domains in both the N- and C-terminal regions of the molecule. More importantly, the two halves of rPLD1 can associate, and this may be essential to bring the two HKD domains together to form an active catalytic center, These findings provide new insights into the catalytic mechanism of enzymes of the PLD superfamily.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.							BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; PARK SK, 1997, J BIOL CHEM, V272, P29268; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Ponting CP, 1996, PROTEIN SCI, V5, P914; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; SCHMUTZ C, 1995, VIROLOGY, V213, P19, DOI 10.1006/viro.1995.1542; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; WANG XM, 1994, J BIOL CHEM, V269, P20312; Zhao Y, 1997, PROTEIN SCI, V6, P2655	27	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34679	34682		10.1074/jbc.273.52.34679	http://dx.doi.org/10.1074/jbc.273.52.34679			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856987	hybrid			2022-12-25	WOS:000077719700005
J	Kim, E; Ambroziak, P; Veniant, MM; Hamilton, RL; Young, SG				Kim, E; Ambroziak, P; Veniant, MM; Hamilton, RL; Young, SG			A gene-targeted mouse model for familial hypobetalipoproteinemia - Low levels of apolipoprotein B mRNA in association with a nonsense mutation in exon 26 of the apolipoprotein B gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; EMBRYONIC LETHALITY; RNA-METABOLISM; MICE; EXPRESSION; TRANSPORT; KNOCKOUT; HETEROZYGOTES; HOMOZYGOTES; DEFECTS	Familial hypobetalipoproteinemia, a syndrome characterized by abnormally low plasma levels of low density lipoprotein cholesterol, is caused by mutations in the apolipoprotein (apo) B gene that interfere with the synthesis of a full-length apoB100, In many cases of familial hypobetalipoproteinemia, nonsense or frameshift mutations result in the synthesis of a truncated apoB protein. To understand why these mutations result in low plasma cholesterol levels, we used gene targeting in mouse embryonic stem cells to introduce a nonsense mutation (N1785Stop) into exon 26 of the mouse Apob gene. The sole product of this mutant Apob allele was a truncated apoB, apoB39, Mice homozygous for this "apoB39-only" (Apob(39)) allele had low plasma levels of apoB39 and markedly reduced plasma levels of very low density lipoprotein and low density lipoprotein cholesterol when fed a high fat diet. Analysis of liver and intestinal RNA from heterozygous apoB39-only mice revealed that the Apob(39) mRNA levels were 60-70% lower than those from the wild-type allele. Interestingly, apoB39 was not cleared as rapidly from the plasma as apoB48, The apoB39-only mice provide new insights into the mechanisms of familial hypobetalipoproteinemia and the structural features of apoB that are important for lipoprotein metabolism.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kim, E (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; Boren J, 1998, J CLIN INVEST, V101, P1084, DOI 10.1172/JCI1847; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; DAVIDSON NO, 1994, TRENDS CARDIOVAS MED, V4, P231, DOI 10.1016/1050-1738(94)90039-6; Farese RV, 1996, J LIPID RES, V37, P347; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FARESE RV, 1992, J LIPID RES, V33, P569; FARESE RV, 1996, P NATL ACAD SCI USA, V93, P6398; Forte T, 1972, Adv Lipid Res, V10, P1; HAMILTON RL, 1969, P 1968 DEUEL C LIP T, P3; Hasty P., 1993, Gene targeting: a practical approach., P1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hogan B, 1994, MANIPULATING MOUSE E; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; HOMANICS GE, 1995, TERATOLOGY, V51, P1, DOI 10.1002/tera.1420510102; HUANG LS, 1995, J CLIN INVEST, V96, P2152, DOI 10.1172/JCI118269; ISHIBASHI S, 1994, P NATL ACAD SCI USA, V91, P4431, DOI 10.1073/pnas.91.10.4431; Kessler O, 1996, MOL CELL BIOL, V16, P4426; Kim E, 1998, J CLIN INVEST, V101, P1468; KODURI RK, 1991, CIRCULATION, V84, P227; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRUL ES, 1989, ARTERIOSCLEROSIS, V9, P856, DOI 10.1161/01.ATV.9.6.856; Li XH, 1996, J LIPID RES, V37, P210; Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181; LINTON MF, 1993, J LIPID RES, V34, P521; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAQUAT LE, 1995, RNA, V1, P453; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MILNE R, 1989, J BIOL CHEM, V264, P19754; Nielsen LB, 1998, CIRCULATION, V98, P13, DOI 10.1161/01.CIR.98.1.13; NISHINA PM, 1990, J LIPID RES, V31, P859; OTWAY S, 1967, J PHYSIOL-LONDON, V190, P309, DOI 10.1113/jphysiol.1967.sp008210; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; STEINBERG D, 1979, J CLIN INVEST, V64, P292, DOI 10.1172/JCI109451; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; YOUNG SG, 1987, J BIOL CHEM, V262, P16604; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025; YOUNG SG, 1987, J CLIN INVEST, V79, P1842, DOI 10.1172/JCI113026; YOUNG SG, 1994, HUM MOL GENET, V3, P741; YOUNG SG, 1986, J BIOL CHEM, V261, P2995; Young SG, 1996, METHOD ENZYMOL, V263, P120	46	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33977	33984		10.1074/jbc.273.51.33977	http://dx.doi.org/10.1074/jbc.273.51.33977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852051	hybrid			2022-12-25	WOS:000077542200017
J	Liu, B; Hassler, DF; Smith, GK; Weaver, K; Hannun, YA				Liu, B; Hassler, DF; Smith, GK; Weaver, K; Hannun, YA			Purification and characterization of a membrane bound neutral pH optimum magnesium-dependent and phosphatidylserine-stimulated sphingomyelinase from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; P55 TNF-RECEPTOR; ACID SPHINGOMYELINASE; HUMAN FIBROBLASTS; INDUCED APOPTOSIS; CELL-DIFFERENTIATION; SIGNAL-TRANSDUCTION; CERAMIDE GENERATION; PROTEIN; MEDIATOR	Sphingomyelin hydrolysis and ceramide generation catalyzed by sphingomyelinases (SMase) are hey components of the signaling pathways in cytokine- and stress-induced cellular responses. In this study, we report the partial purification and characterization of the membrane bound, neutral pH optimal, and magnesium-dependent SMase (N-SMase) from rat brain. Proteins from Triton X-100 extract of brain membrane were purified sequentially with DEAE-Sephacel, heparin-Sepharose, ceramic hydroxyapatite, Mono Q, phenyl-superose, and Superose 12 column chromatography. After eight purification steps, the specific activity of the enzyme increased by 3030-fold over the brain homogenate. The enzyme hydrolyzed sphingomyelin but not phosphatidylcholine and its activity was dependent upon magnesium with an optimal pH of 7.5 and a native pi of 5.2. Delipidation of the enzyme through chromatographic purification or by extraction with 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid followed by gel filtration revealed that the enzyme became increasingly dependent on phosphatidylserine (PS). Up to 20-fold stimulation was observed with PS whereas other lipids examined were either ineffective or only mildly stimulatory. The K-m of the enzyme for substrate sphingomyelin (3.4 mol %) was not affected by PS. The highly purified enzyme was inhibited by glutathione with a >95% inhibition observed with 3 mM glutathione and with a Hill number calculated at approximately 8. The significance of these results to the regulation of N-SMase is discussed.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Glaxo Wellcome Inc, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Mol Sci, Res Triangle Pk, NC 27709 USA	Duke University; Duke University; GlaxoSmithKline; GlaxoSmithKline	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem, 171 Ashley Ave, Charleston, SC 29425 USA.				NIGMS NIH HHS [GM43825, GM-17426, F32 GM017426-02, F32 GM017426] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017426, R37GM043825, R01GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; Albi E, 1997, BIOCHEM BIOPH RES CO, V236, P29, DOI 10.1006/bbrc.1997.6803; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Bradshaw CD, 1996, BIOCHEM MOL BIOL INT, V40, P709; CARRE JB, 1989, J NEUROCHEM, V52, P1294, DOI 10.1111/j.1471-4159.1989.tb01878.x; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; Chmura SJ, 1996, CANCER RES, V56, P2711; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; Degnan BM, 1996, ANN CLIN LAB SCI, V26, P234; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; GATT S, 1976, BIOCHEM BIOPH RES CO, V68, P235, DOI 10.1016/0006-291X(76)90034-6; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HOSTETLER KY, 1979, J LIPID RES, V20, P456; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; Koppenhoefer U, 1997, FEBS LETT, V414, P444, DOI 10.1016/S0014-5793(97)01035-1; LEVRAN O, 1991, P NATL ACAD SCI USA, V88, P3748, DOI 10.1073/pnas.88.9.3748; Liu B, 1997, SEMIN CELL DEV BIOL, V8, P311, DOI 10.1006/scdb.1997.0153; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Longo CA, 1997, AM J RESP CELL MOL, V16, P605, DOI 10.1165/ajrcmb.16.5.9160843; MARUYAMA EN, 1989, J NEUROCHEM, V52, P611, DOI 10.1111/j.1471-4159.1989.tb09163.x; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NILSSON A, 1968, BIOCHIM BIOPHYS ACTA, V164, P575, DOI 10.1016/0005-2760(68)90187-2; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PETKOVA DH, 1990, COMP BIOCHEM PHYS B, V95, P685, DOI 10.1016/0305-0491(90)90305-D; RAMACHANDRAN CK, 1990, BIOCHEM BIOPH RES CO, V167, P607, DOI 10.1016/0006-291X(90)92068-B; RAO BG, 1976, J LIPID RES, V17, P506; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SPERKER ER, 1983, J NEUROCHEM, V40, P1182, DOI 10.1111/j.1471-4159.1983.tb08112.x; STRUM JC, 1994, J BIOL CHEM, V269, P15493; Suchard SJ, 1997, BLOOD, V89, P2139, DOI 10.1182/blood.V89.6.2139; TAMIYAKOIZUMI K, 1989, J BIOCHEM, V106, P593, DOI 10.1093/oxfordjournals.jbchem.a122901; TAYAMA M, 1993, BIOCHEM J, V290, P401, DOI 10.1042/bj2900401; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wiesner DA, 1997, J BIOL CHEM, V272, P9868; YAMAGUCHI S, 1977, J BIOL CHEM, V252, P3805	52	113	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34472	34479		10.1074/jbc.273.51.34472	http://dx.doi.org/10.1074/jbc.273.51.34472			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852115	hybrid			2022-12-25	WOS:000077542200081
J	Sen Gupta, S; DeWitt, ND; Allen, KE; Slayman, CW				Sen Gupta, S; DeWitt, ND; Allen, KE; Slayman, CW			Evidence for a salt bridge between transmembrane segments 5 and 6 of the yeast plasma-membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT LETHAL MUTATIONS; IN-VITRO TRANSLATION; SACCHAROMYCES-CEREVISIAE; SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; SECRETORY VESICLES; FUNCTIONAL-ROLE; ALPHA-SUBUNIT; TRANSPORT	The plasma-membrane H+-ATPase of Saccharomyces cerevisiae, which belongs to the P-2 subgroup of cation-transporting ATPases, is encoded by the PMA1 gene and functions physiologically to pump protons out of the cell. This study has focused on hydrophobic transmembrane segments M5 and M6 of the H+-ATPase. In particular, a conserved aspartate residue near the middle of M6 has been found to play a critical role in the structure and biogenesis of the ATPase, Site-directed mutants in which Asp-730 was replaced by an uncharged residue (Asn or Val) were abnormally sensitive to trypsin, consistent with the idea that the proteins were poorly folded, and immunofluorescence confocal microscopy showed them to be arrested in the endoplasmic reticulum, Similar defects are known to occur when either Arg-695 or His-701 in M5 is replaced by a neutral residue (Dutra, M. B., Ambesi, A., and Slayman, C. W. (1998) J. Biol Chem. 273, 17411-17417). To search for possible charge-charge interactions between Asp-730 and Arg-695 or His-701, double mutants were constructed in which positively and negatively charged residues were swapped or eliminated. Strikingly, two of the double mutants (R695D/D730R and R695A/D730A) regained the capacity for normal biogenesis and displayed near-normal rates of ATP hydrolysis and ATP-dependent HC pumping. These results demonstrate that neither Arg-695 nor Asp-730 is required for enzymatic activity or proton transport, but suggest that there is a salt bridge between the two residues, linking M5 and M6 of the 100-kDa polypeptide.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University; Yale University	Slayman, CW (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA.			Sengupta, Soma/0000-0003-4577-1397	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM015761, R01GM015761] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM15761] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Ambesi A, 1998, ACTA PHYSIOL SCAND, V163, P107; Arguello JM, 1996, J BIOL CHEM, V271, P24610, DOI 10.1074/jbc.271.40.24610; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3169; Dutra MB, 1998, J BIOL CHEM, V273, P17411, DOI 10.1074/jbc.273.28.17411; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRILLINGOS S, 1995, BIOCHEMISTRY-US, V34, P9368, DOI 10.1021/bi00029a012; HAGER KM, 1986, P NATL ACAD SCI USA, V83, P7693, DOI 10.1073/pnas.83.20.7693; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Padmanabha KP, 1997, FOLIA MICROBIOL, V42, P245, DOI 10.1007/BF02818996; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; Portillo F, 1997, FEBS LETT, V402, P136, DOI 10.1016/S0014-5793(96)01515-3; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Schekman R, 1982, MOL BIOL YEAST SACCH, VII, P361; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Shin JM, 1997, ANN NY ACAD SCI, V834, P65, DOI 10.1111/j.1749-6632.1997.tb52226.x; SMITH DL, 1993, J BIOL CHEM, V268, P22469; VanHuysse JW, 1996, FEBS LETT, V389, P179, DOI 10.1016/0014-5793(96)00578-9; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	40	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34328	34334						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852098				2022-12-25	WOS:000077542200064
J	Beaumont, V; Hepworth, MB; Luty, JS; Kelly, E; Henderson, G				Beaumont, V; Hepworth, MB; Luty, JS; Kelly, E; Henderson, G			Somatostatin receptor desensitization in NG108-15 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-GAMMA-SUBUNITS; MU-OPIOID RECEPTOR; AGONIST-INDUCED DESENSITIZATION; KINASE-C; CALCIUM CHANNELS; BETA(2)-ADRENERGIC RECEPTOR; BETA-2-ADRENERGIC RECEPTORS; FUNCTIONAL DESENSITIZATION; DEPENDENT PHOSPHORYLATION	In NG108-15 cells inhibition of both N-type calcium channel current and adenylyl cyclase by somatostatin (SRIF) was not sustained but rapidly desensitized in the continued presence of the drug. The degree and rate of desensitization were concentration-dependent, and the desensitization was homologous with respect to the delta-opioid receptor. We have been unable to obtain evidence for the involvement of G protein-coupled receptor kinases (GRKs) in this desensitization. SRIF-induced desensitization of N-type calcium channel currents was not reduced in cells stably overexpressing a dominant negative mutant of GRK2 or following intracellular dialysis with GRK2- and GRK3-blocking peptides or with heparin, Inhibitors of protein kinase A, protein kinase C, and protein kinase G were also without effect. In contrast, both the rate and degree of SRIF-induced desensitization were reduced by pretreatment with phenylarsine oxide or concanavalin A, both inhibitors of receptor endocytosis. Furthermore, SRIF-induced desensitization was enhanced by monensin, which prevents receptor recycling back to the plasma membrane. Similarly, SRIF-induced desensitization of adenylyl cyclase inhibition was not reduced in cells stably overexpressing dominant negative mutant GRK2 but was reduced in cells pretreated with the receptor endocytosis inhibitor hyperosmotic sucrose or concanavalin A. These data are consistent with the view that SRIF-induced desensitization in NG108-15 cells results from receptor internalization.	Univ Bristol, Sch Med Sci, Dept Pharmacol, Bristol BS8 1TD, Avon, England	University of Bristol	Henderson, G (corresponding author), Univ Bristol, Sch Med Sci, Dept Pharmacol, Univ Walk, Bristol BS8 1TD, Avon, England.	graeme.henderson@bristol.ac.uk	Henderson, Graeme/AAC-5104-2022	Beaumont, Vahri/0000-0002-6488-2175				AKBAR M, 1994, FEBS LETT, V348, P192, DOI 10.1016/0014-5793(94)00603-2; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Beaumont V, 1997, BRIT J PHARMACOL, V122, pP4; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BITO H, 1994, J BIOL CHEM, V269, P12722; Bohm SK, 1997, BIOCHEM J, V322, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN BL, 1971, BIOCHEM J, V121, P561, DOI 10.1042/bj1210561; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DELASQUE N, 1994, CIBA FOUND S, V190, P89; Delmas P, 1998, J PHYSIOL-LONDON, V506, P319, DOI 10.1111/j.1469-7793.1998.319bw.x; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DOCHERTY RJ, 1988, J PHYSIOL-LONDON, V398, P33, DOI 10.1113/jphysiol.1988.sp017027; EDWARDS RJ, 1987, BRIT J PHARMACOL, V90, P501, DOI 10.1111/j.1476-5381.1987.tb11199.x; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; HARRIS GC, 1991, J NEUROSCI, V11, P2574; Hepworth MB, 1996, BRIT J PHARMACOL, V117, pP321; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HERTEL C, 1985, J BIOL CHEM, V260, P2547; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Holtmann MH, 1996, J BIOL CHEM, V271, P23566, DOI 10.1074/jbc.271.38.23566; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Koenig JA, 1997, BRIT J PHARMACOL, V120, P52, DOI 10.1038/sj.bjp.0700859; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KONG GH, 1994, J BIOL CHEM, V269, P13084; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LAW SF, 1993, J BIOL CHEM, V268, P10721; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LUTHIN DR, 1993, J BIOL CHEM, V268, P5990; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MERINEY SD, 1994, NATURE, V369, P336, DOI 10.1038/369336a0; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; MILLER SW, 1993, SOC NEUR ABSTR, V19; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Morikawa H, 1998, BRIT J PHARMACOL, V123, P1111, DOI 10.1038/sj.bjp.0701733; Mundell SJ, 1998, BIOCHEM PHARMACOL, V55, P595, DOI 10.1016/S0006-2952(97)00466-8; Mundell SJ, 1997, MOL PHARMACOL, V51, P991, DOI 10.1124/mol.51.6.991; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; OZCELEBI F, 1995, MOL PHARMACOL, V48, P818; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rao RV, 1997, MOL PHARMACOL, V51, P185, DOI 10.1124/mol.51.2.185; RAYMOND JR, 1994, BIOCHEMISTRY-US, V33, P11264, DOI 10.1021/bi00203a023; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Roth A, 1997, DNA CELL BIOL, V16, P111, DOI 10.1089/dna.1997.16.111; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; SHEN KZ, 1993, PFLUEGERS ARCH EUR J, V418, P614; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; THEKKUMKARA TJ, 1995, MOL CELL BIOCHEM, V146, P79, DOI 10.1007/BF00926885; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; TWERY MJ, 1989, BRAIN RES, V497, P315, DOI 10.1016/0006-8993(89)90277-1; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; VANETTI M, 1993, FEBS LETT, V331, P260, DOI 10.1016/0014-5793(93)80349-Y; Viana F, 1996, J NEUROSCI, V16, P6000; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WANG HL, 1990, NEUROSCIENCE, V38, P335, DOI 10.1016/0306-4522(90)90032-Y; YASUDA K, 1992, J BIOL CHEM, V267, P20422	74	69	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33174	33183		10.1074/jbc.273.50.33174	http://dx.doi.org/10.1074/jbc.273.50.33174			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837885	hybrid			2022-12-25	WOS:000077462500015
J	Chu, GX; Li, L; Sato, Y; Harrer, JM; Kadambi, VJ; Hoit, BD; Bers, DM; Kranias, EG				Chu, GX; Li, L; Sato, Y; Harrer, JM; Kadambi, VJ; Hoit, BD; Bers, DM; Kranias, EG			Pentameric assembly of phospholamban facilitates inhibition of cardiac function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; SARCOPLASMIC-RETICULUM; MYOCARDIAL-CONTRACTILITY; LIPID BILAYERS; PHOSPHORYLATION; OVEREXPRESSION; MUTAGENESIS; DOMAIN; HEARTS; PUMP	Phospholamban has been proposed to coexist as pentamers and monomers in native sarcoplasmic reticulum membranes. To determine its functional unit in vivo, we reintroduced wild-type (pentameric) or monomeric mutant (C41F) phospholamban in the hearts of phospholamban knockout mice. Transgenic lines, expressing similar levels of mutant or wild-type phospholamban, were identified, and their cardiac phenotypes were characterized in parallel. Sarcoplasmic reticulum Ca2+ transport assays indicated similar decreases in SERCA2 Ca2+ affinity by mutant or wild-type phospholamban, However, the time constants of relaxation and Ca2+ transient decline in isolated cardiomyocytes were diminished to a greater extent by wild-type than mutant phospholamban, even without significant differences in the amplitudes of myocyte contraction and Ca2+ transients between the two groups. Langendorff perfusion also indicated that mutant phospholamban was not capable of depressing the enhanced relaxation parameters of the phospholamban knockout hearts to the same extent as wild-type phospholamban, Moreover, in vivo assessment of mouse hemodynamics revealed a greater depression of cardiac function in wild-type than mutant phospholamban hearts. Thus, the mutant or monomeric form of phospholamban was not as effective in slowing Ca2+ decline or relaxation in cardiomyocytes, hearts, or intact animals as wild-type or pentameric phospholamban. These findings suggest that pentameric assembly of phospholamban is necessary for optimal regulation of myocardial contractility in vivo.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Internal Med, Div Cardiol, Cincinnati, OH 45267 USA; Loyola Univ, Dept Physiol, Maywood, IL 60153 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Loyola University Chicago	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Bers, Donald M/C-4507-2012	Bers, Donald/0000-0002-2237-9483	NCRR NIH HHS [1P40RR12358] Funding Source: Medline; NHLBI NIH HHS [HL-52318, HL-26057] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR012358] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318, R37HL026057, R01HL026057] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Autry JM, 1997, J BIOL CHEM, V272, P15872, DOI 10.1074/jbc.272.25.15872; BASSANI RA, 1992, J PHYSIOL-LONDON, V453, P591, DOI 10.1113/jphysiol.1992.sp019246; Chu GX, 1997, CIRC RES, V81, P485, DOI 10.1161/01.RES.81.4.485; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; Cornea RL, 1997, BIOCHEMISTRY-US, V36, P2960, DOI 10.1021/bi961955q; FUJII J, 1989, J BIOL CHEM, V264, P12950; HARRER JM, 1994, MOL CELL BIOCHEM, V140, P185, DOI 10.1007/BF00926757; Hoit BD, 1997, AM J PHYSIOL-HEART C, V273, pH2528, DOI 10.1152/ajpheart.1997.273.5.H2528; Kadambi VJ, 1996, J CLIN INVEST, V97, P533, DOI 10.1172/JCI118446; Karim CB, 1998, BIOCHEMISTRY-US, V37, P12074, DOI 10.1021/bi980642n; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Kirchhefer U, 1998, BIOPHYS J, V74, pA358; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; Li L, 1998, AM J PHYSIOL-HEART C, V274, pH1335, DOI 10.1152/ajpheart.1998.274.4.H1335; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; WATANABE Y, 1991, J BIOCHEM, V110, P40, DOI 10.1093/oxfordjournals.jbchem.a123540; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; Wolska B.M., 1996, AM J PHYSIOL, V271, P391; YOUNG EF, 1989, MEMBRANE BIOCHEM, V8, P95, DOI 10.3109/09687688909082263	27	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33674	33680		10.1074/jbc.273.50.33674	http://dx.doi.org/10.1074/jbc.273.50.33674			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837953	hybrid			2022-12-25	WOS:000077462500083
J	Gu, MY; Du, XP				Gu, MY; Du, XP			A novel ligand-binding site in the zeta-form 14-3-3 protein recognizing the platelet glycoprotein Ib alpha and distinct from the c-Raf-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR BINDING; PHOSPHORYLATED TRYPTOPHAN-HYDROXYLASE; IX COMPLEX; MEMBRANE GLYCOPROTEIN; SHEAR-STRESS; KINASE-C; T-CELLS; GP-IB; 14-3-3-PROTEINS; ACTIVATION	We reported previously that the zeta-form 14-3-3 protein (14-3-3 zeta) binds to a platelet adhesion receptor, glycoprotein (GP) Ib-M, and this binding is dependent on the SGHSL sequence at the C terminus of GPIb alpha. In this study, we have identified a binding site in the helix I region of 14-3-3 zeta (residues 202-231) required for binding to GPIb-IX complex and to the cytoplasmic domain of GPIb alpha. We also show that phosphorylation-dependent binding of c-Raf to 14-3-3 zeta requires helix G (residues 163-187) but not helix I. Thus, the GPIb alpha-binding site is distinct from the binding sites for RSXpSXP motif-dependent ligands. Furthermore, we show that wild type 14-3-3 zeta has a higher affinity for GPIb-IX complex than recombinant GPIb alpha cytoplasmic domain. Deletion of helices A and B (residues 1-32) disrupts 14-3-3 zeta dimerization and decreases its affinity for GPIb-IX. Disruption of 14-3-3 zeta dimerization, however, does not reduce 14-3-3 zeta binding to recombinant GPIb alpha cytoplasmic domain. This suggests a dual site recognition mechanism in which a 14-5-3 zeta dimer inter;acts with both GPIb alpha and GPIb beta (known to contain a phosphorylation-dependent binding site), resulting in high affinity binding.	Univ Illinois, Dept Pharmacol MC868, Coll Med, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Du, XP (corresponding author), Univ Illinois, Dept Pharmacol MC868, Coll Med, 835 S Wolcott Ave, Chicago, IL 60612 USA.	xdu@uic.edu			NHLBI NIH HHS [HL52547] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052547, R01HL062350] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AITKEN A, 1995, BIOCHEM SOC T, V23, P605, DOI 10.1042/bst0230605; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Banik U, 1997, J BIOL CHEM, V272, P26219, DOI 10.1074/jbc.272.42.26219; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Calverley DC, 1998, BLOOD, V91, P1295, DOI 10.1182/blood.V91.4.1295; CHOW TW, 1992, BLOOD, V80, P113; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1987, BLOOD, V69, P1524; DU XP, 1993, J BIOL CHEM, V268, P23087; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FOX JEB, 1989, J BIOL CHEM, V264, P9520; FOX JEB, 1987, J BIOL CHEM, V262, P12627; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KROLL MH, 1993, J BIOL CHEM, V268, P3520; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Meller N, 1996, MOL CELL BIOL, V16, P5782; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OKUMURA T, 1976, THROMB RES, V8, P701, DOI 10.1016/0049-3848(76)90250-4; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Ware J, 1998, THROMB HAEMOSTASIS, V79, P466; WYLER B, 1986, BIOCHEM J, V234, P373, DOI 10.1042/bj2340373; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	45	47	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33465	33471		10.1074/jbc.273.50.33465	http://dx.doi.org/10.1074/jbc.273.50.33465			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837925	hybrid			2022-12-25	WOS:000077462500055
J	Maehrel, C; Cordat, E; Mus-Veteau, I; Leblanc, G				Maehrel, C; Cordat, E; Mus-Veteau, I; Leblanc, G			Structural studies of the melibiose permease of Escherichia coli by fluorescence resonance energy transfer - I. Evidence for ion-induced conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENTS; CARRIER PROTEIN; BINDING-PROPERTIES; ACIDIC RESIDUES; SUGAR BINDING; NA+; TRANSPORT; VESICLES; H+; MUTAGENESIS	Further insight into the cosubstrate-induced structural change of the melibiose permease (MelB) of Escherichia coli has been sought by investigating the binding and spectroscopic properties of the fluorescent sugar 2'-(N-5-dimethylaminonaphthalene-1-sulfonyl)-aminoethyl 1 -thio-beta-D-galactopyranoside (Dns(2)-S-Gal) and related analogs (Dns(3)-S-Gal or Dns(6)-S-Gal with a propyl or hexyl instead of an ethyl linker, respectively) interacting with MelB in membrane vesicles or in proteoliposomes. The three analogs efficiently inhibit melibiose transport and bind to MelB in a sodium-dependent fashion, Their dissociation constants (K-d) are in the micromolar range in the presence of NaCl and an order of magnitude higher in its absence. In the presence of NaCl and Dns(2)-S-Gal, sample excitation at 335 or 297 nm gives rise to a fluorescent signal at around 465 nm, whereas Dns(2)-S-Gal or Dns(6) S-Gal emits a fluorescence light at 490 or 506 nm, respectively. Detailed study of the Dns2-S-Gal signal elicited by a 297 nm illumination indicates that a tryptophan-mediated fluorescence resonance energy transfer phenomenon is involved in the response. All fluorescence signals below 500 nm are prevented by addition of melibiose in excess, and the kinetic constants describing their dependence on the probe or NaCl concentrations closely correlate with the probe binding constants. Finally, the Dns(2)-S-Gal signal recorded in sodium-free medium is red shifted by up to 25 nm from that recorded in the presence of NaCl, Taken together, these results suggest (i) that the fluorescence signals below 500 nm arise from Dns-S-Gal molecules bound to MelB, (ii) the presence of a highly hydrophobic environment close to or at the sugar-binding site, the polarity of which increases on moving away from the sugar-binding site, and (iii) that the interaction of sodium ions with MelB enhances the hydrophobicity of this environment. These results are consistent with the induction of a cooperative change of the structure of the sugar binding site or of its immediate vicinity by the ions.	CEA, Dept Biol Cellulaire & Mol, F-06238 Villefranche Sur Mer, France; CNRS, ERS 1253, F-06238 Villefranche Sur Mer, France	CEA; Centre National de la Recherche Scientifique (CNRS)	Leblanc, G (corresponding author), CEA, Dept Biol Cellulaire & Mol, F-06238 Villefranche Sur Mer, France.		Mus-veteau, Isabelle/M-8875-2016	Mus-veteau, Isabelle/0000-0001-5739-7684				BASSILANA M, 1987, J BIOL CHEM, V262, P16865; BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BOTFIELD MC, 1992, J BIOL CHEM, V267, P1818; BRANDOLIN G, 1980, BIOCHIM BIOPHYS ACTA, V592, P592, DOI 10.1016/0005-2728(80)90103-6; CHEN RF, 1967, ARCH BIOCHEM BIOPHYS, V120, P609, DOI 10.1016/0003-9861(67)90526-7; Cordat E, 1998, J BIOL CHEM, V273, P33198, DOI 10.1074/jbc.273.50.33198; DAMIANOFORANO E, 1986, J BIOL CHEM, V261, P6893; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; Gwizdek C, 1997, BIOCHEMISTRY-US, V36, P8522, DOI 10.1021/bi970312n; HAMA H, 1994, J BIOL CHEM, V269, P1063; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MusVeteau I, 1996, BIOCHEMISTRY-US, V35, P12053, DOI 10.1021/bi961372g; MUSVETEAU I, 1995, BIOCHEMISTRY-US, V34, P7775; OVERATH P, 1979, BIOCHEMISTRY-US, V18, P1, DOI 10.1021/bi00568a001; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POURCHER T, 1991, BIOCHEM BIOPH RES CO, V178, P1176, DOI 10.1016/0006-291X(91)91016-6; POURCHER T, 1990, PHILOS T ROY SOC B, V326, P411, DOI 10.1098/rstb.1990.0021; POURCHER T, 1993, J BIOL CHEM, V268, P3209; POURCHER T, 1995, BIOCHEMISTRY-US, V34, P4412, DOI 10.1021/bi00013a033; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; ROSSI B, 1980, J BIOL CHEM, V255, P9936; SCHULDINER S, 1975, J BIOL CHEM, V250, P1361; SCHULDINER S, 1975, J BIOL CHEM, V250, P3679; SCHULDINER S, 1977, BIOCHIM BIOPHYS ACTA, V472, P399, DOI 10.1016/0304-4157(77)90004-1; WILSON DM, 1992, J BACTERIOL, V174, P3083, DOI 10.1128/JB.174.9.3083-3086.1992; YAMASHITA MM, 1990, P NATL ACAD SCI USA, V87, P5648, DOI 10.1073/pnas.87.15.5648; YAZYU H, 1984, J BIOL CHEM, V259, P4320; ZANI ML, 1993, J BIOL CHEM, V268, P3216; ZANI ML, 1994, J BIOL CHEM, V269, P24883	32	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33192	33197		10.1074/jbc.273.50.33192	http://dx.doi.org/10.1074/jbc.273.50.33192			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837887	hybrid			2022-12-25	WOS:000077462500017
J	Sun, DX; McDonnell, M; Chen, XS; Lakkis, MM; Li, HW; Isaacs, SN; Elsea, SH; Patel, PI; Funk, CD				Sun, DX; McDonnell, M; Chen, XS; Lakkis, MM; Li, HW; Isaacs, SN; Elsea, SH; Patel, PI; Funk, CD			Human 12(R)-lipoxygenase and the mouse ortholog - Molecular cloning, expression, and gene chromosomal assignment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONATE 12-LIPOXYGENASE; EPIDERMAL LIPOXYGENASE; FUNCTIONAL EXPRESSION; HUMAN 5-LIPOXYGENASE; CDNA CLONING; ACID; 15-LIPOXYGENASE; LOCALIZATION; LEUKOCYTES; SEQUENCE	Expressed sequence tag information was used to clone the full-length sequence for a new human lipoxygenase from the B cell line CCL-156, A related mouse sequence with 83% nucleotide identity to the human sequence was also cloned. The human lipoxygenase, when expressed via the baculovirus/insect cell system produced an approximate to 80-kDa protein capable of metabolizing arachidonic acid to a product identified as 12-hydroxyeicosatetraenoic acid by mass spectrometry. Using chiral phase-high performance liquid chromatography, the product was identified as >98% 12(R)-hydroxyeicosatetraenoic acid as opposed to the S-stereoisomer formed by all other known mammalian lipoxygenases, The single copy human 12(R)-lipoxygenase gene was localized to the chromosome 17p13 region, the locus where most other lipoxygenase genes are known to reside. By reverse transcription-polymerase chain reaction, but not by Northern blot, analysis the 12(R)-lipoxygenase mRNA was detected in B cells and adult skin. However, the related mouse lipoxygenase mRNA was highly expressed in epidermis of newborn mice and to a lesser extent in adult brain cortex, By in situ hybridization the mouse lipoxygenase gene was demonstrated to be temporally and spatially regulated during embryogenesis, Expression was induced at embryonic day 15.5 in epidermis, nasal epithelium, and surface of the tongue. These results broaden the mammalian lipoxygenase family to include a 12(R)-lipoxygenase whose biological function remains to be determined.	Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Stellar Chance Labs 805, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Baylor College of Medicine; Baylor College of Medicine	Funk, CD (corresponding author), Univ Penn, Ctr Expt Therapeut, Dept Pharmacol, Stellar Chance Labs 805, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Sun, Duxin/AAA-1774-2022; Funk, Colin D/A-9518-2010; Isaacs, Stuart/HGA-3405-2022; Patel, Pragna/H-9129-2017	Funk, Colin/0000-0001-7029-4233; Elsea, Sarah/0000-0002-1400-8519; Patel, Pragna/0000-0003-3584-1072	NHLBI NIH HHS [HL53558] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053558] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; Boeglin WE, 1998, P NATL ACAD SCI USA, V95, P6744, DOI 10.1073/pnas.95.12.6744; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; CHEN XS, 1994, J BIOL CHEM, V269, P13979; FUNK CD, 1992, P NATL ACAD SCI USA, V89, P3962, DOI 10.1073/pnas.89.9.3962; Funk CD, 1996, J BIOL CHEM, V271, P23338, DOI 10.1074/jbc.271.38.23338; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; HADA T, 1991, BIOCHIM BIOPHYS ACTA, V1083, P89, DOI 10.1016/0005-2760(91)90128-5; HAYASHI M, 1986, J CELL BIOL, V102, P2302, DOI 10.1083/jcb.102.6.2302; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HUSSAIN H, 1994, AM J PHYSIOL, V266, pC243, DOI 10.1152/ajpcell.1994.266.1.C243; Jisaka M, 1997, J BIOL CHEM, V272, P24410, DOI 10.1074/jbc.272.39.24410; Kaufman M.H., 1992, ATLAS MOUSE DEV, P291; Kinzig A, 1997, FEBS LETT, V402, P162, DOI 10.1016/S0014-5793(96)01517-7; Krieg P, 1998, BBA-LIPID LIPID MET, V1391, P7, DOI 10.1016/S0005-2760(97)00214-2; Kritzik MR, 1997, BBA-GENE STRUCT EXPR, V1352, P267, DOI 10.1016/S0167-4781(97)00005-5; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P3406; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; NELSON MJ, 1994, CURR OPIN STRUC BIOL, V4, P878, DOI 10.1016/0959-440X(94)90270-4; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1991, AM J PHYSIOL, V260, P13; Sun D, 1998, CYTOGENET CELL GENET, V81, P79, DOI 10.1159/000014993; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; van Tuinen P, 1987, Genomics, V1, P374, DOI 10.1016/0888-7543(87)90042-5; VANTUINEN P, 1988, AM J HUM GENET, V43, P587; WALSTRA P, 1987, BIOCHIM BIOPHYS ACTA, V921, P312, DOI 10.1016/0005-2760(87)90032-4; WHEELAN P, 1993, BIOL MASS SPECTROM, V22, P465, DOI 10.1002/bms.1200220808; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0; YAMAMOTO S, 1993, J LIPID MEDIATOR, V6, P69; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142; YOSHIMOTO T, 1992, J BIOL CHEM, V267, P24805	40	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33540	33547		10.1074/jbc.273.50.33540	http://dx.doi.org/10.1074/jbc.273.50.33540			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837935	hybrid			2022-12-25	WOS:000077462500065
J	Weber, J; Senior, AE				Weber, J; Senior, AE			Effects of the inhibitors azide, dicyclohexylcarbodiimide, and aurovertin on nucleotide binding to the three F-1-ATPase catalytic sites measured using specific tryptophan probes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; ATP HYDROLYSIS; GAMMA-SUBUNIT; SUBSTITUTION; MGADP; MUTATION; SYNTHASE; ADP	Equilibrium nucleotide binding to the three catalytic sites of Escherichia coli F-1-ATPase was measured in the presence of the inhibitors azide, dicyclohexylcarbodiimide, and aurovertin to elucidate mechanisms of inhibition. Fluorescence signals of beta-Trp-331 and beta-Trp-148 substituted in catalytic sites were used to determine nucleotide binding parameters. Azide brought about small decreases in K-d(MgATP) and K-d(MgADP), Notably, under MgATP hydrolysis conditions, it caused all enzyme molecules to assume a state with three catalytic site-bound MgATP and zero bound MgADP, These results rule out the idea that azide inhibits by "trapping" MgADP, Rather, azide blocks the step at which signal transmission between catalytic sites promotes multisite hydrolysis, Aurovertin bound with stoichiometry of 1.8 (mol/mol of F-1) and allowed significant residual turnover. Cycling of the aurovertin-free beta-subunit catalytic site through three normal conformations was indicated by MgATP binding data. Aurovertin did not change the normal ratio of 1 bound MgATP/2 bound MgADP in catalytic sites. The results indicate that it acts to slow the switch of catalytic site affinities ("binding change step") subsequent to MgATP hydrolysis, Dicyclohexylcarbodiimide shifted the ratio of catalytic site-bound MgATP/MgADP from 1:2 to 1.6:1.4, without affecting K-d(MgATP) values. Like azide, it also appears to affect activity at the step after MgATP binding, in which signal transmission between catalytic sites promotes MgATP hydrolysis.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025349, R01GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; HARRIS DA, 1989, BIOCHIM BIOPHYS ACTA, V974, P156, DOI 10.1016/S0005-2728(89)80368-8; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; Linnett P E, 1979, Methods Enzymol, V55, P472; Lobau S, 1997, J BIOL CHEM, V272, P3648, DOI 10.1074/jbc.272.6.3648; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; MUELLER DM, 1994, EUR J BIOCHEM, V222, P991, DOI 10.1111/j.1432-1033.1994.tb18950.x; MURATALIEV MB, 1991, BIOCHEMISTRY-US, V30, P8305, DOI 10.1021/bi00098a004; Nakamoto RK, 1996, J MEMBRANE BIOL, V151, P101, DOI 10.1007/s002329900061; NOUMI T, 1987, FEBS LETT, V213, P381, DOI 10.1016/0014-5793(87)81526-0; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; RAO R, 1988, J BIOL CHEM, V263, P5569; SATRE M, 1980, J BACTERIOL, V142, P768, DOI 10.1128/JB.142.3.768-776.1980; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; TAKEDA K, 1985, J BIOCHEM-TOKYO, V97, P1401, DOI 10.1093/oxfordjournals.jbchem.a135194; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TOMMASINO M, 1985, BIOCHEMISTRY-US, V24, P3972; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; WISE JG, 1984, BIOCHEMISTRY-US, V23, P1426, DOI 10.1021/bi00302a014; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449; YOSHIDA M, 1982, J BIOL CHEM, V257, P33	31	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33210	33215		10.1074/jbc.273.50.33210	http://dx.doi.org/10.1074/jbc.273.50.33210			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837890	hybrid			2022-12-25	WOS:000077462500020
J	Cao, WG; Barany, F				Cao, WG; Barany, F			Identification of TaqI endonuclease active site residues by Fe2+-mediated oxidative cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORV RESTRICTION-ENDONUCLEASE; CRYSTAL-STRUCTURE; DIRECTED MUTAGENESIS; DNA-BINDING; ACETOACETATE DECARBOXYLASE; PROTEIN CLEAVAGE; RECOGNITION; MECHANISM; RESOLUTION; SEQUENCES	Metal cofactors (Mg2+ and Mn2+) modulate both specific DNA binding and strand cleavage in the TaqI endonuclease (Cao, W,, Mayer, A. N., and Barany, F. (1995) Biochemistry 34, 2276-2283), This work attempts to establish the structural basis of TaqI-DNA-metal(2+) interactions using an affinity cleavage technique. The protein was cleaved by localized hydroxyl radicals generated by oxidizing Fe2+ within the metal binding sites. Cleavage fragments were separated by SDS-polyacrylamide gel electrophoresis, and cleavage sites were determined using micropeptide sequencing. Eleven amino acid residues in the vicinity of cleavage sites were selected for site-directed mutagenesis, The negative charge at Asp(137) is essential for DNA cleavage but not required for sequence specific binding. Mutations at Asp(142) abolish both specific binding and catalysis, except for D142E, which converts TaqI into a completely Mn2+-dependent endonuclease. The positive charge at Lys(158) appears to be important for both specific binding and catalysis, Mutations at other sites affect binding and/or catalysis to different degrees, except Trp(113) and Glu(135), which appear to be nonessential for the TaqI enzyme activity. The critical residues for TaqI function are distinct from the PDX14-20(E/D)XK catalytic motif elucidated from other endonucleases.	Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, New York, NY 10021 USA	Cornell University	Cao, WG (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Strang Canc Prevent Ctr, Hearst Microbiol Res Ctr,Dept Microbiol, 1300 York Ave,Box 62, New York, NY 10021 USA.	wgc@mail.med.cornell.edu			NATIONAL CANCER INSTITUTE [P01CA065930] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA65930-02-04] Funding Source: Medline; NIGMS NIH HHS [GM-41337-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; *APPL BIOS INC, 1992, COMPL GUID EV IS SYN; ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; BARANY F, 1988, GENE, V65, P149, DOI 10.1016/0378-1119(88)90452-0; BARANY F, 1992, GENE, V112, P3, DOI 10.1016/0378-1119(92)90296-2; BARANY F, 1987, GENE, V56, P13, DOI 10.1016/0378-1119(87)90154-5; BARANY F, 1988, GENE, V63, P167; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CAO W, 1997, BIOCHEM J, V333, P425; Cao WG, 1997, GENE, V197, P205, DOI 10.1016/S0378-1119(97)00264-3; CAO WG, 1995, BIOCHEMISTRY-US, V34, P2276, DOI 10.1021/bi00007a023; CHENG XD, 1995, GENE, V157, P139, DOI 10.1016/0378-1119(95)00670-2; CUENOUD B, 1992, TETRAHEDRON LETT, V33, P895, DOI 10.1016/S0040-4039(00)91569-7; ERMACORA MR, 1992, P NATL ACAD SCI USA, V89, P6383, DOI 10.1073/pnas.89.14.6383; ETTNER N, 1993, J AM CHEM SOC, V115, P2546, DOI 10.1021/ja00059a081; ETTNER N, 1995, BIOCHEMISTRY-US, V34, P22, DOI 10.1021/bi00001a004; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; HONG R, 1997, GENE, V188, P35; JELTSCH A, 1992, FEBS LETT, V304, P4, DOI 10.1016/0014-5793(92)80576-3; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11086, DOI 10.1021/bi963125i; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; MAYER AN, 1994, J BIOL CHEM, V269, P29067; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794; SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010; SIKSNYS V, 1994, GENE, V142, P1, DOI 10.1016/0378-1119(94)90347-6; SOUNDAR S, 1993, J BIOL CHEM, V268, P5264; Taylor J D, 1994, Methods Mol Biol, V30, P263; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Vipond IB, 1996, BIOCHEMISTRY-US, V35, P1712, DOI 10.1021/bi9523926; WAUGH DS, 1993, P NATL ACAD SCI USA, V90, P9596, DOI 10.1073/pnas.90.20.9596; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; XU SY, 1991, J BIOL CHEM, V266, P4425; ZEBALA JA, 1992, J BIOL CHEM, V267, P8106; ZEBALA JA, 1992, J BIOL CHEM, V267, P8097	43	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33002	33010		10.1074/jbc.273.49.33002	http://dx.doi.org/10.1074/jbc.273.49.33002			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830053	hybrid			2022-12-25	WOS:000077329100092
J	Cirri, P; Chiarugi, P; Taddei, L; Raugei, G; Camici, G; Manao, G; Ramponi, G				Cirri, P; Chiarugi, P; Taddei, L; Raugei, G; Camici, G; Manao, G; Ramponi, G			Low molecular weight protein-tyrosine phosphatase tyrosine phosphorylation by c-Src during platelet-derived growth factor-induced mitogenesis correlates with its subcellular targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PDGF RECEPTOR; PHOSPHOTYROSINE; CELLS; GENE; LOCALIZATION; FAMILY	The low molecular weight phosphotyrosine phosphatase (LMW-PTP) is an enzyme that is involved in the early events of platelet-derived growth factor (PDGF) receptor signal transduction, Our previous results have shown that LMW-PTP is able to specifically bind and dephosphorylate activated PDGF receptor, thus modulating PDGF-induced mitogenesis, In particular LMW-PTP is involved in pathways that regulate the transcription of the immediately early genes myc and fos in response to growth factor stimulation. In this study we have established that, in nontransformed NIH3T3 cells, LMW-PTP exists constitutively in cytosolic and cytoskeleton-associated localization and that, after PDGF stimulation, c-Src is able to bind and to phosphorylate LMW-PTP only in the cytoskeleton-associated fraction. As a consequence of its tyrosine phosphorylation, LMW-PTP significantly increases its catalytic activity, After PDGF stimulation these two LMW-PTP pools act on distinct substrates, contributing in different manners to the PDGF receptor signaling, The cytoplasmic LMW-PTP fraction exerts its well known action on activated PDGF receptor. On the other hand we have now demonstrated that the cytoskeleton-associated LMW-PTP acts specifically on a few not yet identified proteins that become tyrosine-phosphorylated in response to the PDGF receptor activation. Finally, these two LMW-PTP pools markedly differ in the timing of the processes in which they are involved. The cytoplasmic LMW-PTP pool exerts its action within a few minutes from PDGF receptor activation (short term action), while tyrosine phosphorylation of cytoskeleton-associated LMW-PTP lasts for more than 40 min (long term action). In conclusion LMW-PTP is a striking example of an enzyme that exerts different functions and undergoes different regulation in consequence of its subcellular localization.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Raugei, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	raugei@cesit1.unifi.it	Chiarugi, Paola/CDD-7988-2022; Camici, Giovanni/H-1631-2018	raugei, giovanni/0000-0003-1294-786X; Camici, Giovanni/0000-0002-0523-0695; Chiarugi, Paola/0000-0001-7655-2969				Chen HC, 1996, EUR J BIOCHEM, V235, P495, DOI 10.1111/j.1432-1033.1996.00495.x; CHIARUGI P, 1992, FEBS LETT, V310, P9, DOI 10.1016/0014-5793(92)81134-8; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 1996, BIOCHEM BIOPH RES CO, V219, P21, DOI 10.1006/bbrc.1996.0174; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Clark SF, 1998, J CELL BIOL, V140, P1211, DOI 10.1083/jcb.140.5.1211; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Fincham VJ, 1996, J CELL BIOL, V135, P1551, DOI 10.1083/jcb.135.6.1551; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PATCH LA, 1995, J CELL SCI, V108, P1371; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1994, ADV PROT PHOSPHATASE, V8, P1; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Snapp EL, 1997, J CELL BIOL, V139, P1775, DOI 10.1083/jcb.139.7.1775; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	24	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32522	32527		10.1074/jbc.273.49.32522	http://dx.doi.org/10.1074/jbc.273.49.32522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829986	hybrid			2022-12-25	WOS:000077329100025
J	Kimura-Someya, T; Iwaki, S; Yamaguchi, A				Kimura-Someya, T; Iwaki, S; Yamaguchi, A			Site-directed chemical modification of cysteine-scanning mutants as to transmembrane segment II and its flanking regions of the Tn10-encoded metal-tetracycline/H+ antiporter reveals a transmembrane water-filled channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOSE PERMEASE; TRANSPOSON TN10; HYDROPHILIC DOMAINS; SUPPRESSOR MUTATION; RESISTANCE PROTEIN; MEMBRANE TOPOLOGY; SEQUENCE MOTIF; ACTIVE EFFLUX; MUTAGENESIS	Cysteine-scanning mutants, E32C to G62C, of the metal-tetracycline/H+ antiporter were constructed in order to precisely determine the membrane topology around putative transmembrane segment II. None of the mutants lost the ability to confer tetracycline resistance, indicating that the cysteine mutation in each mutant did not alter the protein conformation. [C-14]N-Ethylmaleimide (NEM) binding to these cysteine mutants in isolated membranes was then investigated. The peptide chain of this region passes through the membrane at least once because residues 36 and 65 are exposed on the outside and inside surfaces of the membrane, respectively (Kimura, T., Ohnuma, M., Sawai, T., and Yamaguchi, A. (1997) J. Biol. Chem. 272, 580-585). However, there was no continuous segment in which all of the introduced cysteine residues showed almost no reactivity with [C-14]NEM. The proportion of the unbound positions in the second half downstream from position 45 was 55% (10/18), which was clearly higher than that in the first half (21%; 3/14), suggesting that the second half is a transmembrane segment. Positions reactive to NEM appear periodically in the second half. They are located on one side of the helical wheel, suggesting that this side of the transmembrane helix faces a water-filled channel. The cysteine mutants as to the reactive positions in the second half were severely inactivated by NEM except for the P59C mutant, whereas the A40C mutant was the only one inactivated by NEM in the first half. These results suggest that the water-filled channel along this helical region may be a substrate translocation pathway.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 5670047, Japan.		Kimura-Someya, Tomomi/C-4169-2017	Kimura-Someya, Tomomi/0000-0003-2232-1801				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P12644, DOI 10.1021/bi00210a012; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P6408, DOI 10.1021/bi970233b; Frillingos S, 1997, PROTEIN SCI, V6, P431; Frillingos S, 1996, BIOCHEMISTRY-US, V35, P5333, DOI 10.1021/bi953068d; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P269, DOI 10.1021/bi9618629; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; FRILLINGOS S, 1994, BIOCHEMISTRY-US, V33, P8074, DOI 10.1021/bi00192a012; HASHIMOTOGOTOH T, 1995, GENE, V152, P271, DOI 10.1016/0378-1119(94)00750-M; He MM, 1996, BIOCHEMISTRY-US, V35, P12909, DOI 10.1021/bi960876b; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; Kimura T, 1998, BIOCHEMISTRY-US, V37, P5475, DOI 10.1021/bi973188g; Kimura T, 1996, FEBS LETT, V388, P50, DOI 10.1016/0014-5793(96)00514-5; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1997, BIOCHEMISTRY-US, V36, P6941, DOI 10.1021/bi9631879; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Kimura T, 1996, BIOCHEMISTRY-US, V35, P15896, DOI 10.1021/bi961568g; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVY SB, 1992, ANTIMICROB AGENTS CH, V36, P695, DOI 10.1128/AAC.36.4.695; MANOIL C, 1986, SCIENCE, V233, P1043; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; SAHINTOTH M, 1993, PROTEIN SCI, V2, P1024, DOI 10.1002/pro.5560020615; SAHINTOTH M, 1994, PROTEIN SCI, V3, P2302, DOI 10.1002/pro.5560031215; SAHINTOTH M, 1994, PROTEIN SCI, V3, P240; SOMEYA Y, 1995, BIOCHEMISTRY-US, V34, P7, DOI 10.1021/bi00001a002; Someya Y, 1997, BBA-BIOENERGETICS, V1322, P230, DOI 10.1016/S0005-2728(97)00088-1; WEITZMAN C, 1995, BIOCHEMISTRY-US, V34, P9374, DOI 10.1021/bi00029a013; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; Yamaguchi A, 1996, BIOCHEMISTRY-US, V35, P4359, DOI 10.1021/bi952116r; YAMAGUCHI A, 1993, BIOCHEMISTRY-US, V32, P5698, DOI 10.1021/bi00072a027; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAGUCHI A, 1995, BIOCHEMISTRY-US, V34, P11800, DOI 10.1021/bi00037a018; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	38	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32806	32811		10.1074/jbc.273.49.32806	http://dx.doi.org/10.1074/jbc.273.49.32806			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830026	hybrid			2022-12-25	WOS:000077329100065
J	Noad, RJ; Al-Kaff, NS; Turner, DS; Covey, SN				Noad, RJ; Al-Kaff, NS; Turner, DS; Covey, SN			Analysis of polypurine tract-associated DNA plus-strand priming in vivo utilizing a plant pararetroviral vector carrying redundant ectopic priming elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAULIFLOWER MOSAIC-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; SEQUENCE FEATURES IMPORTANT; MURINE LEUKEMIA-VIRUS; RNASE-H; 35S PROMOTER; REPLICATION; DISCONTINUITIES; CLEAVAGE	Initiation of DNA plus-strand synthesis in most reverse-transcribing elements requires primer generation by reverse transcriptase-associated RNase H at one or more template polypurine tracts (PPTs). We have exploited infectious clones of the plant pararetrovirus cauliflower mosaic virus carrying redundant ectopic plus-strand priming elements to study priming in vivo. Ectopic priming generated an additional discontinuity in progeny virion DNA during infection of plants. We found that altering the length of the 13-base pair PPT by +/-25% significantly reduced priming efficiency. A short pyrimidine tract 5' to the PPT, highly conserved among diverse reverse-transcribing elements, was shown to play an important role in PPT recognition in vivo. The predominant DNA plus-strand 5' end remained 3 nucleotides from the PPT 3' end in mutant primers that were longer or shorter than the wild-type primer. Use of an ectopic redundant primer to study replication-dependent priming was validated by demonstrating that it could rescue infectivity following destruction of the wild-type priming elements. We propose a model for plant pararetroviral plus-strand priming in which pyrimidines enhance PPT recognition during polymerase-dependent RNase H cleavages, and suggest that fidelity of primer maturation during polymerase-independent cleavages involves PPT length measurement and 3' end recognition by RNase H.	John Innes Ctr, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Covey, SN (corresponding author), John Innes Ctr, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.			Noad, Rob/0000-0002-0279-8461				ALKAFF N, 1994, J GEN VIROL, V75, P3137, DOI 10.1099/0022-1317-75-11-3137; CHARNEAU P, 1992, J VIROL, V66, P2814, DOI 10.1128/JVI.66.5.2814-2820.1992; Coffin JM, 1996, VIROLOGY, P1767; Covey Simon N., 1998, V81, P53; COVEY SN, 1986, EMBO J, V11, P2763; COVEY SN, 1992, GENETIC ENG PLANT VI, P217; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GABRIEL A, 1993, REVERSE TRANSCRIPTAS, P275; GUILLEY H, 1983, EMBO J, V2, P277, DOI 10.1002/j.1460-2075.1983.tb01417.x; HARRIS JD, 1981, VIROLOGY, V113, P573, DOI 10.1016/0042-6822(81)90185-9; HEYMAN T, 1995, J MOL BIOL, V253, P291, DOI 10.1006/jmbi.1995.0553; HOWARTH AJ, 1981, VIROLOGY, V112, P678, DOI 10.1016/0042-6822(81)90313-5; HUNGNES O, 1992, VIROLOGY, V190, P440, DOI 10.1016/0042-6822(92)91230-R; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; KUPIEC JJ, 1988, NUCLEIC ACIDS RES, V16, P9557, DOI 10.1093/nar/16.20.9557; Kupiec JJ, 1996, J GEN VIROL, V77, P1987, DOI 10.1099/0022-1317-77-9-1987; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MAULE AJ, 1985, NUCLEIC ACIDS RES, V13, P7359, DOI 10.1093/nar/13.20.7359; MEDBERRY SL, 1990, NUCLEIC ACIDS RES, V18, P5505, DOI 10.1093/nar/18.18.5505; Noad RJ, 1997, NUCLEIC ACIDS RES, V25, P1123, DOI 10.1093/nar/25.6.1123; Palaniappan C, 1996, J BIOL CHEM, V271, P2063, DOI 10.1074/jbc.271.47.29605; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PIETRZAK M, 1985, GENE, V33, P169, DOI 10.1016/0378-1119(85)90091-5; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; RATTRAY AJ, 1987, J VIROL, V61, P2843, DOI 10.1128/JVI.61.9.2843-2851.1987; RICHARDS KE, 1981, FEBS LETT, V134, P67, DOI 10.1016/0014-5793(81)80552-2; Sambrook J., 2002, MOL CLONING LAB MANU; TURNER DS, 1988, VIRUS RES, V9, P49, DOI 10.1016/0168-1702(88)90049-4; Turner DS, 1996, J VIROL, V70, P5414, DOI 10.1128/JVI.70.8.5414-5421.1996; TURNER DS, 1993, VIRUS RES, V28, P171, DOI 10.1016/0168-1702(93)90134-9; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; [No title captured]	35	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32568	32575		10.1074/jbc.273.49.32568	http://dx.doi.org/10.1074/jbc.273.49.32568			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829993	hybrid			2022-12-25	WOS:000077329100032
J	Xiao, GZ; Wang, D; Benson, MD; Karsenty, G; Franceschi, RT				Xiao, GZ; Wang, D; Benson, MD; Karsenty, G; Franceschi, RT			Role of the alpha(2)-integrin in osteoblast-specific gene expression and activation of the Osf2 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; MURINE MC3T3-E1 CELLS; ASCORBIC-ACID; INTEGRIN EXPRESSION; FACTOR-BETA; CLEIDOCRANIAL DYSPLASIA; EXTRACELLULAR-MATRIX; CHICKEN OSTEOBLASTS; COLLAGEN-SYNTHESIS; BONE-FORMATION	Extracellular matrix molecules such as type I collagen are required for the adhesion, migration, proliferation, and differentiation of a number of cell types including osteoblasts, Matrix components often affect cell function by interacting with members of the integrin family of cell surface receptors, Previous work showed that collagen matrix synthesis, induced by addition of ascorbic acid to cells, precedes and is essential for the expression of osteoblast markers and induction of the osteocalcin promoter in murine MC3T3-E1 cells. This later response requires OSE2, the promoter element recognized by Osf2 (also called Cbfa1/AML3/PEBP2 alpha A), a recently identified osteoblast-specific transcription factor. Osteoblasts express several integrins including alpha 2 beta 1 which is a major receptor for type I collagen. This paper examines the role of the alpha(2)-integrin subunit in osteocalcin promoter activation and osteoblast differentiation. Disruption of alpha(2)-integrin-ECM interactions with a blocking antibody or DGEA peptide containing the cell-binding domain of type I collagen blocked activation of the mouse osteocalcin gene 2 promoter by ascorbic acid as well as induction of endogenous osteocalcin mRNA and mineralization. Furthermore, anti-alpha(2)-integrin blocking antibody or peptide reduced ascorbic acid-dependent binding of Osf2 to OSE2 without affecting levels of transcription factor mRNA Time course studies revealed that ascorbic acid-dependent binding of Osf2 to OSE2 preceded increases in osteocalcin and bone sialoprotein expression and this increase in Osf2 binding was not accompanied by comparable changes in levels of transcription factor mRNA or protein. Taken together, these studies demonstrate that an alpha(2)-integrin-collagen interaction is required for activation of Osf2 and induction of osteoblast-specific gene expression. Furthermore, matrix signals may regulate Osf2 through a post-translational pathway or via an accessory factor.	Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Baylor College of Medicine	Franceschi, RT (corresponding author), Univ Michigan, Sch Dent, Dept Periodont Prevent & Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.		Benson, M. Douglas/L-9125-2019		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011723, R01DE012211, R01DE011290] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE12211, DE11723, DE-AR11290] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLOVER J, 1992, J CELL SCI, V103, P267; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FRANCESCHI RT, 1992, NUTR REV, V50, P65; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; Frendo JL, 1998, J BIOL CHEM, V273, P30509, DOI 10.1074/jbc.273.46.30509; GERSTENFELD LC, 1987, DEV BIOL, V122, P49, DOI 10.1016/0012-1606(87)90331-9; GRONOWICZ GA, 1994, J BONE MINER RES, V9, P193, DOI 10.1002/jbmr.5650090208; Gronthos S, 1997, J BONE MINER RES, V12, P1189, DOI 10.1359/jbmr.1997.12.8.1189; GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HUGHES DE, 1993, J BONE MINER RES, V8, P527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IBARAKI K, 1992, J BONE MINER RES, V7, P743; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Mahmoodian F, 1996, ARCH BIOCHEM BIOPHYS, V336, P86, DOI 10.1006/abbi.1996.0535; MARSH ME, 1995, J BONE MINER RES, V10, P1635; McCauley LK, 1996, J CELL BIOCHEM, V61, P638, DOI 10.1002/(SICI)1097-4644(19960616)61:4<638::AID-JCB18>3.0.CO;2-B; Moursi AM, 1996, J CELL SCI, V109, P1369; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; QUARLES LD, 1992, J BONE MINER RES, V7, P683; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; ROECKEL D, 1994, EXP CELL RES, V211, P42, DOI 10.1006/excr.1994.1056; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; SCHNEIDER WC, 1957, METHOD ENZYMOL, V3, P680, DOI 10.1016/S0076-6879(57)03442-4; SCHWIMMER R, 1995, J CELL SCI, V108, P2487; Sinha RK, 1996, BONE, V18, P451, DOI 10.1016/8756-3282(96)00044-0; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; Takeuchi Y, 1996, J BIOL CHEM, V271, P3938; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGARI A, 1995, JPN J PHARMACOL, V68, P255, DOI 10.1254/jjp.68.255; WINNARD RG, 1995, J BONE MINER RES, V10, P1969; WU JE, 1994, DEV DYNAM, V199, P292, DOI 10.1002/aja.1001990405; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; YOUNG MF, 1994, MAMM GENOME, V5, P108, DOI 10.1007/BF00292337; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110	49	303	312	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32988	32994		10.1074/jbc.273.49.32988	http://dx.doi.org/10.1074/jbc.273.49.32988			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830051	hybrid			2022-12-25	WOS:000077329100090
J	Charnock, SJ; Spurway, TD; Xie, HF; Beylot, MH; Virden, R; Warren, RAJ; Hazlewood, GP; Gilbert, HJ				Charnock, SJ; Spurway, TD; Xie, HF; Beylot, MH; Virden, R; Warren, RAJ; Hazlewood, GP; Gilbert, HJ			The topology of the substrate binding clefts of glycosyl hydrolase family 10 xylanases are not conserved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENS SUBSPECIES CELLULOSA; PSEUDOMONAS-FLUORESCENS; STREPTOMYCES-LIVIDANS; CRYSTAL-STRUCTURE; SITE; FIMI; MECHANISMS; CELLULASES; SEQUENCE; MODE	The crystal structures of family 10 xylanases indicate that the distal regions of their active sites are quite different, suggesting that the topology of the substrate binding clefts of these enzymes may vary. To test this hypothesis, we have investigated the rate and pattern of xylooligosaccharide cleavage by the family 10 enzymes, Pseudomonas fluorescens subsp. cellulosa xylanase A (XYLA) and Cellulomonas fimi exoglucanase, Cex. The data showed that Cex contained three glycone and two aglycone binding sites, while XYLA had three glycone and four aglycone binding sites, supporting the view that the topologies of substrate binding clefts in family 10 glycanases are not highly conserved. The importance of residues in the substrate binding cleft of XYLA in catalysis and ligand binding were evaluated using site-directed mutagenesis. In addition to providing insight into the function of residues in the glycone region of the active site, the data showed that the aromatic residues Phe-181, Tyr-255, and Tyr-220 play important roles in binding xylose moieties, via hydrophobic interactions, at subsites +1, +3, and +4, respectively. Interestingly, the F181A mutation caused a much larger reduction in the activity of the enzyme against xylooligosaccharides compared with xylan. These data, in conjunction with a previous study (Charnock, S. J., Lakey, J. H., Virden, R., Hughes, N., Sinnott, M. L., Hazlewood, G;. P., Pickersgill, R., and Gilbert, H. J. (1997) J. Biol. Chem. 272, 2942-2951), suggest that the binding of xylooligosaccharides at the -2 and +1 subsites ensures that the substrates occupy the -1 and +1 subsites and thus preferentially form productive complexes with the enzyme. Loss of ligand binding at either subsite results in small substrates forming nonproductive complexes with XYLA by binding to distal regions of the substrate binding cleft.	Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Dept Biochem & Genet, Newcastle Upon Tyne NE4 4HH, Tyne & Wear, England; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z1, Canada; Babraham Inst, Lab Mol Enzymol, Cambridge CB2 4AT, England	Newcastle University - UK; Newcastle University - UK; University of British Columbia; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Gilbert, HJ (corresponding author), Newcastle Univ, Dept Biol & Nutr Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@newcastle.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIELY P, 1985, TRENDS BIOTECHNOL, V3, P286, DOI 10.1016/0167-7799(85)90004-6; BIELY P, 1981, EUR J BIOCHEM, V119, P559, DOI 10.1111/j.1432-1033.1981.tb05644.x; BIELY P, 1993, BIOCHIM BIOPHYS ACTA, V1162, P246, DOI 10.1016/0167-4838(93)90288-3; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DEREWENDA U, 1994, J BIOL CHEM, V269, P20811; DOMINGUEZ R, 1995, NAT STRUCT BIOL, V2, P569, DOI 10.1038/nsb0795-569; EVANS EA, 1974, J LABELLED COMPD, V10, P569, DOI 10.1002/jlcr.2590100407; GILBERT HJ, 1993, J GEN MICROBIOL, V139, P187, DOI 10.1099/00221287-139-2-187; HALL J, 1989, MOL MICROBIOL, V3, P1211, DOI 10.1111/j.1365-2958.1989.tb00271.x; HARRIS GW, 1994, STRUCTURE, V2, P1107, DOI 10.1016/S0969-2126(94)00112-X; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HRMOVA M, 1995, J BIOL CHEM, V270, P14556, DOI 10.1074/jbc.270.24.14556; MACLEOD AM, 1994, BIOCHEMISTRY-US, V33, P6371, DOI 10.1021/bi00186a042; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MOREAU A, 1994, EUR J BIOCHEM, V219, P261, DOI 10.1111/j.1432-1033.1994.tb19937.x; Notenboom V, 1998, BIOCHEMISTRY-US, V37, P4751, DOI 10.1021/bi9729211; ONEILL GP, 1986, APPL ENVIRON MICROB, V52, P737, DOI 10.1128/AEM.52.4.737-743.1986; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; Spurway TD, 1997, J BIOL CHEM, V272, P17523, DOI 10.1074/jbc.272.28.17523; SUGANUMA T, 1978, J BIOCHEM-TOKYO, V84, P293, DOI 10.1093/oxfordjournals.jbchem.a132130; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; WHITE A, 1994, BIOCHEMISTRY-US, V33, P12546, DOI 10.1021/bi00208a003; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; Withers SG, 1995, PROGR BIOTECHNOL, V10, P97, DOI 10.1016/S0921-0423(06)80097-3	26	94	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32187	32199		10.1074/jbc.273.48.32187	http://dx.doi.org/10.1074/jbc.273.48.32187			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822697	hybrid			2022-12-25	WOS:000077207000079
J	Falkenberg, M; Elias, P; Lehman, IR				Falkenberg, M; Elias, P; Lehman, IR			The herpes simplex virus type 1 helicase-primase - Analysis of helicase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; ORIGIN-BINDING-PROTEIN; CIRCLE DNA-REPLICATION; POLYMERASE; GENE; IDENTIFICATION; COMPLEX; SUBUNIT; ICP8	The rate of unwinding of duplex DNA by the herpes simplex virus type 1 (HSV-1)-encoded helicase-primase (primosome) was determined by measuring the rate of appearance of single strands from a circular duplex DNA containing a 40-nucleotide 5' single-stranded tail, i.e. a preformed replication fork, in the presence of the HSV-1 single strand DNA-binding protein, infected cell protein 8 (ICP8). With this substrate, the rate at low ionic strength was highly sensitive to Mg2+ concentration. The Mg2+ dependence was a reflection of both the requirement for ICP8 for helicase activity and the ability of ICPS to reverse the helicase reaction as a consequence of its capacity to anneal homologous single strands at Mg2+ concentrations in excess of 3 mM. The rate of unwinding of duplex DNA by the HSV-1 primosome was also determined indirectly by measuring the rate of leading strand synthesis with a preformed replication fork as template in the presence of the T7 DNA polymerase. The value of 60-65 base pairs unwound/s by both methods is consistent with the rate of 50 base pairs/s estimated for the rate of fork movement in vivo during replication of pseudorabies virus, another herpesvirus. Interaction with the helicase-primase did not increase its helicase activity.	Stanford Univ, Beckman Ctr, Dept Biochem, Stanford, CA 94305 USA; Univ Gothenburg, Dept Biochem Med, S-41390 Gothenburg, Sweden	Stanford University; University of Gothenburg	Lehman, IR (corresponding author), Stanford Univ, Beckman Ctr, Dept Biochem, B-400, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026538] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26538] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENPORAT T, 1977, J VIROL, V22, P734, DOI 10.1128/JVI.22.3.734-741.1977; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; ELIAS P, 1986, P NATL ACAD SCI USA, V83, P6322, DOI 10.1073/pnas.83.17.6322; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; HERNANDEZ TR, 1990, J BIOL CHEM, V265, P11227; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; Marsden HS, 1997, J VIROL, V71, P6390, DOI 10.1128/JVI.71.9.6390-6397.1997; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; PURIFOY DJM, 1977, NATURE, V269, P621, DOI 10.1038/269621a0; Skaliter R, 1996, J VIROL, V70, P1132, DOI 10.1128/JVI.70.2.1132-1136.1996; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; VAUGHAN PJ, 1985, J VIROL, V53, P501, DOI 10.1128/JVI.53.2.501-508.1985; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988	23	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32154	32157		10.1074/jbc.273.48.32154	http://dx.doi.org/10.1074/jbc.273.48.32154			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822692	hybrid			2022-12-25	WOS:000077207000074
J	Zhang, JC; Sakthivel, R; Kniss, D; Graham, CH; Strickland, DK; McCrae, KR				Zhang, JC; Sakthivel, R; Kniss, D; Graham, CH; Strickland, DK; McCrae, KR			The low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor regulates cell surface plasminogen activator activity on human trophoblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; UROKINASE-TYPE-1 INHIBITOR COMPLEX; SINGLE-CHAIN UROKINASE; BOUND UROKINASE; ALPHA(2)-MACROGLOBULIN RECEPTOR; PLACENTAL TROPHOBLASTS; ENDOCYTIC RECEPTOR; SERPIN COMPLEXES; TYPE-1 COMPLEX; HUMAN TISSUES	The low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP/alpha(2)MR) mediates the internalization of numerous ligands, including prourokinase (pro-UK) and complexes between two-chain urokinase (tc-u-PA) and plasminogen activator inhibitor type-1 (PAI-I), It has been suggested that through its ability to internalize these ligands, LRP/alpha(2)MR may regulate the expression of plasminogen activator activity on cell surfaces; this hypothesis, however, has not been experimentally confirmed. To address this issue, we assessed the ability of LRP/alpha(2)MR to regulate plasminogen activator activity on human trophoblast cells, which express both LRP/alpha(2)MR and the urokinase receptor (uPAR). Trophoblasts internalized and degraded exogenous I-125-pro-UK (primarily following its conversion to tc-u-PA and incorporation into tc-u-PA.PAI: complexes) in an LRP/alpha(2)MR-dependent manner, which was inhibited by the LRP/alpha(2)MR receptor associated protein, Receptor-associated protein also caused a similar to 50% reduction in cell surface plasminogen activator activity and delayed the regeneration of unoccupied uPAR by cells on which uPAR were initially saturated with pro-UK. Identical effects were caused by anti-LRP/alpha(2)MR antibodies. These results demonstrate that LRP/alpha(2)MR promotes the expression of cell surface plasminogen activator activity on trophoblasts by facilitating the clearance of tc-u-PA.PAI complexes and regeneration of unoccupied cell surface uPAR.	Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Amer Red Cross, Jerome H Holland Lab, Rockville, MD 20855 USA; Ohio State Univ, Coll Med, Dept Obstet & Gynecol, Columbus, OH 43210 USA; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; American Red Cross; University System of Ohio; Ohio State University; Queens University - Canada	McCrae, KR (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol Oncol, BRB3,10900 Euclid Ave, Cleveland, OH 44106 USA.				NHLBI NIH HHS [HL50827, HL50784] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050827, R01HL050784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; ASTEDT B, 1986, THROMB HAEMOSTASIS, V56, P63; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; CAO DR, 1995, J IMMUNOL, V154, P1817; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CONESE M, 1995, BIOL CHEM H-S, V376, P143; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; COUKOS G, 1994, AM J PATHOL, V144, P383; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; DISS EM, 1992, AM J OBSTET GYNECOL, V167, P1046, DOI 10.1016/S0002-9378(12)80036-6; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1991, SEMIN THROMB HEMOST, V17, P194, DOI 10.1055/s-2007-1002609; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; GAFVELS ME, 1992, J BIOL CHEM, V267, P21230; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GRAHAM CH, 1994, EXP CELL RES, V214, P93, DOI 10.1006/excr.1994.1237; GRAHAM CH, 1993, EXP CELL RES, V206, P204, DOI 10.1006/excr.1993.1139; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1994, ANN NY ACAD SCI, V737, P14, DOI 10.1111/j.1749-6632.1994.tb44298.x; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIGAZI A, 1995, J BIOL CHEM, V21, P17375; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Higazi AAR, 1996, PLACENTA, V17, P683, DOI 10.1016/S0143-4004(96)80019-1; IRVING JA, 1995, PLACENTA, V16, P413, DOI 10.1016/0143-4004(95)90100-0; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; KJOLLER L, 1995, MOL CELL ENDOCRINOL, V109, P209, DOI 10.1016/0303-7207(95)03504-Z; KNISS DA, 1994, J REPROD MED, V39, P249; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; KUONNAS M, 1993, J BIOL CHEM, V268, P21862; KUONNAS MZ, 1992, J BIOL CHEM, V267, P12420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MIKUS P, 1993, EUR J BIOCHEM, V218, P1071, DOI 10.1111/j.1432-1033.1993.tb18467.x; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MOESTRUP SK, 1993, J BIOL CHEM, V268, P13691; Multhaupt HAB, 1996, AM J PATHOL, V148, P1985; MULTHAUPT HAB, 1994, LAB INVEST, V71, P392; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; NYKJAER A, 1990, BIOCHIM BIOPHYS ACTA, V1052, P399, DOI 10.1016/0167-4889(90)90149-8; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; OLSON D, 1992, J BIOL CHEM, V267, P9129; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; Rabbani SA, 1997, J CELL PHYSIOL, V172, P137, DOI 10.1002/(SICI)1097-4652(199708)172:2<137::AID-JCP1>3.0.CO;2-P; RAGNO P, 1993, FEBS LETT, V323, P279, DOI 10.1016/0014-5793(93)81357-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRICKLAND S, 1992, CELL, V71, P355, DOI 10.1016/0092-8674(92)90503-5; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WATANABE Y, 1994, ARTERIOSCLER THROMB, V14, P1000, DOI 10.1161/01.ATV.14.6.1000; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; WEI Y, 1994, J BIOL CHEM, V269, P32380; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WITTMAACK FM, 1995, ENDOCRINOLOGY, V136, P340, DOI 10.1210/en.136.1.340; Zhang JC, 1996, BLOOD, V88, P3880, DOI 10.1182/blood.V88.10.3880.bloodjournal88103880; ZINI JM, 1992, BLOOD, V79, P2917	73	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32273	32280		10.1074/jbc.273.48.32273	http://dx.doi.org/10.1074/jbc.273.48.32273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822706	hybrid			2022-12-25	WOS:000077207000088
J	Jeffers, M; Koochekpour, S; Fiscella, M; Sathyanarayana, BK; Vande Woude, GF				Jeffers, M; Koochekpour, S; Fiscella, M; Sathyanarayana, BK; Vande Woude, GF			Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor	ONCOGENE			English	Article						Met; oncogene; signaling	HEPATOCYTE GROWTH-FACTOR; GRB2 BINDING-SITE; SCATTER FACTOR; EPITHELIAL-CELLS; TRANSFORMING ACTIVITY; FACTOR/SCATTER FACTOR; CARBOXY-TERMINUS; PROTOONCOGENE; MUTATIONS; GENE	The Met tyrosine kinase receptor has been implicated in human cancer. Here we have examined the signaling requirements of three oncogenic forms of this molecule: wild type Met in response to ligand/autocrine stimulation, Met which has been mutationally activated, and Tpr-Met (a constitutively active truncated Met fusion protein). Previous studies have demonstrated the importance of a Grb2 binding site, and of specific tyrosine residues (i.e. Y8,9 and Y14,15) for Met function, and we have now explored the relevance of these and other sites for oncogenic Met signaling. Following substitution of various intracellular tyrosines for phenylalanine, we find that the transforming activity of each Met oncogene is dependent upon tyrosines Y8,9 and Y14,15, in addition to two novel tyrosines (Y6 and Y10) not previously implicated in Met signaling. Tyrosines Y6 and Y10 influence a variety of Met-mediated responses both in vitro (transformation, mitogenicity and invasion), and in vivo (tumorigenicity and metastasis). We also show that Tpr-Met is much more dependent on its Grb2 binding site for biological activity than are the other oncogenic forms of the Met receptor. Thus, although the three Met oncogenes examined are similar in their dependency on a number of specific tyrosines for activity, the signaling strategy employed by Tpr-Met can be differentiated from that of the other two.	NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vande Woude, GF (corresponding author), NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, POB B, Ft Detrick, MD 21702 USA.			KOOCHEKPOUR, SHAHRIAR/0000-0001-6649-5788				ALBINI A, 1987, CANCER RES, V47, P3239; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Higashio K, 1993, EXS, V65, P351; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwashita T, 1996, ONCOGENE, V12, P481; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KANDA H, 1993, ONCOGENE, V8, P3047; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	62	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2691	2700		10.1038/sj.onc.1202209	http://dx.doi.org/10.1038/sj.onc.1202209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840933				2022-12-25	WOS:000077146700002
J	Menjo, M; Kaneko, Y; Ogata, E; Ikeda, K; Nakanishi, M				Menjo, M; Kaneko, Y; Ogata, E; Ikeda, K; Nakanishi, M			Critical role for p27(Kip1) in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3)	ONCOGENE			English	Article						androgen; cancer; endocrine therapy; cell cycle; p27(Kip1) Cdk inhibitor	HUMAN BREAST-CANCER; DEPENDENT KINASE-ACTIVITY; GROWTH-FACTOR; INHIBITOR P27(KIP1); ESTROGEN-RECEPTOR; G1 PHASE; EXPRESSION; D1; ACTIVATION; PROGRESSION	The molecular mechanisms underlying androgen-regulated cancer growth and the frequent development of refractoriness to endocrine therapy remain unknown. In this study functional and quantitative alterations in cell cycle regulators after androgen depletion were examined in androgen-dependent mouse mammary carcinoma cells (SC-3) as a model system to clarify the initial response of cancer cells to anti-androgen therapy. FAGS analysis of SC-3 cells cultured with or without 10(-7) M testosterone revealed that suppression of cell growth after hormone withdrawal was due to G1 arrest. Although cyclin D1/Cdk4 activity decreased along with a reduced level of cyclin D1 protein, this was a later event (48-72 h) than the G1 arrest (24 h). Taken together with the results that constitutive expression of cyclin D1 in SC-3 cells did not overcome the growth suppression following androgen depletion, the existence of an alternative pathway(s) causing G1 arrest was suggested. Cyclin E/Cdk2 and cyclin A/Cdk2 activities decreased significantly at 24 h without apparent changes in the amounts of Cdk2, cyclin E or cyclin A. Among various Cdk inhibitors (CKIs) examined, p27(Kip1) was upregulated at both mRNA and protein levels at 24 h after androgen depletion. In addition, immunoprecipitation-Western analysis showed that the amount of p27(Kip1) associated with Cdk2 complexes increased as early as 24 h. These results suggest that p27(Kip1) CKI is a critical target in the initial response of cancer cells to androgen depletion and plays a key role in Cdk2 inactivation through association with the kinase complex, leading to cell cycle arrest.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan	Japanese Foundation for Cancer Research	Nakanishi, M (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.							Altucci L, 1996, ONCOGENE, V12, P2315; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Goldhirsch A, 1996, SEMIN ONCOL, V23, P494; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Liu Y, 1996, CANCER RES, V56, P31; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lu S, 1997, CANCER RES, V57, P4511; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINESITA T, 1965, CANCER RES, V25, P1168; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOGUCHI S, 1987, CANCER RES, V47, P263; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	41	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2619	2627		10.1038/sj.onc.1202193	http://dx.doi.org/10.1038/sj.onc.1202193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840925				2022-12-25	WOS:000077058900009
J	Mu, J; Roach, PJ				Mu, J; Roach, PJ			Characterization of human glycogenin-2, a self-glucosylating initiator of liver glycogen metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ENDOGENOUS RENAL ACCEPTOR; DNA-BINDING DOMAINS; COS CELLS; XYLOSYL TRANSFER; LEUCINE-ZIPPER; BIOSYNTHESIS; PROTEINS; BIOGENESIS; IDENTIFICATION	Glycogenin-a is a recently described self-glucosylating protein potentially involved in the initiation of glycogen biosynthesis (Mu, J., Skurat, A. V., and Roach, P. J. (1997) J. Biol. Chem. 272, 27589-27597). In human liver extracts, most of the glycogenin-2 was only detectable after treatment with alpha-amylase. Similarly, purifed high M-r glycogen was only detected after release by alpha-amylase treatment. Based on analysis by polymerase chain reaction, the predominant isoform in liver was glycogenin-2 beta. Glycogenin-a was found in Ewing's sarcoma RD-ES cells where, however, it was not associated with high M-r carbohydrate. Both human liver and human RD-ES cell extracts also contained glycogenin-l. Glycogenin-l and glycogenin-2 interact with one another, based on in vitro interactions and co-immunoprecipitation from liver and cell extracts. Mutation of Tyr-196 in glycogenin-a to a Phe residue abolished the ability of glycogenin-g to self-glucosylate but not to interact with glycogenin-l. Stable overexpression of glycogenin-2 alpha in Rat-1 fibroblast cells resulted in a 5-fold increase in the level of glycogen present in the low speed pellet but little change in the low speed supernatant. This result is important since it indicates that the level of glycogenin-2 can determine glycogen accumulation and hence has the potential to control glycogen synthesis.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Roach, PJ (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.			Mu, James/0000-0001-8081-2401	NIDDK NIH HHS [DK27221, DK20542] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027221, R37DK027221, P60DK020542, R56DK027221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MD, 1994, FEBS LETT, V342, P38, DOI 10.1016/0014-5793(94)80580-6; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; Baque S, 1997, FEBS LETT, V417, P355, DOI 10.1016/S0014-5793(97)01299-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CAO YJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P293, DOI 10.1006/abbi.1995.1295; CAO YJ, 1993, J BIOL CHEM, V268, P14687; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ERCAN N, 1994, J BIOL CHEM, V269, P22328; GANNON MC, 1996, TRENDS GLYCOSCI GLYC, V8, P163; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harris Robert A., 1997, P267; KOVAR H, 1990, ONCOGENE, V5, P1067; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MEEZAN E, 1994, J BIOL CHEM, V269, P11503; Mu J, 1997, J BIOL CHEM, V272, P27589, DOI 10.1074/jbc.272.44.27589; Mu J, 1996, J BIOL CHEM, V271, P26554, DOI 10.1074/jbc.271.43.26554; Pathak D., 1992, CURR OPIN STRUC BIOL, V2, P116, DOI [10.1016/0959-440X(92)90186-B, DOI 10.1016/0959-440X(92)90186-B]; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; RAPPOLD GA, 1993, HUM GENET, V92, P315, DOI 10.1007/BF01247327; Roach PJ, 1997, PROG NUCLEIC ACID RE, V57, P289, DOI 10.1016/S0079-6603(08)60284-6; RODEN L, 1994, J BIOL CHEM, V269, P11509; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; ROSEN G, 1997, CANC MED, V2, P2503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Skurat Alexander V., 1996, P213; SKURAT AV, 1994, J BIOL CHEM, V269, P25534; SKURAT AV, 1993, J BIOL CHEM, V268, P14701; Skurat AV, 1996, ARCH BIOCHEM BIOPHYS, V328, P283, DOI 10.1006/abbi.1996.0174; Skurat AV, 1997, EUR J BIOCHEM, V245, P147, DOI 10.1111/j.1432-1033.1997.t01-1-00147.x; SMYTHE C, 1989, EUR J BIOCHEM, V183, P205, DOI 10.1111/j.1432-1033.1989.tb14914.x; SMYTHE C, 1990, EUR J BIOCHEM, V189, P199, DOI 10.1111/j.1432-1033.1990.tb15477.x; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; Trempe G L, 1976, Recent Results Cancer Res, P33	36	30	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34850	34856		10.1074/jbc.273.52.34850	http://dx.doi.org/10.1074/jbc.273.52.34850			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857012	hybrid			2022-12-25	WOS:000077719700030
J	Rangan, VS; Joshi, AK; Smith, S				Rangan, VS; Joshi, AK; Smith, S			Fatty acid synthase dimers containing catalytically active beta-ketoacyl synthase or malony/acetyltransferase domains in only one subunit can support fatty acid synthesis at the acyl carrier protein domains of both subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAMMARY-GLAND; ESCHERICHIA-COLI; MULTIFUNCTIONAL ENZYME; IN-VITRO; SYNTHETASE; EXPRESSION; THIOESTERASE; COMPLEMENTATION; CONSTRUCTION; PURIFICATION	A double-tagging, dual affinity chromatographic procedure, which permits isolation of dimers independently mutated in each subunit, has been exploited to probe the functional topology of the animal fatty acid synthase, Dimers were engineered in which the chain-terminating thioesterase reaction was compromised by mutation of the (active-site) serine residue in both subunits; these dimers assembled two long-chain fatty acyl moieties, which remained covalently linked to the 4'-phosphopantetheine residues of the two acyl carrier protein domains. Significantly, dimers that contained an additional mutation that compromised the activity of either the beta-ketoacyl synthase or malonyl/acetyltransferase activity in only one subunit also assembled two long-chain acyl moieties, In contrast, in a control experiment, introduction of an additional mutation that compromised the function of the acyl carrier protein domain in only one subunit resulted in the assembly of only one long-chain acyl moiety per dimer, Because the beta-ketoacyl synthase and malonyl/acetyltransferase domains are located near the amino terminus of the polypeptide and the acyl carrier protein domain near the carboxyl terminus, these results support a modified model for the animal fatty acid synthase in which head-to-tail functional contacts are possible both within as well as between subunits.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Smith, S (corresponding author), Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA.	ssmith@lanminds.com			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHANG SI, 1990, ACCOUNTS CHEM RES, V23, P363, DOI 10.1021/ar00179a003; Joshi AK, 1998, BIOCHEMISTRY-US, V37, P2515, DOI 10.1021/bi971886v; JOSHI AK, 1993, BIOCHEM J, V296, P143, DOI 10.1042/bj2960143; Joshi AK, 1998, J BIOL CHEM, V273, P4937, DOI 10.1074/jbc.273.9.4937; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; KIM IC, 1977, ARCH BIOCHEM BIOPHYS, V178, P475, DOI 10.1016/0003-9861(77)90218-1; KUMAR S, 1972, J BIOL CHEM, V247, P4749; LIBERTINI LJ, 1979, ARCH BIOCHEM BIOPHYS, V192, P47, DOI 10.1016/0003-9861(79)90070-5; LIBERTINI LJ, 1978, J BIOL CHEM, V253, P1393; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; Rangan VS, 1996, J BIOL CHEM, V271, P31749, DOI 10.1074/jbc.271.49.31749; SINGH N, 1984, J BIOL CHEM, V259, P3605; Smith S, 1975, Methods Enzymol, V35, P65, DOI 10.1016/0076-6879(75)35139-2; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH S, 1985, EUR J BIOCHEM, V152, P547, DOI 10.1111/j.1432-1033.1985.tb09230.x; SMITH S, 1971, J BIOL CHEM, V246, P6428; STERN A, 1982, J BIOL CHEM, V257, P799; STOOPS JK, 1979, J BIOL CHEM, V254, P7418; STOOPS JK, 1981, J BIOL CHEM, V256, P5128; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; Witkowski A, 1996, BIOCHEMISTRY-US, V35, P10569, DOI 10.1021/bi960910m; Witkowski A, 1997, BIOCHEMISTRY-US, V36, P16338, DOI 10.1021/bi972242q	24	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34949	34953		10.1074/jbc.273.52.34949	http://dx.doi.org/10.1074/jbc.273.52.34949			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857025	hybrid			2022-12-25	WOS:000077719700043
J	Yu, JM; Yu, ZK; Wessling-Resnick, M				Yu, JM; Yu, ZK; Wessling-Resnick, M			Expression of SFT (stimulator of Fe transport) is enhanced by iron chelation in HeLa cells and by hemochromatosis in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY HEMOCHROMATOSIS; TRANSFERRIN RECEPTOR; IDIOPATHIC HEMOCHROMATOSIS; FUNCTIONAL EXPRESSION; SURFACE EXPRESSION; K562 CELLS; PROTEIN; SYSTEM; MICE; BETA(2)-MICROGLOBULIN	SFT (stimulator of Fe transport) is a novel transport protein that has been found to facilitate uptake of iron presented to cells as either Fe(II) or Fe(III). When HeLa cells are exposed to the iron chelator desferrioxamine, levels of SFT mRNA increase in an actinomycin D-sensitive manner. In contrast, cells exposed to high levels of iron down-regulate SFT expression in a time-dependent and reversible fashion. Thus, homeostatic regulation of SFT expression not only ensures that sufficient levels of iron are maintained but also limits excessive assimilation to prevent potentially harmful effects of this toxic metal. The unexpected observation that SFT transcript levels are up-regulated in hemochromatosis patients therefore suggests that enhanced SFT expression contributes to the etiology of this iron overload disorder.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Wessling-Resnick, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	wessling@hsph.harvard.edu			NIDDK NIH HHS [DK52371, DK34854] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052371, P30DK034854] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZHERNANDEZ X, 1991, BIOCHIM BIOPHYS ACTA, V1070, P205, DOI 10.1016/0005-2736(91)90165-5; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Barton JC, 1996, NAT MED, V2, P394, DOI 10.1038/nm0496-394; BATEY RG, 1980, DIGEST DIS SCI, V25, P340, DOI 10.1007/BF01308057; DUANE P, 1992, EUR J GASTROEN HEPAT, V4, P661; EGYED A, 1988, BRIT J HAEMATOL, V68, P483, DOI 10.1111/j.1365-2141.1988.tb04241.x; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Feder JN, 1997, J BIOL CHEM, V272, P14025, DOI 10.1074/jbc.272.22.14025; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; INMAN RS, 1993, J BIOL CHEM, V268, P8521; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; NUNEZ MT, 1992, J BIOL CHEM, V267, P11490; OCHS M, 1995, MOL MICROBIOL, V15, P119, DOI 10.1111/j.1365-2958.1995.tb02226.x; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; PIETRANGELO A, 1991, HEPATOLOGY, V14, P1083, DOI 10.1002/hep.1840140623; Raja KB, 1996, GUT, V38, P765, DOI 10.1136/gut.38.5.765; RICHARDSON D, 1991, BIOCHIM BIOPHYS ACTA, V1093, P20, DOI 10.1016/0167-4889(91)90133-I; Rothenberg BE, 1996, P NATL ACAD SCI USA, V93, P1529, DOI 10.1073/pnas.93.4.1529; Santos M, 1998, BLOOD, V91, P3059, DOI 10.1182/blood.V91.8.3059.3059_3059_3065; Santos M, 1996, J EXP MED, V184, P1975, DOI 10.1084/jem.184.5.1975; Scheiber B, 1998, HEPATOLOGY, V27, P1075, DOI 10.1002/hep.510270424; SCHONHORN JE, 1995, J BIOL CHEM, V270, P3698, DOI 10.1074/jbc.270.8.3698; SHEEHAN RG, 1976, AM J PHYSIOL, V231, P1438, DOI 10.1152/ajplegacy.1976.231.5.1438; SIGEL A, 1998, METAL IONS BIOL SYST, V35; STREMMEL W, 1987, EUR J CLIN INVEST, V17, P136, DOI 10.1111/j.1365-2362.1987.tb02393.x; Waheed A, 1997, P NATL ACAD SCI USA, V94, P12384, DOI 10.1073/pnas.94.23.12384; Yu JM, 1998, J BIOL CHEM, V273, P6909, DOI 10.1074/jbc.273.12.6909; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	36	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34675	34678		10.1074/jbc.273.52.34675	http://dx.doi.org/10.1074/jbc.273.52.34675			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856986	hybrid			2022-12-25	WOS:000077719700004
J	Zeng, WZ; Xu, X; Popov, S; Mukhopadhyay, S; Chidiac, P; Swistok, J; Danho, W; Yagaloff, KA; Fisher, SL; Ross, EM; Muallem, S; Wilkie, TM				Zeng, WZ; Xu, X; Popov, S; Mukhopadhyay, S; Chidiac, P; Swistok, J; Danho, W; Yagaloff, KA; Fisher, SL; Ross, EM; Muallem, S; Wilkie, TM			The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; TRANSITION-STATE; ALPHA-SUBUNITS; ACINAR-CELLS; GAIP; HYDROLYSIS; FAMILY; BINDS; BETA	Regulators of heterotrimeric G protein signaling (RGS) proteins are GTPase-activating proteins (GAPs) that accelerate GTP hydrolysis by G(q) and Gi alpha subunits, thus attenuating signaling. Mechanisms that provide more precise regulatory specificity have been elusive. We report here that an N-terminal domain of RGS4 discriminated among receptor signaling complexes coupled via G(q). Accordingly, deletion of the N-terminal domain of RGS4 eliminated receptor selectivity and reduced potency by 10(4)-fold. Receptor selectivity and potency of inhibition were partially restored when the RGS4 box was added together with an N-terminal peptide. In vitro reconstitution experiments also indicated that sequences flanking the RGS4 box were essential for high potency GAP activity. Thus, RGS4 regulates G, class signaling by the combined action of two domains: 1) the RGS box accelerates GTP hydrolysis by G alpha(q) and 2) the N terminus conveys high affinity and receptor-selective inhibition. These activities are each required for receptor selectivity and high potency inhibition of receptor-coupled G(q) signaling.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Hoffmann La Roche Inc, Dept Metab Dis, Nutley, NJ 07110 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Roche Holding	Wilkie, TM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Chidiac, Peter/L-5906-2015	Chidiac, Peter/0000-0001-8365-6109				Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; WANG J, 1998, IN PRESS G PROTEINS; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Xu X, 1996, J BIOL CHEM, V271, P24684, DOI 10.1074/jbc.271.40.24684; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; Zeng WZ, 1996, J BIOL CHEM, V271, P18520, DOI 10.1074/jbc.271.31.18520	21	219	221	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34687	34690		10.1074/jbc.273.52.34687	http://dx.doi.org/10.1074/jbc.273.52.34687			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856989	hybrid			2022-12-25	WOS:000077719700007
J	Close, BE; Colley, KJ				Close, BE; Colley, KJ			In vivo autopolysialylation and localization of the polysialyltransferases PST and STX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; DEVELOPMENTALLY-REGULATED MEMBER; POLYSIALIC ACID UNITS; SECRETORY PROTEIN; GOLGI-APPARATUS; N-CAM; TRANSMEMBRANE DOMAIN; MOUSE ST8SIA-II; LUNG-CARCINOMA; SIGNAL ANCHOR	A select group of mammalian proteins have been shown to possess alpha 2,8-polysialylated oligosaccharide chains. The best studied of these proteins is the neural cell adhesion molecule (NCAM). Polysialylation of NCAM has been shown to decrease NCAM-dependent and independent cell adhesion; PST (ST8Sia PT) and STX (ST8Sia II) are the two polysialyltransferases responsible for NCAM polysialylation. Recent studies revealed that PST itself is autopolysialylated in vitro (Muhlenhoff, M., Eckhardt, NI., Bethe, A., Frosch, M., and Gerardy-Schahn, R. (1996) EMBO J. 15, 6943-6950). Here we report studies on the biosynthesis and localization of the PST and STX polysialyltransferases. Both PST and STX are expressed as high molecular mass, polydisperse forms that are associated with the cell and found soluble in the medium. Analysis of these high molecular mass forms by glycosidase digestion and serial immunoprecipitation/immunoblot experiments demonstrated that PST and STX are autopolysialylated in vivo. Indirect immunofluorescence microscopy and immunoprecipitation analyses demonstrated that autopolysialylated PST and STX are localized in the Golgi, on the cell surface, and in the extracellular space; The cell surface and extracellular localization of these polysialylated polysialyltransferases suggest that their polysialic acid chains, like those of NCAM, may modulate cell interactions.	Univ Illinois, Coll Med, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Colley, KJ (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Biol, 1819 W Polk St,M-C 536, Chicago, IL 60612 USA.	karenc@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063843, R29GM048134, R01GM048134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW BA, 1973, J BIOL CHEM, V248, P5751; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRILES EB, 1977, J BIOL CHEM, V252, P1107; Cho SK, 1997, GLYCOCONJUGATE J, V14, P809, DOI 10.1023/A:1018533804015; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FINNE J, 1983, BIOCHEM BIOPH RES CO, V112, P482, DOI 10.1016/0006-291X(83)91490-0; FINNE J, 1987, J IMMUNOL, V138, P4402; GLICK MC, 1991, PROG CLIN BIOL RES, V366, P267; GUAN JL, 1984, CELL, V37, P779, DOI 10.1016/0092-8674(84)90413-6; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HINTON DA, 1995, EXP CELL RES, V219, P640, DOI 10.1006/excr.1995.1274; Hirmo S, 1996, GLYCOCONJUGATE J, V13, P1005, DOI 10.1007/BF01053196; INOUE S, 1978, BIOCHEM BIOPH RES CO, V83, P1018, DOI 10.1016/0006-291X(78)91497-3; Jaskiewicz E, 1996, J BIOL CHEM, V271, P26395, DOI 10.1074/jbc.271.42.26395; KIBBELAAR RE, 1989, J PATHOL, V159, P23, DOI 10.1002/path.1711590108; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kojima N, 1997, J BIOCHEM-TOKYO, V122, P1265; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; Ma JY, 1997, J BIOL CHEM, V272, P672; Martersteck CM, 1996, GLYCOBIOLOGY, V6, P289, DOI 10.1093/glycob/6.3.289; MICHALIDES R, 1994, INT J CANCER, P34; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; Phillips GR, 1997, DEV BRAIN RES, V102, P143, DOI 10.1016/S0165-3806(97)00069-2; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RATNAM S, 1981, BIOCHIM BIOPHYS ACTA, V673, P435, DOI 10.1016/0304-4165(81)90475-X; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1988, AM J PATHOL, V133, P596; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Shur BD, 1993, CURR OPIN CELL BIOL, V5, P854, DOI 10.1016/0955-0674(93)90035-O; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; TROY FA, 1995, SIALIC ACID MOL REGU, P95; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; Zhu GF, 1997, GLYCOBIOLOGY, V7, P987, DOI 10.1093/glycob/7.7.987; Zhu GF, 1998, GLYCOBIOLOGY, V8, P831, DOI 10.1093/glycob/8.8.831; ZUBER C, 1992, J BIOL CHEM, V267, P9965	62	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34586	34593		10.1074/jbc.273.51.34586	http://dx.doi.org/10.1074/jbc.273.51.34586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852130	hybrid			2022-12-25	WOS:000077542200096
J	Orsini, MJ; Benovic, JL				Orsini, MJ; Benovic, JL			Characterization of dominant negative arrestins that inhibit beta(2)-adrenergic receptor internalization by distinct mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; EPIDERMAL GROWTH-FACTOR; VISUAL ARRESTIN; ALPHA(2)-ADRENERGIC RECEPTORS; ARRESTIN/CLATHRIN INTERACTION; PHOSPHORYLATION-RECOGNITION; MEDIATED ENDOCYTOSIS; TYROSINE KINASE; WILD-TYPE	Arrestins have been shown to act as adaptor proteins that mediate the interaction of G protein-coupled receptors with the endocytic machinery. In this study, the role of arrestin-3 in receptor internalization was investigated by constructing different arrestin-3 minigenes that could potentially act as dominant negative inhibitors of arrestin function. Expression of arrestin-3 proteins containing amino acids 1-320 or 201-409 resulted in the inhibition of beta(2)-adrenergic receptor internalization in HEK-293 cells by approximately 40%, Both of these arrestins were diffusely localized within the cytoplasm of transfected cells, were unable to mediate redistribution of receptors to clathrin-coated pits, and did not localize to coated pits in either the presence or absence of receptor and agonist, Arrestin-3(1-320), but not arrestin-3(201-409), bound to light-activated phosphorylated rhodopsin with an affinity comparable with that of wild-type arrestin-3. In contrast, expression of arrestin-3 proteins composed of only the clathrin binding domain, arrestin-3(284-409), arrestin-3(290-409) resulted in the constitutive localization of these arrestins to coated pits. Arrestin-3(284-409) and arrestin-3(290-409) acted as dominant negative inhibitors of wild-type arrestin function, inhibiting receptor internalization by 70 and 30%, respectively, Carboxyl-terminal deletions of arrestin-3 retained the ability to promote internalization until residues amino-terminal to amino acid 350 were deleted, suggesting that residues in this region also compose part of the clathrin binding domain in addition to the major binding site between residues 371-379, These studies characterize at least two distinct mechanisms, competition for either receptor or clathrin binding, by which dominant negative arrestins inhibit receptor internalization and further define residues within arrestin-3 that constitute the clathrin binding domain.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	benovic@lac.jci.tju.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007705] Funding Source: NIH RePORTER; NIDDK NIH HHS [5-T32-DK07705] Funding Source: Medline; NIGMS NIH HHS [GM47419] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Goodman OB, 1997, J BIOL CHEM, V272, P15017, DOI 10.1074/jbc.272.23.15017; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1993, J BIOL CHEM, V268, P16879; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Haasemann M, 1998, J CELL SCI, V111, P917; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	44	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34616	34622		10.1074/jbc.273.51.34616	http://dx.doi.org/10.1074/jbc.273.51.34616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852134	hybrid			2022-12-25	WOS:000077542200100
J	Shen, JC; Gray, MD; Oshima, J; Kamath-Loeb, AS; Fry, M; Loeb, LA				Shen, JC; Gray, MD; Oshima, J; Kamath-Loeb, AS; Fry, M; Loeb, LA			Werner syndrome protein I. DNA helicase and DNA exonuclease reside on the same polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECQ; SYNDROME GENES; HOMOLOG; BLOOMS; CELLS; SGS1; INTERACTS	Werner Syndrome (WS) is a human progeroid disorder characterized by genomic instability. The gene defective in WS encodes a 3' --> 5' DNA helicase (Gray, M. D., Shen, J.-C., Kamath-Loeb, A. S., Blank, A., Sopher, B. L., Martin, G. M., Oshima, J., and Loeb, L. A.(1997) Nat. Genet. 17, 100-103). Sequence alignment analysis identified an N-terminal motif in WRN that is homologous to several exonucleases. Using combined molecular genetic, biochemical, and immunochemical approaches, we demonstrate that WRN also exhibits an integral DNA exonuclease activity. First, whereas wild-tape recombinant WRN possesses both helicase and exonuclease activities, mutant WRN lacking the nuclease domain does not display exonucleolytic activity. In contrast, WRN proteins with defective helicase activity are active in exonucleolytic digestion of DNA. Second, the exonuclease co-purifies with the 160-kDa WRN protein and its associated DNA helicase and ATPase activities through successive steps of ion exchange and affinity chromatography, suggesting that all three activities are physically associated. Lastly, anti-WRN antiserum specifically coprecipitates the WRN helicase and exonuclease activities indicating that both activities reside on the same antigenic WRN polypeptide. The association of an exonuclease with WRN distinguishes it from other RecQ homologs and raises the possibility that the distinct phenotypic characteristics of WS may be due in part to a defective exonuclease.	Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NCI NIH HHS [R35-CA-39909] Funding Source: Medline; NIAID NIH HHS [AI-01751] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; Courcelle J, 1997, FASEB J, V11, pA1368; Ellis NA, 1997, CURR OPIN GENET DEV, V7, P354, DOI 10.1016/S0959-437X(97)80149-9; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kornberg A., 1992, DNA REPLICATION; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MARTIN GM, 1970, LAB INVEST, V23, P86; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook J., 2002, MOL CLONING LAB MANU; SHARF R, 1988, BIOCHEMISTRY-US, V27, P2990, DOI 10.1021/bi00408a049; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Tada S, 1996, CELL STRUCT FUNCT, V21, P123, DOI 10.1247/csf.21.123; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	36	203	205	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34139	34144		10.1074/jbc.273.51.34139	http://dx.doi.org/10.1074/jbc.273.51.34139			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852073	hybrid			2022-12-25	WOS:000077542200039
J	Siegmund, A; Grant, A; Angeletti, C; Malone, L; Nichols, JW; Rudolph, HK				Siegmund, A; Grant, A; Angeletti, C; Malone, L; Nichols, JW; Rudolph, HK			Loss of Drs2p does not abolish transfer of fluorescence-labeled phospholipids across the plasma membrane of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASES; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; YEAST; CELL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PROTEINS; GLYCOSYLATION; TRANSLOCATION	The yeast DRS2 gene, which is required for growth at 23 degrees C or below, encodes a member of a P-type ATPase subgroup reported to transport aminophospholipids between the leaflets of the plasma membrane. Here, we evaluated the potential role of Drs2p in phospholipid transport. When examined by fluorescence microscopy, a drs2 null mutant showed no defect in the uptake or distribution of fluorescent-labeled 1-palmitoyl-2[6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl (NBD))aminocaproyl]phosphatidylserine) or 1-myristoyl-2[6-NBD-aminocaproyl]phosphatidylethanolamine. Quantification of the amount of cell-associated NBD fluorescence using flow cytometry indicated a significant decrease in the absence of Drs2p, but this decrease was not restricted to the aminophospholipids (phosphatidylserine and phosphatidylethanolamine) and was dependent on culture conditions. Furthermore, the absence of Drs2p had no effect on the amount of endogenous PE exposed to the outer leaflet of the plasma membrane as detected by labeling with trinitrobenzene sulfonic acid. The steady state pool of Drs2p, which was shown to reside predominantly in the plasma membrane, increased upon shift to low temperature or exposure to various divalent cations (Mn2+, Co2+, Ni2+, and Zn2+ but not Ca2+ or Mg2+), conditions that also inhibited the growth of a drs2 null mutant. The data presented here call into question the identification of Drs2p as the exclusive or major amino-phospholipid translocase in yeast plasma membranes (Tang, X,, Halleck, M, S,, Schlegel, R, A., and Williamson, P, (1996) Science 272, 1495-1497).	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	University of Stuttgart; Emory University	Rudolph, HK (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.	rudolph@po.uni-stuttgart.de			NIGMS NIH HHS [GM52410] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM052410] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aballay A, 1995, BIOCHEM J, V312, P919, DOI 10.1042/bj3120919; ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; AMES BN, 1960, J BIOL CHEM, V235, P769; BARFIELD KD, 1985, BIOCHEM BIOPH RES CO, V128, P389, DOI 10.1016/0006-291X(85)91691-2; Catty P, 1997, FEBS LETT, V409, P325, DOI 10.1016/S0014-5793(97)00446-8; CONNOR J, 1994, J BIOL CHEM, V269, P2399; CZICHI U, 1977, J BIOL CHEM, V252, P7901; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Diaz C, 1996, J MEMBRANE BIOL, V151, P1, DOI 10.1007/s002329900051; EGNER R, 1995, MOL CELL BIOL, V15, P5879; FADOK VA, 1992, J IMMUNOL, V148, P2207; GRANT AM, 1998, THESIS EMORY U; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; Kean LS, 1997, J CELL BIOL, V138, P255, DOI 10.1083/jcb.138.2.255; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MARINETTI GV, 1976, CHEM PHYS LIPIDS, V16, P239, DOI 10.1016/0009-3084(76)90019-0; Marriott M, 1979, J BACTERIOL, V139, P566; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; NICHOLS JW, 1985, BIOCHEMISTRY-US, V24, P6390, DOI 10.1021/bi00344a011; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; RIPMASTER TL, 1993, MOL CELL BIOL, V13, P7901, DOI 10.1128/MCB.13.12.7901; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SERRANO R, 1978, MOL CELL BIOCHEM, V22, P51; Sherman F., 1986, METHODS YEAST GENETI; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; VANDERWILDEN W, 1973, Z NATURFORSCH C, VC 28, P416; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34399	34405		10.1074/jbc.273.51.34399	http://dx.doi.org/10.1074/jbc.273.51.34399			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852106	hybrid			2022-12-25	WOS:000077542200072
J	Zhang, ZP; Gambone, CJ; Gabriel, JL; Wolfgang, CL; Soprano, KJ; Soprano, DR				Zhang, ZP; Gambone, CJ; Gabriel, JL; Wolfgang, CL; Soprano, KJ; Soprano, DR			Arg(278), but not Lys(229) or Lys(236), plays an important role in the binding of retinoic acid by retinoic acid receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; LIGAND-BINDING; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; BETA; ALPHA; DOMAIN; IDENTIFICATION; ISOFORMS; RESIDUES	The diverse biological actions of retinoic acid (RA) are mediated by retinoic acid receptors (RAR alpha, beta and gamma) and retinoid X receptors (RXR alpha beta, and gamma), Although the Ligand-binding domains of RARs share the same novel folding pattern, many RAR subtype-specific retinoids have been synthesized indicating that the ligand-binding pocket of each RAR subtype has unique features. Previously we have demonstrated the importance for RA binding and RA-dependent transactivation of Arg(276) of RAR alpha alone and in RAR beta Arg(269) in conjunction with Lys(220). In this study, we have examined the role of the homologous amino acid residues (Lys(229) and Arg(278)) in RAR gamma for these activities. Like RAR alpha but dissimilar to RAR beta, Arg(278) in RAR gamma alone was found to play an important role in RA binding and RA-dependent transactivation. Since Lys(236) in RAR gamma was suggested from the crystal structure of holo-RAR gamma to interact with RA, we also examined its role and that of its homologs in RAR alpha and RAR beta. Despite the suggestion from the crystal structure, neither Lys(236) nor its homologs in RAR alpha and RAR beta play a role in the binding of RA or RA-dependent transactivation. It is likely that Lys(236) in RAR gamma and its homologs in RAR alpha and RAR beta are solvent exposed rather than pointing into the RA-binding pocket.	Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Immunol & Microbiol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, DR (corresponding author), Temple Univ, Dept Biochem, Sch Med, 3420 N Broad St, Philadelphia, PA 19140 USA.	dsoprano@nimbus.ocis.temple.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01076] Funding Source: Medline; NIDDK NIH HHS [DK44517] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENBROOK D, 1988, NATURE, V333, P444; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DOKOH S, 1981, ANAL BIOCHEM, V116, P211, DOI 10.1016/0003-2697(81)90346-8; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GUDAS L, 1994, RETINOIDS, P453; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; Lamour FPY, 1996, MOL CELL BIOL, V16, P5386; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P369; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; Ostrowski J, 1998, J BIOL CHEM, V273, P3490, DOI 10.1074/jbc.273.6.3490; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; Scafonas A, 1997, J BIOL CHEM, V272, P11244; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TAIRIS N, 1995, J BIOL CHEM, V270, P18380, DOI 10.1074/jbc.270.31.18380; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; Wolfgang CL, 1997, J BIOL CHEM, V272, P746, DOI 10.1074/jbc.272.2.746; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	29	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34016	34021		10.1074/jbc.273.51.34016	http://dx.doi.org/10.1074/jbc.273.51.34016			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852056	hybrid			2022-12-25	WOS:000077542200022
J	Grallert, H; Rutkat, K; Buchner, J				Grallert, H; Rutkat, K; Buchner, J			GroEL traps dimeric and monomeric unfolding intermediates of citrate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; HEAT-SHOCK; COENZYME-A; IN-VIVO; PROTEIN; COMPLEX; MECHANISM; BINDING; CYCLE	The prokaryotic molecular chaperone GroE is increasingly expressed under heat shock conditions, GroE protects cells by preventing the irreversible aggregation of thermally unfolding proteins. Here, the interaction of GroE with thermally unfolding citrate synthase (CS) was dissected into sever;al steps that occur before irreversible aggregation, and the conformational states of the unfolding protein recognized by GroEL were determined, The kinetic analysis of CS unfolding revealed the formation of inactive dimeric and monomeric intermediates. GroEL binds both intermediates without affecting the unfolding pathway. Furthermore, the dimeric intermediates are not protected against dissociation in the presence of GroEL. Monomeric CS is stably associated with GroEL, thus preventing further irreversible unfolding steps and subsequent aggregation. During refolding, monomeric CS is encapsulated inside the cavity of GroEL.GroES complexes. Taken together our results suggest that for protection of cells against heat stress both the ability of GroEL to interact with a large variety of nonnative conformations of proteins and the active, GroES-dependent refolding of highly unfolded species are important.	Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany	University of Regensburg	Buchner, J (corresponding author), Univ Regensburg, Inst Biophys & Phys Biochem, Univ Str 31, D-93040 Regensburg, Germany.	johannes.buchner@biologie.uni-regensbur	Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				Beissinger M, 1998, BIOL CHEM, V379, P245; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; BURSTON SG, 1992, ANN NY ACAD SCI, V672, P1; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Gervasoni P, 1998, J MOL BIOL, V275, P663, DOI 10.1006/jmbi.1997.1481; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goloubinoff P, 1997, FEBS LETT, V407, P215, DOI 10.1016/S0014-5793(97)00348-7; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRAGEROV AI, 1991, FEBS LETT, V291, P222, DOI 10.1016/0014-5793(91)81289-K; HEGERL R, 1982, ULTRAMICROSCOPY, V9, P109, DOI 10.1016/0304-3991(82)90233-9; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P58; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hoshino M, 1996, J MOL BIOL, V262, P575, DOI 10.1006/jmbi.1996.0536; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; LILIE H, 1995, P NATL ACAD SCI USA, V92, P8100, DOI 10.1073/pnas.92.18.8100; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; Perrett S, 1997, J MOL BIOL, V269, P892, DOI 10.1006/jmbi.1997.1081; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; SRERE PA, 1966, J BIOL CHEM, V241, P2157; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WIEGAND G, 1984, J MOL BIOL, V174, P205, DOI 10.1016/0022-2836(84)90373-5; WIELAND O, 1964, BIOCHEM Z, V339, P35; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZHI W, 1991, BIOCHEMISTRY-US, V30, P9281, DOI 10.1021/bi00102a021	44	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33305	33310		10.1074/jbc.273.50.33305	http://dx.doi.org/10.1074/jbc.273.50.33305			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837903	hybrid			2022-12-25	WOS:000077462500033
J	Pauly, PC; Harris, DA				Pauly, PC; Harris, DA			Copper stimulates endocytosis of the prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED PITS; CELL-SURFACE; NULL MICE; PRP GENE; RECEPTOR; BINDING; REGION; BRAIN	Prion diseases result from conformational alteration of PrPC, a cell surface glycoprotein expressed in brain, spinal cord, and several peripheral tissues, into PrPSc, a protease-resistant isoform that is the principal component of infectious prion particles. Although a great deal is known about the pathogenic role of PrPSc, the physiological function of PrPC has remained a mystery. Several lines of evidence have recently suggested the possibility that PrPC may play a role in the metabolism of copper. To further investigate the interaction of PrPC and copper, we have analyzed the effect of this metal ion on the endocytic trafficking of PrPC in cultured neuroblastoma cells, We report here that copper rapidly and reversibly stimulates endocytosis of PrPC from the cell surface. This effect may be physiologically relevant and suggests the hypothesis that PrPC could serve as a recycling receptor for uptake of copper ions from the extracellular milieu.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Harris, David/0000-0002-6985-5790	NIA NIH HHS [AG16462, AG12925] Funding Source: Medline; NINDS NIH HHS [5T32NS07071] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG016462, R01AG012925] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1998, J NEUROCHEM, V70, P1686; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; Colling SB, 1997, BRAIN RES, V755, P28, DOI 10.1016/S0006-8993(97)00087-5; Colling SB, 1996, NEUROSCI LETT, V209, P49, DOI 10.1016/0304-3940(96)12596-9; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Dodelet VC, 1998, BLOOD, V91, P1556, DOI 10.1182/blood.V91.5.1556.1556_1556_1561; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; Harris DA, 1996, CURR TOP MICROBIOL, V207, P77; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; LINDNER MC, 1991, BIOCH COPPER; MANSON J, 1992, DEVELOPMENT, V115, P117; MANSON JC, 1995, NEURODEGENERATION, V4, P113; McKenzie D, 1998, J BIOL CHEM, V273, P25545, DOI 10.1074/jbc.273.40.25545; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; PAN KM, 1992, PROTEIN SCI, V1, P1343, DOI 10.1002/pro.5560011014; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; SMITH RM, 1983, NEUROBIOLOGY TRACE E, V1, P1; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453	36	513	530	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33107	33110		10.1074/jbc.273.50.33107	http://dx.doi.org/10.1074/jbc.273.50.33107			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837873	hybrid			2022-12-25	WOS:000077462500003
J	Rebbeor, JF; Connolly, GC; Dumont, ME; Ballatori, N				Rebbeor, JF; Connolly, GC; Dumont, ME; Ballatori, N			ATP-dependent transport of reduced glutathione on YCF1, the yeast orthologue of mammalian multidrug resistance associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATE EXPORT PUMP; MRP GENE; SACCHAROMYCES-CEREVISIAE; CANALICULAR TRANSPORT; MEMBRANE-VESICLES; SECRETORY VESICLES; BILIARY-EXCRETION; KIDNEY-CELLS; MUTANT RATS; HYPERBILIRUBINEMIA	The transport systems involved in the export of cellular reduced glutathione (GSH) have not been identified, although recent studies implicate a role for some of the multidrug resistance associated proteins (MRP), including MRP1 and MRP2. The present study examined the hypothesis that the yeast orthologue of MRP, Ycf1p, mediates ATP-dependent GSH transport. [H-3]GSH transport was measured in vacuolar membrane vesicles iso lated from a control strain ol Saccharomyces cerevisiae (DTY165), the isogenic DTY167 strain that lacks a functional Ycf1p, and in DTY167 transformed with a 2-mu m plasmid vector containing YCF1, GSH transport in control vacuolar membrane vesicles was mediated largely by an ATP-dependent, low affinity pathway (K-m = 15 +/- 4 mM). ATP-dependent [H-3]GSH transport was cis-inhibited by substrates of the yeast Ycf1p transporter and inhibited by 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, probenecid, and sulfinpyrazone, inhibitors of MRP1 and MRP2, but was minimally affected by membrane potential or pH gradient uncouplers. In contrast, ATP-dependent GSH transport was not seen in vacuolar membrane vesicles isolated from the DTY167 yeast strain without a functional Ycf1p but was restored to near wild-type levels in the DTY167 strain transformed with YCF1 and expressing the vacuolar Ycf1p transporter. On the other hand, expression and functional activity of a bile acid transporter, Bat1p, and of the V-type ATPase were similar in all three yeast strains. These results provide direct evidence for ATP-dependent low affinity transport of GSH by the yeast Ycf1p transporter. Because of the structural and functional homology between Ycf1p and MRP1 and MRP2, these data support the hypothesis that GSH efflux from mammalian cells is mediated by these membrane proteins.	Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Rebbeor, JF (corresponding author), Univ Rochester, Sch Med, Dept Environm Med, 575 Elmwood Ave,Box EHSC, Rochester, NY 14642 USA.	rebbeor@envmed.rochester.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247, R01ES006484] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48823] Funding Source: Medline; NIEHS NIH HHS [ES06484, ES01247] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALLATORI N, 1995, J BIOL CHEM, V270, P3594, DOI 10.1074/jbc.270.8.3594; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617, DOI 10.1152/ajpgi.1992.263.5.G617; Ballatori N, 1996, AM J PHYSIOL-REG I, V270, pR1156, DOI 10.1152/ajpregu.1996.270.5.R1156; BALLATORI N, 1986, J BIOL CHEM, V261, P6216; BALLATORI N, 1982, SCIENCE, V216, P61, DOI 10.1126/science.7063871; BALLATORI N, 1998, IN PRESS SEMIN LIVER; Buchler M, 1996, J BIOL CHEM, V271, P15091; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Chianale J., 1997, Hepatology, V26, p293A; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; FELLER N, 1995, FEBS LETT, V368, P385, DOI 10.1016/0014-5793(95)00677-2; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; FERNANDEZCHECA JC, 1988, AM J PHYSIOL, V18, pG403; GEKELER V, 1995, BIOCHEM BIOPH RES CO, V208, P345, DOI 10.1006/bbrc.1995.1344; HINCHMAN CA, 1994, J TOXICOL ENV HEALTH, V41, P387, DOI 10.1080/15287399409531852; HINCHMAN CA, 1991, J BIOL CHEM, V266, P22179; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; Ito K, 1996, INT HEPATOL COMMUN, V4, P291, DOI 10.1016/0928-4346(96)00259-9; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; JASPERS CJ, 1985, PHYTOCHEMISTRY, V24, P703; Jedlitschky G, 1996, CANCER RES, V56, P988; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Keppler D, 1997, BIOL CHEM, V378, P787; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; Lee TK, 1997, YALE J BIOL MED, V70, P287; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; Li LQ, 1997, YALE J BIOL MED, V70, P301; Li LQ, 1998, J BIOL CHEM, V273, P16184, DOI 10.1074/jbc.273.26.16184; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Lorico A, 1997, CANCER RES, V57, P5238; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPHEIM DJ, 1978, BIOCHIM BIOPHYS ACTA, V524, P121, DOI 10.1016/0005-2744(78)90110-9; Ortiz DF, 1997, J BIOL CHEM, V272, P15358, DOI 10.1074/jbc.272.24.15358; Paul S, 1996, P NATL ACAD SCI USA, V93, P6929, DOI 10.1073/pnas.93.14.6929; Paulusama C. C., 1997, Hepatology, V26, p292A; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PENNINCKX MJ, 1993, ADV MICROB PHYSIOL, V34, P239, DOI 10.1016/S0065-2911(08)60031-4; Rappa G, 1997, CANCER RES, V57, P5232; Rebbeor JF, 1998, BIOCHEM J, V334, P723, DOI 10.1042/bj3340723; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SCHNEIDER E, 1995, BRIT J CANCER, V71, P738, DOI 10.1038/bjc.1995.144; Stride BD, 1997, MOL PHARMACOL, V52, P344, DOI 10.1124/mol.52.3.344; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; TAKIKAWA H, 1991, HEPATOLOGY, V14, P352, DOI 10.1002/hep.1840140223; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; Twentyman PR, 1996, EUR J CANCER, V32A, P1002, DOI 10.1016/0959-8049(96)00067-6; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; Wemmie JA, 1997, MOL MICROBIOL, V25, P683, DOI 10.1046/j.1365-2958.1997.5061868.x; Weymann Alexander, 1997, Hepatology, V26, p291A; WILLSKY GR, 1979, J BIOL CHEM, V254, P3326; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	68	66	68	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33449	33454		10.1074/jbc.273.50.33449	http://dx.doi.org/10.1074/jbc.273.50.33449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837923	hybrid			2022-12-25	WOS:000077462500053
J	Tahara, M; Coorssen, JR; Timmers, K; Blank, PS; Whalley, T; Scheller, R; Zimmerberg, J				Tahara, M; Coorssen, JR; Timmers, K; Blank, PS; Whalley, T; Scheller, R; Zimmerberg, J			Calcium can disrupt the SNARE protein complex on sea urchin egg secretory vesicles without irreversibly blocking fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN LIGHT-CHAIN; CORTICAL-GRANULE EXOCYTOSIS; TETANUS TOXIN; CLOSTRIDIAL NEUROTOXINS; CHROMAFFIN CELLS; PROTEOLYTIC CLEAVAGE; SYNAPTIC VESICLES; TRIGGERED FUSION; MEMBRANE-FUSION; YEAST VACUOLES	The homotypic fusion of sea urchin egg cortical vesicles (CV) is a system in which to correlate the biochemistry and physiology of membrane fusion, Homologues of vesicle-associated membrane protein (VAMP), syntaxin, and SNAP-25 were identified in CV membranes. A VAMP and syntaxin immunoreactive band at a higher apparent molecular mass (approximate to 70 kDa) was detected; extraction and analysis confirmed that the band contained VAMP, SNAP-25, and syntaxin. This complex was also identified by immunoprecipitation and by sucrose gradient analysis. VAMP in the complex was insensitive to proteolysis by tetanus toxin, All criteria identify the SNARE complex as that described in other secretory systems. Complexes exist pre-formed on individual CV membranes and form between contacting CV, Most notably, CV SNARE complexes are disrupted in response to [Ca2+](free) that trigger maximal fusion. N-Ethylmaleimide, which blocks fusion at or before the Ca2+-triggering step, blocks complex disruption by Ca2+. However, disruption is not blocked by lysophosphatidylcholine, which transiently arrests a late stage of fusion, Since removal of lysophosphatidylcholine from Ca2+-treated CV is known to allow fusion, complex disruption occurs independently from the membrane fusion step. As Ca2+ disrupts rather than stabilizes the complex, the presumably coiled coil SNARE interactions are not needed at the time of fusion, These findings rule out models of fusion in which SNARE complex formation goes to completion ("zippers-up") after Ca2+ binding removes a "fusion clamp."	NICHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; Univ Stirling, Dept Biol & Mol Sci, Stirling FK9 4LA, Scotland; Stanford Univ, Med Ctr,Howard Hughes Med Inst, Beckman Ctr Mol & Genet Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Stirling; Howard Hughes Medical Institute; Stanford University	Zimmerberg, J (corresponding author), NICHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA.	joshz@helix.nih.gov	Blank, Paul/Q-9673-2019	Whalley, Tim/0000-0003-3362-0006				AHNERTHILGER G, 1993, NEUROSCIENCE, V53, P547, DOI 10.1016/0306-4522(93)90219-6; Avery J, 1997, J CELL SCI, V110, P1555; BAKER PF, 1978, NATURE, V276, P513, DOI 10.1038/276513a0; BARK IC, 1994, P NATL ACAD SCI USA, V91, P4621, DOI 10.1073/pnas.91.11.4621; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Conner S, 1997, MOL REPROD DEV, V48, P106; CRABB JH, 1985, J CELL BIOL, V101, P2263, DOI 10.1083/jcb.101.6.2263; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; Hajduch E, 1997, BIOCHEM J, V321, P233, DOI 10.1042/bj3210233; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HOHNEZELL B, 1994, FEBS LETT, V355, P131, DOI 10.1016/0014-5793(94)01192-3; Kretzschmar S, 1996, NEUROSCI RES, V26, P141, DOI 10.1016/S0168-0102(96)01086-3; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LLINAS R, 1994, J PHYSIOL-LONDON, V477, P129, DOI 10.1113/jphysiol.1994.sp020177; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MOY GW, 1983, DEV BIOL, V100, P267, DOI 10.1016/0012-1606(83)90221-X; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PELLEGRINI LL, 1994, FEBS LETT, V353, P319, DOI 10.1016/0014-5793(94)01070-6; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; Peng XR, 1997, MOL BIOL CELL, V8, P399, DOI 10.1091/mbc.8.3.399; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schulz JR, 1997, DEV BIOL, V191, P80, DOI 10.1006/dbio.1997.8712; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Timmers Kim, 1997, Journal of General Physiology, V110, p23A; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VACQUIER VD, 1975, DEV BIOL, V43, P62, DOI 10.1016/0012-1606(75)90131-1; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; VOGEL SS, 1992, J BIOL CHEM, V267, P25640; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHALLEY T, 1994, BIOCHEM J, V302, P391, DOI 10.1042/bj3020391; WHALLEY T, 1988, BIOSCIENCE REP, V8, P335, DOI 10.1007/BF01115224; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WHITAKER M, 1987, BIOSCIENCE REP, V7, P383, DOI 10.1007/BF01362502; ZIMMERBERG J, 1991, ANN NY ACAD SCI, V635, P307, DOI 10.1111/j.1749-6632.1991.tb36501.x; Zimmerberg J, 1995, COLD SPRING HARB SYM, V60, P589, DOI 10.1101/SQB.1995.060.01.063; ZIMMERBERG J, 1988, J MEMBRANE BIOL, V101, P199, DOI 10.1007/BF01872835; ZIMMERBERG J, 1985, J CELL BIOL, V101, P2398, DOI 10.1083/jcb.101.6.2398	61	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33667	33673		10.1074/jbc.273.50.33667	http://dx.doi.org/10.1074/jbc.273.50.33667			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837952	hybrid			2022-12-25	WOS:000077462500082
J	Trommsdorff, R; Borg, JP; Margolis, B; Herz, J				Trommsdorff, R; Borg, JP; Margolis, B; Herz, J			Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; BETA-PEPTIDE DEPOSITION; ONSET ALZHEIMER-DISEASE; ABL TYROSINE KINASE; ALPHA-2-MACROGLOBULIN RECEPTOR; HIGH-AFFINITY; PTB DOMAIN; DISTINCT; BRAIN	Apolipoprotein E, alpha(2)-macroglobulin, and amyloid precursor protein (APP) are involved in the development of Alzheimer's disease. All three proteins are ligands for the low density lipoprotein (LDL) receptor-related protein (LRP), an abundant neuronal surface receptor that has also been genetically linked to Alzheimer's disease. The cytoplasmic tails of LRP and other members of the LDL receptor gene family contain NPxY motifs that are required for receptor endocytosis. To investigate whether these receptors may have functions that go beyond ligand internalization, e.g. possible roles in cellular signaling, we searched for proteins that might interact with the cytoplasmic tails of the receptors. A family of adaptor proteins containing protein interaction domains that can interact with NPxY motifs has previously been described. Using yeast 2-hybrid and protein coprecipitation approaches in vitro, we show that the neuronal adaptor proteins FE65 and mammalian Disabled bind to the cytoplasmic tails of LRP, LDL receptor, and APP, where they can potentially serve as molecular scaffolds for the assembly of cytosolic multiprotein complexes. FE65 contains two distinct protein interaction domains that interact with LRP and APP, respectively, raising the possibility that LRP can modulate the intracellular trafficking of APP. Tyrosine-phosphorylated mammalian Disabled can recruit nonreceptor tyrosine kinases, such as src and abl, to the cytoplasmic tails of the receptors to which it binds, suggesting a molecular pathway by which receptor/ligand interaction on the cell surface could generate an intracellular signal.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Borg, Jean-Paul/AAX-8096-2020	Borg, Jean-Paul/0000-0001-8418-3382	NHLBI NIH HHS [HL20948, R37 HL063762] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R37HL063762] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bales KR, 1997, NAT GENET, V17, P263, DOI 10.1038/ng1197-263; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1998, CURR TOP MICROBIOL, V228, P23; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; McLoughlin DM, 1996, FEBS LETT, V397, P197; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHNEIDER WJ, 1983, J CELL BIOL, V97, P1635, DOI 10.1083/jcb.97.5.1635; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLNOW TE, 1994, J CELL SCI, V107, P719; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	43	481	504	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33556	33560		10.1074/jbc.273.50.33556	http://dx.doi.org/10.1074/jbc.273.50.33556			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837937	hybrid			2022-12-25	WOS:000077462500067
J	Minning, DM; Goldberg, DE				Minning, DM; Goldberg, DE			Determinants of Ascaris hemoglobin octamer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-SEQUENCE; PSEUDOTERRANOVA-DECIPIENS; ESCHERICHIA-COLI; OXYGEN AVIDITY; TYROSINE B10; SUUM; BINDING; REQUIREMENT; SUBTILISIN; PROTEASE	The oxygen-avid, homooctameric hemoglobin of Ascaris (AH) has an unusual structure. Each polypeptide consists of two tandem globin folds followed by a highly charged COOH-terminal tail that contains four direct repeats of His-Lys-Glu-Glu (HKEE). Deletion analysis of the AH tail determined that at least two of the four HKEE repeats are required for efficient octamer formation. Surprisingly, the first four residues of the tail (Glu-His-His-Glu) alone were moderately effective in promoting multimerization. The hemoglobin from Pseudoterranova decipiens (PH) also consists of two globin domains followed by a shorter COOH-terminal extension containing only one HKEE repeat. Interchanging the tails of AH and PH revealed that the PH tail is moderately effective in promoting octamer formation. Dissociation analysis of wild-type and mutant AH and PH revealed that the intact octamers are stabilized by interactions between residues within the globin folds, not the tail. Mutational and biochemical studies revealed that one key interaction is contributed by isoleucine 15, which lies in the unusually long AB loop of AH. We propose that the AH tail plays no role in stabilization of the quaternary structure once formed but rather functions as an intramolecular chaperone, aiding assembly of the nascent AH octamer.	Washington Univ, Sch Med, Dept Mol Microbiol, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Howard Hughes Med Inst, 660 S Euclid Ave,Box 8230, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; DIXON B, 1991, P NATL ACAD SCI USA, V88, P5655, DOI 10.1073/pnas.88.13.5655; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Huang SC, 1996, J BIOL CHEM, V271, P958, DOI 10.1074/jbc.271.2.958; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; LEE YC, 1992, FEMS MICROBIOL LETT, V92, P73, DOI 10.1016/0378-1097(92)90544-X; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; MINNING DM, 1995, J BIOL CHEM, V270, P22248, DOI 10.1074/jbc.270.38.22248; MORRISON HG, 1993, BIOTECHNIQUES, V14, P454; OKAZAKI T, 1965, BIOCHIM BIOPHYS ACTA, V111, P496, DOI 10.1016/0304-4165(65)90059-0; PERUTZ MF, 1993, CURR BIOL, V3, P249, DOI 10.1016/0960-9822(93)90174-M; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; WINTHER JR, 1994, J BIOL CHEM, V269, P22007; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	26	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32644	32649		10.1074/jbc.273.49.32644	http://dx.doi.org/10.1074/jbc.273.49.32644			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830004	hybrid			2022-12-25	WOS:000077329100043
J	Rys-Sikora, KE; Gill, DL				Rys-Sikora, KE; Gill, DL			Fatty acid-mediated calcium sequestration within intracellular calcium pools	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; LIVER MICROSOMAL VESICLES; RABBIT SKELETAL-MUSCLE; PLANAR LIPID BILAYERS; ENDOPLASMIC-RETICULUM; ANION CHANNEL; MEMBRANE-PROTEIN; ARACHIDONIC-ACID; CA2+ RELEASE; CELL-GROWTH	Intracellular Ca2+ pools play an essential role in generating Ca2+ signals. The heterogeneity of intracellular Ca2+ pools reflects the complex and dynamic character of the endoplasmic reticulum within which they reside. Translocation of Ca2+ between distinct subcompartments of the endoplasmic reticulum is mediated by a sensitive and specific GTP-activated process involving formation of reversible communicating junctions (Rys-Sikora, K. E., Ghosh, T. K., and Gill, D. L. (1994) J. Biol. Chem. 269, 31607-31613), In the presence of palmitate at 10 mu M or above, this GTP-activated mechanism mediates substantial Ca2+ accumulation within a specific Ca2+-pumping pool, The fatty acid- and GTP-dependent accumulation of Ca2+ was highly chain length-specific; pentadecanoate (C-15) and palmitate (C-16) were equally effective, whereas fatty acids of shorter or longer chain length were either marginally effective or devoid of effect. Fatty acids with one or more unsaturated carbons were without effect, regardless of chain length, Palmitate-induced Ca2+ accumulation was immediately terminated with 2 mu M palmitoyl-CoA, a blocker of the GTP-activated Ca2+-translocating mechanism, The anion transport inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid completely prevented both palmitate- and oxalate-mediated GTP-dependent Ca2+ accumulation, with EC50 similar to 30 mu M. Ca2+ sequestered in the presence of palmitate and GTP could be immediately and completely released by A23187, whereas the sequestered Ca2+ was remarkably resistant to release induced by inositol 1,4,5-trisphosphate (InsP(3)). In contrast, oxalate-sequestered Ca2+ within the same pool could be effectively released by either ionophore or InsP(3). The results indicate that fatty acids are specifically transported into the lumen of a subset of Ca2+ pools, wherein they mediate substantial sequestration of Ca2+ in a distinct membrane-associated substate that is not readily releasable by opened InsP(3)-sensitive Ca2+ channels.	Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Gill, DL (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.				NHLBI NIH HHS [HL55426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUMRAD NA, 1984, J BIOL CHEM, V259, P8945; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Ahern GP, 1998, BIOPHYS J, V74, P2335, DOI 10.1016/S0006-3495(98)77943-3; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049; CARSTEN ME, 1971, J ULTRA MOL STRUCT R, V35, P554, DOI 10.1016/S0022-5320(71)80011-4; CHEAH AM, 1981, BIOCHIM BIOPHYS ACTA, V648, P113, DOI 10.1016/0005-2736(81)90025-0; CHEUH SH, 1986, J BIOL CHEM, V261, P13883; CHUEH SH, 1987, J BIOL CHEM, V262, P13857; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Clark AG, 1997, BIOPHYS J, V73, P168, DOI 10.1016/S0006-3495(97)78057-3; COMERFORD JG, 1988, BIOCHEM J, V249, P89, DOI 10.1042/bj2490089; COMERFORD JG, 1993, BIOCHEM J, V289, P561, DOI 10.1042/bj2890561; DAWSON AP, 1985, FEBS LETT, V185, P147, DOI 10.1016/0014-5793(85)80759-6; DEMEIS L, 1974, J CELL BIOL, V62, P505, DOI 10.1083/jcb.62.2.505; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GILL DL, 1988, J EXP BIOL, V139, P105; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; GILL DL, 1986, NATURE, V320, P461, DOI 10.1038/320461a0; GILL DL, 1984, J BIOL CHEM, V259, P807; GILL DL, 1993, HDB EXPT PHARM GTPAS, V108, P625; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; Graber MN, 1997, J BIOL CHEM, V272, P29546, DOI 10.1074/jbc.272.47.29546; Graber MN, 1996, J BIOL CHEM, V271, P883, DOI 10.1074/jbc.271.2.883; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HERBETTE LG, 1984, J BIOL CHEM, V259, P1325; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Ibrahimi A, 1996, P NATL ACAD SCI USA, V93, P2646, DOI 10.1073/pnas.93.7.2646; KASAI M, 1979, BIOCHIM BIOPHYS ACTA, V557, P243, DOI 10.1016/0005-2736(79)90106-8; KATZ AM, 1982, BIOCHIM BIOPHYS ACTA, V687, P17, DOI 10.1016/0005-2736(82)90165-1; Kourie JI, 1996, BIOPHYS J, V70, P202, DOI 10.1016/S0006-3495(96)79564-4; Kourie JI, 1996, AM J PHYSIOL-CELL PH, V270, pC1675, DOI 10.1152/ajpcell.1996.270.6.C1675; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; LESLIE BA, 1988, CELL CALCIUM, V9, P9, DOI 10.1016/0143-4160(88)90033-4; MARTONOSI AN, 1982, CALCIUM CELL FUNCTIO, P38; MESSINEO FC, 1984, J BIOL CHEM, V259, P1336; Millman JS, 1997, CELL, V89, P673, DOI 10.1016/S0092-8674(00)80248-2; MORIER N, 1994, BIOPHYS J, V67, P590, DOI 10.1016/S0006-3495(94)80519-3; MULLANEY JM, 1987, J BIOL CHEM, V262, P13865; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; RUSTENBECK I, 1992, CELL CALCIUM, V13, P193, DOI 10.1016/0143-4160(92)90007-F; RYSSIKORA KE, 1994, J BIOL CHEM, V269, P31607; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; SHORT AD, 1993, J BIOL CHEM, V268, P25887; STORCH J, 1991, J BIOL CHEM, V266, P13473; TANIFUJI M, 1987, J MEMBRANE BIOL, V99, P103, DOI 10.1007/BF01871230; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THOMAS AP, 1988, J BIOL CHEM, V263, P2704; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; WATRAS J, 1984, J BIOL CHEM, V259, P1319; Yuto J, 1997, BIOPHYS J, V72, P720, DOI 10.1016/S0006-3495(97)78708-3; Zakim D, 1996, P SOC EXP BIOL MED, V212, P5	62	22	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32627	32635		10.1074/jbc.273.49.32627	http://dx.doi.org/10.1074/jbc.273.49.32627			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830002	hybrid			2022-12-25	WOS:000077329100041
J	Li, JJ; Oberley, LW; Fan, M; Colburn, NH				Li, JJ; Oberley, LW; Fan, M; Colburn, NH			Inhibition of AP-1 and NF-kappa B by manganese-containing superoxide dismutase in human breast cancer cells	FASEB JOURNAL			English	Article						tumor suppressor gene; redox; transcription factor; MCF-7 cells; TPA	EPIDERMAL GROWTH-FACTOR; PHORBOL ESTER; TRANSCRIPTION FACTOR; HYDROGEN-PEROXIDE; NEOPLASTIC TRANSFORMATION; LUNG FIBROBLASTS; MAMMALIAN-CELLS; MESSENGER-RNA; JB6 CELLS; CIS-FOS	One of the primary antioxidant enzymes, manganese-containing superoxide dismutase (MnSOD), has shown the ability to reverse malignant phenotypes in a variety of human tumor cells that are low or absent in MnSOD expression. We have observed that overexpression of human MnSOD in human breast cancer MCF-7 cells inhibits tumor growth both in vitro and in vivo. The signaling pathway underlying the MnSOD induced tumor suppression is unknown. We demonstrate here that transcriptional and DNA binding ability of AP-1 and NF-kappa B, but not SP-1, were inhibited (by 50%) in the MCF-7 cell line overexpressing MnSOD, When transiently expressing, MnSOD inhibited AP-I but increased NF-kappa B transactivation, which can be abolished by sodium pyruvate, a hydrogen peroxide scavenger. To analyze the target genes responsible for MnSOD-induced tumor suppression, genes related to tumor growth and responsive to AP-1 or NF-kappa B were analyzed. AP-1 responsive collagenase I, stromelysin I, and NF-kappa B responsive IL-1 and IL-6 were down-regulated in the MnSOD stable transfectants compared to the control cell lines. Since TPA induces differentiation in human breast cancer cells and up-regulates MnSOD gene in HeLa cells, MnSOD expression and AP-1 and NF-kappa B activity were measured under TPA treatment. The results showed that TPA induced endogenous MnSOD expression and inhibited both AP-1 and NF-kappa B, Together, these results suggest that tumor suppression by overexpressing MnSOD is related to a modulation of AP-1 and NF-kappa B, which causes a downregulation of genes responsible for tumor malignant phenotype.	NCI, Gene Regulat Sect, Lab Biochem Physiol, Frederick, MD 21702 USA; Univ Iowa, Radiat Res Lab, Iowa City, IA 52242 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Iowa	Li, JJ (corresponding author), NCI, Gene Regulat Sect, Lab Biochem Physiol, Frederick, MD 21702 USA.	lij@mail.ncifcrf.gov		Li, Jian Jian/0000-0003-3694-9675	NATIONAL CANCER INSTITUTE [R01CA041267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 41267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Amstad PA, 1997, CARCINOGENESIS, V18, P479, DOI 10.1093/carcin/18.3.479; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOWDEN GT, 1990, RADIAT RES, V121, P235, DOI 10.2307/3577771; CERUTTI P, 1994, ENVIRON HEALTH PERSP, V102, P123, DOI 10.2307/3432228; CERUTTI PA, 1985, SCIENCE, V227, P7634; Chen JX, 1996, IEEE COMPUT SCI ENG, V3, P13, DOI 10.1109/MCSE.1996.556508; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; CRAWFORD D, 1988, ONCOGENE, V3, P27; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Denhardt DT, 1996, CRIT REV ONCOGENESIS, V7, P261, DOI 10.1615/CritRevOncog.v7.i3-4.70; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DONG Z, 1995, MOL CARCINOG, V19, P204; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; FUJII J, 1991, J BIOL CHEM, V266, P23142; GALLEMANN D, 1990, ANAL BIOCHEM, V191, P347, DOI 10.1016/0003-2697(90)90230-7; GUILBAUD N, 1988, MOL CELL ENDOCRINOL, V56, P157, DOI 10.1016/0303-7207(88)90020-2; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISSANDOU M, 1988, CANCER RES, V48, P6943; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; KENNEDY MJ, 1992, CANCER RES, V52, P1278; Kiningham KK, 1997, CANCER RES, V57, P5265; KOGA M, 1990, CANCER RES, V50, P4849; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li JJ, 1996, CANCER RES, V56, P483; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li JJ, 1997, CANCER RES, V57, P3569; LI JJ, 1995, ONCOGENE, V10, P1989; LI JJ, 1995, BIOCHEM BIOPH RES CO, V216, P610, DOI 10.1006/bbrc.1995.2666; MARTIN MB, 1995, J BIOL CHEM, V270, P25244, DOI 10.1074/jbc.270.42.25244; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NAVARRO S, 1991, BLOOD, V77, P461; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OBERLEY LW, 1989, J CELL PHYSIOL, V138, P50, DOI 10.1002/jcp.1041380109; OBERLEY LW, 1988, MOL CELL BIOCHEM, V84, P147, DOI 10.1007/BF00421049; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1989, FREE RADICAL BIO MED, V6, P379, DOI 10.1016/0891-5849(89)90083-X; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; OSBORNE CK, 1981, J CLIN INVEST, V67, P943, DOI 10.1172/JCI110144; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; SCHERCK R, 1991, EMBO J, V10, P2247; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHMIDT KN, 1996, BIOL INTERMEDIATES, V5, P63; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SINGH N, 1995, INT J CANCER, V62, P107, DOI 10.1002/ijc.2910620120; SLAGA TJ, 1981, SCIENCE, V213, P1023, DOI 10.1126/science.6791284; SPITZ DR, 1990, ARCH BIOCHEM BIOPHYS, V279, P249, DOI 10.1016/0003-9861(90)90489-L; STCLAIR DK, 1994, FREE RADICAL BIO MED, V16, P275, DOI 10.1016/0891-5849(94)90153-8; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; Yan T, 1996, CANCER RES, V56, P2864; YANG MZ, 1994, EUR J BIOCHEM, V222, P651, DOI 10.1111/j.1432-1033.1994.tb18909.x; Zhang N, 1996, BIOCHEM BIOPH RES CO, V220, P171, DOI 10.1006/bbrc.1996.0376	67	96	101	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1713	1723		10.1096/fasebj.12.15.1713	http://dx.doi.org/10.1096/fasebj.12.15.1713			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837861				2022-12-25	WOS:000077574500013
J	Koga, J; Yamauchi, T; Shimura, M; Ogawa, N; Oshima, K; Umemura, K; Kikuchi, M; Ogasawara, N				Koga, J; Yamauchi, T; Shimura, M; Ogawa, N; Oshima, K; Umemura, K; Kikuchi, M; Ogasawara, N			Cerebrosides A and C, sphingolipid elicitors of hypersensitive cell death and phytoalexin accumulation in rice plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE RESISTANCE RESPONSE; HOST-PATHOGEN INTERACTIONS; SCHIZOPHYLLUM-COMMUNE; ANTIFUNGAL ACTIVITY; FUNCTIONAL MOIETY; TOBACCO PLANTS; GENE; CERAMIDE; PROTEIN; GANGLIOSIDES	When plants interact with certain pathogens, they protect themselves by generating various chemical and physical barriers called the hypersensitive response. These barriers are induced by molecules called elicitors that are produced by pathogens. In the present study, the most active elicitors of the hypersensitive response in rice were isolated from the rice pathogenic fungus Magnaporthe grisea, and their structures were identified as cerebrosides A and C, sphingolipids that were previously isolated as inducers of cell differentiation in the fungus Schizophyllum commune. Treatment of rice leaves with cerebroside A induced the accumulation of antimicrobial compounds (phytoalexins), cell death, and increased resistance to subsequent infection by compatible pathogens. The degradation products of cerebroside A (fatty acid methyl ester, sphingold base, and glucosyl sphingoid base) showed no elicitor activity. Hydrogenation of the 8E-double bond in the sphingold base moiety or the 3E-double bond in the fatty acid moiety of cerebroside A did not alter the elicitor activity, whereas hydrogenation of the 4E-double bond in the sphingold base moiety led to a 12-fold decrease in elicitor activity. Furthermore, glucocerebrosides hom Gaucher's spleen consisting of (E)-4-sphingenine and cerebrosides hom rice bran mainly consisting of (4E,8E)-4,8-sphingadienine and (4E,8Z)-4,8-sphingadienine showed no elicitor activity. These results indicate that the methyl group at C-9 and the 4E-double bond in the sphingoid base moiety of cerebrosides A and C are the key elements determining the elicitor activity of these compounds. This study is the first to show that sphingolipids have elicitor activity in plants.	Meiji Seika Kaisha Ltd, Biosci Labs, Sakado, Saitama 3500289, Japan; Plant Biol Def Syst Labs, Niigata 9590422, Japan; Denka Seiken Co Ltd, Div Res & Dev, Niigata 9591836, Japan	Meiji Holdings Co., Ltd.; Denka Company Limited	Koga, J (corresponding author), Meiji Seika Kaisha Ltd, Biosci Labs, 5-3-1 Chiyoda, Sakado, Saitama 3500289, Japan.			Koga, Jinichiro/0000-0003-2106-9894				BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BOSTOCK RM, 1981, SCIENCE, V212, P67, DOI 10.1126/science.212.4490.67; BREMER EG, 1984, J BIOL CHEM, V259, P6818; CARTWRIGHT D, 1977, NATURE, V267, P511, DOI 10.1038/267511a0; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; Dixon R A, 1990, Adv Genet, V28, P165; FUJINO Y, 1985, AGR BIOL CHEM TOKYO, V49, P2753, DOI 10.1080/00021369.1985.10867139; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; KAWAI G, 1989, BIOCHIM BIOPHYS ACTA, V1001, P185; KAWAI G, 1983, BIOCHIM BIOPHYS ACTA, V754, P243, DOI 10.1016/0005-2760(83)90138-8; KAWAI G, 1985, AGR BIOL CHEM TOKYO, V49, P2137, DOI 10.1080/00021369.1985.10867040; KAWAI G, 1986, J BIOL CHEM, V261, P779; KEEN NT, 1992, PLANT MOL BIOL, V19, P109, DOI 10.1007/BF00015609; KEEN NT, 1975, SCIENCE, V187, P74, DOI 10.1126/science.187.4171.74; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Koga J, 1997, PHYTOCHEMISTRY, V44, P249, DOI 10.1016/S0031-9422(96)00534-1; KOGA J, 1995, TETRAHEDRON, V51, P7907, DOI 10.1016/0040-4020(95)00423-6; Koga Jinichiro, 1998, Annals of the Phytopathological Society of Japan, V64, P97, DOI 10.3186/jjphytopath.64.97; KREUTTER D, 1987, J BIOL CHEM, V262, P1633; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MATSUMOTO K, 1980, Annals of the Phytopathological Society of Japan, V46, P307, DOI 10.3186/jjphytopath.46.307; MIDLAND SL, 1993, J ORG CHEM, V58, P2940, DOI 10.1021/jo00063a007; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; MITTLER R, 1995, PLANT CELL, V7, P29, DOI 10.1105/tpc.7.1.29; Mittler R, 1996, PLANT CELL, V8, P1991, DOI 10.1105/tpc.8.11.1991; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; OBATA K, 1977, NATURE, V266, P369, DOI 10.1038/266369a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; Ryerson DE, 1996, PLANT CELL, V8, P393, DOI 10.1105/tpc.8.3.393; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SHARP JK, 1984, J BIOL CHEM, V259, P1321; SHARP JK, 1984, J BIOL CHEM, V259, P1312; SITRIN RD, 1988, J ANTIBIOT, V41, P469, DOI 10.7164/antibiotics.41.469; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Wang H, 1996, PLANT CELL, V8, P375, DOI 10.1105/tpc.8.3.375; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	49	122	137	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31985	31991		10.1074/jbc.273.48.31985	http://dx.doi.org/10.1074/jbc.273.48.31985			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822670	hybrid			2022-12-25	WOS:000077207000052
J	Sheikh, MS; Antinore, MJ; Huang, Y; Fornace, AJ				Sheikh, MS; Antinore, MJ; Huang, Y; Fornace, AJ			Ultraviolet-irradiation-induced apoptosis is mediated via ligand independent activation of tumor necrosis factor receptor 1	ONCOGENE			English	Article						UV; TNF alpha; caspase cascade; DNA damage	KAPPA-B ACTIVATION; RADIATION-INDUCED APOPTOSIS; DOMAIN-CONTAINING RECEPTOR; BREAST-CARCINOMA CELLS; DEATH DOMAIN; CYSTEINE PROTEASES; CD95 FAS/APO-1; PROTEIN; LIGHT; TRAIL	Ultraviolet (UV)-irradiation has been shown to induce jun N-terminal kinase activity via aggregation-mediated activation of tumor necrosis factor receptor 1 (TNFR1) but the role of TNFR1 in mediating UV-induced apoptosis has not been explored. Using p53-null cells, me demonstrate that UV-stimulated ligand independent activation of TNFR1 plays a major role in mediating the apoptotic effects of UV-irradiation. UV-irradiation and TNF alpha acted in a synergistic manner to induce apoptosis, UV-irradiation stimulated the aggregation-mediated activation of TNFR1 which was coupled with activation of caspase 8, the most proximal caspase in TNF alpha signaling pathway, CrmA and the dominant negative versions of FADD, caspase 8 and caspase 10, that block the apoptotic axis of TNFR1 at different levels, also independently inhibited the UV-induced apoptosis, The engagement of the membrane initiated events was specific for UV-irradiation since neither CrmA nor the dominant negative FADD, caspase 8 or caspase 10 blocked the ionizing radiation-induced apoptosis, Cisplatin and melphalan, the UV-mimetic agents known to elicit UV-type DNA damage, also induced apoptosis but differed from UV in that both of the former agents engaged the caspase cascade at a level distal to FADD. Consistent with these findings cisplatin also did not stimulate TNFR1 aggregation. Together these results indicate that DNA damage pel se was not sufficient to activate the membrane TNFR1. Based on our results we propose that the plasma membrane initiated events play a predominant role in mediating UV-irradiation-induced apoptosis and that UV-irradiation appears to engage the apoptotic axis of TNFR1 and perhaps those of other membrane death receptors to transduce its apoptotic signals.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; Brash DE, 1996, J INVEST DERMATOL S, V1, P136; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; FAN SJ, 1995, CANCER RES, V55, P1649; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Friedberg ECW GC, 1995, DNA REPAIR MUTAGENES, P19; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Keane MM, 1996, CANCER RES, V56, P4791; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; KONDO S, 1995, CANCER RES, V55, P6166; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; MARTIN SJ, 1991, INT J RADIAT BIOL, V59, P1001, DOI 10.1080/09553009114550891; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SCHWARZ A, 1995, J INVEST DERMATOL, V102, P422; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	38	110	114	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2555	2563		10.1038/sj.onc.1202292	http://dx.doi.org/10.1038/sj.onc.1202292			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840918				2022-12-25	WOS:000077058900002
J	Tsatsanis, C; Patriotis, C; Tsichlis, PN				Tsatsanis, C; Patriotis, C; Tsichlis, PN			Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappa B	ONCOGENE			English	Article						Tpl-2; NF kappa B; nuclear factor of activated T cells; interleukin 2	PROTEIN-KINASE; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; INTERLEUKIN-2 ENHANCER; CYCLOSPORINE-A; CALCINEURIN; PHOSPHORYLATION; FAMILY; ALPHA; RECEPTOR	The Tpl-2 kinase activates the nuclear factor of activated T cells (NFAT) and induces IL-2 expression in T-cell lines. Here we show that the activation of the IL-2 promoter by Tpl-2 is inhibited by mutant signaling molecules that inhibit the mitogen-activated protein kinase (MAPK) or the calcineurin/NFAT pathways and is promoted by combinations of signaling molecules that activate these pathways, We, therefore, conclude that signals generated by the convergence of the MAPK and the calcineurin/NFAT pathway are necessary and sufficient for the activation of the IL-2 promoter by Tpl-2. The activation of both the IL-2 promoter and an NEAT-driven minimal promoter were shown to depend on signals transduced by Raf1. However, it was only the IL-2 promoter whose activation by Tpl-2 was fully blocked by the dominant negative mutant MEK1S218/222A and the MEK1/MEK2 inhibitor PD098059, Since the activation of NEAT is MAPK-dependent these findings suggested that the activation of MAPK by Tpl-2 is either independent or only partially dependent on MEK1 and MEK2, In addition, they suggested that the activation of the IL-2 promoter is under the control of not only NFAT but also a second factor whose activation is MEK-dependent. Experiments in COS-1 and EL-4 cells confirmed both hypotheses and revealed that the second factor activated by Tpl-2 is NF-kappa B, While the activation of the IL-2 promoter and an NEAT-driven minimal promoter by Tpl-2 was fully blocked by the dominant negative mutant NFAT Delta 418, it was only partially blocked by the calcineurin inhibitor cyclosporin A suggesting that the Tpl-2-mediated NFAT activation is under the control of a combination of calcineurin-dependent and independent pathways. Both pathways were fully blocked by Bcl-2 or Bcl-X-L.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Tsichlis, PN (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.		Tsatsanis, Christos/AAM-9362-2020	Tsatsanis, Christos/0000-0003-1214-4151	NCI NIH HHS [CA38047, CA06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038047, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Ballester A, 1997, J IMMUNOL, V159, P1613; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BIGNON C, 1993, BIOTECHNIQUES, V15, P243; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Erny KM, 1996, ONCOGENE, V13, P2015; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRUMAN DA, 1995, MOL CELL BIOL, V15, P3857; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; Ghosh P, 1996, J BIOL CHEM, V271, P7700, DOI 10.1074/jbc.271.13.7700; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luo C, 1996, MOL CELL BIOL, V16, P3955; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PANG L, 1995, BIOCHEM J, V307, P513, DOI 10.1042/bj3070513; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Simeonidis S, 1997, P NATL ACAD SCI USA, V94, P14372, DOI 10.1073/pnas.94.26.14372; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	52	67	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2609	2618		10.1038/sj.onc.1202460	http://dx.doi.org/10.1038/sj.onc.1202460			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840924				2022-12-25	WOS:000077058900008
J	Morsomme, P; Dambly, S; Maudoux, O; Boutry, M				Morsomme, P; Dambly, S; Maudoux, O; Boutry, M			Single point mutations distributed in 10 soluble and membrane regions of the Nicotiana plumbaginifolia plasma membrane PMA2 H+-ATPase activate the enzyme and modify the structure of the C-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PLANT DEFENSE RESPONSE; SARCOPLASMIC-RETICULUM; SCANNING MUTAGENESIS; DELETION ANALYSIS; FUNGAL PATHOGENS; GENE; IDENTIFICATION; DOMAIN; LYSOPHOSPHATIDYLCHOLINE	The Nicotiana plumbaginifolia pma2 (plasma membrane H+-ATPase) gene is capable of functionally replacing the H+-ATPase genes of the yeast Saccharomyces cerevisiae, provided that the external pH is kept above 5.0, Single point mutations within the pma2 gene were previously identified that improved H+-ATPase activity and allowed yeast growth at pH 4.0. The aim of the present study was to identify most of the PMA2 positions, the mutation of which would lead to improved growth and to determine whether all these mutations result in similar enzymatic and structural modifications. We selected additional mutants in total 42 distinct point mutations localized in 30 codons, They were distributed in 10 soluble and membrane regions of the enzyme. Most mutant PMA2 H+-ATPases were characterized by a higher specific activity, lower inhibition by ADP, and lower stimulation by lysophosphatidylcholine than wild-type PMA2. The mutants thus seem to be constitutively activated. Partial tryptic digestion and immunodetection showed that the PMA2 mutants had a conformational change making the C-terminal region more accessible. These data therefore support the hypothesis that point mutations in various H+-ATPase parts displace the inhibitory C-terminal region, resulting in enzyme activation. The high density of mutations within the first half of the C-terminal region suggests that this part is involved in the interaction between the inhibitory C-terminal region and the rest of the enzyme.	Catholic Univ Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	Universite Catholique Louvain	Boutry, M (corresponding author), Catholic Univ Louvain, Unite Biochim Physiol, Pl Croix Sud 2-20, B-1348 Louvain, Belgium.	boutry@fysa.ucl.ac.be	Morsomme, Pierre/AAD-9600-2019	Boutry, Marc/0000-0002-2315-6900; Morsomme, Pierre/0000-0001-7780-7230				Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; ANAND S, 1995, BBA-BIOMEMBRANES, V1234, P127, DOI 10.1016/0005-2736(94)00281-S; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; ERASO P, 1994, J BIOL CHEM, V269, P10393; EWING NN, 1994, PLANT PHYSIOL, V106, P547, DOI 10.1104/pp.106.2.547; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; GABER RF, 1992, INT REV CYTOL, V137A, P299; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; Gomes E, 1996, FEBS LETT, V398, P48, DOI 10.1016/S0014-5793(96)01218-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; JOHANSSON F, 1993, PLANT CELL, V5, P321, DOI 10.2307/3869599; JOSEPHSON L, 1977, BIOCHEMISTRY-US, V16, P4572, DOI 10.1021/bi00640a006; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICHELET B, 1995, PLANT PHYSIOL, V108, P1, DOI 10.1104/pp.108.1.1; MONK BC, 1994, J BIOENERG BIOMEMBR, V26, P101, DOI 10.1007/BF00763222; MORIAU L, 1993, PLANT MOL BIOL, V21, P955, DOI 10.1007/BF00023594; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; PALMGREN MG, 1988, PHYSIOL PLANTARUM, V74, P11, DOI 10.1111/j.1399-3054.1988.tb04934.x; PALMGREN MG, 1994, J BIOL CHEM, V269, P3027; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Portillo F, 1997, FEBS LETT, V402, P136, DOI 10.1016/S0014-5793(96)01515-3; PORTILLO F, 1989, FEBS LETT, V247, P381, DOI 10.1016/0014-5793(89)81375-4; RAO R, 1996, MYCOTA, V3, P29; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SCHALLER GE, 1988, PLANTA, V173, P508; SCHLESSER A, 1988, J BIOL CHEM, V263, P19480; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SetoYoung D, 1996, J BIOL CHEM, V271, P581, DOI 10.1074/jbc.271.1.581; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; TRECO DA, 1989, CURRENT PROTOCOLS MO; VERAESTRELLA R, 1994, PLANT PHYSIOL, V104, P209, DOI 10.1104/pp.104.1.209; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WACH A, 1990, EUR J BIOCHEM, V189, P675, DOI 10.1111/j.1432-1033.1990.tb15536.x; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; Wang GF, 1996, J BIOL CHEM, V271, P25438, DOI 10.1074/jbc.271.41.25438; Xing T, 1996, PLANT CELL, V8, P555, DOI 10.2307/3870332	43	108	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34837	34842		10.1074/jbc.273.52.34837	http://dx.doi.org/10.1074/jbc.273.52.34837			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857010	hybrid			2022-12-25	WOS:000077719700028
J	Wakamori, M; Yamazaki, K; Matsunodaira, H; Teramoto, T; Tanaka, I; Niidome, T; Sawada, K; Nishizawa, Y; Sekiguchi, N; Mori, E; Mori, Y; Imoto, K				Wakamori, M; Yamazaki, K; Matsunodaira, H; Teramoto, T; Tanaka, I; Niidome, T; Sawada, K; Nishizawa, Y; Sekiguchi, N; Mori, E; Mori, Y; Imoto, K			Single tottering mutations responsible for the neuropathic phenotype of the P-type calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CA2+ CHANNELS; BETA-SUBUNIT; ALPHA(1) SUBUNIT; CHARGE MOVEMENT; SKELETAL-MUSCLE; PURKINJE-CELLS; MUTANT MICE; NEURONS; ATAXIA; BRAIN	Recent genetic and molecular biological analyses have revealed many forms of inherited channelopathies. Homozygous ataxic mice, tottering (tg) and leaner (tg(1a)) mice, have mutations in the P/Q-type Ca2+ channel alpha(1A) subunit gene. Although their clinical phenotypes, histological changes, and locations of gene mutations are known, it remains unclear what phenotypes the mutant Ca2+ channels manifest, or whether the altered channel properties are the primary consequence of the mutations. To address these questions, we have characterized the electrophysiological properties of Ca2+ channels in cerebellar Purkinje cells, where the P-type is the dominant Ca2+ channel, dissociated from the normal, tg, and tg(1a) mice, and compared them with the properties of the wild-type and mutant alpha(1A) channels recombinantly expressed with the alpha(2) and beta subunits in baby hamster kidney cells. The most striking feature of Ca2+ channel currents of mutant Purkinje cells was a marked reduction in current density, being reduced to similar to 60 and similar to 40% of control in tg and tg(1a) mice, respectively, without changes of cell size. The Ca2+ channel currents in the tg Purkinje cells showed a relative increase in non-inactivating component in voltage-dependent inactivation. Besides the same change, those of the tg(1a) mice showed a more distinct change in voltage dependence of activation and inactivation, being shifted in the depolarizing direction by similar to 10 mV, with a broader voltage dependence of inactivation. In the recombinant expression system, the tg channel with a missense mutation (P601L) and one form of the two possible tg(1a) aberrant splicing products, tg(1a) (short) channel, showed a significant reduction in current density, while the other form of the tg(1a) channels, tg(1a) (long), had a current density comparable to the normal control. On the other hand, the shift in voltage dependence of activation and inactivation was observed only for the tg(1a) (long) channel. Comparison of properties of the native and recombinant mutant channels suggests that single tottering mutations are directly responsible for the neuropathic phenotypes of reduction in current density and deviations in gating behavior, which lead to neuronal death and cerebellar atrophy.	Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 4448585, Japan; Eisai Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Eisai Co Ltd	Imoto, K (corresponding author), Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 4448585, Japan.	Keiji@nips.ac.jp	Wakamori, Minoru/AAE-2661-2019	Wakamori, Minoru/0000-0001-8574-3310; Imoto, Keiji/0000-0002-2861-5985				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Dickie MM, 1964, MOUSE NEWS LETT, V30, P31; Doroshenko PA, 1997, NEUROPHARMACOLOGY, V36, P865, DOI 10.1016/S0028-3908(97)00032-4; DUNG HC, 1972, TEX REP BIOL MED, V30, P23; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; GALLI C, 1995, J NEUROSCI, V15, P1172; GLOSSMANN H, 1990, REV PHYSL BIOCH PHAR, V114, P1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HECKROTH JA, 1994, BRAIN RES, V658, P93, DOI 10.1016/S0006-8993(09)90014-2; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; LEHMANNHORN F, 1987, MUSCLE NERVE, V10, P363, DOI 10.1002/mus.880100414; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P197, DOI 10.1113/jphysiol.1980.sp013358; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; Lorenzon NM, 1998, J NEUROSCI, V18, P4482; MEIER H, 1971, J HERED, V62, P297, DOI 10.1093/oxfordjournals.jhered.a108176; Melliti K, 1996, J PHYSIOL-LONDON, V490, P363, DOI 10.1113/jphysiol.1996.sp021150; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NIIDOME T, 1994, BIOCHEM BIOPH RES CO, V203, P1821, DOI 10.1006/bbrc.1994.2399; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; REGEHR WG, 1994, NEURON, V12, P605, DOI 10.1016/0896-6273(94)90216-X; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; Sidman RL., 1965, CATALOG NEUROLOGICAL, DOI [10.4159/harvard.9780674424326, DOI 10.4159/HARVARD.9780674424326]; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; VAGHY PL, 1988, TRENDS PHARMACOL SCI, V9, P398, DOI 10.1016/0165-6147(88)90066-1; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; Wakamori M, 1998, J NEUROPHYSIOL, V79, P622, DOI 10.1152/jn.1998.79.2.622; WAKAMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P1170, DOI 10.1006/bbrc.1993.2374; WAKAMORI M, 1993, J PHYSIOL-LONDON, V463, P585, DOI 10.1113/jphysiol.1993.sp019612; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; Yue Q, 1997, AM J HUM GENET, V61, P1078, DOI 10.1086/301613; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	58	174	178	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34857	34867		10.1074/jbc.273.52.34857	http://dx.doi.org/10.1074/jbc.273.52.34857			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857013	hybrid			2022-12-25	WOS:000077719700031
J	Hofer, A; Ekanem, JT; Thelander, L				Hofer, A; Ekanem, JT; Thelander, L			Allosteric regulation of Trypanosoma brucei ribonucleotide reductase studied in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CALF THYMUS; PROTEIN; EFFECTORS; SUBUNIT; BINDING; SYSTEM; CELLS; R1	Trypanosoma brucei is the causative agent for African sleeping sickness, We have made in vitro and in vivo studies on the allosteric regulation of the trypanosome ribonucleotide reductase, a key enzyme in the production of dNTPs needed for DNA synthesis. Results with the isolated recombinant trypanosome ribonucleotide reductase showed that dATP specifically directs pyrimidine ribonucleotide reduction instead of being a general negative effector as in other related ribonucleotide reductases, whereas dTTP and dGTP directed GDP and ADP reduction, respectively. Pool measurements of NDPs, NTPs, and dNTPs in the cultivated bloodstream form of trypanosomes exposed to deoxyribonucleosides or inhibited by hydroxyurea confirmed our in vitro allosteric regulation model of ribonucleotide reductase, Interestingly, the trypanosomes had extremely low CDP and CTP pools, whereas the dCTP pool was comparable with that of other dNTPs, The trypanosome ribonucleotide reductase seems adapted to this situation by having a high affinity for the CDP/UDP-specific effector dATP and a high catalytic efficiency, K-cat/K-m, for CDP reduction. Thymidine and deoxyadenosine were readily taken up and phosphorylated to dTTP and dATP, respectively, the latter in a nonsaturating manner. This uncontrolled uptake of deoxyadenosine strongly inhibited trypanosome proliferation, a valuable observation in the search for new trypanocidal nucleoside analogues.	Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Umea University	Hofer, A (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.			Hofer, Anders/0000-0003-2890-2957				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; AVERETT DR, 1983, J BIOL CHEM, V258, P9831; BIANCHI V, 1986, P NATL ACAD SCI USA, V83, P986, DOI 10.1073/pnas.83.4.986; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BYERS TL, 1992, BIOCHEM J, V283, P755, DOI 10.1042/bj2830755; CHELLO PL, 1972, J PARASITOL, V58, P298, DOI 10.2307/3278092; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; ERIKSSON S, 1979, BIOCHEMISTRY-US, V18, P2948, DOI 10.1021/bi00581a005; ERIKSSON S, 1981, J BIOL CHEM, V256, P193; Hajduk S. L., 1990, Tropical and Geographical Medicine., P268; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hofer A, 1997, P NATL ACAD SCI USA, V94, P6959, DOI 10.1073/pnas.94.13.6959; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; KHYM JX, 1975, CLIN CHEM, V21, P1245; LOPEZ G, 1992, J NEUROCHEM, V59, P338; MATHEWS CK, 1990, BIOCHEMISTRY-US, P763; NICANDER B, 1985, J BIOL CHEM, V260, P5376; Nocentini G, 1996, CRIT REV ONCOL HEMAT, V22, P89, DOI 10.1016/1040-8428(95)00187-5; NYHOLM S, 1993, J BIOL CHEM, V268, P26200; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; SHEWACH DS, 1992, ANAL BIOCHEM, V206, P178, DOI 10.1016/S0003-2697(05)80030-2; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANHAVERBEKE DA, 1978, J LIQ CHROMATOGR, V1, P507; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; WOO KM, 1992, J BIOL CHEM, V267, P20429	28	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34098	34104		10.1074/jbc.273.51.34098	http://dx.doi.org/10.1074/jbc.273.51.34098			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852067	hybrid			2022-12-25	WOS:000077542200033
J	Stafford, GA; Morse, RH				Stafford, GA; Morse, RH			Mutations in the AF-2/hormone-binding domain of the chimeric activator GAL4 center dot estrogen receptor center dot VP16 inhibit hormone-dependent transcriptional activation and chromatin remodeling in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ESTROGEN-RECEPTOR; LIGAND-BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; NUCLEAR RECEPTORS; CRYSTAL-STRUCTURE; LIVING CELLS; DNA-BINDING; IN-VIVO; TRANSACTIVATION; REPRESSOR	GAL4.estrogen receptor.VP16 (GAL4.ER.VP16), which contains the GAL4 DNA-binding domain, the human EB hormone binding (AF-2) domain, and the VP16 activation domain, functions as a hormone-dependent transcriptional activator in yeast (Louvion, J.-F., Havaux-Copf, B., and Picard, D, (1993) Gene (Amst.) 131, 129-134). Previously, we showed that this activator can remodel chromatin in yeast in a hormone-dependent manner, in this work, we show that a weakened VP16 activation domain in GAL4.ER.VP16 still allows hormone-dependent chromatin remodeling, but mutations in the AF-2 domain that abolish activity in the native ER, also eliminate the ability of GAL4.ER.VP16 to activate transcription and to remodel chromatin. These findings suggest that an important role of the AF-2 domain in the native ER is to mask the activation potential of the AF-1 activation domain in the unliganded state; upon ligand activation, a conformational change releases AF-2-mediated repression and transcriptional activation ensues. We also show that the AF-2 domain, although inactive at simple promoters on its own in yeast, can enhance transcription by the MCM1 activator in hormone-dependent manner, consistent with its having a role in activation as well as repression in the native ER.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Mol Genet Program, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Morse, RH (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Mol Genet Program, Albany, NY 12201 USA.	randall.morse@wadsworth.org		Morse, Randall/0000-0003-0000-8718	NIGMS NIH HHS [GM51993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051993] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD JD, 1993, GENE DEV, V7, P857, DOI 10.1101/gad.7.5.857; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheskis BJ, 1997, J BIOL CHEM, V272, P11384; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; deMedeiros SRB, 1997, J BIOL CHEM, V272, P18250, DOI 10.1074/jbc.272.29.18250; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GILBERT DM, 1992, NUCLEIC ACIDS RES, V20, P4525, DOI 10.1093/nar/20.17.4525; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Joyeux A, 1997, MOL ENDOCRINOL, V11, P193, DOI 10.1210/me.11.2.193; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; Kladde MP, 1996, EMBO J, V15, P6290, DOI 10.1002/j.1460-2075.1996.tb01019.x; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Lee HS, 1996, J BIOL CHEM, V271, P25727, DOI 10.1074/jbc.271.42.25727; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; LYTTLE CR, 1992, J STEROID BIOCHEM, V42, P677, DOI 10.1016/0960-0760(92)90108-U; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Miller J.H., 1972, EXPT MOL GENETICS; MORSE RH, 1991, J MOL BIOL, V222, P133, DOI 10.1016/0022-2836(91)90198-F; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; Ryan MP, 1998, MOL CELL BIOL, V18, P1774, DOI 10.1128/MCB.18.4.1774; Shiau SP, 1996, GENE, V179, P205, DOI 10.1016/S0378-1119(96)00345-9; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SIKORSKI RS, 1989, GENETICS, V122, P19; Stafford GA, 1997, J BIOL CHEM, V272, P11526; SVAREN J, 1994, EMBO J, V13, P4856, DOI 10.1002/j.1460-2075.1994.tb06812.x; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	53	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34240	34246		10.1074/jbc.273.51.34240	http://dx.doi.org/10.1074/jbc.273.51.34240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852087	hybrid			2022-12-25	WOS:000077542200053
J	Vucic, D; Kaiser, WJ; Miller, LK				Vucic, D; Kaiser, WJ; Miller, LK			A mutational analysis of the baculovirus inhibitor of apoptosis Op-IAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; SIGNALING COMPLEX; MAMMALIAN-CELLS; GENE; DROSOPHILA; PROTEIN; P35; FAMILY; EXPRESSION	A family of antiapoptotic regulators known as inhibitors of apoptosis (IAPs) was initially identified and functionally described in baculoviruses, and IAP homologues are now known in insects, birds, and mammals. Baculovirus and Drosophila IAPs inhibit apoptosis induced by Drosophila proapoptotic proteins Reaper, HID, and GRIM and physically interact with them through their baculovirus IAP repeat (BIR) region. Here we examined the functional importance of BIR and RING finger motifs of Orgyia pseudotsugata nuclear polyhedrosis virus Op-IAP and D-IAP1 in binding to and inhibiting HID. In the absence of both the BIR1 and RING motifs, the BIR2 regions of Op-IAP and D-IAP1 were able to associate with HID and block; HID-induced apoptosis. Mutation of conserved amino acid residues within the BIR and RING finger motifs revealed that the conserved residues within BIR2 were essential for Op-IAP to inhibit apoptosis. However, most of the conserved residues of the BIR2 were not required for HID binding. A region at the carboxy-proximal end of BIR2 was essential for the association of OP-IAP with HID. Thus binding to HID is necessary but not sufficient to block HID-induced apoptosis: the conserved residues within BIR2 must have an additional role in blocking apoptosis. These findings demonstrate that the region encompassing a single BIR of Op-IAP and D-IAP1 can be sufficient for physical interaction with and inhibition of apoptosis induced by HID.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Miller, LK (corresponding author), Univ Georgia, Dept Entomol, Athens, GA 30602 USA.		Kaiser, William/A-3079-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038262] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38262] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CLEM JR, 1997, BACULOVIRUSES, P237; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; Harvey AJ, 1997, CELL DEATH DIFFER, V4, P733, DOI 10.1038/sj.cdd.4400294; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328	38	61	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33915	33921		10.1074/jbc.273.51.33915	http://dx.doi.org/10.1074/jbc.273.51.33915			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852042	hybrid			2022-12-25	WOS:000077542200008
J	Bommel, HM; Reif, A; Frohlich, LG; Frey, A; Hofmann, H; Marecak, DM; Groehn, V; Kotsonis, P; La, ML; Koster, S; Meinecke, M; Bernhardt, M; Weeger, M; Ghisla, S; Prestwich, GD; Pfleiderer, W; Schmidt, HHW				Bommel, HM; Reif, A; Frohlich, LG; Frey, A; Hofmann, H; Marecak, DM; Groehn, V; Kotsonis, P; La, ML; Koster, S; Meinecke, M; Bernhardt, M; Weeger, M; Ghisla, S; Prestwich, GD; Pfleiderer, W; Schmidt, HHW			Anti-pterins as tools to characterize the function of tetrahydrobiopterin in NO synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SUBUNIT DIMERIZATION; OXYGENASE DOMAIN; L-ARGININE; HEME; PURIFICATION; COFACTOR; BINDING; ENZYME; RAT	Nitric oxide synthases (NOS) are homodimeric enzymes that NADPH-dependently convert L-arginine to nitric oxide and L-citrulline. Interestingly, all NOS also require (6R)-5,6,7,8-tetrahydro-L-biopterin (H(4)Bip) for maximal activity although the mechanism is not fully understood. Basal NOS activity, i.e. that in the absence of exogenous H(4)Bip, has been attributed to enzyme-associated H(4)Bip. To elucidate further H(4)Bip function in purified NOS, we developed two types of pterin-based NOS inhibitors, termed anti-pterins. In contrast to type II anti-pterins, type I anti-pterins specifically displaced enzyme-associated H(4)Bip and inhibited H(4)Bip-stimulated NOS activity in a fully competitive manner but, surprisingly, had no effect on basal NOS activity. Moreover, for a number of different NOS preparations basal activity (percent of V-max) was frequently higher than the percentage of pterin saturation and was not affected by preincubation of enzyme with H(4)Bip. Thus, basal NOS activity appeared to be independent of enzyme-associated H(4)Bip. The lack of intrinsic 4a-pterincarbinolamine dehydratase activity argued against classical H(4)Bip redox cycling in NOS. Rather, H(4)Bip was required for both maximal activity and stability of NOS by binding to the oxygenase/dimerization domain and preventing monomerization and inactivation during L-arginine turnover. Since anti-pterins were also effective in intact cells, they may become useful in modulating states of pathologically high nitric oxide formation.	Univ Wurzburg, Dept Pharmacol & Toxicol, D-97078 Wurzburg, Germany; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Konstanz, Fac Chem, D-78434 Constance, Germany; Univ Konstanz, Fac Biol, D-78434 Constance, Germany	University of Wurzburg; Utah System of Higher Education; University of Utah; University of Konstanz; University of Konstanz	Schmidt, HHW (corresponding author), Univ Wurzburg, Dept Pharmacol & Toxicol, Versbacher Str 9, D-97078 Wurzburg, Germany.	schmidt@toxi.uni-wuerzburg.de			NIGMS NIH HHS [GM44836] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GROEHN V, 1997, THESIS U KONSTANZ KO; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HAUER CR, 1993, J BIOL CHEM, V268, P4828; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; HYUN J, 1995, BIOCHEM BIOPH RES CO, V206, P380, DOI 10.1006/bbrc.1995.1052; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KOSTER S, 1995, EUR J BIOCHEM, V231, P414, DOI 10.1111/j.1432-1033.1995.tb20714.x; KWON NS, 1989, J BIOL CHEM, V264, P20496; List BM, 1996, BIOCHEM J, V315, P57, DOI 10.1042/bj3150057; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MOUREY RJ, 1993, BIOCHEMISTRY-US, V32, P1719, DOI 10.1021/bi00058a004; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Prestwich GD, 1997, PHOTOCHEM PHOTOBIOL, V65, P222, DOI 10.1111/j.1751-1097.1997.tb08548.x; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SRIVASTAVA S, 1986, EUR J BIOCHEM, V156, P447, DOI 10.1111/j.1432-1033.1986.tb09602.x; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Witteveen CFB, 1996, J BIOL CHEM, V271, P4143; YUAN CS, 1995, J BIOL CHEM, V270, P16140, DOI 10.1074/jbc.270.27.16140	42	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33142	33149		10.1074/jbc.273.50.33142	http://dx.doi.org/10.1074/jbc.273.50.33142			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837881	Green Submitted, hybrid			2022-12-25	WOS:000077462500011
J	Carver, LA; LaPres, JJ; Jain, S; Dunham, EE; Bradfield, CA				Carver, LA; LaPres, JJ; Jain, S; Dunham, EE; Bradfield, CA			Characterization of the Ah receptor-associated protein, ARA9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ARYL-HYDROCARBON RECEPTOR; GLUCOCORTICOID RECEPTOR; DIOXIN RECEPTOR; FK506-BINDING IMMUNOPHILIN; DNA-BINDING; PROGESTERONE-RECEPTOR; INSITU HYBRIDIZATION; SIGNAL-TRANSDUCTION; STEROID-HORMONES	The unliganded aryl hydrocarbon receptor (AHR) is found in a complex with other proteins including the 90-kDa heat shock protein (Hsp90) and a 37-kDa protein we refer to as ARA9. We found that the three tetratricopeptide repeats found in the COOH terminus of ARA9 are necessary and sufficient for interaction with the AHR complex. Conversely, the AHR's "repressor"/Hsp90 binding domain is required for interaction with ARA9. Because ARA9 closely resembles the 52-kDa FK506-binding protein (FKBP52), found in the unliganded glucocorticoid receptor (GR) complex, we compared the binding specificities of ARA9 and FKBP52 for AHR and GR. In co-immunoprecipitation experiments, ARA9 specifically associated with AHR-Hsp90 complex but not with GR-Hsp90 complexes. In addition, ARA9 showed a greater capacity than FKBP52 to associate with AHR-Hsp90 complexes. The biological importance of this interaction was suggested by the observation that in a yeast expression system ARA9 expression enhanced the response of AHR to the agonist beta-napthoflavone, decreasing the EC,, by greater than 5-fold and increasing the maximal response 2.5-fold. In contrast, co-expression of FKBP52 had no effect on AHR signaling. In addition, although ARA9 contains a domain similar to that found in other FK506-binding proteins, ARA9 binding to H-3-FK506 could not be detected. Finally, we have characterized the developmental and expression pattern of ARA9 in the developing mouse embryo and mapped the ARA9 locus to human chromosome 11q13.3.	Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA	University of Wisconsin System; University of Wisconsin Madison; Northwestern University	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	bradfield@oncology.wisc.edu		jain, sanjay/0000-0003-2804-127X	NATIONAL CANCER INSTITUTE [P30CA007175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005703, R37ES005703, T32ES007015, R29ES005703] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175] Funding Source: Medline; NIEHS NIH HHS [ES05703, ES07015] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bartel P. L., 1993, CELLULAR INTERACTION, P153; BRUNELLI JP, 1993, YEAST, V9, P1299, DOI 10.1002/yea.320091203; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DILELLA AG, 1992, BIOCHEM BIOPH RES CO, V189, P819, DOI 10.1016/0006-291X(92)92276-4; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Duina AA, 1998, J BIOL CHEM, V273, P10819, DOI 10.1074/jbc.273.18.10819; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; DURRIN LK, 1987, MOL CELL BIOL, V7, P3008, DOI 10.1128/MCB.7.8.3008; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENRY EC, 1993, BIOCHEM J, V294, P95, DOI 10.1042/bj2940095; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; Jain S, 1998, MECH DEVELOP, V73, P117, DOI 10.1016/S0925-4773(98)00038-0; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; KRALLI A, 1995, P NATL ACAD SCI USA, V92, P4701, DOI 10.1073/pnas.92.10.4701; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEBEAU MM, 1994, CYTOGENET CELL GENET, V66, P172, DOI 10.1159/000133694; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICKERSON M, 1956, NATURE, V178, P697, DOI 10.1038/178697b0; NING YM, 1993, J BIOL CHEM, V268, P6073; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1992, BIOCHEM BIOPH RES CO, V182, P55, DOI 10.1016/S0006-291X(05)80111-1; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; Perdew GH, 1996, BIOCHEM MOL BIOL INT, V39, P589; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; POLAND A, 1994, MOL PHARMACOL, V46, P915; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PROKIPCAK RD, 1989, ARCH BIOCHEM BIOPHYS, V274, P648, DOI 10.1016/0003-9861(89)90480-3; Ratajczak T, 1996, BIOCHEM BIOPH RES CO, V220, P208, DOI 10.1006/bbrc.1996.0382; RENOIR JM, 1994, J STEROID BIOCHEM, V48, P101, DOI 10.1016/0960-0760(94)90256-9; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; TAI PKK, 1994, BIOCHEMISTRY-US, V33, P10666, DOI 10.1021/bi00201a014; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	63	165	172	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33580	33587		10.1074/jbc.273.50.33580	http://dx.doi.org/10.1074/jbc.273.50.33580			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837941	hybrid			2022-12-25	WOS:000077462500071
J	Fann, MC; Maloney, PC				Fann, MC; Maloney, PC			Functional symmetry of UhpT, the sugar phosphate transporter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOCOCCUS-LACTIS; ANION-EXCHANGE; TRANSLOCATION PATHWAY; MEMBRANE-PROTEINS; RECONSTITUTION; MECHANISM; CARRIER; SYSTEM; SOLUBILIZATION; DETERGENT	UhpT, the sugar phosphate transporter of Escherichia coli, acts to exchange internal inorganic phosphate for external hexose 6-phosphate. Because of this operational asymmetry, we studied. variants in which right-side-out (RSO) or inside-out (ISO) orientations could be analyzed independently to ask whether the inward- and outward-facing UhpT surfaces have different substrate specificities. To study the RSO orientation, we constructed a histidine-tagged derivative, His(10)K291C/ K294N, in which the sole external tryptic cleavage site (Lys(294)) had been removed. Functional assay as well as immunoblot analysis showed that trypsin treatment of proteoliposomes containing His(10)K291C/K294N led to loss of about 50% of the original population, reflecting retention of only the RSO population. To study the ISO orientation, we used a His(10)V284C derivative, in which a newly inserted external cysteine (Cys(284)) conferred sensitivity to the thiol-reactive agent, 3-(N-maleimidylpropionyl)biocytin, In this case, 3-(N-maleimidylpropionyl)biocytin treatment of proteoliposomes containing His(10)V284C gave about a 60% loss of activity, and immunodetection of biotin showed parallel modification of an equivalent fraction of the original population. Together, such findings indicate that the UhpT RSO and ISO orientations are in about equal proportion in proteoliposomes and that a single population can be generated by exposure of these derivatives to the appropriate agent, This allowed us to study proteoliposomes with UhpT functioning in RSO orientation (His(10)K291C/K294N) or ISO orientation (His(10)V284C) with respect to the kinetics of glucose 6-phosphate transport by phosphate-loaded proteoliposomes and;also the inhibitions found with 2-deoxy-glucose 6-phosphate, mannose 6-phosphate, galactose 6-phosphate, fructose 6-phosphate, and inorganic phosphate, We found no significant differences in the behavior of UhpT in its different orientations, indicating that the transporter possesses an overall functional symmetry.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Maloney, PC (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM024195, R01GM024195] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24195] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P2576; AMBUDKAR SV, 1986, P NATL ACAD SCI USA, V83, P280, DOI 10.1073/pnas.83.2.280; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; CHEN CC, 1986, J BIOL CHEM, V261, P2599; Fann MC, 1998, J MEMBRANE BIOL, V164, P187, DOI 10.1007/s002329900404; FLUGGE UI, 1992, BIOCHIM BIOPHYS ACTA, V1110, P112, DOI 10.1016/0005-2736(92)90301-2; FRIEDRICH MJ, 1987, J BACTERIOL, V169, P3556, DOI 10.1128/jb.169.8.3556-3563.1987; Fu DX, 1998, J BIOL CHEM, V273, P17962, DOI 10.1074/jbc.273.28.17962; Heijne G., 1988, EUR J BIOCHEM, V174, P671; ISLAND MD, 1993, J BACTERIOL, V175, P5028, DOI 10.1128/JB.175.16.5028-5034.1993; ISLAND MD, 1992, J BACTERIOL, V174, P2754, DOI 10.1128/JB.174.9.2754-2762.1992; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; KADNER RJ, 1993, J BIOENERG BIOMEMBR, V25, P637; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MALONEY PC, 1990, MICROBIOL REV, V54, P1; Matos M, 1996, J BIOL CHEM, V271, P18571, DOI 10.1074/jbc.271.31.18571; NARAYANAREDDY K, 1991, BIOCHEM INT, V25, P733; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Racker E., 1985, RECONSTITUTION TRANS; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; SCHWARZ M, 1994, J BIOL CHEM, V269, P29481; SONNA LA, 1988, J BIOL CHEM, V263, P6625; Tamai E, 1997, PROTEIN EXPRES PURIF, V10, P275, DOI 10.1006/prep.1997.0754; VIGNERON L, 1995, BBA-BIOMEMBRANES, V1236, P95, DOI 10.1016/0005-2736(95)00028-2; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	30	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33735	33740		10.1074/jbc.273.50.33735	http://dx.doi.org/10.1074/jbc.273.50.33735			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837961	hybrid			2022-12-25	WOS:000077462500091
J	Schnackerz, KD; Mozzarelli, A				Schnackerz, KD; Mozzarelli, A			Plasticity of the tryptophan synthase active site probed by P-31 MMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-ACETYLSERINE SULFHYDRYLASE; D-SERINE DEHYDRATASE; NUCLEAR MAGNETIC-RESONANCE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; 3-DIMENSIONAL STRUCTURE; BIENZYME COMPLEX; ALPHA-SUBUNIT; DIALKYLGLYCINE DECARBOXYLASE; ALPHA(2)BETA(2) COMPLEX	The functional properties of tryptophan synthase alpha(2)beta(2) complex are modulated by a variety of allosteric effecters, including pH, monovalent cations, and alpha-subunit ligands, The dynamic properties of the beta-active site were probed by P-31 NMR spectroscopy of the enzyme-bound coenzyme pyridoxal 5'-phosphate. The P-31 NMR signal of the cofactor phosphate of the internal aldimine exhibits a single peak at 3.73 ppm with a line width of 12 Hz, In the presence of saturating concentrations of sodium ions, the P-31 Signal shifts to 3.97 ppm concomitant with a change in line width to 35 Hz. The latter indicates that sodium ions decrease the conformational flexibility of the coenzyme, In the absence of ions, lowering pH leads to the appearance of a second peak at 4.11 ppm, the intensity of which decreases in the presence of cesium ions. Addition of L-serine in the presence of sodium ions leads to the formation of the external aldimine, the first metastable catalytic intermediate, The P-31 Signal does not change its position, but a change in line width from 35 to 5 Hz is observed, revealing that this species is characterized by a consider;able degree of rotational freedom around the coenzyme C-O bond. In the presence of L-serine and either cesium ions or the allosteric effector indole-3-acetylglycine, the accumulation of the second catalytic intermediate, alpha-aminoacrylate, is observed. The P-31 Signal is centered at 3.73 ppm with a line width of 5 Hz, indicating that the phosphate group of the coenzyme in the external aldimine and the alpha-aminoacrylate exhibits the same flexibility but a slightly different state of ionization. Because the alpha-aminoacrylate intermediate but not the external aldimine triggers the allosteric signal to the alpha subunit, other portions of the beta-active site modify their dynamic properties in response to the progress of the catalytic process. A narrow line width was also observed for the quinonoid species formed by nucleophilic attack of indoline to the alpha-aminoacrylate, The P-31 Signal moves downfield to 4.2 ppm, indicating a possible change of the ionization state of the phosphate group. Thus, the modification of either the ionization state of the coenzyme phosphate or its flexibility or both are, at least in part, responsible for the conformational events that accompany the catalytic process.	Univ Wurzburg, Theodor Boveri Inst Biowissensch, D-97074 Wurzburg, Germany; Univ Parma, Inst Nazl Fis Mat, Ist Sci Biochim, I-43100 Parma, Italy	University of Wurzburg; University of Parma	Schnackerz, KD (corresponding author), Univ Wurzburg, Biozentrum, D-97074 Wurzburg, Germany.		Mozzarelli, Andrea/C-3615-2014	Mozzarelli, Andrea/0000-0003-3762-0062				ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; ANTSON AA, 1993, BIOCHEMISTRY-US, V32, P4195, DOI 10.1021/bi00067a006; ANTSON AA, 1994, ADV LIF SCI-SERIES, P187; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; GORENSTEIN DG, 1975, J AM CHEM SOC, V97, P898, DOI 10.1021/ja00837a039; HOHENESTER E, 1994, BIOCHEMISTRY-US, V33, P13561, DOI 10.1021/bi00250a008; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; KOJIRO CL, 1989, ARCH BIOCHEM BIOPHYS, V268, P67, DOI 10.1016/0003-9861(89)90565-1; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LEJA CA, 1995, BIOCHEMISTRY-US, V34, P5652; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1995, SUBCELLULAR BIOCH, V24, P107; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; MOZZARELLI A, 1991, INT UNION B, V199, P273; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; PERACCHI A, 1995, BIOCHEMISTRY-US, V34, P9459, DOI 10.1021/bi00029a022; Peracchi A, 1996, BIOCHEMISTRY-US, V35, P1872, DOI 10.1021/bi951889c; Rhee S, 1996, BIOCHEMISTRY-US, V35, P4211, DOI 10.1021/bi952506d; ROY M, 1988, BIOCHEMISTRY-US, V27, P6698, DOI 10.1021/bi00418a009; Schnackerz KD, 1995, ARCH BIOCHEM BIOPHYS, V324, P71, DOI 10.1006/abbi.1995.9927; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P1536, DOI 10.1021/bi00575a023; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12152, DOI 10.1021/bi00038a008; SCHNACKERZ KD, 1979, BIOCHEMISTRY-US, V18, P3557, DOI 10.1021/bi00583a019; SCHNACKERZ KD, 1986, PYRIDOXAL PHOSPHAT A, P245; SCHNACKERZ KD, 1983, BIOCHEM BIOPH RES CO, V111, P1536; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; STRAMBINI GB, 1992, BIOCHEMISTRY-US, V31, P7535, DOI 10.1021/bi00148a014; STRAMBINI GB, 1992, BIOCHEMISTRY-US, V31, P7527, DOI 10.1021/bi00148a013; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; TONEY MD, 1995, J MOL BIOL, V245, P151, DOI 10.1006/jmbi.1994.0014; Vaccari S, 1996, BIOPHYS CHEM, V61, P9, DOI 10.1016/0301-4622(96)00020-8; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; Yang LH, 1996, PROTEIN EXPRES PURIF, V8, P126, DOI 10.1006/prep.1996.0082; YANOFSKY C, 1972, ENZYMES, V3, P1	43	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33247	33253		10.1074/jbc.273.50.33247	http://dx.doi.org/10.1074/jbc.273.50.33247			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837895	hybrid			2022-12-25	WOS:000077462500025
J	Reginato, MJ; Bailey, ST; Krakow, SL; Minami, C; Ishii, S; Tanaka, H; Lazar, MA				Reginato, MJ; Bailey, ST; Krakow, SL; Minami, C; Ishii, S; Tanaka, H; Lazar, MA			A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE-RECEPTOR; BINDING-PROTEIN-ALPHA; OB GENE-EXPRESSION; ADIPOCYTE DIFFERENTIATION; ESTROGEN-RECEPTOR; PPAR-GAMMA; NUCLEAR RECEPTORS; DB/DB MICE; LIGAND; TRANSCRIPTION	Thiazolidinediones (TZDs) constitute an exciting new class of antidiabetic compounds, which function as activating ligands for peroxisome proliferator-activated receptor gamma (PPAR gamma). Until now, there has been an excellent correlation between in vivo hypoglycemic potency and in vitro binding and activation of PPAR gamma by TZDs. We have characterized MCC-555, a novel thiazolidinedione ligand for PPAR gamma with unique functional properties. The antidiabetic potency of this compound is greater than that of other TZDs, including BRL49653, yet its binding affinity for PPAR gamma is less than 1/10 that of BRL49653. The effect of MCC-555 binding on PPAR gamma transcriptional activity is highly context-specific such that it can function as a full agonist, partial agonist, or antagonist depending on the cell type or DNA binding site. These transcriptional properties are partly explained by unique partial agonism of coactivator recruitment to PPAR gamma. The properties of MCC-555 are mechanistically distinct from those of the estrogen receptor partial agonist and antagonist tamoxifen because the N terminus of PPAR gamma is not required for activation by MCC-555, and MCC-555 does not stimulate corepressor recruitment to PPAR gamma. The context selectivity of MCC-555 may contribute to its enhanced hypoglycemic potency in vivo despite reduced affinity for PPAR gamma relative to other TZDs.	Univ Penn, Sch Med, Dept Med & Genet, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Mitsubishi Chem Corp, Yokohama Res Ctr, Yokohama, Kanagawa 227, Japan	University of Pennsylvania; University of Pennsylvania; Mitsubishi Chemical Holdings Corporation; Mitsubishi Chemical	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med & Genet, Div Endocrinol Diabet & Metab, 611 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019; Reginato, Mauricio/I-6155-2013; Bailey, Shannon/B-8045-2014	Reginato, Mauricio/0000-0002-7541-4094; 				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Casini T, 1997, INT J CANCER, V70, P473, DOI 10.1002/(SICI)1097-0215(19970207)70:4<473::AID-IJC17>3.0.CO;2-G; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHAWLA A, 1993, J BIOL CHEM, V268, P16265; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Dorkin TJ, 1997, SEMIN CANCER BIOL, V8, P21, DOI 10.1006/scbi.1997.0049; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; Henry RR, 1997, ENDOCRIN METAB CLIN, V26, P553, DOI 10.1016/S0889-8529(05)70267-X; Hollenberg AN, 1997, J BIOL CHEM, V272, P5283, DOI 10.1074/jbc.272.8.5283; ISHII S, 1996, DIABETES S2, V45, pA141; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; JORDAN VC, 1995, BREAST CANCER RES TR, V36, P267, DOI 10.1007/BF00713399; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LeDouarin B, 1996, PHILOS T R SOC B, V351, P569, DOI 10.1098/rstb.1996.0056; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MCDONNELL DP, 1995, ANN NY ACAD SCI, V761, P121, DOI 10.1111/j.1749-6632.1995.tb31374.x; ONATE SA, 1995, SCIENCE, V270, P1354; Park KS, 1997, DIABETES, V46, P1230, DOI 10.2337/diabetes.46.7.1230; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	45	173	181	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32679	32684		10.1074/jbc.273.49.32679	http://dx.doi.org/10.1074/jbc.273.49.32679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830009	hybrid			2022-12-25	WOS:000077329100048
J	Tugal, T; Zou-Yang, XH; Gavin, K; Pappin, D; Canas, B; Kobayashi, R; Hunt, T; Stillman, B				Tugal, T; Zou-Yang, XH; Gavin, K; Pappin, D; Canas, B; Kobayashi, R; Hunt, T; Stillman, B			The Orc4p and Orc5p subunits of the Xenopus and human origin recognition complex are related to Orc1p and Cdc6p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; CELL-CYCLE; S-PHASE; CHROMOSOMAL REPLICATION; DROSOPHILA HOMOLOG; MASS-SPECTROMETRY; RE-REPLICATION	The location of origins of DNA replication within the Saccharomyces cerevisiae genome is primarily determined by the origin recognition complex (ORC) interacting with specific DNA sequences. The analogous situation in vertebrate cells is far less clear, although ORC subunits have been identified in several vertebrate organisms including Xenopus laevis. Monoclonal antibodies were raised against Xenopus Orc1p and used for single-step immunoaffinity purification of the entire ORC from an egg extract. Six polypeptides (similar to 110, 68, 64, 48, 43, and 27 kDa) copurified with Xenopus Orc1p, Protein sequencing also showed the 64-kDa protein to be the previously identified Xenopus Orc2p. Microsequencing of the 43- and 48-kDa proteins that copurified with Orc1p and Orc2p led to their identification as the Orc4p and Orc5p subunits, respectively. Peptide sequences from the 43-kDa protein also allowed the isolation of cDNAs encoding the Xenopus, mouse, and human ORC4 subunits, Human ORC5 was also cloned; its sequence displayed extensive homology to both Drosophila and yeast ORC5. Surprisingly, comparison of the amino acid sequences of Orc1p, Orc4p, and Orc5p suggests that they are structurally related to each other and to the replication initiation protein, Cdc6p. Finally, we present the sequence of the putative Xenopus and human Orc3p.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Imperial Canc Res Fund, London WC2A 3PX, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cancer Research UK; Cold Spring Harbor Laboratory	Stillman, B (corresponding author), POB 100, Cold Spring Harbor, NY 11724 USA.		Hunt, Tim/O-8544-2019; CANAS, BENITO/O-9256-2019	Hunt, Tim/0000-0001-5174-6038; Stillman, Bruce/0000-0002-9453-4091; Pappin, Darryl/0000-0002-8981-8401	NCI NIH HHS [CA13016] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; CAIRNS J, 1966, J MOL BIOL, V15, P372, DOI 10.1016/S0022-2836(66)80233-4; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Dillin A, 1997, GENETICS, V147, P1053; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; EHRENHOFERMURRAY AE, 1995, SCIENCE, V270, P1671, DOI 10.1126/science.270.5242.1671; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; Fox CA, 1997, SCIENCE, V276, P1547, DOI 10.1126/science.276.5318.1547; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hardy CFJ, 1996, MOL CELL BIOL, V16, P1832; Harlow E., 1988, ANTIBODIES LAB MANUA; Hori Y, 1996, MOL BIOL CELL, V7, P409, DOI 10.1091/mbc.7.3.409; HUBERMAN JA, 1966, P NATL ACAD SCI USA, V55, P599, DOI 10.1073/pnas.55.3.599; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; Ishiai M, 1997, GENOMICS, V46, P294, DOI 10.1006/geno.1997.5003; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Kornberg A., 1992, DNA REPLICATION; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; Lee DG, 1997, MOL CELL BIOL, V17, P7159, DOI 10.1128/MCB.17.12.7159; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MOCK KK, 1992, RAPID COMMUN MASS SP, V6, P233, DOI 10.1002/rcm.1290060402; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Neuwald AF, 1997, NUCLEIC ACIDS RES, V25, P1665, DOI 10.1093/nar/25.9.1665; NEWLON CS, 1993, CURR OPIN GENET DEV, V3, P752, DOI 10.1016/S0959-437X(05)80094-2; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pak DTS, 1997, CELL, V91, P311, DOI 10.1016/S0092-8674(00)80415-8; Pappin D J, 1997, Methods Mol Biol, V64, P165; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wolf DA, 1996, J BIOL CHEM, V271, P32503, DOI 10.1074/jbc.271.51.32503	71	81	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32421	32429		10.1074/jbc.273.49.32421	http://dx.doi.org/10.1074/jbc.273.49.32421			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829972	hybrid			2022-12-25	WOS:000077329100011
J	Wang, DM; Yu, X; Brecher, P				Wang, DM; Yu, X; Brecher, P			Nitric oxide and N-acetylcysteine inhibit the activation of mitogen-activated protein kinases by angiotensin II in rat cardiac fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION; INTRACELLULAR GLUTATHIONE; DIFFERENTIAL ACTIVATION; INDUCED HYPERTROPHY; CROSS-TALK; PC12 CELLS; INDUCTION; RECEPTOR; STRESS	Angiotensin II acts on the cardiac fibroblast to produce a mitogenic response. Nitric oxide and N-acetylcysteine have been used to determine if oxidative stress influenced the effects of angiotensin II on the cardiac fibroblast. Angiotensin II activated the mitogen-activated protein kinases designated extracellular signal-regulated kinases within 5 min by interacting with the AT(1) receptor. This activation was completely independent of protein kinase C and was inhibited when farnesylation was blocked, implicating Ras involvement, Pretreatment of cardiac fibroblasts with either N-acetylcysteine for 8 h or nitric oxide for 10 min suppressed this activation by angiotensin II in a dose-dependent manner. However, when both agents were added, inhibition was essentially complete. This combined effect of N-acetylcysteine and nitric oxide to block ERKs activation also was found if the activity was stimulated by either another growth factor (platelet-derived growth factor) or by the addition of phorbol ester, suggesting the effect was not limited to the receptor site alone. The results are consistent with the hypothesis that hormonal activation of mitogenic steps such as ERKs is influenced by increased oxidative stress, which is reduced by the combined effects of N-acetylcysteine and nitric oxide.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Brecher, P (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St, Boston, MA 02118 USA.	pbrecher@bu.edu			NHLBI NIH HHS [HL53471, HL55001] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053471] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akaike T, 1998, P SOC EXP BIOL MED, V217, P64; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; Brecher P, 1996, TRENDS CARDIOVAS MED, V6, P193, DOI 10.1016/S1050-1738(96)00072-2; BRUNET J, 1995, FREE RADICAL BIO MED, V19, P627, DOI 10.1016/0891-5849(95)00077-B; Du J, 1996, BIOCHEM BIOPH RES CO, V218, P934, DOI 10.1006/bbrc.1996.0165; DUFF JL, 1995, CARDIOVASC RES, V30, P511, DOI 10.1016/0008-6363(95)00088-7; EskildsenHelmond YEG, 1997, J MOL CELL CARDIOL, V29, P2545, DOI 10.1006/jmcc.1997.0491; Farivar RS, 1996, CIRC RES, V78, P759; Faruqi RM, 1997, AM J PHYSIOL-HEART C, V273, pH817, DOI 10.1152/ajpheart.1997.273.2.H817; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; Foresti R, 1997, J BIOL CHEM, V272, P18411, DOI 10.1074/jbc.272.29.18411; Gow AJ, 1998, AM J PHYSIOL-LUNG C, V274, pL112, DOI 10.1152/ajplung.1998.274.1.L112; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; Kim H, 1997, BIOCHEMISTRY-US, V36, P13677, DOI 10.1021/bi970837f; KISS Z, 1995, BBA-MOL CELL RES, V1265, P93, DOI 10.1016/0167-4889(94)00242-7; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Liao DF, 1996, CIRC RES, V79, P1007, DOI 10.1161/01.RES.79.5.1007; Malarkey K, 1996, CELL SIGNAL, V8, P123, DOI 10.1016/0898-6568(95)02036-5; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; Muller B, 1996, BRIT J PHARMACOL, V119, P1281, DOI 10.1111/j.1476-5381.1996.tb16034.x; Navarro J, 1997, FREE RADICAL BIO MED, V22, P1203, DOI 10.1016/S0891-5849(96)00554-0; Powis G, 1997, Adv Pharmacol, V38, P329; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1995, J MOL CELL CARDIOL, V27, P1151, DOI 10.1016/0022-2828(95)90051-9; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takizawa T, 1997, HYPERTENSION, V30, P1035, DOI 10.1161/01.HYP.30.5.1035; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Wink DA, 1997, J BIOL CHEM, V272, P11147; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; YIM CY, 1994, J IMMUNOL, V152, P5796; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592; Zou YZ, 1998, CIRC RES, V82, P337, DOI 10.1161/01.RES.82.3.337	44	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33027	33034		10.1074/jbc.273.49.33027	http://dx.doi.org/10.1074/jbc.273.49.33027			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830056	hybrid			2022-12-25	WOS:000077329100095
J	Zhang, Y; Cao, L; Kiani, CG; Yang, BL; Yang, BB				Zhang, Y; Cao, L; Kiani, CG; Yang, BL; Yang, BB			The g3 domain of versican inhibits mesenchymal chondrogenesis via the epidermal growth factor like motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUBSTRATUM ADHESION; PROTEOGLYCAN PG-M; LINK PROTEIN; CHICK; TISSUES; DIFFERENTIATION; ASSOCIATION; EXPRESSION; OUTGROWTH; SEQUENCE	Versican is a highly expressed proteoglycan in zones of developing tissues. To investigate whether versican plays a role in cell differentiation, we studied its role in mesenchymal condensation and chondrogenesis. Here we report that a mini-versican gene product inhibits mesenchymal chondrogenesis but not condensation. The mini-versican-treated mesenchymal cultures form fewer, smaller cartilaginous nodules and produced lower levels of link protein and type II collagen. The versican G3 domain alone, but not G1, was sufficient to inhibit mesenchymal chondrogenesis. Deletion of two epidermal growth factor (EGF)-like motifs in the G3 domain abolished the effect of versican, The G3 domain of aggrecan, which does not contain an EGF-like motif, did not inhibit mesenchymal chondrogenesis, We also generated a chimera construct containing the two EGF-like motifs of versican and the G3 domain of aggrecan, and we observed that this chimera construct inhibited chondrogenesis to a lesser extent than did the full-length versican G3 construct. Direct transfection of mesenchymal cells with different constructs produced similar results. Furthermore, treatment with versican antisense oligonucleotides and transfection with a versican antisense construct promoted chondrogenesis, Taken together, our results strongly suggest that versican inhibits mesenchymal chondrogenesis via its EGF-like motifs.	Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							AULTHOUSE AL, 1987, DEV BIOL, V120, P377, DOI 10.1016/0012-1606(87)90240-5; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; Fang JM, 1996, DEV BIOL, V180, P701, DOI 10.1006/dbio.1996.0339; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Freeman M, 1997, DEVELOPMENT, V124, P261; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; NASO MF, 1994, J BIOL CHEM, V269, P32999; NASO MF, 1995, GENOMICS, V29, P297, DOI 10.1006/geno.1995.1251; Pagan R, 1997, HEPATOLOGY, V25, P598, DOI 10.1002/hep.510250318; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; SERRERO G, 1996, INT J OBESITY S3, V20, P58; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; STIRPE NS, 1987, DEV BIOL, V124, P77, DOI 10.1016/0012-1606(87)90461-1; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1994, J CELL SCI, V107, P2581; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YANG BB, 1997, MATRIX BIOL, V16, P537; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	33	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33054	33063		10.1074/jbc.273.49.33054	http://dx.doi.org/10.1074/jbc.273.49.33054			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830060	hybrid			2022-12-25	WOS:000077329100099
J	Chen, WX; Borchers, AH; Dong, ZG; Powell, MB; Bowden, GT				Chen, WX; Borchers, AH; Dong, ZG; Powell, MB; Bowden, GT			UVB irradiation-induced activator protein-1 activation correlates with increased c-fos gene expression in a human keratinocyte cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; AP-1 ACTIVITY; SKIN CARCINOGENESIS; PHORBOL ESTER; IN-VITRO; TRANSFORMATION; RADIATION; ELEMENT; MICE; STIMULATION	The effects of WE irradiation on transcription factor activator protein-1 (AP-1) DNA binding and AP-1 transactivation were studied in a human keratinocyte cell line, HaCaT. UVB-induced AP-1 binding to a consensus AP-1 binding site was observed by gel shift assays with maximum stimulation at 12 h after UVB irradiation. A promoter region of the human collagenase-1 gene containing the same AP-1 binding sequence linked to a luciferase reporter gene was stably transfected into HaCaT cells. UVB irradiation significantly increased luciferase activity in these stably transfected cells, with maximum activity observed at 24 h after UVB irradiation. c-Fos and Jun D were identified by antibody clearing assays as the main components of the bound AP-1 complexes. Inhibition of transcription with actinomycin D and inhibition of protein synthesis with cycloheximide significantly abrogated the effect of WE on AP-1 DNA binding, indicating that transcription and translation were required for AP-1 activation. Northern and Western analyses revealed a correlation between increased AP-1 activity and accumulation of c-fos mRNA and c-Fos protein after UVB irradiation. WE irradiation increased c-fos transcription in HaCaT cells stably transfected with a plasmid containing the human c-fos promoter driving a luciferase reporter gene. These results suggest that increased c-fos expression may play an important role in UVB-induced AP-1 activation in HaCaT cells.	Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Arizona Center Cancer Care; University of Arizona; University of Minnesota System	Bowden, GT (corresponding author), Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Radiat Oncol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P01CA027502, P30CA023074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23074, CA-27502] Funding Source: Medline; NIEHS NIH HHS [P30 ESO6694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANATHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Assefa Z, 1997, J INVEST DERMATOL, V108, P886, DOI 10.1111/1523-1747.ep12292595; Barthelman M, 1998, CANCER RES, V58, P711; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Berton TR, 1996, NUTR CANCER, V26, P353, DOI 10.1080/01635589609514491; Borchers AH, 1997, MOL CARCINOGEN, V19, P258, DOI 10.1002/(SICI)1098-2744(199708)19:4<258::AID-MC7>3.0.CO;2-8; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BUSCHER M, 1988, ONCOGENE, V3, P301; BUZZELL RA, 1993, OTOLARYNG CLIN N AM, V26, P1; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; EPSTEIN JH, 1970, PHOTOCHEM PHOTOBIOL, V12, P57, DOI 10.1111/j.1751-1097.1970.tb06038.x; Fisher GJ, 1998, J CLIN INVEST, V101, P1432, DOI 10.1172/JCI2153; Goldman R, 1998, ARCH BIOCHEM BIOPHYS, V350, P10, DOI 10.1006/abbi.1997.0478; HALL EJ, 1988, AM J CLIN ONCOL-CANC, V11, P220, DOI 10.1097/00000421-198806000-00003; HOLLADAY K, 1992, MOL CARCINOGEN, V5, P16, DOI 10.1002/mc.2940050106; Huang C., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P64; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Isoherranen K, 1998, CELL SIGNAL, V10, P191, DOI 10.1016/S0898-6568(97)00100-9; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JANKNECHT R, 1993, EMBO J, V12, P5057; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; MATSUI MS, 1995, PHOTOCARCINOGENESIS, P21; MATSUI MS, 1995, SKIN CANC MECH HUMAN, P21; MILLER AD, 1984, CELL, V36, P51; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenberger SF, 1996, ONCOGENE, V12, P2301; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SHAH G, 1993, CANCER RES, V53, P38; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485	47	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32176	32181		10.1074/jbc.273.48.32176	http://dx.doi.org/10.1074/jbc.273.48.32176			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822695	hybrid			2022-12-25	WOS:000077207000077
J	Koduri, RS; Baker, SF; Snitko, Y; Han, SK; Cho, WH; Wilton, DC; Gelb, MH				Koduri, RS; Baker, SF; Snitko, Y; Han, SK; Cho, WH; Wilton, DC; Gelb, MH			Action of human group IIa secreted phospholipase A(2) on cell membranes - Vesicle but not heparinoid binding determines rate of fatty acid release by exogenously added enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; INTERFACIAL CATALYSIS; PANCREATIC PHOSPHOLIPASE-A2; PLATELET PHOSPHOLIPASE-A2; P388D(1) MACROPHAGES; SIGNAL-TRANSDUCTION; BILAYER INTERFACE; MAST-CELLS; IDENTIFICATION; BIOSYNTHESIS	Human group IIa phospholipase A(2) (hIIa-PLA2) is a highly basic protein that is secreted hom a number of cells during inflammation and may play a role in arachidonate liberation and in destruction of invading bacteria. It has been proposed that rodent group IIa PLA, is anchored to cell surfaces via attachment to heparan sulfate proteoglycan and that this interaction facilitates lipolysis. hIIa-PLA2 contains 13 lysines, 2 histidines, and 10 arginines that fall into 10 clusters. A panel of 26 hIIa-PLA2 mutants were prepared in which 1-4 basic residues in each cluster were changed to glutamate or aspartate (charge reversal). A detailed analysis of the affinities of these mutants for anionic vesicles and for heparin and heparan sulfate in vitro and of the specific activities of these proteins for hydrolysis of vesicles in vitro and of living cell. membranes reveal the following trends: 1) the affinity of hIIa-PLA2 for heparin and heparan sulfate is modulated not by a highly localized site of basic residues but by diffuse sites that partially overlap with the interfacial binding site. In contrast, only those residues on the interfacial binding site of hIIa-PLA2 are involved in binding to membranes; 2) the relative ability of these mutants to hydrolyze cellular phospholipids when enzymes were added exogenously to CHO-T(1, NIH-3T3, and RAW 264.7 cells correlates with their relative in vitro affinity for vesicles and not with their affinity for heparin and heparan sulfate. 3) The rates of exogenous hIIa-PLA2-cataIyzed fatty acid release from wild type CHO-K1 cells and two mutant lines, one lacking glycosaminoglycan and one lacking heparan sulfate, were similar. Thus basic residues that modulate interfacial binding are important for plasma membrane fatty acid release by exogenously added hIIa-PLA2. Binding of hIIa-PLA2 to cell surface heparan sulfate does not modulate plasma membrane phospholipid hydrolysis by exogenously added hIIa-PLA2.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Southampton, Dept Biochem, Southampton SO16 7PX, Hants, England; Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Southampton; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36235] Funding Source: Medline; NIGMS NIH HHS [GM53987, GM52598] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R01HL036235, R37HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052598, R01GM053987] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BAYBURT T, 1995, ANAL BIOCHEM, V232, P7, DOI 10.1006/abio.1995.9967; Conrad H. E., 1998, HEPARIN BINDING PROT; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DICCIANNI MB, 1990, BIOCHIM BIOPHYS ACTA, V1046, P242, DOI 10.1016/0005-2760(90)90237-R; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; DUA R, 1995, J BIOL CHEM, V270, P263, DOI 10.1074/jbc.270.1.263; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; ELSBACH P, 1993, IMMUNOBIOLOGY, V187, P417, DOI 10.1016/S0171-2985(11)80354-2; ErsdalBadju E, 1997, J BIOL CHEM, V272, P19393, DOI 10.1074/jbc.272.31.19393; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FADOK VA, 1993, J IMMUNOL, V151, P4274; FONTEH AN, 1994, J IMMUNOL, V152, P5438; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Ghomashchi F, 1998, BIOCHEMISTRY-US, V37, P6697, DOI 10.1021/bi972525i; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V905, P1, DOI 10.1016/0005-2736(87)90002-2; JAIN MK, 1995, METHOD ENZYMOL, V249, P567; KINKAID A, 1991, BIOCHEM J, V278, P843, DOI 10.1042/bj2780843; Kinkaid Adrian R., 1997, Biochemical Society Transactions, V25, p497S; Kinkaid AR, 1998, BBA-LIPID LIPID MET, V1390, P173, DOI 10.1016/S0005-2760(97)00181-1; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; MA YH, 1994, J LIPID RES, V35, P2049; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; MIZUSHIMA H, 1989, J BIOCHEM-TOKYO, V105, P520, DOI 10.1093/oxfordjournals.jbchem.a122699; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1988, J BIOCHEM-TOKYO, V104, P884, DOI 10.1093/oxfordjournals.jbchem.a122577; Othman R, 1996, BBA-LIPID LIPID MET, V1303, P92, DOI 10.1016/0005-2760(96)00083-5; PRUZANSKI W, 1993, J LIPID MEDIATOR, V8, P161; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Snitko Y, 1997, BIOCHEM J, V321, P737, DOI 10.1042/bj3210737; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Spirio LN, 1996, CANCER RES, V56, P955; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VERGER R, 1982, BIOCHEMISTRY-US, V21, P6883, DOI 10.1021/bi00269a040; VIAL D, 1995, J BIOL CHEM, V270, P17327, DOI 10.1074/jbc.270.29.17327; WAITE M, 1987, PHOSPHGOLIPASES; Weiss J, 1990, Adv Exp Med Biol, V275, P103; WONG PYK, 1990, ADV EXP MED BIOL, V275, P1990; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P12400, DOI 10.1021/bi962972i	61	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32142	32153		10.1074/jbc.273.48.32142	http://dx.doi.org/10.1074/jbc.273.48.32142			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822691	hybrid			2022-12-25	WOS:000077207000073
J	Roy, B; Cathcart, MK				Roy, B; Cathcart, MK			Induction of 15-lipoxygenase expression by IL-13 requires tyrosine phosphorylation of Jak2 and Tyk2 in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ACTIVATED HUMAN MONOCYTES; INTERLEUKIN-4 RECEPTOR; SIGNAL-TRANSDUCTION; INTERFERON-GAMMA; RETICULOCYTE LIPOXYGENASE; MAMMALIAN LIPOXYGENASES; CELL-TYPES; OXYGENATION; OXIDATION	The enzyme 15-lipoxygenase (15-LO) participates in the dioxygenation of polyenoic fatty acids. This activity leads to the degradation of mitochondrial membranes during reticulocyte differentiation, the production of pro- and anti-inflammatory mediators by a variety of cell types, and the oxidation of lipids in atherosclerotic lesions. The cytokines, IL-4 and IL-13, are reported to induce the expression of 15-LO in human peripheral blood monocytes, In this report we explore the signaling mechanisms involved in the IL-13-mediated induction of 15-LO expression. First we demonstrate that the delayed induction of 15-LO requires continuous stimulation of monocytes for a minimum period of 12 h, We also found that tyrosine kinase inhibitors blocked the induction of 15-LO in a dose-dependent manner. By immunoprecipitation and antiphosphotyrosine blotting experiments, IL-13 was shown to induce tyrosine phosphorylation of Jak2 and Tyk2, but not Jak1 or Jak3, within 5 min of treatment in human monocytes, To investigate whether the early induction of tyrosine phosphorylation of both Jak2 and Tyk2 was ultimately involved in 15-LO expression, we generated antisense oligodeoxyribonucleotides (ODNs) against Tyk2 and Jak2. We employed a cationic lipid-mediated delivery technique to transfect the monocytes and found that both antisense ODNs inhibited expression of their target proteins by 75-85%. The treatments were specific and did not affect the expression of each other. Furthermore, the antisense ODNs to Jak2 and Tyk2 both inhibited the induction of expression of 15-LO in monocytes treated with IL-13, Parallel experiments with sense ODNs to Jak2 and Tyk2 did not affect their protein levels or the induction of 15-LO by IL-13, and down-regulation of Jak1 also did not affect expression of 15-LO, Our results suggest the novel finding that IL-13 can induce tyrosine phosphorylation of both Jak2 and Tyk2 in primary human monocytes, This occurs as an early and essential signal transduction event for the IL-13-mediated induction of 15-LO expression. These data represent the first characterization of upstream kinases involved in the induced expression of 15-LO.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Cathcart, MK (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	cathcam@cesmtp.ccf.org						ADUNYAH SE, 1995, BIOCHEM BIOPH RES CO, V206, P103, DOI 10.1006/bbrc.1995.1015; BADR KF, 1992, KIDNEY INT, V42, pS101; BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BOSCO MC, 1994, BLOOD, V83, P2995, DOI 10.1182/blood.V83.10.2995.2995; BOSCO MC, 1994, BLOOD, V83, P3462; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; Cornicelli JA, 1996, ARTERIOSCL THROM VAS, V16, P1488, DOI 10.1161/01.ATV.16.12.1488; Debinski W, 1996, J BIOL CHEM, V271, P22428, DOI 10.1074/jbc.271.37.22428; DEWIT H, 1994, BLOOD, V84, P608; ESPINOZADELGADO I, 1994, BLOOD, V83, P3332; FISCHER DB, 1992, KIDNEY INT, V41, P1155, DOI 10.1038/ki.1992.176; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FORDHUTCHINSON AW, 1991, EICOSANOIDS, V4, P65; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HUGOU I, 1995, ATHEROSCLEROSIS, V113, P189, DOI 10.1016/0021-9150(94)05446-P; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1994, J LIPID RES, V35, P1749; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; Lee YJ, 1996, J IMMUNOL, V157, P1559; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; LI Q, 1994, J BIOL CHEM, V269, P17508; Li Q, 1997, J BIOL CHEM, V272, P2404, DOI 10.1074/jbc.272.4.2404; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Murata T, 1997, INT J CANCER, V70, P230, DOI 10.1002/(SICI)1097-0215(19970117)70:2<230::AID-IJC15>3.0.CO;2-M; Murata T, 1997, CELL IMMUNOL, V175, P33, DOI 10.1006/cimm.1996.1051; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; Obiri NI, 1997, J BIOL CHEM, V272, P20251, DOI 10.1074/jbc.272.32.20251; Obiri NI, 1997, J IMMUNOL, V158, P756; PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; TAKAHASHI Y, 1993, EUR J BIOCHEM, V218, P165, DOI 10.1111/j.1432-1033.1993.tb18362.x; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; Weiler SR, 1996, BLOOD, V87, P3688, DOI 10.1182/blood.V87.9.3688.bloodjournal8793688; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wielbo D, 1997, BIOCHEM BIOPH RES CO, V232, P794, DOI 10.1006/bbrc.1997.6329; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959; Yu CR, 1998, J IMMUNOL, V161, P218; Zhang JG, 1997, J BIOL CHEM, V272, P9474; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	55	69	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32023	32029		10.1074/jbc.273.48.32023	http://dx.doi.org/10.1074/jbc.273.48.32023			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822675	hybrid			2022-12-25	WOS:000077207000057
J	Pochampally, R; Fodera, B; Chen, LH; Shao, WJ; Levine, EA; Chen, JD				Pochampally, R; Fodera, B; Chen, LH; Shao, WJ; Levine, EA; Chen, JD			A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells	ONCOGENE			English	Article						MDM2; p53; oncogene; tumor suppressor; apoptosis; caspase; isoform	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; PROTEOLYTIC CLEAVAGE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; ONCOGENE; ONCOPROTEIN; EXPRESSION; GENE	The MDM2 oncogene product is a regulator of the p53 tumor suppressor. MDM2 is cleaved by Caspase 3 (CPP32) during apoptosis after aspartic acid-361, generating a 60 kd fragment. Here we report that human tumor cell lines often express high levels of a 60 kd MDM2 isoform (p60) in the absence of apoptosis. We demonstrate that p60 is a product of caspase cleavage of full length MDM2 after residue 361. The protease that cleaves MDM2 in non-apoptotic cells appears to be distinct from the apoptosis-specific Caspase 3, since Caspase 3 substrate poly(ADP-ribose) polymerase (PARP) is not cleaved in cells producing p60. The p60 form of MDM2 is a significant fraction of the p53-bound MDM2 protein in certain tumor cells, suggesting that it functions in the regulation of p53. p60 is also detected in breast tumors overexpressing MDM2. These observations suggest that MDM2 is regulated by caspase processing in non-apoptotic cells, and may account for the MDM2 proteins of similar mobility seen in tumors and other cell lines.	Louisiana State Univ, Med Ctr, Dept Microbiol, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Stanley S Scott Canc Ctr, Dept Surg, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University System	Chen, JD (corresponding author), Louisiana State Univ, Med Ctr, Dept Microbiol, 1901 Perdido St, New Orleans, LA 70112 USA.			Pochampally, Radhika/0000-0002-4263-0364	NCI NIH HHS [CA72915] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072915] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; BUESORAMOS CE, 1993, BLOOD, V82, P2617; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; CORDONCARDO C, 1994, CANCER RES, V54, P794; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Gorgoulis VG, 1996, J PATHOL, V180, P129; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Landers JE, 1997, CANCER RES, V57, P3562; LANDERS JE, 1994, ONCOGENE, V9, P2745; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	41	60	60	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2629	2636		10.1038/sj.onc.1202206	http://dx.doi.org/10.1038/sj.onc.1202206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840926				2022-12-25	WOS:000077058900010
J	Higuchi, M; Proske, RJ; Yeh, ETH				Higuchi, M; Proske, RJ; Yeh, ETH			Inhibition of mitochondrial respiratory chain complex I by TNF results in cytochrome c release, membrane permeability transition, and apoptosis	ONCOGENE			English	Article						reactive oxygen species; caspases; apoptosis; necrosis; cytochrome	TUMOR-NECROSIS-FACTOR; MANGANOUS SUPEROXIDE-DISMUTASE; FAS-MEDIATED APOPTOSIS; CYTO-TOXICITY; ELECTRON-TRANSPORT; CELL-LINES; GENERATION; PROTEASE; BCL-2; INDUCTION	Mitochondria have been shown to play a key role in apoptosis induction. However, the sequence of changes that occur in the mitochondria in the initial step of apoptosis has not been clearly elucidated, Here, we showed that mitochondrial respiratory chain (MRC) complex I was inhibited during the early phase of TNF- or serum withdrawal apoptosis, The importance of complex I inhibition in apoptosis is also supported by the observation that rotenone, an inhibitor of complex I but not that of other complexes, could induce apoptosis in a manner comparable to TNF, We hypothesized that inhibition of complex I could affect electron flow through other complexes leading to cytochrome c release by an antioxidant-sensitive pathway and caspase 3 activation followed by the induction of membrane permeability transition (MPT). This hypothesis is supported by the following observations: (1) TNF and rotenone induced MPT and cytochrome c release; (2) TNF-induced complex I inhibition was observed prior to cytochrome c release and MPT induction; (3) MPT induction was inhibited by a caspase 3 inhibitor, z-DEVD-CH2F, and an antioxidant pyrrolidine dithiocarbamate (PDTC), whereas cytochrome c release was only inhibited by PDTC, Thus, these results suggest that MRC complex I plays a key role in apoptosis signalings.	Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Higuchi, M (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, 2121 W Holcombe, Houston, TX 77030 USA.							Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GABAI VL, 1992, TISSUE CELL, V24, P171, DOI 10.1016/0040-8166(92)90090-T; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; Guidarelli A, 1996, BIOCHEM J, V317, P371, DOI 10.1042/bj3170371; HARTLEY A, 1994, J NEUROCHEM, V63, P1987; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HIGUCHI M, 1995, J IMMUNOL METHODS, V178, P173, DOI 10.1016/0022-1759(94)00254-T; HIGUCHI M, 1992, J IMMUNOTHER, V12, P41, DOI 10.1097/00002371-199207000-00005; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KSENZENKO M, 1983, FEBS LETT, V155, P19, DOI 10.1016/0014-5793(83)80200-2; KULL FC, 1981, CANCER RES, V41, P4885; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACHO A, 1995, BLOOD, V86, P2481; Marchetti P, 1996, J IMMUNOL, V157, P4830; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PASTORINO JG, 1995, ARCH BIOCHEM BIOPHYS, V318, P175, DOI 10.1006/abbi.1995.1218; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; RUTKA JT, 1988, INT J CANCER, V41, P573, DOI 10.1002/ijc.2910410417; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	42	108	111	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2515	2524		10.1038/sj.onc.1202485	http://dx.doi.org/10.1038/sj.onc.1202485			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824162				2022-12-25	WOS:000076927300011
J	Lanoix, J; Mullick, A; He, YL; Brave, R; Skup, D				Lanoix, J; Mullick, A; He, YL; Brave, R; Skup, D			Wild-type egr1/Krox24 promotes and dominant-negative mutants inhibit, pluripotent differentiation of p19 embryonal carcinoma cells	ONCOGENE			English	Article						EC cells; differentiation; Krox24; egr1; transcription factors	BINDING TRANSCRIPTION FACTOR; ACID RECEPTORS RARS; RETINOIC ACID; GENE-EXPRESSION; PROTO-ONCOGENE; C-FOS; NEUROECTODERMAL DIFFERENTIATION; MICE LACKING; FACTOR EGR-1; NGFI-A	The zinc-finger transcription factor Krox24 was analysed for its role in differentiation in P19 embryonal carcinoma cells. Reciprocal dominant negative mutants consisting of Krox24 deleted for a crucial region of the zinc-finger domain (Delta Krox24) or of the zinc-finger region alone (Delta Krox24Zf) abolished the activation of transcription by Krox24 in P19 cells. Expression of Krox24 led to spontaneous differentiation of P19 cells in a lineage-independent fashion. Krox24 transfected populations, as well as individual clones randomly picked from them, displayed a nide array of diverse morphologies and expressed markers characteristic of a variety of differentiated cells. The dominant negative mutants blacked differentiation of P19 cells, We conclude that expression of Krox24 is sufficient for pluripotent differentiation of embryonal carcinoma cells, and that expression of Krox24 or other egr family members is essential to this process.	Univ Montreal, Inst Canc Montreal, Ctr Rech Louis Charles Simard, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08543 USA	Universite de Montreal; Universite de Montreal; Bristol-Myers Squibb	Skup, D (corresponding author), Univ Montreal, Inst Canc Montreal, Ctr Rech Louis Charles Simard, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.							BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I; BERNSTEIN SH, 1991, CELL GROWTH DIFFER, V2, P273; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; CARMAN JA, 1995, DNA CELL BIOL, V14, P581, DOI 10.1089/dna.1995.14.581; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DARLAND T, 1991, ONCOGENE, V6, P1367; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; HERDEGEN T, 1991, J COMP NEUROL, V313, P178, DOI 10.1002/cne.903130113; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Levi G, 1996, DEVELOPMENT, V122, P113; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUO JM, 1995, MECH DEVELOP, V53, P61, DOI 10.1016/0925-4773(95)00424-6; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PRINCE VE, 1991, J VIROL, V65, P1801; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STARNAUD R, 1989, ONCOGENE, V4, P1077; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; THIEL G, 1994, J BIOL CHEM, V269, P15294; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115	60	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2495	2504		10.1038/sj.onc.1202166	http://dx.doi.org/10.1038/sj.onc.1202166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824160				2022-12-25	WOS:000076927300009
J	Canaves, JM; Montal, M				Canaves, JM; Montal, M			Assembly of a ternary complex by the predicted minimal coiled-coil-forming domains of syntaxin, SNAP-25, and synaptobrevin - A circular dichroism study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; PROTEIN-PROTEIN INTERACTIONS; MEMBRANE-FUSION COMPLEX; SYNAPTIC VESICLE FUSION; BETA-SHEET PROTEIN; G B1 DOMAIN; CONFORMATIONAL-ANALYSIS; TERMINAL DOMAIN; CLOSTRIDIAL NEUROTOXINS; BOTULINAL NEUROTOXINS	The assembly of target (t-SNARE) and vesicle-associated SNAP receptor (V-SNARE) proteins is a critical step for the docking of synaptic vesicles to the plasma membrane. Syntaxin-1A, SNAP-25, and synaptobrevin-2 (also known as vesicle-associated membrane protein, or VAMP-2) bind to each other with high affinity, and their binding regions are predicted to form a trimeric coiled-coil. Here, we have designed three peptides, which correspond to sequences located in the syntaxin-1A H3 domain, the C-terminal domain of SNAP-25, and a conserved central domain of synaptobrevin-2, that exhibit a high propensity to form a minimal trimeric coiled-coil. The peptides were synthesized by solid phase methods, and their interactions were studied by CD spectroscopy. In aqueous solution, the peptides were unstructured and showed no interactions with each other. In contrast, upon the addition of moderate amounts of trifluoroethanol (30%), the peptides adopted an alpha-helical structure and displayed both homomeric and heteromeric interactions. The interactions observed in ternary mixtures induce a stabilization of peptide structure that is greater than that predicted from individual binary interactions, suggesting the formation of a higher order structure compatible-with the assembly of a trimeric coiled-coil.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Montal, M (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	montal@biomail.ucsd.edu						Adamson J. Gordon, 1993, Current Opinion in Biotechnology, V4, P428, DOI 10.1016/0958-1669(93)90008-K; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARCHER BT, 1990, J BIOL CHEM, V265, P17267; Arunkumar AI, 1997, BBA-PROTEIN STRUCT M, V1338, P69, DOI 10.1016/S0167-4838(96)00191-4; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; BINZ T, 1994, J BIOL CHEM, V269, P1617; Blanco FJ, 1997, FOLD DES, V2, P123, DOI 10.1016/S1359-0278(97)00017-5; BLANCO FJ, 1995, EUR J BIOCHEM, V230, P634; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BROWN JE, 1971, BIOCHEMISTRY-US, V10, P470, DOI 10.1021/bi00779a019; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; Dong A, 1998, ARCH BIOCHEM BIOPHYS, V355, P275, DOI 10.1006/abbi.1998.0718; DYSON HJ, 1992, J MOL BIOL, V226, P819, DOI 10.1016/0022-2836(92)90634-V; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Feng YB, 1996, J AM CHEM SOC, V118, P10351, DOI 10.1021/ja961260c; Ferrer-Montiel AV, 1998, FEBS LETT, V435, P84, DOI 10.1016/S0014-5793(98)01012-6; Foran P, 1996, BIOCHEMISTRY-US, V35, P2630, DOI 10.1021/bi9519009; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Gerst JE, 1997, J BIOL CHEM, V272, P16591, DOI 10.1074/jbc.272.26.16591; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Grote E, 1996, J CELL BIOL, V132, P537, DOI 10.1083/jcb.132.4.537; Gutierrez LM, 1997, J BIOL CHEM, V272, P2634, DOI 10.1074/jbc.272.5.2634; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; Hamada D, 1997, J MOL BIOL, V269, P479, DOI 10.1006/jmbi.1997.1055; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hao JC, 1997, J NEUROSCI, V17, P1596; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HODGES R S, 1990, Peptide Research, V3, P123; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; Jayaraman G, 1996, BIOCHEM BIOPH RES CO, V222, P33, DOI 10.1006/bbrc.1996.0693; Kee Y, 1996, J NEUROSCI, V16, P1975; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Luidens MK, 1996, BIOPOLYMERS, V39, P367, DOI 10.1002/(SICI)1097-0282(199609)39:3<367::AID-BIP8>3.3.CO;2-C; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MacPhee CE, 1997, FEBS LETT, V416, P265, DOI 10.1016/S0014-5793(97)01224-6; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; Martin F, 1996, BIOCHEM J, V320, P201, DOI 10.1042/bj3200201; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; MUNOZ V, 1995, J MOL BIOL, V247, P648, DOI 10.1006/jmbi.1994.0170; Najbar LV, 1997, BIOCHEMISTRY-US, V36, P11525, DOI 10.1021/bi970730s; NARAYANAN U, 1986, J AM CHEM SOC, V108, P2431, DOI 10.1021/ja00269a049; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; Pellizzari R, 1996, J BIOL CHEM, V271, P20353, DOI 10.1074/jbc.271.34.20353; RamirezAlvarado M, 1997, PROTEIN SCI, V6, P162; Regazzi R, 1996, EMBO J, V15, P6951, DOI 10.1002/j.1460-2075.1996.tb01087.x; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; Schmid FX., 1989, SPECTRAL METHODS CHA, P251; Schonbrunner N, 1996, J MOL BIOL, V260, P432, DOI 10.1006/jmbi.1996.0412; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Vinogradov AA, 1996, INT J PEPT PROT RES, V47, P467; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Williamson LC, 1996, J BIOL CHEM, V271, P7694, DOI 10.1074/jbc.271.13.7694; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526; Zhong PY, 1997, BIOCHEMISTRY-US, V36, P4317, DOI 10.1021/bi9625408; ZHOU NE, 1992, BIOPOLYMERS, V32, P419, DOI 10.1002/bip.360320419; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	77	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34214	34221		10.1074/jbc.273.51.34214	http://dx.doi.org/10.1074/jbc.273.51.34214			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852083	hybrid			2022-12-25	WOS:000077542200049
J	Wang, WY; Xia, J; Kass, RS				Wang, WY; Xia, J; Kass, RS			MinK-KvLQT1 fusion proteins, evidence for multiple stoichiometries of the assembled I-sK channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINK POTASSIUM CHANNELS; K+-CHANNEL; XENOPUS-OOCYTES; EXPRESSION; CLONING; ISK; MUTATIONS; HEART; K(V)LQT1; MEMBRANE	I-sK, a slowly activating delayed rectifier K+ current through channels formed by the assembly of two channel proteins KvLQT1 and MinK, modulates the repolarization of cardiac action potentials, Mutations that map to the KvLQT1 and minK genes account for more than 50% of an inherited cardiac disorder, the Long QT syndrome (Splawski, I., Tristani-Firouzi, Ra,, Lehmann, M. H., Sanguinetti, M. C., and Keating, M. T. (1997) Nat. Genet. 17, 338-340), Despite the importance of these channels to human cardiac function, the molecular basis of their uniquely slow gating properties as well as the stoichiometry and interaction sites of these two subunits are still unclear. We have constructed several fusion channel proteins to begin investigating the stoichiometry of these two subunits and the role of voltage-dependent subunit assembly in channel gating, Functional properties of these constructs were measured using whole cell patch clamp recordings of transiently transfected Chinese hamster ovary cells, The constructs we tested are as follows: MK24 (C terminus of MinK linked to N terminus of KvLQT1); KK40 (a tandem homodimer of KvLQT1); and MKK44 (C terminus of MinK linked to N terminus of KK40), In control experiments (no DNA, control DNA, or only MinK), no ti:me-dependent K+ current was observed. Expression of KvLQT1 or KK40 produced currents that activate and inactivate in a voltage-dependent manner as reported by others for KvLQT1. In contrast, expression of MK24 and MKK44 elicited current with activation kinetics and voltage dependence very similar to native I,,and identical to currents expressed by cells co-transfected with independent MinK and KvLQT1 cDNA, Expression of MK24 plus additional MinK significantly slows current kinetics. Our data raise the possibility 1) of multiple MinK/KvLQT1 stoichiometries and 2) indicate that uniquely slow kinetics of I-sK channels is due to voltage-dependent conformational changes of the channel protein and not to assembly of channel subunits.	Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University	Kass, RS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	rsk20@columbia.edu			NHLBI NIH HHS [1R01-HL-44365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; CUI J, 1994, J GEN PHYSIOL, V104, P87, DOI 10.1085/jgp.104.1.87; Davies MP, 1996, CIRC RES, V78, P15, DOI 10.1161/01.RES.78.1.15; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; FOLANDER K, 1990, P NATL ACAD SCI USA, V87, P2975, DOI 10.1073/pnas.87.8.2975; FREEMAN LC, 1993, CIRC RES, V73, P968, DOI 10.1161/01.RES.73.5.968; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HONORE E, 1991, EMBO J, V10, P2805, DOI 10.1002/j.1460-2075.1991.tb07829.x; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; Kass RS, 1997, CIRCULATION, V96, P1720; KASS RS, 1994, CARDIAC ELECTROPHYSI, P74; KASS RS, 1996, MOL PHYSL PHARM CARD, P169; KRAFTE D S, 1992, Biophysical Journal, V61, pA378; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MCCORMACK K, 1993, BIOPHYS J, V65, P1740, DOI 10.1016/S0006-3495(93)81202-5; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; Tzounopoulos T, 1998, BIOPHYS J, V74, P2299, DOI 10.1016/S0006-3495(98)77939-1; VARNUM MD, 1995, NEURON, V14, P407, DOI 10.1016/0896-6273(95)90296-1; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17	33	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34069	34074		10.1074/jbc.273.51.34069	http://dx.doi.org/10.1074/jbc.273.51.34069			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852064	hybrid			2022-12-25	WOS:000077542200030
J	Zeilinger, S; Mach, RL; Kubicek, CP				Zeilinger, S; Mach, RL; Kubicek, CP			Two adjacent protein binding motifs in the cbh2 (cellobiohydrolase II-encoding) promoter of the fungus Hypocrea jecorina (Trichoderma reesei) cooperate in the induction by cellulose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; A GENE-EXPRESSION; ASPERGILLUS-NIDULANS; SACCHAROMYCES-CEREVISIAE; TRANSFORMATION SYSTEM; CCAAT-BINDING; CLONING; DNA; YEAST; BETA	The cellulase system of the filamentous fungus Hypocrea jecorina (Trichoderma reesei) consists of several cellobiohydrolases, endoglucanases, and beta-glucosidases, encoded by separate genes, which are coordinately expressed in the presence of cellulose or the disaccharide sophorose, Using cell-free extracts from sophorose-induced and noninduced mycelia and various fragments of the cbh2 promoter of H. jecorina in electrophoretic mobility shift assay (EMSA) analysis and performing in vitro and in vivo footprinting analysis, we detected the nucleotide sequence 5'-ATTGGGTAATA-3' (consequently named cbh2-activating element (CAE)) to bind a protein complex with different migration in EMSA of induced and noninduced cell-free extracts. EMSA analysis, employing oligonucleotide fragments containing specifically mutated versions of CAE, revealed that protein binding requires the presence of an intact copy of either one of two adjacent motifs: a CCAAT (=ATTGG) box on the template strand and a GTAATA box can the coding strand, whereas a simultaneous mutation ill both completely abolished binding. H. jecorina transformants, containing correspondingly mutated versions of the cbh2 promoter fused to the Escherichia coli hph gene as a reporter, expressed hph in a manner paralleling the efficacy of CAE-protein complex formation in EMSA, suggesting that the presence of either of both motifs is required for induction of cbh2 gene transcription. Antibody supershift experiments with anti-HapC antiserum as well as EMSA competition experiments with CCAAT binding promoter fragments of the Aspergillus nidulans amdS promoter suggest that the H. jecorina CCAAT box binding complex contains a homologue of HapC, The nature of the adjacent, GTAATA-binding protein(s) and its cooperation with the HapC homologue in cbh2 gene induction is discussed.	Vienna Univ Technol, Inst Biochem Technol & Mikrobiol, Mikrobielle Biochem Abt, A-1060 Vienna, Austria	Technische Universitat Wien	Zeilinger, S (corresponding author), Vienna Univ Technol, Inst Biochem Technol & Mikrobiol, Mikrobielle Biochem Abt, Getreidemarkt 9-1725, A-1060 Vienna, Austria.	szeiling@mail.zserv.tuwien.ac.at	Zeilinger, Susanne/AAX-6578-2020; Robert, Mach/AAU-8968-2020	Zeilinger, Susanne/0000-0003-3112-0948; Mach, Robert, L./0000-0003-2375-7244				ARAMAYO R, 1993, EMBO J, V12, P2039, DOI 10.1002/j.1460-2075.1993.tb05853.x; BARNETT CC, 1991, BIO-TECHNOL, V9, P562, DOI 10.1038/nbt0691-562; CarleUrioste JC, 1997, J BIOL CHEM, V272, P10169, DOI 10.1074/jbc.272.15.10169; Chen HX, 1998, GENETICS, V148, P123; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELGOGARY S, 1989, P NATL ACAD SCI USA, V86, P6138, DOI 10.1073/pnas.86.16.6138; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; Gottschalk G., 1988, Biochemistry and genetics of cellulose degradation, P3; GRUBER F, 1990, CURR GENET, V18, P447, DOI 10.1007/BF00309915; GRUBER F, 1990, CURR GENET, V18, P71, DOI 10.1007/BF00321118; HAHN S, 1988, MOL CELL BIOL, V8, P655, DOI 10.1128/MCB.8.2.655; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; HenriqueSilva F, 1996, BIOCHEM BIOPH RES CO, V228, P229, DOI 10.1006/bbrc.1996.1646; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Ilmen M, 1997, APPL ENVIRON MICROB, V63, P1298; Ilmen M, 1996, MOL GEN GENET, V253, P303, DOI 10.1007/s004380050326; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kato M, 1998, MOL GEN GENET, V257, P404, DOI 10.1007/s004380050664; Kato M, 1997, MOL GEN GENET, V254, P119, DOI 10.1007/s004380050399; KUBICEK CP, 1988, J GEN MICROBIOL, V134, P1215; Kubicek CP, 1998, TRICHODERMA GLIOCLAD, V1, P49; Kuhls K, 1996, P NATL ACAD SCI USA, V93, P7755, DOI 10.1073/pnas.93.15.7755; Litzka O, 1998, EUR J BIOCHEM, V251, P758, DOI 10.1046/j.1432-1327.1998.2510758.x; MACH RL, 1994, CURR GENET, V25, P567, DOI 10.1007/BF00351679; Mach RL, 1996, MOL MICROBIOL, V21, P1273, DOI 10.1046/j.1365-2958.1996.00094.x; MANDELS M, 1978, PROCESS BIOCHEM, V13, P6; MANDELS M, 1962, J BACTERIOL, V83, P400, DOI 10.1128/JB.83.2.400-408.1962; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MULDER W, 1994, MOL GEN GENET, V245, P96, DOI 10.1007/BF00279755; Papagiannopoulos P, 1996, MOL GEN GENET, V251, P412, DOI 10.1007/s004380050184; PENTTILA M, 1991, APPLIED MOL GENETICS, P85; PINKHAM JL, 1985, MOL CELL BIOL, V5, P3410, DOI 10.1128/MCB.5.12.3410; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RONCHI A, 1995, NUCLEIC ACIDS RES, V23, P4565, DOI 10.1093/nar/23.22.4565; SALOHEIMO A, 1994, MOL MICROBIOL, V13, P219, DOI 10.1111/j.1365-2958.1994.tb00417.x; Saloheimo M, 1997, EUR J BIOCHEM, V249, P584, DOI 10.1111/j.1432-1033.1997.00584.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANGL H, 1993, CURR GENET, V23, P115, DOI 10.1007/BF00352009; STERNBERG D, 1979, J BACTERIOL, V139, P761, DOI 10.1128/JB.139.3.761-769.1979; STRAUSS J, 1995, FEBS LETT, V376, P103, DOI 10.1016/0014-5793(95)01255-5; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TEERI TT, 1987, GENE, V51, P43, DOI 10.1016/0378-1119(87)90472-0; van Peij NNME, 1998, MOL MICROBIOL, V27, P131, DOI 10.1046/j.1365-2958.1998.00666.x; VANHEESWIJCK R, 1991, NUCLEIC ACIDS RES, V19, P2655, DOI 10.1093/nar/19.10.2655; Ward M., 1993, TRICHODERMA REESEI C, P153; Wolschek MF, 1998, NUCLEIC ACIDS RES, V26, P3862, DOI 10.1093/nar/26.16.3862; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	51	73	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34463	34471		10.1074/jbc.273.51.34463	http://dx.doi.org/10.1074/jbc.273.51.34463			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852114	hybrid			2022-12-25	WOS:000077542200080
J	Hang, B; Sagi, J; Singer, B				Hang, B; Sagi, J; Singer, B			Correlation between sequence-dependent glycosylase repair and the thermal stability of oligonucleotide duplexes containing 1,N-6-ethenoadenine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN 3-METHYLADENINE-DNA GLYCOSYLASE; DNA-POLYMERASE INSERTION; ESCHERICHIA-COLI; NUCLEOTIDE EXCISION; HELIX STABILITY; BASE SEQUENCE; ADDUCT; KINETICS; PURIFICATION; SPECIFICITY	Previous experiments on DNA sequence context reported that base modification, replication, and repair are affected by the nature of neighbor bases. We now report that repair by mammalian alkylpurine-DNA-N-glycosylases (APNG) of 15-mer oligonucleotides with a central 1,N-6-ethenoadenine (epsilon A), flanked by 5' and 3' tandem bases, is also highly sequence dependent. Oligonucleotides with the central sequences -GG epsilon AGG- or -CC epsilon ACC- are repaired 3-5-fold more efficiently than those containing -AA epsilon AAA- or -TT epsilon ATT- when using human or mouse APNG, Melting curves of the same duplexes showed that oligomers with G.C/C.G neighbors were less denatured than those with A.T/T.A neighbors at 37 degrees C. This sequence-dependent difference in denaturation correlates with the relative thermodynamic stability of oligomers with G.C/C.G or A.T/T.A neighbors. The dependence of repair on thermal stability was confirmed by enzyme reactions performed over 0-45 degrees C. Under these conditions, repair of epsilon A flanked by G.C/C.G was dramatically increased at 37 degrees C with continuous increase up to 45 degrees C, in contrast to that with flanking A.T/T.A pairs, which was in agreement with the degree of denaturation of these duplexes, These results indicate that the thermodynamic stability conferred by base pairs flanking epsilon A plays an essential role in maintaining the integrity of the duplex structure which is necessary for repair.	Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Donner Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Singer, B (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Donner Lab, Berkeley, CA 94720 USA.				NCI NIH HHS [CA 47723, CA 72079] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047723, R01CA072079] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allawi HT, 1998, BIOCHEMISTRY-US, V37, P2170, DOI 10.1021/bi9724873; Arghavani MB, 1998, BIOCHEMISTRY-US, V37, P8575, DOI 10.1021/bi980237w; ARNOLD FH, 1987, BIOCHEMISTRY-US, V26, P4068, DOI 10.1021/bi00387a049; BASU AK, 1993, BIOCHEMISTRY-US, V32, P12793, DOI 10.1021/bi00210a031; Bender K, 1996, NUCLEIC ACIDS RES, V24, P2087, DOI 10.1093/nar/24.11.2087; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BLOOM LB, 1993, BIOCHEMISTRY-US, V32, P11247, DOI 10.1021/bi00092a039; BORDEN KL, 1992, BIOCHEMISTRY-US, V23, P5411; BORER PN, 1975, HDB BIOCH MOL BIOL N, V1, P589; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURNS PA, 1987, J MOL BIOL, V194, P385, DOI 10.1016/0022-2836(87)90668-1; CAI H, 1993, J BIOL CHEM, V268, P23567; CAROTHERS AM, 1990, P NATL ACAD SCI USA, V87, P5464, DOI 10.1073/pnas.87.14.5464; CMARIK JL, 1992, J BIOL CHEM, V267, P6672; Delagoutte E, 1997, J MOL BIOL, V266, P703, DOI 10.1006/jmbi.1996.0830; DEMPLE B, 1982, J BIOL CHEM, V257, P13776; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DOLAN ME, 1988, CARCINOGENESIS, V9, P2139, DOI 10.1093/carcin/9.11.2139; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; EFTEDAL I, 1994, ANN NY ACAD SCI, V726, P312, DOI 10.1111/j.1749-6632.1994.tb52836.x; FOLEY CK, 1991, MUTAT RES, V255, P89, DOI 10.1016/0921-8777(91)90021-G; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GALLINARI PSU, 1996, BIOCHEMISTRY-US, V35, P12926; GOODMAN MF, 1994, ANN NY ACAD SCI, V726, P132, DOI 10.1111/j.1749-6632.1994.tb52804.x; Hang B, 1997, BIOCHEMISTRY-US, V36, P15411, DOI 10.1021/bi971367s; Hang B, 1998, CARCINOGENESIS, V19, P1339, DOI 10.1093/carcin/19.8.1339; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; Hashim MF, 1996, J BIOL CHEM, V271, P9160, DOI 10.1074/jbc.271.15.9160; JONES M, 1987, GENETICS, V115, P605; KE SH, 1995, BIOCHEMISTRY-US, V34, P4593, DOI 10.1021/bi00014a012; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1820, DOI 10.1021/bi00221a014; LANE A, 1992, BIOCHEMISTRY-US, V31, P12087, DOI 10.1021/bi00163a018; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Litinski V, 1997, CARCINOGENESIS, V18, P1609, DOI 10.1093/carcin/18.8.1609; MARNETT LJ, 1993, CHEM RES TOXICOL, V6, P771, DOI 10.1021/tx00036a005; McDowell JA, 1996, BIOCHEMISTRY-US, V35, P14077, DOI 10.1021/bi9615710; Mekhovich O, 1998, BIOCHEMISTRY-US, V37, P571, DOI 10.1021/bi971544p; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MU D, 1994, NUCLEIC ACIDS RES, V22, P4869, DOI 10.1093/nar/22.23.4869; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NELSON JW, 1981, BIOPOLYMERS, V20, P2509, DOI 10.1002/bip.1981.360201204; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; PETRUSKA J, 1985, J BIOL CHEM, V260, P7533; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; Rao S, 1996, MUTAT RES-FUND MOL M, V356, P179, DOI 10.1016/0027-5107(96)00052-8; RICHARDSON FC, 1989, J BIOL CHEM, V264, P838; ROSS H, 1993, CANCER RES, V53, P1273; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; RYDBERG B, 1992, CANCER RES, V52, P1377; RYDBERG D, 1991, P NATL ACAD SCI USA, V86, P6839; Sagi J, 1998, CHEM RES TOXICOL, V11, P329, DOI 10.1021/tx9701992; Sander M, 1996, NUCLEIC ACIDS RES, V24, P3926, DOI 10.1093/nar/24.20.3926; SantaLucia J, 1996, BIOCHEMISTRY-US, V35, P3555, DOI 10.1021/bi951907q; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SCICCHITANO D, 1982, BIOCHEM BIOPH RES CO, V109, P995, DOI 10.1016/0006-291X(82)92038-1; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; SEEBERG E, 1990, P NATL ACAD SCI USA, V87, P191, DOI 10.1073/pnas.87.1.191; SHIBUTANI S, 1993, BIOCHEMISTRY-US, V32, P7531, DOI 10.1021/bi00080a027; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGER B, 1990, MUTAT RES, V233, P45, DOI 10.1016/0027-5107(90)90150-3; SINGER B, 1984, CARCINOGENESIS, V5, P1165, DOI 10.1093/carcin/5.9.1165; SINGER B, 1992, P NATL ACAD SCI USA, V89, P9386, DOI 10.1073/pnas.89.20.9386; Singer B, 1997, CHEM RES TOXICOL, V10, P713, DOI 10.1021/tx970011e; SKOPEK TR, 1992, P NATL ACAD SCI USA, V89, P7866, DOI 10.1073/pnas.89.17.7866; TIANBING X, 1997, BIOCHEMISTRY-US, V36, P12486; WERNTGES H, 1986, NUCLEIC ACIDS RES, V14, P3773, DOI 10.1093/nar/14.9.3773; WYATT MD, 1995, BIOCHEMISTRY-US, V34, P13034, DOI 10.1021/bi00040a014; YAREMA KJ, 1994, J MOL BIOL, V236, P1034, DOI 10.1016/0022-2836(94)90010-8	70	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33406	33413		10.1074/jbc.273.50.33406	http://dx.doi.org/10.1074/jbc.273.50.33406			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837917	hybrid			2022-12-25	WOS:000077462500047
J	Arcaro, A; Volinia, S; Zvelebil, MJ; Stein, R; Watton, SJ; Layton, MJ; Gout, I; Ahmadi, K; Downward, J; Waterfield, MD				Arcaro, A; Volinia, S; Zvelebil, MJ; Stein, R; Watton, SJ; Layton, MJ; Gout, I; Ahmadi, K; Downward, J; Waterfield, MD			Human phosphoinositide 3-kinase C2 beta, the role of calcium and the C2 domain in enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHOSPHATIDYLINOSITOL 3-KINASE; FUNCTIONAL DIVERSITY; SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT; PROTEIN-KINASE; BINDING-SITE; SYNAPTOTAGMIN; CLONING; MEMBRANE; IDENTIFICATION	The cDNA for a human Class II phosphoinositide 3-kinase (PI 3-kinase C2 beta) with a C2 domain was cloned from a U937 monocyte cDNA library and the enzyme expressed in mammalian and insect cells. Like other Class II PI 3-kinases in vitro, PI 3-kinase C2 beta utilizes phosphatidylinositol (PI) and PI 4-monophosphate but not PI 4,5-biphosphate as substrates in the presence of Mg2+. Remarkably, and unlike other PI 3-kinases, the enzyme can use either Mg-ATP or Ca-ATP to generate PI 3-monophosphate. PI 3-kinase C2 beta, like the Class I PI 3-kinases, but unlike PI 3-kinase C2 alpha, is sensitive to low nanomolar levels of the inhibitor wortmannin. The enzyme is not regulated by the small GTP-binding protein Pas. The C2 domain of the enzyme bound anionic phospholipids such as PI and phosphatidylserine in vitro, but did not co-operatively bind Ca2+ and phospholipids. Deletion of the C2 domain increased the lipid kinase activity suggesting that it functions as a negative regulator of the catalytic domain. Although presently it is not known whether PI 3-kinase C2 beta is regulated by Ca2+ in vivo, our results suggest a novel role for Ca2+ ions in phosphate transfer reactions.	UCL, Ludwig Inst Canc Res, London W1P 8BT, England; Univ Ferrara, Dipartmento Biochim & Biol Mol, I-44100 Ferrara, Italy; Imperial Canc Res Fund, London WC2A 3PX, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; University of Ferrara; Cancer Research UK; University of London; University College London	Waterfield, MD (corresponding author), UCL, Ludwig Inst Canc Res, 91 Riding House St, London W1P 8BT, England.	mike@ludwig.ucl.ac.uk	Volinia, Stefano/A-3029-2010; Volinia, Stefano/AAA-9264-2019; Arcaro, Alexandre/G-1711-2010; Stein, Robert C/N-6679-2015; Layton, Meredith/E-9171-2014	Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Arcaro, Alexandre/0000-0001-9107-2947; Stein, Robert C/0000-0003-2969-0415; Zvelebil, Marketa/0000-0001-8018-5591; Downward, Julian/0000-0002-2331-4729				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; EXLEY M, 1994, J BIOL CHEM, V269, P15140; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Inukai K, 1996, J BIOL CHEM, V271, P5317, DOI 10.1074/jbc.271.10.5317; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ono F, 1998, J BIOL CHEM, V273, P7731, DOI 10.1074/jbc.273.13.7731; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Panaretou C, 1997, J BIOL CHEM, V272, P2477; PONS S, 1995, MOL CELL BIOL, V15, P4453; Ponting CP, 1996, PROTEIN SCI, V5, P162; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; Woscholski R, 1997, TRENDS BIOCHEM SCI, V22, P427, DOI 10.1016/S0968-0004(97)01120-1; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	56	108	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33082	33090		10.1074/jbc.273.49.33082	http://dx.doi.org/10.1074/jbc.273.49.33082			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830063	hybrid			2022-12-25	WOS:000077329100102
J	Kojima, K; Kitada, S; Shimokata, K; Ogishima, T; Ito, A				Kojima, K; Kitada, S; Shimokata, K; Ogishima, T; Ito, A			Cooperative formation of a substrate binding pocket by alpha- and beta-subunits of mitochondrial processing peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; PRECURSOR PROTEINS; SYNTHETIC PEPTIDE; CLEAVAGE; PROTEASE; MATRIX; RECOGNITION; IMPORT; SITE; PEP	Mitochondrial processing peptidase (MPP) specifically recognizes a large variety of mitochondrial precursor proteins and cleaves off N-terminal extension peptides. The enzyme is a metalloprotease and forms a heterodimer consisting of structurally related alpha- and beta-subunits, To investigate the responsibility of MPP subunits for substrate recognition, we monitored interaction of the fluorescent-labeled peptide substrates with the MPP and its subunits, The specific binding of the peptide to the MPP was confirmed by findings of the direct participation of arginine residues in the binding, which are located at position -2 and the position distal to the cleavage site and are essential for the cleavage reaction. MPP bound the substrate peptides with high affinity only in the dimeric complex, and each subunit monomer had about a 30-fold less affinity than the complex. The individual subunit required arginines at different positions in the peptide for binding, although their affinities were much lower than that of MPP. Fluorescence quenching analysis showed that the peptide bound to MPP was buried in the enzyme. Thus, both subunits of MPP might be required for formation of a substrate binding pocket with multiple subsites lying across them.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan	Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.							ARRETZ M, 1994, J BIOL CHEM, V269, P4959; Boteva R, 1996, ARCH BIOCHEM BIOPHYS, V332, P323, DOI 10.1006/abbi.1996.0348; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; GELI V, 1990, J BIOL CHEM, V265, P19216; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; Luciano P, 1997, J MOL BIOL, V272, P213, DOI 10.1006/jmbi.1997.1231; MIURA S, 1986, BIOCHEM BIOPH RES CO, V134, P1151, DOI 10.1016/0006-291X(86)90371-2; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1994, J BIOL CHEM, V269, P24673; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SAGARA Y, 1984, J BIOCHEM-TOKYO, V96, P1743, DOI 10.1093/oxfordjournals.jbchem.a135007; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Shimokata K, 1997, J BIOCHEM-TOKYO, V122, P1019; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1991, J BIOL CHEM, V266, P6416	28	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32542	32546		10.1074/jbc.273.49.32542	http://dx.doi.org/10.1074/jbc.273.49.32542			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829989	hybrid			2022-12-25	WOS:000077329100028
J	Lambert, PF; Kashanchi, F; Radonovich, MF; Shiekhattar, R; Brady, JN				Lambert, PF; Kashanchi, F; Radonovich, MF; Shiekhattar, R; Brady, JN			Phosphorylation of p53 serine 15 increases interaction with CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR TFIIH; TUMOR-SUPPRESSOR PROTEIN; CREB-BINDING PROTEIN; DNA-DAMAGE; MDM-2 ONCOGENE; IN-VITRO; COACTIVATORS; APOPTOSIS; COMPLEX	p53 exerts its cell cycle regulatory effects through its ability to function as a sequence-specific DNA binding transcription factor. CREB-binding protein (CBP)/p300, through its interaction with the N terminus of p53, acts as a coactivator for p53 and increases the sequence-specific DNA-binding activity of p53 by acetylating its C terminus. The same N-terminal domain of p53 has recently been shown to be phosphorylated at Ser(15) in response to gamma-irradiation. Remarkably, we now demonstrate that phosphorylation of p53 at Ser(15) increases its ability to recruit CBP/p300. The increase in CBP/p300 binding was followed by an increase in the overall level of acetylation of the C terminus of p53. These results provide a mechanism for the activation of p53-regulated genes following DNA damage, through a signaling pathway linking p53 N-terminal kinase and C-terminal acetyltransferase activities.	NCI, Virus Tumor Biol Sect, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA; Wistar Inst, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); The Wistar Institute	Brady, JN (corresponding author), NCI, Virus Tumor Biol Sect, Lab Receptor Biol & Gene Express, NIH, Bldg 41,Rm B403, Bethesda, MD 20892 USA.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Meek DW, 1997, BIOCHEM SOC T, V25, P416, DOI 10.1042/bst0250416; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Rathmell WK, 1997, CANCER RES, V57, P68; Rotman G, 1997, CANCER SURV, V29, P285; Scolnick DM, 1997, CANCER RES, V57, P3693; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	50	359	369	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33048	33053		10.1074/jbc.273.49.33048	http://dx.doi.org/10.1074/jbc.273.49.33048			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830059	hybrid			2022-12-25	WOS:000077329100098
J	Holt, KH; Campbell, KP				Holt, KH; Campbell, KP			Assembly of the sarcoglycan complex - Insights for muscular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SARCOGLYCAN; BETA-SARCOGLYCAN; CYSTIC-FIBROSIS; GENE; MUTATIONS; HAMSTER; IDENTIFICATION; CFTR	Four unique transmembrane glycoproteins comprise the sarcoglycan complex in striated muscle. The sarcoglycan complex contributes to maintenance of sarcolemma integrity. A shared feature of four types of autosomal recessive limb girdle muscular dystrophy (LGMD) is that mutations in a single sarcoglycan gene result in the loss of all sarcoglycans at the sarcolemma. The mechanism of destabilization is unknown. We report here our findings of sarcoglycan complex biosynthesis in a heterologous cell system. We demonstrate that the sarcoglycans are glycosylated and assemble into a complex that resides in the plasma membrane. Complex assembly was dependent on the simultaneous synthesis of all four sarcoglycans. Mutant sarcoglycans block complex formation and insertion of the sarcoglycans into the plasma membrane. This constitutes the first biochemical evidence to support the idea that the molecular defect in sarcoglycan-deficient LGMD is because of aberrant sarcoglycan complex assembly and trafficking, which leads to the absence of the complex from the sarcolemma.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, 400 EMRB, Iowa City, IA 52242 USA.			Campbell, Kevin/0000-0003-2066-5889				BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HOMBURGER F, 1962, MED EXP, V6, P339; Jung D, 1996, FEBS LETT, V381, P15, DOI 10.1016/0014-5793(96)00056-7; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MIZUNO Y, 1995, AM J PATHOL, V146, P530; Nigro V, 1997, HUM MOL GENET, V6, P601, DOI 10.1093/hmg/6.4.601; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; PASSOSBUENO MR, 1995, HUM MOL GENET, V4, P1163; Petrof BJ, 1998, MOL CELL BIOCHEM, V179, P111, DOI 10.1023/A:1006812004945; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; Vainzof M, 1996, HUM MOL GENET, V5, P1963, DOI 10.1093/hmg/5.12.1963; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; YOSHIDA M, 1994, EUR J BIOCHEM, V222, P1055, DOI 10.1111/j.1432-1033.1994.tb18958.x	22	105	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34667	34670		10.1074/jbc.273.52.34667	http://dx.doi.org/10.1074/jbc.273.52.34667			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856984	hybrid			2022-12-25	WOS:000077719700002
J	Lagree, V; Froger, A; Deschamps, S; Pellerin, I; Delamarche, C; Bonnec, G; Gouranton, J; Thomas, D; Hubert, JF				Lagree, V; Froger, A; Deschamps, S; Pellerin, I; Delamarche, C; Bonnec, G; Gouranton, J; Thomas, D; Hubert, JF			Oligomerization state of water channels and glycerol facilitators - Involvement of loop E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEPHROGENIC DIABETES-INSIPIDUS; MAJOR INTRINSIC PROTEIN; LENS FIBER MEMBRANES; AQUAPORIN CHIP; EXPRESSION; SEQUENCE; MIP	The major intrinsic protein (MIP) family includes water channels aquaporins (AQPs) and facilitators for small solutes such as glycerol (GlpFs), Velocity sedimentation on sucrose gradients demonstrates that heterologous AQPcic expressed in yeast or Xenopus oocytes behaves as an homotetramer when extracted by n-octyl beta-D-glucopyranoside (OG) and as a monomer when extracted by SDS, We performed an analysis of GlpF solubilized from membranes of Escherichia coli or of mRNA-injected Xenopus oocytes, The GlpF protein extracted either by SDS or by nondenaturing detergents, OG and Triton X-100, exhibits sedimentation coefficients only compatible with a monomeric form of the protein in micelles, We then substituted in loop E of AQPcic two amino acids predicted to play a role in the functional/structural properties of the MIPs, In two expression systems, yeast and oocytes, the mutant AQPcic-S205D is monomeric in OG and in SDS, The A209K mutation does not modify the tetrameric form of the heterologous protein in OG, This study shows that the serine residue at position 205 is essential for AQPcic tetramerization, Because the serine in this position is highly conserved among aquaporins and systematically replaced by an acid aspartic in GlpFs, we postulate that glycerol facilitators are monomers whereas aquaporins are organized in tetramers, Our data suggest that the role of loop E in MIP properties partly occurs through its ability to allow oligomerization of the proteins.	Univ Rennes 1, CNRS, UPRESA 6026, F-35042 Rennes, Bretagne, France	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Hubert, JF (corresponding author), Univ Rennes 1, CNRS, UPRESA 6026, Campus Beaulieu,Batiment 13, F-35042 Rennes, Bretagne, France.	jfhubert@univ-rennes1.fr	DELAMARCHE, Christian/A-2138-2010; THOMAS, Danniel/AAJ-5033-2020	DELAMARCHE, Christian/0000-0002-8963-0062; THOMAS, Danniel/0000-0002-9650-0434				AERTS T, 1990, J BIOL CHEM, V265, P8675; Bai LQ, 1996, J BIOL CHEM, V271, P5171; BEURON F, 1995, J BIOL CHEM, V270, P17414, DOI 10.1074/jbc.270.29.17414; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; Heymann JB, 1998, J STRUCT BIOL, V121, P191, DOI 10.1006/jsbi.1997.3951; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Konig N, 1997, J MOL BIOL, V265, P590, DOI 10.1006/jmbi.1996.0763; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagree V, 1998, J BIOL CHEM, V273, P12422, DOI 10.1074/jbc.273.20.12422; LeCaherec F, 1996, EUR J BIOCHEM, V241, P707, DOI 10.1111/j.1432-1033.1996.00707.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mulders SM, 1997, AM J PHYSIOL-RENAL, V273, pF451, DOI 10.1152/ajprenal.1997.273.3.F451; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; MURAMATSU S, 1989, NUCLEIC ACIDS RES, V17, P4378; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PRESTON GM, 1993, J BIOL CHEM, V268, P17; RINGLER P, 1998, BIOL CELL, V90, P33; Schulte DJ, 1997, COMP BIOCHEM PHYS B, V118, P35, DOI 10.1016/S0305-0491(97)00015-1; SHI LB, 1994, J BIOL CHEM, V269, P10417; SMITH BL, 1991, J BIOL CHEM, V266, P6407; SWEET G, 1990, J BACTERIOL, V175, P1087; VANHOEK AN, 1991, J BIOL CHEM, V266, P16633; Verbavatz JM, 1997, J CELL SCI, V110, P2855; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; WALZ T, 1994, J BIOL CHEM, V269, P1583; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; ZHANG RB, 1993, BIOCHEMISTRY-US, V32, P2938, DOI 10.1021/bi00063a002	30	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33949	33953		10.1074/jbc.273.51.33949	http://dx.doi.org/10.1074/jbc.273.51.33949			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852047	hybrid			2022-12-25	WOS:000077542200013
J	Malencik, DA; Anderson, SR				Malencik, DA; Anderson, SR			Binding of 9-anthroylcholine monitors the interactions of adenosine cyclic 3 ',5 '-phosphate-dependent protein kinase with MgATP, substrates, and regulatory subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; AMINO-ACID-SEQUENCE; CATALYTIC SUBUNIT; PHOSPHORYLASE-KINASE; BOVINE HEART; GLYCOGEN-PHOSPHORYLASE; RABBIT SKELETAL; TURKEY GIZZARD; MUSCLE; CALMODULIN	The isolated catalytic subunit of cAMP-dependent protein kinase and smooth muscle myosin light chain kinase undergo interactions with the fluorescent dye 9-anthroylcholine (9AC) that are responsive to the two enzymes' associations with substrates and effectors. Additionally, the binding of 9AC is highly sensitive to subtle structural or functional differences among closely related protein kinases, Skeletal muscle myosin light chain kinase and the catalytically active chymotryptic fragment of the gamma-subunit of phosphorylase kinase do not associate with 9AC, The 1:1 Fluorescent complex of the isolated catalytic subunit of cAMP-dependent protein kinase with 9AC exhibits a dissociation constant of 21 mu M. The association of the catalytic subunit with either of the regulatory subunits, R-I and R-II, results in decreases in the observed 9AC fluorescence that are reversed upon the addition of cAMP. The effects of MgATP and of polypeptide substrates (Kemptide, troponin I, protamine) on the 9AC-catalytic subunit complex are consistent with a general noncompetitive model in which the interactions of 9AC and the other ligands with the enzyme are mutually antagonistic but not purely competitive.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Anderson, SR (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.	malencid@ucs.orst.edu			NIDDK NIH HHS [DK13912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ANDERSON SR, 1971, BIOCHEMISTRY-US, V10, P4162, DOI 10.1021/bi00799a002; AUSIO J, 1992, BIOPHYS J, V61, P1656, DOI 10.1016/S0006-3495(92)81969-0; Beavo J A, 1975, Adv Cyclic Nucleotide Res, V5, P241; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BOHNERT JL, 1982, BIOCHEMISTRY-US, V21, P5570, DOI 10.1021/bi00265a029; BUILDER SE, 1980, J BIOL CHEM, V255, P2350; Carlson G M, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P41; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; CORBIN JD, 1981, J BIOL CHEM, V256, P1671; Dills W L, 1979, Adv Cyclic Nucleotide Res, V10, P199; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FISCHER EH, 1955, J BIOL CHEM, V216, P121; GIULIANO KA, 1995, ANNU REV BIOPH BIOM, V24, P405, DOI 10.1146/annurev.biophys.24.1.405; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARRIS WR, 1990, J BIOL CHEM, V265, P11740; HARTSHORNE DJ, 1981, ANNU REV PHYSIOL, V43, P519, DOI 10.1146/annurev.ph.43.030181.002511; Haughland R.P., 1996, HDB FLUORESCENT PROB; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; HOPPE J, 1979, TRENDS BIOCHEM SCI, V4, P282, DOI 10.1016/0968-0004(79)90302-5; ITO M, 1989, J BIOL CHEM, V264, P13971; KERRICK WGL, 1980, PFLUG ARCH EUR J PHY, V386, P207, DOI 10.1007/BF00587470; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Krebs E G, 1968, Adv Enzyme Regul, V6, P245, DOI 10.1016/0065-2571(68)90016-2; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KREBS EG, 1956, BIOCHIM BIOPHYS ACTA, V20, P150, DOI 10.1016/0006-3002(56)90273-6; LAPORTE DC, 1980, J BIOL CHEM, V255, P2343; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; Lew J, 1997, J BIOL CHEM, V272, P1507, DOI 10.1074/jbc.272.3.1507; LU FJ, 1973, BIOCHEMISTRY-US, V12, P3479, DOI 10.1021/bi00742a019; MADSEN NB, 1983, BIOCHEMISTRY-US, V22, P4460, DOI 10.1021/bi00288a017; MALENCIK DA, 1991, BIOCHEM BIOPH RES CO, V174, P344, DOI 10.1016/0006-291X(91)90526-D; MALENCIK DA, 1983, ANAL BIOCHEM, V132, P34, DOI 10.1016/0003-2697(83)90422-0; MALENCIK DA, 1982, BIOCHEMISTRY-US, V21, P4031, DOI 10.1021/bi00260a019; MALENCIK DA, 1986, BIOCHEMISTRY-US, V25, P709, DOI 10.1021/bi00351a031; MALENCIK DA, 1993, MOL CELL BIOCHEM, V128, P31, DOI 10.1007/BF01076755; MCCLURE WO, 1967, BIOCHEMISTRY-US, V6, P559, DOI 10.1021/bi00854a025; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; ORR JW, 1994, J BIOL CHEM, V269, P8383; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PETERS KA, 1977, BIOCHEMISTRY-US, V16, P5691, DOI 10.1021/bi00645a007; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; Schachman H. K., 1992, ANAL ULTRACENTRIFUGA; SCHACHMAN HK, 1963, BIOCHEMISTRY-US, V2, P887, DOI 10.1021/bi00905a001; SCHREIBER WE, 1981, BIOCHEMISTRY-US, V20, P5239, DOI 10.1021/bi00521a022; SEERY VL, 1972, BIOCHEMISTRY-US, V11, P707, DOI 10.1021/bi00755a006; SOBIESZEK A, 1991, EUR J BIOCHEM, V199, P735, DOI 10.1111/j.1432-1033.1991.tb16178.x; SOBIESZEK A, 1985, SMOOTH MUSCLE CONTRA, P283; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TAKIO K, 1982, P NATL ACAD SCI-BIOL, V79, P2544, DOI 10.1073/pnas.79.8.2544; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; [No title captured]	64	0	0	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34049	34056		10.1074/jbc.273.51.34049	http://dx.doi.org/10.1074/jbc.273.51.34049			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852061	hybrid			2022-12-25	WOS:000077542200027
J	Perez-Vilar, J; Hill, RL				Perez-Vilar, J; Hill, RL			Identification of the half-cystine residues in porcine submaxillary mucin critical for multimerization through the D-domains - Roles of the CGLCG motif in the D1- and D3-domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; RAT SMALL-INTESTINE; VONWILLEBRAND-FACTOR; MOLECULAR-CLONING; XENOPUS-LAEVIS; SUBCELLULAR-LOCALIZATION; CDNA; CONTAINS; REGION; RICH	Plasmids encoding the amino-terminal region of porcine submaxillary mucin were modified by site-specific mutagenesis to assess the roles of individual half-cystine residues in the assembly of disulfide-linked multimers of mucin, COS-7 cells with the plasmid containing C1199A expressed primarily monomers, suggesting that half-cystine 1199 in the D3-domain is involved in forming mucin multimers, This residue is in the sequence C(1199)SWRYEPCG, which is highly conserved in the D3-domain of other secreted mucins and human prepro-von Willebrand factor. In contrast, cells with the plasmid containing C1276A expressed trimers like those: with unmutated plasmid, suggesting that half-cystine 1276 is not involved in formation of disulfide-bonded multimers, The roles of the half-cystines in the CGLCG motifs in the assembly of disulfide-bonded multimers of mucin were also assessed. Cells with plasmidis in which both half-cystines in the motif in the D1- or D3-domain of mucin are replaced by alanine expressed proteins that were poorly secreted, suggesting that these mutations impair normal folding of the expressed proteins, A plasmid with a mutant D1-domain motif expressed monomers, whereas one with a mutant D3-domain motif expressed monomers and trimers, However, the trimers expressed by the latter plasmid were assembled in nonacidic compartments, as judged by expression studies in the presence of monensin, which inhibits trimer formation by unmutated plasmid, but not by the mutant plasmid. These results suggest that the CGLCG motif in the HI-domain is required for multimerization in the trans-Golgi complex. However, the CGLCG motif in the D3-domain appears to prevent formation of mucin multimers in non-acidic compartments of the-cell, Plasmids encoding the D1- and D2-domains, the D1- and D3-domains, or only the D3-domain also expressed oligomers in the presence of monensin, suggesting that the three D-domains must be contiguous to avoid multimerization in non-acidic compartments. It is possible that these motifs in mucins are engaged in the thiol-disulfide interchange reactions during the assembly of disulfide-bonded multimers of mucin.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hill, RL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	hill@biochem.duke.edu			PHS HHS [25766] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; AZUMA H, 1993, J BIOL CHEM, V268, P2821; Bell SL, 1998, EUR J BIOCHEM, V253, P123, DOI 10.1046/j.1432-1327.1998.2530123.x; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DESCHUYTENEER M, 1988, J BIOL CHEM, V263, P2452; DONG ZG, 1994, J BIOL CHEM, V269, P6753; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; Gao Z, 1998, J BIOL CHEM, V273, P3415, DOI 10.1074/jbc.273.6.3415; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUM JR, 1992, J BIOL CHEM, V267, P6480; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; Joba W, 1997, J BIOL CHEM, V272, P1805, DOI 10.1074/jbc.272.3.1805; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; Legan PK, 1997, J BIOL CHEM, V272, P8791, DOI 10.1074/jbc.272.13.8791; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; OHMORI H, 1994, J BIOL CHEM, V269, P17833; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; PROBST JC, 1992, J BIOL CHEM, V267, P6310; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SADLER JE, 1991, J BIOL CHEM, V266, P22777; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; van Klinken BJW, 1998, GLYCOBIOLOGY, V8, P67, DOI 10.1093/glycob/8.1.67; XU GQ, 1992, J BIOL CHEM, V267, P5401	41	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34527	34534		10.1074/jbc.273.51.34527	http://dx.doi.org/10.1074/jbc.273.51.34527			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852122	hybrid			2022-12-25	WOS:000077542200088
J	Sanchis, D; Fleury, C; Chomiki, N; Goubern, M; Huang, QL; Neverova, M; Gregoire, F; Easlick, J; Raimbault, S; Levi-Meyrueis, C; Miroux, B; Collins, S; Seldin, M; Richard, D; Warden, C; Bouillaud, F; Ricquier, D				Sanchis, D; Fleury, C; Chomiki, N; Goubern, M; Huang, QL; Neverova, M; Gregoire, F; Easlick, J; Raimbault, S; Levi-Meyrueis, C; Miroux, B; Collins, S; Seldin, M; Richard, D; Warden, C; Bouillaud, F; Ricquier, D			BMCP1, a novel mitochondrial carrier with high expression in the central nervous system of humans and rodents, and respiration uncoupling activity in recombinant yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PROTEIN HOMOLOG; THERMOGENESIS; MEDIATOR; TISSUE	We report here the cloning and functional analysis of a novel homologue of the mitochondrial carriers predominantly expressed in the central nervous system and referred to as BMCP1 ((b) under bar rain (m) under bar itochondrial (c) under bar arrier (p) under bar rotein-(1) under bar). The predicted amino acid sequence of this novel mitochondrial carrier indicates a level of identity of 39, 31, or 30%, toward the mitochondrial oxoglutarate carrier, phosphate carrier, or adenine nucleotide translocator, respectively, and a level of identity of 34, 38, or 39% with the mitochondrial uncoupling proteins UCP1, UCP2, or UCP3, respectively. Northern analysis of mouse, rat, or human tissues demonstrated that mRNA of this novel gene is mainly expressed in brain, although it is 10-30-fold less expressed in other tissues. In situ hybridization analysis of brain showed it is particularly abundant in cortex, hippocampus, thalamus, amygdala, and hypothalamus. Chromosomal mapping indicates that BMCP1 is located on chromosome X off mice and at Xq24 in man. Expression of the protein in yeast strongly impaired growth rate. Analysis of respiration of total recombinant yeast or yeast spheroplasts and in particular of the relationship between respiratory rate and membrane potential of yeast spheroplasts revealed a marked uncoupling activity of respiration, suggesting that although BMCP1 sequence is more distant from the uncoupling proteins (UCPs), this protein could be a fourth member of the UCP family.	CNRS, Ctr Rech Endocrinol Mol & Dev, F-92190 Meudon, France; Univ Calif Davis, Rowe Genet & Pediat, Davis, CA 95616 USA; INRA, Ecole Prat Hautes Etud, F-78352 Jouy En Josas, France; Univ Laval, Fac Med, Dept Physiol, Quebec City, PQ G1K 7P4, Canada; Duke Univ, Med Ctr, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Davis; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Laval University; Duke University	Ricquier, D (corresponding author), CNRS, Ctr Rech Endocrinol Mol & Dev, 9 Rue Jules Hetzel, F-92190 Meudon, France.		Sanchis, Daniel/B-5644-2009; Bouillaud, Frédéric R/L-3238-2017; Miroux, Bruno/E-9267-2017; Sanchis, Daniel/C-8077-2009	Bouillaud, Frédéric R/0000-0002-7518-9237; Sanchis, Daniel/0000-0003-0047-8533; Miroux, Bruno/0000-0002-3066-4700	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054021, R01DK052581] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK54021, R01 DK 53883, R01 DK52581] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARECHAGA I, 1993, BIOCHEM J, V296, P693, DOI 10.1042/bj2960693; Averet N, 1998, MOL CELL BIOCHEM, V184, P67, DOI 10.1023/A:1006830810440; Beauseigneur F, 1996, BIOCHEM J, V320, P571, DOI 10.1042/bj3200571; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; BRAND MD, 1994, BBA-BIOENERGETICS, V1187, P132, DOI 10.1016/0005-2728(94)90099-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; NICHOLLS DG, 1974, EUR J BIOCHEM, V50, P305, DOI 10.1111/j.1432-1033.1974.tb03899.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Richard D, 1998, J COMP NEUROL, V397, P549; RICQUIER D, 1991, FASEB J, V5, P2237, DOI 10.1096/fasebj.5.9.1860614; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; ROLFE FS, 1994, BIOCHIM BIOPHYS ACTA, V1118, P405; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740	20	263	274	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34611	34615		10.1074/jbc.273.51.34611	http://dx.doi.org/10.1074/jbc.273.51.34611			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852133	hybrid, Green Published			2022-12-25	WOS:000077542200099
J	Breuer, P; Braulke, T				Breuer, P; Braulke, T			Stabilization of mutant 46-kDa mannose 6-phosphate receptors by proteasomal inhibitor lactacystin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CYTOPLASMIC TAIL; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; LIGAND INTERACTIONS; LYSOSOMAL PROTEINS; MEMBRANE-PROTEIN; CELL-SURFACE; DEGRADATION; PHOSPHORYLATION; BINDING	Palmitoylation of cysteine residue 34 within the 67-amino acid cytoplasmic domain of the 46-kDa mannose g-phosphate receptor (MPR 46), which may be anchored to the lipid bilayer, prevents the receptor from entering lysosomes (Schweizer, A., Kornfeld, S., and Rohrer, J, (1996) J, Cell Biol. 132, 577-584). In the present study, we examined the importance of the spacing between the transmembrane domain and the palmitoylation anchor site in the cytoplasmic domain for stability and trafficking of MPR 46. MPR 46 mutants with deletions of residues 20-23 and 24-29 expressed in baby hamster kidney cells were rapidly degraded with half-lives of less than 10 h. The replacement of residues 24-29 by alanine resulted in prolongation of receptor stability (t(1/2) approximate to 20 h). Whereas mutant MPR 46 could not be detected in lysosomal fractions and inhibitors of lysosomal proteases failed to prevent degradation, treatment with the proteasome inhibitor lactacystin resulted in increased stability of mutant MPR 46. Pulse-chase experiments at low temperature and the acquirement of endoglucosaminidase H-resistant oligosaccharides indicate that the majority of mutant MPR 46 is degraded after leaving the Golgi compartment. Altered trafficking of mutant MPR 46 may be the result of decreased palmitoylation reaching 40% of wild type receptors. The data suggest that the spacing between the transmembrane domain and the proposed palmitoylation anchor site in the cytoplasmic domain of MPR 46 is important for a post Golgi sorting step preventing receptor degradation by multiple proteolytic systems including the proteasome.	Univ Gottingen, Inst Biochem 2, D-37073 Gottingen, Germany	University of Gottingen	Braulke, T (corresponding author), Univ Gottingen, Inst Biochem 2, Gosslerstr 12D, D-37073 Gottingen, Germany.	braulke@ukb2-00.uni-bc.gwdg.de	Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braulke T, 1996, Subcell Biochem, V27, P15; BRAULKE T, 1988, BIOL CHEM H-S, V369, P441, DOI 10.1515/bchm3.1988.369.1.441; BRAUN M, 1989, EMBO J, V8, P3633, DOI 10.1002/j.1460-2075.1989.tb08537.x; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAMKE H, 1992, BIOCHEM J, V281, P225, DOI 10.1042/bj2810225; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GRIFFITHS G, 1990, J CELL SCI, V95, P441; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HEMER F, 1993, J BIOL CHEM, V268, P17108; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KIESS W, 1988, J BIOL CHEM, V263, P9339; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; KORNER C, 1994, J BIOL CHEM, V269, P16529; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MATZNER U, 1992, DEVELOPMENT, V114, P965; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; SAHAGIAN GG, 1984, BIOL CELL, V51, P207, DOI 10.1111/j.1768-322X.1984.tb00300.x; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Sleat DE, 1997, J BIOL CHEM, V272, P731, DOI 10.1074/jbc.272.2.731; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	41	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33254	33258		10.1074/jbc.273.50.33254	http://dx.doi.org/10.1074/jbc.273.50.33254			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837896	hybrid			2022-12-25	WOS:000077462500026
J	Chen, LH; Johnson, RC; Milgram, SL				Chen, LH; Johnson, RC; Milgram, SL			P-CIP1, a novel protein that interacts with the cytosolic domain of peptidylglycine alpha-amidating monooxygenase, is associated with endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-PROCESSING ENZYME; IMMATURE SECRETORY GRANULES; TRANS-GOLGI NETWORK; CARRIER MEMBRANE-PROTEINS; PREDICTING COILED COILS; PANCREATIC BETA-CELLS; ROUTING DETERMINANTS; RAB PROTEINS; ATT-20 CELLS; BREFELDIN-A	The cytosolic domain of the peptide processing enzyme peptidylglycine cu-amidating monooxygenase (PAM) contains signals that direct its trafficking in the secretory and endosomal pathways. Using the yeast two-hybrid system, Alam et al. (Alam, M. R., Caldwell, B. D., Johnson, R. C., Darlington, D. N., Mains, R. E., and Eipper, B. A. (1996) J. Biol. Chem. 271, 28636) identified three proteins that interact with a fragment of the PAM. cytosolic domain containing these targeting signals. We cloned the rat and human cDNAs encoding PAM COOH-terminal interactor protein-1 (P-CIP1), Both cDNAs contain an open reading frame that encodes a novel protein of 435 amino acids. The P-CIP1 protein is highly conserved from rat to human (85% identity) but does not display significant homology to proteins in the GenBank data base. In vitro, P-CIP1 interacts with the cytosolic domain of wild type PAM-1, but does not interact with mutant PAM-1 proteins that fail to target correctly when expressed in endocrine cells. P-CIP1 contains multiple consensus serine/threonine phosphorylation sites and a region predicted to form a coiled-coil at the COOH terminus. When expressed in endocrine cells or fibroblasts, P-CIP1 is distributed in a punctate pattern in the perinuclear area but does not significantly overlap the distribution of transfected wild type PAM-1, The distribution of P-CIP1 displays significant overlap with the distribution of the Secretory carrier membrane proteins, internalized Texas Red-conjugated transferrin, and Rab11. The data suggest that P-CIP1 associates with vesicles in the recycling endosomal pathway, and may play a role in regulating the trafficking of integral membrane PAM.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21205 USA	University of North Carolina; University of North Carolina Chapel Hill; Johns Hopkins University	Milgram, SL (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, CB 7545, Chapel Hill, NC 27599 USA.	milg@med.unc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032948, R56DK032948, R37DK032948, R29DK050744] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32948, R29DK50744] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Alam MR, 1996, J BIOL CHEM, V271, P28636, DOI 10.1074/jbc.271.45.28636; ANAND PK, 1992, OBES SURG, V2, P327, DOI 10.1381/096089292765559918; ARVAN P, 1991, J BIOL CHEM, V266, P14171; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; BRAND SH, 1991, J BIOL CHEM, V266, P18949; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; Calhoun BC, 1996, YALE J BIOL MED, V69, P1; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DUNN KW, 1992, J CELL BIOL, V117, P301, DOI 10.1083/jcb.117.2.301; EIPPER BA, 1993, ANN NY ACAD SCI, V680, P147, DOI 10.1111/j.1749-6632.1993.tb19681.x; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HAN KK, 1993, INT J BIOCHEM, V25, P957, DOI 10.1016/0020-711X(93)90108-Q; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KOEDAM JA, 1992, J CELL BIOL, V116, P617, DOI 10.1083/jcb.116.3.617; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Kuliawat R, 1997, J CELL BIOL, V137, P595, DOI 10.1083/jcb.137.3.595; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LADINSKY MS, 1992, EUR J CELL BIOL, V59, P92; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SHIELDS D, 1991, PEPTIDE BIOSYNTHESIS, P37; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; Singleton DR, 1997, J CELL SCI, V110, P2099; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; YUN HY, 1995, J BIOL CHEM, V270, P30075	49	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33524	33532		10.1074/jbc.273.50.33524	http://dx.doi.org/10.1074/jbc.273.50.33524			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837933	hybrid			2022-12-25	WOS:000077462500063
J	Iwabuchi, K; Handa, K; Hakomori, S				Iwabuchi, K; Handa, K; Hakomori, S			Separation of "glycosphingolipid signaling domain" from caveolin-containing membrane fraction in mouse melanoma B16 cells and its role in cell adhesion coupled with signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; PHOSPHATIDYLCHOLINE BILAYERS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; GANGLIOSIDE GM1; PROTEIN; SURFACE; KINASE; SRC; LOCALIZATION	Two membrane subfractions, one enriched in GM3 ganglioside and the other containing caveolin, were separated from low density detergent-insoluble membrane fraction prepared by sucrose density gradient centrifugation of postnuclear fraction of mouse melanoma B16 cells. The GM3-enriched subfraction, separated by anti-GM3 monoclonal antibody DH2, contained sphingomyelin, cholesterol, c-Src, and Rho A but not caveolin. In contrast, the caveolin-containing subfraction, separated by anti-caveolin antibody, contained neither GM3, c-Src, nor Rho A but did contain glucosylceramide, has, a very small quantity of sphingomyelin, and a very large quantity of cholesterol. The GM3/c-Src-enriched membrane subfraction was characterized by (i) maintenance of GM3-dependent adhesion and (ii) susceptibility to being activated for signal transduction through GM3. P-32-phosphorylation of c-Src (M-r 60,000) together with two other components (M-r 45,000 and 29,000) was enhanced in the fraction bound to dishes coated with asialo-GM2 (Gg3) or with anti-GM3 monoclonal antibody DH2, detected by incubation with [gamma-P-32]ATP 37 degrees C for 5 min. GM3-dependent adhesion of B16 cells to Gg3-coated dishes and associated signaling were not reduced or abolished in the presence of either filipin or nystatin, which are cholesterol-binding reagents known to abolish caveolae structure and function. B16 melanoma cells incubated with filipin (0.16-0.3 mu g/ml) or with nystatin (25 mu g/ml) for 30 min showed depletion of cholesterol in detergent-insoluble membrane fraction but were still capable of binding to Gg3-coated plate and capable of the associated signaling. Thus, the GM3-enriched subfraction, involved in cell adhesion and capable of sending signals through GM3, represents a membrane domain distinguishable from caveolin-containing subfraction or caveolae. This microdomain is hereby termed the "glycosphingolipid signaling domain" or "glycosignaling domain".	Pacific NW Res Inst, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Hakomori, S (corresponding author), Pacific NW Res Inst, 720 Broadway, Seattle, WA 98122 USA.	hakomori@u.washington.edu			NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE K, 1983, J BIOL CHEM, V258, P1793; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; DOHI T, 1988, CANCER RES, V48, P5680; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GAMBLE W, 1978, J LIPID RES, V19, P1068; HAKOMORI S, 1993, BIOCHEM SOC T, V21, P583, DOI 10.1042/bst0210583; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; KANFER JN, 1983, HDB LIPID RES SPHING, P437; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KLENK E, 1960, Z VERDAUUNGS STOFFWE, V20, P180; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; NORES GA, 1987, J IMMUNOL, V139, P3171; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; OTSUJI E, 1995, INT J ONCOL, V6, P319; PALADE GE, 1953, J APPL PHYS, V24, P1424; RAHMANN H, 1994, PROG BRAIN RES, V101, P127; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; ROCK P, 1991, BIOCHEMISTRY-US, V30, P19, DOI 10.1021/bi00215a003; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SEYAMA Y, 1974, J BIOCHEM-TOKYO, V75, P837, DOI 10.1093/oxfordjournals.jbchem.a130455; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song Y, 1998, J BIOL CHEM, V273, P2517, DOI 10.1074/jbc.273.5.2517; Sorice M, 1997, J LIPID RES, V38, P969; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; SWAIM WD, 1994, J BIOL CHEM, V269, P19466; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; Yates AJ, 1998, ANN NY ACAD SCI, V845, P57, DOI 10.1111/j.1749-6632.1998.tb09662.x; YOKOYAMA K, 1995, FEBS LETT, V368, P477, DOI 10.1016/0014-5793(95)00714-K; YOUNG WW, 1979, J EXP MED, V150, P1008, DOI 10.1084/jem.150.4.1008	52	268	273	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33766	33773		10.1074/jbc.273.50.33766	http://dx.doi.org/10.1074/jbc.273.50.33766			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837965	hybrid			2022-12-25	WOS:000077462500095
J	Filipsson, K; Karlsson, S; Ahren, B				Filipsson, K; Karlsson, S; Ahren, B			Evidence for contribution by increased cytoplasmic Na+ to the insulinotropic action of PACAP38 in HIT-T15 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; PANCREATIC B-CELLS; ADENYLATE-CYCLASE; STIMULATES INSULIN; BETA-CELLS; GLUCAGON-SECRETION; INTRACELLULAR PH; SODIUM-CHANNELS; CALCIUM INFLUX; CYCLIC-AMP	Pituitary adenylate cyclase-activating polypeptide (PACAP) is localized to pancreatic nerve terminals and stimulates insulin secretion. The insulinotropic effect of PACAP38 in insulin-producing HIT-T15 cells is accompanied by increases in cellular cAMP and cytoplasmic Ca2+ ([Ca2+](cyt)). As also intracellular Na+ is important for insulin secretion after glucose and other cAMP forming peptides, we examined the Na+ dependence of the insulinotropic effect of PACAP38 in HIT-T15 cells. We found that PACAP38 (100 nM)-induced insulin secretion was diminished by approximately 50% by removal of extracellular Na+ (replaced by equimolar N-methyl-D-glucamine). In contrast, removal of Na+ did not diminish the formation of cellular cAMP (measured by radioimmunoassay) or the increase in [Ca2+](cyt) (measured in FURA-2AM-loaded cell suspensions) induced by PACAP38. Furthermore, PACAP-38 increased the cytoplasmic Na+ ([Na+](cyt)) in single HIT-T15 cells as measured by the fluorophore sodium-binding benzofran isophthalate. This increase was reduced by removal of extracellular Na+ and by inhibition of protein kinase A by H-89. We conclude that the insulinotropic action of PACAP38 is Na+-dependent. We propose that PACAP38 opens plasma membrane Na+ channels by an action partially mediated by cAMP and protein kinase A, and the subsequent raise in [Na+](cyt) elicits insulin secretion by an as yet unsolved mechanism.	Lund Univ, Dept Med, S-20502 Malmo, Sweden	Lund University	Filipsson, K (corresponding author), Malmo Univ Hosp, Dept Med, Wallenberg Lab, 2nd Floor, S-20502 Malmo, Sweden.	karin.filipsson@medforsk.mas.lu.se						AfKlinteberg K, 1996, ENDOCRINOLOGY, V137, P2791, DOI 10.1210/en.137.7.2791; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; BERGGREN PO, 1994, BIOCHEM SOC T, V22, P12, DOI 10.1042/bst0220012; Bertrand G, 1996, BRIT J PHARMACOL, V117, P764, DOI 10.1111/j.1476-5381.1996.tb15256.x; BIDEN TJ, 1986, AM J PHYSIOL, V250, pC207, DOI 10.1152/ajpcell.1986.250.2.C207; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; DAVIES J, 1994, BIOCHEM J, V304, P295, DOI 10.1042/bj3040295; DONATSCH P, 1977, J PHYSIOL-LONDON, V267, P357, DOI 10.1113/jphysiol.1977.sp011817; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; Filipsson K, 1998, REGUL PEPTIDES, V74, P167, DOI 10.1016/S0167-0115(98)00037-8; Filipsson K, 1998, AM J PHYSIOL-ENDOC M, V274, pE834, DOI 10.1152/ajpendo.1998.274.5.E834; Filipsson K, 1997, J CLIN ENDOCR METAB, V82, P3093, DOI 10.1210/jc.82.9.3093; FRIDOLF T, 1992, CELL TISSUE RES, V269, P275, DOI 10.1007/BF00319618; FRIDOLF T, 1991, BIOCHEM BIOPH RES CO, V179, P701, DOI 10.1016/0006-291X(91)91429-G; GILON P, 1993, FEBS LETT, V315, P353, DOI 10.1016/0014-5793(93)81193-4; Grapengiesser E, 1996, BIOCHEM BIOPH RES CO, V226, P830, DOI 10.1006/bbrc.1996.1436; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELLMAN B, 1975, J PHYSIOL-LONDON, V252, P701, DOI 10.1113/jphysiol.1975.sp011166; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; Hidaka H, 1994, ESSAYS BIOCHEM, V28, P73; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; KALLEN RG, 1993, MOL NEUROBIOL, V7, P383, DOI 10.1007/BF02769184; KAWAI K, 1992, LIFE SCI, V50, P257, DOI 10.1016/0024-3205(92)90332-J; Klinteberg KAF, 1996, ANN NY ACAD SCI, V805, P543; Koshimura K, 1997, PEPTIDES, V18, P877, DOI 10.1016/S0196-9781(97)00019-3; LEECH CA, 1995, ENDOCRINOLOGY, V136, P1530, DOI 10.1210/en.136.4.1530; LINDSTROM P, 1986, BIOCHEM J, V239, P199, DOI 10.1042/bj2390199; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Miura Y, 1996, BIOCHEM BIOPH RES CO, V224, P67, DOI 10.1006/bbrc.1996.0985; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; REALE V, 1995, J MEMBRANE BIOL, V145, P267; Sharp GWG, 1996, AM J PHYSIOL-CELL PH, V271, pC1781, DOI 10.1152/ajpcell.1996.271.6.C1781; Straub SG, 1996, J BIOL CHEM, V271, P1660, DOI 10.1074/jbc.271.3.1660; TREBILCOCK R, 1990, MOL CELL ENDOCRINOL, V71, P21, DOI 10.1016/0303-7207(90)90070-O; WATSON EL, 1989, BIOCHEM PHARMACOL, V38, P1069, DOI 10.1016/0006-2952(89)90250-5; YADA T, 1994, J BIOL CHEM, V269, P1290; Yoshihashi K, 1996, JPN J PHYSIOL, V46, P473, DOI 10.2170/jjphysiol.46.473; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	40	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32602	32607		10.1074/jbc.273.49.32602	http://dx.doi.org/10.1074/jbc.273.49.32602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829998	hybrid			2022-12-25	WOS:000077329100037
J	Kwok, Y; Hurley, LH				Kwok, Y; Hurley, LH			Topoisomerase II site-directed alkylation of DNA by psorospermin and its effect on topoisomerase II-mediated DNA cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAKAGE-REUNION REACTION; ANTITUMOR DRUGS; SEQUENCE SELECTIVITY; ABASIC SITES; COMPLEX; POISONS; MECHANISM; XANTHONE; BINDING; LESIONS	Psorospermin, a plant-derived antitumor agent, has been shown to selectively alkylate a guanine at the topoisomerase II cleavage site to trap the topoisomerase II-DNA cleaved complex. The results of this study provide further important insight into the mechanism of the topoisomerase II site-directed alkylation of DNA by psorospermin and its subsequent effects on the topoisomerase II-induced DNA cleavage. First, we demonstrate that the topoisomerase II-induced alkylation of DNA by psorospermin occurs at a time preceding the topoisomerase II-mediated strand cleavage event, because it occurs in the absence of Mg2+. We confirm that the alkylation of DNA by psorospermin takes place at N-7 of guanine in the presence of topoisomerase II, because substitution of the target guanine by 7-deazaguanine prevents alkylation. Because the stimulation of the topoisomerase II-induced DNA cleavage by psorospermin can be slowly reversed by the addition of excess salt, this indicates that alkylation of DNA by psorospermin traps a reversible topoisomerase II-DNA complex, Both the DNA alkylation by psorospermin in the presence of topoisomerase II and the enzyme-mediated DNA cleavage elevated by psorospermin are more enhanced at acidic pH values, in accordance with the increased stability of the topoisomerase ZI-DNA complex at acidic pH values. Finally, our results suggest that it is the psorospermin-DNA adducts, not the abasic sites resulting from depurination, that are responsible for the stimulation of the topoisomerase II-mediated cleavage. Because the precise location of the psorospermin within the topoisomerase II cleavage site is known, together with the covalent DNA linkage chemistry and the conformation of the psorospermin-DNA adduct, this structural insight provides an excellent opportunity for the design and synthesis of new, more effective topoisomerase II poisons.	Univ Texas, Coll Pharm, Drug Dynam Inst, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Hurley, LH (corresponding author), Univ Texas, Coll Pharm, Drug Dynam Inst, Austin, TX 78712 USA.							Binaschi M, 1997, CANCER RES, V57, P1710; CASSADY JM, 1990, J NAT PROD, V53, P23, DOI 10.1021/np50067a003; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Critchlow SE, 1996, BIOCHEMISTRY-US, V35, P7387, DOI 10.1021/bi9603175; FAN JY, 1995, J MED CHEM, V38, P408, DOI 10.1021/jm00003a003; Hansen M, 1996, J AM CHEM SOC, V118, P5553; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P1148, DOI 10.1074/jbc.272.2.1148; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; KONG XB, 1992, MOL PHARMACOL, V41, P237; KUPCHAN SM, 1980, J NAT PROD, V43, P296, DOI 10.1021/np50008a010; LEE MP, 1989, J BIOL CHEM, V264, P21779; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Marians KJ, 1997, J BIOL CHEM, V272, P9401; Marx G, 1997, BIOCHEMISTRY-US, V36, P15884, DOI 10.1021/bi971858c; Osheroff N, 1994, Adv Pharmacol, V29B, P105; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P6402, DOI 10.1021/bi00394a015; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PERMANA PA, 1994, CANCER RES, V54, P3191; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pommier Yves, 1997, P153; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROBINSON MJ, 1991, J BIOL CHEM, V266, P14585; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WARPEHOSKI MA, 1988, CHEM RES TOXICOL, V1, P315, DOI 10.1021/tx00006a001; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681	31	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33020	33026		10.1074/jbc.273.49.33020	http://dx.doi.org/10.1074/jbc.273.49.33020			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830055	hybrid			2022-12-25	WOS:000077329100094
J	Lubkowski, J; Yang, F; Alexandratos, J; Merkel, G; Katz, RA; Gravuer, K; Skalka, AM; Wlodawer, A				Lubkowski, J; Yang, F; Alexandratos, J; Merkel, G; Katz, RA; Gravuer, K; Skalka, AM; Wlodawer, A			Structural basis for inactivating mutations and pH-dependent activity of avian sarcoma virus integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRAL INTEGRATION; CATALYTIC DOMAIN; DIVALENT-CATIONS; RESIDUES; SITE	Crystallographic studies of the catalytic core domain of avian sarcoma virus integrase (ASV IN) have provided the most detailed picture so far of the active site of this enzyme, which belongs to an important class of targets for designing drugs against AIDS. Recently, cryst als of an inactive D64N mutant were obtained under conditions identical to those used for the native enzyme. Data were collected at different pH values and in the presence of divalent cations, Data were also collected at low pH for the crystals of the native ASV IN core domain. In the structures of native ASV IN at pH 6.0 and below, as well as in all structures of the D64N mutants, the side chain of the active site residue Asx-64 (Asx denotes Asn or Asp) is rotated by similar to 150 degrees around the C alpha-C beta bond, compared with the structures at higher pH. In the new structures, this residue makes hydrogen bands with the amide group of Asn-160, and thus, the usual metal-binding site, consisting of Asp-64, Asp-121, and Glu-157, is disrupted. Surprisingly, however, a single Zn2+ can still bind to Asp-121 in the mutant, without restoration of the activity of the enzyme. These structures have elucidated an unexpected mechanism of inactivation of the enzyme by lowering the pH or by mutation, in which a protonated side chain of Asx-64 changes its orientation and interaction partner.	NCI, Macromol Struct Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Fox Chase Cancer Center	Wlodawer, A (corresponding author), NCI, Macromol Struct Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA.		Gravuer, Kelly/AAJ-4802-2020	Gravuer, Kelly/0000-0002-2567-658X	NATIONAL CANCER INSTITUTE [R35CA047486, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, CA-47486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; GOFF SP, 1992, ANNU REV GENET, V26, P527, DOI 10.1146/annurev.ge.26.120192.002523; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lubkowski J, 1998, P NATL ACAD SCI USA, V95, P4831, DOI 10.1073/pnas.95.9.4831; MULLER B, 1993, P NATL ACAD SCI USA, V90, P11633, DOI 10.1073/pnas.90.24.11633; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S	16	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32685	32689		10.1074/jbc.273.49.32685	http://dx.doi.org/10.1074/jbc.273.49.32685			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830010	hybrid			2022-12-25	WOS:000077329100049
J	Noji, M; Inoue, K; Kimura, N; Gouda, A; Saito, K				Noji, M; Inoue, K; Kimura, N; Gouda, A; Saito, K			Isoform-dependent differences in feedback regulation and subcellular localization of serine acetyltransferase involved in cysteine biosynthesis from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-L-SERINE; HIGHER-PLANTS; SPINACH-CHLOROPLASTS; O-ACETYLSERINE; SYNTHASE O-ACETYLSERINE(THIOL)-LYASE; METHIONINE BIOSYNTHESIS; SULFATE ASSIMILATION; ESCHERICHIA-COLI; PURIFICATION; LEAVES	Serine acetyltransferase (SATase; EC 2.3.1.30), which catalyzes the formation of O-acetyI-L-serine (OAS) from acetyl-CoA and L-serine, plays a regulatory role in the biosynthesis of cysteine by its property of feedback inhibition by cysteine in bacteria and certain plants, Three cDNA clones encoding SATase isoforms (SAT-c, SAT-p, and SAT-m) have been isolated from Arabidopsis thaliana. However, the significance of the feedback regulation has not yet been clear in these different isoforms of SATase from A. thaliana. We constructed the overexpression vectors for cDNAs encoding three SATase isoforms of A. thaliana and analyzed the inhibition of SATase activity by cysteine using the recombinant SATase proteins. In the case of SAT-c, the activity was feedback-inhibited by a low concentration of cysteine (the concentration that inhibits 50% activity; IC50 = 1.8 mu M). By contrast, SAT-p and SAT-m were feedback inhibition-insensitive isozymes, We also determined the subcellular localization of three SATase isozymes by the transient expression of fusion proteins of each SATase N-terminal region with jellyfish green fluorescent protein (GFP) in 4-week-old Arabidopsis leaves. The SAT-c-GFP fusion protein was stayed in cytosol, whereas SAT-p-GFP and SAT-m-GFP fusion proteins were localized in chloroplasts and in mitochondria, respectively. These results suggest that these three SATase isoforms, which are localized in the different organelles, are subjected to different feedback regulation, presumably so as to play the particular roles for the production of OAS and cysteine in Arabidopsis cells. Regulatory circuit of cysteine biosynthesis in the plant cells is discussed.	Chiba Univ, Fac Pharmaceut Sci, Mol Biol Lab,Res Ctr Med Resources, Inage Ku, Chiba 2638522, Japan	Chiba University	Saito, K (corresponding author), Chiba Univ, Fac Pharmaceut Sci, Mol Biol Lab,Res Ctr Med Resources, Inage Ku, Yayoi Cho 1-33, Chiba 2638522, Japan.	ksaito@p.chiba-u.ac.jp	Saito, Kazuki/D-2670-2009	Saito, Kazuki/0000-0001-6310-5342				ASCANO A, 1977, PHYTOCHEMISTRY, V16, P889, DOI 10.1016/S0031-9422(00)86686-8; BAECKER PA, 1980, ANAL BIOCHEM, V102, P16, DOI 10.1016/0003-2697(80)90310-3; BERGMANN L, 1993, SULFUR NUTRITION AND ASSIMILATION IN HIGHER PLANTS, P109; BOGDANOVA N, 1995, FEBS LETT, V358, P43, DOI 10.1016/0014-5793(94)01392-E; BRUNOLD C, 1982, PLANTA, V155, P321, DOI 10.1007/BF00429459; BRUNOLD C, 1989, PLANTA, V179, P228, DOI 10.1007/BF00393693; BRUNOLD C, 1993, SULFUR NUTRITION AND ASSIMILATION IN HIGHER PLANTS, P61; Brunold Christian, 1997, Progress in Botany, V58, P164; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; DROUX M, 1992, ARCH BIOCHEM BIOPHYS, V295, P379, DOI 10.1016/0003-9861(92)90531-Z; DROUX M, 1995, ARCH BIOCHEM BIOPHYS, V316, P585, DOI 10.1006/abbi.1995.1078; HELL R, 1990, PLANTA, V180, P603, DOI 10.1007/BF02411460; Hell R, 1997, PLANTA, V202, P138, DOI 10.1007/s004250050112; HELL R, 1995, PLANT PHYSIOL, V109, P1498; Howarth JR, 1997, BBA-GENE STRUCT EXPR, V1350, P123, DOI 10.1016/S0167-4781(96)00213-8; Kim Hoyeun, 1997, P307; KREBBERS E, 1988, PLANT MOL BIOL, V11, P745, DOI 10.1007/BF00019515; Kredich N.M., 1996, ESCHERICHIA COLI SAL, P514; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; Kuske CR, 1996, PLANT PHYSIOL, V112, P659, DOI 10.1104/pp.112.2.659; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leustek T, 1996, PHYSIOL PLANTARUM, V97, P411, DOI 10.1034/j.1399-3054.1996.970228.x; LUNN JE, 1990, PLANT PHYSIOL, V94, P1345, DOI 10.1104/pp.94.3.1345; Murillo M, 1995, CELL MOL BIOL RES, V41, P425; NAKAMURA K, 1988, PLANT CELL PHYSIOL, V29, P689; NAKAMURA K, 1990, AGR BIOL CHEM TOKYO, V54, P649, DOI 10.1080/00021369.1990.10870005; NEUENSCHWANDER U, 1991, PLANT PHYSIOL, V97, P253, DOI 10.1104/pp.97.1.253; RAVANEL S, 1995, ARCH BIOCHEM BIOPHYS, V316, P572, DOI 10.1006/abbi.1995.1077; RENNENBERG H, 1982, PHYTOCHEMISTRY, V21, P2771, DOI 10.1016/0031-9422(80)85045-X; RENNENBERG H, 1983, PLANT PHYSIOL, V73, P560, DOI 10.1104/pp.73.3.560; Roberts MA, 1996, PLANT MOL BIOL, V30, P1041, DOI 10.1007/BF00020814; ROLLAND N, 1992, PLANT PHYSIOL, V98, P927, DOI 10.1104/pp.98.3.927; RUFFET ML, 1994, PLANT PHYSIOL, V104, P597, DOI 10.1104/pp.104.2.597; RUFFET ML, 1995, EUR J BIOCHEM, V227, P500, DOI 10.1111/j.1432-1033.1995.tb20416.x; SAITO K, 1995, J BIOL CHEM, V270, P16321, DOI 10.1074/jbc.270.27.16321; Saito K, 1999, BOOK SOIL P, P267; SAITO K, 1994, PLANT PHYSIOL, V106, P887, DOI 10.1104/pp.106.3.887; SAITO K, 1994, J BIOL CHEM, V269, P28187; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith FW, 1997, PLANT J, V12, P875, DOI 10.1046/j.1365-313X.1997.12040875.x; SMITH IK, 1971, BIOCHIM BIOPHYS ACTA, V227, P288, DOI 10.1016/0005-2744(71)90061-1; SMITH IK, 1972, PLANT PHYSIOL, V50, P477, DOI 10.1104/pp.50.4.477; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Takahashi H, 1996, PLANT PHYSIOL, V112, P273, DOI 10.1104/pp.112.1.273; Takahashi H, 1997, P NATL ACAD SCI USA, V94, P11102, DOI 10.1073/pnas.94.20.11102; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; YAMAGUCHI T, 1995, BBA-PROTEIN STRUCT M, V1251, P91, DOI 10.1016/0167-4838(95)00085-9	47	160	176	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32739	32745		10.1074/jbc.273.49.32739	http://dx.doi.org/10.1074/jbc.273.49.32739			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830017	hybrid			2022-12-25	WOS:000077329100056
J	Plemper, RK; Egner, R; Kuchler, K; Wolf, DH				Plemper, RK; Egner, R; Kuchler, K; Wolf, DH			Endoplasmic reticulum degradation of a mutated ATP-binding cassette transporter Pdr5 proceeds in a concerted action of Sec61 and the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MULTIDRUG TRANSPORTER; PROTEIN-DEGRADATION; PROTEOLYTIC SYSTEMS; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; ER DEGRADATION; YEAST; GENE; COMPLEX	Degradation of misfolded or tightly regulated proteins in the endoplasmic reticulum (ER) is performed by the cytosolic ubiquitin-proteasome system and therefore requires their prior transport back to the cytosol. Here, we report on the extraction and degradation mechanism of a polytopic membrane protein. Rapid proteasomal degradation of a mutated form of the ATP-binding cassette transporter Pdr5 retained in the ER is initialized at the lumenal face of the ER membrane. Using different antibodies directed against the cytosolic tails or a lumenal loop of the transmembrane protein, it could be demonstrated that the turnover of Pdr5* demands the concerted action of both the Sec61 translocon and the ubiquitin-proteasome system. We observed a stabilization of the entire molecule within the ER membrane in yeast mutants characterized by a reduced translocation capacity or by functionally attenuated proteasomes. Moreover, no degradation intermediates were detected in any of the mutants that impede degradation of Pdr5*. Therefore, initial steps are rate-limiting for cleavage and mutations that impede downstream events prevent initiation of the process. Our data suggest that ER degradation is a mechanistically highly integrated process, requiring the combined operation of components of the degradation system acting at the lumenal face of the ER membrane, the Sec61 translocon, and the ubiquitin-proteasome system.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria; Bioctr, A-1030 Vienna, Austria	University of Stuttgart; University of Vienna	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.		kuchler, karl/AAL-6937-2020	kuchler, karl/0000-0003-2719-5955				[Anonymous], 1991, Methods Enzymol, V194, P1; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JONES EW, 1991, J BIOL CHEM, V266, P7963; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KUCHLER K, 1992, ENDOCR REV, V13, P499, DOI 10.1210/er.13.3.499; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; RUPP S, 1995, EUR J BIOCHEM, V231, P115, DOI 10.1111/j.1432-1033.1995.tb20677.x; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; SIKORSKI RS, 1989, GENETICS, V122, P19; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500	42	147	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32848	32856		10.1074/jbc.273.49.32848	http://dx.doi.org/10.1074/jbc.273.49.32848			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830032	hybrid			2022-12-25	WOS:000077329100071
J	Garnero, P; Borel, O; Byrjalsen, I; Ferreras, M; Drake, FH; McQueney, MS; Foged, NT; Delmas, PD; Delaisse, JM				Garnero, P; Borel, O; Byrjalsen, I; Ferreras, M; Drake, FH; McQueney, MS; Foged, NT; Delmas, PD; Delaisse, JM			The collagenolytic activity of cathepsin K is unique among mammalian proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOCLASTIC BONE-RESORPTION; I COLLAGEN; MATRIX METALLOPROTEINASE-9; DEGRADATION PRODUCTS; HYPERREACTIVE SITES; RABBIT SPLEEN; IDENTIFICATION; EXPRESSION; SUSCEPTIBILITY; LOCALIZATION	Type I collagen fibers account for 90% of the organic matrix of bone. The degradation of this collagen is a major event during bone resorption, but its mechanism is unknown. A series of data obtained in biological models strongly suggests that the recently discovered cysteine proteinase cathepsin K plays a key role in bone resorption, Little is known, however, about the actual action of cathepsin K on type I collagen. Here, we show that the activity of cathepsin K alone is sufficient to dissolve completely insoluble collagen of adult human cortical bone, We found that the collagenolytic activity of cathepsin K is directed both outside the helical region of the molecule, i.e, the typical activity of cysteine proteinases, and at various sites inside the helical region, hitherto believed to resist all mammalian proteinases but the collagenases of the matrix metalloproteinase family and the neutrophil elastase, This property of cathepsin K is unique among mammalian proteinases and is reminiscent of bacterial collagenases, It is likely to be responsible for the key role of cathepsin K in bone resorption.	Hop Edouard Herriot, INSERM, U403, F-69437 Lyon 03, France; Ctr Clin & Basic Res, Ballerup 2750, Denmark; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Center Clinical & Basic Research; GlaxoSmithKline	Garnero, P (corresponding author), Hop Edouard Herriot, INSERM, U403, Pav F, F-69437 Lyon 03, France.	garnero@cismsun.univ-lyon1.fr	Foged, Niels T/AHA-2122-2022	Delaisse, Jean-Marie/0000-0001-7370-1500				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bonde M, 1997, J BONE MINER RES, V12, P1028, DOI 10.1359/jbmr.1997.12.7.1028; BONDE M, 1994, CLIN CHEM, V40, P2022; Bossard MJ, 1996, J BIOL CHEM, V271, P12517, DOI 10.1074/jbc.271.21.12517; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; DANIELSEN CC, 1990, BIOCHEM J, V272, P697, DOI 10.1042/bj2720697; Delaisse Jean-Marie, 1992, P289; DELAISSE JM, 1980, BIOCHEM J, V192, P365, DOI 10.1042/bj1920365; DELAISSE JM, 1985, BIOCHEM BIOPH RES CO, V133, P483, DOI 10.1016/0006-291X(85)90932-5; EECKOUT Y, 1988, CONTROL TISSUE DAMAG, P237; ETHERINGTON DJ, 1977, CONNECT TISSUE RES, V5, P135, DOI 10.3109/03008207709152264; ETHERINGTON DJ, 1987, COLLAGEN REL RES, V7, P185; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; FIRSCHEIN HE, 1966, ANAL BIOCHEM, V14, P296, DOI 10.1016/0003-2697(66)90140-0; FRENCH MF, 1992, J PROTEIN CHEM, V11, P83, DOI 10.1007/BF01025095; FRENCH MF, 1987, BIOCHEMISTRY-US, V26, P681, DOI 10.1021/bi00377a004; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; HANSON DA, 1992, J BONE MINER RES, V7, P1251; Inui T, 1997, J BIOL CHEM, V272, P8109, DOI 10.1074/jbc.272.13.8109; Kafienah W, 1998, BIOCHEM J, V330, P897, DOI 10.1042/bj3300897; KAHUDO S, 1997, BIOCHEM BIOPH RES CO, V234, P600; KIRSCHKE H, 1982, BIOCHEM J, V201, P367, DOI 10.1042/bj2010367; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; LECROISEY A, 1979, BIOCHEM J, V179, P33; LittlewoodEvans A, 1997, BONE, V20, P81, DOI 10.1016/S8756-3282(96)00351-1; MACIEWICZ RA, 1987, COLLAGEN REL RES, V7, P295; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; Mano H, 1996, BIOCHEM BIOPH RES CO, V223, P637, DOI 10.1006/bbrc.1996.0947; Murphy Gillian, 1993, P287; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA Y, 1995, LAB INVEST, V72, P311; SANESHIGE S, 1995, BIOCHEM J, V309, P721, DOI 10.1042/bj3090721; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; VAES G, 1988, CLIN ORTHOP RELAT R, P239	37	462	477	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32347	32352		10.1074/jbc.273.48.32347	http://dx.doi.org/10.1074/jbc.273.48.32347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822715	hybrid			2022-12-25	WOS:000077207000097
J	Park, H; Go, YM; John, PLS; Maland, MC; Lisanti, MP; Abrahamson, DR; Jo, H				Park, H; Go, YM; John, PLS; Maland, MC; Lisanti, MP; Abrahamson, DR; Jo, H			Plasma membrane cholesterol is a key molecule in shear stress-dependent activation of extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-B-CHAIN; VASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE PRODUCTION; GROWTH-FACTOR; PROTEIN-KINASE; CAROTID BIFURCATION; CAVEOLAE MEMBRANE; RECEPTOR FUNCTION; TYROSINE KINASES; FLOW	Shear stress, the dragging force generated by fluid now, differentially activates extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) in bovine aortic endothelial cells (BAEC) (Jo, H., Sipos, IL, Go, Y. M, Law, R, Rong, J., and McDonald, J.M. (1997) J. Biol. Chem. 272, 1395-1401). Here, we examine whether cholesterol-enniched compartments in the plasma membrane are responsible for such differential regulation. Pretreatment of BAEC with a cholesterol-binding antibiotic, filipin, did not inhibit shear-dependent activation of JNK In contrast, filipin and other membrane-permeable cholesterol-binding agents (digitonin and nystatin), but not the lipid-binding agent xylazine, inhibited shear-dependent activation of ERK The effect of cholesterol-binding drugs did not appear to be due to membrane permeabilization, since treatment of BAEC with a detergent, Triton X-100 which also permeabilizes membranes, did not inhibit shear-dependent activation of ERK. Furthermore, shear-dependent activation of ERK but not JNK, was inhibited by cyclodextrin, a membrane-impermeable cholesterol-binding agent, which removes cell-surface cholesterol Moreover, the effects of cyclodextrin were prevented by adding cholesterol during the incubation. These results indicate that cholesterol or cholesterol-sensitive compartments in the plasma membrane play a selective and essential role in activation of ERK but not JNK by shear stress. Although exposure to shear stress (1 h) increased the number of caveolae by 3-fold, treatment with filipin had no effect in either control or shear-exposed cells suggesting that caveolae density per se is not a crucial determinant in shear-dependent ERK activation In summary, the current study suggests that cholesterol-sensitive microdomains in the plasma membrane, such as caveolae-like domains,play a critical role in differential activation of ERK and JNK by shear stress.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Yeshiva University; Albert Einstein College of Medicine	Jo, H (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, G019C Volker Hall, Birmingham, AL 35294 USA.	Jo@path.uab.edu	Jo, Hanjoong/L-6216-2019; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Jo, Hanjoong/0000-0003-1833-372X; Lisanti, Michael/0000-0003-2034-1382; 	NHLBI NIH HHS [HL53601] Funding Source: Medline; NIDDK NIH HHS [DK52483] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL053601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052483] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert AD, 1996, BBA-BIOMEMBRANES, V1285, P47, DOI 10.1016/S0005-2736(96)00145-9; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; BISCHOF JC, 1995, BIOPHYS J, V68, P2608, DOI 10.1016/S0006-3495(95)80445-5; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; ELIAS PM, 1978, J CELL BIOL, V78, P577, DOI 10.1083/jcb.78.2.577; Fielding CJ, 1997, J LIPID RES, V38, P1503; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Frangos JA, 1996, BIOCHEM BIOPH RES CO, V224, P660, DOI 10.1006/bbrc.1996.1081; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; JO H, 1991, AM J PHYSIOL, V260, pH1992, DOI 10.1152/ajpheart.1991.260.6.H1992; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; KUCHAN MJ, 1994, AM J PHYSIOL, V267, pC753, DOI 10.1152/ajpcell.1994.267.3.C753; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li YS, 1996, MOL CELL BIOL, V16, P5947; LIMBIRD LE, 1976, MOL PHARMACOL, V12, P559; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MORITA T, 1993, BIOCHEM BIOPH RES CO, V197, P256, DOI 10.1006/bbrc.1993.2469; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NARAYANASWAMI V, 1993, BIOCHEMISTRY-US, V32, P12420, DOI 10.1021/bi00097a021; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NUNEZ MT, 1982, BIOCHEMISTRY-US, V21, P4139, DOI 10.1021/bi00260a034; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SCHNITZER JE, 1994, BIOCHEM BIOPH RES CO, V199, P11, DOI 10.1006/bbrc.1994.1185; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P47; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502	60	134	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32304	32311		10.1074/jbc.273.48.32304	http://dx.doi.org/10.1074/jbc.273.48.32304			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822710	hybrid			2022-12-25	WOS:000077207000092
J	Reichert, A; Rothbauer, U; Morl, M				Reichert, A; Rothbauer, U; Morl, M			Processing and editing of overlapping tRNAs in human mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; MESSENGER-RNA; SEQUENCES; TRNA(TYR); GENOME; ENZYME	Overlapping tRNA genes in mitochondria of many metazoans introduce a problem for the processing of such polycistronic primary transcripts. Using runoff transcripts and an S100 extract from HeLa cell mitochondria, the processing of the human mitochondrial tRNA(Tyr)/tRNA(Cys) precursor (carrying an overlap of one base) was investigated: tRNA(Cys) is released in its complete form carrying the overlapping residue at the first position, whereas tRNA(Tyr) lacks that nucleotide at the discriminator position. Partial deletion of tRNA(Cys) Or complete replacement by a non-tRNA-like sequence does not alter the processing reaction and indicates that the upstream tRNA(Tyr) alone is recognized by a 3'-endonuclease activity. The truncated 3'-end of this tRNA(Tyr) is then completed in an editing reaction that incorporates the missing residue. The processing of this tRNA overlap seems to be species-specific, because an overlapping tRNA precursor (tRNA(Ser)(AGY)/tRNA(Leu)(CUN)) from opossum mitochondria is not recognized by the human extract. Because processing activities for overlapping and nonoverlapping tRNA precursors could not be separated, it seems that one general activity is responsible for the 3'-end processing of mitochondrial tRNAs and that this activity coevolved with the particular overlap between tRNA(Tyr) and tRNA(Cys) in human mitochondria, being unable to recognize overlaps between other tRNAs.	Univ Munich, Inst Zool, Max Planck Inst Evolut Anthropol, D-80333 Munich, Germany	Max Planck Society; University of Munich	Morl, M (corresponding author), Univ Munich, Inst Zool, Max Planck Inst Evolut Anthropol, Luisenstr 14, D-80333 Munich, Germany.	moerl@zi.biologie.uni-muenchen.de	Rothbauer, Ulrich/C-7712-2018; Reichert, Andreas/A-4090-2012	Rothbauer, Ulrich/0000-0001-5923-8986; Reichert, Andreas/0000-0001-9340-3113; Morl, Mario/0000-0003-0972-9386				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ATTARDI G, 1985, INT REV CYTOL, V93, P93, DOI 10.1016/S0074-7696(08)61373-X; BEIER H, 1991, ESSENTIAL MOL BIOL P, V2, P221; CARRARA G, 1989, CELL, V58, P37, DOI 10.1016/0092-8674(89)90400-5; CHEN JY, 1988, J BIOL CHEM, V263, P13677; DEUTSCHER M, 1995, TRNA STRUCTURE BIOSY, P143; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; HETZER M, 1993, NUCLEIC ACIDS RES, V21, P5526, DOI 10.1093/nar/21.23.5526; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; JANKE A, 1994, GENETICS, V137, P243; LONERGAN KM, 1993, SCIENCE, V259, P812, DOI 10.1126/science.8430334; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885; Rossmanith W, 1995, PROG CELL R, V5, P143; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; Sambrook J., 2002, MOL CLONING LAB MANU; Sinha KM, 1998, J BIOL CHEM, V273, P6853, DOI 10.1074/jbc.273.12.6853; SURRATT CK, 1990, J BIOL CHEM, V265, P22506; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; Tomita K, 1996, NUCLEIC ACIDS RES, V24, P4987, DOI 10.1093/nar/24.24.4987; YOKOBORI S, 1995, NATURE, V377, P490, DOI 10.1038/377490a0; Yokobori S, 1997, J MOL BIOL, V265, P95, DOI 10.1006/jmbi.1996.0728; YOKOBORI S, 1995, P NATL ACAD SCI USA, V92, P10432, DOI 10.1073/pnas.92.22.10432; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006	27	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31977	31984		10.1074/jbc.273.48.31977	http://dx.doi.org/10.1074/jbc.273.48.31977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822669	hybrid			2022-12-25	WOS:000077207000051
J	Mangano, R; Piddini, E; Carramusa, L; Duhig, T; Feo, S; Fried, M				Mangano, R; Piddini, E; Carramusa, L; Duhig, T; Feo, S; Fried, M			Chimeric amplicons containing the c-myc gene in HL60 cells	ONCOGENE			English	Article						HL60 chimeric amplicon; fiber-FISH; MYC amplification; amplicon organization; illegitimate recombination; inverted and direct repeats	HUMAN BREAST-CANCER; HUMAN NEUROBLASTOMA; FRAGILE SITES; AMPLIFICATION; ONCOGENE; EXPRESSION; DNA; DIFFERENTIATION; PROLIFERATION; SEQUENCES	The major amplicon present in HL60 cells is chimeric in nature being composed of 70 kb of DNA sequence derived from the MYC locus linked to 80 kb of novel DNA sequence derived from a non contiguous region located telomeric to the c-myc gene at 8q24 (Feo et al,, 1996), Here we show by fluorescence in situ hybridization (FISH) that these coamplified sequences, MCR (Myc Coamplified Region), are derived from a locus located 3-4 Mb telomeric to the c-myc gene in the q24.2-24.3 region of chromosome 8. Genomic cloning and Southern blot analysis indicate the arrangement of chimeric amplicons are in tandem arrays, Analysis of the DNA sequences at the juncture of the MYC locus and the NICR suggest that these non syntenic regions were joined by nonhomologous recombination events, Visualization of the organization of the amplified DNA by fiber-FISH analysis illustrates we have cloned the complete amplicon, This is the first complete mammalian amplicon to be cloned and have its structure visualized. In addition to the major class of tandemly repeated amplicons, a second class of amplicons was detected by fiber-FISH in which the extent of the MCR component is about twice the size of the MCR component in the major amplicon, These longer amplicons most likely contain inverted repeats of MCR and MYC region sequences. Whether the amplicons contain mixtures of these two types of structures or separate amplicons only contain one type of structure has not yet been resolved. Properties of the MCR sequences responsible for retention in the chimeric HL60 amplicons upon long term passage are discussed.	Imperial Canc Res Fund, London WC2A 3PX, England; Univ Palermo, Dipartimento Biol Cellulare & Sviluppo, I-90123 Palermo, Italy; Univ Palermo, Ctr Oncobiol Sperimentale, I-90123 Palermo, Italy	Cancer Research UK; University of Palermo; University of Palermo	Fried, M (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Feo, Salvatore/C-1333-2012	Feo, Salvatore/0000-0003-3877-2906; Piddini, Eugenia/0000-0003-3901-076X				AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS SJ, 1987, BLOOD, V70, P1233; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; Elkahloun AG, 1996, GENE CHROMOSOME CANC, V17, P205, DOI 10.1002/(SICI)1098-2264(199612)17:4<205::AID-GCC2>3.3.CO;2-#; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Feo S, 1996, ONCOGENE, V13, P1521; FEO S, 1994, ONCOGENE, V9, P955; FORD M, 1986, CELL, V45, P425, DOI 10.1016/0092-8674(86)90328-4; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; HECHT F, 1990, CANCER GENET CYTOGEN, V44, P37, DOI 10.1016/0165-4608(90)90195-G; Heiskanen M, 1996, GENET ANAL-BIOMOL E, V12, P179, DOI 10.1016/1050-3862(95)00134-4; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; Tanner MM, 1996, CANCER RES, V56, P3441; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	27	15	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2771	2777		10.1038/sj.onc.1202434	http://dx.doi.org/10.1038/sj.onc.1202434			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840941				2022-12-25	WOS:000077146700010
J	Carter, RE; Sorkin, A				Carter, RE; Sorkin, A			Endocytosis of functional epidermal growth factor receptor-green fluorescent protein chimera	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA A431 CELLS; COATED PIT ADAPTINS; KINASE-ACTIVITY; EGF-RECEPTOR; TRANSFERRIN RECEPTOR; DOWN-REGULATION; INTERNALIZATION; BINDING; PHOSPHORYLATION; DEGRADATION	A chimera of the epidermal growth factor receptor (EGFR) and green fluorescent protein (GFP) has been engineered by fusing GFP to the carboxyl terminus of EGFR. Data are provided to demonstrate that the GFP moiety does not affect the expected functioning of EGFR. EGFR-GFP becomes phosphorylated at tyrosine residues in response to EGF and is capable of phosphorylating endogenous substrates and initiating signaling cascades. EGF-dependent association of the chimeric receptor with the clathrin adaptor protein AP-2, involved in endocytosis, and with Shc adaptor protein, which binds in close proximity to the fusion point, is not affected by the GFP moiety. Receptor down-regulation and internalization occur at rates similar to those in cells expressing wild-type EGFR. Western blot analysis reveals that lysosomal degradation of EGFR-GFP proceeds from the extracellular domain and that GFP is not preferentially cleaved. Time-dependent co-localization of EGFR-GFP and Texas Red-conjugated EGF in living cells using digital deconvolution microscopy demonstrates the trafficking of ligand-receptor complexes through the early and multivesicular endosomes followed by segregation of the ligand and receptor at the late stages of endocytosis. Time-lapse optical analysis of the early stages of endocytosis reveals localization of EGFR-GFP in the tubular-vesicular endosomal compartments. Rapid dynamics of membrane movement and fusion within these compartments were observed. This approach and the fidelity of the biochemical properties of the EGFR-GFP demonstrate that real-time visualization of trafficking and protein interactions of tyrosine kinase receptors in the presence or absence of the ligand are feasible.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sorkin, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.	alexander.sorkin@uchsc.edu		Sorkin, Alexander/0000-0002-4446-1920	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46817] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BERTICS PJ, 1988, J BIOL CHEM, V263, P3610; BERTICS PJ, 1985, J CELL BIOCHEM, V29, P195, DOI 10.1002/jcb.240290304; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1985, J CELL SCI, P173; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SOLER C, 1994, J BIOL CHEM, V269, P12320; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; SORKIN A, 1991, J CELL BIOL, V112, P55, DOI 10.1083/jcb.112.1.55; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STOSCHECK CM, 1984, J CELL PHYSIOL, V120, P296, DOI 10.1002/jcp.1041200306; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; WILEY HS, 1991, J BIOL CHEM, V266, P11083	36	183	186	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					35000	35007		10.1074/jbc.273.52.35000	http://dx.doi.org/10.1074/jbc.273.52.35000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857032	hybrid			2022-12-25	WOS:000077719700050
J	Gimenez-Roqueplo, AP; Celerier, J; Schmid, G; Corvol, P; Jeunemaitre, X				Gimenez-Roqueplo, AP; Celerier, J; Schmid, G; Corvol, P; Jeunemaitre, X			Role of cysteine residues in human angiotensinogen - Cys(232) is required for angiotensinogen pro major basic protein complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT ANGIOTENSINOGEN; BIOCHEMICAL-PROPERTIES; HUMAN HYPERTENSION; RENIN SUBSTRATE; DISULFIDE BONDS; PREGNANCY SERUM; CDNA SEQUENCE; HUMAN-PLASMA; EXPRESSION; RADIOIMMUNOASSAY	The M235T polymorphism of human angiotensinogen is associated with essential and pregnancy-induced hypertension. A covalent complex is formed between angiotensinogen and the proform of the eosinophil major basic protein (proMBP) during pregnancy. The sequence of human angiotensinogen contains four cysteines. Their function was analyzed. Presence of free cysteines was demonstrated by their alkylation with iodo[C-14]acetic:acid. A disulfide bond between Cys(18) and Cys(138) using a fully N-deglycosylated mutant of human angiotensinogen was identified by tryptic digestion and mass spectrometry. We produced angiotensinogen proMBP complex by co-transfection of COS-7 cells and by co-culturing transfected CHO-K1 cells. Experiments with 8 mutated recombinant angiotensinogen, in which one or more of the four cysteines were replaced by alanine, demonstrated that Cys(232) in involved in complex formation and could interact with the M235T variant. The angiotensinogen.proMBp complex was isolated by molecular sieving, Hydrolysis of the complex by human renin was 7 times slower than hydrolysis of monomeric form, whatever the M235T genotype, The complex:monomeric angiotensinogen ratio was greater for Met(235) (72%) than for Thr(235) (58%) angiotensinogen. These data suggest a new pathophysiological explanation for the genetic association between M235T angiotensinogen polymorphism and pregnancy-induced hypertension.	Coll France, INSERM, U36, Chaire Med Expt & Endocrinol Renale, F-75005 Paris, France; F Hoffmann La Roche & Co Ltd, Pharmaceut Res Gene Technol, CH-4002 Basel, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Roche Holding	Gimenez-Roqueplo, AP (corresponding author), Coll France, INSERM, U36, Chaire Med Expt & Endocrinol Renale, 3 Rue Ulm, F-75005 Paris, France.	jeunemaitre@hbroussais.fr	GIMENEZ-ROQUEPLO, Anne-Paule/T-6752-2018; JEUNEMAITRE, Xavier/AAQ-4853-2021	GIMENEZ-ROQUEPLO, Anne-Paule/0000-0002-4816-670X; JEUNEMAITRE, Xavier/0000-0001-5925-381X				BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BING J, 1972, ACTA PATH MICRO IM A, VA 80, P646; Brasier AR, 1996, HYPERTENSION, V27, P465, DOI 10.1161/01.HYP.27.3.465; CAMPBELL DJ, 1985, J CLIN INVEST, V75, P1880, DOI 10.1172/JCI111902; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; Cohen P, 1996, J CLIN ENDOCR METAB, V81, P3505, DOI 10.1210/jc.81.10.3505; Corvol P, 1997, ENDOCR REV, V18, P662, DOI 10.1210/er.18.5.662; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; GENAIN C, 1984, J CLIN ENDOCR METAB, V59, P478, DOI 10.1210/jcem-59-3-478; Gimenez-Roqueplo AP, 1998, J BIOL CHEM, V273, P21232, DOI 10.1074/jbc.273.33.21232; GimenezRoqueplo AP, 1996, J BIOL CHEM, V271, P9838, DOI 10.1074/jbc.271.16.9838; GORDON DB, 1976, P SOC EXP BIOL MED, V153, P314; Haaning J, 1996, EUR J BIOCHEM, V237, P159, DOI 10.1111/j.1432-1033.1996.0159n.x; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P10328, DOI 10.1021/bi960309o; HINGELFELDT U, 1990, EUR J CLIN PHARMACOL, V38, P125; INOUE I, 1995, J BIOL CHEM, V270, P11430, DOI 10.1074/jbc.270.19.11430; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KAGEYAMA R, 1984, BIOCHEMISTRY-US, V23, P3603, DOI 10.1021/bi00311a006; LENZ T, 1993, PLACENTA, V14, P695, DOI 10.1016/S0143-4004(05)80386-8; Mathews S, 1996, PROTEIN EXPRES PURIF, V7, P81, DOI 10.1006/prep.1996.0012; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; NAGASE M, 1994, BIOSCI BIOTECH BIOCH, V58, P1884, DOI 10.1271/bbb.58.1884; OKHUBO H, 1983, P NATL ACAD SCI USA, V80, P2196; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1995, J BIOL CHEM, V270, P13645, DOI 10.1074/jbc.270.23.13645; POPKENHARRIS P, 1994, J ALLERGY CLIN IMMUN, V94, P1282, DOI 10.1016/0091-6749(94)90343-3; SATO Y, 1985, LIFE SCI, V37, P371, DOI 10.1016/0024-3205(85)90508-9; SHIONOIRI H, 1983, BIOCHEM MED METAB B, V29, P14, DOI 10.1016/0006-2944(83)90049-2; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEIN PE, 1989, BIOCHEM J, V262, P103, DOI 10.1042/bj2620103; TETLOW HJ, 1985, J ENDOCRINOL, V109, P257; TEWKSBURY DA, 1986, CLIN CHIM ACTA, V158, P7, DOI 10.1016/0009-8981(86)90110-5; TEWKSBURY DA, 1982, HYPERTENSION, V4, P729, DOI 10.1161/01.HYP.4.5.729; TEWKSBURY DA, 1989, AM J HYPERTENS, V2, P411, DOI 10.1093/ajh/2.5.411; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, P1197; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TYRON ES, 1995, HYPERTENS PREGNANCY, V14, P327; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; WARD K, 1993, NAT GENET, V4, P59, DOI 10.1038/ng0593-59; Wink DA, 1997, J BIOL CHEM, V272, P11147; ZHU HX, 1995, BIOCHEMISTRY-US, V34, P15307, DOI 10.1021/bi00046a040	46	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34480	34487		10.1074/jbc.273.51.34480	http://dx.doi.org/10.1074/jbc.273.51.34480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852116	hybrid			2022-12-25	WOS:000077542200082
J	Havelaar, AC; Mancini, GMS; Beerens, CEMT; Souren, RMA; Verheijen, FW				Havelaar, AC; Mancini, GMS; Beerens, CEMT; Souren, RMA; Verheijen, FW			Purification of the lysosomal sialic acid transporter - Functional characteristics of a monocarboxylate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; MEMBRANE-GLYCOPROTEINS; STORAGE DISEASE; ANION TRANSPORT; CDNA CLONING; PROTEIN; CARRIER; MITOCHONDRIA; LACTATE; SIALOGLYCOPROTEIN	Sialic acid and glucuronic acid are monocarboxylated monosaccharides, which are normally present in sugar side chains of glycoproteins, glycolipids, and glycosaminoglycans, After degradation of these compounds in lysosomes, the free monosaccharides are released from the lysosome by a specific membrane transport system. This transport system is deficient in the human hereditary lysosomal sialic acid storage diseases (Salla disease and infantile sialic acid storage disease, OMIM 269920). The lysosomal sialic acid transporter from rat liver has now been purified to apparent homogeneity in a reconstitutively active form by a combination of hydroxyapatite, lectin, and ion exchange chromatography. A 57-kDa protein correlated with transport activity. The transporter recognized structurally different types of acidic monosaccharides, Like sialic acid, glucuronic acid, and iduronic acid. Transport of glucuronic acid was inhibited by a number of aliphatic monocarboxylates (i.e. lactate, pyruvate, and valproate), substituted monocarboxylates, and several dicarboxylates. cis-Inhibition, trans-stimulation, and competitive inhibition experiments with radiolabeled glucuronic acid as well as radiolabeled L-lactate demonstrated that L-lactate is transported by the lysosomal sialic acid transporter, L-Lactate transport was proton gradient-dependent, saturable with a K-m of 0.4 mM, and mediated by a single mechanism. These data show striking biochemical and structural similarities of the lysosomal sialic acid transporter with the known monocarboxylate transporters of the plasma membrane (MCCT1, MCT2, MCT3, and Mev).	Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Verheijen, FW (corresponding author), Erasmus Univ, Dept Clin Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.							AKASAKI K, 1991, J BIOCHEM-TOKYO, V110, P922, DOI 10.1093/oxfordjournals.jbchem.a123690; ARAI K, 1993, J BIOL CHEM, V268, P5649; BALKOVETZ DF, 1988, J BIOL CHEM, V263, P13823; BENAVIDES J, 1982, BIOCHEM PHARMACOL, V31, P1633, DOI 10.1016/0006-2952(82)90392-6; BISACCIA F, 1988, BIOCHIM BIOPHYS ACTA, V933, P229, DOI 10.1016/0005-2728(88)90030-8; BLOM HJ, 1990, BIOCHEM J, V268, P621, DOI 10.1042/bj2680621; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; Carpenter L, 1996, BBA-BIOMEMBRANES, V1279, P157, DOI 10.1016/0005-2736(95)00254-5; CASEY JR, 1992, J BIOL CHEM, V267, P11940; FUJITA H, 1991, BIOCHEM BIOPH RES CO, V178, P444, DOI 10.1016/0006-291X(91)90127-S; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Gadian DG, 1996, J INHERIT METAB DIS, V19, P548, DOI 10.1007/BF01799115; Gahl WASJ, 1995, METABOLIC MOL BASIS, V7th, P3763; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HIMENO M, 1989, J BIOCHEM-TOKYO, V105, P449, DOI 10.1093/oxfordjournals.jbchem.a122685; KIM CM, 1992, J BIOL CHEM, V267, P23113; KIM S, 1993, J BIOCHEM-TOKYO, V114, P126; KYOUDEN T, 1992, J BIOCHEM-TOKYO, V111, P770, DOI 10.1093/oxfordjournals.jbchem.a123834; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LIPMAN BJ, 1990, J BIOL CHEM, V265, P2142; MALATHI P, 1983, BIOCHIM BIOPHYS ACTA, V735, P314, DOI 10.1016/0005-2736(83)90144-X; MANCINI GMS, 1992, P NATL ACAD SCI USA, V89, P6609, DOI 10.1073/pnas.89.14.6609; MANCINI GMS, 1989, J BIOL CHEM, V264, P15247; MANCINI GMS, 1991, J CLIN INVEST, V87, P1329, DOI 10.1172/JCI115136; OKAZAKI I, 1992, J BIOCHEM, V111, P763, DOI 10.1093/oxfordjournals.jbchem.a123833; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Penefsky H S, 1979, Methods Enzymol, V56, P527; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; Price NT, 1998, BIOCHEM J, V329, P321; SCHLEUTKER J, 1995, AM J HUM GENET, V57, P893; SCHULTE S, 1995, EUR J BIOCHEM, V233, P947, DOI 10.1111/j.1432-1033.1995.947_3.x; TAMAI I, 1995, BIOCHEM BIOPH RES CO, V214, P482, DOI 10.1006/bbrc.1995.2312; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yoon HY, 1997, BIOCHEM BIOPH RES CO, V234, P90, DOI 10.1006/bbrc.1997.6588	40	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34568	34574		10.1074/jbc.273.51.34568	http://dx.doi.org/10.1074/jbc.273.51.34568			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852127	Green Published, hybrid			2022-12-25	WOS:000077542200093
J	Kershnar, E; Wu, SY; Chiang, CM				Kershnar, E; Wu, SY; Chiang, CM			Immunoaffinity purification and functional characterization of human transcription factor IIH and RNA polymerase II from clonal cell lines that conditionally express epitope-tagged subunits of the multiprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TATA-BINDING PROTEIN; NONPHOSPHORYLATED FORM; PREINITIATION COMPLEX; BASAL TRANSCRIPTION; PROMOTER CLEARANCE; PHOSPHORYLATION; INITIATION; DNA; ELONGATION	Purification of multiprotein complexes such as transcription factor (TF) LIN and RNA polymerase II (pol II) has been a tedious task by conventional chromatography. To facilitate the purification, we have developed an effective scheme that allows human TFIIH and pol II to be isolated from HeLa-derived cell lines that conditionally express the FLAG-tagged p62 subunit of human TFIIH and the RPB9 subunit of human pol II, respectively. An approximate 2000-fold enrichment of FLAG-tagged TFIIH and a 1000-fold enhancement of total pol II are achieved by a one-step immunoaffinity purification. The purified complexes are functional in mediating basal and activated transcription, regardless of whether TATA-binding protein or TFIID is used as the TATA-binding factor. Interestingly, repression of basal transcription by the positive cofactor PC4 is alleviated by increasing amounts of TFIID, TFIIH, and pol II holoenzyme, suggesting that phosphorylation of PC4 by these proteins may cause a conformational change in the structure of PC4 that allows for preinitiation complex formation and initiation of transcription. Furthermore, pol II complexes with different phosphorylation states on the carboxyl-terminal domain of the largest subunit are selectively purified from the inducible pol II cell line, making it possible to dissect the role of carboxyl-terminal domain phosphorylation in the transcription process in a highly defined in vitro transcription system.	Univ Illinois, Dept Biochem, Roger Adams Lab 430, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chiang, CM (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 430, 600 S Mathews Ave, Urbana, IL 61801 USA.	c-chiang@uiuc.edu						Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; Awrey DE, 1997, J BIOL CHEM, V272, P14747, DOI 10.1074/jbc.272.23.14747; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; Fu JH, 1998, J MOL BIOL, V280, P317, DOI 10.1006/jmbi.1998.1557; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GERARD M, 1991, J BIOL CHEM, V266, P20940; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; HULL MW, 1995, GENE DEV, V9, P481, DOI 10.1101/gad.9.4.481; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KANG ME, 1993, J BIOL CHEM, V268, P25033; Khazak V, 1998, MOL CELL BIOL, V18, P1935, DOI 10.1128/MCB.18.4.1935; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Kugel JF, 1998, P NATL ACAD SCI USA, V95, P9232, DOI 10.1073/pnas.95.16.9232; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; Lee D, 1998, NATURE, V393, P389, DOI 10.1038/30770; LeRoy G, 1998, J BIOL CHEM, V273, P7134, DOI 10.1074/jbc.273.12.7134; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Neugebauer KM, 1997, GENE DEV, V11, P3279, DOI 10.1101/gad.11.24.3279; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; Pan GH, 1997, J BIOL CHEM, V272, P24563, DOI 10.1074/jbc.272.39.24563; REINBERG D, 1987, J BIOL CHEM, V262, P3310; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROY R, 1994, J BIOL CHEM, V269, P9826; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Svetlov V, 1998, J BIOL CHEM, V273, P10827, DOI 10.1074/jbc.273.18.10827; Thompson NE, 1996, METHOD ENZYMOL, V274, P513; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; Treich Isabelle, 1992, Gene Expression, V2, P31; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEST ML, 1995, GENETICS, V140, P1223; Winkler GS, 1998, J BIOL CHEM, V273, P1092, DOI 10.1074/jbc.273.2.1092; WOYCHIK NA, 1991, J BIOL CHEM, V266, P19053; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854; Wu SY, 1996, BIOTECHNIQUES, V21, P718; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Wu SY, 1998, EMBO J, V17, P4478, DOI 10.1093/emboj/17.15.4478; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZHANG J, 1991, J BIOL CHEM, V266, P2290	77	30	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34444	34453		10.1074/jbc.273.51.34444	http://dx.doi.org/10.1074/jbc.273.51.34444			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852112	hybrid			2022-12-25	WOS:000077542200078
J	Steegmaier, M; Yang, B; Yoo, JS; Huang, B; Shen, M; Yu, S; Luo, Y; Scheller, RH				Steegmaier, M; Yang, B; Yoo, JS; Huang, B; Shen, M; Yu, S; Luo, Y; Scheller, RH			Three novel proteins of the syntaxin/SNAP-25 family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; BINDING-PROTEIN; VESICULAR TRANSPORT; VESICLE TRAFFICKING; SYNAPTIC VESICLES; MEMBRANE; FUSION; RECEPTORS	Intracellular membrane traffic is thought to be regulated in part by soluble N-ethylmaleimide-sensitive factor-attachment protein receptors (SNAREs) through the formation of complexes between these proteins present on vesicle and target membranes. All known SNARE-mediated fusion events involve members of the syntaxin and vesicle-associated membrane protein families, The diversity of mammalian membrane compartments predicts the existence of a large number of different syntaxin and vesicle-associated membrane protein geenes. To further investigate the spectrum of SNAREs and their roles in membrane trafficking we characterized three novel members of the syntaxin and SNAP-25 (synaptosome-associated protein of 25 kDa) subfamilies, The proteins are broadly expressed, suggesting at general role in vesicle trafficking, and localize to distinct membrane compartments. Syntaxin 8 co-localizes with markers of the endoplasmic reticulum, Syntaxin 17, a divergent member of the syntaxin family, partially overlaps with endoplasmic reticulum markers, and SNAP-29 is broadly localized on multiple membranes, SNAP-29 does not contain a predicted membrane anchor characteristic of other SNAREs. In vitro studies established that SNAP-29 is capable of binding to a broad range of syntaxins.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Rigel Inc, Sunnyvale, CA 94086 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.	scheller@cmgm.stanford.edu						AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Genetic Computer Group, 1994, PROGR MAN WISC PACK; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Hay JC, 1996, J BIOL CHEM, V271, P5671, DOI 10.1074/jbc.271.10.5671; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; HESS DT, 1992, J NEUROSCI, V12, P4634; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; KREIBICH G, 1983, METHOD ENZYMOL, V96, P530; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; PREKERIS R, 1998, IN PRESS J CELL BIOL, V143; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; WADA I, 1991, J BIOL CHEM, V266, P19599; Wang H, 1997, GENE, V199, P39, DOI 10.1016/S0378-1119(97)00343-0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375	45	160	170	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34171	34179		10.1074/jbc.273.51.34171	http://dx.doi.org/10.1074/jbc.273.51.34171			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852078	hybrid			2022-12-25	WOS:000077542200044
J	Knight, CG; Morton, LF; Onley, DJ; Peachey, AR; Messent, AJ; Smethurst, PA; Tuckwell, DS; Farndale, RW; Barnes, MJ				Knight, CG; Morton, LF; Onley, DJ; Peachey, AR; Messent, AJ; Smethurst, PA; Tuckwell, DS; Farndale, RW; Barnes, MJ			Identification in collagen type I of an integrin alpha(2)beta(1)-binding site containing an essential GER sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-REACTIVE SITES; AGGREGATORY SITES; PEPTIDE-SYNTHESIS; RECOGNITION SITE; BINDING-SITE; ADHESION; DOMAIN; INTEGRIN-ALPHA-2-BETA-1; SUPPRESSION; PROTECTION	The collagen type I-derived fragment alpha(1)(I)CB3 is known to recognize the platelet collagen receptor integrin alpha(2)beta(1) as effectively as the parent collagen, although it lacks platelet-aggregatory activity. We have synthesized the fragment as seven overlapping peptides that spontaneously assemble into triple helices. On the basis of their capacity to bind purified alpha(2)beta(1) and the recombinant alpha(2) A-domain, and their ability to support alpha(2)beta(1)-mediated cell adhesion, we identified two peptides, CB3(I)-5 and -6, which contain an alpha(2)beta(1) recognition site. Synthesis of the peptide CB3(I)-5/6, containing the overlap sequence between peptides 5 and 6, allowed us to locate the binding site within the 15-residue sequence, GFP*GERGVEGPP*GPA (where P* represents hydroxyproline), corresponding to residues 502-516 of the collagen type I alpha(1) chain. The Glu and Arg residues in the GER triplet were found to be essential for recognition since substitution of either residue with Ala caused a loss of alpha(2) A-domain binding. By contrast, substitution of the Glu in GVE did not reduce binding, but rather enhanced it slightly. We were unable to detect significant recognition of alpha(2)beta(1) by the peptide CB3(I)-2 containing the putative alpha(2)beta(1) recognition sequence DGEA. Peptides CB3(I)-1 to -6, together with peptide CB3(I)-5/6, exhibited good platelet-aggregatory activity, in some cases better than collagen. However, peptide CB3(I)-7 was inactive, suggesting the presence of an inhibitory element that might account for the lack of aggregatory activity of the parent alpha(1)(I)CB3 fragment.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Strangeways Res Lab, Cambridge CB1 4RN, England; Univ Cambridge, E Anglian Blood Ctr, Div Transfus Med, Cambridge CB2 2PT, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Cambridge; University of Cambridge; University of Manchester	Barnes, MJ (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.							Barnes M. J, 1982, COLLAGEN HLTH DISEAS, P179; Barnes MJ, 1998, INT CONGR SER, V1155, P299; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; CARPINO LA, 1994, J CHEM SOC CHEM COMM, P201, DOI 10.1039/c39940000201; CHAN BMC, 1993, J CELL BIOL, V120, P537, DOI 10.1083/jcb.120.2.537; COLLER BS, 1989, BLOOD, V74, P182; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Fields CG, 1996, LETT PEPT SCI, V3, P3, DOI 10.1007/BF00131080; Grab B, 1996, J BIOL CHEM, V271, P12234, DOI 10.1074/jbc.271.21.12234; KADLER K, 1995, FIBRIL FORMING COLLA, V5; KEHREL B, 1995, PLATELETS, V6, P11, DOI 10.3109/09537109509013256; Kehrel B, 1998, BLOOD, V91, P491; KEHREL B, 1995, SEMIN THROMB HEMOST, V21, P123, DOI 10.1055/s-2007-1000386; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; MARTINEZ J, 1978, INT J PEPT PROT RES, V12, P277; Messent AJ, 1998, J CELL SCI, V111, P1127; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; Morton LF, 1997, J BIOL CHEM, V272, P11044; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; PACKMAN LC, 1995, TETRAHEDRON LETT, V36, P7523, DOI 10.1016/0040-4039(95)01522-1; QUIBELL M, 1994, J CHEM SOC CHEM COMM, P2343, DOI 10.1039/c39940002343; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; STAATZ WD, 1990, J BIOL CHEM, V265, P4778; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TUCKWELL D, 1995, J CELL SCI, V108, P1629; ZIJENAH LS, 1990, THROMB RES, V59, P553, DOI 10.1016/0049-3848(90)90415-9	36	229	241	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33287	33294		10.1074/jbc.273.50.33287	http://dx.doi.org/10.1074/jbc.273.50.33287			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837901	hybrid			2022-12-25	WOS:000077462500031
J	Lametschwandtner, G; Brocard, C; Fransen, M; Van Veldhoven, P; Berger, J; Hartig, A				Lametschwandtner, G; Brocard, C; Fransen, M; Van Veldhoven, P; Berger, J; Hartig, A			The difference in recognition of terminal tripeptides as peroxisomal targeting signal 1 between yeast and human is due to different affinities of their receptor Pex5p to the cognate signal and to residues adjacent to it	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN-FLUORESCENT PROTEIN; SACCHAROMYCES-CEREVISIAE; FIREFLY LUCIFERASE; MAMMALIAN-CELLS; PTS1 RECEPTOR; IMPORT; BIOGENESIS; IDENTIFICATION; CATALASE; MEMBRANE	Pex5p is the receptor for the peroxisomal targeting signal 1 (PTS1) that consists of a C-terminal tripeptide (consensus (S/A/C)(K/R/H)(L/M)). Hexadecapeptides recognized by Pex5p from Homo sapiens and Saccharomyces cerevisiae were identified by screening a two-hybrid peptide library, and the targeting ability of the peptides was demonstrated using the green fluorescent protein as reporter. The PTS1 receptors recognized in a species-specific manner a broad range of C-terminal tripeptides, and these are reported herein. In addition, residues upstream of the tripeptide influenced the strength of the interaction in the two-hybrid system as well as in an in vitro competition assay. In peptides interacting with the human protein, hydrophobic residues were found with high frequency especially at positions -2 and -5, whereas peptides interacting with S. cerevisiae Pex5p were more hydrophilic and frequently contained arginine at position -2, In instances where the terminal tripeptide deviated from the consensus, upstream residues exerted a greater influence on the ability of the hexadecapeptides to bind Pex5p.	Univ Vienna, Inst Biochem & Mol Zellbiol, A-1030 Vienna, Austria; Vienna Bioctr, Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria; Catholic Univ Louvain, Fac Geneeskunde, Dept Mol Celbiol, Afdeling Farmakol, B-3000 Louvain, Belgium; Univ Vienna, Klin Inst Neurol, A-1090 Vienna, Austria	University of Vienna; Ludwig Boltzmann Institute; Vienna Biocenter (VBC); Universite Catholique Louvain; University of Vienna	Hartig, A (corresponding author), Univ Vienna, Inst Biochem & Mol Zellbiol, Dr Bohrgasse 9, A-1030 Vienna, Austria.	AH@abc.UniVie.AC.AT	Fransen, Marc/C-6262-2008; , Van Veldhoven Paul/U-6359-2019; Fransen, Marc/ADL-0723-2022; Berger, Johannes/A-9122-2014	Fransen, Marc/0000-0001-9284-1197; , Van Veldhoven Paul/0000-0002-4478-2564; Berger, Johannes/0000-0003-0182-2658; Hartig, Andreas/0000-0003-3334-2763				AITCHISON JD, 1991, J BIOL CHEM, V266, P23197; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bairoch A, 1998, NUCLEIC ACIDS RES, V26, P38, DOI 10.1093/nar/26.1.38; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bolivar F, 1979, Methods Enzymol, V68, P245; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCARD C, 1994, BIOCHEM BIOPH RES CO, V204, P1016, DOI 10.1006/bbrc.1994.2564; Brocard C, 1997, EMBO J, V16, P5491, DOI 10.1093/emboj/16.18.5491; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DIDION T, 1992, FEBS LETT, V303, P113, DOI 10.1016/0014-5793(92)80500-G; Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; Elgersma Y, 1996, J CELL BIOL, V135, P97, DOI 10.1083/jcb.135.1.97; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ERDMANN R, 1994, YEAST, V10, P1173, DOI 10.1002/yea.320100905; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fransen M, 1996, ANAL BIOCHEM, V242, P26, DOI 10.1006/abio.1996.0423; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; GIETL C, 1990, P NATL ACAD SCI USA, V87, P5773, DOI 10.1073/pnas.87.15.5773; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; Gurvitz A, 1998, HISTOCHEM CELL BIOL, V110, P15, DOI 10.1007/s004180050260; HARTIG A, 1992, NUCLEIC ACIDS RES, V20, P5677, DOI 10.1093/nar/20.21.5677; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Monosov EZ, 1996, J HISTOCHEM CYTOCHEM, V44, P581, DOI 10.1177/44.6.8666743; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Paton VG, 1997, J BIOL CHEM, V272, P18945, DOI 10.1074/jbc.272.30.18945; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Purdue PE, 1996, J CELL BIOL, V134, P849, DOI 10.1083/jcb.134.4.849; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; ROGGENKAMP R, 1992, CELL BIOCHEM FUNCT, V10, P193, DOI 10.1002/cbf.290100309; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; Subramani S, 1996, J BIOL CHEM, V271, P32483, DOI 10.1074/jbc.271.51.32483; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; Vanhooren JCT, 1996, EUR J BIOCHEM, V239, P302, DOI 10.1111/j.1432-1033.1996.0302u.x; Wiemer EAC, 1997, J CELL BIOL, V136, P71, DOI 10.1083/jcb.136.1.71; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152	55	158	165	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33635	33643		10.1074/jbc.273.50.33635	http://dx.doi.org/10.1074/jbc.273.50.33635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837948	hybrid			2022-12-25	WOS:000077462500078
J	Letourneur, F; Cosson, P				Letourneur, F; Cosson, P			Targeting to the endoplasmic reticulum in yeast cells by determinants present in transmembrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE GAS1 PROTEIN; RECEPTOR COMPLEX; GOLGI-APPARATUS; PLASMA-MEMBRANE; RETENTION; ER; TRANSPORT; RETRIEVAL; LOCALIZATION; REQUIREMENTS	The transmembrane domains (TMDs) of many type I integral membrane proteins contain determinants that cause localization in the endoplasmic reticulum (ER) in mammalian cells by an unknown mechanism. Here we show that the yeast ER localization machinery recognizes determinants in TMDs that are very similar to those identified previously irt mammalian cells. These determinants are recognized in post-ER compartments and recycled back to the ER, thus acting as ER retrieval signals. Moreover determinants in TMDs are inefficiently sorted in several previously characterized yeast mutants with defects in the ER retrieval machinery. Similar ER retrieval signals sire also recognized in the TMDs of polytopic integral membrane proteins, apparently by the same sorting machinery. The isolation of new mutants defective in sorting of membrane determinants might provide a better understanding of the molecular mechanisms involved in this process.	Ctr Med Univ Geneva, Dept Morphol, CH-1211 Geneva 4, Switzerland; Inst Biol & Chim Prot, F-69367 Lyon, France	University of Geneva	Cosson, P (corresponding author), Ctr Med Univ Geneva, Dept Morphol, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.			Letourneur, Francois/0000-0003-2232-6127				BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Bednarek SY, 1996, TRENDS CELL BIOL, V6, P468, DOI 10.1016/0962-8924(96)84943-9; BOEHM J, 1994, EMBO J, V13, P3696, DOI 10.1002/j.1460-2075.1994.tb06679.x; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BONIFACINO JS, 1991, EMBO J, V10, P840; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DELAHUNTY MD, 1993, J BIOL CHEM, V268, P12017; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GAYNOR EC, 1994, J CELL BIOL, V127, P636; HENNECKE S, 1993, J BIOL CHEM, V268, P26607; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; JONES DH, 1990, BIOTECHNIQUES, V8, P178; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Maniatis T., 1982, MOL CLONING LAB MANU; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; NISHIKAWA S, 1993, P NATL ACAD SCI USA, V90, P8179, DOI 10.1073/pnas.90.17.8179; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; SATO K, 1995, MOL BIOL CELL, V6, P1459, DOI 10.1091/mbc.6.11.1459; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N	35	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33273	33278		10.1074/jbc.273.50.33273	http://dx.doi.org/10.1074/jbc.273.50.33273			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837899	hybrid			2022-12-25	WOS:000077462500029
J	Wang, YQ; Agerberth, B; Lothgren, A; Almstedt, A; Johansson, J				Wang, YQ; Agerberth, B; Lothgren, A; Almstedt, A; Johansson, J			Apolipoprotein A-I binds and inhibits the human antibacterial/cytotolic peptide LL-37	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDE; FAMILY; IMMUNITY; PROTEIN; PLASMA; PR-39	The antibacterial and cytotoxic activity of the human cathelicidin peptide LL-37 is inhibited by plasma. Because LL-37 does not undergo rapid degradation in human plasma, we postulated that this inhibition results from binding of LL-37 to unidentified proteins. An LL-37 binding plasma protein has now been isolated by affinity chromatography, SDS-polyacrylamide gel electrophoresis of proteins that bound to an LL-37 column revealed one band with a molecular mass of about 26 kDa, and amino acid sequence analysis identified the protein as apolipoprotein A-I (apoA-I), Biomolecular interaction analysis using surface plasmon resonance showed that LL-37 and isolated apoA-I bind with an apparent K-d in the low micromolar range. 50 mu M of apoA-I inhibits the antibacterial activity of 50 mu M LL-37 by about 50% of the inhibition exhibited by plasma. In addition, anti-apoA-I IgG completely blocks the plasma inhibition of LL-37 antibacterial activity up to a peptide concentration of 25 mu m and blocks most of the plasma inhibition at higher LL-37 concentrations. These results indicate that apoA-I is the main LL-37 binding protein in human plasma and may work as a scavenger of LL-37, thus suggesting a novel mechanism involved in the regulation of a cathelicidin peptide.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Pharmacia & Upjohn AB, Res, S-11287 Stockholm, Sweden	Karolinska Institutet; Pfizer; Pharmacia Corporation	Johansson, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	jan.johansson@mbb.ki.se		wang, yuqin/0000-0002-3063-3066; Johansson, Jan/0000-0002-8719-4703				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; BLACKBURN WD, 1991, J LIPID RES, V32, P1911; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; CABIAUX V, 1994, EUR J BIOCHEM, V224, P1019, DOI 10.1111/j.1432-1033.1994.01019.x; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; HAMILTON KK, 1993, J BIOL CHEM, V268, P3632; HULTMARK D, 1983, EMBO J, V2, P571, DOI 10.1002/j.1460-2075.1983.tb01465.x; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; Mahoney MM, 1995, FEBS LETT, V377, P519, DOI 10.1016/0014-5793(95)01390-3; PANYUTICH A, 1991, AM J RESP CELL MOL, V5, P101, DOI 10.1165/ajrcmb/5.2.101; RITONJA A, 1989, FEBS LETT, V255, P211, DOI 10.1016/0014-5793(89)81093-2; Sorensen O, 1997, J IMMUNOL METHODS, V206, P53, DOI 10.1016/S0022-1759(97)00084-7; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O	21	104	114	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33115	33118		10.1074/jbc.273.50.33115	http://dx.doi.org/10.1074/jbc.273.50.33115			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837875	hybrid			2022-12-25	WOS:000077462500005
J	Aiyar, A; Sugden, B				Aiyar, A; Sugden, B			Fusions between Epstein-Barr viral nuclear antigen-1 of Epstein-Barr virus and the large T-antigen of simian virus 40 replicate their cognate origins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; MAMMALIAN-CELLS; BINDING-PROTEIN; TUMOR-ANTIGEN; BOVINE PAPILLOMAVIRUS; PLASMID MAINTENANCE; STABLE REPLICATION; LATENT ORIGIN; SV40 ORIGIN; GENE	Epstein-Barr viral nuclear antigen-1 (EBNA-1) is required for the stable replication of plasmids that contain oriP, the origin of DNA synthesis used during the latent phase of the Epstein-Barr virus life cycle. EBNA-1 acts post-synthetically through unknown mechanisms to facilitate the continued synthesis of oriP plasmids in ensuing S phases. In contrast to viral replicons such as that of SV40, DNA synthesis of oriP is restricted to a single round during each cell cycle. Large T-antigen of SV40 is a DNA helicase and activates the synthesis of SV40 DNA by recruiting cellular proteins required for DNA synthesis to the origin of SV40, Using fusion proteins of EBNA-1 and large T-antigen, we tested whether tethering large T-antigen to oriP is sufficient to initiate multiple rounds of DNA synthesis from oriP during each cell cycle. We report here that, although these fusion proteins retain the biological activities of both EBNA-1 and large T-antigen, their constituent proteins do not confer the properties of one on the other. Thus, it is not possible to subvert the cellular controls that restrict DNA synthesis from oriP to a single round per cell cycle. These results also provide insights into architectural constraints at oriP and at the SV40 ori.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sugden, B (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	sugden@oncology.wisc.edu			NATIONAL CANCER INSTITUTE [T32CA009075, P30CA007175] Funding Source: NIH RePORTER; NCI NIH HHS [CA-07175, CA-22442, T32-CA-09075] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; Aiyar A, 1996, Methods Mol Biol, V57, P177; Aiyar A, 1998, EMBO J, V17, P6394, DOI 10.1093/emboj/17.21.6394; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; BACCHETTI S, 1977, P NATL ACAD SCI USA, V74, P1590, DOI 10.1073/pnas.74.4.1590; BAUMANN EA, 1985, J VIROL, V54, P882, DOI 10.1128/JVI.54.3.882-885.1985; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BONNEANDREA C, 1995, J VIROL, V69, P2341, DOI 10.1128/JVI.69.4.2341-2350.1995; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; GAHN TA, 1995, J VIROL, V69, P2633, DOI 10.1128/JVI.69.4.2633-2636.1995; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLANDER M, 1973, WILEY SERIES PROBABI, P67; Johnston SD, 1996, J VIROL, V70, P1191, DOI 10.1128/JVI.70.2.1191-1202.1996; KHOURY G, 1977, J VIROL, V23, P167, DOI 10.1128/JVI.23.1.167-176.1977; Kirchmaier AL, 1997, J VIROL, V71, P1766, DOI 10.1128/JVI.71.3.1766-1775.1997; KIRCHMAIER AL, 1995, J VIROL, V69, P1280, DOI 10.1128/JVI.69.2.1280-1283.1995; KIRCHMAIER AL, 1995, VIRAL GENE TECHNIQUE, P65; KNUTSON JC, 1987, ANAL BIOCHEM, V164, P44, DOI 10.1016/0003-2697(87)90365-4; Lacks S A, 1980, Methods Enzymol, V65, P138; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MACKEY D, 1995, J VIROL, V69, P6199, DOI 10.1128/JVI.69.10.6199-6208.1995; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MCKAY R, 1981, NATURE, V289, P810, DOI 10.1038/289810a0; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MIDDLETON T, 1994, J VIROL, V68, P4067, DOI 10.1128/JVI.68.6.4067-4071.1994; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MYERS RM, 1981, CELL, V25, P373, DOI 10.1016/0092-8674(81)90056-8; Piirsoo M, 1996, EMBO J, V15, P1; Puglielli MT, 1996, J VIROL, V70, P5758, DOI 10.1128/JVI.70.9.5758-5768.1996; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; RIO D, 1980, P NATL ACAD SCI-BIOL, V77, P5706, DOI 10.1073/pnas.77.10.5706; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMALE ST, 1986, MOL CELL BIOL, V6, P4077, DOI 10.1128/MCB.6.11.4077; STERNAS L, 1990, J VIROL, V64, P2407; SUGDEN B, 1989, J VIROL, V63, P2644, DOI 10.1128/JVI.63.6.2644-2649.1989; TEGTMEYER P, 1975, J VIROL, V16, P168, DOI 10.1128/JVI.16.1.168-178.1975; TONG X, 1995, J VIROL, V69, P585, DOI 10.1128/JVI.69.1.585-588.1995; USTAV M, 1991, EMBO J, V10, P4321, DOI 10.1002/j.1460-2075.1991.tb05010.x; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991; YATES JL, 1988, CANCER CELL, V6, P197; Zhang D, 1998, NUCLEIC ACIDS RES, V26, P631, DOI 10.1093/nar/26.2.631	61	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33073	33081		10.1074/jbc.273.49.33073	http://dx.doi.org/10.1074/jbc.273.49.33073			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830062	hybrid			2022-12-25	WOS:000077329100101
J	Dam, TK; Oscarson, S; Sacchettini, JC; Brewer, CF				Dam, TK; Oscarson, S; Sacchettini, JC; Brewer, CF			Differential solvation of "core" trimannoside complexes of the Dioclea grandiflora lectin and concanavalin A detected by primary solvent isotope effects in isothermal titration microcalorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE INTERACTIONS; BINDING-SITE; THERMODYNAMICS	The thermodynamics of binding of the Man/Glc-specific seed lectin from Dioclea grandiflora (DGL) to deoxy analogs of the "core" trimannoside, 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside was determined by isothermal titration microcalorimetry (ITC) in the first paper of this series (Dam, T, K., Oscarson, S., and Brewer, C. F. (1998) J. Biol. Chem. 273, 32812-32817). The data showed binding of specific hydroxyl groups on all three residues of the trimannoside, similar to that observed for ConA (Gupta, D., Dam, T. R., Oscarson, S., and Brewer, C. F. (1997) J. Biol. Chem. 272, 6388-6392), However, differences exist in the thermodynamics of binding of monodeoxy analogs of the alpha(1-6) Man residue of the trimannoside to the two lectins. The x-ray crystal structure of DGL complexed to the core trimannoside, presented in the second paper in this series (Rozwarski, D. A, Swami, B. M., Brewer, C. F., and Sacchettini, J. C. (1998) J, Biol. Chem, 273, 32818-32825), showed the overall structure of the complex to be similar to that of the ConA-trimannoside complex. Furthermore, the trimannoside is involved in nearly identical hydrogen bonding interactions in both complexes. However, differences were noted in the arrangement of ordered water molecules in the binding sites of the two lectins, The present study presents ITC measurements of DGL and ConA binding to the monodeoxy analogs of the trimannoside in hydrogen oxide (H2O) and deuterium oxide (D2O). The solvent isotope effects present in the thermodynamic binding data provide evidence for altered solvation of the parent trimannoside complexes at sites consistent with the x-ray crystal structures of both lectins, The results indicate that the differences in the thermodynamics of DGL and ConA binding to alpha(1-6) monodeoxy analogs of the trimannoside do not correlate with solvation differences of the parent trimannoside complexes.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Stockholm Univ, Dept Organ Chem, S-10691 Stockholm, Sweden; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stockholm University; Texas A&M University System; Texas A&M University College Station	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Oscarson, Stefan/0000-0002-8273-4918	NATIONAL CANCER INSTITUTE [R01CA016054, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16054, P30 CA-13330] Funding Source: Medline; NIGMS NIH HHS [GM-45859] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL BBL, 1967, BIOCHIM BIOPHYS ACTA, V147, P262, DOI 10.1016/0005-2795(67)90404-7; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; Dam TK, 1998, J BIOL CHEM, V273, P32812, DOI 10.1074/jbc.273.49.32812; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MOREIRA RA, 1983, PLANTA, V158, P63, DOI 10.1007/BF00395404; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Oscarson S, 1995, CARBOHYD RES, V278, P271, DOI 10.1016/0008-6215(95)00268-5; Quinn D. M., 1991, THEORETICAL BASIS ME; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SAHA SK, 1994, CARBOHYD RES, V254, P157; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	16	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32826	32832		10.1074/jbc.273.49.32826	http://dx.doi.org/10.1074/jbc.273.49.32826			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830029	hybrid			2022-12-25	WOS:000077329100068
J	Leung, IWL; Lassam, N				Leung, IWL; Lassam, N			Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BEARING KINASE; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; BINDING PROTEINS; HUMAN BRAIN; SH3 DOMAIN; IDENTIFICATION; FAMILY; PATHWAY; MEMBER	Mixed lineage kinase-3 (MLK-3) is a mitogen-activated kinase kinase kinase that mediates stress-activating protein kinase (SAPK)/c-Jun NH2-terminal kinase activation. MLK-3 and other MLK family kinases are characterized by the presence of multiple protein-protein interaction domains including a tandem leucine/isoleucine zipper (LZs) motif, Leucine zippers are known to mediate protein dimerization raising the possibility that the tandem leucine/isoleucine zippers may function as a dimerization motif of MLK-3. Using both co-immunoprecipitation and nonreducing SDS-polyacrylamide gel electrophoresis, we demonstrated that MLK-3 forms disulfide bridged homo-dimers and that the LZs motif is sufficient for MLK-3 homodimerization. We next asked whether MLK-3 utilizes a dimerization-based activation mechanism analogous to that of receptor tyrosine kinases. We found that dimerization via the LZs motif is a prerequisite for MLK-3 autophosphorylation. We then demonstrated that co-expression of Cdc42 lead to a substantial increase in MLK-3 dimerization, indicating that binding by this GTPase may induce MLK-3 dimerization. Moreover, the LZs minus form of MLK-3 failed to activate the downstream target SAPK, and expression of a MLK-3 LZs polypeptide was found to block SAPK activation by wild type MLK-3. Taken together, these findings indicate that dimerization plays a pivotal role in MLK-3 activation.	Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto	Lassam, N (corresponding author), Univ Toronto, Dept Med Biophys, Rm 7360,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chan JLK, 1997, J BIOL CHEM, V272, P146; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; EZOE K, 1994, ONCOGENE, V9, P935; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Heldin CH, 1996, CANCER SURV, V27, P7; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; Hirai S, 1998, J BIOL CHEM, V273, P7406, DOI 10.1074/jbc.273.13.7406; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; ING YL, 1994, ONCOGENE, V9, P1745; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; KATOH M, 1995, ONCOGENE, V10, P1447; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Matsui N, 1996, BIOCHEM BIOPH RES CO, V229, P571, DOI 10.1006/bbrc.1996.1845; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; PARK WY, 1995, BIOCHEM BIOPH RES CO, V211, P447, DOI 10.1006/bbrc.1995.1834; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; Sakuma H, 1997, J BIOL CHEM, V272, P28622, DOI 10.1074/jbc.272.45.28622; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; Tanaka S, 1998, J BIOL CHEM, V273, P1281, DOI 10.1074/jbc.273.3.1281; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; VINSON CR, 1992, NEW BIOL, V4, P396; VRANA KE, 1994, J NEUROCHEM, V63, P2014	36	117	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32408	32415		10.1074/jbc.273.49.32408	http://dx.doi.org/10.1074/jbc.273.49.32408			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829970	hybrid			2022-12-25	WOS:000077329100009
J	Wyckoff, TJO; Lin, SH; Cotter, RJ; Dotson, GD; Raetz, CRH				Wyckoff, TJO; Lin, SH; Cotter, RJ; Dotson, GD; Raetz, CRH			Hydrocarbon rulers in UDP-N-acetylglucosamine acyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; LIPID-A BIOSYNTHESIS; ESCHERICHIA-COLI; ANTIBACTERIAL AGENTS; SPECIFICITY; ENDOTOXINS; BACTERIAL	UDP-GlcNAc acyltransferase (LpxA), the first enzyme of lipid A biosynthesis, catalyzes the transfer of an acyl chain activated on acyl carrier protein (ACP) to UDP-GlcNAc. LpxAs are very selective for the lengths of their acyl donor substrates. Escherichia coli LpxA prefers R-3-hydroxymyristoyl-ACP to R-3-hydroxydecanoyl-ACP by a factor of similar to 1000, whereas Pseudomonas aeruginosa LpxA prefers the opposite. E. coli G173M LpxA and the reciprocal P. aeruginosa M169G LpxA show reversed substrate selectivity in vitro and in vivo, demonstrating the existence of precise hydrocarbon rulers in LpxAs.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol, Middle Atlantic Mass Sepct Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54882, GM-51310] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRABETZ W, 1991, ARCH MICROBIOL, V155, P607, DOI 10.1007/BF00245357; BUNNELL E, 1995, CRIT CARE MED S, V23, pA151; BUNNELL E, 1995, CRIT CARE MED S, V23, pA147; CHRIST WJ, 1995, SCIENCE, V268, P80, DOI 10.1126/science.7701344; Dotson GD, 1998, J BACTERIOL, V180, P330, DOI 10.1128/JB.180.2.330-337.1998; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HARDY LW, 1992, P NATL ACAD SCI USA, V89, P9725, DOI 10.1073/pnas.89.20.9725; KARIBIAN D, 1993, J BACTERIOL, V175, P2988, DOI 10.1128/JB.175.10.2988-2993.1993; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LIEBL W, 1989, FEMS MICROBIOL LETT, V65, P299, DOI 10.1016/0378-1097(89)90234-6; Miller J.H., 1972, EXPT MOL GENETICS; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; Raetz CRH, 1998, PROG CLIN BIOL RES, V397, P1; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Steeghs L, 1997, GENE, V190, P263, DOI 10.1016/S0378-1119(97)00005-X; VAGELOS PR, 1966, FED PROC, V25, P1485; WILKS HM, 1988, SCIENCE, V242, P1541, DOI 10.1126/science.3201242; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X	32	77	80	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32369	32372		10.1074/jbc.273.49.32369	http://dx.doi.org/10.1074/jbc.273.49.32369			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829962	hybrid			2022-12-25	WOS:000077329100001
J	Balazy, M; Kaminski, PM; Mao, KY; Tan, JZ; Wolin, MS				Balazy, M; Kaminski, PM; Mao, KY; Tan, JZ; Wolin, MS			S-nitroglutathione, a product of the reaction between peroxynitrite and glutathione that generates nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-DIOXIDE; CYCLIC-GMP; OXIDATIONS; SUPEROXIDE; DONORS	Peroxynitrite (ONOO-) has been shown in studies on vascular relaxation and guanylate cyclase activation to react with glutathione (GSH), generating an intermediate product that promotes a time-dependent production of nitric oxide (NO), In this study, reactions of ONOO- with GSH produced a new substance, which was characterized by liquid chromatography, ultraviolet spectroscopy, and electrospray tandem mass spectrometry, The mass spectrometric data provided evidence that the product of this reaction was S-nitroglutathione (GSNO(2)) and that S-nitrosoglutathione (GSNO) was not a detectable product of this reaction. Further evidence was obtained by comparison of the spectral and chromatographic properties with synthetic standards prepared by reaction of GSH with nitrosonium or nitronium borofluorates, Both the synthetic and ONOO-/GSH-derived GSNO(2) generated a protonated ion, GSNO(2)H(+) at mit 353, which was unusually resistant to decomposition under collision activation, and no fragmentation was observed at collision energy of 25 eV, In contrast, an ion at mit 337 (GSNOH(+)), generated from the synthetic GSNO, readily fragmented with the abundant loss of NO at 9 eV, Reactions of ONOO- with GSH resulted in the generation of NO, which was detected by the head space/NO-chemiluminescence analyzer method, The generation of NO was inhibited by the presence of glucose and/or CO2 in the buffers employed. Synthetic GSNO(2) spontaneously generated NO in a manner that was not significantly altered by glucose or CO2. Thus, ONOO- reacts with GSH to form GSNO(2), and GSNO(2) decomposes in a manner that generates NO.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; New York Med Coll, Dept Physiol, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Balazy, M (corresponding author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.			Balazy, Ph.D., Michael/0000-0003-0218-8820	NHLBI NIH HHS [HL34300, HL43023, HL31069] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031069, R23HL031069, P01HL034300, P01HL043023, R37HL031069] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Artz JD, 1996, CHEM COMMUN, P927, DOI 10.1039/cc9960000927; Balazy Michael, 1994, Polish Journal of Pharmacology, V46, P593; Berlett BS, 1998, P NATL ACAD SCI USA, V95, P2784, DOI 10.1073/pnas.95.6.2784; BRIEN JF, 1991, J PHARMACOL METHOD, V25, P19, DOI 10.1016/0160-5402(91)90019-2; CAMERON DR, 1995, CAN J CHEM, V73, P1627, DOI 10.1139/v95-202; Davidson CA, 1997, AM J PHYSIOL-LUNG C, V273, pL437, DOI 10.1152/ajplung.1997.273.2.L437; Davidson CA, 1996, AM J PHYSIOL-HEART C, V270, pH1038, DOI 10.1152/ajpheart.1996.270.3.H1038; Davidson CA, 1997, NITRIC OXIDE-BIOL CH, V1, P244, DOI 10.1006/niox.1997.0128; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Dowell FJ, 1997, EUR J PHARMACOL, V338, P43, DOI 10.1016/S0014-2999(97)01320-4; Karoui H, 1997, NITRIC OXIDE-BIOL CH, V1, P346, DOI 10.1006/niox.1997.0140; KEEN JH, 1976, J BIOL CHEM, V251, P6183; LIU S, 1994, J PHARMACOL EXP THER, V268, P1114; MAYER B, 1995, J BIOL CHEM, V270, P17355, DOI 10.1074/jbc.270.29.17355; MORO MA, 1995, BRIT J PHARMACOL, V116, P1999, DOI 10.1111/j.1476-5381.1995.tb16404.x; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Pryor WA, 1997, FREE RADICAL BIO MED, V23, P331, DOI 10.1016/S0891-5849(97)00121-4; QUIGANO C, 1997, BIOCHEM J, V322, P167; RADI R, 1991, J BIOL CHEM, V266, P4244; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; White CR, 1997, BIOCHEM J, V328, P517, DOI 10.1042/bj3280517; WU MD, 1994, AM J PHYSIOL, V266, pH2108, DOI 10.1152/ajpheart.1994.266.5.H2108; Zhang HW, 1997, ARCH BIOCHEM BIOPHYS, V339, P183, DOI 10.1006/abbi.1996.9863	24	112	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32009	32015		10.1074/jbc.273.48.32009	http://dx.doi.org/10.1074/jbc.273.48.32009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822673	hybrid			2022-12-25	WOS:000077207000055
J	Ricken, S; Leipziger, J; Greger, R; Nitschke, R				Ricken, S; Leipziger, J; Greger, R; Nitschke, R			Simultaneous measurements of cytosolic and mitochondrial Ca2+ transients in HT29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT CARDIAC MYOCYTES; COLON-CARCINOMA CELLS; ENDOTHELIAL-CELLS; FREE CALCIUM; CONFOCAL MICROSCOPY; FREE CA-2+; FLUORESCENCE; FURA-2; PH; SUSPENSIONS	Loading of HT29 cells with the Ca2+ dye fura-2/AM resulted in an nonhomogeneous intracellular distribution of the dye. Cellular compartments with high fura-2 concentrations were identified by correlation with mitochondrial markers, cellular autofluorescence induced by UV, and dynamic measurement of autofluorescence after inhibition of oxidative phosphorylation. Stimulation with carbachol (10(-4) mol/liter) increased cytosolic, nuclear, and mitochondrial Ca2+ activity ([Ca2+](c), [Ca2+](n), and [Ca2+](m), respectively) measured by UV confocal and conventional imaging. Similar results were obtained with a prototype two-photon microscope (Zeiss, Jena, Germany) allowing for fura-2 excitation. The increase of [Ca2+](m) lagged behind that of [Ca2+](c) and [Ca2+](n) by 10-20 s, and after removing the agonist, [Ca2+](m) also decreased with a delay. A strong increase of [Ca2+](m) occurred only when a certain threshold of [Ca2+](c) (around 1 mu mol/liter) was exceeded. In a very similar way, ATP, neurotensin, and thapsigargin increased [Ca2+](c) and [Ca2+](m). Carbonyl cyanide p-trifluoromethoxyphenylhyrdrazone reversibly reduced the increase of [Ca2+](m). The source of the mitochondrial Ca2+ increase had intra- and extracellular components, as revealed by experiments in low extracellular Ca2+. We conclude that agonist-induced Ca2+ signals are transduced into mitochondria, 1) Mitochondria could serve as a Ca2+ sink, 2) mitochondria could allow the modulation of [Ca2+](c) and [Ca2+](n) signals, and 3) [Ca2+](m) may serve as a stimulatory metabolic signal when a cell is highly stimulated.	Univ Freiburg, Inst Physiol, D-79104 Freiburg, Germany	University of Freiburg	Nitschke, R (corresponding author), Univ Freiburg, Inst Physiol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Nitschke, Roland/F-9525-2010	Nitschke, Roland/0000-0002-9397-8475; Leipziger, Jens/0000-0002-6719-7034				Benning N, 1996, PFLUG ARCH EUR J PHY, V432, P126, DOI 10.1007/s004240050114; Chacon E, 1996, FEBS LETT, V382, P31, DOI 10.1016/0014-5793(96)00138-X; CHACON E, 1992, BIOCHEM J, V281, P871, DOI 10.1042/bj2810871; CHACON E, 1994, BIOPHYS J, V66, P942, DOI 10.1016/S0006-3495(94)80904-X; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; Donnadieu E, 1996, CELL CALCIUM, V20, P53, DOI 10.1016/S0143-4160(96)90050-0; ENG J, 1989, BIOPHYS J, V55, P621, DOI 10.1016/S0006-3495(89)82859-0; Griffiths EJ, 1997, CELL CALCIUM, V21, P321, DOI 10.1016/S0143-4160(97)90120-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTER TE, 1988, AM J PHYSIOL, V255, P304; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; KERST G, 1995, PFLUG ARCH EUR J PHY, V430, P653, DOI 10.1007/BF00386159; KOPP R, 1989, EUR J PHARM-MOLEC PH, V172, P397, DOI 10.1016/0922-4106(89)90021-7; KOTTGEN M, 1994, PFLUG ARCH EUR J PHY, V428, P179, DOI 10.1007/BF00374856; Lawrie AM, 1996, J BIOL CHEM, V271, P10753, DOI 10.1074/jbc.271.18.10753; LEIPZIGER J, 1991, Cellular Physiology and Biochemistry, V1, P273, DOI 10.1159/000154615; LUKACS GL, 1987, BIOCHEM J, V248, P609, DOI 10.1042/bj2480609; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MILLS LR, 1994, 3 DIMENSIONAL CONFOC, P253; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; NATHANSON MH, 1992, CELL CALCIUM, V13, P89, DOI 10.1016/0143-4160(92)90002-A; NICHOLS BJ, 1995, MOL CELL BIOCHEM, V149, P203, DOI 10.1007/BF01076578; NITSCHKE R, 1993, PFLUG ARCH EUR J PHY, V423, P519, DOI 10.1007/BF00374950; NITSCHKE R, 1991, PFLUG ARCH EUR J PHY, V417, P622, DOI 10.1007/BF00372961; Nitschke R, 1997, PFLUG ARCH EUR J PHY, V434, P466, DOI 10.1007/s004240050422; Nitschke R, 1997, PFLUG ARCH EUR J PHY, V433, P653, DOI 10.1007/s004240050327; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; Purkiss JR, 1996, CELL CALCIUM, V20, P21, DOI 10.1016/S0143-4160(96)90047-0; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REERS M, 1989, BIOCHEM J, V257, P131, DOI 10.1042/bj2570131; RINK TJ, 1985, CELL CALCIUM, V6, P133, DOI 10.1016/0143-4160(85)90040-5; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SHEU SS, 1994, J BIOENERG BIOMEMBR, V26, P487, DOI 10.1007/BF00762733; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; STEINBERG SF, 1987, AM J PHYSIOL, V253, pC744, DOI 10.1152/ajpcell.1987.253.5.C744; WILLIFORD DJ, 1990, CIRC RES, V66, P234	42	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34961	34969		10.1074/jbc.273.52.34961	http://dx.doi.org/10.1074/jbc.273.52.34961			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857027	hybrid			2022-12-25	WOS:000077719700045
J	Galibert, L; Tometsko, ME; Anderson, DM; Cosman, D; Dougall, WC				Galibert, L; Tometsko, ME; Anderson, DM; Cosman, D; Dougall, WC			The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappa B, a member of the TNFR superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSFORMING PROTEIN; TERMINAL KINASE; BINDING-SITES; FACTOR FAMILY; TRAF2; DOMAIN; MEMBRANE-PROTEIN-1; ASSOCIATION; MEDIATOR; CLONING	Receptor activator of NF-kappa B (RANK) is a recently identified member of the tumor necrosis factor receptor superfamily and is expressed on activated T cells and dendritic cells. Its cognate ligand (RANKL) plays significant roles in the activation of dendritic cell function and osteoclast differentiation. We demonstrate here the interaction of RANK with tumor necrosis factor receptor-associated factors (TRAFs) 1, 2, 3, 5, and 6 both in vitro and in cells. Mapping of the structural requirements for TRAF/RANK interaction revealed multiple TRAF binding sites clustered in two distinct domains in the RANK cytoplasmic tail. These TRAF binding domains were shown to be functionally important for the RANK-dependent induction of NF-kappa B and c-Jun NH2-terminal kinase activities. Site-directed mutagenesis demonstrated that these TRAF binding sites exhibited. selective binding for different TRAF proteins. In particular, TRAF6 interacted with membrane-proximal determinants distinct from those binding TRAFs 1, 2, 3, and 5. When this membrane-proximal TRAF6 interaction domain was deleted, RANK-mediated NF-kappa B signaling was completely inhibited while c-Jun NH2-terminal kinase activation was partially inhibited. An NH2-terminal truncation mutant of TRAF6 inhibited RANKL-mediated NF-kappa B activation, but failed to affect constitutive signaling induced by receptor overexpression,revealing a selective role for TRAF6 in ligand-induced activation events.	Immunex Res & Dev Corp, Dept Mol Biol, Seattle, WA 98101 USA		Dougall, WC (corresponding author), Immunex Res & Dev Corp, Dept Mol Biol, 51 Univ St, Seattle, WA 98101 USA.			Dougall, William/0000-0001-9487-251X				Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Bonnert TP, 1997, FEBS LETT, V402, P81, DOI 10.1016/S0014-5793(96)01506-2; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; CAOZ, 1996, NATURE, V383, P443; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Fanslow W C, 1994, Semin Immunol, V6, P267, DOI 10.1006/smim.1994.1035; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Nakano H, 1996, J BIOL CHEM, V271, P14661, DOI 10.1074/jbc.271.25.14661; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	31	269	291	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34120	34127		10.1074/jbc.273.51.34120	http://dx.doi.org/10.1074/jbc.273.51.34120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852070	hybrid			2022-12-25	WOS:000077542200036
J	Hocker, M; Raychowdhury, R; Plath, T; Wu, HJ; O'Connor, DT; Wiedenmann, B; Rosewicz, S; Wang, TC				Hocker, M; Raychowdhury, R; Plath, T; Wu, HJ; O'Connor, DT; Wiedenmann, B; Rosewicz, S; Wang, TC			Sp1 and CREB mediate gastrin-dependent regulation of chromogranin A promoter activity in gastric carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-DECARBOXYLASE PROMOTER; PHORBOL 12-MYRISTATE 13-ACETATE; ENTEROCHROMAFFIN-LIKE CELLS; PROTEIN-KINASE; GROWTH-FACTOR; RAT STOMACH; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CAMP	Chromogranin A (CgA) is a multifunctional acidic protein that in the stomach is expressed predominantly in enterochromaffin-like cells (ECL cells) where it is regulated by gastrin, In order to investigate the transcriptional response of the mouse CgA (mCgA) promoter to gastrin stimulation, we studied a 4.8-kilobase mCgA promoter-luciferase reporter gene construct in transiently transfected AGS-B cells, 5'-Deletion analysis and scanning mutagenesis of mCgA 5'-flanking DNA showed that a Sp1/Egr-1 site spanning -88 to -77 base pairs (bp) and a cyclic AMP-responsive element (CRE) at -71 to -64 bp are essential for gastrin-dependent mCgA transactivation. Gastrin stimulation increased cellular Sp1 protein levels and Sp1-binding to the mCgA -88 to -77 bp element, as well as binding of CREB to its consensus motif at -71 to -64 bp. Gastrin also stimulated CREB Ser-133 phosphorylation, and abundance of cellular CREB protein levels. Overexpression of either Sp1 or phosphorylated CREB transactivated the mCgA promoter dose dependently, while coexpression of both transcription factors resulted in an additive mCgA promoter response, mCgA -92 to -64 bp, comprising the Sp1/Egr-1 site and the CRE motif, conferred gastrin responsiveness to a heterologous thymidine kinase promoter system, and therefore functions as a "true" enhancer element. This report demonstrates that Sp1 and CREB mediate CCK-B/gastrin receptor-dependent gene regulation, and that the effect of gastrin on the CgA gene is brought about by cooperative action of both transcription factors.	Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Humboldt Univ, Klinikum Charite, Med Klin Scherpunkt Gastroenterol & Hepatol, D-1086 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, D-1000 Berlin, Germany; Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Univ Calif San Diego, Ctr Mol Genet, San Diego, CA 92161 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of California System; University of California San Diego; University of California System; University of California San Diego	Wang, TC (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, 30 Fruit St, Boston, MA 02114 USA.	Wang@helix.mgh.harvard.edu		Wiedenmann, Bertram/0000-0002-7890-2552	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048077] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 48077] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAUERFEIND R, 1994, ANN NY ACAD SCI, V733, P385; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; CETIN Y, 1991, CELL TISSUE RES, V264, P231, DOI 10.1007/BF00313960; CHANG CY, 1992, MOL ENDOCRINOL, V6, P1362, DOI 10.1210/me.6.9.1362; CHEN D, 1994, GASTROENTEROLOGY, V107, P18, DOI 10.1016/0016-5085(94)90056-6; CHEN JY, 1992, BIOCHEMISTRY-US, V31, P2400, DOI 10.1021/bi00123a027; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DIMALINE R, 1993, AM J PHYSIOL, V264, pG583, DOI 10.1152/ajpgi.1993.264.3.G583; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAKANSON R, 1995, GASTROENTEROLOGY, V108, P1445, DOI 10.1016/0016-5085(95)90693-2; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; Hocker M, 1998, J BIOL CHEM, V273, P23046, DOI 10.1074/jbc.273.36.23046; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1988, CELL, V55, P124; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Koh TJ, 1997, GASTROENTEROLOGY, V113, P1015, DOI 10.1016/S0016-5085(97)70199-9; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Modlin IM, 1996, GASTROENTEROLOGY, V111, P783, DOI 10.1053/gast.1996.v111.agast961110783; MONTMINY MR, 1993, GENE EXPRESSION GEN, P77; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; Nagata A, 1996, P NATL ACAD SCI USA, V93, P11825, DOI 10.1073/pnas.93.21.11825; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Noti JD, 1996, MOL CELL BIOL, V16, P2940; OCONNOR DT, 1993, ANN NY ACAD SCI, V729, P36; Schubert ML, 1996, CURR OPIN GASTROEN, V12, P493, DOI 10.1097/00001574-199611000-00002; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STABILE BE, 1990, ARCH SURG-CHICAGO, V125, P451; SYVERSEN U, 1993, ACTA ONCOL, V32, P161, DOI 10.3109/02841869309083906; TANG K, 1997, J BIOL CHEM, V271, P28382; Tang KC, 1997, J CLIN INVEST, V100, P1180, DOI 10.1172/JCI119630; UHLER MD, 1987, J BIOL CHEM, V262, P15202; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WATKINSON A, 1992, REGUL PEPTIDES, V40, P51, DOI 10.1016/0167-0115(92)90083-7; WU HJ, 1994, J CLIN INVEST, V94, P118, DOI 10.1172/JCI117297; WU HJ, 1995, J CLIN INVEST, V96, P568, DOI 10.1172/JCI118069; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhang ZS, 1996, J BIOL CHEM, V271, P14188, DOI 10.1074/jbc.271.24.14188	52	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34000	34007		10.1074/jbc.273.51.34000	http://dx.doi.org/10.1074/jbc.273.51.34000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852054	hybrid			2022-12-25	WOS:000077542200020
J	Lindorfer, MA; Myung, CS; Savino, Y; Yasuda, H; Khazan, R; Garrison, JC				Lindorfer, MA; Myung, CS; Savino, Y; Yasuda, H; Khazan, R; Garrison, JC			Differential activity of the G protein beta(5)gamma(2) subunit at receptors and effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; BACULOVIRUS EXPRESSION SYSTEM; GTPASE-ACTIVATING PROTEIN; HETEROTRIMERIC G-PROTEINS; RECOMBINANT G-PROTEINS; PHOSPHOLIPASE-C-BETA; COUPLED RECEPTORS; SF9 CELLS; DEPENDENT PHOSPHORYLATION; SELECTIVE ACTIVATION	The G protein beta(5) subunit differs substantially in amino acid sequence from the other known beta subunits suggesting that beta gamma dimers containing this protein may play specialized roles in cell signaling. To examine the functional properties of the beta(5) subunit, recombinant beta(5)gamma(2) dimers were purified from baculovirus-infected Sf9 insect cells using a strategy based on two affinity tags (hexahistidine and FLAG) engineered into the N terminus of the gamma(2) subunit (gamma(2HF)). The function of the pure beta(5)gamma(2HF) dimers was examined in three assays: activation of pure phospholipase C-beta in lipid vesicles; activation of recombinant, type II adenylyl cyclase expressed in Sf9 cell membranes; and coupling of a subunits to the endothelin B (ETB) and M-1 muscarinic receptors. In each case, the efficacy of the beta(5)gamma(2HF) dimer was compared with that of the beta(1)gamma(2HF) dimer, which has demonstrated activity in these assays. The beta(5)gamma(2HF) dimer activated phospholipase C-beta with a potency and efficacy similar to that of beta(1)gamma(2) or beta(1)gamma(2HF); however, it was markedly less effective than the beta(1)gamma(2HF) or beta(1)gamma(2) dimer in its ability to activate type II adenylyl cyclase (EC50 of similar to 700 nM versus 25 nM). Both the beta(5)gamma(2HF) and the beta(1)gamma(2HF) dimers supported coupling of M-1 muscarinic receptors to the G(q) alpha subunit. The ET, receptor coupled effectively to both the G(i) and G(q) alpha subunits in the presence of the beta(1)gamma(2HF) dimer. In contrast, the beta(5)gamma(2HF) dimer only supported coupling of the G(q) alpha subunits to the ETB receptor and did not support coupling of the G(i) alpha subunit. These results suggest that the beta(5)gamma(2HF) dimer binds selectively to G(q) alpha subunits and does not activate the same set of effecters as dimers containing the beta(1) subunit. Overall, the data support a specialized role for the beta(5) subunit in cell signaling.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Garrison, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22908 USA.	jcg8w@virginia.edu		Myung, Chang-Seon/0000-0002-6292-2911	NCI NIH HHS [P01-CA-40042] Funding Source: Medline; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAMORI I, 1992, J BIOL CHEM, V267, P12468; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BOYER JL, 1994, J BIOL CHEM, V269, P2814; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; ELSHOURBAGY NA, 1993, J BIOL CHEM, V268, P3873; ELSHOURBAGY NA, 1992, MOL PHARMACOL, V41, P465; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Figler RA, 1996, MOL PHARMACOL, V50, P1587; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; Jones PG, 1998, BBA-MOL CELL RES, V1402, P288, DOI 10.1016/S0167-4889(98)00017-2; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PARKER EM, 1991, J BIOL CHEM, V266, P519; SHICHI H, 1978, J BIOL CHEM, V253, P7040; Siffert W, 1998, NAT GENET, V18, P45, DOI 10.1038/ng0198-45; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; Wall MA, 1998, STRUCTURE, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Yasuda H, 1998, J BIOL CHEM, V273, P21958, DOI 10.1074/jbc.273.34.21958; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	63	77	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34429	34436		10.1074/jbc.273.51.34429	http://dx.doi.org/10.1074/jbc.273.51.34429			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852110	hybrid			2022-12-25	WOS:000077542200076
J	Medintz, I; Jiang, H; Michels, CA				Medintz, I; Jiang, H; Michels, CA			The role of ubiquitin conjugation in glucose-induced proteolysis of Saccharomyces maltose permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CELL-CYCLE; CATABOLITE INACTIVATION; INDUCED DEGRADATION; URACIL PERMEASE; GENE-EXPRESSION; PROTEIN LIGASE; YEAST; CEREVISIAE; ENDOCYTOSIS	In Saccharomyces, the addition of glucose induces a rapid degradation of maltose permease that is dependent on endocytosis and vacuolar proteolysis (Medintz, I., Jiang, H, Wan, E, K., Cui, W., and Michels, C. A. (1996) J. Bacteriol. 178, 2245-2254). Here we report on the role of ubiquitin conjugation in this process. Deletion of DOA4, which causes decreased levels of available ubiquitin, severely decreases the rate of glucose-induced proteolysis, and this is suppressed by the overproduction of ubiquitin. Overexpression of ubiquitin in an endocytosis-deficient end3-ts strain results in the glucose-stimulated accumulation of a larger molecular weight species of maltose permease, which we demonstrate is a ubiquitin-modified form of the protein by utilizing two ubiquitin alleles with different molecular weights. The size of this ubiquitinated species of maltose permease is consistent with monoubiquitination. A promoter mutation that reduces expression of RSP5/NPI1, a postulated ubiquitin-protein ligase, dramatically reduces the rate of glucose-induced proteolysis of maltose permease. The role of various ubiquitin-conjugating enzymes was investigated using strains carrying mutant alleles ubc1 Delta ubc4 Delta, ubc4 Delta ubc5 Delta, cdc34-ts2/ubc3, and ubc9-ts. Loss of these functions was not shown to effect glucose-induced proteolysis of maltose permease, but loss of Ubc1, -4, and -5 was found to inhibit maltose permease expression at the post-transcriptional level.	CUNY Queens Coll, Dept Biol, Flushing, NY 11367 USA; CUNY, Grad Sch, Flushing, NY 11367 USA	City University of New York (CUNY) System; Queens College NY (CUNY); City University of New York (CUNY) System	Michels, CA (corresponding author), CUNY Queens Coll, Dept Biol, 65-30 Kissena Blvd, Flushing, NY 11367 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049280] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49280] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; CHARRON MJ, 1986, MOL CELL BIOL, V6, P3891, DOI 10.1128/MCB.6.11.3891; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CHENG Q, 1989, GENETICS, V123, P477; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; DUBIN RA, 1985, J BACTERIOL, V164, P605, DOI 10.1128/JB.164.2.605-610.1985; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; GALAN JM, 1994, BIOCHEM BIOPH RES CO, V201, P769, DOI 10.1006/bbrc.1994.1767; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4604; Horak J, 1997, J BACTERIOL, V179, P1541, DOI 10.1128/jb.179.5.1541-1549.1997; HU Z, 1995, CURR GENET, V28, P258, DOI 10.1007/BF00309785; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jiang H, 1997, MOL BIOL CELL, V8, P1293, DOI 10.1091/mbc.8.7.1293; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Lucero P, 1997, FEMS MICROBIOL LETT, V147, P273, DOI 10.1016/S0378-1097(96)00538-1; Martinez P, 1998, J BACTERIOL, V180, P2253, DOI 10.1128/JB.180.8.2253-2256.1998; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V88, P4604; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Robinson KS, 1996, MOL BIOL CELL, V7, P81, DOI 10.1091/mbc.7.1.81; ROHRER J, 1993, MOL BIOL CELL, V4, P511, DOI 10.1091/mbc.4.5.511; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SIKORSKI RS, 1989, GENETICS, V122, P19; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; WARD AC, 1994, YEAST, V10, P441, DOI 10.1002/yea.320100403	49	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34454	34462		10.1074/jbc.273.51.34454	http://dx.doi.org/10.1074/jbc.273.51.34454			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852113	hybrid			2022-12-25	WOS:000077542200079
J	Attmane-Elakeb, A; Mount, DB; Sibella, V; Vernimmen, C; Hebert, SC; Bichara, M				Attmane-Elakeb, A; Mount, DB; Sibella, V; Vernimmen, C; Hebert, SC; Bichara, M			Stimulation by in vivo and in vitro metabolic acidosis of expression of rBSC-1, the Na+-K+(NH4+)-2Cl(-) cotransporter of the rat medullary thick ascending limb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; AMMONIUM TRANSPORT; NEPHRON SEGMENTS; NH4+ TRANSPORT; RABBIT KIDNEY; CELLS; PROTEIN; GENE; PH; ALKALOSIS	To assess whether metabolic acidosis per se regulates rBSC-1, the rat medullary thick ascending limb (MTAL) epical Na+-K+(NH4+)-2Cl(-) cotransporter, rat MTALs were incubated for 16 h in an acid 1:1 mixture of Ham's nutrient mixture F-12 and Dulbecco's modified Eagle's medium. Cotransport activity was estimated in intact cells and membrane vesicles by intracellular pH and Na-22(+) Uptake measurements, respectively; rBSC-1 protein was quantified by immunoblotting analysis and mRNA by quantitative reverse transcription-polymerase chain reaction. As compared with incubation at pH similar to 7.35, acid incubation (pH similar to 7.10) up-regulated by 35-100% rBSC-1 transport activity in cells and membrane vesicles, and rBSC-1 protein and mRNA abundance. In contrast, acid incubation did not alter alkaline phosphatase and Na+/K+-ATPase enzyme activities or beta-actin protein abundance. After 3 h of in vivo chronic metabolic acidosis (CMA) rBSC-1 mRNA abundance increased in freshly harvested MTALs, which was accompanied after 1-6 days of CMA with enhanced rBSC-1 protein abundance, These results demonstrate that both in vivo and in vitro CMA stimulate rBSC-1 expression, which would contribute to the adaptive increase in MTAL absorption and urinary excretion of NH4+ in response to CMA.	Univ Paris 06, INSERM, U356, F-75006 Paris, France; Vanderbilt Univ, Div Nephrol, Nashville, TN 37232 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Vanderbilt University	Bichara, M (corresponding author), Fac Med Xavier Bichat, INSERM, U426, 16 Rue Henri Huchard, F-75870 Paris 18, France.				NIDDK NIH HHS [DK36803, DK02103] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002103, R01DK036803] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amlal H, 1998, J CLIN INVEST, V101, P1045, DOI 10.1172/JCI686; Amlal H, 1996, AM J PHYSIOL-CELL PH, V271, pC455, DOI 10.1152/ajpcell.1996.271.2.C455; AMLAL H, 1994, J BIOL CHEM, V269, P21962; AMLAL H, 1994, AM J PHYSIOL-CELL PH, V267, pC1607, DOI 10.1152/ajpcell.1994.267.6.C1607; Attmane-Elakeb A, 1998, KIDNEY INT, V53, P439, DOI 10.1046/j.1523-1755.1998.00760.x; AttmaneElakeb A, 1997, J BIOL CHEM, V272, P25668, DOI 10.1074/jbc.272.41.25668; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUERKERT J, 1982, J CLIN INVEST, V70, P1, DOI 10.1172/JCI110581; Cano A, 1996, AM J PHYSIOL-RENAL, V271, pF629, DOI 10.1152/ajprenal.1996.271.3.F629; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGAN MG, 1982, AM J PHYSIOL, V242, pF499, DOI 10.1152/ajprenal.1982.242.5.F499; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V271, pF619, DOI 10.1152/ajprenal.1996.271.3.F619; Frick KK, 1997, AM J PHYSIOL-CELL PH, V272, pC1450, DOI 10.1152/ajpcell.1997.272.5.C1450; GAMBA G, 1994, J BIOL CHEM, V269, P17713; GARVIN J L, 1988, American Journal of Physiology, V255, pF57; GOOD DW, 1990, AM J PHYSIOL, V258, pF1345, DOI 10.1152/ajprenal.1990.258.5.F1345; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Igarashi P, 1996, J BIOL CHEM, V271, P9666, DOI 10.1074/jbc.271.16.9666; JURKOVITZ CT, 1992, KIDNEY INT, V42, P595, DOI 10.1038/ki.1992.323; Kaplan MR, 1996, KIDNEY INT, V49, P40, DOI 10.1038/ki.1996.6; KHADOURI C, 1992, AM J PHYSIOL, V262, pF583, DOI 10.1152/ajprenal.1992.262.4.F583; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; Laghmani K, 1997, J CLIN INVEST, V99, P24, DOI 10.1172/JCI119128; LEVIEL F, 1992, J CLIN INVEST, V90, P869, DOI 10.1172/JCI115962; Mount DB, 1997, J MEMBRANE BIOL, V158, P177, DOI 10.1007/s002329900255; MOUNT DB, 1995, J AM SOC NEPHROL, V6, P347; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Pitts R. F., 1973, RENAL PHYSIOL BIOCH, P455; Schmedtje JF, 1996, BBA-MOL CELL RES, V1314, P25, DOI 10.1016/S0167-4889(96)00074-2; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; SIMON E, 1985, J CLIN INVEST, V76, P855, DOI 10.1172/JCI112043; WATTS BA, 1994, J GEN PHYSIOL, V103, P917, DOI 10.1085/jgp.103.5.917; Xu JZ, 1997, AM J PHYSIOL-RENAL, V273, pF739, DOI 10.1152/ajprenal.1997.273.5.F739; YAMAJI Y, 1994, J CLIN INVEST, V94, P1297, DOI 10.1172/JCI117448; Yamaji Y, 1997, AM J PHYSIOL-CELL PH, V272, pC886, DOI 10.1152/ajpcell.1997.272.3.C886; Yang TX, 1996, AM J PHYSIOL-RENAL, V271, pF931, DOI 10.1152/ajprenal.1996.271.4.F931	38	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33681	33691		10.1074/jbc.273.50.33681	http://dx.doi.org/10.1074/jbc.273.50.33681			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837954	hybrid			2022-12-25	WOS:000077462500084
J	Henderson, LM				Henderson, LM			Role of histidines identified by mutagenesis in the NADPH oxidase-associated H+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; HYDROGEN-ION CURRENTS; SMOOTH-MUSCLE CELLS; VIRUS M2 PROTEIN; HUMAN-NEUTROPHILS; ARACHIDONIC-ACID; PLASMA-MEMBRANE; INFLUENZA-VIRUS; CYTOSOLIC COMPONENT; RESPIRATORY BURST	The efflux of protons through a H+ channel acts as the charge compensation pathway for the electrogenic generation of superoxide (O-2(radical anion)) by human neutrophil NADPH oxidase. It has previously been shown that the N-terminal 230 amino acids of the product of the X-linked chronic granulomatous gene gp91(phox) contain all that is required for it to function as the arachidonate-activable, NADPH oxidase-associated H+ channel (Henderson, L. M., Thomas, S., Panting, G., and Chappell, J, B. (1997) Biochem. J, 325, 701-705). To identify functionally important amino acids, Chinese hamster ovary (CHO) cell lines were constructed that expressed point mutations in the N terminus of gp91(phox), No H+ flux was observed in CHO cell lines expressing the N-terminal gp91(phox) mutants H111L, H115L, and H119L, or H115L, or H115K. Partial retention of H+ channel function was, however, observed in the H115D CHO cell line. The addition of arachidonic acid to R91E,R92E CHO cells elicited a full H+ channel response. The buffering capacity and response of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein to H+ were the same in all cell lines. Therefore, it can be concluded that His-115 is important to the ability of gp91(phox) to function as the NADPH oxidase-associated H+ channel and that the mechanism of H+ conduction involves protonation and deprotonation of an amino acid with an appropriate pK value.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Henderson, LM (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	L.M.Henderson@bris.ac.uk						ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BARISH ME, 1984, J PHYSIOL-LONDON, V352, P243, DOI 10.1113/jphysiol.1984.sp015289; BERHEIM L, 1993, J PHYSIOL-LONDON, V470, P313; Bjorgvinsdottir H, 1996, BLOOD, V87, P2005, DOI 10.1182/blood.V87.5.2005.bloodjournal8752005; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; DECOURSEY TE, 1991, BIOPHYS J, V60, P1243, DOI 10.1016/S0006-3495(91)82158-0; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; GARCIAHORSMAN JA, 1995, BIOCHEMISTRY-US, V34, P4428, DOI 10.1021/bi00013a035; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1992, BIOCHEM J, V283, P171, DOI 10.1042/bj2830171; HENDERSON LM, 1988, BIOCHEM J, V255, P285; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1997, BIOCHEM J, V325, P701, DOI 10.1042/bj3250701; HOLMBERG E, 1994, BIOCHEMISTRY-US, V33, P7691, DOI 10.1021/bi00190a024; KAPUS A, 1994, J BIOL CHEM, V269, P4736; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; REAVES B, 1994, FEBS LETT, V351, P448, DOI 10.1016/0014-5793(94)00813-2; Roos D, 1996, BLOOD, V87, P1663; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SANSOM MSP, 1993, PROTEIN ENG, V6, P65, DOI 10.1093/protein/6.1.65; Schrenzel J, 1998, NATURE, V392, P734, DOI 10.1038/33725; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; THOMAS RC, 1982, NATURE, V299, P826, DOI 10.1038/299826a0; TSUNAWAKI S, 1994, BIOCHEM BIOPH RES CO, V199, P1378, DOI 10.1006/bbrc.1994.1383; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; ZHOU YL, 1995, BBA-MOL CELL RES, V1265, P40, DOI 10.1016/0167-4889(94)00207-U	44	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33216	33223		10.1074/jbc.273.50.33216	http://dx.doi.org/10.1074/jbc.273.50.33216			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837891	hybrid			2022-12-25	WOS:000077462500021
J	Jansen, LET; Verhage, RA; Brouwer, JA				Jansen, LET; Verhage, RA; Brouwer, JA			Preferential binding of yeast Rad4 center dot Rad23 complex to damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; ESCHERICHIA-COLI; IN-VITRO; STRAND; GENE; PROTEIN; RAD23	The yeast Rad4 and Rad23 proteins form a complex that is involved in nucleotide excision repair (NER). Their function in this process is not known yet, but genetic data suggest that they act in an early step in NER. We have purified an epitope-tagged Rad4.Rad23 (tRad4.Rad23) complex from yeast cells, using a clone overproducing Rad4 with a hemagglutinin-tag at its C terminus. tRad4.Rad23 complex purified by both conventional and immuno-affinity chromatography complements the in vitro repair defect of rad4 and rad23 mutant extracts, demonstrating that these proteins are functional in NER. Using electrophoretic mobility shift assays, we show preferential binding of the tRad4.Rad23 complex to damaged DNA in vitro. UV-irradiated, as well as N-acetoxy-2-(acetylamino)fluorene-treated DNA, is efficiently bound by the protein complex. These data suggest that Rad4.Rad23 interacts with DNA damage during NER and may play a role in recognition of the damage.	Leiden Univ, Leiden Inst Chem, MGC Dept Mol Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Brouwer, JA (corresponding author), Leiden Univ, Leiden Inst Chem, MGC Dept Mol Genet, POB 9502, NL-2300 RA Leiden, Netherlands.	brouwer@chem.leidenuniv.nl		Jansen, Lars/0000-0002-2158-0345				BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; FLEER R, 1987, MOL CELL BIOL, V7, P1180, DOI 10.1128/MCB.7.3.1180; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Guzder SN, 1997, J BIOL CHEM, V272, P21665, DOI 10.1074/jbc.272.35.21665; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HANSSON J, 1989, J BIOL CHEM, V264, P21788; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; Lombaerts M, 1997, NUCLEIC ACIDS RES, V25, P3974, DOI 10.1093/nar/25.20.3974; LU AL, 1980, NUCLEIC ACIDS RES, V8, P1839, DOI 10.1093/nar/8.8.1839; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Mu D, 1997, J BIOL CHEM, V272, P7570, DOI 10.1074/jbc.272.12.7570; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Verhage RA, 1996, MUTAT RES-DNA REPAIR, V362, P155, DOI 10.1016/0921-8777(95)00045-3; Verhage RA, 1996, NUCLEIC ACIDS RES, V24, P1020, DOI 10.1093/nar/24.6.1020; VERHAGE RA, 1998, NUCL ACID M, V12, P157; VISSE R, 1991, J BIOL CHEM, V266, P7609; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	27	70	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33111	33114		10.1074/jbc.273.50.33111	http://dx.doi.org/10.1074/jbc.273.50.33111			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837874	hybrid			2022-12-25	WOS:000077462500004
J	McIntire, WE; Dingus, J; Schey, KL; Hildebrandt, JD				McIntire, WE; Dingus, J; Schey, KL; Hildebrandt, JD			Characterization of the major bovine brain G(o) alpha isoforms - Mapping the structural differences between the alpha subunit isoforms identifies A variable region of the protein involved in receptor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; BETA-GAMMA-SUBUNITS; GO-ALPHA; LIMITED PROTEOLYSIS; ADENYLATE-CYCLASE; MAMMALIAN BRAIN; AMINO TERMINUS; 2 FORMS; MEMBRANES; CELLS	G(o) is the major G protein in bovine brain, with at least three isoforms, G(oA), G(oB), and G(oC), Whereas alpha(oA) and alpha(oB) arise from a single G(o)alpha gene as alternatively spliced mRNAs, alpha(oA) and alpha(oC) are thought to differ by covalent modification. To test the hypothesis that alpha(oA) and alpha(oC) have different N-terminal lipid modifications, proteolytic fragments of alpha(o) isoforms were immunoprecipitated with an N terminus-specific antibody and analyzed by matrix-assisted laser desorption ionization mass spectrometry. The major masses observed in immunoprecipitates were the same for all three alpha(o) isoforms and corresponded to the predicted mass of a myristoylated N-terminal fragment. Struct ural differences between alpha(oA) and alpha(oC) were also compared before and after limited tryptic proteolysis using SDS-polyacrylamide gel electrophoresis containing 6 M urea, Based upon the alpha(o) subunit fragments produced under activating and nonactivating conditions, differences between alpha(oA) and alpha(oC) were localized to a C-terminal fragment of the protein. This region, involved in receptor and effector interactions, implies divergent signaling roles for these two alpha(o) proteins. Finally, the structural difference between alpha(oA) and alpha(oC) is associated with a difference of at most 2 daltons based upon measurements by electrospay ionization mass spectrometry.	Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA	Medical University of South Carolina	Hildebrandt, JD (corresponding author), Med Univ S Carolina, Dept Pharmacol, 171 Ashley Ave, Charleston, SC 29425 USA.	hildebjd@musc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037219] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37219] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahnert-Hilger G, 1998, EMBO J, V17, P406, DOI 10.1093/emboj/17.2.406; AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; Clapham DE, 1996, NATURE, V379, P297, DOI 10.1038/379297a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CREIGHTON TE, 1980, J MOL BIOL, V137, P61, DOI 10.1016/0022-2836(80)90157-6; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; GRANNEMAN JG, 1990, J NEUROCHEM, V54, P1995, DOI 10.1111/j.1471-4159.1990.tb04903.x; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HALLAK H, 1994, J BIOL CHEM, V269, P4713; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HSU WH, 1990, J BIOL CHEM, V265, P11220; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; INANOBE A, 1990, FEBS LETT, V263, P369, DOI 10.1016/0014-5793(90)81416-L; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; KOHNKEN RE, 1989, J BIOL CHEM, V264, P20688; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagriffoul A, 1996, J BIOL CHEM, V271, P31508, DOI 10.1074/jbc.271.49.31508; Li PP, 1995, NEUROCHEM RES, V20, P1249, DOI 10.1007/BF00995390; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MANDEL JE, 1995, SCIENCE, V267, P1652; MONTMAYEUR JP, 1994, SCIENCE, V263, P95, DOI 10.1126/science.8272874; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MURTAGH JJ, 1994, NUCLEIC ACIDS RES, V22, P842, DOI 10.1093/nar/22.5.842; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NURNBERG B, 1994, BIOCHEM J, V300, P387; Nurnberg B, 1996, FEBS LETT, V389, P61, DOI 10.1016/0014-5793(96)00584-4; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; OVCHINNIKOV YA, 1987, FEBS LETT, V226, P91, DOI 10.1016/0014-5793(87)80557-4; PADRELL E, 1991, J BIOL CHEM, V266, P9771; Qin N, 1997, P NATL ACAD SCI USA, V94, P8866, DOI 10.1073/pnas.94.16.8866; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SHIBASAKI H, 1991, FEBS LETT, V285, P268, DOI 10.1016/0014-5793(91)80814-J; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SPICHER K, 1992, FEBS LETT, V307, P215, DOI 10.1016/0014-5793(92)80770-H; SPICHER K, 1991, BIOCHEM BIOPH RES CO, V175, P473, DOI 10.1016/0006-291X(91)91588-4; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZUBIAUR M, 1993, J NEUROSCI RES, V35, P207, DOI 10.1002/jnr.490350212	63	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33135	33141		10.1074/jbc.273.50.33135	http://dx.doi.org/10.1074/jbc.273.50.33135			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837880	hybrid			2022-12-25	WOS:000077462500010
J	Deora, AB; Ghosh, RN; Tate, SS				Deora, AB; Ghosh, RN; Tate, SS			Progressive C-terminal deletions of the renal cystine transporter, NBAT, reveal a novel bimodal pattern of functional expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; POLYMERASE CHAIN-REACTION; XENOPUS-LAEVIS OOCYTES; HEAVY-CHAIN; RAT-KIDNEY; SURFACE-ANTIGEN; GENETIC-HETEROGENEITY; MOLECULAR-GENETICS; OVERLAP EXTENSION; SLC3A1 GENE	Nearly identical proteins (denoted NAA-Tr, rBAT, D2, NEAT), cloned from mammalian kidneys, induce a largely sodium-independent high-affinity transport system for cystine, basic amino acids, and some neutral amino acids in Xenopus oocytes (system b(0,+)-like). Mutations in the human NEAT gene have been found in several type I cystinurics. In kidney, NEAT is associated with a second, smaller protein (approximately 45 kDa), and this heterodimer has been proposed to be the minimal functional unit of the renal cystine transporter (Wang, Y., and Tate, S, S. (1995) FEBS Lett, 368, 389-392), To delineate regions minimally required for functional expression in oocytes, we constructed a series of C-terminal truncated mutants of rat kidney NEAT (mild-type (WT), 683 amino acids). Expression of these mutants in oocytes yielded an unusual bimodal pattern for the induction of amino acid transport activity. Thus, initial C-terminal truncations aborted elicitation of transport activity. The next mutant in the series, Delta 588-683, exhibited most of the transport-inducing potential inherent in the WT/NBAT. Further deletions again attenuated transport activity. Although both the WT/NBAT and the truncated mutant, Delta 588-683, induce qualitatively similar transport systems, the two forms of the protein exhibit contrasting sensitivities toward a point mutation in which the cysteine residue at position 111 was mutated to serine, This mutation did not greatly affect induction of transport by the WT/NBAT; however, the Delta 588-683 mutant was inactivated by this mutation. Our data further suggest that cysteine 111 is probably the site of disulfide Linkage with an approximately 45-kDa oocyte protein producing a complex equivalent to that seen in kidney membranes.	Cornell Univ Med Coll, Dept Biochem, New York, NY 10021 USA	Cornell University	Tate, SS (corresponding author), Cornell Univ Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	sstate@mail.med.cornell.edu			NIDDK NIH HHS [DK51218] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051218] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Bisceglia L, 1997, AM J HUM GENET, V60, P611; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; Chillaron J, 1997, J BIOL CHEM, V272, P9543; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; Deora AB, 1998, FASEB J, V12, pA1394; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GASPARINI P, 1995, AM J HUM GENET, V57, P781; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GHOSH RN, 1994, J CELL SCI, V107, P2177; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HEMLER ME, 1982, J IMMUNOL, V129, P623; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Horsford J, 1996, KIDNEY INT, V49, P1401, DOI 10.1038/ki.1996.197; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MCGIVAN JD, 1994, BIOCHEM J, V299, P321, DOI 10.1042/bj2990321; MCKUSICK VA, 1994, MENDELIAN INHERITANC, P1751; Miyamoto K, 1996, J BIOL CHEM, V271, P16758, DOI 10.1074/jbc.271.28.16758; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; Palacin M, 1996, BIOCHEM SOC T, V24, P856, DOI 10.1042/bst0240856; PALACIN M, 1994, J EXP BIOL, V196, P123; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; PRAS E, 1995, AM J HUM GENET, V56, P1297; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; SEGAL S, 1995, METABOLIC MOL BASES, P3581; Segawa H, 1997, BIOCHEM J, V328, P657, DOI 10.1042/bj3280657; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; VANWINKLE LJ, 1995, BBA-BIOMEMBRANES, V1233, P213, DOI 10.1016/0005-2736(94)00303-7; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; Wartenfeld R, 1997, AM J HUM GENET, V60, P617; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; Yao SYM, 1998, BIOCHEM J, V330, P745	48	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32980	32987		10.1074/jbc.273.49.32980	http://dx.doi.org/10.1074/jbc.273.49.32980			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830050	hybrid			2022-12-25	WOS:000077329100089
J	Diaz, L; Meera, P; Amigo, J; Stefani, E; Alvarez, O; Toro, L; Latorre, R				Diaz, L; Meera, P; Amigo, J; Stefani, E; Alvarez, O; Toro, L; Latorre, R			Role of the S4 segment in a voltage-dependent calcium-sensitive potassium (hSlo) channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; SODIUM-CHANNELS; SENSING RESIDUES; SKELETAL-MUSCLE; GATING CHARGE; BETA-SUBUNIT; DROSOPHILA; ACTIVATION; MOVEMENT; KINETICS	We investigated the role of individual charged residues of the S4 region of a MaxiK channel (hSlo) in channel gating, We measured macroscopic currents induced by wild type (WT) and point mutants of hSlo in inside-out membrane patches of Xenopus laevis oocytes, Of all the residues tested, only neutralizations of Arg-210 and Arg-213 were associated with a reduction in the number of gating charges as determined using the limiting slope method. Channel activation in WT and mutant channels was interpreted using an allosteric model. Mutations R207Q, R207E, and R210N facilitated channel opening in the absence of Ca2+; however, this facilitation was not observed in the channels Ca2+-bound state. Mutation R2136 behaved similarly to the WT channel in the absence of Ca2+, but Ca2+ was unable to stabilize the open state to the same extent as it does in the WT. Mutations R207Q, R207E, R210N, and R213Q reduced the coupling between Ca2+ binding and channel opening when compared with the WT. Mutations L204R, L204H, Q216R, E219Q, and E219K in the 54 domain showed a similar phenotype to the WT channel. We conclude that the S4 region in the hSlo channel is part of the voltage sensor and that only two charged amino acid residues in this region (Arg-210 and Arg-213) contribute to the gating valence of the channel.	Ctr Estudios Cient, Valdivia 9, Chile; Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Universidad de Chile; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Latorre, R (corresponding author), Ctr Estudios Cient, Casilla 16443, Valdivia 9, Chile.	ramon@cecs.cl	Alvarez, Osvaldo/I-1077-2013; Meera, Pratap B/C-6499-2009	Alvarez, Osvaldo/0000-0001-8558-580X; 				ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Almers W, 1978, Rev Physiol Biochem Pharmacol, V82, P96, DOI 10.1007/BFb0030498; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; Cox DH, 1997, J GEN PHYSIOL, V110, P257, DOI 10.1085/jgp.110.3.257; Cox DH, 1997, J GEN PHYSIOL, V109, P633, DOI 10.1085/jgp.109.5.633; Cui J, 1997, J GEN PHYSIOL, V109, P647, DOI 10.1085/jgp.109.5.647; Dichiara TJ, 1995, J PHYSIOL-LONDON, V489, P403, DOI 10.1113/jphysiol.1995.sp021061; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; Garcia J, 1997, BIOPHYS J, V72, P2515, DOI 10.1016/S0006-3495(97)78896-9; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; Jiang GJ, 1997, P ROY SOC B-BIOL SCI, V264, P731, DOI 10.1098/rspb.1997.0104; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; MCMANUS OB, 1991, J PHYSIOL-LONDON, V443, P739, DOI 10.1113/jphysiol.1991.sp018861; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; MOCZYDLOWSKI E, 1983, J GEN PHYSIOL, V82, P511, DOI 10.1085/jgp.82.4.511; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; OBERHAUSER A, 1988, J GEN PHYSIOL, V92, P67, DOI 10.1085/jgp.92.1.67; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Rothberg BS, 1998, J GEN PHYSIOL, V111, P751, DOI 10.1085/jgp.111.6.751; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Silberberg SD, 1996, BIOPHYS J, V70, P2640, DOI 10.1016/S0006-3495(96)79833-8; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Stefani E, 1997, P NATL ACAD SCI USA, V94, P5427, DOI 10.1073/pnas.94.10.5427; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VERGARA C, 1988, CURR OPIN NEUROBIOL, V3, P321; Wallner M, 1996, P NATL ACAD SCI USA, V93, P14922, DOI 10.1073/pnas.93.25.14922; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; Wei A, 1996, NEUROPHARMACOLOGY, V35, P805, DOI 10.1016/0028-3908(96)00126-8; WU YC, 1995, PROG BIOPHYS MOL BIO, V63, P131, DOI 10.1016/0079-6107(95)00002-5; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	50	99	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32430	32436		10.1074/jbc.273.49.32430	http://dx.doi.org/10.1074/jbc.273.49.32430			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829973	hybrid			2022-12-25	WOS:000077329100012
J	Kalman, K; Pennington, MW; Lanigan, MD; Nguyen, A; Rauer, H; Mahnir, V; Paschetto, K; Kem, WR; Grissmer, S; Gutman, GA; Christian, EP; Cahalan, MD; Norton, RS; Chandy, KG				Kalman, K; Pennington, MW; Lanigan, MD; Nguyen, A; Rauer, H; Mahnir, V; Paschetto, K; Kem, WR; Grissmer, S; Gutman, GA; Christian, EP; Cahalan, MD; Norton, RS; Chandy, KG			ShK-Dap(22), a potent Kv1.3-specific immunosuppressive polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED K+ CHANNELS; HUMAN LYMPHOCYTE-T; POTASSIUM CHANNELS; SHK TOXIN; MACROMOLECULAR STRUCTURES; RAT-BRAIN; ACTIVATION; KV1.3; CHARYBDOTOXIN; INTERFACE	The voltage-gated potassium channel in T lymphocytes, Kv1.3, is an important molecular target for immunosuppressive agents. A structurally defined polypeptide, ShK, from the sea anemone Stichodactyla helianthus inhibited Kv1.3 potently and also blocked Kv1.1, Kv1.4, and Kv1.6 at subnanomolar concentrations. Using mutant cycle analysis in conjunction with complementary mutagenesis of ShK and Kv1.3, and utilizing the structure of ShK, we determined a likely docking configuration for this peptide in the channel. Based upon this topological information, we replaced the critical Lys(22) in ShK with the positively charged, non-natural amino acid diaminopropionic acid (ShK-Dap(22)) and generated a highly selective and potent blocker of the T-lymphocyte channel. ShK-Dap(22), at subnanomolar concentrations, suppressed anti-CD3 induced human T-lymphocyte [H-3]thymidine incorporation in vitro. Toxicity with this mutant peptide was low in a rodent model, with a median paralytic dose of similar to 200 mg/kg body weight following intravenous administration. The overall structure of ShK-Dap(22) in solution, as determined from NMR data, is similar to that of native ShK toxin, but there are some differences in the residues involved in potassium channel binding. Based on these results, we propose that ShK-Dap(22) or a structural analogue may have use as an immunosuppressant for the prevention of graft rejection and for the treatment of autoimmune diseases.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Bachem Biosci Inc, King Of Prussia, PA 19406 USA; Biomol Res Inst, Parkville, Vic 3052, Australia; Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Zeneca Pharmaceut, Dept Resp Inflammatory & Neurol Disorders, Wilmington, DE 19850 USA; Univ Ulm, Dept Appl Physiol, D-89081 Ulm, Germany	University of California System; University of California Irvine; University of California System; University of California Irvine; State University System of Florida; University of Florida; Ulm University	Chandy, KG (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	gchandy@uci.edu		Norton, Raymond/0000-0001-8893-0584; pennington, michael/0000-0001-5446-3447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS014609, R37NS014609, R01NS014609] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54221] Funding Source: Medline; NINDS NIH HHS [NS14609] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; FUJIWARA Y, 1994, CHEM PHARM BULL, V42, P724; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; IKEDA SR, 1992, PFLUGERS ARCH, V422, P210; Kath JC, 1997, ANNU REP MED CHEM, V32, P181, DOI 10.1016/S0065-7743(08)61476-1; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Koo GC, 1997, J IMMUNOL, V158, P5120; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LEONARD RJ, 1992, P NATL ACAD SCI USA, V89, P10094, DOI 10.1073/pnas.89.21.10094; Li HL, 1998, J MOL BIOL, V282, P211, DOI 10.1006/jmbi.1998.2016; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; Nguyen A, 1996, MOL PHARMACOL, V50, P1672; Pallaghy PK, 1997, FEBS LETT, V419, P191, DOI 10.1016/S0014-5793(97)01452-X; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; Pennington MW, 1996, BIOCHEMISTRY-US, V35, P16407, DOI 10.1021/bi962463g; Pennington MW, 1996, BIOCHEM BIOPH RES CO, V219, P696, DOI 10.1006/bbrc.1996.0297; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; Tudor JE, 1998, EUR J BIOCHEM, V251, P133, DOI 10.1046/j.1432-1327.1998.2510133.x; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471	38	212	249	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32697	32707		10.1074/jbc.273.49.32697	http://dx.doi.org/10.1074/jbc.273.49.32697			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830012	hybrid			2022-12-25	WOS:000077329100051
J	Mueller, PP; Grueter, P; Hinnebusch, AG; Trachsel, H				Mueller, PP; Grueter, P; Hinnebusch, AG; Trachsel, H			A ribosomal protein is required for translational regulation of GCN4 mRNA - Evidence for involvement of the ribosome in eIF2 recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; ACID BIOSYNTHETIC GENES; OPEN READING FRAMES; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; CELL-CYCLE; YEAST; ACTIVATOR; SUBUNIT; PHOSPHORYLATION	In amino acid-starved yeast cells, inhibition of the guanine nucleotide exchange factor eIF2B by phosphorylated translation initiation factor 2 results in increased translation of GCN4 mRNA. We isolated a suppressor of a mutant eIF2B. The suppressor prevents efficient GCN4 mRNA translation due to inactivation of the small ribosomal subunit protein Rps31 and results in low amounts of mutant 40 S ribosomal subunits. Deletion of one of two genes encoding ribosomal protein Rps17 also reduces the amounts of 40 S subunits but does not suppress eIF2B mutations or prevent efficient GCN4 translation. Our findings show that Rps31-deficient ribosomes are altered in a way that decreases the eIF2B requirement and that the small ribosomal subunit mediates the effects of low eIF2B activity on cell viability and translational regulation in response to eIF2 phosphorylation.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; Natl Res Inst Biotechnol, RDIF, GBF, D-38124 Braunschweig, Germany	University of Bern; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Helmholtz Association; Helmholtz-Center for Infection Research	Mueller, PP (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	PMU@GBF.DE	Mueller, Peter P./H-8656-2019	Mueller, Peter P./0000-0002-1209-7546				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; ABOVICH N, 1985, MOL CELL BIOL, V5, P3429, DOI 10.1128/MCB.5.12.3429; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHAKRABARTI A, 1992, J BIOL CHEM, V267, P12964; DARNBROUGH C, 1973, J MOL BIOL, V76, P379; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DEBENEDETTI A, 1985, J BIOL CHEM, V260, P3135; DEBENEDETTI A, 1985, J VIROL, V55, P588, DOI 10.1128/JVI.55.3.588-593.1985; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINK GR, 1964, SCIENCE, V146, P525, DOI 10.1126/science.146.3643.525; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; FOIANI M, 1991, MOL CELL BIOL, V11, P3203, DOI 10.1128/MCB.11.6.3203; GROSS M, 1987, J BIOL CHEM, V262, P6899; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HANNIG EM, 1990, GENETICS, V126, P549; HARASHIMA S, 1986, MOL CELL BIOL, V6, P3990, DOI 10.1128/MCB.6.11.3990; HILL DE, 1988, NUCLEIC ACIDS RES, V16, P9253, DOI 10.1093/nar/16.19.9253; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HINNEBUSCH AG, 1996, TRANSLATIONAL CONTRO, P19; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOSHI B, 1995, EUR J BIOCHEM, V228, P31, DOI 10.1111/j.1432-1033.1995.0031o.x; Merrick WC., 1996, TRANSLATION CONTROL, P31; MILLER PF, 1989, GENE DEV, V3, P1217, DOI 10.1101/gad.3.8.1217; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMAIAH KVA, 1992, P NATL ACAD SCI USA, V89, P12063, DOI 10.1073/pnas.89.24.12063; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; SCHREIER MH, 1973, NATURE-NEW BIOL, V242, P35, DOI 10.1038/newbio242035a0; Sherman F., 1986, METHODS YEAST GENETI; THOMAS NSB, 1985, J BIOL CHEM, V260, P9860; THOMAS NSB, 1986, BIOCHEM BIOPH RES CO, V134, P1048, DOI 10.1016/0006-291X(86)90357-8; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WOLFNER M, 1975, J MOL BIOL, V96, P273, DOI 10.1016/0022-2836(75)90348-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32870	32877		10.1074/jbc.273.49.32870	http://dx.doi.org/10.1074/jbc.273.49.32870			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830035	hybrid			2022-12-25	WOS:000077329100074
J	Rozwarski, DA; Swami, BM; Brewer, CF; Sacchettini, JC				Rozwarski, DA; Swami, BM; Brewer, CF; Sacchettini, JC			Crystal structure of the lectin from Dioclea grandiflora complexed with core trimannoside of asparagine-linked carbohydrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RELATE 2 SETS; CONCANAVALIN-A; BINDING-SPECIFICITY; SEEDS; THERMODYNAMICS; ROTATION; SUBUNIT; VECTORS; FAMILY	The seed lectin from Dioclea grandiflora (DGL) has recently been shown to possess high affinity for 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranose, the core trimannoside of asparagine-linked carbohydrates, but lower affinity for biantennary complex carbohydrates. In the previous paper, the thermodynamics of DGL binding to deoxy analogs of the core trimannoside and to a biantennary complex carbohydrate were determined by isothermal titration microcalorimetry. The data suggest that DGL recognizes specific hydroxyl groups of the trimannoside similar to that of the jack bean lectin concanavalin A (ConA) (Gupta, D. Dam, T. K., Oscarson, S., and Brewer, C. F. (1997) J. Biol. Chem. 272, 6388-6392). However, the thermodynamics of DGL binding to certain deoxy analogs and to the complex carbohydrate are different from that of ConA, In the present paper, the x-ray crystal structure of DGL complexed to the core trimannoside was determined to a resolution of 2.6 Angstrom. The overall structure of the DGL complex is similar to the structure of the ConA-trimannoside complex (Naismith, J. H., and Field, R. A. (1996) J. Biol. Chem. 271, 972-976), The location and conformation of the bound trimannoside as well as its hydrogen-bonding interactions in both complexes are nearly identical. However, differences exist in the location of two loops outside of the respective binding sites containing residues 114-125 and 222-227, The latter residues affect the location of a network of hydrogen-bonded water molecules that interact with the trisaccharide. Differences in the arrangement of ordered water molecules in the binding site and/or protein conformational differences outside of the binding site may account for the differences in the thermodynamics of binding of the two lectins to deoxy analogs of the trimannoside. Molecular modeling studies suggest how DGL discriminates against binding the biantennary complex carbohydrate relative to ConA.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330, R01CA016054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16054, P30 CA-13330] Funding Source: Medline; NIGMS NIH HHS [GM-45859] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AINOUZ IL, 1987, PHYTOCHEMISTRY, V26, P1435, DOI 10.1016/S0031-9422(00)81829-4; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BITTIGER H, 1976, CONCANAVALIN TOOL; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BREWER CF, 1986, J BIOL CHEM, V261, P7306; BREWER CF, 1988, GLYCOCONJUGATE J, V5, P159, DOI 10.1007/BF01061205; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; Dam TK, 1998, J BIOL CHEM, V273, P32812, DOI 10.1074/jbc.273.49.32812; Dam TK, 1998, J BIOL CHEM, V273, P12082, DOI 10.1074/jbc.273.20.12082; GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013; GOMES JC, 1994, AGENTS ACTIONS, V41, P132, DOI 10.1007/BF02001905; Gupta D, 1996, EUR J BIOCHEM, V242, P320, DOI 10.1111/j.1432-1033.1996.0320r.x; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; HARDMAN KD, 1972, BIOCHEMISTRY-US, V11, P4910, DOI 10.1021/bi00776a006; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; LORIS R, 1994, J BIOL CHEM, V269, P26722; Loris R, 1996, J BIOL CHEM, V271, P30614, DOI 10.1074/jbc.271.48.30614; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; Moothoo DN, 1998, GLYCOBIOLOGY, V8, P173, DOI 10.1093/glycob/8.2.173; MOREIRA RA, 1983, PLANTA, V158, P63, DOI 10.1007/BF00395404; Moreira Renato De Azevedo, 1995, Revista Brasileira de Fisiologia Vegetal, V7, P7; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; RICHARDSON M, 1984, EUR J BIOCHEM, V144, P101, DOI 10.1111/j.1432-1033.1984.tb08436.x; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; SACK JS, 1988, CHAIN CRYSTALLOGRAPH; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211	30	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32818	32825		10.1074/jbc.273.49.32818	http://dx.doi.org/10.1074/jbc.273.49.32818			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830028	hybrid			2022-12-25	WOS:000077329100067
J	St-Denis, A; Chano, F; Tremblay, P; St-Pierre, Y; Descoteaux, A				St-Denis, A; Chano, F; Tremblay, P; St-Pierre, Y; Descoteaux, A			Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a murine macrophage cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN MONOCYTES; TNF-ALPHA; TYROSINE KINASE; SIGNAL-TRANSDUCTION; MOUSE MACROPHAGES; MAMMALIAN-CELLS	Lipopolysaccharide (LPS), a potent modulator of macrophage functional activity, binds to CD14 and triggers the activation of several protein kinases, leading to the secretion of variety of immunomodulatory molecules such as nitric oxide and proinflammatory cytokines. In this study, we have examined the role of the alpha isoenzyme of protein kinase C (PKC) in the regulation of LPS-initiated signal transduction in macrophages. To this end, we have stably overexpressed a dominant-negative (DN) version of PKC-alpha (DN PKC-alpha) in the murine macrophage cell line RAW 264.7. Clones overexpressing DN PKC-alpha were indistinguishable from the parental line with respect to morphology and growth characteristics. At the functional level, DN PKC-alpha overexpression strongly inhibited LPS-induced interleukin-la mRNA accumulation, and to a lesser extent inducible nitric oxide synthase and tumor necrosis factor-alpha expression. DN-PKC-alpha overexpression did not cause a general unresponsiveness to LPS, as secretion of the matrix metalloproteinase-9 was up-regulated in our DN PKC-alpha-overexpressing clones. Moreover, LPS-induced phosphorylation and degradation of I kappa B alpha, NF-kappa B activation, as well as p38 mitogen-activated protein kinase and Jun N-terminal kinase phosphorylation, were not affected by DN PKC-alpha overexpression. Collectively, these data provide evidence that PKC-alpha regulates selective LPS-induced macrophage functions involved in host defense and inflammation.	Univ Quebec, Inst Armand Frappier, Laval, PQ H7V 1B7, Canada	University of Quebec	Descoteaux, A (corresponding author), Univ Quebec, Inst Armand Frappier, 531 Blvd Prairies, Laval, PQ H7V 1B7, Canada.			St-Pierre, Yves/0000-0002-1948-2041				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Bailly S, 1996, EUR CYTOKINE NETW, V7, P125; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Chang EY, 1997, J IMMUNOL, V159, P2624; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DESCOTEAUX A, 1990, J IMMUNOL, V145, P846; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DING AH, 1995, J LEUKOCYTE BIOL, V57, P174, DOI 10.1002/jlb.57.1.174; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; Folgueira L, 1996, J VIROL, V70, P223, DOI 10.1128/JVI.70.1.223-231.1996; FRANSEN L, 1985, NUCLEIC ACIDS RES, V13, P4417, DOI 10.1093/nar/13.12.4417; FUJIHARA M, 1994, J IMMUNOL, V152, P1898; GEPPERT TD, 1994, MOL MED, V1, P93; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GREEN SJ, 1990, J IMMUNOL, V144, P278; HAMBLETON J, 1995, J EXP MED, V182, P147, DOI 10.1084/jem.182.1.147; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; JAKEN S, 1987, METHOD ENZYMOL, V141, P275; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU MK, 1994, J IMMUNOL, V153, P2642; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; MISCHAK H, 1991, J IMMUNOL, V147, P3891; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; NOVOTNEY M, 1991, BIOCHEMISTRY-US, V30, P5597, DOI 10.1021/bi00236a037; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; Rees S, 1996, BIOTECHNIQUES, V20, P102; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REIMANN T, 1994, J IMMUNOL, V153, P5740; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHAPIRA L, 1994, J IMMUNOL, V153, P1818; SHINJI H, 1994, J IMMUNOL, V153, P5760; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; TANIGUCHI H, 1989, IMMUNOLOGY, V67, P210; TREMBLAY P, 1995, CYTOKINE, V7, P130, DOI 10.1006/cyto.1995.1017; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANRANST M, 1991, CYTOKINE, V3, P231, DOI 10.1016/1043-4666(91)90021-5; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Xie QW, 1997, J BIOL CHEM, V272, P14867, DOI 10.1074/jbc.272.23.14867; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; ZHENG L, 1995, J IMMUNOL, V155, P776	66	89	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32787	32792		10.1074/jbc.273.49.32787	http://dx.doi.org/10.1074/jbc.273.49.32787			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830023	hybrid			2022-12-25	WOS:000077329100062
J	Blackwell, LJ; Bjornson, KP; Modrich, P				Blackwell, LJ; Bjornson, KP; Modrich, P			DNA-dependent activation of the hMutS alpha ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE MISMATCH REPAIR; ESCHERICHIA-COLI; TUMOR-CELLS; REPLICATION FIDELITY; NUCLEAR EXTRACTS; PROTEIN; HETERODIMER; BINDS; MSH2; TRANSLOCATION	ATP hydrolysis by MutS homologs is required for function of these proteins in mismatch repair. However, the function of ATP hydrolysis in the repair reaction is controversial. In this paper we describe a steady-state kinetic analysis of the DNA-activated ATPase of human MutS alpha. Comparison of salt concentration effects on mismatch repair and mismatch-provoked excision in HeLa nuclear extracts with salt effects on the DNA-activated ATPase suggests that ATP hydrolysis by MutS alpha is involved in the rate determining step in the repair pathway. While the ATPase is activated by homoduplex and heteroduplex DNA, the half-maximal concentration for activation by heteroduplex DNA is significantly lower under physiological salt concentrations. Furthermore, at optimal salt concentration, heteroduplex DNA increases the k(cat) for ATP hydrolysis to a greater extent than does homoduplex DNA, We also demonstrate that the degree of ATPase activation is dependent on DNA chain length, with the k(cat) for hydrolysis increasing significantly with chain length of the DNA cofactor. These results are discussed in terms of the translocation (Allen, D, J,, Makhov, A., Grilley, M,, Taylor, J,, Thresher, R,, Modrich, P,, and Griffith, J, D, (1997) EMBO J, 16, 4467-4476) and the molecular switch (Gradia, S,, Acharya, S,, and Fishel, R, (1997) Cell 91, 995-1005) models that invoke distinct roles for ATP hydrolysis in MutS homolog function.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	modrich@biochem.duke.edu		Modrich, Paul/0000-0001-8708-9885	NIGMS NIH HHS [GM45190] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; CHI NW, 1994, J BIOL CHEM, V269, P29984; CLAVERYS JP, 1986, MICROBIOL REV, V50, P133, DOI 10.1128/MMBR.50.2.133-165.1986; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FANG WH, 1993, J BIOL CHEM, V268, P11838; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197; YOUNG MC, 1994, J MOL BIOL, V235, P1436, DOI 10.1006/jmbi.1994.1099; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	44	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32049	32054		10.1074/jbc.273.48.32049	http://dx.doi.org/10.1074/jbc.273.48.32049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822679	hybrid			2022-12-25	WOS:000077207000061
J	Colecraft, HM; Egamino, JP; Sharma, VK; Sheu, SS				Colecraft, HM; Egamino, JP; Sharma, VK; Sheu, SS			Signaling mechanisms underlying muscarinic receptor-mediated increase in contraction rate in cultured heart cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; VENTRICULAR MYOCYTES; PHOSPHOINOSITIDE HYDROLYSIS; GUINEA-PIG; MOLECULAR-CLONING; MULTIGENE FAMILY; PERTUSSIS TOXIN; PURKINJE-FIBERS; HUMAN-PLATELETS; IDENTIFICATION	We have investigated the mechanisms by which stimulation of cardiac muscarinic receptors result in paradoxical stimulatory effects on cardiac function, using cultured neonatal rat ventricular myocytes as a model system. Application of low concentrations of carbachol (CCh) (EC50 = 35 nM) produced an atropine-sensitive decrease in spontaneous contraction rate, while, in cells pretreated with pertussis toxin, higher concentrations of CCh (EC50 = 26 mu M) elicited an atropine-sensitive increase in contraction rate. Oxotremorine, an m(2) muscarinic acetylcholine receptor (mAChR) agonist, mimicked the negative but not the positive chronotropic response to CCh, Reverse transcription followed by polymerase chain reaction carried out on mRNA obtained from single cells indicated that ventricular myocytes express mRNA for the m(1), m(2), and, possibly, m(4) mAChRs, The presence of m(1) and m(2) mAChR protein on the surface membranes of the cultured ventricular myocytes was confirmed by immunofluorescence, The CCh-induced positive chronotropic response was significantly inhibited by fluorescein-tagged antisense oligonucleotides directed against the m(1), but not the m(2) and m(4), mAChR subtypes, The response was also inhibited by antisense oligonucleotides against G(q)alpha protein. Finally, inhibition of CCh-induced phosphoinositide hydrolysis with 500 mu M neomycin or 5 mu M U73122 completely abolished the CCh-induced positive chronotropic response. These results are consistent with the stimulatory effects of mAChR activation on the rate of contractions in cultured ventricular myocytes being mediated through the m(1) mAChR coupled through G(q) to phospholipase C-induced phosphoinositide hydrolysis.	Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Sheu, SS (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA.		Sheu, Shey-Shing/Y-4009-2019	Sheu, Shey-Shing/0000-0003-3838-3601	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033333] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-33333] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNARSSON U, 1988, J PHARMACOL EXP THER, V247, P150; ALBERT PR, 1994, TRENDS PHARMACOL SCI, V15, P250, DOI 10.1016/0165-6147(94)90320-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BROWN JH, 1985, CIRC RES, V57, P532, DOI 10.1161/01.RES.57.4.532; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; Colecraft H. M., 1996, Biophysical Journal, V70, pA392; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; EGLEN RM, 1988, J PHARMACOL EXP THER, V247, P911; ENTZEROTH M, 1990, N-S ARCH PHARMACOL, V341, P432; FORD APDW, 1992, EUR J PHARM-MOLEC PH, V225, P105, DOI 10.1016/0922-4106(92)90089-E; GALLO MP, 1993, J PHYSIOL-LONDON, V471, P41, DOI 10.1113/jphysiol.1993.sp019890; GILMOUR RF, 1985, AM J PHYSIOL, V249, pH735, DOI 10.1152/ajpheart.1985.249.4.H735; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; HARTZELL HC, 1988, PROG BIOPHYS MOL BIO, V52, P165, DOI 10.1016/0079-6107(88)90014-4; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; JAHNEL U, 1992, N-S ARCH PHARMACOL, V346, P88, DOI 10.1007/BF00167576; KENAKIN TP, 1990, EUR J PHARMACOL, V191, P39, DOI 10.1016/0014-2999(90)94094-E; KIMURA H, 1993, COMP BIOCHEM PHYS C, V105, P479, DOI 10.1016/0742-8413(93)90089-4; KORTH M, 1987, BRIT J PHARMACOL, V90, P81, DOI 10.1111/j.1476-5381.1987.tb16827.x; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LEVEY AI, 1991, J NEUROSCI, V11, P3218; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LOKUTA A, 1994, J CARDIOVASC ELECTR, V5, P50, DOI 10.1111/j.1540-8167.1994.tb01114.x; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; PAPPANO AJ, 1991, J CARDIOVASC ELECTR, V2, P262; ROGERS TB, 1986, J PHARMACOL EXP THER, V236, P438; ROSEN MR, 1990, J PHARMACOL EXP THER, V254, P356; Sharma VK, 1997, LIFE SCI, V60, P1023, DOI 10.1016/S0024-3205(97)00043-X; Sharma VK, 1996, CIRC RES, V79, P86, DOI 10.1161/01.RES.79.1.86; SMALLRIDGE RC, 1992, ENDOCRINOLOGY, V131, P1883, DOI 10.1210/en.131.4.1883; STEEL MC, 1993, MOL PHARMACOL, V43, P694; STEIN B, 1993, J MOL CELL CARDIOL, V25, P655, DOI 10.1006/jmcc.1993.1078; Sun LS, 1996, J CARDIOVASC PHARM, V27, P455, DOI 10.1097/00005344-199604000-00001; TIETJE KM, 1991, J BIOL CHEM, V266, P17382; TYSNES OB, 1987, BIOCHEM BIOPH RES CO, V144, P454, DOI 10.1016/S0006-291X(87)80531-4; WATSON SP, 1984, J BIOL CHEM, V259, P3199; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; YAMADA M, 1992, CIRC RES, V70, P477, DOI 10.1161/01.RES.70.3.477; YANG CM, 1993, AM J PHYSIOL, V265, P666	43	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32158	32166		10.1074/jbc.273.48.32158	http://dx.doi.org/10.1074/jbc.273.48.32158			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822693	hybrid			2022-12-25	WOS:000077207000075
J	Gandhi, R; Elble, RC; Gruber, AD; Schreur, KD; Ji, HL; Fuller, CM; Pauli, BU				Gandhi, R; Elble, RC; Gruber, AD; Schreur, KD; Ji, HL; Fuller, CM; Pauli, BU			Molecular and functional characterization of a calcium-sensitive chloride channel from mouse lung	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; EPITHELIAL-CELLS; RECEPTOR SHOWS; CL CHANNELS; CFTR; MICE; DISEASE; CLONING; IDENTIFICATION	A protein (mCLCA1) has been cloned from a mouse lung cDNA library that bears strong sequence homology with the recently described bovine tracheal, Ca2+-sensitive chloride channel protein (bCLCA1), bovine lung endothelial cell adhesion molecule-1 (Lu-ECAM-1), and the human intestinal Ca2+-sensitive chloride channel protein (hCLCA1). In vitro, its 3.1-kilobase message translates into a 100-kDa protein that can be glycosylated to an approximately 125-kDa product. SDS-polyacrylamide gel electrophoresis from lysates of mCLCA1 cDNA-transfected transformed human embryonic kidney cells (HEK293) reveals proteins of 130, 125, and 90 kDa as well as a protein triplet in the 32-38 kDa size range. Western analyses with antisera raised against Lu-ECAM-1 peptides show that the N-terminal region of the predicted open reading frame is present only in the larger size proteins (i.e. 130, 125, and 90 kDa), whereas the C-terminal region of the open reading frame is observed in the 32-38 kDa size proteins, suggesting a posttranslational, proteolytic processing of a precursor protein (125/130 kDa) into 90 kDa and 32-38 kDa components similar to that reported for Lu-ECAM-1, Hydrophobicity analyses predict four transmembrane domains for the 90-kDa protein. The mCLCA1 mRNA is readily detected by Northern analysis and by in situ hybridization in the respiratory epithelia of trachea and bronchi, Transient expression of mCLCA1 in HEK293 cells was associated with an increase in whole cell Cl- current that could be activated by Ca2+ and ionomycin and inhibited by 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, dithiothreitol, and niflumic acid. The discovery of mCLCA1 opens the door for further investigating the possible contribution of a Ca2+-sensitive chloride conductance to the pathogenesis of cystic: fibrosis.	Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	Cornell University; University of Alabama System; University of Alabama Birmingham	Pauli, BU (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Canc Biol Labs, Ithaca, NY 14853 USA.	bup1@cornell.edu	Gruber, Achim D./ABA-4514-2021; Fuller, Cathy/B-4046-2011; JI, HONGLONG/N-7822-2014	JI, HONGLONG/0000-0002-3228-7144	NATIONAL CANCER INSTITUTE [R01CA047668, T32CA009682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK053090] Funding Source: NIH RePORTER; NCI NIH HHS [CA09682, CA47668] Funding Source: Medline; NIDDK NIH HHS [DK53090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; CLIFF WH, 1992, J PHYSL, V262, pC1154; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Gruber AD, 1998, HISTOCHEM CELL BIOL, V110, P43, DOI 10.1007/s004180050263; Gruber AD, 1997, HISTOCHEM CELL BIOL, V107, P411; GRUBER AD, 1998, IN PRESS GENOMICS; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; Jentsch TJ, 1997, BIOESSAYS, V19, P117, DOI 10.1002/bies.950190206; JOHNSON LG, 1995, J CLIN INVEST, V95, P1377, DOI 10.1172/JCI117789; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Rozmahel R, 1996, NAT GENET, V12, P280, DOI 10.1038/ng0396-280; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Wintero AK, 1996, MAMM GENOME, V7, P509, DOI 10.1007/s003359900153; ZHU DZ, 1991, J HISTOCHEM CYTOCHEM, V39, P1137, DOI 10.1177/39.8.1856462; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	32	131	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32096	32101		10.1074/jbc.273.48.32096	http://dx.doi.org/10.1074/jbc.273.48.32096			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822685	hybrid			2022-12-25	WOS:000077207000067
J	Munnes, M; Patrone, G; Schmitz, B; Romeo, G; Doerfler, W				Munnes, M; Patrone, G; Schmitz, B; Romeo, G; Doerfler, W			A 5 '-CG-3 '-rich region in the promoter of the transcriptionally frequently silenced RET protooncogene lacks methylated cytidine residues	ONCOGENE			English	Article						HSCR patients; RET protooncogene promoter; 5 '-CG-3 '-rich region in the RET promoter	NEUROBLASTOMA CELL-LINES; DNA METHYLATION; HIRSCHSPRUNGS-DISEASE; CHLORAMPHENICOL ACETYLTRANSFERASE; NEURONAL DIFFERENTIATION; ADENOVIRUS TYPE-2; MAMMALIAN-CELLS; GENE-EXPRESSION; MESSENGER-RNA; MUTATIONS	In a large proportion of familial and sporadic cases of Hirschsprung disease (HSCR) mutations in the RET (rearranged during transfection) protooncogene have been described. We have investigated the structure of the RET gene promoter and have analysed a region of approximately 1000 nucleotides in its promoter and 5'-upstream segments for the occurrence of 5-methyldeoxycytidine (5-mC) residues by using the bisulfite protocol of the genomic sequencing method. With an estimated sensitivity of about 93% of this technique, not a single 5-mC residue could be detected in the control region of a gene that seems to be silenced or exhibit low activity in many adult tissues. In these experiments, the DNAs of peripheral white blood cells (PWBC) from four healthy individuals, from seven patients with familial HSCR, as well as DNAs from different human tissues and from a human embryonic kidney (HEK) cell line have been included. Tn a DNA segment starting 790 nucleotides upstream of the transcriptional start site of the RET gene, a few 5-mC residues have been identified. This region possibly constitutes the transition site from an unmethylated promoter to a more extensively methylated region in the human genome. The data presented are remarkable in that a highly 5'-CG-3'-enriched segment of the human genome with 49 5'-CG-3' dinucleotide pairs in 400 bp within the putative promoter region is completely devoid of 5-mC residues, although this control region is not actively transcribed in most adult human tissues. By hybridization of a PCR-amplified RET protooncogene cDNA probe harboring exons 9-15 to a membrane (Clontech) containing poly-A selected RNAs from 50 different human tissues, weak RET protooncogene expression in many of the neural cell derived tissues has been detected. RNAs extracted from many other human tissues do not share sequence homologies to this P-32-labeled probe. Mechanisms other than DNA methylation obviously play the crucial role in the inactivation of the RET gene promoter in these tissues. We have also demonstrated by the in vitro premethylation of a RET promoter-chloramphenicol acetyltransferase (CAT) gene construct and transient transfection experiments into neuroblastoma cells that the transcriptional activity of the RET promoter is decreased by HpaII (5'-CCGG-3') methylation and abolished by SssI (5'-CG-3') methylation, Hence, the RET promoter region is sensitive to this regulatory signal. However in vivo, DNA methylation of the promoter region seems not to be the predominant regulatory mechanism for the RET protooncogene, Possibly, in adults the RET gene can be occasionally activated.	Univ Cologne, Inst Genet, D-5000 Cologne 41, Germany; Univ Genoa, Fac Med, I-16148 Genoa, Italy; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy	University of Cologne; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini	Doerfler, W (corresponding author), Univ Cologne, Inst Genet, D-5000 Cologne 41, Germany.							ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BADNER JA, 1990, AM J HUM GENET, V46, P568; BEHNKRAPPA A, 1993, HUM MOL GENET, V2, P993, DOI 10.1093/hmg/2.7.993; BODIAN M, 1963, ANN HUM GENET, V26, P261, DOI 10.1111/j.1469-1809.1963.tb01983.x; BONGARZONE I, 1994, CANCER RES, V54, P2979; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DURBEC P, 1996, NATURE, V381, P785; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLDBERG EL, 1984, INT J EPIDEMIOL, V13, P479, DOI 10.1093/ije/13.4.479; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hofstra RMW, 1996, NAT GENET, V12, P445, DOI 10.1038/ng0496-445; IKEDA I, 1990, ONCOGENE, V5, P1291; ITOH F, 1992, ONCOGENE, V7, P1210; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; Kambouris M, 1996, HUM MUTAT, V8, P64, DOI 10.1002/(SICI)1098-1004(1996)8:1<64::AID-HUMU9>3.0.CO;2-P; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x; KOCHANEK S, 1990, P NATL ACAD SCI USA, V87, P8830, DOI 10.1073/pnas.87.22.8830; KRUCZEK I, 1983, P NATL ACAD SCI-BIOL, V80, P7586, DOI 10.1073/pnas.80.24.7586; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LANGNER KD, 1984, P NATL ACAD SCI-BIOL, V81, P2950, DOI 10.1073/pnas.81.10.2950; LARIMORE TC, 1993, P NATL ACAD SCI USA, V90, P492; LYONNET S, 1994, CR ACAD SCI III-VIE, V317, P358; MARTUCCIELLO G, 1992, PEDIATR SURG INT, V7, P308; MUNNES M, 1995, J VIROL, V69, P2240, DOI 10.1128/JVI.69.4.2240-2247.1995; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; Okamoto E, 1967, J PEDIATR SURG, V2, P437; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, ONCOGENE, V11, P1737; PASSARGE E, 1997, PRINCIPLES PRACTICE, P1527; Patrone G, 1997, FEBS LETT, V419, P76, DOI 10.1016/S0014-5793(97)01435-X; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; PULITI A, 1993, CYTOGENET CELL GENET, V63, P102, DOI 10.1159/000133510; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Takaya K, 1996, J MOL MED-JMM, V74, P617, DOI 10.1007/s001090050065; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; TSUZUKI T, 1995, ONCOGENE, V10, P191; WEISSHAAR B, 1988, J MOL BIOL, V202, P255, DOI 10.1016/0022-2836(88)90456-1; Zeschnigk M, 1997, HUM MOL GENET, V6, P387, DOI 10.1093/hmg/6.3.387	55	34	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2573	2583		10.1038/sj.onc.1202165	http://dx.doi.org/10.1038/sj.onc.1202165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840920				2022-12-25	WOS:000077058900004
J	Jarmuszkiewicz, W; Almeida, AM; Sluse-Goffart, CM; Sluse, FE; Vercesi, AE				Jarmuszkiewicz, W; Almeida, AM; Sluse-Goffart, CM; Sluse, FE; Vercesi, AE			Linoleic acid-induced activity of plant uncoupling mitochondrial protein in purified tomato fruit mitochondria during resting, phosphorylating, and progressively uncoupled respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE OXIDASE; OXIDATIVE-PHOSPHORYLATION; MECHANISM; TRANSPORT	An uncoupling protein was recently discovered in plant mitochondria and demonstrated to function similarly to the uncoupling protein of brown adipose tissue. In this work, green tomato fruit mitochondria were purified on a self-generating Percoll gradient in the presence of 0.5% bovine serum albumin to deplete mitochondria of endogenous free fatty acids. The uncoupling protein activity was induced by the addition of linoleic acid during the resting state, and in the progressively uncoupled state, as well as during phosphorylating respiration in the presence of benzohydroxamic acid, an inhibitor of the alternative oxidase and with succinate (+ rotenone) as oxidizable substrate. Linoleic acid strongly stimulated the resting respiration in fatty acid-depleted mitochondria but had no effect on phosphorylating respiration, suggesting no activity of the uncoupling protein in this respiratory state. Progressive uncoupling of state 4 respiration decreased the stimulation by linoleic acid. The similar respiratory rates in phosphorylating and fully uncoupled respiration in the presence and absence of linoleic acid suggested that a rate-limiting step on the dehydrogenase side of the respiratory chain was responsible for the insensitivity of phosphorylating respiration to Linoleic acid. Indeed, the ADP/O ratio determined by ADP/O pulse method was decreased by linoleic acid, indicating that uncoupling protein was active during phosphorylating respiration and was able to divert energy from oxidative phosphorylation. Moreover, the respiration rates appeared to be determined by membrane potential independently of the presence of linoleic acid, indicating that linoleic acid-induced stimulation of respiration is due to a pure protonophoric activity without any direct effect on the electron transport chain.	Univ Estadual Campinas, Dept Patol Clin, Fac Ciencias Med, NMCE, BR-13083970 Campinas, SP, Brazil; Adam Mickiewicz Univ, Dept Bioenerget, PL-61701 Poznan, Poland; Univ Liege, Lab Bioenerget, Ctr Oxygen Biochem, Inst Chem B6, B-4000 Liege, Belgium	Universidade Estadual de Campinas; Adam Mickiewicz University; University of Liege	Vercesi, AE (corresponding author), Univ Estadual Campinas, Dept Patol Clin, Fac Ciencias Med, NMCE, CP 6111, BR-13083970 Campinas, SP, Brazil.		Vercesi, Aníbal E/C-8767-2012; de Almeida, Andrea Miyasaka/AAY-7847-2020	Vercesi, Anibal Eugenio/0000-0001-6671-7125; Miyasaka Almeida, Andrea/0000-0002-5848-0874; Jarmuszkiewicz, Wieslawa/0000-0001-8550-8337				CRUZHERNANDEZ A, 1995, PLANTA, V197, P569, DOI 10.1007/BF00191562; DAY DA, 1980, BIOCH PLANTS, V2, P197; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gomall A. G, 1949, J BIOL CHEM, V177, P751; Jarmuszkiewicz W, 1998, J BIOL CHEM, V273, P10174, DOI 10.1074/jbc.273.17.10174; JENSEN BD, 1986, ARCH BIOCHEM BIOPHYS, V248, P305, DOI 10.1016/0003-9861(86)90427-3; Jezek P, 1997, J BIOL CHEM, V272, P24272, DOI 10.1074/jbc.272.39.24272; Jezek P, 1996, J BIOL CHEM, V271, P32743, DOI 10.1074/jbc.271.51.32743; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; Kramer R, 1996, KIDNEY INT, V49, P947, DOI 10.1038/ki.1996.133; LEE CP, 1989, BIOCHIM BIOPHYS ACTA, V1000, P371, DOI 10.1016/S0006-3002(89)80032-0; Meesue BJD, 1975, ANNU REV PLANT PHYS, V26, P117; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; VANDENBERGEN CWM, 1994, EUR J BIOCHEM, V226, P1071; Vanlerberghe GC, 1997, ANNU REV PLANT PHYS, V48, P703, DOI 10.1146/annurev.arplant.48.1.703; VERCESI A, 1978, J BIOL CHEM, V253, P6379; Vercesi A. E., 1997, Recent Research Developments in Plant Physiology, V1, P85; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; Wagner AM, 1997, BIOSCIENCE REP, V17, P319, DOI 10.1023/A:1027388729586	21	54	54	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34882	34886		10.1074/jbc.273.52.34882	http://dx.doi.org/10.1074/jbc.273.52.34882			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857016	hybrid, Green Published			2022-12-25	WOS:000077719700034
J	Bibikova, M; Wu, B; Chi, EX; Kim, KH; Trautman, JK; Carroll, D				Bibikova, M; Wu, B; Chi, EX; Kim, KH; Trautman, JK; Carroll, D			Characterization of FEN-1 from Xenopus laevis - cDNA cloning and role in DNA metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; EXONUCLEASE ACTIVITY; MUTATION AVOIDANCE; PURIFIED PROTEINS; REPLICATION FORK; MAMMALIAN-CELLS; 3' EXONUCLEASE; LARGE SUBUNIT	cDNAs for the Xenopus laevis homologue of the endo/exonuclease FEN-1 (DNase IV) have been cloned using a polymerase chain reaction strategy. Products were obtained from two nonallelic Xenopus genes (xFEN-1a and xFEN-1b) that differ from each other by 4.5% in amino acid sequence;Both are 80% identical to mammalian FEN-1 proteins and 55% identical to the yeast homologues. When expressed in Escherichia coli, the Xenopus enzymes showed flap endonuclease activity, a unique feature of this class of nucleases. In addition, expression from the Xenopus cDNAs complemented the temperature and methyl methanesulfonate sensitivity of a yeast rad27 deletion, which eliminates the endogenous FEN-1 gene product. Antiserum raised against xFEN-1 was used to show that the protein accumulates during the middle and late stages of oogenesis, in parallel with other DNA metabolic activities, and that it is localized to the oocyte nucleus. Flap endonuclease activity was demonstrated in oocyte nuclear extracts, and this was inhibited by the anti-xFEN-1 antiserum, The antiserum did not inhibit the major oocyte 5' --> 3' exonuclease activity. DNA synthesis in oocyte extracts was blocked by the antiserum, and the nature of this inhibition suggests that xFEN-1 may be part of a large complex of replication factors. Chromatographic evidence was obtained for the existence of a complex that forms during DNA synthesis and includes proliferating cell nuclear antigen in addition to xFEN-1. These observations support a critical role for xFEN-1 in DNA replication, but indicate that another enzyme must be responsible for the exonuclease function required for homologous recombination in Xenopus oocytes.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Carroll, D (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.	carroll@medschool.med.utah.edu						Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Carroll D, 1996, PROG NUCLEIC ACID RE, V54, P101, DOI 10.1016/S0079-6603(08)60361-X; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORTESE R, 1980, P NATL ACAD SCI-BIOL, V77, P4147, DOI 10.1073/pnas.77.7.4147; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P663; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gerhart J.C., 1980, Biological Regulation and Development, V2, P133; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kornberg A., 1992, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; LEHMAN CW, 1993, MOL CELL BIOL, V13, P6897, DOI 10.1128/MCB.13.11.6897; LEHMAN CW, 1991, P NATL ACAD SCI USA, V88, P10840, DOI 10.1073/pnas.88.23.10840; LEHMAN CW, 1993, ANAL BIOCHEM, V211, P311, DOI 10.1006/abio.1993.1275; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LINDAHL T, 1971, EUR J BIOCHEM, V18, P415, DOI 10.1111/j.1432-1033.1971.tb01258.x; LINDAHL T, 1971, EUR J BIOCHEM, V18, P407, DOI 10.1111/j.1432-1033.1971.tb01257.x; LINDAHL T, 1969, P NATL ACAD SCI USA, V62, P597, DOI 10.1073/pnas.62.2.597; Linn S.M., 1993, NUCLEASES; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MARYON E, 1989, MOL CELL BIOL, V9, P4862, DOI 10.1128/MCB.9.11.4862; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; Stahl F.W, 1979, GENETIC RECOMBINATIO; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; ZIERLER MK, 1985, J BIOL CHEM, V260, P974	64	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34222	34229		10.1074/jbc.273.51.34222	http://dx.doi.org/10.1074/jbc.273.51.34222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852084	hybrid			2022-12-25	WOS:000077542200050
J	Kaji, H; Tai, S; Okimura, Y; Iguchi, G; Takahashi, Y; Abe, H; Chihara, K				Kaji, H; Tai, S; Okimura, Y; Iguchi, G; Takahashi, Y; Abe, H; Chihara, K			Cloning and characterization of the 5 '-flanking region of the human growth hormone secretagogue receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC ORGANIZATION; TRANSCRIPTION; RAT; EXPRESSION; PITUITARY; PROMOTER	Recently, the growth hormone secretagogue receptor (GHS-R) cDNA has been isolated from the pituitary and hypothalamus, To evaluate the regulation of human (h) GHS-R gene expression, we cloned the hGHS-R gene containing the 5'-flanking region of 0.6-2.9 kilobase pairs. Analysis of the hGHS-R transcripts with 5'-rapid amplification of cDNA ends suggested that the putative transcription initiation site was approximately - 453 base pairs upstream of the translation initiation site (+1). There is no typical TATA, CAAT, or GC box but an initiator-like sequence and putative binding sites for several transcription factors around the putative transcription start site. The S'-flanking region inserted into a luciferase reporter vector had promoter activity in GH, cells but had activity indistinguishable from background in HeLa or EP1 cells. The hGHS-R promoter activity in GH, cells increased by deletion of nucleotides from - 1224 to -734, whereas it was decreased by further deletion from -734 to -608. Knowledge of the promoter region of the hGHS-R gene will facilitate elucidation of its transcriptional control.	Kobe Univ, Sch Med, Dept Med, Div 3, Kobe, Hyogo 6500017, Japan	Kobe University	Kaji, H (corresponding author), Kobe Univ, Sch Med, Dept Med, Div 3, Kobe, Hyogo 6500017, Japan.							Adams EF, 1998, J CLIN ENDOCR METAB, V83, P638, DOI 10.1210/jc.83.2.638; ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; Bennett PA, 1997, ENDOCRINOLOGY, V138, P4552, DOI 10.1210/en.138.11.4552; BONDER M, 1987, CELL, V50, P267; de Keyzer Y, 1997, EUR J ENDOCRINOL, V137, P715, DOI 10.1530/eje.0.1370715; ELSHOLTZ HP, 1990, GENE DEV, V4, P43, DOI 10.1101/gad.4.1.43; FAN NC, 1995, MOL CELL ENDOCRINOL, V107, pR1, DOI 10.1016/0303-7207(94)03460-B; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; HOSODA K, 1992, J BIOL CHEM, V267, P18797; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; IKUYAMA S, 1992, MOL ENDOCRINOL, V6, P793, DOI 10.1210/me.6.5.793; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Iwasaki T, 1996, J BIOL CHEM, V271, P22183, DOI 10.1074/jbc.271.36.22183; Kamakura S, 1997, BIOCHEM BIOPH RES CO, V235, P321, DOI 10.1006/bbrc.1997.6770; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MOMANY FA, 1984, ENDOCRINOLOGY, V114, P1531, DOI 10.1210/endo-114-5-1531; Naville D, 1997, BIOCHEM BIOPH RES CO, V230, P7, DOI 10.1006/bbrc.1996.5911; PATCHETT AA, 1995, P NATL ACAD SCI USA, V92, P7001, DOI 10.1073/pnas.92.15.7001; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; Petersenn S, 1998, MOL ENDOCRINOL, V12, P233, DOI 10.1210/me.12.2.233; Poulin G, 1997, MOL CELL BIOL, V17, P6673, DOI 10.1128/MCB.17.11.6673; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; SEARLES RP, 1995, J BIOL CHEM, V270, P157, DOI 10.1074/jbc.270.1.157; SMITH RG, 1993, SCIENCE, V260, P1640, DOI 10.1126/science.8503009; Tremblay JJ, 1998, MOL ENDOCRINOL, V12, P428, DOI 10.1210/me.12.3.428; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; WANG HY, 1992, MOL ENDOCRINOL, V6, P320, DOI 10.1210/me.6.3.320; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	29	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33885	33888		10.1074/jbc.273.51.33885	http://dx.doi.org/10.1074/jbc.273.51.33885			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852035	hybrid			2022-12-25	WOS:000077542200001
J	Kashanchi, F; Duvall, JF; Kwok, RPS; Lundblad, JR; Goodman, RH; Brady, JN				Kashanchi, F; Duvall, JF; Kwok, RPS; Lundblad, JR; Goodman, RH; Brady, JN			The coactivator CBP stimulates human T-cell lymphotrophic virus type I Tax transactivation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; RNA-POLYMERASE-II; LONG TERMINAL REPEAT; GENERAL TRANSCRIPTION FACTORS; LEUKEMIA-VIRUS; HTLV-I; 21-BASE-PAIR REPEATS; ACTIVATION DOMAIN; DNA-BINDING; HISTONE ACETYLTRANSFERASES	Tax interacts with the cellular cyclic AMP-responsive element binding protein (CREB) and facilitates the binding of the coactivator CREB binding protein (CBP), forming a multimeric complex on the cyclic AMP-responsive element (CRE)-like sites in the human T-cell lymphotrophic virus type I (HTLV-I) promoter. The trimeric complex is believed to recruit additional regulatory proteins to the HTLV-I long terminal repeat, but there has been no direct evidence that CBP is required for Tax-mediated transactivation. We present evidence that Tax and CBP activate transcription from the HTLV-I 21 base pair repeats on naked DNA templates. Transcriptional activation of the HTLV-I sequences required both Tax and CBP and could be mediated, by either the N-terminal activation domain of CBP or the full-length protein. Fluorescence polarization binding assays indicated that CBP does not markedly enhance the affinity of Tax for the trimeric complex. Transcription analyses suggest that CBP activates Tax-dependent transcription by promoting transcriptional initiation and reinitiation. The ability of CBP to activate the HTLV-I promoter does not involve the stabilization of Tax binding, but rather depends upon gene activation properties of the co-activator that function in the context of a naked DNA template.	NCI, Lab Receptor Biol & Gene Express, Div Basic Sci, NIH, Bethesda, MD 20892 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Div Mol Med, Portland, OR 97201 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Oregon Health & Science University; Oregon Health & Science University	Brady, JN (corresponding author), NCI, Lab Receptor Biol & Gene Express, Div Basic Sci, NIH, Bldg 41,Rm B403, Bethesda, MD 20892 USA.	bradyj@exchange.nih.gov			NIDDK NIH HHS [DK50014] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050014] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; ARAIS J, 1994, NATURE, V370, P226; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; Clemens KE, 1996, MOL CELL BIOL, V16, P4656; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dallas PB, 1997, J VIROL, V71, P1726, DOI 10.1128/JVI.71.2.1726-1731.1997; DUVALL JF, 1995, J VIROL, V69, P5077, DOI 10.1128/JVI.69.8.5077-5086.1995; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GEIBLER HA, 1997, MOL CELL BIOL, V17, P5156; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GESSAIN A, 1985, LANCET, V2, P407; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASHANCHI F, 1992, NUCLEIC ACIDS RES, V20, P4673, DOI 10.1093/nar/20.17.4673; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LINDHOLM PF, 1991, J BIOCHEM BIOPH METH, V22, P233, DOI 10.1016/0165-022X(91)90071-4; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Parker D, 1996, MOL CELL BIOL, V16, P694; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; SZENTIRMAY MN, 1994, NUCLEIC ACIDS RES, V22, P5341, DOI 10.1093/nar/22.24.5341; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	71	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34646	34652		10.1074/jbc.273.51.34646	http://dx.doi.org/10.1074/jbc.273.51.34646			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852138	hybrid			2022-12-25	WOS:000077542200104
J	Nayler, O; Schnorrer, F; Stamm, S; Ullrich, A				Nayler, O; Schnorrer, F; Stamm, S; Ullrich, A			The cellular localization of the murine serine/arginine-rich protein kinase CLK2 is regulated by serine 141 autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SR SPLICING FACTORS; IN-VIVO; PHOSPHORYLATION; TRANSCRIPTION; FAMILY; CYCLE; 5,6-DICHLORO-1-BETA-D-RIBOFURANOSYLBENZIMIDAZOLE; THREONINE; DOMAINS	Pre-mRNA splicing is catalyzed by a multitude of proteins including serine/arginine-rich (SR) proteins, which are thought to play a crucial role in the formation of spliceosomes and in the regulation of alternative splicing. SR proteins are highly phosphorylated, and their kinases are believed to regulate the recruitment of SR proteins from nuclear storage compartments known as speckles. Recently, a family of autophosphorylating kinases termed CLK (CDC2/CDC28-like kinases) was shown to phosphorylate SR proteins and to influence alternative splicing in overexpression systems. Here we used endogenous CLK2 protein to demonstrate that it displays different biochemical characteristics compared with its overexpressed protein and that it is differentially phosphorylated in vivo. Furthermore, CLK2 changed its nuclear localization upon treatment with the kinase inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. We have also identified a CLK2 autophosphorylation site, which is highly conserved among all CLK proteins, and we show by site-directed mutagenesis that its phosphorylation influences the subnuclear localization of CLK2. Our data suggest that CLK2 localization and possibly activity are influenced by a balance of CLK2 autophosphorylation and the regulation by CLK2 kinases and phosphatases.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Max Planck Inst Neurobiol, D-82152 Martinsried, Germany	Max Planck Society; Max Planck Society	Nayler, O (corresponding author), Max Planck Inst Biochem, Am Klopferspitz 18A, D-82152 Martinsried, Germany.		Schnorrer, Frank/AIE-3578-2022	Schnorrer, Frank/0000-0002-9518-7263				Bauren G, 1996, J CELL BIOL, V133, P929, DOI 10.1083/jcb.133.5.929; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Colwill K, 1996, J BIOL CHEM, V271, P24569, DOI 10.1074/jbc.271.40.24569; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; FU XD, 1995, RNA, V1, P663; GALLINARO H, 1988, J MOL BIOL, V204, P1031, DOI 10.1016/0022-2836(88)90059-9; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; HIMMELSPACH M, 1995, RNA, V1, P794; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; Huet X, 1996, MOL CELL BIOL, V16, P3789; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lee K, 1996, J BIOL CHEM, V271, P27299, DOI 10.1074/jbc.271.44.27299; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; OTTERSON GA, 1993, ONCOGENE, V8, P949; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414	42	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34341	34348		10.1074/jbc.273.51.34341	http://dx.doi.org/10.1074/jbc.273.51.34341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852100	hybrid			2022-12-25	WOS:000077542200066
J	Alioua, A; Tanaka, Y; Wallner, M; Hofmann, F; Ruth, P; Meera, P; Toro, L				Alioua, A; Tanaka, Y; Wallner, M; Hofmann, F; Ruth, P; Meera, P; Toro, L			The large conductance,voltage-dependent, and calcium-sensitive K+ channel, Hslo, is a target of cGMP-dependent protein kinase phosphorylation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; SMOOTH-MUSCLE CELLS; HIGH-CONDUCTANCE; BETA-SUBUNIT; LIPID BILAYERS; PHOSPHATASE 2A; NITRIC-OXIDE; ION CHANNELS; CA CHANNELS; MODULATION	Native large conductance, voltage-dependent, and Ca2+-sensitive K+ channels are activated by cGMP-dependent protein kinase, Two possible mechanisms of kinase action have been proposed: 1) direct phosphorylation of the channel and 2) indirect via PKG-dependent activation of a phosphatase. To scrutinize the first possibility, at the molecular level, we used the human pore-forming alpha-subunit of the Ca2+-sensitive K+ channel, Hslo, and the alpha-isoform of cGMP-dependent protein kinase I. In cell-attached patches of oocytes co-expressing the Hslo channel and the kinase, 8-Br-cGMP significantly increased the macroscopic currents. This increase in current was due to an increase in the channel voltage sensitivity by similar to 20 mV and was reversed by alkaline phosphatase treatment after patch excision, In inside-out patches, however, the effect of purified kinase was negative in 12 of 13 patches. In contrast, and consistent with the intact cell experiments, purified kinase applied to the cytoplasmic side of reconstituted channels increased their open probability, This stimulatory effect was absent when heat-denatured kinase was used. Biochemical experiments show that the purified kinase incorporates gamma-P-33 into the immunopurified Hslo band of similar to 125 kDa, Furthermore, in vivo phosphorylation largely attenuates this labeling in back-phosphorylation experiments. These results demonstrate that the Lu-subunit of large conductance Ca2+-sensitive K+ channels is substrate for G-I alpha kinase in vivo and support direct phosphorylation as a mechanism for PKG-I alpha-induced activation of maxi-K channels.	Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Technical University of Munich	Toro, L (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, BH-612 CHS,Box 951778, Los Angeles, CA 90095 USA.	ltoro@ucla.edu	Wallner, Martin/B-8322-2009; Meera, Pratap B/C-6499-2009	Wallner, Martin/0000-0003-4134-8946; 	NHLBI NIH HHS [HL54970] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054970] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALIOUA A, 1995, AM J PHYSIOL-LUNG C, V268, pL1057, DOI 10.1152/ajplung.1995.268.6.L1057; ARCHER SL, 1994, P NATL ACAD SCI USA, V91, P7583, DOI 10.1073/pnas.91.16.7583; BIALECKI RA, 1995, AM J PHYSIOL-LUNG C, V268, pL152, DOI 10.1152/ajplung.1995.268.1.L152; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; FEIL R, 1993, FEBS LETT, V336, P163, DOI 10.1016/0014-5793(93)81632-A; Fox AJ, 1997, J CLIN INVEST, V99, P513, DOI 10.1172/JCI119187; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; GROMADA J, 1995, DIABETOLOGIA, V38, P1025, DOI 10.1007/BF00402171; Hanner M, 1997, P NATL ACAD SCI USA, V94, P2853, DOI 10.1073/pnas.94.7.2853; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KNAUS HG, 1995, J BIOL CHEM, V270, P22434, DOI 10.1074/jbc.270.38.22434; Krause JD, 1996, NEUROPHARMACOLOGY, V35, P1017, DOI 10.1016/0028-3908(96)00134-7; KUME H, 1995, AM J PHYSIOL-LUNG C, V268, pL221, DOI 10.1152/ajplung.1995.268.2.L221; LANDGRAF W, 1992, J CARDIOVASC PHARM, V20, pS18, DOI 10.1097/00005344-199212001-00005; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Lingle C J, 1996, Ion Channels, V4, P261; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Meera P, 1997, P NATL ACAD SCI USA, V94, P14066, DOI 10.1073/pnas.94.25.14066; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Peng W, 1996, J APPL PHYSIOL, V81, P1264, DOI 10.1152/jappl.1996.81.3.1264; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; Sansom SC, 1997, J BIOL CHEM, V272, P9902; SCORNIK FS, 1993, AM J PHYSIOL, V265, pH1460, DOI 10.1152/ajpheart.1993.265.4.H1460; Silberberg SD, 1996, BIOPHYS J, V70, P2640, DOI 10.1016/S0006-3495(96)79833-8; Stockand JD, 1996, AM J PHYSIOL-CELL PH, V271, pC1669, DOI 10.1152/ajpcell.1996.271.5.C1669; Tanaka Y, 1998, N-S ARCH PHARMACOL, V357, P705, DOI 10.1007/PL00005228; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TORO L, 1990, J GEN PHYSIOL, V96, P373, DOI 10.1085/jgp.96.2.373; Toro L, 1997, SER CENT ES, P47; Vaandrager AB, 1998, P NATL ACAD SCI USA, V95, P1466, DOI 10.1073/pnas.95.4.1466; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WILLIAMS DL, 1988, P NATL ACAD SCI USA, V85, P9360, DOI 10.1073/pnas.85.23.9360; Yamakage M, 1996, AM J PHYSIOL-LUNG C, V270, pL338, DOI 10.1152/ajplung.1996.270.3.L338; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760	50	143	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32950	32956		10.1074/jbc.273.49.32950	http://dx.doi.org/10.1074/jbc.273.49.32950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830046	hybrid			2022-12-25	WOS:000077329100085
J	Brown, BJ; Deng, Z; Karplus, PA; Massey, V				Brown, BJ; Deng, Z; Karplus, PA; Massey, V			On the active site of old yellow enzyme - Role of histidine 191 and asparagine 194	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; REDUCTASE; SEQUENCE; OXIDOREDUCTASE; PURIFICATION; EXPRESSION; MECHANISM; BINDING	Old Yellow Enzyme (OYE) binds phenolic ligands forming long wavelength (500-800 nm) charge-transfer complexes. The enzyme is reduced by NADPH, and oxygen, quinones, and alpha,beta-unsaturated aldehydes and ketones can act as electron accepters to complete catalytic turnover. Solution of the crystal structure of OYE1 from brewer's bottom yeast (Fox, K. M., and Karplus, P. A. (1994) Structure 2, 1089-1105) made it possible to identify histidine 191 and asparagine 194 as amino acid residues that hydrogen-bond with the phenolic ligands, stabilizing the anionic form involved in charge-transfer interaction with the FMN prosthetic group. His-191 and Asn-194 are also predicted to interact with the nicotinamide ring of NADPH in the active site. Mutations of His-191 to Asn, Asn-194 to His, and a double mutation, H191N/N194H, were made of OYE1. It was not possible to isolate the N191H mutant enzyme, but the other two mutant forms had the expected effect on phenolic ligand binding, i,e, decreased binding affinity and decreased charge-transfer absorbance. Reduction of the H191N mutant enzyme by NADPH was similar to that of OYE1, but the reduction rate constant for NADH was greatly decreased. The double mutant enzyme had an increased rate constant for reduction by NADPH, but the reduction rate constant with NADH was lower by a factor of 15. The reactivity of OYE1 and the mutant enzymes with oxygen was similar, but the reactivity of 2-cyclohexenone was greatly decreased by the mutations. The crystal structures of the two mutant forms showed only minor changes from that of the wild type enzyme.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of Michigan System; University of Michigan; Cornell University	Massey, V (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	massey@umich.edu		Karplus, Paul/0000-0001-8725-6292	NCRR NIH HHS [M01RR00042] Funding Source: Medline; NIGMS NIH HHS [GM 11106] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Brown BJ, 1994, FLAVINS AND FLAVOPROTEINS 1993, P391; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR SYSTEM CRYSTA; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; French CE, 1995, BIOCHEM J, V312, P671, DOI 10.1042/bj3120671; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; Karplus PA, 1995, FASEB J, V9, P1518, DOI 10.1096/fasebj.9.15.8529830; Karplus PA, 1997, ACCOUNTS CHEM RES, V30, P330, DOI 10.1021/ar960022j; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; LIU XL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P187, DOI 10.1016/0167-4781(93)90113-R; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MASSEY V, 1986, J BIOL CHEM, V261, P1215; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Massey V., 1984, FLAVINS FLAVOPROTEIN, P191; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; MIRANDA M, 1995, YEAST, V11, P459, DOI 10.1002/yea.320110509; Miura K, 1997, BIOL PHARM BULL, V20, P110; MIURA R, 1986, J BIOCHEM-TOKYO, V99, P901, DOI 10.1093/oxfordjournals.jbchem.a135551; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; SAITO K, 1991, J BIOL CHEM, V266, P20720; Schaller F, 1997, J BIOL CHEM, V272, P28066, DOI 10.1074/jbc.272.44.28066; SCHOPFER LM, 1990, STUDY ENZYMES, P249; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; Theorell H, 1935, BIOCHEM Z, V275, P344; THEORELL H, 1956, ARCH BIOCHEM BIOPHYS, V65, P439, DOI 10.1016/0003-9861(56)90204-1; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; Warburg O, 1933, BIOCHEM Z, V266, P377; WARBURG O, 1932, NATURWISSENSCHAFTEN, V20, P688; WHITBY G, 1957, BIOCHEM J, V54, P437	39	103	106	4	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32753	32762		10.1074/jbc.273.49.32753	http://dx.doi.org/10.1074/jbc.273.49.32753			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830019	hybrid			2022-12-25	WOS:000077329100058
J	Subbaramaiah, K; Chung, WJ; Dannenberg, AJ				Subbaramaiah, K; Chung, WJ; Dannenberg, AJ			Ceramide regulates the transcription of cyclooxygenase-2 - Evidence for involvement of extracellular signal-regulated kinase c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; INTESTINAL EPITHELIAL-CELLS; HUMAN COLON-CANCER; PHORBOL ESTER; GENE-EXPRESSION; GROWTH-FACTOR; INHIBITION; COX-2; SPHINGOMYELINASE; INTERLEUKIN-6	The ceramide signaling pathway is activated by the sphingomyelinase (SMase)-mediated hydrolysis of cell membrane sphingomyelin to ceramide, We determined whether ceramide, a lipid second messenger, induced cyclooxygenase-2 (COX-2) in human mammary epithelial cells. Treatment of cells with neutral SMase or C-2- or C-6-ceramide enhanced prostaglandin E-2 synthesis and increased levels of COX-2 protein and mRNA. Nuclear runoff assays revealed increased rates of COX-2 transcription after treatment with SMase and C-2- and C-6-ceramide, Transient transfections utilizing COX-2 promoter deletion constructs and COX-2 promoter constructs in which specific enhancer elements were mutagenized indicated that the effects of ceramide were mediated via a cAMP response element. The induction of COX-2 by ceramide was inhibited by calphostin C, an inhibitor of protein kinase C, Induction of COX-2 promoter activity by SMase was blocked by overexpressing kinase-deficient Raf-1, Triggering of the ceramide pathway also led to increases in extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAPK) activities; pharmacological inhibitors of MAPK kinase (MEK) and p38 MAPK blocked the induction of COX-2 by SMase. Overexpressing ERK1, JNK, or p38 led to severalfold increases in COX-2 promoter activity. By comparison, overexpression of dominant negatives for ERK1/2, JNK, or p38 blocked the activation of COX-2 promoter activity by SMase, A dominant negative for c-Jun inhibited the activation of COX-2 promoter activity by ceramide, Thus, in response to ceramide, increased MAPK signaling activates c-Jun, which, in turn, induces COX-2 gene expression via the cAMP response element in the COX-2 promoter.	Cornell Univ, Med Ctr, New York Hosp, Dept Med,Div Digest Dis, New York, NY 10021 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Surg, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital	Dannenberg, AJ (corresponding author), Cornell Univ, Med Ctr, New York Hosp, Dept Med,Div Digest Dis, Rm F-231,1300 York Ave, New York, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA068136] Funding Source: NIH RePORTER; NCI NIH HHS [CA68136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DuBois RN, 1996, CANCER RES, V56, P733; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V220, P681, DOI 10.1006/bbrc.1996.0464; HERSCHMAN HR, 1996, BIOCHIM BIOPHYS ACTA, V1299, P1299; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kawamori T, 1998, CANCER RES, V58, P409; Kirtikara K, 1998, MOL CELL BIOCHEM, V181, P41; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipsky PE, 1997, J RHEUMATOL, V24, P9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; MULLERDECKER K, 1995, MOL CARCINOGEN, V12, P31, DOI 10.1002/mc.2940120106; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARETT ML, 1997, INT J ONCOL, V10, P503; Reunanen N, 1998, J BIOL CHEM, V273, P5137, DOI 10.1074/jbc.273.9.5137; Ristimaki A, 1997, CANCER RES, V57, P1276; Sbrissa D, 1997, AM J PHYSIOL-GASTR L, V272, pG1615, DOI 10.1152/ajpgi.1997.272.6.G1615; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TIANO H, 1997, P AM ASSOC CANC RES, V38, P1727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; ZHAI YF, 1993, CANCER RES, V53, P2272; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424	51	184	188	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32943	32949		10.1074/jbc.273.49.32943	http://dx.doi.org/10.1074/jbc.273.49.32943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830045	hybrid			2022-12-25	WOS:000077329100084
J	Lanvers, C; Hempel, G; Blaschke, G; Boos, J				Lanvers, C; Hempel, G; Blaschke, G; Boos, J			Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells	FASEB JOURNAL			English	Article						cellular pharmacokinetics; retinoid X receptor; 13-cis-RA; retinoic acid receptor	ACUTE PROMYELOCYTIC LEUKEMIA; ALL-TRANS; 9-CIS-RETINOIC ACID; 13-CIS-RETINOIC ACID; NONENZYMATIC ISOMERIZATION; INTERFERON ALPHA-2A; THERAPY; PROLIFERATION; EXPRESSION; RECEPTORS	The successful introduction of 13-cis-retinoic acid (13-cis-RA) and all-trans-retinoic acid (all-trans-RA) in the chemoprevention and treatment of cancer along with the discovery of different retinoic acid receptors transactivated by different retinoic acid isomers resulted in a number of in vitro studies of the antitunor effects of single retinoic acid isomers, Since the formation of retinoic acid isomers with different receptor affinities might modulate retinoic acid response in vitro, we determined retinoic acid disposition in HL-60 cells and cell culture medium during incubation with 13-cis-, 9-cis-, and all-trans-RA, In medium, retinoic acids underwent a thiol-radical mediated isomerization resulting in a mixture of 13-cis-, 9-cis-, 9,13-di-cis-, and all-trans-RA. Except for the 9,13-di-cis-RA, all isomers generated in medium were also detected in HL-60 cells. Whereas 9-cis-RA and 13-cis-RA showed similar cellular pharmacokinetics, all-trans-RA reached about fourfold higher concentrations in HL-60 cells com pared to 9-cis-RA and 1-3cis-RA. Due to its better uptake, all-trans-RA. became the main isomer within cells as it was formed in the medium when incubated with 13-cis-RA and 9-cis-RA. Thus, due to the simple chemically induced isomerization and its profound influence on cellular retinoic acid concentrations, studies of the efficacy of single retinoic acid isomers in vitro should be interpreted with caution.	Univ Munster, Dept Pediat Hematol & Oncol, D-48149 Munster, Germany; Univ Munster, Dept Pharmaceut Chem, D-48149 Munster, Germany	University of Munster; University of Munster	Boos, J (corresponding author), Univ Munster, Ctr Pediat, Dept Hematol & Oncol, Albert Schweitzer Str 33, D-48149 Munster, Germany.	boosj@uni-muenster.de	Lanvers-Kaminsky, Claudia/AAY-2071-2021					AGADIR A, 1995, J CLIN ONCOL, V13, P2517, DOI 10.1200/JCO.1995.13.10.2517; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMIENNE C, 1990, BLOOD, V76, P1710; COLLINS SJ, 1987, BLOOD, V70, P1233; FLYNN PJ, 1983, BLOOD, V62, P1211; FONTANA JA, 1986, CANCER-AM CANCER SOC, V57, P209, DOI 10.1002/1097-0142(19860115)57:2<209::AID-CNCR2820570204>3.0.CO;2-K; FRICKEL F, 1984, RETINOIDS, P210; Giannini F, 1997, INT J CANCER, V70, P194; Gudas Lorraine J., 1994, P443; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JONES CS, 1994, NUTR CANCER, V21, P83, DOI 10.1080/01635589409514306; KALIN JR, 1982, DRUG METAB DISPOS, V10, P391; KALIN JR, 1981, DRUG METAB DISPOS, V9, P196; KIZAKI M, 1993, BLOOD, V82, P3592; KOJIMA R, 1994, J BIOL CHEM, V269, P32700; Lanvers C, 1996, J CHROMATOGR B, V685, P233, DOI 10.1016/S0378-4347(96)00192-2; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LUCEK RW, 1985, CLIN PHARMACOKINET, V10, P38, DOI 10.2165/00003088-198510010-00002; Mangelsdorf David J., 1994, P319; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; MUINDI JRF, 1997, CANCER RES, V52, P2138; NILSSON B, 1984, BRIT J HAEMATOL, V57, P365, DOI 10.1111/j.1365-2141.1984.tb02910.x; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; REDFERN CPF, 1995, EUR J CANCER, V31A, P486, DOI 10.1016/0959-8049(95)00066-R; REPA JJ, 1993, P NATL ACAD SCI USA, V90, P7293, DOI 10.1073/pnas.90.15.7293; Reynolds CP, 1994, ADV NEUROBLASTOMA RE, V4, P237; SASS JO, 1995, DRUG METAB DISPOS, V23, P887; SHARMA S, 1994, CANCER RES, V54, P5848; Shih TW, 1997, DRUG METAB DISPOS, V25, P27; SHIH TW, 1986, DRUG METAB DISPOS, V14, P698; TZIMAS G, 1994, DRUG METAB DISPOS, V22, P928; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; URBACH J, 1994, FEBS LETT, V351, P429, DOI 10.1016/0014-5793(94)00090-5; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZHU J, 1995, LEUKEMIA, V9, P302	40	22	22	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1627	1633		10.1096/fasebj.12.15.1627	http://dx.doi.org/10.1096/fasebj.12.15.1627			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837852				2022-12-25	WOS:000077574500004
J	Spinozzi, F; Agea, E; Fizzotti, M; Bassotti, G; Russano, A; Droetto, S; Bistoni, O; Grignani, F; Bertotto, A				Spinozzi, F; Agea, E; Fizzotti, M; Bassotti, G; Russano, A; Droetto, S; Bistoni, O; Grignani, F; Bertotto, A			Role of T-helper type 2 cytokines in down-modulation of Fas mRNA and receptor on the surface of activated CD4(+) T cells: molecular basis for the persistence of the allergic immune response	FASEB JOURNAL			English	Article						apoptosis; PBMC; interferon; interleukin; transforming growth factor	MEDIATED APOPTOSIS; BRONCHIAL-ASTHMA; GENE; LYMPHOCYTES; DISEASE; INTERLEUKIN-4; EXPRESSION; LIGAND; DEATH; MICE	The mechanisms responsible for persistence of T lymphocytes at the sites of allergic inflammation are not completely understood. Activated T cells, usually expressing Fas on their surface, undergo activation-induced apoptotic death, thus limiting the dangerous consequences of a persistent immune reaction. We have previously shown that pulmonary T lymphocytes from untreated asthmatic subjects do not express surface Fas receptors nor do they contain Fas mRNA,yet they display normal levels of Fas ligand. This: is not an inherited defect and is confined to mucosal T cells. To gain insights into the mechanism responsible for these findings, we performed a set of experiments with both purified Dermatophagoides pteronyssinus allergen and recombinant human cytokines: interleukin 2 (IL-2), IL-4, IL-5, transforming growth factor beta(1), interferon gamma, and granulocyte-macrophage colony-stimulating factor (GM-CSF). In vitro exposure of purified CD4(+) lymphocytes to allergen yielded only transient up-regulation of surface Fas but did not influence susceptibility to Fas-mediated cell death. T-helper type 2 cytokines (IL-4, IL-5, and GMCSF) had a dose-dependent and specific inhibitory effect on Fas mRNA, suggesting a new fundamental biological role in the survival of inflammatory cells during allergen exposure.	Univ Perugia, Sch Med, Lab Allergol & Clin Immunol, Dept Clin & Expt Med, I-06122 Perugia, Italy; Univ Perugia, Sch Med, Mol Biol Lab, Dept Clin & Expt Med, I-06122 Perugia, Italy; Univ Perugia, Sch Med, Lab Gastroenterol, Dept Clin & Expt Med, I-06122 Perugia, Italy; Univ Perugia, Sch Med, Dept Pediat, I-06122 Perugia, Italy	University of Perugia; University of Perugia; University of Perugia; University of Perugia	Spinozzi, F (corresponding author), Monteluce Policlin, Lab Allergy & Clin Immunol, Inst Internal Med & Oncol Sci, I-06122 Perugia, Italy.		bistoni, onelia/G-8234-2011					Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; ADACHI T, 1995, AM J RESP CRIT CARE, V151, P618; Akbar AN, 1996, EUR J IMMUNOL, V26, P294, DOI 10.1002/eji.1830260204; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BENDELAC A, 1995, SCIENCE, V269, P185, DOI 10.1126/science.7542402; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; DeLibero G, 1997, IMMUNOL TODAY, V18, P22, DOI 10.1016/S0167-5699(97)80010-2; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Druilhe A, 1996, BLOOD, V87, P2822, DOI 10.1182/blood.V87.7.2822.bloodjournal8772822; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; HOLGATE ST, 1997, LANCET S2, V350, pS115; KAY AB, 1997, PROG ALLERGY CLIN IM, V4, P396; Kong LP, 1997, ARTHRITIS RHEUM, V40, P87, DOI 10.1002/art.1780400113; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MIGLIORATI G, 1993, BLOOD, V81, P1352; Milik AM, 1997, J CLIN INVEST, V99, P1082, DOI 10.1172/JCI119236; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MYSLER E, 1994, J CLIN INVEST, V93, P1029, DOI 10.1172/JCI117051; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; RICI M, 1997, ACI INT, V9, P141; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SANDFORD A, 1996, AM J RESP CRIT CARE, V153, P1794; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPINOZZI F, 1995, MOL MED, V1, P821, DOI 10.1007/BF03401896; SPINOZZI F, 1995, SCAND J IMMUNOL, V41, P504, DOI 10.1111/j.1365-3083.1995.tb03599.x; Spinozzi F, 1998, ANN INTERN MED, V128, P363, DOI 10.7326/0003-4819-128-5-199803010-00004; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Spinozzi F, 1998, IMMUNOL TODAY, V19, P22, DOI 10.1016/S0167-5699(97)01182-1; SPINOZZI F, 1995, IMMUNOLOGY, V86, P379; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Vaishnaw AK, 1997, ARTHRITIS RHEUM, V40, P1917, DOI 10.1002/art.1780401102; Van Parijs L, 1998, SCIENCE, V280, P243; Vella A, 1997, J EXP MED, V186, P325, DOI 10.1084/jem.186.2.325; Vella AT, 1998, P NATL ACAD SCI USA, V95, P3810, DOI 10.1073/pnas.95.7.3810; Wen L, 1998, J IMMUNOL, V160, P1965; Wong B, 1997, J EXP MED, V186, P1939, DOI 10.1084/jem.186.11.1939	42	19	21	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1747	1753		10.1096/fasebj.12.15.1747	http://dx.doi.org/10.1096/fasebj.12.15.1747			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837865				2022-12-25	WOS:000077574500017
J	Mizuguchi, R; Hatakeyama, M				Mizuguchi, R; Hatakeyama, M			Conditional activation of janus kinase (JAK) confers factor independence upon interleukin-3-dependent cells - Essential role of Ras in JAK-triggered mitogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; CYTOKINE RECEPTORS; IL-2 RECEPTOR; GROWTH SIGNAL; RAF-1 KINASE; PROTEIN	Cytokines play crucial roles in the growth and differentiation of hematopoietic cells. They bind to specific cell membrane receptors that usually do not possess intrinsic protein-tyrosine kinase activity. Janus kinases (JAKs) are cytoplasmic protein-tyrosine kinases that physically interact with intracellular domains of the cytokine receptors and have been implicated in playing important roles in signal transduction triggered by the cytokine-cytokine receptor interaction. However, it is still uncertain whether JAK activation alone suffices to induce cell proliferation. In this work, we modified Tyk2, a member of the JAK family, by adding a membrane localization sequence and a chemical dimerizer (coumermycin)-dependent dimerization sequence. The modified Tyk2 was activated in a coumermycin-dependent manner, and the activated Tyk2 conferred cytokine independence upon interleukin-3-dependent pro-B lymphoid cells, This cytokine-independent proliferation was completely inhibited by dominant-negative Ras. These results indicate that activation of JAK through membrane-proximal dimerization is sufficient to induce cell cycle progression and that Ras is essentially involved in JAK-triggered mitogenesis.	Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, Tokyo 1708455, Japan	Japanese Foundation for Cancer Research	Hatakeyama, M (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Viral Oncol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.							CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DASILVA L, 1994, J BIOL CHEM, V269, P18267; Dorsch M, 1997, J EXP MED, V186, P1947, DOI 10.1084/jem.186.12.1947; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MERIDA I, 1991, J IMMUNOL, V147, P2202; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; Nagata Y, 1996, BIOCHEM BIOPH RES CO, V221, P785, DOI 10.1006/bbrc.1996.0674; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; OKUDA K, 1994, J BIOL CHEM, V269, P24602; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SATOH T, 1992, J BIOL CHEM, V267, P25423; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SPENCER DM, 1995, P NATL ACAD SCI USA, V92, P9805, DOI 10.1073/pnas.92.21.9805; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; TORIGOE T, 1992, BLOOD, V80, P617; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	37	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32297	32303		10.1074/jbc.273.48.32297	http://dx.doi.org/10.1074/jbc.273.48.32297			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822709	hybrid			2022-12-25	WOS:000077207000091
J	Halmer, L; Vestner, B; Gruss, C				Halmer, L; Vestner, B; Gruss, C			Involvement of topoisomerases in the initiation of simian virus 40 minichromosome replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; SV40 DNA-REPLICATION; CHROMATIN REPLICATION; INVITRO; INVIVO; NUCLEOSOMES; INHIBITOR; ACCESSIBILITY; CAMPTOTHECIN; DETERMINANT	Topoisomerases provide the unlinking activity necessary for replication fork movement during DNA replication. It is uncertain, however, whether topoisomerases are also required for the initiation of replication. To investigate this point, we have performed pulse-chase experiments with SV40 minichromosomes as template to distinguish between the initiation and the elongation of replication, Using an unfractionated cytosolic extract as a source of replication functions, we found that the addition of topoisomerases at the initiation step significantly increased the number of active chromatin templates, whereas addition of topoisomerases at the elongation step had only minor effects. Minichromosomes with an extended chromatin structure as well as protein-free DNA required less topoisomerase for effective replication initiation. We could exclude the possibility that topoisomerases enhance the origin binding of T antigen, the SV40 replication initiator, and propose instead that the arrangement of nucleosomes influences the diffusion of supercoils during initial DNA unwinding. Efficient initiation therefore requires a high local concentration of topoisomerases to relax the torsional stress.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Gruss, C (corresponding author), Univ Konstanz, Dept Biol, Univ Str 10, D-78457 Constance, Germany.	claudia.gruss@uni-konstanz.de						Alexiadis V, 1997, CHROMOSOMA, V105, P324; Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; AVEMANN K, 1988, MOL CELL BIOL, V8, P3026, DOI 10.1128/MCB.8.8.3026; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BRILL SJ, 1987, NATURE, V326, P414, DOI 10.1038/326414a0; CAIRNS J, 1963, J MOL BIOL, V6, P208, DOI 10.1016/S0022-2836(63)80070-4; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P4553, DOI 10.1093/nar/18.15.4553; CHAMPOUX JJ, 1988, J VIROL, V62, P3675, DOI 10.1128/JVI.62.10.3675-3683.1988; CHAMPOUX JJ, 1992, NUCLEIC ACIDS RES, V20, P3347, DOI 10.1093/nar/20.13.3347; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; Fotedar A, 1996, J BIOL CHEM, V271, P31627, DOI 10.1074/jbc.271.49.31627; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; GRUSS C, 1993, EMBO J, V12, P4533, DOI 10.1002/j.1460-2075.1993.tb06142.x; Halmer L, 1997, MOL CELL BIOL, V17, P2624, DOI 10.1128/MCB.17.5.2624; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISHIMI Y, 1992, J BIOL CHEM, V267, P10910; ISHIMI Y, 1992, J BIOL CHEM, V267, P462; ISHIMI Y, 1992, MOL CELL BIOL, V12, P4007, DOI 10.1128/MCB.12.9.4007; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JAKOBOVITS EB, 1980, NATURE, V285, P263, DOI 10.1038/285263a0; KORNBERG A, 1988, J BIOL CHEM, V263, P1; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Pommier Y, 1998, BIOCHEMISTRY-US, V37, P3818, DOI 10.1021/bi972067d; Quintini G, 1996, MOL CELL BIOL, V16, P2888; RAINWATER R, 1991, VIROLOGY, V181, P408, DOI 10.1016/0042-6822(91)90515-D; RAMSPERGER U, 1995, EMBO J, V14, P3215, DOI 10.1002/j.1460-2075.1995.tb07324.x; RICHTER A, 1988, NUCLEIC ACIDS RES, V16, P10119, DOI 10.1093/nar/16.21.10119; SARAGOSTI S, 1980, CELL, V20, P65, DOI 10.1016/0092-8674(80)90235-4; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; Simmons DT, 1998, J BIOL CHEM, V273, P20390, DOI 10.1074/jbc.273.32.20390; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; Simmons DT, 1998, VIROLOGY, V242, P435, DOI 10.1006/viro.1997.9024; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; STILLMAN B, 1985, EMBO J, V4, P2933, DOI 10.1002/j.1460-2075.1985.tb04026.x; UDVARDY A, 1991, MOL CELL BIOL, V11, P4973, DOI 10.1128/MCB.11.10.4973; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Vestner B, 1998, J BIOL CHEM, V273, P9409, DOI 10.1074/jbc.273.16.9409; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	47	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34792	34798		10.1074/jbc.273.52.34792	http://dx.doi.org/10.1074/jbc.273.52.34792			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857004	hybrid			2022-12-25	WOS:000077719700022
J	Vaillancourt, FH; Han, S; Fortin, PD; Bolin, JT; Eltis, LD				Vaillancourt, FH; Han, S; Fortin, PD; Bolin, JT; Eltis, LD			Molecular basis for the stabilization and inhibition of 2,3-dihydroxybiphenyl 1,2-dioxygenase by t-butanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRADIOL CATECHOL DIOXYGENASES; SUBSTRATE-SPECIFICITY; PSEUDOMONAS-PUTIDA; PROTOCATECHUATE 3,4-DIOXYGENASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 2,3-DIOXYGENASE; MECHANISM; PURIFICATION; PSEUDOALCALIGENES	The steady-state cleavage of catechols by 2,3-dihydroxybiphenyl 1,2-dioxygenase (DHBD), the extradiol dioxygenase of the biphenyl biodegradation pathway, was investigated using a highly active, anaerobically purified preparation of enzyme, The kinetic data obtained using 2,3-dihydroxybiphenyl (DHB) fit a compulsory order ternary complex mechanism in which substrate inhibition occurs. The K-m for dioxygen was 1280 +/- 70 mu M, which is at least 2 orders of magnitude higher than that reported for catechol 2,3-dioxygenases, K-m and K-d for DHB were 22 +/- 2 and 8 +/- 1 mu M, respectively, DI-IBD was subject to reversible substrate inhibition and mechanism-based inactivation. In air-saturated buffer, the partition ratios of catecholic substrates substituted at C-3 were inversely related to their apparent specificity constants, Small organic molecules that stabilized DHBD most effectively also inhibited the cleavage reaction most strongly. The steady-state kinetic data and crystallographic results suggest that the stabilization and inhibition are due to specific interactions between the organic molecule and the active site of the enzyme. t-Butanol stabilized the enzyme and inhibited the cleavage of DHB in a mixed fashion, consistent with the distinct binding sites occupied by t-butanol in the crystal structures of the substrate-free form of the enzyme and the enzyme-DHB complex. In contrast, crystal structures of complexes with catechol and 3-methylcatechol revealed relationships between the binding of these smaller substrates and t-butanol that are consistent with the observed competitive inhibition.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Univ Laval, Dept Biochem, Quebec City, PQ G1K 7P4, Canada	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Laval University	Eltis, LD (corresponding author), Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.		Eltis, Lindsay D/J-8272-2015	Eltis, Lindsay D/0000-0002-6774-8158; Fortin, Pascal/0000-0001-9796-791X	NIGMS NIH HHS [GM-52381] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RH, 1992, APPL ENVIRON MICROB, V58, P647, DOI 10.1128/AEM.58.2.647-654.1992; Arras T, 1998, J BACTERIOL, V180, P2133, DOI 10.1128/JB.180.8.2133-2136.1998; ASTURIAS JA, 1994, J BIOL CHEM, V269, P7807; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bergdoll M, 1998, PROTEIN SCI, V7, P1661, DOI 10.1002/pro.5560070801; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CERDAN P, 1994, J BACTERIOL, V176, P6074, DOI 10.1128/jb.176.19.6074-6081.1994; CERDAN P, 1995, EUR J BIOCHEM, V229, P113, DOI 10.1111/j.1432-1033.1995.0113l.x; Cornish-Bowden A., 1995, ANAL ENZYME KINETIC; DELORENZO V, 1993, GENE, V123, P17, DOI 10.1016/0378-1119(93)90533-9; Elgren TE, 1997, BIOCHEMISTRY-US, V36, P11504, DOI 10.1021/bi970691k; Eltis LD, 1996, J BACTERIOL, V178, P5930, DOI 10.1128/jb.178.20.5930-5937.1996; ELTIS LD, 1993, J BIOL CHEM, V268, P2727; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERSHT A, 1985, ENZYM STRUCTURE MECH, P325; FURUKAWA K, 1987, J BACTERIOL, V169, P924, DOI 10.1128/jb.169.2.924-927.1987; HAIGLER BE, 1990, J BACTERIOL, V172, P457, DOI 10.1128/JB.172.1.457-464.1990; HAN S, 1995, SCIENCE, V270, P976, DOI 10.1126/science.270.5238.976; HAPPE B, 1993, J BACTERIOL, V175, P7313, DOI 10.1128/JB.175.22.7313-7320.1993; HEISS G, 1995, J BACTERIOL, V177, P5865, DOI 10.1128/jb.177.20.5865-5871.1995; HORI K, 1973, J BIOCHEM, V74, P375; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KOBAYASHI T, 1995, J BIOCHEM, V117, P614, DOI 10.1093/oxfordjournals.jbchem.a124753; Kukor JJ, 1996, APPL ENVIRON MICROB, V62, P1728, DOI 10.1128/AEM.62.5.1728-1740.1996; Lendenmann U, 1996, J BACTERIOL, V178, P6227, DOI 10.1128/jb.178.21.6227-6232.1996; Li AJ, 1998, PROTEINS, V32, P111, DOI 10.1002/(SICI)1097-0134(19980701)32:1<111::AID-PROT12>3.0.CO;2-H; MABROUK PA, 1991, J AM CHEM SOC, V113, P4053, DOI 10.1021/ja00011a001; NOZAKI M, 1963, BIOCHEM Z, V338, P582; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASCAL RA, 1987, J AM CHEM SOC, V109, P2854, DOI 10.1021/ja00243a065; POLISSI A, 1993, EMBO J, V12, P3339, DOI 10.1002/j.1460-2075.1993.tb06004.x; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; SANVOISIN J, 1995, J AM CHEM SOC, V117, P7836, DOI 10.1021/ja00134a041; Senda T, 1996, J MOL BIOL, V255, P735, DOI 10.1006/jmbi.1996.0060; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; SMITH TJ, 1995, J MOL GRAPHICS, V13, P122, DOI 10.1016/0263-7855(94)00019-O; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; Spence EL, 1996, J AM CHEM SOC, V118, P8336, DOI 10.1021/ja9607704; WHITTAKER JW, 1990, METHOD ENZYMOL, V188, P82	42	80	81	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34887	34895		10.1074/jbc.273.52.34887	http://dx.doi.org/10.1074/jbc.273.52.34887			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857017	hybrid			2022-12-25	WOS:000077719700035
J	Daugherty, DL; Rozema, D; Hanson, PE; Gellman, SH				Daugherty, DL; Rozema, D; Hanson, PE; Gellman, SH			Artificial chaperone-assisted refolding of citrate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-B; REDUCED LYSOZYME; LAURYL MALTOSIDE; IN-VITRO; RENATURATION; AGGREGATION; CYCLODEXTRINS; DETERGENT; REACTIVATION; COMPETITION	The power of genetic engineering methods, along with increasing genomic information, makes heterologous expression of proteins an extremely important biochemical tool. Unfortunately, proteins obtained in this way often are not in their native form, and folding becomes a crucial step in protein production. We have recently developed a strategy that promotes the folding of chemically denatured proteins via the sequential addition of low molecular weight "artificial chaperones." Here we describe in detail the application of this method to porcine heart citrate synthase. Refolding yields of as high as 65% have been achieved. Mechanistic studies indicate that there are significant differences between artificial chaperone-assisted refolding of citrate synthase and artificial chaperone-assisted refolding of two other proteins that have been examined, carbonic anhydrase B (Rozema, D., and Gellman, S. H. (1996) J, Biol. Chen. 271, 3478-3487) and lysozyme (Rozema, D,, and Gellman, S, H, (1996) Biochemistry 35, 15760-15771), The differences among these three test proteins reveal the range of procedural variation that must be considered in the application of the artificial chaperone method to new proteins.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Gellman, SH (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.	gellman@chem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM08349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANATHAPADMANABH.KP, 1993, INTERACTIONS SURFACT, P319; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BLOXHAM DP, 1980, BIOCHEMISTRY-US, V19, P3979, DOI 10.1021/bi00558a014; BREMS DN, 1988, BIOCHEMISTRY-US, V27, P4541, DOI 10.1021/bi00412a048; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Clark EDB, 1998, CURR OPIN BIOTECH, V9, P157; CLELAND JL, 1992, J BIOL CHEM, V267, P3147; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1992, BIO-TECHNOL, V10, P1013, DOI 10.1038/nbt0992-1013; CLELAND JL, 1993, PROTEIN FOLDING IN V; Connors KA, 1997, CHEM REV, V97, P1325, DOI 10.1021/cr960371r; CONNORS KA, 1995, J PHARM SCI, V84, P843, DOI 10.1002/jps.2600840712; Couthon F, 1996, BIOCHEM BIOPH RES CO, V227, P854, DOI 10.1006/bbrc.1996.1596; DeGrip WJ, 1998, BIOCHEM J, V330, P667; DEYOUNG LR, 1993, ACCOUNTS CHEM RES, V26, P614, DOI 10.1021/ar00036a002; EFTINK MR, 1989, J AM CHEM SOC, V111, P6765, DOI 10.1021/ja00199a041; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; Fenton WA, 1997, PROTEIN SCI, V6, P743; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; GEORGIOU G, 1991, PROTEIN REFOLDING; Goldberg ME, 1996, FOLD DES, V1, P21, DOI 10.1016/S1359-0278(96)00008-9; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Jaenicke R, 1997, ADV PROTEIN CHEM, V50, P1, DOI 10.1016/S0065-3233(08)60318-6; KARUPPIAH N, 1995, BIOCHEM BIOPH RES CO, V211, P60, DOI 10.1006/bbrc.1995.1778; MAEDA Y, 1994, PROTEIN ENG, V7, P1249, DOI 10.1093/protein/7.10.1249; MATSUI Y, 1985, TOP CURR CHEM, V128, P61; MCCOY LF, 1981, BIOCHEMISTRY-US, V20, P3062, DOI 10.1021/bi00514a012; MCEVILY AJ, 1986, J BIOL CHEM, V261, P2593; *MILL CORP, 301 MILL CORP; Pace C N, 1986, Methods Enzymol, V131, P266; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Rozema D, 1996, BIOCHEMISTRY-US, V35, P15760, DOI 10.1021/bi961638j; Rozema D, 1996, J BIOL CHEM, V271, P3478; ROZEMA D, 1995, J AM CHEM SOC, V117, P2373, DOI 10.1021/ja00113a036; SCHOTT H, 1964, J PHYS CHEM-US, V68, P3612, DOI 10.1021/j100794a029; SEMISOTNOV GV, 1990, J MOL BIOL, V213, P561, DOI 10.1016/S0022-2836(05)80215-3; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; TANDON S, 1988, BIOCHIM BIOPHYS ACTA, V955, P19, DOI 10.1016/0167-4838(88)90175-6; WANG Z, 1992, PROTEIN SCI, V1, P522; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; ZARDENETA G, 1992, J BIOL CHEM, V267, P5811	42	102	114	2	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33961	33971		10.1074/jbc.273.51.33961	http://dx.doi.org/10.1074/jbc.273.51.33961			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852049	hybrid			2022-12-25	WOS:000077542200015
J	Mizushima, N; Sugita, H; Yoshimori, T; Ohsumi, Y				Mizushima, N; Sugita, H; Yoshimori, T; Ohsumi, Y			A new protein conjugation system in human - The counterpart of the yeast Apg12p conjugation system essential for autophagy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; DEGRADATION; RANGAP1; MECHANISMS; SENTRIN; MUTANTS; ENZYME; RANBP2	Autophagy is an intracellular process for bulk degradation of cytoplasmic components. We recently found a protein conjugation system essential for autophagy in the yeast, Saccharomyces cerevisiae. The C-terminal glycine of a novel modifier protein, Apg12p, is conjugated to a lysine residue of Apg5p via an isopeptide bead. This conjugation reaction is mediated by Apg7p, a ubiquitin activating enzyme (E1)-like enzyme, and Apg10p, suggesting that it is a ubiquitination-like system (Mizushima, N., Noda, T., Yoshimori, T., Tanaka, Y., Ishii, T., George, M. D., Klionsky, D. J,, Ohsumi, Ri., and Ohsumi, Y. (1998) Nature 395, 395-398). Although autophagy is a ubiquitous process in eukaryotic cells, no molecule involved in autophagy has yet been identified in higher eukaryotes. We reasoned that this conjugation system could be conserved. Here we report cloning and characterization of the human homologue of Apg12 (hApg12). It is a 140-amino acid protein and possesses 27% identity and 48% similarity with the yeast Apg12p, but no apparent homology to ubiquitin. Northern blot analysis showed that its expression was ubiquitous in human tissues. We found that it was covalently attached to another protein. This target protein was identified to be the human Apg5 homologue (hApg5). Mutagenic analyses suggested that this conjugation was formed via an isopeptide bond between the C-terminal glycine of hApg12 and Lys-130 of hApg5. These findings indicate that the Apg12 system is well conserved and may function in autophagy also in human cells.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.		Ohsumi, Yoshinori/C-6449-2009; Mizushima, Noboru/C-3635-2009	Ohsumi, Yoshinori/0000-0003-2384-2166; Mizushima, Noboru/0000-0002-6258-6444				BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Boddy MN, 1996, ONCOGENE, V13, P971; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X; Hershko A, 1996, TRENDS BIOCHEM SCI, V21, P445, DOI 10.1016/S0968-0004(96)10054-2; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Okura T, 1996, J IMMUNOL, V157, P4277; OLVERA J, 1993, J BIOL CHEM, V268, P17967; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X	40	400	417	2	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33889	33892		10.1074/jbc.273.51.33889	http://dx.doi.org/10.1074/jbc.273.51.33889			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852036	hybrid			2022-12-25	WOS:000077542200002
J	Reardon, BJ; Lombardo, CR; Sander, M				Reardon, BJ; Lombardo, CR; Sander, M			Drosophila Rrp1 domain structure as defined by limited proteolysis and biophysical analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; ESCHERICHIA-COLI; DNA-REPAIR; EXONUCLEASE-III; APURINIC ENDONUCLEASE; FUNCTIONAL DOMAINS; STRAND TRANSFERASE; CIRCULAR-DICHROISM; ENZYME; RECOGNITION	Drosophila Rrp1 is a DNA repair nuclease whose C-terminal region shares extensive homology with Escherichia coli exonuclease III, has nuclease activity, and provides resistance to oxidative and alkylating agents in repair-deficient E. coli strains. The N-terminal 421 amino acid region of Rrp1, which binds and renatures homologous single-stranded DNA, does not share homology with any known protein. Proteolysis by endoproteinase Glu-C (protease V8) reduces the Rrp1 protein to a single, cleavage-resistant peptide. The peptide (referred to as Rrp1-C274) begins with the sequence TKTTV, corresponding to cleavage between Glu-405 and Thr-406 of Rrp1, We determined that nuclease activity is intrinsic to Rrp1-C274 although altered when compared with Rrp1; 3'-exonuclease activity is reduced 210-fold, 3'-phosphodiesterase activity is reduced 6.8-fold, and no difference in apurinic/apyrimidinic endonuclease activity is observed. Rrp1 and Rrp1-C274 are both monomers with frictional coefficients of 2.2 and 1.4, respectively. Circular dichroism results indicate that Rrp1-C274 is predominantly cu-helical, while the N-terminal 399 amino acids is predominantly random coil. These results suggest that Rrp1 may have a bipartite structural organization; a highly organized, globular C-terminal domain; and an asymmetric, protease-sensitive random coil-enriched N-terminal region. A shape model for this bipartite structure is proposed and discussed.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill	Reardon, BJ (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	reardon@niehs.nih.gov						Adler A J, 1973, Methods Enzymol, V27, P675; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; COHN FJ, 1943, PROTEINS AMINO ACIDS, P370; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P261; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FARUQI AR, 1991, J CELL SCI, P23; FUJITA H, 1975, F ULTRACENTRIFUGAL A, P64; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GU LY, 1993, NUCLEIC ACIDS RES, V21, P4788, DOI 10.1093/nar/21.20.4788; GU LY, 1994, J BIOL CHEM, V269, P32685; HARDING SE, 1995, ANAL BIOCHEM, V228, P131, DOI 10.1006/abio.1995.1324; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLEY CA, 1991, J CELL SCI, P49; Konigsberg WH, 1995, METHOD ENZYMOL, V262, P331; KUHN K, 1987, BIOL EXTRACELLULAR M, P1; KUNTZ ID, 1971, J AM CHEM SOC, V93, P514, DOI 10.1021/ja00731a036; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue TM, 1995, METHOD ENZYMOL, V259, P427; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LINXWEILER W, 1982, NUCLEIC ACIDS RES, V10, P4845, DOI 10.1093/nar/10.16.4845; LOWENHAUPT K, 1989, J BIOL CHEM, V264, P20568; MacGregor CH, 1996, J BACTERIOL, V178, P5627, DOI 10.1128/jb.178.19.5627-5635.1996; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; PHILLIPS SEV, 1994, ANNU REV BIOPH BIOM, V23, P671, DOI 10.1146/annurev.bb.23.060194.003323; REARDON BJ, 1993, P NATL ACAD SCI USA, V90, P11327, DOI 10.1073/pnas.90.23.11327; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SANDER M, 1995, BIOCHEMISTRY-US, V34, P1267, DOI 10.1021/bi00004a021; Sander M, 1996, NUCLEIC ACIDS RES, V24, P3926, DOI 10.1093/nar/24.20.3926; SANDER M, 1993, J BIOL CHEM, V268, P2075; SANDER M, 1991, NUCLEIC ACIDS RES, V19, P4523, DOI 10.1093/nar/19.16.4523; SEKI S, 1991, J BIOL CHEM, V266, P20797; SPIERING AL, 1986, J BIOL CHEM, V261, P3222; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; WEISS B, 1976, J BIOL CHEM, V251, P1896; WINTERS TA, 1994, NUCLEIC ACIDS RES, V22, P1866, DOI 10.1093/nar/22.10.1866; YANG JT, 1986, METHOD ENZYMOL, V130, P208; [No title captured]	48	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33991	33999		10.1074/jbc.273.51.33991	http://dx.doi.org/10.1074/jbc.273.51.33991			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852053	hybrid			2022-12-25	WOS:000077542200019
J	Shi, DS; Morizono, H; Ha, Y; Aoyagi, I; Tuchman, M; Allewell, NM				Shi, DS; Morizono, H; Ha, Y; Aoyagi, I; Tuchman, M; Allewell, NM			1.85-angstrom resolution crystal structure of human ornithine transcarbamoylase complexed with N-phosphonacetyl-L-ornithine - Catalytic mechanism and correlation with inherited deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANGSTROM RESOLUTION; PROTEIN; CARRIER; MUTANT	The crystal structure of human ornithine transcarbamoylase complexed with the bisubstrate analog N-phosphonacetyl-L-ornithine has been solved at 1.85-Angstrom resolution by molecular replacement. Deleterious mutations produce clinical hyperammonia that, if untreated, results in neurological symptoms or death (ornithine transcarbamylase deficiency). The holoenzyme is trimeric, and as in other transcarbamoylases, each subunit contains an N-terminal domain that binds carbamoyl phosphate and a C-terminal domain that binds L-ornithine. The active site is located in the cleft between domains and contains additional residues fi om an adjacent subunit, Binding of N-phosphonacetyl-L-ornithine promotes domain closure. The resolution of the structure enables the role of active site residues in the catalytic mechanism to be critically examined. The side chain of Cys-303 is positioned so as to be able to interact with the delta-amino group of L-ornithine which attacks the carbonyl carbon of carbamoyl phosphate in the enzyme-catalyzed reaction. This sulfhydryl group forms a charge relay system with Asp-263 and the cw-amino group of L-ornithine, instead of with His-302 and Glu-310, as previously proposed. In common with other ureotelic ornithine transcarbamoylases, the human enzyme lacks a loop of similar to 20 residues between helix H10 and beta-strand B10 which is present in prokaryotic ornithine transcarbamoylases but has a C-terminal extension of 10 residues that interacts with the body of the protein but is exposed. The sequence of this C-terminal extension is homologous to an interhelical loop found in several membrane proteins, including mitochondrial transport proteins, suggesting a possible mode of interaction with the inner mitochondrial membrane.	Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Allewell, NM (corresponding author), Univ Minnesota, Dept Biochem, 1479 Gortner Ave, St Paul, MN 55108 USA.	norma@tc.umn.edu	Morizono, Hiroki/E-9737-2013	Morizono, Hiroki/0000-0002-9678-5564; Shi, Dashuang/0000-0002-5491-1104	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047870] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47870] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; GOLDSMITH JO, 1991, J BIOL CHEM, V266, P18626; GonzalezBarroso MM, 1997, BIOCHEMISTRY-US, V36, P10930, DOI 10.1021/bi971104y; GOUAUX JE, 1987, BIOCHEM BIOPH RES CO, V142, P893; GRAF R, 1993, YEAST, V9, P301, DOI 10.1002/yea.320090310; Ha Y, 1997, P NATL ACAD SCI USA, V94, P9550, DOI 10.1073/pnas.94.18.9550; JAHN O, 1987, ARCH MICROBIOL, V147, P174, DOI 10.1007/BF00415280; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; Jin L, 1997, NAT STRUCT BIOL, V4, P622, DOI 10.1038/nsb0897-622; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOSMAN RP, 1993, PROTEINS, V15, P147, DOI 10.1002/prot.340150206; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIPSCOMB WN, 1994, ADV ENZYMOL RAMB, V68, P67; MANNHAUPT G, 1994, YEAST, V10, P1363, DOI 10.1002/yea.320101014; MARSHALL M, 1980, J BIOL CHEM, V255, P7296; MCDOWALL S, 1990, PROTEIN ENG, V4, P73, DOI 10.1093/protein/4.1.73; Morizono H, 1997, HUM MOL GENET, V6, P963, DOI 10.1093/hmg/6.6.963; Morizono H, 1997, BIOCHEM J, V322, P625, DOI 10.1042/bj3220625; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTWINOSKI Z, 1993, THESIS YALE U NEW HA; SNODGRASS PJ, 1968, BIOCHEMISTRY-US, V7, P3047, DOI 10.1021/bi00849a004; TUCHMAN M, 1995, J MED GENET, V32, P680, DOI 10.1136/jmg.32.9.680; Tuchman M, 1998, J INHERIT METAB DIS, V21, P40, DOI 10.1023/A:1005353407220; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P10762, DOI 10.1073/pnas.92.23.10762; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801	30	63	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34247	34254		10.1074/jbc.273.51.34247	http://dx.doi.org/10.1074/jbc.273.51.34247			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852088	hybrid			2022-12-25	WOS:000077542200054
J	Fox, AH; Kowalski, K; King, GF; Mackay, JP; Crossley, M				Fox, AH; Kowalski, K; King, GF; Mackay, JP; Crossley, M			Key residues characteristic of GATA N-fingers are recognized by FOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; DNA-BINDING DOMAIN; ZINC-FINGER; ERYTHROID DEVELOPMENT; MAMMALIAN-CELLS; IN-VIVO; PROTEIN; GENE; DROSOPHILA	Protein-protein interactions play significant roles in the control of gene expression. These interactions often occur between small, discrete domains within different transcription factors. In particular, zinc fingers, usually regarded as DNA-binding domains, are now also known to be involved in mediating contacts between proteins. We have investigated the interaction between the erythroid transcription factor GATA-1 and its partner, the 9 zinc finger protein, FOG (Friend of GATA). We demonstrate that this interaction represents a genuine finger-finger contact, which is dependent on zinc coordinating residues within each protein. We map the contact domains to the core of the N-terminal zinc finger of GATA-1 and the 6th zinc finger of FOG. Using a scanning substitution strategy we identify key residues within the GATA-1 N-finger which are required for FOG binding. These residues are conserved in the N-fingers of all GATA proteins known to bind FOG, but are not found in the respective C-fingers, This observation may, therefore, account for the particular specificity of FOG for N-fingers, Interestingly, the key N-finger residues are seen to form a contiguous surface, when mapped onto the structure of the N-finger of GATA-1.	Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Sydney	Crossley, M (corresponding author), Univ Sydney, Dept Biochem, G08, Sydney, NSW 2006, Australia.		King, Glenn F/J-5059-2012; Crossley, Merlin/D-7888-2011; Fox, Archa H/H-9219-2014; Mackay, Joel P/D-6834-2011	King, Glenn F/0000-0002-2308-2200; Crossley, Merlin/0000-0003-2057-3642; Fox, Archa H/0000-0003-1962-270X; Mackay, Joel P/0000-0001-7508-8033				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARST HN, 1989, TRENDS GENET, V5, P291, DOI 10.1016/0168-9525(89)90105-4; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; Chang WT, 1996, CELL, V87, P471, DOI 10.1016/S0092-8674(00)81367-7; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Crossley M, 1996, MOL CELL BIOL, V16, P1695; Cubadda Y, 1997, GENE DEV, V11, P3083, DOI 10.1101/gad.11.22.3083; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Feng B, 1998, MOL CELL BIOL, V18, P3983, DOI 10.1128/MCB.18.7.3983; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; Haenlin M, 1997, GENE DEV, V11, P3096, DOI 10.1101/gad.11.22.3096; Huggon IC, 1997, BBA-GENE STRUCT EXPR, V1353, P98, DOI 10.1016/S0167-4781(97)00049-3; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; KOWALSKI K, IN PRESS J BIOL MOL; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LIN WH, 1995, J BIOL CHEM, V270, P25150, DOI 10.1074/jbc.270.42.25150; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MARET W, 1993, METHOD ENZYMOL, V226, P52; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; ORKIN SH, 1992, BLOOD, V80, P575; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; Sambrook J., 2002, MOL CLONING LAB MANU; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1998, GENE DEV, V12, P1176, DOI 10.1101/gad.12.8.1176; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; WHYATT DJ, 1993, EMBO J, V12, P4993, DOI 10.1002/j.1460-2075.1993.tb06193.x; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Wolffe AP, 1997, GENES CELLS, V2, P291, DOI 10.1046/j.1365-2443.1997.1260323.x; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562	57	78	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33595	33603		10.1074/jbc.273.50.33595	http://dx.doi.org/10.1074/jbc.273.50.33595			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837943	hybrid			2022-12-25	WOS:000077462500073
J	Galvagni, F; Cartocci, E; Oliviero, S				Galvagni, F; Cartocci, E; Oliviero, S			The dystrophin promoter is negatively regulated by YY1 in undifferentiated muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; ALPHA-ACTIN PROMOTER; TRANSCRIPTION FACTOR YY1; TINMAN HOMOLOG NKX-2.5; C-FOS GENE; PHYSICAL INTERACTION; MYOBLAST FUSION; ADENOVIRUS E1A; BINDING-FACTOR; DNA ELEMENTS	The dystrophin gene transcription is up-regulated during muscle cell differentiation. Its expression in muscle cells is induced by the binding of the positive regulators serum response factor and dystrophin promoter bending factor (DPBF) on a regulatory CArG element present on the promoter. Here we show that the dystrophin CArG box is also recognized by the zinc finger nuclear factor YY1. Transient transfection experiments show that YY1 negatively regulates dystrophin transcription in C2C12 muscle cells. On the dystrophin CArG element YY1 competes with the structural factor DPBF. We further show that YY1 and DPBF binding to the CArG element induce opposite DNA bends suggesting that their binding induces alternative promoter structures. Along with C2C12 myotube formation YY1 is reduced and we observed that YY1, but not DPBF, is a substrate of m-calpain, a protease that is up-regulated in muscle cell differentiation. Thus, high levels of YY1 in non-differentiated muscle cells down-regulate the dystrophin promoter, at least in part, by interfering with the spatial organization of the promoter.	Univ Siena, Dipartimento Biol Mol, I-53100 Siena, Italy	University of Siena	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.	oliviero@unisi.it	oliviero, salvatore/R-6657-2019; Galvagni, Federico/F-9186-2013	oliviero, salvatore/0000-0002-3405-765X; 	Telethon [970] Funding Source: Medline	Telethon(Fondazione Telethon)		BALCERZAK D, 1995, J CELL SCI, V108, P2077; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRUSTIS JJ, 1994, EUR J CELL BIOL, V64, P320; BUSHEL P, 1995, ONCOGENE, V10, P1361; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHERRINGTON JM, 1989, J VIROL, V63, P1435, DOI 10.1128/JVI.63.3.1435-1440.1989; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; Galvagni F, 1997, MOL CELL BIOL, V17, P1731, DOI 10.1128/MCB.17.3.1731; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Groisman R, 1996, J BIOL CHEM, V271, P5258; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KUMAR A, 1992, CELL MOL BIOL, V38, P477; KWAK KB, 1993, BIOCHIM BIOPHYS ACTA, V1175, P243, DOI 10.1016/0167-4889(93)90212-8; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; MOSS JB, 1994, J BIOL CHEM, V269, P12731; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; PAPADOPOULOS N, 1993, MOL CELL BIOL, V13, P6907, DOI 10.1128/MCB.13.11.6907; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHI Y, 1997, BIOCHIM BIOPHYS ACTA, V1332, P49; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	49	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33708	33713		10.1074/jbc.273.50.33708	http://dx.doi.org/10.1074/jbc.273.50.33708			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837957	hybrid, Green Published			2022-12-25	WOS:000077462500087
J	Mehta, P; Cummings, RD; McEver, RP				Mehta, P; Cummings, RD; McEver, RP			Affinity and kinetic analysis of P-selectin binding to P-selectin glycoprotein ligand-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; ENDOTHELIAL-DERIVED LIGAND; MAJOR CAPPING GROUP; CARBOHYDRATE INTERACTIONS; LEUKOCYTE TRAFFICKING; TYROSINE SULFATION; MOLECULAR-CLONING; HUMAN NEUTROPHILS; AMINO-TERMINUS; CELL-ADHESION	Leukocytes use the cell-surface mucin P-selectin glycoprotein ligand-1 (PSGL-1) to tether to and roll on P-selectin on activated endothelial cells and platelets. By using surface plasmon resonance, we measured the affinity and kinetics of binding of soluble monomeric human P-selectin to immobilized PSGL-1 from human neutrophils. Binding was specific, as documented by its Ca2+-dependence, its inhibition by specific monoclonal antibodies to P-selectin and PSGL-1, and its abrogation by treating PSGL-1 with sialidase, Similar binding was observed for soluble P-selectin that contained the lectin and epidermal growth factor domains plus all nine consensus repeats, and for a soluble construct that contained only the lectin and epidermal growth factor domains, Soluble P-selectin bound saturably to a single class of sites on PSGL-1 with a dissociation constant (K-d) of 320 +/- 20 nM, The measured k(off) was 1.4 +/- 0.1 s(-1), and the calculated k(on) was 4.4 x 10(6) M-1 s(-1). We conclude that monomeric P-selectin binds to PSGL-1 with fast association and dissociation rates and relatively high affinity. These features may be important for efficient tethering and rolling of leukocytes at physiologic densities of PSGL-1 and P-selectin.	Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation	McEver, RP (corresponding author), Univ Oklahoma, Hlth Sci Ctr, WK Warren Med Res Inst, 825 NE 13th St, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054804] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54804] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BEBBINGTON C R, 1991, Methods (Orlando), V2, P136, DOI 10.1016/S1046-2023(05)80214-2; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; Chen SQ, 1997, P NATL ACAD SCI USA, V94, P3172, DOI 10.1073/pnas.94.7.3172; Cho M, 1996, BIOCHEMISTRY-US, V35, P13081, DOI 10.1021/bi961181d; COOKE RM, 1994, BIOCHEMISTRY-US, V33, P10591, DOI 10.1021/bi00201a004; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Giblin PA, 1997, J IMMUNOL, V159, P3498; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; IMAI Y, 1993, NATURE, V361, P555; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; LOWE JB, 1991, J BIOL CHEM, V266, P17467; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MASON DW, 1986, HDB EXPT IMMUNOLOGY, V1; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 1998, IMMUNOLOGIST, V6, P61; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Mehta P, 1997, BLOOD, V90, P2381, DOI 10.1182/blood.V90.6.2381.2381_2381_2389; Moore Kevin L., 1994, Journal of Tissue Culture Methods, V16, P255, DOI 10.1007/BF01540662; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; Poppe L, 1997, J AM CHEM SOC, V119, P1727, DOI 10.1021/ja9610702; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Rosen SD, 1997, BIOCHEM SOC T, V25, P428, DOI 10.1042/bst0250428; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; Setiadi H, 1998, J CELL BIOL, V142, P859, DOI 10.1083/jcb.142.3.859; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0	54	195	201	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32506	32513		10.1074/jbc.273.49.32506	http://dx.doi.org/10.1074/jbc.273.49.32506			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829984	hybrid			2022-12-25	WOS:000077329100023
J	Mertens, PR; Alfonso-Jaume, MA; Steinmann, K; Lovett, DH				Mertens, PR; Alfonso-Jaume, MA; Steinmann, K; Lovett, DH			A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; CELLULAR PROTEINS YB-1; FAR UPSTREAM ELEMENT; IV COLLAGENASE GENE; MATRIX METALLOPROTEINASE-2; PROMOTER RECOGNITION; HAIRPIN FORMATION; BINDING-PROTEINS; FACTOR AP-2; PUR-ALPHA	The matrix metalloproteinase gelatinase A plays a central role in several critical physiologic processes, including angiogenesis, tumor invasion/metastasis, and chronic inflammation. We demonstrate that high level gelatinase A expression is mediated by a unique interaction of two developmentally regulated transcription factors, AP2 and YB-1, within a discrete 40-base pair enhancer element (RE-1) located in the 5'-flanking region of the gelatinase A gene. Electrophoretic mobility shift assay studies and immunoprecipitation experiments confirmed a direct interaction of AP2 with this binding sequence in the form of APS YB-I heteromeric complexes. Binding of AP2-YB-1 complexes to the RE-I sequence results in the formation of extended single-stranded DNA regions and may stabilize DNA conformational changes. Overexpression of YB-1 and AP2 proteins by gelatinase A synthesizing hepatoma HepG2 cells induced a synergistic increase in the RE-1-mediated transcription of nearly 160-fold. Thus, the transcription of gelatinase A is subject to a previously unrecognized interplay of double (AP2) and single-stranded (YB-1) DNA binding transcription factors to yield a highly regulated pattern of gene expression.	Univ Calif San Francisco, Vet Adm Med Ctr, Dept Med 111J, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lovett, DH (corresponding author), Univ Calif San Francisco, Vet Adm Med Ctr, Dept Med 111J, 4150 Clement St, San Francisco, CA 94121 USA.	lovett@maelstrom.ucsf.edu	Mertens, Peter/AAI-7310-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039776, R01DK031398, R56DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 31398, DK 39776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; DavisSmyth T, 1996, J BIOL CHEM, V271, P31679, DOI 10.1074/jbc.271.49.31679; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GLUCKSMANN MA, 1992, CELL, V70, P491, DOI 10.1016/0092-8674(92)90173-A; GlucksmannKuis MA, 1996, CELL, V84, P147, DOI 10.1016/S0092-8674(00)81001-6; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LLOBERAS J, 1995, MOL CELL BIOL, V15, P5092; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MCMURRAY CT, 1991, P NATL ACAD SCI USA, V88, P666, DOI 10.1073/pnas.88.2.666; MCMURRAY CT, 1994, BIOCHEMISTRY-US, V33, P11960, DOI 10.1021/bi00205a035; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Turck J, 1996, J BIOL CHEM, V271, P15074, DOI 10.1074/jbc.271.25.15074; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Zahner G, 1997, KIDNEY INT, V51, P1116, DOI 10.1038/ki.1997.154; Zou YM, 1997, DEVELOPMENT, V124, P793	34	97	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32957	32965		10.1074/jbc.273.49.32957	http://dx.doi.org/10.1074/jbc.273.49.32957			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830047	hybrid			2022-12-25	WOS:000077329100086
J	Schrattenholz, A; Pfeiffer, S; Pejovic, V; Rudolph, R; Godovac-Zimmermann, J; Maelicke, A				Schrattenholz, A; Pfeiffer, S; Pejovic, V; Rudolph, R; Godovac-Zimmermann, J; Maelicke, A			Expression and renaturation of the N-terminal extracellular domain of Torpedo nicotinic acetylcholine receptor alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SECONDARY STRUCTURE; BINDING-SITE; CALIFORNICA; PROTEINS; BUNGAROTOXIN; CHANNEL; SCHIZOPHRENIA; CONFORMATION; ANTAGONISTS	The N-terminal extracellular region (amino acids 1-209) of the alpha-subunit of the nicotinic acetylcholine receptor (nAChR) from Torpedo marmorata electric tissue was expressed as inclusion bodies in Escherichia coli using the pET 3a vector. Employing a novel protocol of unfolding and refolding, in the absence of detergent, a water-soluble globular protein of 25 kDa was obtained displaying approximately 15% alpha-helical and 45% beta-structure. The fragment bound alpha-[H-3]bungarotoxin in 1:1 stoichiometry with a K-D value of 0.5 nM as determined from kinetic measurements (4 nM from equilibrium binding), The kinetics of association of toxin and fragment were of second order, with a similar rate constant (8.2 x 10(5) M-1 s(-1)) as observed previously for the membrane-bound heteropentameric nAChR, Binding of small ligands was demonstrated by competition with alpha-[H-3]bungarotoxin yielding the following K-I values: acetylcholine, 69 mu M; nicotine, 0.42 mu M; anatoxin-a, 3 mu M; tubocurarine, 400 mu M; and methyllycaconitine, 0.12 mu M. The results demonstrate that the N-terminal extracellular region of the nAChR alpha-subunit forms a self-assembling domain that functionally expresses major elements of the ligand binding sites of the receptor.	Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Mol Neurobiol Lab, D-55099 Mainz, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany; Univ Halle Wittenberg, Inst Tech Biochem, D-06120 Halle, Germany	Johannes Gutenberg University of Mainz; Martin Luther University Halle Wittenberg	Schrattenholz, A (corresponding author), Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Mol Neurobiol Lab, 6 Duesbergweg, D-55099 Mainz, Germany.	schratte@mail.uni-mainz.de	Zimmermann, Jasminka Godovac/E-6863-2010					AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; Altschuler EL, 1997, J PEPT RES, V50, P73; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BERTRAND D, 1995, SEMIN NEUROSCI, V7, P75, DOI 10.1006/smns.1995.0010; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BLANCHARD SG, 1979, BIOCHEMISTRY-US, V18, P1875, DOI 10.1021/bi00577a005; BROEKKAMP CLE, 1995, J MED CHEM, V38, P4615, DOI 10.1021/jm00023a001; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; CHAUDHURI JB, 1994, ANN NY ACAD SCI, V721, P374, DOI 10.1111/j.1749-6632.1994.tb47409.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CONTIFINE BM, 1995, ANN NY ACAD SCI, V757, P133, DOI 10.1111/j.1749-6632.1995.tb17470.x; Cooper JC, 1996, EUR J PHARMACOL, V309, P287, DOI 10.1016/0014-2999(96)00294-4; DAMLE VN, 1980, BIOCHEMISTRY-US, V19, P3924, DOI 10.1021/bi00558a006; Dreger M, 1997, BIOCHEMISTRY-US, V36, P839, DOI 10.1021/bi960666z; Edelstein SJ, 1996, BIOL CYBERN, V75, P361, DOI 10.1007/s004220050302; Fraenkel Y, 1996, CRIT REV BIOCHEM MOL, V31, P273, DOI 10.3109/10409239609106586; GEHLE VM, 1991, MOL BRAIN RES, V11, P17, DOI 10.1016/0169-328X(91)90016-Q; GERSHONI JM, 1983, P NATL ACAD SCI-BIOL, V80, P4973, DOI 10.1073/pnas.80.16.4973; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; HAGGERTY JG, 1981, J BIOL CHEM, V256, P8294; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; KAUFMANN M, 1993, J CHROMATOGR, V639, P33, DOI 10.1016/0021-9673(93)83085-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENA C, 1993, TRENDS NEUROSCI, V16, P181, DOI 10.1016/0166-2236(93)90150-K; Lena C, 1997, CURR OPIN NEUROBIOL, V7, P674, DOI 10.1016/S0959-4388(97)80088-8; Leonard S, 1996, SCHIZOPHRENIA BULL, V22, P431, DOI 10.1093/schbul/22.3.431; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; MAELICKE A, 1977, J BIOL CHEM, V252, P4811; MAELICKE A, 1975, COLD SPRING HARB SYM, V40, P231; MAELICKE A, 1992, RECEPTOR SUBUNITS CO, P119; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MIELKE DL, 1988, J BIOL CHEM, V263, P3177; MOORE WM, 1974, FEBS LETT, V45, P145, DOI 10.1016/0014-5793(74)80832-X; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; Ortells MO, 1997, PROTEINS, V29, P391, DOI 10.1002/(SICI)1097-0134(199711)29:3<391::AID-PROT12>3.0.CO;2-I; PEREIRA EFR, 1993, J RECEPTOR RES, V13, P413, DOI 10.3109/10799899309073670; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; SADANA A, 1995, BIOTECHNOL BIOENG, V48, P481, DOI 10.1002/bit.260480510; SAKMANN B, 1992, EMBO J, V11, P2003; Schrattenholz A, 1997, BIOCHEMISTRY-US, V36, P13333, DOI 10.1021/bi9706024; SCHRATTENHOLZ A, 1993, EUR J BIOCHEM, V216, P671, DOI 10.1111/j.1432-1033.1993.tb18187.x; SCHRODER B, 1994, J BIOL CHEM, V269, P10407; Shaw PJ, 1997, J NEUROL, V244, pS3, DOI 10.1007/BF03160574; SIUZDAK G, 1996, MASS SPECTROMETRY BI, P141; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; TZARTOS SJ, 1984, J BIOL CHEM, V259, P1512; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; WEBER M, 1974, MOL PHARMACOL, V10, P1; Weinberger DR, 1997, J CLIN PSYCHIAT, V58, P22; Wells GB, 1998, J BIOL CHEM, V273, P964, DOI 10.1074/jbc.273.2.964; WU CSC, 1990, J PROTEIN CHEM, V9, P119, DOI 10.1007/BF01024993; YAGER P, 1984, BIOPHYS J, V45, P26, DOI 10.1016/S0006-3495(84)84095-3	59	33	36	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32393	32399		10.1074/jbc.273.49.32393	http://dx.doi.org/10.1074/jbc.273.49.32393			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829968	hybrid			2022-12-25	WOS:000077329100007
J	David, CL; Orpiszewski, J; Zhu, XC; Reissner, KJ; Aswad, DW				David, CL; Orpiszewski, J; Zhu, XC; Reissner, KJ; Aswad, DW			Isoaspartate in chrondroitin sulfate proteoglycans of mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CELL-ADHESION MOLECULES; CHONDROITIN SULFATE; IN-VITRO; CARBOXYL METHYLTRANSFERASE; O-METHYLTRANSFERASE; REPAIR; NEUROCAN; ACCUMULATION; EXPRESSION	Mammalian brain contains a high mass protein (HMAP) that is unusually rich in atypical L-isoaspartyl (isoAsp) linkages. HMAP has now been purified from bovine brain by anion exchange, hydroxylapatite, and size exclusion chromatography, It is self-aggregating, acidic, and soluble in 5% trichloroacetic acid. Treatment with chondroitinase ABC eliminates the self-aggregation of HMAP and generates several distinct core proteins with estimated masses of 350-450 (doublet), 180, and 100 kDa, indicating that it is composed mainly of chondroitin sulfate proteoglycans (CSPGs), Most of the isoAsp resides in the 350-450-kDa core protein, which was identified by immunoblotting as phosphacan, a CSPG abundant in adult brain. The regional distribution and developmental profile of HMAP in rat brain support this identification. The 180-kDa core protein contains a tenascin-R-related molecule, consistent with recent observations that phosphacan forms a tight complex with tenascin-R, The average phosphacan molecule in adult brain contains at least seven isoAsp sites. Molecular heterogeneity due to isoAsp may explain some of the complex binding properties phosphacan exhibits with its natural ligands, Formation of isoAsp may be important in the roles that phosphacan and other CSPGs play in development of the nervous system.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Aswad, DW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3205 Bio Sci 2, Irvine, CA 92697 USA.	dwaswad@uci.edu	Reissner, Kathryn J/K-7187-2015		NINDS NIH HHS [NS-17269] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRENNAN TV, 1994, J BIOL CHEM, V269, P24586; BRENNAN TV, 1995, DEAMIDATION ISOASPAR, P65; Chazin W.J., 1995, DEAMIDATION ISOASPAR, P193; CHIRPICH T, 1968, THESIS U CALIFORNIA; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; DAVID CL, 1995, PROTEIN EXPRES PURIF, V6, P312, DOI 10.1006/prep.1995.1041; DIDONATO A, 1993, J BIOL CHEM, V268, P4745; FAIRBANKS G, 1972, Journal of Supramolecular Structure, V1, P66, DOI 10.1002/jss.400010110; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GREEN MR, 1973, ANAL BIOCHEM, V56, P43, DOI 10.1016/0003-2697(73)90167-X; HARLOW E, 1988, ANTIBODIES LABORATOR, P505; HOMER KA, 1993, ANAL BIOCHEM, V214, P435, DOI 10.1006/abio.1993.1520; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1993, J BIOL CHEM, V268, P6174; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1995, DEAMIDATION ISOASPAR, P91; KIANG WL, 1981, J BIOL CHEM, V256, P529; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Lebaron RG, 1996, PERSPECT DEV NEUROBI, V3, P261; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACFARLANE DE, 1984, J BIOL CHEM, V259, P1357; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; Orpiszewski J, 1996, J BIOL CHEM, V271, P22965, DOI 10.1074/jbc.271.38.22965; PESHEVA P, 1994, J CELL SCI, V107, P2323; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; RAGONE R, 1989, PROTEIN ENG, V2, P497, DOI 10.1093/protein/2.7.497; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; ROGERS SW, 1988, J BIOL CHEM, V263, P19850; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; Schmalfeldt M, 1998, J BIOL CHEM, V273, P15758, DOI 10.1074/jbc.273.25.15758; SHITARA K, 1994, J BIOL CHEM, V269, P20189; TESHIMA G, 1995, ISOASPARTATE FORMATI, P167; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WRIGHT HT, 1995, DEAMIDATION ISOASPAR, P229; YAMADA H, 1994, J BIOL CHEM, V269, P10119; Yamamoto A, 1998, J NEUROSCI, V18, P2063	49	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32063	32070		10.1074/jbc.273.48.32063	http://dx.doi.org/10.1074/jbc.273.48.32063			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822681	hybrid			2022-12-25	WOS:000077207000063
J	McCormick, ML; Gaut, JP; Lin, TS; Britigan, BE; Buettner, GR; Heinecke, JW				McCormick, ML; Gaut, JP; Lin, TS; Britigan, BE; Buettner, GR; Heinecke, JW			Electron paramagnetic resonance detection of free tyrosyl radical generated by myeloperoxidase, lactoperoxidase, and horseradish peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HYDROGEN-PEROXIDE; ATHEROSCLEROTIC LESIONS; LIPID-PEROXIDATION; HUMAN-NEUTROPHILS; OXIDATION; DITYROSINE; ANTIOXIDANTS; CHOLESTEROL; CATALYST	Phagocytes secrete the heme protein myeloperoxidase, which is present and active in human atherosclerotic tissue. These cells also generate hydrogen peroxide (H2O2), thereby allowing myeloperoxidase to generate a range of oxidizing intermediates and stable end products. When this system acts on L-tyrosine in vitro, it forms o,o'-dityrosine, which is enriched in atherosclerotic lesions. Myeloperoxidase, therefore, may oxidize artery wall proteins in vivo, cross-linking their L-tyrosine residues. In these studies, we used electron paramagnetic resonance (EPR) spectroscopy to identify an oxidizing intermediate in this reaction pathway and in parallel reactions catalyzed by horseradish peroxidase and lactoperoxidase, Using an EPR flow system to rapidly mix and examine solutions containing horseradish peroxidase, H2O2, and L-tyrosine, we detected free tyrosyl radical (a(2,6)(H) = 6.3 G, a(3,5)(H) = 1.6 G, and a(beta)(H) = 15.0 G), We then used spin trapping techniques with 8-methyl-2-nitrosopropane (MNP) to further identify this intermediate. The resulting three-line spectrum (a(N) = 15.6 G) was consistent with an MNP/tyrosyl radical spin adduct, Additional MNP spin trapping studies with ring-labeled L-[C-13(6)]tyrosine yielded a characteristic eight-line EPR spectrum (a(N) = 15.6 G, a(13)C (2) = 8.0 G, a(13)C (1) = 7.1 G, a(13)C (1) 1.3 G), indicating that the MNP adduct resulted from trapping a carbon-centered radical located on the aromatic ring of L-tyrosine, This same eight-line spectrum was observed when human myeloperoxidase or bovine lactoperoxidase was substituted for horseradish peroxidase, Furthermore, a partially immobilized MNP/tyrosyl radical spin adduct was detected when we exposed a synthetic polypeptide composed of glutamate and L-tyrosine residues to the myeloperoxidase-H2O2-L-tyrosine system. The broadened EPR signal resulting from this MNP/polypeptide adduct was greatly narrowed by proteolytic digestion with Pronase, confirming that the initial spin-trapped radical was protein-bound. Collectively, these results indicate that peroxidases use H2O2 to convert L-tyrosine to free tyrosyl radical. They also support the idea that free tyrosyl radical initiates cross-linking of L-tyrosine residues in proteins. We suggest that this pathway may play an important role in protein and lipid oxidation at sites of inflammation and in atherosclerotic lesions.	Vet Affairs Med Ctr, Res Serv, Iowa City, IA 52246 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52246 USA; Univ Iowa, EPR Facil, Iowa City, IA 52246 USA; Washington Univ, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa; Washington University (WUSTL); Washington University (WUSTL)	McCormick, ML (corresponding author), Vet Affairs Med Ctr, Res Serv, Iowa City, IA 52246 USA.	mccormic@jerry.icva.gov	Gaut, Joseph/ABB-3387-2020; Lin, Tien-Sung/A-3365-2008; Gaut, Joseph/ABD-4600-2021	Buettner, Garry/0000-0002-5594-1903	NIA NIH HHS [AG15013, AG12293] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015013, R01AG012293] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMADO R, 1984, METHOD ENZYMOL, V107, P377; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Barr DP, 1996, J BIOL CHEM, V271, P15498, DOI 10.1074/jbc.271.26.15498; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BRITIGAN BE, 1986, J BIOL CHEM, V261, P4426; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FRANCIS GA, 1993, P NATL ACAD SCI USA, V90, P6631, DOI 10.1073/pnas.90.14.6631; Heinecke JW, 1997, CURR OPIN LIPIDOL, V8, P268, DOI 10.1097/00041433-199710000-00005; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	30	72	72	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32030	32037		10.1074/jbc.273.48.32030	http://dx.doi.org/10.1074/jbc.273.48.32030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822676	hybrid			2022-12-25	WOS:000077207000058
J	Vieira-van Bruggen, D; Kalkman, I; van Gent, T; van Tol, A; Jansen, H				Vieira-van Bruggen, D; Kalkman, I; van Gent, T; van Tol, A; Jansen, H			Induction of adrenal scavenger receptor BI and increased high density lipoprotein-cholesteryl ether uptake by in vivo inhibition of hepatic lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-RELEASABLE LIPASE; RAT-LIVER; SR-BI; HDL-RECEPTOR; IN-VIVO; A-I; ESTER; METABOLISM; TISSUES; OVARIES	Hepatic lipase (HL) and scavenger receptor type B class I (SR-BI) have both been implicated in high density lipoprotein (HDL)-cholesteryl ester uptake in cholesterol-utilizing tissues. Inactivation of HL by gene-directed targeting in mice results in up-regulation of SR-BI expression in adrenal gland (Wang, N,, Weng, W., Breslow, J. L,, and Tall, A R. (1996) J. Biol. Chem, 271, 21001-21004), The net effect on HDL-cholesteryl ester uptake is not known. We determined the impact of acute in vivo inhibition of rat adrenal HL activity by antibodies on SR-BI expression and on human and rat HDL-[H-3]cholesteryl ether (CEth) uptake in the adrenal gland, Rat HDL was isolated from rats in which HL activity had been inhibited for 1 h, The rats were studied under basal conditions (not ACTH-treated) and after previous treatment with ACTH for 6 days (ACTH-treated), Intravenous injection of anti-HL resulted in 70% lowering of adrenal HL activity in both conditions which were maintained for at least 8 h, In not ACTH-treated rats, inhibition of adrenal HL increased adrenal SR-BI mRNA (5.2-fold) and mass (1.6-fold) within 4 h, HL inhibition resulted in 41% and 14% more adrenal accumulation of human HDL[H-3]CEth during 4 and 24 h, respectively. The adrenal uptake of rat HDL-[H-3]CEth increased by 68%, 4 h after the antibody injection. ACTH treatment increased total adrenal HL activity from 3.7 +/- 0.5 milliunits to 34.0 +/- 17.2 milliunits, as well as adrenal SR-BI mRNA from 2.9 +/- 0.7 arbitrary units (A.U.,) to 86.8 +/- 41.1 A.U. and SR-BI mass from 7.7 +/- 1.8 A.U. to 63.16, +/- 46.7 A.U. The human HDL-[H-3]CEth uptake by adrenals was also significantly increased from 0.58 +/- 0.11% of injected dose to 7.24 +/- 1.58% of injected dose. Inhibition of adrenal HL activity did not result in further induction of SR-BI expression and did not affect human HDL-[H-3]CEth uptake. These findings indicate that SR-BI expression may be influenced by changes in HL activity. HL activity is not needed for the SR-BI-mediated HDL-cholesteryl ester uptake by rat adrenal glands.	Erasmus Univ, Dept Biochem, COEUR, Inst Cardiovasc Res, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Internal Med 2, COEUR, Inst Cardiovasc Res, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam	Jansen, H (corresponding author), Erasmus Univ, Dept Biochem, COEUR, Inst Cardiovasc Res, POB 1738, NL-3000 DR Rotterdam, Netherlands.	Jansen@bc1.fgg.eur.nl						Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; BAMBERGER M, 1983, J LIPID RES, V24, P869; Breedveld B, 1997, BIOCHEM J, V321, P425, DOI 10.1042/bj3210425; CALVO D, 1993, J BIOL CHEM, V268, P18929; CASTER WO, 1956, P SOC EXP BIOL MED, V91, P122, DOI 10.3181/00379727-91-22186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; EISENBERG S, 1984, J LIPID RES, V25, P1017; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GROENER JEM, 1986, CLIN CHEM, V32, P283; GROENER JEM, 1989, BIOCHIM BIOPHYS ACTA, V1002, P93, DOI 10.1016/0005-2760(89)90070-2; HIXENBAUGH EA, 1989, J BIOL CHEM, V264, P4222; JANSEN H, 1981, METABOLISM, V30, P428, DOI 10.1016/0026-0495(81)90175-X; JANSEN H, 1985, BIOCHEM BIOPH RES CO, V131, P574, DOI 10.1016/0006-291X(85)91275-6; JANSEN H, 1988, MOL CELL ENDOCRINOL, V57, P7, DOI 10.1016/0303-7207(88)90026-3; JANSEN H, 1980, TRENDS BIOCHEM SCI, V5, P265, DOI 10.1016/0968-0004(80)90033-X; JANSEN H, 1980, BIOCHEM BIOPH RES CO, V92, P53, DOI 10.1016/0006-291X(80)91518-1; JANSEN H, 1980, FEBS LETT, V112, P31; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; KADOWAKI H, 1992, J LIPID RES, V33, P1689; KOVANEN PT, 1979, J BIOL CHEM, V254, P1367; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; MARQUESVIDAL P, 1994, J LIPID RES, V35, P373; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; PERSOON NLM, 1986, EUR J CELL BIOL, V41, P134; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Rajapaksha WRAKJS, 1997, MOL CELL ENDOCRINOL, V134, P59, DOI 10.1016/S0303-7207(97)00173-1; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; VANTHOOFT FM, 1981, BIOCHEM J, V196, P877, DOI 10.1042/bj1960877; VieiravanBruggen D, 1997, MOL CELL ENDOCRINOL, V126, P35, DOI 10.1016/S0303-7207(96)03963-9; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WEISGRABER KH, 1980, J LIPID RES, V21, P316; Xu SZ, 1997, J LIPID RES, V38, P1289	37	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32038	32041						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822677				2022-12-25	WOS:000077207000059
J	Feng, ZW; Joos, HJ; Vallan, C; Muhlbauer, R; Altermatt, HJ; Jaggi, R				Feng, ZW; Joos, HJ; Vallan, C; Muhlbauer, R; Altermatt, HJ; Jaggi, R			Apoptosis during castration-induced regression of the prostate is Fos dependent	ONCOGENE			English	Article						apoptosis; castration; c-Fos; prostate; transcription factor AP-1	PROGRAMMED CELL-DEATH; TRANSCRIPTION FACTOR AP-1; MAMMARY-GLAND INVOLUTION; RAT VENTRAL PROSTATE; C-FOS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; ANDROGEN ABLATION; TRANSGENIC MICE; IN-VIVO	Apoptotic cell death was shown to be accompanied or preceded by an elevated expression of the c-fos protooncogene and DNA binding activity of transcription factor AP-1. We used Fos-deficient mice to study the role of c-Fos during programmed cell death in the prostate. In normal mice apoptosis is induced in the prostate within 2-4 days after castration. Histological features of reduced secretory activity and morphological signs of programmed cell death become obvious. No apparent decrease in secretory activity and no epithelial cell death were observed in Fos-deficient animals after castration. Fragmentation of nuclear DNA was measured by in situ terminal transferase reaction. DNA fragmentation was observed in the prostate epithelium of control mice after castration whereas no similar fragmentation was found in Fos-deficient animals. After castration an AP-1 complex accumulated in the prostate of Fos deficient mice which mainly consists of FosB, Fra-2 and JunD whereas in control animals the AP-1 complex in addition contained c-Fos. Our data strongly suggest that c-Fos is required for programmed cell death of prostate epithelial cells.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Pathol Langgasse, CH-3012 Bern, Switzerland	University of Bern; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Jaggi, R (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35, CH-3010 Bern, Switzerland.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; Bielke W, 1997, CELL DEATH DIFFER, V4, P114, DOI 10.1038/sj.cdd.4400220; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COLOMBEL M, 1992, CANCER RES, V52, P4313; COLOMBEL M, 1995, ONCOGENE, V10, P1269; COLOMBEL M, 1993, AM J PATHOL, V143, P390; COLOMBEL MC, 1995, METHOD CELL BIOL, V46, P369; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; FOLETTA VC, 1994, ONCOGENE, V9, P3305; FREEMAN SN, 1990, BIOCHEM J, V269, P189, DOI 10.1042/bj2690189; FURUYA Y, 1995, ENDOCRINOLOGY, V136, P1898, DOI 10.1210/en.136.5.1898; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; GONZALEZMARTIN C, 1992, DEV BRAIN RES, V68, P83, DOI 10.1016/0165-3806(92)90250-Z; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kueng P, 1997, J CELL BIOL, V139, P1851, DOI 10.1083/jcb.139.7.1851; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; Lund LR, 1996, DEVELOPMENT, V122, P181; MARTI A, 1994, ONCOGENE, V9, P1213; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; OSSOWSKI L, 1979, CELL, V16, P929, DOI 10.1016/0092-8674(79)90108-9; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Preston GA, 1996, MOL CELL BIOL, V16, P211; RAFFO AJ, 1995, CANCER RES, V55, P4438; RENNIE PS, 1989, MOL ENDOCRINOL, V3, P703, DOI 10.1210/mend-3-4-703; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRANGE R, 1992, DEVELOPMENT, V115, P49; Sukharev SA, 1997, CELL DEATH DIFFER, V4, P457, DOI 10.1038/sj.cdd.4400263; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	61	30	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2593	2600		10.1038/sj.onc.1202195	http://dx.doi.org/10.1038/sj.onc.1202195			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840922				2022-12-25	WOS:000077058900006
J	Cohen, SB; Nicol, R; Stavnezer, E				Cohen, SB; Nicol, R; Stavnezer, E			A domain necessary for the transforming activity of SnoN is required for specific DNA binding, transcriptional repression and interaction with TAF(II)110	ONCOGENE			English	Article						oncogene; repression; SnoN; transcription; transformation	THYROID-HORMONE RECEPTOR; ADENOVIRUS E1A PROTEIN; FUNCTIONAL-ANALYSIS; CDNA CLONES; GENE; ACTIVATION; SKI; GAL4; OVEREXPRESSION; IDENTIFICATION	sno is a member of the ski oncogene family and shares ski's ability to transform avian fibroblasts and induce muscle differentiation. Ski and Sno are nuclear proteins that form homodimers and heterodimers, Ski activates transcription of cellular and viral enhancers and we have identified a DNA binding site (GTCTAGAC) through which it represses transcription. In this work, we show that SnoN binds this site and represses transcription of reporters a with this binding site as an upstream element. Using fusions with the Gal4-DNA binding domain in a heterologous reporter assay, we identify a tripartite repression domain in SnoN, A 107 amino acid stretch of the SnoN repression domain, that contains two of the subdomains, is closely related to the minimal region of Ski required for transformation. The third subdomain is unique to SnoN, By analysing deletions involving each of the subdomains, we show that subdomains II and III are also required for DNA binding and cellular transformation. We provide evidence for a quenching mechanism of transcriptional repression by which subdomain II binds to TAF(II)11O.	Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Case Western Reserve University; University System of Ohio; University of Cincinnati	Stavnezer, E (corresponding author), Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.				NCI NIH HHS [CA43600] Funding Source: Medline; NIGMS NIH HHS [T32-GM08056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BOYER PL, 1993, ONCOGENE, V8, P457; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GIVOL I, 1995, GENE, V156, P271, DOI 10.1016/0378-1119(95)00066-F; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HEYMAN HC, 1994, J BIOL CHEM, V269, P26996; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; Mimura N, 1996, FEBS LETT, V397, P253, DOI 10.1016/S0014-5793(96)01165-9; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Pelzer T, 1996, DEV DYNAM, V205, P114; QIAN Z, 1995, J VIROL, V69, P4037, DOI 10.1128/JVI.69.7.4037-4044.1995; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; UM M, 1995, MOL CELL BIOL, V15, P5007; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	35	21	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2505	2513		10.1038/sj.onc.1202177	http://dx.doi.org/10.1038/sj.onc.1202177			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824161				2022-12-25	WOS:000076927300010
J	Brewer, G				Brewer, G			Characterization of c-myc 3 ' to 5 ' mRNA decay Activities in an in vitro system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; CELL-FREE-EXTRACTS; PROTEIN; POLY(A); DEGRADATION; BINDING; TRANSLOCATION; DEADENYLATION; EXONUCLEASE; ONCOGENE	The levels of mRNA and protein encoded by the c-myc protooncogene set the balance between proliferation and differentiation of mammalian cells. Thus, it is essential for the cell to tightly control c-myc expression. Indeed, cells utilize many mechanisms to control c-myc expression, including transcription, RNA processing, translation, and protein stability. We have focused on turnover of c-myc mRNA as a key modulator of the timing and level of c-myc expression. c-myc mRNA is labile in cells, and its half-life is controlled by multiple instability elements located within both the coding region and the S'-untranslated region (3'-UTR), Much work has focused on the protein factors that bind the instability elements, yet little is known about the enzymatic activities that effect the degradation of c-mye mRNA. Here I have utilized a novel cell-free mRNA decay system to characterize the c-mye mRNA decay machinery. This machinery consists of 3' to 5' mRNA decay activities that are Mg2+-dependent, require neither exogenous ATP/GTP nor an ATP-regenerating system, and act independently of a (7)mG(5')ppp(5')G cap structure to deadenylate an exogenous mRNA substrate in a c-mye 3'-UTR-dependent fashion. Following deadenylation, nucleolytic decay of the 3'-UTR occurs generating 3' decay intermediates via a ribonucleolytic activity that can assemble on the c-mye 3'-UTR in a poly(A)-independent manner.	Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University	Brewer, G (corresponding author), Wake Forest Univ, Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA.				NCI NIH HHS [CA52443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Boeck R, 1998, MOL CELL BIOL, V18, P5062, DOI 10.1128/MCB.18.9.5062; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1990, METHOD ENZYMOL, V181, P202; BREWER G, 1992, PROMEGA NOTES, V40, P11; CARUCCIO N, 1994, J BIOL CHEM, V269, P31814; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DEMARIA CT, 1997, PROGR MOL SUBCELLULA, P65; Ford LP, 1997, MOL CELL BIOL, V17, P398, DOI 10.1128/MCB.17.1.398; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; ROSS J, 1986, J MOL BIOL, V188, P579, DOI 10.1016/S0022-2836(86)80008-0; ROSS J, 1987, J BIOL CHEM, V262, P9374; ROSS J, 1995, MICROBIOL REV, V59, P16; ROSS J, 1993, CONTROL MESSENGER RN, P417; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHREIER MH, 1973, J MOL BIOL, V73, P329, DOI 10.1016/0022-2836(73)90346-X; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257	34	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34770	34774		10.1074/jbc.273.52.34770	http://dx.doi.org/10.1074/jbc.273.52.34770			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857001	hybrid			2022-12-25	WOS:000077719700019
J	Gibbins, JM; Briddon, S; Shutes, A; van Vugt, MJ; de Winkel, JGJ; Saito, T; Watson, SP				Gibbins, JM; Briddon, S; Shutes, A; van Vugt, MJ; de Winkel, JGJ; Saito, T; Watson, SP			The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activitor of T cells (LAT) in platelets stimulated by collagen and convulxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; GLYCOPROTEIN-VI; INTEGRIN ALPHA(2)BETA(1); SH2 DOMAINS; EPSILON-RI; ACTIVATION; PROTEIN; INHIBITOR; P72(SYK)	There is extensive evidence to show that phosphatidylinositol 3-kinase plays an important role in signaling by the immune family of receptors, which has recently been extended to include the platelet collagen receptor, glycoprotein VI, In this report we present two potential mechanisms for the regulation of this enzyme on stimulation of platelets by collagen. We show that on stimulation with collagen, the regulatory subunit of phosphatidylinositol 3-kinase associates with the tyrosine-phosphorylated form of the adapter protein linker for activator of T Cells (LAT) and the tyrosine-phosphorylated immunoreceptor tyrosine-based activation motif of the Fc receptor gamma-chain (a component of the collagen receptor complex that includes glycoprotein VI). The associations of the Fc receptor gamma-chain and LAT with p85 are rapid and supported by the Src-homology 2 domains of the regulatory subunit. We did not obtain evidence to support previous observations that the regulatory subunit of phosphatidylinositol 3-kinase is regulated through association with the tyrosine kinase Syk, The present results provide a molecular basis for the regulation of the p85/110 form of phosphatidylinositol 3-kinase by GPVI, the collagen receptor that underlies activation.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Univ Utrecht Hosp, Dept Immunol, NL-3508 GA Utrecht, Netherlands; Chiba Univ, Grad Sch Med, Dept Mol Genet, Chuo Ku, Chiba 2608670, Japan	University of Reading; University of Oxford; Utrecht University; Utrecht University Medical Center; Chiba University	Gibbins, JM (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.	j.m.gibbins@rdg.ac.uk	Watson, Stephen P/Q-6292-2016; Saito, Takashi/C-9684-2009	Watson, Stephen P/0000-0002-7846-7423; Saito, Takashi/0000-0001-9495-3547; Gibbins, Jonathan/0000-0002-0372-5352; Briddon, Stephen/0000-0001-8514-0827	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BOKOCH GM, 1973, BIOCHEM J, V775, P96; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EXLEY M, 1994, J BIOL CHEM, V269, P15140; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Ibarrola I, 1997, BBA-MOL CELL RES, V1357, P348, DOI 10.1016/S0167-4889(97)00034-7; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Jouvin M H, 1995, Semin Immunol, V7, P29, DOI 10.1016/1044-5323(95)90005-5; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; Leduc M, 1998, BIOCHEM J, V333, P389, DOI 10.1042/bj3330389; LEE YH, 1995, FEBS LETT, V358, P105, DOI 10.1016/0014-5793(94)01404-O; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Melendez AJ, 1998, P NATL ACAD SCI USA, V95, P2169, DOI 10.1073/pnas.95.5.2169; Melford SK, 1997, J BIOL CHEM, V272, P27539, DOI 10.1074/jbc.272.44.27539; MITCHELL CA, 1990, P NATL ACAD SCI USA, V87, P9396, DOI 10.1073/pnas.87.23.9396; Mountford JM, 1997, BLOOD, V90, P2993; NUNN DL, 1987, BIOCHEM J, V243, P809, DOI 10.1042/bj2430809; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAOLINI R, 1995, J EXP MED, V181, P247, DOI 10.1084/jem.181.1.247; Park SY, 1998, J CLIN INVEST, V102, P1229, DOI 10.1172/JCI3256; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Robinson A, 1996, BLOOD, V88, P522, DOI 10.1182/blood.V88.2.522.bloodjournal882522; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; vanVugt MJ, 1996, BLOOD, V87, P3593, DOI 10.1182/blood.V87.9.3593.bloodjournal8793593; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1992, J BIOL CHEM, V267, P4686; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	112	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34437	34443		10.1074/jbc.273.51.34437	http://dx.doi.org/10.1074/jbc.273.51.34437			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852111	hybrid			2022-12-25	WOS:000077542200077
J	Hu, SI; Carozza, M; Klein, M; Nantermet, P; Luk, D; Crowl, RM				Hu, SI; Carozza, M; Klein, M; Nantermet, P; Luk, D; Crowl, RM			Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SURVIVAL; KAZAL-TYPE INHIBITOR; HEAT-SHOCK PROTEINS; SEQUENCE-ANALYSIS; FOLLISTATIN; GROWTH; AGRIN; CELLS; TRANSCRIPTION; TEMPERATURES	The human homologue of the Escherichia coli htrA gene product was identified by the differential display analysis of transcripts expressed in osteoarthritic cartilage. This transcript was identified previously as being repressed in SV40-transformed fibroblasts (Zumbrunn, J,, and Trueb, B, (1996) FEBS Lett. 398, 187-192). Levels of HtrA mRNA were elevated similar to 7-fold in cartilage from individuals with osteoarthritis compared with nonarthritic controls, Differential expression of human HtrA protein was confirmed by an immunoblot analysis of cartilage extracts, Human HtrA protein expressed in heterologous systems was secreted and exhibited endoproteolytic activity, including autocatalytic cleavage. Conversion by mutagenesis of the putative active site serine 328 to alanine eliminated the enzymatic activity. Serine 328 was also found to be required for the formation of a stable complex with alpha(1)-antitrypsin. We have determined that the HtrA gene is highly conserved among mammalian species: the amino acid sequences encoded by HtrA cDNA clones from cow, rabbit, and guinea pig are 98% identical to human. In E. coli, a functional htrA gene product is required for cell survival after heat shock or oxidative stress; its role appears to be the degradation of denatured proteins. We propose that mammalian HtrA, with the addition of a new functionality during evolution, i.e. a mac25 homology domain, plays an important role in cell growth regulation.	Novartis Pharmaceut, Arthritus Biol Unit, Summit, NJ 07901 USA	Novartis	Crowl, RM (corresponding author), Novartis Pharmaceut, Arthritus Biol Unit, LSB3225,556 Morris Ave, Summit, NJ 07901 USA.	robert.crowl@pharma.novartis.com						AIGNER T, 1993, J CLIN INVEST, V91, P829, DOI 10.1172/JCI116303; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; BAHL H, 1987, GENE DEV, V1, P57, DOI 10.1101/gad.1.1.57; BIROC SL, 1993, DEV BRAIN RES, V75, P119, DOI 10.1016/0165-3806(93)90071-H; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; FELSON DT, 1990, RHEUM DIS CLIN N AM, V16, P499; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDBERG AL, 1981, METHOD ENZYMOL, V80, P680; HOWELL DS, 1984, OSTEOARTHRITIS DIAGN, P129; JOHANSSON MW, 1994, EUR J BIOCHEM, V223, P389, DOI 10.1111/j.1432-1033.1994.tb19005.x; Kato MV, 1996, ONCOGENE, V12, P1361; KIKUCHI N, 1985, J BIOCHEM-TOKYO, V98, P687, DOI 10.1093/oxfordjournals.jbchem.a135326; KOLOMAR H, 1996, J BACTERIOL, V178, P5925; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; LASKOWSKI M, 1987, BIOCHEMISTRY-US, V26, P202, DOI 10.1021/bi00375a028; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; MCALINDON T, 1990, BRIT J RHEUMATOL, V29, P471; MUIR H, 1995, BIOESSAYS, V17, P1039, DOI 10.1002/bies.950171208; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; Oddis CV, 1996, AM J MED, V100, pS10, DOI 10.1016/S0002-9343(97)89541-1; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; Petraglia F, 1997, PLACENTA, V18, P3, DOI 10.1016/S0143-4004(97)90065-5; Ponting CP, 1997, PROTEIN SCI, V6, P464; RUPP F, 1992, J NEUROSCI, V12, P3535; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SKORKOGLONEK J, 1995, GENE, V163, P47, DOI 10.1016/0378-1119(95)00406-V; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TSCHESCHE H, 1987, BIOL CHEM H-S, V368, P1297, DOI 10.1515/bchm3.1987.368.2.1297; WALTON EA, 1981, SEMIN ARTHRITIS RHEU, V1, P73; Wan JS, 1996, NAT BIOTECHNOL, V14, P1685, DOI 10.1038/nbt1296-1685; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	39	185	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34406	34412		10.1074/jbc.273.51.34406	http://dx.doi.org/10.1074/jbc.273.51.34406			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852107	hybrid			2022-12-25	WOS:000077542200073
J	Luque, T; Hjelmqvist, L; Marfany, G; Danielsson, O; El-Ahmad, M; Persson, B; Jornvall, H; Gonzalez-Duarte, R				Luque, T; Hjelmqvist, L; Marfany, G; Danielsson, O; El-Ahmad, M; Persson, B; Jornvall, H; Gonzalez-Duarte, R			Sorbitol dehydrogenase of Drosophila - Gene, protein, and expression data show a two-gene system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-III ALCOHOL; LIVER-ENZYME; FORMALDEHYDE DEHYDROGENASE; FUNCTIONAL DIFFERENCES; SEQUENCE DETERMINATION; CLASS-I; PATHWAY; CLONING; PURIFICATION; VARIABILITY	The Drosophila melanogaster sorbitol dehydrogenase (SDH) is characterized as a two-enzyme system of the medium chain dehydrogenase/reductase family (MDR). The SDH-1 enzyme has an enzymology with K-m and k(cat) values an order of magnitude higher than those for the human enzyme but with a similar K-cat/K-m ratio. It is a tetramer with identical subunits of similar to 38 kDa. At the genomic level, two genes, Sdh-1 and Sdh-2, have a single transcriptional start site and no functional TATA box. Expression is greater in larvae and adults than in pupae, where it is very low. At all three stages, Sdh-1. constitutes the major transcript. Sdh-1 and Sdh-2 genes were located at positions 84E-F and 86D in polytene chromosomes. The deduced amino acid sequences of the two genes show 90% residue identity. Evaluation of the sequence and modeling of the structure toward that of class I alcohol dehydrogenase (ADH) show altered loop and gap arrangements as in mammalian SDH and establishes that SDH, despite gene multiplicity and larger variability than the "constant" ADH of class III, is an enzyme conserved over wide ranges.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Barcelona, Fac Biol, Dept Genet, E-08071 Barcelona, Spain	Karolinska Institutet; University of Barcelona	Jornvall, H (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.		Marfany, Gemma/I-5668-2015	Marfany, Gemma/0000-0001-7941-983X				BISCHOFF WL, 1976, BIOCHEM GENET, V14, P1019, DOI 10.1007/BF00485134; BISCHOFF WL, 1978, BIOCHEM GENET, V16, P485, DOI 10.1007/BF00484214; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; Carr IM, 1997, EUR J BIOCHEM, V245, P760, DOI 10.1111/j.1432-1033.1997.00760.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; EKLUND H, 1985, BIOCHEMISTRY-US, V24, P8005, DOI 10.1021/bi00348a025; ENGEL W, 1970, HUMANGENETIK, V9, P157, DOI 10.1007/BF00278931; FEITERS MC, 1989, BIOCHEMISTRY-US, V28, P7257, DOI 10.1021/bi00444a017; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GEISEN K, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1032; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; HJELMQVIST L, 1995, P NATL ACAD SCI USA, V92, P10904, DOI 10.1073/pnas.92.24.10904; Hjelmqvist L, 1996, EUR J BIOCHEM, V236, P563, DOI 10.1111/j.1432-1033.1996.00563.x; HURLEY TD, 1994, J MOL BIOL, V239, P415, DOI 10.1006/jmbi.1994.1382; IWATA T, 1995, GENOMICS, V26, P55, DOI 10.1016/0888-7543(95)80082-W; JEFFERY J, 1984, EUR J BIOCHEM, V140, P7, DOI 10.1111/j.1432-1033.1984.tb08059.x; JEFFERY J, 1983, P NATL ACAD SCI-BIOL, V80, P901, DOI 10.1073/pnas.80.4.901; JEFFERY J, 1984, EMBO J, V3, P357, DOI 10.1002/j.1460-2075.1984.tb01811.x; JORNVALL H, 1984, EUR J BIOCHEM, V140, P17, DOI 10.1111/j.1432-1033.1984.tb08061.x; JORNVALL H, 1993, ENZYMOLOGY MOL BIOL, V4, P533; JORNVALL H, 1994, MOL BASIS ALCOHOL US, P221; KARLSSON C, 1989, EUR J BIOCHEM, V186, P543, DOI 10.1111/j.1432-1033.1989.tb15240.x; KARLSSON C, 1993, EUR J BIOCHEM, V216, P103, DOI 10.1111/j.1432-1033.1993.tb18121.x; KARLSSON C, 1991, EUR J BIOCHEM, V198, P761, DOI 10.1111/j.1432-1033.1991.tb16077.x; Karlsson C, 1995, ENZYMOLOGY MOL BIOL, V5, P397; Korkhin Y, 1998, J MOL BIOL, V278, P967, DOI 10.1006/jmbi.1998.1750; LEE FK, 1994, GENOMICS, V21, P354, DOI 10.1006/geno.1994.1276; LINDSTAD RI, 1992, EUR J BIOCHEM, V210, P641, DOI 10.1111/j.1432-1033.1992.tb17465.x; LUQUE T, 1994, EUR J BIOCHEM, V225, P985, DOI 10.1111/j.1432-1033.1994.0985b.x; MARET W, 1989, BIOCHEMISTRY-US, V28, P9944, DOI 10.1021/bi00452a011; MARET W, 1988, BIOCHEMISTRY-US, V27, P1622, DOI 10.1021/bi00405a035; Martinez MC, 1996, EUR J BIOCHEM, V241, P849, DOI 10.1111/j.1432-1033.1996.00849.x; Moreno A, 1996, FEBS LETT, V395, P99, DOI 10.1016/0014-5793(96)01009-5; NG K, 1992, J BIOL CHEM, V267, P24989; Niimi T, 1996, INSECT MOL BIOL, V5, P269, DOI 10.1111/j.1365-2583.1996.tb00101.x; NIIMI T, 1993, EUR J BIOCHEM, V213, P1125, DOI 10.1111/j.1432-1033.1993.tb17862.x; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARTHY AV, 1994, GENE, V140, P121, DOI 10.1016/0378-1119(94)90741-2; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; STOLTZFUS A, 1994, NATURE, V369, P526, DOI 10.1038/369526b0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TILTON RG, 1995, DIABETES, V44, P234, DOI 10.2337/diabetes.44.2.234; WALSH JB, 1995, GENETICS, V139, P421	50	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34293	34301		10.1074/jbc.273.51.34293	http://dx.doi.org/10.1074/jbc.273.51.34293			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852094	hybrid			2022-12-25	WOS:000077542200060
J	Wang, YL; Xiao, L; Thiagalingam, A; Nelkin, BD; Casero, RA				Wang, YL; Xiao, L; Thiagalingam, A; Nelkin, BD; Casero, RA			The identification of a cis-element and a trans-acting factor involved in the response to polyamines and polyamine analogues in the regulation of the human spermidine/spermine N-1-acetyltransferase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMINE N1-ACETYLTRANSFERASE ACTIVITY; S-ADENOSYLMETHIONINE DECARBOXYLASE; MELANOMA CELL-LINES; SMALL MAF PROTEINS; ORNITHINE DECARBOXYLASE; CARCINOMA-CELLS; LUNG-CANCER; RESTRICTION ENDONUCLEASES; GROWTH-INHIBITION; MESSENGER-RNA	The superinduction of spermidine/spermine N-1-acetyltransferase (SSAT) gene has been associated with a cytotoxic response to a new class of antineoplastic polyamine analogues. The initial mechanism of SSAT superinduction is an increase in transcription in response to analogue exposure. This increased transcription appears to be modulated through the association between a nuclear protein factor and a cis-element described here as the polyamine-responsive element (PRE), The PRE was identified as a 9-base pair sequence, 5'-TATGACTAA-3', in the context of a 31-base pair stretch from -1522 to -1492 base pairs; with respect to the SSAT transcriptional start site. This element binds a nuclear factor from polyamine analogue-responsive cells, but not from polyamine analogue-insensitive cells. The labeled PRE was used to clone and identify the transcription factor, Nrf-8, that binds constitutively to the PRE sequence. Although the PRE sequence shares homology to the originally identified Nrf-8 recognition sequence, the two sequences are not identical. The Nrf-2 transcription factor appears only to be present in cell types that are capable of expressing high amounts of SSAT, The results of these studies suggest that Nrf-2, bound to the PRE, plays an important regulatory role of expression of the human SSAT gene.	Johns Hopkins Oncol Ctr, Res Labs, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Casero, RA (corresponding author), Johns Hopkins Oncol Ctr, Res Labs, 424 N Bond St, Baltimore, MD 21231 USA.	casero@welchlink.welch.jhu.edu		Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTE [R01CA051085, P50CA058184] Funding Source: NIH RePORTER; NCI NIH HHS [CA51085, CA58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BASU HS, 1990, BIOCHEM J, V269, P329, DOI 10.1042/bj2690329; BASU HS, 1992, BIOCHEM J, V282, P723, DOI 10.1042/bj2820723; BERGERON RJ, 1989, CANCER RES, V49, P2959; BERGERON RJ, 1988, J MED CHEM, V31, P1183, DOI 10.1021/jm00401a019; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryans M, 1996, BIOCHEM BIOPH RES CO, V226, P618, DOI 10.1006/bbrc.1996.1405; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1995, CANCER CHEMOTH PHARM, V36, P69; CASERO RA, 1989, CANCER RES, V49, P3829; CASERO RA, 1991, J BIOL CHEM, V266, P810; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; CELANO P, 1989, J BIOL CHEM, V264, P8922; CHANG BK, 1992, CANCER CHEMOTH PHARM, V30, P183, DOI 10.1007/BF00686309; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEUERSTEIN BG, 1991, J CELL BIOCHEM, V46, P37, DOI 10.1002/jcb.240460107; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAMEJI T, 1987, J BIOL CHEM, V262, P2427; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LIBBY PR, 1989, CANCER RES, V49, P6226; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MATSUIYUASA I, 1992, CHEM-BIOL INTERACT, V81, P233, DOI 10.1016/0009-2797(92)90080-5; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOSHIER JA, 1993, CANCER RES, V53, P2618; NELKIN BD, 1990, BIOCHEM BIOPH RES CO, V170, P140, DOI 10.1016/0006-291X(90)91251-M; OBAYASHI M, 1992, BIOCHIM BIOPHYS ACTA, V1131, P41, DOI 10.1016/0167-4781(92)90096-I; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PEGG AE, 1994, BIOCHEM SOC T, V22, P846, DOI 10.1042/bst0220846; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1990, BIOCHEM J, V267, P331, DOI 10.1042/bj2670331; PINGOUD A, 1984, BIOCHEMISTRY-US, V23, P5697, DOI 10.1021/bi00319a006; PINGOUD A, 1985, EUR J BIOCHEM, V147, P105, DOI 10.1111/j.1432-1033.1985.tb08725.x; PORTER CW, 1987, BIOCHEM J, V242, P433, DOI 10.1042/bj2420433; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1992, FALK SYMP, V62, P301; RUCKDESCHEL JC, 1986, J CLIN ONCOL, V4, P14, DOI 10.1200/JCO.1986.4.1.14; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; WANG JY, 1993, AM J PHYSIOL, V265, pG331, DOI 10.1152/ajpgi.1993.265.2.G331; Wang Y., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P250; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657; WOSTER PM, 1996, MOL BIOL INTELLIGENC, P171; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P; Xiao L, 1996, BIOCHEM J, V313, P691, DOI 10.1042/bj3130691; Xiao L., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P557	53	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34623	34630		10.1074/jbc.273.51.34623	http://dx.doi.org/10.1074/jbc.273.51.34623			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852135	hybrid			2022-12-25	WOS:000077542200101
J	del Peso, L; Gonzalez, VM; Nunez, G				del Peso, L; Gonzalez, VM; Nunez, G			Caenorhabditis elegans EGL-1 disrupts the interaction of CED-9 with CED-4 and promotes CED-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BCL-2 HOMOLOG BAK; E1B 19K; APOPTOSIS; PROTEIN; SURVIVAL; ENCODES; HETERODIMERIZES; REGULATORS; INDUCTION	In the nematode Caenorhabditis elegans, programmed cell death is implemented by the protease CED-3 whose activity is inhibited by CED-9 through physical associations with the regulator CED-4, The product of a recently described gene, egl-1, binds to and inhibits CED-9. In the present studies, we have addressed the molecular mechanism by which EGL-1 regulates CED-9 function and promotes cell death. Expression of CED-4 and CED-3 resulted in decreased survival and apoptosis of mammalian cells, activities that could be inhibited by CED-9, Importantly, this protective effect of CED-9 was antagonized by EGL-1. Immunoprecipitation analysis showed that EGL-1 binding to CED-9 disrupts the association between CED-4 and CED-9, an activity that required the BH3 motif of EGL-1, Consistent with these results, expression of EGL-1 promoted CED-4-dependent processing of CED-3, and this activity of EGL-1 was mediated through inhibition of CED-9, In mammalian cells, CED-9 is known to target the subcellular localization of CED-4 from the cytosol to intracellular membranes. Expression of EGL-1 resulted in redistribution of CED-4 from intracellular membranes, where it co-localized with CED-9, to the cytoplasm, providing further evidence that EGL-1 regulates CED-4 through CED-9, Finally, the levels of EGL-1 were greatly enhanced by coexpression of CED-9 in both mammalian cells and in a cell-free system, suggesting a. role for CED-9 in the expression and/or stabilization. of EGL-1. These studies provide a mechanism for how EGL-1 functions to antagonize pro-survival of CED-9 and to promote CED-3 activation and programmed cell death.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014; del Peso, Luis/K-9391-2014; Gonzalez, Victor M/F-7396-2010	del Peso, Luis/0000-0003-4014-5688; Gonzalez, Victor M/0000-0001-7538-0552	NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1995, ONCOGENE, V11, P1921; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Han J, 1996, MOL CELL BIOL, V16, P5857; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	35	83	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33495	33500		10.1074/jbc.273.50.33495	http://dx.doi.org/10.1074/jbc.273.50.33495			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837929	hybrid			2022-12-25	WOS:000077462500059
J	DiRusso, CC; Tsvetnitsky, V; Hojrup, P; Knudsen, J				DiRusso, CC; Tsvetnitsky, V; Hojrup, P; Knudsen, J			Fatty Acyl-CoA binding domain of the transcription factor FadR - Characterization by deletion, affinity labeling, and isothermal titration calorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACID METABOLISM; COENZYME-A; PROTEIN; GENE; REPRESSION; EXPRESSION; REGULATOR	The Escherichia coli transcription factor FadR regulates genes required for fatty acid biosynthesis and degradation in an opposing manner. It is acting as an activator of biosynthetic genes and a repressor of degradative genes. The DNA binding of FadR to regions within the promoters of responsive genes and operons is inhibited by long chain acyl-CoA thioesters but not free fatty acids or coenzyme A, The acyl-CoA binding domain of FadR was localized by affinity labeling of the full-length protein and an amino-terminal deletion derivative, FadR Delta 1-167, with a palmitoyl-CoA analogue, 9-pazidophenoxy[9-H-3]nonanoic acid-CoA ester. Analysis of labeled peptides generated by tryptic digestion of the affinity-labeled proteins identified one peptide common to both the full-length protein and the deletion derivative. The amino-terminal sequence of the labeled peptide was SLALGFYHK, which corresponds to amino acids 187-195 in FadR, Isothermal titration calorimetry was used to estimate affinity of the wild-type full-length FadR, a His-tagged derivative, and FadR Delta 1-167 for acyl-CoA The binding was characterized by a large negative Delta H-0, -16 to -20 kcal mol(-1). No binding was detected for the medium chain ligand C8-CoA Full-length wild-type FadR and His(6)-FadR bound oleoyl-CoA and myristoyl-CoA with similar affinities, K-d of 45 and 63 nM and 68 and 59 nM, respectively. The K-d for palmitoyl-CoA binding was about 5-fold higher despite the fact that palmitoyl-CoA is 50-fold more efficient in inhibiting FadR binding to DNA than myristoyl-CoA The results indicate that both acyl-CoA chain length and the presence of double bonds in the acyl chain affect FadR ligand binding.	Odense Univ, Inst Biochem, Inst Mol Biol, DK-5230 Odense M, Denmark; Albany Med Coll, Dept Biochem & Mol Biol, Albany, NY 12208 USA	University of Southern Denmark; Albany Medical College	Knudsen, J (corresponding author), Odense Univ, Inst Biochem, Inst Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.	jkk@biochem.ou.dk	Højrup, Peter/ABG-8477-2020	Hojrup, Peter/0000-0002-7838-6180				Choi JY, 1996, J BIOL CHEM, V271, P3581; CHRISTIE WW, 1982, LIPID ANAL, P54; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DIRUSSO CC, 1993, MOL MICROBIOL, V7, P311, DOI 10.1111/j.1365-2958.1993.tb01122.x; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DiRusso CC, 1996, GWUMC DEPT, P15; Faergeman NJ, 1997, BIOCHEM J, V323, P1; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; KAMIRYO T, 1976, P NATL ACAD SCI USA, V73, P386, DOI 10.1073/pnas.73.2.386; KRAGELUND BB, 1993, J MOL BIOL, V230, P1260, DOI 10.1006/jmbi.1993.1240; MANDRUP S, 1991, BIOCHEM J, V276, P817, DOI 10.1042/bj2760817; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MORTON TA, 1991, J BIOL CHEM, V266, P23824; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; Raman N, 1997, J BIOL CHEM, V272, P30645, DOI 10.1074/jbc.272.49.30645; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; RAMAN N, 1996, THESIS U TENNESEE ME; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; SANCHEZ M, 1973, BIOCHEM J, V170, P565; SIGURSKJOLD BW, 1994, BIOCHEMISTRY-US, V33, P10191, DOI 10.1021/bi00199a048; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	22	51	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33652	33659		10.1074/jbc.273.50.33652	http://dx.doi.org/10.1074/jbc.273.50.33652			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837950	hybrid			2022-12-25	WOS:000077462500080
J	Mannion, BA; Kolesnikova, TV; Lin, SH; Wang, S; Thompson, NL; Hemler, ME				Mannion, BA; Kolesnikova, TV; Lin, SH; Wang, S; Thompson, NL; Hemler, ME			The light chain of CD98 is identified as E16/TA1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION REGULATORY PROTEIN-1; MONOCLONAL-ANTIBODY 4F2; AMINO-ACID-TRANSPORT; CELL-SURFACE ANTIGEN; XENOPUS-LAEVIS OOCYTES; HEAVY-CHAIN; ACTIVATION ANTIGEN; MOLECULAR-CLONING; LIVER DEVELOPMENT; RAT-KIDNEY	The 80/40-kDa CD98 protein. complex was purified using an anti-CD98 heavy chain monoclonal antibody coupled to Sepharose beads. fluted proteins were subjected to preparative SDS-polyacrylamide gel electrophoresis, and protein corresponding to the 40-kDa CD98 light chain was excised. Following proteolysis with trypsin, a peptide fragment was sequenced by mass spectrometry. The nine residues obtained we:re identical to established C-terminal sequences of the human E16 and rat TAI proteins, suggesting that TA1/E16 protein is the CD98 Light chain. Consistent with this, anti-TA1/E16 antibodies specifically immunoblotted the similar to 35-40-kDa light chain present upon immunoprecipitation of the human CD98 complex. Furthermore, anti-CD98 heavy chain antibody specifically co-immunoprecipitated hemagglutinin-tagged light chain from cells transfected with hemagglutinin-tagged E16 cDNA. In conclusion, the CD98 light chain is identical to the TA1/E16 protein, based on partial amino acid sequence identity, antibody crossreactivity, genetic reconstitution evidence, similar molecular size, and comparable cell distribution.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Rhode Isl Hosp, Dept Med, Providence, RI 02903 USA; Rhode Isl Hosp, Dept Pathol, Providence, RI 02903 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Lifespan Health Rhode Island; Rhode Island Hospital; Lifespan Health Rhode Island; Rhode Island Hospital	Hemler, ME (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	Martin_Hemler@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [T32CA009172, R01CA042368] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA9172, CA42368] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZZARONE B, 1984, J CELL BIOL, V98, P1133, DOI 10.1083/jcb.98.3.1133; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; Castagna M, 1997, J EXP BIOL, V200, P269; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; COTNER T, 1983, J EXP MED, V157, P461, DOI 10.1084/jem.157.2.461; Diaz LA, 1997, INT IMMUNOL, V9, P1221, DOI 10.1093/intimm/9.9.1221; DIXON WT, 1990, INT J CANCER, V45, P59, DOI 10.1002/ijc.2910450113; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; GAUGITSCH HW, 1992, J BIOL CHEM, V267, P11267; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEMLER ME, 1982, J IMMUNOL, V129, P623; HEMLER ME, 1983, J IMMUNOL, V131, P334; Higuchi S, 1998, J BONE MINER RES, V13, P44, DOI 10.1359/jbmr.1998.13.1.44; HOLLY A, 1993, LARYNGO RHINO OTOL, V72, P324, DOI 10.1055/s-2007-997909; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; MICHALAK M, 1986, J BIOL CHEM, V261, P92; Ohgimoto S, 1996, J GEN VIROL, V77, P2747, DOI 10.1099/0022-1317-77-11-2747; OHGIMOTO S, 1995, J IMMUNOL, V155, P3585; Okamoto K, 1997, J GEN VIROL, V78, P775, DOI 10.1099/0022-1317-78-4-775; Palacin M, 1998, CURR OPIN CELL BIOL, V10, P455, DOI 10.1016/S0955-0674(98)80058-6; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; PATTERSON JAK, 1984, J INVEST DERMATOL, V83, P210, DOI 10.1111/1523-1747.ep12263581; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POSILLICO JT, 1987, J CLIN ENDOCR METAB, V64, P43, DOI 10.1210/jcem-64-1-43; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; SANG JS, 1995, CANCER RES, V55, P1152; SCHULTZ VD, 1998, IN PRESS TOXICOL APP; TABATA N, 1995, ARCH PATHOL LAB MED, V119, P461; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; Warren AP, 1996, BLOOD, V87, P3676, DOI 10.1182/blood.V87.9.3676.bloodjournal8793676; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; Wolf DA, 1996, CANCER RES, V56, P5012; YAGITA H, 1986, CANCER RES, V46, P1478	41	64	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33127	33129		10.1074/jbc.273.50.33127	http://dx.doi.org/10.1074/jbc.273.50.33127			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837878	hybrid			2022-12-25	WOS:000077462500008
J	Rehrauer, WM; Bruck, I; Woodgate, R; Goodmann, MF; Kowalczykowski, SC				Rehrauer, WM; Bruck, I; Woodgate, R; Goodmann, MF; Kowalczykowski, SC			Modulation of RecA nucleoprotein function by the mutagenic UmuD ' C protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; UV-MUTAGENESIS; HOMOLOGOUS RECOMBINATION; LEXA REPRESSOR; ULTRAVIOLET-LIGHT; SOS MUTAGENESIS; REPAIR; CLEAVAGE; PURIFICATION	The RecA, UmuC, and UmuD' proteins are essential for error-prone, replicative bypass of DNA lesions. Normally, RecA protein mediates homologous pairing of DNA. We show that purified Umu(D')(2)C blocks this recombination function. Biosensor measurements establish that the mutagenic complex binds to the RecA nucleoprotein filament with a stoichiometry of one Umu(D')(2)C complex for every two RecA monomers, Furthermore, Umu(D')(2)C competitively inhibits LexA repressor cleavage but not ATPase activity, implying that Umu(D')(2)C binds in or proximal to the helical groove of the RecA nucleoprotein filament. This binding reduces joint molecule formation and even more severely impedes DNA heteroduplex formation by RecA protein, ultimately blocking all DNA pairing activity and thereby abridging participation in recombination function. Thus, Umu(D')(2)C restricts the activities of the RecA nucleoprotein filament and presumably, in this manner, recruits it for mutagenic repair function. This modulation by Umu(D')(2)C is envisioned as a key event in the transition from a normal mode of genomic maintenance by "error-free" recombinational repair, to one of "error-prone" DNA replication.	Univ Calif Davis, Microbiol Sect, Div Biol Sci, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Div Biol Sci, Davis, CA 95616 USA; Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; NICHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Southern California; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Div Biol Sci, Hutchison Hall, Davis, CA 95616 USA.			Woodgate, Roger/0000-0001-5581-4616	NIAID NIH HHS [AI-18987] Funding Source: Medline; NIGMS NIH HHS [GM-42554] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042554] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILONE A, 1991, BIOCHIMIE, V73, P479, DOI 10.1016/0300-9084(91)90115-H; BRIDGES BA, 1985, P NATL ACAD SCI USA, V82, P4193, DOI 10.1073/pnas.82.12.4193; BRIDGES BA, 1984, MOL GEN GENET, V196, P364, DOI 10.1007/BF00328073; BRIDGES BA, 1988, MUTAT RES, V198, P343, DOI 10.1016/0027-5107(88)90012-7; BRIDGES BA, 1985, MUTAT RES, V150, P133, DOI 10.1016/0027-5107(85)90110-1; Bruck I, 1996, J BIOL CHEM, V271, P10767, DOI 10.1074/jbc.271.18.10767; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; DUTREIX M, 1992, MOL GEN GENET, V232, P489, DOI 10.1007/BF00266254; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Harmon FG, 1996, J BIOL CHEM, V271, P23874, DOI 10.1074/jbc.271.39.23874; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; KATO T, 1977, MOL GEN GENET, V156, P121, DOI 10.1007/BF00283484; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Konola JT, 1998, J MOL BIOL, V276, P405, DOI 10.1006/jmbi.1997.1531; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; LAVERY PE, 1990, J BIOL CHEM, V265, P4004; LEBOWITZ J, 1985, THESIS J HOPKINS U B; MOREAU PL, 1988, J BACTERIOL, V170, P2493, DOI 10.1128/jb.170.6.2493-2500.1988; Nastri HG, 1997, MOL MICROBIOL, V25, P967, DOI 10.1111/j.1365-2958.1997.mmi533.x; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; Rehrauer WM, 1996, J BIOL CHEM, V271, P23865, DOI 10.1074/jbc.271.39.23865; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; Sommer S, 1998, MOL MICROBIOL, V28, P281, DOI 10.1046/j.1365-2958.1998.00803.x; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; STASIAK A, 1984, COLD SPRING HARB SYM, V49, P561, DOI 10.1101/SQB.1984.049.01.063; STEINBORN G, 1978, MOL GEN GENET, V165, P87, DOI 10.1007/BF00270380; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; Szpilewska H, 1995, BIOCHIMIE, V77, P848, DOI 10.1016/0300-9084(95)90002-0; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WOODGATE R, 1991, MOL GEN GENET, V229, P10, DOI 10.1007/BF00264207; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; YU X, 1993, J MOL BIOL, V231, P29, DOI 10.1006/jmbi.1993.1254	40	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32384	32387		10.1074/jbc.273.49.32384	http://dx.doi.org/10.1074/jbc.273.49.32384			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829966	hybrid, Green Submitted			2022-12-25	WOS:000077329100005
J	Buisson, A; Nicole, O; Docagne, F; Sartelet, H; MacKenzie, ET; Vivien, D				Buisson, A; Nicole, O; Docagne, F; Sartelet, H; MacKenzie, ET; Vivien, D			Up-regulation of a serine protease inhibitor in astrocytes mediates the neuroprotective activity of transforming growth factor beta 1	FASEB JOURNAL			English	Article						excitotoxicity; serpins; neuronal cell death; apoptosis	NEURONAL DEATH; EXPRESSION; APOPTOSIS; TGF-BETA-1; DISEASE; INJURY; GENE; GROWTH-FACTOR-BETA-1; NEUROTOXICITY; DEGENERATION	Serine proteases play a key role in the fundamental biology of the central nervous system (CNS), and recent data suggest their involvement in the pathophysiology of neurodegenerative diseases, Little is known about the physiological regulation of these proteases in the CNS, Among the multiple growth factors present in the brain, transforming growth factor beta 1 (TGF-beta 1) has been described as an injury-related growth factor. However, its beneficial or deleterious role remains unclear. In the present study, we investigated the influence of TGF-beta 1 in apoptosis and necrosis, two mechanisms involved in ischemic neuronal death. We show that TGF-beta 1 exerts a neuroprotective role restricted to necrosis induced by N-methyl-D-aspartate. This effect is observable only in the obligatory presence of TGF-beta 1-responsive astrocytes, We demonstrate that this neuroprotective activity is mediated through an up-regulation of a serine protease inhibitor (PAI-1) in astrocytes, These results underline the involvement of serine proteases and extracellular matrix components such as the PAI-1/t-PA axis in the excitotoxic cascade, Moreover, regardless of the underlying mechanisms of t-PA involvement in excitotoxic injury, our observations might warn against the use of tissular plasminogen activator as an alternative therapy for the treatment of hypoxic-ischemic injury in the brain.	Univ Caen, CNRS UMR 6551, Neurosci Lab, F-14074 Caen, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie	Buisson, A (corresponding author), Univ Caen, CNRS UMR 6551, Neurosci Lab, Bd H Becquerel,BP 5229, F-14074 Caen, France.		Docagne, Fabian/S-8308-2018; buisson, alain/AAI-8218-2020; Mackenzie, Eric Thomson/L-1938-2015; Nicole, Olivier/AAZ-2865-2020	buisson, alain/0000-0002-4281-7911; Nicole, Olivier/0000-0001-9981-1820; VIVIEN, DENIS/0000-0002-7636-2185; Docagne, Fabian/0000-0003-1745-0625; MacKenzie, Eric T/0000-0003-1057-7033				AGID Y, 1991, LANCET, V337, P1321, DOI 10.1016/0140-6736(91)92989-F; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DEBROCK S, 1997, BIOCHIM BIOPHYS ACTA, V1337, P267; deLuca A, 1996, J NEUROSCI, V16, P4174; FLANDERS KC, 1995, NEUROLOGY, V45, P1561, DOI 10.1212/WNL.45.8.1561; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; KRIEGLSTEIN K, 1998, NEUROPROTECTIVE SIGN, P119; LEHRMANN E, 1995, EXP NEUROL, V131, P114, DOI 10.1016/0014-4886(95)90013-6; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; PITTMAN RN, 1995, J NEUROCHEM, V64, P566; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; Prehn JHM, 1996, NEUROPHARMACOLOGY, V35, P249, DOI 10.1016/0028-3908(96)00001-9; PREHN JHM, 1994, NEUROSCIENCE, V60, P7, DOI 10.1016/0306-4522(94)90198-8; Rose K, 1993, IN VITRO BIOL METHOD, P46; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNTON AJ, 1994, CANCER RES, V54, P1337; Tsirka SE, 1997, J NEUROSCI, V17, P543; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092	32	110	113	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1683	1691		10.1096/fasebj.12.15.1683	http://dx.doi.org/10.1096/fasebj.12.15.1683			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837858				2022-12-25	WOS:000077574500010
J	Hartsfield, CL; Alam, J; Choi, AMK				Hartsfield, CL; Alam, J; Choi, AMK			Transcriptional regulation of the heme oxygenase 1 gene by pyrrolidine dithiocarbamate	FASEB JOURNAL			English	Article						antioxidants; gene transcription; activator protein 1; gene expression	NF-KAPPA-B; LUNG INJURY; INTRACELLULAR LEVEL; INTACT-CELLS; BASAL LEVEL; AP-1; INDUCTION; ANTIOXIDANTS; EXPRESSION; ACTIVATION	Heme oxygenase 1 (HO-1), a stress response protein, is highly induced in response tn various agents causing oxidative stress including ultraviolet irradiation, sodium arsenite, hyperoxia, and glutathione depletors, We recently characterized the induction of HO-1 gene expression by nitric oxide (NO) and postulated that the addition of an antioxidant, such as pyrrolidine dithiocarbamate (PDTC), would attenuate HO-1 induction in response to NO, Surprisingly, PDTC was a very potent inducer of HO-1 gene expression, causing increases in the steady-state level of HO-1 mRNA in rat aortic vascular smooth muscle (aVSM) cells in a time- and concentration-dependent manner, PDTC-induced HO-1 gene expression correlated with a rise in protein levels and was dependent on both increased gene transcription and mRNA stability, Deletional analyses of the proximal promoter and the entire 5' distal upstream region of the HO-1 gene (11 kbp) were performed including the two 5' distal enhancers, SX2 and AB1, located 4 kbp and 10 kbp upstream of the transcription site, respectively. Plasmid vectors containing various fragments of this region were linked to a chloramphenicol acetyl transferase (CAT) reporter gene, stably transfected into RAW 264.7 cells, and transfectants were assayed for CAT activity after treatment with PDTC, We show that the AB1 distal enhancer plays an important role in mediating PDTC-induced HO-1 gene transcription, Mutational analyses of this enhancer showed that the activator protein 1 (AP-1) regulatory element is crucial for PDTC-induced HO-1 gene transcription, Electrophoretic mobility shift assays supported this data, demonstrating increased AP-1 DNA binding activity after PDTC treatment, Taken together, our data demonstrate that the antioxidant PDTC enhances HO-1 gene transcription and that the induction appears to be mediated by AP-1 activation of regulatory elements specific to the distal enhancer AB1.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Connecticut VA HealthCare Syst, W Haven, CT 06516 USA; Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Alton Ochsner Med Fdn & Ochsner Clin, Dept Mol Genet, New Orleans, LA 70121 USA; Louisiana State Univ, Dept Biochem & Mol Biol, Ctr Med, New Orleans, LA 70121 USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Johns Hopkins University; Ochsner Health System; Louisiana State University System	Choi, AMK (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St,LCI 105, New Haven, CT 06520 USA.	augus-tine.choi@yale.edu	Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X	NHLBI NIH HHS [R29 HL-55330] Funding Source: Medline; NIAID NIH HHS [R01 AI-42365] Funding Source: Medline; NIDDK NIH HHS [DK 43135] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043135] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; ABRAHAM NG, 1988, INT J BIOCHEM, V20, P543, DOI 10.1016/0020-711X(88)90093-6; ALAM J, 1994, J BIOL CHEM, V269, P25049; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; ALAM J, 1992, J BIOL CHEM, V267, P21894; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Borrello S, 1997, ARCH BIOCHEM BIOPHYS, V348, P289, DOI 10.1006/abbi.1997.0355; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; delArco PG, 1996, J BIOL CHEM, V271, P26335; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee PJ, 1996, AM J RESP CELL MOL, V14, P556, DOI 10.1165/ajrcmb.14.6.8652184; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nathens AB, 1997, AM J RESP CELL MOL, V17, P608, DOI 10.1165/ajrcmb.17.5.2661; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; Otterbein L, 1997, AM J PHYSIOL-LUNG C, V272, pL268; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; REISINGER EC, 1990, LANCET, V335, P679, DOI 10.1016/0140-6736(90)90802-C; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P2865; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VILE GF, 1993, J BIOL CHEM, V268, P14678; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87	32	88	88	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1675	1682		10.1096/fasebj.12.15.1675	http://dx.doi.org/10.1096/fasebj.12.15.1675			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837857				2022-12-25	WOS:000077574500009
J	Lebrun, P; Mothe-Satney, I; Delahaye, L; Van Obberghen, E; Baron, V				Lebrun, P; Mothe-Satney, I; Delahaye, L; Van Obberghen, E; Baron, V			Insulin receptor substrate-1 as a signaling molecule for focal adhesion kinase pp125(FAK) and pp60(src)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE TYROSINE KINASE; FACTOR-I RECEPTOR; SWISS 3T3 CELLS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; BIOLOGICAL-ACTIVITY; CROSS-TALK; PHOSPHORYLATION; INTEGRIN; PROTEIN	Insulin receptor substrate-1 (IRS-1) is a major substrate of insulin and insulin-like growth factor-I receptors, which upon phosphorylation on tyrosine docks several signaling molecules. Recently, IRS-I was found to interact with alpha(v)beta(3) integrins upon insulin stimulation. Integrins are transmembrane proteins that play an important role in adhesion between cells and between cells and extracellular matrix. One of the major proteins implicated in integrin signaling is pp125(FAK), a cytosolic tyrosine kinase, which upon integrin engagement becomes tyrosine-phosphorylated and subsequently binds to c-Src, Here, we established a mammalian two-hybrid system to show that pp125(FAK) binds to IRS-1, This association depends largely on the C terminus of pp125(FAK); but not on pp125(FAK) tyrosine kinase activity, Furthermore, we observed co-immunoprecipitation of pp125(FAK) with IRS-1 in 293 cells, suggesting a possible biological function of this association. When IRS-I was expressed in 293 cells together with pp125(FAK) Or Src, We found extensive IRS-1 tyrosine phosphorylation. In pp125(FAK) expressing cells, this was concomitant with increased association of IRS-1 with Src homology 2-containing proteins such as growth factor receptor-bound protein 2, phosphatidylinositol (PI) 3-kinase p85 alpha subunit, and Src homology 8-containing protein-tyrosine phosphatase-a, In addition, pp125(FAK)-induced association of IRS-l with PI S-kinase resulted in increased PI 3-kinase activity. In contrast, no change in mitogen-activated protein kinase activity was observed, indicating that pp125(FAK)-induced association between IRS-I and growth factor receptor-bound protein 2 does not affect the mitogen-activated protein kinase pathway. Moreover, we found that engagement of integrins induced IRS-l tyrosine phosphorylation. Considering our results together, we suggest that integrins and insulin/insulin-like growth factor-I receptor signaling pathways converge at an early point in the signaling cascade, which is the IRS-1 protein.	INSERM, U145, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Van Obberghen, E (corresponding author), INSERM, U145, Ave Valombrose, F-06107 Nice 2, France.	vanobbeg@unice.fr	MOTHE-SATNEY, ISABELLE/Q-6377-2016; LEBRUN, Patricia/O-5765-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385; 				ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Crouch DH, 1996, ONCOGENE, V12, P2689; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FREYCHET P, 1971, BIOCHEM BIOPH RES CO, V43, P400, DOI 10.1016/0006-291X(71)90767-4; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rocchi S, 1996, ENDOCRINOLOGY, V137, P4944, DOI 10.1210/en.137.11.4944; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; SCHWARTZ MA, 1992, P NATL ACAD SCI USA, V89, P6138, DOI 10.1073/pnas.89.13.6138; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Ueno H, 1997, ONCOGENE, V14, P3067, DOI 10.1038/sj.onc.1201153; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU LF, 1997, ONCOGENE, V15, P961	67	60	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32244	32253		10.1074/jbc.273.48.32244	http://dx.doi.org/10.1074/jbc.273.48.32244			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822703	hybrid			2022-12-25	WOS:000077207000085
J	Newton, R; Seybold, J; Kuitert, LME; Bergmann, M; Barnes, PJ				Newton, R; Seybold, J; Kuitert, LME; Bergmann, M; Barnes, PJ			Repression of cyclooxygenase-2 and prostaglandin E-2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VASCULAR ENDOTHELIAL-CELLS; MESSENGER-RNA DECAY; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; PHORBOL ESTER; IN-VIVO; POSTTRANSCRIPTIONAL REGULATION; EPITHELIAL-CELLS; SYNTHASE-2 GENE	The two cyclooxygenase (COX) isoforms convert arachidonic acid to precursor prostaglandins (PGs). Upregulation of COX-2 is responsible for increased PG production in inflammation and is antagonized by corticosteriods such as dexamethasone. In human pulmonary A549 cells, interleukin-1 beta (IL-1 beta) increases prostaglandin E-2 (PGE(2)) synthesis via dexamethasone-sensitive induction of COX-a, Nuclear run-off assays showed that COX-2 transcription rate was repressed 25-40% by dexamethasone, while PGE(2) release, COX activity, and COX-2 protein were totally repressed. At the mRNA level, complete repression of COX-2 was only observed at later (6 h) time points. Preinduced COX-2 mRNA was also potently repressed by dexamethasone, yet suppression of transcription by actinomycin D showed little effect. This dexamethasone-dependent repression involved a reduced COX-2 mRNA half-life, was blocked by actinomycin D or cycloheximide, and was antagonized by the steroid antagonist RU38486, Repression of IL-1 beta-induced PGE(2) release, COX activity, and COX-2 protein by actinomycin D was only effective within the first hour following IL-1 beta treatment, while dexamethasone was effective when added up to 10 h later, suggesting a functional role for post-transcriptional mechanisms of repression. Following dexamethasone treatment, shortening of the average length of COX-2 mRNA poly(A) tails was observed. Finally, ligation of the COX-2 3'-UTR to a heterologous reporter failed to confer dexamethasone sensitivity. In conclusion, these data indicate a major role for post-transcriptional mechanisms in the dexamethasone-dependent repression of COX-2 that require de novo glucocorticoid receptor-dependent transcription and translation. This mechanism involves shortening of the COX-2 poly(A) tail and requires determinants other than just the 3'-UTR for specificity.	Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Thorac Med, London SW3 6LY, England; Univ Giessen, Dept Internal Med, D-35392 Giessen, Germany	Imperial College London; Justus Liebig University Giessen	Newton, R (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.	robert.newton@ic.ac.uk	Newton, Robert/C-6814-2012	Newton, Robert/0000-0002-4919-8498; Barnes, Peter/0000-0002-5122-4018; Seybold, Joachim/0000-0003-1444-8976	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Beato M, 1996, ANN NY ACAD SCI, V784, P93, DOI 10.1111/j.1749-6632.1996.tb16231.x; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DEVALIA JL, 1993, RESP MED, V87, P405, DOI 10.1016/0954-6111(93)90064-7; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HERSCHMAN HR, 1994, PROG NUCLEIC ACID RE, V47, P113, DOI 10.1016/S0079-6603(08)60251-2; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Newton R, 1996, LIFE SCI, V60, P67, DOI 10.1016/S0024-3205(96)00590-5; Newton R, 1997, FEBS LETT, V418, P135, DOI 10.1016/S0014-5793(97)01362-8; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RAZANAJAONA D, 1992, CELL GROWTH DIFFER, V3, P299; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; ROUSELL J, 1995, J BIOL CHEM, V270, P7213, DOI 10.1074/jbc.270.13.7213; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YANG L, 1994, J BIOL CHEM, V269, P32732; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	53	169	169	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32312	32321		10.1074/jbc.273.48.32312	http://dx.doi.org/10.1074/jbc.273.48.32312			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822711	hybrid			2022-12-25	WOS:000077207000093
J	Matsuguchi, T; Kraft, AS				Matsuguchi, T; Kraft, AS			Regulation of myeloid cell growth by distinct effectors of Ras	ONCOGENE			English	Article						ras; cell growth; myeloid cells; apoptosis; kip1	DEPENDENT KINASE INHIBITOR; NUCLEOTIDE DISSOCIATION STIMULATOR; PROTEIN-KINASE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; INDEPENDENT PATHWAYS; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; TRANSFORMATION; AKT; P27(KIP1)	To examine the biochemical pathways by which activated Ha-Ras(G12V) (Ha-RasV12) induces factor-independent growth of myeloid cells, Ha-Ras effector loop mutations, including Y40C, T35S, and E37G, were analysed in a mouse factor-dependent myeloid cell line, WT19. Expression of a single effector loop mutant, Ha-Ras(G12V, Y40C) (Ha-RasV12C40), inhibited factor-withdrawal apoptosis, suggesting that activation of the phosphatidylinositol 3'-kinase (Pl3K) pathway is essential to prevent cell death. Neither Ha-Ras (G12V, T35S) (Ha-RasV12S35), which activates the Ran signaling pathway, nor Ha-Ras(G12V, E37G) (Ha-RasV12G37), which stimulates the RalGDS pathway, did not have significant effects on factor-withdrawal apoptosis of myeloid cells. Although Ha-RasV12C40 inhibited apoptosis, it did not stimulate entry into the cell cycle. Cell lines containing the combination of Ha-RasV12G37 and Ha-RasV12C40 were capable of factor-independent cell growth, while expression of the other combinations of the Ha-Ras effector mutants were not. The combined expression of Bcl-2 and Ha-RasV12G37 was not sufficient to stimulate factor independent growth, suggesting that Ha-RasV12C40 activates additional signals, besides blocking apoptosis, which are critical for factor-independent growth of myeloid cells. In factor-starved myeloid cells, inducible expression of Ha-RasV12G37 results in decreased level of p27(Kip1) protein, a cyclin-dependent kinase inhibitor (CKI). These data suggest that the factor-independent growth of myeloid cells requires the activation of at least two pathways, one inhibiting factor-withdrawal apoptosis, and another causing cell cycle progression.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NIDDK NIH HHS [DK44741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BOSWELL HS, 1990, EXP HEMATOL, V18, P452; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murai H, 1997, J BIOL CHEM, V272, P10483; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RINAUDO MS, 1995, BLOOD, V86, P80, DOI 10.1182/blood.V86.1.80.bloodjournal86180; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	50	13	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2701	2709		10.1038/sj.onc.1202201	http://dx.doi.org/10.1038/sj.onc.1202201			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840934				2022-12-25	WOS:000077146700003
J	Schneider, E; Montenarh, M; Wagner, P				Schneider, E; Montenarh, M; Wagner, P			Regulation of CAK kinase activity by p53	ONCOGENE			English	Article						cyclin H; tms1; CAK kinase; TFIIH; p53; CTD phosphorylation	CDK-ACTIVATING KINASE; RNA-POLYMERASE-II; DNA-BINDING ACTIVITY; RING FINGER PROTEIN; FISSION YEAST; INDUCED APOPTOSIS; GROWTH ARREST; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; SUBSTRATE-SPECIFICITY	The growth suppressor p53 is an important key element which controls cell cycle progression in response to cellular stress like DNA damage. Its ability to act as transcriptional activator or repressor links transcription and cell cycle control. Several target genes selectively transactivated by p53 are implicated in growth control, apoptosis and DNA repair. Here we report the interaction of p53 with another important dual player of cell cycle control and transcription, the protein kinase complex CDK7/cyclin H/Mat1 (CDK activating kinase, CAK kinase). This is implicated in the activating phosphorylation of CDK2/cyclin A kinase required to allow cells to proceed through the G(1)/S transition, and on the other hand, as a component of the basal transcription factor TFIIH found to be necessary for CTD phosphorylation of RNA polymerase II in order to allow elongation of transcription. Based on previous binding studies of p53 with other C-terminal interaction partners of p53 we demonstrate a direct physical interaction of p53 with cyclin H in vitro and in vivo. As a consequence of this interaction we tested the influence of p53 on the kinase activity of CAK kinase for CTD and CDK2 phosphorylation. The addition of wild type p53 to the kinase reactions resulted in a significant downregulation of CDK2 phosphorylation and CTD phosphorylation by the CDK activating kinase. On the other hand addition of a mutant p53His175 failed to downregulate CDK2 and CTD phosphorylation by the CDK activating kinase. In an attempt to support our findings in vivo we measured CAK kinase activity in p21(-/-) and p53(-/-) mice embryonal fibroblasts under conditions when p53 gets activated by irradiation. In the case of p21(-/-) cells this led to a significant reduction of CTD phosphorylation activity of the CDK activating kinase by irradiation of the cells. On the other hand in p53(-/-) cells no downregulation of CTD phosphorylation activity of CAK kinase was observed indicating that this kind of negative regulation of CAK kinase activity is exclusively due to a functional p53. These findings imply a direct involvement of p53 in triggering growth arrest by its interaction with the CDK activating kinase complex without the need of cyclin-dependent kinase inhibitors (CKIs) and potentially suggest a new mechanism for p53-dependent apoptosis.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Wagner, P (corresponding author), Univ Saarland, Bldg 44, D-66421 Homburg, Germany.							Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; APPEL K, 1995, ONCOGENE, V11, P1971; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bureik M, 1997, BIOL CHEM, V378, P1361, DOI 10.1515/bchm.1997.378.11.1361; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; Hecker D, 1996, ONCOGENE, V12, P953; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; Knippschild U, 1996, ONCOGENE, V13, P1387; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	43	58	61	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	1998	17	21					2733	2741		10.1038/sj.onc.1202504	http://dx.doi.org/10.1038/sj.onc.1202504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840937				2022-12-25	WOS:000077146700006
J	Sweetser, MT; Hoey, T; Sun, YL; Weaver, WM; Price, GA; Wilson, CB				Sweetser, MT; Hoey, T; Sun, YL; Weaver, WM; Price, GA; Wilson, CB			The roles of nuclear factor of activated T cells and Ying-Yang 1 in activation-induced expression of the interferon-gamma promoter in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYCLOSPORINE-SENSITIVE ELEMENT; ACCESSORY MOLECULE CD28; FACTOR-ALPHA GENE; TRANSCRIPTION FACTOR; DNA-BINDING; INTERLEUKIN-2 PROMOTER; REGULATORY ELEMENTS; CYTOKINE GENES; LYMPHOCYTES-T	Nuclear factor of activated T cells (NFAT) plays an important role in expression of many cytokine genes including interleukin-a and interleukin-4. However, its role in interferon-gamma (IFN-gamma) expression is not well understood. In the current studies, two strong NFAT-binding sites in the IFN-gamma promoter mere identified by DNase I footprint analysis at positions -280 to -270 and -163 to - 155. NFATp bound independently to both sites and was required for the formation of a composite element with AP-1 spanning position -163 to -147. In Jurkat T cells and primary lymphocytes, activation-induced expression of IFN-gamma reporter constructs containing point mutations in either NFAT site or the AP-1 component of the composite site was decreased by similar to 40-65%. Despite elimination of both strong NFAT-binding sites, the IFN-gamma promoter remained completely sensitive to inhibition by cyclosporin. This suggests that other elements in the IFN-gamma promoter, such as the IFN-gamma proximal element, are sufficient for cyclosporin sensitivity of this gene. Ying-Yang I (YY1), a potential inhibitor of IFN-gamma expression, binds to sites located between the two NFAT sites. Mutation of the YY1 sites alone had Little effect on IFN-gamma promoter activity. However, mutation of both the NFAT and YY1-binding sites abolished activation-induced expression in primary murine splenocytes but not in Jurkat T cells. This suggests that under some conditions, YY1 may play a positive role in activation-induced transcription of IFN-gamma.	Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Tularik Inc, S San Francisco, CA 94080 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Sweetser, MT (corresponding author), Univ Washington, Dept Pediat, Box 356320,1959 NE Pacific, Seattle, WA 98195 USA.	msweet@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018184, R37HD018184, P30HD028834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001449] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01449] Funding Source: Medline; NICHD NIH HHS [HD18184, P30 HD28834] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Amasaki Y, 1998, J IMMUNOL, V160, P2324; Aune TM, 1997, MOL CELL BIOL, V17, P199, DOI 10.1128/MCB.17.1.199; Barbulescu K, 1997, EUR J IMMUNOL, V27, P1098, DOI 10.1002/eji.1830270509; Barbulescu K, 1998, J IMMUNOL, V160, P3642; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; Campbell PM, 1996, TRANSPLANTATION, V61, P933, DOI 10.1097/00007890-199603270-00016; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; Cron RQ, 1997, J IMMUNOL METHODS, V205, P145, DOI 10.1016/S0022-1759(97)00065-3; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOPPESEYLER F, 1991, J VIROL, V65, P5613, DOI 10.1128/JVI.65.10.5613-5618.1991; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JENKINS F, 1995, J IMMUNOL, V155, P1240; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Luo C, 1996, MOL CELL BIOL, V16, P3955; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Penix LA, 1996, J BIOL CHEM, V271, P31964, DOI 10.1074/jbc.271.50.31964; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; PRIESCHL EE, 1995, J IMMUNOL, V155, P4963; PRIESCHL EE, 1995, J IMMUNOL, V154, P6112; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; STIMAC E, 1988, MOL CELL BIOL, V8, P3734, DOI 10.1128/MCB.8.9.3734; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Ye JP, 1996, MOL CELL BIOL, V16, P4744; YE JP, 1994, J BIOL CHEM, V269, P25728; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995	71	116	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34775	34783		10.1074/jbc.273.52.34775	http://dx.doi.org/10.1074/jbc.273.52.34775			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857002	hybrid			2022-12-25	WOS:000077719700020
J	Fulda, S; Scaffidi, C; Susin, SA; Krammer, PH; Kroemer, G; Peter, ME; Debatin, KM				Fulda, S; Scaffidi, C; Susin, SA; Krammer, PH; Kroemer, G; Peter, ME; Debatin, KM			Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INDUCED APOPTOSIS; CHEMOTHERAPY-INDUCED APOPTOSIS; SIGNALING COMPLEX DISC; CD95 APO-1/FAS SYSTEM; CYTOCHROME-C; NEUROBLASTOMA-CELLS; NUCLEAR APOPTOSIS; BCL-2; BCL-X(L); DEATH	Different classes of anticancer drugs may trigger apoptosis by acting on different subcellular targets and by activating distinct signaling pathways, Here, we report that betulinic acid (BetA) is a prototype cytotoxic agent that triggers apoptosis by a direct effect on mitochondria. In isolated mitochondria, BetA directly induces loss of transmembrane potential independent of a benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone-inhibitable caspase. This is inhibited by bongkrekic acid, an agent that stabilizes the permeability transition pore complex. Mitochondria undergoing BetA-induced permeability transition mediate cleavage of caspase-8 (FLICE/MACH/Mch5) and caspase-8 (CPP32/Yama) in a cell-free system. Soluble factors such as cytochrome c or apoptosis-inducing factor released from BetA-treated mitochondria are sufficient for cleavage of caspases and nuclear fragmentation. Addition of cytochrome c to cytosolic extracts results in cleavage of caspase-8, but not of caspase-8. However, supernatants of mitochondria, which have undergone permeability transition, and partially purified apoptosis-inducing factor activate both caspase-8 and caspase-3 in cytosolic extracts and suffice to activate recombinant caspase-8. These findings show that induction of mitochondrial permeability transition alone is sufficient to trigger the full apoptosis program and that some cytotoxic drugs such as BetA may induce apoptosis via a direct effect on mitochondria.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany; German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany; CNRS, Unite Propre Rech 420, F-94801 Villejuif, France	Ulm University; Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS)	Debatin, KM (corresponding author), Univ Ulm, Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	klaus-michael.debatin@medizin.uni-ulm.d	KROEMER, Guido/B-4263-2013; Debatin, Klaus-Michael/J-9704-2014; Watzl, Carsten/B-4911-2013; Susin, Santos A/Q-6754-2017; Fulda, Simone/D-5864-2011; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; Debatin, Klaus-Michael/0000-0002-8397-1886; Watzl, Carsten/0000-0001-5195-0995; Susin, Santos A/0000-0002-3366-1628; Fulda, Simone/0000-0002-0459-6417; Peter, Marcus Ernst/0000-0003-3216-036X				Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Debatin KM, 1996, CELL DEATH DIFFER, V3, P185; Debatin KM, 1997, J NATL CANCER I, V89, P750, DOI 10.1093/jnci/89.11.750; Decaudin D, 1997, CANCER RES, V57, P62; DOLE M, 1994, CANCER RES, V54, P3253; DOLE MG, 1995, CANCER RES, V55, P2576; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; FRIESEN C, 1997, LEUKEMIA BALTIMORE, V1, P1833; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; Kim CN, 1997, CANCER RES, V57, P3115; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Los M, 1997, BLOOD, V90, P3118, DOI 10.1182/blood.V90.8.3118; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mueller Martina, 1997, Journal of Clinical Investigation, V99, P403; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OEHM A, 1992, J BIOL CHEM, V267, P10709; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SUSIN SA, 1997, J EXP MED, V186, P5; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	45	326	344	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33942	33948		10.1074/jbc.273.51.33942	http://dx.doi.org/10.1074/jbc.273.51.33942			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852046	hybrid			2022-12-25	WOS:000077542200012
J	Lund, EG; Kerr, TA; Sakai, J; Li, WP; Russell, DW				Lund, EG; Kerr, TA; Sakai, J; Li, WP; Russell, DW			cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulatory of lipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-2; NUCLEAR RECEPTOR LXR; A REDUCTASE-ACTIVITY; ALKANE HYDROXYLASE; BILE-ACID; PSEUDOMONAS-OLEOVORANS; STEROL 27-HYDROXYLASE; XYLENE MONOOXYGENASE; TRANSGENIC MICE; CELL-MEMBRANES	Oxysterols regulate the expression of genes involved in cholesterol and Lipid metabolism and serve as intermediates in cholesterol catabolism. Among the most potent of regulatory oxysterols is 25-hydroxycholesterol, whose biosynthetic enzyme has not yet been isolated. Here, we report the cloning of cholesterol 25-hydroxylase cDNAs from the mouse and human, The encoded enzymes are polytopic membrane proteins of 298 and 272 amino acids, respectively, which contain clusters of histidine residues that are essential for catalytic activity. Unlike most other sterol hydroxylases, cholesterol 25-hydroxylase is not a cytochrome P450, but rather it is a member of a small family of enzymes that utilize diiron cofactors to catalyze the hydroxylation of hydrophobic substrates. The cholesterol 25-hydroxylase gene lacks introns, and in the human it is located on chromosome 10q23. The murine gene is expressed at low levels in multiple tissues. Expression of cholesterol 25-hydroxylase in transfected cells reduces the biosynthesis of cholesterol from acetate and suppresses the cleavage of sterol regulatory element binding protein-1 and -2, The data suggest that cholesterol 25-hydroxylase has the capacity to play an important role in regulating lipid metabolism by synthesizing a co-repressor that blocks sterol regulatory element binding protein processing and ultimately leads to inhibition of gene transcription.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Russell, DW (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	russell@utsw.swmed.edu	Kerr, Thomas/C-2190-2011	Kerr, Thomas/0000-0002-7432-3289; Russell, David/0000-0002-0277-403X; Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1974, J BIOL CHEM, V249, P7306; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; GOLDSTEIN JL, 1973, P NATL ACAD SCI USA, V70, P2804, DOI 10.1073/pnas.70.10.2804; Harlow E., 1988, ANTIBODIES LAB MANUA; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Ishibashi S, 1996, J BIOL CHEM, V271, P18017, DOI 10.1074/jbc.271.30.18017; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KANDUTSCH AA, 1973, J BIOL CHEM, V248, P8408; KANDUTSCH AA, 1974, J BIOL CHEM, V249, P6057; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KOK M, 1989, J BIOL CHEM, V264, P5435; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; Schwarz M, 1998, CURR OPIN LIPIDOL, V9, P113, DOI 10.1097/00041433-199804000-00006; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SMITH M, 1985, ANNU REV GENET, V19, P423, DOI 10.1146/annurev.genet.19.1.423; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; SUZUKI M, 1991, J BACTERIOL, V173, P1690, DOI 10.1128/jb.173.5.1690-1695.1991; THIGPEN AE, 1993, J CLIN INVEST, V92, P903, DOI 10.1172/JCI116665; Uwabe K, 1997, NEUROSCIENCE, V80, P501, DOI 10.1016/S0306-4522(97)00112-7; VANBEILEN JB, 1992, J BIOL CHEM, V267, P9194; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YANOFSKY C, 1987, ESCHERICHIA COLI SAL, V2, P1453	46	246	260	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34316	34327		10.1074/jbc.273.51.34316	http://dx.doi.org/10.1074/jbc.273.51.34316			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852097	hybrid			2022-12-25	WOS:000077542200063
J	Murthy, KS; Makhlouf, GM				Murthy, KS; Makhlouf, GM			Differential regulation of phospholipase A(2) (PLA(2))-dependent Ca2+ signaling in smooth muscle by cAMP- and cGMP-dependent protein kinases - Inhibitory phosphorylation of PLA(2) by cyclic nucleotide-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM-INDEPENDENT PHOSPHOLIPASE; ACTIVATING-FACTOR ACETYLHYDROLASE; CYTOSOLIC PHOSPHOLIPASE-A2; ARACHIDONIC-ACID; LONGITUDINAL MUSCLE; CA-2+ LEVELS; CELLS; GMP; MOBILIZATION	Both cAMP- and cGMP-dependent protein kinases inhibit agonist-stimulated phospholipase C-beta (PLC-beta) activity and inositol 1,4,5-trisphosphate-dependent Ca2+ release in vascular and visceral smooth muscle. In smooth muscle of the intestinal longitudinal layer, however, the initial steps in Ca2+ mobilization involve activation of cytosolic PLA(2) (cPLA(2)) and arrachidonic acid (AA)-dependent stimulation of Ca2+ influx. The present study examined whether cAMP- and cGMP-dependent protein kinases are capable of regulating these processes also. Agents that activated cAMP-dependent protein kinase (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole 3',5'-cyclic monophosphothioate (Sp-isomer) and isoproterenol), cGMP-dependent protein kinase (8-(4-chlorophenylthio)-guanosine 3',5'-cyclic monophosphate and Na nitroprusside), or both kinases (vasoactive intestinal peptide and isoproterenol >1 mu M) induced phosphorylation of cPLA(2) and inhibition of agonist-stimulated cPLA(2) activity. Phosphorylation and inhibition of cPLA(2) activity by cGMP- and cGMP-dependent protein kinases were blocked by the corresponding selective inhibitors (cAMP-dependent protein kinase, N-[2(p-bromocinnamylamino)ethyl]-5-isoquinoline- sulfonamide hydrochloride (H-89) and myristoylated protein kinase inhibitor (14-22) amide; cGMP-dependent protein kinase, (8R,9S,11S)-(-)-9-methoxy-carbamyl-8-methyl-2,3,9,10-tetrahydro-8,11-epoxy- 1H,8H,11H,-2,7b,11a-trizadizobenzo (a,g)cycloocta(c,d,e)-trinden-1-one (KT-5823)). In contrast, AA-stimulated Ca2+ influx was inhibited by agents that activated cGMP-dependent protein kinase only; the inhibition was selectively blocked by KT-5823. The study provides the first evidence of inhibitory phosphorylation of cPLA(2) in vivo by cAMP- and cGMP-dependent protein kinases. Inhibition of cPLA(2) activity and AA-induced Ca2+ influx partly account for the ability of cAMP-dependent protein kinase and/or cGMP-dependent protein kinase to cause relaxation. Their importance resides in their location at the inception of the Ca2+ signaling cascade.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Makhlouf, GM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, POB 980711, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028300, R37DK015564, R01DK015564] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-28300, DK-15564] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BITAR KN, 1986, J BIOL CHEM, V261, P6591; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; CHEN XL, 1992, AM J PHYSIOL, V263, pC468, DOI 10.1152/ajpcell.1992.263.2.C468; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DAMRON DS, 1993, J BIOL CHEM, V268, P27335; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Dennis EA, 1983, ENZYMES, P307; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; JIANG H, 1992, J BIOL CHEM, V267, P1015; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUEMMERLE JF, 1994, AM J PHYSIOL, V266, pC1421, DOI 10.1152/ajpcell.1994.266.5.C1421; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; Kuemmerle John F., 1998, Cell Biochemistry and Biophysics, V28, P31, DOI 10.1007/BF02738308; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIHLING L, 1993, CELL, V72, P269; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LINCOLN TM, 1990, AM J PHYSIOL, V258, pC399, DOI 10.1152/ajpcell.1990.258.3.C399; MCINTOSH JM, 1995, J BIOL CHEM, V270, P3518, DOI 10.1074/jbc.270.8.3518; MURTHY KS, 1993, AM J PHYSIOL, V264, pG967, DOI 10.1152/ajpgi.1993.264.5.G967; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; MURTHY KS, 1995, AM J PHYSIOL-GASTR L, V269, pG93, DOI 10.1152/ajpgi.1995.269.1.G93; MURTHY KS, 1995, AM J PHYSIOL-CELL PH, V268, pC171, DOI 10.1152/ajpcell.1995.268.1.C171; NEMONOFF RA, 1993, J BIOL CHEM, V268, P1960; QUI ZH, 1993, J BIOL CHEM, V268, P24506; QUI ZH, 1994, J BIOL CHEM, V269, P19480; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RASHATWAR SS, 1987, P NATL ACAD SCI USA, V84, P5685, DOI 10.1073/pnas.84.16.5685; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SZEWCZAK SM, 1990, AM J PHYSIOL, V259, pG239, DOI 10.1152/ajpgi.1990.259.2.G239; TACHADO SD, 1989, INVEST OPHTH VIS SCI, V30, P2232; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819	47	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34519	34526		10.1074/jbc.273.51.34519	http://dx.doi.org/10.1074/jbc.273.51.34519			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852121	hybrid			2022-12-25	WOS:000077542200087
J	Rodriguez, K; Talamantez, J; Huang, W; Reed, SH; Wang, Z; Chen, L; Feaver, WJ; Friedberg, EC; Tomkinson, AE				Rodriguez, K; Talamantez, J; Huang, W; Reed, SH; Wang, Z; Chen, L; Feaver, WJ; Friedberg, EC; Tomkinson, AE			Affinity purification and partial characterization of a yeast multiprotein complex for nucleotide excision repair using histidine-tagged Rad14 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR IIH; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCTS; FACTOR-B; REPLICATION; ENDONUCLEASE; TFIIH; RECOMBINATION	The nucleotide excision repair (NER) pathway of eukaryotes involves similar to 30 polypeptides. Reconstitution of this pathway with purified components is consistent with the sequential assembly of NER proteins at the DNA lesion. However, recent studies have suggested that NER proteins may be pre-assembled in a high molecular weight complex in the absence of DNA damage. To examine this model further, we have constructed a histidine-tagged version of the yeast DNA damage recognition protein Rad14. Affinity purification of this protein from yeast nuclear extracts resulted in the co-purification of Rad1, Rad7, Rad10, Rad16, Rad23, RPA, RPB1, and TFIIH proteins, whereas none of these proteins bound to the affinity resin in the absence of recombinant Rad14. Furthermore, many of the co-purifying proteins were present in approximately equimolar amounts. Co-elution of these proteins was also observed when the nuclear extract was fractionated by gel filtration, indicating that the NER proteins were associated in a complex with a molecular mass of >1000 kDa prior to affinity chromatography. The affinity purified NER complex catalyzed the incision of W-irradiated DNA in an ATP-dependent reaction, We conclude that active high molecular weight complexes of NER proteins exist in undamaged yeast cells.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, SW Med Ctr, Dept Pathol, Lab Mol Pathol, San Antonio, TX 78245 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Kentucky	Tomkinson, AE (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 7703 Floyd Curl Dr, San Antonio, TX 78245 USA.	tomkinson@uthscsa.edu	Huang, Wenya/G-9115-2011; Rodriguez, Karl A/F-2689-2012	Reed, Simon/0000-0002-4711-0560	NCI NIH HHS [CA-67978, CA-12428] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067978, R37CA012428, R55CA067978, R01CA012428] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; BANG DD, 1995, NUCLEIC ACIDS RES, V23, P1679, DOI 10.1093/nar/23.10.1679; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BARDWELL L, 1990, BIOCHEMISTRY-US, V29, P3119, DOI 10.1021/bi00464a031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DAVIES AA, 1995, J BIOL CHEM, V270, P24638, DOI 10.1074/jbc.270.42.24638; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P233; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; GUZDER SN, 1993, P NATL ACAD SCI USA, V90, P5433, DOI 10.1073/pnas.90.12.5433; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Guzder SN, 1997, J BIOL CHEM, V272, P21665, DOI 10.1074/jbc.272.35.21665; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; He ZG, 1997, NUCLEIC ACIDS RES, V25, P1136, DOI 10.1093/nar/25.6.1136; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JONES JS, 1990, NUCLEIC ACIDS RES, V18, P3281, DOI 10.1093/nar/18.11.3281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADURA K, 1990, NUCLEIC ACIDS RES, V18, P4737, DOI 10.1093/nar/18.16.4737; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; NAUMOVSKI L, 1988, MOL GEN GENET, V213, P400, DOI 10.1007/BF00339609; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; PEROZZI G, 1986, MOL CELL BIOL, V6, P1497, DOI 10.1128/MCB.6.5.1497; Reed SH, 1998, J BIOL CHEM, V273, P29481, DOI 10.1074/jbc.273.45.29481; ROBINSON GW, 1986, P NATL ACAD SCI USA, V83, P1842, DOI 10.1073/pnas.83.6.1842; Rodriguez K, 1996, J BIOL CHEM, V271, P20551, DOI 10.1074/jbc.271.34.20551; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SCHILD D, 1992, YEAST, V8, P385, DOI 10.1002/yea.320080506; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Sung P, 1996, J BIOL CHEM, V271, P10821, DOI 10.1074/jbc.271.18.10821; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; TOMKINSON AE, 1994, BIOCHEMISTRY-US, V33, P5305, DOI 10.1021/bi00183a038; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; You ZY, 1998, MOL CELL BIOL, V18, P2668, DOI 10.1128/MCB.18.5.2668	50	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34180	34189		10.1074/jbc.273.51.34180	http://dx.doi.org/10.1074/jbc.273.51.34180			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852079	hybrid			2022-12-25	WOS:000077542200045
J	Efanova, IB; Zaitsev, SV; Zhivotovsky, B; Kohler, M; Efendic, S; Orrenius, S; Berggren, PO				Efanova, IB; Zaitsev, SV; Zhivotovsky, B; Kohler, M; Efendic, S; Orrenius, S; Berggren, PO			Glucose and tolbutamide induce apoptosis in pancreatic beta-cells - A process dependent on intracellular Ca2+ concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-SECRETION; B-CELL; IN-VITRO; CALCIUM; ISLETS; TOXICITY; MECHANISMS; CULTURE; RELEASE; HYPERGLYCEMIA	High concentrations of glucose are considered to be toxic for the pancreatic beta-cell. However, the mechanisms underlying beta-cell dysfunction and resulting cell death are not fully characterized. In the present study we have demonstrated that incubation of pancreatic islets and beta-cells from ob/ob mice and Wistar rats with glucose induced a process of apoptotic beta-cell death, as shown by DNA laddering, TdT-mediated dUTP-biotin nick end-labeling (TUNEL) technique, and by using DNA-staining dye HOECHST 33342. The obtained results show that the percentage of apoptotic cells was dependent on glucose concentration, being minimal at 11 mM glucose. At a concentration of 100 mu M, aurintricarboxylic acid, an inhibitor of endonuclease activity, almost completely inhibited apoptosis triggered by 17 mM glucose. We have also shown that long term incubation with 100 mu M sulfonylurea, tolbutamide, triggered apoptosis in pancreatic beta-cells. The process of beta-cell death induced by high glucose concentration and tolbutamide were Ca2+-dependent, because introduction to the culture medium of 50 mu M D-600 or 200 mu M diazoxide, which blocked glucose- and tolbutamide-induced [Ca2+](i) increase, inhibited apoptosis. Thus, this study shows for the first time that high glucose concentrations and tolbutamide induce apoptosis in pancreatic beta-cells, and that this process is Ca2+-dependent.	Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden; Karolinska Inst, Div Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden; Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Moscow 119899, Russia	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Lomonosov Moscow State University	Berggren, PO (corresponding author), Karolinska Hosp, Karolinska Inst, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden.	perolof@enk.ks.se	Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482; Berggren, Per-Olof/0000-0001-8991-413X; Kohler, Martin/0000-0001-6487-4303				ANDERSSON A, 1978, DIABETOLOGIA, V14, P397, DOI 10.1007/BF01228134; ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BERRIDGE MJ, 1994, MOL CELL ENDOCRINOL, V98, P119, DOI 10.1016/0303-7207(94)90129-5; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; DAVALLI AM, 1993, TRANSPLANTATION, V56, P148, DOI 10.1097/00007890-199307000-00028; EFENDIC S, 1991, J INTERN MED, V229, P9; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HENQUIN JC, 1980, DIABETOLOGIA, V18, P151, DOI 10.1007/BF00290493; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; KAISER N, 1991, ENDOCRINOLOGY, V129, P2067, DOI 10.1210/endo-129-4-2067; KINDMARK H, 1992, FEBS LETT, V303, P85, DOI 10.1016/0014-5793(92)80483-W; LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; LING ZD, 1993, DIABETES, V42, P56, DOI 10.2337/diabetes.42.1.56; McConkey DJ, 1996, MOL ASPECTS MED, V17, P1, DOI 10.1016/0098-2997(95)00006-2; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; Moran A, 1997, J CLIN INVEST, V99, P534, DOI 10.1172/JCI119190; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; NILSSON T, 1987, BIOCHEM J, V248, P329, DOI 10.1042/bj2480329; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; Simonson DC, 1992, INT TXB DIABETES MEL, P635; UNGER RH, 1985, DIABETOLOGIA, V28, P119; VANHAEFTEN TW, 1993, NETH J MED, V42, P30; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042	33	302	311	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33501	33507		10.1074/jbc.273.50.33501	http://dx.doi.org/10.1074/jbc.273.50.33501			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837930	hybrid			2022-12-25	WOS:000077462500060
J	Grue, P; Grasser, A; Sehested, M; Jensen, PB; Uhse, A; Straub, T; Ness, W; Boege, F				Grue, P; Grasser, A; Sehested, M; Jensen, PB; Uhse, A; Straub, T; Ness, W; Boege, F			Essential mitotic functions of DNA topoisomerase II alpha are not adopted by topoisomerase II beta in human h69 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER CELLS; CHROMOSOME STRUCTURE; NIH-3T3 CELLS; PROTEIN; CYCLE; LOCALIZATION; INHIBITORS; CONDENSATION; SEGREGATION; RESISTANCE	Unique functions of mammalian DNA-topoisomerases II alpha and -beta are suggested by their distinct cellular distribution and chromatin binding at mitosis, Here, we studied H69-VP cells that, due to a homozygous mutation, express topoisomerase II alpha mostly outside the nucleus. In these cells topoisomerase II beta showed a normal nuclear localization, However, at mitosis it diffused away from the chromatin despite the nuclear lack of the alpha-isoform. 80% of these cells performed chromosome condensation and disjunction with the aid of cytosolic topoisomerase II alpha, which bound to the mitotic chromatin with low affinity. However, the genotype of these cells was highly polyploid indicating an increased rate of non-disjunction. In 20% of the mutant cells neither topoisomerase II isoform was bound to the mitotic chromatin, which appeared as an unstructured DNA spheroid unable to undergo disjunction and cytokinesis, Parental H69 cells expressing topoisomerase II alpha inside the nucleus exhibited high affinity binding of the enzyme to the mitotic chromatin, Their genotype was mostly diploid and stable. We conclude (i) that high affinity chromatin binding of topoisomerase II alpha is essential for chromosome condensation/disjunction and (ii) that topoisomerase II beta does not adopt these functions.	Univ Wurzburg, Med Poliklin, D-97070 Wurzburg, Germany; Univ Copenhagen, Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Finsen Ctr, DK-2100 Copenhagen, Denmark; Univ Wurzburg, Inst Anat, D-97070 Wurzburg, Germany	University of Wurzburg; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Wurzburg	Boege, F (corresponding author), Univ Wurzburg, Med Poliklin, Klin Str 6-8, D-97070 Wurzburg, Germany.		Boege, Fritz/H-3261-2019; Straub, Tobias/B-2023-2009	Straub, Tobias/0000-0002-0547-0453				Anderson H, 1996, CELL GROWTH DIFFER, V7, P83; Andreassen PR, 1997, J CELL BIOL, V136, P29, DOI 10.1083/jcb.136.1.29; BOEGE F, 1995, AM J PATHOL, V146, P1302; BROCK I, 1995, CANCER RES, V55, P459; Chaly N, 1996, CHROMOSOME RES, V4, P457, DOI 10.1007/BF02265053; CHEN M, 1995, CANCER RES, V55, P1509; CLARKE DJ, 1993, J CELL SCI, V105, P563; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; FELDHOFF PW, 1994, CANCER RES, V54, P756; GORBSKY GJ, 1994, CANCER RES, V54, P1042; HARKER WG, 1995, CANCER RES, V55, P4962; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; JENKINS JR, 1992, NUCLEIC ACIDS RES, V20, P5587, DOI 10.1093/nar/20.21.5587; JENSEN PB, 1993, BRIT J CANCER, V67, P311, DOI 10.1038/bjc.1993.58; Jensen S, 1996, MOL GEN GENET, V252, P79, DOI 10.1007/BF02173207; Kimura K, 1996, J BIOL CHEM, V271, P21439, DOI 10.1074/jbc.271.35.21439; KREIPE H, 1993, AM J PATHOL, V142, P3; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mirski SEL, 1997, EXP CELL RES, V237, P452, DOI 10.1006/excr.1997.3805; MIRSKI SEL, 1995, CANCER RES, V55, P2129; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; Rattner JB, 1996, J CELL BIOL, V134, P1097, DOI 10.1083/jcb.134.5.1097; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; SUMNER AT, 1995, EXP CELL RES, V217, P440, DOI 10.1006/excr.1995.1107; SUMNER AT, 1996, CHROMOSOME RES, V4, P4; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAAGEPERA S, 1994, MOL BIOL CELL, V5, P1243, DOI 10.1091/mbc.5.11.1243; Takano H., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P451; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Turley H, 1997, BRIT J CANCER, V75, P1340, DOI 10.1038/bjc.1997.227; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Wessel I, 1997, CANCER RES, V57, P4451; WOESSNER RD, 1990, CANCER RES, V50, P2901; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; YU Q, 1997, BIOCHEMISTRY-US, V36, P5968	37	109	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33660	33666		10.1074/jbc.273.50.33660	http://dx.doi.org/10.1074/jbc.273.50.33660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837951	hybrid			2022-12-25	WOS:000077462500081
J	Hu, MCT; Tang-Oxley, Q; Qiu, WR; Wang, YP; Mihindukulasuriya, KA; Afshar, R; Tan, TH				Hu, MCT; Tang-Oxley, Q; Qiu, WR; Wang, YP; Mihindukulasuriya, KA; Afshar, R; Tan, TH			Protein phosphatase X interacts with c-Rel and stimulates c-Rel/nuclear factor kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; KINASE; CASCADE	Nuclear factor kappa B (NF-kappa B) and the Rel family of proteins are pleiotropic transcription factors that play central roles in the immune and inflammatory responses, as well as apoptosis. Here, we identified a serine/threonine protein phosphatase X (PPX; also called protein phosphatase 4 (PP4)) that specifically associated with c-Rel, NF-kappa B p50, and RelA. The amino acid sequences of human and mouse PPX are 100% identical, and the PPX gene was mapped to human chromosome 16 p11.2. Overexpression of PPX, but not catalytically inactive PPX mutants, stimulated the DNA-binding activity of c-Rel and activated NF-kappa B-mediated transcription These results suggest that PPX is a novel activator of c-Rel/NF-kappa B.	Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Amgen; Baylor College of Medicine	Hu, MCT (corresponding author), Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA.		Tan, Tse-Hua/E-3983-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Mihindukulasuriya, Kathie/0000-0001-9372-3758	NIAID NIH HHS [T32-AI07483, R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007483, R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BREWIS ND, 1992, BIOCHIM BIOPHYS ACTA, V1171, P231, DOI 10.1016/0167-4781(92)90129-N; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; LAI JH, 1995, MOL CELL BIOL, V15, P4260; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347	14	63	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33561	33565		10.1074/jbc.273.50.33561	http://dx.doi.org/10.1074/jbc.273.50.33561			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837938	hybrid			2022-12-25	WOS:000077462500068
J	Underhill, DM; Chen, JM; Allen, LAH; Aderem, A				Underhill, DM; Chen, JM; Allen, LAH; Aderem, A			MacMARCKS is not essential for phagocytosis in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLASMA-MEMBRANE; MARCKS FAMILY; PHOSPHORYLATION; SUBSTRATE; CALMODULIN	MacMARCKS (also known as myristoylated alanine-rich protein kinase C substrate (MARCKS)-related protein) is a member of the MARCKS family of protein kinase C substrates, MacMARCKS contains within it a basic effector domain that contains the serine residues that are phosphorylated by protein kinase C, as well as a calcium/calmodulin and actin-binding site. Two previous reports demonstrated that a macrophage cell line expressing a mutant form of MacMARCKS that lacks the effector domain is defective in phagocytosis and cell adhesion (Zhu, Z., Bao, Z., and Li, J. (1995) J. Biol. Chem. 270, 17652-17655; Li, J., Zhu, Z., and Bao, Z. (1996) J. Biol. Chem. 271, 12985-12990), We report here that macrophages from MacMARCKS null mice phagocytose and spread normally, Thus, although MacMARCKS is recruited to phagosomes, it is not absolutely required for phagocytosis.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Bayer Corp, Div Pharmaceut, Berkeley, CA 94701 USA; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Inflamat Program, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Washington; University of Washington Seattle; Bayer AG; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Aderem, A (corresponding author), Univ Washington, Dept Immunol, H-574 Hlth Sci,Box 357650, Seattle, WA 98195 USA.		UNDERHILL, DAVID/ABE-2185-2021	Allen, Lee-Ann/0000-0001-8929-6968; Underhill, David/0000-0002-2989-658X	NIAID NIH HHS [AI25032, AI32972] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI025032, R01AI032972, R01AI025032] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Chang S, 1996, J BIOL CHEM, V271, P1174, DOI 10.1074/jbc.271.2.1174; Chen JM, 1996, P NATL ACAD SCI USA, V93, P6275, DOI 10.1073/pnas.93.13.6275; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Myat MM, 1998, CURR BIOL, V8, P677, DOI 10.1016/S0960-9822(98)70273-8; Schleiff E, 1996, J BIOL CHEM, V271, P26794, DOI 10.1074/jbc.271.43.26794; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; UNDERHILL DM, 1997, CYTOSKELETAL MEMBRAN, P157; Vergeres G, 1998, BIOCHEM J, V330, P5, DOI 10.1042/bj3300005; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	19	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33619	33623		10.1074/jbc.273.50.33619	http://dx.doi.org/10.1074/jbc.273.50.33619			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837946	hybrid			2022-12-25	WOS:000077462500076
J	Abrami, L; Fivaz, M; Decroly, E; Seidah, NG; Jean, F; Thomas, G; Leppla, SH; Buckley, JT; van der Goot, FG				Abrami, L; Fivaz, M; Decroly, E; Seidah, NG; Jean, F; Thomas, G; Leppla, SH; Buckley, JT; van der Goot, FG			The pore-forming toxin proaerolysin is activated by furin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE GLYCOPROTEIN GP160; PLANAR LIPID BILAYERS; PROTEOLYTIC ACTIVATION; PROTECTIVE ANTIGEN; MEMBRANE-CHANNEL; CELL-SURFACE; PROPROTEIN CONVERTASE; PSEUDOMONAS-EXOTOXIN; ERYTHROCYTE RECEPTOR; DIPHTHERIA-TOXIN	Aerolysin is secreted as an inactive dimeric precursor by the bacterium Aeromonas hydrophila. Proteolytic cleavage within a mobile loop near the C terminus of the protoxin is required for oligomerization and channel formation. This loop contains the sequence KVRRAR(432), which should be recognized by mammalian proprotein convertases such as furin, PACE4, and PC5/6A. Here we show that these three proteases cleave proaerolysin after Arg-432 in vitro, yielding active toxin. We also investigated the potential role of these enzymes in the in vivo activation of the protoxin. We found that Chinese hamster ovary cells were able to convert the protoxin to aerolysin in the absence of exogenous proteases and that activation did not require internalization of the toxin, The furin inhibitor alpha(1)-antitrypsin Portland reduced the rate of proaerolysin activation in vivo, and proaerolysin processing was even further reduced in furin-deficient FD11 Chinese hamster ovary cells, The cells were also less sensitive to proaerolysin than wild type cells; however, transient transfection of FD11 cells with the cDNA encoding furin conferred normal sensitivity to the protoxin. Together these findings argue that furin catalyzes the cell-surface activation of proaerolysin in vivo.	Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; NIDR, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Geneva; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Oregon Health & Science University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Victoria	van der Goot, FG (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva, Switzerland.		van der Goot, Gisou G/B-2279-2012; Seidah, Nabil/I-3596-2013	van der Goot, Gisou G/0000-0002-8522-274X; Seidah, Nabil/0000-0001-6503-9342; ABRAMI, laurence/0000-0002-1774-0481; DECROLY, Etienne/0000-0002-6046-024X; Fivaz, Marc/0000-0003-1003-7934	NICHD NIH HHS [HD30236] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD030236] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; ALTWEGG M, 1989, CRC CR REV MICROBIOL, V16, P253, DOI 10.3109/10408418909105478; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BUCKLEY JT, 1990, BIOCHEM CELL BIOL, V68, P221, DOI 10.1139/o90-029; Cabiaux V, 1997, BIOCHEMISTRY-US, V36, P15224, DOI 10.1021/bi971216p; CHAPMAN RE, 1994, EMBO J, V13, P2305, DOI 10.1002/j.1460-2075.1994.tb06514.x; CHIRON MF, 1994, J BIOL CHEM, V269, P18167; Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; DAILY OP, 1981, J CLIN MICROBIOL, V13, P769, DOI 10.1128/JCM.13.4.769-777.1981; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Decroly E, 1997, FEBS LETT, V405, P68, DOI 10.1016/S0014-5793(97)00156-7; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DELAMORENA ML, 1993, J INFECT DIS, V168, P215, DOI 10.1093/infdis/168.1.215; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GARRED O, 1995, J BIOL CHEM, V270, P10817; Gordon VM, 1997, INFECT IMMUN, V65, P4130, DOI 10.1128/IAI.65.10.4130-4134.1997; GORDON VM, 1995, INFECT IMMUN, V63, P82, DOI 10.1128/IAI.63.1.82-87.1995; Gordon VM, 1997, INFECT IMMUN, V65, P3370, DOI 10.1128/IAI.65.8.3370-3375.1997; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRUBER HJ, 1994, MOL MICROBIOL, V14, P1093, DOI 10.1111/j.1365-2958.1994.tb01341.x; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARDIE KR, 1995, MOL MICROBIOL, V17, P1035, DOI 10.1111/j.1365-2958.1995.mmi_17061035.x; HOWARD SP, 1985, J BACTERIOL, V163, P336, DOI 10.1128/JB.163.1.336-340.1985; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; Inocencio NM, 1997, J BIOL CHEM, V272, P1344, DOI 10.1074/jbc.272.2.1344; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; ISHIKAWA Y, 1992, NUCLEIC ACIDS RES, V20, P4367, DOI 10.1093/nar/20.16.4367; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; Kamidate T, 1997, ANAL BIOCHEM, V244, P62, DOI 10.1006/abio.1996.9832; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moniatte M, 1996, FEBS LETT, V384, P269, DOI 10.1016/0014-5793(96)00328-6; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; SCHMID SL, 1990, J CELL BIOL, V111, P2307, DOI 10.1083/jcb.111.6.2307; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1994, J BIOL CHEM, V269, P30496; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x	58	121	125	6	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32656	32661		10.1074/jbc.273.49.32656	http://dx.doi.org/10.1074/jbc.273.49.32656			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830006	hybrid			2022-12-25	WOS:000077329100045
J	Ding, L; Traer, E; McIntyre, TM; Zimmerman, GA; Prescott, SM				Ding, L; Traer, E; McIntyre, TM; Zimmerman, GA; Prescott, SM			The cloning and characterization of a novel human diacylglycerol kinase, DGK iota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; 3'-UNTRANSLATED REGION; LYSOPHOSPHATIDIC ACID; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-C; CDNA-CLONING; ZINC-FINGER; HAND MOTIFS; PROTEIN	Diacylglycerol (DAG) plays a central role in both the synthesis of complex lipids and in intracellular signaling; diacylglycerol kinase (DGR) catalyzes the phosphorylation of DAG, which yields phosphatidic acid. A family of DGKs has been identified in multicellular organisms over the past few years, but the physiological function(s) of this diversity is not clear. One clue has come from the Drosophila DGK2, rdgA, since mutations in this gene cause retinal degeneration. We isolated a novel DGK, which we designated DGK iota, from human retina and brain libraries. DGK iota contains two cysteine-rich repeats, a region similar to the phosphorylation site domain of myristoylated alanine-rich C kinase substrate, a conserved catalytic domain, and four ankyrin repeats at its C terminus. By primary structure, it is most similar to human DGK zeta and Drosophila rdgA, An >12-kilobase mRNA for DGK iota was detected only in brain and retina among the tissues examined. In cells transfected with the DGK iota cDNA, we detected an approximately 130-kDa protein by immunoassay, and activity assays demonstrated that it encodes a functional DAG kinase, The protein was found to be in both the cytoplasm and nucleus with the localization controlled by PRC isoforms alpha and gamma. The gene encoding DGK iota was localized to human chromosome 7q32.3-33, which is known to be a locus for an inherited form of retinitis pigmentosa. These results have defined a novel isoform of DAG kinase, which may have important cellular functions in the retina and brain.	Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Nora Eccles Treadwell Cardiovasc Res & Training I, Huntsman Canc Inst, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Prescott, SM (corresponding author), Univ Utah, Dept Med, Suite 4220,Bldg 533, Salt Lake City, UT 84112 USA.				NATIONAL CANCER INSTITUTE [R01CA059548, P30CA042014] Funding Source: NIH RePORTER; NCI NIH HHS [CA59548, CA42014] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED S, 1993, J BIOL CHEM, V268, P10709; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Cao Y, 1998, GENOMICS, V49, P327, DOI 10.1006/geno.1998.5268; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; FU T, 1992, FEBS LETT, V307, P301, DOI 10.1016/0014-5793(92)80700-Q; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Houssa B, 1997, J BIOL CHEM, V272, P10422; INOUE H, 1989, J BIOL CHEM, V264, P5996; KAI M, 1994, J BIOL CHEM, V269, P18492; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; Masai I, 1997, J NEUROBIOL, V32, P695, DOI 10.1002/(SICI)1097-4695(19970620)32:7<695::AID-NEU5>3.0.CO;2-#; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SCHWARTZ ML, 1995, J BIOL CHEM, V270, P26364, DOI 10.1074/jbc.270.44.26364; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Tanguay RL, 1996, MOL CELL BIOL, V16, P146; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; VANCORVEN EJ, 1992, BIOCHEM J, V281, P163, DOI 10.1042/bj2810163; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; Yamada K, 1997, BIOCHEM J, V321, P59, DOI 10.1042/bj3210059	37	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32746	32752		10.1074/jbc.273.49.32746	http://dx.doi.org/10.1074/jbc.273.49.32746			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830018	hybrid			2022-12-25	WOS:000077329100057
J	Frank, G; Qiu, JZ; Somsouk, M; Weng, YH; Somsouk, L; Nolan, JP; Shen, BH				Frank, G; Qiu, JZ; Somsouk, M; Weng, YH; Somsouk, L; Nolan, JP; Shen, BH			Partial functional deficiency of E160D flap endonuclease-1 mutant in vitro and in vivo is due to defective cleavage of DNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; POLYMERASE-I; 5'-NUCLEASE DOMAIN; REPLICATION FORK; ESCHERICHIA-COLI; MU-TRANSPOSASE; 3' EXONUCLEASE; ACTIVE-SITE; RNASE-H	To assess the roles of the active site residues Glu(160) and Asp(181) of human FEN-1 nuclease in binding and catalysis of the flap DNA substrate and in vivo biological processes of DNA damage and repair, five different amino acids were replaced at each site through site-directed mutagenesis of the FEN-1 gene. The mutants were then expressed in Escherichia coli and purified using a His-tag. Even though the mutants bind to the flap DNA to different degrees, most of the mutants lost flap nuclease activity with the exception of an E160D mutant. This mutant retained wild type-like binding ability, specificity, and partial catalytic activity. Detailed steady state and pre-steady state kinetic analysis revealed that the functional deficiency of this mutant was due to retardation of the endonucleolytic cleavage. When the mutant enzyme E160D was expressed in yeast, it partially complements the biological functions of the homologous yeast gene, RAD27, and reverses the hyper-temperature lethality and hypersensitivity to methyl methanesulfonate, in a manner corresponding to the in vitro activity.	City Hope Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; Los Alamos Natl Lab, Div Life Sci, Los Alamos, NM 87545 USA	City of Hope; City of Hope; Beckman Research Institute of City of Hope; United States Department of Energy (DOE); Los Alamos National Laboratory	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Cell & Tumor Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	bshen@coh.org	Sy, Lina/AFM-9458-2022	Sy, Lina/0000-0003-2762-9266; Shen, Binghui/0000-0002-4408-407X	NATIONAL CANCER INSTITUTE [R29CA073764, R01CA073764] Funding Source: NIH RePORTER; NCI NIH HHS [CA73764-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; BUDD ME, 1995, J BIOL CHEM, V270, P26766, DOI 10.1074/jbc.270.45.26766; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Curley JF, 1997, J AM CHEM SOC, V119, P12691, DOI 10.1021/ja972014j; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kimura S, 1997, NUCLEIC ACIDS RES, V25, P4970, DOI 10.1093/nar/25.24.4970; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Mizrahi V, 1996, NUCLEIC ACIDS RES, V24, P4845, DOI 10.1093/nar/24.24.4845; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; ROBINS P, 1994, J BIOL CHEM, V269, P28535; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; WAGA S, 1994, J BIOL CHEM, V269, P10923; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Xu Y, 1997, J MOL BIOL, V268, P284, DOI 10.1006/jmbi.1997.0967; Zhu FX, 1997, BIOCHEMISTRY-US, V36, P5947, DOI 10.1021/bi962889v	52	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33064	33072		10.1074/jbc.273.49.33064	http://dx.doi.org/10.1074/jbc.273.49.33064			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830061	hybrid			2022-12-25	WOS:000077329100100
J	Georgellis, D; Kwon, O; De Wulf, P; Lin, ECC				Georgellis, D; Kwon, O; De Wulf, P; Lin, ECC			Signal decay through a reverse phosphorelay in the arc two-component signal transduction system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; PROTEIN ASPARTATE PHOSPHATASES; ENTEROCOCCUS-FAECIUM BM4147; ESCHERICHIA-COLI K-12; MAP KINASE CASCADE; BACILLUS-SUBTILIS; RESPONSE REGULATOR; SENSOR PROTEIN; HISTIDINE KINASE; MULTISTEP PHOSPHORELAY	Escherichia coli senses and signals anoxic or low redox conditions in its growth environment by the Are two-component system. Under those conditions, the tripartite sensor kinase ArcB undergoes autophosphorylation at the expense of ATP and subsequently transphosphorylates its cognate response regulator ArcA through a His --> Asp --> His --> Asp phosphorelay pathway. In this study we used various combinations of wild-type and mutant ArcB domains to analyze in vitro the pathway for signal decay. The results indicate that ArcA-P dephosphorylation does not occur by direct hydrolysis but by transfer of the phosphoryl group to the secondary transmitter and subsequently to the receiver domain of ArcB. This reverse phosphorelay involves both the conserved His-717 of the secondary transmitter domain and the conserved Asp-576 of the receiver domain of ArcB but not the conserved His-292 of its primary transmitter domain. This novel pathway for signal decay mag generally apply to signal transduction systems with tripartite sensor kinases.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Lin, ECC (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.		Georgellis, Dimitris/U-2517-2017	Georgellis, Dimitris/0000-0002-6114-795X; De Wulf, Peter/0000-0001-9772-5881	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030693, R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40993, GM30693] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; Alex LA, 1996, P NATL ACAD SCI USA, V93, P3416, DOI 10.1073/pnas.93.8.3416; ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; Bren A, 1996, P NATL ACAD SCI USA, V93, P10090, DOI 10.1073/pnas.93.19.10090; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; Chang C, 1996, TRENDS BIOCHEM SCI, V21, P129, DOI 10.1016/0968-0004(96)10019-0; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; DAHL MK, 1992, J BIOL CHEM, V267, P14509; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; Haldimann A, 1997, J BACTERIOL, V179, P5903, DOI 10.1128/jb.179.18.5903-5913.1997; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; Hoch JA, 1995, 2 COMPONENT SIGNAL T; HRABAK EM, 1992, J BACTERIOL, V174, P3011, DOI 10.1128/JB.174.9.3011-3020.1992; Hsing WH, 1997, J BACTERIOL, V179, P3729, DOI 10.1128/jb.179.11.3729-3735.1997; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1992, J BACTERIOL, V174, P3972, DOI 10.1128/jb.174.12.3972-3980.1992; IUCHI S, 1993, J BIOL CHEM, V268, P23972; IUCHI S, 1990, MOL MICROBIOL, V4, P715, DOI 10.1111/j.1365-2958.1990.tb00642.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; IUCHI S, 1995, 2 COMPONENT SIGNAL T, P223; Jourlin C, 1996, MOL MICROBIOL, V20, P1297, DOI 10.1111/j.1365-2958.1996.tb02648.x; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Kato M, 1997, CELL, V88, P717, DOI 10.1016/S0092-8674(00)81914-5; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KLENK AP, 1997, NATURE, V290, P364; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lin ECC, 1996, ESCHERICHIA COLI SAL, P1526; LOIS AF, 1993, J BIOL CHEM, V268, P4370; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Magasanik Boris, 1996, P281; Matsushika A, 1998, J BACTERIOL, V180, P3973, DOI 10.1128/JB.180.15.3973-3977.1998; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; Ogino T, 1998, MOL MICROBIOL, V27, P573, DOI 10.1046/j.1365-2958.1998.00703.x; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARIKINSON JS, 1995, 2 COMPONENT SIGNAL T, P9; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; Perego M, 1997, P NATL ACAD SCI USA, V94, P8612, DOI 10.1073/pnas.94.16.8612; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Perraud AL, 1998, MOL MICROBIOL, V27, P875, DOI 10.1046/j.1365-2958.1998.00716.x; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Raivio TL, 1997, J BACTERIOL, V179, P7724, DOI 10.1128/jb.179.24.7724-7733.1997; RUDOLPH J, 1995, EMBO J, V14, P667, DOI 10.1002/j.1460-2075.1995.tb07045.x; SANNA MG, 1995, MOL MICROBIOL, V15, P1069, DOI 10.1111/j.1365-2958.1995.tb02282.x; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; Skarphol K, 1997, J BACTERIOL, V179, P1413, DOI 10.1128/jb.179.4.1413-1416.1997; STEVENS AM, 1992, J BACTERIOL, V174, P2935, DOI 10.1128/JB.174.9.2935-2942.1992; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; TANAKA T, 1991, J BACTERIOL, V173, P5507, DOI 10.1128/jb.173.17.5507-5515.1991; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; Uhl MA, 1996, J BIOL CHEM, V271, P33176, DOI 10.1074/jbc.271.52.33176; UTSUMI R, 1994, GENE, V140, P73, DOI 10.1016/0378-1119(94)90733-1; WALKER MS, 1993, J BIOL CHEM, V268, P8391; WRIGHT GD, 1993, BIOCHEMISTRY-US, V32, P5057, DOI 10.1021/bi00070a013	64	111	115	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32864	32869		10.1074/jbc.273.49.32864	http://dx.doi.org/10.1074/jbc.273.49.32864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830034	Green Published, hybrid			2022-12-25	WOS:000077329100073
J	Price, ER; Horstmann, MA; Wells, AG; Weilbaecher, KN; Takemoto, CM; Landis, MW; Fisher, DE				Price, ER; Horstmann, MA; Wells, AG; Weilbaecher, KN; Takemoto, CM; Landis, MW; Fisher, DE			alpha-melanocyte-stimulating hormone signaling regulates expression of microphthalmia, a gene deficient in Waardenburg syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; TYROSINASE GENE; HUMAN HOMOLOG; FACTOR CREB; CYCLIC-AMP; PROTEIN; CAMP; MUTATIONS; KINASE; CELLS	The pituitary peptide alpha-melanocyte-stimulating hormone (alpha-MSH) stimulates melanocytes to up-regulate cAMP, but the downstream targets of cAMP are not well understood mechanistically. One consequence of alpha-MSH stimulation is increased melanization attributable to induction of pigmentation enzymes, including tyrosinase, which catalyzes a rate-limiting step in melanin synthesis. The tyrosinase promoter is a principle target of the melanocyte transcription factor Microphthalmia (Mi), a factor for which deficiency in humans causes Waardenburg syndrome II. We show here that both alpha-MSH and forskolin, a drug that increases cAMP, stimulate a rapid increase in Mi mRNA and protein levels in both melanoma cell lines and primary melanocytes. This up-regulation requires a cAMP-responsive element within the Mi promoter, and the pathway leading to Mi stimulation is subject to tight homeostatic regulation. Although cAMP signaling is ubiquitous, the Mi promoter was seen to be cAMP-responsive in melanocytes but not in non-melanocytes. Moreover, dominant negative interference with Mi impeded successful alpha-MSH stimulation of tyrosinase, The regulation of Mi expression via alpha-MSH thus provides a direct mechanistic link to pigmentation. In addition, because the human melanocyte and deafness condition Waardenburg syndrome is sometimes caused by haploinsufficiency of Mi, its modulation by alpha-MSH suggests therapeutic strategies targeted at up-regulating the remaining wild type Mi allele.	Dana Farber Canc Res Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Fisher, DE (corresponding author), Dana Farber Canc Res Inst, Dept Pediat Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.		Takemoto, Clifford M/Y-7558-2018					ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; Ferguson CA, 1997, PIGM CELL RES, V10, P127, DOI 10.1111/j.1600-0749.1997.tb00474.x; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LERNER AB, 1993, ANN NY ACAD SCI, V680, P1, DOI 10.1111/j.1749-6632.1993.tb19670.x; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Price ER, 1998, J BIOL CHEM, V273, P17983, DOI 10.1074/jbc.273.29.17983; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Tachibana M, 1997, PIGM CELL RES, V10, P25, DOI 10.1111/j.1600-0749.1997.tb00462.x; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; URABE K, 1993, PIGM CELL RES, V6, P186, DOI 10.1111/j.1600-0749.1993.tb00601.x; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; ZAKUT R, 1993, ONCOGENE, V8, P2221	38	187	193	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33042	33047		10.1074/jbc.273.49.33042	http://dx.doi.org/10.1074/jbc.273.49.33042			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830058	hybrid			2022-12-25	WOS:000077329100097
J	Steiner, H; Capell, A; Pesold, B; Citron, M; Kloetzel, PM; Selkoe, DJ; Romig, H; Mendla, K; Haass, C				Steiner, H; Capell, A; Pesold, B; Citron, M; Kloetzel, PM; Selkoe, DJ; Romig, H; Mendla, K; Haass, C			Expression of Alzheimer's disease-associated presenilin-1 is controlled by proteolytic degradation and complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMYLOID PRECURSOR; IN-VIVO; ENDOPLASMIC-RETICULUM; MUTANT PRESENILIN-1; MISSENSE MUTATIONS; TRANSFECTED CELLS; PROTEIN-PRECURSOR; TRANSGENIC MICE; PROTEASOME; MEMBRANE	Numerous mutations causing early onset Alzheimer's disease have been identified in the presenilin (PS) genes, particularly the PSI gene. Like the mutations identified within the beta-amyloid precursor protein gene, PS mutations cause the increased generation of a highly neurotoxic variant of amyloid beta-peptide. PS proteins are proteolytically processed to an N-terminal similar to 30-kDa (NTF) and a C-terminal similar to 20-kDa fragment (CTF20) that form a heterodimeric complex. We demonstrate that this complex is resistant to proteolytic degradation, whereas the full-length precursor is rapidly degraded. Degradation of the PS1 holoprotein is sensitive to inhibitors of the proteasome. Formation of a heterodimeric complex is required for the stability of both PS1 fragments, since fragments that do not co-immunoprecipitate with the PS complex are rapidly degraded by the proteasome. Mutant PS fragments not incorporated into the heterodimeric complex lose their pathological activity in abnormal amyloid beta-peptide generation even after inhibition of their proteolytic degradation. The PS1 heterodimeric complex can be attacked by proteinases of the caspase superfamily that generate an similar to 10-kDa proteolytic fragment (CTP10) from CTF20. CTF10 is rapidly degraded most Likely by a calpain-like cysteine proteinase. From these data we conclude that PS1 metabolism is highly controlled by multiple proteolytic activities indicating that subtle changes in fragment generation/degradation might be important for Alzheimer's disease-associated pathology.	Cent Inst Mental Hlth, Dept Biol Mol, D-68159 Mannheim, Germany; Amgen Inc, Thousand Oaks, CA 91320 USA; Humboldt Univ, Fac Med Charite, Ctr Med Expt, Inst Biochem, D-10117 Berlin, Germany; Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Boehringer Ingelheim KG, Dept Biol Res, D-55126 Ingelheim, Germany	Central Institute of Mental Health; Amgen; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Harvard Medical School; Boehringer Ingelheim	Haass, C (corresponding author), Cent Inst Mental Hlth, Dept Biol Mol, J5, D-68159 Mannheim, Germany.							ABERLE H, 1997, EMBO J, V16, P3779; Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brockhaus M, 1998, NEUROREPORT, V9, P1481, DOI 10.1097/00001756-199805110-00043; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Bush KT, 1997, J BIOL CHEM, V272, P9086; Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Grunberg J, 1998, NEUROREPORT, V9, P3293; Grunberg J, 1998, BIOCHEMISTRY-US, V37, P2263, DOI 10.1021/bi972106l; GRUNBERG J, 1997, ALZHEIMERS RES, V3, P253; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARDING CV, 1995, J IMMUNOL, V155, P1767; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee MK, 1997, NAT MED, V3, P756, DOI 10.1038/nm0797-756; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Marambaud P, 1998, MOL MED, V4, P147, DOI 10.1007/BF03401912; Mercken M, 1996, FEBS LETT, V389, P297, DOI 10.1016/0014-5793(96)00608-4; Murayama O, 1997, NEUROSCI LETT, V229, P61, DOI 10.1016/S0304-3940(97)00417-5; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREZTUR, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIMAN R, 1990, J NEUROSCI, V10, P2400; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Tysoe C, 1998, AM J HUM GENET, V62, P70, DOI 10.1086/301672; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	65	174	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32322	32331		10.1074/jbc.273.48.32322	http://dx.doi.org/10.1074/jbc.273.48.32322			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822712	hybrid			2022-12-25	WOS:000077207000094
J	Strobel, T; Tai, YT; Korsmeyer, S; Cannistra, SA				Strobel, T; Tai, YT; Korsmeyer, S; Cannistra, SA			BAD partly reverses paclitaxel resistance in human ovarian cancer cells	ONCOGENE			English	Article						apoptosis; BAD; drug resistance; paclitaxel; ovarian cancer	INDUCED APOPTOSIS; IN-VIVO; BCL-2 PHOSPHORYLATION; NEUROBLASTOMA-CELLS; MYELOID-LEUKEMIA; BCL-X(L); DEATH; TAXOL; EXPRESSION; OVEREXPRESSION	Although paclitaxel is an important chemotherapy agent for the treatment of patients with epithelial ovarian cancer, its utility is significantly limited by the frequent development of drug resistance, Recent evidence suggests that resistance to chemotherapy may be partly related to defects in the apoptotic pathway. In this study me have investigated whether enhancement of apoptotic pathway function through stable expression of the BAD protein is capable of sensitizing human epithelial ovarian cancer cells to the effects of chemotherapy. Expression of HA-BAD in sis separate clonal transfectants from two different ovarian cancer cell lines was found to significantly enhance the cytotoxic effects of paclitaxel, vincristine, and, to a lesser extent, etoposide, Enhancement of paclitaxel-induced apoptosis in HA-BAD-expressing clones was demonstrated by trypan blue exclusion, clonogenic cell assay, and flow cytometric evaluation. Importantly, this effect was associated with binding of HA-BAD to BCL-x(L) and concomitant disruption of BAX:BCL-x(L) interaction. Taken together, these data suggest that the development of small molecules which mimic the effects of BAD may represent a new class of drugs capable of preventing or reversing resistance to chemotherapy agents such as paclitaxel.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Div Mol Oncol, St Louis, MO 63110 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Washington University (WUSTL)	Cannistra, SA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA60670] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060670] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, BLOOD, V81, P2215; Blagosklonny MV, 1996, CANCER RES, V56, P1851; CABRAL FR, 1983, J CELL BIOL, V97, P22, DOI 10.1083/jcb.97.1.22; CANNISTRA SA, 1985, BLOOD, V65, P414; CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DOLE MG, 1995, CANCER RES, V55, P2576; Dole MG, 1996, CANCER RES, V56, P5734; Dumontet C, 1996, CANCER RES, V56, P1091; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Haber M, 1995, J BIOL CHEM, V270, P31269, DOI 10.1074/jbc.270.52.31269; Haldar S, 1996, CANCER RES, V56, P1253; Horwitz S B, 1994, Ann Oncol, V5 Suppl 6, pS3; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1997, CANCER RES, V57, P1109; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; IZQUIERDO MA, 1995, JNCI-J NATL CANCER I, V87, P1230; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Strobel T, 1997, CANCER RES, V57, P1228; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Strobel T, 1997, ONCOGENE, V14, P2753, DOI 10.1038/sj.onc.1201132; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	37	32	34	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2419	2427		10.1038/sj.onc.1202180	http://dx.doi.org/10.1038/sj.onc.1202180			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824152				2022-12-25	WOS:000076927300001
J	Shiman, R; Gray, DW				Shiman, R; Gray, DW			Formation and fate of tyrosine - Intracellular partitioning of newly synthesized tyrosine in mammalian liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE-HYDROXYLASE ACTIVITY; AMINO-ACID-TRANSPORT; PERFUSED-RAT-LIVER; METABOLISM INVIVO; CELLS; PROTEIN; TETRAHYDROBIOPTERIN; AMINOTRANSFERASE; HEPATOCYTES; SYSTEM	Tyrosine in an hepatocyte is transported from the plasma, synthesized from phenylalanine, or released during protein turnover. Effects of phenylalanine and tyrosine on the formation and fate (partitioning) of tyrosine from the different sources were examined in primary rat hepatocyte cultures. Rates of tyrosine degradation, transport, incorporation into and release from protein, and synthesis from phenylalanine were measured as well as the intracellular dilution of labeled tyrosine and phenylalanine incorporated into protein. We found tyrosine had little effect on phenylalanine hydroxylation over a wide range of conditions, that transported tyrosine and tyrosine from phenylalanine are in different metabolic pools, and that there appears to be channeling of newly synthesized tyrosine during degradation. In addition, under some conditions, intracellular partitioning of tyrosine is determined by tyrosine concentration. Specifically, if extracellular tyrosine is low and phenylalanine is at a normal plasma level, tyrosine use in protein synthesis takes precedence over tyrosine degradation or export. It is proposed that the mechanism controlling this is kinetic, based on relative rates of tyrosyl-tRNA formation and tyrosine degradation and export. A quantitative model of tyrosine and phenylalanine in-flow and out-flow in hepatocytes is given, incorporating tyrosine synthesis, degradation, plasma membrane transport, and tyrosine and phenylalanine use and release during protein turnover.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol H171, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Shiman, R (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol H171, Hershey, PA 17033 USA.							ANDERSON LE, 1973, ANAL BIOCHEM, V51, P173, DOI 10.1016/0003-2697(73)90465-X; BAKER RE, 1979, J BIOL CHEM, V254, P9633; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BERRY MN, 1991, ISOLATED HEPATOCYTES, V21, P126; CARR FPA, 1981, BIOCHEM J, V198, P655, DOI 10.1042/bj1980655; CHEESEMAN CI, 1991, PROG BIOPHYS MOL BIO, V55, P71, DOI 10.1016/0079-6107(91)90001-9; DEAK F, 1978, BIOCHIM BIOPHYS ACTA, V526, P626, DOI 10.1016/0005-2744(78)90153-5; DIAMONDSTONE TI, 1966, ANAL BIOCHEM, V16, P395, DOI 10.1016/0003-2697(66)90220-X; DICKSON AJ, 1981, FEBS LETT, V127, P28, DOI 10.1016/0014-5793(81)80333-X; DUCH DS, 1991, J NUTR BIOCHEM, V2, P411, DOI 10.1016/0955-2863(91)90110-Q; FLAIM KE, 1982, J BIOL CHEM, V257, P2932; Granner D. K., 1970, METHODS ENZYMOL    A, V17, P633; GROENEWALD JV, 1984, INT J BIOCHEM, V16, P1, DOI 10.1016/0020-711X(84)90045-4; HALEY CJ, 1978, ARCH BIOCHEM BIOPHYS, V189, P524, DOI 10.1016/0003-9861(78)90242-4; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HSIEH MC, 1979, J EXP ZOOL, V208, P161, DOI 10.1002/jez.1402080204; HUTSON SM, 1987, AM J PHYSIOL, V252, pE291, DOI 10.1152/ajpendo.1987.252.3.E291; Kappock TJ, 1996, CHEM REV, V96, P2659, DOI 10.1021/cr9402034; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; KILBERG MS, 1985, CURR TOP CELL REGUL, V25, P133; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MILLER MR, 1975, J BIOL CHEM, V250, P1132; Mitchell G, 1995, METABOLIC MOL BASES, P1077; MITNAUL LJ, 1995, P NATL ACAD SCI USA, V92, P885, DOI 10.1073/pnas.92.3.885; MOLDAWER LL, 1983, BIOCHEM J, V210, P811, DOI 10.1042/bj2100811; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; RUNDGREN M, 1977, J BIOL CHEM, V252, P5094; SALTER M, 1986, BIOCHEM J, V233, P499, DOI 10.1042/bj2330499; SALTER M, 1986, BIOCHEM J, V234, P635, DOI 10.1042/bj2340635; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; SHIMAN R, 1985, CHEM BIOCH PTERINS, V2, P179; SMITH JD, 1960, VIROLOGY, V12, P185, DOI 10.1016/0042-6822(60)90193-8; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; TOLMAN EL, 1973, J BIOL CHEM, V248, P4552; WARD WF, 1978, J BIOL CHEM, V253, P3581; WILT S, 1993, THESIS PENNSYLVANIA; XIA T, 1994, J BIOL CHEM, V269, P24657	39	59	59	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34760	34769		10.1074/jbc.273.52.34760	http://dx.doi.org/10.1074/jbc.273.52.34760			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857000	hybrid			2022-12-25	WOS:000077719700018
J	Skerjanc, IS; Petropoulos, H; Ridgeway, AG; Wilton, S				Skerjanc, IS; Petropoulos, H; Ridgeway, AG; Wilton, S			Myocyte enhancer factor 2C and Nkx2-5 up-regulate each other's expression and initiate cardiomyogenesis in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR MEF2C; MYOSIN HEAVY-CHAIN; BONE MORPHOGENETIC PROTEINS; MUSCLE GENE-EXPRESSION; HEART TUBE FORMATION; HELIX-LOOP-HELIX; CARDIAC-MUSCLE; MADS-BOX; VENTRAL MORPHOGENESIS	The Nkx2-5 homeodomain protein plays a key role in cardiomyogenesis. Ectopic expression in frog and zebrafish embryos results in an enlarged myocardium; however, expression of Nkx2-5 in fibroblasts was not able to trigger the development of beating cardiac muscle. In order to examine the ability of Nkx2-5 to modulate endogenous cardiac specific gene expression in cells undergoing early stages of differentiation, P19 cell Lines overexpressing Nkx2-5 were differentiated in the absence of Me2SO. Nkx2-5 expression induced cardiomyogenesis in these cultures aggregated without Me2SO. During differentiation into cardiac muscle, Nkx2-5 expression resulted in the activation of myocyte enhancer factor 2C (MEF2C), but not MEF2A, -B, or -D. In order to compare the abilities of Nkx2-5 and MEF2C to induce cellular differentiation, P19 cells overexpressing MEF2C were aggregated in the absence of Me2SO. Similar to Nkx2-5, MEF2C expression initiated cardiomyogenesis, resulting in the up-regulation of Brachyury T, bone morphogenetic protein-4, Nkx2-5, GATA-4, cardiac cu-actin, and myosin heavy chain expression. These findings indicate the presence of a positive regulatory network between Nkx2-5 and MEF2C and show that both factors can direct early stages of cell differentiation into a cardiomyogenic pathway.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.		Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Black BL, 1996, J BIOL CHEM, V271, P26659, DOI 10.1074/jbc.271.43.26659; BODMER R, 1993, DEVELOPMENT, V118, P719; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen JN, 1996, DEVELOPMENT, V122, P3809; Cleaver OB, 1996, DEVELOPMENT, V122, P3549; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; Evans T, 1997, TRENDS CARDIOVAS MED, V7, P75, DOI 10.1016/S1050-1738(97)00010-8; Fishman MC, 1997, CELL, V91, P153, DOI 10.1016/S0092-8674(00)80397-9; Fishman MC, 1997, DEVELOPMENT, V124, P2099; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HIDAKA K, 1995, BIOCHEM BIOPH RES CO, V213, P555, DOI 10.1006/bbrc.1995.2167; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Huang WY, 1998, BIOCHEM J, V330, P871, DOI 10.1042/bj3300871; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P529, DOI 10.1007/BF02255843; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Mohun T, 1997, CURR OPIN GENET DEV, V7, P628, DOI 10.1016/S0959-437X(97)80010-X; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Papaioannou VE, 1997, TRENDS GENET, V13, P212, DOI 10.1016/S0168-9525(97)01144-X; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Schulz RA, 1996, ONCOGENE, V12, P1827; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; SKERJANC IS, 1994, MOL CELL BIOL, V1464, P8451; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zou YM, 1997, DEVELOPMENT, V124, P793	75	115	131	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34904	34910		10.1074/jbc.273.52.34904	http://dx.doi.org/10.1074/jbc.273.52.34904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857019	hybrid			2022-12-25	WOS:000077719700037
J	Alvarez-Dominguez, C; Stahl, PD				Alvarez-Dominguez, C; Stahl, PD			Interferon-gamma selectively induces Rab5a synthesis and processing in mononuclear cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LISTERIA-MONOCYTOGENES; MEMBRANE ASSOCIATION; GDP/GTP EXCHANGE; GTPASE; ENDOCYTOSIS; ENDOSOME; FUSION; ACTIVATION; PHAGOSOME; RECEPTOR	Macrophage activation by interferon (IFN)-gamma is characterized by enhanced phagocytosis and killing of internalized pathogens. We studied the effects of IFN-gamma on Rab5a, a GTPase involved in both endocytosis and phagocytosis. IFN-gamma induced the synthesis of Rab5a in mononuclear cells as detected by immunoprecipitation and by Western blotting. Rab5a messenger RNA levels were also increased. Elevated protein expression was detected as early as 6 h following IFN-gamma and was maximal at 24 h. Following IFN-gamma, membrane association of Rab5a:GTP was substantially increased. Rab5b and Rab5c, as well as Rab7 and Rab11, Rab GTPases localized in the endosomal-lysosomal pathway, were unaffected by IFN-gamma. Moreover, Rab5a expression in non-macrophages was unaltered by IFN-gamma.. Rab5a is at prenylated protein, and newly synthesized Rab5a was rapidly processed following IFN-gamma. However, elevated geranylgeranylation was not Rab5a-specific since all the Rab5 isoforms were more rapidly prenylated in vitro using cytosol from IFN-gamma-treated cells. Last, guanine nucleotide exchange on Rab5a was elevated about 3-fold in the presence of cytosol from IFN-gamma-treated cells. The selective effect of IFN-gamma on Rab5a, synthesis, processing, and nucleotide exchange suggests that Rab isoforms have closely associated but not identical functions and that selective enhancement of membrane trafficking may play a key role in intracellular killing.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	pstahl@cellbio.wustl.edu	Stahl, Philip/D-6315-2012; Alvarez-Dominguez, Carmen/J-4675-2014	Alvarez-Dominguez, Carmen/0000-0002-4585-6959				AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; AlvarezDominguez C, 1997, J CELL SCI, V110, P731; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; HIGGINBOTHAM JN, 1992, CLIN EXP IMMUNOL, V88, P492; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; KIELIAN MC, 1981, J EXP MED, V153, P1015, DOI 10.1084/jem.153.4.1015; LI GP, 1993, ARCH BIOCHEM BIOPHYS, V304, P471, DOI 10.1006/abbi.1993.1377; Mukhopadhyay A, 1997, J CELL BIOL, V136, P1227, DOI 10.1083/jcb.136.6.1227; PETER M, 1992, J CELL SCI, V102, P857; Pontow SE, 1996, J BIOL CHEM, V271, P30736, DOI 10.1074/jbc.271.48.30736; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SCHWAN WR, 1994, P NATL ACAD SCI USA, V91, P6428, DOI 10.1073/pnas.91.14.6428; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	21	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33901	33904		10.1074/jbc.273.51.33901	http://dx.doi.org/10.1074/jbc.273.51.33901			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852039	hybrid			2022-12-25	WOS:000077542200005
J	Bar Shimon, M; Goldshleger, R; Karlish, SJD				Bar Shimon, M; Goldshleger, R; Karlish, SJD			Specific Cu2+-catalyzed oxidative cleavage of Na,K-ATPase at the extracellular surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; P-TYPE ATPASES; BETA-SUBUNIT; ALPHA-SUBUNIT; AMINO-ACIDS; CATION OCCLUSION; DISULFIDE BONDS; BINDING DOMAIN; NA/K-ATPASE; TOPOLOGY	This paper describes specific Cu2+-catalyzed oxidative cleavage of alpha and beta subunits of Na,K-ATPase at the extracellular surface. Incubation of right side-out renal microsomal vesicles with Cu2+ ions, ascorbate, and H2O2 produces two major cleavages of the alpha subunit within the extracellular loop between trans-membrane segments M7 and M8 and L7/8. Minor cleavages are also detected in loops L9/10 and L5/6. In the beta subunit two cleavages are detected, one before the first S-S bridge and the other between the second and third S-S bridges. Na,K-ATPase and Rb+ occlusion are inactivated after incubation with Cu2+/ascorbate/H2O2. These observations are suggestive of a site-specific mechanism involving cleavage of peptide bonds close to a bound Cu2+ ion. This mechanism allows several inferences on subunit interactions and spatial organization. The two cleavage sites in L7/8 of the alpha subunit and two cleavage sites of the beta subunit identify interacting segments of the subunits, L7/8 is also close to L9/10 and to cation occlusion sites. Comparison of the locations of Cu2+-catalyzed cleavages with Fe2+-catalyzed cleavages (Goldshleger, R., and Karlish, S. J. D. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 9596-9601) suggests division of the membrane sector into two domains comprising M1-M6 and M7-M10/M beta, respectively.	Weizmann Inst Sci, Dept Biochem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biochem, IL-76100 Rehovot, Israel.							ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHOU WY, 1995, J BIOL CHEM, V270, P25935, DOI 10.1074/jbc.270.43.25935; CHOW DC, 1995, J EXP BIOL, V198, P1; Colonna TE, 1997, J BIOL CHEM, V272, P12366, DOI 10.1074/jbc.272.19.12366; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; Fiedler B, 1996, J BIOL CHEM, V271, P29312, DOI 10.1074/jbc.271.46.29312; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GEERING K, 1993, AM J PHYSIOL, V265, pC1169, DOI 10.1152/ajpcell.1993.265.4.C1169; GHAIM JB, 1995, BIOCHEMISTRY-US, V34, P11311, DOI 10.1021/bi00036a002; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; Goldshleger R, 1998, ACTA PHYSIOL SCAND, V163, P89; GROSSMAN Z, 1990, EXP PARASITOL, V70, P62, DOI 10.1016/0014-4894(90)90086-R; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JOGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Melle-Milovanovic D, 1998, J BIOL CHEM, V273, P11075, DOI 10.1074/jbc.273.18.11075; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; Or E, 1996, BIOCHEMISTRY-US, V35, P6853, DOI 10.1021/bi960093q; Or E, 1998, BIOCHEMISTRY-US, V37, P8197, DOI 10.1021/bi9730442; PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027; Rice WJ, 1997, J BIOL CHEM, V272, P31412, DOI 10.1074/jbc.272.50.31412; SARVAZYAN NA, 1995, J BIOL CHEM, V270, P26528, DOI 10.1074/jbc.270.44.26528; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SIGMAN DS, 1990, ANNU REV BIOCHEM, V62, P797; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	41	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34190	34195		10.1074/jbc.273.51.34190	http://dx.doi.org/10.1074/jbc.273.51.34190			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852080	hybrid			2022-12-25	WOS:000077542200046
J	Burd, AL; El-Kouhen, R; Erickson, LJ; Loh, HH; Law, PY				Burd, AL; El-Kouhen, R; Erickson, LJ; Loh, HH; Law, PY			Identification of serine 356 and serine 363 as the amino acids involved in etorphine-induced down-regulation of the mu-opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; UBIQUITIN-DEPENDENT PROTEOLYSIS; COOH-TERMINAL TAIL; PROTEIN-KINASE-C; INDUCED INTERNALIZATION; CARBOXYL-TERMINUS; OPIATE RECEPTOR; BETA-ARRESTIN; PHOSPHORYLATION; RESIDUES	Agonist-induced internalization of G protein-coupled receptors is influenced by many structural determinants including the carboxyl tail. To investigate the role of serine and threonine residues within the carboxyl tail, several mutants were constructed by truncating the carboxyl tail of the hemagglutinin-tagged mu-opioid receptor, thereby removing serines and threonines systematically. Neuro(2A) cells stably expressing the truncated receptors did not exhibit a significant alteration in the affinity of [H-3]diprenorphine or etorphine for the receptor or the potency of etorphine to inhibit forskolin-stimulated adenylyl cyclase activity. Chronic etorphine treatment resulted in a Lime-dependent down-regulation of all the truncated receptors, except MOR1TAG355D, thus revealing the importance of the four amino acids between Ser(355) and Glu(359) (STIE). Surprisingly, deletion of the STIE sequence resulted in a receptor that down-regulated the same as the wild-type receptor. The involvement of multiple amino acids within the carboxyl tail was demonstrated by combining alanine substitutions of several putative G-protein-coupled receptor kinase phosphorylation sites. Systematic analysis of these receptors indicated that mutation of Ser(356) and Ser(363) to alanine attenuated agonist-mediated down-regulation. The magnitude of etorphine-induced phosphorylation of this mutant receptor, however, was similar to that of the wild-type mu-opioid receptor. Thus, phosphorylation of the carboxyl tail of the mu-opioid receptor is not an obligatory event for etorphine-induced down-regulation of the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Burd, AL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	litt0044@maroon.tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA7339, DA05695, DA5064] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA005695, R01DA007339] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; Chakrabarti S, 1997, MOL PHARMACOL, V52, P105, DOI 10.1124/mol.52.1.105; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng Y. C., 1973, BIOCHEM PHARMACOL, V22, P413; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Fukushima Y, 1997, J BIOL CHEM, V272, P19464, DOI 10.1074/jbc.272.31.19464; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; GUCKER S, 1992, MOL PHARMACOL, V42, P656; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; LAW PY, 1983, MOL PHARMACOL, V24, P413; Lee KB, 1998, J BIOL CHEM, V273, P12967, DOI 10.1074/jbc.273.21.12967; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PEI G, 1995, MOL PHARMACOL, V48, P173; Pohl M, 1997, J BIOL CHEM, V272, P18179, DOI 10.1074/jbc.272.29.18179; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; SMITH SA, 1998, INT NARC RES C JUL 2, P33; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; WALSETH TF, 1989, J BIOL CHEM, V264, P21106; WHITE AA, 1978, ANAL BIOCHEM, V85, P451, DOI 10.1016/0003-2697(78)90242-7; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	31	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34488	34495		10.1074/jbc.273.51.34488	http://dx.doi.org/10.1074/jbc.273.51.34488			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852117	hybrid			2022-12-25	WOS:000077542200083
J	Pazin, MJ; Hermann, JW; Kadonaga, JT				Pazin, MJ; Hermann, JW; Kadonaga, JT			Promoter structure and transcriptional activation with chromatin templates assembled in vitro - A single Gal4-VP16 dimer binds to chromatin or to DNA with comparable affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; IN-VITRO; NUCLEOSOME DISRUPTION; FACILITATED BINDING; HIV-1 ENHANCER; DROSOPHILA; GAL4; PROTEIN; YEAST; GENES	To gain a better understanding of the role of chromatin in the regulation of transcription by RNA polymerase II, we examined the relation between promoter structure and the ability of Gal4-VP16 to function with chromatin templates assembled in vitro. First, to investigate whether there are synergistic interactions among multiple bound factors, we studied promoter constructions containing one or five Gal4 sites and found that a single recognition site is sufficient for Gal4-VP16 to bind to chromatin, to induce nucleosome rearrangement, and to activate transcription. Notably, we observed that Gal4-VP16 binds to a single site in chromatin with affinity comparable with that which it binds to naked DNA, even in the absence of ATP-dependent nucleosome remodeling activity. Second, to explore the relation between translational nucleosome positioning and transcriptional activation, we analyzed a series of promoter constructions in which nucleosomes were positioned by Gal4-VP16 at different locations relative to the RNA start site. These experiments revealed that the positioning of a nucleosome over the RNA start site is not an absolute barrier to transcriptional activation. Third, to determine the contribution of core promoter elements to transcriptional activation with chromatin templates, we tested the ability of Gal4-VP16 to activate transcription with TATA box-versus DPE-driven core promoters and found that the TATA box is not required to achieve transcriptional activation by Gal4-VP16 with chromatin templates. These results suggest that a single protomer of a strong activator is able to bind to chromatin, to, induce nucleosome remodeling, and to activate transcription in conjunction with a broad range of chromatin structures and core promoter elements.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr,0347 Pacific Hall,Rm 2212B, La Jolla, CA 92093 USA.			Pazin, Michael/0000-0002-7561-3640	NIGMS NIH HHS [GM 46995] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046995] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BARTON MC, 1994, GENE DEV, V8, P2453, DOI 10.1101/gad.8.20.2453; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Bulger M., 1994, METH MOL G, V5, P241; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; BURKE TW, 1998, IN PRESS COLD SPRING, V63; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; GEORGE CP, 1995, MOL CELL BIOL, V15, P1049; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Krude T, 1996, CURR BIOL, V6, P511, DOI 10.1016/S0960-9822(02)00529-8; Langst G, 1998, EMBO J, V17, P3135, DOI 10.1093/emboj/17.11.3135; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIMBIRD LE, 1986, CELL SURFACE RECEPTO, P73; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LIRADEVITO LM, 1995, GENE, V153, P203, DOI 10.1016/0378-1119(94)00764-J; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; NEDOSPASOV SA, 1980, BIOCHEM BIOPH RES CO, V92, P532, DOI 10.1016/0006-291X(80)90366-6; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; PATTERSON HG, 1994, MOL CELL BIOL, V14, P4002, DOI 10.1128/MCB.14.6.4002; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pazin MJ, 1998, CHROMATIN PRACTICAL, P173; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; Robinson KM, 1998, BBA-REV CANCER, V1378, pM1, DOI 10.1016/S0304-419X(98)00008-0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Ryan MP, 1998, MOL CELL BIOL, V18, P1774, DOI 10.1128/MCB.18.4.1774; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VASHEE S, 1993, J BIOL CHEM, V268, P24699; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677; Xu M, 1998, MOL CELL BIOL, V18, P1201, DOI 10.1128/MCB.18.3.1201	67	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34653	34660		10.1074/jbc.273.51.34653	http://dx.doi.org/10.1074/jbc.273.51.34653			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852139	hybrid			2022-12-25	WOS:000077542200105
J	Riba, I; Gaskell, SJ; Cho, HJ; Widger, WR; Kohn, H				Riba, I; Gaskell, SJ; Cho, HJ; Widger, WR; Kohn, H			Evidence for the location of bicyclomycin binding to the Escherichia coli transcription termination factor Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL PROPERTIES; PROTEIN-RHO; MICROCOCCUS-LUTEUS; ATPASE ACTIVITY; MUTANT-RHO; RNA; SITE; IDENTIFICATION; DERIVATIVES; REACTIVITY	The commercial antibiotic bicyclomycin (Bcm) has been shown to target the essential transcription termination factor Rho in Escherichia coli, Little is known about the Bcm binding domain in Rho, A recent structure-activity relationship study led us to evaluate the reductive amination probe, 5a-(3-formylanilino)dihydrobicyclomycin (FD-Bcm), Biochemical studies showed that FD-Bcm possessed inhibitory activities comparable to Bcm in Rho-dependent ATPase and transcription termination assays, Incubation of Rho with FD-Bcm, ATP, and poly(C) followed by NaBH4 reduction and dialysis led to an appreciable loss of ATPase activity. Inclusion of Bcm with FD-Bcm in the reductive amination reaction protected Rho, indicating that Bcm and FD-Bcm competed for the same binding site in Rho, Incubation of Rho with FD-Bcm and poly(C) followed by NaBH4 reduction provided a sample with residual ATPase activity (12%). Mass spectrometric analysis indicated the presence of two proteins in an approximate 1.2:1 ratio, whose masses corresponded to wild-type Rho (47,010 Dal and lysine-modified Rho (47,417 Dal, respectively. Trypsin digestion of the Rho sample followed by high performance liquid chromatography separation and tandem mass spectrometry analysis identified the site of modification as Lys(181) within the combined tryptic fragment, Gly-Leu-Ile-Val-Ala-Pro-Pro-Lys-Ala-Gly-Lys (residues 174-184), Similar analysis of a lesser modified sample (following incubation with inclusion of ATP) showed that addition had again occurred at Lys(181) These findings provide the first structural information concerning the site of Bcm binding in Rho.	Univ Manchester, Michael Barber Ctr Mass Spectrometry, Manchester M60 1QD, Lancs, England; Univ Houston, Dept Chem, Houston, TX 77204 USA; Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Manchester; University of Houston System; University of Houston; University of Houston System; University of Houston	Gaskell, SJ (corresponding author), Univ Manchester, Michael Barber Ctr Mass Spectrometry, PO Box 88, Manchester M60 1QD, Lancs, England.							ABUZAR S, 1989, J ORG CHEM, V54, P4000, DOI 10.1021/jo00277a052; ABUZAR S, 1990, J AM CHEM SOC, V112, P3114, DOI 10.1021/ja00164a036; ABUZAR S, 1989, J AM CHEM SOC, V111, P4985; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CHO H, 1998, THESIS U HOUSTON; Cho HJ, 1997, J ORG CHEM, V62, P5432, DOI 10.1021/jo970575n; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; ENGEL D, 1984, NUCLEIC ACIDS RES, V12, P7389, DOI 10.1093/nar/12.19.7389; FERRIGE AG, 1991, RAPID COMMUN MASS SP, V5, P374, DOI 10.1002/rcm.1290050810; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; Horiguchi T, 1997, J MOL BIOL, V269, P514, DOI 10.1006/jmbi.1997.1059; KAMIYA T, 1972, J ANTIBIOT, V25, P576, DOI 10.7164/antibiotics.25.576; KNOPF KW, 1975, EUR J BIOCHEM, V53, P371, DOI 10.1111/j.1432-1033.1975.tb04077.x; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magyar A, 1996, J BIOL CHEM, V271, P25369, DOI 10.1074/jbc.271.41.25369; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MIYAMURA S, 1973, J ANTIBIOT, V26, P479, DOI 10.7164/antibiotics.26.479; MIYAMURA S, 1972, J ANTIBIOT, V25, P610, DOI 10.7164/antibiotics.25.610; MIYOSHI T, 1972, J ANTIBIOT, V25, P569, DOI 10.7164/antibiotics.25.569; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NISHIDA M, 1972, J ANTIBIOT, V25, P594, DOI 10.7164/antibiotics.25.594; NISHIDA M, 1972, J ANTIBIOT, V25, P582, DOI 10.7164/antibiotics.25.582; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nowatzke WL, 1997, J BACTERIOL, V179, P5238, DOI 10.1128/jb.179.16.5238-5240.1997; O IS, 1994, J BIOL CHEM, V269, P5009; ODA T, 1972, J MOL BIOL, V71, P799; Park H, 1996, J ORG CHEM, V61, P7764, DOI 10.1021/jo961004i; Park H, 1996, J ORG CHEM, V61, P7750, DOI 10.1021/jo961002y; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Santillan A, 1996, J ORG CHEM, V61, P7756, DOI 10.1021/jo961003q; SEIFRIED SE, 1988, J BIOL CHEM, V263, P13511; SHARP JA, 1983, J BIOL CHEM, V258, P3482; SILVERMAN RB, 1992, ORGANIC CHEM DRUG DE, pCH5; SOMEYA A, 1979, J ANTIBIOT, V32, P402, DOI 10.7164/antibiotics.32.402; TANAKA N, 1979, ANTIBIOTICS NY, V5, P18; WILLIAMS RM, 1988, CHEM REV, V88, P511, DOI 10.1021/cr00085a004; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	48	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34033	34041		10.1074/jbc.273.51.34033	http://dx.doi.org/10.1074/jbc.273.51.34033			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852059	hybrid			2022-12-25	WOS:000077542200025
J	Paavola, CD; Hemmerich, S; Grunberger, D; Polsky, I; Bloom, A; Freedman, R; Mulkins, M; Bhakta, S; McCarley, D; Wiesent, L; Wong, B; Jarnagin, K; Handel, TM				Paavola, CD; Hemmerich, S; Grunberger, D; Polsky, I; Bloom, A; Freedman, R; Mulkins, M; Bhakta, S; McCarley, D; Wiesent, L; Wong, B; Jarnagin, K; Handel, TM			Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID-ARTHRITIS; BIOLOGICAL RESPONSES; COUPLED RECEPTORS; NMR ASSIGNMENTS; HIV-1 ENTRY; T-CELLS; CHEMOKINE; EXPRESSION; IL-8; INFLAMMATION	To address the role of dimerization in the function of the monocyte chemoattractant protein-1, MCP-1, we mutated residues that comprise the core of the dimerization interface and characterized the ability of these mutants to dimerize and to bind and activate the MCP-1 receptor, CCR2b, One mutant, P8A*, does not dimerize. However, it has wild type binding affinity, stimulates chemotaxis, inhibits adenylate cyclase, and stimulates calcium influx with wild type potency and efficacy. These data suggest that MCP-1 binds and activates its receptor as a monomer. In contrast, Y13A*, another monomeric mutant, has a 100-fold weaker binding affinity, is a much less potent inhibitor of adenylate cyclase and stimulator of calcium influx, and is unable to stimulate chemotaxis. Thus Tyr(13) may make important contacts with the receptor that are required for high affinity binding and signal transduction, We also explored whether a mutant, [1+9-76]MCP-1 (MCP-1 lacking residues 2-8), antagonizes wild type MCP-1 by competitive inhibition, or by a dominant negative mechanism wherein heterodimers of MCP-1 and [1+9-76]MCP-1 bind to the receptor but are signaling incompetent. Consistent with the finding that MCP-1 can bind and activate the receptor as a monomer, we demonstrate that binding of MCP-1 in the presence of [1+9-76]MCP-1 over a range of concentrations of both ligands fits well to a simple model in which monomeric [1+9-76]MCP-I functions as a competitive inhibitor of monomeric MCP-1, These results are crucial for elucidating the molecular details of receptor binding and activation, for interpreting mutagenesis data, for understanding how antagonistic chemokine variants function, and for the design of receptor antagonists.	Roche Biosci, Palo Alto, CA 94304 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	Roche Holding; University of California System; University of California Berkeley	Handel, TM (corresponding author), Roche Biosci, 3401 Hillview Ave, Palo Alto, CA 94304 USA.			Bloom, Joseph/0000-0002-6731-5539; BHAKTA, SUNIL/0000-0002-1554-7098	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037113] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI037113] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Beall CJ, 1996, BIOCHEM J, V313, P633, DOI 10.1042/bj3130633; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; BLUE DR, 1994, J PHARMACOL EXP THER, V268, P1588; BRIERLEY RA, 1990, ANN NY ACAD SCI, V589, P350, DOI 10.1111/j.1749-6632.1990.tb24257.x; BUETTNER HM, 1989, J IMMUNOL METHODS, V123, P25, DOI 10.1016/0022-1759(89)90026-4; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLARE JJ, 1991, GENE, V105, P205, DOI 10.1016/0378-1119(91)90152-2; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOERRING DS, 1992, FUNCTIONAL STRUCTURA; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; FARRELL BE, 1990, CELL MOTIL CYTOSKEL, V16, P279, DOI 10.1002/cm.970160407; FENG LL, 1995, J CLIN INVEST, V95, P1009, DOI 10.1172/JCI117745; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; HOSAKA S, 1994, CLIN EXP IMMUNOL, V97, P451; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jarnagin K, 1996, J BIOL CHEM, V271, P28277, DOI 10.1074/jbc.271.45.28277; KANE JF, 1995, CURR OPIN BIOTECH, V6, P494, DOI 10.1016/0958-1669(95)80082-4; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Krathwohl MD, 1997, P NATL ACAD SCI USA, V94, P9875, DOI 10.1073/pnas.94.18.9875; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leong SR, 1997, PROTEIN SCI, V6, P609; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Lowman HB, 1997, PROTEIN SCI, V6, P598; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Newton RC, 1997, METHOD ENZYMOL, V287, P174; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; Proost P, 1996, INT J CLIN LAB RES, V26, P211, DOI 10.1007/BF02602952; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RIVERO MA, 1989, CHEM ENG SCI, V44, P2881, DOI 10.1016/0009-2509(89)85098-5; ROBINSON E, 1995, CLIN EXP IMMUNOL, V101, P398; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; Taub Dennis D., 1996, Cytokine and Growth Factor Reviews, V7, P355, DOI 10.1016/S1359-6101(97)89237-4; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VADDI K, 1994, J LEUKOCYTE BIOL, V55, P756, DOI 10.1002/jlb.55.6.756; Wenzel U, 1997, KIDNEY INT, V51, P770, DOI 10.1038/ki.1997.108; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	71	166	179	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33157	33165		10.1074/jbc.273.50.33157	http://dx.doi.org/10.1074/jbc.273.50.33157			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837883	hybrid			2022-12-25	WOS:000077462500013
J	Takaoka, AS; Yamada, T; Gotoh, M; Kanai, Y; Imai, K; Hirohashi, S				Takaoka, AS; Yamada, T; Gotoh, M; Kanai, Y; Imai, K; Hirohashi, S			Cloning and characterization of the human beta(4)-integrin gene promoter and enhancers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; INTEGRIN BETA-4 GENE; NF-KAPPA-B; ALPHA(6)BETA(4) INTEGRIN; ALPHA-6-BETA-4 INTEGRIN; TRANSCRIPTION FACTOR; CARCINOMA-CELLS; DIFFERENTIAL EXPRESSION; HEMIDESMOSOME FORMATION; GENOMIC ORGANIZATION	The cell-surface adhesion molecule alpha(6)beta(4)-integrin is a receptor for laminins and a component of hemidesmosomes, beta(4)-Integrin expression is restricted to proliferating basal keratinocytes in the epidermis and is suppressed when differentiation commences. Altered beta(4)-integrin expression levels correlate significantly with the aggressive behavior of cancers, In order to clarify the mechanisms that regulate transcription of the beta(4)-integrin gene, we cloned its 5'-flanking region. This 5'-flanking region was found to have a high G + C content and not to contain either TATA or CAAT boxes, Nested delimitation and reporter analyses mapped a basal promoter to nucleotides -106 to +105, surrounding the most proximal transcription initiation site. Gel retardation and mutational analyses revealed that cooperation between AP1 and Ets, interacting with other factors, mediated the promoter activity. In addition to the promoter element, enhancer activity was found in the first intron (+1905/+3933) and in a sequence upstream of the promoter region (-414/-107), These findings should facilitate our understanding of the regulation of beta(4)-integrin gene expression in processes such as cell growth and differentiation, apoptosis, and cancer development and metastasis.	Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Sapporo Med Univ, Sch Med, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	National Cancer Center - Japan; Sapporo Medical University	Hirohashi, S (corresponding author), Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	shirohas@gan2.ncc.go.jp						Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P9727, DOI 10.1073/pnas.92.21.9727; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; Buttice G, 1996, ONCOGENE, V13, P2297; CARICO E, 1993, GYNECOL ONCOL, V49, P61, DOI 10.1006/gyno.1993.1087; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; Chao C, 1996, CANCER RES, V56, P4811; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; COSTANTINI RM, 1990, CANCER RES, V50, P6107; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FALCIONI R, 1994, INT J ONCOL, V5, P573; FALCIONI R, 1986, CANCER RES, V46, P5772; Gambarotta G, 1996, ONCOGENE, V13, P1911; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; GROSSMAN HB, 1984, J UROLOGY, V132, P834, DOI 10.1016/S0022-5347(17)49883-1; GROSSMAN HB, 1986, J UROLOGY, V136, P953, DOI 10.1016/S0022-5347(17)45139-1; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HALL PA, 1991, J PATHOL, V165, P33, DOI 10.1002/path.1711650107; HOGERVORST F, 1990, EMBO J, V9, P765, DOI 10.1002/j.1460-2075.1990.tb08171.x; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Iacovacci S, 1997, MAMM GENOME, V8, P448, DOI 10.1007/s003359900467; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; Kim SY, 1997, CANCER RES, V57, P38; KIMMEL KA, 1986, CANCER RES, V46, P3614; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBERT M, 1994, AM J PATHOL, V144, P787; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Martinez R, 1997, CANCER RES, V57, P1180; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; Nakayama T, 1996, AM J PATHOL, V149, P1931; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; NERLOV C, 1991, ONCOGENE, V6, P1583; Niessen CM, 1996, J CELL SCI, V109, P1695; Pulkkinen L, 1997, LAB INVEST, V76, P823; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; Sambrook J., 1989, MOL CLONING LAB MANU, P79; Satyamoorthy K, 1997, NUCLEIC ACIDS RES, V25, P3169, DOI 10.1093/nar/25.15.3169; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; Serini G, 1996, J NATL CANCER I, V88, P442, DOI 10.1093/jnci/88.7.442; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; SOLLBERG S, 1992, J INVEST DERMATOL, V98, P864, DOI 10.1111/1523-1747.ep12457080; STANBRIDGE E, 1969, EXP CELL RES, V57, P397, DOI 10.1016/0014-4827(69)90166-9; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TANAKA M, 1995, CANCER RES, V55, P3228; Tennenbaum T, 1996, CELL GROWTH DIFFER, V7, P615; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VANWAES C, 1991, CANCER RES, V51, P2395; VANWAES C, 1995, CANCER RES, V55, P5434; Wade DP, 1997, J BIOL CHEM, V272, P30387, DOI 10.1074/jbc.272.48.30387; Welter JF, 1995, ONCOGENE, V11, P2681; WERNERT N, 1992, AM J PATHOL, V140, P119; Yamada T, 1996, LAB INVEST, V75, P589; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	72	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33848	33855		10.1074/jbc.273.50.33848	http://dx.doi.org/10.1074/jbc.273.50.33848			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837976	hybrid			2022-12-25	WOS:000077462500106
J	Yamada, M; Hayatsu, N; Matsuura, A; Ishikawa, F				Yamada, M; Hayatsu, N; Matsuura, A; Ishikawa, F			Y '-Help1, a DNA helicase encoded by the yeast subtelomeric Y ' element, is induced in survivors defective for telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNERS-SYNDROME GENES; IMMORTAL HUMAN-CELLS; SACCHAROMYCES-CEREVISIAE; HOLLIDAY JUNCTIONS; ESCHERICHIA-COLI; BLOOMS-SYNDROME; PROTEIN; SEQUENCES; RNA; RECOMBINATION	The yeast Y' element is a highly polymorphic repetitive sequence present in the subtelomeric regions of many yeast telomeres. The Y' element is classed as either Y'-L or Y'-S, depending on its length. It has been reported that survivors arising from telomerase-deficient yeast mutants compensate for telomere loss by the amplification of Y' elements. The total Saccharomyces cerevisiae genome DNA data base was searched for Y' elements, and 11 Y'-Ls and eight Y'-Ss were identified. As reported previously, many of the sequences were found to contain long open reading frames which potentially encode helicase. We examined the expression of the Y' elements in telomerase-deficient Delta tlc1 survivors, in which the TLC1 gene encoding the yeast telomerase template RNA had been disrupted, and found that the Y' element is highly expressed in the survivors, but not in the wild-type cells. Moreover, we demonstrated that the survivors produce a Y'-encoded protein designated as Y'-Help1 (Y'-helicase protein 1), and that this protein possesses helicase activity. Therefore, we suggest that the Y' element has a novel and potentially important role in trans, in addition to the well characterized role in cis, in telomerase-independent telomere maintenance in yeast.	Tokyo Inst Technol, Dept Life Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Nippon Kayaku Co Ltd, Dept Anticanc Drugs, Kita Ku, Tokyo 1158588, Japan	Tokyo Institute of Technology; Nippon Kayaku Co., Ltd.	Ishikawa, F (corresponding author), Tokyo Inst Technol, Dept Life Sci, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	fishikaw@bio.titech.ac.jp	Matsuura, Akira/J-3864-2017; Matsuura, Akira/AAO-1572-2021; Ishikawa, Fuyuki/AAU-4056-2021	Matsuura, Akira/0000-0002-2300-7227; Matsuura, Akira/0000-0002-2300-7227; Ishikawa, Fuyuki/0000-0002-5580-2305				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Biessmann H, 1997, Ciba Found Symp, V211, P53; Biessmann H, 1997, CHROMOSOMA, V106, P63, DOI 10.1007/s004120050225; BORK P, 1993, NUCLEIC ACIDS RES, V21, P751, DOI 10.1093/nar/21.3.751; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; GALLWITZ D, 1980, NUCLEIC ACIDS RES, V8, P1043, DOI 10.1093/nar/8.5.1043; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; HARLOW E, 1988, ANTIBODIES; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; HODGMAN TC, 1988, NATURE, V333, P578, DOI 10.1038/333578a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HOROWITZ H, 1984, MOL CELL BIOL, V4, P2509, DOI 10.1128/MCB.4.11.2509; JAGER D, 1989, MOL CELL BIOL, V9, P5754; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kaiser C., 1994, METHODS YEAST GENETI; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; Lendvay TS, 1996, GENETICS, V144, P1399; LINGNER J, 1995, SCIENCE, V269, P1533, DOI 10.1126/science.7545310; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LOUIS EJ, 1990, GENETICS, V124, P533; LOUIS EJ, 1994, GENETICS, V136, P789; LOUIS EJ, 1992, GENETICS, V131, P559; LUE NF, 1995, J BIOL CHEM, V270, P21453, DOI 10.1074/jbc.270.37.21453; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; TAYLOR AF, 1992, CELL, V69, P1063, DOI 10.1016/0092-8674(92)90626-N; VOLLRATH D, 1988, P NATL ACAD SCI USA, V85, P6027, DOI 10.1073/pnas.85.16.6027; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; Watt PM, 1996, GENETICS, V144, P935; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; ZAKIAN VA, 1988, MOL CELL BIOL, V8, P2257, DOI 10.1128/MCB.8.5.2257	56	66	84	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33360	33366		10.1074/jbc.273.50.33360	http://dx.doi.org/10.1074/jbc.273.50.33360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837911	hybrid			2022-12-25	WOS:000077462500041
J	Dewilde, S; Blaxter, M; Van Hauwaert, ML; Van Houte, K; Pesce, A; Griffon, N; Kiger, L; Marden, MC; Vermeire, S; Vanfleteren, J; Esmans, E; Moens, L				Dewilde, S; Blaxter, M; Van Hauwaert, ML; Van Houte, K; Pesce, A; Griffon, N; Kiger, L; Marden, MC; Vermeire, S; Vanfleteren, J; Esmans, E; Moens, L			Structural, functional, and genetic characterization of Gastrophilus hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONVERTEBRATE GLOBIN GENES; INSECT CHIRONOMUS-THUMMI; AMINO-ACID SUBSTITUTION; SPERM WHALE MYOGLOBIN; LIGAND-BINDING; ASCARIS HEMOGLOBIN; INTRON POSITIONS; CENTRAL EXON; EVOLUTION; SEQUENCES	Hemoglobin of Gastrophilus intestinalis (Insecta, Diptera), was purified and characterized. At least two isoforms have been identified by isoelectrofocusing, mass spectrometry, and genomic Southern blotting. Functional studies show a high oxygen affinity due to a low ligand dissociation rate (k(off) = 2.4 s(-1)) and a relatively high autoxidation rate (t(1/2) = 1.6/h), The globins were separated under denaturing conditions, and the sequence of Hb1 (M-r = 17,965 +/- 2) was determined at the protein and DNA level, The open reading frame codes for a polypeptide of 150 amino acids. Although the globin is distantly related to globins from other species, it has a low penalty score against globin templates. Freshly isolated hemoglobin was crystallized from polyethylene glycol. Crystals contain two hemoglobin molecules per asymmetric unit. Solution of the three-dimensional structure by molecular replacement could not be achieved, possibly due to the presence of three protein isoforms in the crystals. In order to determine its three-dimensional structure, G. intestinalis Hb1 was overexpressed in Escherichia coli, resulting in a fully functional molecule as confirmed by Ligand binding affinity. The globin gene contains two introns at positions D7.0 and G7.0. The D7.0 intron is unprecedented, suggesting that globin gene evolution is much more complex than originally thought.	Univ Instelling Antwerp, Dept Biochem, B-2610 Wilrijk, Belgium; Univ Edinburgh, Inst Cell Anim & Populat Biol, Ashworth Labs, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Antwerp, Nucleoside Res & Mass Spectrometry Unit, B-2020 Antwerp, Belgium; Univ Genoa, INFM, Dipartimento Fis, I-16132 Genoa, Italy; Univ Genoa, IST, Ctr Biotechnol Avanzate, I-16132 Genoa, Italy; Hop Bicetre, INSERM, U473, F-94275 Le Kremlin Bicetre, France; State Univ Ghent, Dept Biol, B-9000 Ghent, Belgium	University of Antwerp; University of Edinburgh; University of Antwerp; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Genoa; University of Genoa; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Ghent University	Moens, L (corresponding author), Univ Instelling Antwerp, Dept Biochem, Univ Pl 1, B-2610 Wilrijk, Belgium.		Blaxter, Mark/O-2535-2019; Kiger, Laurent/Q-1686-2018; Pesce, Alessandra/A-3660-2015; Marden, Michael/AAA-5923-2020; Blaxter, Mark L/B-4113-2010; Marden, Michael C/G-3139-2012	Blaxter, Mark L/0000-0003-2861-949X; Marden, Michael C/0000-0002-5254-6385				ALLEN G, 1989, LAB TECHNIQUES BIOCH, V9; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ANTOINE M, 1984, NATURE, V310, P795, DOI 10.1038/310795a0; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BLAXTER ML, 1994, J BIOL CHEM, V269, P30181; Bolognesi M, 1997, PROG BIOPHYS MOL BIO, V68, P29, DOI 10.1016/S0079-6107(97)00017-5; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; CARVER TE, 1992, J BIOL CHEM, V267, P14443; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; Cho G, 1997, J MOL EVOL, V44, P573, DOI 10.1007/PL00006180; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; CRAIK CS, 1980, P NATL ACAD SCI-BIOL, V77, P1384, DOI 10.1073/pnas.77.3.1384; CRAIK CS, 1981, NATURE, V291, P87, DOI 10.1038/291087a0; CUTRUZZOLA F, 1991, FEBS LETT, V282, P281, DOI 10.1016/0014-5793(91)80495-O; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; DESANCTIS G, 1988, J MOL BIOL, V200, P725, DOI 10.1016/0022-2836(88)90483-4; Dewilde S, 1998, J BIOL CHEM, V273, P13583, DOI 10.1074/jbc.273.22.13583; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DIXON B, 1992, TRENDS BIOCHEM SCI, V17, P486; DIXON B, 1992, J MOL EVOL, V35, P131, DOI 10.1007/BF00183224; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUDAKA M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P185; GIBSON QH, 1989, J BIOL CHEM, V264, P100; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; GILBERT W, 1993, GENE, V135, P137, DOI 10.1016/0378-1119(93)90058-B; Gilbert W, 1997, P NATL ACAD SCI USA, V94, P7698, DOI 10.1073/pnas.94.15.7698; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GOLDFISCHER S, 1971, J MICROSC-PARIS, V10, P305; GOODMAN M, 1988, J MOL EVOL, V27, P236, DOI 10.1007/BF02100080; GOODMAN M, 1983, H-S Z PHYSIOL CHEM, V364, P205, DOI 10.1515/bchm2.1983.364.1.205; GORG A, 1995, ELECTROPHORESIS, V16, P1079, DOI 10.1002/elps.11501601183; Hankeln T, 1997, GENE, V205, P151, DOI 10.1016/S0378-1119(97)00518-0; HARDISON RC, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P272; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; HIGASHIMOTO Y, 1993, BIOCHEM BIOPH RES CO, V193, P182, DOI 10.1006/bbrc.1993.1607; HUBER R, 1971, EUR J BIOCHEM, V19, P42, DOI 10.1111/j.1432-1033.1971.tb01285.x; JELLIE AM, 1996, J MOL EVOL, V42, P241; KAO WY, 1994, J MOL EVOL, V38, P241; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KEILIN D, 1946, BIOCHEM J, V40, P855, DOI 10.1042/bj0400855; Kiger L, 1998, BIOPHYS J, V75, P990, DOI 10.1016/S0006-3495(98)77587-3; KLOEK AP, 1993, GENE, V129, P215, DOI 10.1016/0378-1119(93)90271-4; LAMAR GN, 1980, J BIOL CHEM, V255, P66; LESLIE A, 1996, CRYSTALLOGRAPHIC COM, P110; LOGSDON JM, 1995, P NATL ACAD SCI USA, V92, P8507, DOI 10.1073/pnas.92.18.8507; LONG MY, 1995, CURR OPIN GENET DEV, V5, P774, DOI 10.1016/0959-437X(95)80010-3; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRory JE, 1997, DNA CELL BIOL, V16, P95, DOI 10.1089/dna.1997.16.95; MOENS L, 1992, FEBS LETT, V312, P105, DOI 10.1016/0014-5793(92)80915-4; NAITO Y, 1991, P NATL ACAD SCI USA, V88, P6672, DOI 10.1073/pnas.88.15.6672; NASSIF NT, 1994, J MOL EVOL, V39, P47, DOI 10.1007/BF00178248; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PHELPS CF, 1972, BIOCHEM J, V129, P891, DOI 10.1042/bj1290891; Rashid AK, 1997, J BIOL CHEM, V272, P2992, DOI 10.1074/jbc.272.5.3000; ROGERS JH, 1990, FEBS LETT, V268, P339, DOI 10.1016/0014-5793(90)81282-S; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; SMERDON SJ, 1995, BIOCHEMISTRY-US, V34, P8715, DOI 10.1021/bi00027a022; STEIGEMANN W, 1979, J MOL BIOL, V127, P309, DOI 10.1016/0022-2836(79)90332-2; Stoltzfus A, 1997, P NATL ACAD SCI USA, V94, P10739, DOI 10.1073/pnas.94.20.10739; STOLTZFUS A, 1993, CURR BIOL, V3, P215, DOI 10.1016/0960-9822(93)90336-M; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1173, P75, DOI 10.1016/0167-4781(93)90245-9; Tan MK, 1997, J MOL EVOL, V44, P637, DOI 10.1007/PL00006187; Trotman CNA, 1998, TRENDS GENET, V14, P132, DOI 10.1016/S0168-9525(98)01400-0; Tyshenko MG, 1997, BBA-GENE STRUCT EXPR, V1353, P131, DOI 10.1016/S0167-4781(97)00065-1; VINOGRADOV SN, 1993, COMP BIOCHEM PHYS B, V106, P1, DOI 10.1016/0305-0491(93)90002-M; VINOGRADOV SN, 1992, COMP BIOCHEM PHYS B, V103, P759, DOI 10.1016/0305-0491(92)90193-U; WINNEPENNINCKX B, 1993, TRENDS GENET, V9, P409; WITTENBERG BA, 1965, ARCH BIOCHEM BIOPHYS, V111, P576, DOI 10.1016/0003-9861(65)90237-7; YAMAUCHI K, 1995, BBA-GENE STRUCT EXPR, V1264, P53, DOI 10.1016/0167-4781(95)00114-V; YAMAUCHI K, 1992, BIOCHIM BIOPHYS ACTA, V1171, P81, DOI 10.1016/0167-4781(92)90142-M; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; [No title captured]	80	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32467	32474		10.1074/jbc.273.49.32467	http://dx.doi.org/10.1074/jbc.273.49.32467			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829978	hybrid			2022-12-25	WOS:000077329100017
J	Harrington, DJ; Adachi, K; Royer, WE				Harrington, DJ; Adachi, K; Royer, WE			Crystal structure of deoxy-human hemoglobin beta 6 Glu -> Trp - Implications for the structure and formation of the sickle cell fiber	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYHEMOGLOBIN-S; POLYMERIZATION; RESOLUTION; SOLUBILITY	An atomic-level understanding of the interactions between hemoglobin molecules that contribute to the formation of pathological fibers in sickle cell disease remains elusive. By exploring crystal structures of mutant hemoglobins with altered polymerization properties, insight can be gained into sickle cell hemoglobin (HbS) polymerization. We present here the 2.0-Angstrom resolution deoxy crystal structure of human hemoglobin mutated to tryptophan at the beta 6 position, the site of the glutamate --> valine mutation in HbS. Unlike leucine and isoleucine, which promote polymerization relative to RbS, tryptophan inhibits polymerization. Our results provide explanations for the altered polymerization properties and reveal a fundamentally different double strand that may provide a model for interactions within a fiber and/or interactions leading to heterogeneous nucleation.	Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01655 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Hematol, Philadelphia, PA 19104 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Royer, WE (corresponding author), Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Program Mol Med, 55 Lake Ave N, Worcester, MA 01655 USA.				NHLBI NIH HHS [R01 HL 58879] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058879] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; ADACHI K, 1994, BLOOD, V84, P1; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BENESCH RE, 1982, NATURE, V299, P231, DOI 10.1038/299231a0; BIHOREAU MT, 1992, PROTEIN SCI, V1, P145; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; CRETEGNY I, 1993, J MOL BIOL, V230, P733, DOI 10.1006/jmbi.1993.1195; DYKES GW, 1979, J MOL BIOL, V130, P451, DOI 10.1016/0022-2836(79)90434-0; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FERRONE RA, 1985, J MOL BIOL, V193, P611; FITZGERALD PMD, 1979, J MOL BIOL, V132, P603; GREER J, 1971, J MOL BIOL, V59, P107, DOI 10.1016/0022-2836(71)90416-5; Harrington DJ, 1997, J MOL BIOL, V272, P398, DOI 10.1006/jmbi.1997.1253; INGRAM VM, 1956, NATURE, V178, P792, DOI 10.1038/178792a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS MR, 1991, J STRUCT BIOL, V107, P196, DOI 10.1016/1047-8477(91)90022-O; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MAGDOFFFAIRCHILD B, 1979, P NATL ACAD SCI USA, V76, P223, DOI 10.1073/pnas.76.1.223; Mirchev R, 1997, J MOL BIOL, V265, P475, DOI 10.1006/jmbi.1996.0759; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; NAGEL RL, 1980, NATURE, V283, P832, DOI 10.1038/283832a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PADLAN EA, 1985, J BIOL CHEM, V260, P8280; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WATOWICH SJ, 1993, J STRUCT BIOL, V111, P161, DOI 10.1006/jsbi.1993.1047; WISHNER BC, 1975, J MOL BIOL, V98, P179, DOI 10.1016/S0022-2836(75)80108-2; [No title captured]	33	12	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32690	32696		10.1074/jbc.273.49.32690	http://dx.doi.org/10.1074/jbc.273.49.32690			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830011	hybrid			2022-12-25	WOS:000077329100050
J	Guissouma, H; Ghorbel, MT; Seugnet, I; Ouatas, T; Demeneix, BA				Guissouma, H; Ghorbel, MT; Seugnet, I; Ouatas, T; Demeneix, BA			Physiological regulation of hypothalamic TRH transcription in vivo is T-3 receptor isoform specific	FASEB JOURNAL			English	Article						nonviral gene transfer; polyethylenimine; thyroid hormone; mouse; central nervous system	THYROID-HORMONE RECEPTOR; THYROTROPIN-RELEASING-HORMONE; DIFFERENTIAL EXPRESSION; NEGATIVE REGULATION; GENE PROMOTER; RAT-BRAIN; BETA; ALPHA; ACTIVATION; PITUITARY	Thyroid hormone (tri-iodo-thyronine, T-3) exerts transcriptional effects on target genes in responsive cells. These effects are determined by DNA/protein interactions governed by the type of T-3 receptors (TRs) in the cell. As TRs show tissue and developmental variations, regulation is best addressed in an integrated in vivo model. We examined TR subtype effects on thyrotropin-releasing hormone (TRH) transcription and on the pituitary/thyroid axis end point: thyroid hormone secretion. Polyethylenimine sewed to transfect a TRH-luciferase construct containing 554 bp of the rat TRH promoter into the hypothalami of newborn mice. Transcription from the TRH promoter was regulated in a physiologically faithful manner, being significantly increased in hypothyroidism and decreased in T-3-treated animals. Moreover, when various ligand binding forms of mouse or chicken TR beta and TR alpha were expressed with TRH-luciferase, all forms of TR beta gave T-3-dependent regulation of TRH transcription, whereas transcription was T-3 insensitive with each TR alpha tested. Moreover, chicken TR alpha increased TRH transcription sixfold, whereas mouse TR alpha decreased transcription. These transcriptional effects had correlated physiological consequences: expression of the chicken TR alpha in the hypothalamus of newborn mice raised circulating T-4 levels by fourfold, whereas mouse TR alpha had opposite effects. Thus, TR subtypes have distinct, physiologically relevant effects on TRH transcription.	Museum Natl Hist Nat, Lab Physiol Gen & Comparee, URA CNRS 90, F-75231 Paris 5, France	Museum National d'Histoire Naturelle (MNHN)	Demeneix, BA (corresponding author), Museum Natl Hist Nat, Lab Physiol Gen & Comparee, URA CNRS 90, 7 Rue Cuvier, F-75231 Paris 5, France.	demeneix@mnhn.fr						Balkan W, 1998, ENDOCRINOLOGY, V139, P252, DOI 10.1210/en.139.1.252; BRADLEY DJ, 1989, P NATL ACAD SCI USA, V86, P7250, DOI 10.1073/pnas.86.18.7250; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; DELUZE A, 1993, P NATL ACAD SCI USA, V90, P7322, DOI 10.1073/pnas.90.15.7322; DEMENEIX BA, 1978, GEN COMP ENDOCR, V35, P77, DOI 10.1016/0016-6480(78)90170-3; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORMAN BM, 1991, GENE, V105, P9, DOI 10.1016/0378-1119(91)90507-8; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goula D, 1998, GENE THER, V5, P712, DOI 10.1038/sj.gt.3300635; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HOLLENBERG AN, 1995, J BIOL CHEM, V270, P14274, DOI 10.1074/jbc.270.24.14274; KOLLER KJ, 1987, P NATL ACAD SCI USA, V84, P7329, DOI 10.1073/pnas.84.20.7329; Langlois MF, 1997, J BIOL CHEM, V272, P24927, DOI 10.1074/jbc.272.40.24927; LECHAN RM, 1993, ENDOCRINOLOGY, V132, P2461, DOI 10.1210/en.132.6.2461; LEE SL, 1988, J BIOL CHEM, V263, P16604; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; McNabb F.M.A., 1992, THYROID HORMONES, P283; SAKURAI A, 1992, BIOCHEM BIOPH RES CO, V185, P78, DOI 10.1016/S0006-291X(05)80957-X; Schwartz B, 1995, HUM GENE THER, V6, P1515, DOI 10.1089/hum.1995.6.12-1515; SEGERSON TP, 1987, ENDOCRINOLOGY, V121, P98, DOI 10.1210/endo-121-1-98; SJOBERG M, 1992, DEVELOPMENT, V114, P39; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; WOOD WM, 1989, J BIOL CHEM, V264, P14840	29	35	37	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1755	1764		10.1096/fasebj.12.15.1755	http://dx.doi.org/10.1096/fasebj.12.15.1755			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837866				2022-12-25	WOS:000077574500018
J	Keeney, DS; Skinner, C; Travers, JB; Capdevila, JH; Nanney, LB; King, LE; Waterman, MR				Keeney, DS; Skinner, C; Travers, JB; Capdevila, JH; Nanney, LB; King, LE; Waterman, MR			Differentiating keratinocytes express a novel cytochrome P450 enzyme, CYP2B19, having arachidonate monooxygenase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXYGENASES; ESCHERICHIA-COLI; EPOXYEICOSATRIENOIC ACIDS; EPIDERMAL-KERATINOCYTES; CALCIUM; CELLS; GENE; CDNA; LOCALIZATION; LORICRIN	The novel cytochrome P450, CYP2B19, is a specific cellular marker of late differentiation in skin keratinocytes. CYP2B19 was discovered in fetal mouse skin where its onset of expression coincides spatially (upper cell layer) and temporally (day 15.5) with the appearance of loricrin-expressing keratinocytes during the stratification stage of fetal epidermis. CYP2B19 is also present postnatally in the differentiated keratinocytes of the epidermis, sebaceous glands, and hair follicles. CYP2B19 mRNA is tightly coupled to the differentiated (granular cell) keratinocyte phenotype in vivo and in vitro. In primary mouse epidermal keratinocytes, it is specifically up-regulated and correlated temporally with calcium-induced differentiation and expression of the late differentiation genes loricrin and profilaggrin. Recombinant CYP2B19 metabolizes arachidonic acid and generates 14,15- and 11,12-epoxyeicosatrienoic (EET) acids, and 11-, 12-, and 15-hydroxyeicosatetraenoic (HETE) acids (20, 35, 18, 7, and 7% of total metabolites, respectively). Arachidonic acid metabolism was stereoselective for 11S,12R- and 14S,15R-EET, and 11S-, 12R-, and 15R-HETE. The CYP2B19 metabolites 11,12- and 14,15-EET are endogenous constituents of murine epidermis and are present in similar proportions to that generated by the enzyme in vitro, suggesting that CYP2B19 might be the primary enzymatic source of these EETs in murine epidermis.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Dermatol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med Nephrol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Plast Surg, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA; Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Keeney, DS (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem & Med Dermatol, 607 Light Hall, Nashville, TN 37232 USA.	diane.keeney@vanderbilt.edu		Travers, Jeffrey/0000-0001-7232-1039	NIAMS NIH HHS [P30 AR41943] Funding Source: Medline; NIDDK NIH HHS [P30 DK26657] Funding Source: Medline; PHS HHS [P30 E00267] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAER AN, 1995, J INVEST DERMATOL, V104, P251, DOI 10.1111/1523-1747.ep12612793; BAER AN, 1991, J LIPID RES, V32, P341; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Baron A, 1997, J PHYSIOL-LONDON, V504, P537, DOI 10.1111/j.1469-7793.1997.537bd.x; BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; BLESSING M, 1987, EMBO J, V6, P567, DOI 10.1002/j.1460-2075.1987.tb04792.x; Boeglin WE, 1998, P NATL ACAD SCI USA, V95, P6744, DOI 10.1073/pnas.95.12.6744; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1996, ADV MOL CEL, V14, P317; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; FEINGOLD KR, 1991, ADV LIPID RES, V24, P57; FRIEDBERG T, 1992, BIOCHEM J, V287, P775, DOI 10.1042/bj2870775; GARNER WL, 1995, PROSTAG LEUKOTR ESS, V52, P349, DOI 10.1016/0952-3278(95)90037-3; Gotoh O, 1993, CYTOCHROME P450, P207; Halkier BA, 1996, METHOD ENZYMOL, V272, P268, DOI 10.1016/S0076-6879(96)72032-3; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HENNINGS H, 1989, CARCINOGENESIS, V10, P777, DOI 10.1093/carcin/10.4.777; HOHL D, 1993, DIFFERENTIATION, V54, P25, DOI 10.1111/j.1432-0436.1993.tb00656.x; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; Jenkins CM, 1997, ARCH BIOCHEM BIOPHYS, V347, P93, DOI 10.1006/abbi.1997.0318; JOHN GH, 1994, ARCH BIOCHEM BIOPHYS, V314, P367, DOI 10.1006/abbi.1994.1455; KEENEY DS, 1995, MOL ENDOCRINOL, V9, P1091, DOI 10.1210/me.9.8.1091; Keeney DS, 1998, J BIOL CHEM, V273, P9279, DOI 10.1074/jbc.273.15.9279; LI LW, 1993, J CELL PHYSIOL, V154, P643, DOI 10.1002/jcp.1041540324; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; MARCELO CL, 1992, J INVEST DERMATOL, V99, P703, DOI 10.1111/1523-1747.ep12614196; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; NAKAYAMA K, 1993, GENE, V136, P333, DOI 10.1016/0378-1119(93)90490-T; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NICOLAIDES N, 1974, SCIENCE, V186, P19, DOI 10.1126/science.186.4158.19; NOSHIRO M, 1988, BIOCHEMISTRY-US, V27, P6434, DOI 10.1021/bi00417a035; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; RANDOLPH RK, 1995, ARCH BIOCHEM BIOPHYS, V318, P6, DOI 10.1006/abbi.1995.1197; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; WILLIAMS ML, 1992, SEMIN DERMATOL, V11, P169; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0; YAMAZAKI S, 1993, J BIOCHEM-TOKYO, V114, P652, DOI 10.1093/oxfordjournals.jbchem.a124232; YUSPA SH, 1982, CANCER RES, V42, P2344	42	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32071	32079		10.1074/jbc.273.48.32071	http://dx.doi.org/10.1074/jbc.273.48.32071			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822682	hybrid			2022-12-25	WOS:000077207000064
J	Huynh, KD; Bardwell, VJ				Huynh, KD; Bardwell, VJ			The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT	ONCOGENE			English	Article						POZ domain; BCL-6; transcriptional repression; N-CoR; SMRT	NUCLEAR HORMONE RECEPTORS; GERMINAL-CENTER FORMATION; ZINC-FINGER PROTEINS; CENTER B-CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; POSITION-EFFECT VARIEGATION; GAGA TRANSCRIPTION FACTOR; NON-HODGKINS-LYMPHOMAS; BTB/POZ DOMAIN; DNA-BINDING	Virtually all diffuse large cell lymphomas and a significant fraction of follicular lymphomas contain translocations and/or point mutations in the 5' noncoding region of the putative oncogene BCL-6, that are presumed to deregulate its expression. BCL-6 encodes a Cys(2)-His(2) zinc finger transcriptional repressor with a POZ domain at its amino-terminus, The POZ (or BTB) domain, a 120-amino-acid motif, mediates homomeric and, in some proteins, heteromeric POZ-POZ interactions. In addition, the POZ domain is required for transcriptional repression of several proteins, including BCL-6, Using a yeast two-hybrid screen, we identified N-CoR and SMRT as BCL-6 interacting proteins. Both N-CoR and SMRT, which were originally identified as co-repressors for the unliganded nuclear thyroid hormone and retinoic acid receptors, are components of large complexes containing histone deacetylases, We show that the interaction between BCL-6 and these co-repressors is also detected in the more physiologically relevant mammalian two-hybrid assay. The POZ domain is necessary and sufficient for interaction with these corepressors. BCL-6 and N-CoR co-localize to punctate regions of the nucleus. Furthermore, when BCL-6 is bound to its consensus recognition sequence in vivo, it can interact with N-CoR and SMRT, We find, in vitro, that POZ domains from a variety of other POZ domain-containing proteins, including the transcriptional repressor PLZF, as well as ZID, GAGA and a vaccinia virus protein, SalF17R, also interact with varying affinities with N-CoR and SMRT, We find that BCL-6 POZ domain mutations that disrupt the interaction with N-CoR and SMRT no longer repress transcription. In addition, these mutations no longer self associate suggesting that self interaction is required for interaction with the co-repressors and for repression. More recently N-CoR has also been implicated in transcriptional repression by the Mad/Mxi proteins. Our demonstration that N-CoR and SMRT interact with the POZ domain containing proteins indicates that these co-repressors are likely involved in the mediation of repression by multiple classes of repressors and may explain, in part, how POZ domain containing repressors mediate transcriptional repression.	Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Biochem Mol Biol & Biophys Program, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Bardwell, VJ (corresponding author), Univ Minnesota, Dept Biochem, 4-225 Millard Hall,435 Delaware St SE, Minneapolis, MN 55455 USA.				NATIONAL CANCER INSTITUTE [R29CA071540] Funding Source: NIH RePORTER; NCI NIH HHS [5R29CA71540, R29 CA071540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; Baron BW, 1997, GENE CHROMOSOME CANC, V19, P14, DOI 10.1002/(SICI)1098-2264(199705)19:1<14::AID-GCC3>3.0.CO;2-3; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1993, GENE CHROMOSOME CANC, V8, P149, DOI 10.1002/gcc.2870080303; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1995, ONCOGENE, V11, P2689; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FLENGHI L, 1995, AM J PATHOL, V147, P405; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOWARD ST, 1991, VIROLOGY, V180, P633, DOI 10.1016/0042-6822(91)90077-O; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; Kaplan J, 1997, NUCLEIC ACIDS RES, V25, P1108, DOI 10.1093/nar/25.6.1108; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LO CF, 1994, BLOOD, V83, P1757; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P217; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OHNO H, 1994, JPN J CANCER RES, V85, P592, DOI 10.1111/j.1349-7006.1994.tb02401.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Pittaluga S, 1996, J PATHOL, V179, P145; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Seyfert VL, 1996, ONCOGENE, V12, P2331; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; SOELLER WC, 1993, MOL CELL BIOL, V13, P7961, DOI 10.1128/MCB.13.12.7961; STEIN H, 1992, NEOPLASTIC HEMATOPAT, P675; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wilkinson JR, 1997, J BIOL CHEM, V272, P23824, DOI 10.1074/jbc.272.38.23824; XIONG WC, 1993, GENE DEV, V7, P1085, DOI 10.1101/gad.7.6.1085; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, BIOCHEM BIOPH RES CO, V53, P2732; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	73	249	255	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2473	2484		10.1038/sj.onc.1202197	http://dx.doi.org/10.1038/sj.onc.1202197			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824158	Bronze			2022-12-25	WOS:000076927300007
J	Giglione, C; Parmeggiani, A				Giglione, C; Parmeggiani, A			Raf-1 is involved in the regulation of the interaction between guanine nucleotide exchange factor and Ha-Ras - Evidences for a function of Raf-1 and phosphatidylinositol 3-kinase upstream to Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SWITCH-II REGION; SDC25 C-DOMAIN; STRUCTURAL REQUIREMENTS; MUSCARINIC RECEPTORS; CATALYTIC DOMAIN; IN-VITRO; BINDING; KINASE; IDENTIFICATION	The observation that activated c-Ha-Ras p21 interacts with diverse protein ligands suggests the existence of mechanisms that regulate multiple interactions with Ras. This work studies the influence of the has effector c-Raf-l on the action of guanine nucleotide exchange factors (GEFs) on Ha-Ras in vitro. Purified GEFs (the catalytic domain of yeast Sdc25p and the full-length and catalytic domain of mouse CDC25Mm) and the Ras binding domains (RBDs) of Raf-l (Raf (1-149) and Raf (51-131)) were used. Our results show that not only the intrinsic GTP/GTP exchange on Ha-Ras but also the GEF-stimulated exchange is inhibited in a concentration-dependent manner by the RBDs of Raf. Conversely, the scintillation proximity assay, which monitors the effect of GEF on the Ras Raf complex, showed that the binding of Raf and GEF to Ha-Ras GTP is mutually exclusive. The various GEFs used yielded comparable results. It is noteworthy that under more physiological conditions mimicking the cellular GDP/GTP ratio, Raf enhances the GEF-stimulated GDP/GTP exchange on Ha-Ras, in agreement with the sequestration of Ras GTP by Raf. Consistent with our results, the OFF-stimulated exchange of Ha-Ras GTP was also inhibited by another effector of Ras, the RED (amino acid residues 133-314) of phosphatidylinositol S-kinase p110 alpha. Our data show that Raf-l and phosphatidylinositol I-kinase can influence the upstream activation of Ha-Ras. The interference between Ras effecters and GEF could be a regulatory mechanism to promote the activity of Ha-Ras in the cell.	Ecole Polytech, Grp Biophys, Equipe 2, F-91128 Palaiseau, France	Institut Polytechnique de Paris	Parmeggiani, A (corresponding author), Ecole Polytech, Grp Biophys, Equipe 2, F-91128 Palaiseau, France.	andrea@poly.polytechnique.fr		Giglione, Carmela/0000-0002-7475-1558				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Baouz S, 1997, J BIOL CHEM, V272, P6671, DOI 10.1074/jbc.272.10.6671; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; CRECHET JB, 1993, J BIOL CHEM, V268, P14836; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; Giglione C, 1997, J BIOL CHEM, V272, P25128, DOI 10.1074/jbc.272.40.25128; Gorman C, 1996, J BIOL CHEM, V271, P6713, DOI 10.1074/jbc.271.12.6713; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOWE LR, 1993, ONCOGENE, V8, P2583; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JONESMK, 1998, J BIOL CHEM, V273, P1782; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1995, ONCOGENE, V11, P447; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; Sermon BA, 1996, J BIOL CHEM, V271, P1566, DOI 10.1074/jbc.271.3.1566; SKINNER RH, 1994, ANAL BIOCHEM, V223, P259, DOI 10.1006/abio.1994.1582; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; TORTI M, 1992, J BIOL CHEM, V267, P8293; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; VICIANA PR, 1996, EMBO J, V15, P2442; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	52	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34737	34744		10.1074/jbc.273.52.34737	http://dx.doi.org/10.1074/jbc.273.52.34737			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856997	hybrid			2022-12-25	WOS:000077719700015
J	McPhee, JC; Dang, YL; Davidson, N; Lester, HA				McPhee, JC; Dang, YL; Davidson, N; Lester, HA			Evidence for a functional interaction between integrins and G protein-activated inward rectifier K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; XENOPUS-OOCYTES; POTASSIUM CHANNEL; HUMAN NEUTROPHILS; SUBCELLULAR-LOCALIZATION; MOLECULAR-PROPERTIES; NEUROBLASTOMA-CELLS; CARBOXYL-TERMINUS; I-KACH; EXPRESSION	Heteromultimeric G protein-activated inward rectifier K+ (GIRK) channels, abundant in heart and brain, help to determine the cellular membrane potential as well as the frequency and duration of electrical impulses. The sequence arginine-glycine aspartate (RGD), located extracellularly between the first membrane-spanning region and the pore, is conserved among all identified GIRK subunits but is not found in the extracellular domain of any other cloned K+ channels. Many integrins, which, like channels, are integral membrane proteins, recognize this RGD sequence on other proteins, usually in the extracellular matrix. We therefore asked whether GIRK activity might be regulated by direct interaction with integrin, Here, we present evidence that mutation of the RGD site to RGE, particularly on the GIRK4 subunit, decreases or abolishes GIRK current. Furthermore, wild-type channels can be co-immunoprecipitated with integrin, The total cellular amount of expressed mutant GIRK channel protein is the same as the wild-type protein; however, the amount of mutant channel protein that localizes to the plasma membrane is decreased relative to wild-type, most likely accounting for the diminished GIRK current detected. GIRK channels appear to bind directly to integrin and to require this interaction for proper GIRK channel membrane localization and function.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Lester, HA (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029836] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29836] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; ARCANGELI A, 1993, J CELL BIOL, V122, P1131, DOI 10.1083/jcb.122.5.1131; BIANCHI L, 1995, BIOCHEM BIOPH RES CO, V210, P823, DOI 10.1006/bbrc.1995.1732; BORREGAARD N, 1994, J LEUKOCYTE BIOL, V56, P80, DOI 10.1002/jlb.56.1.80; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; COREY JL, 1994, J BIOL CHEM, V269, P14759; DALTON SL, 1995, MOL BIOL CELL, V6, P1781, DOI 10.1091/mbc.6.12.1781; DASCAL N, 1995, P NATL ACAD SCI USA, V92, P6758, DOI 10.1073/pnas.92.15.6758; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Derst C, 1997, BIOCHEM BIOPH RES CO, V230, P641, DOI 10.1006/bbrc.1996.6024; Doupnik CA, 1996, NEUROPHARMACOLOGY, V35, P923, DOI 10.1016/0028-3908(96)00125-6; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Ehrengruber MU, 1997, P NATL ACAD SCI USA, V94, P7070, DOI 10.1073/pnas.94.13.7070; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; GAWANTKA V, 1992, DEVELOPMENT, V115, P595; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INANOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022, DOI 10.1006/bbrc.1995.2072; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; IVANINA T, 1994, BIOCHEMISTRY-US, V33, P8786, DOI 10.1021/bi00195a021; Ji S, 1998, J BIOL CHEM, V273, P1324, DOI 10.1074/jbc.273.3.1324; Jones LS, 1996, TRENDS NEUROSCI, V19, P68; JONES LS, 1995, SOC NEUR ABSTR, V21, P1973; KIRSCH J, 1995, J NEUROSCI, V15, P4148; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; Li EG, 1998, J VIROL, V72, P2055, DOI 10.1128/JVI.72.3.2055-2061.1998; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Memmo LM, 1998, J CELL SCI, V111, P425; PANETTI TS, 1995, J BIOL CHEM, V270, P18593, DOI 10.1074/jbc.270.31.18593; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; QUICK MW, 1994, METH NEUROSCI, V19, P261; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SENGELOV H, 1994, J IMMUNOL, V153, P804; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Silverman SK, 1996, P NATL ACAD SCI USA, V93, P15429, DOI 10.1073/pnas.93.26.15429; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	52	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34696	34702		10.1074/jbc.273.52.34696	http://dx.doi.org/10.1074/jbc.273.52.34696			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856991	hybrid, Green Accepted			2022-12-25	WOS:000077719700009
J	Bhunia, AK; Arai, T; Bulkley, G; Chatterjee, S				Bhunia, AK; Arai, T; Bulkley, G; Chatterjee, S			Lactosylceramide mediates tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 (ICAM-1) expression and the adhesion of neutrophil in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LOW-DENSITY LIPOPROTEINS; ACTIVATED PROTEIN-KINASE; PROXIMAL TUBULAR CELLS; C-FOS EXPRESSION; NF-KAPPA-B; LEUKOCYTE ADHESION; IMMUNE-SYSTEM; PROLIFERATION; ATHEROSCLEROSIS	The endothelial expression of adhesion molecules by proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) has been suggested to contribute to the initiation of atherosclerotic plaque formation. Since lactosylceramide (LacCer) accumulates in large quantities in human atherosclerotic plaque, we have explored its role in TNF-alpha-induced expression of intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells and their consequent adhesion to polymorphonuclear leukocytes (PMNs). We found that TNF-alpha increased LacCer synthesis by way of stimulating the activity of UDP-galactose:glucosylceramide beta(1-->4)galactosyltransferase in a time-dependent fashion. The TNF-alpha-induced expression of ICAM-1 was abrogated by D-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), an inhibitor of UDP-galactose:glucosylceramide beta(1-->4)-galactosyltransferase. However, the addition of LacCer reversed the D-PDMP effect on TMF-alpha-induced ICAM-1 expression in human umbilical vein endothelial cells. Northern hybridization analysis of mRNA levels and enzyme-linked immunosorbent assays revealed that LacCer (5 mu M) specifically stimulated ICAM-1 at both the transcriptional and translational levels. This was accompanied by the adhesion of PMNs, which was visualized by confocal microscopy. Further studies revealed that LacCer stimulated the endogenous generation of superoxide radicals (O-2(radical anion)) about 5-fold compared with the control by specifically activating plasma membrane-associated NADPH-dependent oxidase. This phenomenon was blocked by the antioxidant N-acetyl-L-cysteine, pyrrolidine dithiocarbamate, and the NADPM oxidase inhibitor, diphenylene iodonium. Overexpression of endogeneous CuZn-superoxide dismutase via an adenoviral vector carrying cDNA for CuZn-superoxide dismutase, also inhibited LacCer-induced ICAM-1 expression in endothelial cells. In sum, our findings suggest that LacCer may play the role of a lipid second messenger in TNF-alpha-induced pathogenesis by activating an oxidant-sensitive transcriptional pathway that leads to the adhesion of PMNs to endothelial cells.	Johns Hopkins Univ, Sch Med, Dept Pediat, Lipid Res Atherosclerosis Unit, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University	Chatterjee, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Lipid Res Atherosclerosis Unit, 600 N Wolfe St, Baltimore, MD 21287 USA.	Chatter@welchlink.welch.jhu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031764, R01DK031722] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0-1-HL47212] Funding Source: Medline; NIDDK NIH HHS [DK 31764, R0-1-DK-31722] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai T, 1998, CIRC RES, V82, P540, DOI 10.1161/01.RES.82.5.540; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; CARLOS T, 1991, BLOOD, V77, P2266; CHATTERJEE S, 1987, BIOCHIM BIOPHYS ACTA, V923, P136, DOI 10.1016/0304-4165(87)90136-X; CHATTERJEE S, 1983, P NATL ACAD SCI-BIOL, V80, P1313, DOI 10.1073/pnas.80.5.1313; Chatterjee S, 1997, INDIAN J BIOCHEM BIO, V34, P56; Chatterjee S, 1997, GLYCOBIOLOGY, V7, P703, DOI 10.1093/glycob/7.5.703; CHATTERJEE S, 1991, BIOCHEM BIOPH RES CO, V181, P554, DOI 10.1016/0006-291X(91)91225-2; Chatterjee S, 1996, J LIPID RES, V37, P1334; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CHATTERJEE S, 1986, J LIPID RES, V23, P513; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; CHEMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; Hakomori SI, 1983, SPINGOLIPID CHEM, P52; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKNER BS, 1991, J EXP MED, V173, P1553; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LO SK, 1993, AM J PHYSIOL, V264, pL406; LOURY OH, 1951, J BIOL CHEM, V193, P265; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; Mann MJ, 1997, J CLIN INVEST, V99, P1295, DOI 10.1172/JCI119288; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MUKHIN DN, 1995, ARTERIOSCL THROM VAS, V15, P1607, DOI 10.1161/01.ATV.15.10.1607; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; RADIN NS, 1993, ADV LIPID RES, V26, P183; RICE GE, 1990, J EXP MED, V171, P1369, DOI 10.1084/jem.171.4.1369; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; WETHEIMER SJ, 1992, J BIOL CHEM, V267, P12030	47	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34349	34357		10.1074/jbc.273.51.34349	http://dx.doi.org/10.1074/jbc.273.51.34349			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852101	hybrid			2022-12-25	WOS:000077542200067
J	Ho, CK; Pei, Y; Shuman, S				Ho, CK; Pei, Y; Shuman, S			Yeast and viral RNA 5 ' triphosphatases comprise a new nucleoside triphosphatase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPPING ENZYME; SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; ESCHERICHIA-COLI; METHYLTRANSFERASE ACTIVITY; CAP METHYLTRANSFERASE; GUANYLYLTRANSFERASE; 5'-TRIPHOSPHATASE; SUBUNIT; ASSOCIATION	Saccharomyces cerevisiae Cet1p catalyzes the first step of mRNA capping, the hydrolysis of the gamma phosphate of triphosphate-terminated RNA to form a 5' diphosphate end. The RNA triphosphatase activity of Cet1p is magnesium-dependent and has a turnover number of 1 s(-1), Here we show that purified recombinant Cet1p possesses a robust ATPase activity (K-m = 2.8 mu M; V-max = 25 s(-1)) in the presence of manganese. Cobalt is: also an effective cofactor, but magnesium, calcium, copper, and zinc are not. Cet1p displays broad specificity in converting ribonucleoside triphosphates and deoxynucleoside triphosphates to their respective diphosphates. The manganese- and cobalt-dependent nucleoside triphosphatase of Cet1p resembles the nucleoside triphosphatase activities of the baculovirus LEF-4 and vaccinia virus D1 capping enzymes. Cet1p, LEF-4, and D1 share three collinear sequence motifs, Mutational analysis establishes that conserved glutamate and arginine: side chains within these motifs are essential for the RNA triphosphatase and ATPase activities of Cet1p in vitro and for Cet1p function in vivo. These findings are in accord with the effects of single alanine mutations at analogous positions of vaccinia capping enzyme. We suggest that the metal-dependent RNA triphosphatases encoded by yeast and DNA viruses comprise a novel family of phosphohydrolase enzymes with a common active site.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.		Pei, Yi/D-8998-2011; Ho, KIong/GPP-6051-2022	Pei, Yi/0000-0002-3466-760X; 				Bisaillon M, 1997, VIROLOGY, V236, P1, DOI 10.1006/viro.1997.8698; CONG PJ, 1995, MOL CELL BIOL, V15, P6222; Gross CH, 1998, J VIROL, V72, P7057, DOI 10.1128/JVI.72.9.7057-7063.1998; GROSS CH, 1998, IN PRESS J VIROL; HIGMAN MA, 1994, J BIOL CHEM, V269, P14974; Ho CK, 1996, J VIROL, V70, P6658, DOI 10.1128/JVI.70.10.6658-6664.1996; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; HO CK, 1998, J BIOL CHEM, V273; ITOH N, 1987, J BIOL CHEM, V262, P1989; ITOH N, 1984, J BIOL CHEM, V259, P3930; JIN J, 1998, IN PRESS J VIROL; MAO XD, 1994, J BIOL CHEM, V269, P24472; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Myette JR, 1996, J BIOL CHEM, V271, P11936, DOI 10.1074/jbc.271.20.11936; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1990, J BIOL CHEM, V265, P11960; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; Silva E, 1998, MOL CELL BIOL, V18, P4612, DOI 10.1128/MCB.18.8.4612; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Tsukamoto T, 1998, BIOCHEM BIOPH RES CO, V243, P101, DOI 10.1006/bbrc.1997.8038; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; Yamada-Okabe T, 1998, NUCLEIC ACIDS RES, V26, P1700, DOI 10.1093/nar/26.7.1700; Yu L, 1996, J VIROL, V70, P6162, DOI 10.1128/JVI.70.9.6162-6168.1996; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	33	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34151	34156		10.1074/jbc.273.51.34151	http://dx.doi.org/10.1074/jbc.273.51.34151			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852075	hybrid			2022-12-25	WOS:000077542200041
J	Yasuda, T; Yasuda, T; Ohmachi, Y; Katsuki, M; Yokoyama, M; Murata, A; Monden, M; Matsubara, K				Yasuda, T; Yasuda, T; Ohmachi, Y; Katsuki, M; Yokoyama, M; Murata, A; Monden, M; Matsubara, K			Identification of novel pancreas-specific regulatory sequences in the promoter region of human pancreatic secretory trypsin inhibitor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PTF1; RAT EXOCRINE PANCREAS; HUMAN GROWTH-HORMONE; TRANSGENIC MICE; CACCC ELEMENT; ACINAR-CELLS; DNA; EXPRESSION; ENHANCER; BINDING	The human pancreatic secretory trypsin inhibitor (PSTI) genes introduced into mice are specifically expressed in pancreas. The 1.0 kilobase pairs of PSTI 5'-flanking sequence directed preferential expression of a linked reporter chloramphenicol acetyltransferase, which was active in a PSTI-expressing pancreatic cell line (AR42j) but not in a PSTI-nonexpressing fibroblast cell line (XC). Two positively acting elements were found, Region I (-161/-116) and Region PI (-103/-74), as defined by transfection and binding assays with ARA2j cells. Region II is sufficient for the pancreas-specific expression, but the presence of both Regions I and II is needed for the maximum activity. Sequence studies also revealed that these two elements differ from the previously identified recognition sequence for pancreas transcription factor 1 (PTF1), When the same set of experiments was done with XC cells, one negatively acting element was identified, Region IV(-154/-137), Interestingly, Regions I and IV share a core sequence (-149/ -139), CAATCAATAAC. These results suggest that this novel element regulates the human PSTI gene expression positively in pancreatic cells but negatively in nonpancreatic cells.	Osaka Univ, Sch Med, Dept Surg, Osaka 5650871, Japan; Osaka Univ, Inst Mol & Cellular Biol, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1080071, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 01940031, Japan	Osaka University; Osaka University; University of Tokyo	Yasuda, T (corresponding author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Higashinari Ku, 1-3-3 Nakamichi, Osaka 5378511, Japan.							BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUSETTI NJ, 1995, BIOCHEM J, V311, P643, DOI 10.1042/bj3110643; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FODOR E, 1991, BIOCHEMISTRY-US, V30, P8102, DOI 10.1021/bi00247a002; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Greene L J, 1976, Methods Enzymol, V45, P813; GUERIN SL, 1990, J BIOL CHEM, V265, P22035; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HORII A, 1987, BIOCHEM BIOPH RES CO, V149, P635, DOI 10.1016/0006-291X(87)90415-3; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; KAZAL LA, 1948, J AM CHEM SOC, V70, P3034, DOI 10.1021/ja01189a060; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; LASKOWSKI M, 1953, J BIOL CHEM, V204, P797; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MATSUDA K, 1983, RES COMMUN CHEM PATH, V40, P301; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; ORNITZ DM, 1985, COLD SPRING HARB SYM, V50, P399, DOI 10.1101/SQB.1985.050.01.050; ORNITZ DM, 1985, NATURE, V313, P600, DOI 10.1038/313600a0; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; SCHAFFNER G, 1988, J MOL BIOL, V201, P81, DOI 10.1016/0022-2836(88)90440-8; SIMKOVIC D, 1962, FOLIA BIOL-PRAGUE, V8, P221; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; STRATOWA C, 1986, P NATL ACAD SCI USA, V83, P4292, DOI 10.1073/pnas.83.12.4292; TOMITA N, 1987, FEBS LETT, V225, P113, DOI 10.1016/0014-5793(87)81141-9; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEINRICH SL, 1991, MOL CELL BIOL, V11, P4985, DOI 10.1128/MCB.11.10.4985; YAMAMOTO T, 1985, BIOCHEM BIOPH RES CO, V132, P605, DOI 10.1016/0006-291X(85)91176-3; YASUDA T, 1993, GENE, V131, P275	40	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34413	34421		10.1074/jbc.273.51.34413	http://dx.doi.org/10.1074/jbc.273.51.34413			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852108	hybrid			2022-12-25	WOS:000077542200074
J	Askjaer, P; Jensen, TH; Nilsson, J; Englmeier, L; Kjems, J				Askjaer, P; Jensen, TH; Nilsson, J; Englmeier, L; Kjems, J			The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 REV; HIV-1 REV; PROTEIN IMPORT; MUTATIONAL ANALYSIS; ACTIVATION DOMAIN; RESPONSE ELEMENT; MESSENGER-RNA; BINDING-SITES; LEPTOMYCIN-B; IDENTIFICATION	Nuclear export of intron-containing human immunodeficiency virus type 1 (HIV-1) RNA is mediated by the viral Rev protein that contains both an RNA binding domain specific for the viral Rev response element (RRE) and a nuclear export signal (NES). The cellular CRM1 (Exportin1) protein functions as a nuclear export receptor for proteins carrying a Rev-like NES in a process that also requires the GTP bound form of the Ran GTPase. Using purified recombinant factors, we show by co-precipitation, gel mobility shift and protein footprinting assays that full-length Rev protein interacts directly with CRM1 in vitro independently of both the integrity of the characteristic leucine residues of the NES and the presence of the cytotoxin leptomycin B (LMB), Addition of RanGTP induces the formation of an RRE-Rev-CRM1-RanGTP complex that is sensitive to LMB, NES mutations, and Ran being charged with GTP. Within this complex, CRM1 is readily cross-linked to Cys(89) near the NES of Rev. By protein footprinting, we demonstrate that the NES of Rev and two regions in CRM1 become inaccessible to endoproteinases upon binding suggesting that these regions are involved in protein-protein interactions. Our data are consistent with a model in which CRM1 is the nuclear export receptor for the Rev-RRE ribonucleoprotein complex and that RanGTP binds to a preformed Rev-CRM1 complex and specifies a functional interaction with the NES.	Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark; European Mol Biol Lab, D-69117 Heidelberg, Germany	Aarhus University; European Molecular Biology Laboratory (EMBL)	Kjems, J (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Jensen, Torben H/G-2954-2017; Askjaer, Peter/I-3316-2012; Kjems, Jorgen/I-3490-2016; Englmeier, Ludwig/AAU-8430-2020	Askjaer, Peter/0000-0003-3192-4428; Kjems, Jorgen/0000-0003-4128-9317; Nilsson, Jakob/0000-0003-4100-1125				Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; COCHRANE AW, 1989, VIROLOGY, V173, P335, DOI 10.1016/0042-6822(89)90252-3; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hammarskjold ML, 1997, SEMIN CELL DEV BIOL, V8, P83, DOI 10.1006/scdb.1996.0127; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Izaurralde E, 1998, RNA, V4, P351; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jensen A, 1998, J MOL BIOL, V283, P245, DOI 10.1006/jmbi.1998.2085; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; JENSEN TH, 1995, J BIOL CHEM, V270, P13777, DOI 10.1074/jbc.270.23.13777; Jensen TH, 1997, FEBS LETT, V414, P50, DOI 10.1016/S0014-5793(97)00988-5; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; MALIM MH, 1991, J VIROL, V65, P4248, DOI 10.1128/JVI.65.8.4248-4254.1991; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MERMER B, 1990, NUCLEIC ACIDS RES, V18, P2037, DOI 10.1093/nar/18.8.2037; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OLSEN HS, 1991, J ACQ IMMUN DEF SYND, V4, P558; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pasquinelli AE, 1997, P NATL ACAD SCI USA, V94, P14394, DOI 10.1073/pnas.94.26.14394; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Richards SA, 1997, SCIENCE, V276, P1842, DOI 10.1126/science.276.5320.1842; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; Tange TO, 1996, J BIOL CHEM, V271, P10066, DOI 10.1074/jbc.271.17.10066; VENKATESH LK, 1990, VIROLOGY, V178, P327, DOI 10.1016/0042-6822(90)90414-M; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	51	163	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33414	33422		10.1074/jbc.273.50.33414	http://dx.doi.org/10.1074/jbc.273.50.33414			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837918	hybrid			2022-12-25	WOS:000077462500048
J	Buettner, C; Harney, JW; Larsen, PR				Buettner, C; Harney, JW; Larsen, PR			The 3 '-untranslated region of human type 2 iodothyronine deiodinase mRNA contains a functional selenocysteine insertion sequence element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROXINE; PROPYLTHIOURACIL; TRIIODOTHYRONINE; EUKARYOTES; SECRETION; CLONING; INVITRO	Type 2 deiodinase (D2) catalyzes the 5'-deiodination of thyroxine to form 3,5,3'-triiodothyronine. Two mammalian D2 cDNAs have been identified containing 2 kilobases (kb) of the 7-kb mRNA including the complete coding sequence. Both contain in-frame TGA codons, which should serve as selenocysteine codons. However, the selenocysteine insertion sequence (SECIS) elements required for the decoding of UGA as a selenocysteine in the 3'-untranslated region (UTR) of the mRNA are not present. We have identified two overlapping expressed sequence tag clones, which contain the missing 4.4-kb 3'-UTR of the human D2 (hD2) cDNA. Computer analysis predicts a stem loop structure 280 base pairs 5' to the polyadenylation site, which has potent SECIS activity. A fragment containing these sequences hybridizes to D2 mRNA in human thyroid. A G to A mutation in the essential AUGA motif of this element abolished its function. Transfection of the hD2 coding region plus the 3'-UTR results in the expression of D2, and its in vitro transcribed mRNA programs D2 activity in Xenopus oocytes. This is the first identification of a SECIS element in a mammalian D2 cDNA and establishes that hD2 is a bona fide selenoprotein.	Brigham & Womens Hosp, Div Thyroid, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Larsen, PR (corresponding author), Brigham & Womens Hosp, Div Thyroid, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	larsen@rascal.med.harvard.edu			NIDDK NIH HHS [DK 36256] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036256] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Andersson B, 1996, ANAL BIOCHEM, V236, P107, DOI 10.1006/abio.1996.0138; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BELASCO JG, 1998, CONTROL MESSENGER RN; BERRY MJ, 1990, MOL ENDOCRINOL, V4, P743, DOI 10.1210/mend-4-5-743; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; GEFFNER DL, 1975, J CLIN INVEST, V55, P224, DOI 10.1172/JCI107925; JANSSEN OE, 1995, J BIOL CHEM, V270, P28234; JANSSEN OE, 1992, J BIOL CHEM, V267, P13998; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P815, DOI 10.1210/jcem-66-4-815; KAPLAN MM, 1984, J CLIN ENDOCR METAB, V59, P253, DOI 10.1210/jcem-59-2-253; KIM SW, 1998, IN PRESS ENDOCRINOLO; LARSEN PR, 1995, ANNU REV NUTR, V15, P323, DOI 10.1146/annurev.nu.15.070195.001543; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; LEONARD JL, 1997, 79 ANN M AM END SOC, P2; LOPRESTI JS, 1989, J CLIN INVEST, V84, P1650, DOI 10.1172/JCI114343; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/0968-0004(96)10025-6; Martin GW, 1998, RNA, V4, P65; Martin GW, 1996, RNA, V2, P171; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SABERI M, 1975, J CLIN INVEST, V55, P218, DOI 10.1172/JCI107924; SALVATORE D, 1995, J CLIN INVEST, V96, P2421, DOI 10.1172/JCI118299; Salvatore D, 1996, ENDOCRINOLOGY, V137, P3308, DOI 10.1210/en.137.8.3308; Salvatore D, 1996, J CLIN INVEST, V98, P962, DOI 10.1172/JCI118880	27	61	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33374	33378		10.1074/jbc.273.50.33374	http://dx.doi.org/10.1074/jbc.273.50.33374			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837913	hybrid			2022-12-25	WOS:000077462500043
J	Hanada, K; Hara, T; Fukasawa, M; Yamaji, A; Umeda, M; Nishijima, M				Hanada, K; Hara, T; Fukasawa, M; Yamaji, A; Umeda, M; Nishijima, M			Mammalian cell mutants resistant to a sphingomyelin-directed cytolysin - Genetic and biochemical evidence for complex formation of the LCB1 protein with the LCB2 protein for serine palmitoyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SPHINGOLIPID SYNTHESIS; CAUSES CONTRACTION; EISENIA-FOETIDA; CELOMIC FLUID; BIOSYNTHESIS; CLONING; SACCHAROMYCES; MEMBRANES; EARTHWORM	Lysenin, a hemolytic protein derived from the earthworm Eisenia foetida, has a high affinity for sphingomyelin. Chinese hamster ovary (CHO) cells exhibited a high cytolytic sensitivity to lysenin, but treatment with sphingomyelinase rendered the cells resistant to lysenin. Temperature-sensitive CHO mutant cells defective in sphingolipid synthesis were resistant to lysenin, and this lysenin resistance was suppressed by metabolic complementation of sphingolipids. Selection of lysenin-resistant variants from mutagenized CHO cells yielded two types of sphingomyelin-deficient mutants, both of which showed less lysenin binding capability than wildtype cells. One mutant strain was severely defective in sphingomyelin synthesis but not glycosphingolipid synthesis, and another strain (designated LY-B) was incapable of de novo synthesis of any sphingolipid species and had no activity of serine palmitoyltransferase (SPT; EC 2.3.1.50) catalyzing the first step of sphingolipid biosynthesis. LY-B cells lacked the LCB1 protein, a component of SPT, and transfection of LY-B cells with the hamster LCB1 cDNA restored both SPT activity and sphingolipid synthesis to the cells. Expression of an affinity peptide-tagged LCB1 protein in LY-B cells caused the endogenous LCB2 protein to adsorb to a tag affinity matrix. In addition, an anti-hamster LCB2 protein antibody co-immunoprecipitated both SPT activity and the wild-type LCB1 protein with the LCB2 protein. Thus, cell surface sphingomyelin ia; essential for lysenin-induced cytolysis, and lysenin is a useful tool for isolation of sphingomyelin-deficient mutants, Moreover, these results demonstrate that the SPT enzyme comprises both the LCB1 and LCB2 proteins.	Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, Tokyo 1628640, Japan; Japan Sci & Technol Corp, CREST, Shinjuku Ku, Tokyo 1628640, Japan; Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, Tokyo 1130021, Japan	National Institute of Infectious Diseases (NIID); Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science	Hanada, K (corresponding author), Natl Inst Infect Dis, Dept Biochem & Cell Biol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	hanak@nih.go.jp						BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; FISHMAN PH, 1978, J LIPID RES, V19, P304; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANADA K, 1991, BIOCHIM BIOPHYS ACTA, V1086, P151, DOI 10.1016/0005-2760(91)90002-Y; HANADA K, 1990, J BIOL CHEM, V265, P22137; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Lange S, 1997, J BIOL CHEM, V272, P20884, DOI 10.1074/jbc.272.33.20884; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1983, BIOCHIM BIOPHYS ACTA, V754, P284, DOI 10.1016/0005-2760(83)90144-3; Milochau A, 1997, BBA-PROTEIN STRUCT M, V1337, P123, DOI 10.1016/S0167-4838(96)00160-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; Sekizawa Y, 1996, BIOMED RES-TOKYO, V17, P197, DOI 10.2220/biomedres.17.197; Sekizawa Y, 1997, GENE, V191, P97, DOI 10.1016/S0378-1119(97)00047-4; SVENNERHOLM E, 1963, BIOCHIM BIOPHYS ACTA, V70, P432, DOI 10.1016/0006-3002(63)90773-X; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; YOGEESWARAN G, 1974, BIOCHEM BIOPH RES CO, V56, P1010, DOI 10.1016/S0006-291X(74)80289-5; YU RK, 1972, J LIPID RES, V13, P680; ZHAO C, 1994, J BIOL CHEM, V269, P21480	30	161	163	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33787	33794		10.1074/jbc.273.50.33787	http://dx.doi.org/10.1074/jbc.273.50.33787			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837968	hybrid			2022-12-25	WOS:000077462500098
J	Kashio, N; Matsumoto, W; Parker, S; Rothstein, DM				Kashio, N; Matsumoto, W; Parker, S; Rothstein, DM			The second domain of the CD45 protein tyrosine phosphatase is critical for interleukin-2 secretion and substrate recruitment of TCR-zeta in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE-COMMON ANTIGEN; T-CELL RECEPTOR; MUTATIONAL ANALYSIS; DISTINCT ISOFORMS; FOCAL ADHESIONS; KINASE-ACTIVITY; PHOSPHORYLATION; ACTIVATION; LAR; LCK	The CD45 protein tyrosine phosphatase (PTPase) has been shown to regulate the activity of Lck and Fyn protein tyrosine kinases in T cells. However, it is not clear that these constitute the only CD45 substrates. Moreover, the manner by which PTPase activity and substrate recruitment are regulated, is poorly understood. Previous in vitro studies suggest that the first cytoplasmic PTPase domain (D1) of CD45 is the active PTPase, which may be regulated by an enzymatically inactive second PTPase domain (D2), However, the function of CD45 D2 in vivo is unknown. In this study, reconstitution of CD45(-) T cells with specific CD45 PTPase mutants allowed demonstration of a critical role for D2 in TCR-mediated interleukin (IL)-2 production. Specifically, replacement of CD45 D2 with that of the LAR PTPase to form a CD45/LAR:D2 chimera, abrogates CD45-dependent IL-2 production. This effect cannot be accounted for by loss of PTPase activity per se. The expression of D1 substrate-trapping mutants reveals an in vivo interaction between CD45 and TCR-zeta that is dependent on CD45 D2, Thus, cells expressing CD45 lacking D2 exhibit abnormal TCR-mediated signaling characterized by hyperphosphorylation of zeta and deficient ZAP-70 phosphorylation, These data suggest an essential role for CD45 D2 in TCR-regulated IL-2 production through substrate recruitment of the zeta chain.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA	Yale University	Rothstein, DM (corresponding author), Yale Univ, Sch Med, Dept Med, LCI 208,333 Cedar St, New Haven, CT 06520 USA.	david.rothstein@yale.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036317] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36317] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Basadonna GP, 1998, P NATL ACAD SCI USA, V95, P3821, DOI 10.1073/pnas.95.7.3821; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BURNS CM, 1994, J BIOL CHEM, V269, P13594; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; Doro U, 1996, MOL CELL BIOL, V16, P4996; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IIDA N, 1994, J BIOL CHEM, V269, P28576; ITOH M, 1992, J BIOL CHEM, V267, P12356; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; Lazarovits AI, 1996, NATURE, V380, P717, DOI 10.1038/380717a0; LEICHLEIDER R, 1993, J BIOL CHEM, V268, P21478; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MCFARLAND EDC, 1995, J BIOL CHEM, V270, P28103; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MCKENNEY DW, 1995, J BIOL CHEM, V270, P24949, DOI 10.1074/jbc.270.42.24949; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; Ng DHW, 1996, J BIOL CHEM, V271, P1295, DOI 10.1074/jbc.271.3.1295; NIKLINSKA BB, 1994, MOL CELL BIOL, V14, P8078, DOI 10.1128/MCB.14.12.8078; NOVAK TJ, 1994, IMMUNITY, V1, P109, DOI 10.1016/1074-7613(94)90104-X; Onodera H, 1996, J BIOL CHEM, V271, P22225, DOI 10.1074/jbc.271.36.22225; OSTERGAARD HL, 1933, P NATL ACAD SCI USA, V8689, P89; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RALPH SJ, 1987, EMBO J, V6, P1251, DOI 10.1002/j.1460-2075.1987.tb02361.x; ROSS SE, 1994, BIOCHEM BIOPH RES CO, V198, P88, DOI 10.1006/bbrc.1994.1013; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1988, J EXP MED, V168, P1553; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8689; TAN XH, 1993, J BIOL CHEM, V268, P6835; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4	51	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33856	33863		10.1074/jbc.273.50.33856	http://dx.doi.org/10.1074/jbc.273.50.33856			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837977	hybrid			2022-12-25	WOS:000077462500107
J	Dabrowski, M; Spahn, CMT; Schafer, MA; Patzke, S; Nierhaus, KH				Dabrowski, M; Spahn, CMT; Schafer, MA; Patzke, S; Nierhaus, KH			Protection patterns of tRNAs do not change during ribosomal translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA BINDING; AMINOACYL-TRANSFER RNA; COLI TRANSFER RNAPHE; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; MESSENGER-RNA; P-SITES; SYNTHETASE; TRANSCRIPTS; MODEL	The translocation reaction of two tRNAs on the ribosome during elongation of the nascent peptide chain is one of the most puzzling reactions of protein biosynthesis. We show here that the ribosomal contact patterns of the two tRNAs at A and P sites, although strikingly different from each other, hardly change during the translocation reaction to the P and E sites, respectively, The results imply that the ribosomal micro-environment of the tRNAs remains the same before and after translocation and thus suggest that a movable ribosomal do main exists that tightly binds two tRNAs and carries them together with the mRNA during the translocation reaction from the A-P region to the P-E region. These findings lead to a new explanation for the translocation reaction.	Max Planck Inst Mol Genet, AG Ribosomen, D-14195 Berlin, Germany	Max Planck Society	Nierhaus, KH (corresponding author), Max Planck Inst Mol Genet, AG Ribosomen, Ihnestr 73, D-14195 Berlin, Germany.		Patzke, Sebastian/G-9909-2019	Patzke, Sebastian/0000-0001-6821-197X				Alexeeva EV, 1996, NUCLEIC ACIDS RES, V24, P2228, DOI 10.1093/nar/24.12.2228; BEYER D, 1994, J BIOL CHEM, V269, P30713; BILGIN N, 1988, BIOCHIMIE, V70, P611, DOI 10.1016/0300-9084(88)90244-1; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BOMMER U, 1996, SUBCELLULAR FRACTION, P271; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; BULLARD JM, 1995, J MOL BIOL, V252, P572, DOI 10.1006/jmbi.1995.0521; Burkhardt N, 1998, CRIT REV BIOCHEM MOL, V33, P95, DOI 10.1080/10409239891204189; DABROWSKI M, 1995, EMBO J, V14, P4872, DOI 10.1002/j.1460-2075.1995.tb00168.x; DOUTHWAITE S, 1983, EUR J BIOCHEM, V131, P261, DOI 10.1111/j.1432-1033.1983.tb07258.x; Enriquez JA, 1996, P NATL ACAD SCI USA, V93, P8300, DOI 10.1073/pnas.93.16.8300; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GRAIFER DM, 1992, BIOCHIM BIOPHYS ACTA, V1171, P56, DOI 10.1016/0167-4781(92)90139-Q; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; HARDESTY B, 1990, RIBOSOME, P366; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; Junemann R, 1998, BIOL CHEM, V379, P807, DOI 10.1515/bchm.1998.379.7.807; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Nierhaus KH, 1998, P NATL ACAD SCI USA, V95, P945, DOI 10.1073/pnas.95.3.945; NIERHAUS KH, 1993, MOL MICROBIOL, V9, P661, DOI 10.1111/j.1365-2958.1993.tb01726.x; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; SARUYAMA H, 1986, MOL GEN GENET, V204, P221, DOI 10.1007/BF00425502; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4703; Spahn CMT, 1998, BIOL CHEM, V379, P753; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P20473, DOI 10.1074/jbc.270.35.20473; Wadzack J, 1997, J MOL BIOL, V266, P343, DOI 10.1006/jmbi.1996.0788	33	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32793	32800		10.1074/jbc.273.49.32793	http://dx.doi.org/10.1074/jbc.273.49.32793			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830024	hybrid			2022-12-25	WOS:000077329100063
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Quality control by proteases in the endoplasmic reticulum - Removal of a protease-sensitive site enhances expression of human P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; CYSTIC-FIBROSIS; PROTEINS; DEGRADATION; MUTANTS; CELLS; CFTR; TRANSPORT; INSERTION; MUTATIONS	Human P-glycoprotein is synthesized in HEK 293 cells as two major products: the 150-kDa core-glycosylated intermediate and the 170-kDa mature proteins. The 150- and 170-kDa proteins were not detected in mutants such as Gr341C, The major protein in this mutant was a 130-kDa proteolytic degradation product. This result suggested that the mutant protein was misfolded and sensitive to proteolytic digestion during or immediately after synthesis. We found that mutation of Arg(113), located in the first extracellular loop of P-glycoprotein and near the consensus glycosylation sites, to Ala, Lys, Glu, Met, or Cys blocked formation of the 130-kDa product. Introduction of R113A into mutant G341C resulted in the synthesis of a mature (170 kDa) and functional transporter. Similarly, when R113A was introduced into misprocessed mutants, there was increased synthesis of the 150-kDa core-glycosylated intermediate. Maturation of the core-glycosylated intermediate into the mature enzyme, however, was not observed. These results suggest that polytopic proteins are accessible to proteases in the lumen of the endoplasmic reticulum during biosynthesis and that proteases are important contributors to the quality control mechanism involved in protein folding, It is also shown that unstable proteins can be made more stable by removal of hypersensitive proteolytic sites.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Duncan EA, 1998, J BIOL CHEM, V273, P17801, DOI 10.1074/jbc.273.28.17801; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1994, J BIOL CHEM, V269, P28683; Miura H, 1996, BIOCHEM BIOPH RES CO, V227, P684, DOI 10.1006/bbrc.1996.1569; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Zhang JT, 1996, MOL BIOL CELL, V7, P1709, DOI 10.1091/mbc.7.11.1709	25	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32373	32376		10.1074/jbc.273.49.32373	http://dx.doi.org/10.1074/jbc.273.49.32373			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829963	hybrid			2022-12-25	WOS:000077329100002
J	Zhang, Y; Koushik, S; Dai, RJ; Mivechi, NF				Zhang, Y; Koushik, S; Dai, RJ; Mivechi, NF			Structural organization and promoter analysis of murine heat shock transcription factor-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DNA-BINDING; FACTOR-I; BIDIRECTIONAL PROMOTER; FACTOR AP-2; HELA-CELLS; TATA-LESS; EXPRESSION; PHOSPHORYLATION; STRESS	Heat shock factor-1 (HSF-1) activates transcription of heat shock proteins in eukaryotes. Several overlapping genomic clones containing the murine HSF-1 gene were isolated from a phage genomic library. Results indicate that the HSF-1 gene contains 13 exons that span at least 30 kilobase pairs. Sequence analysis of the 5'-untranslated region of HSF-1 suggests that it contains sequences of a recently described Bop1 gene in reverse orientation within its first 331 base pairs (bp) upstream of the translation initiation site. The minimal promoter sequence required for HSF-1 basal expression was identified by deletion analysis from -4 kilobase pairs to -331 bp of the promoter fused to a luciferase reporter gene using transient transfection assays. Results indicate that 331 bp upstream of the HSF-1 translation start site is required for maximal basal expression in NIH3T3 and F9 cells. This fragment also results in high levels of luciferase activity in the reverse orientation, that is, 5' to the Bop1 gene, suggesting that this segment is bidirectional and could be utilized for basal expression of both HSF-1 and Bop1 genes. This segment of the promoter contains recognition elements for Spl and CCAAT-box binding transcription factors, which when mutated in either sense or antisense orientations to the HSF-1 gene results in a reduction of basal expression by 50-75% relative to mild type, suggesting that these sites are critical for basal expression of both HSF-1 and Bop1 genes.	Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Grp, Augusta, GA 30912 USA; Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Mivechi, NF (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, Gene Regulat Grp, 1120 15th St,CB2803, Augusta, GA 30912 USA.	mivechi@immag.mcg.edu			NATIONAL CANCER INSTITUTE [R01CA062130] Funding Source: NIH RePORTER; NCI NIH HHS [CA62130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BUONO P, 1993, FEBS LETT, V328, P243, DOI 10.1016/0014-5793(93)80936-O; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; CUNNIFF NFA, 1993, J BIOL CHEM, V268, P8317; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; Guarguaglini G, 1997, BIOCHEM J, V325, P277, DOI 10.1042/bj3250277; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Leppa S, 1997, J BIOL CHEM, V272, P15293, DOI 10.1074/jbc.272.24.15293; LIAO WC, 1994, GENE, V146, P183, DOI 10.1016/0378-1119(94)90291-7; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MIVECHI NF, 1992, CANCER RES, V52, P6815; MIVECHI NF, 1995, CANCER RES, V55, P5512; MIVECHI NF, 1994, LEUKEMIA RES, V18, P597, DOI 10.1016/0145-2126(94)90041-8; MORGAN WD, 1987, MOL CELL BIOL, V7, P1129, DOI 10.1128/MCB.7.3.1129; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; Newton EM, 1996, MOL CELL BIOL, V16, P839; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHILLING LJ, 1995, CELL GROWTH DIFFER, V6, P541; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; ZHU QS, 1994, J NEUROSCI, V14, P7393; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	55	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32514	32521		10.1074/jbc.273.49.32514	http://dx.doi.org/10.1074/jbc.273.49.32514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829985	hybrid			2022-12-25	WOS:000077329100024
J	Closs, EI; Enseleit, F; Koesling, D; Pfeilschifter, JM; Schwarz, PM; Forstermann, U				Closs, EI; Enseleit, F; Koesling, D; Pfeilschifter, JM; Schwarz, PM; Forstermann, U			Coexpression of inducible NO synthase and soluble guanylyl cyclase in colonic enterocytes: a pathophysiologic signaling pathway for the initiation of diarrhea by gram-negative bacteria?	FASEB JOURNAL			English	Article						NO synthase mRNA; ribonuclease protection analysis; anti-NO synthase antibodies; dexamethasone; aminoguanidine; lipopolysaccharide	NITRIC-OXIDE SYNTHASE; PIG SKELETAL-MUSCLE; GLUCOCORTICOIDS INHIBIT; SELECTIVE-INHIBITION; KAPPA-B; EXPRESSION; INDUCTION; AMINOGUANIDINE; TRANSDUCTION; PURIFICATION	Infectious diarrhea is often caused by the exotoxins of gram-negative bacteria such as Escherichia coli. However, these organisms also contain lipopolysaccharide (LPS) endotoxin. LPS induces nitric oxide synthase II (NOS II, inducible NOS) in various types of cells. We now demonstrate by RNase protection analysis, Western blot, and immunohistochemistry that the expression of NOS II mRNA and protein is markedly induced in colonic enterocytes of mice that ingest LPS with their drinking water. Using the same techniques, significant levels of soluble guanylyl cyclase (GC-S), the effector enzyme of NO, were found constitutively expressed in the mucosa. This creates a pathophysiologic autocrine pathway producing increased levels of cyclic GMP and leading to hypersecretion and diarrhea. In fact, the LPS-induced diarrhea developed in parallel with the NOS II induction. Diarrhea could be controlled with orally administered dexamethasone, which prevented the LPS-stimulated induction of NOS II (RNase protection analysis and Western blot). Diarrhea was also blocked by oral aminoguanidine, an inhibitor of NOS II activity. These data suggest that in addition to the known heat-labile and heat-stable exotoxins, gram-negative bacteria may induce diarrhea through the release of endotoxins that induce a NOS II-GC-S autocrine pathway in mucosal epithelium.	Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany; Free Univ Berlin, Dept Pharmacol, D-14195 Berlin, Germany; Univ Frankfurt, Dept Pharmacol, D-60509 Frankfurt, Germany	Johannes Gutenberg University of Mainz; Free University of Berlin; Goethe University Frankfurt	Forstermann, U (corresponding author), Univ Mainz, Dept Pharmacol, Obere Zahlbacher Str 67, D-55101 Mainz, Germany.		Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				BLANKENSHIP LL, 1991, MICROCIRC ENDOTH LYM, V7, P57; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIROSA M, 1990, BIOCHEM BIOPH RES CO, V172, P1246, DOI 10.1016/0006-291X(90)91583-E; Ford H, 1997, J PEDIATR SURG, V32, P275, DOI 10.1016/S0022-3468(97)90194-9; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; FORSTERMANN U, 1995, N-S ARCH PHARMACOL, V352, P351; GARBERS DL, 1994, MOL BIOL CELL, V5, P1; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Gath I, 1997, FEBS LETT, V410, P319, DOI 10.1016/S0014-5793(97)00615-7; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; GRIFFITHS MJD, 1993, BRIT J PHARMACOL, V110, P963, DOI 10.1111/j.1476-5381.1993.tb13907.x; GUTHMANN F, 1992, N-S ARCH PHARMACOL, V346, P537; Hoffman RA, 1997, AM J PHYSIOL-GASTR L, V272, pG383, DOI 10.1152/ajpgi.1997.272.2.G383; JANN K, 1987, REV INFECT DIS, V9, pS517; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Kleinert H, 1996, J BIOL CHEM, V271, P6039, DOI 10.1074/jbc.271.11.6039; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE MM, 1987, J INFECT DIS, V155, P377, DOI 10.1093/infdis/155.3.377; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; MULSCH A, 1988, J PHARMACOL EXP THER, V247, P283; NAKANE M, 1988, BIOCHEM BIOPH RES CO, V157, P1139, DOI 10.1016/S0006-291X(88)80992-6; Nitsch DD, 1997, AM J PATHOL, V150, P889; RACHMILEWITZ D, 1995, GUT, V36, P718, DOI 10.1136/gut.36.5.718; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Schwarz PM, 1998, NEUROSCIENCE, V82, P255; SCHWARZ PM, 1998, IN PRESS MOL PHARM, V54; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; Wedel BJ, 1997, FEBS LETT, V410, P29, DOI 10.1016/S0014-5793(97)00358-X	34	17	17	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1643	1649		10.1096/fasebj.12.15.1643	http://dx.doi.org/10.1096/fasebj.12.15.1643			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837854				2022-12-25	WOS:000077574500006
J	Stockinger, W; Hengstschlager-Ottnad, E; Novak, S; Matus, A; Huttinger, M; Bauer, J; Lassmann, H; Schneider, WJ; Nimpf, J				Stockinger, W; Hengstschlager-Ottnad, E; Novak, S; Matus, A; Huttinger, M; Bauer, J; Lassmann, H; Schneider, WJ; Nimpf, J			The low density lipoprotein receptor gene family - Differential expression of two alpha(2)-macroglobulin receptors in the brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN OOCYTE RECEPTOR; APOLIPOPROTEIN-E RECEPTOR-2; ALPHA-2-MACROGLOBULIN RECEPTOR; ALZHEIMERS-DISEASE; TRANSPORT PROTEIN; CHOROID-PLEXUS; BINDING; LOCALIZATION; NEURONS; CELLS	LR7/8B is a member of the low density lipoprotein receptor gene family that is specifically synthesized in the brain. Here we have functionally expressed in 293 cells the splice variant harboring eight ligand binding repeats (LR8B), As assessed by confocal microscopy, the expressed receptor is localized to the plasma membrane. Importantly, in cell binding experiments, we demonstrate that this protein is a receptor for activated cy,macroglobulin, Because to date low density lipoprotein receptor-related protein (LRP) has been shown to be the only alpha(2)-macroglobulin receptor in brain, we became interested in the expression pattern of both proteins at the cellular level in the brain. LR7/8B is expressed in large neurons and Purkinje cells of the cerebellum and in cells constituting brain barrier systems such as the epithelial cells of the choroid plexus, the arachnoidea, and the endothelium of penetrating blood vessels. Anti-LR7/8B antibody stains the plasma membrane, dendrites, and vesicular structures close to the cell membrane of neurons, especially of Purkinje cells. In contrast, LRP is present in patchy regions around large neurons and most prominently in the glomeruli of the stratum granulare of the cerebellum. This suggests that, contrary to LR7/8B, LRP is expressed in synaptic regions of the neurons; furthermore, there is a striking difference in the expression patterns of LR7/8B and LRP in the choroid plexus. Whereas LRP shows base-lateral and apical localization in the epithelial cells, LR7/8B is restricted to the apical cell aspect facing the cerebrospinal fluid. Finally, these studies were extended to cultured primary rat neurons, where double immunofluorescence labeling with anti-LR7/8B and anti-microtubuli-associated protein 2 (MAPS) confirmed the somatodendritic expression of the receptor. Based upon these data, we propose that LR7/8B is involved in the clearance of alpha(2)-macroglobulin proteinase complexes and/or of other substrates bound to alpha(2)-macroglobulin from the cerebrospinal fluid and from the surface of neurons.	Bioctr, Dept Mol Genet, A-1030 Vienna, Austria; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Vienna, Dept Med Chem, A-1090 Vienna, Austria; Univ Vienna, Inst Neurol, A-1090 Vienna, Austria	University of Vienna; Friedrich Miescher Institute for Biomedical Research; University of Vienna; University of Vienna	Schneider, WJ (corresponding author), Bioctr, Dept Mol Genet, Dr Bohrgasse 9-2, A-1030 Vienna, Austria.	JNIMPF@mol.univie.ac.at	Bauer, Jan/F-5429-2011; Lassmann, Hans/Z-2269-2019	Bauer, Jan/0000-0001-5802-8047; Lassmann, Hans/0000-0001-8617-5052				Angeletti RH, 1997, P NATL ACAD SCI USA, V94, P283, DOI 10.1073/pnas.94.1.283; Avramoglu RK, 1998, J BIOL CHEM, V273, P6057, DOI 10.1074/jbc.273.11.6057; BARTLETT WP, 1984, J NEUROSCI, V4, P1944; Bauer J, 1988, Adv Exp Med Biol, V240, P199; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; Brandes C, 1997, GENOMICS, V42, P185, DOI 10.1006/geno.1997.4702; Brown MD, 1997, BRAIN RES, V747, P313, DOI 10.1016/S0006-8993(96)01321-2; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; de Chaves EIP, 1997, J BIOL CHEM, V272, P30766, DOI 10.1074/jbc.272.49.30766; GEORGE R, 1987, J BIOL CHEM, V262, P16838; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOODRUM JF, 1995, J NEUROCHEM, V64, P408; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HERMIER D, 1985, BIOCHIM BIOPHYS ACTA, V836, P105, DOI 10.1016/0005-2760(85)90226-7; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; Kim DH, 1997, J BIOL CHEM, V272, P8498, DOI 10.1074/jbc.272.13.8498; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAMARRE J, 1991, LAB INVEST, V65, P3; LI CX, 1991, J BIOL CHEM, V266, P9263; Lindstedt KA, 1997, J BIOL CHEM, V272, P30221, DOI 10.1074/jbc.272.48.30221; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MOLLGARD K, 1988, DEV BIOL, V128, P207, DOI 10.1016/0012-1606(88)90283-7; NIMPF J, 1988, J LIPID RES, V29, P657; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; THOMAS T, 1989, DEV BIOL, V134, P38, DOI 10.1016/0012-1606(89)90076-6; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; VANGOOL D, 1993, NEUROBIOL AGING, V14, P233, DOI 10.1016/0197-4580(93)90006-W; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; WOLF BB, 1992, AM J PATHOL, V141, P37; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321	45	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32213	32221		10.1074/jbc.273.48.32213	http://dx.doi.org/10.1074/jbc.273.48.32213			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822699	hybrid			2022-12-25	WOS:000077207000081
J	Kawahara, A; Kobayashi, T; Nagata, S				Kawahara, A; Kobayashi, T; Nagata, S			Inhibition of Fas-induced apoptosis by Bcl-2	ONCOGENE			English	Article						apoptosis; Bcl-2; caspase; Fas	SIGNALING COMPLEX DISC; MEDIATED CELL-DEATH; PROTEASE ACTIVATION; T-CELLS; FAMILY; LIGAND; FLICE; REGULATORS; RESISTANCE; EXPRESSION	Jurkat cells express Fas, and rapidly undergo apoptosis in response to Fas ligand or an agonistic anti-Fas antibody. This apoptotic pathway is mediated by a cascade of caspases, In this report, we show that Fas activation induced the processing of caspase 8 in Jurkat cells with a time frame similar to the activation of caspase 3 and the proteolysis of nuclear proteins. Jurkat cell transformants that overexpress Bcl-2 were partially but not completely resistant to the Fas-induced apoptosis. Little processing of caspase 8 was observed upon Fas activation in these transformants. Furthermore, although caspase 8 was recruited to Fas upon Fas activation in the parental Jurkat cells, the recruitment of caspase 8 to Fas was inhibited in the transformants overexpressing Bcl-2, These results suggest that Bcl-2 inhibits Fas-induced apoptosis by preventing the formation of the death-inducing signaling complex that is composed of Fas, FADD/MORT1, and caspase 8.	Osaka Biosci Inst, Osaka 5650874, Japan; Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; MBL Co Ltd, Ina Labs, Nagano 3960002, Japan	Osaka University	Nagata, S (corresponding author), NICHHD, Mol Genet Lab, NIH, Bldg 6B,Room 420, Bethesda, MD 20892 USA.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEMON SA, 1995, J IMMUNOL, V155, P4644; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peter ME, 1997, EUR J IMMUNOL, V27, P1207, DOI 10.1002/eji.1830270523; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wyllie A H, 1980, Int Rev Cytol, V68, P251	38	59	67	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	1998	17	20					2549	2554		10.1038/sj.onc.1202192	http://dx.doi.org/10.1038/sj.onc.1202192			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840917				2022-12-25	WOS:000077058900001
J	Liu, W; Clark, WA; Sharma, P; Northup, JK				Liu, W; Clark, WA; Sharma, P; Northup, JK			Mechanism of allosteric regulation of the rod cGMP phosphodiesterase activity by the helical domain of transducin alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; RESONANCE ENERGY-TRANSFER; GTP-GAMMA-S; G-PROTEIN; OUTER SEGMENTS; ADENYLYL-CYCLASE; SIGNAL-TRANSDUCTION; RETINAL RODS; INHIBITORY SUBUNIT; MOLECULAR-CLONING	The G protein alpha subunit (G alpha) is composed of two distinct folding domains: a GTP-binding Ras-like domain and an alpha helical domain QID). We have recently reported that the helical domain (HDt) of the vertebrate visual transducin alpha subunit (G alpha(t)) synergizes activation of retinal cyclic GMP phosphodiesterase (PDE) by activated G alpha(t) (Liu, W., and Northup, J. K., (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 12878-12883). Here, we examine the molecular basis for this HD-based signaling regulation, and we provide a new model for the activation of the target effector. The HD proteins derived from visual transducin or taste gustducin alpha subunits, but no other Get HD proteins, each attenuate the PDE catalytic core (P alpha beta) and synergize G alpha(t) stimulation of the holoPDE (P alpha beta gamma(2)) with similar apparent affinities. The data from studies of both HDt-mediated attenuation and stimulation indicate that the HDt and the PDE inhibitory subunit (P gamma) interact with PDE at independent sites and that P alpha beta contains the binding sites for HD. The saturation of both processes by HDt displays positive cooperativity with Hill coefficients of 1.5 for the attenuation of P alpha beta activity and 2.1 for synergism of holoPDE activation. Our data suggest the that G alpha(t)-HDt regulates PDE by allosterically decreasing the affinity of P alpha beta for P gamma and thus simultaneously facilitating the interaction of the activated G alpha(t)-Ras-like domain with P gamma. Thus, we propose a new model for the high efficiency of PDE activation as well as deactivation, and, overall, a novel mechanism for controlling fidelity, sensitivity, and efficacy of G protein signaling.	NIDCD, Lab Cellular Biol, NIH, Rockville, MD 20850 USA; NINDS, Neurochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Northup, JK (corresponding author), NIDCD, Lab Cellular Biol, NIH, 5 Res Ct, Rockville, MD 20850 USA.							ANTONELLI M, 1994, FEBS LETT, V340, P249, DOI 10.1016/0014-5793(94)80148-7; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BENJAMIN DR, 1995, J MOL BIOL, V254, P681, DOI 10.1006/jmbi.1995.0647; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; Berger AL, 1997, J BIOL CHEM, V272, P2714, DOI 10.1074/jbc.272.5.2714; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; CLERC A, 1992, J BIOL CHEM, V267, P6620; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; ERICKSON JW, 1993, J BIOL CHEM, V268, P3328; ERIKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FAWZI AB, 1991, J BIOL CHEM, V266, P12194; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HAMM HE, 1998, ANNU REV BIOCHEM, V66, P669; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HOON MA, 1995, BIOCHEM J, V309, P629, DOI 10.1042/bj3090629; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; JONES DT, 1987, J BIOL CHEM, V262, P14241; KROLL S, 1989, J BIOL CHEM, V264, P4490; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; Liu Y, 1996, J BIOL CHEM, V271, P26900, DOI 10.1074/jbc.271.43.26900; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; Scholich K, 1997, P NATL ACAD SCI USA, V94, P9602, DOI 10.1073/pnas.94.18.9602; SEGEL IH, 1975, ENZYME KINETICS, P367; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1991, J BIOL CHEM, V266, P10711; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; Wieland T, 1997, J BIOL CHEM, V272, P8853; YEE R, 1978, J BIOL CHEM, V253, P8902	60	20	22	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34284	34292		10.1074/jbc.273.51.34284	http://dx.doi.org/10.1074/jbc.273.51.34284			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852093	hybrid			2022-12-25	WOS:000077542200059
J	Swanson, AK; Stoltzfus, CM				Swanson, AK; Stoltzfus, CM			Overlapping Cis sites used for splicing of HIV-1 env/nef and rev mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRE-MESSENGER-RNA; BRANCH SITE; MAMMALIAN INTRONS; TAT EXON-2; IN-VITRO; IDENTIFICATION; SELECTION; INVITRO; 3'-SPLICE-SITE	Alternative splicing is used to generate more than 30 human immunodeficiency virus type 1 (HIV-1) spliced and unspliced mRNAs from a single primary transcript. The abundance of HIV-1 mRNAs is determined by the efficiencies with which its different 5' and 3' splice sites are used. Three splice sites (A4c, A4a, and A4b) are upstream of the rev initiator AUG. RNAs spliced at A4c, A4a, and A4b are used as mRNAs for Rev. Another 3' splice site (A5) is immediately downstream of the rev initiator. RNAs spliced at A5 are used as mRNAs for Env and Nef, In this report, primer extension analysis of splicing intermediates was used to show that there are eight branch points in this region, all of which map to adenosine residues. In addition, cis elements recognized by the cellular splicing machinery overlap; the two most 3' branch points overlap with the AG dinucleotides at rev 3' splice sites A4a and A4b, Competition of the overlapping cis sites for different splicing factors may play a role in maintaining the appropriate balance of mRNAs in HIV-1-infected cells. In support of this possibility, mutations at rev 3' splice site A4b AG dinucleotide dramatically increased splicing of the env/nef 3' splice site A5, This correlated with increased usage of the four most 3' branch points, which include those within the rev 3' splice site AG dinucleotides. Consistent with these results, analysis of a mutant in which three of the four env/nef branch points were inactivated indicated that use of splice site A5 was inhibited and splicing was shifted predominantly to the most 5' rev 3' splice site A4c with preferential use of the two most 5' branch points. Our results suggest that spliceosomes formed at rev A4a-4b, rev A4c, and env/nef A5 3' splice sites each recognize different subsets of the eight branch point sequences.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Stoltzfus, CM (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI036073, R01AI036073] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36073] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; Chiara MD, 1996, MOL CELL BIOL, V16, P3317; CULLEN BR, 1991, ANNU REV MICROBIOL, V45, P219; Damier L, 1997, BIOCHEM BIOPH RES CO, V237, P182, DOI 10.1006/bbrc.1997.7091; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYHRMIKKELSEN H, 1995, J BIOL CHEM, V270, P24060, DOI 10.1074/jbc.270.41.24060; GATTONI R, 1988, NUCLEIC ACIDS RES, V16, P2389, DOI 10.1093/nar/16.6.2389; GE H, 1990, P NATL ACAD SCI USA, V87, P3338, DOI 10.1073/pnas.87.9.3338; HELFMAN DM, 1989, NUCLEIC ACIDS RES, V17, P5633, DOI 10.1093/nar/17.14.5633; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Moore M., 1993, RNA WORLD, P303; NOBLE JCS, 1988, GENE DEV, V2, P1460, DOI 10.1101/gad.2.11.1460; OREILLY MM, 1995, VIROLOGY, V213, P373, DOI 10.1006/viro.1995.0010; PURCELL DFJ, 1993, J VIROL, V67, P6365, DOI 10.1128/JVI.67.11.6365-6378.1993; RIGGS NL, 1994, VIROLOGY, V202, P264, DOI 10.1006/viro.1994.1342; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SADAIE MR, 1988, P NATL ACAD SCI USA, V85, P9224, DOI 10.1073/pnas.85.23.9224; Sambrook J., 2002, MOL CLONING LAB MANU; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Wentz MP, 1997, J VIROL, V71, P8542, DOI 10.1128/JVI.71.11.8542-8551.1997; Wu SP, 1997, EMBO J, V16, P4421, DOI 10.1093/emboj/16.14.4421	28	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34551	34557		10.1074/jbc.273.51.34551	http://dx.doi.org/10.1074/jbc.273.51.34551			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852125	hybrid			2022-12-25	WOS:000077542200091
J	Tomasello, E; Olcese, L; Vely, F; Geourgeon, C; Blery, M; Moqrich, A; Gautheret, D; Djabali, M; Mattei, MG; Vivier, E				Tomasello, E; Olcese, L; Vely, F; Geourgeon, C; Blery, M; Moqrich, A; Gautheret, D; Djabali, M; Mattei, MG; Vivier, E			Gene structure, expression pattern, and biological activity of mouse killer cell activating receptor-associated protein (KARAP)/DAP-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; INHIBITORY RECEPTORS; SIGNAL-TRANSDUCTION; COMPLEX; BINDING; FAMILY; RECONSTITUTION; TRANSMEMBRANE; SPECIFICITY; SEGMENTS	Natural killer cell and T cell subsets express at their cell surface a repertoire of receptors for MHC class I molecules, the natural killer cell receptors (NKRs), NKRs are characterized by the existence of inhibitory and activating isoforms, which are encoded by highly homologous but separate genes present in the same locus. Inhibitory isoforms express an intracytoplasmic immunoreceptor tyrosine-based inhibition motif, whereas activating isoforms lack any immunoreceptor tyrosine-based inhibition motif but harbor a charged amino acid residue in their transmembrane domain. We previously characterized KARAP (killer cell activating receptor-associated protein), a novel disulfide-linked tyrosine-phosphorylated dimer that selectively associates with the activating NKR isoforms. We report here the identification of the mouse KARAP gene, its localization on chromosome 7 and its genomic organization in five exons. Point mutation and transfection studies revealed that KARAP is a novel signaling transmembrane subunit whose transduction function depends on the integrity of an intracytoplasmic immunoreceptor tyrosine-based activation motif. In contrast to previous members of the immunoreceptor tyrosine-based activation motif polypeptide family, KARAP is ubiquitously expressed on hematopoietic and nonhematopoietic cells, suggesting its association with a broad range of activating receptors in a variety of tissues.	CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13228 Marseille 09, France; IBCP, CNRS, UPR 412, F-69367 Lyon 07, France; CNRS, EP 91, F-13402 Marseille 20, France; Fac Med Timone, INSERM, U491, Marseille, France; Inst Univ France, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut Universitaire de France	Vivier, E (corresponding author), CNRS Marseille Luminy, INSERM, Ctr Immunol, Case 906, F-13228 Marseille 09, France.	vivier@ciml.univ-mrs.fr	Vivier, Eric/F-8939-2010; Vély, Frédéric/HHM-3894-2022	Vivier, Eric/0000-0001-7022-8287; Vely, Frederic/0000-0002-1682-0949; moqrich, aziz/0000-0002-1937-1675; Gautheret, Daniel/0000-0002-1508-8469; BLERY, Mathieu/0000-0003-4738-6038; Mattei, Marie-Genevieve/0000-0002-6027-7058; Tomasello, Elena/0000-0002-6839-5219				BEAUFILS P, 1993, EMBO J, V12, P5105, DOI 10.1002/j.1460-2075.1993.tb06205.x; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Blery M, 1997, J BIOL CHEM, V272, P8989; Bottino C, 1996, EUR J IMMUNOL, V26, P1816, DOI 10.1002/eji.1830260823; Campbell KS, 1998, EUR J IMMUNOL, V28, P599, DOI 10.1002/(SICI)1521-4141(199802)28:02<599::AID-IMMU599>3.3.CO;2-6; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DONNADIEU E, 1994, J BIOL CHEM, V269, P32828; Fleischer B, 1996, INFECT IMMUN, V64, P987, DOI 10.1128/IAI.64.3.987-994.1996; GABERT J, 1987, CELL, V50, P545, DOI 10.1016/0092-8674(87)90027-4; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hoglund P, 1997, IMMUNOL REV, V155, P11, DOI 10.1111/j.1600-065X.1997.tb00936.x; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; Lewis LA, 1997, J IMMUNOL, V159, P2292; Long EO, 1997, CURR OPIN IMMUNOL, V9, P344, DOI 10.1016/S0952-7915(97)80080-5; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; Mandelboim O, 1998, P NATL ACAD SCI USA, V95, P3798, DOI 10.1073/pnas.95.7.3798; Mason LH, 1998, J IMMUNOL, V160, P4148; Moretta A, 1997, CURR OPIN IMMUNOL, V9, P694, DOI 10.1016/S0952-7915(97)80051-9; Olcese L, 1997, J IMMUNOL, V158, P5083; Pao LI, 1998, J IMMUNOL, V160, P3305; PAOLINI R, 1995, J EXP MED, V181, P247, DOI 10.1084/jem.181.1.247; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Smith KM, 1998, J IMMUNOL, V161, P7; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Vely F, 1997, J IMMUNOL, V159, P2075; Vely F, 1997, EUR J IMMUNOL, V27, P3010, DOI 10.1002/eji.1830271138; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wilson MJ, 1997, TISSUE ANTIGENS, V49, P574, DOI 10.1111/j.1399-0039.1997.tb02804.x	40	135	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34115	34119		10.1074/jbc.273.51.34115	http://dx.doi.org/10.1074/jbc.273.51.34115			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852069	hybrid			2022-12-25	WOS:000077542200035
J	Willows, RD; Beale, SI				Willows, RD; Beale, SI			Heterologous expression of the Rhodobacter capsulatus BchI, -D, and -H genes that encode magnesium chelatase subunits and characterization of the reconstituted enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MG-CHELATASE; PROTOPORPHYRIN-IX; ESCHERICHIA-COLI; BACTERIOCHLOROPHYLL; BIOSYNTHESIS; LOCALIZATION; SPHAEROIDES; PROTEINS; CHLOROPLASTS; ASSAY	Magnesium chelatase inserts Mg2+ into protoporphyrin IX in the chlorophyll and bacteriochlorophyll biosynthetic pathways. In photosynthetic bacteria, the products of three genes, bchI, bchD, and bchA, are required for magnesium chelatase activity. These genes from Rhodobacter capsulatus were cloned separately into expression plasmids pET3a and pET15b. The pET15b constructs produced NH2-terminally His(6)-tagged proteins, All proteins were highly expressed and were purified to near homogeneity. The BchI and BchH proteins were soluble, BchD proteins were insoluble, inactive inclusion bodies that were renatured by rapid dilution from 6 M urea. The presence of BchI in the solution into which the urea solution of BchD was diluted increased the yield of active Echo. A molar ratio of 1 BchI:1 BchD was sufficient for maximum renaturation of Echo. All of the proteins were active in the magnesium chelatase assay except His-tagged BchI, which was inactive and inhibited in incubations containing non-His-tagged BchI, Expressed BchH proteins contained tightly bound protoporphyrin IX, and they were susceptible to inactivation by light. Maximum magnesium chelatase activity per mol of BchD occurred at a stoichiometry of 4 BchI:l BchD, The optimum reaction pH was 8.0. The reaction exhibited Michaelis-Menten kinetics with respect to protoporphyrin IX and BchH.	Brown Univ, Div Biol & Med, Providence, RI 02912 USA	Brown University	Beale, SI (corresponding author), Brown Univ, Div Biol & Med, Providence, RI 02912 USA.		Willows, Robert/C-1537-2010	Willows, Robert/0000-0002-0731-2950				BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; CASTELFRANCO PA, 1978, ARCH BIOCHEM BIOPHYS, V183, P365; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FUESLER TP, 1984, PLANT PHYSIOL, V75, P662, DOI 10.1104/pp.75.3.662; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; Gibson LCD, 1996, PLANT PHYSIOL, V111, P61, DOI 10.1104/pp.111.1.61; Gorchein Abel, 1993, Biochemical Society Transactions, V21, p201S; Guo RB, 1998, PLANT PHYSIOL, V116, P605, DOI 10.1104/pp.116.2.605; Hansson M, 1997, P NATL ACAD SCI USA, V94, P13351, DOI 10.1073/pnas.94.24.13351; Harlow E., 1988, ANTIBODIES LAB MANUA; Jensen PE, 1996, J BIOL CHEM, V271, P16662, DOI 10.1074/jbc.271.28.16662; Kannangara CG, 1997, MOL GEN GENET, V254, P85, DOI 10.1007/s004380050394; KWAK JH, 1995, ANAL BIOCHEM, V228, P178, DOI 10.1006/abio.1995.1335; MARRS B, 1981, J BACTERIOL, V146, P1003, DOI 10.1128/JB.146.3.1003-1012.1981; Moan J, 1997, INT J CANCER, V70, P90, DOI 10.1002/(SICI)1097-0215(19970106)70:1<90::AID-IJC14>3.0.CO;2-H; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Papenbrock J, 1997, PLANT J, V12, P981, DOI 10.1046/j.1365-313X.1997.12050981.x; Petersen BL, 1998, J BACTERIOL, V180, P699, DOI 10.1128/JB.180.3.699-704.1998; Petersen BL, 1996, HEREDITAS, V125, P93, DOI 10.1111/j.1601-5223.1996.00093.x; REVILLA Y, 1986, J BIOL CHEM, V261, P6486; RICHTER ML, 1982, BIOCHIM BIOPHYS ACTA, V717, P255, DOI 10.1016/0304-4165(82)90177-5; Sambrook J., 2002, MOL CLONING LAB MANU; WALKER CJ, 1991, P NATL ACAD SCI USA, V88, P5789, DOI 10.1073/pnas.88.13.5789; WALKER CJ, 1994, BIOCHEM J, V299, P277, DOI 10.1042/bj2990277; WALKER CJ, 1992, PLANT PHYSIOL BIOCH, V30, P263; Walker CJ, 1997, BIOCHEM J, V327, P321; WALKER CJ, 1995, PHYSIOL PLANTARUM, V94, P419, DOI 10.1111/j.1399-3054.1995.tb00948.x; Willows RD, 1996, EUR J BIOCHEM, V235, P438, DOI 10.1111/j.1432-1033.1996.00438.x; WILLOWS RD, 1997, PLANT PHYSIOL, V111, pS155; YANG ZM, 1990, J BACTERIOL, V172, P5001, DOI 10.1128/jb.172.9.5001-5010.1990	30	52	61	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34206	34213		10.1074/jbc.273.51.34206	http://dx.doi.org/10.1074/jbc.273.51.34206			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852082	hybrid			2022-12-25	WOS:000077542200048
J	Wong, AW; He, SM; Grubb, JH; Sly, WS; Withers, SG				Wong, AW; He, SM; Grubb, JH; Sly, WS; Withers, SG			Identification of Glu-540 as the catalytic nucleophile of human beta-glucuronidase using electrospray mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-REACTIVITY RELATIONSHIPS; MUCOPOLYSACCHARIDOSIS TYPE-VII; ESCHERICHIA-COLI; ACTIVE-SITE; LAC-Z; GLYCOSYL HYDROLASES; GALACTOSIDASE; MECHANISM; ACID; SELECTFLUOR	Human beta-glucuronidase is a member of the Family 2 glycosylhydrolases that cleaves beta-D-glucuronic acid residues from the nonreducing termini of glycosaminoglycans. The enzyme is shown to catalyze glycoside bond hydrolysis with net retention of anomeric configuration, presumably via a mechanism involving a covalent glucuronyl-enzyme intermediate. Incubation of human beta-glucuronidase with 2-deoxy-2-fluoro-beta-D-glucuronyl fluoride resulted in time-dependent inactivation of the enzyme through the accumulation of a covalent 2-deoxy-2-fluoro-alpha-D-glucuronyl-enzyme, as observed by electrospray mass spectrometry. Regeneration of the free enzyme by hydrolysis or transglycosylation and removal of excess inactivator demonstrated that the covalent intermediate was kinetically competent. Peptic digestion of the 2-deoxy-2-fluoro-alpha-D-glucuronyl-enzyme intermediate and subsequent analysis by liquid chromatography coupled with electrospray ionization triple quadrupole mass spectrometry indicated the presence of a 2-deoxy-2-fluoro-alpha-D-glucuronyl peptide. Sequence determination of the labeled peptide by tandem mass spectrometry in the daughter ion scan mode permitted the identification of Glu-540 as the catalytic nucleophile within the sequence S (E) under bar YGAET.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	University of British Columbia; Saint Louis University	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca						Burkart MD, 1997, J AM CHEM SOC, V119, P11743, DOI 10.1021/ja9723904; CSUK R, 1988, ADV CARBOHYD CHEM BI, V46, P73, DOI 10.1016/S0065-2318(08)60165-1; DENOOY AEJ, 1995, TETRAHEDRON, V51, P8023, DOI 10.1016/0040-4020(95)00417-7; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GRUBB JH, 1993, FASEB J, V7, pA1255; GYORGYDEAK Z, 1995, CARBOHYD RES, V268, P85, DOI 10.1016/0008-6215(94)00313-5; Heeres A, 1997, CARBOHYD RES, V299, P221, DOI 10.1016/S0008-6215(97)00030-X; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Ho K J, 1991, Protein Expr Purif, V2, P63, DOI 10.1016/1046-5928(91)90011-7; Howard S, 1997, BIOCHEM BIOPH RES CO, V238, P896, DOI 10.1006/bbrc.1997.7148; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; LAL GS, 1993, J ORG CHEM, V58, P2791, DOI 10.1021/jo00062a023; LEATHERBARROW RJ, 1990, GRAFIT VERSION 3 03; MIAO SC, 1994, J BIOL CHEM, V269, P10975; PAIGEN K, 1989, PROG NUCLEIC ACID RE, V37, P155; Richard JP, 1996, BIOCHEMISTRY-US, V35, P12377, DOI 10.1021/bi961028j; Richard JP, 1996, BIOCHEMISTRY-US, V35, P12387, DOI 10.1021/bi961029b; Richard JP, 1998, BIOCHEMISTRY-US, V37, P4305, DOI 10.1021/bi972655r; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; SHIPLEY JM, 1993, AM J HUM GENET, V52, P517; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; TOMATSU S, 1991, AM J HUM GENET, V48, P89; VERVOORT R, 1993, HUM MUTAT, V2, P443, DOI 10.1002/humu.1380020604; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WU BM, 1994, J BIOL CHEM, V269, P23681	28	38	40	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34057	34062		10.1074/jbc.273.51.34057	http://dx.doi.org/10.1074/jbc.273.51.34057			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852062	hybrid			2022-12-25	WOS:000077542200028
J	Gottlob, K; Fulco, M; Levrero, M; Graessmann, A				Gottlob, K; Fulco, M; Levrero, M; Graessmann, A			The hepatitis B virus HBx protein inhibits caspase 3 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; X-GENE; APOPTOSIS; ACTIVATION; TRANSACTIVATION; PROTEASES; CRMA; RAS; MYC	The hepatitis B virus-encoded HBx protein coactivates transcription of viral and cellular genes, and it is believed to play an important role in hepatitis B virus-related liver cancer. HBx has been shown to alter the coordinated balance between proliferation and programmed cell death, being able to either induce or block apoptosis, Here, we demonstrate for the first time that the HBx is a potent caspase 3 inhibitor. Rat fibroblasts (REV2) and hepatoma cells (Hep) synthesizing the HBx protein were resistant to various apoptotic stimuli such as growth factor depletion, tumor necrosis factor alpha, or anti-Fas antibodies administration. In these cells, HBK prevented DNA fragmentation and cell death in the absence of de novo protein synthesis, with a similar efficiency as the competitive caspase 3 substrates inhibitors VAD-FMK and DEVD-FMK. Protein extracts obtained from the HBx positive cells contained a very low caspase activity, and addition of anti-HBx antibody restored the endogenous caspase activity. To obtain a functional map of the anti-caspase activity of HBx, various cell lines were established that synthesized either N-terminally or C-terminally truncated HBx molecules. These gene dissection experiments revealed that the regions required for the anti-caspase activity overlap with the two known transactivation domains of HBx.	Free Univ Berlin, Inst Biochem & Mol Biol, D-14195 Berlin, Germany; Univ Rome La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Univ Cagliari, Dept Internal Med, I-09124 Cagliari, Italy	Free University of Berlin; Sapienza University Rome; University of Cagliari	Graessmann, A (corresponding author), Free Univ Berlin, Inst Biochem & Mol Biol, Arnimallee 22, D-14195 Berlin, Germany.		Levrero, Massimo/G-5680-2016	Levrero, Massimo/0000-0002-4978-0875				BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FISHER M, 1995, VIRUS GENES, V10, P99; Gottlob K, 1998, CANCER RES, V58, P3566; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; Huang JK, 1996, J VIROL, V70, P5582, DOI 10.1128/JVI.70.8.5582-5591.1996; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; LIN KH, 1994, CANCER RES, V44, P5219; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NATOLI G, 1994, ONCOGENE, V9, P2837; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TAKADA S, 1994, ONCOGENE, V9, P341; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; WANG XW, 1995, CANCER RES, V55, P6012; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	32	109	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33347	33353		10.1074/jbc.273.50.33347	http://dx.doi.org/10.1074/jbc.273.50.33347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837909	hybrid			2022-12-25	WOS:000077462500039
J	Li, H; Zhao, LL; Yang, ZY; Funder, JW; Liu, JP				Li, H; Zhao, LL; Yang, ZY; Funder, JW; Liu, JP			Telomerase is controlled by protein kinase C alpha in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; TETRAHYMENA TELOMERASE; MAMMALIAN TELOMERASE; RNA; PURIFICATION; ACTIVATION; COMPONENT; SEQUENCE; TEMPLATE; FAMILY	Telomerase, a specialized RNA-directed DNA polymerase that extends telomeres of eukaryotic chromosomes, is repressed in human somatic tissues and becomes activated during tumor progression in most human cancers. To date, little is known about how telomerase is activated and controlled in cancer, although activation is thought to be involved in cancer cell immortalization. Here, we report that human telomerase-associated protein 1 (hTEP1) and the telomerase catalytic subunit (human telomerase reverse transcriptase (hTERT)) are phosphoproteins and that their phosphorylation is a prerequisite for the activation of telomerase in intact human breast cancer cells. Identified by hTEP1 peptide affinity chromatography, protein kinase C alpha mediates the phosphorylation of hTEP1 and hTERT and induces a marked increase in telomerase activity. Thus, phosphorylation of hTEP1 and hTERT by protein kinase C alpha represents an essential step in the generation of a functional telomerase complex in the initiation and maintenance of telomerase activity in human cancer.	Baker Med Res Inst, Mol Signalling Lab, Prahran, Vic 3181, Australia	Baker Heart and Diabetes Institute	Liu, JP (corresponding author), Baker Med Res Inst, POB 6492,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	jun-ping.liu@baker.edu.au		Liu, Jun-Ping/0000-0001-7442-2116				BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; de Lange T, 1998, NATURE, V392, P753, DOI 10.1038/33790; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; LEE SA, 1992, CANCER RES, V52, P3750; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; WOODGETT JR, 1989, ANAL BIOCHEM, V180, P237, DOI 10.1016/0003-2697(89)90423-5; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	38	178	191	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33436	33442		10.1074/jbc.273.50.33436	http://dx.doi.org/10.1074/jbc.273.50.33436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837921	hybrid			2022-12-25	WOS:000077462500051
J	Prado, GN; Mierke, DF; Pellegrini, M; Taylor, L; Polgar, P				Prado, GN; Mierke, DF; Pellegrini, M; Taylor, L; Polgar, P			Motif mutation of bradykinin B2 receptor second intracellular loop and proximal C terminus is critical for signal transduction, internalization, and resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ANGIOTENSIN-II RECEPTOR; G-PROTEIN; CARBOXYL-TERMINUS; FUNCTIONAL EXPRESSION; DRUG DESIGN; KEY ROLE; BINDING; ACTIVATION; DOMAINS	In the search for the structural elements participating in signal transduction, internalization, and resensitization of the bradykinin B2 receptor, we identified two critical motifs, one in the second intracellular loop (IC2), the other in the proximal C terminus. We previously described the contribution of tyrosines within each of the two motifs (Tyr(131) and Tyr(322)) to signal transduction and receptor internalization (Prado, G. N., Taylor, L., and Polgar, P. (1997) J. Biol. Chem 272, 14638-14642). Here, we investigate the effect of exchanging both tyrosine residues simultaneously for alanine, phenylalanine, or serine, termed YAYA (Y131A/Y322A), YFYF (Y131/Y322F), and YSYS (Y131S/Y322S) receptors, respectively. All of these mutants bound bradykinin (BK) normally, with a K-d of approximately 1.1 nM. However, although phosphoinositide (PI) turnover in response to BK by Y131A and Y131S proved negligible, the YAYA mutant returned BK-activated PI turnover to wild type (WT), In contrast, PI turnover with YSYS remained unresponsive to BK, Importantly, the pattern of BK-activated arachidonate release differed markedly in the mutant receptors. For example, whereas Y131S ablated BK-activated arachidonic acid release, conversion of this mutant to YSYS returned the BK-activated receptor function to a level above that of WT. However, YAYA showed only a partial recovery from the poor BK response of Y131A These and additional results suggest that Tyr(131) and Tyr(322) interact cooperatively in conjunction with at least two separate signaling functions. Given these results, a molecular model of the receptor was generated with the IC2 and the proximal C terminus in close spatial proximity. Conformations were identified to provide structural explanation for these observations. The conserved Thr(137) in the IC2 was next substituted with proline (T137P) to prevent phosphorylation at this position or with aspartate (T137D) to emulate phosphorylation. The T137P mutant demonstrated no change from WT with respect to either BK-activated PI turnover or arachidonic acid release. However, the mutant exhibited a markedly reduced capacity to internalize. It also resensitized poorly. The T137D mutant lacked both BK responsive activities. However, it internalized and resensitized normally, as did WT. These final results suggest that Thr137 is functioning as a switch in termination of signal transduction and the initiation of internalization.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA; Brown Univ, Dept Mol Pharmacol, Div Biol & Med, Providence, RI 02912 USA	Boston University; Brown University; Brown University	Prado, GN (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.		Pellegrini, Maria/W-6005-2019	Pellegrini, Maria/0000-0003-3817-4412; Polgar, Peter/0000-0002-9112-1101	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054082, R01GM054082] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25776] Funding Source: Medline; NIA NIH HHS [AG00115] Funding Source: Medline; NIGMS NIH HHS [GM54082] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Castano MEM, 1998, AM J PHYSIOL-RENAL, V274, pF532, DOI 10.1152/ajprenal.1998.274.3.F532; Chastain CJ, 1997, FEBS LETT, V413, P169, DOI 10.1016/S0014-5793(97)00884-3; Conchon S, 1997, J BIOL CHEM, V272, P25566, DOI 10.1074/jbc.272.41.25566; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DONNELLY D, 1994, PROTEIN ENG, V7, P645, DOI 10.1093/protein/7.5.645; Doughty SW, 1996, BIOCHEM SOC T, V24, P259, DOI 10.1042/bst0240259; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; Haasemann M, 1998, J CELL SCI, V111, P917; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Jarnagin K, 1996, J BIOL CHEM, V271, P28277, DOI 10.1074/jbc.271.45.28277; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; Lee NH, 1996, MOL PHARMACOL, V50, P140; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; Miyamoto A, 1997, J BIOL CHEM, V272, P19601, DOI 10.1074/jbc.272.31.19601; MORO O, 1993, J BIOL CHEM, V268, P22273; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PARKER EM, 1995, J BIOL CHEM, V270, P6482, DOI 10.1074/jbc.270.12.6482; Paterlini G, 1997, J MED CHEM, V40, P3254; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Pyne NJ, 1997, BIOCHEM J, V328, P689; RICUPERO D, 1993, AGENTS ACTIONS, V40, P110, DOI 10.1007/BF01976759; RICUPERO DA, 1997, BIOCHEM J, V327, P1; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Shibata T, 1996, BIOCHEM BIOPH RES CO, V218, P383, DOI 10.1006/bbrc.1996.0067; TAYLOR L, 1992, BIOCHEM BIOPH RES CO, V188, P786, DOI 10.1016/0006-291X(92)91125-A; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; VANBUUREN AR, 1993, J PHYS CHEM-US, V97, P9206, DOI 10.1021/j100138a023; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WilkBlaszczak MA, 1996, J NEUROPHYSIOL, V76, P3559, DOI 10.1152/jn.1996.76.5.3559; WOLSING DH, 1993, J PHARMACOL EXP THER, V266, P253; Xie W, 1997, J BIOL CHEM, V272, P24948, DOI 10.1074/jbc.272.40.24948; YANAGA F, 1991, BIOCHIM BIOPHYS ACTA, V1094, P139	46	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33548	33555		10.1074/jbc.273.50.33548	http://dx.doi.org/10.1074/jbc.273.50.33548			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837936	hybrid			2022-12-25	WOS:000077462500066
J	Rahimi, N; Hung, W; Tremblay, E; Saulnier, R; Elliott, B				Rahimi, N; Hung, W; Tremblay, E; Saulnier, R; Elliott, B			c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; FACTOR AUTOCRINE LOOP; TPR-MET ONCOPROTEIN; HUMAN BREAST-CANCER; SCATTER FACTOR; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; HGF RECEPTOR; FACTOR EXPRESSION; EPITHELIAL-CELLS	Overexpression and amplification of hepatocyte growth factor (HGF) receptor (Met) have been detected in many types of human cancers, suggesting a critical role for Met in growth and development of malignant cells. However, the molecular mechanism by which Met contributes to tumorigenesis is not well known. The tyrosine kinase c-Src has been implicated as a modulator of cell proliferation, spreading, and migration; these functions are also regulated by Met. To explore whether c-Src kinase is involved in HGF-induced cell growth, a mouse mammary carcinoma cell line (SP1) that co-expresses HGF and Met and a nonmalignant epithelial cell line (Mv1Lu) that expresses Met but not HGF were used. In this study, we have shown that c-Src kinase activity is constitutively elevated in SP1 cells and is induced in response to HGF in Mv1Lu cells. In addition, c-Src kinase associates with Met following stimulation with HGF, The enhanced activity of c-Src kinase also correlates with its ability to associate with Met. Expression of a dominant negative double mutant of c-Src (SRC-RF), lacking both kinase activity (K295R) and a regulatory tyrosine residue (Y527F), in SP1 cells significantly reduced c-Src kinase activity and strongly blocked HGF-induced motility and colony growth in soft agar. In contrast, expression of the dominant negative c-Src mutant had no effect on HGF-induced cell proliferation on plastic. Taken together, our data strongly suggest that HGF-induced association of c-Src with Met and c-Src activation play a critical role in HGF-induced cell motility and anchorage-independent growth of mammary carcinomas and further support the notion that the presence of paracrine and autocrine HGF loops contributes significantly to the transformed phenotype of carcinoma cells.	Queens Univ, Dept Pathol, Canc Res Labs, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Elliott, B (corresponding author), Queens Univ, Dept Pathol, Canc Res Labs, Kingston, ON K7L 3N6, Canada.	elliottb@post.queensu.ca		Rahimi, Nader/0000-0002-6745-1725				ATFI A, 1994, J BIOL CHEM, V269, P30688; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; ELLIOTT BE, 1992, INT J CANCER, V51, P416, DOI 10.1002/ijc.2910510314; FERRACINI R, 1995, ONCOGENE, V10, P739; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hall CL, 1996, ONCOGENE, V13, P2213; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; MIZUNO K, 1993, J BIOCHEM-TOKYO, V114, P96, DOI 10.1093/oxfordjournals.jbchem.a124147; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; OKADA T, 1994, J BIOL CHEM, V269, P3563; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; ROSEN N, 1986, J BIOL CHEM, V261, P3754; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Saulnier R, 1996, EXP CELL RES, V222, P360, DOI 10.1006/excr.1996.0045; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Seth P, 1996, CANCER RES, V56, P1346; TAJIMA H, 1991, FEBS LETT, V291, P229, DOI 10.1016/0014-5793(91)81291-F; Tuck AB, 1996, AM J PATHOL, V148, P225; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; WANG Y, 1994, AM J PATHOL, V144, P675; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; YAMASHITA J, 1994, CANCER RES, V54, P1630; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHU H, 1994, J BIOL CHEM, V269, P29943	59	145	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33714	33721		10.1074/jbc.273.50.33714	http://dx.doi.org/10.1074/jbc.273.50.33714			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837958	hybrid			2022-12-25	WOS:000077462500088
J	Zhou, J; Wu, K; Fernandes, CL; Cheng, AL; Finch, PW				Zhou, J; Wu, K; Fernandes, CL; Cheng, AL; Finch, PW			Keratinocyte growth factor down-regulates expression of the sucrase-isomaltase gene in Caco-2 intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; DNA-BINDING PROTEINS; RAT SMALL-INTESTINE; CRYPT-VILLUS AXIS; MESSENGER-RNA; TRANSCRIPTION; PROMOTER; HOMEOPROTEIN; CYTOKINES; RECEPTOR	The molecular mechanisms that regulate the proliferation and differentiation of intestinal mucosal epithelial cells are not well understood. Keratinocyte growth factor (KGF) is an epithelial cell-specific growth factor that may be involved in the maintenance of mucosal epithelial populations and in mediating epithelial repair after injury, The sucrase-isomaltase (SI) gene, which encodes an enterocyte brush border disaccharidase, has served as a model for study of intestinal-specific gene expression and differentiation. KGF down-regulated SI mRNA and protein expression in Caco-2 intestinal epithelial cells but not the expression of other brush border enzymes. The down-regulation was dose- and time-dependent and specifically blocked by anti-KGF antibodies, Transfection experiments using SI promoter constructs demonstrated that KGF decreased SI gene transcription. In contrast, the stability of SI mRNA was not affected by incubation of Caco-2 cells with KGF, Electrophoretic mobility shift analysis demonstrated that binding of nuclear proteins to the SI footprint (SIF) 3 and SIF4 regulatory elements within the SI promoter region was increased in Caco-2 cells that had been incubated with KGF, In transfect;ion experiments using a construct in which tandem copies of the SIF4-binding site were inserted upstream of the SV40 promoter and luciferase gene, incubation with KGF resulted in a significant decrease in luciferase activity. However, transfection with a similar construct containing tandem copies of SIF3 had no significant effect on SV40 promoter activity following KGF treatment, SIF4 may bind E4BP4, a previously identified transcriptional repressor protein, This factor may in part mediate the decrease in SI transcription by KGF in Caco-2 cells.	Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Finch, PW (corresponding author), Mt Sinai Med Ctr, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	pfinch@smtplink.mssm.edu			NIDDK NIH HHS [DK47102] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047102] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AUDUS KL, 1990, PHARM RES-DORDR, V7, P435, DOI 10.1023/A:1015800312910; BajajElliott M, 1997, AM J PATHOL, V151, P1469; BARNARD JA, 1991, AM J PHYSIOL, V261, pG994; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; Brauchle M, 1996, AM J PATHOL, V149, P521; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHANDRASENA G, 1992, CELL MOL BIOL, V38, P243; Chen WJ, 1995, BBA-GENE STRUCT EXPR, V1264, P388, DOI 10.1016/0167-4781(95)00182-4; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; CROSS HS, 1991, AM J PHYSIOL, V261, pC1173; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; Finch PW, 1997, AM J PATHOL, V151, P1619; Finch PW, 1996, GASTROENTEROLOGY, V110, P441, DOI 10.1053/gast.1996.v110.pm8566591; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORDON JI, 1993, GASTROENTEROLOGY, V104, P315; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; HALL PA, 1994, J CELL SCI, V107, P3569; HENTHORN PS, 1988, J BIOL CHEM, V263, P12011; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1767; KOYAMA S, 1989, J CLIN INVEST, V83, P1768, DOI 10.1172/JCI114080; LEEPER LL, 1990, AM J PHYSIOL, V258, pG52, DOI 10.1152/ajpgi.1990.258.1.G52; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MIURA N, 1993, EUR J CELL BIOL, V60, P376; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P820; SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TANAKA T, 1992, J IMMUNOL, V149, P481; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRABER PG, 1992, AM J PHYSIOL, V262, pG123, DOI 10.1152/ajpgi.1992.262.1.G123; WU GD, 1994, J BIOL CHEM, V269, P17080; WU GD, 1992, J BIOL CHEM, V267, P7863; WU GD, 1993, GASTROENTEROLOGY, V104, pA290; Ziambaras T, 1996, J BIOL CHEM, V271, P1237, DOI 10.1074/jbc.271.2.1237	44	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33367	33373		10.1074/jbc.273.50.33367	http://dx.doi.org/10.1074/jbc.273.50.33367			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837912	hybrid			2022-12-25	WOS:000077462500042
J	Bussler, H; Linder, M; Linder, D; Reinwald, E				Bussler, H; Linder, M; Linder, D; Reinwald, E			Determination of the disulfide bonds within a B domain variant surface glycoprotein from Trypanosoma congolense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGENIC VARIATION; STRUCTURAL MOTIFS; ENDOTHELIAL-CELLS; POINT MUTATIONS; BRUCEI; GENE; BINDING; ADHESION	The disulfide bonds within a variant surface glycoprotein from Trypanosoma congolense have been determined. L-[S-35]Cysteine metabolically labeled protein was digested with trypsin, and radiolabeled peptides were separated by reversed-phase high performance liquid chromatography, and putative cystine-containing peptides mere subdigested with other proteases and analyzed after further purification by amino acid sequencing and mass spectrometry. All eight cysteine residues of the protein, located within the N-terminal domain, are covalently linked. The four disulfide bonds are between cysteines 16/236, 171/193, 195/206, and 286/298. This is, for the first time, the determination of disulfide bonds within a variant surface glycoprotein belonging to the B-type, As all the eight cysteines of BENat 1.3 variant surface glycoprotein are positionally conserved, the cystine pattern of this protein can be regarded as a prototype of disulfide bonding within B-type variant surface glycoproteins. Although the cysteine residues of B-type variant surface glycoproteins are located at completely different positions in the protein chain compared with A-type variant surface glycoproteins, the positions of the disulfide bonds can easily be integrated into the A-type tertiary structure. This result implies that, despite their enormous amino acid sequence variability, variant surface glycoproteins, regardless of their subtype, can fold into a similar tertiary structure.	Free Univ Berlin, Inst Vet Biochem, D-14163 Berlin, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	Free University of Berlin; Justus Liebig University Giessen	Reinwald, E (corresponding author), Free Univ Berlin, Inst Vet Biochem, Oertzenweg 19b, D-14163 Berlin, Germany.							ALLEN G, 1983, BIOCHEM J, V209, P481, DOI 10.1042/bj2090481; BALTZ T, 1991, EMBO J, V10, P1653, DOI 10.1002/j.1460-2075.1991.tb07688.x; BANKS KL, 1978, J PROTOZOOL, V25, P241, DOI 10.1111/j.1550-7408.1978.tb04405.x; BANKS KL, 1979, J PROTOZOOL, V26, P103, DOI 10.1111/j.1550-7408.1979.tb02740.x; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; Borst P, 1996, ARCH MED RES, V27, P379; Carrington M, 1996, MOL BIOCHEM PARASIT, V81, P119, DOI 10.1016/0166-6851(96)02706-5; CARRINGTON M, 1991, J MOL BIOL, V221, P823, DOI 10.1016/0022-2836(91)80178-W; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4; FREYMANN D, 1990, J MOL BIOL, V216, P141, DOI 10.1016/S0022-2836(05)80066-X; HEMPHILL A, 1995, PARASITOL RES, V81, P412, DOI 10.1007/BF00931503; JACKSON PR, 1978, J PROTOZOOL, V25, P471, DOI 10.1111/j.1550-7408.1978.tb04170.x; JOHNSON JG, 1979, BIOCHEM J, V178, P689, DOI 10.1042/bj1780689; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MASTERSON WJ, 1988, J IMMUNOL, V140, P3194; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; RAUSCH S, 1994, EUR J BIOCHEM, V223, P813, DOI 10.1111/j.1432-1033.1994.tb19057.x; RAUTENBERG P, 1980, PARASITOLOGY, V80, P113, DOI 10.1017/S0031182000000561; REINWALD E, 1978, H-S Z PHYSIOL CHEM, V359, P939, DOI 10.1515/bchm2.1978.359.2.939; REINWALD E, 1981, BIOCHIM BIOPHYS ACTA, V668, P119, DOI 10.1016/0005-2795(81)90155-0; RICEFICHT AC, 1982, NATURE, V298, P676, DOI 10.1038/298676a0; SHAKIBAEI M, 1994, J STRUCT BIOL, V112, P125, DOI 10.1006/jsbi.1994.1014; Valdes J, 1996, NUCLEIC ACIDS RES, V24, P1809, DOI 10.1093/nar/24.10.1809; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905; VICKERMAN K, 1969, NATURE, V224, P1125, DOI 10.1038/2241125a0; VICKERMAN K, 1969, J CELL SCI, V5, P163; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	28	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32582	32586		10.1074/jbc.273.49.32582	http://dx.doi.org/10.1074/jbc.273.49.32582			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829995	hybrid			2022-12-25	WOS:000077329100034
J	Guenzi, E; Galli, G; Grgurina, I; Gross, DC; Grandi, G				Guenzi, E; Galli, G; Grgurina, I; Gross, DC; Grandi, G			Characterization of the syringomycin synthetase gene cluster - A link between prokaryotic and eukaryotic peptide synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRINGAE PV SYRINGAE; AMINO-ACID RACEMASE; OPEN READING FRAME; NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; SYRB-GENE; BIOSYNTHESIS; PURIFICATION; SURFACTIN	With this work we have completed the characterization of the syringomycin synthetase gene cluster. In particular, by sequencing additional 28.5 kilobase pairs we show that the nine modules involved in the binding of the nine amino acids of syringomycin are localized on SyrB and SyrE, with SyrE carrying eight modules. The recombinant SyrE and the first and second modules of SyrE (SyrE1 and SyrE2) have been expressed in Escherichia coli and purified. The biochemical data indicate that SyrB binds threonine, the putative precursor of the last amino acid of syringomycin, whereas SyrE1 and SyrE2 bind serine, the first and the second amino acids of syringomycin, respectively. On the basis of the sequence analysis and the biochemical data presented here, it appears that syringomycin synthetase is unique among peptide synthetases in that its genetic organization does not respect the "colinearity rule" according to which the order of the amino acid binding modules along the chromosome parallels the order of the amino acids on the peptide. This feature, together with the absence of a single transcription unit and the absence of epimerase-like domains make syringomycin synthetase more related to the eukaryotic peptide synthetases than to the bacterial counterparts.	Chiron SpA, Dept Biol Mol, I-53100 Siena, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Washington State Univ, Dept Plant Pathol, Pullman, WA 99164 USA	Novartis; Sapienza University Rome; Washington State University	Grandi, G (corresponding author), Chiron SpA, Dept Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.	grandi@iris02.biocine.it		Grandi, Guido/0000-0001-9724-2185				Bachmann RC., 1994, NAT PROD LETT, V4, P159, DOI 10.1080/10575639408043899; COQUE JJR, 1991, MOL MICROBIOL, V5, P1125, DOI 10.1111/j.1365-2958.1991.tb01885.x; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; GRGURINA I, 1994, EXPERIENTIA, V50, P130, DOI 10.1007/BF01984950; Guenzi E, 1998, J BIOL CHEM, V273, P14403, DOI 10.1074/jbc.273.23.14403; Hutchison ML, 1997, MOL PLANT MICROBE IN, V10, P347, DOI 10.1094/MPMI.1997.10.3.347; INAGAKI K, 1987, AGR BIOL CHEM TOKYO, V51, P173, DOI 10.1080/00021369.1987.10867978; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; LIM YH, 1993, J BACTERIOL, V175, P4213, DOI 10.1128/JB.175.13.4213-4217.1993; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; MENKHAUS M, 1993, J BIOL CHEM, V268, P7678; MERRIMAN TR, 1995, J BACTERIOL, V177, P252, DOI 10.1128/jb.177.1.252-258.1995; MO YY, 1991, J BACTERIOL, V173, P5784, DOI 10.1128/jb.173.18.5784-5792.1991; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; PFEIFER E, 1995, BIOCHEMISTRY-US, V34, P7450, DOI 10.1021/bi00022a019; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; QUIGLEY NB, 1993, MOL MICROBIOL, V9, P787, DOI 10.1111/j.1365-2958.1993.tb01738.x; RUSNAK F, 1991, BIOCHEMISTRY-US, V30, P2916, DOI 10.1021/bi00225a027; Sambrook J., 1989, MOL CLONING, V2.9, P14; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; SEGRE A, 1989, FEBS LETT, V255, P27, DOI 10.1016/0014-5793(89)81054-3; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1016/0378-1097(94)00459-5; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; Surette MG, 1996, J BIOL CHEM, V271, P939, DOI 10.1074/jbc.271.2.939; Takemoto JY, 1992, MOL SIGNALS PLANT MI, P247; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; ULLRICH C, 1991, BIOCHEMISTRY-US, V30, P6503, DOI 10.1021/bi00240a022; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; WEIGEL BJ, 1988, J BACTERIOL, V170, P3817, DOI 10.1128/jb.170.9.3817-3826.1988; XU GW, 1988, J BACTERIOL, V170, P5680, DOI 10.1128/jb.170.12.5680-5688.1988; Zhang JH, 1997, APPL ENVIRON MICROB, V63, P2771, DOI 10.1128/AEM.63.7.2771-2778.1997; ZHANG JH, 1995, J BACTERIOL, V177, P4009, DOI 10.1128/jb.177.14.4009-4020.1995	32	157	169	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32857	32863		10.1074/jbc.273.49.32857	http://dx.doi.org/10.1074/jbc.273.49.32857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830033	hybrid			2022-12-25	WOS:000077329100072
J	Qiu, WQ; Walsh, DM; Ye, Z; Vekrellis, K; Zhang, JM; Podlisny, MB; Rosner, MR; Safavi, A; Hersh, LB; Selkoe, DJ				Qiu, WQ; Walsh, DM; Ye, Z; Vekrellis, K; Zhang, JM; Podlisny, MB; Rosner, MR; Safavi, A; Hersh, LB; Selkoe, DJ			Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CELLULAR-LOCALIZATION; PEPTIDE; CELLS; AGGREGATION; METABOLISM; MAMMALS	Excessive cerebral accumulation of the 42-residue amyloid beta-protein (A beta) is an early and invariant step in the pathogenesis of Alzheimer's disease. Many studies have examined the cellular production of A beta from its membrane-bound precursor, including the role of the presenilin proteins therein, but almost nothing is known about how A beta is degraded and cleared following its secretion. We previously screened neuronal and nonneuronal cell lines for the production of proteases capable of degrading naturally secreted A beta under biologically relevant conditions and concentrations. The major such protease identified was a metalloprotease released particularly by a microglial cell line, BV-2. We have now purified and characterized the protease and find that it is indistinguishable from insulin-degrading enzyme (IDE), a thiol metalloendopeptidase that degrades small peptides such as insulin, glucagon, and atrial natriuretic peptide. Degradation of both endogenous and synthetic A beta at picomolar to nanomolar concentrations was completely inhibited by the competitive IDE substrate, insulin, and by two other IDE inhibitors. Immunodepletion of conditioned medium with an IDE antibody removed its A beta-degrading activity. IDE was present in BV-2 cytosol, as expected, but was also released into the medium by intact, healthy cells. To confirm the extracellular occurrence of IDE in vivo, we identified intact IDE in human cerebrospinal fluid of both normal and Alzheimer subjects. In addition to its ability to degrade A beta, IDE activity was unexpectedly found be associated with a time-dependent oligomerization of synthetic A beta at physiological levels in the conditioned media of cultured cells; this process, which may be initiated by IDE-generated proteolytic fragments of A beta, was prevented by three different IDE inhibitors. We conclude that a principal protease capable of down-regulating the levels of secreted A beta extracellularly is IDE.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Kentucky, Albert B Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Chicago; University of Kentucky	Selkoe, DJ (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 75 Ave Louis Pasteur, Boston, MA 02115 USA.			Qiu, Wei Qiao (Wendy)/0000-0002-2082-2410	NATIONAL INSTITUTE ON AGING [R01AG012749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007062, R01DA002243] Funding Source: NIH RePORTER; NIA NIH HHS [AG12749] Funding Source: Medline; NIDA NIH HHS [DA 07062, DA 02243] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; Authier F, 1996, CLIN INVEST MED, V19, P149; BECKER AB, 1995, METHOD ENZYMOL, V248, P693; BURDICK D, 1992, J BIOL CHEM, V267, P546; Chesneau V, 1997, ENDOCRINOLOGY, V138, P3444, DOI 10.1210/en.138.8.3444; GARCIA JV, 1989, J CELL BIOL, V108, P177, DOI 10.1083/jcb.108.1.177; GOWING E, 1994, J BIOL CHEM, V269, P10987; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KUO WL, 1994, J BIOL CHEM, V269, P22599; KUO WL, 1993, ENDOCRINOLOGY, V132, P604, DOI 10.1210/en.132.2.604; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; MARKS N, 1994, PEPTIDES, V15, P175, DOI 10.1016/0196-9781(94)90188-0; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Mentlein R, 1998, J NEUROCHEM, V70, P721; Paresce DM, 1997, J BIOL CHEM, V272, P29390, DOI 10.1074/jbc.272.46.29390; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; Podlisny M. B., 1995, Society for Neuroscience Abstracts, V21, P1281; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; Qiu WQ, 1997, J BIOL CHEM, V272, P6641, DOI 10.1074/jbc.272.10.6641; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; ROTH R A, 1985, Diabetes Research and Clinical Practice, V1, P31, DOI 10.1016/S0168-8227(85)80026-7; Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SEMPLE JW, 1992, INT IMMUNOL, V4, P1161, DOI 10.1093/intimm/4.10.1161; Seta KA, 1997, BIOCHEM BIOPH RES CO, V231, P167, DOI 10.1006/bbrc.1997.6066; STENTZ FB, 1985, ENDOCRINOLOGY, V116, P926, DOI 10.1210/endo-116-3-926; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; THAM A, 1993, J NEURAL TRANSM-PARK, V5, P165, DOI 10.1007/BF02257671; VANNOSTRAND WE, 1994, BBA-PROTEIN STRUCT M, V1209, P165, DOI 10.1016/0167-4838(94)90180-5; WALSH DM, 1994, NATURE, V367, P27, DOI 10.1038/367027a0	36	681	715	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32730	32738		10.1074/jbc.273.49.32730	http://dx.doi.org/10.1074/jbc.273.49.32730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830016	hybrid			2022-12-25	WOS:000077329100055
J	Berlanga, JJ; Herrero, S; de Haro, C				Berlanga, JJ; Herrero, S; de Haro, C			Characterization of the hemin-sensitive eukaryotic initiation factor 2 alpha kinase from mouse nonerythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EIF-2-ALPHA KINASE; GCN2 PROTEIN-KINASE; TRANSLATIONAL CONTROL; YEAST; CLONING; EIF-2; CDNA; EXPRESSION; HOMOLOGY	The heme-regulated eukaryotic initiation factor 2 alpha (eIF2 alpha) kinase (heme-regulated inhibitor (HRI)) is activated by heme deficiency in reticulocytes and plays an important role in translational control in these cells. Previously, HRI was cloned from rabbit reticulocytes and rat brain, but a heme-regulated eIF2 alpha kinase activity has only been purified from erythroid cells. In this study, we report the purification of a heme-sensitive eIF2 alpha kinase activity from both mouse liver and NIH 3T3 cell extracts. Furthermore, we have cloned and characterized this mouse Liver eIF2 alpha kinase (mHRI), which exhibits 83 and 94% identities to rabbit and rat HRIs, respectively. Both the purified enzyme and recombinant mHRI exhibited an autokinase and an eIF2 alpha kinase activity, and both activities were inhibited in vitro by hemin. In addition, wild-type mHRI, but not the inactive mHRI-K196R mutant, was autophosphorylated in vivo when it was expressed in 293 cells. Quantitation of mHRI mRNA expression in various mouse tissues by reverse transcription-polymerase chain reaction revealed relatively high levels in liver, kidney, and testis. These results provide strong evidence that mHRI is a ubiquitous eIF2 alpha kinase of mammalian cells, suggesting that it could play important roles in the translational regulation of nonerythroid tissues.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	de Haro, C (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Canto Blanco, E-28049 Madrid, Spain.		Berlanga, Juan José/N-1718-2015	Berlanga, Juan José/0000-0002-2408-6561				CHEFALO PJ, 1994, J BIOL CHEM, V269, P25788; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS MJ, 1994, MOL BIOL REP, V19, P201, DOI 10.1007/BF00986962; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CROSBY JS, 1994, MOL CELL BIOL, V14, P3906, DOI 10.1128/MCB.14.6.3906; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Dever TE, 1998, P NATL ACAD SCI USA, V95, P4164, DOI 10.1073/pnas.95.8.4164; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HEMS R, 1966, BIOCHEM J, V101, P284, DOI 10.1042/bj1010284; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Jackson RJ, 1991, TRANSLATION EUKARYOT, P193; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELLOR H, 1994, J BIOL CHEM, V269, P10201; MENDEZ R, 1994, J BIOL CHEM, V269, P6170; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; PAL JK, 1991, BIOCHEMISTRY-US, V30, P2555, DOI 10.1021/bi00223a037; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Sambrook J., 2002, MOL CLONING LAB MANU; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	30	77	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32340	32346		10.1074/jbc.273.48.32340	http://dx.doi.org/10.1074/jbc.273.48.32340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822714	hybrid			2022-12-25	WOS:000077207000096
J	Yang, XH; Stennicke, HR; Wang, BK; Green, DR; Janicke, RU; Srinivasan, A; Seth, P; Salvesen, GS; Froelich, CJ				Yang, XH; Stennicke, HR; Wang, BK; Green, DR; Janicke, RU; Srinivasan, A; Seth, P; Salvesen, GS; Froelich, CJ			Granzyme B mimics apical caspases - Description of a unified pathway for trans-activation of executioner caspase-3 and -7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; PROTEASE; APOPTOSIS; FAMILY; CPP32; DELIVERY; HOMOLOG	Granzyme B (GrB) is predicted to trigger apoptosis by activating preferred caspases, but the zymogens that are directly processed by the granzyme and the requirements for these interactions remain unclarified. We examined this dilemma by comparing the kinetics and pattern of GrB-mediated activation of the executioner caspase-7 in vitro and in vivo. GrB rapidly activates procaspase-7 in vitro by cleaving between the large and small subunits leaving the propeptide intact. During GrB-mediated apoptosis, the caspase-7 propeptide is removed and cleavage occurs between the subunits, Strikingly, caspase-7 is unprocessed in caspase-3-deficient MCF-7 cells exposed to GrB bud is rapidly activated when the cells are solubilized. Transfection with caspase-3 restores the removal of the caspase-7 propeptide and the capacity of GrB to subsequently activate the caspase. The data suggest that GrB activates caspase-3, which then removes the propeptide of caspase-7 allowing activation by GrB, Thus GrB initiates the death pathway by processing the accessible caspase-3, and the caspase-7 propeptide regulates transactivation of the zymogen by granzyme. As a consequence, two proteases, caspase-3 and GrB, are required to activate procaspase-7.	Evanston NW Healthcare Res Inst, Evanston, IL 60201 USA; Burnham Inst, La Jolla, CA 92307 USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; IDUN Pharmaceut, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA; NCI, Med Branch, NIH, Bethesda, MD 20892 USA	Sanford Burnham Prebys Medical Discovery Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; La Jolla Institute for Immunology; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Froelich, CJ (corresponding author), Evanston NW Healthcare Res Inst, WH Bldg,Rm B643,2650 Ridge Ave, Evanston, IL 60201 USA.	granzyme@merle.acns.nwu.edu	Yang, Jim/B-3776-2010; Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015402] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51399-04] Funding Source: Medline; NIA NIH HHS [R01 AG15402] Funding Source: Medline; PHS HHS [A140646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SETH P, 1994, BIOCHEM BIOPH RES CO, V203, P582, DOI 10.1006/bbrc.1994.2222; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361	34	159	169	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34278	34283		10.1074/jbc.273.51.34278	http://dx.doi.org/10.1074/jbc.273.51.34278			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852092	hybrid			2022-12-25	WOS:000077542200058
J	Dianov, G; Bischoff, C; Piotrowski, J; Bohr, VA				Dianov, G; Bischoff, C; Piotrowski, J; Bohr, VA			Repair pathways for processing of 8-oxoguanine in DNA by mammalian cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; POLYMERASE-BETA; OXIDATIVE DAMAGE; NUCLEAR ANTIGEN; GLYCOSYLASE; RECONSTITUTION; REQUIREMENT; PROTEIN; CLONING; TRANSCRIPTION	The repair pathways involved in the removal of 8-oxo-7,8-dihydroguanine (8-oxoguanine) in DNA by mammalian cell extracts have been examined. Closed circular DNA constructs containing a single 8-oxoguanine at a defined site were used as substrates to determine the patch size generated after in vitro repair by mammalian cell extracts. Restriction analysis of the repair incorporation in the vicinity of the lesion indicated that up to 75% of the 8-oxoguanine was repaired via the single nucleotide replacement mechanism in both human and mouse cell extracts. Approximately 25% of the 8-oxoguanine lesions were repaired by the long patch repair pathway. Repair incorporation 5' to the lesion, characteristic for nucleotide excision repair, was not significant. Elimination of the DNA polymerase beta (pol beta)-dependent single nucleotide base excision repair pathway in extracts prepared from pol beta-deficient mouse cells resulted in extension of the repair gap to 4-5 nucleotides 3' to the lesion in 50% of the repair events, suggesting the increased involvement of the long patch repair pathway. However, about one-half of the 8-oxoguanine repair was still accomplished through replacement of only one nucleotide in the pol beta-deficient cell extracts. These data indicate the existence of an alternative pol beta-independent single nucleotide repair patch pathway for processing of 8-oxoguanine in DNA.	NIA, Genet Mol Lab, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Inst Struct & Mol Biol, DK-8000 Aarhus, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University	Bohr, VA (corresponding author), NIA, Genet Mol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020					AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; ASAHINA H, 1994, MUTAT RES-DNA REPAIR, V315, P229, DOI 10.1016/0921-8777(94)90034-5; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Jaiswal M, 1998, NUCLEIC ACIDS RES, V26, P2184, DOI 10.1093/nar/26.9.2184; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; Nealon K, 1996, NUCLEIC ACIDS RES, V24, P3763, DOI 10.1093/nar/24.19.3763; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PRASAD R, 1996, J BIOL CHEM, V271, P1600; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sandigursky M, 1997, NUCLEIC ACIDS RES, V25, P4557, DOI 10.1093/nar/25.22.4557; SATOH MS, 1993, P NATL ACAD SCI USA, V90, P6335, DOI 10.1073/pnas.90.13.6335; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465	39	205	208	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33811	33816		10.1074/jbc.273.50.33811	http://dx.doi.org/10.1074/jbc.273.50.33811			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837971	hybrid			2022-12-25	WOS:000077462500101
J	Gao-Sheridan, HS; Kemper, MA; Khayat, R; Tilley, GJ; Armstrong, FA; Sridhar, V; Prasad, GS; Stout, CD; Burgess, BK				Gao-Sheridan, HS; Kemper, MA; Khayat, R; Tilley, GJ; Armstrong, FA; Sridhar, V; Prasad, GS; Stout, CD; Burgess, BK			A T14C variant of Azotobacter vinelandii ferredoxin I undergoes facile [3Fe-4S]degrees to [4Fe-4S](2+) conversion in vitro but not in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; SITE-DIRECTED MUTAGENESIS; ARCHAEON PYROCOCCUS-FURIOSUS; MAGNETIC CIRCULAR-DICHROISM; DESULFOVIBRIO-AFRICANUS FERREDOXIN; REDUCED 3FE-4S CLUSTER; AMINO-ACID-SEQUENCE; 4FE-4S CLUSTER; SPECTROSCOPIC CHARACTERIZATION; SULFOLOBUS-ACIDOCALDARIUS	[4Fe-4S](2+/+) clusters that are ligated by Cys-X-X-Cys-X-X-Cys sequence motifs share the general feature of being hard to convert to [3Fe-4S](+/0) clusters, whereas those that contain a Cys-X-X-Asp-X-X-Cys motif undergo facile and reversible cluster interconversion, Little is known about the factors that control the in vivo assembly and conversion of these clusters. In this study we have designed and constructed a 3Fe to 4Fe cluster conversion variant of Azotobacter vinelandii ferredoxin I (FdI) in which the sequence that ligates the [3Fe-4S] cluster in native FdI was altered by converting a nearby residue, Thr-14, to Cys, Spectroscopic and electrochemical characterization shows that when purified in the presence of dithionite, T14C FdI is an O-2-sensitive 8Fe protein. Both the new and the indigenous clusters have reduction potentials that are significantly shifted compared with those in native FdI, strongly suggesting a significantly altered environment around the clusters. Interestingly, whole cell EPR have revealed that T14C FdI exists as a 7Fe protein in vivo. This 7Fe form of T14C FdI is extremely similar to native FdI in its spectroscopic, electrochemical, and structural features. However, unlike native FdI which does not undergo facile cluster conversion, the 7Fe form T14C FdI quickly converts to the 8Fe form with a high efficiency under reducing conditions.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Oxford, Dept Chem, Oxford OX1 3QR, England; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of California System; University of California Irvine; University of Oxford; Scripps Research Institute	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036325, R01GM045209, P01GM048495] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45209, GM-36325, GM-48495] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aono S, 1997, FEBS LETT, V412, P501, DOI 10.1016/S0014-5793(97)00834-X; ARMSTRONG FA, 1993, METHOD ENZYMOL, V227, P479, DOI 10.1016/0076-6879(93)27020-H; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; BELL SH, 1982, FEBS LETT, V142, P143, DOI 10.1016/0014-5793(82)80238-X; BERTINI I, 1993, FEBS LETT, V332, P268, DOI 10.1016/0014-5793(93)80647-D; BOVIERLAPIERRE G, 1987, BIOCHIM BIOPHYS ACTA, V913, P20, DOI 10.1016/0167-4838(87)90227-5; BRETON JL, 1995, EUR J BIOCHEM, V233, P937, DOI 10.1111/j.1432-1033.1995.937_3.x; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUSCHI M, 1979, BIOCHEM BIOPH RES CO, V91, P623, DOI 10.1016/0006-291X(79)91567-5; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; Busch JLH, 1997, BIOCHEM J, V323, P95, DOI 10.1042/bj3230095; BUTT JN, 1991, J AM CHEM SOC, V113, P8948, DOI 10.1021/ja00023a054; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; Butt JN, 1997, J AM CHEM SOC, V119, P9729, DOI 10.1021/ja971403a; Calzolai L, 1996, J AM CHEM SOC, V118, P2513, DOI 10.1021/ja953744z; CALZOLAI L, 1995, BIOCHEMISTRY-US, V34, P11373, DOI 10.1021/bi00036a010; Calzolai L, 1997, J AM CHEM SOC, V119, P9341, DOI 10.1021/ja9715455; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CLARK WM, 1961, OXIDATION REDUCTION; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Duff JLC, 1996, J AM CHEM SOC, V118, P8593, DOI 10.1021/ja961465l; Gao-Sheridan HS, 1998, J BIOL CHEM, V273, P5514, DOI 10.1074/jbc.273.10.5514; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; GORST CM, 1995, BIOCHEMISTRY-US, V34, P600, DOI 10.1021/bi00002a027; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; HELTZEL A, 1994, J BACTERIOL, V176, P4790, DOI 10.1128/JB.176.15.4790-4793.1994; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HOWARD JB, 1991, ADV PROTEIN CHEM, V42, P199; HU ZG, 1994, BIOCHEMISTRY-US, V33, P14475, DOI 10.1021/bi00252a014; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; ISAS JM, 1994, J BIOL CHEM, V269, P19404; ISAS JM, 1995, J BIOL CHEM, V270, P21258, DOI 10.1074/jbc.270.36.21258; JENSEN GM, 1994, THESIS U SO CALIFORN; JOHNSON MK, 1994, ENCY INORGANIC CHEM, P1896; Kemper MA, 1998, BIOCHEMISTRY-US, V37, P12829, DOI 10.1021/bi9810499; Kemper MA, 1997, J BIOL CHEM, V272, P15620, DOI 10.1074/jbc.272.25.15620; KENT TA, 1985, J BIOL CHEM, V260, P6871; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; LINDAHL PA, 1990, J CLUST SCI, V1, P29; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANODORI A, 1992, BIOCHEMISTRY-US, V31, P2703, DOI 10.1021/bi00125a010; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MARTIN AE, 1990, P NATL ACAD SCI USA, V87, P598, DOI 10.1073/pnas.87.2.598; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MORGAN TV, 1988, J BIOL CHEM, V263, P1370; MORGAN TV, 1984, FEBS LETT, V167, P137, DOI 10.1016/0014-5793(84)80848-0; MOURA JJG, 1984, EUR J BIOCHEM, V141, P319, DOI 10.1111/j.1432-1033.1984.tb08194.x; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; OKAWARA N, 1988, J BIOCHEM-TOKYO, V104, P196, DOI 10.1093/oxfordjournals.jbchem.a122441; ORMEJOHNSON WH, 1973, IRON SULFUR PROTEINS, V2, P195; Reyntjens B, 1997, J BIOL INORG CHEM, V2, P595, DOI 10.1007/s007750050174; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHEN B, 1995, P NATL ACAD SCI USA, V92, P10064, DOI 10.1073/pnas.92.22.10064; SHEN BH, 1994, J BIOL CHEM, V269, P8564; SHEN BH, 1993, J BIOL CHEM, V268, P25928; STEPHENS PJ, 1991, BIOCHEMISTRY-US, V30, P3200, DOI 10.1021/bi00227a007; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; STOUT CD, 1988, J BIOL CHEM, V263, P9256; STOUT CD, 1989, J MOL BIOL, V205, P545, DOI 10.1016/0022-2836(89)90225-8; STOUT CD, 1993, J BIOL CHEM, V268, P25920; STOUT GH, 1988, P NATL ACAD SCI USA, V85, P1020, DOI 10.1073/pnas.85.4.1020; THOMSON AJ, 1981, BIOCHIM BIOPHYS ACTA, V637, P423, DOI 10.1016/0005-2728(81)90047-5; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; THOMSON AJ, 1991, FEBS LETT, V285, P230, DOI 10.1016/0014-5793(91)80807-F; Yannone SM, 1997, J BIOL CHEM, V272, P14454, DOI 10.1074/jbc.272.22.14454	72	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33692	33701		10.1074/jbc.273.50.33692	http://dx.doi.org/10.1074/jbc.273.50.33692			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837955	hybrid			2022-12-25	WOS:000077462500085
J	Larsson, K; Bohl, F; Sjostrom, I; Akhtar, N; Strand, D; Mechler, BM; Grabowski, R; Adler, L				Larsson, K; Bohl, F; Sjostrom, I; Akhtar, N; Strand, D; Mechler, BM; Grabowski, R; Adler, L			The Saccharomyces cerevisiae SOP1 and SOP2 genes, which act in cation homeostasis, can be functionally substituted by the Drosophila lethal(2)giant larvae tumor suppressor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II HEAVY-CHAIN; PLASMA-MEMBRANE; SALT TOLERANCE; SHUTTLE VECTORS; BUD FORMATION; YEAST-CELLS; K+-ATPASE; PROTEIN; TRANSPORT; NA+	By complementation of a salt-sensitive mutant of Saccharomyces cerevisiae, we cloned the SOP1 gene, encoding a 114.5-kDa protein of 1033 amino acids. Cells deleted for SOP1 exhibited sensitivity to sodium stress, but showed no sensitivity to general osmotic stress. Following exposure of sop1 Delta cells to NaCl stress, the intracellular Na+ level and the Na+/K+ ratio rose to values significantly higher than in wild type cells. Deletion of SOP2, encoding a protein sharing 54% amino acid identity with Sop1p, produced only slight Na+ sensitivity. Cells carrying a sop1 Delta sop2 Delta double deletion became, however, hypersensitive to Na+ and exhibited increased sensitivity also to Li+ and K+, suggesting involvement of both SOP1 and SOP2 in cation homeostasis. The predicted amino acid sequences of Sop1p and Sop2p show significant homologies with the cytoskeletal-associated protein encoded by the Drosophila Lethal(2)giant larvae tumor suppressor gene. Immunolocalization of Sop1p revealed a cytoplasmic distribution and cell fractionation studies showed that a significant fraction of Sop1p was recovered in a sedimentable fraction of the cytosolic material. Expression of a Drosophila l(2)gl cDNA in the sop1 Delta sop2 Delta strain partially restored the Na+ tolerance of the cells, indicating a functional relationship between the Sop proteins and the tumor suppressor protein, and a novel function in cell homeostasis for this family of proteins extending from yeast to human.	Univ Gothenburg, Dept Cell & Mol Biol, SE-40530 Gothenburg, Sweden; Deutsch Krebsforschungszentrum, Dept Dev Genet, D-69120 Heidelberg, Germany	University of Gothenburg; Helmholtz Association; German Cancer Research Center (DKFZ)	Adler, L (corresponding author), Univ Gothenburg, Dept Cell & Mol Biol, Box 462, SE-40530 Gothenburg, Sweden.	Lennart.Adler@gmm.gu.se						AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; [Anonymous], [No title captured]; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BIDWAI AP, 1995, J BIOL CHEM, V270, P10395, DOI 10.1074/jbc.270.18.10395; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; ERIKSSON P, 1995, MOL MICROBIOL, V17, P95, DOI 10.1111/j.1365-2958.1995.mmi_17010095.x; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HANAHAN D, 1983, J MOL BIOL, V166, P577; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; Imai J, 1996, GENETICS, V142, P359; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOB L, 1987, CELL, V50, P215, DOI 10.1016/0092-8674(87)90217-0; Jakobs R, 1996, J MOL BIOL, V264, P484, DOI 10.1006/jmbi.1996.0656; Kalmes A, 1996, J CELL SCI, V109, P1359; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KO CH, 1990, GENETICS, V125, P305; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MECHLER BM, 1994, J BIOSCIENCES, V19, P537; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Miller JH, 1973, EXPT MOL GENETICS; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; RAMOS J, 1994, J BACTERIOL, V176, P249, DOI 10.1128/JB.176.1.249-252.1994; ROBINSON LC, 1992, P NATL ACAD SCI USA, V89, P28, DOI 10.1073/pnas.89.1.28; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SERRANO R, 1994, NATO ADV SCI INST SE, V86, P371; SERRANO R, 1991, MOL CELLULAR BIOL YE, V1, P523; Sherman F., 1983, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; STRAND D, 1994, J CELL BIOL, V127, P1361, DOI 10.1083/jcb.127.5.1361; STRAND D, 1994, J CELL BIOL, V127, P1345, DOI 10.1083/jcb.127.5.1345; STRAND D, 1995, ONCOGENE, V11, P291; TOMUTSUNE D, 1993, NATURE, V365, P69; TOROK I, 1993, ONCOGENE, V8, P1537; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; White WH, 1997, GENETICS, V147, P43; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x	57	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33610	33618		10.1074/jbc.273.50.33610	http://dx.doi.org/10.1074/jbc.273.50.33610			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837945	Green Published, hybrid			2022-12-25	WOS:000077462500075
J	Maul, RS; Zhang, HX; Reid, JD; Pedigo, NG; Kaetzel, DM				Maul, RS; Zhang, HX; Reid, JD; Pedigo, NG; Kaetzel, DM			Identification of a cell type-specific enhancer in the distal 5 '-region of the platelet-derived growth factor A-chain gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; NUCLEASE-SENSITIVE REGION; SMOOTH-MUSCLE CELLS; PDGF-A; ALPHA-SUBUNIT; TRANSCRIPTIONAL REGULATION; MESANGIAL CELLS; PROMOTER REGION; MAMMALIAN-CELLS; PHORBOL ESTER	Transient transfection analysis of DNA subfragments from the distal 5'-flanking region of the human platelet-derived growth factor A-chain gene (-18.3 to -1.8 kilobase pairs (kb)) revealed enhancer and silencer elements that contribute significantly to transcriptional regulation. Two adjacent regions (-8.2 to -7.5 kb and -7.5 to -7.0 kb) enhanced transcription of both A-chain and heterologous thymidine kinase promoters, whereas repression was observed in two other nearby regions (-9.9 to -8.2 kb and -7.0 to -5.9 kb), The -7.5 to -7.0-kb fragment, or J, was the strongest enhancer, and its activity was localized to a 66-base pair element (A-chain cell type-specific enhancer (ACE 66)), ACE66 activity was highly cell type-specific, with greatest activity seen in choriocarcinoma cell lines (4-10-fold enhancement). progressive 5'- and 8'-deletions of the ACE66 revealed distribution of activity across the element, with nucleo tides 1-33 being critical for function. Electrophoretic mobility shift assays revealed cell type-specific patterns of high affinity protein binding to the element. Ethylation interference footprinting of JEG-3 extract localized guanine contacts on nucleotides 1-18 of both strands of the ACE element, whereas more extensive contacts were made with the phosphate backbone (nucleotides 1-32), The ACE66 element is a potent transcriptional regulator in placental cells and represents a valuable model of long distance regulation in a growth factor gene.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Kaetzel, DM (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Pharmacol, MS305,800 Rose St, Lexington, KY 40536 USA.	dmkaetz@pop.uky.edu			NIDDK NIH HHS [DK45518] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045518] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BHANDARI B, 1995, J BIOL CHEM, V270, P5541, DOI 10.1074/jbc.270.10.5541; BIDWELL MC, 1995, ENDOCRINOLOGY, V136, P5189, DOI 10.1210/en.136.11.5189; Bonifer C, 1996, CRIT REV EUKAR GENE, V6, P285, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.90; BONTHRON D, 1992, GENOMICS, V13, P257, DOI 10.1016/0888-7543(92)90240-S; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUNING H, 1995, NUCLEIC ACIDS RES, V23, P1443, DOI 10.1093/nar/23.8.1443; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; FENSTERMAKER RA, 1993, J BIOL CHEM, V268, P10482; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROUPP ER, 1994, J BIOL CHEM, V269, P22178; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; Henderson AJ, 1995, CRIT REV EUKAR GENE, V5, P255, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.30; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; KAMACHI Y, 1993, MOL CELL BIOL, V13, P5206, DOI 10.1128/MCB.13.9.5206; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Latinkic BV, 1996, NUCLEIC ACIDS RES, V24, P1345, DOI 10.1093/nar/24.7.1345; Li LX, 1996, DEV BRAIN RES, V96, P204, DOI 10.1016/S0165-3806(96)00116-2; LIN XH, 1992, J BIOL CHEM, V267, P25614; Lindahl P, 1997, DEVELOPMENT, V124, P3943; Liu B, 1996, J BIOL CHEM, V271, P26281, DOI 10.1074/jbc.271.42.26281; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MENDOZA AE, 1990, P NATL ACAD SCI USA, V87, P2177, DOI 10.1073/pnas.87.6.2177; NILSON JH, 1983, J BIOL CHEM, V258, P2087; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; ROSS R, 1986, ACTA MED SCAND S, V715, P33; Schatteman GC, 1996, DEV BIOL, V176, P133, DOI 10.1006/dbio.1996.9988; SCHATTEMAN GC, 1995, TERATOLOGY, V51, P351, DOI 10.1002/tera.1420510602; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; SILVER BJ, 1989, P NATL ACAD SCI USA, V86, P1056, DOI 10.1073/pnas.86.3.1056; SILVER BJ, 1992, BIOFACTORS, V86, P217; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; STARKSEN NF, 1987, J BIOL CHEM, V262, P14381; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TSAI TF, 1988, BIOCHEM BIOPH RES CO, V153, P39, DOI 10.1016/S0006-291X(88)81186-0; UMESS LD, 1990, CELL, V63, P47; WANG ZY, 1994, BIOCHEM BIOPH RES CO, V198, P103, DOI 10.1006/bbrc.1994.1015; WANG ZY, 1994, NUCLEIC ACIDS RES, V22, P457, DOI 10.1093/nar/22.3.457; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	60	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33239	33246		10.1074/jbc.273.50.33239	http://dx.doi.org/10.1074/jbc.273.50.33239			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837894	hybrid			2022-12-25	WOS:000077462500024
J	Cachia, O; El Benna, J; Pedruzzi, E; Descomps, B; Gougerot-Pocidalo, MA; Leger, CL				Cachia, O; El Benna, J; Pedruzzi, E; Descomps, B; Gougerot-Pocidalo, MA; Leger, CL			alpha-tocopherol inhibits the respiratory burst in human monocytes - Attenuation of p47(phox) membrane translocation and phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LOW-DENSITY-LIPOPROTEIN; SUPEROXIDE ANION PRODUCTION; VITAMIN-E; NADPH OXIDASE; LIPID OXIDATION; ACTIVATION; MACROPHAGES; ANTIOXIDANT; COMPONENTS	Vitamin E (alpha-tocopherol), one of the most important natural antioxidants, is assumed to be beneficial in the prevention of cardiovascular diseases. alpha-Tocopherol exhibits acyl-peroxyl-radical scavenger properties and exerts cell-mediated actions in the hemovascular compartment, such as inhibition of superoxide anion (O-2(radical anion)) production by leukocytes. The aim of this study was to examine the mechanism underlying the inhibitory effect of alpha-tocopherol on O-2(radical anion) production by human monocytes. In activated monocytes O-2(radical anion) is produced by the NADPH-oxidase enzyme complex. The oxidase activation elicited by phorbol myristate acetate (PMA) requires membrane translocation of several cytosolic factors. Ne found that in human PMA-stimulated adherent monocytes, alpha-tocopherol (but not beta-tocopherol) inhibited O-2(radical anion) production in intact cells but had no effect on a membrane preparation containing activated NADPH-oxidase, suggesting that alpha-tocopherol impairs the assembly process of the enzyme complex. We showed that translocation and phosphorylation of the cytosolic factor p47(phox) were reduced in monocytes preincubated with alpha-tocopherol. We verified that the tryptic phosphopeptide map of monocyte p47(phox) was similar to that of neutrophil p47(phox), indicating that several serine residues were phosphorylated. Peptides whose phosphorylation is dependent on protein kinase C (PKC) were phosphorylated to a lesser degree when p47(phox) was immunoprecipitated from alpha-tocopherol-treated monocytes, In vitro, the activity of PKC from monocytes was inhibited by alpha-tocopherol in a specific manner compared with that of beta-tocopherol or Trolox(R). Membrane translocation of PKC was not affected. These results show that alpha-tocopherol inhibits O-2(radical anion) production by human adherent monocytes by impairing the assembly of the NADPH-oxidase and suggest that the inhibition of phosphorylation and translocation of the cytosolic factor p47(phox) results from a decrease in PBC activity.	Fac Med Xavier Bichat, INSERM, U 479, F-75018 Paris, France; Fac Med Montpellier, Inst Biol, Lab Biol & Biochim Lipides, F-34000 Montpellier, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	El Benna, J (corresponding author), Fac Med Xavier Bichat, INSERM, U 479, 16 Rue Henri Huchard, F-75018 Paris, France.		pedruzzi, eric/B-6050-2017					Aviram M, 1996, METABOLISM, V45, P1069, DOI 10.1016/S0026-0495(96)90005-0; BABIOR BM, 1988, ARCH BIOCHEM BIOPHYS, V264, P361, DOI 10.1016/0003-9861(88)90300-1; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; Cachia O, 1998, ATHEROSCLEROSIS, V138, P263, DOI 10.1016/S0021-9150(98)00028-8; CHANG ZL, 1993, IMMUNOLOGY, V80, P360; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Devaraj S, 1996, J CLIN INVEST, V98, P756, DOI 10.1172/JCI118848; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; EPAND RM, 1990, TRENDS PHARMACOL SCI, V11, P317, DOI 10.1016/0165-6147(90)90234-Y; ESTERBAUER H, 1989, FETT WISS TECHNOL, V91, P316, DOI 10.1002/lipi.19890910805; GEY KF, 1995, J NUTR BIOCHEM, V6, P206, DOI 10.1016/0955-2863(95)00032-U; JANERO DR, 1991, FREE RADICAL BIO MED, V11, P129, DOI 10.1016/0891-5849(91)90193-7; JOHNSTON RB, 1978, J EXP MED, V148, P115; KADRIHASSANI N, 1995, J BIOL CHEM, V270, P15111, DOI 10.1074/jbc.270.25.15111; KANNO T, 1995, FREE RADICAL RES, V22, P431, DOI 10.3109/10715769509147551; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Q, 1994, J BIOL CHEM, V269, P17508; LIEBLER DC, 1995, LIPIDS, V30, P789, DOI 10.1007/BF02533953; MACHLIN IJ, 1984, HDB VITAMINS, P99; MARKERT M, 1984, METHOD ENZYMOL, V105, P358; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; PRINCEN HMG, 1995, ARTERIOSCL THROM VAS, V15, P325, DOI 10.1161/01.ATV.15.3.325; SAKAMOTO W, 1990, INT J VITAM NUTR RES, V60, P338; SRIVASTAVA S, 1989, MOL CELL BIOCHEM, V91, P99, DOI 10.1007/BF00228084; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; SUZUKAWA M, 1994, ATHEROSCLEROSIS, V110, P77, DOI 10.1016/0021-9150(94)90070-1; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URANO S, 1988, BIOCHEM BIOPH RES CO, V150, P469, DOI 10.1016/0006-291X(88)90544-X	35	203	210	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32801	32805		10.1074/jbc.273.49.32801	http://dx.doi.org/10.1074/jbc.273.49.32801			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830025	hybrid			2022-12-25	WOS:000077329100064
J	Caselli, A; Marzocchini, R; Camici, G; Manao, G; Moneti, G; Pieraccini, G; Ramponi, G				Caselli, A; Marzocchini, R; Camici, G; Manao, G; Moneti, G; Pieraccini, G; Ramponi, G			The inactivation mechanism of low molecular weight phosphotyrosine-protein phosphatase by H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-SULFENIC ACID; GROWTH-FACTOR; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; NADH PEROXIDASE; NITRIC-OXIDE; REDOX CENTER; KAPPA-B; PHOSPHORYLATION; GENERATION	Low molecular weight phosphotyrosine-protein phosphatase (LMW-PTP) shares no general sequence homology with other PTPs, although it has an active site sequence motif CXXXXXR and a reaction mechanism identical to those of all PTPs, The main function of this enzyme is the down-regulation of platelet-derived growth factor and insulin receptors, Both human LMW-PTP isoenzymes are inactivated by H2O2. The enzymes are protected from inactivation by P-i, a competitive inhibitor, suggesting that the H2O2 reaction is directed to active site. Analysis of free thiols performed on the inactivated enzymes demonstrates that only two out of the eight LMW-PTP cysteines are modified. Time-course high performance liquid chromatography-electrospray mass spectrometry, together with specific radiolabeling and tryptic fingerprint analyses, enables us to demonstrate that H2O2 causes the oxidation of Cys-12 and Cys-17 to form a disulfide bond. Because both residues are localized into the active site region, this modification inactivates the enzyme, Fluorescence spectroscopy experiments suggest that the fold of the enzyme is modified during oxidation by H2O2. Because a physiological concentration of H2O2 produces enzyme inactivation and considering that the activity is restored by reduction with low molecular weight thiols, we suggest that oxidative stress conditions and other processes producing hydrogen peroxide regulate the LMW-PTP in the cell.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy; Univ Florence, Serv Spettrometria Massa, Ctr Interdipartimentale, I-50139 Florence, Italy	University of Florence; University of Florence	Ramponi, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	prot@scibio.unifi.it	Caselli, Anna/O-7512-2014; Camici, Giovanni/H-1631-2018	Caselli, Anna/0000-0001-8140-3415; Pieraccini, Giuseppe/0000-0003-3103-3924; Camici, Giovanni/0000-0002-0523-0695				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CASELLI A, 1995, FEBS LETT, V374, P249, DOI 10.1016/0014-5793(95)01120-4; CASELLI A, 1994, J BIOL CHEM, V269, P24878; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; FAULSTICH H, 1993, ANAL BIOCHEM, V208, P357, DOI 10.1006/abio.1993.1061; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Halliwell B, 1989, FREE RADICAL BIO MED, P416; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Marzocchini R, 1998, FEBS LETT, V426, P52, DOI 10.1016/S0014-5793(98)00308-1; MILLER H, 1991, J BIOL CHEM, V266, P19342; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; POOLE LB, 1989, J BIOL CHEM, V264, P12330; Poole LB, 1996, BIOCHEMISTRY-US, V35, P65, DOI 10.1021/bi951888k; Rigacci S, 1996, J BIOL CHEM, V271, P1278, DOI 10.1074/jbc.271.3.1278; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; STEIN E, 1988, GENE DEV, V12, P667; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tailor P, 1997, J BIOL CHEM, V272, P5371, DOI 10.1074/jbc.272.9.5371; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s	31	186	189	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32554	32560		10.1074/jbc.273.49.32554	http://dx.doi.org/10.1074/jbc.273.49.32554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829991	hybrid			2022-12-25	WOS:000077329100030
J	Rensing, C; Sun, Y; Mitra, B; Rosen, BP				Rensing, C; Sun, Y; Mitra, B; Rosen, BP			Pb(II)-translocating P-type ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADMIUM RESISTANCE DETERMINANT; STAPHYLOCOCCUS-AUREUS PLASMID-PI258; GENE; ENCODES; TRANSPORT; DISEASE; PI258	The cad operon of Staphylococcus aureus plasmid pI258, which confers cadmium resistance, encodes a transcriptional regulator, CadC, and CadA, an ATP-coupled Cd(II) pump that is a member of the superfamily of cation-translocating P-type ATPases, The Escherichia coli homologue of CadA, termed ZntA, is a Zn(II)/Cd(II) pump. The results described in this paper support the hypothesis that ZntA and CadA are Pb(II) pumps, First, CadC is a metal-responsive repressor that responds to soft metals in the order Pb>Cd>Zn, Second, both CadA and ZntA confer resistance to Pb(II), Third, transport of Zn-65(II) in everted membrane vesicles of E. coli catalyzed by either of these two P-type ATPase superfamily members is inhibited by Pb(II).	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu	Rensing, Christopher/D-3947-2011; Sun, Yan/A-7461-2008	Rensing, Christopher/0000-0002-5012-7953; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM18973, GM54102, GM55425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054102, R37GM055425, R01GM055425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachmann B.J., 1987, ESCHERICHIA COLI SAL, P1190; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CORBISIER P, 1993, FEMS MICROBIOL LETT, V110, P231, DOI 10.1111/j.1574-6968.1993.tb06325.x; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; INNIS MA, 1990, PCR PROTOCOLS; Kuroda M, 1998, METHOD ENZYMOL, V292, P82; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MILLE J, 1992, SHORT COURSE BACTERI; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ODERMATT A, 1992, ANN NY ACAD SCI, V671, P484, DOI 10.1111/j.1749-6632.1992.tb43836.x; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; RENSING C, 1998, IN PRESS BIOCH CELL; RENSING C, 1998, MOL BIOL TOXICOLOGY; ROSEN BP, 1998, METALLOPROTEINS, V34; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Solioz M, 1997, FEBS LETT, V412, P165, DOI 10.1016/S0014-5793(97)00770-9; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; YOON KP, 1991, J BACTERIOL, V173, P7636, DOI 10.1128/jb.173.23.7636-7642.1991; YOON KP, 1991, J BACTERIOL, V173, P7643, DOI 10.1128/jb.173.23.7643-7649.1991; 1998, FED REG, V63, P30301	29	151	159	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32614	32617		10.1074/jbc.273.49.32614	http://dx.doi.org/10.1074/jbc.273.49.32614			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830000	hybrid			2022-12-25	WOS:000077329100039
J	Simoneau, JA; Kelley, DE; Neverova, M; Warden, CH				Simoneau, JA; Kelley, DE; Neverova, M; Warden, CH			Overexpression of muscle uncoupling protein 2 content in human obesity associates with reduced skeletal muscle lipid utilization	FASEB JOURNAL			English	Article						UCP; body fat; substrate utilization; insulin sensitivity; energy expenditure	BROWN ADIPOSE-TISSUE; GENE-EXPRESSION; FATTY-ACIDS; INSULIN; THERMOGENESIS; LINKAGE; MARKERS; CLONING; HOMOLOG; HORMONE	Uncoupling proteins (UCP) may influence thermogenesis. Since skeletal muscle plays an important role in energy homeostasis and substrate oxidation, this study was undertaken to test the hypotheses that skeletal muscle UCP2 content is altered in obesity and could be linked to basal energy expenditure, insulin sensitivity, or substrate oxidation within skeletal muscle under postabsorptive (fasting) conditions. To examine these possibilities, limb basal energy expenditure and respiratory quotient (bRQ) were measured in 18 obese nondiabetic (Ob) and lean individuals (L). Total body fat (%) ranged from 11% to 46%, In addition, insulin-stimulated rates of glucose disposal (Rd) were measured under euglycemic hyperinsulinemic conditions. Biopsy of vastus lateralis muscle was used to measure cytochrome c oxidase (COX) enzyme activity and UCP2 content. Whereas low muscle COX activity was found in the Ob compared to L (6.9+/-1.6 vs, 9.6+/-1.2 U/g; P<0.001), skeletal muscle UCP2 content in Ob was significantly higher than in L (48+/-9 vs. 33+/-12 arbitrary units/g; P<0.05). Moreover, UCP2 content was positively correlated with percent of total body fat (r=0.57; P<0.05) and bRQ (r=0.59; P<0.01), but not with visceral fat (r=0.17; P=0.49), basal energy expenditure (r=0.07; P=0.79) or Rd (r=-0.23; P=0.34). In summary, these results indicate that if development of obesity in humans is mediated by defective expression of UCP2 within skeletal muscle, then this effect is not observed in people with established obesity. The present study also suggests that skeletal muscle UCP2 content is not related to basal energy expenditure or insulin sensitivity in humans, However, the increased content of UCP2 within skeletal muscle in obesity appears to coincide with a reduced postabsorptive lipid utilization by muscle.	Univ Laval, Dept Prevent & Social Med, Div Kinesiol, St Foy, PQ G1K 7P4, Canada; Univ Pittsburgh, Dept Endocrinol, Pittsburgh, PA 15261 USA; Univ Calif Davis, Rowe Program Genet, Livermore, CA 95616 USA; Univ Calif Davis, Dept Pediat, Livermore, CA 95616 USA; Univ Calif Davis, Dept Biol Chem, Livermore, CA 95616 USA; Univ Calif Davis, Dept Med, Livermore, CA 95616 USA	Laval University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Simoneau, JA (corresponding author), Univ Laval, Dept Prevent & Social Med, Div Kinesiol, St Foy, PQ G1K 7P4, Canada.	Jean-Aime.Simoneau@kin.msp.ulaval.ca			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052581, R01DK049200] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49200, DK52581] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argyropoulos G, 1998, DIABETES, V47, P685, DOI 10.2337/diabetes.47.4.685; Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; Bienengraeber M, 1998, BIOCHEMISTRY-US, V37, P3, DOI 10.1021/bi972463w; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; COLBERG SR, 1995, J CLIN INVEST, V95, P1846, DOI 10.1172/JCI117864; DeFronzo RA, 1979, AM J PHYSIOL, V233, P214; Elbein SC, 1997, DIABETES, V46, P2105, DOI 10.2337/diab.46.12.2105; EVANS WJ, 1982, MED SCI SPORT EXER, V14, P101; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; HEATON JM, 1972, J ANAT, V112, P35; HIKADA S, 1998, BIOCHIM BIOPHYS ACTA, V1389, P178; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; JEZEK P, 1994, J BIOL CHEM, V269, P26184; KELLEY D, 1997, OBES RES, V5, pS21; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Lanni A, 1997, FEBS LETT, V418, P171, DOI 10.1016/S0014-5793(97)01375-6; Liu QY, 1998, GENE, V207, P1, DOI 10.1016/S0378-1119(97)00596-9; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Masaki T, 1997, FEBS LETT, V418, P323, DOI 10.1016/S0014-5793(97)01404-X; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Norman RA, 1997, AM J HUM GENET, V60, P166; Otabe S, 1998, DIABETES, V47, P840, DOI 10.2337/diabetes.47.5.840; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; SIMONEAU JA, 1995, FASEB J, V9, P273, DOI 10.1096/fasebj.9.2.7781930; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433; Stich V, 1997, J CLIN ENDOCR METAB, V82, P739, DOI 10.1210/jc.82.3.739; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; THAETE FL, 1995, INT J OBESITY, V19, P464; Urhammer SA, 1997, DIABETOLOGIA, V40, P1227, DOI 10.1007/s001250050811; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; [No title captured]	40	52	54	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1739	1745		10.1096/fasebj.12.15.1739	http://dx.doi.org/10.1096/fasebj.12.15.1739			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837864				2022-12-25	WOS:000077574500016
J	Caughey, B; Raymond, GJ; Bessen, RA				Caughey, B; Raymond, GJ; Bessen, RA			Strain-dependent differences in beta-sheet conformations of abnormal prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE MINK ENCEPHALOPATHY; INFECTED BRAIN; SCRAPIE; FORM; PRP; SPECTROSCOPY; AGGREGATION; CONVERSION; DIVERSITY; PEPTIDES	Strain diversity in the transmissible spongiform encephalopathies (TSEs) has been proposed to be determined by variations in the conformation of the abnormal, protease-resistant form of prion protein (PrP-res). me have investigated whether infection of hamsters with three TSE strains resulted in the formation of PrP-res with different conformations using limited proteinase K (PK) digestion and infrared spectroscopy. PrP-res isolated from the brains of hamsters infected with the hyper (HY), drowsy (DY), and 263K TSE strains yielded similar SDS-polyacrylamide gel electrophoresis profiles prior to PK treatment. However, after limited digestion with PK, the PrP-res from the DY strain exhibited a fragmentation pattern that was distinct from that of the other two strains. Infrared spectra of HY and 263K PrP-res each had major absorption bands in the amide I region at 1626 and 1636 cm(-1) both prior to and after digestion with PK. These bands were not evident in the DY PrP-res spectra, which had a unique band at 1629-1630 cm(-1) and stronger band intensity at both 1616 and 1694-1695 cm(-1). Because absorbances from 1616 to 1636 cm(-1) of protein infrared spectra are attributed primarily to beta-sheet structures, these findings indicate that the conformations of HY and 263K PrP-res differ hom DY PrP-res at least in structural regions with beta-sheet secondary structure. These results support the hypothesis that strain-specific PrP-res conformers can self-propagate by converting the normal prion protein to the abnormal conformers that induce phenotypically distinct TSE diseases.	NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, Hamilton, MT 59840 USA; Creighton Univ, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Creighton University	Caughey, B (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, NIH, 903 S 4th St, Hamilton, MT 59840 USA.	byron_caughey@nih.gov						BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; Bessen RA, 1997, J BIOL CHEM, V272, P15227, DOI 10.1074/jbc.272.24.15227; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; Bruce M E, 1991, Curr Top Microbiol Immunol, V172, P125; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DONG A, 1990, BIOCHEMISTRY-US, V29, P3303, DOI 10.1021/bi00465a022; DONG AC, 1995, J PHARM SCI-US, V84, P415, DOI 10.1002/jps.2600840407; FINK A, 1997, FOLDING DESIGN, V3, pR9; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; JEFFREY M, 1994, NEUROPATH APPL NEURO, V20, P535, DOI 10.1111/j.1365-2990.1994.tb01007.x; KASCSAK RJ, 1985, J GEN VIROL, V66, P1715, DOI 10.1099/0022-1317-66-8-1715; KASCSAK RJ, 1991, TRANSMISSIBLE SPONGI, P139; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; MERZ PA, 1981, ACTA NEUROPATHOL, V54, P63, DOI 10.1007/BF00691333; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2939; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Rubenstein R, 1998, BIOCHEM BIOPH RES CO, V246, P100, DOI 10.1006/bbrc.1998.8542; Smith CJ, 1997, FEBS LETT, V405, P378, DOI 10.1016/S0014-5793(97)00220-2; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; WILEY CA, 1987, LAB INVEST, V57, P646	38	257	262	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32230	32235		10.1074/jbc.273.48.32230	http://dx.doi.org/10.1074/jbc.273.48.32230			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822701	hybrid			2022-12-25	WOS:000077207000083
J	Higuchi, M; Honda, T; Proske, RJ; Yeh, ETH				Higuchi, M; Honda, T; Proske, RJ; Yeh, ETH			Regulation of reactive oxygen species-induced apoptosis and necrosis by caspase 3-like proteases	ONCOGENE			English	Article						reactive oxygen species; caspases; apoptosis; necrosis; cytochrome c	PROGRAMMED CELL-DEATH; MANGANOUS SUPEROXIDE-DISMUTASE; FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; CYTOCHROME-C; U937 CELLS; THYMOCYTE APOPTOSIS; CYTO-TOXICITY; FACTOR-ALPHA; ACTIVATION	Reactive oxygen species (ROS) and caspases have been implicated as potential mediators of cell death. However, their mechanistic relationship remains to be elucidated, Here we investigated the roles of caspases in apoptosis and necrosis induced by ROS, generated by the mixture of xanthine and xanthine oxidase (X/XO), A low concentration of XO (0.025 U/ml) induced DNA fragmentation with little cellular membrane damage 3 h after treatment, suggesting the induction of apoptosis, The same treatment induced membrane blebbing, a morphological change typical of apoptosis, 15 min after treatment, A high concentration of XO (0.1 U/ml) damaged cell membranes with little concomitance of DNA fragmention, suggesting the induction of necrosis, ROS also activated caspase 3-like proteases and caspase 3 itself together with the release of cytochrome c which might be the cause of caspase activation. Apoptosis induced by low concentrations of XO and necrosis induced by high concentrations of XO was inhibited by z-DEVD-CH2F, an irreversible inhibitor of caspase 3. However, rapid induction of membrane blebbing was not inhibited by z-DEVD-CH2F. These results suggest that both apoptosis and necrosis could be induced by ROS through the activation of caspase 3-like protease; however, caspase 3 activation is not needed for ROS-induced membrane blebbing.	Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Higuchi, M (corresponding author), Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA.							Barinaga M, 1996, SCIENCE, V273, P735, DOI 10.1126/science.273.5276.735; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; CHANG DJ, 1992, BIOCHEM BIOPH RES CO, V188, P538, DOI 10.1016/0006-291X(92)91089-9; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COHEN JJ, 1984, J IMMUNOL, V132, P38; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; Eguchi Y, 1997, CANCER RES, V57, P1835; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; HIGUCHI M, 1995, J IMMUNOL METHODS, V178, P173, DOI 10.1016/0022-1759(94)00254-T; HIGUCHI M, 1992, J IMMUNOTHER, V12, P41, DOI 10.1097/00002371-199207000-00005; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KULL FC, 1981, CANCER RES, V41, P4885; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LYNCH RE, 1978, J BIOL CHEM, V253, P4697; MALORNI W, 1993, FEBS LETT, V327, P75, DOI 10.1016/0014-5793(93)81043-Y; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Palomba L, 1996, FEBS LETT, V390, P91, DOI 10.1016/0014-5793(96)00634-5; RUBIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P450, DOI 10.1016/0003-9861(84)90010-9; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Shimizu S, 1996, ONCOGENE, V12, P2045; Tsang SY, 1996, BIOCHEM J, V317, P13, DOI 10.1042/bj3170013; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WONG GHW, 1995, BBA-MOL BASIS DIS, V1271, P205, DOI 10.1016/0925-4439(95)00029-4; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	42	173	174	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2753	2760		10.1038/sj.onc.1202211	http://dx.doi.org/10.1038/sj.onc.1202211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840939				2022-12-25	WOS:000077146700008
J	Cayrol, C; Ducommun, B				Cayrol, C; Ducommun, B			Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21	ONCOGENE			English	Article						cyclin-dependent kinases; p21Cip1; PCNA; degradation	S-PHASE; INHIBITOR; P27(KIP1); PROTEIN; PATHWAY; G(1); PHOSPHORYLATION; CELLS; PROGRESSION; RADIATION	The cyclin-dependent kinase (CDK) inhibitor p21(Cip1/Waf1) plays an essential role in the control of cell proliferation by modulating the activity of cyclin/CDK complexes in response to various intracellular or extracellular signals. Small variations in p21 expression levels may determine whether it acts as an inhibitor or an assembly factor for cyclin/CDK complexes. It is therefore critical to better characterize the mechanisms regulating p21 abundance. Here, we show, using a tetracycline-regulated system in p53-deficient DLD-1 human colon cancer cells, that p21 protein levels and stability are regulated by the proteasome-dependent degradation pathway and by association with its partners, CDKs and PCNA, A p21 mutant deficient for interaction with CDKs, p21(CDK-), displayed an enhanced stability and greatly reduced sensitivity to proteasome-mediated proteolysis, indicating that association with cyclin/CDK complexes may trigger p21 degradation. In contrast, a p21 mutant impaired in the interaction with PCNA, p21(PCNA-), exhibited a decreased stability, suggesting that association with PCNA protects p21 from proteasome-dependent degradation. Furthermore, the abundance of p21 itself, in addition to protein-protein interactions, may also modulate p21 stability since we found that high levels of p21 expression overcome proteasome-dependent regulation of p21 accumulation.	Univ Toulouse 3, CNRS, IPBS, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, IPBS, 205 Route Narbonne, F-31077 Toulouse, France.		DUCOMMUN, Bernard/B-3208-2008; CAYROL, Corinne/C-2106-2011	CAYROL, Corinne/0000-0002-7813-4397; DUCOMMUN, Bernard/0000-0002-7126-8368				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hirai A, 1997, J BIOL CHEM, V272, P13; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	34	124	126	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2437	2444		10.1038/sj.onc.1202189	http://dx.doi.org/10.1038/sj.onc.1202189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824154				2022-12-25	WOS:000076927300003
J	Crawford, MJ; Goldberg, DE				Crawford, MJ; Goldberg, DE			Regulation of the Salmonella typhimurium flavohemoglobin gene - A new pathway for bacterial gene expression in response to nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ACTIVATED MACROPHAGES; SUPEROXIDE-DISMUTASE; BACILLUS-SUBTILIS; COMPLEX-FORMATION; FUR REGULON; IRON; IDENTIFICATION; PROTEIN; RELEASE	Flavohemoglobins, a family of two-domain proteins with homology to vertebrate hemoglobins, are found in a variety of prokaryotic and eukaryotic microorganisms. Recent studies suggest a role for these proteins in nitrogen oxide metabolism. We now show that nitric oxide donors positively regulate a chromosomal flavohemoglobin (hmp)/lacZ operon fusion in Salmonella typhimurium. hmp gene expression in the presence of NO. is independent of the SoxS, OxyR, and FNR transcription factors and instead relies on inactivation of the iron-dependent Fur repressor. Other Fur-repressed promoters in S. typhimurium are also activated by an NO. donor,In contrast to the wild-type strain, an hmp(-) mutant requires markedly lower concentrations of NO to induce the hmp/lacZ fusion, whereas its response to iron chelation is equivalent to wild type. These data unveil a new pathway for NO-dependent gene expression in S. typhimurium.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	goldberg@borcim.wustl.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; Baumler AJ, 1996, GENE, V183, P207, DOI 10.1016/S0378-1119(96)00560-4; Chen L, 1998, MOL CELL, V1, P795, DOI 10.1016/S1097-2765(00)80079-9; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; CRAMM R, 1994, J BIOL CHEM, V269, P7349; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; CRAWFORD MJ, 1995, J BIOL CHEM, V270, P6991, DOI 10.1074/jbc.270.12.6991; Crosa JH, 1997, MICROBIOL MOL BIOL R, V61, P319, DOI 10.1128/.61.3.319-336.1997; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Fang FC, 1997, INFECT IMMUN, V65, P5371, DOI 10.1128/IAI.65.12.5371-5375.1997; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; FOSTER JW, 1992, J BACTERIOL, V174, P4317, DOI 10.1128/JB.174.13.4317-4323.1992; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hirasaki A, 1996, J PHARMACOL EXP THER, V278, P1269; JOSHI M, 1994, BIOCHEM BIOPH RES CO, V202, P535, DOI 10.1006/bbrc.1994.1961; LaCelle M, 1996, J BACTERIOL, V178, P3803, DOI 10.1128/jb.178.13.3803-3808.1996; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; MARAGOS CM, 1993, CANCER RES, V53, P564; Miller JH., 1972, EXPT MOL GENETICS; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; NIEDERHOFFER EC, 1990, J BACTERIOL, V172, P1930, DOI 10.1128/jb.172.4.1930-1938.1990; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; OGAWA KI, 1995, J BACTERIOL, V177, P1409, DOI 10.1128/jb.177.5.1409-1413.1995; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PAPPSZABO E, 1994, INFECT IMMUN, V62, P2662; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Ramamurthi A, 1997, CHEM RES TOXICOL, V10, P408, DOI 10.1021/tx960183w; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STERNBERG NL, 1991, METHOD ENZYMOL, V204, P18; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; STRAUCH KL, 1985, J BACTERIOL, V161, P673, DOI 10.1128/JB.161.2.673-680.1985; Takaya N, 1997, FEBS LETT, V414, P545, DOI 10.1016/S0014-5793(97)01069-7; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; VANIN AF, 1993, BIOCHIM BIOPHYS ACTA, V1177, P37, DOI 10.1016/0167-4889(93)90154-H; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	46	98	100	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34028	34032		10.1074/jbc.273.51.34028	http://dx.doi.org/10.1074/jbc.273.51.34028			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852058	hybrid			2022-12-25	WOS:000077542200024
J	Deng, XM; Ito, T; Carr, B; Mumby, M; May, WS				Deng, XM; Ito, T; Carr, B; Mumby, M; May, WS			Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; SIGNAL-TRANSDUCTION; NUCLEAR-ENVELOPE; OKADAIC ACID; APOPTOSIS; MITOCHONDRIA; SUBUNIT; GROWTH; TRANSCRIPTION	Interleukin 3 (IL-3) stimulates the net growth of murine factor-dependent NSF/N1.H7 and FDC-P1/ER myeloid cells by stimulating proliferation and suppressing apoptosis, Recently, we discovered that Bcl2 is phosphorylated at an evolutionarily conserved serine residue (Ser(70)) after treatment with the survival agonists IL-3 or bryostatin 1, a potent activator of protein kinase (Ito, T., Deng, X., Carr, B,, and May, W, S, (1997) J. Biol, Chem. 272, 11671-11673), In addition, an intact Ser(70) was found to be required for Bcl2's ability to suppress apoptosis after IL-3 withdrawal or toxic chemotherapy, We; now show that phosphorylation of Bc12 occurs rapidly after the addition of agonist to IL-3-deprived cells and can be reversed by the action of an okadaic acid (OA)-sensitive phosphatase. A role for protein phosphatase (PP) A as the Bc12 regulatory phosphatase is supported by several observations: 1) dephosphorylation of Bc12 is blocked by OA, a potent PP1 and PP2A inhibitor; 2) intracellular PP2A, but not PP1, co-localizes with Bc12; 3) the purified PP2Ac catalytic subunit directly dephosphorylates Bc12 in vitro in an OA-sensitive manner; 4) the purified PP2Ac catalytic subunit preferentially dephosphorylates Bc12 in vitro compared with PP1 and PP2B; 5) reciprocal immunoprecipitation studies indicate a direct interaction between PP2A and hemagglutinin (HA)-Bcl2; and 6) treatment of factor-deprived cells with bryostatin 1 dramatically increases the association between PP2A and Bc12, Increased association between Bc12 and PP2A occurs 15 min after agonist stimulation when Bcl2 phosphorylation has peaked and immediately before dephosphorylation. An agonist-induced increased association of PP2A and Bc12 fails to occur in cells expressing the inactive, phosphorylation-negative S70A Bcl2 mutant, which indicates that an intact Ser(70) site is necessary and sufficient for the interaction to occur. Functional phosphorylation of Bc12 at Ser(70) is proposed to be a dynamic process regulated by the sequential action of an agonist-activated Bc12 kinase and PP2A.	Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	May, WS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, 9-104 Med Res Bldg, Galveston, TX 77555 USA.	smay@utmb.edu			NCI NIH HHS [CA44649, CA47993] Funding Source: Medline; NHLBI NIH HHS [HL31107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044649, R01CA047993] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSWELL HS, 1990, EXP HEMATOL, V18, P794; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; COHEN P, 1989, FEBS LETT, V250, P601, DOI 10.1016/0014-5793(89)80804-X; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GONG CX, 1994, J NEUROCHEM, V62, P803; GONG CX, 1993, J NEUROCHEM, V61, P921, DOI 10.1111/j.1471-4159.1993.tb03603.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MAY WS, 1994, J BIOL CHEM, V269, P26865; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nagase T, 1997, J BIOCHEM, V122, P178; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	39	117	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34157	34163		10.1074/jbc.273.51.34157	http://dx.doi.org/10.1074/jbc.273.51.34157			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852076	hybrid			2022-12-25	WOS:000077542200042
J	Jitrapakdee, S; Gong, QM; MacDonald, MJ; Wallace, JC				Jitrapakdee, S; Gong, QM; MacDonald, MJ; Wallace, JC			Regulation of rat pyruvate carboxylase gene expression by alternate promoters during development, in genetically obese rats and in insulin-secreting cells - Multiple transcripts with 5 '-end heterogeneity modulate translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; AMINO-ACID-SEQUENCE; MESSENGER-RNA; PANCREATIC-ISLETS; BETA-CELL; 5' END; 2 PROMOTERS; GLUCOSE; CDNA; PREADIPOCYTES	A previous study on the gene structure of rat pyruvate carboxylase revealed that two tissue-specific promoters are responsible for the production of multiple transcripts with 5'-end heterogeneity (Jitrapakdee, S,, Booker, G. W., Cassady, W., and Wallace, J. C. (1997) J. Biol. Ghent. 272, 20522-20530), Here we report transcription and translation regulation of pyruvate carboxylase (PC) expression during development and in genetically obese rats. The abundance of PC mRNAs was low in fetal liver but increased by 2-4-fold within 7 days after birth, concomitant with an 8-fold increase in the amount of immunoreactive PC and its activity and then decreased during the weaning period. Reverse transcriptase polymerase chain reaction analysis indicated that the proximal promoter was activated during the suckling period and reduced in activity at weaning. In genetically obese Zucker rats, adipose PC was 4-5-fold increased, concomitant with a 5-6-fold increase in mRNA level. Reverse transcriptase-polymerase chain reaction analysis also showed that the proximal promoter was activated in the hyperlipogenic condition. Conversely, transcription of the proximal promoter was not detectable in various liver cell lines, suggesting that this promoter was not functional under cell culture conditions, In rat pancreatic islets and insulinoma cells, only transcripts D and E, generated from the distal promoter of the PC gene, were expressed. Glucose increased PC transcripts from the distal promoter when the insulinoma cells were maintained in 10 mM glucose, We conclude that the proximal promoter of the rat PC gene plays a major role in gluconeogenesis and lipogenesis, whereas the distal promoter is necessary for anaplerosis, In vitro translation and in vivo polysome profile analysis indicated that transcripts C and E were translated with similar translational efficiencies that are substantially greater than that of transcript D, suggesting that 5'-untranslated regions play a role in translational control.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Wisconsin, Childrens Diabet Ctr, Madison, WI 53706 USA	University of Adelaide; University of Wisconsin System; University of Wisconsin Madison	Wallace, JC (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	jwallace@biochem.adelaide.edu.au	, John/AAP-5150-2020					ANGUS CW, 1981, BIOCHEM BIOPH RES CO, V103, P1216, DOI 10.1016/0006-291X(81)90252-7; BALLARD FJ, 1965, BIOCHEM J, V95, P191, DOI 10.1042/bj0950191; BALLARD FJ, 1967, J LIPID RES, V8, P73; Barritt GJ, 1985, PYRUVATE CARBOXYLASE, P147; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; CLARK JB, 1983, P SOC EXP BIOL MED, V173, P68; EXTON JH, 1967, J BIOL CHEM, V242, P2622; FREYTAG SO, 1984, J BIOL CHEM, V259, P2831; Gamberino WC, 1997, J NEUROCHEM, V69, P2312; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; Hsu MH, 1996, J BIOL CHEM, V271, P13584, DOI 10.1074/jbc.271.23.13584; Jitrapakdee S, 1996, BIOCHEM BIOPH RES CO, V223, P695, DOI 10.1006/bbrc.1996.0958; Jitrapakdee S, 1997, J BIOL CHEM, V272, P20522, DOI 10.1074/jbc.272.33.20522; JITRAPAKDEE S, 1996, BIOCHEM J, V316, P630; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHN DA, 1995, GENE, V165, P331, DOI 10.1016/0378-1119(95)00557-M; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LOPEZCASILLAS F, 1991, EUR J BIOCHEM, V201, P119, DOI 10.1111/j.1432-1033.1991.tb16264.x; LOPEZCASILLAS F, 1989, GENE, V83, P311, DOI 10.1016/0378-1119(89)90117-0; LOPEZCASILLAS F, 1991, ENDOCRINOLOGY, V129, P1049, DOI 10.1210/endo-129-2-1049; LUO XC, 1989, P NATL ACAD SCI USA, V86, P4042, DOI 10.1073/pnas.86.11.4042; LYNCH CJ, 1992, AM J PHYSIOL, V262, pE698; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MACKAY N, 1994, BIOCHEM BIOPH RES CO, V202, P1009, DOI 10.1006/bbrc.1994.2029; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; ROHDE M, 1991, ARCH BIOCHEM BIOPHYS, V290, P197, DOI 10.1016/0003-9861(91)90608-L; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Wallace JC, 1998, INT J BIOCHEM CELL B, V30, P1, DOI 10.1016/S1357-2725(97)00147-7; Webb GC, 1997, CYTOGENET CELL GENET, V79, P151, DOI 10.1159/000134707; WEXLER ID, 1994, BBA-MOL BASIS DIS, V1227, P46, DOI 10.1016/0925-4439(94)90105-8; YAMADA S, 1980, IN VITRO CELL DEV B, V16, P559; YEUNG D, 1967, BIOCHEM J, V105, P1219, DOI 10.1042/bj1051219; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P1766, DOI 10.1073/pnas.90.5.1766; ZHANG J, 1995, BIOCHEM J, V306, P205, DOI 10.1042/bj3060205; ZHANG S, 1995, J ENDOCRINOL, V147, P33, DOI 10.1677/joe.0.1470033	40	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34422	34428		10.1074/jbc.273.51.34422	http://dx.doi.org/10.1074/jbc.273.51.34422			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852109	hybrid			2022-12-25	WOS:000077542200075
J	Kuroki, R; Yutani, K				Kuroki, R; Yutani, K			Structural and thermodynamic responses of mutations at a Ca2+ binding site engineered into human lysozyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; STABILITY; YEAST; STABILIZATION; SECRETION; PROTEINS	Structural determinants of Ca2+ binding sites within proteins typically comprise several acidic residues in appropriate juxtaposition. Three residues (Ala-83, Gln86, and Ala-92)in human lysozyme are characteristically mutated to Lys, Asp, and Asp, respectively, in natural Ca2+ binding lysozymes and alpha-lactalbumins. The effects of these mutations on the stability and Ca2+ binding properties of human lysozyme were investigated using calorimetry and were interpreted with crystal structures. The double mutant, in which Glu-86 and Ala-92 were replaced with Asp, clearly showed Ca2+ binding affinity, whereas neither point mutant showed Ca2+ affinity, indicating that both residues are essential. The further mutation of Ala-83 --> Lys did not affect the Ca2+ binding of the double mutant. The point mutations Ala-83 --> Lys and Glu-86 --> Asp did not affect the stability, whereas the mutation Ala-92 --> Asp was about 1.3 kcal/mol less stable. Structural analyses showed that both Asp-86 and Lys-83 were exposed to solvent. Side chains of Asp-86 and Asp-91 were rotated in opposite directions about chi 1 angle, as if to reduce the electrostatic repulsion. The charged amino acids at the Ca2+ binding site did not significantly affect stability of the protein, possibly because of the local conformational change of the side chains.	Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan	Kirin Brewery Company Limited; Osaka University	Kuroki, R (corresponding author), Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, 1-13-5 Fukuura, Yokohama, Kanagawa 236, Japan.	r-kuroki@kirin.co.jp						ARTYMIUK PJ, 1981, J MOL BIOL, V152, P737, DOI 10.1016/0022-2836(81)90125-X; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; GODOVAC-ZIMMERMANN J, 1988, BIOL CHEM H-S, V369, P1109, DOI 10.1515/bchm3.1988.369.2.1109; HAEZEBROUCK P, 1993, PROTEIN ENG, V6, P643, DOI 10.1093/protein/6.6.643; INAKA K, 1991, J BIOL CHEM, V266, P12599; INAKA K, 1991, J BIOL CHEM, V266, P20666; Jolles P., 1996, LYSOZYMES MODEL ENZY; KIDOKORO S, 1987, BIOPOLYMERS, V26, P213, DOI 10.1002/bip.360260205; KIKUCHI M, 1988, P NATL ACAD SCI USA, V85, P9411, DOI 10.1073/pnas.85.24.9411; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; KUROKI R, 1992, BIOCHEMISTRY-US, V31, P8323, DOI 10.1021/bi00150a028; KUROKI R, 1992, P NATL ACAD SCI USA, V89, P6803, DOI 10.1073/pnas.89.15.6803; KUROKI R, 1992, J BIOL CHEM, V267, P24297; LEVINE M, 1982, CLIN PSYCHOL REV, V2, P1, DOI 10.1016/0272-7358(82)90002-2; MIYANOHARA A, 1983, P NATL ACAD SCI-BIOL, V80, P1, DOI 10.1073/pnas.80.1.1; NITTA K, 1988, BIOL CHEM H-S, V369, P671, DOI 10.1515/bchm3.1988.369.2.671; NITTA K, 1987, FEBS LETT, V223, P405, DOI 10.1016/0014-5793(87)80328-9; OOBATAKE M, 1993, PROG BIOPHYS MOL BIO, V59, P237, DOI 10.1016/0079-6107(93)90002-2; OOBATAKE M, 1989, J BIOCH, V104, P433; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1974, J MOL BIOL, V86, P665, DOI 10.1016/0022-2836(74)90188-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLMAN JA, 1976, BIOPOLYMERS, V15, P999, DOI 10.1002/bip.1976.360150513; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; Strynadka NCJ, 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WILSON KP, 1992, J BIOL CHEM, V267, P10842; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; ZOLLER MJ, 1973, METHOD ENZYMOL, V100, P468	31	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34310	34315		10.1074/jbc.273.51.34310	http://dx.doi.org/10.1074/jbc.273.51.34310			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852096	hybrid			2022-12-25	WOS:000077542200062
J	Sakakibara, Y; Yanagisawa, K; Katafuchi, J; Ringer, DP; Takami, Y; Nakayama, T; Suiko, M; Liu, MC				Sakakibara, Y; Yanagisawa, K; Katafuchi, J; Ringer, DP; Takami, Y; Nakayama, T; Suiko, M; Liu, MC			Molecular cloning, expression, and characterization of novel human SULT1C sulfotransferases that catalyze the sulfonation of N-hydroxy-2-acetylaminofluorene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; RAT-LIVER; PROTEINS; BINDING; GENERATION; ACTIVATION; CDNAS; IV	Upon sulfonation, carcinogenic hydroxyarylamines such as N-hydroxy-2-acetylaminofluorene (N-OH-2AAF) can be further activated to form ultimate carcinogens in vivo. Previous studies have shown that a SULT1C1 sulfotransferase is primarily responsible for the sulfonation of N-OH-2AAF in rat liver. In the present study, two novel human sulfotransferases shown to be members of the SULT1C sulfotransferase subfamily based on sequence analysis have been cloned, expressed, and characterized. Comparisons of the deduced amino acid sequence encoded by the human SULT1C sulfotransferase cDNA 1 reveal 63.7, 61.6, and 85.1% identity to the amino acid sequences of rat SULT1C1 sulfotransferase, mouse SULT1C1 sulfotransferase, and rabbit SULT1C sulfotransferase. In contrast, the deduced amino acid sequence of the human SULT1C sulfotransferase 2 cDNA displays 62.9, 63.1, 63.1, and 62.5% identity to the amino acid sequences of the human SULT1C sulfotransferase 1, rat SULT1C1 sulfotransferase, mouse SULT1C1 sulfotransferase, and rabbit SULT1C sulfotransferase. Recombinant human SULT1C sulfotransferases 1 and 2, expressed in Escherichia coli and purified to near electrophoretic homogeneity, were shown to cross-react with the antiserum against the rat liver SULT1C1 sulfotransferase and exhibited sulfonating activities with N-OH-2AAF as substrate. Tissue-specific expression of these novel human SULT1C sulfotransferases were examined by employing the Northern blotting technique. The results provide a foundation for the investigation into the functional relevance of these new SULT1C sulfotransferases in different human tissues/organs.	Univ Texas, Ctr Hlth, Dept Biochem, Tyler, TX 75710 USA; Oklahoma Med Res Fdn, Noble Ctr Biomed Res, Oklahoma City, OK 73104 USA; Miyazaki Med Coll, Dept Biochem, Miyazaki 88916, Japan	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); Oklahoma Medical Research Foundation; University of Miyazaki	Liu, MC (corresponding author), Univ Texas, Ctr Hlth, Dept Biochem, POB 2003, Tyler, TX 75710 USA.	liu@uthct.edu						ABUZEID M, 1992, CARCINOGENESIS, V13, P1307, DOI 10.1093/carcin/13.8.1307; ANDREWS LS, 1978, BIOCHEM PHARMACOL, V27, P2399, DOI 10.1016/0006-2952(78)90351-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEBAUN JR, 1970, SCIENCE, V167, P184, DOI 10.1126/science.167.3915.184; DEBAUN JR, 1970, CANCER RES, V30, P577; Falany C., 1993, HUMAN DRUG METABOLIS, P101; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERNANDO PHP, 1993, BIOSCI BIOTECH BIOCH, V5, P1974; Fujita K, 1997, J BIOCHEM-TOKYO, V122, P1052; Glatt H, 1997, FASEB J, V11, P314, DOI 10.1096/fasebj.11.5.9141497; GONG DW, 1991, J BIOCHEM-TOKYO, V110, P226, DOI 10.1093/oxfordjournals.jbchem.a123561; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Her CT, 1997, GENOMICS, V41, P467, DOI 10.1006/geno.1997.4683; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; Kadlubar F. F., 1985, POLYCYCLIC HYDROCARB, P341; KADLUBAR FF, 1976, CANCER RES, V36, P2350; KATO R, 1986, CRIT REV TOXICOL, V16, P307, DOI 10.3109/10408448609037466; KIEHLBAUCH CC, 1995, J BIOL CHEM, V270, P18941, DOI 10.1074/jbc.270.32.18941; KING CM, 1968, SCIENCE, V159, P1351, DOI 10.1126/science.159.3821.1351; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LIU MC, 1984, P NATL ACAD SCI-BIOL, V81, P3695, DOI 10.1073/pnas.81.12.3695; Michejda C J, 1994, Adv Pharmacol, V27, P331, DOI 10.1016/S1054-3589(08)61038-8; Miyawaki A, 1996, EMBO J, V15, P2050, DOI 10.1002/j.1460-2075.1996.tb00558.x; Mulder G.J., 1990, CONJUGATION REACTION, P107; NAGATA K, 1993, J BIOL CHEM, V268, P24720; Nagata K, 1997, MUTAT RES-FUND MOL M, V376, P267, DOI 10.1016/S0027-5107(97)00052-3; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RINGER DP, 1990, CANCER RES, V50, P5301; Saeki Y, 1998, J BIOCHEM-TOKYO, V124, P55, DOI 10.1093/oxfordjournals.jbchem.a022097; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKURA RD, 1981, ARCH BIOCHEM BIOPHYS, V211, P352, DOI 10.1016/0003-9861(81)90464-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENGOORBERGH JAM, 1985, CARCINOGENESIS, V6, P1635, DOI 10.1093/carcin/6.11.1635; Wang J, 1998, MOL PHARMACOL, V53, P274, DOI 10.1124/mol.53.2.274; WATABE T, 1982, SCIENCE, V215, P403, DOI 10.1126/science.6800033; WEINSHILBOUM R, 1994, CONJUGATION DECONJUG, P45, DOI DOI 10.1007/978-3-642-78429-3; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; YAMAZOE Y, 1994, CHEM-BIOL INTERACT, V92, P107, DOI 10.1016/0009-2797(94)90057-4	39	112	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33929	33935		10.1074/jbc.273.51.33929	http://dx.doi.org/10.1074/jbc.273.51.33929			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852044	hybrid			2022-12-25	WOS:000077542200010
J	Scott, PH; Lawrence, JC				Scott, PH; Lawrence, JC			Attenuation of mammalian target of rapamycin activity by increased cAMP in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; P70 S6 KINASE; SMOOTH-MUSCLE CELLS; PHAS-I; TRANSLATIONAL REGULATOR; INITIATION FACTOR-4E; RAT ADIPOCYTES; CYCLIC-AMP; INSULIN; PHOSPHORYLATION	Incubating 3T3-L1 adipocytes with forskolin, which increases intracellular cAMP by activating adenylate cyclase, mimicked rapamycin by attenuating the effect of insulin on stimulating the phosphorylation of four (S/T)P sites in PHAS-I, a downstream target of the mammalian target of rapamycin (mTOR) signaling pathway. To investigate the hypothesis that increasing cAMP inhibits mTOR, the protein kinase activity of mTOR was measured in an immune complex assay with recombinant PHAS-I as substrate. Both forskolin and 8-(4-chlorophenylthio) adenosine 3'-5'-monophosphate (CPT-cAMP) prevented the activation of mTOR by insulin in adipocytes, but neither agent affected mTOR activity when added directly to the immunopurified protein. In contrast, the cAMP phosphodiesterase inhibitor, theophylline, inhibited mTOR activity not only when added to intact adipocytes but also when added to immunopurified mTOR in vitro, demonstrating that certain methylxanthines are able to inhibit mTOR independently of increasing cAMP. Forskolin and CPT-cAMP blocked the effect of insulin on increasing mTOR phosphorylation, which was assessed using mTAb1, an antibody whose binding is inhibited by phosphorylation of mTOR. Although the mTAb1 epitope contains a consensus site for protein kinase B, neither agent inhibited the activation of protein kinase B produced by insulin, These findings support the interpretation that increasing cAMP attenuates the effects of insulin on PHAS-I, p70(S6K), and other downstream targets of the mTOR signaling pathway by inhibiting the phosphorylation and activation of mTOR.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Lawrence, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22938 USA.			Scott, Pam/0000-0001-5548-4039	NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK52753, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753, R01DK028312] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHENG HC, 1986, J BIOL CHEM, V261, P989; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; Fadden P, 1997, J BIOL CHEM, V272, P10240; FROST V, 1995, J BIOL CHEM, V270, P26698, DOI 10.1074/jbc.270.44.26698; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Scott PH, 1997, FEBS LETT, V409, P171, DOI 10.1016/S0014-5793(97)00500-0; Scott PH, 1996, BIOCHEM J, V318, P965, DOI 10.1042/bj3180965; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315	42	66	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34496	34501		10.1074/jbc.273.51.34496	http://dx.doi.org/10.1074/jbc.273.51.34496			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852118	hybrid			2022-12-25	WOS:000077542200084
J	Koopman, JL; Slomp, J; de Bart, ACW; Quax, PHA; Verheijen, JH				Koopman, JL; Slomp, J; de Bart, ACW; Quax, PHA; Verheijen, JH			Mitogenic effects of urokinase on melanoma cells are independent of high affinity blinding to the urokinase receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RENAL-CELLS; PLASMINOGEN-ACTIVATOR; NUDE-MICE; PROTEOLYTIC CLEAVAGE; MESANGIAL CELLS; SYSTEM; PROLIFERATION; PROTEIN; BINDING; DOMAIN	The structural and functional properties of the urokinase-type plasminogen activator (u-PA) that are involved in the mitogenic effect of this proteolytic enzyme on human melanoma cells M14 and IF6 and the role of the u-PA receptor (u-PAR) in transducing this signal were analyzed. Native u-PA petrified from urine induced a mitogenic response in quiescent IF6 and M14 cells that ranged from 25 to 40% of the mitogenic response obtained by fetal calf serum. The half-maximum response in M14 and IF6 cells was reached at u-PA concentrations of approximately 35 and 60 nM, respectively. Blocking the proteolytic activity of u-PA resulted in a 30% decrease of the mitogenic effect, whereas inhibition of plasmin activity did not alter the mitogenic effect. No mitogenic response was elicited by low molecular weight u-PA, lacking the growth factor domain and the kringle domain. The ATF domain of u-PA induced a mitogenic response that was similar to complete u-PA. Defucosylated ATF and recombinant u-PA purified from Escherichia coli lacking all post-translational modifications did not induce a mitogenic response. Blocking the interaction of u-PA with u-PAR, using a specific monoclonal antibody, did not alter the mitogenic effect induced by u-PA. The binding of radiolabeled u-PA to M14 and IF6 cells was characterized by high affinity binding mediated by u-PAR and low affinity binding to an unknown binding site. These results demonstrate that proteolytically inactive u-PA is able to induce a mitogenic response in quiescent melanoma cells in vitro by a mechanism that involves the ATF domain but is independent of high affinity binding to u-PAR, Furthermore, it suggests that u-PA is able to bind with low affinity to a hitherto unidentified membrane associated protein that could be involved in u-PA-induced signal transduction.	TNO Prevent & Hlth, Gaubius Lab, NL-2301 CE Leiden, Netherlands	Netherlands Organization Applied Science Research	Verheijen, JH (corresponding author), TNO Prevent & Hlth, Gaubius Lab, POB 2215, NL-2301 CE Leiden, Netherlands.		Quax, Paul/ABD-5294-2020; Quax, Paul/W-8520-2019	Quax, Paul/0000-0002-6853-5760; 				AMICI C, 1989, INT J CANCER, V43, P171, DOI 10.1002/ijc.2910430131; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BARON-VAN EVERCOOREN A, 1987, DEV BRAIN RES, V36, P101, DOI 10.1016/0165-3806(87)90068-X; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; deVries TJ, 1996, FIBRINOLYSIS, V10, P91, DOI 10.1016/S0268-9499(96)80058-0; Duffy M J, 1990, Blood Coagul Fibrinolysis, V1, P681; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; GLASS WF, 1988, J CLIN INVEST, V82, P1992, DOI 10.1172/JCI113819; GUDEWICZ PW, 1987, BIOCHEM BIOPH RES CO, V147, P1176, DOI 10.1016/S0006-291X(87)80193-6; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; HE CJ, 1991, BIOCHEM BIOPH RES CO, V176, P1408, DOI 10.1016/0006-291X(91)90443-B; Jiang YP, 1996, BLOOD, V87, P2775, DOI 10.1182/blood.V87.7.2775.bloodjournal8772775; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; KATANO M, 1984, J CANCER RES CLIN, V108, P197, DOI 10.1007/BF00402467; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KIRCHHEIMER JC, 1988, CARCINOGENESIS, V9, P2121, DOI 10.1093/carcin/9.11.2121; KIRCHHEIMER JC, 1989, P NATL ACAD SCI USA, V86, P5424, DOI 10.1073/pnas.86.14.5424; KLUFT C, 1983, ADV BIOTECHNOLOGICAL, V2, P97; MAZAR AP, 1992, FIBRINOLYSIS, V6, P49, DOI 10.1016/0268-9499(92)90094-X; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NGUYEN G, 1994, KIDNEY INT, V46, P208, DOI 10.1038/ki.1994.261; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; PLOUG M, 1991, J BIOL CHEM, V266, P1926; QUAX PHA, 1991, J CELL BIOL, V115, P191, DOI 10.1083/jcb.115.1.191; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SCHMITT M, 1992, BIOL CHEM H-S, V373, P611, DOI 10.1515/bchm3.1992.373.2.611; VANMUIJEN GNP, 1989, ANTICANCER RES, V9, P879; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VAUGHAN DE, 1990, FIBRINOLYSIS, V4, P141, DOI 10.1016/S0268-9499(05)80045-1	36	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33267	33272		10.1074/jbc.273.50.33267	http://dx.doi.org/10.1074/jbc.273.50.33267			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837898	Green Published, hybrid			2022-12-25	WOS:000077462500028
J	Nguyen, M; Branton, PE; Roy, S; Nicholson, DW; Alnemri, ES; Yeh, WC; Mak, TW; Shore, GC				Nguyen, M; Branton, PE; Roy, S; Nicholson, DW; Alnemri, ES; Yeh, WC; Mak, TW; Shore, GC			E1A-induced processing of procaspase-8 can occur independently of FADD and is inhibited by Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC-INDUCED APOPTOSIS; ENZYME-LIKE PROTEASES; INDUCED CELL-DEATH; CYTOCHROME-C; SIGNALING COMPLEX; ADENOVIRUS; E1A; PROTEIN; P53; RECEPTOR	Expression of the 243-residue form of the adenovirus E1A protein in the absence of other viral proteins triggers apoptosis by a pathway that requires p53. This pathway includes processing and activation of initiator procaspase-8, redistribution of cytochrome c, and activation of procaspase-3. Bcl-2 functions at or upstream of procaspase-8 processing to inhibit all of these events and prevent cell death. This contrasts with the antiapoptotic influence of Bcl-2 family proteins in the cell death pathway induced by Fats ligand or tumor necrosis factor (TNF), in which Bcl-2 typically acts downstream of Fas/TNFR1-mediated activation of caspase-8. Moreover, E1A induces procaspase-8 processing and cell death in cells deleted of FADD, an adaptor protein critical for Fas/TNFR1 activation of caspase-8. The results indicate that E1A is capable of activating caspase-8 by a Bcl-2-inhibitable pathway that does not involve autocrine stimulation of FADD-dependent death receptor pathways.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Merck Frosst Canada Inc, Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Amgen Inst, Toronto, ON M5G 2C1, Canada	McGill University; Merck & Company; Jefferson University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.	shore@medcor.mcgill.ca	Alnemri, Emad S/B-4526-2010					Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Boulakia CA, 1996, ONCOGENE, V12, P529; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Green DR, 1997, SCIENCE, V278, P1246, DOI 10.1126/science.278.5341.1246; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Mueller CM, 1996, J IMMUNOL, V157, P5329; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ng FWH, 1998, J BIOL CHEM, V273, P3140, DOI 10.1074/jbc.273.6.3140; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	44	33	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33099	33102		10.1074/jbc.273.50.33099	http://dx.doi.org/10.1074/jbc.273.50.33099			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837871	hybrid			2022-12-25	WOS:000077462500001
J	Prasad, GVR; Coury, LA; Finn, F; Zeidel, ML				Prasad, GVR; Coury, LA; Finn, F; Zeidel, ML			Reconstituted aquaporin 1 water channels transport CO2 across membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; CELL; PERMEABILITIES	Biological membranes provide selective barriers to a number of molecules and gases. However, the factors that affect permeability to gases remain unclear because of the difficulty of accurately measuring gas movements. To determine the roles of lipid composition and the aquaporin 1 (AQP1) water channel in altering CO2 flux across membranes, we developed a fluorometric assay to measure CO2 entry into vesicles. Maximal CO2 flux was similar to 1000-fold above control values with 0.5 mg/ml carbonic anhydrase, Unilamellar phospholipid vesicles of varying composition gave widely varying water permeabilities but similar CO2 permeabilities at 25 degrees C. When AQP1 purified fr om human red blood cells was reconstituted into proteoliposomes, however, it increased water and CO2 permeabilities markedly. Both increases were abolished with HgCl2, and the mercurial inhibition was reversible with beta-mercaptoethanol. We conclude that unlike water and small nonelectrolytes, CO2 permeation is not significantly altered by lipid bilayer composition or fluidity. AQP1 clearly serves to increase CO2 permeation, likely through the water pore; under certain circumstances, gas permeation through membranes is protein-mediated.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div,Lab Epithelial Cell Biol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Med, Prot Purificat Lab, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zeidel, ML (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Renal Electrolyte Div,Lab Epithelial Cell Biol, 3550 Terr St, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43955] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FINKELSTEIN A, 1986, WATER MOVEMENT LIPID; GARVIN J L, 1988, American Journal of Physiology, V255, pF57; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; Lavelle JP, 1997, AM J PHYSIOL-RENAL, V273, pF67, DOI 10.1152/ajprenal.1997.273.1.F67; Nakhoul NL, 1998, AM J PHYSIOL-CELL PH, V274, pC543, DOI 10.1152/ajpcell.1998.274.2.C543; Negrete HO, 1996, J BIOL CHEM, V271, P11627, DOI 10.1074/jbc.271.20.11627; Negrete HO, 1996, AM J PHYSIOL-RENAL, V271, pF886, DOI 10.1152/ajprenal.1996.271.4.F886; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; PIQUERAS AI, 1993, AM J PHYSIOL, V266, pC121; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; SMITH BL, 1991, J BIOL CHEM, V266, P6407; Stein W., 1990, CHANNELS CARRIERS PU; WAISBREN SJ, 1994, NATURE, V368, P332, DOI 10.1038/368332a0; ZEIDEL ML, 1994, BIOCHEMISTRY-US, V33, P1606, DOI 10.1021/bi00172a042; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; Zeidel ML, 1996, AM J PHYSIOL-RENAL, V271, pF243, DOI 10.1152/ajprenal.1996.271.2.F243	22	121	124	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33123	33126		10.1074/jbc.273.50.33123	http://dx.doi.org/10.1074/jbc.273.50.33123			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837877	hybrid			2022-12-25	WOS:000077462500007
J	Prost, S; Ford, JM; Taylor, G; Doig, J; Harrison, DJ				Prost, S; Ford, JM; Taylor, G; Doig, J; Harrison, DJ			Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS HBX PROTEIN; PRIMARY HEPATOCELLULAR CARCINOMAS; NUCLEOTIDE EXCISION-REPAIR; NECROSIS-FACTOR-ALPHA; LIVER-CELL DYSPLASIA; P53 MUTATIONS; TRANSGENIC MICE; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION	The mechanisms by which the hepatitis B x protein (HBx) contributes to hepatocarcinogenesis remain unclear. However, interaction with the tumor suppressor gene p53 and inhibition of p53-dependent cellular functions, including nucleotide excision repair, could be central to this process. We studied the levels of global repair (removal of cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts) and transcription-coupled repair (removal of CPDs in both strands of the dihydrofolate reductase gene) in primary wild-type and p53-null mouse hepatocytes. We show that global repair of CPDs appears to be more efficient in mouse hepatocytes than in other commonly studied rodent cells and approaches the levels of human cells and that p53 is required for global genomic DNA repair of CPDs but not for transcription-coupled repair. We then investigated the effect of HBx expression on hepatocyte nucleotide excision repair. We demonstrate that HBx expression affects DNA repair in a p53-dependent manner. Transient HBx expression reduces global DNA repair in wild-type cells to the level of p53-null hepatocytes and has no effect on the repair of a transfected damaged plasmid. Therefore, in viral hepatitis, the hepatitis B virus could inhibit the p53-dependent component of global repair leading, over time, to accumulation of genetic defects and fostering carcinogenesis.	Univ Edinburgh, Sch Med, Dept Pathol, Edinburgh EH8 9AG, Midlothian, Scotland; Stanford Univ, Sch Med, Dept Med & Genet, Stanford, CA 94305 USA	University of Edinburgh; Stanford University	Prost, S (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.			prost, sandrine/0000-0002-0140-7115; Ford, James/0000-0002-2513-7025				Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bellamy COC, 1997, J PATHOL, V183, P177, DOI 10.1002/(SICI)1096-9896(199710)183:2<177::AID-PATH909>3.0.CO;2-E; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; BUETOW KH, 1992, P NATL ACAD SCI USA, V89, P9622, DOI 10.1073/pnas.89.20.9622; Capovilla A, 1997, BIOCHEM BIOPH RES CO, V232, P255, DOI 10.1006/bbrc.1997.6269; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COHEN C, 1994, MODERN PATHOL, V7, P536; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; deVries A, 1997, MOL CARCINOGEN, V19, P46, DOI 10.1002/(SICI)1098-2744(199705)19:1<46::AID-MC7>3.3.CO;2-O; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FREBOURG T, 1992, CANCER RES, V52, P6976; Greenblatt MS, 1997, CANCER RES, V57, P426; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HENKLER F, 1995, CANCER RES, V55, P6084; HOSONO S, 1993, ONCOGENE, V8, P491; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim SO, 1996, CANCER RES, V56, P3831; KISO S, 1994, HEPATOLOGY, V20, P1303, DOI 10.1016/0270-9139(94)90772-2; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; LaraPezzi E, 1996, HEPATOLOGY, V24, P392; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin Y, 1997, CANCER RES, V57, P5137; LIVNI N, 1995, CANCER, V75, P2420, DOI 10.1002/1097-0142(19950515)75:10<2420::AID-CNCR2820751006>3.0.CO;2-6; Lunn RM, 1997, CANCER RES, V57, P3471; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; ODA T, 1994, CANCER LETT, V83, P197, DOI 10.1016/0304-3835(94)90319-0; Oshikawa O, 1996, BIOCHEM BIOPH RES CO, V222, P770, DOI 10.1006/bbrc.1996.0819; Prost S, 1998, FASEB J, V12, P181, DOI 10.1096/fasebj.12.2.181; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TAKADA S, 1997, ONCOGENE, V15, P1898; TANAKA S, 1993, CANCER RES, V53, P2884; TERAMOTO T, 1994, CANCER RES, V54, P231; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VREESWIJK MPG, 1994, J BIOL CHEM, V269, P31858; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YEN TS, 1996, J BIOMED SCI, V30, P20; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; ZHAO M, 1994, VIRCHOWS ARCH, V424, P613, DOI 10.1007/BF01069741	52	71	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33327	33332		10.1074/jbc.273.50.33327	http://dx.doi.org/10.1074/jbc.273.50.33327			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837906	hybrid			2022-12-25	WOS:000077462500036
J	Xu, XXS; Vanderziel, C; Bennett, CF; Monia, BP				Xu, XXS; Vanderziel, C; Bennett, CF; Monia, BP			A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; RECEPTOR-ASSOCIATED FACTOR-2; NECROSIS-FACTOR-ALPHA; ENDOTHELIAL-CELLS; ANTISENSE OLIGONUCLEOTIDES; GROWTH-FACTOR; EXPRESSION; PATHWAY; TRANSCRIPTION	Cytokines such as tumor necrosis factor (TNF alpha) play fundamental roles in the pathophysiology of inflammation and immunity-related diseases. Despite rapid advances in our understanding of cytokine biology in recent years, definitive knowledge of the cytokine cell signaling pathways remains elusive due to the enormous complexity of these pathways and the lack of specific biological tools and reagents. Using highly specific antisense oligonucleotides that target the mRNA encoding c-Raf kinase and Ha-Ras, we show here that inhibition of c-raf and Ha-ras expression blocks the up-regulation of E-selectin and vascular adhesion molecule-1 induced by TNF alpha in endothelial cells. Induction of intercellular adhesion molecule-1 was also reduced, although to a much lesser extent, by treatment with antisense oligonucleotides. We also show that inhibition of c-raf kinase expression decreased extracellular signal-regulated kinase and c-Jun N-terminal kinase (JNK) kinase stimulation by TNF alpha. Furthermore, antisense inhibition of JNK2 also blocked TNF alpha-mediated induction of E-selectin, whereas PD98059 (mitogen-activated protein kinase kinase 1 and 2 inhibitor) had no effect on this process. These results indicate that TNF alpha induction of E-selectin and vascular adhesion molecule-1 in endothelial cells occurs through signaling pathways that are, at least in part, dependent on c-Raf kinase, Ha-Ras, and JNK2.	ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Monia, BP (corresponding author), ISIS Pharmaceut, Dept Mol Pharmacol, 2280 Faraday Ave, Carlsbad, CA 92008 USA.	bmonia@ISISph.com						Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT CF, 1994, J IMMUNOL, V152, P3530; BERTRAND F, 1995, J BIOL CHEM, V270, P24435, DOI 10.1074/jbc.270.41.24435; Bischoff J, 1997, J CLIN INVEST, V99, P373, DOI 10.1172/JCI119168; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DAngelo G, 1997, J CELL BIOCHEM, V67, P353, DOI 10.1002/(SICI)1097-4644(19971201)67:3<353::AID-JCB7>3.3.CO;2-2; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Eder J, 1997, TRENDS PHARMACOL SCI, V18, P319, DOI 10.1016/S0165-6147(97)01097-3; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; Fiers W, 1996, J INFLAMM, V47, P67; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HSU H, 1986, CELL, V84, P299; Introna M, 1997, ARTERIOSCL THROM VAS, V17, P423, DOI 10.1161/01.ATV.17.3.423; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kanno T, 1996, J IMMUNOL, V157, P5277; KOONG AC, 1994, CANCER RES, V54, P5273; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mandiyan S, 1997, ANTISENSE NUCLEIC A, V7, P539, DOI 10.1089/oli.1.1997.7.539; Mantovani A, 1997, THROMB HAEMOSTASIS, V78, P406; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1996, CANCER SURV, V27, P101; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McIntyre TM, 1997, THROMB HAEMOSTASIS, V78, P302; Min W, 1997, J IMMUNOL, V159, P3508; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Monia BP, 1997, ANTI-CANCER DRUG DES, V12, P327; MONIA BP, 1992, J BIOL CHEM, V267, P19954; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X	44	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33230	33238		10.1074/jbc.273.50.33230	http://dx.doi.org/10.1074/jbc.273.50.33230			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837893	hybrid			2022-12-25	WOS:000077462500023
J	Hilbi, H; Moss, JE; Hersh, D; Chen, YJ; Arondel, J; Banerjee, S; Flavell, RA; Yuan, JY; Sansonetti, PJ; Zychlinsky, A				Hilbi, H; Moss, JE; Hersh, D; Chen, YJ; Arondel, J; Banerjee, S; Flavell, RA; Yuan, JY; Sansonetti, PJ; Zychlinsky, A			Shigella-induced apoptosis is dependent on Caspase-1 which binds to IpaB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; MAMMALIAN HOMOLOG; EPITHELIAL-CELLS; MICE DEFICIENT; FLEXNERI; MACROPHAGES	We report here that the Shigella invasion plasmid antigen (Ipa)B, which is sufficient to induce apoptosis in macrophages, binds to caspase (Casp)-1, but not to Casp-8 or Casp-3, Casp-1 is activated and its specific substrate interleukin-1 beta is cleaved shortly after Shigella infection. Macrophages isolated from Casp-1 knockout mice are not susceptible to Shigella-induced apoptosis, although they respond normally to other apoptotic stimuli. Shigella kills macrophages from casp-3, casp-11, and p53 knock-out mice as well as macrophages overexpressing Bcl-2, We propose that Shigella induces apoptosis by directly activating Casp-1 through IpaB, bypassing signal transduction events and caspases upstream of Casp-1. Taken together these data indicate that Shigella-induced apoptosis is distinct from other forms of apoptosis and seems uniquely dependent on Casp-1.	NYU Med Ctr, Skirball Inst, New York, NY 10016 USA; NYU Med Ctr, Dept Microbiol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA; Inst Pasteur, Unite Pathogenie Microbienne Mol, INSERM, U389, F-75724 Paris 15, France; BASF Biores Corp, Worcester, MA 01605 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	New York University; New York University; New York University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; BASF; Howard Hughes Medical Institute; Yale University; Harvard University; Harvard Medical School	Zychlinsky, A (corresponding author), NYU Med Ctr, Skirball Inst, 540 1st Ave, New York, NY 10016 USA.	zychlinsky@saturn.med.nyu.edu	Hilbi, Hubert/A-6874-2008; Hilbi, Hubert/AAU-5815-2020	Hilbi, Hubert/0000-0002-5462-9301	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042780, R01AI037720] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37720, AI42780] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chen YJ, 1996, EMBO J, V15, P3853, DOI 10.1002/j.1460-2075.1996.tb00759.x; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gillespie MT, 1998, CYTOKINE GROWTH F R, V9, P109, DOI 10.1016/S1359-6101(98)00004-5; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Hilbi H, 1997, INFECT IMMUN, V65, P5165, DOI 10.1128/IAI.65.12.5165-5170.1997; Islam D, 1997, INFECT IMMUN, V65, P739, DOI 10.1128/IAI.65.2.739-749.1997; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LINDBERG AA, 1993, VACCINE, V11, P168, DOI 10.1016/0264-410X(93)90014-O; Menard R, 1996, P NATL ACAD SCI USA, V93, P1254, DOI 10.1073/pnas.93.3.1254; MENARD R, 1993, J BACTERIOL, V175, P5899; Menard R, 1996, TRENDS MICROBIOL, V4, P220, DOI 10.1016/0966-842X(96)10039-1; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RON D, 1992, BIOTECHNIQUES, V13, P866; SANSONETTI PJ, 1981, INFECT IMMUN, V34, P75, DOI 10.1128/IAI.34.1.75-83.1981; SANSONETTI PJ, 1995, J CLIN INVEST, V96, P884, DOI 10.1172/JCI118135; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thirumalai K, 1997, INFECT IMMUN, V65, P787, DOI 10.1128/IAI.65.2.787-793.1997; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, BRIT MED BULL, V53, P478; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zychlinsky A, 1997, TRENDS MICROBIOL, V5, P201, DOI 10.1016/S0966-842X(97)01044-5; Zychlinsky A, 1996, INFECT IMMUN, V64, P5357, DOI 10.1128/IAI.64.12.5357-5365.1996; ZYCHLINSKY A, 1994, J CLIN INVEST, V94, P1328, DOI 10.1172/JCI117452; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	45	321	342	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32895	32900		10.1074/jbc.273.49.32895	http://dx.doi.org/10.1074/jbc.273.49.32895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830039	Green Published, hybrid			2022-12-25	WOS:000077329100078
J	Poynter, ME; Daynes, RA				Poynter, ME; Daynes, RA			Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor kappa B signaling, and reduces inflammatory cytokine production in aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-ASSOCIATED DECLINE; TRANSCRIPTION FACTOR; LIPID-PEROXIDATION; PPAR-ALPHA; FATTY-ACIDS; RAT-LIVER; DIFFERENTIAL EXPRESSION; DIETARY RESTRICTION; TARGETED DISRUPTION; BINDING-EFFICIENCY	In aged mice, the redox-regulated transcription factor nuclear factor-kappa B (NF-kappa B) becomes constitutively active in many tissues, as well as in cells of the hematopoietic system. This oxidative stress-induced activity promotes the production of a number of pro-inflammatory cytokines, which can contribute to the pathology of many disease states associated with aging. The administration to aged mice of agents capable of activating the alpha isoform of the peroxisome proliferator-activated receptor (PPAR alpha) was found to restore the cellular redox balance, evidenced by a lowering of tissue lipid peroxidation, an elimination of constitutively active NF-kappa B, and a loss in spontaneous inflammatory cytokine production. Aged animals bearing a null mutation in PPAR alpha failed to elicit these changes following treatment with PPAR alpha activators, but remained responsive to vitamin E supplementation. Aged C57BL/6 mice were found to express reduced transcript levels of PPAR alpha and the peroxisome-associated genes acyl-CoA oxidase and catalase. Supplementation of these aged mice with PPAR alpha activators or with vitamin E caused elevations in these transcripts to levels seen in young animals. Our results suggest that PPAR alpha and the genes under its control play a role in the evolution of oxidative stress excesses observed in aging.	Univ Utah, Dept Pathol, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Daynes, RA (corresponding author), Univ Utah, Dept Pathol, 50 N Med Dr, Salt Lake City, UT 84132 USA.	daynes.office@path.med.utah.edu		Poynter, Matthew/0000-0002-7578-4570	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007491] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R37CA025917, R01CA025917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011475] Funding Source: NIH RePORTER; NCI NIH HHS [CA25917] Funding Source: Medline; NIA NIH HHS [AG11475] Funding Source: Medline; NICHD NIH HHS [5T32 HD07491] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; ARAGNO M, 1993, BIOCHEM PHARMACOL, V46, P1689, DOI 10.1016/0006-2952(93)90572-E; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barja G, 1996, LIPIDS, V31, P963, DOI 10.1007/BF02522690; Beharka A, 1997, METHOD ENZYMOL, V282, P247; Beier K, 1997, FEBS LETT, V412, P385, DOI 10.1016/S0014-5793(97)00805-3; BEIER K, 1993, VIRCHOWS ARCH B, V63, P139, DOI 10.1007/BF02899254; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Boccuzzi G, 1997, FREE RADICAL BIO MED, V22, P1289, DOI 10.1016/S0891-5849(96)00543-6; BOGGS SS, 1978, P SOC EXP BIOL MED, V157, P424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Buege J A, 1978, Methods Enzymol, V52, P302; BUNKER VW, 1992, MED LAB SCI, V49, P299; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHOE M, 1995, FREE RADICAL BIO MED, V18, P977, DOI 10.1016/0891-5849(94)00217-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chorinchath BB, 1996, J IMMUNOL, V156, P1525; DANENBERG HD, 1992, ANTIMICROB AGENTS CH, V36, P2275, DOI 10.1128/AAC.36.10.2275; DAYNES RA, 1993, J IMMUNOL, V150, P5219; DEMOZ A, 1992, LIPIDS, V27, P968, DOI 10.1007/BF02535573; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; ERSHLER WB, 1993, J AM GERIATR SOC, V41, P176, DOI 10.1111/j.1532-5415.1993.tb02054.x; ERSHLER WB, 1993, LYMPHOKINE CYTOK RES, V12, P225; Fan CY, 1996, J BIOL CHEM, V271, P24698, DOI 10.1074/jbc.271.40.24698; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FRANKENBERGER M, 1994, BIOCHEM J, V304, P87, DOI 10.1042/bj3040087; GEARING KL, 1994, J NUTR, V124, pS1284, DOI 10.1093/jn/124.suppl_8.1284S; GEARING KL, 1994, BIOCHEM BIOPH RES CO, V199, P255, DOI 10.1006/bbrc.1994.1222; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Gonzalez FJ, 1995, TOXICOL LETT, V82-3, P117, DOI 10.1016/0378-4274(95)03548-6; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; HAGIHARA M, 1984, J GERONTOL, V39, P269, DOI 10.1093/geronj/39.3.269; Helenius M, 1996, J MOL CELL CARDIOL, V28, P487, DOI 10.1006/jmcc.1996.0045; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; HERTZ R, 1987, BIOCHIM BIOPHYS ACTA, V917, P57, DOI 10.1016/0005-2760(87)90283-9; HOFFMAN R, 1992, ATHEROSCLEROSIS, V93, P105, DOI 10.1016/0021-9150(92)90204-T; HUBERMAN M, 1995, J NEUROL SCI, V130, P161, DOI 10.1016/0022-510X(95)00016-U; HUELL M, 1995, ACTA NEUROPATHOL, V89, P544; HYDE SR, 1992, INFECT IMMUN, V60, P976, DOI 10.1128/IAI.60.3.976-982.1992; Inoue I, 1997, BIOCHEM BIOPH RES CO, V237, P606, DOI 10.1006/bbrc.1997.7196; Inoue I, 1998, LIFE SCI, V63, P135, DOI 10.1016/S0024-3205(98)00249-5; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KLUCIS E, 1984, MOL CELL BIOCHEM, V65, P73; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; Lee SST, 1996, ANN NY ACAD SCI, V804, P524, DOI 10.1111/j.1749-6632.1996.tb18642.x; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, J BIOL CHEM, V271, P1764, DOI 10.1074/jbc.271.3.1764; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MASTERS CJ, 1995, MECH AGEING DEV, V80, P69, DOI 10.1016/0047-6374(94)01563-2; MEYDANI SN, 1986, MECH AGEING DEV, V34, P191, DOI 10.1016/0047-6374(86)90034-5; MEYDANI SN, 1995, AM J CLIN NUTR, V62, P1462; MIHARA M, 1980, BIOCHEM MED METAB B, V23, P302, DOI 10.1016/0006-2944(80)90040-X; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; MOHAN PF, 1993, AM J MED SCI, V306, P10, DOI 10.1097/00000441-199307000-00004; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Parmentier JH, 1997, BIOCHEM PHARMACOL, V54, P889, DOI 10.1016/S0006-2952(97)00256-6; Peters JM, 1996, MOL PHARMACOL, V50, P67; Rao MS, 1996, ANN NY ACAD SCI, V804, P573, DOI 10.1111/j.1749-6632.1996.tb18646.x; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; Schoonjans K, 1996, J LIPID RES, V37, P907; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEMSEI I, 1989, BIOCHEM BIOPH RES CO, V164, P620, DOI 10.1016/0006-291X(89)91505-2; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SOHAL RS, 1981, AGE PIGMENTS; Soliman MS, 1997, BIOCHEM PHARMACOL, V53, P1369, DOI 10.1016/S0006-2952(97)87956-7; Spencer NFL, 1995, ANN NY ACAD SCI, V774, P200; Spencer NFL, 1997, INT IMMUNOL, V9, P745, DOI 10.1093/intimm/9.5.745; Spencer NFL, 1996, EXP GERONTOL, V31, P393, DOI 10.1016/0531-5565(95)02033-0; Spencer NFL, 1997, INT IMMUNOL, V9, P1581, DOI 10.1093/intimm/9.10.1581; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Sterchele PF, 1996, ARCH BIOCHEM BIOPHYS, V326, P281, DOI 10.1006/abbi.1996.0077; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; TAMURA H, 1990, CARCINOGENESIS, V11, P445; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; Vazquez M, 1996, BRIT J PHARMACOL, V117, P1155, DOI 10.1111/j.1476-5381.1996.tb16710.x; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	97	455	466	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32833	32841		10.1074/jbc.273.49.32833	http://dx.doi.org/10.1074/jbc.273.49.32833			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830030	hybrid			2022-12-25	WOS:000077329100069
J	Sugita, S; Ichtchenko, K; Khvotchev, M; Sudhof, TC				Sugita, S; Ichtchenko, K; Khvotchev, M; Sudhof, TC			alpha-latrotoxin receptor CIRL/latrophilin 1 (CL1) defines an unusual family of ubiquitous G-protein-linked receptors - G-protein coupling not required for triggering exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WIDOW SPIDER VENOM; PC12 CELLS; CA2+-ACTIVATED SECRETION; NEUROTRANSMITTER RELEASE; MONOCLONAL-ANTIBODIES; TRANSMITTER RELEASE; SYNAPTIC VESICLES; MOLECULAR-CLONING; CHROMAFFIN CELLS; BINDING	alpha-Latrotoxin, a potent excitatory neurotoxin, binds to two receptors: a G-protein-coupled receptor called CIRL/latrophilin 1 (CL1) and a cell-surface protein called neurexin I alpha. We now show that CL1 belongs to a family of closely related receptors called CL1, CL2, and CL3, CLs exhibit an unusual multidomain structure with similar alternative splicing and large extra- and intracellular sequences, CLs share domains with other G-protein-coupled receptors, lectins, and olfactomedins/myocilin. In addition, CLs contain a novel, widespread cysteine-rich domain that may direct endoproteolytic processing of CLs during transport to the cell surface. Although the mRNAs for CLs are enriched in brain, CLs are ubiquitously expressed in all tissues. To examine how binding of alpha-latrotoxin to CL1 triggers exocytosis, we used PC12 cells transfected with human growth hormone. Ca2+-dependent secretion of human growth hormone from transfected PC12 cells was triggered by KCl depolarization or alpha-latrotoxin and was inhibited by tetanus toxin and by phenylarsine oxide, a phosphoinositide kinase inhibitor. When CL1 was transfected into PC12 cells, their response to alpha-latrotoxin was sensitized dramatically. A similar sensitization to alpha-latrotoxin was observed with different splice variants of CL1, whereas CL2 and CL3 were inactive in this assay. A truncated form of CL1 that contains only a single transmembrane region and presumably is unable to mediate G-protein-signaling was as active as wild type CL1 in alpha-latrotoxin-triggered exocytosis. Our data show that CL1, CL2, and CL3 perform a general and ubiquitous function as G-protein-coupled receptors in cellular signaling. In addition, CL1 serves a specialized role as an alpha-latrotoxin receptor that does not require G-protein-signaling for triggering exocytosis, This suggests that as an alpha-latrotoxin receptor, CL1 recruits alpha-latrotoxin to target membranes without participating in exocytosis directly.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Ctr Basic Neurosci, Dallas, TX 75235 USA.	tsudho@mednet.swmed.edu	Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549; Sugita, Shuzo/0000-0002-9182-873X; Ichtchenko, Konstantin/0000-0002-2198-1325	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH52804] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Bittner MA, 1998, J NEUROSCI, V18, P2914; CATTANEO A, 1986, BIOCHEMISTRY-US, V25, P2730, DOI 10.1021/bi00357a068; DANIELSON PE, 1994, J NEUROSCI RES, V38, P468, DOI 10.1002/jnr.490380413; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORIO A, 1978, J NEUROCYTOL, V7, P193, DOI 10.1007/BF01217918; GRASSO A, 1980, NATURE, V283, P774, DOI 10.1038/283774a0; HAMANN J, 1995, J IMMUNOL, V155, P1942; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; Khvotchev M, 1998, J BIOL CHEM, V273, P21451, DOI 10.1074/jbc.273.34.21451; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; MCMAHON HT, 1990, J NEUROCHEM, V55, P2039, DOI 10.1111/j.1471-4159.1990.tb05793.x; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MELDOLESI J, 1983, NEUROSCIENCE, V10, P997, DOI 10.1016/0306-4522(83)90238-5; MELDOLESI J, 1984, P NATL ACAD SCI-BIOL, V81, P620, DOI 10.1073/pnas.81.2.620; MISLER S, 1987, AM J PHYSIOL, V253, pC469, DOI 10.1152/ajpcell.1987.253.3.C469; Nagano T, 1998, MOL BRAIN RES, V53, P13, DOI 10.1016/S0169-328X(97)00271-4; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; PASHKOV V, 1993, NEUROSCIENCE, V56, P695, DOI 10.1016/0306-4522(93)90366-N; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHAEFER T, 1994, ANN NY ACAD SCI, V710, P356, DOI 10.1111/j.1749-6632.1994.tb26642.x; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUDHOF TC, 1993, CELL, V75, P1; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WICK PF, 1993, J BIOL CHEM, V268, P10983; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; YOKOE H, 1993, P NATL ACAD SCI USA, V90, P4655, DOI 10.1073/pnas.90.10.4655	48	143	151	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32715	32724		10.1074/jbc.273.49.32715	http://dx.doi.org/10.1074/jbc.273.49.32715			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830014	hybrid			2022-12-25	WOS:000077329100053
J	Duvet, S; Cocquerel, L; Pillez, A; Cacan, R; Verbert, A; Moradpour, D; Wychowski, C; Dubuisson, J				Duvet, S; Cocquerel, L; Pillez, A; Cacan, R; Verbert, A; Moradpour, D; Wychowski, C; Dubuisson, J			Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; HUMAN KDEL RECEPTOR; GOLGI-APPARATUS; QUALITY-CONTROL; TRANSMEMBRANE PROTEINS; MEMBRANE GLYCOPROTEIN; RECOMBINANT VACCINIA; MONOCLONAL-ANTIBODY; ALPHA-MANNOSIDASE; SECRETORY PATHWAY	The hepatitis C virus (HCV) genome encodes two envelope glycoproteins (El and E2). These glycoproteins interact to form a noncovalent heterodimeric complex which in the cell accumulates in endoplasmic reticulum (ER)-like structures. The transmembrane domain of E2, at least, is involved in HCV glycoprotein complex localization in this compartment. In principle, ER localization of a protein can be the consequence of actual retention in this organelle or of retrieval from the Golgi. To determine which of these two mechanisms is responsible for HCV glycoprotein complex accumulation in the ER, the precise localization of these protei;ls was studied by immunofluorescence, and the processing of their glycans was analyzed. Immunolocalization of HCV glycoproteins after nocodazole treatment suggested an ER retention. In addition, HCV glycoprotein glycans were not modified by Golgi enzymes, indicating that the ER localization of these proteins is not because of their retrieval from the cis Golgi. Retention of HCV glycoprotein complexes in the ER without retrieval suggests that this compartment plays an important role for the acquisition of the envelope of HCV particles. A true retention in the ER was also observed for E2 expressed in the absence of El or for a chimeric protein containing the ectodomain of CD4 in fusion with the transmembrane domain of E2. These data indicate that, in HCV glycoprotein complex, the transmembrane domain of E2, at least, is responsible for true retention in the ER, without recycling through the Golgi.	Inst Biol Lille, CNRS, UMR 319, Epuipe Hepatite C, F-59021 Lille, France; Inst Pasteur Lille, F-59021 Lille, France; Univ Sci & Technol, CNRS, UMR 111, F-59655 Villeneuve Dascq, France; Univ Hosp, Dept Med 2, D-79106 Freiburg, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; University of Freiburg	Dubuisson, J (corresponding author), Inst Biol Lille, CNRS, UMR 319, Epuipe Hepatite C, 1 Rue Calmette,BP447, F-59021 Lille, France.	jdubuis@infobiogen.fr	Cocquerel, Laurence/P-1951-2016; Dubuisson, Jean/E-6813-2016; Moradpour, Darius/G-7918-2017	Cocquerel, Laurence/0000-0002-2136-5178; Dubuisson, Jean/0000-0003-1626-7693; Moradpour, Darius/0000-0003-1977-6792				AHN KS, 1993, J BIOL CHEM, V268, P18726; Andersson AM, 1997, J VIROL, V71, P4717, DOI 10.1128/JVI.71.6.4717-4727.1997; ARMSTRONG J, 1991, J CELL SCI, V98, P567; BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; BISCHOFF J, 1986, J BIOL CHEM, V261, P4758; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; FournillierJacob A, 1996, J GEN VIROL, V77, P1055, DOI 10.1099/0022-1317-77-5-1055; Francki RIB, 1991, ARCH VIROL         S, V2, P223; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Griffiths G, 1992, Semin Cell Biol, V3, P367, DOI 10.1016/1043-4682(92)90022-N; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harrison Stephen C., 1996, P59; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HOBMAN TC, 1995, MOL BIOL CELL, V6, P7, DOI 10.1091/mbc.6.1.7; Hussy P, 1996, VIRUS RES, V45, P45, DOI 10.1016/0168-1702(96)01365-2; Isidoro C, 1996, J BIOL CHEM, V271, P26138, DOI 10.1074/jbc.271.42.26138; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KMIECIK D, 1995, GLYCOBIOLOGY, V5, P483, DOI 10.1093/glycob/5.5.483; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOCKER JK, 1994, J BIOL CHEM, V269, P28263; MACHAMER CE, 1987, J CELL BIOL, V105, P1205, DOI 10.1083/jcb.105.3.1205; Martire G, 1996, J BIOL CHEM, V271, P3541; MATSUURA Y, 1994, VIROLOGY, V205, P141, DOI 10.1006/viro.1994.1629; MATSUURA Y, 1993, SEMIN VIROL, V4, P297, DOI 10.1006/smvy.1993.1026; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; Michalak JP, 1997, J GEN VIROL, V78, P2299, DOI 10.1099/0022-1317-78-9-2299; MIZUSHIMA H, 1994, J VIROL, V68, P6215, DOI 10.1128/JVI.68.10.6215-6222.1994; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; Pettersson R F, 1991, Curr Top Microbiol Immunol, V170, P67; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; SARASTE J, 1991, J CELL SCI, V100, P415; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Shenkman M, 1997, P NATL ACAD SCI USA, V94, P11363, DOI 10.1073/pnas.94.21.11363; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; TAI T, 1975, J BIOL CHEM, V250, P8569; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WEISZ OA, 1993, J CELL BIOL, V122, P1185, DOI 10.1083/jcb.122.6.1185; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970	58	131	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32088	32095		10.1074/jbc.273.48.32088	http://dx.doi.org/10.1074/jbc.273.48.32088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822684	hybrid			2022-12-25	WOS:000077207000066
J	Kops, O; Eckerskorn, C; Hottenrott, S; Fischer, G; Mi, HF; Tropschug, M				Kops, O; Eckerskorn, C; Hottenrott, S; Fischer, G; Mi, HF; Tropschug, M			Ssp1, a site-specific parvulin homolog from Neurospora crassa active in protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL CIS/TRANS ISOMERASES; DIHYDROFOLATE-REDUCTASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; BINDING-PROTEIN; RNA-POLYMERASE; CELL-DIVISION; WW DOMAIN; CYCLOPHILIN; GENE	Peptidyl-prolyl cis-trans-isomerases (PPIases) are enzymes capable of isomerizing a Xaa-Pro peptide bond. Three families of PPIases are known: cyclophilins, FK-BPs, and parvulins, The physiological functions of the PPIases are only poorly understood. Eucaryotic members of the parvulin family have recently been shown to be essential for regulation of mitosis. Here we describe the purification and characterization of Ssp1, an abundant parvulin homolog from Neurospora crassa, which is unique among the known eucaryotic parvulins in containing a polyglutamine stretch between the N-terminal WW domain and the C-terminal PPIase domain. Ssp1 is a site-specific PPIase with respect to the amino acid N-terminal to the proline residue. Peptides with glutamate, phosphoserine, or phosphothreonine in the -1-position proved to be the best substrates. Ssp1 is not only able to isomerize small peptides but is also active in protein folding, as shown with mouse dihydrofolate reductase, Using the substrate specificity of Ssp1, we could identify Glu(81).Pro(82) as a PPIase-sensitive site in folding of dihydrofolate reductase, These results demonstrate that Ssp1 is a potent mediator of protein folding and that parvulins can serve as tools to elucidate rate-limiting steps in protein folding reactions.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Max Planck Inst Biochem, D-81377 Munich, Germany; Max Planck Gesell, Forschungsstelle Enzymol Prot Faltung, D-06120 Halle, Germany	University of Freiburg; Max Planck Society; Max Planck Society	Tropschug, M (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	tropschu@uni-freiburg.de						BROHL S, 1994, YEAST, V10, P719, DOI 10.1002/yea.320100604; Chen B, 1996, J BIOL CHEM, V271, P6537, DOI 10.1074/jbc.271.11.6537; Clark AC, 1997, J MOL BIOL, V268, P512, DOI 10.1006/jmbi.1997.0969; Dolinski K, 1997, MOL BIOL CELL, V8, P2267, DOI 10.1091/mbc.8.11.2267; DOLINSKI K, 1997, GUIDEBOOK MOL CHAPER, P359; Eckerskorn C, 1996, ELECTROPHORESIS, V17, P899, DOI 10.1002/elps.1150170511; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; IWAKURA M, 1993, BIOCHEMISTRY-US, V32, P13566, DOI 10.1021/bi00212a024; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; Lu KP, 1996, NATURE, V380, P544; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; MATOUSCHEK A, 1995, P NATL ACAD SCI USA, V92, P6319, DOI 10.1073/pnas.92.14.6319; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Miklos GLG, 1998, SCIENCE, V279, P1287; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; NUNBERG JH, 1980, CELL, V19, P355, DOI 10.1016/0092-8674(80)90510-3; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; RASSOW J, 1995, MOL CELL BIOL, V15, P2654; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; Scholz C, 1997, J MOL BIOL, V273, P752, DOI 10.1006/jmbi.1997.1301; Scholz C, 1997, FEBS LETT, V414, P69, DOI 10.1016/S0014-5793(97)00979-4; SCHONBRUNNER ER, 1991, J BIOL CHEM, V266, P3630; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; SMITH DR, 1980, NUCLEIC ACIDS RES, V8, P2255, DOI 10.1093/nar/8.10.2255; STUART RA, 1987, EMBO J, V6, P2131, DOI 10.1002/j.1460-2075.1987.tb02480.x; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TEXTER FL, 1992, BIOCHEMISTRY-US, V31, P5687, DOI 10.1021/bi00140a001; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; TROPSCHUG M, 1990, NATURE, V346, P674, DOI 10.1038/346674a0; TROPSCHUG M, 1988, J BIOL CHEM, V263, P14433; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Vogel G, 1997, SCIENCE, V278, P1883, DOI 10.1126/science.278.5345.1883; vonAhsen O, 1997, EMBO J, V16, P4568, DOI 10.1093/emboj/16.15.4568	49	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31971	31976		10.1074/jbc.273.48.31971	http://dx.doi.org/10.1074/jbc.273.48.31971			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822668	hybrid			2022-12-25	WOS:000077207000050
J	LaFevre-Bernt, M; Sicheri, F; Pico, A; Porter, M; Kuriyano, J; Miller, WT				LaFevre-Bernt, M; Sicheri, F; Pico, A; Porter, M; Kuriyano, J; Miller, WT			Intramolecular regulatory interactions in the Src family kinase Hck probed by mutagenesis of a conserved tryptophan residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-SRC; INTERMOLECULAR AUTOPHOSPHORYLATION; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; GENE-PRODUCT; NEF PROTEIN; SH3 DOMAINS; ACTIVATION; PHOSPHORYLATION	Intramolecular interactions between the Src homology domains (SH2 and SH3) and the catalytic domains of Src family kinases result in repression of catalytic activity. The crystal structure of the Src family kinase Hck, with its regulatory domains intact, has been solved. It predicts that a conserved residue, Trp(260), at the end of the linker between the SH2 and the catalytic domains plays an important role in regulation by the SH3 and SH2 domains. We have mutated this residue and compared the activities of C-terminally phosphorylated wild type Hck and W260A Hck, The W260A mutant has a higher specific activity than wild type Hck. The W260A mutant requires autophosphorylation at Tyr(416) for full activity, but it is not activated by ligand binding to the SH3 or SH2 domains. This mutation also changes the accessibility of the SH2 and SH3 domains to their cognate peptide ligands, Our results indicate that Trp(260) plays a critical role in the coupling of the regulatory domains to the catalytic domain, as well. as in positioning the ligand binding surfaces.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biophys, New York, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Howard Hughes Medical Institute; Rockefeller University	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower T-6, Stony Brook, NY 11794 USA.		Pico, Alexander/HCH-4305-2022; Sicheri, Frank/F-8856-2013	Pico, Alexander/0000-0001-5706-2163				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; FERRACINI R, 1990, ONCOGENE RES, V5, P205; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LIU XQ, 1993, ONCOGENE, V8, P1119; Mayer BJ, 1997, CURR BIOL, V7, pR295, DOI 10.1016/S0960-9822(06)00141-2; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	35	89	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32129	32134		10.1074/jbc.273.48.32129	http://dx.doi.org/10.1074/jbc.273.48.32129			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822689	hybrid			2022-12-25	WOS:000077207000071
J	Talasz, H; Sapojnikova, N; Helliger, W; Lindner, H; Puschendorf, B				Talasz, H; Sapojnikova, N; Helliger, W; Lindner, H; Puschendorf, B			In vitro binding of H1 histone subtypes to nucleosomal organized mouse mammary tumor virus long terminal repeat promotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; CHROMATIN FRAGMENTS; DNA INTERACTIONS; LINKER HISTONE; S-PHASE; VARIANTS; PHOSPHORYLATION; CONDENSATION; GENE; TRANSCRIPTION	The binding of all known linker histones, named Hla through H1e, including H1 degrees and H1t, to a model chromatin complex based on a DNA fragment containing the mouse mammary tumor virus long terminal repeat promotor was systematically studied. As for the histone subtype H1b, we found a dissociation constant of 8-16 nM to a single mononucleosome (210 base pairs), whereas the binding constant of all other subtypes varied between 2 and 4 nM. Most of the H1 histones, namely H1a, H1c, H1d/e, and H1 degrees, completely aggregate polynucleosomes (1.3 kilobase pairs, 6 nucleosomes) at 270-360 nM, corresponding to a molar ratio of six to eight H1 molecules per reconstituted nucleosome, To form aggregates with the histones H1t and H1b, however, greater amounts of protein were required. Furthermore, our results show that specific types of in vivo phosphorylation of the linker histone tails influence both the binding to mononucleosomes and the aggregation of polynucleosomes, S phase-specific phosphorylation with one to three phosphate groups at specific sites in the C terminus influences neither the binding to a mononucleosome nor the aggregation of polynucleosomes, In contrast, highly phosphorylated H1 histones with four to five phosphate groups in the C and N termini reveal a very high binding affinity to a mononucleosome but a low chromatin aggregation capability. These findings suggest that specific S phase or mitotic phosphorylation sites act independently and have distinct functional roles.	Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria; Georgian Acad Sci, Inst Phys, GE-380077 Tbilisi, Georgia	University of Innsbruck; National Academy of Sciences of Georgia	Talasz, H (corresponding author), Univ Innsbruck, Inst Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.		Sapojnikova, Nelly/H-4340-2017	Sapojnikova, Nelly/0000-0001-6126-6185				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BARTOLOME S, 1995, J BIOL CHEM, V270, P22514, DOI 10.1074/jbc.270.38.22514; BRADBURY EM, 1975, EUR J BIOCHEM, V52, P605, DOI 10.1111/j.1432-1033.1975.tb04032.x; CLARK DJ, 1988, EUR J BIOCHEM, V178, P225, DOI 10.1111/j.1432-1033.1988.tb14447.x; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CORBETT S, 1980, EXP CELL RES, V128, P127, DOI 10.1016/0014-4827(80)90395-X; DANNA JA, 1981, BIOCHEMISTRY-US, V20, P4501, DOI 10.1021/bi00518a041; DANNA JA, 1979, BIOCHEMISTRY-US, V18, P943, DOI 10.1021/bi00573a002; DELUCIA F, 1994, BIOCHEM BIOPH RES CO, V198, P32, DOI 10.1006/bbrc.1994.1005; DRABENT B, 1993, BIOCHIM BIOPHYS ACTA, V1216, P311, DOI 10.1016/0167-4781(93)90162-7; DRABENT B, 1995, MAMM GENOME, V6, P505, DOI 10.1007/BF00356166; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; Hayes JJ, 1996, J BIOL CHEM, V271, P25817, DOI 10.1074/jbc.271.42.25817; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; HOHMANN P, 1976, J BIOL CHEM, V251, P3685; ISENBERG I, 1979, ANNU REV BIOCHEM, V48, P159, DOI 10.1146/annurev.bi.48.070179.001111; Kaludov NK, 1997, J BIOL CHEM, V272, P15120, DOI 10.1074/jbc.272.24.15120; Khadake JR, 1997, BIOCHEMISTRY-US, V36, P1041, DOI 10.1021/bi961617p; KINKADE JM, 1966, J BIOL CHEM, V241, P5798; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LENNOX RW, 1984, J BIOL CHEM, V259, P669; LIAO LW, 1981, J BIOL CHEM, V256, P124; LINDNER H, 1988, J CHROMATOGR, V450, P309, DOI 10.1016/S0021-9673(01)83585-8; LINDNER H, 1990, CHROMATOGRAPHIA, V30, P518, DOI 10.1007/BF02269797; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; LINDNER H, 1995, ELECTROPHORESIS, V16, P604, DOI 10.1002/elps.1150160197; LINDNER H, 1997, PROGR HPLC, V5, P97; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PANYIM S, 1969, BIOCHEM BIOPH RES CO, V37, P1042, DOI 10.1016/0006-291X(69)90237-X; RALL SC, 1971, J BIOL CHEM, V246, P7175; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; RUIZCARRILLO A, 1980, BIOCHEMISTRY-US, V19, P2544, DOI 10.1021/bi00553a002; SHEROD G, 1970, BIOCHEMISTRY-US, V9, P4611; TALASZ H, 1993, BIOCHEMISTRY-US, V32, P1188, DOI 10.1021/bi00055a025; Talasz H, 1996, BIOCHEMISTRY-US, V35, P1761, DOI 10.1021/bi951914e; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1985, EUR J BIOCHEM, V147, P143, DOI 10.1111/j.1432-1033.1985.tb08730.x; URA K, 1994, J BIOL CHEM, V269, P27171; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; WOLFFE AP, 1993, METH MOL G, V2, P314; YASUDA H, 1986, J BIOL CHEM, V261, P2349; ZALENSKAYA IA, 1981, NUCLEIC ACIDS RES, V9, P473, DOI 10.1093/nar/9.3.473; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239; ZUBAY G, 1959, J MOL BIOL, V1, P1, DOI 10.1016/S0022-2836(59)80002-4	51	58	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32236	32243		10.1074/jbc.273.48.32236	http://dx.doi.org/10.1074/jbc.273.48.32236			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822702	hybrid			2022-12-25	WOS:000077207000084
J	Yanagawa, S; Lee, JS; Ishimoto, A				Yanagawa, S; Lee, JS; Ishimoto, A			Identification and characterization of a novel line of Drosophila Schneider S2 cells that respond to wingless signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT-POLARITY GENE; DISC CELLS; WNT GENES; PROTEIN; ARMADILLO; HOMOLOG; PRODUCT; ENCODES; FAMILY; MELANOGASTER	Wingless (Wg) treatment of Drosophila wing disc clone 8 cells leads to Armadillo (Arm) protein elevation, and this effect has been used as the basis of in vitro assays for Wg protein. Previously analyzed stocks of Drosophila Schneider S2 cells could not respond to added Wg, because they lack the Wg receptor, Dfrizzled-2. However, we found that a line of S2 cells obtained from another source express Dfrizzled-2 and Dfrizzled-1. Thus, we designated this cell line as S2R+ (S2 receptor plus). S2R+ cells respond to addition of extracellular Wg by elevating Arm and DE-cadherin protein levels and by hyperphosphorylating Dsh, just as clone 8 cells do. Moreover, overexpression of Wg in S2R+, but not in S2 cells, induced the same changes in Dsh, Arm, and DE-cadherin proteins as induced in clone 8 cells, indicating that these events are common effects of Wg signaling, which occurs in cells expressing functional Wg receptors. In addition, unphosphorylated Dsh protein in S2 cells was phosphorylated as a consequence of expression of Dfrizzled-2 or mouse Frizzled-6, suggesting that basal structures common to various frizzled family proteins trigger this phosphorylation of Dsh, S2R+ cells are as sensitive to Wg as are clone 8 cells but can grow in simpler medium. Therefore, the S2R+ cell line is likely to prove highly useful for in vitro analyses of Wg signaling.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Dept Viral Oncol, Kyoto 6068507, Japan	Kyoto University	Yanagawa, S (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Dept Viral Oncol, Kyoto 6068507, Japan.							Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEEL DJ, 1992, ROUX ARCH DEV BIOL, V201, P120, DOI 10.1007/BF00420423; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1992, TRENDS GENET, V8, P243, DOI 10.1016/0168-9525(92)90394-J; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; THIESEN H, 1994, DEVELOPMENT, V120, P347; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; Wang YS, 1996, J BIOL CHEM, V271, P4468; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; Yanagawa SI, 1997, J BIOL CHEM, V272, P25243, DOI 10.1074/jbc.272.40.25243; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	35	127	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32353	32359		10.1074/jbc.273.48.32353	http://dx.doi.org/10.1074/jbc.273.48.32353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822716	hybrid			2022-12-25	WOS:000077207000098
J	Daphna-Iken, D; Shankar, DB; Lawshe, A; Ornitz, DM; Shackleford, GM; MacArthur, CA				Daphna-Iken, D; Shankar, DB; Lawshe, A; Ornitz, DM; Shackleford, GM; MacArthur, CA			MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia	ONCOGENE			English	Article						fibroblast growth factor; FGF8; fgf8; mammary tumorigenesis; oncogenesis; breast cancer	KERATINOCYTE GROWTH-FACTOR; BREAST-CANCER CELLS; GENE-EXPRESSION; TUMOR VIRUS; PROVIRAL INSERTION; CARCINOMA-CELLS; FACTOR FAMILY; RECEPTOR; FGF-8; ACTIVATION	Prior studies have identified Fibroblast Growth Factor-8 (Fgf8) as a possible proto-oncogene in mouse mammary tumorigenesis. We now report on the generation of two types of Fgf8 transgenic mice that each utilize the mouse mammary tumor virus (MMTV) promoter. The first transgene (MMTV-Fgf8b) results in the overexpression of the FGF8b isoform exclusively. Male and female MMTV-Fgf8b transgenic mice are viable and fertile. RNA for FGF8b is detected in mammary gland and salivary gland tissues of transgenic mice by Northern blot analysis. Nearly 85% of breeding transgenic female mice developed mammary lobular adenocarcinomas by 12 months of age, while no tumors developed in nontransgenic littermates. Salivary gland tumors occurred in some animals, always in association with mammary tumors. Several MMTV-Fgf8b transgenic mice had lung metastases at necropsy. The second transgene (MMTV-Fgf8) uses the entire Fgf8 gene and potentially encodes all FGF8 isoforms. Fgf8 is expressed by this transgene in several tissues in addition to those described above, notably the ovaries. The two MMTV-Fgf8 founders developed mammary ductal adenocarcinomas at five and eight months of age, and both displayed ovarian stromal hyperplasia. The founders expressing either transgene did not successfully nurse their pups. These results demonstrate that production of FGF8b, and possibly other FGF8 isoforms, in the mammary and salivary glands contributes to oncogenesis, and that ovarian expression results in stromal hyperplasia.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA USA; Univ So Calif, Sch Med, Dept Pediat, Los Angeles, CA 90027 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90027 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Children's Hospital Los Angeles; University of Southern California; University of Southern California; Washington University (WUSTL)	MacArthur, CA (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.			Ornitz, David/0000-0003-1592-7629	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD053229] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060673, R01CA070106] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 70106, R01 CA 60673] Funding Source: Medline; NICHD NIH HHS [N01-HD-53229] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; Haraguchi S, 1997, MOL CELL ENDOCRINOL, V129, P145, DOI 10.1016/S0303-7207(97)04053-7; HARAGUCHI S, 1992, INT J CANCER, V52, P928, DOI 10.1002/ijc.2910520617; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; IMAGAWA W, 1994, BIOCHEM BIOPH RES CO, V204, P1165, DOI 10.1006/bbrc.1994.2585; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kapoun AM, 1997, ONCOGENE, V14, P2985, DOI 10.1038/sj.onc.1201146; Kitsberg DI, 1996, ONCOGENE, V13, P2507; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LeRicousse S, 1996, P NATL ACAD SCI USA, V93, P5072, DOI 10.1073/pnas.93.10.5072; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Payson RA, 1996, ONCOGENE, V13, P47; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ULICH TR, 1994, AM J PATHOL, V144, P862; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; Wu J, 1997, J STEROID BIOCHEM, V62, P1, DOI 10.1016/S0960-0760(97)00022-8; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	46	60	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2711	2717		10.1038/sj.onc.1202212	http://dx.doi.org/10.1038/sj.onc.1202212			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840935				2022-12-25	WOS:000077146700004
J	Penna, D; Schmidt, A; Beermann, F				Penna, D; Schmidt, A; Beermann, F			Tumors of the retinal pigment epithelium metastasize to inguinal lymph nodes and spleen in tyrosinase-related protein 1 SV40 T antigen transgenic mice	ONCOGENE			English	Article						metastasis; pigmentation; retinal pigment epithelium; transgenic mice; TRP-1; tyrosinase	MALIGNANT SKIN MELANOMA; FUSION GENE; MOUSE; PROMOTER; EXPRESSION; ADENOCARCINOMA; MELANOCYTES; HYPERPLASIA; ACTIVATION; SURVIVAL	The pigment epithelium of the retina (RPE) is derived from the optic cup and is essential for function and development of the eye. We produced a transgenic mouse line that expresses simian virus (SV40) transforming sequences under control of the 1.4 kb tyrosinase-related protein 1 (TRP-1) promoter, targeting expression of T antigen (Tag) to the RPE. In transgenic embryos, RPE cells proliferated in the anterior part of the eye and near the optic nerve. This resulted in formation of tumors, which were pigmented and of epithelial origin. In 3 months-old mice, pigmented cells were detected in spleen and inguinal lymph nodes. In spleen, tyrosinase, TRP-1 and SV40 Tag were expressed and tyrosinase was enzymatically active, Pigmented regions were positive for an epithelial marker, cytokeratin. Cell lines were established from tumor and metastases and kept in culture for more than 2 months. These were pigmented, and maintained expression of tyrosinase, TRP-1, cytokeratin and SV40 Tag. This demonstrates that RPE tumor cells metastasize to lymph node and spleen. In conclusion, the metastasis from TRP-1/Tag RPE tumors towards spleen and lymph nodes serves as potential tool to investigate biology and metastasis of tumors derived from the pigment epithelium.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland	Swiss Institute Experimental Cancer Research	Beermann, F (corresponding author), Swiss Inst Expt Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							ALBERT DM, 1972, ARCH OPHTHALMOL-CHIC, V88, P70; ANAND R, 1994, INVEST OPHTH VIS SCI, V35, P3533; BEERMANN F, 1993, MECH DEVELOP, V42, P59, DOI 10.1016/0925-4773(93)90098-I; BEERMANN F, 1992, P NATL ACAD SCI USA, V89, P2809, DOI 10.1073/pnas.89.7.2809; BRADL M, 1991, P NATL ACAD SCI USA, V88, P164, DOI 10.1073/pnas.88.1.164; CABLE J, 1995, MECH DEVELOP, V50, P139, DOI 10.1016/0925-4773(94)00331-G; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHAR D, 1994, MALIGNANT MELANOMA, P343; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; delMarmol V, 1996, FEBS LETT, V381, P165, DOI 10.1016/0014-5793(96)00109-3; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FAN JT, 1995, AM J OPHTHALMOL, V119, P243, DOI 10.1016/S0002-9394(14)73887-5; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; Frayer W C, 1966, Trans Am Ophthalmol Soc, V64, P586; GARNER A, 1970, BRIT J OPHTHALMOL, V54, P715, DOI 10.1136/bjo.54.11.715; Greer CH, 1952, T OPHTHAL SOC UK, V72, P265; HUDSPETH AJ, 1973, INVEST OPHTH VISUAL, V12, P354; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; KLEINSZANTO A, 1991, P NATL ACAD SCI USA, V88, P169, DOI 10.1073/pnas.88.1.169; LOEFFLER KU, 1996, GRAEFES ARCH CLIN EX, V234, P70; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176; MINTZ B, 1992, P NATL ACAD SCI USA, V89, P11421, DOI 10.1073/pnas.89.23.11421; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8822, DOI 10.1073/pnas.90.19.8822; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; POWELL MB, 1995, MOL CARCINOGEN, V12, P82, DOI 10.1002/mc.2940120205; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROBINSON W, 1987, BASIC CLIN ASPECTS M, P155; SCHMIDT A, 1994, P NATL ACAD SCI USA, V91, P4756, DOI 10.1073/pnas.91.11.4756; SHIELDS JA, 1994, ARCH OPHTHALMOL-CHIC, V112, P650, DOI 10.1001/archopht.1994.01090170094029; SINGH S, 1994, EPITHELIAL CELL BIOL, V3, P79; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STEINBERG RH, 1979, RETINA PIGMENTED EPI, V1, P32; Tief K, 1997, PIGM CELL RES, V10, P153; Tief K, 1996, EUR J BIOCHEM, V241, P12, DOI 10.1111/j.1432-1033.1996.0012t.x; Tief K, 1996, DEV DYNAM, V205, P445, DOI 10.1002/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I; Zhao SL, 1997, INT REV CYTOL, V171, P225; Zhu H, 1998, J INVEST DERMATOL, V110, P247, DOI 10.1046/j.1523-1747.1998.00133.x	42	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2601	2607		10.1038/sj.onc.1202196	http://dx.doi.org/10.1038/sj.onc.1202196			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840923				2022-12-25	WOS:000077058900007
J	Fuks, F; Milner, J; Kouzarides, T				Fuks, F; Milner, J; Kouzarides, T			BRCA2 associates with acetyltransferase activity when bound to P/CAF	ONCOGENE			English	Article						BRCA2; P/CAF; histone acetyltransferase	HISTONE ACETYLTRANSFERASE; ACTIVATION; GENE; CBP	Predisposition to hereditary breast cancer has been attributed in part to inherited mutations in the BRCA2 gene. The large protein it encodes is still poorly characterized with respect to functions. We have previously shown that BRCA2 has transcriptional activation potential conferred by its amino-terminal third exon, Here, me show that BRCA2 interacts with a transcriptional co-activator protein, P/CAF, which possesses histone acetyltransferase activity, The interaction with P/CAF is demonstrated in vitro as well as in vivo and is shown to be mediated by residues 290-453 of BRCA2, Consistent with the binding to an acetyltransferase, BRCA2 is shown to associate with acetyltransferase activity in nuclear extracts. Contrary to a recent report, we find no evidence in support of an intrinsic HAT activity in BRCA2 amino-terminus. Our results further substantiate the notion that BRCA2 has transcriptional activation function and suggest that one mechanism by which BRCA2 regulates transcription may be through the recruitment of histone-modifying activity of the P/CAF co-activator.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Nordling M, 1998, CANCER RES, V58, P1372; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	19	82	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2531	2534		10.1038/sj.onc.1202475	http://dx.doi.org/10.1038/sj.onc.1202475			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824164				2022-12-25	WOS:000076927300013
J	Min, KS; Liu, XB; Fabritz, J; Jaquette, J; Abell, AN; Ascoli, M				Min, KS; Liu, XB; Fabritz, J; Jaquette, J; Abell, AN; Ascoli, M			Mutations that induce constitutive activation and mutations that impair signal transduction modulate the basal and/or agonist-stimulated internalization of the lutropin/choriogonadotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDIG TUMOR-CELLS; HUMAN CHORIO-GONADOTROPIN; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; BETA-ADRENERGIC-RECEPTOR; LUTEINIZING-HORMONE; MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; CYTOPLASMIC TAIL; INDUCED PHOSPHORYLATION; INDUCED DESENSITIZATION	Previous results from this laboratory suggested that the same active conformation of the lutropin/choriogonadotropin receptor (LHR) is involved in the stimulation of G proteins and in triggering the internalization of the bound agonist, We have now analyzed two naturally occurring, constitutively active mutants of the human LHR, These mutations were introduced into the rat LHR (rLHR) and are designated L435R and D556Y, Cells expressing rLHR-D556Y bind human choriogonadotropin (hCG) with normal affinity, exhibit a 25-fold increase in basal cAMP and respond to hCG with a normal increase in cAMP accumulation. This mutation does not affect the internalization of the free receptor, but it enhances the internalization of the agonist-occupied receptors similar to 3-fold. Cells expressing rLHR-L435R also bind hCG with normal affinity, exhibit a 47-fold increase in basal cAMP, and do not respond to hCG with a further increase in cAMP accumulation. This mutation enhances the internalization of the free and agonist-occupied receptors similar to 2- and similar to 17-fold, respectively, We conclude that the state of activation of the rLHR can modulate its basal and/or agonist-stimulated internalization. Since the internalization of hCG is involved in the termination of hCG actions, we suggest that the lack of responsiveness detected in cells expressing rLHR-L435R is due to the fast rate of internalization of the bound hCG. The finding that membranes expressing rLHR-L435R (a system where internalization does not occur) respond to hCG with an increase in adenylyl cyclase activity supports this suggestion.	Univ Iowa, Dept Pharmacol, Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Physiol & Biophys, Coll Med, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Ascoli, M (corresponding author), Univ Iowa, Dept Pharmacol, Coll Med, 2-319A BSB, Iowa City, IA 52242 USA.	mario-ascoli@uiowa.edu			NCI NIH HHS [CA-40629] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abell AN, 1997, J BIOL CHEM, V272, P14586, DOI 10.1074/jbc.272.23.14586; ASCOLI M, 1984, J CELL BIOL, V99, P1242, DOI 10.1083/jcb.99.4.1242; ASCOLI M, 1982, J BIOL CHEM, V257, P13306; ASCOLI M, 1987, ENDOCRINOLOGY, V120, P1161, DOI 10.1210/endo-120-3-1161; ASCOLI M, 1978, P NATL ACAD SCI USA, V75, P99, DOI 10.1073/pnas.75.1.99; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Beau I, 1997, J BIOL CHEM, V272, P5241, DOI 10.1074/jbc.272.8.5241; BERLIN CM, 1965, MOL PHARMACOL, V1, P149; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; Dhanwada KR, 1996, MOL ENDOCRINOL, V10, P544, DOI 10.1210/me.10.5.544; Fabritz J, 1998, BIOCHEMISTRY-US, V37, P664, DOI 10.1021/bi972355+; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; HOELSCHER SR, 1991, ENDOCRINOLOGY, V128, P2837, DOI 10.1210/endo-128-6-2837; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Latronico AC, 1998, J CLIN ENDOCR METAB, V83, P2435, DOI 10.1210/jc.83.7.2435; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LLOYD CE, 1983, J CELL BIOL, V96, P521, DOI 10.1083/jcb.96.2.521; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REN Q, 1993, J BIOL CHEM, V268, P16483; ROCHE PC, 1985, LUTEINIZING HORMONE, P17; SANCHEZYAGUE J, 1993, ENDOCRINOLOGY, V132, P1007, DOI 10.1210/en.132.3.1007; SEGALOFF DL, 1981, J BIOL CHEM, V256, P1420; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; SHENKER A, 1998, G PROTEINS DIS, P139; SZEKERS PG, 1997, MOL PHARM, V53, P759; VANAILUUTHI MT, 1992, BIOCHEMISTRY-US, V31, P8377; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; WANG H, 1991, J BIOL CHEM, V266, P780; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	53	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34911	34919		10.1074/jbc.273.52.34911	http://dx.doi.org/10.1074/jbc.273.52.34911			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857020	hybrid			2022-12-25	WOS:000077719700038
J	Rizzo, V; McIntosh, DP; Oh, P; Schnitzer, JE				Rizzo, V; McIntosh, DP; Oh, P; Schnitzer, JE			In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAXING FACTOR; MEMBRANE-PROTEIN; IN-VIVO; CELLS; MICRODOMAINS; RELEASE; BINDING; VESICLES; RAS	Acute changes in pressure or shear stress induce the rapid release of nitric oxide (NO) from the vascular endothelium resulting in vasodilation. Endothelial nitric oxide synthase (eNOS) regulates this flow-induced NO secretion. The subcellular location of flow-induced eNOS activity in the endothelium in vivo as well as the mechanisms by which hemodynamic forces regulate eNOS activity are unknown. The luminal cell surface of the endothelium, which is directly exposed to circulating blood stressors, has been examined for eNOS expression and functional activity. Immunoelectron microscopy of rat lung tissue shows eNOS labeling on the endothelial cell surface primarily within caveolae. Subcellular fractionation to purify luminal endothelial cell plasma membranes and their caveolae directly from rat lungs reveals that eNOS is not only concentrated but also enzymatically active in caveolae. Increasing vascular flow and pressure in situ rapidly activates caveolar eNOS with apparent eNOS dissociation from caveolin and association with calmodulin, Hemodynamic forces resulting from increased flow appear to transmit through caveolae to release eNOS from its inhibitory association with caveolin, apparently to allow more complete activation by calmodulin and other possible effectors. These data demonstrate a physiological relevant mechanotransduction event directly in caveolae at the luminal endothelial cell surface. Caveolae may serve as flow-sensing organelles with the necessary molecular machinery to transduce rapidly, mechanical stimuli and thereby regulate eNOS activity.	Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Schnitzer, JE (corresponding author), Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA.	jschnitz@bidmc.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052766, R01HL058216, F32HL009857] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58216, HL52766, HL09857] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; COOKE JP, 1991, J CLIN INVEST, V88, P1663, DOI 10.1172/JCI115481; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KUCHAN MJ, 1994, AM J PHYSIOL, V267, pC753, DOI 10.1152/ajpcell.1994.267.3.C753; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LEE J, 1995, ANN BIOMED ENG, V23, P226, DOI 10.1007/BF02584425; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lipowsky HH, 1995, FLOW DEPENDENT REGUL; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; OBRIEN AJ, 1995, HISTOCHEM CELL BIOL, V103, P221, DOI 10.1007/BF01454027; Oh P., 1997, Molecular Biology of the Cell, V8, p207A; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1993, CARDIOVASC RES, V27, P1380, DOI 10.1093/cvr/27.7.1380; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Rizzo V, 1998, J BIOL CHEM, V273, P26323, DOI 10.1074/jbc.273.41.26323; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; Schnitzer J. E., 1997, VASCULAR ENDOTHELIUM, P77; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1988, AM J PHYSIOL, V254, pH425, DOI 10.1152/ajpheart.1988.254.3.H425; Schnitzer JE, 1996, SCIENCE, V274, P239, DOI 10.1126/science.274.5285.239; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHNITZER JE, 1995, ANN BIOMED ENG, V23, pS34; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Skalak Thomas C., 1996, Microcirculation (Philadelphia), V3, P143, DOI 10.3109/10739689609148284; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595	47	242	248	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34724	34729		10.1074/jbc.273.52.34724	http://dx.doi.org/10.1074/jbc.273.52.34724			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856995	hybrid			2022-12-25	WOS:000077719700013
J	Andreadis, JD; Black, LW				Andreadis, JD; Black, LW			Substrate mutations that bypass a specific Cpn10 chaperonin requirement for protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIOPHAGE-T4 REPLICATION; CRYSTAL-STRUCTURE; CONTROLLED RATES; GENE-PRODUCTS; 31 MUTATIONS; HOST-CELL; GROEL; HEAD; MORPHOGENESIS	The bacteriophage T4 GroES homologue, gp31, in conjunction with the Escherichia coli chaperonin GroEL, is both necessary and sufficient to fold the T4 major capsid protein, gp23, to a state competent for capsid assembly as shown by in vivo expression studies. GroES is unable to function in this role as a productive co-chaperonin. The sequencing and characterization of mutations within gp23 that confer GroEL and gp31 chaperonin-independent folding of the mutant protein suggest that the chaperonin requirements are due to specific sequence determinants or structures in critical regions of gp23 that behave in an additive fashion to confer a chaperonin bypass phenotype. Conservative amino acid substitutions in these critical regions enable gp23 to fold in a GroEL-gp31 chaperonin-independent mode, albeit less efficiently than wild type, both in vivo and in vitro. Although the presence of functional GroEL-gp31 enhances folding of the mutated gp23 in vivo, GroEL-GroES has no such effect. Site-directed mutagenesis experiments suggest that a translational pausing mechanism is not responsible for the bypass mutant phenotype. Polyhead reassembly experiments are also consistent with direct, post-translational effects of the bypass mutations on polypeptide folding. Given our finding that gp31 is not required for the binding of the major capsid protein to GroEL and that active GroES is incapable of folding the gp23 polypeptide chain to native conformation, our results suggest co-chaperonin specificity in the folding of certain substrates.	Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Black, LW (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.	lblack@umaryland.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI011676, R01AI011676, R37AI011676] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11676] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREADIS JD, 1997, THESIS U MARYLAND BA; Black Lindsay W., 1994, P218; BLACK LW, 1976, J VIROL, V17, P894, DOI 10.1128/JVI.17.3.894-905.1976; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clark AC, 1997, J MOL BIOL, V268, P512, DOI 10.1006/jmbi.1997.0969; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; CROMBIE T, 1992, J MOL BIOL, V228, P7, DOI 10.1016/0022-2836(92)90486-4; DING YH, 1995, BIOCHEMISTRY-US, V34, P14918, DOI 10.1021/bi00045a037; DOERMANN AH, 1984, J VIROL, V51, P315, DOI 10.1128/JVI.51.2.315-320.1984; DRIEL RV, 1977, J MOL BIOL, V114, P61, DOI 10.1016/0022-2836(77)90283-2; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GRAY TE, 1993, J MOL BIOL, V232, P1197, DOI 10.1006/jmbi.1993.1471; Grimaud R, 1998, J BACTERIOL, V180, P1148, DOI 10.1128/JB.180.5.1148-1153.1998; Hanninen AL, 1997, VIROLOGY, V227, P207, DOI 10.1006/viro.1996.8308; HARTL FU, 1994, NATURE, V371, P557, DOI 10.1038/371557a0; Haynes JA, 1996, VIROLOGY, V221, P67, DOI 10.1006/viro.1996.0353; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunt JF, 1997, CELL, V90, P361, DOI 10.1016/S0092-8674(00)80343-8; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; JOHNSON K, 1992, J MOL BIOL, V224, P601, DOI 10.1016/0022-2836(92)90547-W; Karam J. D., 1994, MOL BIOL BACTERIOPHA; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; KUNISAWA T, 1992, J THEOR BIOL, V159, P287, DOI 10.1016/S0022-5193(05)80725-8; LAEMMLI UK, 1970, J MOL BIOL, V49, P99, DOI 10.1016/0022-2836(70)90379-7; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Landry SJ, 1996, P NATL ACAD SCI USA, V93, P11622, DOI 10.1073/pnas.93.21.11622; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MASSON JM, 1986, GENE, V47, P179, DOI 10.1016/0378-1119(86)90061-2; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MOTTAGUITABAR S, 1994, EMBO J, V13, P249, DOI 10.1002/j.1460-2075.1994.tb06255.x; NIVINSKAS R, 1988, GENE, V73, P251, DOI 10.1016/0378-1119(88)90332-0; PURVIS IJ, 1987, J MOL BIOL, V193, P413, DOI 10.1016/0022-2836(87)90230-0; REPOILA F, 1995, THESIS U P SABATIER; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; Saibil H, 1996, STRUCTURE, V4, P1, DOI 10.1016/S0969-2126(96)00002-0; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHOWE MK, 1973, NATURE-NEW BIOL, V242, P70, DOI 10.1038/newbio242070a0; SIMON LD, 1974, NATURE, V252, P451, DOI 10.1038/252451a0; SIMON LD, 1984, J VIROL, V51, P321, DOI 10.1128/JVI.51.2.321-328.1984; STEVEN AC, 1991, J STRUCT BIOL, V106, P221, DOI 10.1016/1047-8477(91)90072-5; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; Thanaraj TA, 1996, PROTEIN SCI, V5, P1594, DOI 10.1002/pro.5560050814; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; WUNDERLI H, 1977, J SUPRAMOL STR CELL, V7, P135, DOI 10.1002/jss.400070202; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZONDLO J, 1995, BIOCHEMISTRY-US, V34, P10334, DOI 10.1021/bi00033a003	61	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34075	34086		10.1074/jbc.273.51.34075	http://dx.doi.org/10.1074/jbc.273.51.34075			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852065	hybrid			2022-12-25	WOS:000077542200031
J	Chen, PF; Berka, V; Tsai, AL; Wu, KK				Chen, PF; Berka, V; Tsai, AL; Wu, KK			Effects of Asp-369 and Arg-372 mutations on heme environment and function in human endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC CYTOCHROME P-450-CAM; L-ARGININE; CATALYTIC ACTIVITY; BINDING; EXPRESSION; COMPLEXES; BRAIN; PURIFICATION; CLONING; ENZYME	Eight polar amino acid residues in the putative substrate-binding region from Thr-360 to Val-379 in human endothelial nitric-oxide synthase (eNOS) (Thr-360, Arg-365, Cys-368, Asp-369, Arg-372, Tyr-373, Glu-377, and Asp-378) were individually mutated. Only two of these residues, Asp-369 and Arg-372, were found to be essential for enzyme activity. A further series of mutants was generated by replacing these two residues with various amino acids and the mutant proteins were expressed in a baculovirus system, Mutant eNOS had a very low L-citrulline formation activity with the exception of D369E and R372K, which retained 27% and 44% of the wild-type enzyme activity, respectively, Unlike the wild-type enzyme, all mutants except D369E, R372K, and R372M had a low spin heme (Soret peak at 416 nm), All the Asp-369 mutants had higher K-d values for L-arginine (1-10 mM) than wild-type eNOS (0.4 mu M) and an unstable heme-CO complex, and except for D369E, had a very low (6R)5,6,7,8-Letrahydro-L-biopterin (BH4) content. In contrast, each of Arg-372 mutants retained a considerable amount of BH4, had a moderate reduction in L-arginine affinity, and had a more stable heme-CO complex. 1-Phenylimidazole did not bind to wild-type eNOS home, but bound to all Asp-369 and Arg-372 mutants (K-d ranged from 10 to 65 mu M) except R372K, Heme spin-state changes caused by binding of 3,5-lutidine appeared to depend on both charge and size of the side chains of residues 369 and 372, Furthermore, all Asp-369 and Arg-372 mutants were defective in dimer formation. These results suggest that residues Asp-369 and Arp-372 in eNOS play a critical role in oxygenase domain active-site structure and activity.	Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Houston, TX 77225 USA; Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Chen, PF (corresponding author), Univ Texas, Sch Med, Div Hematol, POB 20708,6431 Fannin, Houston, TX 77225 USA.	gfchen@heart.med.uth.tmc.edu	Wu, Kenneth Kun-Yu/B-1070-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50676] Funding Source: Medline; NIGMS NIH HHS [GM-44911] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MASTERS BSS, 1998, ASBMB M MAY 16 20 19; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Migita CT, 1997, BIOCHEMISTRY-US, V36, P10987, DOI 10.1021/bi970823+; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SONO M, 1982, J BIOL CHEM, V257, P5496; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL, V65, P287; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020	33	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34164	34170		10.1074/jbc.273.51.34164	http://dx.doi.org/10.1074/jbc.273.51.34164			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852077	hybrid			2022-12-25	WOS:000077542200043
J	Cordat, E; Mus-Veteau, I; Leblanc, G				Cordat, E; Mus-Veteau, I; Leblanc, G			Structural studies of the melibiose permease of Escherichia coli by fluorescence resonance energy transfer - II. Identification of the tryptophan residues acting as energy donors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-SPANNING SEGMENTS; ACIDIC RESIDUES; NA+; MUTAGENESIS; TRANSPORT; DISTANCES; SUGAR; SITES	In the accompanying paper, we demonstrated the presence of a fluorescence resonance energy transfer (FRET) between the tryptophans of the melibiose permease (MelB) of Escherichia coli and a fluorescent sugar, 2'-(N-5-dimethylaminonaphthalene-1-sulfonyl)-aminoethyl-1-thio-beta-D-galactopyranoside (Dns(2)-S-Gal) bound at the sugar-binding site (Maehrel, C., Cordat, E,, Mus-Veteau, I., and Leblanc, G. (1998) J. Biol. Chem. 273, 33192-33197). To identify the tryptophans that transfer their energy to the fluorescent sugar, we analyzed the FRET properties of MelB mutants carrying the replacement of each of the eight MelB tryptophans by a phenylalanine. The data indicate that Trp(64), localized in loop 2-3 from the N-terminal domain, and Trp(299), localized in helix IX in the C-terminal domain, are responsible for up to 80% of the FRET signal. Moreover, by assuming that only Trp(299) transfers energy to Dns(2)-S-Gal in mutant W64F, whereas only Trp(64) transfers energy to Dns(2)-S-Gal in mutant W299F, we calculated that Trp(299) and Trp(64) are about 14 and 20 Angstrom away from the probe, respectively. In addition, we observed that mutating Trp(342) localized in helix X of the C-terminal domain, produces a significant increase of the polarity of the fluorescent sugar environment, suggesting its proximity to the sugar-binding site. Taken together, these data provide additional support for the suggestion that (i) the sugar-binding site is localized in the C-terminal part of the transporter, probably close to membrane segments IX and X, and (ii) the N-terminal domain, and particularly cytoplasmic loop 2-3, is also close to the sugar-binding site.	CEA, Dept Biol Cellulaire & Mol, Lab J Moetz, F-06238 Villefranche Sur Mer, France; CNRS, ERS 1253, F-06238 Villefranche Sur Mer, France	CEA; Centre National de la Recherche Scientifique (CNRS)	Leblanc, G (corresponding author), CEA, Dept Biol Cellulaire & Mol, Lab J Moetz, F-06238 Villefranche Sur Mer, France.	leblanc@ccrv.obs-vlfr.fr	Mus-veteau, Isabelle/M-8875-2016	Mus-veteau, Isabelle/0000-0001-5739-7684				BOTFIELD MC, 1988, J BIOL CHEM, V263, P12909; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CHABBERT M, 1991, BIOCHEMISTRY-US, V30, P7615, DOI 10.1021/bi00244a034; CHAPMAN ER, 1992, BIOCHEMISTRY-US, V31, P12819, DOI 10.1021/bi00166a016; EPPS DE, 1987, J BIOL CHEM, V262, P10570; Fairclough R H, 1978, Methods Enzymol, V48, P347; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; HAMA H, 1993, J BIOL CHEM, V268, P10060; ISAAC VE, 1995, BIOCHEMISTRY-US, V34, P15276, DOI 10.1021/bi00046a036; Kaback H R, 1974, Methods Enzymol, V31, P698; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lankiewicz L, 1997, ACTA BIOCHIM POL, V44, P477, DOI 10.18388/abp.1997_4398; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maehrel C, 1998, J BIOL CHEM, V273, P33192, DOI 10.1074/jbc.273.50.33192; MUSVETEAU I, 1995, BIOCHEMISTRY-US, V34, P6775, DOI 10.1021/bi00020a024; MusVeteau I, 1996, BIOCHEMISTRY-US, V35, P12053, DOI 10.1021/bi961372g; PEERCE BE, 1986, P NATL ACAD SCI USA, V83, P8092, DOI 10.1073/pnas.83.21.8092; POURCHER T, 1993, J BIOL CHEM, V268, P3209; POURCHER T, 1995, BIOCHEMISTRY-US, V34, P4412, DOI 10.1021/bi00013a033; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; ZANI ML, 1993, J BIOL CHEM, V268, P3216; ZANI ML, 1994, J BIOL CHEM, V269, P24883	27	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33198	33202		10.1074/jbc.273.50.33198	http://dx.doi.org/10.1074/jbc.273.50.33198			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837888	hybrid			2022-12-25	WOS:000077462500018
J	Fan, JS; Zhang, QA; Li, M; Tochio, H; Yamazaki, T; Shimizu, M; Zhang, MJ				Fan, JS; Zhang, QA; Li, M; Tochio, H; Yamazaki, T; Shimizu, M; Zhang, MJ			Protein inhibitor of neuronal nitric-oxide synthase, PIN, binds to a 17-amino acid residue fragment of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGENASE DOMAIN; NERVOUS-SYSTEM; LIGHT-CHAINS; MYOSIN-V; BRAIN; SENSITIVITY; NMR; DIMERIZATION; RESONANCES; SUBUNIT	Neuronal nitric-oxide synthase (nNOS) is the primary nitric oxide (NO) regulator in neurons. The activity of the enzyme is inhibited by a protein inhibitor called PIN. We were able to purify large quantities of PIN overexpressed in bacterial cells. Analytical ultracentrifugation and chemical cross-linking studies showed that PIN exists as a monomer at low concentrations. The protein forms a high order aggregate at elevated concentrations. We have shown, using NMR spectroscopy, that the previously identified PIN-binding domain (PINB) of nNOS (residues 161-245) adopts a random coil structure in solution. By titrating N-15-labeled PINE with unlabeled PIN, the PIN-binding region of nNOS was precisely mapped to a 17-residue peptide fragment from Met-228 to His-244 of nNOS. MMR titration experiments also showed that PIN binds to nNOS with a 1:2 stoichiometry. A synthetic peptide corresponding to the identified PIN-binding region of nNOS was used to study the interaction between PIN and nNOS in detail. The functional implications of the results obtained from this study are discussed.	Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Peoples R China; Osaka Univ, Inst Prot Res, Suita, Osaka 565, Japan; Biomol Engn Res Inst, Suita, Osaka 565, Japan	Hong Kong University of Science & Technology; Osaka University	Zhang, MJ (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water bay, Hong Kong, Peoples R China.		Tochio, Hidehito/GWV-0429-2022; Tochio, Hidehito/F-6109-2011	Tochio, Hidehito/0000-0003-3843-3330; Zhang, Mingjie/0000-0001-9404-0190				Aoki C, 1997, BRAIN RES, V750, P25, DOI 10.1016/S0006-8993(96)01147-X; Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, METHOD ENZYMOL, V269, P119; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Dawson VL, 1996, J NEUROSCI, V16, P2479; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gillardon F, 1998, NEUROSCIENCE, V84, P81, DOI 10.1016/S0306-4522(97)00479-X; Greenwood MT, 1997, BIOCHEM BIOPH RES CO, V238, P617, DOI 10.1006/bbrc.1997.7361; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; RAND MJ, 1995, ANNU REV PHYSIOL, V57, P659; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; Tochio H, 1998, NAT STRUCT BIOL, V5, P965, DOI 10.1038/2940; WILLIAMS CV, 1994, J NEUROSCI, V14, P1746, DOI 10.1523/JNEUROSCI.14-03-01746.1994; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; WU HH, 1994, SCIENCE, V265, P1593, DOI 10.1126/science.7521541; ZHANG M, 1998, IN PRESS BIOCH CELL; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	36	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33472	33481		10.1074/jbc.273.50.33472	http://dx.doi.org/10.1074/jbc.273.50.33472			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837926	hybrid			2022-12-25	WOS:000077462500056
J	Hu, YM; Ding, LY; Spencer, DM; Nunez, G				Hu, YM; Ding, LY; Spencer, DM; Nunez, G			WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; 3-DIMENSIONAL STRUCTURE; ADENYLATE KINASE; CYTOCHROME-C; CED-4; APOPTOSIS; PROTEIN; DOMAIN; CASPASES	The casp9 protein plays a critical role in apoptosis induced by a variety of death stimuli. A regulator of apoptosis, Apaf-1, binds to and activates pro-casp9 in the presence of cytochrome c and dATP, a requirement that is bypassed by deletion of the WD-40 repeats located in the C-terminal half of Apaf-1, In this report, we used constitutively active Apaf-1 mutant lacking the WD-40 repeat region to study the mechanism and regulation of pro-casp9 activation. Mutational analysis revealed that only a small portion of the CED-4 homologous region (residues 456-559) could be deleted without destroying the ability of Apaf-1-(1-559) to activate pro-casp9. Apaf-1 can self-associate to form oligomers, Disruption of Apaf-1 self-association by deletion (Delta 109-559) or mutation of the P-loop region (K149R) abrogated Apaf-1-mediated pro-casp9 activation. Forced oligomerization of the caspase recruitment domain of Apaf-1 was sufficient for pro-casp9 activation. Dimerization of chimeric Fpk-pro-casp9 protein with the dimerizer drug FK1012 induced pro-casp9 processing and apoptosis in cells. Significantly, the C-terminal region containing WD-40 repeats interacted with its N-terminal CED-4 homologous region, as determined by immunoprecipitation experiments. Importantly, expression of the WD-40 repeat region inhibited Apaf-1 self-association and proteolytic activation of pro-casp9. These studies provide a mechanism by which Apaf-1 promotes autoactivation of pro-casp9 through Apaf-1 self-association, a process that is negatively regulated by the WD-40 repeats.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Baylor College of Medicine	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014		NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline; PHS HHS [T32A107413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Cardozo TJ, 1998, J MOL MODEL, V4, P83, DOI 10.1007/s008940050134; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COHEN PL, 1992, IMMUNOL TODAY, V13, P427, DOI 10.1016/0167-5699(92)90066-G; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; James C, 1997, CURR BIOL, V7, P246, DOI 10.1016/S0960-9822(06)00120-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7451, DOI 10.1021/bi00484a014; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	35	206	218	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33489	33494		10.1074/jbc.273.50.33489	http://dx.doi.org/10.1074/jbc.273.50.33489			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837928	hybrid			2022-12-25	WOS:000077462500058
J	Metzler, B; Hu, YH; Sturm, G; Wick, G; Xu, QB				Metzler, B; Hu, YH; Sturm, G; Wick, G; Xu, QB			Induction of mitogen-activated protein kinase phosphatase-1 by arachidonic acid in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; C-JUN; GROWTH-FACTOR; MAP KINASE; NADPH-OXIDASE; EPITHELIAL-CELLS; ANGIOTENSIN-II; TRANSCRIPTION FACTOR; ENDOTHELIAL-CELLS; MESANGIAL CELLS	Arachidonic acid (AA) and its metabolites play important roles in a variety of biological processes, such as signal transduction, contraction, chemotaxis, and cell proliferation and differentiation. It was demonstrated recently that AA can activate mitogen-activated protein kinases (MAPKs), which are crucial for transducing signals initiating cell growth and apoptosis. Here we studied the effect of AA on the induction of MAPK phosphatase-1 (MKP-1) in vascular smooth muscle cells (VSMCs) and found that AA stimulated induction of MKP-1 mRNA and proteins in VSMCs in a time- and dose-dependent manner. Specific inhibitors of cyclooxygenase-, lipoxygenase-, and cytochrome P450-dependent metabolism did not affect AA-induced MKP-1 expression, indicating that eicosanoid biosynthesis was not involved in this process. The glutathione precursor N-acetylcysteine, an antioxidant, abolished AA-stimulated MKP-1 gene expression, whereas inhibition of protein kinase C by calphostin C had no influence on MKP-1 induction. VSMC pretreatment with genistein, a tyrosine kinase inhibitor, completely blocked AA-stimulated MKP-1 induction. MAPK kinase inhibitor PD 98059 did abolish AA-stimulated activation of extracellular signal-regulated kinases but not MKP-1 induction. Furthermore, agonists that increase AA release stimulated MKP-1 induction and activation of MAPKs, including extracellular signal-regulated kinases and c-Jun NH2-terminal protein kinases or stress-activated protein kinases, Taken together, our findings demonstrate that AA induced MKP-1 expression in VSMCs via activation of tyrosine kinases involving AA-induced free radical generation, suggesting an important role for MKP-1 in the regulation of AA-initiated signal transduction in VSMCs.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria	Austrian Academy of Sciences	Xu, QB (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.							AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSI DR, 1993, ONCOGENE, V8, P2015; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CIVAN MM, 1994, INVEST OPHTH VIS SCI, V35, P2876; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOPER CL, 1985, CIRC RES, V56, P97, DOI 10.1161/01.RES.56.1.97; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELL KR, 1989, BIOCHEM J, V258, P171, DOI 10.1042/bj2580171; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; Force T, 1998, HYPERTENSION, V31, P152, DOI 10.1161/01.HYP.31.1.152; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; Harwalkar S, 1998, HYPERTENSION, V31, P809, DOI 10.1161/01.HYP.31.3.809; HATA Y, 1993, PROSTAGLANDINS, V45, P129, DOI 10.1016/0090-6980(93)90028-6; HENDERSON LM, 1993, EUR J BIOCHEM, V211, P157, DOI 10.1111/j.1432-1033.1993.tb19882.x; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Hu YH, 1997, J BIOL CHEM, V272, P9113; Irons CE, 1996, AM J PHYSIOL-CELL PH, V270, pC1642, DOI 10.1152/ajpcell.1996.270.6.C1642; KIKKAWA U, 1988, PHILOS T ROY SOC B, V320, P313, DOI 10.1098/rstb.1988.0079; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; Liu YS, 1996, J BIOL CHEM, V271, P3604; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V17, P433, DOI 10.1016/S0735-1097(10)80111-1; OWEN NE, 1986, AM J PHYSIOL, V250, pC584, DOI 10.1152/ajpcell.1986.250.4.C584; PALMBERG L, 1987, J CELL SCI, V88, P151; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAKATA A, 1987, J IMMUNOL, V138, P4353; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THOMAS DJ, 1992, CARCINOGENESIS, V13, P447, DOI 10.1093/carcin/13.3.447; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; TROPEA MM, 1993, J PHARMACOL EXP THER, V264, P930; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Xu QB, 1997, HYPERTENSION, V30, P106, DOI 10.1161/01.HYP.30.1.106; Xu QB, 1997, J CLIN INVEST, V100, P1089, DOI 10.1172/JCI119619; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; Zou YP, 1998, INT J MOL MED, V1, P827	66	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33320	33326		10.1074/jbc.273.50.33320	http://dx.doi.org/10.1074/jbc.273.50.33320			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837905	hybrid			2022-12-25	WOS:000077462500035
J	Thurmond, DC; Ceresa, BP; Okada, S; Elmendorf, JS; Coker, K; Pessin, JE				Thurmond, DC; Ceresa, BP; Okada, S; Elmendorf, JS; Coker, K; Pessin, JE			Regulation of insulin-stimulated GLUT4 translocation by Munc18c in 3T3L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORTER GLUT4; SYNTAXIN-BINDING PROTEIN; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; GLUT4-CONTAINING VESICLES; CARDIAC MYOCYTES; SNAP RECEPTORS; YEAST SEC1; IN-VIVO; MEMBRANE	Insulin stimulates glucose transporter (GLUT) 4 vesicle translocation from intracellular storage sites to the plasma membrane in 3T3L1 adipocytes through a VAMP2- and syntaxin 4-dependent mechanism. We have observed that Munc18c, a mammalian homolog of the yeast syntaxin-binding protein n-Sec1p, competed for the binding of VAMPS to syntaxin 4, Consistent with an inhibitory function for Munc18c, expression of Munc18c, but not the related Munc18b isoform, prevented the insulin stimulation of GLUT4 and IRAP/vp165 translocation to the plasma membrane without any significant effect on GLUT1 trafficking. As expected, overexpressed Munc18c was found to co-immunoprecipitate with syntaxin 4 in the basal state. However, these complexes were found to dissociate upon insulin stimulation. Furthermore, endogenous Munc18c was predominantly localized to the plasma membrane and its distribution was not altered by insulin stimulation. Although expression of enhanced green fluorescent protein-Munc18c primarily resulted in a dispersed cytosolic distribution, co-expression with syntaxin 4 resulted in increased localization to the plasma membrane. Together, these data suggest that Munc18c inhibits the docking/fusion of GLUT4-containing vesicles by blocking the binding of VAMPS to syntaxin 4, Insulin relieves this inhibition by inducing the dissociation of Munc18c from syntaxin 4 and by sequestering Munc18c to an alternative plasma membrane binding site.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Pessin, JE (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	jeffrey-pessin@uiowa.edu			NIDDK NIH HHS [DK09813, DK33823, DK25925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033823, F32DK009813, R37DK033823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BALDINI G, 1991, J BIOL CHEM, V266, P4037; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Calakos N, 1996, PHYSIOL REV, V76, P1; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; Fischer Y, 1997, J BIOL CHEM, V272, P7085, DOI 10.1074/jbc.272.11.7085; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHELLER RH, 1995, NEURON, V14, P893; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Sevilla L, 1997, ENDOCRINOLOGY, V138, P3006, DOI 10.1210/en.138.7.3006; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127	57	202	208	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33876	33883		10.1074/jbc.273.50.33876	http://dx.doi.org/10.1074/jbc.273.50.33876			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837979	hybrid			2022-12-25	WOS:000077462500109
J	Yoshida, H; Haze, K; Yanagi, H; Yura, T; Mori, K				Yoshida, H; Haze, K; Yanagi, H; Yura, T; Mori, K			Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins - Involvement of basic leucine zipper transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PROMOTER ELEMENT; DNA-BINDING PROTEIN; FACTOR CBF/NF-Y; CCAAT-BINDING; TRANSMEMBRANE PROTEIN; MALFOLDED PROTEINS; GRP78/BIP PROMOTER; UNFOLDED PROTEINS; CA2+ DEPLETION; HUMAN-GENE	When unfolded proteins accumulate in the endoplasmic reticulum (ER), transcription of glucose-regulated proteins (GRPs) representing ER-resident molecular chaperones is markedly induced via the unfolded protein response (UPR) pathway. In contrast to recent progress in the analysis of yeast UPR, both cis-acting elements and transactivators responsible for mammalian UPR have remained obscure, Here, we analyzed the promoter regions of human GRP78, GRP94, and calreticulin genes and identified a novel element designated the ER stress response element (ERSE), ERSE, with a consensus of CCAATN(9)CCACG, was shown to be necessary and sufficient for induction of these GRPs, Using yeast one-hybrid screening, we isolated a human cDNA encoding a basic leucine zipper (bZIP) protein, ATF6, as a putative ERSE-binding protein. When overexpressed in HeLa cells, ATF6 enhanced transcription of GRP genes in an ERSE-dependent manner, whereas CREB-RP, another bZIP protein closely related ito ATF6, specifically inhibited GRP induction. Endogenous ATF6 constitutively expressed as a 90-kDa protein was converted to a 50-kDa protein in ER-stressed cells, which appeared to be important for the cellular response to ER stress. These results suggest that, as in yeast, bZIP proteins are involved in mammalian UPR, acting through newly defined ERSE.	HSP Res Inst, Kyoto 6008813, Japan		Mori, K (corresponding author), HSP Res Inst, Kyoto Res Pk, Kyoto 6008813, Japan.	kazumori@hsp.co.jp	Mori, Kazutoshi/K-6106-2015	Yoshida, Hiderou/0000-0002-5773-1408				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; Ikeda J, 1997, BIOCHEM BIOPH RES CO, V230, P94, DOI 10.1006/bbrc.1996.5890; Kawahara T, 1998, J BIOL CHEM, V273, P1802, DOI 10.1074/jbc.273.3.1802; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; Khanna A, 1996, BIOCHEM J, V319, P81, DOI 10.1042/bj3190081; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; Koivunen P, 1997, GENOMICS, V42, P397, DOI 10.1006/geno.1997.4750; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; LIOU HC, 1990, SCIENCE, V247, P1581, DOI 10.1126/science.2321018; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MENKENS AE, 1994, P NATL ACAD SCI USA, V91, P2522, DOI 10.1073/pnas.91.7.2522; Mori K, 1998, J BIOL CHEM, V273, P9912, DOI 10.1074/jbc.273.16.9912; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; PLA M, 1993, PLANT MOL BIOL, V21, P259, DOI 10.1007/BF00019942; RAMAKRISHNAN M, 1995, DNA CELL BIOL, V14, P373, DOI 10.1089/dna.1995.14.373; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; ROY B, 1995, MOL CELL BIOL, V15, P2263; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Sambrook J., 2002, MOL CLONING LAB MANU; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SRINIVASAN M, 1993, DNA CELL BIOL, V12, P807, DOI 10.1089/dna.1993.12.807; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; Welihinda AA, 1998, MOL CELL BIOL, V18, P1967, DOI 10.1128/MCB.18.4.1967; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	55	952	1000	1	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33741	33749		10.1074/jbc.273.50.33741	http://dx.doi.org/10.1074/jbc.273.50.33741			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837962	hybrid			2022-12-25	WOS:000077462500092
J	Dam, TK; Oscarson, S; Brewer, CF				Dam, TK; Oscarson, S; Brewer, CF			Thermodynamics of binding of the core trimannoside of asparagine-linked carbohydrates and deoxy analogs to Dioclea grandiflora lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCANAVALIN-A; LIGAND-BINDING; SPECIFICITY; SITE; OLIGOSACCHARIDES; RECOGNITION; ANTIBODY; SEEDS	The Man/Glc-specific seed lectin from Dioclea grandiflora (DGL) is a member of the Diocleinae subtribe that includes the jack bean lectin concanavalin A (ConA). Both DGL and ConA bind with high affinity to the "core" trimannoside moiety, 3,6-di-O-(alpha-D-mannopyranosyl)-alpha-D-mannopyranoside, which is present in asparagine-linked carbohydrates. Recent hemagglutination inhibition studies suggest that DGL and ConA recognize similar epitopes of the trisaccharide but possess different binding specificities for complex carbohydrates (Gupta, D., Oscarson, S., Raju, T. S., Stanley, P., Toone, E. J., and Brewer, C. F. (1996) Eur. J. Biochem. 242, 320-326). In the present study, we have used isothermal titration microcalorimetry to determine the thermodynamics of binding of DGL to a complete set of monodeoxy analogs of the core trimannoside as web as a tetradeoxy analog. The thermodynamic data indicate that DGL recognizes the 2-, 3-, 4-, and 6-hydroxyl groups of the alpha(1,6) Man residue, the 3- and 4-hydroxyl group of the alpha(1, 3) Man residue, and the 2- and 4-hydroxyl groups of the central Man residue of the trimannoside. The thermodynamic data for the tetradeoxy analog lacking the 3- and I-hydroxyl group of the alpha(1, 3) Man residue, and the 2- and 4-hydroxyl groups of the central Man residue of the trimannoside are consistent with the involvement of these hydroxyl groups in binding. While the overall pattern of data for DGL binding to the deoxy analogs is similar to that for ConA (Gupta, D., Dam, T. K., Oscarson, S., and Brewer, C. F. (1997) J. Biol. Chem. 272, 6388-6392), differences exist in the data for certain monodeoxy analogs binding to the two lectins. Differences are also observed in the thermodynamics of binding of DGL and ConA to a biantennary complex carbohydrate. In the following paper (Rozwarski, D. A., Swami, B. M., Brewer, C. F., and Sacchettini, J. C. (1998) J. Biol. Chem. 273, 32818-32825), the x-ray crystal structure of DGL complexed to the core trimannoside is presented, and a comparison is made of the thermodynamic binding data for DGL and ConA as well as the structures of their respective trimannoside complexes.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Stockholm Univ, Dept Organ Chem, S-10691 Stockholm, Sweden	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stockholm University	Brewer, CF (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Oscarson, Stefan/0000-0002-8273-4918	NATIONAL CANCER INSTITUTE [P30CA013330, R01CA016054] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002309] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16054, P30 CA-13330] Funding Source: Medline; NCRR NIH HHS [1-S10-RR02309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGRAWAL BBL, 1967, BIOCHIM BIOPHYS ACTA, V147, P262, DOI 10.1016/0005-2795(67)90404-7; BREWER CF, 1986, J BIOL CHEM, V261, P7306; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; CHERVENAK MC, 1994, J AM CHEM SOC, V116, P10533, DOI 10.1021/ja00102a021; Dam TK, 1998, J BIOL CHEM, V273, P12082, DOI 10.1074/jbc.273.20.12082; Goldstein I. J., 1986, LECTINS PROPERTIES F, P35; GOMES JC, 1994, AGENTS ACTIONS, V41, P132, DOI 10.1007/BF02001905; Gupta D, 1996, EUR J BIOCHEM, V242, P320, DOI 10.1111/j.1432-1033.1996.0320r.x; Gupta D, 1997, J BIOL CHEM, V272, P6388, DOI 10.1074/jbc.272.10.6388; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; LEMIEUX RU, 1991, CIBA F SYMP, V158, P231; LEMIEUX RU, 1989, CHEM SOC REV, V18, P347, DOI 10.1039/cs9891800347; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MOREIRA RA, 1983, PLANTA, V158, P63, DOI 10.1007/BF00395404; MUNSKE GR, 1984, ARCH BIOCHEM BIOPHYS, V233, P582, DOI 10.1016/0003-9861(84)90482-X; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Oscarson S, 1995, CARBOHYD RES, V278, P271, DOI 10.1016/0008-6215(95)00268-5; Oscarson S, 1998, CARBOHYD RES, V309, P207, DOI 10.1016/S0008-6215(98)00107-4; RICHARDSON M, 1984, EUR J BIOCHEM, V144, P101, DOI 10.1111/j.1432-1033.1984.tb08436.x; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SAHA SK, 1994, CARBOHYD RES, V254, P157; SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	26	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32812	32817		10.1074/jbc.273.49.32812	http://dx.doi.org/10.1074/jbc.273.49.32812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830027	hybrid			2022-12-25	WOS:000077329100066
J	Liu, YZ; Chrivia, JC; Latchman, DS				Liu, YZ; Chrivia, JC; Latchman, DS			Nerve growth factor up-regulates the transcriptional activity CBP through activation of the p42/p44(MAPK) cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NEUROTROPHIC FACTORS; SENSORY NEURONS; COACTIVATOR CBP; PC12 CELLS; CREB; PHOSPHORYLATION; CAMP; DIFFERENTIATION; SPECIFICITY	Cyclic AMP response element-binding protein-binding protein (CBP) functions as a transcriptional coactivator through interactions with a number of cellular and viral transcription factors. It has been suggested to play a central integrative role in gene regulation. However, little is known about signal cascades that can regulate CBP activity. Here we show that either nerve growth factor (NGF) or cAMP treatment led to enhanced activity of CBP in PC12 cells. The C-terminal glutamine-rich activation domain of CBP was shown to be responsible for induction by NGF and cAMP. NGF-induced enhancement of CBP activity was also observed in protein kinase A (PKA)-deficient PC12 cells, whereas cAMP failed to increase the transcriptional activity of CBP in these cells. Moreover, the specific PKA inhibitor H-89 blocked cAMP-induced but not NGF-induced up-regulation of CBP activity. The up-regulation of CBP transcriptional activity in response to NGF was, however, prevented by the specific inhibitor of mitogen-activated protein kinase (p42/44(MAPK)) activation, PD98059, which had no effect on the up-regulation induced by cyclic AMP, indicating that activation of the mitogen-activated protein kinase signal pathway is specifically involved in the NGF-induced activation of CBP, In addition, expression of a dominant-negative interfering mutant of p42/44(MAPK) prevent the NGF-mediated induction of the CBP activity, whereas expression of a p42/44(MAPK) constitutively active mutant can enhance the transcriptional activity of CBP. These data indicate that activation of the p42/p44(MAPK) cascade mediates the up-regulation of the transcriptional activity of CBP by NGF, whereas the similar up-regulation induced by cyclic AMP is mediated by PKA activation.	UCL, Dept Mol Pathol, London W1P 6DB, England; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA	University of London; University College London; Saint Louis University	Latchman, DS (corresponding author), UCL, Dept Mol Pathol, 46 Cleveland St, London W1P 6DB, England.							ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAMA T, 1986, P NATL ACAD SCI USA, V86, P1756; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KEE BL, NATURE, V376, P348; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEGAL A, 1996, ANNU REV NEUROSCI, V19, P463; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WATSON A, 1995, J BIOL CHEM, V270, P9655, DOI 10.1074/jbc.270.16.9655; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	42	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32400	32407		10.1074/jbc.273.49.32400	http://dx.doi.org/10.1074/jbc.273.49.32400			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829969	hybrid			2022-12-25	WOS:000077329100008
J	Reverter, D; Vendrell, J; Canals, F; Horstmann, J; Aviles, FX; Fritz, H; Sommerhoff, CP				Reverter, D; Vendrell, J; Canals, F; Horstmann, J; Aviles, FX; Fritz, H; Sommerhoff, CP			A carboxypeptidase inhibitor from the medical leech Hirudo medicinalis - Isolation, sequence analysis, cDNA cloning, recombinant expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC PROCARBOXYPEPTIDASE-A; MAST-CELL PROTEINASE; 3-DIMENSIONAL STRUCTURE; POTATO CARBOXYPEPTIDASE; MOLECULAR-DYNAMICS; ESCHERICHIA-COLI; COMPLEX; AMPLIFICATION; PURIFICATION; ACTIVATION	A novel metallocarboxypeptidase inhibitor was isolated from the medical leech Hirudo medicinalis, Amino acid sequence analysis provided a nearly complete primary structure. which was subsequently verified and completed by cDNA cloning using reverse transcriptase-polymerase chain reaction/rapid amplification of cDNA end techniques. The inhibitor, called LCI (leech carboxypeptidase inhibitor), is a cysteine-rich polypeptide composed of 66 amino acid residues. It does not show sequence similarity to any other protein except at its C-terminal end. In this region, the inhibitor shares the amino acid sequence -Thr-Cys-X-Pro-Tyr-Val-X with Solanacea carboxypeptidase inhibitors, suggesting a similar mechanism of inhibition where the C-terminal tail of the inhibitor interacts with the active center of metallocarboxypeptidases in a substrate-like manner. This hypothesis is supported by the hydrolytic release of the C-terminal glutamic acid residue of LCI after binding to the enzyme. Heterologous overexpression of LCI in Escherichia coli, either into the medium or as an intracellular thioredoxin fusion protein, yields a protein with full inhibitory activity, Both in the natural and recombinant forms, LCI is a tightly binding, competitive inhibitor of different types of pancreatic-like carboxypeptidases, with equilibrium dissociation constants K-i of 0.2-0.4 x 10(-9) M for the complexes with the pancreatic enzymes A1, A2, and B and plasma carboxypeptidase B, Circular dichroism and nuclear magnetic resonance spectroscopy analysis indicate that recombinant LCT is a compactly folded globular protein, stable to a wide range of pH and denaturing conditions.	Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Ciencies, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Inst Biol Fonamental, E-08193 Barcelona, Spain; Univ Munich, Surg Clin, Dept Clin Chem & Clin Biochem, D-80336 Munich, Germany	Autonomous University of Barcelona; Autonomous University of Barcelona; University of Munich	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Unitat Ciencies, E-08193 Barcelona, Spain.	fx.aviles@blues.uab.es	Reverter, David/H-5360-2015; Vendrell, Josep/A-6731-2010; Avilés, Francesc Xavier/A-2664-2015; Aviles, Francesc Xavier/F-3482-2019	Reverter, David/0000-0002-5347-0992; Vendrell, Josep/0000-0002-9378-4742; Avilés, Francesc Xavier/0000-0002-1399-6789; Aviles, Francesc Xavier/0000-0002-1399-6789				Arizono N, 1996, CLIN EXP IMMUNOL, V106, P55, DOI 10.1046/j.1365-2249.1996.d01-803.x; ASCENZI P, 1995, MOL ASPECTS MED, V16, P215, DOI 10.1016/0098-2997(95)00002-X; AVILES FX, 1993, EUR J BIOCHEM, V211, P381, DOI 10.1111/j.1432-1033.1993.tb17561.x; AVILES FX, 1993, INNOVATIONS PROTEASE; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4092; CASADABAN MJ, 1987, BIOCHEMISTRY-US, V26, P8012; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COLL M, 1991, EMBO J, V10, P1; Douch PGC, 1996, INT J PARASITOL, V26, P91, DOI 10.1016/0020-7519(95)00086-0; FINK E, 1986, BIOL CHEM H-S, V367, P1235, DOI 10.1515/bchm3.1986.367.2.1235; FRITZ H, 1990, BIOL CHEM HOPPESEYLE, V371; FRITZ JD, 1991, NUCLEIC ACIDS RES, V19, P3747, DOI 10.1093/nar/19.13.3747; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GOMISRUTH FX, 1995, EMBO J, V14, P4387, DOI 10.1002/j.1460-2075.1995.tb00117.x; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HASS GM, 1981, METHOD ENZYMOL, V80, P778; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOMANDBERG GA, 1989, ARCH BIOCHEM BIOPHYS, V270, P153, DOI 10.1016/0003-9861(89)90017-9; Hooper N. M., 1996, ZINC METALLOPROTEASE; HUNTLEY JF, 1990, PARASITE IMMUNOL, V12, P85, DOI 10.1111/j.1365-3024.1990.tb00938.x; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Miller HRP, 1996, VET IMMUNOL IMMUNOP, V54, P331, DOI 10.1016/S0165-2427(96)05696-6; Mittl PRE, 1997, STRUCTURE, V5, P253, DOI 10.1016/S0969-2126(97)00183-4; MOLINA MA, 1992, GENE, V116, P129, DOI 10.1016/0378-1119(92)90508-M; MOLINA MA, 1994, J BIOL CHEM, V269, P21467; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Normant E, 1995, P NATL ACAD SCI USA, V92, P12225, DOI 10.1073/pnas.92.26.12225; OLIVA B, 1995, EUR BIOPHYS J, V24, P1, DOI 10.1007/BF00216825; OLIVA B, 1991, BIOCHEM BIOPH RES CO, V176, P616, DOI 10.1016/S0006-291X(05)80228-1; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Reverter D, 1998, J BIOL CHEM, V273, P3535, DOI 10.1074/jbc.273.6.3535; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Sakharov DV, 1997, J BIOL CHEM, V272, P14477, DOI 10.1074/jbc.272.22.14477; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P369; SEEMULLER U, 1980, H-S Z PHYSIOL CHEM, V361, P1841; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718	47	75	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32927	32933		10.1074/jbc.273.49.32927	http://dx.doi.org/10.1074/jbc.273.49.32927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830043	hybrid			2022-12-25	WOS:000077329100082
J	Yakushi, T; Yokota, N; Matsuyama, S; Tokuda, H				Yakushi, T; Yokota, N; Matsuyama, S; Tokuda, H			LolA-dependent release of a lipid-modified protein from the inner membrane of Escherichia coli requires nucleoside triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; CYTOPLASMIC MEMBRANE; LIPOPROTEIN; LOCALIZATION; TRANSLOCATION; TRANSPORT; MACHINERY; MECHANISM; BACTERIA; MODEL	The outer membrane-directed lipoproteins are released from the inner membrane of Escherichia coli as a complex with LolA, a periplasmic chaperone. The LolA-dependent release of lipoproteins is critical for lipoprotein sorting as it depends on the outer membrane-specific sorting signal. To clarify molecular events involved in the LolA-dependent lipoprotein release, we attempted to establish an in vitro assay system. The major outer membrane lipoprotein (Lpp) was found to lose its release competence soon after being processed to mature Lpp in the inner membrane and therefore could not be used as a substrate for an in vitro system. An Lpp derivative, L10P, was constructed and found to retain the release competence long after its maturation. L10P was synthesized and radiolabeled in spheroplasts in the absence of LolA; therefore, it remained anchored to the inner membrane of spheroplasts. Right-side out membrane vesicles containing L10P were then prepared and used to examine the release of L10P. In addition to LolA, L10P release absolutely required nucleoside triphosphate (NTP). A non-hydrolyzable NTP analogue strongly inhibited the NTP-dependent release. The outer membrane-specific sorting signal was essential for the in vitro release of L10P, Furthermore, L10P released in vitro was specifically incorporated into the outer membrane, These results indicate that the in vitro release of L10P represents an in vivo reaction and requires energy.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	atokuda@hongo.ecc.u-tokyo.ac.jp						ALEXANDER DM, 1994, MOL MICROBIOL, V11, P1059, DOI 10.1111/j.1365-2958.1994.tb00383.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRAUN V, 1975, BIOCHIM BIOPHYS ACTA, V415, P335, DOI 10.1016/0304-4157(75)90013-1; CHOI DS, 1986, J BIOL CHEM, V261, P8953; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; INOUYE M, 1974, P NATL ACAD SCI USA, V71, P2396, DOI 10.1073/pnas.71.6.2396; LEE N, 1977, BIOCHIM BIOPHYS ACTA, V465, P650, DOI 10.1016/0005-2736(77)90280-2; MATSUYAMA S, 1989, J BIOL CHEM, V264, P3583; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; MIZUNO T, 1979, J BIOCHEM-TOKYO, V86, P991, DOI 10.1093/oxfordjournals.jbchem.a132631; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; TOKUDA H, 1994, FEBS LETT, V346, P65, DOI 10.1016/0014-5793(94)00317-3; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Yakushi T, 1997, J BACTERIOL, V179, P2857, DOI 10.1128/jb.179.9.2857-2862.1997; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YU F, 1984, J BIOL CHEM, V259, P6013	23	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32576	32581		10.1074/jbc.273.49.32576	http://dx.doi.org/10.1074/jbc.273.49.32576			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829994	hybrid			2022-12-25	WOS:000077329100033
J	Field, H; Farjah, M; Pal, A; Gull, K; Field, MC				Field, H; Farjah, M; Pal, A; Gull, K; Field, MC			Complexity of trypanosomatid endocytosis pathways revealed by Rab4 and Rab5 isoforms in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; AFRICAN TRYPANOSOMES; TERMINAL DOMAIN; MEMBRANE-FUSION; FAMILY; CELLS; ACTIVATION; MECHANISM; GTPASES; YPT51P	Small G proteins of the Rab family are responsible for vesicle fusion and control nux during intracellular transport. Rab5 is important in endosome maturation and Rab4 in recycling of endocytic material, Three Rab5 isoforms identified so far in mammals and three in the yeast genome suggest that conservation of multiple Rab5 isoforms is required for sophisticated regulation of endocytosis, Trypanosoma brucei homologues of Rab5 and Rab4 (TbRab5A and TbRab4) have been identified. Here we report cloning of a second Rab5 homologue, TbRab5Bp, The TbRAB5A and -5B genes are not linked in the genome, and phylogenetic reconstruction indicates that multiple Rab5 isoforms in yeast, mammals, and trypanosomes evolved independently. Northern blots demonstrate that TbRab5A, -5B, and TbRab4 messages are expressed in bloodstream form (BSF) and procyclic forms of the parasite even though endocytosis is not very active in the latter form. mRNA levels of TbRab5A and -4 are constitutive. Multiple-sized TbRab5B messages at very low abundance are detected, with greater expression in BSF, Also, the TbRab5B mRNA has a large 3'-untranslated region suggestive of potentially complex regulation, and therefore TbRab5Bp may be an important regulator of differential endocytosis levels between BSF and procyclic stage parasites, Affinity purified antibodies raised to C-terminal peptide sequences of all three TbRab proteins recognized small vesicular cytoplasmic structures, which for TbRab5Ap and -5Bp are predominantly near the flagellar pocket. TbRab5Bp colocalizes with invariant surface glycoprotein 100 (ISG(100)), a protein entering the endocytotic pathway in BSF parasites, whereas in procyclic cells populations of vesicles stained with both TbRab5Ap and -5Bp substantially overlap; TbRab5 proteins are therefore components of the endocytotic pathway, TbRab4p localizes to vesicular structures throughout the cytoplasm, with some overlap with TbRab5Bp, but the majority occupying a different compartment to the TbRab5s, Therefore the trypanosome endosomal system has been functionally dissected for the first time; these reagents provide a unique opportunity for manipulation of the protozoan endosomal system to further our understanding of drug uptake mechanisms and virulence.	Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Cell Biol Lab, London SW7 2AY, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Imperial College London; University of Manchester	Field, MC (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biochem, Cell Biol Lab, Exhibit Rd, London SW7 2AY, England.		Field, Mark/AAD-6455-2021	Field, Mark/0000-0002-4866-2885	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; BUCCI C, 1995, GUIDEBOOK SMALL GTPA, P324; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; Duszenko Michael, 1993, V2 (PARTS A AND B), P227; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; Field H, 1997, J BIOL CHEM, V272, P10498, DOI 10.1074/jbc.272.16.10498; FIELD MC, 1995, MOL BIOCHEM PARASIT, V69, P131, DOI 10.1016/0166-6851(94)00209-6; Field MC, 1995, EXP PARASITOL, V81, P313, DOI 10.1006/expr.1995.1122; Hager KM, 1997, NATURE, V385, P823, DOI 10.1038/385823a0; HAJDUK SL, 1994, ANNU REV MICROBIOL, V48, P139, DOI 10.1146/annurev.mi.48.100194.001035; Harlow E., 1988, ANTIBODIES LAB MANUA; Juvet LK, 1997, HEPATOLOGY, V25, P1204, DOI 10.1002/hep.510250524; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazar T, 1997, TRENDS BIOCHEM SCI, V22, P468, DOI 10.1016/S0968-0004(97)01150-X; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Magez S, 1997, J CELL BIOL, V137, P715, DOI 10.1083/jcb.137.3.715; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Nelson W J, 1991, Semin Cell Biol, V2, P375; Nolan DP, 1997, J BIOL CHEM, V272, P29212, DOI 10.1074/jbc.272.46.29212; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Sherwin T, 1993, Methods Mol Biol, V21, P407; Shibata H, 1997, J BIOL CHEM, V272, P14542, DOI 10.1074/jbc.272.23.14542; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; STEELEMORTIMER O, 1994, EMBO J, V13, P34, DOI 10.1002/j.1460-2075.1994.tb06232.x; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; SWAFFORD DL, 1993, PHYLOGENETIC ANAL US; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; Wilson AL, 1996, BIOCHEM J, V318, P1007, DOI 10.1042/bj3181007; ZERIAL M, 1992, METHOD ENZYMOL, V219, P398	43	78	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32102	32110		10.1074/jbc.273.48.32102	http://dx.doi.org/10.1074/jbc.273.48.32102			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822686	hybrid			2022-12-25	WOS:000077207000068
J	de Jong, R; van Wijk, A; Heisterkamp, N; Groffen, J				de Jong, R; van Wijk, A; Heisterkamp, N; Groffen, J			C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells	ONCOGENE			English	Article						C3G; Crkl; integrin; Bcr/Abl p210	CHRONIC MYELOGENOUS LEUKEMIA; SRC HOMOLOGY-3 DOMAIN; PROTOONCOGENE PRODUCT; ADAPTER PROTEIN; SIGNALING PATHWAYS; KINASE PATHWAY; CRK PROTEINS; R-RAS; C-ABL; P130(CAS)	The SH2-SH3 adaptor protein Crkl has been implicated in the signal transduction pathways of several membrane-bound receptors. Tyrosine phosphorylation of proteins associated with such signalling complexes can generate binding sites for the Crkl SH2-domain and can recruit proteins constitutively bound to Crkl via the Crkl SH3 domain into such complexes. In the current study we show that Crkl, but only a minor amount of the related Crk, form constitutive complexes in vivo with guanine nucleotide exchange factor C3G in 3T3 fibroblasts. Adhesion of both normal and transformed cells to fibronectin or other extracellular matrix proteins consistently induces the tyrosine-phosphorylation of C3G. Adhesion-induced tyrosine phosphorylation of C3G is dependent on an intact cytoskeleton and peaks at 5-10 min after attachment. In contrast, 3T3 cells stably transfected with Bcr/Abl P210 show a prominent reduction in the amount of C3G complexed to Crkl and do not exhibit tyrosine-phosphorylation of C3G upon spreading and attachment. These data establish that integrin-mediated cell adhesion results in Crkl-mediated tyrosine phosphorylation of C3G, a pathway which can be disrupted by Bcr/Abl.	Childrens Hosp Los Angeles, Inst Res, Dept Pathol, Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA; USC, Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Groffen, J (corresponding author), Childrens Hosp Los Angeles, Inst Res, Dept Pathol, Sect Mol Carcinogenesis, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R01CA047456, R55CA047456, R01CA050248] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47456, CA 50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; DEJONG R, 1995, ONCOGENE, V11, P1469; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1995, ONCOGENE, V10, P1465; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6476; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; NICHOLS GL, 1994, BLOOD, V84, P2912; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA T, 1994, J BIOL CHEM, V269, P22925; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; TANAKA T, 1994, P NATL ACAD SCI USA, V91, P3433; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	39	30	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2805	2810		10.1038/sj.onc.1202207	http://dx.doi.org/10.1038/sj.onc.1202207			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840945				2022-12-25	WOS:000077146700014
J	Saville, MK; Watson, RJ				Saville, MK; Watson, RJ			The cell-cycle regulated transcription factor B-Myb is phosphorylated by cyclin A/Cdk2 at sites that enhance its transactivation properties	ONCOGENE			English	Article						B-Myb; cyclin A; Cdk2; phosphorylation; transcriptional regulation	GENE V-MYB; C-MYB; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; S-PHASE; HEMATOPOIETIC-CELLS; EXPRESSION; PRODUCT; ACTIVATION; PROLIFERATION	Expression of the B-Myb transcription factor is upregulated during late G(1) phase of the cell cycle by an E2F-dependent transcriptional mechanism. B-Myb is specifically phosphorylated during S phase, suggesting that a cyclin-dependent kinase (Cdk) regulates its activity. Consistent with this notion, the S phase-specific cyclin A/Cdk2 was found previously to enhance B-Myb transactivation activity in cotransfected cells. In this study we provide evidence that B-Myb is a direct physiological target for cyclin A/Cdk2. We demonstrate that B-Myb is an in vitro substrate for cyclin A/Cdk2, but not for cyclin D1/Cdk4 or cyclin E/Cdk2. By mutating candidate Cdk2 phosphorylation sites, we show that B-Myb is phosphorylated at Thr447, Thr490, Thr497 and Ser581 by cyclin A/Cdk2 in vitro and that these sites are also phosphorylated in cycling U-2 OS cells. Inhibition of endogenous Cdk2 by dominant negative Cdk2 attenuated phosphorylation of Thr447, Thr490 and Thr497, but had no effect upon Ser581 modification. B-Myb transactivation activity was significantly reduced in a mutant containing amino acid substitutions at all four identified cyclin A/Cdk2 sites and was constitutively low in Saos-2 cells where endogenous cyclin A/Cdk2 activity was unable to phosphorylate ectopically expressed B-Myb. These data indicate that phosphorylation by cyclin A/Cdk2 is directly involved in enhancing B-Myb transactivation activity and that levels of endogenous cyclin A/Cdk2 activity may contribute to cell line-specific B-Myb function.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, London SW7 2AZ, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Sect Virol & Cell Biol, St Marys Campus, London SW7 2AZ, England.							Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bennett JD, 1996, ONCOGENE, V13, P1073; Bies J, 1996, ONCOGENE, V12, P355; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brandt TL, 1997, J BIOL CHEM, V272, P6278, DOI 10.1074/jbc.272.10.6278; Chang ZF, 1998, J BIOL CHEM, V273, P12095, DOI 10.1074/jbc.273.20.12095; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOOS G, 1993, ONCOGENE, V8, P1775; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Horton LE, 1997, ONCOGENE, V14, P491, DOI 10.1038/sj.onc.1200851; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kamano H, 1995, ONCOGENE, V11, P2575; KATO J, 1983, GENE DEV, V7, P331; KITAGAWA M, 1995, ONCOGENE, V10, P229; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NOMURA N, 1998, NUCLEIC ACIDS RES, V16, P11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PEEPER DS, 1995, ONCOGENE, V10, P39; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Saville MK, 1998, ADV CANCER RES, V72, P109; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TASHIRO S, 1995, ONCOGENE, V10, P1699; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; Zarkowska T, 1997, ONCOGENE, V14, P249, DOI 10.1038/sj.onc.1200824; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	66	71	75	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	1998	17	21					2679	2689		10.1038/sj.onc.1202503	http://dx.doi.org/10.1038/sj.onc.1202503			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840932				2022-12-25	WOS:000077146700001
J	Jing, NJ; Hogan, ME				Jing, NJ; Hogan, ME			Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; NMR-SPECTROSCOPY; DNA APTAMER; IN-VITRO; INHIBITION; ASSIGNMENT; ANALOGS; PROTEIN	Recently, we have described the design and characterization of oligonucleotides containing only G and T bases, i.e. T30695 and T30177, that are potent inhibitors of human immunodeficiency virus type 1 (HIV-1) replication in culture (Jing, N,, Rando, R, F,, Pommier, Y,, and Hogan, M, E, (1997) Biochemistry 36, 12498-12505), To understand that observation and to rationalize the generally high thermal stability of oligonucleotide folding for these compounds, we have used NMR methods, coupled to molecular modeling, to obtain a high resolution structure model for T30695, which is the most potent of the integrase inhibitors that have been identified thus far. Modeling and NMR data obtained in the presence of Li+ ions show that T30695 assumes an intramolecular fold with a distorted G-octet core and a set of three open, partially disordered loops. This is referred to as Li+-form structure. The NMR-based model suggests that, upon coordination with three K+ equivalents, the central G-octet becomes more regular and that the loop domains become orderly and compact. This is referred to as K+-form structure. Based upon the assay of inhibition of HIV-1 integrase, T30695 demonstrated a strong inhibition of HIV-1 integrase activity as the K+-form structure, but a poor inhibition of HIV-1 integrase activity as the Li+-form structure. The structure/activity analysis suggests that the K+-induced conformation transition of the tetrad-forming oligonucleotides, such as T30695 and T30177, plays a key role in inhibition of HIV-1 integrase activity.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Genometrix Inc, The Woodlands, TX 77381 USA	Baylor College of Medicine	Jing, NJ (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.	njing@bcm.tmc.edu; mhogan@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032894] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07676] Funding Source: Medline; NIAID NIH HHS [R01 AI32894] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CUSHMAN M, 1995, J MED CHEM, V38, P443, DOI 10.1021/jm00003a007; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; Feigon J, 1995, METHOD ENZYMOL, V261, P225; Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967; Jing NJ, 1997, BIOCHEMISTRY-US, V36, P12498, DOI 10.1021/bi962798y; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; MAZUMDER A, 1994, P NATL ACAD SCI USA, V91, P5771, DOI 10.1073/pnas.91.13.5771; Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u; Mazumder A, 1996, MOL PHARMACOL, V49, P621; MAZUMDER A, 1995, BIOCHEMISTRY-US, V34, P15111, DOI 10.1021/bi00046a018; MOUSCADET JF, 1994, J BIOL CHEM, V269, P21635; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754; SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105; SKLENAR V, 1986, FEBS LETT, V208, P94, DOI 10.1016/0014-5793(86)81539-3; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P53	21	141	146	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34992	34999		10.1074/jbc.273.52.34992	http://dx.doi.org/10.1074/jbc.273.52.34992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857031	hybrid			2022-12-25	WOS:000077719700049
J	Martasek, P; Miller, RT; Liu, Q; Roman, LJ; Salerno, JC; Migita, CT; Raman, CS; Gross, SS; Ikeda-Saito, M; Masters, BSS				Martasek, P; Miller, RT; Liu, Q; Roman, LJ; Salerno, JC; Migita, CT; Raman, CS; Gross, SS; Ikeda-Saito, M; Masters, BSS			The C331A mutant of neuronal nitric-oxide synthase is defective in arginine binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT DIMERIZATION; OXYGENASE DOMAIN; TETRAHYDROBIOPTERIN; HEME; BRAIN; PURIFICATION; COFACTOR; SITE; IDENTIFICATION; FLAVOPROTEIN	It has been proposed that Cys(99) of human endothelial nitric oxide synthase (eNOS) is responsible for tetrahydrobiopterin (BH,) binding. To examine this possibility rigorously, we expressed rat neuronal NOS (nNOS) in Escherichia coli, with the homologous Cys(331) to Ala mutation, and characterized structural and functional attributes of the purified, mutated enzyme, C331A-nNOS, as isolated, was catalytically incompetent. Upon prolonged incubation with L-arginine (L-Arg), not only BH4 binding but also catalytic activity could be restored. In contrast to wild-type nNOS (WT-nNOS), which exhibits an absorbance maximum at 407 nm that shifts immediately upon L-arginine addition to a high spin form, the C331A-nNOS mutant, as isolated, exhibited an absorbance maximum at 420 nm, C331A-nNOS, as isolated, did not bind detectable levels of either [H-3]N-omega-nitro-L-arginine or [H-3]BH4, but [H-3]BH4 binding was reinstated after extended incubation with excess L-arginine, On the other hand, C331A-nNOS and WT-NOS were identical with regard to imidazole binding affinity, CaM binding affinity, and rates of cytochrome c and 2,6-dichlorophenolindophenol reduction. EPR spectroscopy revealed conversion of low to high spin heme after extended incubation with high concentrations of L-arginine (0.1-10 mM). The estimated K-d for L-arginine binding to C331A-nNOS was two orders of magnitude greater than WT-nNOS (>100 mu M versus 2-3 mu M). Here we propose that Cys(331) plays an important role in stabilizing L-arginine binding to nNOS, Our findings suggest that the primary dysfunction in the C331A mutant of nNOS, as isolated, is disruption of the BH4-substrate binding interactions as broadcast from this mutated cysteine residue. Prolonged incubation with L-arginine appears to cause remodeling of the mutant protein to a form similar to that of WT-nNOS, allowing for normalized BH4 binding and nitric oxide synthetic activity.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Cornell Univ, Coll Med, Dept Pharmacol, New York, NY 10021 USA; Rensselaer Polytech Inst, Dept Biol, Troy, NY 12180 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	University of Texas System; University of Texas Health San Antonio; Cornell University; Rensselaer Polytechnic Institute; Case Western Reserve University	Masters, BSS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA.	masters@uthscsa.edu	salerno, john c/A-2595-2014; Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008; Martasek, Pavel/G-6622-2017	Martasek, Pavel/0000-0001-6165-4444; Raman, C. S./0000-0002-1036-3193	NHLBI NIH HHS [HL30050, HL 50656] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050656, R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; Boyhan A, 1997, BIOCHEM J, V323, P131, DOI 10.1042/bj3230131; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; KIRSCHNER K, 1966, P NATL ACAD SCI USA, V56, P1661, DOI 10.1073/pnas.56.6.1661; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; KWON NS, 1989, J BIOL CHEM, V264, P20496; Masters B, 1967, METHOD ENZYMOL, V10, P565; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P11839, DOI 10.1021/bi953015w; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Wang Y, 1997, J BIOL CHEM, V272, P11392; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	38	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34799	34805		10.1074/jbc.273.52.34799	http://dx.doi.org/10.1074/jbc.273.52.34799			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857005	hybrid			2022-12-25	WOS:000077719700023
J	Oshiro, N; Fukata, Y; Kaibuchi, K				Oshiro, N; Fukata, Y; Kaibuchi, K			Phosphorylation of moesin by Rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SERINE-THREONINE KINASE; ACTIN STRESS FIBERS; FOCAL ADHESIONS; GROWTH-FACTOR; ADP-RIBOSYLATION; PUTATIVE TARGET; TERMINAL DOMAIN; CELL MOTILITY; EZRIN	Rho-associated kinase (Rho-kinase), which is activated by the small GTPase Rho, phosphorylates moesin at Thr(558) in vitro. Here, using a site- and phosphorylation state-specific antibody, we found that the expression of dominant active RhoA in COS7 cells induced moesin phosphorylation and the formation of microvilli-like structures at apical membranes where the Thr(558)-phosphorylated moesin accumulated, whereas the expression of dominant negative Rho-kinase inhibited both of these processes. The expression of dominant active Rho-kinase also induced moesin phosphorylation. When COS7 cells expressing moesin or moesin(T558A) (substitution of Thr by Ala) were cultured under serum-depleted conditions, there were few microvilli-like structures, whereas microvilli-like structures remained in the cells expressing moesin(T558D) (substitution of Thr by Asp). The expression of moesinT558A inhibited the dominant active RhoA-induced formation of microvilli-like structures. These results indicate that Rho-kinase regulates moesin phosphorylation downstream of Rho in vivo and that the phosphorylation of moesin by Rho-kinase plays a crucial role in the formation of microvilli-like structures.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan	Nara Institute of Science & Technology	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, 8916-5 Takayama, Ikoma 6300101, Japan.			Fukata, Yuko/0000-0001-7724-8643				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1997, J CELL SCI, V110, P3011; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Inagaki M, 1997, J BIOCHEM, V121, P407; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kureishi Y, 1997, J BIOL CHEM, V272, P12257, DOI 10.1074/jbc.272.19.12257; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura F, 1996, BIOCHEM BIOPH RES CO, V226, P650, DOI 10.1006/bbrc.1996.1410; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKAISHI K, 1995, ONCOGENE, V11, P39; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044	45	189	198	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34663	34666		10.1074/jbc.273.52.34663	http://dx.doi.org/10.1074/jbc.273.52.34663			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856983	hybrid			2022-12-25	WOS:000077719700001
J	Aman, MJ; Lamkin, TD; Okada, H; Kurosaki, T; Ravichandran, KS				Aman, MJ; Lamkin, TD; Okada, H; Kurosaki, T; Ravichandran, KS			The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; FC-RECEPTORS; SIGNAL-TRANSDUCTION; AKT PROTOONCOGENE; INDUCED APOPTOSIS; PATHWAYS; INSULIN; PHOSPHORYLATION	The serine-threonine kinase Akt/PKB is activated downstream of phosphatidylinositol 3-kinase in response to several growth factor stimuli and has been implicated in the promotion of cell survival. Although both phosphatidylinositol 3,4,5-trisphosphate (PIP3) and phosphatidylinositol 3,4-bisphosphate (PI 3,4-P-2) have been implicated in the regulation of Akt activity in vitro, the relative roles of these two phospholipids in vivo are not well understood. Co-ligation of the B cell receptor (BCR) and the inhibitory F(c)gamma RIIB1 on B cells results in the recruitment of the 5'-inositol phosphatase SHIP to the signaling complex. Since SHIP is known to cleave PIP3 to generate PI 3,4-P-2 both in vivo and in vitro, and Akt activity has been reported to be regulated by either PIP3 or PI3,4-P-2, we hypothesized that recruitment of SHIP through F(c)gamma RIIB1 co-cross-linking to the BCR in B cells might regulate Akt activity. The nature of this regulation, positive or negative, might also reveal the relative contribution of PIP3 and PI 3,4-P-2 to Akt activation in vivo. Here we report that Akt is activated by stimulation through the BCR in a phosphatidylinositol 3-kinase-dependent manner and that this activation is inhibited by co-cross-linking of the ECR to F(c)gamma RIIB1. Using mutants of F(c)gamma RIIB1 and SHIP-deficient B cells, we demonstrate that inhibition of Akt activity is mediated by the immune cell tyrosine-based inhibitory motif within F(c)gamma RIIB1 as well as SHIP. The SHIP-dependent inhibition of Akt activation also suggests that PIP3 plays a greater role in Akt activation than PI 3,4-P-2) in vivo.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Kansai Med Univ, Dept Mol Genet, Moriguchi, Osaka 570, Japan	University of Virginia; University of Virginia; Kansai Medical University	Ravichandran, KS (corresponding author), Univ Virginia, Beirne Carter Ctr Immunol Res, MR-4,Rm 4012F, Charlottesville, VA 22908 USA.		Okada, Hidetaka/AAP-7775-2020; okada, hidetaka/C-6990-2011; Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X	NIAID NIH HHS [AI43425] Funding Source: Medline; NIGMS NIH HHS [GM55761] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055761] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ashman RF, 1996, J IMMUNOL, V157, P5; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Beckwith M, 1996, BLOOD, V87, P202; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kiener PA, 1997, J BIOL CHEM, V272, P3838, DOI 10.1074/jbc.272.6.3838; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MUTA T, 1994, NATURE, V369, P340, DOI 10.1038/369340a0; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ravetch JV, 1997, CURR OPIN IMMUNOL, V9, P121, DOI 10.1016/S0952-7915(97)80168-9; Scharenberg AM, 1996, CELL, V87, P961, DOI 10.1016/S0092-8674(00)81790-0; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Yamashita Y, 1996, J EXP MED, V184, P113, DOI 10.1084/jem.184.1.113	45	165	170	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33922	33928		10.1074/jbc.273.51.33922	http://dx.doi.org/10.1074/jbc.273.51.33922			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852043	hybrid			2022-12-25	WOS:000077542200009
J	Parker, SK; Detrich, HW				Parker, SK; Detrich, HW			Evolution, organization, and expression of alpha-tubulin genes in the Antarctic fish Notothenia coriiceps - Adaptive expansion of a gene family by recent gene duplication, inversion, and divergence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; BETA-TUBULIN; MESSENGER-RNA; UBIQUITOUS TRANSCRIPTION; DROSOPHILA-MELANOGASTER; SEQUENCE HETEROGENEITY; ALPHA-1-TUBULIN GENE; TRYPANOSOMA-BRUCEI; TEMPERATE FISH	To assess the organization and expression of tubulin genes in ectothermic vertebrates, we have chosen the Antarctic yellowbelly rockcod, Notothenia coriiceps,as a model system. The genome of N. coriiceps contains similar to 15 distinct DNA fragments complementary to alpha-tubulin cDNA probes, which suggests that the alpha-tubulins of this cold-adapted fish are encoded by a substantial multigene family. From an N. coriiceps testicular DNA library, we isolated a 13.8-kilobase pair genomic clone that contains a tightly linked cluster of three cr-tubulin genes, designated NeGTb alpha a, NcGTb alpha b, and NcGTb alpha c. Two of these genes, NcGTb alpha a and NcGTb alpha b, are linked in head-to-head (5' to 5') orientation with similar to 500 bp separating their start codons, whereas NcGTb alpha a and NcGTb alpha c are linked tail-to-tail (3' to 3') with similar to 2.5 kilobase pairs between their stop codons. The exons, introns, and untranslated regions of the three alpha-tubulin genes are strikingly similar in sequence, and the intergenic region between the alpha a and ab genes is significantly palindromic. Thus, this cluster probably evolved by duplication, inversion, and divergence of a common ancestral alpha-tubulin gene. Expression of the NcGTb alpha c gene is cosmopolitan, with its mRNA most abundant in hematopoietic, neural, and testicular tissues, whereas NcGTb alpha a and NcGTb alpha b transcripts accumulate primarily in brain. The differential expression of the three genes is consistent with distinct suites of putative promoter and enhancer elements. We propose that cold adaptation of the microtubule system of Antarctic fishes is based in part on expansion of the alpha- and beta-tubulin gene families to ensure efficient synthesis of tubulin polypeptides.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Northeastern University	Detrich, HW (corresponding author), Northeastern Univ, Dept Biol, 414 Mugar Hall,360 Huntington Ave, Boston, MA 02115 USA.	iceman@neu.edu						ALEXANDRAKI D, 1981, MOL CELL BIOL, V1, P1125, DOI 10.1128/MCB.1.12.1125; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALTIMORE D, 1981, CELL, V24, P592, DOI 10.1016/0092-8674(81)90082-9; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRUHAT A, 1990, NUCLEIC ACIDS RES, V18, P2861, DOI 10.1093/nar/18.10.2861; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUTTGEREIT D, 1993, J CELL SCI, V105, P721; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEVELAND DW, 1981, J BIOL CHEM, V256, P3130; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CLEVELAND DW, 1998, TRENDS BIOCHEM SCI, V13, P339; DAYHOFF MO, 1979, ATLAS PROTEIN SEQUEN; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; Detrich HW, 1997, COMP BIOCHEM PHYS A, V118, P501, DOI 10.1016/S0300-9629(97)00012-1; DETRICH HW, 1986, J BIOL CHEM, V261, P922; DETRICH HW, 1987, J BIOL CHEM, V262, P8360; DETRICH HW, 1993, CELL MOTIL CYTOSKEL, V24, P156, DOI 10.1002/cm.970240303; DETRICH HW, 1990, CELL MOTIL CYTOSKEL, V17, P174, DOI 10.1002/cm.970170305; DETRICH HW, 1989, BIOCHEMISTRY-US, V28, P10085, DOI 10.1021/bi00452a031; DeWitt HH., 1971, Antarctic map folio series Am Geographical Soc, VNo. 15, P1; di Prisco Guido, 1998, P339; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Eastman J. T, 1993, ANTARCTIC FISH BIOL; FAGO A, 1992, EUR J BIOCHEM, V210, P963, DOI 10.1111/j.1432-1033.1992.tb17501.x; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASCH A, 1989, P NATL ACAD SCI USA, V86, P3215, DOI 10.1073/pnas.86.9.3215; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GRAHAM GJ, 1995, J THEOR BIOL, V175, P71, DOI 10.1006/jtbi.1995.0122; GREENE JJ, 1988, CURRENT PROTOCOLS MO; HAIR A, 1993, MOL CELL BIOL, V13, P7925, DOI 10.1128/MCB.13.12.7925; HAWKINS JD, 1996, GENE STRUCTURE EXPRE; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HINZ U, 1992, DEVELOPMENT, V116, P543; HUANG PL, 1984, MOL CELL BIOL, V4, P1372, DOI 10.1128/MCB.4.7.1372; HUDSON AP, 1980, EUR J BIOCHEM, V112, P203, DOI 10.1111/j.1432-1033.1980.tb07195.x; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; JOHNSTON IA, 1977, J COMP PHYSIOL, V119, P195, DOI 10.1007/BF00686565; KENNETT JP, 1977, J GEOPHYS RES-OC ATM, V82, P3843, DOI 10.1029/JC082i027p03843; KIMMEL BE, 1985, GENE, V35, P237, DOI 10.1016/0378-1119(85)90002-2; Kohler J, 1996, NUCLEIC ACIDS RES, V24, P2543, DOI 10.1093/nar/24.13.2543; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LANDFEAR SM, 1983, MOL CELL BIOL, V3, P1070, DOI 10.1128/MCB.3.6.1070; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; LOENEN WAM, 1983, GENE, V26, P171, DOI 10.1016/0378-1119(83)90187-7; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MARTIN AP, 1992, NATURE, V357, P153, DOI 10.1038/357153a0; McInerney JO, 1996, MOL MAR BIOL BIOTECH, V5, P344; MICHIELS F, 1991, NUCLEIC ACIDS RES, V19, P4515, DOI 10.1093/nar/19.16.4515; MIDDLETON KM, 1989, NUCLEIC ACIDS RES, V17, P5041, DOI 10.1093/nar/17.13.5041; MORESCALCHI A, 1997, P 3 M ANT BIOL, P365; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Murphy DB, 1991, CURR OPIN CELL BIOL, V3, P43, DOI 10.1016/0955-0674(91)90164-T; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; ODENWALD WF, 1989, GENE DEV, V3, P158, DOI 10.1101/gad.3.2.158; ODONNELL KH, 1994, MOL CELL BIOL, V14, P6398, DOI 10.1128/MCB.14.9.6398; ODONNELL KH, 1994, NUCLEIC ACIDS RES, V22, P4712, DOI 10.1093/nar/22.22.4712; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; PARKER SK, 1996, MOL BIOL CELL, V75, pA45; PRATT LF, 1988, EMBO J, V7, P931, DOI 10.1002/j.1460-2075.1988.tb02898.x; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Serrano N, 1997, DEVELOPMENT, V124, P2527; SILFLOW CD, 1985, MOL CELL BIOL, V5, P2389, DOI 10.1128/MCB.5.9.2389; Small DJ, 1998, J MOL EVOL, V47, P156, DOI 10.1007/PL00006372; SMITH MAK, 1980, PHYSIOL ZOOL, V53, P373, DOI 10.1086/physzool.53.4.30157875; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Spruell P, 1996, HEREDITY, V76, P317, DOI 10.1038/hdy.1996.49; SULLIVAN KF, 1986, J BIOL CHEM, V261, P3317; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; SWEZEY RR, 1982, BIOCHEMISTRY-US, V21, P4496, DOI 10.1021/bi00261a047; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TRIEZENBERG SJ, 1995, CURRENT PROTOCOLS MO; WILLIAMS RC, 1985, BIOCHEMISTRY-US, V24, P2790, DOI 10.1021/bi00332a029; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; Zhao YQ, 1998, J BIOL CHEM, V273, P14745, DOI 10.1074/jbc.273.24.14745	85	24	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34358	34369		10.1074/jbc.273.51.34358	http://dx.doi.org/10.1074/jbc.273.51.34358			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852102	hybrid			2022-12-25	WOS:000077542200068
J	Rhee, JM; Gruber, CA; Brodie, TB; Trieu, M; Turner, EE				Rhee, JM; Gruber, CA; Brodie, TB; Trieu, M; Turner, EE			Highly cooperative homodimerization is a conserved property of neural POU proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; MIDLINE GLIA; EXPRESSION; OCT-1; GENE; FLEXIBILITY; RECOGNITION; SPECIFICITY	POU-domain proteins have been shown to play important roles in the development of the nervous, endocrine, and immune systems. However, the distinctive DNA recognition properties of the six major POU subclasses have not been well defined. Here, we have used random oligonucleotide selection and competitive binding assays to determine the optimal DNA recognition elements for the POU-III and POU-VI protein classes, represented by Brn-2 and Brn-5, respectively. The optimal Brn-5 consensus binding sequence GCATAA(T/A)TTAT strongly resembles that previously determined for the POU-IV (Brn-3) class, whereas Brn-2 exhibits highest affinity for non-octamer sites of the form ATG(A/C)AT(A/T)(0-2) ATTNAT and for octamer sites that contain a full associated heptamer sequence. Brn-2, Brn-3.0, and their invertebrate homologues all. exhibit highly cooperative homodimerization on the Brn-2 consensus sequence, demonstrating that cooperative dimerization is a general property of these neural POU proteins. However, modified sites to which Brn-2 binds only as a monomer mediate the transcriptional effects of Brn-2 better than the consensus sequence, demonstrating that dimerization on these sites diminishes the transactivation ability of the protein, Together with the findings of our prior studies these data greatly facilitate the identification of functional POU recognition elements in the regulatory regions of neural genes.	Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Program Neurosci, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Turner, EE (corresponding author), Univ Calif San Diego, Dept Psychiat, 0603,9500 Gilman Dr, La Jolla, CA 92093 USA.	eturner@ucsd.edu	Turner, Eric e/K-3556-2015	Turner, Eric e/0000-0001-5499-6788	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH058447] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33442] Funding Source: Medline; NIMH NIH HHS [MH01581, MH58447] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALVAREZBOLADO G, 1995, J COMP NEUROL, V355, P237, DOI 10.1002/cne.903550207; ANDERSEN B, 1993, J BIOL CHEM, V268, P23390; ANDERSON MG, 1995, GENE DEV, V9, P123, DOI 10.1101/gad.9.1.123; ANGUS J, 1995, ONCOGENE, V11, P691; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BENDALL AJ, 1993, EUR J BIOCHEM, V217, P799, DOI 10.1111/j.1432-1033.1993.tb18308.x; BULLEIT RF, 1994, J NEUROSCI, V14, P1584, DOI 10.1523/JNEUROSCI.14-03-01584.1994; Certel K, 1996, MOL CELL BIOL, V16, P1813; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FRANTZ GD, 1994, J NEUROSCI, V14, P472; Gruber CA, 1997, MOL CELL BIOL, V17, P2391, DOI 10.1128/MCB.17.5.2391; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; Klemm JD, 1996, GENE DEV, V10, P27, DOI 10.1101/gad.10.1.27; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Malik KF, 1996, MOL BRAIN RES, V38, P209, DOI 10.1016/0169-328X(95)00308-F; OKAMOTO K, 1993, J BIOL CHEM, V268, P7449; POELLINGER L, 1989, MOL CELL BIOL, V9, P747, DOI 10.1128/MCB.9.2.747; POMERANTZ JL, 1994, BIOCHEMISTRY-US, V33, P10851, DOI 10.1021/bi00202a001; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SIVARAJA M, 1994, BIOCHEMISTRY-US, V33, P9845, DOI 10.1021/bi00199a005; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; Turner EE, 1996, P NATL ACAD SCI USA, V93, P15097, DOI 10.1073/pnas.93.26.15097; vanLeeuwen HC, 1997, EMBO J, V16, P2043, DOI 10.1093/emboj/16.8.2043; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	31	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34196	34205		10.1074/jbc.273.51.34196	http://dx.doi.org/10.1074/jbc.273.51.34196			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852081	hybrid			2022-12-25	WOS:000077542200047
J	Tesco, G; Kim, TW; Diehlmann, A; Beyreuther, K; Tanzi, RE				Tesco, G; Kim, TW; Diehlmann, A; Beyreuther, K; Tanzi, RE			Abrogation of the presenilin 1 beta-catenin interaction and preservation of the heterodimeric presenilin 1 complex following caspase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; CAENORHABDITIS-ELEGANS; PROTEOLYTIC CLEAVAGE; APOPTOSIS; BRAIN; ENDOPROTEOLYSIS; PROTEIN; CELLS; OCCUR	beta-Catenin has previously been shown to interact with presenilin 1 (PS1) in transfected cells. Here we report that beta-catenin co-immunoprecipitates with the endogenous C-terminal fragment of presenilin 1 (PS1-CTF) but not with the endogenous CTF of presenilin 2 (PS2-CTF) in H4 human neuroglioma cells. During staurosporine (STS)-induced cell death, beta-catenin and PS1-CTF undergo a caspase-mediated cleavage. After 12 h of STS treatment, the beta-catenin PS1-CTF interaction is abrogated. While PS1-CTF immunoprecipitated with all caspase-cleaved species of beta-catenin, beta-catenin holoprotein did not co-immunoprecipitate with the "alternative" caspase-derived PS1-CTF (PS1-aCTF). Thus, the abrogation of the beta-catenin PS1-CTF complex was due to caspase cleavage of PS1-CTF. beta-Catenin co-immunoprecipitated with PS1-NTF, but only when PS1-NTF was associated with PS1-CTF, Even though PS1-NTF CTF complex stability was not altered by caspase cleavage, its ability to bind beta-catenin was abolished, Thus, while the PS1-NTF CTF complex is preserved after caspase cleavage, it may no longer be fully functional.	Massachusetts Gen Hosp, Genet & Aging Unit, Charlestown, MA 02129 USA; Harvard Med Sch, Charlestown, MA 02129 USA; Zentrum Mol Biol, INF 282, D-69120 Heidelberg, Germany	Harvard University; Massachusetts General Hospital; Ruprecht Karls University Heidelberg	Tanzi, RE (corresponding author), Massachusetts Gen Hosp E, Dept Neurol, Genet & Aging Unit, 149 13th St, Charlestown, MA 02129 USA.	tanzi@helix.mgh.harvard.edu	Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454				Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Kim TW, 1997, CURR OPIN NEUROBIOL, V7, P683, DOI 10.1016/S0959-4388(97)80089-X; Kim TW, 1997, J BIOL CHEM, V272, P11006; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; TANZI RE, 1998, SCI AM MOL NEUROLOGY, P55; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	26	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33909	33914		10.1074/jbc.273.51.33909	http://dx.doi.org/10.1074/jbc.273.51.33909			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852041	hybrid			2022-12-25	WOS:000077542200007
J	Vazquez, G; de Boland, AR; Boland, RL				Vazquez, G; de Boland, AR; Boland, RL			1 alpha,25-dihydroxy-vitamin-D-3-induced store-operated Ca2+ influx in skeletal muscle cells - Modulation by phospholipase C, protein kinase C, and tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; SENSITIVE G-PROTEIN; CHICK MYOBLASTS; PLASMA-MEMBRANE; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL-TRANSDUCTION; CULTURED MYOBLASTS; DROSOPHILA TRP; HUMAN HOMOLOG; VITAMIN-D	In skeletal muscle cells the steroid hormone 1 alpha,25-dihydroxy-vitamin-D-3 (1,25(OH)(2)D-3) nongenomically promotes Ca2+ release from intracellular stores and cation influx through both L-type and store-operated Ca2+ (SOC) channels. In the present work we evaluated the regulation and kinetics of the 1,25(OH)(2)D-3-stimulated SOC influx in chick muscle cells, Stimulation with 10(-9) M 1,25(OH)(2)D-3 in Ca2+-free medium resulted in a rapid (40-60 s) but transient [Ca2+](i) rise, which correlated with sterol-dependent inositol 1,4,5-trisphosphate production. The SOC influx stimulated by the hormone was insensitive to both L-type channel antagonists and polyphosphoinositide-specific phospholipase C (PPI-PLC) inhibitors but was fully inhibitable by La3+ and Ni2+. PPI-PLC blockade prior to 1,25(OH)(2)D-3 stimulation suppressed both the [Ca2+](i) transient and the SOC influx. 1,25(OH)(2)D-3-induced SOC entry was markedly increased after 3 min of treatment (30% above basal) and then rapidly reached a steady-state level, The sterol-stimulated SOC influx was prevented by protein kinase C and tyrosine kinase inhibitors but unaffected by blockade of the protein kinase A pathway. None of these inhibitors altered the thapsigargin-induced SOC entry, suggesting the operation of a signaling mechanism different from that for sterol-dependent SOC influx, The present results indicate that 1,25(OH)(2)D-3-induced activation of PPI-PLC is upstream to Ca2+ influx through SOC channels and point for a role of both protein kinase C and tyrosine kinases but; not protein kinase A in the regulation of the sterol-dependent SOCE pathway.	Univ Nacl Sur, Dept Biol Bioquim & Farm, RA-8000 Bahia Blanca, Buenos Aires, Argentina	National University of the South	Boland, RL (corresponding author), Univ Nacl Sur, Dept Biol Bioquim & Farm, San Juan 670, RA-8000 Bahia Blanca, Buenos Aires, Argentina.	rboland@criba.edu.ar						ALTER CA, 1994, LIFE SCI, V54, P107; BERS D, 1994, METHOD CELL BIOL, P21; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BERVEN LA, 1995, BIOCHEM PHARMACOL, V49, P1373, DOI 10.1016/0006-2952(95)00050-A; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BLACKMORE PF, 1993, CELL SIGNAL, V5, P521; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; BOLAND R, 1995, MOL CELL ENDOCRINOL, V114, P1, DOI 10.1016/0303-7207(95)03650-V; BOLAND R, 1986, ENDOCR REV, V7, P434, DOI 10.1210/edrv-7-4-434; BREDT DS, 1989, BIOCHEM BIOPH RES CO, V159, P976, DOI 10.1016/0006-291X(89)92204-3; DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898-6568(94)00042-5; DEBOLAND AR, 1994, J BIOL CHEM, V269, P8675; DEBOLAND AR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P98, DOI 10.1016/0167-4889(93)90076-2; DEBOLAND AR, 1995, BBA-LIPID LIPID MET, V1257, P274, DOI 10.1016/0005-2760(95)00083-O; Densmore JJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1494, DOI 10.1152/ajpcell.1996.271.5.C1494; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; GAMETCHU B, 1993, FASEB J, V7, P1283, DOI 10.1096/fasebj.7.13.8405814; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HARRISON SM, 1987, BIOCHIM BIOPHYS ACTA, V925, P133, DOI 10.1016/0304-4165(87)90102-4; IANNONE MA, 1989, J BIOL CHEM, V264, P20177; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V548, P1989; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; Lee H, 1997, J BIOL CHEM, V272, P21831, DOI 10.1074/jbc.272.35.21831; LEE KM, 1993, J BIOL CHEM, V268, P9945; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; LIU YO, 1994, BIOCHEM PHARMACOL, V48, P1265; LLOPIS J, 1992, BIOCHEM J, V284, P243, DOI 10.1042/bj2840243; Lundgren T, 1997, CALCIFIED TISSUE INT, V60, P79, DOI 10.1007/s002239900189; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; Miura Y, 1997, J PHYSIOL-LONDON, V503, P387, DOI 10.1111/j.1469-7793.1997.387bh.x; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; Morelli S, 1996, MOL CELL ENDOCRINOL, V122, P207, DOI 10.1016/0303-7207(96)03886-5; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Preuss KD, 1997, BIOCHEM BIOPH RES CO, V240, P167, DOI 10.1006/bbrc.1997.7528; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; Snedecor G.W., 1967, STAT METHODS; Suh BC, 1996, J BIOL CHEM, V271, P32753, DOI 10.1074/jbc.271.51.32753; TEPEL M, 1994, J BIOL CHEM, V269, P26239; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VAZQUEZ G, 1993, BIOCHEM MOL BIOL INT, V31, P677; VAZQUEZ G, 1995, BBA-MOL CELL RES, V1269, P91, DOI 10.1016/0167-4889(95)00097-C; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V234, P125, DOI 10.1006/bbrc.1997.6590; Vazquez G, 1996, BBA-MOL CELL RES, V1310, P157, DOI 10.1016/0167-4889(95)00158-1; Vazquez G, 1997, BIOCHEM BIOPH RES CO, V239, P562, DOI 10.1006/bbrc.1997.7501; VILLALOBOS C, 1995, PFLUG ARCH EUR J PHY, V430, P923, DOI 10.1007/BF01837406; VILLAMEYTIDE MLT, 1993, REV ESPANOLA ENFERME, V2, P18; WELSHONS WV, 1993, MOL CELL ENDOCRINOL, V94, P183, DOI 10.1016/0303-7207(93)90167-I; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; XU X, 1995, J BIOL CHEM, V270, P29169, DOI 10.1074/jbc.270.49.29169; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	57	59	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33954	33960		10.1074/jbc.273.51.33954	http://dx.doi.org/10.1074/jbc.273.51.33954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852048	hybrid			2022-12-25	WOS:000077542200014
J	Zhang, L; Yu, LD; Yu, CA				Zhang, L; Yu, LD; Yu, CA			Generation of superoxide anion by succinate-cytochrome c reductase from bovine heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; ENERGY TRANSDUCTION; ELECTRON-TRANSFER; B-C1 COMPLEX; RECONSTITUTION; UBIQUINONE; RADICALS; VESICLES	Production of superoxide anion (O-2(radical anion), measured as the chemiluminescence of the 2-methyl-6-(p-methoxyphenyl)-3,7-dihydroimidazo[ 1,2-a]pyrazin-3-one hydrochloride (MCLA)-O-2(radical anion) adduct, was observed during electron transfer from succinate to cytochrome c by reconstituted succinate-cytochrome c reductase-phospholipid vesicles replenished with succinate dehydrogenase, Addition of carbonyl cyanide-p-trifluoromethoxyphenylhydrazone or detergent to the reconstituted reductase-phospholipid vesicles abolished O-2(radical anion) production, suggesting that O-2(radical anion) generation is caused by the membrane potential generated during electron transfer through the cytochrome bc(1) complex. Production of O-2(radical anion) was also observed during electron transfer from succinate to cytochrome c by antimycin-treated reductase, in which similar to 99.7% of the reductase activity was inhibited. The rate of O-2(radical anion) production was closely related to the rate of antimycin-insensitive cytochrome c reduction. Factors affecting antimycin-insensitive reduction of cytochrome c also affected O-2(radical anion) production and vice versa. When the oxygen concentration in the system was decreased, the rate of O-2(radical anion) production and cytochrome c reduction by antimycin-treated reductase decreased. When the concentrations of MCLA and cytochrome c were increased, the rate of O-2(radical anion) production and cytochrome c reduction by antimycin-treated reductase increased. The rate of antimycin-insensitive cytochrome c reduction was sensitive to Q(o) site inhibitors such as 5-undecyl-6-hydroxy-4,7-dioxobenzothiazole, These results indicate that generation of O-2(radical anion) during the oxidation of ubiquinol by the cytochrome be, complex results from a leakage of the second electron of ubiquinol from its Q cycle electron transfer pathway to interact with oxygen. The electron-leaking site is located at the reduced cytochrome b(566) or ubisemiquinone of the Q(o) site because addition of MCLA to antimycin-treated cytochrome be, complex, in the presence of catalytic amounts of succinate-cytochrome c reductase, delayed cytochrome b reduction by succinate, In the presence of oxidized cytochrome c, purified succinate dehydrogenase also catalyzed oxidation of succinate to generate O-2(radical anion). When succinate dehydrogenase was reconstituted with the be, particles to form succinate-cytochrome c reductase, the production of O-2(radical anion) diminished. These results suggest that reduced FAD of succinate dehydrogenase is the electron donor for oxygen to produce O-2(radical anion) in the absence of their immediate electron acceptor and in the presence of cytochrome c.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.				NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030721, R01GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATTIE DS, 1982, J BIOL CHEM, V257, P4745; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; LOSCHEN G, 1973, FEBS LETT, V33, P84, DOI 10.1016/0014-5793(73)80165-6; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NAKANO M, 1990, METHOD ENZYMOL, V186, P585; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; NOHL H, 1978, BIOCHEM J, V134, P707; SONE N, 1977, J BIOCHEM-TOKYO, V81, P519, DOI 10.1093/oxfordjournals.jbchem.a131485; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YU C, 1980, BIOCHIM BIOPHYS ACTA, V591, P409, DOI 10.1016/0005-2728(80)90172-3; YU CA, 1974, J BIOL CHEM, V249, P4905; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137	22	210	219	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33972	33976		10.1074/jbc.273.51.33972	http://dx.doi.org/10.1074/jbc.273.51.33972			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852050	hybrid			2022-12-25	WOS:000077542200016
J	Artigues, A; Crawford, DL; Iriarte, A; Martinez-Carrion, M				Artigues, A; Crawford, DL; Iriarte, A; Martinez-Carrion, M			Divergent Hsc70 binding properties of mitochondrial and cytosolic aspartate aminotransferase - Implications for their segregation to different cellular compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP70 MOLECULAR CHAPERONES; STRUCTURAL FEATURES; PRECURSOR PROTEIN; STRESS PROTEINS; IMPORT; SPECIFICITY; PEPTIDES; KINETICS; SITES; DNAK	Cytosolic Hsc70 discriminates between the homologous mitochondrial and cytosolic isozymes of aspartate aminotransferase, binding exclusively the mitochondrial form. By screening a library of synthetic peptides spanning the sequence of the mitochondrial enzyme, we have identified binding sites in this polypeptide that interact with Hsc70. These potential binding sites are scattered over the entire sequence and map to secondary structure elements, particularly the alpha-helix, that are partly exposed on the surface of the native protein. Several peptides corresponding to analogous positions in the cytosolic enzyme sequence do not bind to Hsc70. Phylogenetic analyses suggest that Hsc70 binding sequences have diverged as a consequence of biochemical specialization ensuring differential interaction of each isozyme with the cellular machinery in charge of protein folding and translocation.	Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Martinez-Carrion, M (corresponding author), Univ Missouri, Sch Biol Sci, Div Biochem & Mol Biol, 5007 Rockhill Rd, Kansas City, MO 64110 USA.	mshoemaker@cctr.umkc.edu		Crawford, Douglas/0000-0002-6239-4012	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038412] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038341] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38412] Funding Source: Medline; NIGMS NIH HHS [GM-38341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI F, 1989, J BIOL CHEM, V264, P4782; Artigues A, 1997, J BIOL CHEM, V272, P16852, DOI 10.1074/jbc.272.27.16852; Artigues A, 1997, TECH PROT CHEM, V8, P481, DOI 10.1016/S1080-8914(97)80048-8; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Endo T, 1996, J BIOL CHEM, V271, P4161; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; Gething MJ, 1995, COLD SPRING HARB SYM, V60, P417, DOI 10.1101/SQB.1995.060.01.046; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5431; JANSONIUS JN, 1987, BIOL MACROMOL, V3, P87; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LEACH FR, 1986, METHOD ENZYMOL, V133, P51; MARTINEZCARRION M, 1967, J BIOL CHEM, V242, P2397; MATTINGLY JR, 1987, BIOCHEM BIOPH RES CO, V149, P859, DOI 10.1016/0006-291X(87)90487-6; MATTINGLY JR, 1993, J BIOL CHEM, V268, P26320; MCKAY DB, 1993, ADV PROTEIN CHEM, V44, P67, DOI 10.1016/S0065-3233(08)60564-1; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; Nagata H, 1998, BIOCHEMISTRY-US, V37, P6924, DOI 10.1021/bi980164g; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SONDEREGGER P, 1977, J BIOL CHEM, V252, P609; Swofford D.L., 1989, PAUP PHYLOGENETIC AN; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; TERADA K, 1995, MOL CELL BIOL, V15, P3708; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	45	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33130	33134		10.1074/jbc.273.50.33130	http://dx.doi.org/10.1074/jbc.273.50.33130			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837879	hybrid			2022-12-25	WOS:000077462500009
J	Lener, D; Tanchou, V; Roques, BP; Le Grice, SFJ; Darlix, JL				Lener, D; Tanchou, V; Roques, BP; Le Grice, SFJ; Darlix, JL			Involvement of HIV-1 nucleocapsid protein in the recruitment of reverse transcriptase into nucleoprotein complexes formed in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROVIRAL DNA-SYNTHESIS; AMINO-ACID-RESIDUES; PRIMER TRANSFER-RNA; STRAND TRANSFER; IN-VITRO; ANNEALING ACTIVITIES; ZINC-FINGER; H ACTIVITY; BINDING	Retroviral reverse transcription takes place within the virion core, where nucleocapsid (NC) protein (NCp) molecules cover the dimeric RNA genome. NCp thus has structural roles in the virion core but is also extensively involved in viral DNA synthesis and virion assembly. To further characterize the role of human immunodeficiency virus type 1 NCp7 during replication of the viral genome, we investigated the relationship between NCp7 and reverse transcriptase (RT) either directly or within nucleoprotein complexes in vitro. We show that NCp7 interacts directly with RT and enhances synthesis of full-length cDNA by increasing RT processivity. Using NCp7 mutants, we show that the complete amino acid sequence of NCp7 is required for functional interactions with RT. Our results suggest that NCp7 plays a role in recruitment of RT into stable and functional nucleoprotein complexes during viral DNA synthesis.	Ecole Normale Super Lyon, LaboRetro, Unite Virol Humaine, INSERM 412, F-69364 Lyon 07, France; Univ Paris 05, Mol Pharmacol Lab, INSERM, U266,Unite Enseignement Rech Sci Pharmaceut & Bio, F-75005 Paris, France; Case Western Reserve Univ, Sch Med, Div Infect Dis, Cleveland, OH 44106 USA	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Case Western Reserve University	Darlix, JL (corresponding author), Ecole Normale Super Lyon, LaboRetro, Unite Virol Humaine, INSERM 412, 46 Allee Italie, F-69364 Lyon 07, France.		LUC, DARLIX JEAN/AAE-9268-2020	Lener, Daniela/0000-0001-8266-8810	NIGMS NIH HHS [GM 52263] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052263] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; BARAT C, 1993, J MOL BIOL, V231, P185, DOI 10.1006/jmbi.1993.1273; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Berthoux L, 1997, J VIROL, V71, P6973, DOI 10.1128/JVI.71.9.6973-6981.1997; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; CHEN MJ, 1980, P NATL ACAD SCI-BIOL, V77, P1296, DOI 10.1073/pnas.77.3.1296; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DARLIX JL, 1982, J MOL BIOL, V160, P147, DOI 10.1016/0022-2836(82)90172-3; DEROCQUIGNY H, 1993, NUCLEIC ACIDS RES, V21, P823; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; Poon DTK, 1996, J VIROL, V70, P6607, DOI 10.1128/JVI.70.10.6607-6616.1996; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Swanstrom R., 1997, P263; TANCHOU V, 1994, AIDS RES HUM RETROV, V10, P983, DOI 10.1089/aid.1994.10.983; Tanchou V, 1998, J VIROL, V72, P4442, DOI 10.1128/JVI.72.5.4442-4447.1998; TANCHOU V, 1995, J MOL BIOL, V252, P563, DOI 10.1006/jmbi.1995.0520; Telesnitsky A., 1997, P121; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; YOU JC, 1994, J BIOL CHEM, V269, P31491	32	82	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33781	33786		10.1074/jbc.273.50.33781	http://dx.doi.org/10.1074/jbc.273.50.33781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837967	hybrid			2022-12-25	WOS:000077462500097
J	Monagle, P; Berry, L; O'Brodovich, H; Andrew, M; Chan, A				Monagle, P; Berry, L; O'Brodovich, H; Andrew, M; Chan, A			Covalent heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate complexes - Characterization of novel anticoagulants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; CLOT-BOUND THROMBIN; UNFRACTIONATED HEPARIN; VENOUS THROMBOSIS; FIBRIN MONOMER; ANTITHROMBIN; GLYCOSAMINOGLYCANS; EFFICACY; PENTASACCHARIDE	Heparin cofactor II is a naturally occurring anticoagulant that acts by specifically inhibiting thrombin and is facilitated by the binding of glycosaminoglycans such as heparin and dermatan sulfate. In vivo, heparin cofactor II-glycosaminoglycan complexes dissociate, leaving the inhibitor less active in its ability to function as a component of the anticoagulation pathway. We have produced permanently activated heparin cofactor II molecules by covalent linkage to either heparin or dermatan sulfate. Covalent heparin cofactor II-heparin and heparin cofactor II dermatan sulfate complexes had catalytic antithrombin activities similar to those of the corresponding starting heparin and dermatan sulfate (86% and 110% of standard heparin and dermatan sulfate activity, respectively). Both heparin cofactor II-heparin and heparin cofactor II-dermatan sulfate had fast bimolecular rate constants of 1.4 x 10(7) M-1 s(-1) and 1.3 x 107 M-1 s(-1), respectively, for reaction with thrombin, The intravenous half-life of the covalent complexes in rabbits was significantly longer than that of free heparin or dermatan sulfate (4.4, 8.4, 0.33, and 0.50 h for heparin cofactor II-heparin, heparin cofactor II-dermatan sulfate, heparin, and dermatan sulfate, respectively). Given their unique properties, these conjugates may have a clinical application for long term, selective inhibition of thrombin.	Hamilton Civ Hosp, Res Ctr, Henderson Gen Div, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L85 4J9, Canada; Univ Toronto, Hosp Sick Children, Res Inst,Dept Pediat,Resp Res Div, MRC,Grp Dev Lung Biol, Toronto, ON M5G 1X8, Canada	McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Chan, A (corresponding author), Hamilton Civ Hosp, Res Ctr, Henderson Gen Div, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Chan, Anthony K. C./AAR-8892-2021	Chan, Anthony K. C./0000-0003-1551-3995; Monagle, Paul/0000-0002-3970-8984				BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; BENDAYAN P, 1994, THROMB HAEMOSTASIS, V71, P576; BOREL E, 1953, HELV CHIM ACTA, V36, P801, DOI 10.1002/hlca.19530360406; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; Chan A, 1997, J BIOL CHEM, V272, P22111, DOI 10.1074/jbc.272.35.22111; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; COHEN AT, 1994, THROMB HAEMOSTASIS, V72, P793; DAHLMAN T, 1990, BRIT J OBSTET GYNAEC, V97, P221, DOI 10.1111/j.1471-0528.1990.tb01785.x; DAWES J, 1992, THROMB HAEMOSTASIS, V67, P468; ESTES JW, 1969, CLIN PHARMACOL THER, V10, P329; GAILANI D, 1993, BLOOD COAGUL FIBRIN, V4, P15, DOI 10.1097/00001721-199304010-00003; Hatton MWC, 1997, AM J PHYSIOL-ENDOC M, V272, pE824, DOI 10.1152/ajpendo.1997.272.5.E824; HATTON MWC, 1980, ANAL BIOCHEM, V106, P417, DOI 10.1016/0003-2697(80)90542-4; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; Huang Y, 1996, ANAL BIOCHEM, V240, P227, DOI 10.1006/abio.1996.0352; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Iacoviello L, 1996, THROMB HAEMOSTASIS, V76, P1102; JAQUES LB, 1976, LANCET, V7996, P1157; KITZ R, 1962, J BIOL CHEM, V237, P3245; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; KRUEGER RC, 1987, ANAL BIOCHEM, V167, P295, DOI 10.1016/0003-2697(87)90167-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; MAGGI A, 1987, HAEMOSTASIS, V17, P329; MARKARIAN M, 1971, BIOL NEONATE, V71, P84; Marsh N A, 1990, Blood Coagul Fibrinolysis, V1, P133; MATTHIASSON SE, 1995, HAEMOSTASIS, V25, P203; MERTON RE, 1987, THROMB HAEMOSTASIS, V58, P839; MILLE B, 1994, J BIOL CHEM, V269, P29435; OFOSU FA, 1987, BIOCHEM J, V243, P579, DOI 10.1042/bj2430579; OFOSU FA, 1987, BIOCHEM J, V248, P889, DOI 10.1042/bj2480889; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; Venosi S, 1997, J INT MED RES, V25, P98, DOI 10.1177/030006059702500207; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; YOUNG E, 1992, THROMB HAEMOSTASIS, V67, P639; ZAMMIT A, 1995, BLOOD, V85, P720, DOI 10.1182/blood.V85.3.720.bloodjournal853720	38	10	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33566	33571		10.1074/jbc.273.50.33566	http://dx.doi.org/10.1074/jbc.273.50.33566			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837939	hybrid			2022-12-25	WOS:000077462500069
J	Du, KY; Montminy, M				Du, KY; Montminy, M			CREB is a regulatory target for the protein kinase Akt/PKB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CYCLIC-AMP; PHOSPHORYLATION; MICE; GENE; AKT; TRANSLOCATION; TRANSCRIPTION; ACTIVATION; BINDING	The nuclear factor CREB stimulates the expression of cellular genes following its protein kinase A-mediated phosphorylation at Ser-133. Ser-133 phosphorylation, in turn, activates target gene expression by promoting recruitment of the co-activator CBP, Recent studies showing that CREE and its paralog CREM are required for survival of certain cell types prompted us to examine whether CREB is a nuclear target for activation via the growth factor-dependent Ser/Thr kinase Akt/PKB. When overexpressed in serum-stimulated cells, Akt/PKB potently induced Ser-133 phosphorylation of CREB and promoted recruitment of CBP, Correspondingly, Akt/PKB stimulated target gene expression via CREB in a phospho(Ser-133) dependent manner. Akt/PKB induced CREB activity only in response to serum stimulation, and this effect was suppressed by the phosphatidylinositol 3-kinase inhibitor LY 294002. Our results support the notion that Akt/PKB promotes cell survival, at least in part, by stimulating the expression of cellular genes via the CREB/CBP nuclear transduction pathway.	Harvard Univ, Sch Med, Dept Cell Biol, Joslin Diabet Ctr,Res Div, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Montminy, M (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Joslin Diabet Ctr,Res Div, Joslin Pl, Boston, MA 02215 USA.							Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Blendy JA, 1996, NATURE, V380, P162, DOI 10.1038/380162a0; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Nantel F, 1996, NATURE, V380, P159, DOI 10.1038/380159a0; PESO LD, 1997, SCIENCE, V278, P687; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	21	800	813	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32377	32379		10.1074/jbc.273.49.32377	http://dx.doi.org/10.1074/jbc.273.49.32377			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829964	hybrid			2022-12-25	WOS:000077329100003
J	Raynes, DA; Guerriero, V				Raynes, DA; Guerriero, V			Inhibition of Hsp70 ATPase activity and protein renaturation by a novel Hsp70-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; HSC70; ACTIVATION; FEATURES; SEQUENCE; BAG-1; HIP	A cDNA that codes for an Hsp70-interacting protein (HspBP1) was isolated from a human heart cDNA library using the yeast two-hybrid system. The derived amino acid sequence is unique and therefore represents a new regulator of Hsp70. Northern blots of RNA from human tissues indicate that HspBP1 mRNA has a size of approximately 1.7 kilobase pairs and is present in all tissues analyzed but is most abundant in heart and skeletal muscle. Western blot analysis revealed a protein of approximately 40 kilodaltons detected in cell extracts. The ATPase domain of Hsp70 demonstrated binding to HspBP1. Further experiments showed binding of HspBP1 to Hsp70 and Hsc70 in a total heart extract. HspBP1 (8 mu M) inhibited approximately 90% of the Hsp40-activated Hsp70 ATPase activity. HspBP1 prevented ATP binding to Hsp70, and therefore this is the likely mechanism of inhibition. Hsp40-activated ATPase activity is essential for the renaturation activity of Hsp70; therefore, the effects of HspBP1 on renaturation of luciferase in a reticulocyte lysate and a defined system were examined. HspBP1 inhibited renaturation with half-maximal inhibition at 2 mu M. These data indicate that we have identified a novel Hsp70-interacting protein that inhibits Hsp70 chaperone activity.	Univ Arizona, Dept Anim Sci, Tucson, AZ 85721 USA	University of Arizona	Guerriero, V (corresponding author), Univ Arizona, Dept Anim Sci, Tucson, AZ 85721 USA.	guerrier@u.arizona.edu						Ali A, 1997, CELL STRESS CHAPERON, V2, P229, DOI 10.1379/1466-1268(1997)002<0229:PAOHBA>2.3.CO;2; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARTEL PL, 1993, CELLULAR INTERACTION, P53; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; CRY DM, 1994, TRENDS BIOCHEM SCI, V19, P176; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KARLIN S, 1993, P NATL ACAD SCI USA, V90, P5873, DOI 10.1073/pnas.90.12.5873; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	25	85	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32883	32888		10.1074/jbc.273.49.32883	http://dx.doi.org/10.1074/jbc.273.49.32883			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830037	hybrid			2022-12-25	WOS:000077329100076
J	Cheng, YJ; Lotan, R				Cheng, YJ; Lotan, R			Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL DIFFERENTIATION; ACTIVATION FUNCTION AF-2; NUCLEAR RECEPTORS; CARCINOMA-CELLS; MESSENGER-RNA; CO-REPRESSOR; HUMAN GENOME; HUMAN HEAD; SEQUENCE; CANCER	The effects of retinoids such as all-trans-retinoic acid (ATRA) on cell growth, differentiation, and apoptosis are thought to be mediated by nuclear retinoid receptors, which are involved in ligand-dependent transcriptional activation of target genes. Using differential display, we identified the cDNA of a novel gene, designated retinoic acid-inducible gene 1 (RAIG1), which was induced by ATRA in the squamous carcinoma cell line UMSCC-22B, Two RAIG1 transcripts of 2.4 and 6.8 kilobase pairs, respectively, have the same ORF that encodes a 357-amino acid polypeptide. RAIG1 mRNA is expressed at high level in fetal and adult lung tissues. Induction of RAIG1 expression by ATRA is rapid (within 2 h) and dose-dependent in the range between 1 nM to 1 mu M. The constitutive RAIG1 mRNA levels, which were low in three of five head and neck and four of six lung cancer cell lines, increased after ATRA treatment in most cell lines. The deduced RAIG1 protein sequence contains seven transmembrane domains, characteristic of G protein-coupled receptors, A fusion protein of RAIG1 and the green fluorescent protein was localized in the cell surface membrane and perinuclear vesicles in transiently transfected cells. RAIG1 was mapped to chromosome 12p12.3-p13, Our results provide novel evidence for a possible interaction between retinoid and G protein signaling pathways.	Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lotan, R (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA.	rlotan@notes.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [U19CA068437, P01CA052051, P30CA016672] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; GALVINPARTON PA, 1990, J BIOL CHEM, V265, P17771; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JETTEN AM, 1990, INT J CANCER, V45, P195, DOI 10.1002/ijc.2910450135; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAUTER K, 1995, NATURE, V377, P321; KURIE JM, 1994, BBA-MOL CELL RES, V1222, P88, DOI 10.1016/0167-4889(94)90028-0; KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LeDouarin B, 1997, BIOCHEM SOC T, V25, P605, DOI 10.1042/bst0250605; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOTAN R, 1994, CANCER RES, V54, pS1987; Lotan R, 1997, ENVIRON HEALTH PERSP, V105, P985, DOI 10.2307/3433315; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MorrissKay GM, 1996, FASEB J, V10, P961, DOI 10.1096/fasebj.10.9.8801178; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; ONATE SA, 1995, SCIENCE, V270, P1354; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shalinsky DR, 1997, CANCER RES, V57, P162; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Tarasova NI, 1997, J BIOL CHEM, V272, P14817, DOI 10.1074/jbc.272.23.14817; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wahle E, 1997, PROG NUCLEIC ACID RE, V57, P41, DOI 10.1016/S0079-6603(08)60277-9; Wang Y., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P275; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Zahn S, 1997, EUR J IMMUNOL, V27, P935, DOI 10.1002/eji.1830270420; ZOU CP, 1994, CANCER RES, V54, P5479	47	115	126	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					35008	35015		10.1074/jbc.273.52.35008	http://dx.doi.org/10.1074/jbc.273.52.35008			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857033	hybrid			2022-12-25	WOS:000077719700051
J	Li, XQ; Zhao, XN; Fang, Y; Jiang, X; Duong, T; Fan, C; Huang, CC; Kain, SR				Li, XQ; Zhao, XN; Fang, Y; Jiang, X; Duong, T; Fan, C; Huang, CC; Kain, SR			Generation of destabilized green fluorescent protein transcription reporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ORNITHINE DECARBOXYLASE; INTRACELLULAR DEGRADATION; GENE-EXPRESSION; MAMMALIAN-CELLS; CODON USAGE; PROTEOLYSIS; PROTEASES; MUTATIONS; ENZYME	The green fluorescent protein (GFP) is a widely used reporter in gene expression and protein localization studies. GFP is a stable protein; this property allows its accumulation and easy detection in cells. However, this stability also limits its application in studies that require rapid reporter turnover. We created a destabilized GFP for use in such studies by fusing amino acids 422-461 of the degradation domain of mouse ornithine decarboxylase (MODC) to the C-terminal end of an enhanced variant of GFP (EGFP), The fusion protein, unlike EGFP, was unstable in the presence of cycloheximide and had a fluorescence half-life of 2 h, Western blot analysis indicated that the fluorescence decay of EGFP-MODC-(422-461) was correlated with degradation of the fusion protein. We mutated key amino acids in the PEST sequence of EGFP-MODC-(422-461) and identified several mutants with variable half-lives. The suitability of destabilized EGFP as a transcription reporter was tested by linking it to NF kappa B binding sequences and monitoring tumor necrosis factor cu-mediated NF kappa B activation. We obtained time course induction and dose response kinetics similar to secreted alkaline phosphatase obtained in transfected cells. This result did not occur when unmodified EGFP was used as the reporter. Because of its autofluorescence, destabilized EGFP can be used to directly correlate gene induction with biochemical change, such as NF kappa B translocation to the nucleus.	CLONTECH Labs Inc, Palo Alto, CA 94303 USA		Li, XQ (corresponding author), CLONTECH Labs Inc, 1020 E Meadow Circle, Palo Alto, CA 94303 USA.	xqli@clontech.com						ABRAMS SB, 1998, CIRCADIAN RHYTHMS AR, P24; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; CHALFIE M, 1995, PHOTOCHEM PHOTOBIOL, V62, P651, DOI 10.1111/j.1751-1097.1995.tb08712.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1990, J BIOL CHEM, V265, P11823; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; INOUYE S, 1994, FEBS LETT, V351, P211, DOI 10.1016/0014-5793(94)00859-0; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yang TT, 1996, NUCLEIC ACIDS RES, V24, P4592, DOI 10.1093/nar/24.22.4592	34	598	640	1	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34970	34975		10.1074/jbc.273.52.34970	http://dx.doi.org/10.1074/jbc.273.52.34970			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857028	hybrid			2022-12-25	WOS:000077719700046
J	Missler, M; Hammer, RE; Sudhof, TC				Missler, M; Hammer, RE; Sudhof, TC			Neurexophilin binding to alpha-neurexins - A single LNS domain functions as an independently folding ligand-binding unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; HIGH-AFFINITY BINDING; HSV-TK EXPRESSION; LATROTOXIN RECEPTOR; SURFACE PROTEINS; BETA-NEUREXINS; SYNAPSIN-I; FAMILY; NEUROLIGINS; EXOCYTOSIS	alpha-Neurexins (I alpha, II alpha, and III alpha) are receptor-like proteins expressed in hundreds of isoforms on the neuronal cell surface. The extracellular domains of alpha-neurexins are composed of six LNS repeats, named after homologous sequences in the Laminin A G domain, Neurexins, and Sex hormone-binding globulin, with three interspersed epidermal growth factor-like domains. Purification of neurexin I alpha revealed that it is tightly complexed to a secreted glycoprotein called neurexophilin 1, Neurexophilin 1 is a member of a family of at least four genes and resembles a neuropeptide, suggesting a function as an endogenous ligand for alpha-neurexins, We have now used recombinant proteins and knockout mice to investigate which isoforms and domains of different neurexins and neurexophilins interact with each other. We show that neurexophilins 1 and 3 but not 4 (neurexophilin 2 is not expressed in rodents) bind to a single individual LNS domain, the second overall LNS domain in all three alpha-neurexins, Although this domain is alternatively spliced, all splice variants bind, suggesting that alternative splicing does not regulate binding, Using homologous recombination to disrupt the neurexophilin 1 gene, we generated mutant mice that do not express detectable neurexophilin 1 mRNA, Mice lacking neurexophilin 1 are viable with no obvious morbidity or mortality. However, homozygous mutant mice exhibit male sterility, probably because homologous recombination resulted in the co-insertion into the neurexophilin gene of herpes simplex virus thymidine kinase, which is known to cause male sterility. In the neurexophilin 1 knockout mice, neurexin I alpha is complexed with neurexophilin 3 but not neurexophilin 4, suggesting that neurexophilin 1 is redundant with neurexophilin 3 and that neurexophilins 1 and 3 but not 4 bind to neurexins, This hypothesis was confirmed using expression experiments, Our data reveal that the six LNS and three epidermal growth factor domains of neurexins are independently folding ligand-binding domains that may interact with distinct targets, The results support the notion that neurexophilins represent a family of extracellular signaling molecules that interact with multiple receptors including all three alpha-neurexins.	Univ Texas, SW Med Sch, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Sch, Howard Hughes Med Inst, Rm Y5-322,5323 Harry Hines Blvd, Dallas, TX 75235 USA.	tsudho@mednet.swmed.edu		Missler, Markus/0000-0001-8008-984X; Hammer, Robert E./0000-0001-5487-7551	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804, R37MH052804] Funding Source: NIH RePORTER; NIMH NIH HHS [MH52804] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BRAUN RE, 1990, BIOL REPROD, V43, P684, DOI 10.1095/biolreprod43.4.684; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; ESSER V, 1988, J BIOL CHEM, V263, P13282; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Hata Y, 1996, J NEUROSCI, V16, P2488; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; HUTTNER KM, 1993, BIOL REPROD, V49, P251, DOI 10.1095/biolreprod49.2.251; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Missler M, 1998, J NEUROSCI, V18, P3630; Missler M, 1998, J NEUROCHEM, V71, P1339; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OSTMAN A, 1993, J BIOL CHEM, V268, P13372; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; Petrenko AG, 1996, J NEUROSCI, V16, P4360; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROTHBERG JM, 1992, J MOL BIOL, V227, P367, DOI 10.1016/0022-2836(92)90891-M; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCOTT J, 1985, J CELL SCI, P19; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; ZHAO XO, 1995, J BIOL CHEM, V270, P29413, DOI 10.1074/jbc.270.49.29413	34	85	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34716	34723		10.1074/jbc.273.52.34716	http://dx.doi.org/10.1074/jbc.273.52.34716			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9856994	hybrid			2022-12-25	WOS:000077719700012
J	Duprez, V; Blank, U; Chretien, S; Gisselbrecht, S; Mayeux, P				Duprez, V; Blank, U; Chretien, S; Gisselbrecht, S; Mayeux, P			Physical and functional interaction between p72(syk) and erythropoietin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; COLONY-STIMULATING FACTOR; TRANSDUCING ADAPTER MOLECULE; SRC HOMOLOGY-2 DOMAINS; C-MYC INDUCTION; FC-EPSILON-RI; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; RESPONSIVE CELLS	Erythropoietin (Epo) regulates the proliferation and differentiation of erythroid cells through interaction with a cell surface receptor (EpoR) that belongs to the cytokine receptor family. The Jak2 tyrosine kinase was previously shown to bind to the EpoR, to be activated upon Epo stimulation, and to play a critical role ill Epo-induced proliferation. However, little is known about the role of other tyrosine kinases in Epo signaling. In this paper, we examined whether Syk was involved in EpoR activation. Coimmunoprecipitation experiments showed that the phosphorylated EpoR was associated with the Syk kinase in activated UT7 cells. The interaction of Epo with its receptor led to an increased kinase activity. The use of recombinant Syk Src homology 2 (SH2) domains expressed in tandem or individually revealed that both N- and C-SH2 domains of Syk participated in EpoR binding with a major contribution of the C-terminal SH2 domain. Far Western blotting further indicated that Syk directly binds to the EpoR and that the interaction of Syk with EpoR only occurred after Epo activation. These data suggest that phosphorylation of EpoR on tyrosine residues may mediate Syk binding to the receptor through interaction between the two SH2 domains of Syk and tyrosines of the receptor. We propose that in addition to Jak2, Syk protein kinase may be a component of EpoR signaling.	Hop Cochin, INSERM, Unite 363, F-75674 Paris, France; Inst Natl Transfus Sanguine, F-75015 Paris, France; Inst Pasteur, Unite Immunoallergie, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Duprez, V (corresponding author), Hop Cochin, INSERM, Unite 363, 27 Rue Faubourg St Jacques, F-75674 Paris, France.	duprez@cochin.inserm.fr	Chretien, Stany/M-5166-2018	Blank, Ulrich/0000-0002-2661-2983				AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AVANZI GC, 1988, BRIT J HAEMATOL, V69, P359, DOI 10.1111/j.1365-2141.1988.tb02374.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRUNATI AM, 1995, FEBS LETT, V367, P149, DOI 10.1016/0014-5793(95)00555-N; CHAN AC, 1994, J IMMUNOL, V152, P4758; Chin H, 1998, BLOOD, V91, P3734; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; D'Andrea AD, 1990, CURR OPIN CELL BIOL, V2, P648, DOI 10.1016/0955-0674(90)90106-O; DAMEN J, 1992, BLOOD, V80, P1923; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DARBY C, 1994, J IMMUNOL, V152, P5429; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; HANAZONO Y, 1993, BLOOD, V81, P3193; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Hermine O, 1996, BLOOD, V87, P1746; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOMATSU N, 1991, CANCER RES, V51, P341; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW CL, 1994, J BIOL CHEM, V269, P12310; MAYEUX P, 1987, J BIOL CHEM, V262, P13985; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOJCHOWSKI DM, 1989, BLOOD, V74, P952; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	56	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33985	33990		10.1074/jbc.273.51.33985	http://dx.doi.org/10.1074/jbc.273.51.33985			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852052	hybrid			2022-12-25	WOS:000077542200018
J	Kamath-Loeb, AS; Shen, JC; Loeb, LA; Fry, M				Kamath-Loeb, AS; Shen, JC; Loeb, LA; Fry, M			Werner syndrome protein - II. Characterization of the integral 3 '-> 5 '-DNA exonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME GENE; ESCHERICHIA-COLI; SYNDROME CELLS; DNA HELICASE; MUTATIONS; MUTANTS; ACID	In addition to its DNA helicase activity, Werner syndrome protein (WRN) also possesses an exonuclease activity (Shen, J.-C., Gray, M. D., Kamath-Loeb, A. S,, Fry, M., Oshima, J., and Loeb, L. A. (1998) J. Biol. Chem. 273, 34139-34144). Here we describe the properties of nearly homogeneous WRN exonuclease. WRN exonuclease hydrolyzes a recessed strand in a partial DNA duplex but does not significantly digest single-stranded DNA, blunt-ended duplex, or a protruding strand of a partial duplex. Although DNA is hydrolyzed in the absence of nucleoside triphosphates, nuclease activity is markedly stimulated by ATP, dATP, or CTP. WRN exonuclease digests DNA with a 3' --> 5' directionality to generate 5'-dNMP products, and DNA strands terminating with either a 3'-OH or 3'-PO4 group are hydrolyzed to similar extents. A recessed DNA strand with a single 3'-terminal mismatch is hydrolyzed more efficiently by WRN than one with a complementary nucleotide, but the enzyme fails to hydrolyze a DNA strand terminating with two mismatched bases. WRN exonuclease is distinguished from known mammalian DNA nucleases by its covalent association with a DNA helicase, preference for a recessed DNA strand, stimulation by ATP, ability to equally digest DNA with 3'-OH or 3'-PO4 termini, and its preferential digestion of DNA with a single 3'-terminal mismatch.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.	laloeb@u.washington.edu; mickey@tx.technion.ac.il			NCI NIH HHS [CA-39903] Funding Source: Medline; NIA NIH HHS [AG-01751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039903] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; DEMPLE B, 1983, J BACTERIOL, V153, P1079, DOI 10.1128/JB.153.2.1079-1082.1983; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; Kornberg A., 1992, DNA REPLICATION; Matsumoto T, 1998, INT J MOL MED, V1, P71; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; OSHIMA J, 1996, HUM MOL GENET, V12, P109; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; RICHARDSON CC, 1964, J BIOL CHEM, V239, P242; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schulz VP, 1996, HUM GENET, V97, P750; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; WEISMANSHOMER P, 1993, J BIOL CHEM, V268, P3306; WEISS B, 1976, J BIOL CHEM, V251, P1896; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	33	186	187	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34145	34150		10.1074/jbc.273.51.34145	http://dx.doi.org/10.1074/jbc.273.51.34145			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852074	hybrid			2022-12-25	WOS:000077542200040
J	Liu, XF; Hwang, H; Cao, LG; Wen, DZ; Liu, NL; Graham, RM; Zhou, MD				Liu, XF; Hwang, H; Cao, LG; Wen, DZ; Liu, NL; Graham, RM; Zhou, MD			Release of the neuregulin functional polypeptide requires its cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR FAMILY; FACTOR-ALPHA; HEREGULIN; PROTEIN; MEMBER; GENE; HER4/P180(ERBB4); PHOSPHORYLATION	Based on both in vivo and in vitro studies, we have shown previously that the intracellular domain of a membrane-bound isoform of the growth factor, neuregulin, regulates proteolytic release of its extracellular domain ErbB receptor-activating ligand. To investigate the mechanism(s) involved in this regulation, a series of intracellular domain mutants were constructed and tested for susceptibility to proteolytic processing after transient transfection in COS-7 cells. These studies revealed that regulation of extracellular domain cleavage by the intracellular domain is sequence-specific and involves three distinct 30-60-residue segments. The presence of any two of these three segments is both necessary and sufficient for proteolytic processing, and resistance to proteolysis is not due to an alteration in cellular localization or transport. Evidence was also obtained that regulation of extracellular domain processing involves initial intracellular domain dimerization. Thus, with expression of a construct encoding only the intracellular domain, dimerization could be demonstrated in cross-linking experiments. Furthermore, resistance to proteolytic processing of a construct lacking a large portion of the intracellular domain was rescued with a chimera, in which the intracellular domain was replaced with a spontaneously dimerizing Fc fragment. Taken together these studies indicate that intracellular domain interactions are critically involved in the spacial and temporal control of growth and development by membrane-bound neuregulin isoforms.	St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Kensington, NSW 2052, Australia; Amgen Inc, Thousand Oaks, CA 91320 USA	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of New South Wales Sydney; Amgen	Zhou, MD (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St,Level 6, Darlinghurst, NSW 2010, Australia.	m.zhou@victorchang.unsw.edu.au						ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HARANO T, 1994, J BIOL CHEM, V269, P20305; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Liu XF, 1998, P NATL ACAD SCI USA, V95, P13024, DOI 10.1073/pnas.95.22.13024; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Sambrook J., 2002, MOL CLONING LAB MANU; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	30	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34335	34340		10.1074/jbc.273.51.34335	http://dx.doi.org/10.1074/jbc.273.51.34335			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852099	hybrid			2022-12-25	WOS:000077542200065
J	Sando, JJ; Chertihin, OI; Owens, JM; Kretsinger, RH				Sando, JJ; Chertihin, OI; Owens, JM; Kretsinger, RH			Contributions to maxima in protein kinase C activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; PHOSPHATIDYLSERINE BILAYERS; MIXED MICELLES; DOMAINS; DIACYLGLYCEROL; SUBSTRATE; CALCIUM; PHOSPHATIDYLCHOLINES; IDENTIFICATION; PHOSPHOLIPIDS	In many lipid systems, the activity of protein kinase C (PKC) exhibits a peak followed by a decline as the mol % of one component is increased. In these systems, an increase in one lipid component is always at the expense of another or accompanied by a change in total lipid concentration. Here we report that in saturated phosphatidylserine (PS)/phosphatidylcholine (PC)/diacylglycerol (DAG) mixtures, increasing PS or DAG at the expense of PC revealed an optimal mol % PS, dependent on mol % DAG, with higher mol % PS diminishing activity. The decrease at high mol % PS is probably not attributable simply to more gel-phase lipid due to the higher melting temperature of saturated PS versus PC because a similar peak in activity occurred in unsaturated lipid systems. Increasing the total lipid concentration at suboptimal mol % PS provided the same activity as higher mol % PS at lower total lipid concentration. However, at optimal mol % PS, activity increased and then decreased as a function of total lipid concentration, PKC autophosphorylation also exhibited an optimum as a function of mol % PS, and increasing the PRC concentration increased the mol % PS at which activity decreased, both for autophosphorylation and for heterologous phosphorylation. Formation of two-dimensional crystals of PKC on lipid monolayers also exhibited a peak. as a function of mol % PS, and the unit cell size of the crystals formed shifts from 50 x 50 Angstrom at low mol % PS to 75 x 75 Angstrom at higher PS. Collectively, these data suggest the existence of optimal lipid compositions for PKC activation, with increased quantity of these domains serving to dilute out enzyme-substrate aggregates and/or enzyme-enzyme aggregates on the lipid surface.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Immunol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Sando, JJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, POB 448, Charlottesville, VA 22908 USA.	jjs@virginia.edu			NIGMS NIH HHS [GM31184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZZI MD, 1992, BIOCHEMISTRY-US, V31, P1125, DOI 10.1021/bi00119a022; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; BOLEN EJ, 1992, BIOCHEMISTRY-US, V31, P5945, DOI 10.1021/bi00140a034; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; CASAL HL, 1987, BIOCHEMISTRY-US, V26, P4408, DOI 10.1021/bi00388a033; CASAL HL, 1987, BIOCHEMISTRY-US, V26, P7395, DOI 10.1021/bi00397a030; CAZAUBON S, 1990, EUR J BIOCHEM, V194, P799, DOI 10.1111/j.1432-1033.1990.tb19472.x; COONEY RV, 1992, CARCINOGENESIS, V13, P1107, DOI 10.1093/carcin/13.7.1107; DAS S, 1984, BIOCHEM BIOPH RES CO, V124, P491, DOI 10.1016/0006-291X(84)91580-8; Dibble ARG, 1996, BIOPHYS J, V71, P1877, DOI 10.1016/S0006-3495(96)79387-6; EPAND RM, 1985, BIOCHEMISTRY-US, V24, P7029; Goldberg EM, 1998, BIOCHEMISTRY-US, V37, P5623, DOI 10.1021/bi9719354; HANNUN YA, 1985, J BIOL CHEM, V260, P39; Hinderliter AK, 1997, BIOCHEMISTRY-US, V36, P6141, DOI 10.1021/bi962715d; HOMMEL U, 1996, NAT STRUCT BIOL, V116, P68; HUANG C, 1994, BBA-BIOMEMBRANES, V1189, P7, DOI 10.1016/0005-2736(94)90273-9; HUBBARD SR, 1991, SCIENCE, V254, P1776; Hurley JH, 1997, PROTEIN SCI, V6, P477; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KINGSLEY PB, 1979, CHEM PHYS LIPIDS, V24, P135, DOI 10.1016/0009-3084(79)90083-5; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE MH, 1992, BIOCHEMISTRY-US, V31, P1576; LEVENTHAL PS, 1993, J BIOL CHEM, V268, P13906; MAURER MC, 1992, ARCH BIOCHEM BIOPHYS, V298, P561, DOI 10.1016/0003-9861(92)90450-B; NAKADATE T, 1987, J BIOL CHEM, V262, P11507; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; Owens JM, 1998, J STRUCT BIOL, V121, P61, DOI 10.1006/jsbi.1997.3956; RANDO RR, 1984, BIOCHEM BIOPH RES CO, V122, P818, DOI 10.1016/S0006-291X(84)80107-2; RANDO RR, 1992, BIOCHEMISTRY-US, V31, P2211, DOI 10.1021/bi00123a001; Rao YP, 1997, J LIPID RES, V38, P2446; SANDO JJ, 1983, P NATL ACAD SCI-BIOL, V80, P2642, DOI 10.1073/pnas.80.9.2642; Sando JJ, 1996, BIOCHEM J, V317, P583, DOI 10.1042/bj3170583; Slater SJ, 1996, J BIOL CHEM, V271, P4627; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAYLOR RP, 1978, ARCH BIOCHEM BIOPHYS, V187, P197, DOI 10.1016/0003-9861(78)90023-1; Vinton BB, 1998, BIOCHEM J, V330, P1433, DOI 10.1042/bj3301433; WALKER JM, 1988, J BIOL CHEM, V263, P4537; WALKER JM, 1990, J BIOL CHEM, V265, P8016; WALKER JM, 1989, CALCIUM PROTEIN SIGN, P29; YANG L, 1995, BIOCHEMISTRY-US, V34, P1500, DOI 10.1021/bi00005a005; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	49	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34022	34027		10.1074/jbc.273.51.34022	http://dx.doi.org/10.1074/jbc.273.51.34022			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852057	hybrid			2022-12-25	WOS:000077542200023
J	Wischmeyer, E; Doring, F; Karschin, A				Wischmeyer, E; Doring, F; Karschin, A			Acute suppression of inwardly rectifying Kir2.1 channels by direct tyrosine kinase phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KV1.3 POTASSIUM CHANNEL; GROWTH-FACTOR RECEPTOR; K+ CHANNEL; PROTEIN-PHOSPHORYLATION; NEUROTROPHIN RECEPTORS; DEPENDENT SUPPRESSION; INSULIN-RECEPTOR; ION CHANNELS; MODULATION; ACTIVATION	Signaling via cytosolic and receptor tyrosine kinases is associated with cell growth and differentiation but also targets onto transmitter receptors and ion channels. Here, regulation by tyrosine kinase (TK) activity was investigated for inwardly rectifying K+ (Kir2.1) channels that control membrane excitability in many central neurons. In mammalian tsA-201 cells, the membrane-permeable protein tyrosine phosphatase inhibitor, perorthovanadate (100 mu M), suppressed currents through recombinant Kir2.1 channels by 60 +/- 20%, Coapplication of the TK inhibitor genistein (100 mu M:) completely abolished this effect. Native Kir2.1 channels in rat basophilic leukocytes were affected by manipulation of the TK and protein tyrosine phosphatase activity in a qualitatively similar manner. Site mutation of a tyrosine consensus residue for TK phosphorylation in the C-terminal domain of Kir2.1 generated channel properties indistinguishable from wild-type Kir2.1 channels. However, Kir2.1Y242F channels were no longer suppressed following exposure to perorthovanadate, indicating that the channel is a direct substrate for TKs. After coexpression of nerve growth factor receptor with Kir2.1 channels in tsA-201 cells and Xenopus oocytes, the activity of Kir2.1 was rapidly suppressed by applied nerve growth factor (0.5 mu g/ml) by 31 +/- 10 and 21 +/- 15%, respectively, Acute inhibition was also evoked by epidermal growth factor and insulin via endogenous insulin receptors, indicating that Kir2.1 channels may serve as a general target for neurotrophic growth factors in the brain.	Max Planck Inst Biophys Chem, Dept Mol Neurobiol Signal Transduct, D-37070 Gottingen, Germany	Max Planck Society	Karschin, A (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Neurobiol Signal Transduct, Fassberg 11, D-37070 Gottingen, Germany.	akarsch@gwdg.de		Doring, Frank/0000-0003-1017-1498				Arnoult C, 1997, EMBO J, V16, P1593, DOI 10.1093/emboj/16.7.1593; Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; Bowlby MR, 1997, J GEN PHYSIOL, V110, P601, DOI 10.1085/jgp.110.5.601; Cachero TG, 1998, CELL, V93, P1077, DOI 10.1016/S0092-8674(00)81212-X; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECHANT G, 1994, PROG NEUROBIOL, V42, P347, DOI 10.1016/0301-0082(94)90075-2; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; Felsch JS, 1998, P NATL ACAD SCI USA, V95, P5051, DOI 10.1073/pnas.95.9.5051; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jonas EA, 1996, J NEUROSCI, V16, P1645; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Karschin C, 1996, J NEUROSCI, V16, P3559; Karschin C, 1997, MOL CELL NEUROSCI, V10, P131, DOI 10.1006/mcne.1997.0655; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Liu SQJ, 1998, J NEUROSCI, V18, P2881; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; Molokanova E, 1997, J NEUROSCI, V17, P9068; Paillart C, 1997, J PHARMACOL EXP THER, V280, P521; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCAVO L, 1991, P NATL ACAD SCI USA, V88, P6214, DOI 10.1073/pnas.88.14.6214; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHARMA N, 1993, J CELL BIOL, V123, P1835, DOI 10.1083/jcb.123.6.1835; SIEGELBAUM SA, 1994, CURR BIOL, V4, P242, DOI 10.1016/S0960-9822(00)00054-3; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; TIMPE LC, 1994, J NEUROSCI, V14, P1195, DOI 10.1523/JNEUROSCI.14-03-01195.1994; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; WISCHMEYER E, 1995, PFLUG ARCH EUR J PHY, V429, P809, DOI 10.1007/BF00374805; Wischmeyer E, 1996, P NATL ACAD SCI USA, V93, P5819, DOI 10.1073/pnas.93.12.5819	42	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34063	34068		10.1074/jbc.273.51.34063	http://dx.doi.org/10.1074/jbc.273.51.34063			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852063	hybrid			2022-12-25	WOS:000077542200029
J	Bell, W; Sun, WN; Hohmann, S; Wera, S; Reinders, A; De Virgilio, C; Wiemken, A; Thevelein, JM				Bell, W; Sun, WN; Hohmann, S; Wera, S; Reinders, A; De Virgilio, C; Wiemken, A; Thevelein, JM			Composition and functional analysis of the Saccharomyces cerevisiae trehalose synthase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST TREHALOSE-6-PHOSPHATE SYNTHASE; PHOSPHATASE COMPLEX; MOLECULAR-CLONING; ESCHERICHIA-COLI; BAKERS-YEAST; REGULATORY MUTANT; HEAT-SHOCK; GLUCOSE; GENE; GLYCOLYSIS	In the yeast Saccharomyces cerevisiae, trehalose-6-phosphate synthase (TPS) and trehalose-6-phosphate phosphatase (TPP), which convert glucose 6-phosphate plus UDP-glucose to trehalose, are part of the trehalose synthase complex. In addition to the TPS1 (previously also called GGS1, CIF1, BYP1, FDP1, GLC6, and TSS1) and TPS2 (also described as HOG2 and PFK3) gene products, this complex also contains a regulatory subunit encoded by TSL1. We have constructed a set of isogenic strains carrying all possible combinations of deletions of these three genes and of TPS3, a homologue of TSL1 identified by systematic sequencing, Deletion of TPS1 totally abolished TPS activity and measurable trehalose, whereas deletion of any of the other genes in most cases reduced both. Similarly, deletion of TPS2 completely abolished TPP activity, and deletion of any of the other genes resulted in a reduction of this activity. Therefore, it appears that all subunits are required for optimal enzymatic activity. Since we observed measurable trehalose in strains lacking all but the TPS1 gene, some phosphatase activity in addition to Tps2 can hydrolyze trehalose 6-phosphate, Deletion of TPS3, in particular in a tsl1 Delta background, reduced both TPS and TPP activities and trehalose content, Deletion of TPS2, TSL1, or TPS3 and, in particular, of TSL1 plus TPS3 destabilized the trehalose synthase complex. We conclude that Tps3 is a fourth subunit of the complex with functions partially redundant to those of Tsl1. Among the four genes studied, TPS1 is necessary and sufficient for growth on glucose and fructose. Even when overproduced, none of the other subunits could take over this function of Tps1 despite the homology shared by all four proteins. A portion of Tps1 appears to occur in a form not bound by the complex. Whereas TPS activity in the complex is inhibited by P-i, P-i stimulates the monomeric form of Tps1, We discuss the possible role of differentially regulated Tps1 in a complex-bound or monomeric form in light of the requirement of Tps1 for trehalose production and for growth on. glucose and fructose.	Katholieke Univ Leuven, Lab Mol Celbiol, B-3001 Heverlee, Belgium; Univ Basel, Inst Bot, CH-4056 Basel, Switzerland	KU Leuven; University of Basel	Thevelein, JM (corresponding author), Katholieke Univ Leuven, Lab Mol Celbiol, Kardinaal Mercierlaan 92, B-3001 Heverlee, Belgium.		Thevelein, Johan M./AAK-4203-2021; Hohmann, Stefan/K-9895-2013; De Virgilio, Claudio/B-4707-2012; Thevelein, Johan M./A-7897-2013	Hohmann, Stefan/0000-0002-0809-1985; Thevelein, Johan M./0000-0002-2626-0180; Reinders, Anke/0000-0001-5351-3940; De Virgilio, Claudio/0000-0001-8826-4323				BELL W, 1992, EUR J BIOCHEM, V209, P951, DOI 10.1111/j.1432-1033.1992.tb17368.x; BLAZQUEZ MA, 1993, FEBS LETT, V329, P51, DOI 10.1016/0014-5793(93)80191-V; CABIB E, 1958, J BIOL CHEM, V231, P259; DEVIRGILIO C, 1993, EUR J BIOCHEM, V212, P315; EBERHARDT I, 1995, CURR GENET, V27, P306, DOI 10.1007/BF00352097; Ferreira JC, 1996, BIOCHEM MOL BIOL INT, V38, P259; GIAEVER HM, 1988, J BACTERIOL, V170, P2841, DOI 10.1128/jb.170.6.2841-2849.1988; GONZALEZ MI, 1992, YEAST, V8, P183, DOI 10.1002/yea.320080304; HOHMANN S, 1993, CURR GENET, V23, P281, DOI 10.1007/BF00310888; Hohmann S, 1996, MOL MICROBIOL, V20, P981, DOI 10.1111/j.1365-2958.1996.tb02539.x; HOHMANN S, 1992, J BACTERIOL, V174, P4183, DOI 10.1128/jb.174.12.4183-4188.1992; HOTTIGER T, 1987, J BACTERIOL, V169, P5518, DOI 10.1128/jb.169.12.5518-5522.1987; KAASEN I, 1992, J BACTERIOL, V174, P889, DOI 10.1128/jb.174.3.889-898.1992; KAASEN I, 1994, GENE, V145, P9, DOI 10.1016/0378-1119(94)90316-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONDESBOROUGH J, 1991, J GEN MICROBIOL, V137, P323, DOI 10.1099/00221287-137-2-323; LONDESBOROUGH J, 1993, EUR J BIOCHEM, V216, P841, DOI 10.1111/j.1432-1033.1993.tb18206.x; NEVES MJ, 1995, CURR GENET, V27, P110, DOI 10.1007/BF00313424; NEVES MJ, 1991, FEBS LETT, V283, P19, DOI 10.1016/0014-5793(91)80544-D; Reinders A, 1997, MOL MICROBIOL, V24, P687, DOI 10.1046/j.1365-2958.1997.3861749.x; Sherman F., 1986, METHODS YEAST GENETI; THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466; THEVELEIN JM, 1995, TRENDS BIOCHEM SCI, V20, P3, DOI 10.1016/S0968-0004(00)88938-0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; VANAELST L, 1993, MOL MICROBIOL, V8, P927; VANAELST L, 1991, EMBO J, V10, P2095, DOI 10.1002/j.1460-2075.1991.tb07742.x; VANDEPOLL KW, 1977, MOL GEN GENET, V154, P61, DOI 10.1007/BF00265577; VANDEPOLL KW, 1974, J BACTERIOL, V117, P965, DOI 10.1128/JB.117.3.965-970.1974; VANDERCAMMEN A, 1989, EUR J BIOCHEM, V182, P613, DOI 10.1111/j.1432-1033.1989.tb14870.x; VANDERPL.JB, 1974, BIOCHEM BIOPH RES CO, V56, P580, DOI 10.1016/0006-291X(74)90643-3; VUORIO OE, 1993, EUR J BIOCHEM, V216, P849, DOI 10.1111/j.1432-1033.1993.tb18207.x; Winderickx J, 1996, MOL GEN GENET, V252, P470, DOI 10.1007/s004380050252; ZAMENHOF S, 1957, METHOD ENZYMOL, V3, P696, DOI 10.1016/S0076-6879(57)03446-1	33	164	184	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33311	33319		10.1074/jbc.273.50.33311	http://dx.doi.org/10.1074/jbc.273.50.33311			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837904	hybrid			2022-12-25	WOS:000077462500034
J	Du, GG; Imredy, JP; MacLennan, DH				Du, GG; Imredy, JP; MacLennan, DH			Characterization of recombinant rabbit cardiac and skeletal muscle Ca2+ release channels (ryanodine receptors) with a novel [H-3]ryanodine binding assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM VESICLES; CALCIUM-RELEASE; FUNCTIONAL EXPRESSION; FEET STRUCTURES; CA-2+; COMPLEX; CDNA; PURIFICATION; CELLS; THAPSIGARGIN	A rapid assay for high affinity [H-3]ryanodine binding to 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS)-solubilized recombinant or native Ca2+ release channel proteins (ryanodine receptor, RyR) was devised. The key to preservation of high affinity [H-3]ryanodine binding sites in the presence of increasing concentrations of CHAPS was the addition of phosphatidylcholine, This assay was used to characterize the equilibrium and kinetic properties of [H-3]ryanodine binding to recombinant skeletal (RyR1) and cardiac (RyR2) Ca2+ release channels and the effects on binding of physiological modulators including ATP, Ca2+, and Mg2+. Both RyR1 and RyR2 had a single high affinity ryanodine binding site and low affinity sites, but [H-3]ryanodine binding to recombinant RyR2 was not sensitive to ATP activation or Ca2+ inactivation and was less sensitive to Mg2+ inhibition. The [H-3]ryanodine binding assay was used to estimate the expression level of recombinant RyR2 and RyR1, and to show that RyR2 can be expressed at very high level in HEK-293 cells. Analysis of the properties of recombinant RyR2 and RyR1 by measurement of intracellular Fura-2 fluorescence revealed that the different properties of RyR2 and RyR1 are retained in the recombinant expressed proteins.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto	MacLennan, DH (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	david.maclennan@utoronto.ca						AIREY JA, 1990, J BIOL CHEM, V265, P14187; ANDERSON K, 1989, J BIOL CHEM, V264, P1329; CAMPBELL KP, 1981, J BIOL CHEM, V256, P4626; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; Chen SRW, 1997, BIOPHYS J, V73, P1904, DOI 10.1016/S0006-3495(97)78221-3; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; Du GG, 1996, CELL CALCIUM, V20, P355, DOI 10.1016/S0143-4160(96)90041-X; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; HOLME EC, 1990, RECEPTOR BIOCH PRACT; IMAGAWA T, 1992, J BIOCHEM-TOKYO, V112, P508, DOI 10.1093/oxfordjournals.jbchem.a123930; IMAGAWA T, 1989, J BIOCHEM-TOKYO, V106, P342, DOI 10.1093/oxfordjournals.jbchem.a122855; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1988, BIOCHEM BIOPH RES CO, V151, P441, DOI 10.1016/0006-291X(88)90613-4; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Needleman DH, 1997, ANAL BIOCHEM, V248, P173, DOI 10.1006/abio.1997.2125; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1991, MOL PHARMACOL, V39, P679; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TONG J, 1999, IN PRESS J BIOL CHEM, V274; Tong JF, 1997, J BIOL CHEM, V272, P26332, DOI 10.1074/jbc.272.42.26332; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938; Zucchi R, 1997, PHARMACOL REV, V49, P1	40	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33259	33266		10.1074/jbc.273.50.33259	http://dx.doi.org/10.1074/jbc.273.50.33259			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837897	hybrid			2022-12-25	WOS:000077462500027
J	Nowell, SA; Leakey, JEA; Warren, JF; Lang, NP; Frame, LT				Nowell, SA; Leakey, JEA; Warren, JF; Lang, NP; Frame, LT			Identification of enzymes responsible for the metabolism of heme in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN INJURY; HUMAN-LIVER; RAT-BRAIN; UDP-GLUCURONOSYLTRANSFERASE; BILIVERDIN REDUCTASE; GILBERTS-SYNDROME; OXYGENASE-1 HO-1; CARBON-MONOXIDE; IN-VIVO; EXPRESSION	The major enzymes involved in the degradation of heme were identified in human platelets. It was determined that heme oxygenase activity levels in umbilical cord blood platelets were higher, whereas biliverdin reductase activity levels were comparable with that found in platelets from adults. In membranes prepared from adenosine diphosphate-activated platelets, UDP-glucuronic acid-dependent bilirubin conjugation was detected, whereas activity was negligible in unactivated platelets and undetected in serum and heat-inactivated platelets, and in platelets prepared from umbilical cord blood. Platelet fractions were analyzed by Western blot and shown to express heme oxygenase, biliverdin reductase, and UDP-glucuronosyltransferases, and there was concordance with known developmental profiles found in other tissues. Heme oxygenase expression was higher, whereas UGT expression was lower, in neonatal compared with adult platelets. These data suggest that platelets are involved in multiple steps of heme and bilirubin metabolism and that developmental regulation of these enzymes may be similar to that in other human tissues.	John L McClellan Mem Vet Affairs Med Ctr, Surg Serv 112LR, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Surg Oncol, Little Rock, AR 72205 USA; Natl Ctr Toxicol Res, Div Microbiol & Chem HFT230, Jefferson, AR 72079 USA; Reece Ctr, Inst Environm & Human Hlth, Lubbock, TX 79416 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Food & Drug Administration (FDA)	Lang, NP (corresponding author), John L McClellan Mem Vet Affairs Med Ctr, Surg Serv 112LR, 4300 W 7th St, Little Rock, AR 72205 USA.				NATIONAL CANCER INSTITUTE [R01CA058697, R01CA055751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015722] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58697, CA 55751] Funding Source: Medline; NIA NIH HHS [AG 15722] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BISSELL DM, 1972, BLOOD-J HEMATOL, V40, P812, DOI 10.1182/blood.V40.6.812.812; BROWN AL, 1982, TOPICS LEARNING LEAR, V2, P1; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; CASTELLANI R, 1995, BRAIN RES, V696, P268, DOI 10.1016/0006-8993(95)00535-X; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74, DOI 10.1165/ajrcmb.13.1.7598940; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; COUGHTRIE MWH, 1986, ANAL BIOCHEM, V159, P198, DOI 10.1016/0003-2697(86)90328-3; DEMORAIS SMF, 1992, GASTROENTEROLOGY, V102, P577, DOI 10.1016/0016-5085(92)90106-9; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; DENNERY PA, 1995, FREE RADICAL BIO MED, V19, P395, DOI 10.1016/0891-5849(95)00032-S; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/S0006-8993(96)00680-4; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; GUENGERICH FP, 1978, BIOCHEMISTRY-US, V17, P3633, DOI 10.1021/bi00610a033; Hume R, 1996, BLOOD, V87, P762, DOI 10.1182/blood.V87.2.762.bloodjournal872762; JONES AL, 1995, BIOCHEM BIOPH RES CO, V208, P855, DOI 10.1006/bbrc.1995.1414; LANDAW SA, 1970, J CLIN INVEST, V49, P914, DOI 10.1172/JCI106311; LIN JHC, 1989, ARCH BIOCHEM BIOPHYS, V270, P623, DOI 10.1016/0003-9861(89)90545-6; LINCOLN BC, 1988, ANAL BIOCHEM, V170, P485, DOI 10.1016/0003-2697(88)90662-8; MAINES MD, 1993, ARCH BIOCHEM BIOPHYS, V300, P320, DOI 10.1006/abbi.1993.1044; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1992, CLIN APPL FUNCTIONS; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MCCOUBREY WK, 1994, GENE, V139, P155, DOI 10.1016/0378-1119(94)90749-8; MILLS DCB, 1968, J PHYSIOL-LONDON, V195, P715, DOI 10.1113/jphysiol.1968.sp008484; MORI H, 1991, JPN J CANCER RES, V82, P755, DOI 10.1111/j.1349-7006.1991.tb02698.x; NEUZIL J, 1993, FEBS LETT, V331, P281, DOI 10.1016/0014-5793(93)80353-V; NOWELL S, 1997, 8 N AM ISSX M HILT H, P92; OWENS D, 1975, J MED GENET, V12, P152, DOI 10.1136/jmg.12.2.152; PIMSTONE NR, 1971, J CLIN INVEST, V50, P1264; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; RITTER JK, 1991, J BIOL CHEM, V266, P1043; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; TENHUNEN R, 1970, BIOCHEMISTRY-US, V9, P298, DOI 10.1021/bi00804a016; Tiribelli C, 1996, HEPATOLOGY, V24, P1296; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vallis KA, 1996, CARCINOGENESIS, V17, P649, DOI 10.1093/carcin/17.4.649; VANROY FP, 1971, CLIN CHIM ACTA, V31, P109, DOI 10.1016/0009-8981(71)90367-6; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WALTERS MI, 1970, MICROCHEM J, V15, P231, DOI 10.1016/0026-265X(70)90045-7; WEBER CM, 1994, J NEUROCHEM, V63, P953; WILLIAMS M, 1994, BBA-LIPID LIPID MET, V1211, P310, DOI 10.1016/0005-2760(94)90155-4; WISHART GJ, 1978, BIOCHEM J, V174, P485, DOI 10.1042/bj1740485; Wu TW, 1994, LIFE SCI, V54, pP477	44	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33342	33346		10.1074/jbc.273.50.33342	http://dx.doi.org/10.1074/jbc.273.50.33342			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837908	hybrid			2022-12-25	WOS:000077462500038
J	Sata, M; Walsh, K				Sata, M; Walsh, K			Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APO-1/FAS RECEPTOR/LIGAND SYSTEM; DRUG-INDUCED APOPTOSIS; DEATH FACTOR; LIGAND; ACTIVATION; PROTEIN; PATHWAY; LYSOPHOSPHATIDYLCHOLINE; DISTINCT	Fas (CD-95/APO-1) is a death receptor that initiates an apoptotic signal when activated by its ligand, Fast. Normal vascular endothelial cells are resistant to Fas-mediated apoptosis though they express both Fas and Fast. Oxidized low density lipoprotein (OxLDL) or lysophosphatidylcholine (LPC), a major component of OxLDL, induces endothelial cell suicide by sensitizing endothelial cells to Fas-mediated apoptosis. Here, we show that endothelial cell apoptosis by OxLDL and LPC-C16:0 was dose-dependent and correlated with down-regulation of FLICE-inhibitory protein (FLIP), an intracellular caspase inhibitor, FLIP down-regulation also occurred when endothelial cells were treated with toxic doses of LPC-C18:0 or minimally modified low density lipoprotein (LDL), In contrast, FLIP was not down-regulated by native LDL, acetylated LDL, LPC-C12:0, cholesterol, or 7-ketocholesterol, which are not toxic to endothelial cells. The cytotoxicity of oxidized lipids was reversed by transfecting endothelial cells with a FLIP expression plasmid. The results demonstrate, for the first time, FLIP regulation under conditions that lead to pathological tissue destruction.	Tufts Univ, St Elizabeths Med Ctr, Sch Med, Div Cardiovasc Res, Brighton, MA 02135 USA; Tufts Univ, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA	St. Elizabeth's Medical Center; Tufts University; Tufts University	Walsh, K (corresponding author), Tufts Univ, St Elizabeths Med Ctr, Sch Med, Div Cardiovasc Res, 736 Cambridge St, Brighton, MA 02135 USA.	kwalsh@opal.tufts.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R37AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50692] Funding Source: Medline; NIA NIH HHS [AG15052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; CHEN JK, 1986, J CELL PHYSIOL, V129, P207, DOI 10.1002/jcp.1041290212; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Dimmeler S, 1997, CIRCULATION, V95, P1760; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; FRANCIS MJ, 1991, IMMUNOLOGY, V73, P249; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; GALLE J, 1995, KIDNEY INT, V47, P45, DOI 10.1038/ki.1995.5; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JUCKETT MB, 1995, AM J PATHOL, V147, P782; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Murugesan G, 1996, J CLIN INVEST, V97, P2736, DOI 10.1172/JCI118728; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Perlman H, 1998, EMBO J, V17, P3576, DOI 10.1093/emboj/17.13.3576; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sakai M, 1996, ARTERIOSCL THROM VAS, V16, P600, DOI 10.1161/01.ATV.16.4.600; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Sata M, 1998, NAT MED, V4, P415, DOI 10.1038/nm0498-415; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; STEIN O, 1980, BIOCHIM BIOPHYS ACTA, V620, P631, DOI 10.1016/0005-2760(80)90155-1; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Strand S, 1998, NAT MED, V4, P588, DOI 10.1038/nm0598-588; SUGIYAMA S, 1994, CIRC RES, V74, P565, DOI 10.1161/01.RES.74.4.565; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; WONG GHW, 1994, J IMMUNOL, V152, P1751; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	47	132	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33103	33106		10.1074/jbc.273.50.33103	http://dx.doi.org/10.1074/jbc.273.50.33103			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837872	hybrid			2022-12-25	WOS:000077462500002
J	Taules, M; Rius, E; Talaya, D; Lopez-Girona, A; Bachs, O; Agell, N				Taules, M; Rius, E; Talaya, D; Lopez-Girona, A; Bachs, O; Agell, N			Calmodulin is essential for cyclin-dependent kinase 4 (Cdk4) activity and nuclear accumulation of cyclin D1-Cdk4 during G(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-ALPHA; CELL-CYCLE; ACTIVATING KINASE; NRK CELLS; RETINOBLASTOMA PROTEIN; GENE-PRODUCT; G1; LOCALIZATION; PROGRESSION; EXPRESSION	Although it is known that calmodulin is involved in G(1) progression, the calmodulin-dependent G(1) events are not well understood. We have analyzed here the role of calmodulin in the activity, the expression, and the intracellular location of proteins involved in G(1) progression. The addition of anti-calmodulin drugs to normal rat kidney cells in early G(1) inhibited cyclin-dependent kinase 4 (Cdk4) and Cdk2 activities, as well as retinoblastoma protein phosphorylation. Protein levels of cdk4, cyclin D1, cyclin D2, cyclin E, p21, and p27 were not affected after CaM inhibition, whereas decreases in the amount of cyclin A and Cdc2 were observed. The decrease of Cdk4 activity was due neither to changes in its association to cyclin D1 nor to changes in the amount of p21 or p27 bound to cyclin D1-Cdk4 complexes. Calmodulin inhibition also produced a translocation of nuclear cyclin D1 and Cdk4 to the cytoplasm.. This translocation could be responsible for the decreased Cdk4 activity upon calmodulin inhibition, Immuno:precipitation, calmodulin affinity chromatography, and direct binding experiments indicated that calmodulin associates with Cdk4 and cyclin D1 through a calmodulin-binding protein. The facts that Hsp90 interacts with Cdk4 and that its inhibition induced Cdk4 and cyclin D1 translocation to the cytoplasm point to Hsp90 as a good candidate for being the calmodulin-binding protein involved in the nuclear accumulation of Cdk4 and cyclin D1.	Univ Barcelona, Fac Med, Inst Invest Biomed August Pi & Sunyer, Dept Cell Biol, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Agell, N (corresponding author), Univ Barcelona, Fac Med, Inst Invest Biomed August Pi & Sunyer, Dept Cell Biol, Casanova 143, E-08036 Barcelona, Spain.		Agell, Neus/E-9640-2016	Agell, Neus/0000-0002-1205-6074; Taules, Marta/0000-0003-2895-7376				BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOSCH M, 1994, CELL CALCIUM, V16, P446, DOI 10.1016/0143-4160(94)90074-4; Botz J, 1996, MOL CELL BIOL, V16, P3401; BOYNTON AL, 1980, BIOCHEM BIOPH RES CO, V95, P745, DOI 10.1016/0006-291X(80)90849-9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; CHAFOULEAS JG, 1984, CELL, V36, P73, DOI 10.1016/0092-8674(84)90075-8; Dai K, 1996, J BIOL CHEM, V271, P22030, DOI 10.1074/jbc.271.36.22030; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DOU QP, 1994, J BIOL CHEM, V269, P1306; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EILAM Y, 1988, GEN MICROBIOL, V143, P1063; Geng Y, 1996, ONCOGENE, V12, P1173; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; HARPER JW, 1993, CELL, V75, P805; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LOPEZGIRONA A, 1992, BIOCHEM BIOPH RES CO, V184, P1517, DOI 10.1016/S0006-291X(05)80055-5; LopezGirona A, 1995, BIOCHEM BIOPH RES CO, V217, P566, DOI 10.1006/bbrc.1995.2813; LOPEZGIRONA A, 1995, CELL CALCIUM, V18, P30, DOI 10.1016/0143-4160(95)90043-8; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mahony D, 1998, ONCOGENE, V16, P603, DOI 10.1038/sj.onc.1201570; MARIDOR G, 1993, J CELL SCI, V106, P535; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Morris TA, 1998, EXP CELL RES, V240, P218, DOI 10.1006/excr.1997.3925; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; Pinol-Roma Serafin, 1993, Trends in Cell Biology, V3, P151, DOI 10.1016/0962-8924(93)90135-N; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SASAKI Y, 1982, BIOCHEM BIOPH RES CO, V104, P451, DOI 10.1016/0006-291X(82)90658-1; Schmalz D, 1996, J CELL SCI, V109, P2401; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sweitzer TD, 1996, P NATL ACAD SCI USA, V93, P14574, DOI 10.1073/pnas.93.25.14574; TAKUWA N, 1993, J BIOL CHEM, V268, P138; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tomono M, 1996, BIOCHEM J, V317, P675, DOI 10.1042/bj3170675; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	64	75	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33279	33286		10.1074/jbc.273.50.33279	http://dx.doi.org/10.1074/jbc.273.50.33279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837900	hybrid			2022-12-25	WOS:000077462500030
J	Muhlenbeck, F; Haas, E; Schwenzer, R; Schubert, G; Grell, M; Smith, C; Scheurich, P; Wajant, H				Muhlenbeck, F; Haas, E; Schwenzer, R; Schubert, G; Grell, M; Smith, C; Scheurich, P; Wajant, H			TRAIL/Apo2L activates c-Jun NH2-terminal kinase (JNK) via caspase-dependent and caspase-independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; DOMAIN-CONTAINING RECEPTOR; INDUCED CELL-DEATH; APOPTOSIS-MEDIATING RECEPTOR; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; TNF-ALPHA; TERMINAL KINASE; CD95 FAS/APO-1	In this study we show that TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), also called Apo2L, activates the c-Jun N-terminal kinase (JNK). Interestingly, TRAIL-induced JNK activation occurs in a cell type-specific manner, In HeLa cells, TRAIL-induced JNK activation can be completely blocked with the cysteine protease inhibitor zVAD-fmk, whereas the same inhibitor has no, or even a stimulatory, effect on JNK activation in Kym-1 cells, Hence, TRAIL can engage at least two independent pathways leading to JNK activation, one that is cysteine protease-dependent and one that is cysteine protease-independent. To investigate whether the cysteine protease-dependent signaling of TRAIL leading to JNK activation is related to the apoptotic pathway engaged by this ligand, me investigated HeLa cells stably overexpressing a dominant negative mutant of FADD (Fas-associating protein with death domain) (GFP(green fluorescent protein)Delta FADD). In these cells, TRAIL-induced cell death and activation of the apoptosis executioner caspase-8 (FLICE/MACH) and caspase-3 (YAMA, CPP-32, Apopain), that belong to caspase subfamily of cysteine proteases, were abrogated, whereas JNK activation remained unaffected and was still sensitive toward z-VAD-fmk. Similar data were found in HeLa cells overexpressing Apo1/Fas and GFP Delta FADD upon stimulation with agonistic antibodies. These data suggest that cross-linking of the TRAIL receptors and Apo1/Fas, respectively, engages a FADD-dependent pathway leading to the activation of apoptotic caspases and, in parallel, a FADD-independent pathway leading to the stimulation of one or more cysteine proteases capable to activate JNK but not sufficient for the induction of cell death.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Immunex Res & Dev Corp, Seattle, WA 98101 USA	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; Cahill MA, 1996, ONCOGENE, V13, P2087; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	69	130	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					33091	33098		10.1074/jbc.273.49.33091	http://dx.doi.org/10.1074/jbc.273.49.33091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830064	hybrid			2022-12-25	WOS:000077329100103
J	Dibrov, E; Fu, S; Lemire, BD				Dibrov, E; Fu, S; Lemire, BD			The Saccharomyces cerevisiae TCM62 gene encodes a chaperone necessary for the assembly of the mitochondrial succinate dehydrogenase (Complex II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; IRON-SULFUR PROTEIN; YEAST NUCLEAR GENE; MOLECULAR CHAPERONES; RESPIRATORY-CHAIN; FUNCTIONAL COMPLEMENTATION; FLAVOPROTEIN SUBUNIT; POLYPEPTIDE-BINDING; CRYSTAL-STRUCTURE; CLONING	The assembly of the mitochondrial respiratory chain is mediated by a large number of helper proteins. To better understand the biogenesis of the yeast succinate dehydrogenase (SDH), we searched for assembly-defective mutants. SDH is encoded by the SDR1, SDH2, SDH3, and SDH4 genes. The holoenzyme is composed of two domains. The membrane extrinsic domain, consisting of Sdh1p and Sdh2p, contains a covalent FAD cofactor and three iron-sulfur clusters. The membrane intrinsic domain, consisting of Sdh3p and Sdh4p, is proposed to bind two molecules of ubiquinone and one heme. me isolated one mutant that is respiration-deficient with a specific loss of SDH oxidase activity. SDH is not assembled in this mutant. The complementing gene, TCM62 (also known as SCYBR044C), does not encode an SDH subunit and is not essential for cell viability. It encodes a mitochondrial membrane protein of 64,211 Da. The Tcm62p sequence is 17.3% identical to yeast hsp80, a molecular chaperone. The Tcm62p amino terminus is in the mitochondrial matrix, whereas the carboxyl terminus is accessible from the intermembrane space. Tcm62p forms a complex containing at least three SDH subunits. We propose that Tcm62p functions as a chaperone in the assembly of yeast SDH.	Univ Alberta, Dept Biochem, MRC, Canada Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Dept Biochem, MRC, Canada Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada.	bernard.lemire@ualberta.ca						ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; Bonnefoy N, 1996, MOL GEN GENET, V251, P204; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; BRUEL C, 1995, J BIOL CHEM, V270, P22321, DOI 10.1074/jbc.270.38.22321; Bruel C, 1996, J BIOENERG BIOMEMBR, V28, P59; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAIGNANFORNIER B, 1994, J BIOL CHEM, V269, P15469; DEKOK J, 1975, BIOCHIM BIOPHYS ACTA, V387, P441, DOI 10.1016/0005-2728(75)90084-5; Dibrov E, 1997, J BIOL CHEM, V272, P9175; Ellis RJ, 1997, BIOCHEM BIOPH RES CO, V238, P687, DOI 10.1006/bbrc.1997.7339; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLERUM DM, 1994, P NATL ACAD SCI USA, V91, P8452, DOI 10.1073/pnas.91.18.8452; GLICK BS, 1991, METHOD CELL BIOL, V34, P389; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOVAC L, 1967, SCIENCE, V158, P1564, DOI 10.1126/science.158.3808.1564; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LJUNGDAHL PO, 1989, J BIOL CHEM, V264, P3723; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; LOMBARDO A, 1989, J BIOL CHEM, V264, P18874; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSPERT S, 1993, P NATL ACAD SCI USA, V90, P10967, DOI 10.1073/pnas.90.23.10967; Rospert S, 1996, EMBO J, V15, P764, DOI 10.1002/j.1460-2075.1996.tb00412.x; ROSPERT S, 1993, FEBS LETT, V335, P358, DOI 10.1016/0014-5793(93)80419-U; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SPENCER JFT, 1989, YEAST GENETICS MANUA, P30; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; Wang ZG, 1996, J BIOL CHEM, V271, P4887; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	58	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32042	32048		10.1074/jbc.273.48.32042	http://dx.doi.org/10.1074/jbc.273.48.32042			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822678	hybrid			2022-12-25	WOS:000077207000060
J	Podust, VN; Tiwari, N; Stephan, S; Fanning, E				Podust, VN; Tiwari, N; Stephan, S; Fanning, E			Replication factor C disengages from proliferating cell nuclear antigen (PCNA) upon sliding clamp formation, and PCNA itself tethers DNA polymerase delta to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SIMIAN VIRUS-40 ORIGIN; SACCHAROMYCES-CEREVISIAE; LARGE SUBUNIT; STRANDED-DNA; CALF THYMUS; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; ACCESSORY PROTEINS; COMPLEX-FORMATION	Replication factor C (RF-C) and proliferating cell nuclear antigen (PCNA) assemble a complex, called sliding clamp, onto DNA. The clamp in turn loads DNA polymerases (pol) delta and epsilon to form the corresponding holoenzymes, which play an essential role in replication of eukaryotic chromosomal DNA and in several DNA repair pathways. To determine the fate of RF-C after loading of PCNA onto DNA, we tagged the RF-C subunit p37 with a protein kinase A recognition motif, so that the recombinant five-subunit RF-C complex could be P-32-labeled and quantitatively detected in femtomolar amounts. Nonspecific binding of RF-C to DNA was minimized by replacing the p140 subunit with an N-terminally truncated p140 subunit lacking the previously identified nonspecific DNA binding domain. Neither of these modifications impaired the clamp loading activity of the recombinant RF-C. Using gel filtration techniques, we demonstrated that RF-C dissociated from the DNA after clamp loading or pol delta holoenzyme assembly, while PCNA or PCNA pol delta complex remained bound to DNA. PCNA catalytically loaded onto the template-primer was sufficient by itself to tether pol delta and stimulate DNA replication. The readdition of RF-C to the isolated PCNA DNA complex did not further stimulate pol delta DNA synthesis. We conclude that pol delta holoenzyme consists of PCNA and pol delta core and that RF-C serves only to load PCNA clamp.	Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA; Vanderbilt Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Fanning, E (corresponding author), Vanderbilt Univ, Dept Mol Biol, Box 1820,Stn B, Nashville, TN 37235 USA.	fannine@ctrvax.vanderbilt.edu			NIGMS NIH HHS [GM 52948] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; EKI T, 1992, J BIOL CHEM, V267, P7284; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gibbs E, 1997, J BIOL CHEM, V272, P2373; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hindges R, 1997, BIOL CHEM, V378, P345; HUANG CC, 1981, J BIOL CHEM, V256, P4087; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1989, P NATL ACAD SCI USA, V86, P7361, DOI 10.1073/pnas.86.19.7361; LEE SH, 1991, J BIOL CHEM, V266, P594; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Maga G, 1996, BIOCHEMISTRY-US, V35, P5764, DOI 10.1021/bi952455k; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; McAlear MA, 1996, GENETICS, V142, P65; MOAREFI I, 1993, J VIROL, V67, P4492; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; Podust VN, 1998, J BIOL CHEM, V273, P12935, DOI 10.1074/jbc.273.21.12935; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SCHMITT B, 1984, EUR J BIOCHEM, V144, P127, DOI 10.1111/j.1432-1033.1984.tb08440.x; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TorresRamos CA, 1997, J BIOL CHEM, V272, P25445, DOI 10.1074/jbc.272.41.25445; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Uhlmann F, 1996, P NATL ACAD SCI USA, V93, P6521, DOI 10.1073/pnas.93.13.6521; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1996, DNA REPLICATION EUKA, P461; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WEISER T, 1991, J BIOL CHEM, V266, P10420; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	72	65	78	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					31992	31999		10.1074/jbc.273.48.31992	http://dx.doi.org/10.1074/jbc.273.48.31992			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822671	hybrid			2022-12-25	WOS:000077207000053
J	Das, KC; Guo, XL; White, CW				Das, KC; Guo, XL; White, CW			Protein kinase C delta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MURINE MACROPHAGES; ESCHERICHIA-COLI; PHORBOL ESTER; TAXOL; CELLS; ALPHA; LIPOPOLYSACCHARIDE; INTERLEUKIN-1; ACTIVATION	Bacterial lipopolysaccharide can induce manganese superoxide dismutase (MnSOD) gene expression in a variety of cells. Paclitaxel (taxol) shares many properties of lipopolysaccharide. Here we report that paclitaxel can induce MnSOD gene expression in human lung adenocarcinoma cell line A549 in a time- and dose-dependent manner. Additional anticancer drugs, vinblastine and vincristine, also induced MnSOD gene expression. We have shown previously (Das, K. C., and White, C. W. (1997) J. Biol. Chem. 272, 14914-14920) that these drugs can activate protein kinase C (PKC). The PKC agonists thymeleatoxin (0.5 mu M) and 12-deoxyphorbol 13-phenylacetate 20-acetate (dPPA; 10 nM) potently induced MnSOD gene expression. Calphostin C and GF109203X, both specific inhibitors of PKC, each inhibited MnSOD gene expression by anticancer agents. Down-regulation of PKC by prolonged treatment with phorbol 12-myristate 13-acetate (PMA) also inhibited induction of MnSOD by anticancer drugs, indicating an important role of PKC in MnSOD signaling by these agents. Of 11 PKC isoenzymes, only PKC delta translocated to the cell membrane after stimulation with anticancer drugs. By contrast, dPPA, PMA, and thymeleatoxin caused translocation of PKC alpha, beta I, delta, and mu isotypes. Anticancer drug-stimulated cells also had increased total PKC activity in membrane and cytosolic fractions. Thus, paclitaxel, vinblastine, and vincristine each specifically activate PKC delta, whereas PMA, thymeleatoxin, and dPPA activate multiple isoenzymes. PKC delta was the only isoform activated by each agent in both groups of compounds effective in MnSOD induction.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	National Jewish Health	Das, KC (corresponding author), Univ Texas, Ctr Hlth, Dept Mol Biol, 11937 US Highway 271, Tyler, TX 75708 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052732, P50HL057144] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52732, HL 57144] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; FORMAN HJ, 1981, LAB INVEST, V45, P1; FREEMAN BA, 1986, EXP LUNG RES, V10, P203, DOI 10.3109/01902148609061493; FUJII J, 1991, J BIOL CHEM, V266, P23142; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; ITO M, 1986, BIOCHEMISTRY-US, V25, P4179, DOI 10.1021/bi00363a002; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KIFEY SC, 1994, CARCINOGENESIS, V15, P319; KIRIKAE F, 1995, INFECT IMMUN, V63, P486, DOI 10.1128/IAI.63.2.486-497.1995; KRALL J, 1988, J BIOL CHEM, V263, P1910; KUMAR N, 1981, J BIOL CHEM, V256, P435; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; Martelly I, 1989, CURR OPIN CELL BIOL, V1, P206, DOI 10.1016/0955-0674(89)90088-4; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBERLEY LW, 1987, ARCH BIOCHEM BIOPHYS, V254, P69, DOI 10.1016/0003-9861(87)90082-8; PRIVALLE CT, 1988, J BIOL CHEM, V263, P4274; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIAVONE JR, 1988, J BIOL CHEM, V263, P4269; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WATANABE K, 1982, FED PROC, V41, P2292; WHITSETT JA, 1992, AM J PHYSIOL, V262, pL688, DOI 10.1152/ajplung.1992.262.6.L688; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	38	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34639	34645		10.1074/jbc.273.51.34639	http://dx.doi.org/10.1074/jbc.273.51.34639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852137	hybrid			2022-12-25	WOS:000077542200103
J	Haque, SJ; Harbor, P; Tabrizi, M; Yi, TL; Williams, BRG				Haque, SJ; Harbor, P; Tabrizi, M; Yi, TL; Williams, BRG			Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; INTERLEUKIN-4 RECEPTOR; TRANSCRIPTION FACTOR; MOTH-EATEN; INSULIN; GROWTH; KINASE; PHOSPHORYLATION; ACTIVATION; COMPONENT	Binding of interleukin (IL)-4 to its transmembrane receptor results in the Jak-mediated tyrosine phosphorylation of a number of protein components of the IL-4 signaling cascade, including Jak1, Jak2, Jak3,Tyk2, IL-4R alpha, IRS-1, IRS-2, and Stat6 in appropriate cell types. However, the protein-tyrosine phosphatases (PTPs) that dephosphorylate these proteins and terminate signaling remained unidentified. We have noted that IL-4-dependent activation of State is sustained longer in fibroblasts than in lymphoid cells. Because Shp-1, an SH2 domain-containing PTP, is expressed primarily in hematopoietic cells, we examined whether Shp-1 activity could regulate IL-4-dependent cell signaling. Expression of an Shp-1 transgene in NIH 3T3 cells markedly reduces both IL-4-dependent State activation and Stat6-mediated transcription of IL-4-responsive genes. In accord with this, IL-4 treatment of bone marrow-derived macrophages from viable motheaten mice that express substantially reduced levels of Shp-1 activity show remarkably enhanced activation of Stat6. In addition, Stat6 activation by IL-4 is significantly enhanced in pre-B cells derived from motheaten (Shp-1 nub mutant) mice compared with normal pre-B cells derived from control animals. These data clearly implicate Shp-1 in the negative regulation of the IL-4/IL-13-activated Jak-Stat pathway.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Haque, SJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Room NN1-12,9500 Euclid Ave, Cleveland, OH 44195 USA.	haquej@cesmtp.ccf.org	Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Aman NJ, 1997, CURR BIOL, V7, pR784, DOI 10.1016/S0960-9822(06)00405-2; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Callard RE, 1996, IMMUNOL TODAY, V17, P108, DOI 10.1016/0167-5699(96)80600-1; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; HAQUE SJ, 1995, J BIOL CHEM, V270, P25709, DOI 10.1074/jbc.270.43.25709; Haque SJ, 1998, SEMIN ONCOL, V25, P14; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Jiao HY, 1997, EXP HEMATOL, V25, P592; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Keegan AD, 1996, IMMUNOLOGIST, V4, P194; KINGMULLER U, 1995, CELL, V80, P729; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Migone TS, 1998, P NATL ACAD SCI USA, V95, P3845, DOI 10.1073/pnas.95.7.3845; Mikita T, 1996, MOL CELL BIOL, V16, P5811; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PalmerCrocker RL, 1996, J CLIN INVEST, V98, P604, DOI 10.1172/JCI118829; PAUL WE, 1991, BLOOD, V77, P1859; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244; YANG W, 1998, BLOOD, V91, P1; YANG W, 1998, IN PRESS EXP HEMATOL; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	35	146	157	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33893	33896		10.1074/jbc.273.51.33893	http://dx.doi.org/10.1074/jbc.273.51.33893			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852037	hybrid			2022-12-25	WOS:000077542200003
J	Li, T; Rosazza, JPN				Li, T; Rosazza, JPN			NMR identification of an acyl-adenylate intermediate in the aryl-aldehyde oxidoreductase catalyzed reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE QUANTUM NMR; ACID; PURIFICATION	A new one-pot synthesis was designed to prepare benzoyl-AMP under anhydrous conditions in N,N-dimethylformamide. Reaction of benzoic acid with N,N'-carbonyldiimidazole and subsequently with 5'-adenosyl monophosphate gave the mixed anhydride in 76% isolated yield. The structure of benzoyl-AMP was confirmed by mass spectroscopy and H-1-, P-31-, and C-13-NMR, The purity of the preparation was greater than 98% as indicated by P-31- and C-13-NMR. Purified aryl-aldehyde oxidoreductase was incubated in NMR tubes together with either carboxy-C-13-benzoyl-AMP or carboxy-C-13-benzoic acid to demonstrate that benzoyl-AMP is an active intermediate during the enzymatic reduction of benzoic acid to benzaldehyde.	Univ Iowa, Coll Pharm, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Coll Pharm, Ctr Biocatalysis & Bioproc, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Rosazza, JPN (corresponding author), Univ Iowa, Coll Pharm, Div Med & Nat Prod Chem, Iowa City, IA 52242 USA.	john-rosazza@uiowa.edu						ARMSTRONG DW, 1979, J MOL EVOL, V13, P103, DOI 10.1007/BF01732866; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BERG P, 1958, J BIOL CHEM, V233, P608; Chang KH, 1997, BIOCHEMISTRY-US, V36, P15650, DOI 10.1021/bi971262p; CHRISTNER JE, 1964, J BIOL CHEM, V239, P3997; DEMOSS JA, 1956, P NATL ACAD SCI USA, V42, P325, DOI 10.1073/pnas.42.6.325; Dieckmann R, 1997, EUR J BIOCHEM, V247, P1074, DOI 10.1111/j.1432-1033.1997.01074.x; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P818, DOI 10.1021/bi00649a014; GROSS GG, 1972, EUR J BIOCHEM, V31, P585, DOI 10.1111/j.1432-1033.1972.tb02569.x; KATO N, 1991, AGR BIOL CHEM TOKYO, V55, P757, DOI 10.1080/00021369.1991.10870679; KELLER U, 1984, BIOCHEMISTRY-US, V23, P1479, DOI 10.1021/bi00302a022; KELLERMAN GM, 1958, J BIOL CHEM, V231, P427; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; KOSOW DP, 1962, J BIOL CHEM, V237, P3633; Li T, 1997, J BACTERIOL, V179, P3482, DOI 10.1128/jb.179.11.3482-3487.1997; LOFTFIELD RB, 1966, BIOCHIM BIOPHYS ACTA, V130, P426, DOI 10.1016/0304-4165(66)90239-X; MAO LF, 1992, J BIOL CHEM, V267, P3143; MICHELSON AM, 1964, BIOCHIM BIOPHYS ACTA, V80, P242, DOI 10.1016/0926-6550(64)90096-9; SIEGEL L, 1963, BIOCHEM BIOPH RES CO, V13, P307, DOI 10.1016/0006-291X(63)90490-X; SOLY RR, 1991, J MOL BIOL, V219, P69, DOI 10.1016/0022-2836(91)90858-4; Staab H.A., 1962, ANGEW CHEM INT EDIT, V1, P351, DOI [10.1002/anie.196203511, DOI 10.1002/ANIE.196203511]; VIGNAIS PV, 1958, BIOCHIM BIOPHYS ACTA, V29, P263, DOI 10.1016/0006-3002(58)90183-5; WICJRAMASINGKE NSM, 1991, BIOCHEMISTRY-US, V30, P2768	24	19	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34230	34233		10.1074/jbc.273.51.34230	http://dx.doi.org/10.1074/jbc.273.51.34230			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852085	hybrid			2022-12-25	WOS:000077542200051
J	Okuno, S; Shimizu, S; Ito, T; Nomura, M; Hamada, E; Tsujimoto, Y; Matsuda, H				Okuno, S; Shimizu, S; Ito, T; Nomura, M; Hamada, E; Tsujimoto, Y; Matsuda, H			Bcl-2 prevents caspase-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CYTOCHROME-C; MEDIATED APOPTOSIS; PROTEASES; INHIBITION; PROTEIN; RELEASE; MITOCHONDRIA; EXPRESSION; INDUCTION	Nitric oxide (NO) is implicated in apoptosis and has both cytotoxic and cytoprotective effects. Exogenous NO induced the death of PC12 and HeLa cells via a process showing features of both apoptosis: and necrosis, with chromatin condensation, nuclear compaction, and mitochondrial swelling. Activation of caspases was not observed during NO-induced cell death. In addition, cell death was not inhibited by peptide caspase inhibitors or by expression of p35, a baculovirus-encoded caspase inhibitor, indicating that NO-induced cell death was independent of caspases. NO-induced cell death was enhanced by Bar expression in a caspase-independent manner and prevented by the anti-cell death protein Bcl-2. Although Bcl-2 has previously been shown to prevent cell. death by inhibiting caspase activation, these results indicate that it can also prevent cell death via a caspase-independent mechanism.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Surg 1, Osaka 5650871, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan	Osaka University; Osaka University	Shimizu, S (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Surg 1, 2-2 Yamadaoka, Osaka 5650871, Japan.							BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brockhaus F, 1998, EXP CELL RES, V238, P33, DOI 10.1006/excr.1997.3778; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Hasegawa J, 1996, CANCER RES, V56, P1713; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MEBNER UK, 1996, J BIOL CHEM, V271, P20192; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nicotera P, 1997, TRENDS PHARMACOL SCI, V18, P189, DOI 10.1016/S0165-6147(97)90619-2; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1996, ONCOGENE, V12, P2251; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SUSIN SA, 1996, J EXP MED, V184, P1; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	33	144	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34272	34277		10.1074/jbc.273.51.34272	http://dx.doi.org/10.1074/jbc.273.51.34272			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852091	hybrid			2022-12-25	WOS:000077542200057
J	Sutton, MD; Carr, KM; Vicente, N; Kaguni, JM				Sutton, MD; Carr, KM; Vicente, N; Kaguni, JM			Escherichia coli DnaA protein - The N-terminal domain and loading of DnaB helicase at the E-coli chromosomal origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; LAMBDA-REPLICATION ORIGIN; BACTERIOPHAGE-LAMBDA; O-PROTEIN; STRANDED-DNA; PHAGE-LAMBDA; INITIATION; BINDING; COMPLEX; GENE	Initiation of DNA replication at the Escherichia coli chromosomal origin occurs through an ordered series of events that depends first on the binding of DnaA protein, the replication initiator, to DnaA box sequences followed by unwinding of an AT-rich region. A step that follows is the binding of DnaB helicase at oriC so that it is properly positioned at each replication fork. We show that DnaA protein actively mediates the entry of DnaB at oriC. One region (amino acids 111-148) transiently binds to DnaB as determined by surface plasmon resonance. A second functional domain, possibly involving formation of a unique nucleoprotein structure, promotes the stable binding of DnaB during the initiation process and is inactivated in forming an intermediate termed the prepriming complex by removal of the N-terminal 62 residues. Based on similarities :in the replication process between prokaryotes and eukaryotes, these results suggest that a similar mechanism may load the eukaryotic replicative helicase.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Kaguni, JM (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	kaguni@pilotk.msu.edu	Vicente, Natallia/HCI-4226-2022	Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; CASSLER MR, 1995, EMBO J, V14, P5833, DOI 10.1002/j.1460-2075.1995.tb00271.x; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GOTFRIED F, 1977, J BACTERIOL, V130, P963, DOI 10.1128/JB.130.2.963-964.1977; HANSEN EB, 1982, NUCLEIC ACIDS RES, V10, P7373, DOI 10.1093/nar/10.22.7373; HANSEN EB, 1984, MOL GEN GENET, V196, P387, DOI 10.1007/BF00436184; HANSEN FG, 1979, MOL GEN GENET, V175, P135, DOI 10.1007/BF00425529; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1992, J BIOL CHEM, V267, P23083; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; Kaguni JM, 1997, MOL CELLS, V7, P145; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KLEIN A, 1980, EUR J BIOCHEM, V105, P1, DOI 10.1111/j.1432-1033.1980.tb04467.x; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lee YS, 1997, J BIOL CHEM, V272, P83; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; MCMACKEN R, 1983, MECHANISMS DNA REPLI, P819; NOMURA N, 1991, GENE, V108, P15; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; Schaper S, 1997, PROTEINS, V28, P1; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; Sutton MD, 1997, J MOL BIOL, V271, P693, DOI 10.1006/jmbi.1997.1209; Sutton MD, 1997, J MOL BIOL, V274, P546, DOI 10.1006/jmbi.1997.1425; Sutton MD, 1997, J BIOL CHEM, V272, P23017, DOI 10.1074/jbc.272.37.23017; SUTTON MD, 1995, J BACTERIOL, V177, P6657, DOI 10.1128/jb.177.22.6657-6665.1995; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSURIMOTO T, 1981, NUCLEIC ACIDS RES, V9, P1789, DOI 10.1093/nar/9.8.1789; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; ZAHN K, 1985, EMBO J, V4, P3605, DOI 10.1002/j.1460-2075.1985.tb04124.x; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	56	133	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34255	34262		10.1074/jbc.273.51.34255	http://dx.doi.org/10.1074/jbc.273.51.34255			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852089	hybrid			2022-12-25	WOS:000077542200055
J	Thompson, MA; Weinshilboum, RM				Thompson, MA; Weinshilboum, RM			Rabbit lung indolethylamine N-methyltransferase - cDNA and gene cloning and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; BRAIN; EXPRESSION; LIVER; ELECTROPHORESIS; NEUROTOXINS; METHYLATION; PROTEINS; DNA	Indolethylamine N-methyltransferase (INMT) catalyzes the N-methylation of tryptamine and structurally related compounds. This-reaction has been studied because of its possible role in the in vivo synthesis of psychoactive compounds or neurotoxins and has been characterized biochemically in preparations of rabbit lung. Therefore, we set out to purify rabbit lung INMT, to clone and express its cDNA, and to clone and structurally characterize its gene as steps toward understanding the function and regulation of this enzyme. Rabbit lung INMT was purified and partial amino acid sequence was obtained, A polymerase chain reaction-based approach was then used to clone a rabbit lung INMT cDNA with a 792-base pair open reading frame that encoded a 263-amino acid protein with a predicted molecular mass of 29 kDa. When the cDNA was expressed in COS-1 cells, the encoded protein catalyzed the methylation of tryptamine and structurally related compounds, and was inhibited by two products of the reaction, S-adenosyl-L-homocysteine (AdoHcy) and N,N-dimethyltryptamine, as well as antimigraine drugs that are structurally related to N,N-dimethyltryptamine. Northern blot analysis demonstrated the presence of 2.0-kilobase mRNA species in rabbit lung, liver and, at lower levels, in brain, The cDNA was then used to clone the rabbit INMT gene. That gene had three exons and was structurally similar to the genes for nicotinamide N-methyltransferase and phenylethanolamine N-methyltransferase in several species. Cloning and expression of a rabbit lung INMT cDNA and cloning of the rabbit INMT gene represent important steps toward determination of the function and regulation of this mammalian methyltransferase enzyme.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Pharmacol, Rochester, MN 55905 USA	Mayo Clinic	Weinshilboum, RM (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Pharmacol, 200 1st St SW, Rochester, MN 55905 USA.	weinshilboum.richard@mayo.edu			NIGMS NIH HHS [R01 GM35720, R01 GM28157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028157, R01GM035720] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKSOY S, 1994, J BIOL CHEM, V269, P14835; AKSOY S, 1995, GENOMICS, V29, P555, DOI 10.1006/geno.1995.9966; ANSHER SS, 1986, J BIOL CHEM, V261, P3996; AXELROD J, 1962, J PHARMACOL EXP THER, V138, P28; AXELROD J, 1961, SCIENCE, V134, P343, DOI 10.1126/science.134.3475.343; BAETGE EE, 1988, P NATL ACAD SCI USA, V85, P3648, DOI 10.1073/pnas.85.10.3648; BATTER DK, 1988, J NEUROSCI RES, V19, P367, DOI 10.1002/jnr.490190313; BHIKHARIDAS B, 1975, J NEUROCHEM, V24, P203, DOI 10.1111/j.1471-4159.1975.tb07653.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN HT, 1995, J IMMUNOL, V154, P6365; CLELAND WW, 1963, NATURE, V198, P463, DOI 10.1038/198463a0; COLLINS MA, 1992, BRAIN RES, V570, P154, DOI 10.1016/0006-8993(92)90576-U; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HERMAN KS, 1985, J BIOL CHEM, V260, P2336; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; KENNEDY B, 1995, J CLIN INVEST, V95, P2896, DOI 10.1172/JCI117996; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lee LG, 1997, NUCLEIC ACIDS RES, V25, P2816, DOI 10.1093/nar/25.14.2816; LYON ES, 1982, J BIOL CHEM, V257, P7531; MANDELL AJ, 1974, LIFE SCI, V14, P1, DOI 10.1016/0024-3205(74)90241-0; MATSUBARA K, 1992, J NEUROCHEM, V59, P511, DOI 10.1111/j.1471-4159.1992.tb09400.x; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MORITA S, 1992, MOL BRAIN RES, V13, P313, DOI 10.1016/0169-328X(92)90214-V; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nagatsu T, 1997, NEUROSCI RES, V29, P99, DOI 10.1016/S0168-0102(97)00083-7; NAOI M, 1989, BIOCHEM BIOPH RES CO, V161, P1213, DOI 10.1016/0006-291X(89)91371-5; Naoi M, 1997, J NEURAL TRANSM-SUPP, P89; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PORTA R, 1979, J BIOCH, V10, P919; RINI J, 1989, CLIN CHIM ACTA, V186, P359; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAAVEDRA JM, 1972, SCIENCE, V175, P1365, DOI 10.1126/science.175.4028.1365; SAAVEDRA JM, 1973, J NEUROCHEM, V20, P743, DOI 10.1111/j.1471-4159.1973.tb00035.x; SUH YH, 1994, J NEUROCHEM, V63, P1603; VANLOON JA, 1992, BIOCHEM PHARMACOL, V44, P775, DOI 10.1016/0006-2952(92)90416-G; WARNER DR, 1995, BBA-PROTEIN STRUCT M, V1246, P160, DOI 10.1016/0167-4838(94)00186-K; WEINSHILBOUM R, 1989, PHARMACOL THERAPEUT, V43, P77, DOI 10.1016/0163-7258(89)90048-X; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; WYATT RJ, 1973, AM J PSYCHIAT, V130, P754, DOI 10.1176/ajp.130.7.754; Yan L, 1998, DNA CELL BIOL, V17, P659, DOI 10.1089/dna.1998.17.659; Yan L, 1997, BIOCHEM PHARMACOL, V54, P1139, DOI 10.1016/S0006-2952(97)00325-0	43	31	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34502	34510		10.1074/jbc.273.51.34502	http://dx.doi.org/10.1074/jbc.273.51.34502			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852119	hybrid			2022-12-25	WOS:000077542200085
J	Hinkovska-Galcheva, VT; Boxer, LA; Mansfield, PJ; Harsh, D; Blackwood, A; Shayman, JA				Hinkovska-Galcheva, VT; Boxer, LA; Mansfield, PJ; Harsh, D; Blackwood, A; Shayman, JA			The formation of ceramide-1-phosphate during neutrophil phagocytosis and its role in liposome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; IGG-DEPENDENT PHAGOCYTOSIS; LEUKEMIA HL-60 CELLS; MEMBRANE-FUSION; PHOSPHOLIPASE-D; DIACYLGLYCEROL KINASE; CYCLE ARREST; CERAMIDE; SPHINGOSINE; AGGREGATION	Ceramide, a product of agonist-stimulated sphingomyelinase activation, is known to be generated during the phagocytosis of antibody-coated erythrocytes by polymorphonuclear leukocytes. Agonist-stimulated formation of ceramide-1-phosphate is now shown to occur in (PO4)-P-32-labeled neutrophils. Ceramide-1-phosphate is formed by a calcium-dependent ceramide kinase, found predominately in the neutrophil plasma membrane. The neutrophil kinase is specific for ceramide because, in contrast to the bacterial diglyceride kinase, ceramide is not phosphorylated under conditions specific for diglyceride phosphorylation, Conversely, 1,2-diacylglycerol does not serve as substrate for the neutrophil ceramide kinase, Ceramide kinase activation occurs in a time-dependent fashion, reaching peak activity 10 min after formyl peptide stimulation and challenge with antibody coated erythrocytes. The lipid kinase activity is optimal at pH 6.8. Because the formation of the phagolysosome is a critical event in phagocytosis, the effect of ceramide-1-phosphate in promoting the fusion of liposomes was determined. Both the addition of increasing concentrations of sphingomyelinase D and ceramide phosphate promoted liposomal fusion, In summary, ceramide-1-phosphate is formed during phagocytosis through activation of ceramide kinase. Ceramide-1-phosphate may promote phagolysosome formation.	Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Div Hematol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Dept Internal Med, Div Nephrol, 1560 MSRBII,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	jshayman@umich.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487, P50DK039255] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20065] Funding Source: Medline; NIDDK NIH HHS [DK39255, DK41487] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; BOXER GJ, 1985, HOSP PRACT, V40, P69; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; DUZGUNES N, 1987, BIOCHEMISTRY-US, V26, P8435, DOI 10.1021/bi00399a061; DUZGUNES N, 1981, BIOCHIM BIOPHYS ACTA, V642, P182, DOI 10.1016/0005-2736(81)90148-6; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FOREHAND JR, 1993, J IMMUNOL, V151, P4918; FRANCIS JW, 1990, BIOCHIM BIOPHYS ACTA, V1025, P1, DOI 10.1016/0005-2736(90)90183-O; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HINKOVSKAGALCHE.V, 1998, BLOOD, V91, P1; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JOLLES J, 1981, BIOCHEM J, V194, P283, DOI 10.1042/bj1940283; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KANOH H, 1983, J BIOL CHEM, V258, P1767; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; Kolesnick Richard, 1992, Trends in Cell Biology, V2, P232, DOI 10.1016/0962-8924(92)90310-J; KOLESNICK RN, 1990, J BIOL CHEM, V265, P18803; MEDLOCK KA, 1988, BIOCHEMISTRY-US, V27, P7079, DOI 10.1021/bi00418a061; MERRILL AH, 1994, CURR TOP MEMBR, V40, P361, DOI 10.1016/S0070-2161(08)60988-0; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; POMMIER CG, 1983, J EXP MED, V157, P1844, DOI 10.1084/jem.157.6.1844; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; Suchard SJ, 1997, BLOOD, V89, P2139, DOI 10.1182/blood.V89.6.2139; Suchard SJ, 1997, J IMMUNOL, V158, P4961; SYNDERMAN R, 1988, INFLAMMATION BASIC P, P309; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; WOODIN AM, 1966, BIOCHEM J, V99, P493, DOI 10.1042/bj0990493	40	105	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33203	33209		10.1074/jbc.273.50.33203	http://dx.doi.org/10.1074/jbc.273.50.33203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837889	hybrid			2022-12-25	WOS:000077462500019
J	Keener, J; Josaitis, CA; Dodd, JA; Nomura, M				Keener, J; Josaitis, CA; Dodd, JA; Nomura, M			Reconstitution of yeast RNA polymerase I transcription in vitro from purified components - TATA binding protein is not required for basal transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; RDNA TRANSCRIPTION; RIBOSOMAL-RNA; COMPLEX-FORMATION; INITIATION; PROMOTER; SUBUNIT; GENE; DNA; INVITRO	Five purified protein components, RNA polymerase I, Rrn3p, core factor, TBP (TATA-binding protein), and upstream activation factor, are sufficient for high level transcription in vitro from the Saccharomyces cerevisiae rDNA promoter. Rrn3p and pol I form a complex in solution that is active in specific initiation. Three protein components, pol I, Rrn3p, and core factor, and promoter sequence to -38, suffice for basal transcription. Unlike pol II and pol III, yeast pol I basal transcription does not require TBP. Instead, TBP, upstream activation factor, and the upstream. element of the promoter together stimulate pol I basal transcription to a fully activated level. The role of TBP in pol I transcription is fundamentally different from its role in pol II or pol III transcription.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Nomura, M (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.	mnomura@uci.edu			NIGMS NIH HHS [GM35949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035949, R01GM035949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; CHOE SY, 1992, NUCLEIC ACIDS RES, V20, P279, DOI 10.1093/nar/20.2.279; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Harlow E., 1988, ANTIBODIES LAB MANUA; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; KAISER C, 1994, METHODS YEAST GENETI, P151; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Keener J, 1997, P NATL ACAD SCI USA, V94, P13458, DOI 10.1073/pnas.94.25.13458; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; KLEMENZ R, 1980, NUCLEIC ACIDS RES, V8, P2679, DOI 10.1093/nar/8.12.2679; KLOOTWIJK J, 1979, NUCLEIC ACIDS RES, V6, P27, DOI 10.1093/nar/6.1.27; KULKENS T, 1991, NUCLEIC ACIDS RES, V19, P5363, DOI 10.1093/nar/19.19.5363; Lalo D, 1996, J BIOL CHEM, V271, P21062, DOI 10.1074/jbc.271.35.21062; Lin CW, 1996, MOL CELL BIOL, V16, P6436; LUE NF, 1990, J BIOL CHEM, V265, P18091; Milkereit P, 1998, EMBO J, V17, P3692, DOI 10.1093/emboj/17.13.3692; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; MUSTERS W, 1989, NUCLEIC ACIDS RES, V17, P9661, DOI 10.1093/nar/17.23.9661; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P3962, DOI 10.1073/pnas.88.9.3962; NOGI Y, 1993, MOL CELL BIOL, V13, P114, DOI 10.1128/MCB.13.1.114; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P7025; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Reeder R. H., 1995, NUCL ACIDS MOL BIOL, V9, P251; RIGGS DL, 1995, J BIOL CHEM, V270, P6205, DOI 10.1074/jbc.270.11.6205; RIGGS DL, 1990, J BIOL CHEM, V265, P7596; RIVA M, 1982, J BIOL CHEM, V257, P4570; SCHNAPP A, 1991, J BIOL CHEM, V266, P24588; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; Steffan JS, 1998, MOL CELL BIOL, V18, P3752, DOI 10.1128/MCB.18.7.3752; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	45	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33795	33802		10.1074/jbc.273.50.33795	http://dx.doi.org/10.1074/jbc.273.50.33795			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837969	hybrid			2022-12-25	WOS:000077462500099
J	Kieffer, B; Dillmann, B; Lefevre, JF; Goumon, Y; Aunis, D; Metz-Boutigue, MH				Kieffer, B; Dillmann, B; Lefevre, JF; Goumon, Y; Aunis, D; Metz-Boutigue, MH			Solution conformation of the synthetic bovine proenkephalin-A(209-237) by H-1 NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; PROLINE RESIDUES; PEPTIDE-B; ENKEPHALIN; PROTEINS; PROGRAM; HELICES; ENERGY; DOMAIN; BRAIN	Proenkephalin-A has been described to generate enkephalins, opoid peptides, and several derived peptides, which display various biological effects, including antinociception and immunological enhancement. Recently, we have isolated from bovine chromaffin grannies a new antibacterial peptide, named enkelytin, which corresponds to the bisphosphorylated form of PEAP(209-237) (Goumon, Y., Strub, J. M., Moniatte, M., Nullans, G., Poteur, L., Hubert, P., Van Dorsselaer, A., Aunis, D., and Metz-Boutigue, M. H. (1996) Eur. J. Biochem. 235, 516-525). In this paper, the three-dimensional solution structure of synthetic PEAP(209-237) was investigated by NMR. These studies indicate that this peptide, which is unstructured in water, folds into an cu-helical structure in trifluoroethanol/water (1/1). NMR data revealed two possible three-dimensional models of PEAP(209-237). In both models, the proline residue Pro-227 induces a 90 degrees hinge between two alpha-helical segments (Ser-215 to Ser-221 and Glu-228 to Arg-232) leading to an overall L-shaped structure for the molecule. The negative charge of PEAP(209-237) and the low amphipathy of the two alpha-helical segments imply new mechanisms to explain the antibacterial activity of enkelytin.	INSERM, U338, F-67084 Strasbourg, France; CNRS, UPR 9003, F-67400 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS)	Metz-Boutigue, MH (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Kieffer, Bruno/AAE-8999-2019; Dominique, Aunis/W-1419-2019	Kieffer, Bruno/0000-0002-2033-4679; DILLMANN, Baudouin/0000-0003-4498-5780				AUBRY A, 1989, BIOPOLYMERS, V28, P27, DOI 10.1002/bip.360280106; AUE WP, 1976, J CHEM PHYS, V64, P2229, DOI 10.1063/1.432450; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROWN SC, 1988, J MAGN RESON, V77, P166, DOI 10.1016/0022-2364(88)90042-X; BRUNGER AT, 1992, XPLOR SOFTWARE MANUA; Chang DK, 1997, J PEPT RES, V49, P432; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; CHU SS, 1995, BIOPOLYMERS, V35, P583, DOI 10.1002/bip.360350604; COMB M, 1982, NATURE, V295, P663, DOI 10.1038/295663a0; CREAMER TP, 1995, PROTEIN SCI, V4, P1305, DOI 10.1002/pro.5560040706; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; DSOUZA NB, 1988, J BIOL CHEM, V263, P2548; Gesell J, 1997, J BIOMOL NMR, V9, P127, DOI 10.1023/A:1018698002314; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; Goumon Y, 1998, J BIOL CHEM, V273, P29847, DOI 10.1074/jbc.273.45.29847; HUGHES J, 1975, NATURE, V258, P577, DOI 10.1038/258577a0; KILPATRICK DL, 1981, P NATL ACAD SCI-BIOL, V78, P3265, DOI 10.1073/pnas.78.5.3265; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis R V, 1980, Adv Biochem Psychopharmacol, V22, P167; LEWIS RV, 1983, ANNU REV PHARMACOL, V23, P353, DOI 10.1146/annurev.pa.23.040183.002033; LINDBERG I, 1986, BIOCHEM BIOPH RES CO, V139, P1024, DOI 10.1016/S0006-291X(86)80280-7; LISTON D, 1984, SCIENCE, V225, P734, DOI 10.1126/science.6547780; MARION D, 1989, J MAGN RESON, V84, P425, DOI 10.1016/0022-2364(89)90391-0; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; MARTENS GJM, 1984, NATURE, V310, P251, DOI 10.1038/310251a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILON A, 1990, BIOCHEMISTRY-US, V29, P65, DOI 10.1021/bi00453a009; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; POLINSKY A, 1992, BIOPOLYMERS, V32, P399, DOI 10.1002/bip.360320416; Salzet M, 1997, BRAIN RES, V768, P224, DOI 10.1016/S0006-8993(97)00646-X; SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; Stefano GB, 1998, IMMUNOL TODAY, V19, P265, DOI 10.1016/S0167-5699(98)01268-7; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; TERWILLIGER TC, 1982, BIOPHYS J, V37, P353, DOI 10.1016/S0006-3495(82)84683-3; Vignal E, 1998, EUR J BIOCHEM, V253, P221, DOI 10.1046/j.1432-1327.1998.2530221.x; WATKINSON A, 1989, J BIOL CHEM, V264, P3061; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; ZAGORSKI MG, 1991, BIOCHEMISTRY-US, V30, P8009, DOI 10.1021/bi00246a019	44	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33517	33523		10.1074/jbc.273.50.33517	http://dx.doi.org/10.1074/jbc.273.50.33517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837932	hybrid			2022-12-25	WOS:000077462500062
J	May, GHW; Allen, KE; Clark, W; Funk, M; Gillespie, DAF				May, GHW; Allen, KE; Clark, W; Funk, M; Gillespie, DAF			Analysis of the interaction between c-Jun and c-Jun N-terminal kinase in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; SIGNAL-TRANSDUCTION; V-JUN; HA-RAS; TRANSCRIPTIONAL ACTIVATION; INDUCED APOPTOSIS; MAP KINASES; PHOSPHORYLATION; STRESS; DOMAIN	Regulation of c-Jun transcriptional activity is believed to depend on a physical interaction with c-Jun N-terminal kinase (JNK) that facilitates signal-regulated phosphorylation of multiple regulatory phosphoacceptor sites within the activation domain. Here we have investigated the structural requirements and consequences of regulatory phosphorylation for the interaction between c-Jun and JNK in vivo. We show that binding of JNK to c-Jun in vivo does not require JNK catalytic activity or the presence of the potential phosphoacceptor sites within c-Jun. and that JNK retains the capacity to bind to a pseudo-phosphorylated mutant of c-Jun where these sites are replaced by phospho-mimetic aspartic acid residues. The c-Jun delta region docking site is essential for interaction with JNK in vivo but is not sufficient, because a c-Jun mutant that retains this region but that lacks the C-terminal DNA-binding domain fails to interact. Experiments using purified recombinant c-Jun and JNK proteins show that the c-Jun DNA-binding domain harbors an auxiliary interaction domain that has the potential to bind to JNK independently. Our results suggest that JNK can be tethered passively to c-Jun in situ through multiple interacting regions and, when activated, can stimulate c-Jun phosphorylation without necessarily dissociating from its substrate. Auxiliary interactions mediated by the DNA-binding domain could play a role in targeting JNK preferentially to c-Jun in specific homo- or heterodimeric complexes.	Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; MediGene GmbH, D-82152 Martinsried, Germany	Beatson Institute	May, GHW (corresponding author), Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Abate C, 1990, Semin Cancer Biol, V1, P19; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kilbey A, 1996, ONCOGENE, V12, P2409; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; Mizukami Y, 1997, J BIOL CHEM, V272, P16657, DOI 10.1074/jbc.272.26.16657; Nehme A, 1997, CANCER RES, V57, P3253; NISHIMURA T, 1988, ONCOGENE, V3, P659; OEHLER T, 1993, ONCOGENE, V8, P1141; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Peverali FA, 1996, EMBO J, V15, P3943, DOI 10.1002/j.1460-2075.1996.tb00768.x; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798	45	34	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33429	33435		10.1074/jbc.273.50.33429	http://dx.doi.org/10.1074/jbc.273.50.33429			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837920	hybrid			2022-12-25	WOS:000077462500050
J	Nagase, M; Abe, J; Takahashi, K; Ando, J; Hirose, S; Fujita, T				Nagase, M; Abe, J; Takahashi, K; Ando, J; Hirose, S; Fujita, T			Genomic organization and regulation of expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID SHEAR-STRESS; HERITABLE HYPERLIPIDEMIC RABBIT; MONOCYTE CHEMOTACTIC PROTEIN-1; VASCULAR ENDOTHELIAL-CELLS; NITRIC-OXIDE PRODUCTION; SMOOTH-MUSCLE CELLS; SCAVENGER RECEPTOR; RESPONSE ELEMENT; CHAIN PROMOTER; ATHEROSCLEROSIS	Lectin-like oxidized low-density lipoprotein receptor (LOX-1) is a recently identified receptor for oxidized low-density lipoprotein, one of the major atherogenic substances. Although LOX-1 was reported to be expressed abundantly in endothelial cells, including atheromatous lesions, the regulation of LOX-1 gene has not yet been clarified. In the present study, we isolated the rat LOX-1 gene and investigated the regulation of gene expression. The rat LOX-1 gene was encoded by a single copy gene spanning over 19 kilobases and consisted of eight exons. Exon boundaries correlated well with the functional domain boundaries of the receptor protein. The promoter region contained putative TATA and CAAT boxes and multiple cis-elements such as NF-kappa B, AP-1 and AP-2 sites, and a shear stress response element. Northern blot analysis revealed that LOX-1 gene expression was up-regulated 9-fold by shear stress, 21-fold by lipopolysaccharide, and 4-fold by tumor necrosis factor-cy, in cultured vascular endothelial cells. LOX-1 was also expressed in macrophages but not in vascular smooth muscle cells. These data provide important information for elucidating the molecular mechanisms of LOX-1 gene regulation and suggest a role for LOX-1 in the pathophysiology of atherosclerotic cardiovascular disease.	Univ Tokyo, Sch Med, Dept Internal Med 4, Bunkyo Ku, Tokyo 1120015, Japan; Tokyo Inst Technol, Dept Biol Sci, Kanagawa 2268503, Japan; Univ Tokyo, Grad Sch Med, Dept Biomed Engn, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; Tokyo Institute of Technology; University of Tokyo	Nagase, M (corresponding author), Univ Tokyo, Sch Med, Dept Internal Med 4, Bunkyo Ku, 3-28-6 Mejirodai, Tokyo 1128688, Japan.							Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KORENAGA R, 1994, BIOCHEM BIOPH RES CO, V198, P213, DOI 10.1006/bbrc.1994.1030; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Nagase M, 1998, BIOCHEM J, V330, P1417, DOI 10.1042/bj3301417; Nagase M, 1997, BIOCHEM BIOPH RES CO, V237, P496, DOI 10.1006/bbrc.1997.7176; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOKOYAMA M, 1990, BIOCHEM BIOPH RES CO, V168, P301, DOI 10.1016/0006-291X(90)91708-Z	31	89	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33702	33707		10.1074/jbc.273.50.33702	http://dx.doi.org/10.1074/jbc.273.50.33702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837956	hybrid			2022-12-25	WOS:000077462500086
J	Nagayama, Y; Namba, H; Yokoyama, N; Yamashita, S; Niwa, M				Nagayama, Y; Namba, H; Yokoyama, N; Yamashita, S; Niwa, M			Role of asparagine-linked oligosaccharides in protein folding, membrane targeting, and thyrotropin and autoantibody binding of the human thyrotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSH RECEPTOR; CARBOHYDRATE MOIETY; SIGNAL-TRANSDUCTION; GLYCOSYLATION SITES; MOLECULAR-CLONING; HORMONE-RECEPTOR; LIGAND-BINDING; INTACT-CELLS; IN-VITRO; EXPRESSION	The amino-terminal ectodomain of thyrotropin (TSH) receptor (TSHR) is heavily glycosylated with asparagine-linked (N-linked) oligosaccharides. The present studies were designed to evaluate how acquisition and processing of N-linked oligosaccharides play a role in the functional maturation of human TSHR, A glycosylation inhibitor tunicamycin, which inhibits the first step of N-linked glycosylation (acquisition of N-linked oligosaccharides), and a series of mutant Chinese hamster ovary (CHO)-Lec cells defective in the different steps of glycosylation processing were used. Inhibition of acquisition of N-linked oligosaccharides by tunicamycin treatment in CHO cells stably expressing TSHR produced nonglycosylated TSHR, which was totally nonfunctional, In contrast, all of the TSHRs synthesized in mutant CHO-Lec1, 2, and 8 cells (mannose-rich, sialic acid-deficient, and galactose-deficient oligosaccharides, respectively) bound TSH and produced cAMP in response to TSH with an affinity and an EC50 similar to those in TSHR expressed in parental CHO cells (CHO-TSHR; sialylated oligosaccharides). However, Lec1-TSHR and Lec2-TSHR were not efficiently expressed on the cell surface, whereas the expression levels of Lec8-TSHR and CHO-TSHR were essentially identical. All of the TSHRs expressed in CHO-Lec cells cleaved into two subunits. Finally, anti-TSHR autoantibodies from Graves' patients interacted with all of the TSHRs harboring different oligosaccharides to a similar extent. These data demonstrate that acquisition and processing of N-linked oligosaccharides of TSHR appear to be essential for correct folding in the endoplasmic reticulum and for cell surface targeting in the Gels apparatus. We also show that complex type carbohydrates are not crucially involved in the interaction of TSHR with TSH and anti-TSHR autoantibodies.	Nagasaki Univ, Sch Med, Dept Pharmacol 1, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Nat Med, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Internal Med 1, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University; Nagasaki University	Nagayama, Y (corresponding author), Nagasaki Univ, Sch Med, Dept Pharmacol 1, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	nagayama@net.nagasaki-u.ac.jp	Yamashita, Shunichi/GVS-9508-2022	Yamashita, Shunichi/0000-0001-6399-6261				Chazenbalk GD, 1997, ENDOCRINOLOGY, V138, P2893, DOI 10.1210/en.138.7.2893; Chazenbalk GD, 1996, ENDOCRINOLOGY, V137, P4586, DOI 10.1210/en.137.11.4586; Couet J, 1996, J BIOL CHEM, V271, P4545; Da Costa CR, 1998, J BIOL CHEM, V273, P11874, DOI 10.1074/jbc.273.19.11874; DATTATREYAMURTY B, 1992, ENDOCRINOLOGY, V131, P2437, DOI 10.1210/en.131.5.2437; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Davis DP, 1997, MOL ENDOCRINOL, V11, P550, DOI 10.1210/me.11.5.550; EDGE ASB, 1984, J BIOL CHEM, V259, P4710; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GINSBERG J, 1983, CLIN ENDOCRINOL, V19, P305, DOI 10.1111/j.1365-2265.1983.tb00003.x; GREEN ED, 1988, J BIOL CHEM, V263, P25; GROSSMANN M, 1995, J BIOL CHEM, V270, P29378, DOI 10.1074/jbc.270.49.29378; Grossmann M, 1997, ENDOCRINOLOGY, V138, P92, DOI 10.1210/en.138.1.92; HARA T, 1989, J BIOCHEM-TOKYO, V106, P236, DOI 10.1093/oxfordjournals.jbchem.a122838; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; KASAGI K, 1986, J CLIN ENDOCR METAB, V62, P855, DOI 10.1210/jcem-62-5-855; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1994, ENDOCRINOLOGY, V135, P1060, DOI 10.1210/en.135.3.1060; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Osuga Y, 1998, ENDOCRINOLOGY, V139, P671, DOI 10.1210/en.139.2.671; PETAJAREPO UE, 1993, BIOCHEM J, V292, P839, DOI 10.1042/bj2920839; Rapoport B, 1996, J CLIN ENDOCR METAB, V81, P2525, DOI 10.1210/jc.81.7.2525; RUSSO D, 1991, MOL ENDOCRINOL, V5, P1607, DOI 10.1210/mend-5-11-1607; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; SCHNEIDER AB, 1988, ENDOCRINOLOGY, V122, P2428, DOI 10.1210/endo-122-6-2428; Seetharamaiah GS, 1997, J IMMUNOL, V158, P2798; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHI YF, 1993, THYROID, V3, P129, DOI 10.1089/thy.1993.3.129; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; SMITH PL, 1992, J BIOL CHEM, V267, P19140; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; Tanaka K, 1998, ENDOCRINOLOGY, V139, P852, DOI 10.1210/en.139.3.852; Tanaka K, 1996, BIOCHEM BIOPH RES CO, V228, P21, DOI 10.1006/bbrc.1996.1611; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; Vlase H, 1997, ENDOCRINOLOGY, V138, P1658, DOI 10.1210/en.138.4.1658; Wright A, 1998, J IMMUNOL, V160, P3393; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	45	37	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33423	33428		10.1074/jbc.273.50.33423	http://dx.doi.org/10.1074/jbc.273.50.33423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837919	hybrid			2022-12-25	WOS:000077462500049
J	Oliver, FJ; de la Rubia, G; Rolli, V; Ruiz-Ruiz, MC; de Murcia, G; Menissier-de Murcia, J				Oliver, FJ; de la Rubia, G; Rolli, V; Ruiz-Ruiz, MC; de Murcia, G; Menissier-de Murcia, J			Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis - Lesson from an uncleavable mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SIGNALS; MOLECULAR NICK-SENSOR; EXPRESSION VECTOR; DNA-DAMAGE; CELL-DEATH; IDENTIFICATION; CYTOTOXICITY; INHIBITION; CHROMATIN; PROTEASES	We have studied the apoptotic response of poly(ADP-ribose) polymerase (PARP)-/- cells to different inducers and the consequences of the expression of an uncleavable mutant of PARP on the apoptotic process, The absence of PARP drastically increases the sensitivity of primary bone marrow PARP-/- cells to apoptosis induced by an alkylating agent but not by a topoisomerase I inhibitor CPT-11 or by interleukin-3 removal. cDNA of wild type or of an uncleavable PARP mutant (D214A-PARP) has been introduced into PARP-/- fibroblasts, which were exposed to anti-CD95 or an alkylating agent to induce apoptosis. The expression of D214A-PARP results in a significant delay of cell death upon CD95 stimulation, Morphological analysis shows a retarded cell shrinkage and nuclear condensation. Upon treatment with an alkylating agent, expression of wild-type PARP cDNA into PARP-deficient mouse embryonic fibroblasts results in the restoration of the cell viability, and the D214A-PARP mutant had no further effect on cell recovery. In conclusion, PARP-/- cells are extremely sensitive to apoptosis induced by triggers (like alkylating agents), which activates the base excision repair pathway of DNA, and the cleavage of PARP during apoptosis facilitates cellular disassembly and ensures the completion and irreversibility of the process.	Ecole Super Biotechnol Strasbourg, CEA, Lab Convent, CNRS,UPR 9003, F-67400 Illkirch Graffenstaden, France; CSIC, Inst Parasitol & Biomed, Granada 18001, Spain	CEA; Centre National de la Recherche Scientifique (CNRS); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Oliver, FJ (corresponding author), Ecole Super Biotechnol Strasbourg, CEA, Lab Convent, CNRS,UPR 9003, Blvd Sebastien Brant, F-67400 Illkirch Graffenstaden, France.	Javier.Oliver@esbs1.u-strasbg.fr	Oliver, Javier/S-1725-2018; Ruiz-Ruiz, Carmen/I-8792-2017	Oliver, Javier/0000-0001-8468-1998; Ruiz-Ruiz, Carmen/0000-0002-6243-6227				Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; COURTNEY M, 1985, NATURE, V313, P149, DOI 10.1038/313149a0; Dantzer F, 1998, NUCLEIC ACIDS RES, V26, P1891, DOI 10.1093/nar/26.8.1891; DEMURCIA G, 1988, BIOCHEM CELL BIOL, V66, P626, DOI 10.1139/o88-072; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DING RC, 1994, CANCER RES, V54, P4627; GINER H, 1992, GENE, V114, P279, DOI 10.1016/0378-1119(92)90588-G; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kusiak JW, 1996, MOL CHEM NEUROPATHOL, V28, P153, DOI 10.1007/BF02815217; LAUTIER D, 1994, BBA-MOL CELL RES, V1221, P215, DOI 10.1016/0167-4889(94)90243-7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LECAM E, 1994, J MOL BIOL, V235, P1062, DOI 10.1006/jmbi.1994.1057; Leist M, 1997, BIOCHEM BIOPH RES CO, V233, P518, DOI 10.1006/bbrc.1997.6491; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NIEDERGANG C, 1979, EUR J BIOCHEM, V102, P43, DOI 10.1111/j.1432-1033.1979.tb06261.x; OEI SL, 1997, REV PHYSIOL BIOCHEM, V131, P4135; PEITSCH MC, 1993, NUCLEIC ACIDS RES, V21, P4206, DOI 10.1093/nar/21.18.4206; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Rolli V, 1997, BIOCHEMISTRY-US, V36, P12147, DOI 10.1021/bi971055p; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SCHREIBER V, 1994, GENE, V150, P411, DOI 10.1016/0378-1119(94)90466-9; SCHREIBER V, 1992, M S-MED SCI, V8, P134, DOI 10.4267/10608/3085; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; SIMONIN F, 1993, J BIOL CHEM, V268, P8529; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Trucco C, 1996, FEBS LETT, V399, P313, DOI 10.1016/S0014-5793(96)01347-6; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509	46	636	654	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33533	33539		10.1074/jbc.273.50.33533	http://dx.doi.org/10.1074/jbc.273.50.33533			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837934	hybrid			2022-12-25	WOS:000077462500064
J	Yu, LJ; Orlandi, L; Wang, P; Orr, MS; Senderowicz, AM; Sausville, EA; Silvestrini, R; Watanabe, N; Piwnica-Worms, H; O'Connor, PM				Yu, LJ; Orlandi, L; Wang, P; Orr, MS; Senderowicz, AM; Sausville, EA; Silvestrini, R; Watanabe, N; Piwnica-Worms, H; O'Connor, PM			UCN-01 abrogates G(2) arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; HAMSTER OVARY CELLS; PROTEIN-KINASE; SELECTIVE INHIBITOR; TYROSINE KINASE; FISSION YEAST; G2 PHASE; PHOSPHORYLATES CDC2; ANTITUMOR-ACTIVITY; P34(CDC2) KINASE	We have previously demonstrated that UCN-01, a potent protein kinase inhibitor currently in phase I clinical trials for cancer treatment, abrogates G(2) arrest following DNA damage. Here we used murine FT210 cells, which contain temperature-sensitive Cdc2 mutations, to determine if UCN-01 abrogates G(2) arrest through a Cdc2-dependent pathway. We report that UCN-01 cannot induce mitosis in DNA-damaged FT210 cells at the nonpermissive temperature for Cdc2 function. Failure to abrogate G(2) arrest was not due to UCN-01-inactivation at the elevated temperature because parental FM3A cells, which have wild-type Cdc2, were sensitive to UCN-01-induced G(2) checkpoint abrogation. Having established that UCN-01 acted through Cdc2, we next assessed UCN-01's effect on the Cdc2-inhibitory kinase, WeelHu, and the Cdc2-activating phosphatase, Cdc25C, We found that WeelHu was indeed inactivated in UCN01-treated cells, possibly just prior to Cdc2 activation and entry of DNA-damaged cells into mitosis, This inhibition appeared, however, to be a consequence of a further upstream action since in vitro studies revealed purified WeelHu was relatively resistant to UCN-01-inhibition. Consistent with such an upstream action, UCN-01 also promoted the hyperphosphorylation (activation) of Cdc25C in DNA-damaged cells, Our results suggest that UCN-01 abrogates G(2) checkpoint function through inhibition of a kinase residing upstream of Cdc2, WeelHu, and Cdc25C, and that changes observed in these mitotic regulators are downstream consequences of UCN-01's actions.	NCI, Mol Pharmacol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NCI, Dev Therapeut Program, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA; NCI, Clin Trials Unit, Med Branch,Div Clin Sci, NIH, Bethesda, MD 20892 USA; Ist Nazl Studio & Cura Tumori, I-20133 Milan, Italy; Tsukuba Life Sci Ctr, Gene Bank, Ibaraki 3050074, Japan; Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Howard Hughes Med Inst, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fondazione IRCCS Istituto Nazionale Tumori Milan; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	O'Connor, PM (corresponding author), Agouron Pharmaceut Inc, 3565 Gen Atom Ct, San Diego, CA 92121 USA.		Piwnica-Worms, Helen/C-5214-2012					AKINAGA S, 1993, CANCER CHEMOTH PHARM, V32, P183, DOI 10.1007/BF00685833; AKINAGA S, 1994, CANCER CHEMOTH PHARM, V33, P273; AKINAGA S, 1991, CANCER RES, V51, P4888; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FAN SJ, 1995, CANCER RES, V55, P1649; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFMANN J, 1994, BIOCHEM BIOPH RES CO, V199, P937, DOI 10.1006/bbrc.1994.1319; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; LEE MS, 1994, J BIOL CHEM, V269, P30530; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LOCK RB, 1992, CANCER RES, V52, P1817; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MINEO C, 1986, EXP CELL RES, V167, P53, DOI 10.1016/0014-4827(86)90203-X; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OConnor PM, 1997, CANCER SURV, V29, P151; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; OGG S, 1994, J BIOL CHEM, V269, P30461; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; ROBERGE M, 1994, CANCER RES, V54, P6115; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; Shao RG, 1997, CANCER RES, V57, P4029; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAKAHASHI I, 1989, J ANTIBIOT, V42, P571, DOI 10.7164/antibiotics.42.571; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Tsuchida E, 1997, INT J RADIAT ONCOL, V39, P1153, DOI 10.1016/S0360-3016(97)00549-X; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WANG QZ, 1995, CELL GROWTH DIFFER, V6, P927; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x	61	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33455	33464		10.1074/jbc.273.50.33455	http://dx.doi.org/10.1074/jbc.273.50.33455			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837924	hybrid			2022-12-25	WOS:000077462500054
J	Kitada, S; Kojima, K; Shimokata, K; Ogishima, T; Ito, A				Kitada, S; Kojima, K; Shimokata, K; Ogishima, T; Ito, A			Glutamate residues required for substrate binding and cleavage activity in mitochondrial processing peptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; YEAST MITOCHONDRIA; PROTEIN IMPORT; BETA-SUBUNIT; PRECURSOR PROTEINS; SYNTHETIC PEPTIDE; BC(1) COMPLEX; MATRIX; FAMILY; IDENTIFICATION	Mitochondrial processing peptidase, a metalloendopeptidase consisting of alpha- and beta-subunits, specifically recognizes a large variety of mitochondrial precursor proteins and cleaves off N-terminal extension peptides. The enzyme requires the basic amino acid residues in the extension peptides for effective and specific cleavage. To elucidate the mechanism involved in the molecular recognition of substrate by the enzyme, several glutamates around the active site of the rat beta-subunit, which has a putative metal-binding motif, (HXXEH60)-X-56, were mutated to alanines or aspartates, and effects on kinetic parameters, metal binding, and substrate binding of the enzyme were analyzed. None of mutant proteins analyzed was impaired in dimer formation with the alpha-subunit. Mutation of glutamates at positions 79, 129, and 136, in addition to an active site glutamate at position 59, resulted in a marked decrease in cleavage efficiency. Together with sequence alignment data, glutamate 136 appears to be involved in metal binding. Glutamate 129 is mostly responsible for the catalysis, as there was a considerable decrease in k(cat) value by the mutation. Mutation of glutamate 79 led to decrease in k(cat) value and increase in K-m values. Substrate binding experiments using an environmentally sensitive fluorescence probe attached to the peptide showed that the mutation caused a remarkable environmental change at the binding site to the N-terminal region of the substrate peptide and decreased binding of the peptide, thereby suggesting that glutamate 79 participates primarily in substrate binding. Thus, some glutamate residues required far substrate binding and cleavage activity have been identified.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan	Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.	a.itoscc@mbox.nc.kyushu-u.ac.jp						ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1993, BIOCHEM J, V292, P137, DOI 10.1042/bj2920137; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KALOUSEK F, 1988, P NATL ACAD SCI USA, V85, P7536, DOI 10.1073/pnas.85.20.7536; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; KITADA S, 1993, BIOCHEM BIOPH RES CO, V190, P289, DOI 10.1006/bbrc.1993.1044; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Luciano P, 1997, J MOL BIOL, V272, P213, DOI 10.1006/jmbi.1997.1231; Luciano P, 1996, EXPERIENTIA, V52, P1077, DOI 10.1007/BF01952105; MIURA S, 1986, BIOCHEM BIOPH RES CO, V134, P1151, DOI 10.1016/0006-291X(86)90371-2; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1994, J BIOL CHEM, V269, P24673; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; PERLMAN RK, 1994, J BIOL CHEM, V269, P33140; POLLOCK RA, 1988, EMBO J, V7, P3493, DOI 10.1002/j.1460-2075.1988.tb03225.x; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; ROHLEN DA, 1991, FEBS LETT, V278, P75, DOI 10.1016/0014-5793(91)80087-J; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; SAGARA Y, 1984, J BIOCHEM-TOKYO, V96, P1743, DOI 10.1093/oxfordjournals.jbchem.a135007; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; SCHNEIDER A, 1994, J BIOL CHEM, V269, P8635; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; SHATZ G, 1996, SCIENCE, V271, P1519; Shimokata K, 1998, J BIOL CHEM, V273, P25158, DOI 10.1074/jbc.273.39.25158; Shimokata K, 1997, J BIOCHEM-TOKYO, V122, P1019; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; THORNTON K, 1993, J BIOL CHEM, V268, P19906; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x	45	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32547	32553		10.1074/jbc.273.49.32547	http://dx.doi.org/10.1074/jbc.273.49.32547			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829990	hybrid			2022-12-25	WOS:000077329100029
J	Mize, GJ; Ruan, HJ; Low, JJ; Morris, DR				Mize, GJ; Ruan, HJ; Low, JJ; Morris, DR			The inhibitory upstream open reading frame from mammalian S-adenosylmethionine decarboxylase mRNA has a strict sequence specificity in critical positions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5' TRANSCRIPT LEADER; MESSENGER-RNA; TRANSLATIONAL CONTROL; NEUROSPORA-CRASSA; STOP CODONS; EXPRESSION; PEPTIDE; YEAST	The upstream open reading frame (uORF) in the 5' leader of the mammalian mRNA encoding S-adenosylmethionine decarboxylase (AdoMetDC) serves as a negative regulatory element by suppressing translation of the associated downstream cistron, Certain changes in the amino acid sequence of the hexapeptide (sequence MAGDIS) encoded by the uORF destroy suppressive activity, implying specific interaction with a cellular target. In this paper, we examine the extent of alterations that can be tolerated in this uORF, The mammalian AdoMetDC uORF inhibits downstream translation when placed into the 5' leader of a yeast mRNA with characteristics resembling those in mammalian cells, suggesting that the encoded peptide has a similar target across species. Using yeast for the initial screen, we tested the specificity of the critical three codons at the 3' end of the uORF by saturation mutagenesis. Altered uORFs selected from the primary yeast screen were then retested in mammalian cells. The requirements at codons 4 and 5 mere quite stringent; only aspartic acid at codon 4 yielded a fully suppressive peptide, and only valine could substitute productively for isoleucine at codon 5. The specificity at codon 6 was much looser, with many substitutions retaining suppressive activity in both yeast and mammalian cells.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.		Morris, David/G-4503-2011		NCI NIH HHS [CA39053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; Cao JH, 1996, MOL CELL BIOL, V16, P603; Cao JH, 1996, MOL CELL BIOL, V16, P7109; DEGNIN CR, 1993, J VIROL, V67, P5514, DOI 10.1128/JVI.67.9.5514-5521.1993; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GRANT CM, 1994, MOL CELL BIOL, V14, P606, DOI 10.1128/MCB.14.1.606; HILL JR, 1993, J BIOL CHEM, V268, P726; HILL JR, 1992, J BIOL CHEM, V267, P21886; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; KEAN LS, 1993, J CELL BIOL, V123, P1403, DOI 10.1083/jcb.123.6.1403; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Luo ZL, 1996, J BACTERIOL, V178, P2172, DOI 10.1128/jb.178.8.2172-2177.1996; MILLER PF, 1989, GENE DEV, V3, P1217, DOI 10.1101/gad.3.8.1217; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; MORRIS DR, 1997, RNA METABOLISM POST, P165; Richter, 1997, ANAL MRNA FORMATION, P305, DOI 10.1016/B978-012587545-5/50017-3; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; SCHLEISS MR, 1991, J VIROL, V65, P6782, DOI 10.1128/JVI.65.12.6782-6789.1991; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0	24	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32500	32505		10.1074/jbc.273.49.32500	http://dx.doi.org/10.1074/jbc.273.49.32500			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829983	hybrid			2022-12-25	WOS:000077329100022
J	Shuttleworth, TJ; Thompson, JL				Shuttleworth, TJ; Thompson, JL			Muscarinic receptor activation of arachidonate-mediated Ca2+ entry in HEK293 cells is independent of phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; BISCOCLAURINE ALKALOIDS; <CA2+>(I) OSCILLATIONS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; EXTRACELLULAR PH; XENOPUS-OOCYTES; EXOCRINE CELL; ION CHANNELS; FATTY-ACIDS	Receptor-enhanced entry of Ca2+ in non-excitable cells is generally ascribed to a capacitative mechanism in which the activation of the entry pathway is specifically dependent on the emptying of agonist-sensitive intracellular Ca2+ stores. Although such entry can be clearly demonstrated under conditions of maximal or near-maximal stimulation, it is uncertain whether such a mechanism can operate during the oscillatory [Ca2+](i) signals that are frequently seen following stimulation with low concentrations of agonists. In this study, we report that the stimulation of human m3 muscarinic receptors stably transfected into HEK293 cells results in the appearance of a novel arachidonate-mediated Ca2+ entry pathway. We show that the generation of arachidonic acid and the activation of this pathway are specifically associated with stimulation at the low agonist concentrations that typically give rise to oscillatory [Ca2+](i) signals. At such agonist concentrations, however, the generation of arachidonic acid is independent of the simultaneous activation of the phospholipase C-inositol 1,4,5-trisphosphate pathway. We further show that the arachidonate-mediated Ca2+ entry demonstrates characteristics that distinguish it from the corresponding capacitative pathway in the same cells and therefore is likely to represent an entirely distinct pathway that is specifically responsible for the receptor-enhanced entry of Ca2+ during [Ca2+], oscillations.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Shuttleworth, TJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pharmacol & Physiol, POB 711,601 Elmwood Ave, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM 40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Akagi K, 1997, JPN J PHARMACOL, V75, P33, DOI 10.1254/jjp.75.33; AKIBA S, 1992, BIOCHEM PHARMACOL, V44, P45, DOI 10.1016/0006-2952(92)90036-I; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BERRIDGE MJ, 1994, BIOCHEM J, V302, P545, DOI 10.1042/bj3020545; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIXON JF, 1984, J BIOL CHEM, V259, P4418; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; HASHIZUME T, 1991, BIOCHEM PHARMACOL, V41, P419, DOI 10.1016/0006-2952(91)90539-H; Hou W, 1996, AM J PHYSIOL-CELL PH, V271, pC1735; Hug MJ, 1996, PFLUG ARCH EUR J PHY, V432, P278, DOI 10.1007/s004240050134; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN PY, 1991, J IMMUNOL, V146, P1609; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; MALAYEV A, 1995, J MEMBRANE BIOL, V146, P101; MARTIN SC, 1994, FEBS LETT, V352, P32, DOI 10.1016/0014-5793(94)00913-9; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; MOCHIZUKIODA N, 1993, J NEUROCHEM, V61, P1882, DOI 10.1111/j.1471-4159.1993.tb09830.x; Morris AJ, 1997, BIOCHEM SOC T, V25, P1151, DOI 10.1042/bst0251151; MUALLEM S, 1989, AM J PHYSIOL, V257, pG917, DOI 10.1152/ajpgi.1989.257.6.G917; Munaron L, 1997, CELL CALCIUM, V22, P179, DOI 10.1016/S0143-4160(97)90011-7; NEGULESCU PA, 1995, AM J PHYSIOL-GASTR L, V269, pG770, DOI 10.1152/ajpgi.1995.269.5.G770; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PACKHAM DE, 1995, CELL CALCIUM, V17, P399, DOI 10.1016/0143-4160(95)90086-1; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROSSIER MF, 1993, ENDOCRINOLOGY, V132, P1035, DOI 10.1210/en.132.3.1035; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SATO T, 1993, FEBS LETT, V323, P23, DOI 10.1016/0014-5793(93)81440-B; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; SHUTTLEWORTH TJ, 1994, CELL CALCIUM, V15, P457, DOI 10.1016/0143-4160(94)90110-4; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; THORN P, 1995, J PHYSIOL-LONDON, V482, P275, DOI 10.1113/jphysiol.1995.sp020516; VANDERZEE L, 1995, BIOCHEM J, V305, P859, DOI 10.1042/bj3050859; Wakabayashi I, 1996, BIOCHEM BIOPH RES CO, V221, P762, DOI 10.1006/bbrc.1996.0670; YANG J, 1995, MOL PHARMACOL, V48, P477	48	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32636	32643		10.1074/jbc.273.49.32636	http://dx.doi.org/10.1074/jbc.273.49.32636			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830003	hybrid			2022-12-25	WOS:000077329100042
J	Allen, S; Khan, S; Tam, SP; Koschinsky, M; Taylor, P; Yacoub, M				Allen, S; Khan, S; Tam, SP; Koschinsky, M; Taylor, P; Yacoub, M			Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity	FASEB JOURNAL			English	Article						calcium signaling; VCAM-1; E-selectin; endothelial cells	LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; ALPHA-2-MACROGLOBULIN RECEPTOR; FAMILIAL HYPERCHOLESTEROLEMIA; APOLIPOPROTEIN-E; CELL LINE; BINDING; PLASMINOGEN; ATHEROSCLEROSIS	Lp(a) is a major inherited risk factor for premature atherosclerosis. The mechanism of Lp(a) atherogenicity has not been elucidated, but likely involves both its ability to interfere with plasminogen activation and its atherogenic potential as a lipoprotein particle after receptor-mediated uptake. We demonstrate that Lp(a) stimulates production of vascular cell. adhesion molecule 1 (VCAM-1) and E-selectin in cultured human coronary artery endothelial cells (HCAEC). This effect resulted from a rise in intracellular free calcium induced by Lp(a) and could be inhibited by the intracellular calcium chelator, BAPTA/AM. The involvement of the LDL and VLDL receptors in Lp(a) activation of HCAEC were ruled out since Lp(a) induction of adhesion molecules was not prevented by an antibody (IgGC7) to the LDL receptor or by receptor-activating protein, an antagonist of ligand binding to the VLDL receptor. Addition of alpha(2)-macroglobulin as well as treatment with heparinase, chondroitinase,ABC, and sodium chlorate did not decrease levels of VCAM-1 and E-selectin stimulated by Lp(a), suggesting that neither the low density lipoprotein receptor-related protein nor cell-surface proteoglycans are involved in Lp(a)-induced adhesion molecule production. Neither does the binding site on HCAEC responsible for adhesion molecule production by Lp(a) appear to involve plasminogen receptors, as levels of VCAM-1 and E-selectin were not significantly decreased by the addition of glu-plasminogen, the lysine analog E-aminocaproic acid, or by trans-4-(aminomethyl)-cyclohexanecarboxymethylic acid (tranexamic acid), which acts by binding to the lysine binding sites carried on the kringle structures in plasminogen. In contrast, recombinant apolipoprotein (a) [r-apo(a)] competed with Lp(a) and attenuated the expression of VCAM-1 and E-selectin. In summary, we have identified a calcium-dependent interaction of Lp(a) with HCAEC capable of inducing potent surface expression of VCAM-1 and E-selectin that does not appear to involve any of the known potential Lp(a) binding sites. Because leukocyte recruitment to the vessel wall appears to represent one of the important early events in atherogenesis, this newly described endothelial cell-activating effect of Lp(a) places it at a crucial juncture in the initiation of atherogenic disease and may lead to a better understanding of the role of Lp(a) in the vascular biology of atherosclerosis.	Univ London Imperial Coll Sci Technol & Med, Dept Cardiothorac Surg, Harefield Hosp,Heart Sci Ctr, FRCS,Royal Brompton & Harefield NHS, Harefield UB9 6JH, Middx, England; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Queens University - Canada	Yacoub, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Cardiothorac Surg, Harefield Hosp,Heart Sci Ctr, FRCS,Royal Brompton & Harefield NHS, Hill End Rd, Harefield UB9 6JH, Middx, England.			Koschinsky, Marlys/0000-0002-2643-2288				ALLEN SP, 1998, IN PRESS J CLIN INVE; BARBIR M, 1992, LANCET, V340, P1500, DOI 10.1016/0140-6736(92)92756-6; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; BUDDE T, 1994, ARTERIOSCLER THROMB, V14, P1730, DOI 10.1161/01.ATV.14.11.1730; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; Hackman A, 1996, CIRCULATION, V93, P1334, DOI 10.1161/01.CIR.93.7.1334; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HAVEKES LM, 1987, BIOCHEM J, V247, P739, DOI 10.1042/bj2470739; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; JI ZS, 1993, J BIOL CHEM, V268, P10160; KOSCHINSKY ML, 1993, J BIOL CHEM, V268, P19819; KOSTNER GM, 1993, ARTERIOSCLER THROMB, V13, P1101, DOI 10.1161/01.ATV.13.7.1101; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MARZ W, 1993, FEBS LETT, V325, P271, DOI 10.1016/0014-5793(93)81087-G; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MCTIGUE K, 1997, J CLIN INVEST, V100, P2170; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; NACHMAN RL, 1992, BLOOD, V79, P1897, DOI 10.1182/blood.V79.8.1897.bloodjournal7981897; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PRITCHARD KA, 1991, ARTERIOSCLER THROMB, V11, P1175, DOI 10.1161/01.ATV.11.5.1175; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; Sangrar W, 1997, BIOCHEMISTRY-US, V36, P10353, DOI 10.1021/bi962433d; Scanu A M, 1991, Adv Intern Med, V36, P249; SCHAEFER HIMB, 1993, CELL CALCIUM, V14, P507, DOI 10.1016/0143-4160(93)90009-U; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smalley DM, 1996, ARTERIOSCL THROM VAS, V16, P585, DOI 10.1161/01.ATV.16.4.585; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; TAM SP, 1991, J BIOL CHEM, V266, P16764; Tam SP, 1996, J LIPID RES, V37, P518; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	39	72	76	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1765	1776		10.1096/fasebj.12.15.1765	http://dx.doi.org/10.1096/fasebj.12.15.1765			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837867				2022-12-25	WOS:000077574500019
J	Dougherty, C; Barucha, J; Schofield, PR; Jacobson, KA; Liang, BT				Dougherty, C; Barucha, J; Schofield, PR; Jacobson, KA; Liang, BT			Cardiac myocytes rendered ischemia resistant by expressing the human adenosine A(1) or A(3) receptor	FASEB JOURNAL			English	Article						heart; purinergic; ventricular myocyte; gene transfer	INTRACORONARY ADENOSINE; REPERFUSION; INJURY; CLONING; GENE	Adenosine is an important mediator of the endogenous defense against ischemia-induced injury in the heart. Adenosine can achieve cardioprotection by mediating the effect of ischemic preconditioning and by protecting against myocyte injury when it is present during the infarct-producing ischemia. A novel adenosine A(3) receptor can mediate this protective function. One approach to achieve cardioprotection is to enhance myocardial sensitivity to the endogenous adenosine by increasing the number of adenosine receptors instead of administering an adenosine receptor agonist. The objective of the present study was to investigate whether genetic manipulation of the cardiac myocyte, achieved by gene transfer and overexpression of the human A(3) receptor cDNA, renders the myocytes resistant to the deleterious effect of ischemia. Prolonged hypoxia with glucose deprivation, causing myocyte injury and adenosine release, was used to simulate ischemia in cultured chick embryo ventricular myocytes. During simulated ischemia, cultured myocytes with enhanced expression of the human A(3) receptor and showed significantly higher ATP content, fewer cells killed, and less creatine kinase released into the medium than either control or mock-transfected myocytes. Also, increased expression of the A(3) receptor caused an enhanced cardioprotective effect by the preconditioning ischemia. Overexpressing the adenosine A(1) receptor also led to increased protection against ischemia-induced myocyte injury as well as an enhanced preconditioning effect. Thus, increasing the receptor level improves the myocyte sensitivity to the endogenous adenosine, which in turn causes all of the cardioprotective effects found for exogenously administered adenosine agonists. The study provides the first proof for the new concept that an increased expression of the human A(3) receptor in the cardiac myocyte can be an important cardioprotective therapeutic approach.	Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Garvan Inst Med Res, Sydney, NSW, Australia; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; Garvan Institute of Medical Research; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liang, BT (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, 3610 Hamilton Walk, Philadelphia, PA 19104 USA.		Jacobson, Kenneth Alan/A-1530-2009; Schofield, Peter/C-9669-2011	Jacobson, Kenneth Alan/0000-0001-8104-1493; Trivedi, Julie/0000-0002-2784-0662; Schofield, Peter/0000-0003-2967-9662	Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline; NHLBI NIH HHS [R01 HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031117] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atkinson MR, 1997, NEUROSCI RES, V29, P73, DOI 10.1016/S0168-0102(97)00073-4; BABBITT DG, 1989, CIRCULATION, V80, P1388, DOI 10.1161/01.CIR.80.5.1388; DOOREY AJ, 1983, CIRC RES, V53, P192, DOI 10.1161/01.RES.53.2.192; ELY SW, 1985, J THORAC CARDIOV SUR, V90, P549; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; HOLMSEN H, 1966, ANAL BIOCHEM, V17, P456, DOI 10.1016/0003-2697(66)90181-3; Jiang JL, 1996, J MED CHEM, V39, P4667, DOI 10.1021/jm960457c; KIM HO, 1994, J MED CHEM, V37, P3614, DOI 10.1021/jm00047a018; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; Liang BT, 1996, NUCLEIC ACIDS RES, V24, P1382, DOI 10.1093/nar/24.7.1382; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; Matherne GP, 1997, P NATL ACAD SCI USA, V94, P6541, DOI 10.1073/pnas.94.12.6541; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; OLAFSSON B, 1987, CIRCULATION, V76, P1135, DOI 10.1161/01.CIR.76.5.1135; REIBEL DK, 1978, AM J PHYSIOL, V234, pH620; RINIVAS M, 1997, MOL PHARMACOL, V52, P683; Song YJ, 1996, AM J PHYSIOL-CELL PH, V271, pC1233; STAMBAUGH K, 1997, AM J PHYSIOL, V273, pH5010; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425	22	58	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1785	1792		10.1096/fasebj.12.15.1785	http://dx.doi.org/10.1096/fasebj.12.15.1785			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837869	Green Accepted			2022-12-25	WOS:000077574500021
J	Bakos, E; Evers, R; Szakacs, G; Tusnady, GE; Welker, E; Szabo, K; de Haas, M; van Deemter, L; Borst, P; Varadi, A; Sarkadi, B				Bakos, E; Evers, R; Szakacs, G; Tusnady, GE; Welker, E; Szabo, K; de Haas, M; van Deemter, L; Borst, P; Varadi, A; Sarkadi, B			Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TUMOR-CELLS; INCREASED SENSITIVITY; MEMBRANE TOPOLOGY; ANTICANCER DRUGS; LEUKOTRIENE C-4; P-GLYCOPROTEIN; INSECT CELLS; EXPORT PUMP; GLUTATHIONE; TRANSPORT	The human multidrug resistance protein (MRP1) causes drug resistance by extruding drugs from tumor cells. In addition to an MDR-like core, MRP1 contains an N-terminal membrane-bound region (TMD0) connected to the core by a cytoplasmic linker (L-0). We have studied truncated MRP1 versions containing either the MDR-like core alone or the core plus linker L-0, produced in the baculovirus-insect (Sf9) cell system. Their function was examined in isolated membrane vesicles. Full-length MRP1 showed ATP-dependent, vanadate-sensitive accumulation of leukotriene C-4 and N-ethylmaleimide glutathione. In addition, leukotriene C-4-stimulated, vanadate-dependent nucleotide occlusion was detected. The MDR-like core was virtually inactive. Co-expression of the core with the N-terminal region including L-0 fully restored MRP1 function. Unexpectedly, a truncated MRP1 mutant lacking the entire TMD, region but still containing L-0 behaved like wild-type MRP1 in vesicle uptake and nucleotide trapping experiments. We also expressed the MRP1 constructs in polarized canine kidney derived MDCKII cells. Like wild-type MRP1, the MRP1 protein without the TMD, region was routed to the lateral plasma membrane and transported dinitrophenyl glutathione and daunorubicin, The TMD0L0 and the MRP1 minus TMD0L0 remained in an intracellular compartment. Taken together, these experiments strongly suggest that the TMD0 region is neither required for the transport function of MRP1 nor for its proper routing to the plasma membrane.	Hungarian Acad Sci, Natl Inst Haematol & Immunol, Res Grp, H-1113 Budapest, Hungary; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1051 Budapest, Hungary; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Hungarian Academy of Sciences; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Netherlands Cancer Institute	Sarkadi, B (corresponding author), Hungarian Acad Sci, Natl Inst Haematol & Immunol, Res Grp, Daroczi U 24, H-1113 Budapest, Hungary.	B.Sarkadi@ohvi.hu	Varadi, Andras/A-2055-2012; Tusnády, Gábor E./AAI-1136-2021; Sarkadi, Balazs/I-5024-2013; Welker, Ervin/AAC-6493-2022; Tusnády, Gábor E/A-3207-2009; Szakacs, Gergely/A-2580-2009	Tusnády, Gábor E./0000-0001-8105-0285; Tusnády, Gábor E/0000-0001-8105-0285; Szakacs, Gergely/0000-0002-9311-7827				Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; COLE SPC, 1994, CANCER RES, V54, P5902; Deeley RG, 1997, SEMIN CANCER BIOL, V8, P193, DOI 10.1006/scbi.1997.0070; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; Evers R, 1998, J CLIN INVEST, V101, P1310, DOI 10.1172/JCI119886; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; HIPFNER DR, 1998, IN PRESS BR J CANC; Hollo Z, 1996, FEBS LETT, V383, P99, DOI 10.1016/0014-5793(96)00237-2; Jedlitschky G, 1996, CANCER RES, V56, P988; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEIER I, 1994, J BIOL CHEM, V269, P27807; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Lorico A, 1997, CANCER RES, V57, P5238; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Rappa G, 1997, CANCER RES, V57, P5232; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zaman GJR, 1996, FEBS LETT, V391, P126, DOI 10.1016/0014-5793(96)00718-1	32	266	271	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32167	32175		10.1074/jbc.273.48.32167	http://dx.doi.org/10.1074/jbc.273.48.32167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822694	hybrid			2022-12-25	WOS:000077207000076
J	Larrain, J; Carey, DJ; Brandan, E				Larrain, J; Carey, DJ; Brandan, E			Syndecan-1 expression inhibits myoblast differentiation through a basic fibroblast growth factor-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; SKELETAL-MUSCLE DIFFERENTIATION; CELL-SURFACE; FACTOR-RECEPTOR; FACTOR-BETA; MYOGENIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; STRUCTURAL REQUIREMENTS; EXTRACELLULAR-MATRIX; BINDING	Expression of syndecan-1, a cell-surface heparan sulfate proteoglycan, is down-regulated during skeletal muscle differentiation (Larrain, J., Cizmeci-Smith, G,, Troncoso, V., Stahl, R, C,, Carey, D, J,, and Brandan, E. (1997) J. Biol. Chem, 272, 18418-18424). We examined the role of syndecan-1 in basic fibroblast growth factor (bFGF)-dependent inhibition of myogenesis. C2C12 myoblasts were stably transfected with an expression plasmid containing the rat syndecan-1 coding region cDNA. Constitutive syndecan-1 expression resulted in a strongly diminished capacity of the transfected clones to differentiate and to express skeletal muscle-specific markers such as fusion, creatine kinase, and myosin. The expression of myogenin, a master transcription factor for muscle differentiation, was also reduced and delayed. Analysis of the induction of a myogenin promoter-driven reporter revealed that syndecan-1 expression resulted in a 6-7-fold increase in sensitivity to bFGF-dependent inhibition of myogenin expression. Transfecting the cells with a plasmid containing myogenin cDNA reversed the inhibition of myogenin transcriptional activation and myosin expression in syndecan-1-transfected cells; however, cell fusion was not observed. These results demonstrate that syndecan-1 expression enhances cell responsiveness to bFGF and inhibits myoblast fusion and suggest that muscle terminal differentiation is regulated by syndecan-1 expression.	Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Calular & Mol, Santiago, Chile; Penn State Coll Med, Henry Hood MD Res Program, Sigfried & Janet Weis Ctr Res, Danville, PA 17822 USA	Pontificia Universidad Catolica de Chile; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Brandan, E (corresponding author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Calular & Mol, Casilla 114-D, Santiago, Chile.	ebrandan@genes.bio.puc.cl	Brandan, Enrique/A-7063-2017	Brandan, Enrique/0000-0002-6820-5059	FIC NIH HHS [TW 00093] Funding Source: Medline; NINDS NIH HHS [NS21925] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; AVIEZER D, 1994, J BIOL CHEM, V269, P114; Aviezer D, 1997, MOL CELL BIOL, V17, P1938, DOI 10.1128/MCB.17.4.1938; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDAN E, 1987, J NEUROBIOL, V18, P271, DOI 10.1002/neu.480180303; BRANDAN E, 1991, EUR J CELL BIOL, V55, P209; Brandan E, 1998, BASIC APPL MYOL, V8, P107; Brandan E, 1996, EUR J CELL BIOL, V71, P170; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CAMPOS A, 1993, EUR J BIOCHEM, V216, P587, DOI 10.1111/j.1432-1033.1993.tb18178.x; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; Carey DJ, 1997, BIOCHEM J, V327, P1; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; DELAIN D, 1975, EXP CELL RES, V93, P495, DOI 10.1016/0014-4827(75)90480-2; DICKSON G, 1990, NATURE, V344, P348, DOI 10.1038/344348a0; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; FLORINI JR, 1993, ADV EXP MED BIOL, V343, P319; Forsten KE, 1997, J CELL PHYSIOL, V172, P209, DOI 10.1002/(SICI)1097-4652(199708)172:2<209::AID-JCP8>3.0.CO;2-S; HANNON K, 1992, DEV BIOL, V151, P137, DOI 10.1016/0012-1606(92)90221-2; HAUSCHKA SD, 1966, P NATL ACAD SCI USA, V55, P119, DOI 10.1073/pnas.55.1.119; HU JS, 1990, J BIOL CHEM, V265, P7914; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Larrain J, 1997, J BIOL CHEM, V272, P18418, DOI 10.1074/jbc.272.29.18418; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MACMALMAN CD, 1992, DEV DYNAM, V195, P127; MALI M, 1993, J BIOL CHEM, V268, P24215; MEGE RM, 1992, J CELL SCI, V103, P897; Melo F, 1996, J CELL BIOCHEM, V62, P227, DOI 10.1002/(SICI)1097-4644(199608)62:2<227::AID-JCB11>3.0.CO;2-I; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PACIFICI M, 1980, EXP CELL RES, V126, P143, DOI 10.1016/0014-4827(80)90479-6; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rawls A, 1997, CELL, V89, P5, DOI 10.1016/S0092-8674(00)80175-0; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; REYES AA, 1990, CELL REGUL, V1, P567, DOI 10.1091/mbc.1.8.567; Russo S, 1998, J CELL SCI, V111, P691; SAITOH O, 1992, EXP CELL RES, V200, P70, DOI 10.1016/S0014-4827(05)80072-2; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SOLURSH M, 1990, DEV BIOL, V140, P83, DOI 10.1016/0012-1606(90)90055-N; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	52	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32288	32296		10.1074/jbc.273.48.32288	http://dx.doi.org/10.1074/jbc.273.48.32288			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822708	hybrid			2022-12-25	WOS:000077207000090
J	Vonlanthen, S; Heighway, J; Tschan, MP; Borner, MM; Altermatt, HJ; Kappeler, A; Tobler, A; Fey, MF; Thatcher, N; Yarbrough, WG; Betticher, D				Vonlanthen, S; Heighway, J; Tschan, MP; Borner, MM; Altermatt, HJ; Kappeler, A; Tobler, A; Fey, MF; Thatcher, N; Yarbrough, WG; Betticher, D			Expression of p16INK4a/p16 alpha and p19ARF/p16 beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression	ONCOGENE			English	Article						CDKN2; p16INK4a/p16 alpha; p19ARF/p16 beta; p53; methylation; non-small cell lung carcinoma	TUMOR-SUPPRESSOR GENE; INK4A LOCUS; P16(INK4) PROTEIN; DNA METHYLATION; CYCLE ARREST; P16 MTS1; INACTIVATION; RB; SENESCENCE; MUTATIONS	The CDKN2 locus expresses two different mRNA transcripts, designated alpha and beta. The protein product of the or transcript is the cell cycle inhibitor and tumour suppressor p16INK4a. The beta transcript is translated in an alternate reading frame (ARF) and in humans encodes a 15 kDa protein (p19ARF). Immunohistochemical and Western analysis of p16INK4a has shown that the protein is downregulated in a significant number of tumours, but less is known on the expression of the p19ARF, We have examined the expression of p16INK4a and p19ARF in resectable non-small cell lung cancer (NSCLC) by immunostaining (n=49) and multiplex RT-PCR (n=28). In order to investigate the mechanism responsible for p16INK4a downregulation, exon 1 alpha methylation was analysed in a PCR-based assay. Of 49 tumours examined by immunostaining, 24 and 20 tumours expressed p16INK4a and p19ARF at nil to low levels, respectively, p19ARF was localized primarily to the nuclei of tumour cells, but was also seen to varying degrees in nuclei of lymphocytes, chondrocytes, fibroblasts, and epithelial cells. No tumour with normal p16INK4a had decreased p19ARF expression, Among 16 tumours with nil to low p16INK4a expression, 11 tumours exhibited full methylation of at least one site within exon 1 alpha and these tumours showed normal p19ARF expression. In contrast, no methylation of exon 1 alpha was observed in five tumours which also lacked p19ARF, In normal lung, p16INK4a and p19ARF were not expressed at detectable levels, the multiplex RT-PCR results were balanced, and sites within exon 1 alpha were strongly methylated. In tumours, imbalanced multiplex RT-PCR data (p16INK4a < p19ARF) predicted methylation of exon 1 alpha (P = 0.0006) as well as downregulation of p16INK4a, p19ARF downregulation was inversely correlated with p53 overexpression (P = 0.025), whilst negative immunostaining for p16INK4a was inversely correlated with pRb downregulation (P = 0.003) and directly correlated with p53 overexpression as assessed by immunostaining (P = 0.015), Our results show that: (1) p16INK4a and p19ARF expression are altered in almost half of resectable NSCLC; (2) methylation within exon 1 alpha is a frequent, but not the only mechanism of p16INK4a downregulation; and that (3) the inverse association of p19ARF and p53 alteration is consistent with a linked pathway.	Univ Bern, Dept Clin Res, CH-3012 Bern, Switzerland; Univ Bern, Inst Med Oncol, CH-3012 Bern, Switzerland; Univ Bern, Inst Pathol, CH-3012 Bern, Switzerland; Christie Hosp, Dept Med Oncol, Manchester, Lancs, England; Univ N Carolina, Dept Surg, Div Otorhinolaryngol, Chapel Hill, NC USA	University of Bern; University of Bern; University of Bern; Christie NHS Foundation Trust; Christie Hospital; University of North Carolina; University of North Carolina Chapel Hill	Betticher, D (corresponding author), Univ Bern, Inst Med Oncol, Inselspital, CH-3010 Bern, Switzerland.	daniel.betticher@insel.ch	Borner, Markus/B-7583-2011; Betticher, Daniel C/G-5849-2013	Tschan, Mario P./0000-0001-5897-3647				Arap W, 1997, ONCOGENE, V15, P2013, DOI 10.1038/sj.onc.1201389; Betticher DC, 1997, INT J CANCER, V74, P556, DOI 10.1002/(SICI)1097-0215(19971021)74:5<556::AID-IJC14>3.0.CO;2-4; Betticher DC, 1996, BRIT J CANCER, V73, P294, DOI 10.1038/bjc.1996.52; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BORNER MM, 1998, IN PRESS BR J CANC; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GONZALEZZULUETA M, 1995, J NATL CANCER I, V87, P1383, DOI 10.1093/jnci/87.18.1383; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Herman JG, 1997, CANCER RES, V57, P837; HERMAN JG, 1995, CANCER RES, V55, P4525; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; Liggett WH, 1996, CANCER RES, V56, P4119; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1995, ONCOGENE, V11, P1211; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; SHAPIRO GI, 1995, CANCER RES, V55, P505; Shores C., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P277; Singer-Sam J., 1993, Experientia Supplementum (Basel), V64, P358; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; TAM SW, 1994, CANCER RES, V54, P5816; *UICC AM JOINT COM, 1987, MAN STAG CANC; World Health Organization, 1981, HIST TYP LUNG TUM; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	46	107	113	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2779	2785		10.1038/sj.onc.1202501	http://dx.doi.org/10.1038/sj.onc.1202501			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840942				2022-12-25	WOS:000077146700011
J	Choi, SW; Park, SW; Lee, KY; Kim, KM; Chung, YJ; Rhyu, MG				Choi, SW; Park, SW; Lee, KY; Kim, KM; Chung, YJ; Rhyu, MG			Fractional allelic loss in gastric carcinoma correlates with growth patterns	ONCOGENE			English	Article						gastric carcinoma; fractional allelic loss; loss of heterozygosity; growth pattern	TUMOR-SUPPRESSOR GENES; P53; HETEROZYGOSITY; RETINOBLASTOMA; CARCINOGENESIS; DELETIONS; CANCER	To gain an insight into the genetic events underlying morphological phenotypes, we analysed 58 gastric carcinoma tissues for the genome-wide allelotype study using microsatellite markers. Based on a binomial distribution, loss of heterozygosity (LOH) that was significantly more frequent than expected (P < 0.05) thus interpreted as nonrandom LOH selected during tumorigenesis. The overall extent of chromosomes undergoing LOH i.e. fractional allelic loss (FAL, the ratio of LOH-positive markers to the total number of informative markers) was measured in each tumor patient. Nonrandom LOH was found on 17p (48.0%), 18q (38.4%), 13q (38.1%) and 9p (36.4%). Overall, there were no significant phenotypes correlated with allelic loss on specific chromosome regions. Based on a bimodal distribution of FAL values with two peaks bordered by a mean of 0.233, tumors were classified into LOH-related (> 0.233) and LOH-unrelated (< 0.233) types. Among 24 patients with LOH-related tumors, increase in the infiltrative type of growth pattern was found to correspond with a significant trend of increasing FAL values. This study shows that the growth pattern of gastric carcinoma is correlated with FAL, suggesting that a malignant phenotype is influenced by LOH event.	Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Microbiol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Rhyu, MG (corresponding author), Catholic Univ Korea, Coll Med, Dept Internal Med, 505 Bampo Dong,Socho Gu, Seoul 137701, South Korea.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Barrett MT, 1996, ONCOGENE, V12, P1873; Cho JH, 1996, LAB INVEST, V74, P835; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; HARPER JW, 1993, CELL, V75, P805; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kerangueven F, 1997, CANCER RES, V57, P5469; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MCKIE AB, 1993, INT J CANCER, V55, P598, DOI 10.1002/ijc.2910550414; MING SC, 1977, CANCER, V39, P2475, DOI 10.1002/1097-0142(197706)39:6<2475::AID-CNCR2820390626>3.0.CO;2-L; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; Schultz DC, 1996, CANCER RES, V56, P1997; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850	21	37	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2655	2659		10.1038/sj.onc.1202188	http://dx.doi.org/10.1038/sj.onc.1202188			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840929				2022-12-25	WOS:000077058900013
J	Mendoza, SM; Konishi, T; Miller, CW				Mendoza, SM; Konishi, T; Miller, CW			Integration of SV40 in human osteosarcoma DNA	ONCOGENE			English	Article						SV40; integration; osteosarcoma	LARGE-T-ANTIGEN; HUMAN PLEURAL MESOTHELIOMA; PERIPHERAL-BLOOD CELLS; NORMAL HUMAN-TISSUES; LARGE-TUMOR-ANTIGEN; HUMAN BRAIN-TUMORS; SIMIAN-VIRUS 40; HEALTHY-INDIVIDUALS; HUMAN-FIBROBLASTS; CHOROID-PLEXUS	Simian virus 40 (SV40) has been demonstrated in several types of tumors, including osteosarcoma, by polymerase chain reaction (PCR), We detected SV40 sequences by PCR, followed by hybridization, in nine of 35 osteosarcoma tumors and one of 11 osteosarcoma explants, PCR can detect fewer than one virus per cell but gives little detail of the gross structure and abundance of the virus, Analysis by Southern blotting of total DNA from ten osteosarcomas, positive for SV40 by PCR, found viral integration in half of these. Analysis showed integration of one to four copies per cell of rearranged SV40. No SV40 was detectable on blots of the remaining five SV40(+) osteosarcomas, perhaps because of the lesser sensitivity of direct hybridization. Inactivation of the p53 and Rb tumor suppressors is a key activity of SV40 T-antigen, Unexpectedly, correlation of these findings with our prior studies indicated that five of ten osteosarcomas positive for SV40 DNA had mutations of p53, and two had deleted Rb, Apparently clonal integration with pre-existing alteration of a tumor suppressor gene, suggests that SV40 may play a role in the final conversion to malignant osteosarcoma.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Mendoza, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Res Inst, Dept Med,Div Hematol Oncol, Davis 5019, Los Angeles, CA 90048 USA.							BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CHESTERS PM, 1983, J INFECT DIS, V147, P676, DOI 10.1093/infdis/147.4.676; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fields BN, 1996, VIROLOGY; FOX N, 1989, SCIENCE, V244, P460, DOI 10.1126/science.2785714; HUNTER DJ, 1994, J VIROL, V68, P787, DOI 10.1128/JVI.68.2.787-796.1994; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; Lednicky JA, 1997, INT J CANCER, V72, P791; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P299; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Martini F, 1996, CANCER RES, V56, P4820; MILLER CW, 1990, CANCER RES, V50, P7950; Miller CW, 1997, ONCOGENE, V15, P231, DOI 10.1038/sj.onc.1201185; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Miller CW, 1996, CANCER GENET CYTOGEN, V86, P136, DOI 10.1016/0165-4608(95)00216-2; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; Pepper C, 1996, THORAX, V51, P1074, DOI 10.1136/thx.51.11.1074; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; ROWE WP, 1968, CANCER RES, V28, P1319; Sambrook J, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P569; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; Stewart AR, 1996, VIROLOGY, V221, P355, DOI 10.1006/viro.1996.0386; Strickler H, 1997, CANCER RES, V57, P3319; Strickler HD, 1996, CANCER EPIDEM BIOMAR, V5, P473; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292	37	60	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2457	2462		10.1038/sj.onc.1202179	http://dx.doi.org/10.1038/sj.onc.1202179			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824156				2022-12-25	WOS:000076927300005
J	Aliverti, A; Deng, Z; Ravasi, D; Piubelli, L; Karplus, PA; Zanetti, G				Aliverti, A; Deng, Z; Ravasi, D; Piubelli, L; Karplus, PA; Zanetti, G			Probing the function of the invariant glutamyl residue 312 in spinach ferredoxin-NADP(+) reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PHTHALATE DIOXYGENASE REDUCTASE; NADP+ REDUCTASE; CATALYTIC MECHANISM; ANGSTROM RESOLUTION; DEHYDROGENASE; BINDING; COMPLEX; FAMILY	Ferredoxin-NADP(+) reductase, the prototype of a large family of structurally related flavoenzymes, pairs single electrons carried by ferredoxin I and transfers them as a hydride to NADP(+). Four mutants of the enzyme, in which Glu-312 was replaced with Asp, Gin, Leu, and Ala to probe the role of the residue charge, size, and polarity in the enzyme activity, have been heterologously expressed, purified, and characterized through steady-state, rapid kinetic studies, Ligand-binding experiments, and three-dimensional structure determination by x-ray crystallography. The E312L mutant was the only one that was almost inactive (similar to 1%), whereas unexpectedly the E312A reductase was 10-100% active with the various acceptors tested. Rapid kinetic absorption spectroscopy studies demonstrated that flavin reduction by NADPH was impaired in the mutants. Furthermore, NADP(H) binding was partially perturbed. These functional and structural studies lead us to conclude that Glu-312 does not fulfil the role of proton donor during catalysis, but it is required for proper binding of the nicotinamide ring of NADP(H). In addition, its charge modulates the two one-electron redox potentials of the flavin to stabilize the semiquinone form.	Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; Cornell Univ, Div Biol Sci, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of Milan; Cornell University	Zanetti, G (corresponding author), Univ Milan, Dipartimento Fisiol & Biochim Gen, Via Celoria 26, I-20133 Milan, Italy.	gzanetti@imiucca.csi.unimi.it	Aliverti, Alessandro/B-7875-2017	Aliverti, Alessandro/0000-0002-1226-3655; PIUBELLI, LUCIANO/0000-0003-0805-5121; Karplus, Paul/0000-0001-8725-6292				Adolph HW, 1997, BIOCHEMISTRY-US, V36, P8743, DOI 10.1021/bi970398k; ALIVERTI A, 1991, J BIOL CHEM, V266, P17760; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ALIVERTI A, 1993, BIOCHEMISTRY-US, V32, P6374, DOI 10.1021/bi00076a010; ALIVERTI A, 1995, PHOTOSYNTHESIS LIGHT, V2, P653; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BATIE CJ, 1984, J BIOL CHEM, V259, P1976; BATIE CJ, 1986, J BIOL CHEM, V261, P1214; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; Corrado ME, 1996, EUR J BIOCHEM, V239, P662, DOI 10.1111/j.1432-1033.1996.0662u.x; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; GASSNER G, 1994, BIOCHEMISTRY-US, V33, P12184, DOI 10.1021/bi00206a022; GASSNER GT, 1995, BIOCHEMISTRY-US, V34, P13460, DOI 10.1021/bi00041a025; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HURLEY JH, 1994, STRUCTURE, V2, P1007, DOI 10.1016/S0969-2126(94)00104-9; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KARPLUS PA, 1994, J BIOENERG BIOMEMBR, V26, P89, DOI 10.1007/BF00763221; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Liao DI, 1998, STRUCTURE, V6, P23, DOI 10.1016/S0969-2126(98)00004-5; MASSEY V, 1977, J BIOL CHEM, V252, P5612; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; ORELLANO EG, 1993, J BIOL CHEM, V268, P19267; PAI EF, 1983, J BIOL CHEM, V258, P1752; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; ZANETTI G, 1981, FEBS LETT, V129, P201, DOI 10.1016/0014-5793(81)80165-2; ZANETTI G, 1991, CHEM BIOCH FLAVOENZY, V2, P305; ZANETTI G, 1996, FLAVINS FLAVOPROTEIN, P509	30	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34008	34015		10.1074/jbc.273.51.34008	http://dx.doi.org/10.1074/jbc.273.51.34008			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852055	hybrid			2022-12-25	WOS:000077542200021
J	Gadroy, P; Stridsberg, M; Capon, C; Michalski, JC; Strub, JM; Van Dorsselaer, A; Aunis, D; Metz-Boutigue, MH				Gadroy, P; Stridsberg, M; Capon, C; Michalski, JC; Strub, JM; Van Dorsselaer, A; Aunis, D; Metz-Boutigue, MH			Phosphorylation and O-glycosylation sites of human chromogranin A (CGA(79-439)) from urine of patients with carcinoid tumors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDULLARY CHROMAFFIN GRANULES; PARATHYROID CELL SECRETION; N-TERMINAL FRAGMENT; ANTIBACTERIAL ACTIVITY; MESSENGER-RNA; IMMUNOHISTOCHEMICAL LOCALIZATION; HUMAN PANCREASTATIN; SECRETOGRANIN-II; A FRAGMENT; ENDOCRINE	Because of their water-soluble properties, chromogranins (CGs) and chromogranin-derived fragments are released together with catecholamines from adrenal chromaffin cells during stress situations and can be detected in the blood by radiochemical and enzyme assays. It is well known that chromogranins can serve as immunocytochemical markers for neuroendocrine tissues and as a diagnostic tool for neuroendocrine tumors. In 1993, large CGA-derived fragments have been shown to be excreted into the urine in patients with carcinoid tumors and the present study deals with three characterization of the post-translational modifications (phosphorylation and O-glycosylation) located along the largest natural CGA-derived fragment CGA(79-439). Using mild proteolysis of peptidic material, high performance liquid chromatography, sequencing, and mass spectrometry analysis, six post-translational modifications were detected along the C-terminal CGA-derived fragment CGA(79-439). Three O-linked glycosylation sites were located in the core of the protein on Thr(163), Thr(165), and Thr(233), consisting in di-, tri-, and tetrasaccharides. Three phosphorylation sites were located in the middle and C-terminal domain, on serine residues Ser(200), Ser(252), and Ser(315). These modified sites were compared with sequences of others species and discussed in relation with the post-translational modifications that we: have reported previously for bovine CGA.	INSERM, U338, Unite Biol Commun Cellulaire, F-67084 Strasbourg, France; Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden; CNRS, Chim Biol Lab, UMR 111, F-59655 Villeneuve Dascq, France; CNRS, Lab Spectrometrie Masse Bioorgan, URA 31, F-67084 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Uppsala University; Uppsala University Hospital; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Metz-Boutigue, MH (corresponding author), INSERM, U338, Unite Biol Commun Cellulaire, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	metz@neurochem.u-strasbg.fr	Dominique, Aunis/W-1419-2019	Strub, Jean-Marc/0000-0001-6224-3428				Aardal S, 1996, SCAND J CLIN LAB INV, V56, P511, DOI 10.3109/00365519609088807; AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; BARBOSA JA, 1991, ENDOCRINOLOGY, V128, P174, DOI 10.1210/endo-128-1-174; CETIN Y, 1993, P NATL ACAD SCI USA, V90, P2360, DOI 10.1073/pnas.90.6.2360; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; DEGORCE F, 1998, IN PRESS BR J CANC; DESTE L, 1994, CELL TISSUE RES, V277, P341, DOI 10.1007/s004410050161; DILLEN L, 1993, NEUROCHEM INT, V22, P315, DOI 10.1016/0197-0186(93)90016-X; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; EFENDIC S, 1987, P NATL ACAD SCI USA, V84, P7257, DOI 10.1073/pnas.84.20.7257; EIDEN LE, 1987, J NEUROCHEM, V49, P65, DOI 10.1111/j.1471-4159.1987.tb03395.x; ERIKSSON B, 1989, ACTA ONCOL, V28, P325, DOI 10.3109/02841868909111201; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; FUNAKOSHI S, 1989, BIOCHEM BIOPH RES CO, V164, P141, DOI 10.1016/0006-291X(89)91694-X; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; Goumon Y, 1996, EUR J BIOCHEM, V235, P516, DOI 10.1111/j.1432-1033.1996.t01-1-00516.x; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; HELLE KB, 1990, NEUROCHEM INT, V17, P165, DOI 10.1016/0197-0186(90)90139-K; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; HSIAO RJ, 1990, KIDNEY INT, V37, P955, DOI 10.1038/ki.1990.71; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTON JC, 1987, BIOCHEM J, V244, P457, DOI 10.1042/bj2440457; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1988, ENDOCRINOLOGY, V122, P2339, DOI 10.1210/endo-122-5-2339; ISHIZUKA J, 1989, PANCREAS, V4, P277, DOI 10.1097/00006676-198906000-00001; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KIANG WL, 1982, J BIOL CHEM, V257, P1651; KIMURA N, 1995, ENDOCR PATHOL, V6, P35, DOI 10.1007/BF02914987; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEWIS JJ, 1989, BIOCHEM BIOPH RES CO, V163, P667, DOI 10.1016/0006-291X(89)92275-4; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Metz-Boutigue MH, 1998, CELL MOL NEUROBIOL, V18, P249, DOI 10.1023/A:1022573004910; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; Montreuil J, 1986, CARBOHYDRATE ANAL PR, P143; MOULAND AJ, 1991, ENDOCRINOLOGY, V128, P441, DOI 10.1210/endo-128-1-441; O'Connor D T, 1990, Acta Histochem Suppl, V38, P27; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; *OXF MOL LTD, V31 OXF MOL LTD; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PETERSON JB, 1987, J BIOL CHEM, V262, P17264; REINECKE M, 1993, GEN COMP ENDOCR, V90, P251, DOI 10.1006/gcen.1993.1080; RIEKER S, 1988, J NEUROCHEM, V50, P1066, DOI 10.1111/j.1471-4159.1988.tb10574.x; SCHMIDT WE, 1988, P NATL ACAD SCI USA, V85, P8231, DOI 10.1073/pnas.85.21.8231; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1645; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V262, P1; SOSZYNSKI D, 1993, J NEUROENDOCRINOL, V5, P655, DOI 10.1111/j.1365-2826.1993.tb00536.x; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; STRIDSBERG M, 1995, J ENDOCRINOL, V144, P49, DOI 10.1677/joe.0.1440049; STRIDSBERG M, 1993, J ENDOCRINOL, V139, P329, DOI 10.1677/joe.0.1390329; Strub JM, 1996, FEBS LETT, V379, P273, DOI 10.1016/0014-5793(95)01529-9; Strub JM, 1996, J BIOL CHEM, V271, P28533, DOI 10.1074/jbc.271.45.28533; STRUB JM, 1995, EUR J BIOCHEM, V229, P356, DOI 10.1111/j.1432-1033.1995.0356k.x; Strub JM, 1997, J BIOL CHEM, V272, P11928, DOI 10.1074/jbc.272.18.11928; TAMAMURA H, 1990, EUR J BIOCHEM, V191, P33, DOI 10.1111/j.1432-1033.1990.tb19090.x; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taupenot L, 1996, NEUROSCIENCE, V72, P377, DOI 10.1016/0306-4522(96)83172-1; WIEDENMANN B, 1989, VIRCHOWS ARCH B, V58, P95, DOI 10.1007/BF02890062; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130	69	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34087	34097		10.1074/jbc.273.51.34087	http://dx.doi.org/10.1074/jbc.273.51.34087			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852066	hybrid			2022-12-25	WOS:000077542200032
J	Gao, YS; Alvarez, C; Nelson, DS; Sztul, E				Gao, YS; Alvarez, C; Nelson, DS; Sztul, E			Molecular cloning, characterization, and dynamics of rat formiminotransferase cyclodeaminase, a Golgi-associated 58-kDa protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL MEMBRANE-PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; LIVING CELLS; TUBULIN ISOTYPES; BINDING PROTEIN; TRANSPORT; APPARATUS; COMPLEX; ER	A peripherally associated 58-kDa Golgi protein (58K) of unknown function has been previously described (Bloom, G. S., and Brashear, T. A. (1989) J, Biol, Chem, 264, 16083-16092). To molecularly characterize 58K, we used a monoclonal anti-58K antibody (monoclonal antibody 58K-9) to screen a rat liver cDNA expression library. Positive clones were isolated, characterized, and partially sequenced. The obtained sequences show a high level of identity with sequences of porcine formiminotransferase cyclodeaminase (FTCD), suggesting that 58K is rat FTCD. Rat FTCD :is structurally similar to porcine FTCD, a metabolic enzyme involved in conversion of histidine to glutamic acid, and exists in dimeric, tetrameric, and octameric complexes resistant to proteolysis. To define parameters of FTCD association with the Golgi, comparison of its behavior with various Golgi and ER-to-Golgi intermediate compartment marker proteins was examined under specific conditions. The results show that extraction parameters of FTCD are similar to those of GM130, a tightly associated Golgi matrix protein, FTCD appears to be a dynamic component of the Golgi, and a proportion of FTCD molecules cycle between the Golgi and earlier compartments of the secretory pathway. FTCD remains associated with Golgi fragments during microtubule disruption and is not released into cytosol during brefeldin A treatment. Instead, FTCD relocates from the Golgi, but the time course of its redistribution is distinct from that of mannosidase II relocation. FTCD is already dispersed into small punctate structures at a time when mannosidase II is still largely localized to Golgi structures. FTCD is not observed in tubules originating from the Golgi and containing mannosidase II. Instead, it appears to redistribute in small vesicles arranged in a linear "pearls on a string" pattern. These results suggest that FTCD relocation is temporally and spatially distinct from mannosidase II relocation and that; FTCD provides a novel marker to study Golgi dynamics.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Sztul, E (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, BHSB Rm 668, Birmingham, AL 35294 USA.	esztul@bmg.bhs.uab.edu						ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Bannykh SI, 1998, TRENDS CELL BIOL, V8, P21, DOI 10.1016/S0962-8924(97)01184-7; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; Bashour AM, 1998, J BIOL CHEM, V273, P19612, DOI 10.1074/jbc.273.31.19612; BEAUDET R, 1976, BIOCHIM BIOPHYS ACTA, V453, P151, DOI 10.1016/0005-2795(76)90259-2; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; CLERMONT Y, 1995, ANAT REC, V242, P289, DOI 10.1002/ar.1092420302; CLUETT EB, 1993, J CELL BIOL, V120, P15, DOI 10.1083/jcb.120.1.15; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; COOK RJ, 1991, J BIOL CHEM, V266, P4965; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s; FINDLAY WA, 1987, BIOCHEMISTRY-US, V26, P1948, DOI 10.1021/bi00381a024; GarciaMata R, 1997, MOL BIOL CELL, V8, P2371; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; Hennig D, 1998, J BIOL CHEM, V273, P19602, DOI 10.1074/jbc.273.31.19602; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HOE MH, 1995, J BIOL CHEM, V270, P25057, DOI 10.1074/jbc.270.42.25057; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; KUISMANEN E, 1989, METHOD CELL BIOL, V32, P257; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LAHTINEN U, 1992, J CELL SCI, V103, P321; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LEWIS SA, 1987, CELL, V49, P539, DOI 10.1016/0092-8674(87)90456-9; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; MACKENZIE RE, 1980, J BIOL CHEM, V255, P9474; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MURLEY LL, 1993, J BIOL CHEM, V268, P22820; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; RAMBOURG A, 1979, AM J ANAT, V154, P455, DOI 10.1002/aja.1001540402; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; SARASTE J, 1991, J CELL SCI, V100, P415; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; SZTUL ES, 1985, J CELL BIOL, V100, P1248, DOI 10.1083/jcb.100.4.1248; TANG BL, 1992, J BIOL CHEM, V267, P7072; TANG BL, 1995, EUR J CELL BIOL, V68, P199; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0	54	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33825	33834		10.1074/jbc.273.50.33825	http://dx.doi.org/10.1074/jbc.273.50.33825			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837973	hybrid			2022-12-25	WOS:000077462500103
J	Lin, RS; Rodriguez, C; Veillette, A; Lodish, HF				Lin, RS; Rodriguez, C; Veillette, A; Lodish, HF			Zinc is essential for binding of p56(lck) to CD4 and CD8 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; AMINO-TERMINAL DOMAIN; HUMAN IMMUNODEFICIENCY VIRUS; METAL-LINKED DIMER; CYTOPLASMIC DOMAINS; SIGNAL-TRANSDUCTION; TAT PROTEIN; P56LCK; RECEPTOR; ANTIGEN	Binding of the protein tyrosine kinase p56(lck) to T-cell co-receptors CD4 and CD8 alpha is necessary for T-lymphocyte development and activation. Association of p56(lck) with CD4 requires two conserved cysteine residues in the cytosolic domain of CD4 and two in the amino terminus of p56(lck), consistent with the notion that these four residues coordinate a single metal atom (1-5). Here we demonstrate that Zn2+ is essential for complex formation. In an in vitro binding reaction, Zn2+ mediates p56(lck) association with a glutathione S-transferase (GST) fusion protein containing the cytosolic domains of CD4 or CD8 alpha; no other metals tested support binding. Treatment of preformed GST-CD4.p56(lck) dimers with the Zn2+ chelators 1,10-O-phenanthroline or 8-hydroxyquinoline-5-sulfonic acid results in dissociation of GST-CD4 from p56(lck), consistent with the finding of Huse et al. (5) that Zn2+ is contained within similar complexes. Furthermore, we show that, within live cells, CD4.p56(lck) and CD8 alpha.p56(lck) interactions occur in a zinc-dependent fashion. Specifically, pretreatment of the human Jurkat T-cell line with membrane permeable zinc chelators disrupts CD4.p56(lck) complexes, and treatment of COS cells co-expressing CD8a and p56(lck) with such chelators likewise leads to dissociation of CD8 alpha.p56(lck) complexes. CD4.p56(lck) and CD8 alpha.p56(lck) represent the first examples of intracellular proteins that require zinc as a bridge for heterodimerization.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; McGill Univ, Ctr Canc, Montreal, PQ H3G 1Y6, Canada	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); McGill University	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			rodriguez, carlos/0000-0001-9593-8680	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AULD DS, 1988, METHOD ENZYMOL, V158, P110, DOI 10.1016/0076-6879(88)58051-5; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BRAMSON HN, 1991, J BIOL CHEM, V266, P16219; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; Huse M, 1998, J BIOL CHEM, V273, P18729, DOI 10.1074/jbc.273.30.18729; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Maret W, 1997, P NATL ACAD SCI USA, V94, P2233, DOI 10.1073/pnas.94.6.2233; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1990, ONCOGENE, V5, P1455; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Weil R, 1996, CURR TOP MICROBIOL, V205, P63; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	25	74	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32878	32882		10.1074/jbc.273.49.32878	http://dx.doi.org/10.1074/jbc.273.49.32878			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830036	hybrid			2022-12-25	WOS:000077329100075
J	Navarro, F; Navas, P; Burgess, JR; Bello, RI; De Cabo, R; Arroyo, A; Villalba, JM				Navarro, F; Navas, P; Burgess, JR; Bello, RI; De Cabo, R; Arroyo, A; Villalba, JM			Vitamin E and selenium deficiency induces expression of the ubiquinone-dependent antioxidant system at the plasma membrane	FASEB JOURNAL			English	Article						lipid peroxidation; oxidative stress; plasma membrane; ubiquinone; vitamin E and selenium deficiency	HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; PHOSPHOLIPASE A(2) ACTIVITY; COENZYME-Q REDUCTASE; RAT-LIVER CYTOSOL; LIPID-PEROXIDATION; OXIDATIVE STRESS; DT-DIAPHORASE; SUBMITOCHONDRIAL PARTICLES; ELECTRON-TRANSPORT; ALPHA-TOCOPHEROL	We have used a model of dietary deficiency that leads to a chronic oxidative stress to evaluate responses that are adaptations invoked to boost cellular defense systems. Long-Evans hooded rats were fed with a diet lacking vitamin E (E) and selenium (Se) for 7 wk from weaning leading to animals deficient in both nutrients (-E -Se). In the absence of an electron donor, liver plasma membranes from these rats were more sensitive to lipid peroxidation, although they contained 40% greater amounts of ubiquinone than the plasma membranes from rats consuming diets with sufficient vitamin E and Se (+E +Se). The incubation of plasma membranes with NAD(P)H resulted in protection against peroxidation, and this effect was more pronounced in -E -Se membranes. Deficiency was accompanied by a twofold increase in redox activities associated with trans plasma membrane electron transport such as ubiquinone reductase and ascorbate free radical reductase. Staining with a polyclonal antibody against pig liver cytochrome b(5) reductase, which acts as one ubiquinone reductase in the plasma membrane, showed an increased expression of the enzyme in membranes from -E -Se rats. Little DT-diaphorase activity was measured in +E +Se plasma membranes, but this activity was dramatically increased in -E -Se plasma membranes. No such increase was found in liver cytosols, which contained elevated activity of calcium-independent phospholipase A(2). Thus, ubiquinone-dependent antioxidant protection in +E +Se plasma membranes is based primarily on NADH-cytochrome bg reductase, whereas additional protection needed in -E -Se plasma membranes is supported by the increase of ubiquinone levels, increased expression of the cytochrome br,reductase, and translocation of soluble DT-diaphorase to the plasma membrane. Our results indicate that, in the absence of vitamin E and Se, enhancement of ubiquinone-dependent reductase systems can fulfill the membrane antioxidant protection.	Univ Cordoba, Fac Ciencias, Dept Cellular Biol, E-14004 Cordoba, Spain; Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA	Universidad de Cordoba; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Villalba, JM (corresponding author), Univ Cordoba, Fac Ciencias, Dept Cellular Biol, Avd S Alberto Magno S-N, E-14004 Cordoba, Spain.	bclvimoj@lucano.uco.es	de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/E-7996-2010; NAVAS, PLACIDO/R-5943-2019; Navarro Roldán, Francisco/H-8611-2015; de Cabo, Rafael/J-5230-2016	de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0003-2830-5693; NAVAS, PLACIDO/0000-0002-4115-7966; Navarro Roldán, Francisco/0000-0002-6384-5575; de Cabo, Rafael/0000-0002-3354-2442				ABERG F, 1994, CHEM-BIOL INTERACT, V91, P1, DOI 10.1016/0009-2797(94)90002-7; Barroso MP, 1997, J BIOENERG BIOMEMBR, V29, P259, DOI 10.1023/A:1022462111175; BENES SE, 1995, PHYSIOL PLANTARUM, V94, P124, DOI 10.1111/j.1399-3054.1995.tb00793.x; BEYER RE, 1994, J BIOENERG BIOMEMBR, V26, P349, DOI 10.1007/BF00762775; Beyer RE, 1996, P NATL ACAD SCI USA, V93, P2528, DOI 10.1073/pnas.93.6.2528; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; Burgess JR, 1996, J NUTR BIOCHEM, V7, P366, DOI 10.1016/S0955-2863(96)00057-5; CONSTANTINESCU A, 1994, MOL ASPECTS MED, V15, P57, DOI 10.1016/0098-2997(94)90013-2; CONSTANTINESCU A, 1993, J BIOL CHEM, V268, P10906; CRAWFORD DR, 1994, METHODS ENZYMOL, V234, P175; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; ERNSTER L, 1992, BIOFACTORS, V3, P241; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FORSMARKANDREE P, 1995, FREE RADICAL BIO MED, V19, P749, DOI 10.1016/0891-5849(95)00076-A; GOLDMAN R, 1993, FREE RADICAL BIO MED, V15, P542, DOI 10.1016/0891-5849(93)90453-2; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; HALLIWELL B, 1989, FREE RADICAL BIO MED, V2, P1; KAGAN VE, 1992, BIOCHEM BIOPH RES CO, V186, P74, DOI 10.1016/S0006-291X(05)80777-6; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; KamalEldin A, 1996, LIPIDS, V31, P671, DOI 10.1007/BF02522884; KIM C, 1995, PROTOPLASMA, V184, P111, DOI 10.1007/BF01276907; KUO CF, 1995, J NUTR, V125, P1419; Landi L, 1997, FREE RADICAL BIO MED, V22, P329, DOI 10.1016/S0891-5849(96)00294-8; LEI XG, 1995, J NUTR, V125, P1438; LI Y, 1992, J BIOL CHEM, V267, P15097; LIEBLER DC, 1993, CRIT REV TOXICOL, V23, P147, DOI 10.3109/10408449309117115; LIND C, 1990, METHOD ENZYMOL, V186, P287; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; May JM, 1996, J BIOL CHEM, V271, P10577, DOI 10.1074/jbc.271.18.10577; Mazur A, 1996, BRIT J NUTR, V76, P899, DOI 10.1079/BJN19960096; NAVARRO F, 1995, BIOCHEM BIOPH RES CO, V212, P138, DOI 10.1006/bbrc.1995.1947; NAVAS P, 1989, CANCER RES, V49, P2147; PASCOE GA, 1987, J CHROMATOGR-BIOMED, V414, P440, DOI 10.1016/0378-4347(87)80071-3; REDDY CC, 1982, BIOCHEM BIOPH RES CO, V107, P75, DOI 10.1016/0006-291X(82)91671-0; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schultz JR, 1996, BIOCHEMISTRY-US, V35, P6595, DOI 10.1021/bi960245h; Slater AFG, 1996, CELL DEATH DIFFER, V3, P57; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; Takahashi T, 1996, J BIOCHEM-TOKYO, V119, P256; TAKAHASHI T, 1995, BIOCHEM J, V309, P883, DOI 10.1042/bj3090883; Takahashi T, 1996, BIOL PHARM BULL, V19, P1005; TAKAHASHI T, 1992, FEBS LETT, V314, P331, DOI 10.1016/0014-5793(92)81499-C; Tokumaru S, 1997, FREE RADICAL RES, V26, P169, DOI 10.3109/10715769709097795; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4; VILLALBA JM, 1995, P NATL ACAD SCI USA, V92, P4887, DOI 10.1073/pnas.92.11.4887; VILLALBA JM, 1996, TREND COMPAR BIOCHEM, V2, P65; Yang MX, 1996, ARCH BIOCHEM BIOPHYS, V331, P69, DOI 10.1006/abbi.1996.0284	51	102	102	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1665	1673		10.1096/fasebj.12.15.1665	http://dx.doi.org/10.1096/fasebj.12.15.1665			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837856				2022-12-25	WOS:000077574500008
J	Cohen, PA; Mani, JC; Lane, DP				Cohen, PA; Mani, JC; Lane, DP			Characterization of a new intrabody directed against the N-terminal region of human p53	ONCOGENE			English	Article						p53 tumour suppressor; single-chain antibody; transactivation	TUMOR-SUPPRESSOR PROTEIN; SINGLE-CHAIN ANTIBODY; DNA-BINDING ACTIVITY; WILD-TYPE P53; INTRACELLULAR EXPRESSION; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; PHOSPHORYLATION SITES; FILAMENTOUS PHAGE; KINETIC-ANALYSIS	Genes encoding the rearranged immunoglobulin heavy and light chain variable regions of DO-1, a monoclonal antibody directed against human p53, have been used to construct a single-chain antibody, DO-1 recognizes an N-terminal epitope in the region involved in the transactivation function of p53 and the binding of Mdm2. The DO-1 single chain scFv expressed in the periplasm of E. coli or at the surface of the filamentous phage M13 retained the immunological specificity and affinity of the full length antibody. Furthermore, the DO-1 recombinant antibody was able to inhibit the in vitro binding of Hdm2, and was shown to be a powerful protecting agent of p53's DNA binding activity at 37 degrees C. The DO-1 single-chain antibody has been used to construct single-chain intracellular antibodies (intrabodies) for expression in the cytoplasm and the nucleus of mammalian cells. These anti-p53 intrabodies were additionally modified by addition of a C-kappa domain to increase cytoplasmic and nuclear stability, Here we show that expression of the DO-1 single-chain antibody in the H1299 cell line results in an inhibition of p53's transactivation function, The DO-1 intrabody is a useful tool to study those functions of p53 driven by the N-terminal region of the protein.	Univ Dundee, Inst Med Sci, Dept Biochem, CRC,Cell Transformat Res Grp, Dundee DD1 4HN, Scotland; CNRS, UMR 9921, UFR Pharm, F-34060 Montpellier 01, France	University of Dundee; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lane, DP (corresponding author), Univ Dundee, Inst Med Sci, Dept Biochem, CRC,Cell Transformat Res Grp, Dundee DD1 4HN, Scotland.		Cohen, Pascale/I-5875-2012; Lane, David P/C-4920-2008	Cohen, Pascale/0000-0001-7016-9598; Lane, David/0000-0003-0551-3545				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BIOCCA S, 1993, BIOCHEM BIOPH RES CO, V197, P422, DOI 10.1006/bbrc.1993.2496; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DUAN LX, 1994, HUM GENE THER, V5, P1315, DOI 10.1089/hum.1994.5.11-1315; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FISCELLA M, 1993, ONCOGENE, V8, P1519; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harlow E., 1988, ANTIBODIES LAB MANUA; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hecker D, 1996, ONCOGENE, V12, P953; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; Jannot CB, 1997, BIOCHEM BIOPH RES CO, V230, P242, DOI 10.1006/bbrc.1996.5930; Jannot CB, 1996, ONCOGENE, V13, P275; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEONARDO AD, 1994, GENE DEV, V8, P2540; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIN YS, 1989, NATURE, V340, P656, DOI 10.1038/340656a0; Lohrum M, 1996, ONCOGENE, V13, P2527; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACIEJEWSKI JP, 1995, NAT MED, V1, P667, DOI 10.1038/nm0795-667; Maki CG, 1996, CANCER RES, V56, P2649; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; MARSTON NJ, 1994, ONCOGENE, V9, P2707; Mayo LD, 1997, CANCER RES, V57, P5013; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; MILLER SPL, 1992, MOL CELL BIOL, V12, P5041; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VARHAVSKY A, 1992, CELL, V69, P725; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Wright M, 1997, GENE THER, V4, P317, DOI 10.1038/sj.gt.3300372; YONEDA Y, 1992, EXP CELL RES, V201, P313, DOI 10.1016/0014-4827(92)90279-H	83	51	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	1998	17	19					2445	2456		10.1038/sj.onc.1202190	http://dx.doi.org/10.1038/sj.onc.1202190			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824155				2022-12-25	WOS:000076927300004
J	Cavallo, D; McLeod, RS; Rudy, D; Aiton, A; Yao, ZM; Adeli, K				Cavallo, D; McLeod, RS; Rudy, D; Aiton, A; Yao, ZM; Adeli, K			Intracellular translocation and stability of apolipoprotein B are inversely proportional to the length of the nascent polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEP G2 CELLS; LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM MEMBRANE; TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; LIPID RECRUITMENT; RAT-LIVER; APO-B; DEGRADATION; SECRETION	We have studied the relationship between the length of apolipoprotein B (apoB) and its intracellular translocation and stability using McArdle RH7777 (McA-RH7777) cells expressing recombinant human apoB variants, ranging in size from B15 to B100, The translocational status of apoB was assessed based on trypsin sensitivity of apoB using isolated microsomes as well as permeabilized cells. In isolated microsomes, shorter apoB variants (less than or equal to B48) were 75-100% resistant to exogenous trypsin digestion, whereas apoB variants larger than B48 were less than 40% trypsin-resistant, Experiments with hepatic microsomes isolated from rat or transgenic mice expressing human B48 and B100 also confirmed the high trypsin accessibility of B100 compared with B48, In permeabilized cells, apoB variants shorter than B48 were relatively resistant to exogenous trypsin (percentage of trypsin-resistant apoB greater than 70%) in contrast to recombinant human B72 and B100, which were only 55 and 42% trypsin-resistant, respectively. The trypsin sensitivity of human B100 was comparable with that of endogenous rat B100 in McA-RH7777 cells as well as endogenous B100 in HepG2 cells (percentages of trypsin-resistant cells were as follows: for human B100 construct, 42 +/- 7.5%; for endogenous McA-RH7777 B100, 52 +/- 2.9%; and for endogenous HepG2 B100, 46 +/- 6.3%). Overall, an inverse correlation between the length of apoB and its resistance to exogenous trypsin was evident irrespective of the model system examined. An inverse relationship was also observed between the size of apoB and its co-translational resistance to proteasomal degradation. Truncated apoB constructs were relatively insensitive to proteasome inhibition by MG132 co-translationally (during the pulse) compared with the full-length B100, which was highly sensitive (apoB recovered in the presence of MG132 as a percentage of control was as follows: B15, 127%; B29, 94%; B48, 110%; B72, 140%; B100, 282%). Post-translationally (over a 2-h chase), a similar inverse relationship was found, with B100 being the least stable in comparison with truncated apoB variants. In summary, as the size of the nascent apoB chain increases, there appears to be a greater cytosolic exposure of the polypeptide, leading to a higher sensitivity to proteasomal degradation.	Univ Windsor, Dept Chem & Biochem, Windsor, ON N9B 3P4, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Dept Pathol & Lab Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Grp, Dept Biochem, Ottawa, ON K1Y 4E9, Canada	University of Windsor; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Adeli, K (corresponding author), Univ Toronto, Hosp Sick Children, Dept Lab Med & Pathobiol, 100 Coll St, Toronto, ON M5G 1L5, Canada.		McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569; Adeli, Khosrow/0000-0002-5839-5709				ADELI K, 1994, J BIOL CHEM, V269, P9166; Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; ADELI K, 1990, FEBS LETT, V2, P345; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; Cartwright IJ, 1996, BIOCHEM J, V314, P977, DOI 10.1042/bj3140977; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1992, J CELL BIOL, V117, P1161, DOI 10.1083/jcb.117.6.1161; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; HAMILTON RL, 1991, J LIPID RES, V32, P529; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Ingram MF, 1996, J LIPID RES, V37, P2202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Macri J, 1997, J BIOL CHEM, V272, P7328, DOI 10.1074/jbc.272.11.7328; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PEASE RJ, 1995, J BIOL CHEM, V270, P7261, DOI 10.1074/jbc.270.13.7261; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; RIVETT AJ, 1993, CURR BIOL, V3, P127, DOI 10.1016/0960-9822(93)90173-L; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SERGEST JP, 1994, ARTERIOSCLER THROMB, V14, P1674; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SNIDERMAN AD, 1988, CAN J CARDIOL SA, V4, P24; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WILKINSON J, 1993, J LIPID RES, V34, P815; Wu XJ, 1997, J BIOL CHEM, V272, P11575; YAO ZM, 1991, J BIOL CHEM, V266, P3300; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	53	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33397	33405		10.1074/jbc.273.50.33397	http://dx.doi.org/10.1074/jbc.273.50.33397			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837916	hybrid			2022-12-25	WOS:000077462500046
J	Malhotra, JD; Tsiotra, P; Karagogeos, D; Hortsch, M				Malhotra, JD; Tsiotra, P; Karagogeos, D; Hortsch, M			Cis-activation of L1-mediated ankyrin recruitment by TAG-1 homophilic cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL GLYCOPROTEIN TAG-1; NEURITE OUTGROWTH; IMMUNOGLOBULIN SUPERFAMILY; HOMOPHILIC BINDING; L1-LIKE MOLECULE; NERVOUS-SYSTEM; GROWTH CONES; AXONIN-1; DROSOPHILA; EXPRESSION	Neural cell adhesion molecules (CAMs) of the immunoglobulin (Ig) superfamily mediate not only cell aggregation but also growth cone guidance and neurite outgrowth. In this study we demonstrate that two neural CAMs, L1-CAM and TAG-1, induce the homophilic aggregation of Drosophila S2 cells but are unable to interact with each other when expressed on different cells (trans-interaction). However, immunoprecipitations from cells co-expressing L1-CAM and TAG-1 showed a strong cis-interaction between the two molecules in the plane of the plasma membrane. TAG-1 is linked to the membrane by a glycosylphosphatidylinositol (GPI) anchor and therefore is unable to directly interact with cytoplasmic proteins. In contrast, L1-CAM-mediated homophilic cell adhesion induces the selective recruitment of the membrane skeleton protein ankyrin to areas of cell contact. Immunolabeling experiments in which S2 cells expressing TAG-1 were mixed with cells co-expressing L1-CAM and TAG-1 demonstrated that the homophilic interaction between TAG-1 molecules results in the cis-activation of L1-CAM to bind ankyrin. This TAG-1-dependent recruitment of the membrane skeleton provides an example of how GPI-anchored CAMs are able to transduce signals to the cytoplasm. Furthermore, such interactions might ultimately result in the recruitment and the activation of other signaling molecules at sites of cell contacts.	Univ Michigan, Dept Anat & Cell Biol, Ann Arbor, MI 48109 USA; Univ Crete, Sch Med, Fdn Res & Technol, Inst Mol Biol & Biotechnol, Heraklion 71110, Crete, Greece; Univ Crete, Sch Med, Dept Basic Sci, Heraklion 71110, Crete, Greece	University of Michigan System; University of Michigan; University of Crete; University of Crete	Hortsch, M (corresponding author), Univ Michigan, Dept Anat & Cell Biol, Ann Arbor, MI 48109 USA.		Tsiotra, Panayoula C./AAE-6086-2019	Tsiotra, Panayoula C./0000-0002-1702-5840; Hortsch, Michael/0000-0002-3750-737X; Karagogeos, Domna/0000-0002-8129-9731	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029388, R01HD029388] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29388] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BIEBER AJ, 1994, METHOD CELL BIOL, V44, P683, DOI 10.1016/S0091-679X(08)60938-3; BRUMMENDORF T, 1993, J NEUROCHEM, V61, P1207, DOI 10.1111/j.1471-4159.1993.tb13611.x; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; DUBREUIL RR, 1994, P NATL ACAD SCI USA, V91, P10285, DOI 10.1073/pnas.91.22.10285; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; GRUMET M, 1984, P NATL ACAD SCI-BIOL, V81, P7989, DOI 10.1073/pnas.81.24.7989; HONIG MG, 1995, DEV BIOL, V167, P563, DOI 10.1006/dbio.1995.1049; HORTSCH M, 1985, J BIOL CHEM, V260, P9137; Hortsch M, 1998, J CELL BIOL, V142, P251, DOI 10.1083/jcb.142.1.251; HORTSCH M, 1995, J BIOL CHEM, V270, P18809, DOI 10.1074/jbc.270.32.18809; Hortsch M, 1998, CELL ADHES COMMUN, V5, P61, DOI 10.3109/15419069809005599; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; KARAGOGEOS D, 1991, DEVELOPMENT, V112, P51; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; Kunz S, 1996, J CELL BIOL, V135, P253, DOI 10.1083/jcb.135.1.253; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; Rader C, 1996, EMBO J, V15, P2056, DOI 10.1002/j.1460-2075.1996.tb00559.x; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; Stoeckli ET, 1996, DEV BIOL, V177, P15, DOI 10.1006/dbio.1996.0141; STOECKLI ET, 1991, J CELL BIOL, V112, P449, DOI 10.1083/jcb.112.3.449; Tsiotra PC, 1996, J BIOL CHEM, V271, P29216, DOI 10.1074/jbc.271.46.29216; YAMAGATA M, 1995, J NEUROSCI, V15, P4556; ZUELLIG RA, 1992, EUR J BIOCHEM, V204, P453, DOI 10.1111/j.1432-1033.1992.tb16655.x	35	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33354	33359		10.1074/jbc.273.50.33354	http://dx.doi.org/10.1074/jbc.273.50.33354			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837910	hybrid			2022-12-25	WOS:000077462500040
J	Nadanaka, S; Kitagawa, H; Sugahara, K				Nadanaka, S; Kitagawa, H; Sugahara, K			Demonstration of the immature glycosaminoglycan tetrasaccharide sequence GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl on recombinant soluble human alpha-thrombomodulin - An oligosaccharide structure on a "part-time" proteoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LINKAGE REGION; SITE-DIRECTED MUTAGENESIS; CHONDROITIN SULFATE; N-ACETYLGALACTOSAMINYLTRANSFERASE; ENDOPLASMIC-RETICULUM; SHARK CARTILAGE; ATTACHMENT SITE; IDENTIFICATION; BIOSYNTHESIS; HYALURONIDASE	Thrombomodulin (TM), a cell surface glycoprotein, is a critical mediator of endothelial anticoagulant defenses occurring both as a chondroitin sulfate proteoglycan (beta-TRI) and a protein (alpha-TRI) unsubstituted by chondroitin sulfate (CS), hence its description as a "part-time" proteoglycan (PG) (Fransson , L. A. (1987) Trends Biochem. Sci. 12, 406-411). Sugar analysis was performed on alpha-TM to investigate a possible biosynthetic mechanism for part-time PGs. Recombinant human alpha-TM, which was expressed in CHO-K1 cells, separated by anion-exchange chromatography from beta-TM, and purified by immunoaffinity chromatography (Nawa, K,, Sakano, K., Fujiwara, H., Sate, Y., Sugiyama, N,, Teruuchi, T,, Iwamoto, M., and Marumoto, Y. (1990) Biochem. Biophys. Res. Commun. 171, 729-737), was used for analysis. Preliminary sugar composition analysis after acid hydrolysis showed Xyl in addition to Gal, GalNAc, GlcNAc, Man, Fuc, and Glc. O-Glycosidically-linked oligosaccharides were liberated by mild alkaline treatment and purified. The isolated oligosaccharide fraction was derivatized with a fluorophore 2-aminobenzamide (2AB), resulting in two fluorescent components, a 2AB-oligosaccharide and a putative 2AB-Glc. Based on structural analysis by a combination of sequential exoglycosidase digestion and 500-MHz H-1 NMR spectroscopy of the 2AB-oligosaccharide, the structure of the oligosaccharide was elucidated as GlcA beta 1-3Gal beta 1-3Gal beta 1-4Xyl, which turned out to represent a glycosaminoglycan (GAG)-protein linkage region tetrasaccharide common to various PGs and was considered to be a biosynthetic intermediate of an immature GAG chain. The results may indicate that at least one class of the so-called part-time PGs bear the linkage tetrasaccharide at the GAG attachment sites and that the critical determining step or the rate-limiting step for PG: biosynthesis is the transfer of the fifth sugar residue, the first hexosamine, rather than xylose.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan.		Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				ASPINALL GO, 1982, POLSACCHARIDES, V1, P37; BIGGE JC, 1995, ANAL BIOCHEM, V230, P616; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; DITTMAN WA, 1990, BLOOD, V75, P329; Dudek AZ, 1997, J BIOL CHEM, V272, P31785, DOI 10.1074/jbc.272.50.31785; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GERLITZ B, 1993, BIOCHEM J, V295, P131, DOI 10.1042/bj2950131; Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0; HASE S, 1978, BIOCHEM BIOPH RES CO, V85, P257, DOI 10.1016/S0006-291X(78)80037-0; HEINEGAR.D, 1972, BIOCHIM BIOPHYS ACTA, V285, P193, DOI 10.1016/0005-2795(72)90191-2; JALKANEN S, 1988, J IMMUNOL, V141, P1615; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; KITAGAWA H, 1995, J BIOL CHEM, V270, P22190, DOI 10.1074/jbc.270.38.22190; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lidholt K, 1997, GLYCOCONJUGATE J, V14, P737, DOI 10.1023/A:1018525602197; LIN JH, 1994, J BIOL CHEM, V269, P25021; MANN DM, 1990, J BIOL CHEM, V265, P5317; MANZI A, 1995, J BIOL CHEM, V270, P9154, DOI 10.1074/jbc.270.16.9154; MCCORMICK D, 1987, P NATL ACAD SCI USA, V84, P4044, DOI 10.1073/pnas.84.12.4044; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; NADANAKA S, 1998, 16 M FED EUR CONN TI; NAWA K, 1990, BIOCHEM BIOPH RES CO, V171, P729, DOI 10.1016/0006-291X(90)91207-9; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; RODEN L, 1985, FED PROC, V44, P373; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; Sugumaran G, 1998, BIOCHEM J, V329, P203, DOI 10.1042/bj3290203; Tamura J, 1996, LIEBIGS ANN, P1239; THONAR EJMA, 1983, J BIOL CHEM, V258, P1564; TSUKADA T, 1987, COMP BIOCHEM PHYS B, V86, P565, DOI 10.1016/0305-0491(87)90449-4; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMADA S, 1995, GLYCOBIOLOGY, V5, P335, DOI 10.1093/glycob/5.3.335; YE J, 1993, J BIOL CHEM, V268, P2373; ZHANG LJ, 1994, J BIOL CHEM, V269, P19295	46	55	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33728	33734		10.1074/jbc.273.50.33728	http://dx.doi.org/10.1074/jbc.273.50.33728			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837960	hybrid			2022-12-25	WOS:000077462500090
J	Nagaya, T; Murata, Y; Yamaguchi, S; Nomura, Y; Ohmori, S; Fujieda, M; Katunuma, N; Yen, PM; Chin, WW; Seo, HS				Nagaya, T; Murata, Y; Yamaguchi, S; Nomura, Y; Ohmori, S; Fujieda, M; Katunuma, N; Yen, PM; Chin, WW; Seo, HS			Intracellular proteolytic cleavage of 9-cis-retinoic acid receptor alpha by cathepsin L-type protease is a potential mechanism for modulating thyroid hormone action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; RESPONSE ELEMENT; KAPPA-B; TRANSCRIPTION FACTORS; AUXILIARY PROTEINS; NUCLEAR RECEPTOR; RXR-BETA; EXPRESSION; BINDING; DEGRADATION	We previously reported that the responsiveness of hepatocytes to thyroid hormone is markedly attenuated when they were cultured as monolayers rather than spheroids. To elucidate the mechanisms underlying the altered responsiveness, thyroid hormone receptor auxiliary proteins in the hepatocytes were analyzed by electrophoretic mobility shift assay. The major thyroid hormone receptor auxiliary protein was identified as 9-cis-retinoic acid receptor alpha (RXR alpha) in the hepatocytes regardless of the culture conditions. The cytoplasmic fraction was shown to contain a protease(s) that cleaves RXR alpha at its amino terminus. The presence of the protease in the cytosol, but not in the nucleus, was ascertained by incubating full-length S-35-labeled RXR alpha with each fraction, Using various protease inhibitors, it was shown that cathepsin L-type protease could participate in the cleavage of the RXR alpha. The enzyme activity was much higher in the monolayers than the spheroids. Inhibition of this enzyme activity in the monolayer hepatocyte resulted in the increase of nuclear RXR alpha protein and the augmentation of T-3-dependent induction of spot 14 mRNA. These results suggest that the changes in cathepsin L-type protease activity in the cytosol may alter the turnover of RXR alpha in the nucleus and modify the function of steroid receptor superfamilies that heterodimerize with RXR alpha.	Nagoya Univ, Environm Med Res Inst, Dept Endocrinol & Metab, Div Mol & Cellular Adapt,Chiikusa Ku, Nagoya, Aichi 4648601, Japan; Tokushima Bunri Univ, Res Inst Hlth, Tokushima 7708514, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA	Nagoya University; Tokushima Bunri University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Seo, HS (corresponding author), Nagoya Univ, Environm Med Res Inst, Dept Endocrinol & Metab, Div Mol & Cellular Adapt,Chiikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	hseo@riem.nagoya-u.ac.jp	Yen, Paul M/V-9857-2019	Yen, Paul/0000-0002-3790-8114				Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P713; BURTON K, 1956, BIOCHEM J, V62, P248; CARILLO S, 1994, ONCOGENE, V9, P1679; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HERMANN T, 1993, ONCOGENE, V8, P55; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; ICHIKAWA K, 1987, MOL CELL ENDOCRINOL, V51, P135, DOI 10.1016/0303-7207(87)90127-4; INUBUSHI T, 1994, J BIOCHEM-TOKYO, V116, P282, DOI 10.1093/oxfordjournals.jbchem.a124520; ISHIDOH K, 1989, FEBS LETT, V259, P71, DOI 10.1016/0014-5793(89)81497-8; KARZAI AW, 1992, BIOL REPROD, V47, P823, DOI 10.1095/biolreprod47.5.823; KATUNUMA N, 1997, J BONE MINER METAB, V15, P1; KATUNUMA N, 1995, BIOTHIOLS, P382; Kikumori T, 1998, ENDOCRINOLOGY, V139, P1715, DOI 10.1210/en.139.4.1715; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE HK, 1994, INT REV EXP PATHOL, V35, P39; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Liu ZQ, 1996, FEBS LETT, V385, P109, DOI 10.1016/0014-5793(96)00360-2; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MatsushimaNishiwaki R, 1996, BIOCHEM BIOPH RES CO, V225, P946, DOI 10.1006/bbrc.1996.1276; MURATA Y, 1989, ENDOCRINOLOGY, V125, P1424, DOI 10.1210/endo-125-3-1424; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; Nagaya T, 1996, BIOCHEM BIOPH RES CO, V226, P426, DOI 10.1006/bbrc.1996.1372; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NILSENHAMILTON M, 1991, MOL CELL ENDOCRINOL, V77, P115, DOI 10.1016/0303-7207(91)90065-Z; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; OKAMURA N, 1995, BBA-GEN SUBJECTS, V1245, P221, DOI 10.1016/0304-4165(95)00109-O; OLBRICHT CJ, 1986, AM J PHYSIOL, V250, P1055; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; RIBEIRO RCJ, 1995, ANN NY ACAD SCI, V758, P366, DOI 10.1111/j.1749-6632.1995.tb24843.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SUGAWARA A, 1995, ENDOCRINOLOGY, V136, P1766, DOI 10.1210/en.136.4.1766; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; YUASA C, 1993, J CELL PHYSIOL, V156, P522, DOI 10.1002/jcp.1041560311; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	58	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33166	33173		10.1074/jbc.273.50.33166	http://dx.doi.org/10.1074/jbc.273.50.33166			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837884	hybrid			2022-12-25	WOS:000077462500014
J	Sampath, R; Gallagher, PJ; Pavalko, FM				Sampath, R; Gallagher, PJ; Pavalko, FM			Cytoskeletal interactions with the leukocyte integrin beta 2 cytoplasmic tail - Activation-dependent regulation of associations with talin and alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CELL-ADHESION; NPXY MOTIF; SUBUNIT; DOMAIN; LFA-1; BINDING; PROTEIN; SITE; MODULATION	Circulating leukocytes are nonadherent but bind tightly to endothelial cells following activation. The increased avidity of leukocyte integrins for endothelial ligands following activation is regulated, in part, by in teraction of the beta 2 subunit cytoplasmic tail with the actin cytoskeleton. We propose a mechanism to explain how tethering of the actin cytoskeleton to leukocyte integrins is regulated. In resting leukocytes, beta 2 integrins are constitutively linked to the actin cytoskeleton via the protein talin. Activation of cells induces proteolysis of talin and dissociation from the beta 2 tail. This phase is transient, however, and is followed by reattachment of actin filaments to integrins that is mediated by the protein alpha-actinin. The association of alpha-actinin with integrins may stabilize the cytoskeleton and promote firm adhesion to and migration across the endothelium. Glutathione S-transferase-beta 2 tail fusion protein/mutagenesis experiments suggest that the affinity of alpha-actinin binding to the beta 2 tail is regulated by a change in the conformation of the tail that unmasks a cryptic alpha-actinin binding domain. Positive and inhibitory domains within the beta 2 tail regulate alpha-actinin binding: a single 11-amino acid region (residues 736-746) is necessary and sufficient for alpha-actinin binding, and a regulatory domain between residues 748-762 inhibits constitutive association of the beta 2 tail with alpha-actinin.	Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Pavalko, FM (corresponding author), Indiana Univ, Sch Med, Dept Physiol & Biophys, 635 Barnhill Dr,MS 377, Indianapolis, IN 46202 USA.	fpavalko@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM047333] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL054118, HL54118, R01 HL054118-03] Funding Source: Medline; NIGMS NIH HHS [GM47333] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Haas TA, 1997, PROTEIN ENG, V10, P1395, DOI 10.1093/protein/10.12.1395; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; PAVALKO FM, 1994, P SOC EXP BIOL MED, V205, P282; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PETER K, 1995, J EXP MED, V181, P315, DOI 10.1084/jem.181.1.315; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0	28	197	199	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33588	33594		10.1074/jbc.273.50.33588	http://dx.doi.org/10.1074/jbc.273.50.33588			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837942	Green Accepted, hybrid			2022-12-25	WOS:000077462500072
J	Kohli, RM; Massey, V				Kohli, RM; Massey, V			The oxidative half-reaction of old yellow enzyme - The role of tyrosine 196	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; REDUCTASE; GENE; DEHYDROGENASE; PURIFICATION; ALDEHYDES; SEQUENCE; BINDING; ACID	Tyrosine 196 in Old Yellow Enzyme (OYE) was mutated to phenylalanine, and the resulting mutant enzyme was characterized to evaluate the mechanistic role of the residue. The residue demonstrates little effect on ligand binding and the reductive half-reaction, but a dramatic slowing by nearly 6 orders of magnitude of its oxidative half-reaction with 2-cyclohexenone. Observation of the oxidative half-reaction with a series of substrates allows us to propose a model describing the mechanism of the oxidative half-reaction. In addition, the curtailed reactivity with enones allows for characterization of the manner in which reduced enzyme primes the substrate for the redox reaction by observation of the Michaelis complex with reduced enzyme bound to substrate.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Massey, V (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.			Kohli, Rahul/0000-0002-7689-5678	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5321; ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; ANGELIS CT, 1977, BIOCHEMISTRY-US, V16, P2922, DOI 10.1021/bi00632a019; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Benson TE, 1997, BIOCHEMISTRY-US, V36, P796, DOI 10.1021/bi962220o; Bevington PR, 1969, DATA REDUCTION ERROR; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; Brown BJ, 1998, J BIOL CHEM, V273, P32753, DOI 10.1074/jbc.273.49.32753; DORDINE RL, 1994, BIOCHEMISTRY-US, V33, P12635, DOI 10.1021/bi00208a014; DUNN MF, 1973, BIOCHEMISTRY-US, V12, P4882, DOI 10.1021/bi00748a012; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; FOX KM, 1993, J MOL BIOL, V234, P502, DOI 10.1006/jmbi.1993.1604; FRENCH CE, 1994, BIOCHEM J, V301, P97, DOI 10.1042/bj3010097; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; KANEKO T, 1988, CHEM-BIOL INTERACT, V67, P295, DOI 10.1016/0009-2797(88)90065-8; Karplus PA, 1995, FASEB J, V9, P1518, DOI 10.1096/fasebj.9.15.8529830; Kohli RM, 1998, BIOTECHNIQUES, V25, P184, DOI 10.2144/98252bm01; LEFLER JE, 1963, RATES EQUILIBRIA ORG; MADANI ND, 1994, P NATL ACAD SCI USA, V91, P922, DOI 10.1073/pnas.91.3.922; MASSEY V, 1986, J BIOL CHEM, V261, P1215; Massey V, 1994, FLAVINS AND FLAVOPROTEINS 1993, P371; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; MATTHEWS RG, 1975, J BIOL CHEM, V250, P9294; Miura K, 1997, BIOL PHARM BULL, V20, P110; NIINO YS, 1995, J BIOL CHEM, V270, P1983, DOI 10.1074/jbc.270.5.1983; PAVIA DL, 1979, INTRO SPECTROSCOPY; SAITO K, 1991, J BIOL CHEM, V266, P20720; SANTIAGO LA, 1993, ARCH BIOCHEM BIOPHYS, V306, P16, DOI 10.1006/abbi.1993.1474; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; THEORELL H, 1935, BIOCHEM Z, V266, P377; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; VAZ ADN, 1994, FASEB J, V8, pA949; Warburg O, 1933, BIOCHEM Z, V266, P377; WONISCH W, 1995, CELL BIOCHEM FUNCT, V13, P91, DOI 10.1002/cbf.290130205; Zollner H., 1991, OXIDATIVE STRESS OXI, P337	38	157	159	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32763	32770		10.1074/jbc.273.49.32763	http://dx.doi.org/10.1074/jbc.273.49.32763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830020	hybrid			2022-12-25	WOS:000077329100059
J	Lee, SA; Dritschilo, A; Jung, M				Lee, SA; Dritschilo, A; Jung, M			Impaired ionizing radiation-induced activation of a nuclear signal essential for phosphorylation of c-Jun by dually phosphorylated c-Jun amino-terminal kinases in ataxia telangiectasia fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; PROTEIN-KINASE; TRANSCRIPTION FACTOR; NH2-TERMINAL KINASE; HA-RAS; ULTRAVIOLET-RADIATION; TRANSDUCTION PATHWAYS; ENHANCER ELEMENT; AP-1 ACTIVITY; IN-VIVO	The c-Jun amino-terminal kinases (JNKs) participate in intracellular signaling in response to cytokines and cellular stresses. JNKs are activated by phosphorylation on two critical residues, the threonine 183 and tyrosine 185, within the TPY motif. The activated JNKs, in turn, phosphorylate the nuclear protein c-Jun, a major component of the transcription factor AP1. In vitro studies have revealed a defect in ionizing radiation-induced activation of the JNK signaling pathway in lymphoblastoid cells from individuals with ataxia telangiectasia (AT). However, the biochemical basis for this signaling defect is not clear. Here, we show that ionizing radiation induces the phosphorylation of endogenous c-Jun in normal fibroblasts but not in AT fibroblasts. The p46 isoforms of dually phosphorylated JNKs were detected in the nuclei of both normal and AT fibroblasts following exposure to ionizing radiation or sham radiation. However, c-Jun kinase activity was detected in normal cells but not in AT cells. Furthermore, an exogenous purified active JNK protein was able to phosphorylate endogenous c-Jun in nuclear extracts only of normal cells and only after the cells were irradiated. Electrophoretic mobility shift assays also showed that the ionizing radiation-induced increase in the DNA binding activity of AP1 observed in normal cells was absent or markedly reduced in AT cell lines. These data suggest that the defect in ionizing radiation-induced signaling through c-Jun in AT cells is the result of impaired function of an unknown nuclear protein or proteins that negatively regulate both JNK and c-Jun.	Georgetown Univ, Med Ctr, Dept Radiat Med, Div Radiat Res, Washington, DC 20007 USA	Georgetown University	Jung, M (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Div Radiat Res, Res Bldg,Rm E211A,3970 Reservoir Rd NW, Washington, DC 20007 USA.	jungm@gunet.georgetown.edu			NATIONAL CANCER INSTITUTE [R29CA063023, R01CA045408, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [CA74175, CA63023, CA45408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDER V, 1992, P NATL ACAD SCI USA, V89, P5341; ALDER V, 1992, J BIOL CHEM, V267, P17001; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown L, 1997, NATURE, V387, P450, DOI 10.1038/387450a0; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; CURRAN T, 1993, ADV SEC MESS PHOSPH, V28, P271; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jung M, 1997, INT J RADIAT ONCOL, V37, P417, DOI 10.1016/S0360-3016(96)00500-7; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1997, BIOCHIM BIOPHYS ACTA, V1333, pO1; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; Kyriakis JM, 1995, ANN NY ACAD SCI, V766, P303, DOI 10.1111/j.1749-6632.1995.tb26683.x; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LADER V, 1995, P NATL ACAD SCI USA, V92, P10585; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; LEE SA, 1992, CANCER RES, V52, P3750; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nehme A, 1997, CANCER RES, V57, P3253; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	68	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32889	32894		10.1074/jbc.273.49.32889	http://dx.doi.org/10.1074/jbc.273.49.32889			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830038	hybrid			2022-12-25	WOS:000077329100077
J	Mancini, JA; Waterman, H; Riendeau, D				Mancini, JA; Waterman, H; Riendeau, D			Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE C-4 SYNTHASE; ARACHIDONIC-ACID; POLYMORPHONUCLEAR LEUKOCYTES; MEMBRANE-PROTEIN; IDENTIFICATION; BIOSYNTHESIS; GLUTATHIONE; EXPRESSION; INHIBITOR; TRANSLOCATION	It has been proposed that 5-lipoxygenase (5-LO)-activating protein (FLAP) is an arachidonate transfer protein for leukotriene biosynthesis, Using the Spodoptera frugiperda (Sf9) insect cells, we demonstrate that FLAP causes a large stimulation (190-fold) of the conversion of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) to 5,12-diHETE when co-expressed with 5-lipoxygenase. We also demonstrate that FLAP can stimulate (2-2.5-fold) the oxygenation of 15(S)-HETE by 5-LO to 5,15-diHETE, The stimulation of both 15(S)-HETE and 15(S)-HETE oxygenation by 5-LO is completely inhibitable by the FLAP inhibitor, MK-886. In order to determine which residues of FLAP are important for 12(S)-HETE and arachidonic acid utilization by 5-LO, various mutants of FLAP were co-expressed with 5-LO in Sf9 cells. The FLAP deletion mutants del 37-53, del 52-58, del 106-108, and del 148-161 and the point mutant D62N were analyzed. The D62N mutation, which reduces the binding of indole inhibitors to FLAP, had no effect on the stimulation of substrate utilization by 5-LO. In contrast to wild type FLAP, the mutant proteins del 37-53, del 106-108, and del 148-161 failed to stimulate 12(S)HETE and arachidonic acid utilization by 5-LO. Only one of the latter three mutations (del 37-53) has been shown to abolish the binding of indole inhibitors to FLAP. These results suggest that the lipid binding site of FLAP overlaps the inhibitor binding site and occupies several regions of the protein not essential for inhibitor binding. Because FLAP can stimulate the utilization of 12(S)-HETE, 15(S)-HETE, and arachidonic acid by 5-LO, FLAP may also function as a more general lipid carrier protein for the biosynthesis of multiple oxygenation products of arachidonic acid in addition to its role in leukotriene biosynthesis.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada	Merck & Company	Mancini, JA (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.							ABRAMOVITZ M, 1993, EUR J BIOCHEM, V215, P105, DOI 10.1111/j.1432-1033.1993.tb18012.x; BRIDEAU C, 1992, CAN J PHYSIOL PHARM, V70, P799, DOI 10.1139/y92-107; Brooks CDW, 1996, J MED CHEM, V39, P2629, DOI 10.1021/jm960088k; Byrum RS, 1997, J EXP MED, V185, P1065, DOI 10.1084/jem.185.6.1065; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DeCarolis E, 1996, EUR J BIOCHEM, V235, P416; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; EVANS JF, 1991, MOL PHARMACOL, V40, P22; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; FRIEDMAN BS, 1993, AM REV RESPIR DIS, V147, P839, DOI 10.1164/ajrccm/147.4.839; Griffiths RJ, 1997, J EXP MED, V185, P1123, DOI 10.1084/jem.185.6.1123; HATZELMANN A, 1993, BIOCHEM PHARMACOL, V45, P101, DOI 10.1016/0006-2952(93)90382-7; HILL E, 1992, J BIOL CHEM, V267, P22048; Jakobsson PJ, 1997, J BIOL CHEM, V272, P22934, DOI 10.1074/jbc.272.36.22934; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Lam BK, 1997, J BIOL CHEM, V272, P13923, DOI 10.1074/jbc.272.21.13923; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; MANCINI JA, 1993, EUR J BIOCHEM, V218, P477, DOI 10.1111/j.1432-1033.1993.tb18399.x; MANCINI JA, 1994, LIFE SCI, V54, P137; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Petrich K, 1996, BIOCHEM J, V314, P911, DOI 10.1042/bj3140911; REID GK, 1990, J BIOL CHEM, V265, P19818; RIENDEAU D, 1993, J LIPID MEDIATOR, V6, P23; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Summers MD, 1987, TEXAS AGR EXPT STATI; THOMAS E, 1995, INFLAMM RES, V44, P121, DOI 10.1007/BF01782022; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; WISEMAN JS, 1987, BIOCHEMISTRY-US, V26, P5684, DOI 10.1021/bi00392a016	31	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32842	32847		10.1074/jbc.273.49.32842	http://dx.doi.org/10.1074/jbc.273.49.32842			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830031	hybrid			2022-12-25	WOS:000077329100070
J	Miller, SC; Furniss, MJ				Miller, SC; Furniss, MJ			Bruton's tyrosine kinase activity and inositol 1,4,5-trisphosphate production are not altered in DT40 lymphoma B cells exposed to power line frequency magnetic fields	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMETRIC RESONANCE MODEL; ANTIGEN RECEPTOR; BIOLOGICAL-SYSTEMS; NERVE-CELLS; ACTIVATION; PHOSPHATASES; PERVANADATE; INHIBITION; MECHANISM	Exposure of wild-type DT40 lymphoma B cells or Bruton's tyrosine kinase (BTK)-deficient DT40 cells reconstituted with the human btk gene to a 1-gauss 60-Hz electromagnetic field (EMF) has been reported to rapidly increase inositol 1,4,5-trisphosphate (Ins 1,4,5-P-3) production (1, 2), Here we have used BTK-deficient DT40 B cells reconstituted with the human btk gene to evaluate the reproducibility of these findings. An experimental design with blinded exposures and anti-IgM treatment to induce Ins 1,4,5-P-3 production as a positive control, showed no significant effect of a 1-gauss 60-Hz EMF on Ins 1,4,5-P-3 production. Because recent work has shown that the activation of BTK was required for EMF-responsiveness (2), we also evaluated the reproducibility of this finding in wild-type DT40 cells. BTK was activated in a dose- and time dependent manner by treatment with the tyrosine phosphatase inhibitor pervanadate. However, the ability to detect BTK activation, as measured by increased autophosphorylation by immune complex kinase assay, was dependent on the kinase buffer. Using cells from the original investigators, no evidence was obtained to support the hypothesis that exposure to a 1-gauss 60-Hz EMF had a causal effect on protein-tyrosine kinase activities affecting Ins 1,4,5-P-3 production.	SRI Int, Signal Transduct Lab, Div Pharmaceut Discovery, Menlo Park, CA 94025 USA	SRI International	Miller, SC (corresponding author), SRI Int, Signal Transduct Lab, Div Pharmaceut Discovery, 333 Ravenswood Ave, Menlo Park, CA 94025 USA.	smiller@unix.sri.com			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048229] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07127] Funding Source: Medline; NIGMS NIH HHS [GM48229] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACKMAN CF, 1994, BIOELECTROMAGNETICS, V15, P239, DOI 10.1002/bem.2250150307; BLACKMAN CF, 1995, FASEB J, V9, P547, DOI 10.1096/fasebj.9.7.7737464; Blackman CF, 1998, BIOELECTROMAGNETICS, V19, P204, DOI 10.1002/(SICI)1521-186X(1998)19:4<204::AID-BEM2>3.0.CO;2-5; Blackman CF, 1996, BIOCHEM BIOPH RES CO, V220, P807, DOI 10.1006/bbrc.1996.0485; BLANCHARD JP, 1994, BIOELECTROMAGNETICS, V15, P217, DOI 10.1002/bem.2250150306; Daum G, 1998, FEBS LETT, V427, P271, DOI 10.1016/S0014-5793(98)00448-7; Deng JB, 1998, J BIOL CHEM, V273, P16787, DOI 10.1074/jbc.273.27.16787; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; GUAN KL, 1991, J BIOL CHEM, V266, P17026; Haque SJ, 1997, P NATL ACAD SCI USA, V94, P8563, DOI 10.1073/pnas.94.16.8563; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KORZHSLEPTSOVA IL, 1995, FEBS LETT, V359, P151, DOI 10.1016/0014-5793(95)00031-4; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; Kristupaitis D, 1998, J BIOL CHEM, V273, P12397, DOI 10.1074/jbc.273.20.12397; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Kurosaki T, 1997, CURR OPIN IMMUNOL, V9, P309, DOI 10.1016/S0952-7915(97)80075-1; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; Miller SC, 1998, RADIAT RES, V150, P1, DOI 10.2307/3579637; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; Valberg PA, 1995, BIOELECTROMAGNETICS, V16, P396, DOI 10.1002/bem.2250160608; Valberg PA, 1997, RADIAT RES, V148, P2, DOI 10.2307/3579533; Wienands J, 1996, P NATL ACAD SCI USA, V93, P7865, DOI 10.1073/pnas.93.15.7865; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251	31	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32618	32626		10.1074/jbc.273.49.32618	http://dx.doi.org/10.1074/jbc.273.49.32618			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830001	hybrid			2022-12-25	WOS:000077329100040
J	Scheller, U; Zimmer, T; Becher, D; Schauer, F; Schunck, WH				Scheller, U; Zimmer, T; Becher, D; Schauer, F; Schunck, WH			Oxygenation cascade in conversion of n-alkanes to alpha,omega-dioic acids catalyzed by cytochrome p450 52A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST CANDIDA-MALTOSA; MULTIGENE FAMILY; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MOLECULAR-CLONING; GENE; IDENTIFICATION; CYP52; TROPICALIS; OXIDATION	Purified recombinant cytochrome P450 52A3 and the corresponding NADPH-cytochrome P450 reductase from the alkane-assimilating yeast Candida maltosa were reconstituted into an active alkane monooxygenase system. Besides the primary product, 1-hexadecanol, the conversion of hexadecane yielded up to five additional metabolites, which were identified by gas chromatography-electron impact mass spectrometry as hexadecanal, hexadecanoic acid, 1,16-hexadecanediol, 16-hydroxyhexadecanoic acid, and 1,16-hexadecanedioic acid. As shown by substrate binding studies, the final product 1,16-hexadecanedioic acid acts as a competitive inhibitor of n-alkane binding and may be important for the metabolic regulation of the P450 activity. Kinetic studies of the individual sequential reactions revealed high V-max values for the conversion of hexadecane, 1-hexadecanol, and hexadecanal (27, 23, and 69 min(-1), respectively), whereas the oxidation of hexadecanoic acid, 1,16-hexadecanediol, and 16-hydroxyhexadecanoic acid occurred at significantly lower rates (9, 9, and 5 min(-1), respectively). 1-Hexadecanol was found to be the main branch point between mono- and diterminal oxidation. Taken together with data on the incorporation of O-18(2)-derived oxygen into the hexadecane oxidation products, the present study demonstrates that a single P450 form is able to efficiently catalyze a cascade of sequential mono- and diterminal monooxygenation reactions from n-alkanes to alpha,omega-dioic acids with high regioselectivity.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Greifswald, Inst Microbiol & Mol Biol, D-17487 Greifswald, Germany; Univ Jena, Inst Physiol 2, D-07740 Jena, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ernst Moritz Arndt Universitat Greifswald; Friedrich Schiller University of Jena	Schunck, WH (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.		Becher, Doerte/B-4454-2015; Schauer, Frieder/N-8070-2017	Becher, Doerte/0000-0002-9630-5735; 				AOYAMA Y, 1978, BIOCHEM BIOPH RES CO, V85, P28, DOI 10.1016/S0006-291X(78)80006-0; BENZ W, 1969, MASSENSPEKTROMETRIE, P181; BLASIG R, 1988, APPL MICROBIOL BIOT, V28, P589, DOI 10.1007/BF00250418; Blau K., 1993, HDB DERIVATIVES CHRO; BODDUPALLI SS, 1992, ARCH BIOCHEM BIOPHYS, V292, P20, DOI 10.1016/0003-9861(92)90045-X; Buhler M., 1984, BIOTECHNOLOGY, V6a, P329; FUKUI S, 1981, ADV BIOCHEM ENG, V19, P217; HANNA JG, 1966, CHEM CARBONYL GROUP, P375; IL'CHENKO A P, 1987, Biokhimiya, V52, P58; KAPPELI O, 1986, MICROBIOL REV, V50, P244; Kargel E, 1996, YEAST, V12, P333; Lottermoser K, 1996, YEAST, V12, P565, DOI 10.1002/(SICI)1097-0061(199605)12:6<565::AID-YEA951>3.0.CO;2-6; MAUERSBERGER S, 1992, APPL MICROBIOL BIOT, V37, P66; MAUERSBERGER S, 1996, NONCONVENTIONAL YEAS, P411; MULLER HG, 1991, FRONTIERS BIOTRANSFO, P87; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OHKUMA M, 1995, DNA CELL BIOL, V14, P163, DOI 10.1089/dna.1995.14.163; OHKUMA M, 1991, DNA CELL BIOL, V10, P271, DOI 10.1089/dna.1991.10.271; Ohkuma M, 1998, J BIOL CHEM, V273, P3948, DOI 10.1074/jbc.273.7.3948; OHKUMA M, 1991, AGR BIOL CHEM TOKYO, V55, P1757, DOI 10.1080/00021369.1991.10870878; REMANE H, 1977, MASSENSPEKTROMETRIE, P80; RIEGE P, 1981, BIOCHEM BIOPH RES CO, V98, P527, DOI 10.1016/0006-291X(81)90872-X; SANGLARD D, 1989, GENE, V76, P121, DOI 10.1016/0378-1119(89)90014-0; SCHELLER U, 1994, J BIOL CHEM, V269, P12779; Scheller U, 1996, ARCH BIOCHEM BIOPHYS, V328, P245, DOI 10.1006/abbi.1996.0170; SCHLENK H, 1960, ANAL CHEM, V32, P1312; SCHUNCK WH, 1989, BIOCHEM BIOPH RES CO, V161, P843, DOI 10.1016/0006-291X(89)92677-6; SCHUNCK WH, 1991, EUR J CELL BIOL, V55, P336; SCHUNCK WH, 1987, ARCH MICROBIOL, V147, P240, DOI 10.1007/BF00463482; SEGHEZZI W, 1992, DNA CELL BIOL, V11, P767, DOI 10.1089/dna.1992.11.767; SEGHEZZI W, 1991, GENE, V106, P51, DOI 10.1016/0378-1119(91)90565-S; Shet MS, 1996, ARCH BIOCHEM BIOPHYS, V330, P199, DOI 10.1006/abbi.1996.0243; TAKAGI M, 1989, AGR BIOL CHEM TOKYO, V53, P2217, DOI 10.1080/00021369.1989.10869646; VAZ ADN, 1994, BIOCHEMISTRY-US, V33, P6442, DOI 10.1021/bi00187a008; VOGEL F, 1992, EUR J CELL BIOL, V57, P285; WATANABE K, 1991, J BIOL CHEM, V266, P2709; WOOLLARD PM, 1983, BIOMED MASS SPECTROM, V10, P143, DOI 10.1002/bms.1200100308; WRIGHT JN, 1990, STEROIDS, V55, P142, DOI 10.1016/0039-128X(90)90102-H; Zimmer T, 1996, BIOCHEM BIOPH RES CO, V224, P784, DOI 10.1006/bbrc.1996.1100	39	121	126	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32528	32534		10.1074/jbc.273.49.32528	http://dx.doi.org/10.1074/jbc.273.49.32528			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829987	hybrid			2022-12-25	WOS:000077329100026
J	Schmid, M; Malicki, D; Nobori, T; Rosenbach, MD; Campbell, K; Carson, DA; Carrera, CJ				Schmid, M; Malicki, D; Nobori, T; Rosenbach, MD; Campbell, K; Carson, DA; Carrera, CJ			Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16(INK4A) (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC)	ONCOGENE			English	Article						non-small cell lung cancer; MTAP; p16(INK4A); cell-cycle regulation; chromosome 9p21	ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE-4 INHIBITOR GENE; IN-SITU HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; ALPHA-INTERFERON; CHROMOSOME 9P; P16/MTS1 GENE; HUMAN GLIOMAS; NECK-CANCER; P18 GENES	Homozygous deletions of the tumor suppressor gene p16(INK4A) and deficiency of methylthioadenosine phosphorylase (MTAP), both located on chromosome 9p21, have been independently reported in non-small cell lung cancer (NSCLC). To determine the frequency of co-deletion of these two genes, we investigated 50 samples of primary NSCLC using a quantitative PCR-ELISA. All specimens were fixed in formalin, paraffin embedded and stored until assayed. Histologic subtypes included 25 adenocarcinomas (50%), 21 squamous cell carcinomas (42%) and four large cell carcinomas (8%). Homozygous deletions of MTAP exon 8 could be detected in 19 of 50 NSCLC samples (38%). Adenocarcinoma (11 of 25, 44%) showed a higher deletion frequency than squamous cell carcinoma (six of 21, 29%). In contrast, homozygous p16(INK4A) deletions were detected in only nine of 50 (18%) samples using specific primers for p16(INK4A) exon 1 alpha. No difference between the histological subtypes and p16(INK4A) deletion frequency was observed. We further investigated the ten samples with MTAP deletions but intact p16(INK4A) exon 1 alpha with primers specific for p16(INK4A) exon 3, the exon nearest to MTAP exon 8. Interestingly, none of the ten samples had deletion of the p16(INK4A) exon 3 coding region. Fine mapping analysis performed in ten samples showed a frequent breakpoint between MTAP exon 4 and exon 5. In addition, p16 protein expression could not be detected in five out of six samples with intact p16 but deleted MTAP locus. These data show a high frequency of homozygous MTAP deletions in NSCLC which is associated with detectable co-deletion of p16(INK4A) only half of the cases. This result suggests the existence either of another tumor suppressor gene telomeric of p16(INK4A) or of deletions involving 3'-untranslated (3'-UTR) regulatory regions of p16(INK4A) that can interfere with its expression or function.	Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Carrera, CJ (corresponding author), Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NCI NIH HHS [R21 CA 68260, U01 CA 64926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA068260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker FG, 1997, J NEURO-ONCOL, V31, P17, DOI 10.1023/A:1005768910871; Batova A, 1997, CANCER RES, V57, P832; Batova A, 1996, BLOOD, V88, P3083, DOI 10.1182/blood.V88.8.3083.bloodjournal8883083; BELLO MJ, 1990, INT J CANCER, V45, P50, DOI 10.1002/ijc.2910450111; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Carrera C. J., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P407; Carrera C J, 1986, Adv Exp Med Biol, V195 Pt B, P643; Cayuela JM, 1996, BLOOD, V87, P2180, DOI 10.1182/blood.V87.6.2180.bloodjournal8762180; Chen ZH, 1996, CANCER RES, V56, P1083; Costello JF, 1996, CANCER RES, V56, P2405; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DREYLING MH, 1995, CANCER RES, V55, P984; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Herman JG, 1997, CANCER RES, V57, P837; HORI H, 1996, CANCER RES, V56, P5633; Jagasia AA, 1996, CANCER LETT, V105, P77, DOI 10.1016/0304-3835(96)04273-5; KAMATANI N, 1981, BIOCHIM BIOPHYS ACTA, V675, P344, DOI 10.1016/0304-4165(81)90024-6; KAMATANI N, 1982, BLOOD, V60, P1387; KAMB A, 1994, SCIENCE, V264, P440; Kim SK, 1997, CANCER RES, V57, P400; Kratzke RA, 1996, CANCER RES, V56, P3415; KUBOTA M, 1983, J BIOL CHEM, V258, P7288; Li XS, 1996, CANCER RES, V56, P5055; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Marchetti A, 1997, J PATHOL, V181, P178, DOI 10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MERLO A, 1994, CANCER RES, V54, P2322; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1991, CANCER RES, V51, P3193; Nobori T, 1996, P NATL ACAD SCI USA, V93, P6203, DOI 10.1073/pnas.93.12.6203; NOBORI T, 1993, CANCER RES, V53, P1098; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLOPADE OI, 1995, P NATL ACAD SCI USA, V92, P6489, DOI 10.1073/pnas.92.14.6489; PEGG AE, 1969, BIOCHEM J, V115, P241, DOI 10.1042/bj1150241; Perry A, 1997, J NEUROPATH EXP NEUR, V56, P999, DOI 10.1097/00005072-199709000-00005; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rao LS, 1997, DIAGN MOL PATHOL, V6, P115, DOI 10.1097/00019606-199704000-00008; Reed AL, 1996, CANCER RES, V56, P3630; REED JA, 1995, CANCER RES, V55, P2713; Rishi AK, 1997, CANCER RES, V57, P5129; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHIMIZU T, 1995, INT J CANCER, V63, P616, DOI 10.1002/ijc.2910630503; Singh AD, 1996, OPHTHALMIC GENET, V17, P39, DOI 10.3109/13816819609057868; STADLER WM, 1994, CANCER RES, V54, P2060; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; Tran PT, 1997, GENE, V186, P263, DOI 10.1016/S0378-1119(96)00718-4; TRAWEEK ST, 1988, BLOOD, V71, P1568; Ueki K, 1996, CANCER RES, V56, P150; VANDERRIET P, 1994, CANCER RES, V54, P1156; Waber P, 1997, ONCOGENE, V15, P1699, DOI 10.1038/sj.onc.1201336; WALKER DG, 1995, CANCER RES, V55, P20; Wiest JS, 1997, CANCER RES, V57, P1; Woloschak M, 1996, CANCER RES, V56, P2493; YOSHIDA S, 1995, CANCER RES, V55, P2756; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	63	80	83	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2669	2675		10.1038/sj.onc.1202205	http://dx.doi.org/10.1038/sj.onc.1202205			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840931				2022-12-25	WOS:000077058900015
J	Pelemans, H; Esnouf, RM; Jonckheere, H; De Clercq, E; Balzarini, J				Pelemans, H; Esnouf, RM; Jonckheere, H; De Clercq, E; Balzarini, J			Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONNUCLEOSIDE INHIBITORS; ESCHERICHIA-COLI; HIV-1; MOLSCRIPT; DESIGN	The highly conserved Tyr-318 is part of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-specific lipophilic pocket of human immunodeficiency virus type I reverse transcriptase (RT) and makes contact within 4 Angstrom with the NNRTIs in all reported RT/NNRTI complexes. Using site-directed mutagenesis, six mutant RTs were constructed bearing the mutations Y318H, Y318K, Y318L, Y318C, Y318W, and Y318F. We found that only the Y318W and Y318F mutant RTs retained substantial RT activity, whereas the catalytic activities of the Y318K, Y318C, Y318H, and Y318L RT mutants were less than 5% of the wild-type activity, The Y318F mutant RT retained substantial sensitivity to the majority of NNRTIs tested, whereas the Y318W mutant RT showed varying degrees of resistance to NNRTIs, Subunit-specific site-directed mutagenesis revealed that there was no difference in the catalytic activity or resistance/sensitivity spectrum toward NNRTIs regardless of whether the Tyr-318 mutation was introduced in both subunits or only in the p66 subunit of RT. Recombinant viruses harboring the Y318F or Y318W mutation in the RT showed a similar resistance/sensitivity pattern to NNRTIs as their corresponding 318 mutant recombinant RTs, Our findings stress a functional or structural role for Tyr-318 in wild-type RT and argue for the design of novel NNRTIs that interact more closely with this amino acid in the NNRTI-specific pocket of human immunodeficiency virus type I RT.	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium	KU Leuven	Balzarini, J (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	Jan.Balzarini@rega.kuleuven.ac.be		De Clercq, Erik/0000-0002-2985-8890				BALZARINI J, 1992, J BIOL CHEM, V267, P11831; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P579; DeClercq E, 1996, REV MED VIROL, V6, P97, DOI 10.1002/(SICI)1099-1654(199606)6:2&lt;97::AID-RMV168&gt;3.0.CO;2-4; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984; Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x; Jonckheere H, 1996, J VIROL METHODS, V61, P113, DOI 10.1016/0166-0934(96)02076-9; KELLAM P, 1994, ANTIMICROB AGENTS CH, V38, P23, DOI 10.1128/AAC.38.1.23; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KORBER B, 1997, HUMAN RETROVIRUSES A; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Pauwels Rudi, 1993, P71; Pelemans H, 1997, J VIROL, V71, P8195, DOI 10.1128/JVI.71.11.8195-8203.1997; Pelemans H, 1998, J GEN VIROL, V79, P1347, DOI 10.1099/0022-1317-79-6-1347; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X; Schinazi R. F., 1997, International Antiviral News, V5, P129	18	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34234	34239		10.1074/jbc.273.51.34234	http://dx.doi.org/10.1074/jbc.273.51.34234			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852086	hybrid			2022-12-25	WOS:000077542200052
J	Guilherme, A; Czech, MP				Guilherme, A; Czech, MP			Stimulation of IRS-1-associated phosphatidylinositol 3-kinase and Akt/protein kinase B but not glucose transport by beta 1-integrin signaling in rat adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; 3T3-L1 ADIPOCYTES; GLUT4 TRANSLOCATION; TYROSINE PHOSPHORYLATION; PHOSPHOTYROSINE PROTEIN; ADIPOSE-CELLS; DNA-SYNTHESIS; ACTIVATION; SUBUNIT; IRS-1	The signal transduction pathway by which insulin stimulates glucose transport is not understood, but a role for complexes of insulin receptor substrate (IRS) proteins and phosphatidylinsitol (PI) 3-kinase as well as for Akt/protein kinase B (PKB) has been proposed. Here, we present evidence suggesting that formation of IRS-1/PI 3-kinase complexes and Akt/PKB activation are insufficient to stimulate glucose transport in rat adipocytes, Cross-linking of beta(1)-integrin on the surface of rat adipocytes by anti-beta(1)-integrin. antibody and fibronectin was found to cause greater IRS-1 tyrosine phosphorylation, IRS-1-associated PI 3-kinase activity, and Akt/PKB activation, detected by anti-serine 473 antibody, than did 1 nM insulin. Clustering of beta(1)-integrin also significantly potentiated stimulation of insulin receptor and IRS-1 tyrosine phosphorylation, IRS-associated PI 3-kinase activity, and Akt/PKB activation caused by submaximal concentrations of insulin. In contrast, beta(1)-integrin clustering caused neither a change in deoxyglucose transport nor an effect on the ability of insulin to stimulate deoxyglucose uptake at any concentration along the entire dose-response relationship range. The data suggest that (i) beta(1)-integrins can engage tyrosine kinase signaling pathways in isolated fat cells, potentially regulating fat cell functions and (ii) either formation of IRS-1/PI 3-kinase complexes and Akt/PKB activation is not necessary for regulation of glucose transport in fat cells or an additional signaling pathway is required.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.	Michael.Czech@ummed.edu			NIDDK NIH HHS [DK30648] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARLBERG K, 1991, EMBO J, V10, P877, DOI 10.1002/j.1460-2075.1991.tb08020.x; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1996, J BIOL CHEM, V271, P29533, DOI 10.1074/jbc.271.47.29533; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; OKADA T, 1994, J BIOL CHEM, V269, P3568; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; STAGSTED J, 1993, J BIOL CHEM, V268, P22809; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WHITE MF, 1994, J BIOL CHEM, V269, P1; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; YU KT, 1984, J BIOL CHEM, V259, P5277	45	101	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33119	33122		10.1074/jbc.273.50.33119	http://dx.doi.org/10.1074/jbc.273.50.33119			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837876	hybrid			2022-12-25	WOS:000077462500006
J	Sun, HW; Hui, CF; Wu, JL				Sun, HW; Hui, CF; Wu, JL			Cloning, characterization, and expression in Escherichia coli of three creatine kinase muscle isoenzyme cDNAs from carp (Cyprinus carpio) striated muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; COMPLETE NUCLEOTIDE-SEQUENCE; HEAVY-CHAIN GENE; MESSENGER-RNA; PROTEIN-KINASE; MITOCHONDRIAL; PURIFICATION; RISE; PHOSPHORYLATION; IDENTIFICATION	In vertebrates, the creatine kinase isoenzyme family consists of four types of isoforms: cytosolic muscle type (RI-CK), cytosolic brain type (B-CK), mitochondrial ubiquitous, acidic type (Miu-CK), and mitochondrial sarcomeric, basic type (Mis-CK). Until recently, the existence of more than one subisoform of CK isoenzyme has been demonstrated only in fishes by starch gel electrophoresis. We report herein the isolation of three full-length cDNAs that correspond to three closely related creatine kinase M-CK genes from common carp (Cyprinus carpio), designated the M1-CK, M2-CK, and M3-CK genes. Using oligonucleotide probes that correspond to the same region but with the most variable sequences, different restricted genomic hybridization patterns have been obtained. These Southern blot results indicate that the three cDNAs come from different genes. Northern blot analysis using probes that correspond to the 3'-untranslated regions further show that all three subisoforms are expressed specifically in carp muscle. The deduced amino acid sequences of these three subisoforms of carp M-CK show about 85% identity to mammalian M-CK isoenzyme. Finally, the three cDNAs have been expressed in Escherichia coli with a molecular mass of approximately 43,000 Da, and these recombinant proteins exhibit creatine kinase activity. All of these data suggest that the M-CK isoenzymes have at least three subisoforms in carp.	Acad Sinica, Inst Zool, Lab Marine Mol Biol & Biotechnol, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 117, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Wu, JL (corresponding author), Acad Sinica, Inst Zool, Lab Marine Mol Biol & Biotechnol, Taipei 115, Taiwan.	ZOJLWU@ccvax.sinica.edu.tw						Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BARRANTES FJ, 1983, P NATL ACAD SCI-BIOL, V80, P5440, DOI 10.1073/pnas.80.17.5440; BENFIELD PA, 1984, J BIOL CHEM, V259, P4979; BENFIELD PA, 1985, GENE, V39, P263, DOI 10.1016/0378-1119(85)90321-X; BILLADELLO JJ, 1985, J BIOL CHEM, V260, P4988; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P351, DOI 10.1016/S0006-291X(05)81064-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENNION S, 1995, J EXP BIOL, V198, P1603; EPPENBERGER HM, 1967, J BIOL CHEM, V242, P204; FERRIS SD, 1978, BIOCHEM GENET, V16, P811, DOI 10.1007/BF00484738; FISHER SE, 1978, J MOL EVOL, V12, P25, DOI 10.1007/BF01732544; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; FUETER R, 1993, BIOCHEMISTRY-US, V32, P7022; Gauvry L, 1996, EUR J BIOCHEM, V236, P887, DOI 10.1111/j.1432-1033.1996.00887.x; GEORGE S, 1984, J BIOL CHEM, V259, P2667; GERLACH GF, 1990, AM J PHYSIOL, V259, pR237, DOI 10.1152/ajpregu.1990.259.2.R237; GIRAUDAT J, 1984, P NATL ACAD SCI-BIOL, V81, P7313, DOI 10.1073/pnas.81.23.7313; HAZEL JR, 1974, PHYSIOL REV, V54, P620, DOI 10.1152/physrev.1974.54.3.620; HEAP SP, 1985, J FISH BIOL, V26, P733, DOI 10.1111/j.1095-8649.1985.tb04313.x; HEMMER W, 1993, FEBS LETT, V327, P35, DOI 10.1016/0014-5793(93)81034-W; HOAR WS, 1969, FISH PHYSIOL, P351; HOSSLE JP, 1986, NUCLEIC ACIDS RES, V14, P1449, DOI 10.1093/nar/14.3.1449; HUGHES BP, 1962, CLIN CHIM ACTA, V7, P579; ISHIDA Y, 1991, FEBS LETT, V283, P37, DOI 10.1016/0014-5793(91)80548-H; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; NAKAGAWA T, 1991, COMP BIOCHEM PHYS B, V98, P349, DOI 10.1016/0305-0491(91)90189-K; ORDAHL CP, 1984, J BIOL CHEM, V259, P5224; PAYNE RM, 1991, BIOCHIM BIOPHYS ACTA, V1089, P352, DOI 10.1016/0167-4781(91)90176-M; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PERRYMAN MB, 1986, BIOCHEM BIOPH RES CO, V140, P981, DOI 10.1016/0006-291X(86)90732-1; PROSSER CL, 1961, COMP ANIMAL PHYSL, P362; QUEST AFG, 1990, FEBS LETT, V262, P299, DOI 10.1016/0014-5793(90)80214-4; QUEST AFG, 1990, FEBS LETT, V269, P457, DOI 10.1016/0014-5793(90)81215-A; ROMAN D, 1985, P NATL ACAD SCI USA, V82, P8394, DOI 10.1073/pnas.82.24.8394; ROSENBERG UB, 1981, EUR J BIOCHEM, V116, P87, DOI 10.1111/j.1432-1033.1981.tb05304.x; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saudrais C, 1996, MOL REPROD DEV, V44, P433, DOI 10.1002/(SICI)1098-2795(199608)44:4&lt;433::AID-MRD2&gt;3.0.CO;2-M; SOLDATI T, 1990, J BIOL CHEM, V265, P4498; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; WALLIMANN T, 1994, CURR BIOL, V4, P42, DOI 10.1016/S0960-9822(00)00008-7; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1985, Cell Muscle Motil, V6, P239; WEST BL, 1984, P NATL ACAD SCI-BIOL, V81, P7007, DOI 10.1073/pnas.81.22.7007; WIRZ T, 1990, J BIOL CHEM, V265, P11656; WOLFF J, 1985, J EXP ZOOL, V234, P471, DOI 10.1002/jez.1402340314; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9	51	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33774	33780		10.1074/jbc.273.50.33774	http://dx.doi.org/10.1074/jbc.273.50.33774			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837966	hybrid			2022-12-25	WOS:000077462500096
J	Doronin, S; Dessauer, C; Johnson, RA				Doronin, S; Dessauer, C; Johnson, RA			Direct photoaffinity labeling of individual cytosolic domains of adenylyl cyclase by [P-32]2 '-deoxy-3 '-AMP and [alpha-P-32]5 '-ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOCHEMICAL CROSS-LINKING; SITE-MEDIATED INHIBITION; NUCLEIC ACID COMPLEXES; CATALYTIC MECHANISM; AQUEOUS-SOLUTION; 2',5'-DIDEOXYADENOSINE; 3'-POLYPHOSPHATES; REQUIREMENTS; ADENOSINE; FORSKOLIN	The susceptibility of purines to form a covalent attachment with proteins upon exposure to UV irradiation was applied to adenylyl cyclase by use of [P-32]2'-d-3'-AMP, a dead-end inhibitor that binds to the posttransition configuration of the enzyme. [P-32]2'-d-3'-AMP was synthesized enzymatically. It and [c-P-32]5'-ATP were used for direct photocross-linking to individually expressed cytosolic domains of adenylyl cyclase, Both the C-1 domain of the type V isozyme (VC1) and the C-2 domain of the type II isozyme (IIC2) were labeled, whether alone or combined, upon photolysis of [P-32]2'-d-3'-AMP in the presence of acetone, Labeling of VC1 and IIC2 was greatly enhanced in the presence of PPi, was almost completely suppressed by 50 mu M 2',5'-dideoxy-3'-ATP, the most potent reported P-site inhibitor of adenylyl cyclases, but was partially suppressed by I mM 3'-IMP, a ligand that does not inhibit the enzyme tia the P-site, Neither 3':5'-cAMP nor 5'-ATP had a major effect on labeling by [P-32]2'-d-3'-AMP. Direct cross-linking of VC1 with [alpha-P-32]5'-ATP was substantially suppressed by 2',5'-dideoxy-3'-ATP and partially suppressed by 2'-d-3'-AMP, whereas cross-linking of IIC2 was less affected by the 3'-triphosphate. The data imply that either cytosolic domain can interact directly with either substrate or P-site ligand and that subunit interaction modifies the susceptibility of each domain to UV-induced covalent modification by either [alpha-P-32]5'-ATP or [P-32]2'-d-3'-AMP.	SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Johnson, RA (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA.		Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280	NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCE R, 1993, PHOTOCHEM PHOTOBIOL, V58, P318, DOI 10.1111/j.1751-1097.1993.tb09568.x; Desaubry L, 1996, J BIOL CHEM, V271, P14028, DOI 10.1074/jbc.271.24.14028; Desaubry L, 1998, J BIOL CHEM, V273, P24972, DOI 10.1074/jbc.273.38.24972; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ELAD D, 1976, PHOTOCHEM PHOTOBIOL, V1, P357; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; HAGAN B, 1977, METHOD ENZYMOL, V46, P65; HAVRON A, 1977, BIOCHEMISTRY-US, V16, P5631, DOI 10.1021/bi00644a038; IVANCHENKO VA, 1975, NUCLEIC ACIDS RES, V2, P1365, DOI 10.1093/nar/2.8.1365; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOHNSON RA, 1994, METHOD ENZYMOL, V238, P31; KNORRE DG, 1988, AFFINITY MODIFICATIO, P60; Krupinski John, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P53; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; SHOSHANI I, 1995, BBA-GEN SUBJECTS, V1245, P37, DOI 10.1016/0304-4165(95)00069-N; SPERLING J, 1976, BIOCHEMISTRY-US, V15, P1489, DOI 10.1021/bi00652a020; SPERLING J, 1978, NUCLEIC ACIDS RES, V5, P2755, DOI 10.1093/nar/5.8.2755; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	29	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32416	32420		10.1074/jbc.273.49.32416	http://dx.doi.org/10.1074/jbc.273.49.32416			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829971	hybrid			2022-12-25	WOS:000077329100010
J	Li-Weber, M; Giasi, M; Krammer, PH				Li-Weber, M; Giasi, M; Krammer, PH			Involvement of Jun and Rel proteins in up-regulation of interleukin-4 gene activity by the T cell accessory molecule CD28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN IL-4 PROMOTER; RESPONSE ELEMENT; MULTIORGAN INFLAMMATION; COSTIMULATORY SIGNALS; ENHANCER ELEMENT; C-REL; ACTIVATION; MICE; TRANSCRIPTION	CD28 serves as a costimulatory cell surface molecule in T cell activation. CD28 signaling may also play a role in balancing the inflammatory/humoral (Th1/Th2) responses during an immune reaction. CD28 costimulation has been shown to promote the production of Th2 cytokines including interleukin (IL)-4, a key cytokine essential for Th2 differentiation and for the pathogenesis of allergic inflammation. In this study, we show that IL-4 mRNA and activity of the IL-4 promoter can be activated by the CD28 signal alone and are further augmented by CD28 costimulation of alpha-CD3- or mitogen-activated Jurkat T cells. Two important IL-4 enhancer elements, positive regulatory element (PRE)-I and P1, are found to respond to CD28 stimulation-induced transactivation. In contrast to the Th1 IL-2 CD28RE, activity of the IL-4 PRE-I and P1 can be induced by the CD28 signal alone. In correlation with CD28-induced transcriptional activation, AP-1 (c-Jun, JunD) and NF-kappa B/Rel (c-Rel, RelA) family members are found to bind to the two regulatory elements PRE-I and P1 upon CD28 stimulation. The data provide the first mapping of the CD28-responsive site in a Th2 cytokine gene, the IL-4 gene. They also show that the CD28 signal can directly activate a gene (e,g. IL-4) at the transcriptional level.	German Canc Res Ctr, Tumor Immunol Program 07730, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Li-Weber, M (corresponding author), German Canc Res Ctr, Tumor Immunol Program 07730, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							ABE E, 1992, P NATL ACAD SCI USA, V89, P2864, DOI 10.1073/pnas.89.7.2864; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BLUESTONE JA, 1995, IMMUNITY, V2, P555, DOI 10.1016/1074-7613(95)90000-4; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; CORRY DB, 1994, J IMMUNOL, V153, P4142; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KING CL, 1995, EUR J IMMUNOL, V25, P587, DOI 10.1002/eji.1830250242; LAI JH, 1994, J BIOL CHEM, V269, P30077; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Li-Weber M, 1998, J IMMUNOL, V161, P1380; Li-Weber M, 1997, IMMUNOBIOLOGY, V198, P170, DOI 10.1016/S0171-2985(97)80038-1; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LiWeber M, 1997, GENE, V188, P253, DOI 10.1016/S0378-1119(96)00820-7; LIWEBER M, 1993, J IMMUNOL, V151, P1371; LiWeber M, 1997, J IMMUNOL, V158, P1194; MAGGI E, 1992, J IMMUNOL, V148, P2142; McGuire KL, 1997, J IMMUNOL, V159, P1319; Palmer EM, 1997, J IMMUNOL, V158, P2654; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; PAUL WE, 1991, BLOOD, V77, P1859; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; ROMANO MF, 1994, CELL IMMUNOL, V156, P371, DOI 10.1006/cimm.1994.1182; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; Rulifson IC, 1997, J IMMUNOL, V158, P658; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEDER RA, 1994, J EXP MED, V179, P299, DOI 10.1084/jem.179.1.299; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Snapper CM, 1996, J IMMUNOL, V156, P183; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; WEBB LMC, 1995, BLOOD, V86, P3479, DOI 10.1182/blood.V86.9.3479.bloodjournal8693479; Weih F, 1996, J IMMUNOL, V157, P3974; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wenner CA, 1997, J IMMUNOL, V158, P765	46	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32460	32466		10.1074/jbc.273.49.32460	http://dx.doi.org/10.1074/jbc.273.49.32460			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829977	hybrid			2022-12-25	WOS:000077329100016
J	Torrents, D; Estevez, R; Pineda, M; Fernandez, E; Lloberas, J; Shi, YB; Zorzano, A; Palacin, M				Torrents, D; Estevez, R; Pineda, M; Fernandez, E; Lloberas, J; Shi, YB; Zorzano, A; Palacin, M			Identification and characterization of a membrane protein (y(+)L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y(+)L - A candidate gene for lysinuric protein intolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; SURFACE-ANTIGEN; HEAVY-CHAIN; EXPRESSION CLONING; RENAL REABSORPTION; CELL ACTIVATION; SYSTEM; CYSTINE; KIDNEY; PREDICTION	We have identified a new human cDNA (y(+)L amino acid transporter-1 (y(+)LAT-1)) that induces system y+L transport activity with 4F2hc (the surface antigen 4F2 heavy chain) in oocytes. Human y(+)LAT-1 is a new member of a family of polytopic transmembrane proteins that are homologous to the yeast high affinity methionine permease MUP1. Other members of this family, the Xenopus laevis IU12 and the human KIAA0245 cDNAs, also co-express amino acid transport activity with 4F2hc in oocytes, with characteristics that are compatible with those of systems L and y(+)L, respectively. y(+)LAT-1 protein forms a approximate to 135-kDa, disulfide bond-dependent heterodimer with 4F2hc in oocytes, which upon reduction results in two protein bands of approximate to 85 kDa (i.e. 4F2hc) and approximate to 40 kDa (y(+)LAT-1). Mutation of the human 4F2hc residue cysteine 109 (Cys-109) to serine abolishes the formation of this heterodimer and drastically reduces the coexpressed transport activity, These data suggest that y(+)LAT-1 and other members of this family are different 4F2 light chain subunits, which associated with 4F2hc, constitute different amino acid transporters. Human y(+)LAT-1 mRNA is expressed in kidney >> peripheral blood leukocytes >> lung > placenta = spleen > small intestine. The human y(+)LAT-1 gene localizes at chromosome 14q11.2 (17cR approximate to 374 kb hom D1451350), within the lysinuric protein intolerance (LPI) locus (Lauteala, T., Sistonen, P., Savontaus, M. L., Mykkanen, J., Simell, J., Lukkarinen, M,, Simmell, O., and Aula, P. (1997) Am. J. Hum. Genet. 60, 1479-1486). LPI is an inherited autosomal disease characterized by a defective dibasic amino acid transport in kidney, intestine, and other tissues. The pattern of expression of human y(+)LAT-1, its coexpressed transport activity with 4F2hc, and its chromosomal location within the LPI locus, suggest y(+)LAT-1 as a candidate gene for LPI.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Fisiol Immunol, E-08028 Barcelona, Spain; NICHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA	University of Barcelona; University of Barcelona; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Palacin, M (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018; Estevez, Raul/D-8610-2015; Lloberas, Jorge/D-4303-2014; Riu, Marta Pineda/I-1497-2015; Torrents, David/G-5785-2015	Estevez, Raul/0000-0003-1579-650X; Lloberas, Jorge/0000-0001-7075-4201; Riu, Marta Pineda/0000-0002-5403-5845; Shi, Yun-Bo/0000-0002-6330-0639; Palacin, Manuel/0000-0002-8670-293X; Torrents, David/0000-0002-6086-9037				ACKERMANN U, 1992, J BIOL CHEM, V267, P12911; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Aloy P, 1997, COMPUT APPL BIOSCI, V13, P231; ANMED A, 1997, J BIOL CHEM, V272, P125; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; Chillaron J, 1997, J BIOL CHEM, V272, P9543; Chillaron J, 1996, J BIOL CHEM, V271, P17761, DOI 10.1074/jbc.271.30.17761; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLOTET J, 1994, COMPUT APPL BIOSCI, V10, P495; DESJEUX JF, 1980, J CLIN INVEST, V65, P1382, DOI 10.1172/JCI109802; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; Estevez R, 1998, FASEB J, V12, P1319, DOI 10.1096/fasebj.12.13.1319; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; FEY YJ, 1995, BIOCHEMISTRY-US, V34, P8744; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GAUGITSCH HW, 1992, J BIOL CHEM, V267, P11267; GEERING K, 1989, AM J PHYSIOL, V257, P851; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAYNES BF, 1981, J IMMUNOL, V126, P1409; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; JAUNIN P, 1992, J BIOL CHEM, V267, P577; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lauteala T, 1997, AM J HUM GENET, V60, P1479, DOI 10.1086/515457; Lauteala T, 1997, HUM GENET, V100, P80, DOI 10.1007/s004390050469; Liang V C, 1997, Cell Res, V7, P179; LUSCHER B, 1985, J IMMUNOL, V135, P3951; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; Mora C, 1996, J BIOL CHEM, V271, P10569, DOI 10.1074/jbc.271.18.10569; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Palacin M, 1998, CURR OPIN CELL BIOL, V10, P455, DOI 10.1016/S0955-0674(98)80058-6; Palacin M, 1996, BIOCHEM SOC T, V24, P856, DOI 10.1042/bst0240856; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Peter GJ, 1996, BIOCHEM J, V318, P915, DOI 10.1042/bj3180915; QUACKENBUSH EJ, 1986, J IMMUNOL, V136, P118; RAJANTIE J, 1980, LANCET, V1, P1219; RAJANTIE J, 1981, J CLIN INVEST, V67, P1078, DOI 10.1172/JCI110120; SANG JS, 1995, CANCER RES, V55, P1152; Santamaria F, 1996, AM J RESP CRIT CARE, V153, P731, DOI 10.1164/ajrccm.153.2.8564125; SIMELL O, 1995, METABOLIC MOL BASES, P3581; SMITH DW, 1987, P NATL ACAD SCI USA, V84, P7711, DOI 10.1073/pnas.84.21.7711; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Yao SYM, 1998, BIOCHEM J, V330, P745; YOSHIDA Y, 1995, J NEUROL SCI, V134, P178, DOI 10.1016/0022-510X(95)00237-1	57	274	287	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32437	32445		10.1074/jbc.273.49.32437	http://dx.doi.org/10.1074/jbc.273.49.32437			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829974	Green Published, hybrid			2022-12-25	WOS:000077329100013
J	Hjeltnes, N; Galuska, D; Bjornholm, M; Aksnes, AK; Lannem, A; Zierath, JR; Wallberg-Henriksson, H				Hjeltnes, N; Galuska, D; Bjornholm, M; Aksnes, AK; Lannem, A; Zierath, JR; Wallberg-Henriksson, H			Exercise-induced overexpression of key regulatory proteins involved in glucose uptake and metabolism in tetraplegic persons: molecular mechanism for improved glucose homeostasis	FASEB JOURNAL			English	Article						GLUT4; glycogen synthase; hexokinase; phosphofructokinase; skeletal muscle fiber type; glucose transport; insulin resistance	RAT SKELETAL-MUSCLE; DEPENDENT DIABETES-MELLITUS; MIDDLE-AGED MEN; ELECTRICAL-STIMULATION; TRANSGENIC MICE; HEXOKINASE-II; CONTRACTILE ACTIVITY; INSULIN-RESISTANCE; GLYCOGEN-SYNTHASE; PARAPLEGIC PATIENTS	Complete spinal cord lesion leads to profound metabolic abnormalities and striking changes in muscle morphology. Here we assess the effects of electrically stimulated leg cyclic; (ESLC) on whole body insulin sensitivity, skeletal muscle glucose metabolism, and muscle fiber morphology in five tetraplegic subjects with complete C-5-C-7 lesions. Physical training (seven ESLC sessions/wk for 8 wk) increased whole body insulin-stimulated glucose uptake by 33+/-13%, concomitant with a 2.1-fold increase in insulin-stimulated (100 mu U/ml) 3-O-methylglucose transport in isolated vastus lateralis muscle. Physical training led to a marked increase in protein expression of GLUT4 (378+/-85%), glycogen synthase (526+/-146%), and hexokinase II (204+/-47%) in vastus lateralis muscle, whereas phosphofructokinase expression (282+/-97%) was not significantly changed. Hexokinase II activity was significantly increased, whereas activity of phosphofructokinase, glycogen synthase, and citrate synthase was not changed after training. Muscle fiber type distribution and fiber area were markedly altered compared to able-bodied subjects before ESLC training, with no change noted in either parameter after ECSL training. In conclusion, muscle contraction improves insulin action on whole body and cellular glucose uptake in cervical cord-injured persons through a major increase in protein expression of key genes involved in the regulation of glucose metabolism. Furthermore, improvements in insulin action on glucose metabolism are independent of changes in muscle fiber type distribution.	Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden; Sunnaas Hosp, N-1450 Nesoddtangen, Norway	Karolinska Institutet; Karolinska University Hospital	Wallberg-Henriksson, H (corresponding author), Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden.	hwh@klinfys.ks.se		Zierath, Juleen/0000-0001-6891-7497				Aksnes AK, 1996, AM J PHYSIOL-ENDOC M, V271, pE593, DOI 10.1152/ajpendo.1996.271.3.E593; ALP PR, 1976, BIOCHEM J, V154, P689, DOI 10.1042/bj1540689; ANDERSEN PH, 1993, ACTA PHYSIOL SCAND, V149, P393, DOI 10.1111/j.1748-1716.1993.tb09635.x; Anderson SL, 1997, ADV GENET, V35, P1, DOI 10.1016/S0065-2660(08)60446-0; BAK JF, 1990, AM J PHYSIOL, V258, pE957, DOI 10.1152/ajpendo.1990.258.6.E957; BANAUCH D, 1975, Z KLIN CHEM KLIN BIO, V13, P101; BAUMAN WA, 1994, METABOLISM, V43, P749, DOI 10.1016/0026-0495(94)90126-0; BOOTH FW, 1991, PHYSIOL REV, V71, P541, DOI 10.1152/physrev.1991.71.2.541; BOOTH FW, 1992, AM J PHYSIOL, V262, pR329, DOI 10.1152/ajpregu.1992.262.3.R329; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang PY, 1996, J BIOL CHEM, V271, P14834, DOI 10.1074/jbc.271.25.14834; CORTEZ MY, 1991, AM J PHYSIOL, V261, pE613; DeFronzo RA, 1979, AM J PHYSIOL, V233, P214; DELA F, 1993, J PHYSIOL-LONDON, V469, P615, DOI 10.1113/jphysiol.1993.sp019833; DELA F, 1992, AM J PHYSIOL, V263, pE1134; DEVLIN JT, 1987, DIABETES, V36, P434, DOI 10.2337/diabetes.36.4.434; DUCKWORTH WC, 1980, DIABETES, V29, P906, DOI 10.2337/diabetes.29.11.906; ETGEN GJ, 1993, AM J PHYSIOL, V264, pR816, DOI 10.1152/ajpregu.1993.264.4.R816; Figoni S F, 1990, J Am Paraplegia Soc, V13, P33; GEISLER WO, 1983, PARAPLEGIA, V21, P364, DOI 10.1038/sc.1983.60; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GREVE JMD, 1993, PARAPLEGIA, V31, P764, DOI 10.1038/sc.1993.119; GRIMBY G, 1976, SCAND J REHABIL MED, V8, P37; GROSSBARD L, 1966, J BIOL CHEM, V241, P3446; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRIKSSON J, 1986, AM J PHYSIOL, V251, pC614, DOI 10.1152/ajpcell.1986.251.4.C614; Hjeltnes N, 1997, AM J PHYSIOL-REG I, V273, pR1072, DOI 10.1152/ajpregu.1997.273.3.R1072; HOOKER SP, 1992, J REHABIL RES DEV, V29, P1, DOI 10.1682/JRRD.1992.07.0001; Host HH, 1998, J APPL PHYSIOL, V84, P798, DOI 10.1152/jappl.1998.84.3.798; HOUMARD JA, 1993, AM J PHYSIOL, V264, pE896, DOI 10.1152/ajpendo.1993.264.6.E896; HOUMARD JA, 1991, AM J PHYSIOL, V261, pE437, DOI 10.1152/ajpendo.1991.261.4.E437; HUGHES VA, 1993, AM J PHYSIOL, V264, pE855, DOI 10.1152/ajpendo.1993.264.6.E855; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P3096, DOI 10.1073/pnas.92.8.3096; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; Koval JA, 1998, AM J PHYSIOL-ENDOC M, V274, pE304, DOI 10.1152/ajpendo.1998.274.2.E304; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LOTTA S, 1991, PARAPLEGIA, V29, P247, DOI 10.1038/sc.1991.35; MANDARINO LJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE701; MARTIN TP, 1992, J APPL PHYSIOL, V72, P1401, DOI 10.1152/jappl.1992.72.4.1401; ODOHERTY R, 1996, J APPL PHYSIOL, V81, P798; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; OPIE LH, 1967, BIOCHEM J, V103, P391, DOI 10.1042/bj1030391; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; PETROFSKY J S, 1984, Journal of Clinical Engineering, V9, P13; PETTE D, 1973, PFLUG ARCH EUR J PHY, V338, P257, DOI 10.1007/BF00587391; PLOUG T, 1990, AM J PHYSIOL, V259, P778; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REN JM, 1994, J BIOL CHEM, V269, P14396; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; RICHTER EA, 1982, J CLIN INVEST, V69, P785, DOI 10.1172/JCI110517; Rincon J, 1996, DIABETES, V45, P615, DOI 10.2337/diabetes.45.5.615; RODGERS MA, 1988, DIABETES CARE, V11, P613; RODNICK KJ, 1992, AM J PHYSIOL, V262, pC9, DOI 10.1152/ajpcell.1992.262.1.C9; SCELSI R, 1986, PARAPLEGIA, V24, P250, DOI 10.1038/sc.1986.35; SCELSI R, 1982, ACTA NEUROPATHOL, V57, P243, DOI 10.1007/BF00692178; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Vestergaard H, 1995, J CLIN INVEST, V96, P2639, DOI 10.1172/JCI118329; VESTERGAARD H, 1993, J CLIN INVEST, V91, P2342, DOI 10.1172/JCI116466; VESTERGAARD H, 1994, AM J PHYSIOL, V266, pE92, DOI 10.1152/ajpendo.1994.266.1.E92; WALLBERGHENRIKSSON H, 1987, ACTA PHYSIOL SCAND, V131, P1; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WALLBERGHENRIKSSON H, 1984, J APPL PHYSIOL, V57, P1045, DOI 10.1152/jappl.1984.57.4.1045; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WALLBERGHENRIKSSON H, 1985, AM J PHYSIOL, V249, pC233, DOI 10.1152/ajpcell.1985.249.3.C233; WEBER FE, 1990, FEBS LETT, V261, P291, DOI 10.1016/0014-5793(90)80574-3; YEKUTIEL M, 1989, PARAPLEGIA, V27, P58, DOI 10.1038/sc.1989.9; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011; ZAMMIT VA, 1976, BIOCHEM J, V160, P447, DOI 10.1042/bj1600447; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885; Zierath Juleen R., 1995, Acta Physiologica Scandinavica, V155, P1	70	93	94	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1998	12	15					1701	1712		10.1096/fasebj.12.15.1701	http://dx.doi.org/10.1096/fasebj.12.15.1701			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837860				2022-12-25	WOS:000077574500012
J	Bhat, A; Johnson, KJ; Oda, T; Corbin, AS; Druker, BJ				Bhat, A; Johnson, KJ; Oda, T; Corbin, AS; Druker, BJ			Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEIN; COLONY-STIMULATING FACTOR; POSITIVE HUMAN LEUKEMIAS; MYELOID CELL-LINE; TYROSINE KINASE; SH2 DOMAIN; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR	A 62-kDa Ras GTPase-activating protein (RasGAP)-associated protein is tyrosine-phosphorylated under a variety of circumstances including growth factor stimulation and in cells transformed by activated tyrosine kinases. A cDNA for p62(dok), reported to be the RasGAP-associated 62-kDa protein, was recently cloned from Abl-transformed cells. In this study, the interactions of p62(dok) with Bcr-Abl and associated proteins were examined. In 32D myeloid cells and Rat-1 fibroblasts transformed by p210(bcr-abl), p62(dok) is, tyrosine-phosphorylated and co-immunoprecipitates with Bcr-Abl, RasGAP, and CrkL, a Src homology 2 (SH2) and SH3 domain-containing adaptor protein. Tyrosine-phosphorylated p62(dok) from cells expressing p210(bcr-abl) bound directly to the SH2 domains of Abl and CrkL in a gel overlay assay. Previous work has shown that an SH2 domain deletion mutant of Bcr-Abl is defective in transforming fibroblasts but remains capable of inducing myeloid growth factor independence. In both fibroblasts and myeloid cells expressing this mutant, p62(dok) is, underphosphorylated as compared with cells expressing full-length p210(bcr-abl) but remains capable of associating with Bcr-Abl, However, in a gel overlay assay, p62(dok) from cells expressing the SH2 domain deletion was incapable of associating directly with SH2 domains of Abl and CrkL. Interestingly, no direct binding between Bcr-Abl and p62(dok) could be demonstrated in a yeast two-hybrid assay. These data suggest that indirect interactions mediate the interaction between Bcr-Abl and p62(dok) and that the SH2 domain of Bcr-Abl is required for hyperphosphorylation of p62(dok). Further, hyperphosphorylation of p62(dok) correlates with the ability of Bcr-Abl to transform fibroblasts but not with the induction of growth factor independence in myeloid cells.	Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, L592,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	drukerb@ohsu.edu	Oda, Tsukasa/ABI-1855-2020	Druker, Brian/0000-0001-8331-8206; Oda, Tsukasa/0000-0002-8941-161X	NCI NIH HHS [CA65823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA065823, R01CA065823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; CARLESSO N, 1994, ONCOGENE, V9, P149; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DARBY C, 1994, J IMMUNOL, V152, P5429; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DRUKER B, 1992, BLOOD, V79, P2215; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOLD MR, 1993, J IMMUNOL, V150, P377; GREENBERGER JS, 1983, P NATL ACAD SCI USA, V80, P2391; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; KANAKURA Y, 1990, BLOOD, V76, P706; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; ODA T, 1994, J BIOL CHEM, V269, P22925; ODA T, 1995, LEUKEMIA, V9, P295; OGAWA W, 1994, J BIOL CHEM, V269, P29602; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; SANCHEZMARGALET V, 1995, ENDOCRINOLOGY, V136, P316, DOI 10.1210/en.136.1.316; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3	44	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32360	32368		10.1074/jbc.273.48.32360	http://dx.doi.org/10.1074/jbc.273.48.32360			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822717	hybrid			2022-12-25	WOS:000077207000099
J	Fuchs, SY; Adler, V; Buschmann, T; Wu, XW; Ronai, Z				Fuchs, SY; Adler, V; Buschmann, T; Wu, XW; Ronai, Z			Mdm2 association with p53 targets its ubiquitination	ONCOGENE			English	Article						p53; ubiquitination; Mdm2; stability	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; E6 ONCOPROTEIN; IN-VIVO; KINASE; PHOSPHORYLATION; DEGRADATION; CELLS; STABILITY	Key to p53 ability to mediate its multiple cellular functions lies in its stability, In the present study we have elucidated the mechanism by which Mdm2 regulates p53 degradation. Using in vitro and in vivo ubiquitination assays we demonstrate that Mdm2 association with p53 targets p53 ubiquitination, Exposure of cells to UV-irradiation inhibits this targeting. Mdm2 which is deficient in p53 binding failed to target p53 ubiquitination, suggesting that the association is essential for Mdm2 targeting ability. While mdm2-p53 complex is found in non-stressed cells, the amount of p53-bound mdm2 is decreased after UV-irradiation, further pointing to the relationship between mdm2 binding and p53 level. Similar to Swiss 3T3 cells, the dissociation of mdm2-p53 complex was also found in UV-treated Scid cells, lacking functional DNA-PK, suggesting that DNA-PK is not sufficient for dissociating mdm2 from p53, Together our studies point to the role of Mdm2, as one of p53-associated proteins, in targeting p53 ubiquitination.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave Levy Pl Box 1130, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA59908] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORDONCARDO C, 1994, CANCER RES, V54, P794; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUCHS SY, 1998, UNPUB; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Rathmell WK, 1997, CANCER RES, V57, P68; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SICILIANO JD, 1997, GENE DEV, V11, P3471; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	42	202	207	1	13	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2543	2547		10.1038/sj.onc.1202200	http://dx.doi.org/10.1038/sj.onc.1202200			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824166				2022-12-25	WOS:000076927300015
J	Ren, Y; Li, R; Zheng, Y; Busch, H				Ren, Y; Li, R; Zheng, Y; Busch, H			Cloning and characterization of GEF-H1, a microtubule-associated guanine nucleotide exchange factor for Rac and Rho GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GTP-BINDING PROTEINS; ACTIN STRESS FIBERS; STRUCTURAL SIMILARITIES; ACTIVATING-PROTEIN; EXPRESSION CLONING; GDP/GTP EXCHANGE; FAMILY GTPASES; CDC42 GTPASES; DBL FAMILY	The Rho-related small GTPases are critical elements involved in regulation of signal transduction cascades from extracellular stimuli to cell nucleus and cytoskeleton, The Dbl-like guanine nucleotide exchange factors (GEF) have been implicated in direct activation of these GTPases. Here we have identified a new member of the Dbl family, GEF-H1, by screening a human HeLa cell cDNA library. GEF-H1 encodes a 100-kDa protein containing the conserved structural array of a Dbl homology domain in tandem with a pleckstrin homology domain and is most closely related to the lfc oncogene, but additionally it contains a unique coiled-coil domain at the carboxyl terminus, Biochemical analysis reveals that GEF-H1 is capable of stimulating guanine nucleotide exchange of Rac and Rho but is inactive toward Cdc42, TC10, or Ras, Moreover, GEF-H1 binds to Rac and Rho proteins in both the GDP- and guanosine 5'-3-O-(thio)triphosphate-bound states without detectable affinity for Cdc42 or Ras. Immunofluorescence reveals that GEF-H1 colocalizes with microtubules through the carboxyl-terminal coiled-coil domain. Overexpression of GEF-H1 in COS-7 cells results in induction of membrane ruffles. These results suggest that GEF-H1 may have a direct role in activation of Rac and/or Rho and in bringing the activated GTPase to specific target sites such as microtubules.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	Baylor College of Medicine; University of Tennessee System; University of Tennessee Health Science Center	Ren, Y (corresponding author), Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM53943] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Best A, 1996, J BIOL CHEM, V271, P3756; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Brill S, 1996, MOL CELL BIOL, V16, P4869; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; PASTERIS NG, 1994, CELL, V79, P669; QUILLIAM LA, 1995, BIOESSAYS, V17, P309; REDDY AB, 1989, CANCER RES, V49, P1763; Ren Y, 1996, PROTEIN EXPRES PURIF, V7, P212, DOI 10.1006/prep.1996.0029; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 2002, MOL CLONING LAB MANU; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; TOKSOZ D, 1994, ONCOGENE, V9, P621; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; WICHE G, 1991, J CELL BIOL, V114, P83, DOI 10.1083/jcb.114.1.83; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	34	238	249	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1998	273	52					34954	34960		10.1074/jbc.273.52.34954	http://dx.doi.org/10.1074/jbc.273.52.34954			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	151KR	9857026	hybrid			2022-12-25	WOS:000077719700044
J	Tatsis, N; Lannigan, DA; Macara, IG				Tatsis, N; Lannigan, DA; Macara, IG			The function of the p190 Rho GTPase-activating protein is controlled by its N-terminal GTP binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SIGNALING PATHWAY; ACTIN CYTOSKELETON; MOLECULAR-CLONING; TYROSINE KINASES; RAN/TC4 GTPASE; RAS PROTEINS; SH2 DOMAINS; 3T3 CELLS; GAP	p190 is a GTPase-activating protein (GAP) for the Rho family of GTPases, The GAP domain of p190 is at the C terminus of the protein. At its N terminus, p190 contains a GTP binding domain of unknown significance. We have introduced a mutation (Ser(36) --> Asn) into this domain of p190 that decreased its ability to bind guanine nucleotide when expressed as a hemagglutinin (HA)-tagged protein in COS cells, In vitro, both the wild type and S36N mutant HA-p190 proteins showed similar GAP activities toward RhoA, but when expressed in NIH 3T3 fibroblasts only wild type p190 appeared able to function as a RhoGAP. Wild type HA-p190 induced a phenotype of rounded cells with long, beaded extensions similar to that seen when Rho function is disrupted by ADP-ribosylation. HA-p190(S36N), although expressed at a similar level to the wild type protein, had no discernible effect on the cells. The beaded extension phenotype induced by wild type HA-p190 required GAP function. A GAP-defective mutant, p190(R1283A), had no effect on cell morphology. Moreover, the beaded extension phenotype could be suppressed by co-expression of a gain-of-function Rho mutant, RhoA(G14V), or Pac mutant, Rac1(G12V). Activation of the Jun kinase (JNK) via muscarinic receptors was inhibited by wild type HA-p190, but JNK activity was enhanced by the S36N mutant, Go-expression of HA-p190 with a fragment containing only the mutated GTP binding domain partially inhibited the beaded extension phenotype, suggesting that it may sequester a factor required for p190 function. Taken together these data demonstrate that within the cell, the Rho/Rac GAP activity of p190 can be regulated by the N-terminal GTP binding domain.	Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Vermont, Cell & Mol Biol Program, Burlington, VT 05405 USA	University of Virginia; University of Vermont	Macara, IG (corresponding author), Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA.	imacara@virginia.edu			NCI NIH HHS [CA 38888] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038888] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRYANT SS, 1995, J BIOL CHEM, V270, P17947, DOI 10.1074/jbc.270.30.17947; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHENG JC, 1995, CELL GROWTH DIFFER, V6, P139; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; SCHLENSTEDT G, 1995, EMBO J, V14, P5367, DOI 10.1002/j.1460-2075.1995.tb00221.x; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Wang DZM, 1997, CANCER RES, V57, P2478; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776	41	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34631	34638		10.1074/jbc.273.51.34631	http://dx.doi.org/10.1074/jbc.273.51.34631			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852136	hybrid			2022-12-25	WOS:000077542200102
J	Catoire, L; Pierron, M; Morvan, C; du Penhoat, CH; Goldberg, R				Catoire, L; Pierron, M; Morvan, C; du Penhoat, CH; Goldberg, R			Investigation of the action patterns of pectinmethylesterase isoforms through kinetic analyses and NMR spectroscopy - Implications in cell wall expansion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUNG BEAN HYPOCOTYL; PECTIN METHYLESTERASE; FLOWERING PLANTS; PECTINESTERASE; POLLEN; ESTERASE	Well characterized pectin samples were incubated with cell wall-bound and -solubilized pure isoforms of pectinmethylesterase from mung bean hypocotyls (Vigna radiata), Both enzyme activity and average product structure were determined at intervals along the deesterification pathway at pH 5.6 and 7,6, The latter analyses were performed by (13)C MMR spectroscopy, and the degree of esterification was probed by both (13)C MMR and potentiometric measurements. A dichotomy was observed in the behavior of the alpha and gamma isoforms when compared with that of the beta isoenzyme. Ideal blockwise deesterification mechanisms reproduced the experimental average structures (methylester distribution) throughout the course of the reaction. In the case of the alpha and gamma isoforms, a single chain mechanism associated with a free carboxyl group at the second nearest neighbor position could be postulated at pH 5.6, whereas some multiple attack character was required to reproduce the data at pH 7.6. Several mechanisms that differed from the preceding ones were compatible with the data for the beta isoform at the two pH values. Both the nature of the polysaccharides produced in these reactions and the role of pectinmethylesterase in the cell wall-stiffening process along the growth gradient are discussed.	Inst Jacques Monod, Lab Enzymol Milieu Struct, F-75251 Paris, France; Ecole Normale Super, Dept Chim, CNRS, URA 1679, F-75231 Paris 05, France; Univ Rouen, Fac Sci, CNRS, SCUEOR,URA 203, F-76821 Mont St Aignan, France; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Rouen Normandie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Goldberg, R (corresponding author), Inst Jacques Monod, Lab Enzymol Milieu Struct, 2 Pl Jussieu, F-75251 Paris, France.	goldberg@ccr.jussieu.fr						ABDULLAH M, 1966, ARCH BIOCHEM BIOPHYS, V114, P595, DOI 10.1016/0003-9861(66)90385-7; ALBANI D, 1991, PLANT MOL BIOL, V16, P501, DOI 10.1007/BF00023417; ANDERSEN AK, 1995, CARBOHYD RES, V273, P93, DOI 10.1016/0008-6215(95)00100-8; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BORDENAVE M, 1994, PLANT PHYSIOL, V106, P1151, DOI 10.1104/pp.106.3.1151; Bordenave M, 1996, PLANT MOL BIOL, V31, P1039, DOI 10.1007/BF00040722; BORDENAVE M, 1993, PHYTOCHEMISTRY, V33, P999, DOI 10.1016/0031-9422(93)85011-F; BORDENAVE M, 1996, MOD METHOD PLANT, V17, P165; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Catoire L, 1998, EUR BIOPHYS J BIOPHY, V27, P127, DOI 10.1007/s002490050118; DEVRIES JA, 1983, CARBOHYD POLYM, V3, P245; GARNIER C, 1993, CARBOHYD RES, V240, P219, DOI 10.1016/0008-6215(93)84185-9; Goldberg R, 1996, PROGR BIOTECHNOL, V14, P151, DOI 10.1016/S0921-0423(96)80253-X; GOLDBERG R, 1986, PLANT CELL PHYSL, V27, P523; Grasdalen H, 1996, CARBOHYD RES, V289, P105, DOI 10.1016/0008-6215(96)00079-1; Greenwood C. T., 1968, ADV CARBOHYD CHEM, V23, P282; HORTON N, 1992, PROTEIN SCI, V1, P169; IMBERTY A, 1993, ADV BIOPH C, V0003; LI YQ, 1994, SEX PLANT REPROD, V7, P145; MARKOVIC O, 1984, EXPERIENTIA, V40, P842; McCann MC, 1996, PROGR BIOTECHNOL, V14, P91, DOI 10.1016/S0921-0423(96)80249-8; MOUSTACAS AM, 1991, BIOCHEM J, V279, P351, DOI 10.1042/bj2790351; MU JH, 1994, PLANT MOL BIOL, V25, P539, DOI 10.1007/BF00043881; Richard L, 1996, GENE, V170, P207, DOI 10.1016/0378-1119(95)00766-0; Roberts K, 1990, CURR OPIN CELL BIOL, V2, P920, DOI 10.1016/0955-0674(90)90093-T; VERSTEEG C, 1979, THESIS WAGENINGEN; WESTERLUND E, 1991, Carbohydrate Polymers, V14, P179; ZHANG GF, 1992, PLANT PHYSIOL, V99, P1070, DOI 10.1104/pp.99.3.1070	28	121	126	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33150	33156		10.1074/jbc.273.50.33150	http://dx.doi.org/10.1074/jbc.273.50.33150			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837882	hybrid			2022-12-25	WOS:000077462500012
J	Diaz, JF; Valpuesta, JM; Chacon, P; Diakun, G; Andreu, JM				Diaz, JF; Valpuesta, JM; Chacon, P; Diakun, G; Andreu, JM			Changes in microtubule protofilament number induced by taxol binding to an easily accessible site - Internal microtubule dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; TUBULIN DOUBLE RINGS; CRYOELECTRON MICROSCOPY; BETA-TUBULIN; GDP-TUBULIN; 3-DIMENSIONAL STRUCTURE; FLEXURAL RIGIDITY; PURIFIED TUBULIN; GTP HYDROLYSIS; AMINO-ACIDS	We have investigated the accessibility of the Taxol-binding site and the effects of Taxol binding on the structures of assembled microtubules. Taxol and docetaxel readily bind to and dissociate from microtubules, reaching 95% ligand exchange equilibrium in less than 3 min under our solution conditions (microtubules were previously assembled fi om GTP-tubulin, GTP-tubulin and microtubule-associated proteins, or GDP-tubulin and taxoid). Microtubules assembled from purified tubulin with Taxol are known to have typically one protofilament less than with the analogue docetaxel and control microtubules. Surprisingly, Taxol binding and exchange induce changes in the structure of preformed microtubules in a relatively short time scale. Cryoelectron microscopy shows changes toward the protofilament number distribution characteristic of Taxol or docetaxel, with a half-time of similar to 0.5 min, employing GDP-tubulin-taxoid microtubules, Correspondingly, synchrotron xray solution scattering shows a reduction in the mean microtubule diameter upon Taxol binding to microtubules assembled from GTP-tubulin in glycerol-containing buffer, with a structural relaxation half-time of similar to 1 min. These results imply that microtubules can exchange protofilaments upon Taxol binding, due to internal dynamics along the microtubule wall, The simplest interpretation of the relatively fast taxoid exchange observed and labeling of cellular microtubules with fluorescent taxoids, is that the Taxol-binding site is at the outer microtubule surface, On the contrary, if Taxol binds at the microtubule lumen in agreement with the electron crystallographic structure of tubulin dimers, our results suggest that the inside of microtubules is easily accessible from the outer solution. Large pores or moving lattice defects in microtubules might facilitate the binding of taxoids, as weil as of possible endogenous cellular ligands of the inner microtubule wall.	CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Katholieke Univ Leuven, Lab Chem Biol Dynam, B-3001 Louvain, Belgium; UAM, CSIC, Ctr Nacl Biotecnol, Madrid 28049, Spain; CCLRC, Daresbury Lab, Warrington WA4 4AD, Cheshire, England	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); KU Leuven; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); STFC Daresbury Laboratory	Andreu, JM (corresponding author), CSIC, Ctr Invest Biol, Velazquez 144, E-28006 Madrid, Spain.	j.m.andreu@fresno.csic.es	Chacon, Pablo/B-4211-2014; Díaz, J. Fernando/M-6853-2019; Díaz, J. Fernando/U-3532-2017; Valpuesta, José M/T-1977-2017; Valpuesta, Jose M/AAA-6002-2019	Chacon, Pablo/0000-0002-3168-4826; Díaz, J. Fernando/0000-0003-2743-3319; Díaz, J. Fernando/0000-0003-2743-3319; Valpuesta, José M/0000-0001-7468-8053; Andreu, Jose M/0000-0001-8064-6933				ANDREU JM, 1989, BIOCHEMISTRY-US, V28, P4036, DOI 10.1021/bi00435a060; ANDREU JM, 1994, J BIOL CHEM, V269, P31785; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; Bras W, 1998, BIOPHYS J, V74, P1509, DOI 10.1016/S0006-3495(98)77863-4; CAPLOW M, 1994, J BIOL CHEM, V269, P23399; CHAU MF, 1998, IN PRESS BIOCHEMISTR; CHRETIEN D, 1991, BIOL CELL, V71, P161, DOI 10.1016/0248-4900(91)90062-R; Chretien D, 1996, STRUCTURE, V4, P1031, DOI 10.1016/S0969-2126(96)00110-4; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; CHRETIEN D, 1992, J CELL BIOL, V117, P1031, DOI 10.1083/jcb.117.5.1031; DEPEREDA JM, 1995, CELL MOTIL CYTOSKEL, V30, P153, DOI 10.1002/cm.970300207; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; Diaz JF, 1998, REV SCI INSTRUM, V69, P286, DOI 10.1063/1.1148510; Diaz JF, 1996, BIOPHYS J, V70, P2408, DOI 10.1016/S0006-3495(96)79809-0; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; Downing KH, 1998, CURR OPIN CELL BIOL, V10, P16, DOI 10.1016/S0955-0674(98)80082-3; DYE RB, 1993, J BIOL CHEM, V268, P6847; Egelman EH, 1998, CURR BIOL, V8, pR288, DOI 10.1016/S0960-9822(98)70175-7; Evangelio JA, 1998, CELL MOTIL CYTOSKEL, V39, P73, DOI 10.1002/(SICI)1097-0169(1998)39:1<73::AID-CM7>3.0.CO;2-H; Felgner H, 1997, J CELL BIOL, V138, P1067, DOI 10.1083/jcb.138.5.1067; Felgner H, 1996, J CELL SCI, V109, P509; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; Hirose K, 1998, J MOL BIOL, V278, P389, DOI 10.1006/jmbi.1998.1709; Hoenger A, 1998, J CELL BIOL, V141, P419, DOI 10.1083/jcb.141.2.419; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; Hyman AA, 1996, CELL, V84, P401, DOI 10.1016/S0092-8674(00)81285-4; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; JIMENEZBARBERO J, 1998, IN PRESS BIOORG MED; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; Kozielski F, 1998, CURR BIOL, V8, P191, DOI 10.1016/S0960-9822(98)70083-1; KURZ JC, 1995, BIOCHEMISTRY-US, V34, P13374, DOI 10.1021/bi00041a014; LANZAVECCHIA S, 1994, J STRUCT BIOL, V113, P225, DOI 10.1006/jsbi.1994.1057; Luduena RF, 1998, INT REV CYTOL, V178, P207; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; Marx A, 1998, EUR BIOPHYS J BIOPHY, V27, P455, DOI 10.1007/s002490050156; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; Menendez M, 1998, J BIOL CHEM, V273, P167, DOI 10.1074/jbc.273.1.167; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; Odde D, 1998, EUR BIOPHYS J BIOPHY, V27, P514, DOI 10.1007/s002490050161; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; Raff EC, 1997, SCIENCE, V275, P70, DOI 10.1126/science.275.5296.70; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; Romberg L, 1998, J CELL BIOL, V140, P1407, DOI 10.1083/jcb.140.6.1407; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sosa H, 1996, J MOL BIOL, V260, P743, DOI 10.1006/jmbi.1996.0434; Souto AA, 1995, ANGEW CHEM INT EDIT, V34, P2710; Suffness Matthew, 1994, In Vivo (Attiki), V8, P867; Thormahlen' M, 1998, J MOL BIOL, V275, P795, DOI 10.1006/jmbi.1997.1503; TILNEY LG, 1973, J CELL BIOL, V59, P267, DOI 10.1083/jcb.59.2.267; VALE RD, 1994, J BIOL CHEM, V269, P23769; VENIER P, 1994, J BIOL CHEM, V269, P13353	66	95	101	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33803	33810		10.1074/jbc.273.50.33803	http://dx.doi.org/10.1074/jbc.273.50.33803			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837970	Green Published, hybrid			2022-12-25	WOS:000077462500100
J	Kim, Y; Ratziu, V; Choi, SG; Lalazar, A; Theiss, G; Dang, Q; Kim, SJ; Friedman, SL				Kim, Y; Ratziu, V; Choi, SG; Lalazar, A; Theiss, G; Dang, Q; Kim, SJ; Friedman, SL			Transcriptional activation of transforming growth factor beta 1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1 - Potential mechanisms for autocrine fibrogenesis in response to injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATIC STELLATE CELLS; ZINC-FINGER PROTEIN; RAT-LIVER FIBROSIS; GENE-EXPRESSION; TGF-BETA; FACTOR-BETA-1 GENE; ITO CELLS; GROWTH-FACTOR-BETA-1; LIPOCYTES; DISEASE	We have explored the regulation of transforming growth factor beta (TGF-beta) activity in tissue repair by examining the interactions of Zf9/core promoter-binding protein, a Kruppel-like zinc finger transcription factor induced early in hepatic stellate cell (HSC) activation, with promoters for TGF-beta 1 and TGF-beta receptors, types I and II. Nuclear extracts from culture-activated HSCs bound avidly by electrophoretic mobility shift assay to two tandem GC boxes within the TGF-beta 1 promoter but minimally to a single GC box; these results correlated with transactivation by Zf9 of TGF-beta 1 promoter-reporters, Zf9 transactivated the full-length TGF-beta 1 promoter in either primary HSCs, HSC-T6 cells (an SV40-immortalized rat RSC line), Hep G2 cells, or Drosophila Schneider (S2) cells. Recombinant Zf9-GST also bound to GC box sequences within the promoters for the types I and II TGF-beta receptors. Both type I and type II TGF-beta receptor promoters were also transactivated by Zf9 in mammalian cells but not in S2 cells. In contrast, Spl significantly transactivated both receptor promoters in S2 cells. These results suggest that (a) Zf9/core promoterbinding protein may enhance TGF-beta activity through transactivation of both the TGF-beta 1 gene and its key signaling receptors, and (b) transactivating potential of Zf9 and Sp1 toward promoters for TGF-beta 1 and its recep tors are not identical and depend on the cellular context.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; NCI, Lab Cell Regulat & Carcinogenesis, Div Basic Sci, NIH, Bethesda, MD 20892 USA; CUNY Mt Sinai Sch Med, Dept Liver Dis, New York, NY 10029 USA; Bayer AG, D-42096 Wuppertal, Germany	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Bayer AG	Friedman, SL (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1123,1425 Madison Ave,Rm 1170-F, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BEDOSSA P, 1995, J HEPATOL, V22, P37; Bieker JJ, 1996, DNA CELL BIOL, V15, P347, DOI 10.1089/dna.1996.15.347; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Bloom BB, 1996, BBA-MOL CELL RES, V1312, P243, DOI 10.1016/0167-4889(96)00043-2; Border W A, 1994, Curr Opin Nephrol Hypertens, V3, P54, DOI 10.1097/00041552-199401000-00007; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DeBleser PJ, 1997, J HEPATOL, V26, P886, DOI 10.1016/S0168-8278(97)80257-7; Friedman S L, 1996, Prog Liver Dis, V14, P101; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; FRIEDMAN SL, 1993, METHODS TOXICOL, V1, P292; Gregory RC, 1996, BLOOD, V87, P1793, DOI 10.1182/blood.V87.5.1793.bloodjournal8751793; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIM SJ, 1989, J BIOL CHEM, V264, P402; Knittel T, 1996, GASTROENTEROLOGY, V111, P745, DOI 10.1053/gast.1996.v111.pm8780581; Knittel T, 1996, HEPATOLOGY, V24, P352; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lalazar A, 1997, GENE, V195, P235, DOI 10.1016/S0378-1119(97)00159-5; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; MICHELSON S, 1994, J VIROL, V68, P5730, DOI 10.1128/JVI.68.9.5730-5737.1994; MILANI S, 1991, AM J PATHOL, V139, P1221; NAKATSUKASA H, 1990, J CLIN INVEST, V85, P1833, DOI 10.1172/JCI114643; Okuno M, 1997, HEPATOLOGY, V26, P913, DOI 10.1053/jhep.1997.v26.pm0009328313; PINZANI M, 1995, HEPATOLOGY, V21, P232, DOI 10.1002/hep.1840210136; RATZIU R, 1997, HEPATOLOGY, V26, pA185; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Reimann T, 1997, FEBS LETT, V403, P57, DOI 10.1016/S0014-5793(97)00024-0; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; ROSENBAUM J, 1995, GASTROENTEROLOGY, V109, P1986, DOI 10.1016/0016-5085(95)90767-X; Saltis J, 1996, CLIN EXP PHARMACOL P, V23, P193, DOI 10.1111/j.1440-1681.1996.tb02595.x; SCHWARTZ SM, 1995, THROMB HAEMOSTASIS, V74, P541; SOGAWA K, 1993, J BIOCHEM, V114, P605, DOI 10.1093/oxfordjournals.jbchem.a124224; WEINER FR, 1990, HEPATOLOGY, V11, P111, DOI 10.1002/hep.1840110119	46	220	227	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33750	33758		10.1074/jbc.273.50.33750	http://dx.doi.org/10.1074/jbc.273.50.33750			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837963	hybrid			2022-12-25	WOS:000077462500093
J	Lyss, G; Knorre, A; Schmidt, TJ; Pahl, HL; Merfort, I				Lyss, G; Knorre, A; Schmidt, TJ; Pahl, HL; Merfort, I			The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappa B by directly targeting p65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; ARNICA; HELENANOLIDES; SUBUNIT; CYTOTOXICITY; DERIVATIVES; ACTIVATION; REDUCTION; AGENTS; ESTERS	The sesquiterpene lactone helenalin is a potent antiinflammatory drug whose molecular mechanism of action remains unclear despite numerous investigations. We have previously shown that helenalin and other sesquiterpene lactones selectively inhibit activation of the transcription factor NF-kappa B, a central mediator of the human immune response. These drugs must target a central step in NF-kappa B pathway, since they inhibit NF-kappa B induction by four different stimuli. It has previously been reported that sesquiterpene lactones exert their effect by inhibiting degradation of I kappa B, the inhibitory subunit of NF-kappa B. These data contradicted our report that I kappa B is not detectable in helenalin-treated, ocadaic acid-stimulated cells. Here we use confocal laser scanning microscopy to demonstrate the presence of I kappa B-released, nuclear NF-kappa B in helenalin-treated, tumor necrosis factor-alpha stimulated cells. These data show that neither I kappa B degradation nor NF-kappa B nuclear translocation are inhibited by helenalin. Rather, we provide evidence that helenalin selectively alkylates the p65 subunit of NF-kappa B. This sesquiterpene lactone is the first anti-inflammatory agent shown to exert its effect by directly modifying NF-kappa B.	Univ Freiburg, Inst Pharmaceut Biol, D-79104 Freiburg, Germany; Univ Dusseldorf, Inst Pharmaceut Biol, D-40225 Dusseldorf, Germany; Univ Hosp, Dept Expt Anaesthesiol, D-79106 Freiburg, Germany	University of Freiburg; Heinrich Heine University Dusseldorf; University of Freiburg	Merfort, I (corresponding author), Univ Freiburg, Inst Pharmaceut Biol, Schanzlestr 1, D-79104 Freiburg, Germany.		Pahl, Heike/AGM-5260-2022; Schmidt, Thomas J/M-1678-2016	Schmidt, Thomas J/0000-0003-2634-9705				APPENDINO G, 1986, GAZZ CHIM ITAL, V116, P637; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL IH, 1980, J PHARM SCI, V69, P537, DOI 10.1002/jps.2600690516; HALL IH, 1979, J PHARM SCI, V68, P537, DOI 10.1002/jps.2600680505; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUPCHAN SM, 1971, J MED CHEM, V14, P1147, DOI 10.1021/jm00294a001; LEE KH, 1973, J MED CHEM, V16, P299, DOI 10.1021/jm00261a034; LEVEN W, 1988, THESIS HEINRICHHEINE; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MERFORT I, 1993, PHYTOCHEMISTRY, V34, P1436, DOI 10.1016/0031-9422(91)80046-4; PICMAN AK, 1979, CHEM-BIOL INTERACT, V28, P83, DOI 10.1016/0009-2797(79)90116-9; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Rungeler P, 1998, PLANTA MED, V64, P588, DOI 10.1055/s-2006-957527; Schmidt TJ, 1997, BIOORGAN MED CHEM, V5, P645, DOI 10.1016/S0968-0896(97)00003-5; Schmidt TJ, 1996, J MOL STRUCT, V385, P99, DOI 10.1016/S0022-2860(96)09349-0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHRODER H, 1990, THROMB RES, V57, P839, DOI 10.1016/0049-3848(90)90151-2; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; WIEBCKE M, 1982, TETRAHEDRON, V38, P2709, DOI 10.1016/0040-4020(82)80026-4; WILLUHN G, 1990, PLANTA MED, V56, P111, DOI 10.1055/s-2006-960899; Willuhn G, 1981, Pharm Unserer Zeit, V10, P1, DOI 10.1002/pauz.19810100101	30	405	417	0	24	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33508	33516		10.1074/jbc.273.50.33508	http://dx.doi.org/10.1074/jbc.273.50.33508			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837931	hybrid			2022-12-25	WOS:000077462500061
J	Marlovits, TC; Abrahamsberg, C; Blaas, D				Marlovits, TC; Abrahamsberg, C; Blaas, D			Soluble LDL minireceptors - Minimal structure requirements for recognition of minor group human rhinovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; INTERCELLULAR-ADHESION MOLECULE-1; HELA-CELLS; PROTEIN; INVITRO; BINDING; ICAM-1; ENTRY	Soluble human low density lipoprotein minireceptors with less than seven ligand binding repeats las are present in the native membrane receptor) were expressed in Sf9 insect cells with a hexa-His tag fused to the C terminus. The recombinant truncated proteins were affinity purified from the tissue culture supernatants by Ni-NTA column chromatography. Minireceptors with more than two repeats bound to rabbit beta very low density lipoprotein and could thus be further purified by affinity chromatography. Binding and cell protection assays indicated that two ligand binding repeats are sufficient for attachment of minor group human rhinoviruses to immobilized receptors, whereas at least three ligand binding repeats are required to protect HeLa cells against viral infection.	Univ Vienna, Inst Biochem, A-1030 Vienna, Austria	University of Vienna	Blaas, D (corresponding author), Univ Vienna, Inst Biochem, Dr Bohr Gasse 9-3, A-1030 Vienna, Austria.		Marlovits, Thomas/A-3568-2019	Marlovits, Thomas/0000-0001-8106-4038				ANDRIES K, 1988, ARCH VIROL, V101, P155, DOI 10.1007/BF01310997; ARRUDA E, 1992, ANTIMICROB AGENTS CH, V36, P1186, DOI 10.1128/AAC.36.6.1186; BARBER DL, 1991, J BIOL CHEM, V266, P18761; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GRUENBERGER M, 1995, J VIROL, V69, P7244, DOI 10.1128/JVI.69.11.7244-7247.1995; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; LONBERGHOLM K, 1976, NATURE, V259, P679, DOI 10.1038/259679a0; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; Marlovits TC, 1998, FASEB J, V12, P695, DOI 10.1096/fasebj.12.9.695; MARLOVITS TC, 1998, IN PRESS J VIROL; NEUBAUER C, 1987, VIROLOGY, V158, P255, DOI 10.1016/0042-6822(87)90264-9; OLSON NH, 1993, P NATL ACAD SCI USA, V90, P507, DOI 10.1073/pnas.90.2.507; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Rueckert RR, 1996, VIROLOGY, P609; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Shafren DR, 1998, J IMMUNOL, V160, P2318; Shigeta S, 1998, ANTIVIR CHEM CHEMOTH, V9, P93, DOI 10.1177/095632029800900201; Simmons T, 1997, J BIOL CHEM, V272, P25531, DOI 10.1074/jbc.272.41.25531; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	31	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33835	33840		10.1074/jbc.273.50.33835	http://dx.doi.org/10.1074/jbc.273.50.33835			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837974	hybrid			2022-12-25	WOS:000077462500104
J	Novina, CD; Cheriyath, V; Roy, AL				Novina, CD; Cheriyath, V; Roy, AL			Regulation of TFII-I activity by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION-FACTOR; BINDING PROTEIN; TATA-LESS; INHIBITION; PROMOTER; RECEPTOR; KINASE	The transcription factor TFII-I binds to distinct promoter sequences including an initiator element in several eukaryotic genes. Here we demonstrate that TFII-I is phosphorylated in vivo at serine/threonine and tyrosine residues in the absence of any apparent extracellular signals, This "basal" phosphorylation of TFII-I is not required and does not affect its specific DNA binding, but is critical for its in vitro transcriptional properties via the V beta promoter. To better assess the functional role of phosphorylation in regulating TFII-I activity, we focused on tyrosine phosphorylation of TFII-I. Ectopically expressed recombinant TFII-I, like its native counterpart, exhibits tyrosine phosphorylation in the absence of distinct extracellular signals. More important, mutation of a potential consensus tyrosine phosphorylation site in TFII-I leads to severe reduction in its basal transcriptional activation of the V beta promoter in vivo. Taken together, these data suggest that tyrosine phosphorylation of TFII-I is important for its initiator-dependent transcriptional activity.	Tufts Univ, Sch Med, Sackler Sch Grad Studies, Dept Pathol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Sackler Sch Grad Studies, Program Immunol, Boston, MA 02111 USA	Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Sch Med, Sackler Sch Grad Studies, Dept Pathol, 136 Harrison Ave, Boston, MA 02111 USA.	aroy@opal.tufts.edu						Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Grueneberg DA, 1997, GENE DEV, V11, P2482, DOI 10.1101/gad.11.19.2482; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; KITAJIMA S, 1994, J BIOL CHEM, V269, P29970; Lee YJ, 1996, J IMMUNOL, V157, P3828; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Novina CD, 1997, METHODS, V12, P254, DOI 10.1006/meth.1997.0477; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Segil N, 1996, GENE DEV, V10, P2389, DOI 10.1101/gad.10.19.2389; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	25	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33443	33448		10.1074/jbc.273.50.33443	http://dx.doi.org/10.1074/jbc.273.50.33443			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837922	hybrid			2022-12-25	WOS:000077462500052
J	Ward, DG; Cavieres, JD				Ward, DG; Cavieres, JD			Affinity labeling of two nucleotide sites on Na,K-ATPase using 2 '(3 ')-O-(2,4,6-trinitrophenyl)8-azidoadenosine 5 '-[alpha-P-32]diphosphate (TNP-8N(3)-[alpha-P-32]ADP) as a photoactivatable probe - Label incorporation before and after blocking the high affinity ATP site with fluorescein isothiocyanate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ADENOSINE-TRIPHOSPHATASE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI F1-ATPASE; SODIUM-PUMP; CONFORMATIONAL-CHANGES; ALPHA-SUBUNIT; NA+/K+-ATPASE; BETA-SUBUNIT; ACTIVE-SITE; SARCOPLASMIC-RETICULUM	ATP and its analogues act on the minimal functional unit of Na,R-ATPase, the alpha beta protomer, with high and low affinity effects. Fluorescein isothiocyanate (FITC) irreversibly blocks the high affinity, or catalytic, ATP site, and yet the surviving K+-phosphatase activity of soluble FITC-modified cup protomers can be photoinactivated by 2'(3')-O-trinitrophenyl (TNP)-8N(3)ADP (Ward, D, G,, and Cavieres, J, D, (1998) J, Biol, Chem, 273, 14277-14284), We have now used TNP-8N(3)-[alpha-P-32]ADP as a photoaffinity label for Na,K-ATPase, The native enzyme can be photolabeled at 5 mu M TNP-8N(3)-[alpha-P-32]ADP, and ATP or FITC treatment prevents labeling of the alpha chain. At 25 mu M, however, TNP-8N(3)-[alpha-P-32]ADP can be incorporated in the FITC-modified alpha chain, concurrently with the inactivation of the K+-phosphatase activity, to an extrapolated level of 0.5-1.2 mol of P-32-probe per mol of a chain. Photoinactivation and labeling are prevented by TNP-ADP, vanadate, or strophanthidin and are promoted by Na+ or Mg2+, but not K+. The cation effects suggest that the fluorescein-modified enzyme incorporates the TNP8N(3)-[alpha-P-32]ADP . Mg complex preferentially, and the free probe when in the E1 enzyme form and after occupation of a low-affinity Na+ site. Partial trypsinolysis reveals that the point of TNP-8N(3)-[alpha-P-32]ADP attachment is on the C-terminal 58-kDa fragment of the FITC-modified a chain. The affinity labeling of the fluorescein enzyme by TNP-8N(3)-[alpha-P-32]ADP endorses the view that two nucleotide sites can be occupied simultaneously in each a subunit of Na,K-ATPase.	Univ Leicester, Dept Cell Physiol & Pharmacol, Transport ATPase Lab, Leicester LE1 9HN, Leics, England	University of Leicester	Cavieres, JD (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Transport ATPase Lab, Leicester LE1 9HN, Leics, England.	jdc7@le.ac.uk		Ward, Douglas/0000-0002-2328-1445	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARORA KK, 1990, J BIOL CHEM, V265, P5324; BEAUGE LA, 1980, J PHYSIOL-LONDON, V301, P7, DOI 10.1113/jphysiol.1980.sp013184; BOND GH, 1982, BIOCHIM BIOPHYS ACTA, V687, P310, DOI 10.1016/0005-2736(82)90560-0; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; CANTLEY LC, 1978, J BIOL CHEM, V253, P7361; CAVIERES JD, 1987, FEBS LETT, V225, P145, DOI 10.1016/0014-5793(87)81147-X; CAVIERES JD, 1975, NATURE, V255, P338, DOI 10.1038/255338a0; CORTAS N, 1991, BIOCHIM BIOPHYS ACTA, V1070, P223, DOI 10.1016/0005-2736(91)90168-8; Czarnecki J, 1979, Methods Enzymol, V56, P642; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6771, DOI 10.1021/bi00442a034; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P159, DOI 10.1113/jphysiol.1967.sp008294; Gatto C, 1997, ARCH BIOCHEM BIOPHYS, V340, P90, DOI 10.1006/abbi.1997.9879; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; Haley B E, 1977, Methods Enzymol, V46, P339; HALEY BE, 1974, P NATL ACAD SCI USA, V71, P3367, DOI 10.1073/pnas.71.9.3367; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; HEGYVARY C, 1981, J BIOL CHEM, V256, P6296; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; HOFFMAN JF, 1966, AM J MED, V41, P666, DOI 10.1016/0002-9343(66)90029-5; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V860, P570, DOI 10.1016/0005-2736(86)90555-9; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KAPLAN JH, 1980, NATURE, V288, P587, DOI 10.1038/288587a0; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1979, NATURE, V282, P333, DOI 10.1038/282333a0; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CT, 1989, BIOCHEMISTRY-US, V28, P9248, DOI 10.1021/bi00450a003; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LINNERTZ H, 1995, EUR J BIOCHEM, V232, P420, DOI 10.1111/j.1432-1033.1995.tb20827.x; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; MADDEN CS, 1994, SODIUM PUMP, P445; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; MURATALIEV MB, 1994, J BIOL CHEM, V269, P15431; NEUFELD AH, 1969, J BIOL CHEM, V244, P6493; NORBY JG, 1971, BIOCHIM BIOPHYS ACTA, V233, P104, DOI 10.1016/0005-2736(71)90362-2; POST RL, 1972, J BIOL CHEM, V247, P6530; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; Schoner W, 1998, EUR J BIOCHEM, V253, P245, DOI 10.1046/j.1432-1327.1998.2530245.x; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SEN AK, 1969, J BIOL CHEM, V244, P6596; SHULL GE, 1986, NATURE, V321, P429, DOI 10.1038/321429a0; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SILLEN LG, 1971, STABILITY CONSTANT S, V1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Thoenges D, 1997, J BIOL CHEM, V272, P16315, DOI 10.1074/jbc.272.26.16315; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; Ward DG, 1998, J BIOL CHEM, V273, P14277, DOI 10.1074/jbc.273.23.14277; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; Weber J, 1997, FEBS LETT, V412, P169, DOI 10.1016/S0014-5793(97)00773-4; Weber J, 1996, J BIOL CHEM, V271, P3474; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010	60	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33759	33765		10.1074/jbc.273.50.33759	http://dx.doi.org/10.1074/jbc.273.50.33759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837964	hybrid			2022-12-25	WOS:000077462500094
J	Callaci, S; Heyduk, E; Heyduk, T				Callaci, S; Heyduk, E; Heyduk, T			Conformational changes of Escherichia coli RNA polymerase sigma(70) factor induced by binding to the core enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER RECOGNITION; SIGMA-70 SUBUNIT; DNA; TRANSCRIPTION; CHROMATOGRAPHY; PURIFICATION; SPECIFICITY; PROTEIN	Mutants of RNA polymerase sigma(70) subunit from Escherichia coli with unique cysteine residues engineered into conserved region I (autoinhibition domain of (sigma(70)), region 2.4 (-10 DNA element binding domain), region 4.2 (-35 DNA element binding domain), and a nonconserved region between regions 1 and 2 were prepared. The chemical reactivity of the cysteine at each position was determined for free sigma(70) and sigma(70) in complex with the core polymerase and was used as a measure of a conformational response of a particular region of the protein to an interaction with the core polymerase. Both increases and decreases in cysteine reactivity were observed in the presence of core polymerase at several positions in sigma(70), providing direct physical evidence for modulation of sigma(70) conformation by the core enzyme. Binding of the core polymerase resulted in increased solvent exposure of DNA binding domains of sigma(70) and in more complex changes in the autoinhibition domain (region 1). Similar conformational changes in sigma(70) were detected using fluorescence probes covalently attached to cysteine residues engineered into sigma(70). Thus, the results obtained provided physical evidence supporting a model in which core enzyme allosterically regulates DNA binding activity of sigma(70) by "unmasking" its DNA binding domains.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Heyduk, T (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	heydukt@wpogate.slu.edu			NIGMS NIH HHS [GM50514] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM050514, R01GM050514] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1970, FED PROC, V29, P1164; BURGESS RR, 1976, J BACTERIOL, V128, P390, DOI 10.1128/JB.128.1.390-393.1976; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Busby S, 1994, Methods Mol Biol, V30, P397; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gopal V, 1997, EUR J BIOCHEM, V244, P613, DOI 10.1111/j.1432-1033.1997.00613.x; GOPAL V, 1994, J MOL BIOL, V242, P9, DOI 10.1006/jmbi.1994.1553; GREGORY JD, 1955, J AM CHEM SOC, V77, P3922, DOI 10.1021/ja01619a073; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HEYDUK T, 1985, EUR J BIOCHEM, V151, P337, DOI 10.1111/j.1432-1033.1985.tb09106.x; Ishihama A, 1990, Adv Biophys, V26, P19, DOI 10.1016/0065-227X(90)90005-E; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; MUJUMDAR RB, 1993, BIOCONJUGATE CHEM, V4, P105, DOI 10.1021/bc00020a001; NARAYANAN CS, 1983, NUCLEIC ACIDS RES, V11, P2701, DOI 10.1093/nar/11.9.2701; Owens JT, 1998, BIOCHEMISTRY-US, V37, P7670, DOI 10.1021/bi980188n; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELYUTCHENKO OA, 1988, BIOORG KHIM, V11, P480; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; TORCHINSKII YM, 1973, SULFHYDRYL DISULFIDE, P7; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WELLMAN A, 1991, BIOCHEM BIOPH RES CO, V177, P140, DOI 10.1016/0006-291X(91)91959-G; YARBROUGH LR, 1979, J BIOL CHEM, V254, P2069	34	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32995	33001		10.1074/jbc.273.49.32995	http://dx.doi.org/10.1074/jbc.273.49.32995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830052	hybrid			2022-12-25	WOS:000077329100091
J	Chapman, ER; Desai, RC; Davis, AF; Tornehl, CK				Chapman, ER; Desai, RC; Davis, AF; Tornehl, CK			Delineation of the oligomerization, AP-2 binding, and synprint binding region of the C2B domain of synaptotagmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL DIVERSITY; TRANSMITTER RELEASE; CALCIUM-DEPENDENCE; SYNAPTIC VESICLES; CA2+ CHANNELS; C-2 DOMAIN; PROTEIN; SYNTAXIN; EXOCYTOSIS; FUSION	Biochemical and genetic studies indicate that synaptotagmin I functions as a Ca2+ sensor during synaptic vesicle exocytosis and as a membrane receptor for the clathrin adaptor complex, AP-2, during endocytosis. These functions involve the interaction of two conserved domains, C2A and C2B, with effector proteins. The C2B domain mediates Ca2+-triggered synaptotagmin oligomerization, binds AP-2 and is important for the interaction of synaptotagmin with Ca2+ channels. Here, we report that these are conserved biochemical properties: Ca2+ promoted the hetero-oligomerization of synaptotagmin I with synaptotagmins III and TV, and all three synaptotagmin isoforms bound the synprint region of the alpha 1B subunit of N-type Ca2+ channels. Using chimeric and truncated C2 domains, we defined a common region of C2B that mediates oligomerization and AP-2 binding, Within this region, two adjacent lysine residues were identified that were critical for synaptotagmin oligomerization, AP-2, and synprint binding. Competition experiments demonstrated that the synprint fragment was an effective inhibitor of synaptotagmin oligomerization and also blocked binding of synaptotagmin to AP-2. In a model for the structure of C2B, the common effector binding site localized to a putative Ca2+-binding loop and a concave region formed by two beta-strands, These studies provide the first structural information regarding C2B target protein recognition and provide the means to selectively disrupt synaptotagmin-effector interactions for functional studies.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Chapman, ER (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, SMI 129,1300 Univ Ave, Madison, WI 53706 USA.			Chapman, Edwin/0000-0001-9787-8140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056827] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56827-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; Babity JM, 1997, P NATL ACAD SCI USA, V94, P2638, DOI 10.1073/pnas.94.6.2638; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chae YK, 1998, J BIOL CHEM, V273, P25659, DOI 10.1074/jbc.273.40.25659; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Damer CK, 1996, J NEUROCHEM, V67, P1661; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Henkel AW, 1996, CURR OPIN NEUROBIOL, V6, P350, DOI 10.1016/S0959-4388(96)80119-X; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kee Y, 1996, J NEUROSCI, V16, P1975; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Rettig J, 1997, J NEUROSCI, V17, P6647; Rothman JE, 1996, PROTEIN SCI, V5, P185; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; SCHELLER RH, 1995, NEURON, V14, P893; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schivell AE, 1996, J BIOL CHEM, V271, P27770, DOI 10.1074/jbc.271.44.27770; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; ULLRICH B, 1994, NEURON, V13, P1281, DOI 10.1016/0896-6273(94)90415-4; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	54	151	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32966	32972		10.1074/jbc.273.49.32966	http://dx.doi.org/10.1074/jbc.273.49.32966			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830048	hybrid			2022-12-25	WOS:000077329100087
J	Giuffre, A; Stubauer, G; Brunori, M; Sarti, P; Torres, J; Wilson, MT				Giuffre, A; Stubauer, G; Brunori, M; Sarti, P; Torres, J; Wilson, MT			Chloride bound to oxidized cytochrome c oxidase controls the reaction with nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN; RESPIRATION; MECHANISM; INHIBITION; TURNOVER; COPPER; FORMS; SITE	The reaction of nitric oxide (NO) with oxidized fast cytochrome c oxidase was investigated by stopped-flow, amperometry, and EPR, using the enzyme as prepared or after "pulsing," A rapid reduction of cytochrome a is observed with the pulsed, but not with the enzyme as prepared. The reactive species (lambda(max) = 424 nm) reacts with NO at k = 2.2 x 10(5) M-1 s(-1) at 20 degrees C and is stable for hours unless Cl- is added, in which ease it decays slowly (t(1/2) similar to 70 min) to an unreactive state (lambda(max) = 423 nm) similar to the enzyme as prepared. Thus, Cl- binding prevents a rapid reaction of NO with the oxidized binuclear center. EPR experiments show no new signals within 15 a after addition of NO to the enzyme as prepared. Amperometric measurements show that the pulsed NO-reactive enzyme reacts with high affinity and a stoichiometry of 1 NO/aa(3), whereas the enzyme as prepared reacts to a very small extent (<20%). In both cases, the reactivity is abolished by pre-incubation with cyanide. These experiments suggest that the effect of "pulsing" the enzyme, which leads to enhanced NO reactivity, arises from removing Cl- bound at the oxidized cytochrome a(3)-Cu-B site.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Essex	Brunori, M (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	brunori@axrma.uniroma1.it	Giuffrè, Alessandro/K-4341-2015; Torres, Jaume/AAJ-4510-2020; Torres, Jaume/A-2179-2011; Sarti, Paolo/D-2946-2009	Giuffrè, Alessandro/0000-0001-5301-0681; Torres, Jaume/0000-0002-1282-9727; Sarti, Paolo/0000-0002-8219-4827; Brunori, Maurizio/0000-0002-7795-1635	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTONINI E, 1977, P NATL ACAD SCI USA, V74, P3128, DOI 10.1073/pnas.74.8.3128; BAKER GM, 1987, J BIOL CHEM, V262, P595; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BOELENS R, 1982, BIOCHIM BIOPHYS ACTA, V679, P84, DOI 10.1016/0005-2728(82)90258-4; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; BRUNORI M, 1979, J BIOL CHEM, V254, P769; Brunori M, 1997, J BIOL CHEM, V272, P19870, DOI 10.1074/jbc.272.32.19870; Butler CS, 1997, BIOCHEMISTRY-US, V36, P16259, DOI 10.1021/bi971481a; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cooper CE, 1997, FEBS LETT, V414, P281, DOI 10.1016/S0014-5793(97)01009-0; Giuffre A, 1996, J BIOL CHEM, V271, P33404, DOI 10.1074/jbc.271.52.33404; LI PM, 1987, BIOCHEMISTRY-US, V26, P2091, DOI 10.1021/bi00382a005; MOODY AJ, 1991, BIOCHIM BIOPHYS ACTA, V1059, P189, DOI 10.1016/S0005-2728(05)80204-X; Moody AJ, 1996, BBA-BIOENERGETICS, V1276, P6; PALMER G, 1988, CHEM SCRIPTA, V28A, P41; SCOTT RA, 1988, ANN NY ACAD SCI, V550, P53, DOI 10.1111/j.1749-6632.1988.tb35322.x; SOULIMANE T, 1995, EUR J BIOCHEM, V227, P588, DOI 10.1111/j.1432-1033.1995.tb20429.x; STEVENS TH, 1979, P NATL ACAD SCI USA, V76, P3320, DOI 10.1073/pnas.76.7.3320; Stubauer G, 1998, BIOCHEM BIOPH RES CO, V245, P459, DOI 10.1006/bbrc.1998.8457; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; Torres J, 1998, J BIOL CHEM, V273, P8756, DOI 10.1074/jbc.273.15.8756; VERKHOVSKY MI, 1995, BIOCHEMISTRY-US, V34, P7483, DOI 10.1021/bi00022a023; WILSON MT, 1981, P NATL ACAD SCI-BIOL, V78, P7115, DOI 10.1073/pnas.78.11.7115; Wilson MT, 1997, BIOCHEM SOC T, V25, P905, DOI 10.1042/bst0250905	26	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32475	32478		10.1074/jbc.273.49.32475	http://dx.doi.org/10.1074/jbc.273.49.32475			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829979	hybrid			2022-12-25	WOS:000077329100018
J	Inohara, N; Gourley, TS; Carrio, R; Muniz, M; Merino, J; Garcia, L; Koseki, T; Hu, YM; Chen, S; Nunez, G				Inohara, N; Gourley, TS; Carrio, R; Muniz, M; Merino, J; Garcia, L; Koseki, T; Hu, YM; Chen, S; Nunez, G			Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURVIVAL-PROMOTING PROTEINS; E1B 19K; CYTOCHROME-C; APOPTOSIS; BAX; INTERACTS; CED-4; INDUCTION; BCL-X(L); FAMILY	We have identified and characterized Diva, which is a novel regulator of apoptosis. Sequence analysis revealed that Diva is a member of the Bcl-2 family of proteins containing Bcl-2 homology domain 1, 2, 3, and 4 (BH1, BH2, BH3, and BH4) regions and a carboxyl-terminal hydrophobic domain. The expression of Diva mRNA was detected in multiple embryonic tissues but was restricted to the ovary and testis in adult mice. The expression of Diva promoted the death of 293T, Ramsey, and T47D cells as well as that of primary sensory neurons, indicating that Diva is a proapoptotic protein. Significantly, Diva lacks critical residues in the conserved BH3 region that mediate the interaction between BH3-containing proapoptotic Bcl-2 homologues and their prosurvival binding partners. Consistent with this, Diva did not bind to cellular Bcl-2 family members including Bcl-2, Bcl-X-L, Bcl-w, Mcl-1, and A1/Bfl-1. Furthermore, mutants of Diva lacking the BH3 region fully retained their proapoptotic activity, confirming that Diva promotes apoptosis in a BH3-independent manner, Significantly, Diva interacted with a viral Bcl-2 homologue (vBcl-2) encoded by the Kaposi's sarcoma-associated herpesvirus. Consistent with these associations, apoptosis induced by Diva was inhibited by vBcl-2 but not by Bcl-X-L. importantly, Diva interacted with Apaf-1, an adapter molecule that activates caspase-9, a central death protease of the apoptotic pathway. The expression of Diva inhibited the binding of Bcl-X-L to Apaf-1, as determined by immunoprecipitation assays. Thus, Diva represents a novel type of proapoptotic Bcl-2 homologue that promotes apoptosis independently of the BH3 region through direct binding to Apaf-1, thus preventing Bcl-X-L from binding to the caspase-9 regulator Apaf-1.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Cantabria, Dept Biol Mol, Unidad Immunol, Santander 39011, Spain; Ctr Med Univ Geneva, Dept Pathol, CH-1211 Geneva 4, Switzerland	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Universidad de Cantabria; University of Geneva	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	Gabriel.Nunez@umich.edu		Carrio, Roberto/0000-0001-5527-8403	NCI NIH HHS [CA-64556, CA-64421] Funding Source: Medline; PHS HHS [T32A107413-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556, K04CA064421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BOYD JM, 1995, ONCOGENE, V11, P1921; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Gibson L, 1996, ONCOGENE, V13, P665; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Koseki T, 1998, P NATL ACAD SCI USA, V95, P5156, DOI 10.1073/pnas.95.9.5156; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MERINO R, 1995, J IMMUNOL, V155, P3830; NOVACK DV, 1994, AM J PATHOL, V145, P61; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	39	146	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32479	32486		10.1074/jbc.273.49.32479	http://dx.doi.org/10.1074/jbc.273.49.32479			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829980	hybrid			2022-12-25	WOS:000077329100019
J	Kosano, H; Stensgard, B; Charlesworth, MC; McMahon, N; Toft, D				Kosano, H; Stensgard, B; Charlesworth, MC; McMahon, N; Toft, D			The assembly of progesterone Receptor-hsp90 complexes using purified proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR; CHAPERONE MACHINERY; RETICULOCYTE LYSATE; MOLECULAR CHAPERONE; HSP90; BINDING; HSP70; P23; PHOSPHORYLATION	The progesterone receptor can be reconstituted into hsp90-containing complexes in vitro and the resulting complexes are needed to maintain hormone binding activity. This process requires ATP/Mg2+, K+, and several axillary proteins. We have developed a defined system for the assembly of progesterone receptor complexes using purified proteins. Five proteins are needed to form complexes that are capable of maintaining hormone binding activity. These include hsp70 and its co-chaperone, hsp40, the hsp70/hsp90-binding protein, Hop, hsp90, and the hsp90-binding protein, p23. The proteins Hip and FKBP52 were not required for this in vitro process even though they have been observed in receptor complexes, Each of the five proteins showed a characteristic concentration dependence. Similar concentrations of hsp70, hsp90, and p23 were needed for optimal assembly, but hsp40 and Hop were effective at about 1/10 the concentration of the other proteins, suggesting: that these two proteins act catalytically or are needed at levels similar to the receptor concentration. ATP was required for the functioning of both hsp70 and hsp90. The binding of hsp70 to the receptor requires hsp40 and about 10 mu M ATP; however, hsp90 binding appears to occur subsequent to hsp70 binding and is optimal with 1 mM ATP, A three-step model is presented to describe the assembly process.	Mayo Clin, Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Teikyo Univ, Fac Pharmaceut Sci, Sagamiko, Kanagawa 19901, Japan	Mayo Clinic; Teikyo University	Toft, D (corresponding author), Mayo Clin, Mayo Grad Sch, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 09140] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HOHFELD J, 1995, CELL, V83, P589; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; Pratt WB, 1998, TRENDS ENDOCRIN MET, V9, P244, DOI 10.1016/S1043-2760(98)00059-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PRATT WB, 1996, STRESS INDUCIBLE CEL, P80; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SMITH DF, 1995, SCI MED, V2, P38; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	43	192	202	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32973	32979		10.1074/jbc.273.49.32973	http://dx.doi.org/10.1074/jbc.273.49.32973			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830049	hybrid			2022-12-25	WOS:000077329100088
J	Nomizu, M; Kuratomi, Y; Malinda, KM; Song, SY; Miyoshi, K; Otaka, A; Powell, SK; Hoffman, MP; Kleinman, HK; Yamada, Y				Nomizu, M; Kuratomi, Y; Malinda, KM; Song, SY; Miyoshi, K; Otaka, A; Powell, SK; Hoffman, MP; Kleinman, HK; Yamada, Y			Cell binding sequences in mouse laminin alpha 1 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL GLOBULAR DOMAIN; AMINO-ACID-SEQUENCE; A-CHAIN; SYNTHETIC PEPTIDE; NEURITE OUTGROWTH; HEPARIN-BINDING; METASTASIS FORMATION; IKVAV SEQUENCE; TUMOR-GROWTH; S-LAMININ	Laminin-1, a multifunctional glycoprotein of the basement membrane, consists of three different subunits, alpha 1, beta 1, and gamma 1 chains. Previously, we used synthetic peptides to screen for biologically active sequences in the laminin alpha 1 chain C-terminal globular domain (G domain) and identified several cell binding sequences (Nomizu, M., Kim, W. H., Yamamura, K., Utani, A., Song, S. Y., Otaka, A., Roller, P. P., Kleinman, H. K., and Yamada, Y. (1995) J. Biol. Chem. 270, 20583-20590). Here, we identify new cell binding sequences on the remainder of the laminin alpha 1 chain by systematic peptide screening, using 208 overlapping synthetic peptides encompassing the central and N-terminal portions of the alpha 1 chain. HT-1080 cell attachment activity to the peptides was evaluated using peptide-coated plastic substrates and peptide-conjugated Sepharose beads. Twenty five peptides showed cell attachment activities on either the peptide-coated plastic substrates and/or the peptide-conjugated Sepharose beads. A-13 (RQVFQVAYIIIKA) showed strongest cell attachment activity in both the assays. Cell attachment to 14 of the peptides was inhibited by heparin. EDTA and integrin antibodies inhibited cell adhesion to two of the peptides, A-13 and A-25, suggesting that these sites likely bind to integrins. These peptides inhibited cell attachment to laminin-l but not to collagen I, suggesting these active sites are available on the intact molecule. Most of active sequences were localized on globular domains suggesting that these structures play a critical role in binding to cell-surface receptors.	NIDR, CDBRB, NIH, Bethesda, MD 20892 USA; Kyoto Univ, Fac Pharmaceut Sci, Sakyo Ku, Kyoto 606, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Kyoto University	Yamada, Y (corresponding author), NIDR, CDBRB, NIH, Bldg 30,Rm 405, Bethesda, MD 20892 USA.							BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; Bodanszky M., 1983, PEPTIDES, V5, P111; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CHARONIS AS, 1988, J CELL BIOL, V107, P1253, DOI 10.1083/jcb.107.3.1253; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Engel J., 1993, MOL CELLULAR ASPECTS, P147, DOI [10.1016/B978-0-12-593165-6.50014-0, DOI 10.1016/B978-0-12-593165-6.50014-0]; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hoffman MP, 1996, J CELL SCI, V109, P2013; HOFFMAN MP, 1995, MOL BIOL CELL, V6, P169; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER DD, 1991, J NEUROSCI, V11, P3960; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KADOYA Y, 1998, IN PRESS DEV DYN; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; Kim WH, 1998, INT J CANCER, V77, P632, DOI 10.1002/(SICI)1097-0215(19980812)77:4<632::AID-IJC25>3.0.CO;2-6; KLEINMAN HK, 1989, ARCH BIOCHEM BIOPHYS, V272, P39, DOI 10.1016/0003-9861(89)90192-6; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; NOMIZU M, 1992, J BIOL CHEM, V267, P14118; NOMIZU M, 1994, J BIOL CHEM, V269, P30386; Nomizu M, 1996, FEBS LETT, V396, P37, DOI 10.1016/0014-5793(96)01060-5; Nomizu M, 1997, J BIOL CHEM, V272, P32198, DOI 10.1074/jbc.272.51.32198; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OTAKA A, 1995, J ORG CHEM, V60, P3967, DOI 10.1021/jo00118a011; PIERSHBACHER MD, 1984, NATURE, V301, P30; Powell SK, 1998, J NEUROSCI RES, V54, P233, DOI 10.1002/(SICI)1097-4547(19981015)54:2<233::AID-JNR11>3.0.CO;2-5; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Richard BL, 1996, EXP CELL RES, V228, P98, DOI 10.1006/excr.1996.0304; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; SAKAMOTO N, 1991, CANCER RES, V51, P903; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SKUBITZ APN, 1990, CANCER RES, V50, P7612; Song SY, 1997, INT J CANCER, V71, P436, DOI 10.1002/(SICI)1097-0215(19970502)71:3<436::AID-IJC22>3.0.CO;2-C; Takagi Y, 1996, J BIOL CHEM, V271, P18074, DOI 10.1074/jbc.271.30.18074; TASHIRO K, 1994, BIOCHEM J, V302, P73, DOI 10.1042/bj3020073; TASHIRO K, 1991, J CELL PHYSIOL, V146, P451, DOI 10.1002/jcp.1041460316; TASHIRO K, 1989, J BIOL CHEM, V264, P16174; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TIMPL R, 1989, EUR J BIOCHEM, V180, P148; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L	51	137	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32491	32499		10.1074/jbc.273.49.32491	http://dx.doi.org/10.1074/jbc.273.49.32491			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829982	hybrid			2022-12-25	WOS:000077329100021
J	Conti, P; Reale, M; Barbacane, RC; Letourneau, R; Theoharides, TC				Conti, P; Reale, M; Barbacane, RC; Letourneau, R; Theoharides, TC			Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase in mice: lack of effects in genetically mast cell deficient W/W-V mice	FASEB JOURNAL			English	Article						chemokines; HDC; histamine; polysaccharide	MESSENGER-RNA; CHEMOTACTIC CYTOKINES; ATOPIC SUBJECTS; CC-CHEMOKINES; RANTES; MONOCYTE; HISTAMINE; PROTEIN; RELEASE; MCP-1	RANTES (regulated upon activation, normal T cell expressed and presumably secreted) and other chemoattractant proteins are members of the intercrine or chemokine family of proinflammatory basic polypeptides. RANTES is a prototype of the C-C chemokine subfamily that acts as a selective chemoattractant for human monocytes and CD4-positive lymphocytes and increases the adherence of monocytes to endothelial cells. However, the role of RANTES in white cells is still unclear. We report here that hrRANTES at 20 ng/50 mu l in mice causes mast cell recruitment 4 h after intramuscular injection, an effect inhibited by anti-RANTES, as evidenced by 0.1% Toluidine blue, a specific dye for coloring mast cells. Injections of PBS (50 mu l) vehicle (negative control) did not produce any appreciable inflammatory response, whereas injection of lipopolysaccharide 20 ng/50 mu l (positive control) generated a marked inflammatory state. When RANTES was injected intramuscularly in genetically mast cell-deficient W/W-v mice, the inflammatory effect was not present. The RANTES injection sites were then excised and studied under an optical and electron microscope. A Northern blot analysis was performed using a probe that was prepared to detect mRNA encoding the histidine decarboxylase (HDC) gene on excised muscle tissue. We found that hrRANTES provoked generation of HDC mRNA from muscle tissue after 4 h. These effects were inhibited by an anti-RANTES antibody and were absent in genetically mast cell-deficient mice. The increasing number of mast cells in the RANTES injection sites led to an augmentation of histamine content compared to controls (PBS). The injection of hrRANTES 20 ng/20 mu l into the sole of a rat paw confirmed the inflammatory and the mast cell recruitment potential of this chemokine. In these studies, hrRANTES injections in muscle tissue provided direct in vivo evidence that RANTES has a significant effect on mast cell, recruitment and HDC mRNA generation.	Univ Chieti, Sch Med, Div Immunol, I-66013 Chieti, Italy; Tufts Univ, Sch Med, Dept Pharmacol, Boston, MA 02111 USA	G d'Annunzio University of Chieti-Pescara; Tufts University	Conti, P (corresponding author), Univ Chieti, Sch Med, Div Immunol, Via Dei Vestini, I-66013 Chieti, Italy.		Reale, Marcella/G-4299-2013; Theoharides, Theoharis C/E-5596-2010	Reale, Marcella/0000-0002-4164-8781; 				Armstead VE, 1997, FASEB J, V11, P1271, DOI 10.1096/fasebj.11.14.9409546; AUSTEN KF, 1982, HOSP PRACT, V17, P98; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BRUNEAU G, 1992, HUM GENET, V90, P235, DOI 10.1007/BF00220068; CHOCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Conti P, 1997, J PATHOL, V183, P352, DOI 10.1002/(SICI)1096-9896(199711)183:3<352::AID-PATH938>3.0.CO;2-L; CONTI P, 1995, IMMUNOLOGY, V86, P434; Conti P, 1997, IMMUNOL LETT, V58, P101, DOI 10.1016/S0165-2478(97)00034-5; Conti P, 1997, BLOOD, V89, P4120, DOI 10.1182/blood.V89.11.4120; CONTI P, 1992, IMMUNOL LETT, V32, P117, DOI 10.1016/0165-2478(92)90103-U; CONTI P, 1995, MOL CELL BIOCHEM, V155, P61; DIMITRIADOU V, 1991, NEUROSCIENCE, V44, P97; GALLI SJ, 1987, AM J PATHOL, V127, P191; GO S, 1980, J HERED, V71, P41, DOI 10.1093/oxfordjournals.jhered.a109308; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KAY AB, 1991, J EXP MED, V173, P775, DOI 10.1084/jem.173.3.775; KITAMURA Y, 1978, BLOOD, V52, P447; KUNA P, 1992, J IMMUNOL, V149, P636; MATSUURA N, 1989, J EXP MED, V170, P1421, DOI 10.1084/jem.170.4.1421; MEININGER CJ, 1992, BLOOD, V79, P958; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; NAKANO T, 1987, FASEB J, V46, P1920; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; TAUB D, 1995, J IMMUNOL, V154, P2393; TAUB DD, 1995, J CLIN INVEST, V95, P1370, DOI 10.1172/JCI117788; THEOHARIDES TC, 1982, NATURE, V297, P229, DOI 10.1038/297229a0; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANOTTEREN GM, 1995, J IMMUNOL, V154, P1900; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153	34	74	74	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1693	1700		10.1096/fasebj.12.15.1693	http://dx.doi.org/10.1096/fasebj.12.15.1693			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837859				2022-12-25	WOS:000077574500011
J	Noel, F; Gumin, GJ; Raju, U; Tofilon, PJ				Noel, F; Gumin, GJ; Raju, U; Tofilon, PJ			Increased expression of prohormone convertase-2 in the irradiated rat brain	FASEB JOURNAL			English	Article							GROWTH-FACTOR EXPRESSION; GENE-EXPRESSION; NEUROPSYCHOLOGIC IMPAIRMENT; PROPROTEIN CONVERTASES; RADIATION INDUCTION; ASTROCYTE CULTURES; IONIZING-RADIATION; FIBROBLAST; CNS; PITUITARY	Changes in gene expression have been suggested to play a role in radiotherapy-induced central nervous system (CNS) injury. To begin to identify radiation-inducible genes in the CNS, we have applied the differential display of reverse transcription-polymerase chain reaction products to RNA extracted from the brain of adult rats. RNA was isolated from a rat brain 6 h after whole-body exposure to 10 Gy and compared with RNA from unirradiated brain. A cDNA band was consistently observed at about 600 bp in samples from the irradiated rat but not from unirradiated (control) rat. Amplification and sequencing of the cDNA revealed that it corresponded to the prohormone convertase-2 (PC2) gene, which is involved in the processing of inert prohormones and neuropeptides to their bioactive forms. Enhanced PC2 expression was detected after irradiation of neuronal cultures but not in cultures of astrocytes, suggesting that the cell type in the CNS responsible for the PC2 induction after in vivo irradiation is the neuron. These results indicate that radiation induces the expression of a neuronal enzyme that is critical to the activation of a number of prohormones and neuropeptides, which may influence the radioresponse of the CNS.	Univ Texas, Md Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tofilon, PJ (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Expt Radiat Oncol, Box 66,1515 Holcombe Blvd, Houston, TX 77030 USA.	ptofilon@notes.mdacc.tmc.edu			NCI NIH HHS [CA72156, CA50207, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072156, P30CA016672, R01CA050207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG C, 1993, NEUROLOGY, V43, P1961, DOI 10.1212/WNL.43.10.1961; BARCELLOSHOFF MH, 1993, CANCER RES, V53, P3880; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; CROSSEN JR, 1994, J CLIN ONCOL, V12, P627, DOI 10.1200/JCO.1994.12.3.627; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DEANGELIS LM, 1989, NEUROLOGY, V39, P789, DOI 10.1212/WNL.39.6.789; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Gobbel GT, 1998, J NEUROSCI, V18, P147; HOCHBERG FH, 1980, NEUROLOGY, V30, P172, DOI 10.1212/WNL.30.2.172; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; ISHIHARA H, 1993, RADIAT RES, V133, P321, DOI 10.2307/3578216; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOTAN M, 1992, J NEUROCHEM, V58, P1637, DOI 10.1111/j.1471-4159.1992.tb10035.x; MAIRE JP, 1987, AM J CLIN ONCOL-CANC, V10, P156, DOI 10.1097/00000421-198704000-00052; Marcinkiewicz M, 1996, ACTA NEUROBIOL EXP, V56, P287; MARTIN M, 1993, RADIAT RES, V134, P63, DOI 10.2307/3578502; Noel F, 1997, RADIAT RES, V147, P484, DOI 10.2307/3579506; Noel F, 1998, NEUROREPORT, V9, P1133, DOI 10.1097/00001756-199804200-00032; Oyarce AM, 1996, J NEUROCHEM, V67, P229; RUBIN P, 1992, INT J RADIAT ONCOL, V24, P93, DOI 10.1016/0360-3016(92)91027-K; SAKUMA S, 1995, RADIAT RES, V143, P1, DOI 10.2307/3578919; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHULTHEISS TE, 1992, BRIT J RADIOL, V65, P737, DOI 10.1259/0007-1285-65-777-737; SCHULTHEISS TE, 1995, INT J RADIAT ONCOL, V31, P1093, DOI 10.1016/0360-3016(94)00655-5; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; VRDOLJAK E, 1994, INT J RADIAT BIOL, V66, P739; WITTE L, 1989, CANCER RES, V49, P5066; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	36	14	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1998	12	15					1725	1730		10.1096/fasebj.12.15.1725	http://dx.doi.org/10.1096/fasebj.12.15.1725			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	147NZ	9837862				2022-12-25	WOS:000077574500014
J	Cao, J; O'Donnell, D; Vu, H; Payza, K; Pou, C; Godbout, C; Jakob, A; Pelletier, M; Lembo, P; Ahmad, S; Walker, P				Cao, J; O'Donnell, D; Vu, H; Payza, K; Pou, C; Godbout, C; Jakob, A; Pelletier, M; Lembo, P; Ahmad, S; Walker, P			Cloning and characterization of a cDNA encoding a novel subtype of rat thyrotropin-releasing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; SPINAL-CORD; FUNCTIONAL EXPRESSION; PRECURSOR PEPTIDES; MOLECULAR-CLONING; PITUITARY-GLAND; TRH RECEPTOR; IDENTIFICATION; BRAIN	A cDNA encoding a thyrotropin-releasing hormone (TRH) receptor expressed in the pituitary was previously cloned (De La Pena, P., Delgado, L. M., Del Camino, D., and Barros, F. (1992) Biochem. J. 284, 891-899; De La Pena, P., Delgado, L. M., Del Camino, D., and Barros, F. (1992) J. Biol. Chem. 267, 25703-25708; Duthie, S. M., Taylor, P, L., Anderson, J,, Cook, J., and Eidne, K, A. (1993) Mol. Cell Endocrinol. 95, R11-R15). We now describe the isolation of a rat cDNA encoding a novel subtype of TRH receptor (termed TRHR2) displaying an overall homology of 50% to the pituitary TRH receptor. Introduction of TRHR2 cDNA in HEK-293 cells resulted in expression of high affinity TRH binding with a different pharmacological profile than the pituitary TRH receptor. De novo expressed receptors were functional and resulted in stimulation of calcium transient as assessed by fluorometric imaging plate reader analysis. The message for TRHR2 was exclusive to central nervous system tissues as judged by Northern blot analysis. Studies of the expression of TRHR-2 message by in situ hybridization revealed a pattern of expression remarkably distinct (present in spinothalamic tract, spinal cord dorsal horn) from that of the pituitary TRH receptor (present in hypothalamus, and ventral horn of the spinal cord, anterior pituitary). Therefore, we have identified a novel, pharmacologically distinct receptor for thyrotropin-releasing hormone that appears to be more restricted to the central nervous system particularly to the sensory neurons of spinothalamic tract and spinal cord dorsal horn, which may account for the sensory antinociceptive actions of TRH.	Astra Res Ctr Montreal, Montreal, PQ H4S 1Z9, Canada		Walker, P (corresponding author), Astra Res Ctr Montreal, 7171 Frederick Banting,Ville St Laurent, Montreal, PQ H4S 1Z9, Canada.	philippe.walker@arcm.ca.astra.com						ALEXANDROVA M, 1991, GEN PHYSIOL BIOPHYS, V10, P287; BEHBEHANI MM, 1990, NEUROPEPTIDES, V15, P161, DOI 10.1016/0143-4179(90)90149-S; BOSCHI G, 1983, BRIT J PHARMACOL, V79, P85, DOI 10.1111/j.1476-5381.1983.tb10499.x; BURT DR, 1989, ANN NY ACAD SCI, V553, P188; CHIZH BA, 1994, NEUROPHARMACOLOGY, V33, P115, DOI 10.1016/0028-3908(94)90105-8; COCKLE SM, 1989, J BIOL CHEM, V264, P7788; DELAPENA P, 1992, BIOCHEM J, V284, P891, DOI 10.1042/bj2840891; DELAPENA P, 1992, J BIOL CHEM, V267, P25703; DUTHIE SM, 1993, MOL CELL ENDOCRINOL, V95, pR11, DOI 10.1016/0303-7207(93)90043-J; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FUKUSUMI S, 1995, REGUL PEPTIDES, V57, P115, DOI 10.1016/0167-0115(95)00026-8; GAILLARD RC, 1992, PHARM CONCEPTS FONDA, P415; HARKNESS DH, 1986, BRAIN RES, V384, P323, DOI 10.1016/0006-8993(86)91168-6; HINUMA S, 1994, BBA-GENE STRUCT EXPR, V1219, P251, DOI 10.1016/0167-4781(94)90046-9; JACKSON DA, 1988, NEUROSCI LETT, V92, P171, DOI 10.1016/0304-3940(88)90055-9; KHARKEVICH DA, 1991, BRAIN RES, V551, P110, DOI 10.1016/0006-8993(91)90920-Q; MATRE V, 1993, BIOCHEM BIOPH RES CO, V195, P179, DOI 10.1006/bbrc.1993.2027; MURRAY NE, 1977, MOL GEN GENET, V150, P53, DOI 10.1007/BF02425325; PHILLIPS WJ, 1989, MOL PHARMACOL, V35, P533; SATOH T, 1993, MOL BRAIN RES, V19, P175, DOI 10.1016/0169-328X(93)90165-L; SATOH T, 1993, MOL BRAIN RES, V20, P353, DOI 10.1016/0169-328X(93)90062-T; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; SELLAR RE, 1993, J MOL ENDOCRINOL, V10, P199, DOI 10.1677/jme.0.0100199; SPRENGEL R, 1994, HDB RECEPTORS CHANNE, P153; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TOLEDOARAL J, 1993, J PHYSIOL-LONDON, V472, P327, DOI 10.1113/jphysiol.1993.sp019949; WU P, 1988, REGUL PEPTIDES, V22, P347, DOI 10.1016/0167-0115(88)90111-5; WU P, 1988, BRAIN RES, V456, P22, DOI 10.1016/0006-8993(88)90342-3; WU P, 1987, ENDOCRINOLOGY, V121, P108, DOI 10.1210/endo-121-1-108; WU W, 1992, NEUROSCI LETT, V142, P143, DOI 10.1016/0304-3940(92)90359-F; ZABAVNIK J, 1993, NEUROSCIENCE, V53, P877, DOI 10.1016/0306-4522(93)90632-P	32	114	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32281	32287		10.1074/jbc.273.48.32281	http://dx.doi.org/10.1074/jbc.273.48.32281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822707	hybrid			2022-12-25	WOS:000077207000089
J	Folkers, GE; van der Burg, B; van der Saag, PT				Folkers, GE; van der Burg, B; van der Saag, PT			Promoter architecture, cofactors, and orphan receptors contribute to cell-specific activation of the retinoic acid receptor beta 2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-DEPENDENT ACTIVATION; HUMAN LUNG-CANCER; EMBRYONAL CARCINOMA-CELLS; THYROID-HORMONE-RECEPTOR; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; X-RECEPTOR; COUP-TF; NUCLEAR RECEPTORS; RESPONSE ELEMENT	Expression of retinoic acid receptor beta (RAR beta) is spatially and temporally restricted during embryonal development. Also during retinoic acid (RA)-dependent embryonal carcinoma (EC) cell differentiation, RAR(beta) expression is initially up-regulated, while in later phases of differentiation expression is down-regulated, by an unknown mechanism. To gain insight into the regulation of RAR beta, we studied the activity of the RAR beta 2 promoter and mutants thereof in various cell lines. While the RAR beta 2 promoter is activated by RA in a limited number of cell lines, synthetic RA-responsive reporters are activated in most cell types. We show that the expression levels of proteins that bind to the beta-retinoic acid response element (RAR/retinoid X receptors and orphan receptors) and also the differential expression of a number of coactivators modulate the RA response on both natural and synthetic reporters, We further show that cell type-specific activation of the RAR beta 2 promoter is dependent on the promoter architecture including the spacing between retinoic acid response element and TATA-box and initiator sequence (beta INR). Mutation within these regions caused a decrease in the activity of this promoter in responsive EC cells, while an increase in activity in non-EC cell lines was observed, Cell-specific complexes were formed on the beta INR, suggesting that the beta INR contributes to cell-specific activation of the promoter. On this basis we propose that promoter context-dependent and more general RA response-determining mechanisms contribute to cell-specific RA-dependent activation of transcription.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	van der Saag, PT (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.		Folkers, Gert E/C-2863-2009	Folkers, Gert E/0000-0003-1070-0505				Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BUTLER AJ, 1995, NUCLEIC ACIDS RES, V23, P4143, DOI 10.1093/nar/23.20.4143; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DAVIS KD, 1993, ENDOCRINOLOGY, V132, P1469, DOI 10.1210/en.132.4.1469; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; Folkers GE, 1996, J STEROID BIOCHEM, V56, P119, DOI 10.1016/0960-0760(95)00229-4; FOLKERS GE, 1993, MOL ENDOCRINOL, V7, P616, DOI 10.1210/me.7.4.616; FOLKERS GE, 1995, MOL CELL BIOL, V15, P5868; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; GEBERT JF, 1991, ONCOGENE, V6, P1859; Gudas Lorraine J., 1994, P443; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781; Hofmann Clementine, 1994, P387; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG SW, 1995, J BIOL CHEM, V270, P3683, DOI 10.1074/jbc.270.8.3683; JONK LJC, 1992, MECH DEVELOP, V36, P165, DOI 10.1016/0925-4773(92)90067-T; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KRUYT FAE, 1992, NUCLEIC ACIDS RES, V20, P6393, DOI 10.1093/nar/20.23.6393; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; KRUYT FAE, 1993, MOL ENDOCRINOL, V7, P604, DOI 10.1210/me.7.4.604; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; Leng X, 1996, MOL CELL BIOL, V16, P2332; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; NEVINS JR, 1993, SEMIN VIROL, V4, P25, DOI 10.1016/1044-5773(93)80005-9; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Okuda A, 1998, EMBO J, V17, P2019, DOI 10.1093/emboj/17.7.2019; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; QIU YH, 1994, TRENDS ENDOCRIN MET, V5, P234, DOI 10.1016/1043-2760(94)P3081-H; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Sanguedolce MV, 1997, EMBO J, V16, P2861, DOI 10.1093/emboj/16.10.2861; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SHEN S, 1992, INT J DEV BIOL, V36, P465; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; VALCARCEL R, 1994, GENE DEV, V8, P3068, DOI 10.1101/gad.8.24.3068; VANDERLEEDE BJM, 1993, MOL CARCINOGEN, V8, P112, DOI 10.1002/mc.2940080208; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; XIAO JH, 1995, J BIOL CHEM, V270, P3001, DOI 10.1074/jbc.270.7.3001; XU XC, 1994, CANCER RES, V54, P3580; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHANG XK, 1994, CANCER RES, V54, P5663	86	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32200	32212		10.1074/jbc.273.48.32200	http://dx.doi.org/10.1074/jbc.273.48.32200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822698	hybrid			2022-12-25	WOS:000077207000080
J	Graness, A; Adomeit, A; Heinze, R; Wetzker, R; Liebmann, C				Graness, A; Adomeit, A; Heinze, R; Wetzker, R; Liebmann, C			A novel mitogenic signaling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of a G(q/11) protein, phosphatidylinositol 3-kinase beta, and protein kinase C is an element of	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CYCLIC-AMP PATHWAY; COUPLED RECEPTORS; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; FAMILY MEMBERS; 3T3 CELLS; GAMMA; EPSILON	The signaling routes connecting G protein-coupled receptors to the mitogen-activated protein kinase (MAPK) pathway reveal a high degree of complexity and cell specificity. In the human colon carcinoma cell line SW-480, we detected a mitogenic effect of bradykinin (BK) that is mediated via a pertussis toxin-insensitive G protein of the G(q/11) family and that involves activation of MAPK. Both BK-induced stimulation of DNA synthesis and activation of MAPK: in response to BK were abolished by two different inhibitors of phosphatidylinositol 3-kinase (PI3K), wortmannin and LY 294002, as well as by two different inhibitors of protein kinase C (PBC), bisindolylmaleimide and Ro 31-8220. Stimulation of SW-480 cells by BK led to increased formation of PI3K lipid products (phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate) and to enhanced translocation of the PKC epsilon isoform hom the cytosol to the membrane. Both effects of BK were inhibited by wortmannin, too. Using subtype-specific antibodies, only the PIER subunits p110 beta and p85, but not p110 alpha and p110 gamma, were detected in SW-480 cells. Finally, p110 beta was found to be co-immunopreaipitated with PKC epsilon. Our data suggest that in SW-480 cells, (i) dimeric PI3K beta is activated via a G(q/11) protein; (ii) PKC epsilon is a downstream target of PI3K beta mediating the mitogenic signal to the MAPK pathway; and (iii) PKC epsilon associates with the p110 subunit of PI3K beta. Thus, these results add a novel possibility to the emerging picture of multiple pathways linking G protein-coupled receptors to MAPK.	Univ Jena, Biol & Pharmaceut Fac, Inst Biochem & Biophys, D-07743 Jena, Germany; Univ Jena, Fac Med, Res Grp Mol Cell Biol, D-07747 Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Liebmann, C (corresponding author), Univ Jena, Biol & Pharmaceut Fac, Inst Biochem & Biophys, Philosophenweg 12, D-07743 Jena, Germany.		Wetzker, Reinhard/AAD-8713-2019					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Asano M, 1997, BRIT J PHARMACOL, V120, P617, DOI 10.1038/sj.bjp.0700955; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hazeki O, 1998, LIFE SCI, V62, P1555, DOI 10.1016/S0024-3205(98)00106-4; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Liebmann C, 1996, J BIOL CHEM, V271, P31098, DOI 10.1074/jbc.271.49.31098; Liebmann C, 1996, BIOCHEM J, V313, P109, DOI 10.1042/bj3130109; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SETHI T, 1991, CANCER RES, V51, P3621; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; TOKER A, 1994, J BIOL CHEM, V269, P32358; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; XU N, 1993, P NATL ACAD SCI USA, V88, P5582; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	42	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32016	32022		10.1074/jbc.273.48.32016	http://dx.doi.org/10.1074/jbc.273.48.32016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822674	hybrid			2022-12-25	WOS:000077207000056
J	Porter, RM; Hutcheson, AM; Rugg, EL; Quinlan, RA; Lane, EB				Porter, RM; Hutcheson, AM; Rugg, EL; Quinlan, RA; Lane, EB			cDNA cloning, expression, and assembly characteristics of mouse keratin 16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; EPIDERMAL KERATINS; COILED-COIL; I KERATINS; GENES; INVITRO; CELLS; DIFFERENTIATION; POLYPEPTIDES; CONSEQUENCES	There has been speculation as to the existence of the mouse equivalent of human type I keratin 16 (K16), The function of this keratin is particularly intriguing because, in normal epidermis, it is usually confined to hair follicles and only becomes expressed in the suprabasal intrafollicular regions when the epidermis is traumatized. Previous studies suggested that K16 is highly expressed in the skin of mice carrying a truncated K10 gene. We therefore used the skin of heterozygous and homozygous mice to create a cDNA library, and we report here the successful cloning and sequencing of mouse K16, Recent in vitro studies suggested that filaments formed by human K16 are shorter than those formed by other type I keratins, One hypothesis put forward was that a proline residue in the 1B subdomain of the helical domain was responsible, The data presented here demonstrate that this proline is not conserved between mouse and human, casting doubt on the proposed function of this proline residue in filament assembly. In vitro assembly studies showed that mouse K16 produced long filaments in vitro, Also, in contrast to previous observations, transfection studies of PtK2 cells showed that mouse K16 (without the proline) and also human K16 (with the proline) can incorporate into the endogenous K8/K18 network without detrimental effect. In addition, K16 from both species can form filaments de novo when transfected with human K5 into immortalized human lens epithelial cells, which do not express keratins, These results suggest that reduced assembly capabilities due to unusual sequence characteristics in helix 1B are not the key to the unique function of K16, Rather, these data implicate the tail domain of K16 as the more likely protein domain that determines the unique functions.	Univ Dundee, Dept Anat & Physiol, Canc Res Campaign Cell Struct Res Grp, Dundee DD1 5EH, Scotland; Univ Dundee, Inst Med Sci, Dept Biochem, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Porter, RM (corresponding author), Univ Dundee, Dept Anat & Physiol, Canc Res Campaign Cell Struct Res Grp, Dow St,Wellcome Trust Bldg Complex, Dundee DD1 5EH, Scotland.	R.M.PORTER@dundee.ac.uk	Quinlan, Roy/A-1348-2012	Quinlan, Roy/0000-0003-0644-4123	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; Baker A, 1997, GENE THER, V4, P773, DOI 10.1038/sj.gt.3300471; CONWAY JF, 1988, INT J BIOL MACROMOL, V10, P79, DOI 10.1016/0141-8130(88)90015-3; Corden L D, 1996, Exp Dermatol, V5, P297, DOI 10.1111/j.1600-0625.1996.tb00133.x; DOWLING LM, 1986, BIOCHEM J, V236, P695, DOI 10.1042/bj2360695; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; HATZFELD M, 1985, J CELL BIOL, V101, P1826, DOI 10.1083/jcb.101.5.1826; HATZFELD M, 1990, J CELL BIOL, V110, P1199, DOI 10.1083/jcb.110.4.1199; HESS JF, 1993, CURR EYE RES, V12, P77, DOI 10.3109/02713689308999499; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; KNAPP B, 1987, J BIOL CHEM, V262, P938; LETAI A, 1992, J CELL BIOL, V116, P1181, DOI 10.1083/jcb.116.5.1181; MANSBRIDGE JN, 1987, J INVEST DERMATOL, V89, P253, DOI 10.1111/1523-1747.ep12471216; MCCORMICK MB, 1991, J CELL BIOL, V113, P1111, DOI 10.1083/jcb.113.5.1111; MCGUIRE J, 1984, BRIT J DERMATOL, V27, P111; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; MCLEAN WHI, 1995, NAT GENET, V9, P273, DOI 10.1038/ng0395-273; MOLL R, 1984, ARCH DERMATOL RES, V276, P349, DOI 10.1007/BF00413355; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; OGUIN WM, 1990, CELLULAR MOL BIOL IN, P301; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Paladini RD, 1996, J CELL BIOL, V132, P381, DOI 10.1083/jcb.132.3.381; PALADINI RD, 1995, BIOCHEM BIOPH RES CO, V215, P517, DOI 10.1006/bbrc.1995.2495; PARAMIO JM, 1994, EXP CELL RES, V215, P319, DOI 10.1006/excr.1994.1348; Porter RM, 1998, J INVEST DERMATOL, V110, P951, DOI 10.1046/j.1523-1747.1998.00218.x; Porter RM, 1996, J CELL BIOL, V132, P925, DOI 10.1083/jcb.132.5.925; QUINLAN RA, 1985, ANN NY ACAD SCI, V455, P282, DOI 10.1111/j.1749-6632.1985.tb50418.x; QUINLAN RA, 1992, CURR EYE RES, V11, P909, DOI 10.3109/02713689209033488; QUINLAN RA, 1989, J CELL SCI, V93, P71; RAYCHAUDHURY A, 1986, MOL CELL BIOL, V6, P539, DOI 10.1128/MCB.6.2.539; Reddan JR, 1997, MOL BIOL CELL, V8, P1654; Reichelt J, 1997, J CELL SCI, V110, P2175; ROSENBERG M, 1988, MOL CELL BIOL, V8, P722, DOI 10.1128/MCB.8.2.722; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; SAWADA K, 1995, CURR EYE RES, V14, P545, DOI 10.3109/02713689508998401; Schweizer Juergen, 1993, P33; STARK HJ, 1987, DIFFERENTIATION, V35, P236, DOI 10.1111/j.1432-0436.1987.tb00174.x; STEINERT PM, 1990, J BIOL CHEM, V265, P8766; STEINERT PM, 1990, CELLULAR MOL BIOL IN, P353; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAHASHI K, 1995, J BIOL CHEM, V270, P18581, DOI 10.1074/jbc.270.31.18581; TROYANOVSKY SM, 1992, EUR J CELL BIOL, V59, P127; TYNER AL, 1986, J CELL BIOL, V103, P1945, DOI 10.1083/jcb.103.5.1945; Wawersik M, 1997, J BIOL CHEM, V272, P32557, DOI 10.1074/jbc.272.51.32557; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILSON CL, 1994, BRIT J DERMATOL, V131, P191	48	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32265	32272		10.1074/jbc.273.48.32265	http://dx.doi.org/10.1074/jbc.273.48.32265			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822705	Green Accepted, hybrid			2022-12-25	WOS:000077207000087
J	Kondo, S; Shinomura, Y; Kanayama, S; Higashimoto, Y; Kiyohara, T; Zushi, S; Kitamura, S; Ueyama, H; Matsuzawa, Y				Kondo, S; Shinomura, Y; Kanayama, S; Higashimoto, Y; Kiyohara, T; Zushi, S; Kitamura, S; Ueyama, H; Matsuzawa, Y			Modulation of apoptosis by endogenous Bcl-x(L) expression in MKN-45 human gastric cancer cells	ONCOGENE			English	Article						bcl-x(L); antisense oligonucleotides; bak; apoptosis; fas; chemotherapy	CHEMOTHERAPY-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; BCL-2 HOMOLOG BAK; IN-VIVO PATTERNS; IMMUNOHISTOCHEMICAL ANALYSIS; SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; ANTICANCER AGENTS; FAS ANTIGEN; DEATH	This study was designed to clarify the role of endogenous Bcl-x(L) expression in modulating apoptosis of malignant cells. Administration of bcl-x-antisense oligonucleotides decreased Bcl-x(L) protein levels in the MKN-45 human gastric cancer cell line. The decrease in Bcl-x(L) protein content resulted in increased cell death induced by serum deprivation or Fas-antibody administration. Flow cytometric analysis revealed that the increased apoptotic cell death was more prominent in bcl-x-antisense-treated cells as compared to control cells, bcl-x-sense-treated cells, or bcl-x-nonsense-treated cells. To inhibit the effect of intrinsic Bcl-x(L) protein, we overexpressed Bak, which binds Bcl-x(L) and inhibits the anti-apoptotic effect of Bcl-x(L), by transfection into MKN-45 cells. Bak-overexpressing cells showed increased apoptotic cell death induced by Fas-antibody when compared to parent cells and MKN-neo-transfected cells. Bak-overexpressing cells also showed greater sensitization to 5-fluorouracil and cisplatin than parent cells and MKN-neo-transfected cells. In conclusion, we demonstrated that administration of bcl-x-antisense oligonucleotides or overexpression of Bak protein induces sensitization to apoptosis in MKN-45 gastric cancer cells, suggesting that endogenous Bcl-x, expression in cancer cells is an important modulator of apoptosis.	Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 5650871, Japan	Osaka University	Kondo, S (corresponding author), Osaka Univ, Sch Med, Dept Internal Med 2, 2-2 Yanadaoka, Suita, Osaka 5650871, Japan.							Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHERBONNELASSER.C, 1997, ONCOGENE, V13, P1489; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Decaudin D, 1997, CANCER RES, V57, P62; DOLE M, 1994, CANCER RES, V54, P3253; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Hayashi H, 1997, JPN J CANCER RES, V88, P49, DOI 10.1111/j.1349-7006.1997.tb00301.x; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAMESAKI S, 1993, CANCER RES, V53, P4251; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Kondo S, 1996, INT J CANCER, V68, P727, DOI 10.1002/(SICI)1097-0215(19961211)68:6<727::AID-IJC6>3.0.CO;2-5; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V149, P1449; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROUQUET N, 1995, ONCOGENE, V11, P1061; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZORNIG M, 1995, ONCOGENE, V10, P2397	32	29	38	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2585	2591		10.1038/sj.onc.1202194	http://dx.doi.org/10.1038/sj.onc.1202194			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840921				2022-12-25	WOS:000077058900005
J	Boucheron, C; Dumon, S; Constantino, S; Santos, R; Moriggl, R; Hennighausen, L; Gisselbrecht, S; Gouilleux, F				Boucheron, C; Dumon, S; Constantino, S; Santos, R; Moriggl, R; Hennighausen, L; Gisselbrecht, S; Gouilleux, F			A single amino acid in the DNA binding regions of STAT5A and STAT5B confers distinct DNA binding specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROLEUKEMIA CELL-LINE; RECEPTOR-ALPHA GENE; GROWTH-HORMONE; ERYTHROID-DIFFERENTIATION; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; STAT5-LIKE FACTOR; LYMPHOID-CELLS	STAT5A and STAT5B are two highly related transcription factors encoded by two distinct genes. STAT5A and STAT5B are activated by a broad range of cytokines and growth factors, Although they can be differentially activated, the functional difference between these two molecules relative to their structure is not known. Here we demonstrated that STAT5A and STAT5B homodimers have distinct DNA binding preferences; Chimeric STATE molecules allowed us to identify a region between amino acid 420 and 545 responsible for the DNA binding specificity. This region is located in the previously characterized DNA binding region of STAT proteins. Sequence comparison between STAT5A and STAT5B from different species showed a difference of 5 amino acids in the region 420-545 between STAT5A and STAT5B. Substitution of these amino acids demonstrated that a glycine residue at position 433 in STAT5B and a glutamic residue at a similar position in STAT5A determined the DNA binding specificity. These data indicate that STAT5A and STAT5B homodimers may have distinct function and probably regulate the expression of common as well as distinct genes.	Hop Cochin, Inst Cochin Genet Mol, INSERM, U363, F-75014 Paris, France; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN 38105 USA; NIH, Biochem & Metab Lab, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA	Gouilleux, F (corresponding author), Hop Cochin, Inst Cochin Genet Mol, INSERM, U363, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Santos, Susana/AAM-8902-2021; Moriggl, Richard/H-8118-2019	Moriggl, Richard/0000-0003-0918-9463; Hennighausen, Lothar/0000-0001-8319-9841; Constantino Rosa Santos, Susana/0000-0002-5711-1292; Gouilleux, Fabrice/0000-0001-6047-1718				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Dajee M, 1996, MOL ENDOCRINOL, V10, P171, DOI 10.1210/me.10.2.171; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Messner B, 1997, J IMMUNOL, V159, P3330; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; Shuai K, 1996, ONCOGENE, V13, P247; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zamorano J, 1998, J IMMUNOL, V160, P3502; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	62	67	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					33936	33941		10.1074/jbc.273.51.33936	http://dx.doi.org/10.1074/jbc.273.51.33936			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852045	hybrid, Green Submitted			2022-12-25	WOS:000077542200011
J	Chiche, JD; Schlutsmeyer, SM; Bloch, DB; de la Monte, SM; Roberts, JD; Filippov, G; Janssens, SP; Rosenzweig, A; Bloch, KD				Chiche, JD; Schlutsmeyer, SM; Bloch, DB; de la Monte, SM; Roberts, JD; Filippov, G; Janssens, SP; Rosenzweig, A; Bloch, KD			Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide cGMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; ANGIOTENSIN-II; ENDOTHELIAL-CELLS; BOVINE AORTA; PROLIFERATION; EXPRESSION; INHIBITION; VASODILATORS; ACTIVATION; ADHESION	Studies in vitro have underestimated the importance of cGMP-dependent protein kinase (PKG) in the modulation of vascular smooth muscle cell (SMC) proliferation and apoptosis in vivo, This is attributable, in part, to a rapid decline in PKG levels as vascular SMC are passaged in culture, We used a recombinant adenovirus encoding PKG (Ad.PKG) to augment kinase activity in cultured rat pulmonary artery SMC (RPaSMC), Incubation of Ad.PKG-infected RPaSMC (multiplicity of infection = 200) with 8-Br-cGMP decreased serum-stimulated DNA synthesis by 85% and cell proliferation at day 5 by 74%. The effect of 8-Br-cGMP on DNA synthesis in Ad.PKG-infected RPaSMC was blocked by KT5823 (PKG inhibitor), but not by KT5720 (cAMP-dependent protein kinase inhibitor). A nitric oxide (NO) donor compound, S-nitrosoglutathione, at concentrations as low as 100 nM, inhibited DNA synthesis in Ad.PKG-infected RPaSMC, but not in uninfected cells or in cells infected with a control adenovirus. In addition, 8-Br-cGMP and S-nitrosoglutathione induced apoptosis in serum-deprived RPaSMC infected with Ad.PKG, but not in uninfected cells or in cells infected with a control adenovirus, These results demonstrate that modulation of PKG levels in vascular SMC can alter the sensitivity of these cells to NO and cGMP, Moreover, these observations suggest an important role for PKG in the regulation of vascular SMC proliferation and apoptosis by NO and cGMP.	Massachusetts Gen Hosp E, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Dept Anesthesia & Crit Care, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Div Cardiol, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Arthritis Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Gen Med Serv, Mol Hepatol Div, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Anesthesia, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA; Catholic Univ Louvain, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	Harvard University; Harvard University; Universite Catholique Louvain	Chiche, JD (corresponding author), Massachusetts Gen Hosp E, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.	chiche@etherdome.mgh.harvard.edu	Chiche, Jean-Daniel/P-5220-2017; de la monte, suzanne/L-7670-2019	Chiche, Jean-Daniel/0000-0002-6433-6254; de la monte, suzanne/0000-0001-5886-2306; Bloch, Donald/0000-0002-6828-4754	NHLBI NIH HHS [K08 HL004237] Funding Source: Medline; NIAAA NIH HHS [AA-10102] Funding Source: Medline; NIAMS NIH HHS [AR-01866] Funding Source: Medline; NIDDK NIH HHS [DK-51179] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001866] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010102] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON PG, 1996, J VASC RES S1, V33, P12; ASSENDER JW, 1992, BIOCHEM J, V288, P527, DOI 10.1042/bj2880527; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; Chubet RG, 1996, BIOTECHNIQUES, V20, P136; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; CORNWELL TL, 1994, AM J PHYSIOL-CELL PH, V267, pC1405, DOI 10.1152/ajpcell.1994.267.5.C1405; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Dey NB, 1998, CIRC RES, V82, P139; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1997, CIRC RES, V81, P970; Dong G, 1996, J BIOL CHEM, V271, P29969, DOI 10.1074/jbc.271.47.29969; DUBEY RK, 1995, J CLIN INVEST, V96, P141, DOI 10.1172/JCI118014; DZAU VJ, 1991, HYPERTENSION, V18, pS115, DOI 10.1161/01.HYP.18.5_Suppl.III115; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; Fukuo K, 1996, HYPERTENSION, V27, P823, DOI 10.1161/01.HYP.27.3.823; Gambaryan S, 1998, P NATL ACAD SCI USA, V95, P9003, DOI 10.1073/pnas.95.15.9003; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Gibbons GH, 1997, AM J CARDIOL, V79, P3, DOI 10.1016/S0002-9149(97)00122-7; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; GUO JP, 1995, AM J PHYSIOL-HEART C, V269, pH1122, DOI 10.1152/ajpheart.1995.269.3.H1122; Hajjar RJ, 1998, P NATL ACAD SCI USA, V95, P5251, DOI 10.1073/pnas.95.9.5251; HAMON M, 1994, CIRCULATION, V90, P1357, DOI 10.1161/01.CIR.90.3.1357; HOBBS AJ, 1997, NITRIC OXIDE LUNG, P1; ISHIMORI K, 1994, REV SCI INSTRUM, V65, P1; Janssens S, 1998, CIRCULATION, V97, P1274, DOI 10.1161/01.CIR.97.13.1274; KANAI AJ, 1995, CIRC RES, V77, P284, DOI 10.1161/01.RES.77.2.284; KARIYA K, 1989, ATHEROSCLEROSIS, V80, P143, DOI 10.1016/0021-9150(89)90022-1; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KOLPAKOV V, 1995, CIRC RES, V76, P305, DOI 10.1161/01.RES.76.2.305; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LINCOLN TM, 1994, HYPERTENSION, V23, P1141, DOI 10.1161/01.HYP.23.6.1141; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Marks DS, 1995, J CLIN INVEST, V96, P2630, DOI 10.1172/JCI118328; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCNAMARA DB, 1993, BIOCHEM BIOPH RES CO, V193, P291, DOI 10.1006/bbrc.1993.1622; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; Nishio E, 1996, BIOCHEM BIOPH RES CO, V221, P163, DOI 10.1006/bbrc.1996.0563; Pollman MJ, 1996, CIRC RES, V79, P748, DOI 10.1161/01.RES.79.4.748; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruth P, 1997, J BIOL CHEM, V272, P10522; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; Sarkar R, 1997, AM J PHYSIOL-HEART C, V272, pH1810, DOI 10.1152/ajpheart.1997.272.4.H1810; Sarkar R, 1996, CIRC RES, V78, P225, DOI 10.1161/01.RES.78.2.225; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; Soff GA, 1997, J CLIN INVEST, V100, P2580, DOI 10.1172/JCI119801; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; Tzeng E, 1997, SURGERY, V122, P255, DOI 10.1016/S0039-6060(97)90016-7; WOLFE L, 1989, J BIOL CHEM, V264, P7734; Yan ZQ, 1998, CIRC RES, V82, P21; YU FS, 1989, AM REV RESPIR DIS, V139, P1144, DOI 10.1164/ajrccm/139.5.1144; Yu SM, 1997, CIRCULATION, V95, P1269; Zhao ZH, 1997, BBA-MOL CELL RES, V1359, P143, DOI 10.1016/S0167-4889(97)00093-1	60	142	145	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34263	34271		10.1074/jbc.273.51.34263	http://dx.doi.org/10.1074/jbc.273.51.34263			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852090	Green Published, hybrid			2022-12-25	WOS:000077542200056
J	Kim, BS; Cheng, HL; Margolis, B; Feldman, EL				Kim, BS; Cheng, HL; Margolis, B; Feldman, EL			Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; P21(RAS)-GTP FORMATION; FUNCTIONAL IMPORTANCE; NEURITE OUTGROWTH; IRS-1; TRANSDUCTION; RAS	The major substrates for the type I insulin-like growth factor (IGF-I) receptor are Shc and insulin receptor substrate (IRS) proteins. In the current study, we report that IGF-I induces a sustained tyrosine phosphorylation of Shc and its association with Grb2 in SH-SY5Y human neuroblastoma cells. The time course of Shc tyrosine phosphorylation parallels the time course of IGF-l-stimulated activation of extracellular signal-regulated kinase (ERK). Transfection of SH-SY5Y cells with a p52 Shc mutant decreases Shc tyrosine phosphorylation and Shc-Grb2 association. This results in the inhibition of IGF-I-mediated ERK tyrosine phosphorylation and neurite outgrowth. In contrast, IGF-I induces a transient tyrosine phosphorylation of IRS-2 and an association of IRS-2 with Grb2. The time course of IRS-2 tyrosine phosphorylation and IRS-2-Grb2 and IRS-2-p85 association closely resembles the time course of IGF-I-mediated membrane ruffling. Treating cells with the phosphatidylinositol 3'-kinase inhibitors wortmannin and LY294002 blocks IGF-I-induced membrane ruffling. The ERK kinase inhibitor PD98059, as well as transfection with the p52 Shc mutant, has no effect on IGF-I-mediated membrane ruffling. Immunolocalization studies show IRS-2 and Grb2, but not Shc, concentrated at the tip of the extending growth cone where membrane ruffling is most active. Collectively, these results suggest that the association of Shc with Grb2 is essential for IGF-I-mediated neurite outgrowth, whereas the IRS-2-Grb2-phosphatidylinositol 3'-kinase complex may regulate growth cone extension and membrane ruffling.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med & Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge 3,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.			Feldman, Eva/0000-0002-9162-2694	NINDS NIH HHS [R01 NS36778, R01 NS38849] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036778, R01NS038849] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHULER D, 1994, MOL ENDOCRINOL, V8, P1139, DOI 10.1210/me.8.9.1139; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; COOPER MJ, 1991, PROG CLIN BIOL RES, V366, P343; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Ishihara H, 1997, J BIOL CHEM, V272, P9581; Ito T, 1996, MOL CELL BIOL, V16, P943; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; KIM B, 1998, IN PRESS ENDOCRINOLO; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Singleton JR, 1996, CANCER RES, V56, P4522; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; VANOBBERGHEN E, 1994, DIABETOLOGIA, V37, pS125, DOI 10.1007/BF00400836; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	66	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34543	34550		10.1074/jbc.273.51.34543	http://dx.doi.org/10.1074/jbc.273.51.34543			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852124	hybrid			2022-12-25	WOS:000077542200090
J	Ray, K; Clapp, P; Goldsmith, PK; Spiegel, AM				Ray, K; Clapp, P; Goldsmith, PK; Spiegel, AM			Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; HUMAN CA2+ RECEPTOR; SENSING RECEPTOR; FUNCTIONAL EXPRESSION; EXTRACELLULAR CALCIUM; MOLECULAR-CLONING; MULTIGENE FAMILY; HORMONE-BINDING; LIGAND-BINDING; RAT	The human calcium receptor (hCaR) is a G-protein-coupled receptor containing 11 potential N-linked glycosylation sites in the large extracellular domain. The number of potential N-linked glycosylation sites actually modified, and the effect on cell surface expression and signal transduction of blocking glycosylation at these sites, was examined by site-directed mutagenesis. Asparagine residues of the consensus sequences (Asn-Xaa-Ser/Thr) for N-linked glycosylation were mutated to glutamine individually and in various combinations to disrupt the potential N-linked glycosylation sites in the context of the full-length receptor. The cDNA constructs were transiently transfected into HEK-293 cells lacking endogeneous hCaR, and expressed receptors were analyzed by mobility differences on irnmunoblots, glycosidase digestion, intact cell enzyme-linked immunoassay, and extracellular calcium-stimulated phosphoinositide hydrolysis assay. Immunoblot analyses and glycosidase digestion studies of the wild type versus mutant receptors demonstrate that, of the 11 potential sites for N-linked glycosylation, eight sites (Asn-90, -130, -261, -287, -446, -468, -488, and -541) are glycosylated; the three remaining sites (Asn-386, -400, and -594) may not be efficiently glycosylated in the native receptor. Sequential mutagenesis of multiple N-linked glycosylation sites and analyses by immunoblotting, immunofluorescence, biotinylation of cell surface proteins, and intact cell enzyme-linked immunoassay indicated that disruption of as few as three glycosylation sites impairs proper processing and expression of the receptor at the cell surface, Disruption of five glycosylation sites reduced cell surface expression by 50-90% depending on which five sites were disrupted. Phosphoinositide hydrolysis assay results for various glycosylation-defective mutant receptors in general correlated well with the level of cell surface expression. Our results demonstrate that among 11 potential N-linked glycosylation sites on the hCaR, eight sites are actually utilized; glycosylation of at least three sites is critical for cell surface expression of the receptor, but glycosylation does not appear to be critical for signal transduction.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Spiegel, AM (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 9N-222, Bethesda, MD 20892 USA.		Centeno, Patricia Pacios/O-8368-2016					Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15; Butters RR, 1997, J BONE MINER RES, V12, P568, DOI 10.1359/jbmr.1997.12.4.568; Chattopadhyay N, 1997, BIOL CHEM, V378, P759; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Davis DP, 1997, MOL ENDOCRINOL, V11, P550, DOI 10.1210/me.11.5.550; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; DING DXH, 1995, J BIOL CHEM, V270, P24580, DOI 10.1074/jbc.270.41.24580; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Goldsmith PK, 1997, J BONE MINER RES, V12, P1780, DOI 10.1359/jbmr.1997.12.11.1780; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; IMPERIALI B, 1995, P NATL ACAD SCI USA, V92, P97, DOI 10.1073/pnas.92.1.97; Innamorati G, 1996, MOL PHARMACOL, V50, P467; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KIFOR O, 1990, J BONE MINER RES, V5, P1003; LIU XB, 1993, J BIOL CHEM, V268, P1513; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RODRIGUEZ CG, 1995, J BIOL CHEM, V270, P25178, DOI 10.1074/jbc.270.42.25178; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722	31	125	127	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 18	1998	273	51					34558	34567		10.1074/jbc.273.51.34558	http://dx.doi.org/10.1074/jbc.273.51.34558			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148PZ	9852126	hybrid			2022-12-25	WOS:000077542200092
J	Geisbrecht, BV; Zhu, D; Schulz, K; Nau, K; Morrell, JC; Geraghty, M; Schulz, H; Erdmann, R; Gould, SJ				Geisbrecht, BV; Zhu, D; Schulz, K; Nau, K; Morrell, JC; Geraghty, M; Schulz, H; Erdmann, R; Gould, SJ			Molecular characterization of Saccharomyces cerevisiae Delta(3),Delta(2)-enoyl-CoA isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; CHAIN DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; PEROXISOMAL BETA-OXIDATION; RAT-LIVER MITOCHONDRIA; ENOYL-COA HYDRATASE; 3-HYDROXYACYL-COA DEHYDROGENASE; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; TRANSCRIPTIONAL CONTROL; 2-ENOYL-COA HYDRATASE; PROTEIN	We report here the identification of the Saccharomyces cerevisiae peroxisomal Delta(3),Delta(2)-enoyl-CoA isomerase, an enzyme that is essential for the beta-oxidation of unsaturated fatty acids. The yeast gene YLR284C was identified in an in silico screen for genes that contain an oleate response element, a transcription factor-binding site common to most fatty acid-induced genes. Growth on oleic acid resulted in a significant increase in YLR284C mRNA, demonstrating that it is indeed an oleate-induced gene. The deduced product of YLR284C contains a type 1 peroxisomal targeting signal-like sequence at its C terminus and localizes to the peroxisome in a PEX8-dependent manner. Removal of YLR284C from the S. cerevisiae genome eliminated growth on oleic acid, but had no effect on peroxisome biogenesis, indicating a role for YLR284C in fatty acid metabolism. Cells lacking YLR284C had no detectable Delta(3),Delta(2)-enoyl-CoA isomerase activity, and a bacterially expressed form of this protein catalyzed the isomerization of 3-cis-octenoyl-CoA to 2-trans-octenoyl-CoA with a specific activity of 16 units/mg. We conclude that YLR284C encodes the yeast peroxisomal Delta(3),Delta(2)-enoyl-CoA isomerase and propose a new name, ECI1, to reflect its enoyl-CoA isomerase activity.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; CUNY City Coll, Dept Chem, New York, NY 10031 USA; Ruhr Univ Bochum, Dept Physiol Chem, D-44780 Bochum, Germany	Johns Hopkins University; Johns Hopkins University; City University of New York (CUNY) System; City College of New York (CUNY); Ruhr University Bochum	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIDDK NIH HHS [DK45787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKERBRACHMANN C, 1998, YEAST, V14, P115; Binstock J F, 1981, Methods Enzymol, V71 Pt C, P403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DELAGARZA MM, 1985, EUR J BIOCHEM, V148, P285, DOI 10.1111/j.1432-1033.1985.tb08837.x; DMOCHOWSKA A, 1990, GENE, V88, P247, DOI 10.1016/0378-1119(90)90038-S; EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; GOULD SJ, 1988, J CELL BIOL, V107, P897, DOI 10.1083/jcb.107.3.897; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; HILTUNEN JK, 1992, J BIOL CHEM, V267, P6646; Hiltunen JK, 1996, ANN NY ACAD SCI, V804, P116, DOI 10.1111/j.1749-6632.1996.tb18612.x; KILPONEN JM, 1990, BIOCHEM J, V269, P223, DOI 10.1042/bj2690223; KUNAU WH, 1978, EUR J BIOCHEM, V91, P533, DOI 10.1111/j.1432-1033.1978.tb12707.x; KUNAU WH, 1988, BIOCHEM SOC T, V16, P418, DOI 10.1042/bst0160418; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; LUO MJ, 1994, J BIOL CHEM, V269, P2384; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; MULLERNEWEN G, 1993, BIOCHEMISTRY-US, V32, P11405; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; Sambrook J., 2002, MOL CLONING LAB MANU; Shoukry K, 1998, J BIOL CHEM, V273, P6892, DOI 10.1074/jbc.273.12.6892; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STOFFEL W, 1965, H-S Z PHYSIOL CHEM, V341, P76, DOI 10.1515/bchm2.1965.341.1.76; STOFFEL W, 1978, H-S Z PHYSIOL CHEM, V359, P1777, DOI 10.1515/bchm2.1978.359.2.1777; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107	41	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33184	33191		10.1074/jbc.273.50.33184	http://dx.doi.org/10.1074/jbc.273.50.33184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837886	hybrid			2022-12-25	WOS:000077462500016
J	Liu, XB; O'Connell, A; Ambudkar, IS				Liu, XB; O'Connell, A; Ambudkar, IS			Ca2+-dependent inactivation of a store-operated Ca2+ current in human submandibular gland cells - Role of a staurosporine-sensitive protein kinase and the intracellular Ca2+ pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; DIVALENT-CATION ENTRY; PAROTID ACINAR-CELLS; PANCREATIC ACINI; CA-2+ ENTRY; MAST-CELLS; DEPLETION; INFLUX; STIMULATION; LINE	Stimulation of human submandibular gland cells with carbachol, inositol trisphosphate (IP3), thapsigargin, or tert-butylhydroxyquinone induced an inward current that was sensitive to external Ca2+ concentration ([Ca2+](e)) and was also carried by external Na+ or Ba2+ (in a Ca2+-free medium) with amplitudes in the order Ca2+ > Ba2+ > Na+. All cation currents were blocked by La3+ and Gd3+ but not by Zn2+. The IP3-stimulated current with 10 mu M 3-deoxy-3-fluoro-D-myo-inositol 1,4,5-triphosphate and 10 mM 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid in the pipette solution, showed 50% inactivation in <5 min and >5 min with 10 and 1 mM [Ca2+](e), respectively. The Na+ current was not inactivated, whereas the Ba2+ current inactivated at a slower rate. The protein kinase inhibitor, staurosporine, delayed the inactivation and increased the amplitude of the current, whereas the protein Ser/Thr phosphatase inhibitor, calyculin A, reduced the current. Thapsigargin- and tert-butylhydroxyquinone-stimulated Ca2+ currents inactivated faster. Importantly, these agents accelerated the inactivation of the IP3-stimulated current. The data demonstrate that internal Ca2+ store depletion-activated Ca2+ current (I-SOC) in this salivary cell line is regulated by a Ca2+-dependent feedback mechanism involving a staurosporine-sensitive protein kinase and the intracellular Ca2+ pump. We suggest that the Ca2+ pump modulates I-SOC by regulating [Ca2+](i) in the region of Ca2+ influx.	NIDR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Ambudkar, IS (corresponding author), NIDR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113, Bethesda, MD 20892 USA.	ambudkar@yoda.nidr.nih.gov		O'Connell, Anne C/0000-0002-1495-3983				BAUM BJ, 1988, MOL CELL BIOCHEM, V82, P67; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Chauthaiwale JV, 1996, PFLUG ARCH EUR J PHY, V432, P105, DOI 10.1007/s004240050111; Chauthaiwale JV, 1998, J MEMBRANE BIOL, V162, P139, DOI 10.1007/s002329900351; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FOSKETT JK, 1994, J BIOL CHEM, V269, P31525; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HE XJ, 1990, J MEMBRANE BIOL, V115, P159, DOI 10.1007/BF01869454; HIRAMATSU Y, 1992, J MEMBRANE BIOL, V129, P277; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; ISHIKAWA T, 1994, PFLUG ARCH EUR J PHY, V427, P203, DOI 10.1007/BF00374525; KAPLAN MD, 1994, PFLUG ARCH EUR J PHY, V428, P439, DOI 10.1007/BF00374563; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; Liu XB, 1998, AM J PHYSIOL-CELL PH, V275, pC571, DOI 10.1152/ajpcell.1998.275.2.C571; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; MERTZ LM, 1992, J MEMBRANE BIOL, V126, P183; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Sakai T, 1997, PFLUG ARCH EUR J PHY, V433, P464, DOI 10.1007/s004240050301; Sakai T, 1996, AM J PHYSIOL-CELL PH, V271, pC284, DOI 10.1152/ajpcell.1996.271.1.C284; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; Tojyo Y, 1995, JPN J PHARMACOL, V69, P381, DOI 10.1254/jjp.69.381; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	30	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33295	33304		10.1074/jbc.273.50.33295	http://dx.doi.org/10.1074/jbc.273.50.33295			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837902	hybrid			2022-12-25	WOS:000077462500032
J	Lopez, M; Gazon, M; Juliant, S; Plancke, Y; Leroy, Y; Strecker, G; Cartron, JP; Bailly, P; Cerutti, M; Verbert, A; Delannoy, P				Lopez, M; Gazon, M; Juliant, S; Plancke, Y; Leroy, Y; Strecker, G; Cartron, JP; Bailly, P; Cerutti, M; Verbert, A; Delannoy, P			Characterization of a UDP-Gal : Gal beta 1-3GalNAc alpha 1,4-galactosyltransferase activity in a Mamestra brassicae cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; HONEYBEE VENOM PHOSPHOLIPASE-A2; BANDEIRAEA-SIMPLICIFOLIA SEEDS; BACULOVIRUS EXPRESSION SYSTEM; SPODOPTERA-FRUGIPERDA CELLS; LEPIDOPTERAN INSECT CELLS; ALPHA-GALACTOSYL IGG; LINKED OLIGOSACCHARIDES; POSTTRANSLATIONAL MODIFICATIONS; MEMBRANE-GLYCOPROTEINS	The binding of Bandeiraea simplicifolia lectin-I isolectin B-4 on the endogenous glycoproteins of different insect cell lines led us to characterize for the first time a UDP-Gal:Gal beta 1-3GalNAc alpha 1,4-galactosyltransferase in a Mamestra brassicae cell line (Mb). The study of the acceptor specificity indicated that the Mb alpha-galactosyltransferase prefers Gal beta 1-3-R as acceptor, and among such glycans, the relative substrate activity V-max/K-m was equal to 20 mu l.mg(-)1.h(-1) for Gal beta 1-3GlcNAc beta 1-O-octyl and to 330 mu l.mg(-1).h(-1) for Gal beta 1-3GalNAc alpha-1-O-benzyl, showing clearly that Gal beta 1-3GalNAc disaccharide was the more suitable acceptor substrate for Rib alpha-galactosyltransferase activity. Nuclear magnetic resonance and mass spectrometry data allowed us to establish that the Mb alpha-galactosyltransferase synthesizes one unique product, Gal alpha 1-4Gal beta 1-3GalNAc alpha 1-O-benzyl, The Gal beta 1-3GalNAc disaccharide is usually present on O-glycosylation sites of numerous asialoglycoproteins and at the nonreducing end of some glycolipids. We observed that Mb alpha 1,4-galactosyltransferase catalyzed the transfer of galactose onto both natural accepters. Finally, we demonstrated that the trisaccharide Gal alpha 1-4Gal beta 1-3GalNAc alpha 1-O-benzyl was able to inhibit anti-PK monoclonal antibody-mediated hemagglutination of human blood group P-1(K) and P-2(K) erythrocytes.	Univ Sci & Technol Lille, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France; CNRS, URA 2209, INRA, Stn Pathol Comparee, F-30380 St Christol Les Ales, France; Inst Natl Transfus Sanguine, INSERM, U76, F-75739 Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm)	Delannoy, P (corresponding author), Univ Sci & Technol Lille, Chim Biol Lab, CNRS, UMR 111, F-59655 Villeneuve Dascq, France.	pdelanno@chouia.univ-lille1.fr		Delannoy, Philippe/0000-0001-6467-7553				ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; BAILLY P, 1992, CARBOHYD RES, V228, P277, DOI 10.1016/S0008-6215(00)90565-2; BAILLY P, 1987, MOL IMMUNOL, V24, P171, DOI 10.1016/0161-5890(87)90089-7; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BOCK K, 1985, J BIOL CHEM, V260, P8545; BURCHELL J, 1989, INT J CANCER, V44, P691, DOI 10.1002/ijc.2910440423; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P655, DOI 10.1016/0005-2736(81)90096-1; CASTRONOVO V, 1987, INVAS METAST, V7, P325; CHATTERJEE S, 1995, GLYCOBIOLOGY, V5, P327, DOI 10.1093/glycob/5.3.327; CHEN WY, 1991, J BIOL CHEM, V266, P4081; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COWLES JW, 1987, TRANSFUSION, V27, P272, DOI 10.1046/j.1537-2995.1987.27387235638.x; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6689, DOI 10.1021/bi00241a008; FOURNET B, 1981, ANAL BIOCHEM, V116, P489, DOI 10.1016/0003-2697(81)90393-6; GALILI U, 1987, J EXP MED, V165, P693, DOI 10.1084/jem.165.3.693; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; GRABENHORST E, 1993, EUR J BIOCHEM, V215, P189, DOI 10.1111/j.1432-1033.1993.tb18022.x; HAATAJA S, 1993, J BIOL CHEM, V268, P4311; HAATAJA S, 1994, J BIOL CHEM, V269, P27466; HARD K, 1993, BIOCHEMISTRY-US, V32, P766, DOI 10.1021/bi00054a005; HAYES CE, 1974, J BIOL CHEM, V249, P1904; HOLGERSSON J, 1990, J BIOCHEM-TOKYO, V108, P766, DOI 10.1093/oxfordjournals.jbchem.a123279; HSIEH P, 1984, J BIOL CHEM, V259, P2375; Hsu TA, 1997, J BIOL CHEM, V272, P9062; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; JEROME KR, 1991, CANCER RES, V51, P2908; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KANG CY, 1988, ADV VIRUS RES, V35, P177; KLENK HD, 1990, IMMUNOCHEMISTRY VIRU, V2, P25; KOTERA Y, 1994, CANCER RES, V54, P2856; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KURODA K, 1989, J VIROL, V63, P1677, DOI 10.1128/JVI.63.4.1677-1685.1989; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; KURODA K, 1986, EMBO J, V5, P1359, DOI 10.1002/j.1460-2075.1986.tb04367.x; KURODA K, 1991, VIROLOGY, V180, P159, DOI 10.1016/0042-6822(91)90019-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanne B, 1996, GLYCOBIOLOGY, V6, P423, DOI 10.1093/glycob/6.4.423; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Lopez M, 1997, GLYCOBIOLOGY, V7, P635, DOI 10.1093/glycob/7.5.635; Lubineau A, 1997, CARBOHYD RES, V300, P161, DOI 10.1016/S0008-6215(97)00043-8; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; LUNDBLAD A, 1980, EUR J BIOCHEM, V104, P323, DOI 10.1111/j.1432-1033.1980.tb04432.x; MANNEBERG M, 1994, PROTEIN SCI, V3, P30; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MURPHY LA, 1977, J BIOL CHEM, V252, P4739; NILSSON B, 1979, J BIOL CHEM, V254, P4545; NOTEBORN MHM, 1992, WORKSH BAC REC PROT, P92; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; Ogonah OW, 1996, BIO-TECHNOL, V14, P197, DOI 10.1038/nbt0296-197; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PONIMASKIN E, 1994, J GEN VIROL, V75, P1163, DOI 10.1099/0022-1317-75-5-1163; Rother RP, 1996, CELL, V86, P185, DOI 10.1016/S0092-8674(00)80090-2; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; STAUDACHER E, 1992, GLYCOCONJUGATE J, V9, P82, DOI 10.1007/BF00731703; STAUDACHER E, 1992, EUR J BIOCHEM, V207, P987, DOI 10.1111/j.1432-1033.1992.tb17134.x; STULTS CLM, 1995, GLYCOCONJUGATE J, V12, P680, DOI 10.1007/BF00731265; TAKEUCHI M, 1991, GLYCOBIOLOGY, V349, P196; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; TETAERT D, 1994, J CHROMATOGR B, V658, P31, DOI 10.1016/0378-4347(94)00223-1; THOMSEN DR, 1990, J CELL BIOCHEM, V43, P67, DOI 10.1002/jcb.240430107; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; TOBIN H, 1987, J EXP MED, V166, P419, DOI 10.1084/jem.166.2.419; VAESSEN RTMJ, 1981, FEBS LETT, V124, P193, DOI 10.1016/0014-5793(81)80134-2; VANDAMME V, 1992, BIOCHIMIE, V74, P89, DOI 10.1016/0300-9084(92)90188-K; vanDie I, 1996, GLYCOBIOLOGY, V6, P157, DOI 10.1093/glycob/6.2.157; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; VEIT M, 1993, ARCH VIROL, V133, P335, DOI 10.1007/BF01313773; VELARDO MA, 1993, J BIOL CHEM, V268, P17902; VOSS T, 1993, ARCH VIROL, V133, P335; WATHEN MW, 1991, BIOCHEMISTRY-US, V30, P2863, DOI 10.1021/bi00225a019; WATKINS WM, 1976, J IMMUNOGENET, V3, P15; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087; WU M, 1995, BIOCHEM BIOPH RES CO, V216, P814; YANG ZT, 1994, J BIOL CHEM, V269, P14620; YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019; YIU SCK, 1992, ANAL BIOCHEM, V202, P188, DOI 10.1016/0003-2697(92)90226-W	85	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 11	1998	273	50					33644	33651		10.1074/jbc.273.50.33644	http://dx.doi.org/10.1074/jbc.273.50.33644			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	146YY	9837949	hybrid			2022-12-25	WOS:000077462500079
J	Lakshminarayanan, V; Drab-Weiss, EA; Roebuck, KA				Lakshminarayanan, V; Drab-Weiss, EA; Roebuck, KA			H2O2 and tumor necrosis factor-alpha induce differential binding of the redox-responsive transcription factors AP-1 and NF-kappa B to the interleukin-8 promoter in endothelial and epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; GLUTATHIONE-S-TRANSFERASE; MONOCYTE CHEMOATTRACTANT PROTEIN-1; NEUTROPHIL CHEMOTACTIC FACTOR; PRO-INFLAMMATORY CYTOKINES; YA SUBUNIT GENE; OXIDATIVE STRESS; DNA-BINDING; C-JUN; COOPERATIVE INTERACTION	We previously demonstrated that tumor necrosis factor-alpha (TNF alpha) and H2O2 differentially regulate interleukin-8 (IL-8) and intercellular adhesion molecule (ICAM-1) gene expression in endothelial and epithelial cells. H2O2 induced IL-8 expression in the A549 and BEAS-2B epithelial cell lines, but not in the human microvessel endothelial cell line, HMEC-1 or human umbilical vein endothelial cells. In contrast, H2O2 induced ICAM-1 only in endothelial cells, Unlike H2O2, the proinflammatory cytokine TNF alpha induced IL-8 and ICAM-1 in both cell types. In this study, me examine the role of the redox-responsive transcription factors AP-1 and nuclear factor-kappa B (NF-kappa B) in the differential expression of IL-8, DNA binding studies using nuclear protein extracts from HMEC-1 and A549 cells stimulated with H2O2 or TNFa demonstrated differential activation and promoter binding of AP-1 and NF-kappa B. H2O2 activated AP-1 but not NF-kappa B in A549, whereas TNF alpha activated AP-1 as well as NF-kappa B. In HMEC-1, TNF alpha activated NF-kappa B but not AP-1, while H2O2 did not activate either transcription factor. The differential activation of the factors was also reflected in their differential binding to the IL-8 promoter. Moreover, the H2O2 concentration dependent increase in epithelial IL-8 mRNA expression directly corresponded to the H2O2 concentration dependent binding of AP-1 to the IL-8 promoter. Supershift analysis revealed H2O2 as well as TNF alpha induced AP-1 complexes containing c-Fos and JunD. TNF alpha induced NF-kappa B complexes containing Rel A (p65), Immunohistochemical staining of HMEC-1 and A549 cells revealed TNFa stimulated nuclear localization of Rel A, whereas no translocation of Rel A was detected in either cell type stimulated by H2O2. These data indicate that the cell type-specific induction of IL-8 gene expression by H2O2 and TNF alpha in HMEC-1 and A549 cells can be explained by the differential binding of AP-1 and NF-kappa B to the IL-8 promoter.	Rush Presbyterian St Lukes Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA	Rush University	Roebuck, KA (corresponding author), Rush Med Coll, Dept Immunol Microbiol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.	kroebuck@rush.edu			NIAMS NIH HHS [AR45835] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045835] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANDREW PJ, 1995, BIOCHEM BIOPH RES CO, V214, P949, DOI 10.1006/bbrc.1995.2378; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; BERGELSON S, 1994, CANCER RES, V54, P36; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; BRADLEY JR, 1993, AM J PATHOL, V142, P1598; Camandola S, 1997, BIOFACTORS, V6, P173, DOI 10.1002/biof.5520060211; COLLETTI LM, 1995, J CLIN INVEST, V95, P134, DOI 10.1172/JCI117630; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DEFORGE LE, 1992, J CLIN INVEST, V90, P2123, DOI 10.1172/JCI116097; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; Jaspers I, 1997, AM J PHYSIOL-LUNG C, V272, pL504, DOI 10.1152/ajplung.1997.272.3.L504; Jornot L, 1997, FEBS LETT, V416, P381, DOI 10.1016/S0014-5793(97)01244-1; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KUKIELKA GL, 1995, J CLIN INVEST, V95, P89, DOI 10.1172/JCI117680; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; Lakshminarayanan V, 1997, J BIOL CHEM, V272, P32910, DOI 10.1074/jbc.272.52.32910; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Li XH, 1998, MOL BRAIN RES, V53, P196, DOI 10.1016/S0169-328X(97)00290-8; Liu SX, 1996, BIOCHEMISTRY-US, V35, P11517, DOI 10.1021/bi960572p; LOOK DC, 1994, J BIOL CHEM, V269, P8952; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Massion PP, 1996, AM J PHYSIOL-LUNG C, V271, pL838, DOI 10.1152/ajplung.1996.271.5.L838; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; Moriuchi H, 1997, J IMMUNOL, V158, P3483; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Muller JM, 1996, ADV EXP MED BIOL, V387, P77; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Muller JM, 1997, EUR J BIOCHEM, V244, P45, DOI 10.1111/j.1432-1033.1997.00045.x; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; Rao GN, 1997, CELL SIGNAL, V9, P181, DOI 10.1016/S0898-6568(96)00139-8; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; ROTHLEIN R, 1988, J IMMUNOL, V141, P1665; ROVIN BH, 1995, KIDNEY INT, V48, P1263, DOI 10.1038/ki.1995.410; Sato M, 1996, J RHEUMATOL, V23, P432; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SICA A, 1990, IMMUNOLOGY, V69, P548; Song S, 1997, BLOOD, V89, P4461, DOI 10.1182/blood.V89.12.4461; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; TAKESHITA A, 1995, J IMMUNOL, V155, P419; TIMBLIN CR, 1995, CANCER RES, V55, P2723; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG P, 1994, BLOOD, V83, P2678, DOI 10.1182/blood.V83.9.2678.bloodjournal8392678; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; Wasserman WW, 1997, ARCH BIOCHEM BIOPHYS, V344, P387, DOI 10.1006/abbi.1997.0215; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Xu YX, 1997, EXP HEMATOL, V25, P413; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	81	198	205	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32670	32678		10.1074/jbc.273.49.32670	http://dx.doi.org/10.1074/jbc.273.49.32670			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830008	hybrid			2022-12-25	WOS:000077329100047
J	Lambert, JR; Nordeen, SK				Lambert, JR; Nordeen, SK			Steroid-selective initiation of chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter is controlled by the site of promoter integration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; GLUCOCORTICOID RECEPTOR; RESPONSE ELEMENT; MMTV PROMOTER; HISTONE ACETYLTRANSFERASE; SIGNALING PATHWAYS; REGULATORY ELEMENT; AGONIST ACTIVITY; GENE-EXPRESSION; DNA	The mouse mammary tumor virus (MMTV) promoter has target sequences recognized by several steroid receptors. We present evidence for a novel mechanism that confers hormone specificity to this promoter. We show that remodeling of MMTV chromatin and the concomitant activation of the MMTV promoter are induced equally by glucocorticoids and progestins in one chromosomal context but are selective for glucocorticoids in another. Furthermore, increased histone acetylation modulates MMTV promoter regulation disparately at the two chromosomal locations. Together, these data indicate that chromosomal architecture commands a crucial role in gene regulation, imposing locus specific selectivity between regulators with similar sequence recognition.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nordeen, SK (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol B216, 4200 E 9th Ave, Denver, CO 80262 USA.				NIDDK NIH HHS [DK09554, DK37061] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037061, F32DK009554] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALFAGEME CR, 1974, J BIOL CHEM, V249, P3729; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; Bonovich MT, 1998, EXP CELL RES, V239, P454, DOI 10.1006/excr.1997.3920; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; DARBRE P, 1986, MOL CELL BIOL, V6, P2847, DOI 10.1128/MCB.6.8.2847; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GARDINER K, 1995, CURR OPIN GENET DEV, V5, P315, DOI 10.1016/0959-437X(95)80045-X; Gass EK, 1998, ENDOCRINOLOGY, V139, P1905, DOI 10.1210/en.139.4.1905; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; MAJORS J, 1983, P NATL ACAD SCI-BIOL, V80, P5866, DOI 10.1073/pnas.80.19.5866; MIESFELD RL, 1989, CRIT REV BIOCHEM MOL, V24, P101, DOI 10.3109/10409238909086395; MOYER ML, 1993, J BIOL CHEM, V268, P22933; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NAGY L, 1997, CELL, V89, P873; NORDEEN SK, 1994, ENDOCRINOLOGY, V134, P1723, DOI 10.1210/en.134.4.1723; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	39	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32708	32714		10.1074/jbc.273.49.32708	http://dx.doi.org/10.1074/jbc.273.49.32708			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830013	hybrid			2022-12-25	WOS:000077329100052
J	Lavie, Y; Fiucci, G; Liscovitch, M				Lavie, Y; Fiucci, G; Liscovitch, M			Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; P-GLYCOPROTEIN; FREE-CHOLESTEROL; PLASMA-MEMBRANE; DRUG-RESISTANCE; BREAST-CANCER; EXPRESSION; TRANSPORT; TRANSCRIPTION; ACCUMULATION	Cancer chemotherapy often results in the development of multidrug resistance (MDR), which is commonly associated with overexpression of P-glycoprotein (P-gp), a plasma membrane drug efflux ATPase, It was shown recently that glycosphingolipids are elevated in MDR cells. Sphingolipids are major constituents of caveolae and of detergent-insoluble, glycosphingolipid-rich membrane domains. Here we report that multidrug-resistant HT-29 human colon adenocarcinoma cells exhibit a 12-fold overexpression of caveolin-1, a 21-kDa coat/adaptor protein of caveolae, Similar observations were made in adriamycin-resistant MCF-7 human breast adenocarcinoma cells. Caveolin-2 expression is also up-regulated in MCF-7-AdrR cells, but neither caveolin-l nor caveolin-2 were detected in MCF-7 cells stably transfected with P-gp, The up-regulation of caveolins is associated with a 5-fold increase in the number of caveolae-like structures observed in plasma membrane profiles of HT-29-MDR cells and with the appearance of a comparable number of caveolae in MCF-7-AdrR cells, A significant fraction (similar to 40%) of cellular P-gp is localized in low density detergent-insoluble membrane fractions derived from either HT-29-RIDR or MCF-7-AdrR cells. The distribution of recombinant P-gp in stably transfected MCF-7 cells was similar, even though these cells do not express caveolins and are devoid of caveolae. The possibility that caveolae contribute to the multidrug resistance and thus are coselected with P-gp during the acquisition of this phenotype is discussed.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Liscovitch, M (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.							Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Bosch I, 1996, BBA-REV CANCER, V1288, pF37, DOI 10.1016/0304-419X(96)00022-4; BREUER W, 1993, AM J PHYSIOL, V265, pC1711, DOI 10.1152/ajpcell.1993.265.6.C1711; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Dimitroulakos J, 1996, NAT MED, V2, P326, DOI 10.1038/nm0396-326; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding CJ, 1997, J LIPID RES, V38, P1503; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GOTTESMAN MM, 1993, CANCER RES, V53, P747; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HOLMBERG M, 1994, ANTI-CANCER DRUG, V5, P598, DOI 10.1097/00001813-199410000-00012; Kaye SB, 1995, AM J MED, V99, pS40, DOI 10.1016/S0002-9343(99)80285-X; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Ling V, 1995, AM J MED, V99, pS31, DOI 10.1016/S0002-9343(99)80283-6; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525	40	271	277	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32380	32383		10.1074/jbc.273.49.32380	http://dx.doi.org/10.1074/jbc.273.49.32380			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829965	hybrid			2022-12-25	WOS:000077329100004
J	Llorca, O; Galan, A; Carrascosa, JL; Muga, A; Valpuesta, JM				Llorca, O; Galan, A; Carrascosa, JL; Muga, A; Valpuesta, JM			GroEL under heat-shock - Switching from a folding to a storing function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONIN ATPASE CYCLE; CRYSTAL-STRUCTURE; CENTRAL CAVITY; COMPLEXES; RELEASE; BINDING; RESOLUTION; MECHANISM; SUBSTRATE; 2.8-ANGSTROM	Chaperonin GroEL from Escherichia coli, together with its cochaperonin GroES, are proteins involved in assisting the folding of polypeptides. GroEL is a tetradecamer composed of two heptameric rings, which enclose a cavity where folding takes place through multiple cycles of substrate and GroES binding and release. GroEL and GroES are also heat-shock proteins, their synthesis being increased during heat-shock conditions to help the cell coping with the thermal stress. Our results suggest that, as the temperature increases, GroEL decreases its protein folding activity and starts acting as a "protein store." The molecular basis of this behavior is the loss of inter-ring signaling, which slows down GroES liberation from GroEL and therefore the release of the unfolded protein from the GroEL cavity, This behavior is reversible, and after heat-shock, GroEL reverts to its normal function. This might have a physiological meaning, since under thermal stress conditions, it may be inefficient for the cell to fold thermounstable proteins that are prone to denaturation.	CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Univ Basque Country, CSIC, Dept Bioquim & Biol Mol, Unidad Asociada, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country	Valpuesta, JM (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, E-28049 Madrid, Spain.	jmv@cnb.uam.es	Llorca, Oscar/K-1144-2014; Valpuesta, José M/T-1977-2017; Muga, Arturo/N-1174-2014; Llorca, Oscar/P-2784-2019; Valpuesta, Jose M/AAA-6002-2019	Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Muga, Arturo/0000-0003-0345-6882; Llorca, Oscar/0000-0001-5705-0699; 				Aharoni A, 1996, J MOL BIOL, V258, P732, DOI 10.1006/jmbi.1996.0282; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; DELAFRAGA LG, 1995, ULTRAMICROSCOPY, V60, P385, DOI 10.1016/0304-3991(95)00080-1; ELLIS RJ, 1996, CHAPERONINS; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Goloubinoff P, 1997, FEBS LETT, V407, P215, DOI 10.1016/S0014-5793(97)00348-7; Gorovits BM, 1997, J BIOL CHEM, V272, P32; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; HUNTER WM, 1978, HDB EXPT IMMUNOLOGY, P608; KREUZER KN, 1983, METHOD ENZYMOL, V100, P144; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Llorca O, 1997, J BIOL CHEM, V272, P32925, DOI 10.1074/jbc.272.52.32925; Llorca O, 1997, FEBS LETT, V405, P195, DOI 10.1016/S0014-5793(97)00186-5; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Llorca O, 1996, J BIOL CHEM, V271, P68, DOI 10.1074/jbc.271.1.68; Llorca O, 1997, J STRUCT BIOL, V118, P31, DOI 10.1006/jsbi.1996.3832; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; Mendoza JA, 1996, BIOCHEM BIOPH RES CO, V229, P271, DOI 10.1006/bbrc.1996.1791; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PEREZPEREZ J, 1995, GENE, V158, P141, DOI 10.1016/0378-1119(95)00127-R; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	38	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32587	32594		10.1074/jbc.273.49.32587	http://dx.doi.org/10.1074/jbc.273.49.32587			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9829996	hybrid			2022-12-25	WOS:000077329100035
J	McVicar, DW; Taylor, LS; Gosselin, P; Willette-Brown, J; Mikhael, AI; Geahlen, RL; Nakamura, MC; Linnemeyer, P; Seaman, WE; Anderson, SK; Ortaldo, JR; Mason, LH				McVicar, DW; Taylor, LS; Gosselin, P; Willette-Brown, J; Mikhael, AI; Geahlen, RL; Nakamura, MC; Linnemeyer, P; Seaman, WE; Anderson, SK; Ortaldo, JR; Mason, LH			DAP12-mediated signal transduction in a natural killer cells - A dominant role for the Syk protein-tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC-RECOGNIZING RECEPTORS; PROTOONCOGENE C-CBL; FC-GAMMA RECEPTOR; CLASS-I MOLECULES; PHOSPHATIDYLINOSITOL 3-KINASE; INHIBITORY RECEPTORS; ANTIGEN RECEPTOR; T-LYMPHOCYTES; NK CELLS; HLA-C	The murine Ly49 family contains nine genes in two subgroups: the inhibitory receptors (Ly49A, B, C, E, F, G2, and I) and the noninhibitory receptors (Ly49D and H), Unlike their inhibitory counterparts, Ly49D and H do not contain immunoreceptor tyrosine-based inhibitory motifs but associate with a recently described coreceptor, DAP12, to transmit positive signals to natural killer (NK) cells. DAP12 is also expressed in myeloid cells, but the receptors coupled to it there are unknown. Here we document the signaling pathways of the Ly49D/ DAP12 complex in NK cells. We show that ligation of Ly49D results in 1) tyrosine phosphorylation of several substrates, including phospholipase C gamma 1, Cbl, and p44/ p42 mitogen-activated protein kinase, and 2) calcium mobilization. Moreover, we demonstrate that although human DAP12 reportedly binds the SH2 domains of both Syk and Zap-70, ligation of Ly49D leads to activation of Syk but not Zap-70. Consistent with this observation, Ly49D/DAP12-mediated calcium mobilization is blocked by dominant negative Syk but not by catalytically inactive Zap-70. These data demonstrate the dependence of DAP12-coupled receptors on Syk and suggest that the outcome of Ly49D/DAP12 engagement mill be regulated by Cbl and culminate in the activation of transcription factors.	NCI, Expt Immunol Lab, Div Basic Sci, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	McVicar, DW (corresponding author), NCI, Expt Immunol Lab, Div Basic Sci, Frederick Canc Res & Dev Ctr,NIH, Bldg 560,Room 31-93, Frederick, MD 21702 USA.	mcvicar@nih.gov	McVicar, Daniel/G-1970-2015; Anderson, Stephen K/B-1727-2012; Nakamura, Mary/ABI-2887-2020	Anderson, Stephen K/0000-0002-7856-4266; Nakamura, Mary/0000-0001-8127-9426; Geahlen, Robert/0000-0001-8400-2924; McVicar, Daniel/0000-0002-1112-5111	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000, CA37372] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON P, 1989, NATURE, V341, P159, DOI 10.1038/341159a0; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Binstadt BA, 1997, IMMUNOL REV, V155, P197, DOI 10.1111/j.1600-065X.1997.tb00952.x; Binstadt BA, 1996, IMMUNITY, V5, P629, DOI 10.1016/S1074-7613(00)80276-9; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; Borges L, 1997, J IMMUNOL, V159, P5192; Bottino C, 1996, EUR J IMMUNOL, V26, P1816, DOI 10.1002/eji.1830260823; BOTTINO C, 1994, EUR J IMMUNOL, V24, P2527, DOI 10.1002/eji.1830241040; Brumbaugh KM, 1997, J EXP MED, V186, P1965, DOI 10.1084/jem.186.12.1965; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Cerboni C, 1998, EUR J IMMUNOL, V28, P1005, DOI 10.1002/(SICI)1521-4141(199803)28:03<1005::AID-IMMU1005>3.0.CO;2-O; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Gesbert F, 1998, J BIOL CHEM, V273, P3986, DOI 10.1074/jbc.273.7.3986; HARRISON ML, 1994, J BIOL CHEM, V269, P955; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; Keshvara LM, 1997, J BIOL CHEM, V272, P10377; Kimura T, 1996, MOL CELL BIOL, V16, P1471; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Lanier LL, 1998, NATURE, V391, P703, DOI 10.1038/35642; Leibson PJ, 1997, IMMUNITY, V6, P655, DOI 10.1016/S1074-7613(00)80441-0; Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x; Mason LH, 1997, J IMMUNOL, V159, P4187; Mason LH, 1998, J IMMUNOL, V160, P4148; MASON LH, 1995, J EXP MED, V182, P293, DOI 10.1084/jem.182.2.293; Mason LH, 1996, J EXP MED, V184, P2119, DOI 10.1084/jem.184.6.2119; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; Nakamura MC, 1997, J EXP MED, V185, P673, DOI 10.1084/jem.185.4.673; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; Olcese L, 1996, J IMMUNOL, V156, P4531; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Peters JD, 1996, J BIOL CHEM, V271, P4755; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Ryan JC, 1997, IMMUNOL REV, V155, P79, DOI 10.1111/j.1600-065X.1997.tb00941.x; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Smith KM, 1998, J IMMUNOL, V161, P7; Takei F, 1997, IMMUNOL REV, V155, P67, DOI 10.1111/j.1600-065X.1997.tb00940.x; Taylor N, 1997, BLOOD, V89, P388, DOI 10.1182/blood.V89.2.388; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	63	185	188	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	1998	273	49					32934	32942		10.1074/jbc.273.49.32934	http://dx.doi.org/10.1074/jbc.273.49.32934			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	144RP	9830044	hybrid			2022-12-25	WOS:000077329100083
J	Blackwell, LJ; Martik, D; Bjornson, KP; Bjornson, ES; Modrich, P				Blackwell, LJ; Martik, D; Bjornson, KP; Bjornson, ES; Modrich, P			Nucleotide-promoted release of hMutS alpha from heteroduplex DNA is consistent with an ATP-dependent translocation Mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MISMATCH REPAIR; BASE PAIRS; PROTEIN; BINDS; RECOGNITION; HETERODIMER; CELLS; MSH2; GENE	ATP hydrolysis by bacterial and eukaryotic MutS activities is required for their function in mismatch correction, and two different models for the role of ATP in MutS function have been proposed. In the translocation model, based on study of bacterial MutS, ATP binding reduces affinity of the protein for a mismatch and activates secondary DNA binding sites that are subsequently used for movement of the protein along the helix contour in a reaction dependent on nucleotide hydrolysis (Allen, D. J., Makhov, A., Grilley, M., Taylor, J., Thresher, R., Modrich, P., and Griffith, J. D. (1997) EMBO J. 16, 4467-4476). The molecular switch model, based on study of human MutS alpha, invokes mismatch recognition by the MutS alpha ADP complex. After recruitment of downstream repair activities to the MutS alpha mismatch complex, ATP binding results in release of MutS alpha from the heteroduplex (Gradia, S., Acharya, S., and Fishel, R.(1997) Cell 91, 995-1005). To further clarify the function of ATP binding and hydrolysis in human MutSa action, we evaluated the effects of ATP, ADP, and nonhydrolyzable ATP analogs on the lifetime of protein DNA complexes. All of these nucleotides were found to increase the rate of dissociation of MutS alpha from oligonucleotide heteroduplexes. These experiments also showed that ADP is not required for mismatch recognition by MutS alpha, but that the nucleotide alters the dynamics of formation and dissociation of specific complexes. Analysis of the mechanism of ATP-promoted dissociation of MutS alpha from a 200-base pair heteroduplex demonstrated that dissociation occurs at DNA ends in a reaction dependent on ATP hydrolysis, implying that release from this molecule involves movement of the protein along the helix contour as predicted for a translocation mechanism. In order to reconcile the relatively large rate of movement of MutS homologs along the helix with their modest rate of ATP hydrolysis, we propose a novel mechanism for protein translocation along DNA that supports directional movement over long distances with minimal energy input.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA	Duke University; Howard Hughes Medical Institute; Duke University; Stanford University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.	modrich@biochem.duke.edu		Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; AU KG, 1992, J BIOL CHEM, V267, P12142; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; GAMPER H, 1985, DNA-J MOLEC CELL BIO, V4, P157, DOI 10.1089/dna.1985.4.157; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; GRILLEY MM, 1992, THESIS DUKE U DURHAM; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hampp R, 1985, METHOD ENZYMAT AN, VVII, P370; Hingorani MM, 1998, CURR BIOL, V8, pR83, DOI 10.1016/S0960-9822(98)70052-1; Iaccarino I, 1996, CURR BIOL, V6, P484, DOI 10.1016/S0960-9822(02)00516-X; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; SENIOR AE, 1992, ARCH BIOCHEM BIOPHYS, V297, P340, DOI 10.1016/0003-9861(92)90682-M; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	27	159	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32055	32062		10.1074/jbc.273.48.32055	http://dx.doi.org/10.1074/jbc.273.48.32055			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822680	hybrid			2022-12-25	WOS:000077207000062
J	Kotani, T; Miyake, T; Tsukihashi, Y; Hinnebusch, AG; Nakatani, Y; Kawaichi, M; Kokubo, T				Kotani, T; Miyake, T; Tsukihashi, Y; Hinnebusch, AG; Nakatani, Y; Kawaichi, M; Kokubo, T			Identification of highly conserved amino-terminal segments of dTAF(II)-230 and yTAF(II)145 that are functionally interchangeable for inhibiting TBP-DNA interactions in vitro and in promoting yeast cell growth in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; MEDIATE TRANSCRIPTIONAL ACTIVATION; GENE ACTIVATION; BOX-BINDING; IN-VIVO; PREINITIATION COMPLEX; DOMAIN; HOLOENZYME; CORE	TFIID is a multiprotein complex composed of TBP and several TAF(II)s, Small amino-terminal segments (TAF N-terminal domain (TAND)) of Drosophila TAF(II)230 (dTAF(II)230) and yeast TAF(II)145 (yTAF(II)145) bind strongly to TBP and inhibit TBP-DNA interactions. yTAF(II)145 TAND (yTAND) was divided into two subdomains, yTaNDI(10-37) and yTANDII(46-71), that function cooperatively, Here, we identify dTANDII: within the amino terminus of dTAF(II)230 at 118-143 amino acids in addition to dTANDI(18-77), reported previously, dTANDII exhibits pronounced sequence similarity to yTANDII, and the two were shown to be functionally equivalent in binding to TBP and inhibiting TBP-DNA interactions in vitro. Alanine scanning mutation analysis demonstrated that Phe-57 (yTANDII) and Tyr-129 (dTANDII) are critically required for the interaction with TBP, Yeast strains containing mutant yTAF(II)145 lacking yTANDI or yTANDII showed a temperature-sensitive growth phenotype, The conserved core of dTANDII could substitute for the yTANDII core, and Phe-57 or Tyr-129 described above was critically required for the function of this segment in promoting normal cell growth at 37 degrees C, In these respects, the impact of yTANDII mutations on cell growth paralleled their effects on TBP binding in vitro, strongly suggesting that the yTAF(II)145-TBP interaction and its negative effects on TFIID binding to core promoters are physiologically important.	Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300101, Japan; NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; NICHD, Labs Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	Nara Institute of Science & Technology; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kokubo, T (corresponding author), Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300101, Japan.							ASO T, 1994, J BIOL CHEM, V269, P26575; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V2; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Farrell S, 1996, GENE DEV, V10, P2359, DOI 10.1101/gad.10.18.2359; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; GUTHRIE C, 1991, GUIDE YEAST GENETICS, P1; Harlow E, 1988, ANTIBODIES LABORATOR, P471; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Ozer J, 1998, J BIOL CHEM, V273, P14293, DOI 10.1074/jbc.273.23.14293; PRINTEN JA, 1994, GENETICS, V138, P609; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; Stargell LA, 1996, TRENDS GENET, V12, P311, DOI 10.1016/0168-9525(96)10028-7; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wilson CJ, 1996, CELL, V84, P235, DOI 10.1016/S0092-8674(00)80978-2; XIAO H, 1995, MOL CELL BIOL, V15, P5757; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0	42	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32254	32264		10.1074/jbc.273.48.32254	http://dx.doi.org/10.1074/jbc.273.48.32254			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822704	hybrid			2022-12-25	WOS:000077207000086
J	Wang, B; Shi, GP; Yao, PM; Li, ZQ; Chapman, HA; Bromme, D				Wang, B; Shi, GP; Yao, PM; Li, ZQ; Chapman, HA; Bromme, D			Human cathepsin F - Molecular cloning, functional expression, tissue localization, and enzymatic characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CYSTEINE PROTEINASE; INVARIANT CHAIN; PROTEASE; PAPAIN; SPECIFICITY; OSTEOCLASTS; INHIBITION; MECHANISM; DISTINCT	A cDNA for a novel human papain-like cysteine protease, designated cathepsin F, has been cloned from a lambda gt10-skeletal muscle cDNA library. The nucleotide sequence encoded a polypeptide of 302 amino acids composed of an 88-residue propeptide and a 214-residue mature protein. Protein sequence comparisons revealed 58% homology with cathepsin W; about 42-43% with cathepsins L, K S, H and O; and 38% with cathepsin B. Sequence comparisons of the propeptides indicated that cathepsin F and cathepsin W may form a new cathepsin subgroup. Northern blot analysis showed high expression levels in heart, skeletal muscle, brain, testis, and ovary; moderate levels in prostate, placenta, Liver, and colon; and no detectable expression in peripheral leukocytes and thymus. The precursor polypeptide of human recombinant cathepsin F, produced in Pichia pastoris, was processed to its active mature form autocatalytically or by incubation with pepsin. Mature cathepsin F was highly active with comparable specific activities toward synthetic substrates as reported for cathepsin L. The protease had a broad pH optimum between 5.2 and 6.8. Similar to cathepsin L, its pH stability at cytosolic pH (7.2) was short, with a half-Life of approximately 2 min. This may suggest a function in an acidic cellular compartment. Transient expression of T7-tagged cathepsin F in COS-7 cells revealed a vesicular distribution of the gene product in the juxtanuclear region of the cells. However, contrary to all known cathepsins, the open reading frame of the cathepsin F cDNA did not encode a signal sequence, thus suggesting that the protease is targeted to the lysosomal compartment via an N-terminal signal peptide-independent lysosomal targeting pathway.	CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Incyte Pharmaceut, Palo Alto, CA 94080 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Incyte	Chapman, HA (corresponding author), CUNY Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave 100th St, New York, NY 10029 USA.	hachapman@bjcs.bwh.harvard.edu; brommd0l@doc.mssm.edu			NHLBI NIH HHS [HL44712] Funding Source: Medline; NIAMS NIH HHS [AR 39191, AR 41331] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041331, P50AR039191] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BROCKLEHURST K, 1987, NEW COMPREHENSIVE BI, V16, P39; BROMME D, 1993, J BIOL CHEM, V268, P4832; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; BROMME D, 1989, BIOCHEM J, V264, P475; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DINGLE JT, 1977, BIOCHEM J, V167, P775, DOI 10.1042/bj1670775; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; INOMATA M, 1984, J BIOCHEM-TOKYO, V95, P1661, DOI 10.1093/oxfordjournals.jbchem.a134779; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; KHOURI HE, 1991, BIOCHEMISTRY-US, V30, P8929, DOI 10.1021/bi00101a003; Kirschke H, 1995, PROTEIN PROFILE, V2, P1587; KIRSCHKE H, 1986, BIOCHEM J, V240, P455, DOI 10.1042/bj2400455; KNIGHT CG, 1980, BIOCHEM J, V189, P447, DOI 10.1042/bj1890447; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; MCGRATH ME, 1995, J MOL BIOL, V247, P251, DOI 10.1006/jmbi.1994.0137; McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297-105; Mehtani S, 1998, J BIOL CHEM, V273, P13236, DOI 10.1074/jbc.273.21.13236; MENARD R, 1991, BIOCHEMISTRY-US, V30, P5531, DOI 10.1021/bi00236a028; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; Sukhova GK, 1998, J CLIN INVEST, V102, P576, DOI 10.1172/JCI181; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TURNSEK T, 1975, BIOCHIM BIOPHYS ACTA, V403, P514, DOI 10.1016/0005-2744(75)90079-0; Urade R, 1997, J BIOCHEM-TOKYO, V122, P834; VELASCO G, 1994, J BIOL CHEM, V269, P27136; Villadangos JA, 1997, J EXP MED, V186, P549, DOI 10.1084/jem.186.4.549; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; von Heijne G, 1994, Subcell Biochem, V22, P1; von Heijne G, 1995, EXS, V73, P67; [No title captured]	42	136	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 27	1998	273	48					32000	32008		10.1074/jbc.273.48.32000	http://dx.doi.org/10.1074/jbc.273.48.32000			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	142NR	9822672	hybrid, Green Published			2022-12-25	WOS:000077207000054
J	Berg, KL; Carlberg, K; Rohrschneider, LR; Siminovitch, KA; Stanley, ER				Berg, KL; Carlberg, K; Rohrschneider, LR; Siminovitch, KA; Stanley, ER			The major SHP-1-binding, tyrosine-phosphorylated protein in macrophages is a member of the KIR/LIR family and an SHP-1 substrate	ONCOGENE			English	Article						macrophage; SHP-1; KIR; LIR-1; PIR-B; PTP	CELL INHIBITORY RECEPTORS; MOTH-EATEN MICE; B-CELLS; PHOSPHATASE; STIMULATION; EXPRESSION; GROWTH; PTP1C	The SH2 domain-containing cytoplasmic protein tyrosine phosphatase, SHP-1, negatively regulates hematopoietic cell signaling, SHP-1 is associated with a tyrosine phosphorylated, plasma membrane-spanning glycoprotein, pp130, in colony stimulating factor-1 stimulated or unstimulated macrophages, This association is phosphotyrosine dependent and is mediated by the amino-terminal SH2 domain of SHP-1, pp130 behaves as a substrate of SHP-1 in vitro and is hyperphosphorylated on tyrosine in SHP-1 deficient macrophages from viable-motheaten mice. Co-immunoprecipitation data indicate that pp130 is the product of the mouse p91/PIR-B gene that encodes a member of the killer cell inhibitory receptor (KIR)/leukocyte immunoglobulin-like receptor (LIR) family. By analogy to the KIRs, p91/PIR-B may represent a novel class of macrophage receptors which act to suppress macrophage activation. These observations identify SHP-1 interactions with and regulation of p91/PIR-B as a potential mechanism for inhibiting the signaling cascades linking extracellular stimuli to macrophage activation and/or development.	Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Immunol, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Yeshiva University; Albert Einstein College of Medicine; Fred Hutchinson Cancer Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Stanley, ER (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA.		Siminovitch, Katherine/K-1475-2013; Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	NATIONAL CANCER INSTITUTE [T32CA009173, R37CA026504, R01CA026504] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26504, 5 T32 CA09173] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; BUSCHER D, 1993, ONCOGENE, V8, P3323; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cosman D, 1997, IMMUNITY, V7, P273, DOI 10.1016/S1074-7613(00)80529-4; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HUBBARD AL, 1975, J CELL BIOL, V64, P438, DOI 10.1083/jcb.64.2.438; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KOO GC, 1993, J IMMUNOL, V151, P6733; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Kuroiwa A, 1998, J BIOL CHEM, V273, P1070, DOI 10.1074/jbc.273.2.1070; LI W, 1991, J BIOL CHEM, V266, P6808; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STANLEY ER, 1994, CYTOKINE HDB, P387; STANLEY ER, 1990, METHOD MOL BIOL, P299; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yokoyama WM, 1997, J EXP MED, V186, P1803, DOI 10.1084/jem.186.11.1803; Yu CCK, 1996, J EXP MED, V183, P371, DOI 10.1084/jem.183.2.371	28	32	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2535	2541		10.1038/sj.onc.1202203	http://dx.doi.org/10.1038/sj.onc.1202203			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824165				2022-12-25	WOS:000076927300014
